<SEC-DOCUMENT>0001213900-25-010915.txt : 20250206
<SEC-HEADER>0001213900-25-010915.hdr.sgml : 20250206
<ACCEPTANCE-DATETIME>20250206153853
ACCESSION NUMBER:		0001213900-25-010915
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		23
FILED AS OF DATE:		20250206
DATE AS OF CHANGE:		20250206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Jyong Biotech Ltd.
		CENTRAL INDEX KEY:			0001954488
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-277725
		FILM NUMBER:		25597133

	BUSINESS ADDRESS:	
		STREET 1:		23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
		STREET 2:		XIZHI DIST.
		CITY:			NEW TAIPEI CITY
		STATE:			F5
		ZIP:			221
		BUSINESS PHONE:		(8862) 27325205

	MAIL ADDRESS:	
		STREET 1:		23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
		STREET 2:		XIZHI DIST.
		CITY:			NEW TAIPEI CITY
		STATE:			F5
		ZIP:			221
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>ea0200696-20.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD><TITLE></TITLE></HEAD>
<BODY STYLE="margin:0;padding:0;border-width:0;text-justify-trim: punctuation; margin: 0; padding: 10pt;"><DIV STYLE="margin:0;padding:0;border-width:0;width:600px;margin: 0 auto;">
	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As filed with the Securities and Exchange Commission on </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">February</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> </FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">6</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, 202</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">5</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;text-align:right;text-indent:0pt;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Registration Statement No. 333</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-277725</FONT></FONT></P>
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></DIV>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:2pt;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> UNITED STATES<BR>SECURITIES AND EXCHANGE COMMISSION<BR>WASHINGTON, D.C. 20549</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:1pt;margin-top:0pt;text-align:center;text-indent:0pt;margin-top:0pt;">____________________________</P>
		 <P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:2pt;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">AMENDMENT NO. </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">9</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> <BR>FORM F-1<BR>REGISTRATION STATEMENT<BR></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">UNDER<BR>THE SECURITIES ACT OF 1933</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:0pt;text-align:center;text-indent:0pt;margin-top:0pt;">____________________________</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:2pt;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:16pt;">Jyong Biotech Ltd.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;text-align:center;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Exact name of Registrant as specified in its charter)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:0pt;text-align:center;text-indent:0pt;margin-top:0pt;">____________________________</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:2pt;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Not Applicable<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Translation of Registrant&#x2019;s name into English)</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.24%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:10pt;">Cayman Islands</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.24%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:10pt;">2834</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:10pt;">Not Applicable</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;">(State or other jurisdiction of <BR>incorporation or organization)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;">(Primary Standard Industrial <BR>Classification Code Number)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;">(I.R.S.&#x00a0;Employer <BR>Identification Number)</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:5pt;margin-top:5pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">23F-3, No. 95, Section&#x00a0;1, Xintai 5</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:58%;vertical-align:super;">th</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Road,<BR>Xizhi District, New Taipei City,<BR>Taiwan, 221<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Tel: +886-2-2732-5205<BR>(Address,&#x00a0;including&#x00a0;zip&#x00a0;code,&#x00a0;and&#x00a0;telephone&#x00a0;number,&#x00a0;including&#x00a0;area&#x00a0;code,&#x00a0;of&#x00a0;Registrant&#x2019;s</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;principal&#x00a0;executive&#x00a0;offices)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:0pt;text-align:center;text-indent:0pt;margin-top:0pt;">____________________________</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:2pt;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cogency Global Inc.<BR>122 East 42</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:58%;vertical-align:super;">nd</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Street, 18</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:58%;vertical-align:super;">th</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Floor<BR>New York, NY 10168<BR>+1(800) 221-0102</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:2pt;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:0pt;text-align:center;text-indent:0pt;margin-top:0pt;">____________________________</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:2pt;margin-top:2pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Copies to:</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 47.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



						<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:0pt;text-align:center;text-indent:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Ross David Carmel, Esq.<BR>Shane Wu, Esq.<BR>Sichenzia Ross Ference Carmel LLP <BR>1185 Avenue of the Americas <BR>31</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;font-style:normal;font-weight:bold;">st</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Floor<BR>New York, NY 10036<BR>Tel: 212</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-930-9700</FONT></FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.09%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.92%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:0pt;text-align:center;text-indent:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Fang Liu, Esq.<BR>VCL Law LLP<BR>1945 Old Gallows Road, Suite 260<BR>Vienna, VA&#x00a0;22182<BR>Tel: 703</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-919-7285</FONT></FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:0pt;text-align:center;text-indent:0pt;margin-top:0pt;">____________________________</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">Approximate date of commencement of proposed sale to the public: as soon as practicable after the effective date of this registration statement.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#x00a0;415 under the Securities Act&#x00a0;of&#x00a0;1933, check the following box. </FONT><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:8pt;">&#9744;</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#x00a0;462(b)&#x00a0;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:8pt;">&#9744;</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;">If this Form is a </FONT><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;">post</FONT><FONT CLASS="nobreak" STYLE="font-size:8pt;">-effective</FONT><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;"> amendment filed pursuant to Rule&#x00a0;462(c)&#x00a0;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:8pt;">&#9744;</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;">If this Form is a </FONT><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;">post</FONT><FONT CLASS="nobreak" STYLE="font-size:8pt;">-effective</FONT><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;"> amendment filed pursuant to Rule&#x00a0;462(d)&#x00a0;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:8pt;">&#9744;</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#x00a0;405 of the Securities Act of 1933.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;">Emerging growth company </FONT><FONT CLASS="CharOverride-7" STYLE="font-family:'Wingdings 24', sans-serif;font-size:8pt;font-style:normal;font-weight:normal;">&#9746;</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;">If an emerging growth company that prepares its financial statements in accordance with U.S.&#x00a0;GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#x2020; provided pursuant to Section&#x00a0;7(a)(2)(B)&#x00a0;of the Securities Act. </FONT><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:8pt;">&#9744;</FONT></P>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;margin-top:8pt;"><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;">&#x2020;<FONT STYLE="width: 24px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The term &#x201c;new or revised</FONT><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;"> financial accounting standard&#x201d; refers to any update issued by the Financial Accounting Standards Board to its</FONT><FONT CLASS="CharOverride-6" STYLE="font-size:8pt;"> Accounting Standards Codification after April&#x00a0;5, 2012.</FONT></P>
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"><P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:8pt;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#x00a0;8(a)&#x00a0;of the Securities Act&#x00a0;of&#x00a0;1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to such Section&#x00a0;8(a), may determine.</FONT></P></DIV>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>








	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:justify;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;">The information in this</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;"> preliminary prospectus is not complete and may be changed. These</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;"> securities may not be sold until the registration statement filed</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;"> with the Securities and Exchange Commission is effective. This preliminary </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;">prospectus is not an offer to sell nor does it </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;">seek an offer to buy these securities in any jurisdiction where </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;">the offer or sale is not permitted.</FONT></P>
		</DIV>
	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		 <P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;color:#d2232a;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;color:#d2232a;">PRELIMINARY PROSPECTUS (Subject</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;color:#d2232a;"> to Completion) <BR>Dated </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-style:italic;font-weight:normal;">February&#x00a0;6, 2025</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:6pt;margin-top:6pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:16pt;"><IMG ALT="" SRC="tjyong_logo.jpg" STYLE="width:67.84px;max-width:100%;"></FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:0pt;margin-top:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:16pt;">Jyong Biotech Ltd.</FONT></P>
		 <P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:0pt;margin-top:0pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;font-size:12pt;"></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;font-size:12pt;">2,352,941</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;font-size:12pt;"> Ordinary Shares</FONT></P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">This is an initial public offering of 2,352,941 ordinary shares of Jyong Biotech Ltd., par value US$0.00001 per share, by Jyong Biotech Ltd.</P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:10pt;margin-top:9.5pt;">We currently anticipate the initial public offering price of our ordinary shares, will be between US$7.50 and US$8.50 per ordinary share. Prior to this offering, there is no public market for our ordinary shares.</P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:10pt;margin-top:9.5pt;">We have applied to have our ordinary shares on the Nasdaq Global Market under the symbol &#x201c;MENS.&#x201d; At this time, the Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) has not yet approved our application to list our Ordinary Shares. We cannot assure you that our application will be approved; however, if it is not approved, we will not complete this offering.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:10pt;margin-top:9.5pt;">We are an &#x201c;emerging growth company&#x201d; and a &#x201c;foreign private issuer&#x201d; under applicable U.S.&#x00a0;federal securities laws, and as such, are eligible for certain reduced public company reporting requirements for this prospectus and future filings. See the sections titled &#x201c;Prospectus Summary&#x00a0;&#x2014;&#x00a0;Implications of Being an Emerging Growth Company&#x201d; and &#x201c;Prospectus Summary&#x00a0;&#x2014;&#x00a0;Implications of Being a Foreign Private Issuer&#x201d; for additional information.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:10pt;margin-top:9.5pt;">We are a Cayman Islands exempted holding company with operations conducted by our subsidiaries. Throughout this prospectus, unless the context indicates otherwise, references to &#x201c;the Company,&#x201d; &#x201c;our Company,&#x201d; and &#x201c;Jyong&#x201d; refer to Jyong Biotech Ltd. &#x201c;We,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to Jyong Biotech Ltd. and its subsidiaries. We currently conduct our business through five wholly owned subsidiaries, including Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd. and Genvace Biotechnology Co., Ltd. in Taiwan, Jyong Biotech International Pte. Ltd. in Singapore, Top ShunXing Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Limited in Hong&#x00a0;Kong, and Innovative Biotech Co., Ltd. in the People&#x2019;s Republic of China, or the PRC, among which Jyong holds the equity interests in its PRC subsidiary through its subsidiary incorporated in Hong&#x00a0;Kong. See &#x201c;Corporate History and Structure&#x201d; for additional details. Investors purchasing our ordinary shares in this initial public offering are purchasing equity securities of our Cayman Islands exempted holding company and are not purchasing equity securities of our operating subsidiaries. In the normal course of our business, we would evaluate the financial condition and capital needs of our subsidiaries periodically and then provide funding for their operations via equity investments and intercompany loans. As of the date of this prospectus, we have provided US$14.5<FONT CLASS="nobreak"> </FONT>million intercompany loans and US$5,000 capital contributions to our Hong Kong subsidiary. None of our subsidiaries have declared or paid any dividends or distributions on equity to their respective holding companies as of the date of this prospectus. We have largely relied, and expect to continuously rely, on dividends or other distributions on equity from our subsidiaries for our cash requirements. We have no plans to declare cash dividends in the near term, but as a holding company, we may depend on receipt of funds from one or more of our subsidiaries if we determine to pay cash dividends to holders of our ordinary shares in the future. While our PRC subsidiary has no operations and generates no revenue as of the date of this prospectus, should it generate revenue in the future, restrictions on currency exchanges in China may limit our ability to freely convert such Renminbi to fund any future business activities outside China or other payments in U.S.&#x00a0;dollars, and capital control measures imposed by the Chinese government may limit our ability to use capital from our PRC subsidiary for business purposes outside of China. See &#x201c;Prospectus Summary&#x00a0;&#x2014;&#x00a0;Holding Company Structure&#x201d; on page 9 for a more detailed description.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, all of our operations are outside of PRC, although we have established one subsidiary in Hong&#x00a0;Kong and one subsidiary in China. We do not expect the listing of our ordinary shares to be materially affected by recent statements by the PRC government indicating an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China<FONT CLASS="nobreak">-based</FONT> issuers, including but not limited to, the cybersecurity review, the merger control review and other regulatory reviews of overseas listing through an offshore holding company. Specifically, on February<FONT CLASS="nobreak"> </FONT>17, 2023, the China Securities Regulatory Commission, or CSRC, issued the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, or the Trial Measures, which became effective on March<FONT CLASS="nobreak"> </FONT>31, 2023. We reasonably believe that the Trial Measures do not apply to us, and as of the date of this prospectus, we have not received any inquiry, notice, warning or sanctions regarding our planned overseas listing from the CSRC and any other PRC governmental authorities. However, due to the extraterritorial reach, the so<FONT CLASS="nobreak">-called</FONT> &#x201c;long arm provisions&#x201d; under the current PRC laws and regulations, there remains regulatory uncertainty with respect to the implementation and interpretation of laws in China. See &#x201c;Risk Factors&#x00a0;&#x2014;&#x00a0;Risks Related to Our Business and Industry &#x2014; We currently have no operations in China although we have established a subsidiary in each of Hong&#x00a0;Kong and China. However, due to the extraterritorial reach (the so<FONT CLASS="nobreak">-called</FONT> &#x201c;long arm provisions&#x201d;) under the current PRC laws and regulations, the Chinese government may exert substantial oversight and influence over the manner in which we must conduct our business and may intervene in or influence our operations at any time, which could result in a material change in our operations and significantly and adversely impact the value of our ordinary shares&#x201d; on page 57 for more details.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>











	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:justify;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;">The information in this</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;"> preliminary prospectus is not complete and may be changed. These</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;"> securities may not be sold until the registration statement filed</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;"> with the Securities and Exchange Commission is effective. This preliminary </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;">prospectus is not an offer to sell nor does it </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;">seek an offer to buy these securities in any jurisdiction where </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;font-size:9pt;">the offer or sale is not permitted.</FONT></P>
		</DIV>
	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event that we elect to expand our operations into China in the future (see &#x201c;Business&#x00a0;&#x2014;&#x00a0;Our Strategies&#x201d; beginning on page&#x00a0;118 for our strategies for future development), there may be certain legal and operational risks associated with having certain operations in China, including that changes in the legal, political and economic policies of the Chinese government, the relations between China and the United&#x00a0;States, or Chinese or United&#x00a0;States regulations may materially and adversely affect our business, financial condition, results of operations and the market price of our ordinary shares. Any such changes may significantly limit or completely hinder our ability to offer or continue to offer our ordinary shares to investors, and may cause the value of our ordinary shares to significantly decline or become worthless. For more information on these risks and other risks you should consider before buying our ordinary shares, see &#x201c;Risk Factors&#x00a0;&#x2014;&#x00a0;Risks Related to Our Business and Industry &#x2014; Changes in the political and economic policies of the Chinese government or in relations between China and the United&#x00a0;States may materially and adversely affect our business, financial condition, results of operations and the market price of our ordinary shares&#x201d; on page 57 for more details.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Furthermore, as more stringent criteria, including the Holding Foreign Companies Accountable Act, or the HFCAA, have been imposed by the SEC and the Public Company Accounting Oversight Board, or the PCAOB, recently, our ordinary shares may be prohibited from trading in the United&#x00a0;States if our auditor cannot be fully inspected. On June<FONT CLASS="nobreak"> </FONT>22, 2021, United States Senate has passed the Accelerating Holding Foreign Companies Accountable Act, or the Accelerating HFCAA, which was signed into law on December<FONT CLASS="nobreak"> </FONT>29, 2022, amending the HFCAA and requiring the SEC to prohibit an issuer&#x2019;s securities from trading on any U.S. stock exchange if its auditor is not subject to PCAOB inspections for two consecutive years instead of three consecutive years. On December<FONT CLASS="nobreak"> </FONT>16, 2021, the PCAOB issued a report on its determinations that it is unable to inspect or investigate completely PCAOB<FONT CLASS="nobreak">-registered</FONT> public accounting firms headquartered in mainland China and in Hong Kong because of positions taken by PRC authorities in those jurisdictions. On August<FONT CLASS="nobreak"> </FONT>26, 2022, the PCAOB signed a Statement of Protocol with the China Securities Regulatory Commission and the PRC Ministry of Finance which was the first step toward opening access for the PCAOB to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong completely. On December<FONT CLASS="nobreak"> </FONT>15, 2022, the PCAOB announced that it was able to secure complete access to inspect and investigate PCAOB<FONT CLASS="nobreak">-registered</FONT> public accounting firms headquartered in mainland China and Hong Kong completely in 2022. The PCAOB Board vacated its previous 2021 determinations that the PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in mainland China and Hong Kong. However, whether the PCAOB will continue to be able to satisfactorily conduct inspections of PCAOB<FONT CLASS="nobreak">-registered</FONT> public accounting firms headquartered in mainland China and Hong Kong is subject to uncertainties and depends on a number of factors out of our and our auditor&#x2019;s control. The PCAOB continues to demand complete access in mainland China and Hong Kong moving forward and is making plans to resume regular inspections in early 2023 and beyond, as well as to continue pursuing ongoing investigations and initiate new investigations as needed. The PCAOB has also indicated that it will act immediately to consider the need to issue new determinations with the HFCAA if needed. Our auditor, WWC, P.C., headquartered in San Mateo, California, is currently subject to inspection by the PCAOB on a regular basis. Therefore, we believe that, as of the date of this prospectus, our auditor is in compliance with PCAOB determinations. </P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">For more information on these risks and other risks you should consider before buying our ordinary shares, see &#x201c;Risk Factors&#x201d; beginning on page 18. We cannot assure you whether Nasdaq or other regulatory authorities will apply additional or more stringent criteria to us. Such uncertainty could cause the market price of our ordinary shares to be materially and adversely affected.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:1pt;width: 70.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 11.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-12" STYLE="font-style:normal;font-weight:bold;">Per ordinary <BR>share</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 15.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 70.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Public offering price</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.53%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.58%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">8.50</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.53%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.53%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.01%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 70.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Underwriting discounts and commissions<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)(2)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.53%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.58%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.60</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.53%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.53%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.01%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,400,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 70.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds, before expenses, to us</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.53%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.58%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.90</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.53%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.53%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.01%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,600,000</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P> <P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:9pt;margin-top:9pt;">*<FONT STYLE="width: 24px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The assumed price range for this offering is $7.50 to $8.50, with $8.50 representing the upper limit of the assumed price range.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>For a description of compensation payable to the underwriters, see &#x201c;Underwriting.&#x201d;</P>
		 <P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents underwriting discounts up to seven percent (7.0%), of gross proceeds of this offering. Does not include a non<FONT CLASS="nobreak">-accountable</FONT> expense allowance. See &#x201c;Underwriting&#x201d; for all compensation to be paid to the underwriters.</P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:9pt;margin-top:9pt;">The underwriters have a 45<FONT CLASS="nobreak">-day</FONT> option to purchase up to an additional 352,941 ordinary shares from us at the initial public offering price less the underwriting discounts and commissions.</P>
		<P CLASS="H3_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:0pt;margin-top:9pt;text-indent:24pt;margin-top:9pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">The Securities and Exchange Commission</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> and state securities regulators have not approved or disapproved of these securities, or determined if this prospectus</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> is truthful or complete. Any representation to the contrary is a criminal offense.</FONT></P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:9pt;margin-top:9pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The underwriters expect </FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">to deliver the ordinary shares against payment in U.S.&#x00a0;dollars in New&#x00a0;York, NY on &#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;, 202</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">5</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:9pt;text-align:center;text-indent:0pt;margin-top:9pt;"><FONT CLASS="CharOverride-13" STYLE="font-size:6pt;">_________________________________________________________</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:2pt;text-align:center;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:12pt;">Joseph Stone Capital, LLC</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:1pt;text-align:center;text-indent:0pt;margin-top:1pt;"><FONT CLASS="CharOverride-13" STYLE="font-size:6pt;">_________________________________________________________</FONT></P>
		 <P CLASS="Text_ind_center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:10pt;margin-top:10pt;">The date of this prospectus is <FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>, 2025 </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1_TOC" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><A NAME="TOC001"></A>TABLE OF CONTENTS</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Page</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T21">PROSPECTUS SUMMARY</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T20">THE OFFERING</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">16</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T19">RISK FACTORS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">18</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T18">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">78</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T17">USE OF PROCEEDS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">79</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T16">DIVIDEND POLICY</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">80</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T15">CAPITALIZATION</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">81</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T555">DILUTION</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">82</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T14">ENFORCEMENT OF CIVIL LIABILITIES</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">84</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T13">CORPORATE HISTORY AND STRUCTURE</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">86</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T666">MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND <BR>RESULTS OF OPERATIONS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">88</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T12">INDUSTRY OVERVIEW</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">107</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T11">BUSINESS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">112</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T10">REGULATIONS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">148</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T9">MANAGEMENT</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">175</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T8">PRINCIPAL SHAREHOLDERS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">180</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T777">RELATED PARTY TRANSACTIONS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">182</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T888">DESCRIPTION OF SHARE CAPITAL</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">184</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T7">SHARES ELIGIBLE FOR FUTURE SALE</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">192</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T6">TAXATION</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">194</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T5">UNDERWRITING</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">199</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T4">EXPENSES RELATED TO THIS OFFERING</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">203</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T3">LEGAL MATTERS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">203</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2">EXPERTS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">204</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T1">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">204</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T25">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-1</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">No dealer, salesperson or other person is authorized to give any information or to represent anything not contained</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. You must</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> not rely on any unauthorized information or representations. This prospectus is an offer to sell only the ordinary shares offered hereby, but only under circumstances</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the ordinary shares.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus or any filed free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United&#x00a0;States. Persons outside the United&#x00a0;States who come into possession of this prospectus or any filed free writing prospectus must inform themselves about, and observe any restrictions relating to, the offering of the ordinary shares and the distribution of this prospectus or any filed free writing prospectus outside of the United&#x00a0;States.</P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Until <FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>, 2025 (the 25<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT>&#x00a0;day after the date of this prospectus), all dealers that buy, sell or trade ordinary shares, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">i</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>







	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T21"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PROSPECTUS SUMMARY</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> and financial statements appearing elsewhere in this prospectus. In addition to this summary, we urge you to read the entire prospectus</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> carefully, especially the risks of investing in our ordinary shares discussed under &#x201c;Risk Factors&#x201d; and information contained in &#x201c;Management&#x2019;s</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> Discussion and Analysis of Financial Condition and Results of Operations&#x201d; before deciding whether to buy our ordinary shares. In addition,</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> this prospectus contains information from a report prepared by Frost&#x00a0;&amp; Sullivan Limited, or Frost&#x00a0;&amp; Sullivan, a </FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">third</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-party</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> market research</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> firm. Frost&#x00a0;&amp; Sullivan was commissioned by us to provide information on the pharmaceutical industry.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OUR MISSION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We endeavor to develop and supply first<FONT CLASS="nobreak">-class</FONT> innovative drugs to meet our customers&#x2019; health needs. We seek to be a valuable business organization that is held in high esteem by the public.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OVERVIEW</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are a science<FONT CLASS="nobreak">-driven</FONT> biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant<FONT CLASS="nobreak">-derived</FONT>) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since our inception in 2002, we have built integrated capabilities that encompass all key functionalities of drug development, including early<FONT CLASS="nobreak">-stage</FONT> drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging our strong research and development capabilities and proprietary platform, we have been developing a series of botanical drug candidates, including our primary botanical drug candidate of MCS<FONT CLASS="nobreak">-2</FONT>, another clinical<FONT CLASS="nobreak">-stage</FONT> botanical drug candidate of PCP, and other preclinical<FONT CLASS="nobreak">-stage</FONT> botanical drug candidates. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">MCS<FONT CLASS="nobreak">-2</FONT> is our new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms, or BPH/LUTS. The development of MCS<FONT CLASS="nobreak">-2</FONT> traces back to 1998, encompassing its composition and Chemistry, Manufacturing, and Controls (&#x201c;CMC&#x201d;). We decided to conduct the Phase II clinical study of MCS<FONT CLASS="nobreak">-2</FONT> in Taiwan in 2002, with the Phase II clinical study initiated in 2004. Additionally, we have conducted the two Phase III trials and two open<FONT CLASS="nobreak">-label</FONT> extension studies for MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-1</FONT> in Taiwan and the US in 2010.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>), we have conducted four Phase III clinical trials for MCS<FONT CLASS="nobreak">-2</FONT> in the U.S. and Taiwan, including two pivotal trials (one in the US and one in Taiwan) and two open<FONT CLASS="nobreak">-label</FONT> extension studies (one in the US and one in Taiwan) using API<FONT CLASS="nobreak">-1</FONT>. The U.S. FDA had concerns about one pivotal Phase III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> in the U.S., which failed to show a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to-treat</FONT> population. The U.S. FDA also had concerns regarding the reproducibility of some of the reported efficacy results for Study MCS<FONT CLASS="nobreak">-2-TWN-a</FONT>. U.S. FDA has had no further comments for the two open<FONT CLASS="nobreak">-label</FONT> extension studies (one in the US and one in Taiwan) using API<FONT CLASS="nobreak">-1</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to these four clinical trials, we found MCS<FONT CLASS="nobreak">-2</FONT> (using API<FONT CLASS="nobreak">-1</FONT>) was well<FONT CLASS="nobreak">-tolerated</FONT> and the incidence of adverse events in the MCS<FONT CLASS="nobreak">-2</FONT> (using API<FONT CLASS="nobreak">-1</FONT>) group were lower than that in the placebo group. The U.S. FDA also raised concerns about whether one new Phase III study with API<FONT CLASS="nobreak">-2</FONT> would be sufficient, particularly in the treatment of symptomatic conditions such as BPH, where the potential effects of bias, investigational site differences, or chance alone are issues. If we are able to satisfy the U.S. FDA that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are sufficiently comparable, we will initiate the MCS<FONT CLASS="nobreak">-2</FONT> Phase III study and the PK study using API<FONT CLASS="nobreak">-2</FONT> simultaneously to support a future NDA submission. The new Phase III study using API<FONT CLASS="nobreak">-2</FONT>, combined with the previous Phase III study using API<FONT CLASS="nobreak">-1</FONT>, will provide more convincing evidence of effectiveness than the results from a single trial. If on the other hand we are unable to satisfy U.S. FDA of comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will perform additional clinical trials for further drug development using API<FONT CLASS="nobreak">-1</FONT> per U.S. FDA requirements. In the interim, we continue to research additional API sources based on our own patent, to pursue additional outsourcing API vendors, and to follow U.S. FDA&#x2019;s guidance for demonstrating comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> to the Agency&#x2019;s satisfaction.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PCP is our new botanical drug candidate developed for the prevention of prostate cancer. PCP focuses on research for preventing prostate cancer. As the PCP study drug is the same as that for MCS<FONT CLASS="nobreak">-2</FONT>, albeit for a different indication, we concluded that conducting a Phase I trial for PCP was unnecessary. Based on the safety and tolerability profile observed in the MCS<FONT CLASS="nobreak">-2</FONT> Phase II clinical trial, we decided to initiate the development of PCP and proceed directly to the Phase II study for its indication in 2013, with the Phase II clinical study commencing </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">1</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">in late 2014. Our PCP Phase II study enrollment and treatment phase using API<FONT CLASS="nobreak">-1</FONT> is now in the source data verification (SDV) stage before drafting the clinical study report (CSR), which may take an additional year or more to complete. After completion of the SDV stage, we will conduct the necessary statistical analysis. While PCP is still in the SDV stage, we are working with the U.S. FDA to establish the comparability of the API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. To date, we have not had any discussions with the TFDA regarding the unavailability of API<FONT CLASS="nobreak">-1</FONT>. We will discuss the statistical results of the PCP using API<FONT CLASS="nobreak">-2</FONT> with Taiwan regulator and proceed with the Phase III PCP study if the U.S. FDA accepts such results and determines that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable. Based on our prior communications with the TFDA, the Chemistry, Manufacturing, and Controls (&#x201c;CMC&#x201d;) and study design for the product are consistent between the U.S. and Taiwan, encompassing two pivotal studies and two open<FONT CLASS="nobreak">-label</FONT> extension studies. The protocol for the Phase III clinical trials was approved by the U.S. FDA in December 2009 and subsequently approved by the TFDA in February 2010. Therefore, we believe the TFDA will give due consideration to the comments provided by the U.S. FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA. As of this date, the Company is still in the process of providing the information required by the U.S. FDA and has not yet successfully demonstrated the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are currently collaborating with a supplier to prepare the API<FONT CLASS="nobreak">-2</FONT> CMC documents required by the U.S. FDA. Should the FDA concur that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API<FONT CLASS="nobreak">-2</FONT>. If the U.S. FDA does not agree that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, we will continue to research additional API sources based on our own patent, to pursue additional outsourcing API vendors, and to follow U.S. FDA&#x2019;s guidance for demonstrating comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> to the U.S. FDA&#x2019;s satisfaction. Our intention to identify another potential supplier and repeat the process of demonstrating comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> is to avoid having to repeat all of your clinical trials. In the event that we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be required to repeat the MCS<FONT CLASS="nobreak">-2</FONT> and PCP clinical trials using API<FONT CLASS="nobreak">-2</FONT>, or to conduct other additional clinical trials as may be required by the U.S. FDA. For further details, see the risk factor titled &#x201c;<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, or to conduct other additional clinical trials as may be required by the U.S. FDA, which could significantly delay our product development efforts and result in increased costs</FONT>&#x201d; on page 31.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We resubmitted a new drug application, or NDA, for MCS<FONT CLASS="nobreak">-2</FONT> with the U.S. FDA on December<FONT CLASS="nobreak"> </FONT>17, 2021 using Active Pharmaceutical Ingredient (API)<FONT CLASS="nobreak">-1</FONT>. We voluntarily withdrew our NDA on November<FONT CLASS="nobreak"> </FONT>30, 2022, in order to develop more information about API<FONT CLASS="nobreak">-2</FONT> for the U.S. FDA&#x2019;s review and to address ongoing questions regarding demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT> and placebo for the primary efficacy endpoint in a clinical study for MCS<FONT CLASS="nobreak">-2</FONT>, and to address other questions FDA had previously identified in our NDA regarding FDA&#x2019;s questions related to the drug substance and product, validation of methods used for measuring the effect of MCS<FONT CLASS="nobreak">-2</FONT>, manufacturing, clinical and nonclinical testing, data, and statistical analyses, among others. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We elected to voluntarily withdraw the application with the option of refiling to address the substantive issues raised by the U.S. FDA that would have likely prevented the agency from approving our NDA at that time. The substantive issues included currently unavailable API<FONT CLASS="nobreak">-1</FONT>, and no statistically significant difference between the drug and placebo in the primary efficacy endpoint in Study MCS<FONT CLASS="nobreak">-2-US-a</FONT>, one of our Phase III pivotal studies. The U.S. FDA also had concerns regarding the reproducibility of some of the reported efficacy results for Study MCS<FONT CLASS="nobreak">-2-TWN-a</FONT>, one of our Phase III pivotal studies. We have conducted four Phase III clinical trials in the U.S. and Taiwan using API<FONT CLASS="nobreak">-1</FONT>, with two pivotal and two open label extension studies. One study in the U.S. failed to show the treatment difference for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to-treat</FONT> (&#x201c;ITT&#x201d;) population. In addition, API<FONT CLASS="nobreak">-1</FONT> supplier withdrew their consent to reference their Drug Master File on file with the U.S. FDA, due to the relocation and restructuring of their manufacturing facility. Under these circumstances, we voluntarily withdrew our NDA. We are continuing to discuss with the U.S. FDA if it would be feasible for us to conduct an additional Phase III trial and Phase I PK study in the US using API<FONT CLASS="nobreak">-2</FONT> to support our NDA re<FONT CLASS="nobreak">-submission</FONT>. We will also have a separate meeting with the U.S. FDA to discuss the Chemistry and Manufacturing, and Control (CMC) information for API<FONT CLASS="nobreak">-2</FONT>, to determine whether API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, as both APIs are the similar drug substance covered by the same patent owned by the Company. We elected to withdraw our NDA on November<FONT CLASS="nobreak"> </FONT>30, 2022, given that our pivotal Phase III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> in the U.S. failed to show a difference between treatment groups for the primary efficacy endpoint in the </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">2</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">intent<FONT CLASS="nobreak">-to-treat</FONT> population. Had we not elected to withdraw under the circumstances, the U.S. FDA may request us to conduct further Phases III clinical trial until the U.S. FDA decides that we have reached the endpoint of Phase III clinical trials for MCS<FONT CLASS="nobreak">-2</FONT>. If we decide to submit the application with the existing data, our NDA would need to provide a rationale for the study failure and a justification for the FDA to approve our application in this circumstance.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We submitted a meeting request to the U.S. FDA on April<FONT CLASS="nobreak"> </FONT>14, 2023, with our very preliminary comparative specifications of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. On June<FONT CLASS="nobreak"> </FONT>26, 2023, U.S. FDA responded to our meeting request regarding refiling the NDA for MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-2</FONT>, and the U.S. FDA informed us that the information we provided on API<FONT CLASS="nobreak">-2</FONT> was not yet sufficient to demonstrate comparability with API<FONT CLASS="nobreak">-1</FONT> since we only provided the preliminary comparative drug substance and drug product specifications between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, and U.S. FDA also mentioned to include the statistically significant difference between MCS<FONT CLASS="nobreak">-2</FONT> and placebo in the primary efficacy endpoint in in Study MCS<FONT CLASS="nobreak">-2-US-a</FONT>, one of our Phase III pivotal studies. The U.S. FDA&#x2019;s conclusions at that time were that without new clinical information with respect to the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> from the previous Phase III using API<FONT CLASS="nobreak">-1</FONT> and the new Phase III using API<FONT CLASS="nobreak">-2</FONT>, any NDA resubmission for MCS<FONT CLASS="nobreak">-2</FONT> would be at risk of the U.S. FDA refusing to accept the application, referred to as &#x201c;Refusal To File&#x201d; (RTF). Given that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are similar drug substances under the same patent owned by us, we seek to demonstrate comparability in our comparative testing data of CMC information. As the U.S. FDA appears to require additional clinical information, we are planning a new Phase III study in the U.S. using API<FONT CLASS="nobreak">-2</FONT>. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As a result of the above developments with FDA, we submitted a Type D Written Response Only (WRO) meeting request to the U.S. FDA on December<FONT CLASS="nobreak"> </FONT>12, 2023. We asked that the U.S. FDA provide a written response to questions focused on obtaining U.S. FDA&#x2019;s review and comments on a new, proposed Phase III clinical trial protocol for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-2</FONT> and a pharmacokinetic (PK) study. We proposed to address CMC data for our proposed drug product in a separate, future meeting. The U.S. FDA granted our WRO meeting request but clarified that they viewed the meeting as a Type C meeting because, in the U.S. FDA&#x2019;s view, it encompasses an entirely new drug development program, including Phase I PK study and Phase III clinical trial for a new product with a new active pharmaceutical ingredient.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The purpose for assessing the comparability of API<FONT CLASS="nobreak">-2</FONT> to API<FONT CLASS="nobreak">-1</FONT> on individual studies is to continue to rely on data from trials using MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) and try to demonstrate to U.S. FDA that API<FONT CLASS="nobreak">-2</FONT> is comparable to API<FONT CLASS="nobreak">-1</FONT>, such that all of the prior trials can be used to support a new NDA. This will be discussed with the U.S.FDA at the CMC meeting, to obtain FDA feedback and seek the U.S. FDA&#x2019;s acceptance that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable and similar drug substances. As the U.S. FDA requires additional clinical information due to a failed MCS<FONT CLASS="nobreak">-2-US-a</FONT> study, we will conduct an additional Phase III pivotal study in the U.S. (MCS<FONT CLASS="nobreak">-2-US-b</FONT>) using API<FONT CLASS="nobreak">-2</FONT>. However, we must conduct API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> comparability studies first and if the FDA accepts such results and determines that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, only then we will be able to conduct the additional Phase III pivotal study using API<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On February<FONT CLASS="nobreak"> </FONT>23, 2024, we received a written response from the U.S. FDA. In the response, the U.S. FDA raised the following concerns:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(i) <FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The U.S. FDA questioned whether one new Phase III study with API<FONT CLASS="nobreak">-2</FONT> would be sufficient, especially in treatment of symptomatic conditions such as BPH, the potential effects of bias, investigational site, or chance alone are concerns. The US. FDA believes results from two positive Phase III efficacy studies provide more convincing evidence of effectiveness than results from a single trial. Additionally, a single Phase III efficacy study could make it challenging to collect the amount of safety information required for a new molecular entity.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(ii) <FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT>The U.S. FDA noted its concern that Study MCS<FONT CLASS="nobreak">-2-US-a</FONT> did not demonstrate a statistically significant difference between the drug and placebo in the primary efficacy endpoint. They also expressed concerns regarding the treatment effect of questionable significance in Study MCS<FONT CLASS="nobreak">-2-TWN-a</FONT>.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(iii) &#x00a0;&#x00a0;The U.S. FDA was concerned that our study plan had not specified either the quantity or quality of the confirmatory evidence, and did not state a specific clinical circumstance, ethical or practical consideration, or unmet medical need that would preclude the conduct of a second adequate and well<FONT CLASS="nobreak">-controlled</FONT> efficacy study.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(iv)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Additionally, regarding the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, the U.S. FDA commented that it will need more information on how we would demonstrate comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. They noted that their determination of whether our original Phase III studies with API<FONT CLASS="nobreak">-1</FONT> would be useful depends on the quality of support for a convincing link between products containing these APIs.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">3</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The U.S. FDA provided comments on our proposed Phase III study, and we are finalizing the protocol for resubmission to the U.S. FDA. In addition, we are in the process of finalizing the PK study protocol per U.S. FDA requirements and hope to satisfy the U.S. FDA of the comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We followed the U.S. FDA&#x2019;s advice to amend the Phase III protocol and develop the Phase I PK protocol. On May<FONT CLASS="nobreak"> </FONT>14, 2024, we submitted a Type B meeting request to the FDA containing the amended protocols for their review and comments. On May<FONT CLASS="nobreak"> </FONT>23, 2024, we received a denial notice from the FDA, stating that it is premature for this stage of drug development, and until the company can provide complete Chemistry, Manufacturing, and Controls (CMC) information on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, the U.S. FDA is unable to reach agreement on protocols designed to establish the safety and efficacy of MCS<FONT CLASS="nobreak">-2</FONT>. We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:6pt;page-break-after:auto;text-indent:24pt;margin-top:6pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:normal;">If our new Phase I PK and Phase III studies using API-2 are successful and after addressing other </FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:normal;">U.S. FDA-i</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:normal;">dentified deficiencies summarized above, we plan to resubmit our NDA for MCS-2 under the same NDA number to the U.S. FDA. The resubmission timeline is unclear at this point, depending on the comments from the U.S. FDA.</FONT> <FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">Another of our </FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">clinical-stage</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> key botanical drug candidates, PCP, is under phase&#x00a0;II trials stage in Taiwan. Another drug candidate, IC, is under preclinical studies.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:6pt;page-break-after:auto;text-indent:24pt;margin-top:6pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">In the event that we are unable to establish comparability between API-1 and API-2, or we are unable to identify an active pharmaceutical ingredient that the FDA agrees is comparable to API-1, we will be required to repeat the MCS-2 and PCP clinical trials using API-2, or to conduct other additional clinical trials as may be required by the U.S. FDA. For further details, see the risk factor titled &#x201c;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API-2 that is sufficiently comparable to API-1, we will be required to repeat our clinical trials for MCS-2 and PCP, or to conduct other additional clinical trials as may be required by the U.S. FDA, which could significantly delay our product development efforts and result in increased costs</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">&#x201d; on page 31.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:6pt;page-break-after:auto;text-indent:24pt;margin-top:6pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">We have not yet proven comparability between API-1 and API-2 and the following chart illustrates and summarizes our current drug API-2 candidates&#x2019; status:</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><IMG ALT="" SRC="ttimeline_002.jpg" STYLE="width:599.04px;max-width:100%;"></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our pipeline features three innovative and differentiated new botanical drug candidates, and we are developing them for (i) the treatment of benign prostate hyperplasia/lower urinary tract symptoms, or BPH/LUTS, (ii) prostate cancer prevention, and (iii) the treatment of interstitial cystitis, respectively.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>MCS<FONT CLASS="nobreak">-2</FONT> is our new botanical drug candidate developed for treatment of BPH/LUTS. MCS<FONT CLASS="nobreak">-2</FONT> is expected to be our core product in the future. MCS<FONT CLASS="nobreak">-2</FONT> is a softgel capsule containing patented active pharmaceutical ingredients derived from botanical raw materials, specifically, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Lycopersicon escultenum L</FONT>. MCS<FONT CLASS="nobreak">-2</FONT> contains, in the largest concentrations, five carotenoids including lycopene, phytoene, phytofluene, tocopherol and beta<FONT CLASS="nobreak">-carotene</FONT>. We developed MCS<FONT CLASS="nobreak">-2</FONT> using chylomicron technology to improve its bioavailability. Chylomicron is a type of lipoprotein particles consisting of triglycerides and phospholipids.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;margin-top:6pt;text-indent:0pt;margin-top:6pt;">We have conducted four Phase&#x00a0;III clinical trials for MCS<FONT CLASS="nobreak">-2</FONT> in the U.S. and Taiwan, including two pivotal trials (one in the US and one in Taiwan) and two open<FONT CLASS="nobreak">-label</FONT> extension studies using API<FONT CLASS="nobreak">-1</FONT>. Our pivotal Phase III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> in the U.S. failed to show a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to-treat</FONT> population. </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">4</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;margin-top:6pt;text-indent:0pt;margin-top:6pt;">We resubmitted an NDA for MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-1</FONT> to the U.S. FDA on December<FONT CLASS="nobreak"> </FONT>17, 2021. On February<FONT CLASS="nobreak"> </FONT>22, 2022, the U.S. FDA accepted our NDA for review &#x201c;with issues identified.&#x201d; In the February<FONT CLASS="nobreak"> </FONT>22, 2022 Filing Issues Identified letter, the U.S. FDA identified, among other things, the lack of demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT> and placebo for the primary efficacy endpoint in the MCS<FONT CLASS="nobreak">-2-US-a</FONT> study. U.S. FDA identified additional issues, including issues regarding pharmacology, toxicology, and our pharmacokinetic submission, statistical analyses, and the content and format of our proposed Prescribing Information. We used one supplier for API<FONT CLASS="nobreak">-1which</FONT> was the basis for the NDA that has since been withdrawn by the Company. The supplier of API<FONT CLASS="nobreak">-1</FONT> sold a parcel of its land and is in the process of relocating and reconstructing its manufacturing facility, and as a result, API<FONT CLASS="nobreak">-1</FONT> is currently not available to us, and for that reason the supplier of API<FONT CLASS="nobreak">-1</FONT> withdrew its consent for us to reference their Drug Master File (DMF) on file with the U.S. FDA. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">If we are able to satisfy U.S. FDA that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, that is, if the U.S. FDA agrees with our comparability data between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, then we may not need to conduct redundant studies using API<FONT CLASS="nobreak">-2</FONT>. If we are unable to demonstrate comparability, we would have to perform more clinical trials. We will work with API vendors to follow the U.S. FDA&#x2019;s guidance to demonstrate comparability. In the event that we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be required to repeat the MCS<FONT CLASS="nobreak">-2</FONT> clinical trials using API<FONT CLASS="nobreak">-2</FONT>. For further details, see the risk factor titled &#x201c;<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs</FONT>&#x201d; on page 31.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">Moreover, we are planning the CMC meeting with U.S. FDA, one purpose of which is to seek the U.S FDA&#x2019;s concurrence that API<FONT CLASS="nobreak">-2</FONT> is comparable to API<FONT CLASS="nobreak">-1</FONT>. Those plans are no more speculative than the fact that we are engaged in an ongoing drug approval process with the U.S. FDA. It is not uncommon to maintain redundant API sources for the same finished drug to minimize the risk of shortages.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">In a Mid<FONT CLASS="nobreak">-Cycle</FONT> meeting and communication with the U.S. FDA on May<FONT CLASS="nobreak"> </FONT>24, 2022, the U.S. FDA also identified the fact that API<FONT CLASS="nobreak">-1</FONT>, the botanical drug substance used in our clinical trials and that was the basis for our NDA, was not available.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">Based upon these observations, we voluntarily withdrew our NDA on November<FONT CLASS="nobreak"> </FONT>30, 2022, to develop more information about API<FONT CLASS="nobreak">-2</FONT> for the U.S. FDA&#x2019;s review, to address the U.S. FDA&#x2019;s concerns of a lack of demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT> and placebo for the primary efficacy endpoint, and to resolve other issues the U.S. FDA had previously identified (and discussed above).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">In the December<FONT CLASS="nobreak"> </FONT>12, 2022 Acknowledge Withdrawal from the U.S. FDA, the U.S. FDA stated that &#x201c;this withdrawal will not prejudice any future decisions on filing&#x201d; if we decide to resubmit our NDA, and we can retain the application number (NDA 212872). The retention of the NDA number signifies the U.S. FDA&#x2019;s acknowledgment that they have not refused to file (RTF) NDA 212872. Instead, the Company voluntarily withdrew it. Retaining the application number allows the U.S. FDA to review the Company&#x2019;s prior submissions when the Company resubmits study and CMC data in the future. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">We have been conducting further research and development on MCS<FONT CLASS="nobreak">-2</FONT> and identified an additional source for the botanical drug substance API<FONT CLASS="nobreak">-2</FONT>. API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are similar drug substances covered by the same patent owned by us; however, because they are sourced from raw materials manufactured in different locations, the U.S. FDA considers them to be different botanical drug substances. Therefore, we will conduct a comparability study for API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">We submitted a meeting request to the U.S. FDA on April<FONT CLASS="nobreak"> </FONT>14, 2023 with our very preliminary comparative specifications of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, and request that the U.S. FDA provide a WRO to questions about our refiling of the NDA for MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-2</FONT>. The U.S. FDA agreed to our request and responded in writing on June<FONT CLASS="nobreak"> </FONT>26, 2023. The U.S. FDA informed us that the information we provided on API<FONT CLASS="nobreak">-2</FONT> was not sufficient to demonstrate comparability with API<FONT CLASS="nobreak">-1</FONT>. In addition to the current unavailability of API<FONT CLASS="nobreak">-1</FONT>, the U.S. FDA explained that we had not demonstrated a statistically significant difference between MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-1</FONT> and placebo in the primary efficacy endpoint in the MCS<FONT CLASS="nobreak">-2-US-a</FONT> study. The U.S. FDA stated that without new clinical information, any resubmission of the NDA for MCS<FONT CLASS="nobreak">-2</FONT> would be at risk of a RTF action from the U.S. FDA. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">5</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">We submitted a Type D WRO meeting request to the U.S. FDA on December<FONT CLASS="nobreak"> </FONT>12, 2023. We asked that the U.S. FDA provide a written response to questions focused on obtaining the U.S. FDA&#x2019;s review and comments on a new, proposed Phase III clinical trial protocol for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-2</FONT> and a Phase I PK study. We proposed to address CMC information for MCS<FONT CLASS="nobreak">-2</FONT> in a separate, future meeting. The U.S. FDA granted our WRO meeting request but clarified that they viewed the meeting as a Type C meeting because it encompasses an entirely new drug development program, including Phase I PK study and Phase III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> made from API<FONT CLASS="nobreak">-2</FONT>, which the U.S. FDA characterizes as a new product with a new active pharmaceutical ingredient.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">The Company provided its proposed additional Phase III study protocol and Phase I PK study synopsis using API<FONT CLASS="nobreak">-2</FONT> on December<FONT CLASS="nobreak"> </FONT>12, 2023, for the U.S. FDA to review and approve the acceptability of the study design. The U.S. FDA sent us written responses on February<FONT CLASS="nobreak"> </FONT>23, 2024, which included comments on the revisions in the Phase III protocol and asked for the SAP (statistical analysis plan) for the Phase&#x00a0;III protocol. The U.S. FDA also asked the Company to develop the protocol for the PK study from the submitted synopsis. The Company is following the U.S. FDA&#x2019;s requirements in each respect. In addition, we will need to perform studies demonstrating that the source of API<FONT CLASS="nobreak">-2</FONT> is sufficiently similar botanical drug substance. We plan to request a meeting with U.S. FDA to discuss their concerns regarding the CMC data separately and by providing to U.S. FDA more analytical testing for the API<FONT CLASS="nobreak">-2</FONT> for the U.S. FDA to assess whether API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">If our new Phase I PK and Phase III studies are successful and we address the other deficiencies the U.S. FDA has previously identified (including clinical, pharmacological, statistical, pharmaceutical manufacturing, validation, and other issues), we plan to resubmit our NDA for MCS<FONT CLASS="nobreak">-2</FONT> under the same NDA number to the U.S. FDA. The resubmission timeline is unclear at this point, depending on the comments from the U.S. FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">BPH/LUTS is the most common urinary tract disease in the middle<FONT CLASS="nobreak">-aged</FONT> male population. According to Frost&#x00a0;&amp; Sullivan, the global prevalence of BPH increased from 88.4&#x00a0;million in 2017 to 94.2&#x00a0;million in 2020, representing an increase of 6.5%. The global BPH drugs market increased from US$3.7&#x00a0;billion in 2017 to US$4.1&#x00a0;billion in 2020, representing a CAGR of 4.6%. We are establishing a strong sales and marketing team that is expected to consist of employees with rich experience in relevant areas and our target markets, and plan to work with both domestic and international business partners to seize market opportunities and to help more patients reduce their distress caused by BPH/LUTS and drug side effects caused by chemical drugs.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PCP:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>PCP is our new botanical drug candidate developed for the prevention of prostate cancer. PCP, like MCS<FONT CLASS="nobreak">-2</FONT>, contains patented active pharmaceutical ingredients derived from botanical raw materials, specifically, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Lycopersicon esculetum L</FONT>. PCP contains, in the largest concentrations, five carotenoids including lycopene, phytoene, phytofluene, tocopherol and beta<FONT CLASS="nobreak">-carotene</FONT>. PCP and MCS<FONT CLASS="nobreak">-2</FONT> are essentially the same in terms of active ingredients, dosage form, strength and route of administration; however, they are different drug candidates targeting different indications. Our PCP Phase II study enrollment and treatment phase using API<FONT CLASS="nobreak">-1</FONT> is in the source data verifications (&#x201c;SDV&#x201d;) stage, which may take an additional year or more to complete. After completion of the SDV stage, we will conduct the necessary statistical analysis. While PCP is still in the SDV stage, we are working with the U.S. FDA to establish the comparability of the API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. To date, we have not had any discussions with the TFDA regarding the unavailability of API<FONT CLASS="nobreak">-1</FONT>. We will discuss the statistical results of the PCP using API<FONT CLASS="nobreak">-2</FONT> with Taiwan regulator and proceed with the Phase III PCP study if the U.S. FDA accepts such results and determines that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable. The PCP shall not proceed to Phase III until the U.S. FDA accepts the results and determines that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable. Based on our prior communications with the TFDA, the Chemistry, Manufacturing, and Controls (&#x201c;CMC&#x201d;) and study design for the product are consistent between the U.S. and Taiwan, encompassing two pivotal studies and two open<FONT CLASS="nobreak">-label</FONT> extension studies. The protocol for the Phase III clinical trials was approved by the U.S. FDA in December 2009 and subsequently approved by the TFDA in February 2010. Therefore, we believe the TFDA will give due consideration to the comments provided by the U.S. FDA.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:8pt;">We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA. As of this date, the Company is still in the process of providing the information required by the U.S. FDA and has not yet successfully demonstrated the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">6</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:8pt;">We are currently collaborating with a supplier to prepare the API<FONT CLASS="nobreak">-2</FONT> CMC documents required by the U.S. FDA. Should the FDA concur that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API<FONT CLASS="nobreak">-2</FONT>. If the U.S. FDA does not agree that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, we will continue to research additional API sources based on our own patent, to pursue additional outsourcing API vendors, and to follow U.S. FDA&#x2019;s guidance for demonstrating comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> to the U.S. FDA&#x2019;s satisfaction. In the event that we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be required to repeat the PCP clinical trials using API<FONT CLASS="nobreak">-2</FONT>. For further details, see the risk factor titled &#x201c;<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs</FONT>&#x201d; on page 31.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;margin-top:6pt;text-indent:0pt;margin-top:6pt;">Prostate cancer begins when cells in the prostate gland start to grow out of control. In general, the more quickly prostate cells grow and divide, the more chances there are for mutations to occur. According to Frost&#x00a0;&amp; Sullivan, the global prevalence of prostate cancer increased from 10.0&#x00a0;million in 2017 to 11.2&#x00a0;million in 2020, representing a CAGR of 3.9%. The global prostate cancer market increased from US$9.7&#x00a0;billion in 2017 to US$12.6&#x00a0;billion in 2019, representing a CAGR of 9.1%. In addition, the prostate<FONT CLASS="nobreak">-specific</FONT> antigen abnormal population, or PSA abnormal population, representing men over 40&#x00a0;years old with a prostate<FONT CLASS="nobreak">-specific</FONT> antigen test value of 4.0 ng/ml or higher, is exposed to a high risk of prostate cancer. From 2015 to 2020, the total number of PSA abnormal populations in the U.S., Taiwan and China increased from 5.0&#x00a0;million to 5.3&#x00a0;million.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">IC:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Interstitial Cystitis (IC) is our additional key new botanical drug candidate which is composed of polysorbate loaded micelles as nanocarriers which could be used in intravenous injection and intravesical instillation. IC may be a candidate for treatment of certain bladder pain symptoms. </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;margin-top:5pt;text-indent:0pt;margin-top:5pt;">IC/BPS, refers to interstitial cystitis and bladder pain symptoms that is often associated with voiding symptomatology and other systemic chronic pain disorders.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">We incurred research and development expenses of approximately US$1.3<FONT CLASS="nobreak"> </FONT>million, US$1.1<FONT CLASS="nobreak"> </FONT>million, and US$0.5<FONT CLASS="nobreak"> </FONT>million for the years ended December&#x00a0;31, 2022 and 2023, and the six months ended June<FONT CLASS="nobreak"> </FONT>30, 2024, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">The accompanying financial statements in this prospectus have been prepared in accordance with accounting principles generally accepted in the United States of America on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Accordingly, the financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should we be unable to continue as a going concern. We concluded that there is substantial doubt about our ability to continue as a going concern for a period of one year from the date that these unaudited interim consolidated financial statements are issued. In addition, our independent registered public accounting firm has issued a report that included an explanatory paragraph referring to our significant net losses, working capital deficit and need to raise additional funds, which also raised substantial doubt about our ability to continue as a going concern as it noted.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">As of the date of this prospectus, we have not generated revenue and we had a net working capital deficit of approximately US$12.5<FONT CLASS="nobreak"> </FONT>million and US$11.7<FONT CLASS="nobreak"> </FONT>million as of December<FONT CLASS="nobreak"> </FONT>31, 2023 and June<FONT CLASS="nobreak"> </FONT>30, 2024, respectively. This deficit included accrued expenses of approximately US$1.1<FONT CLASS="nobreak"> </FONT>million and US$0.9<FONT CLASS="nobreak"> </FONT>million, accounts payable of approximately US$2,000 and US$9,000, short<FONT CLASS="nobreak">-term</FONT> and long<FONT CLASS="nobreak">-term</FONT> loan from banks of approximately US$8.0<FONT CLASS="nobreak"> </FONT>million and US$7.5<FONT CLASS="nobreak"> </FONT>million, which will be due within the next twelve months, other current liabilities of approximately US$5.0<FONT CLASS="nobreak"> </FONT>million and US$3.1<FONT CLASS="nobreak"> </FONT>million due to litigation with Taizhou Bay New District Administrative Committee and commitments with Taizhou Resources Bureau, and accrued interest owed under the loan agreement with related parties of approximately US$0.1<FONT CLASS="nobreak"> </FONT>million and US$0.1<FONT CLASS="nobreak"> </FONT>million as of December<FONT CLASS="nobreak"> </FONT>31, 2023 and June<FONT CLASS="nobreak"> </FONT>30, 2024, respectively. We will return back land using right to the Taizhou Resource Bureau, according to the notification it has issued to us on September<FONT CLASS="nobreak"> </FONT>26, 2024, and $2.9<FONT CLASS="nobreak"> </FONT>million of the land idling fee will be waived by the Taizhou Resource Bureau. As a result, $2.9<FONT CLASS="nobreak"> </FONT>million of other current liabilities due to comments with Taizhou Resources Bureaus will be reversed when we return land using right to the Taizhou Resource Bureau. If we are unable to complete the offering for a sufficient amount in a timely manner, we may need to seek other financing alternatives such as private financing of debt or equity or collaboration agreements. We will seek future funding based on the requirements of our business operations until we obtain regulatory approvals to market and commercialize our drug candidates and generate sufficient revenue from them. We have the ability to exercise discretion and flexibility to deploy our capital resources used in research and development activities according to the amount and timing of our financing activities.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">7</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We cannot guarantee that we are able to obtain future financing in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to: </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>significantly delay, scale back or discontinue the development or commercialization of our product candidates; </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>seek corporate partners for our product candidates when we would otherwise develop our product candidates on our own, or at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>relinquish or license on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves; or </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>significantly curtail or cease operations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing development and commercialization efforts, which will have a material and adverse effect on our business, operating results and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">As of the date of this prospectus, only two botanical drug products have received the U.S. FDA&#x2019;s approval for marketing as prescription drugs. The U.S. FDA has not approved any botanical drug products since 2012. The quality control of botanical drug products is very complex due to the variability of botanical raw material and the need to demonstrate that the therapeutic effect for the tested botanical drug product batches is the targeted constituent (or constituents in the aggregate). It is challenging to ensure batch</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">-to-batch</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;"> consistency, which must be demonstrated to obtain U.S. FDA approval. Minor changes in geographical location of the API source or the manufacturing process can result in meaningful differences in clinical effects and may mean that earlier developed pharmacological, nonclinical and clinical data no longer apply to the changed product. If we are unable to obtain the U.S. FDA&#x2019;s approval for marketing our drug candidates, or if we experience significant delays in doing so, our business could be materially and adversely affected.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OUR STRENGTHS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We believe the following strengths have contributed to our success and differentiate us from others:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Innovative new drug candidate developed for BPH/LUTS;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Diverse drug portfolio and pipeline drug candidates focusing on the treatment of urinary system diseases;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Leading R&amp;D, experiences, capabilities and proprietary platform for any new indications of innovative botanical drugs, expediting successful opportunities for new indications;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Integrated in<FONT CLASS="nobreak">-house</FONT> capabilities that well position us for pharmaceutical innovation from bench to bedside, along with our cooperation with major pharmaceutical companies worldwide; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Visionary and experienced management and R&amp;D team with extensive industry expertise in the new drug application (NDA) process.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Phase III experience to accelerate for the collaboration with pharmaceutical companies.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">OUR WEAKNESS</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We believe that our various weakness could have negative influence on our business, including but not limited to the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>All of our drug candidates are still in the clinical trial stages and have not yet reached the commercialization stage;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our current botanical drug candidates only mainly focus on the treatment of urinary system diseases;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our business is highly dependent on obtaining marketing approval for or successfully commercializing our core drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We may not succeed in the market with substantial competition and rapid technological change.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">8</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OUR STRATEGIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We aim to execute the following business strategies:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Advance the clinical development of our core drug candidate MCS<FONT CLASS="nobreak">-2</FONT> to seek regulatory approval and achieve commercialization in our target markets;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Leverage differentiated approaches to advance our development of other drug candidates, such as PCP, IC and other new small molecule drugs, toward regulatory approvals;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Establish and enhance integrated launch capabilities and strategically build commercial infrastructure customized to each of our drug candidates; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Continue to deepen our pipeline in existing therapeutic areas with new drugs that fit with our expertise, portfolio and strategy.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CORPORATE STRUCTURE</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Corporate Structure</FONT></P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The following diagram sets forth our corporate structure prior to the initial offering:</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><IMG ALT="" SRC="tflow_001.jpg" STYLE="width:590.08px;max-width:100%;"></P>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>No single shareholder among &#x201c;other shareholders&#x201d; beneficially owns more than 5% of our ordinary shares.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Holding Company Structure</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We are a holding company with no business operations of our own and a substantial portion of our assets are located in Taiwan. We conduct all of our operations through our five wholly owned subsidiaries, including Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd. and Genvace Biotechnology Co., Ltd. in Taiwan, Jyong Biotech International Pte. Ltd. in Singapore, Top ShunXing Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Limited in Hong Kong, and Innovative Biotech Co., Ltd. in the PRC, among which Jyong holds the equity interests in its PRC subsidiary through its subsidiary incorporated in Hong Kong. As a result, our ability to pay dividends and to service any debt we may incur overseas largely depends upon dividends paid by our subsidiaries. If our subsidiaries incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Jyong is not prohibited under the laws of the Cayman Islands to provide funding to our subsidiaries through capital contributions or loans, and there are currently no restrictions on transferring funds between our Cayman Islands holding company and subsidiaries in Singapore and Hong&#x00a0;Kong. Our ability to make loans and additional capital contribution to our Taiwan and PRC subsidiaries might be restricted by Taiwan and PRC laws and regulations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In the normal course of our business, Jyong would evaluate the financial condition and capital needs of our subsidiaries periodically and then provide funding for their operations via equity investments and intercompany loans. As of December<FONT CLASS="nobreak"> </FONT>31, 2023 and June<FONT CLASS="nobreak"> </FONT>30, 2024, we have provided US$14.5&#x00a0;million to our Hong&#x00a0;Kong subsidiary for acquiring the patent owned by our Taiwan subsidiary via intercompany loans, and we have also provided US$5,000 to </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">9</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">our Hong&#x00a0;Kong subsidiary via capital contribution. Our Hong&#x00a0;Kong subsidiary borrowed approximately US$2.4&#x00a0;million from third parties to invest in our PRC subsidiary via capital contribution. No other transfer of cash or other types of asset transfers has been made between our Cayman Islands holding company and subsidiaries as of the date of this prospectus.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Our subsidiaries outside of China and Taiwan are permitted, under the respective laws of Singapore and Hong&#x00a0;Kong, to provide funding to Jyong through dividend distribution without restrictions on the amount of the funds. Under Taiwan laws and regulations, there are no restrictions on providing funding to Jyong through dividend distribution except for the withholding tax. Pursuant to the Taiwan Income Tax Act, a withholding tax rate of up to 21% will be applicable to dividends payable by Taiwanese companies to non<FONT CLASS="nobreak">-Taiwan</FONT><FONT CLASS="nobreak">-resident</FONT> enterprises. Our PRC subsidiary has no operations and generates no revenue as of the date of this prospectus, but should it generate revenue in the future, its ability to distribute dividends to us will be limited by foreign exchange restrictions. In addition, restrictions on currency exchanges in China may limit our ability to freely convert Renminbi to fund any future business activities outside China or other payments in U.S.&#x00a0;dollars, and capital control measures imposed by the Chinese government may limit our ability to use capital from our PRC subsidiary for business purposes outside of China. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service<FONT CLASS="nobreak">-related</FONT> foreign exchange transactions, cannot be made in currencies other than Renminbi without complying with certain procedural requirements of the State Administration of Foreign Exchange, or SAFE.&#x00a0;Specifically, approval from or registration with appropriate government authorities is required where Renminbi is to be converted into another currency and remitted out of China to pay capital expenses, such as the repayment of loans denominated in currencies other than Renminbi. As a result, we may need to obtain SAFE approval to use cash generated from the operations of our PRC subsidiary to pay off its debt in a currency other than Renminbi owed to entities outside China, or to make other capital expenditure payments outside China in a currency other than Renminbi. On the other hand, the PRC Enterprise Tax Law (&#x201c;EIT Law&#x201d;) and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by Chinese companies to non<FONT CLASS="nobreak">-PRC</FONT><FONT CLASS="nobreak">-resident</FONT> enterprises unless otherwise exempted or reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the non<FONT CLASS="nobreak">-PRC</FONT><FONT CLASS="nobreak">-resident</FONT> enterprises are incorporated. As of the date of this prospectus, we have not received, nor do we have any present plan to receive dividends paid by our Singapore, Taiwan, Hong&#x00a0;Kong and PRC subsidiaries.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As of the date of this prospectus, we did not adopt any specific cash management policies and procedures in relation to how funds are transferred within/through our group. Our management monitors the cash position of each entity within our group regularly on a monthly basis. In the event that there is a need for cash or a potential short<FONT CLASS="nobreak">-term</FONT> cashflow shortage, it would be reported to our chief financial officer and, subject to the approval by our board of directors, we will enter into an intercompany loan arrangement for relevant subsidiary. Other than the above, we did not adopt or maintain any cash management policies and procedures as of the date of this prospectus.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our Board of Directors has discretion as to whether to distribute dividends, subject to certain requirements of Cayman Islands law. As of the date of this prospectus, we have not paid and do not have any present plan to declare or pay any dividends in the foreseeable future. We currently intend to retain most of our available funds and any future earnings to fund the development and growth of our business. See &#x201c;Risk Factors&#x00a0;&#x2014;&#x00a0;Risks Related to Our Ordinary Shares and This Offering&#x00a0;&#x2014;&#x00a0;Because we do not expect to pay dividends in the foreseeable future after this offering, you must rely on price appreciation of our ordinary shares for return on your investment.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:7pt;margin-top:7pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CORPORATE INFORMATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We were incorporated on January&#x00a0;26, 2018 as an exempted company limited by shares under the laws of Cayman Islands. Our registered office is located at 4<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> Floor, Harbour Place, 103 South Church Street, George Town, P.&#x00a0;O. Box 10240, Grand Cayman KY1 1002, Cayman Islands. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our principal executive offices of our operating subsidiaries are located at 23F<FONT CLASS="nobreak">-3</FONT>, No.<FONT CLASS="nobreak"> </FONT>95, Section&#x00a0;1, Xintai 5<FONT CLASS="CharOverride-5" STYLE="font-size:58%;vertical-align:super;">th</FONT> Road, Xizhi District, New Taipei City, Taiwan, 221.&#x00a0;Our telephone number at this address is +886<FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak">2-2732-5205</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our agent for service of process in the United&#x00a0;States is Cogency Global Inc. located at 122 East 42<FONT CLASS="CharOverride-5" STYLE="font-size:58%;vertical-align:super;">nd</FONT> Street, 18<FONT CLASS="CharOverride-5" STYLE="font-size:58%;vertical-align:super;">th</FONT> Floor, New York, NY 10168.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Investors should contact us for any inquiries through the address and telephone number of our principal executive office. Our principal website is <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">https:</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">//</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">www.healtheverbiotech.com</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">/</FONT>. The information contained on our website is not a part of this prospectus.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">10</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">IMPLICATIONS OF BEING AN EMERGING GROWTH COMPANY</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As a company with less than US$1.235&#x00a0;billion in revenue for our last fiscal year, we qualify as an &#x201c;emerging growth company&#x201d; pursuant to the Jumpstart Our Business Startups Act&#x00a0;of&#x00a0;2012, as amended, or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements compared to those that are otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation requirement under Section&#x00a0;404 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act&#x00a0;of&#x00a0;2002, or Section&#x00a0;404, in the assessment of the emerging growth company&#x2019;s internal control over financial reporting. The JOBS Act also provides that an emerging growth company does not need to comply with any new or revised financial accounting standards until such date that a private company is otherwise required to comply with such new or revised accounting standards. We have elected to take advantage of such exemptions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We will remain an emerging growth company until the earliest of (i)&#x00a0;the last&#x00a0;day of the fiscal year during which we have total annual gross revenue of at least US$1.235&#x00a0;billion; (ii)&#x00a0;the last&#x00a0;day of our fiscal year following the fifth anniversary of the completion of this offering; (iii)&#x00a0;the date on which we have, during the preceding three<FONT CLASS="nobreak">-year</FONT> period, issued more than US$1.0&#x00a0;billion in non<FONT CLASS="nobreak">-convertible</FONT> debt; or (iv)&#x00a0;the date on which we are deemed to be a &#x201c;large accelerated filer&#x201d; under the Securities Exchange&#x00a0;Act&#x00a0;of&#x00a0;1934, as amended, or the Exchange&#x00a0;Act, which would occur if the market value of the ordinary shares that are held by non<FONT CLASS="nobreak">-affiliates</FONT> exceeds US$700&#x00a0;million as of the last business&#x00a0;day of our most recently completed second fiscal quarter. Once we cease to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">IMPLICATIONS OF BEING A FOREIGN PRIVATE ISSUER</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are also considered a &#x201c;foreign private issuer.&#x201d; Accordingly, upon consummation of this offering, we will report under the Exchange&#x00a0;Act as a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;company with foreign private issuer status. This means that, even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange&#x00a0;Act, we will be exempt from certain provisions of the Exchange&#x00a0;Act that are applicable to U.S.&#x00a0;domestic public companies, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the sections of the Exchange&#x00a0;Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange&#x00a0;Act;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the sections of the Exchange&#x00a0;Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the rules under the Exchange&#x00a0;Act requiring the filing with the SEC of quarterly reports on Form&#x00a0;10<FONT CLASS="nobreak">-Q</FONT> containing unaudited financial and other specified information, or current reports on Form&#x00a0;8<FONT CLASS="nobreak">-K</FONT>, upon the occurrence of specified significant events.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S.&#x00a0;residents and any of the following three circumstances applies: (i)&#x00a0;the majority of our executive officers or directors are U.S.&#x00a0;citizens or residents, (ii)&#x00a0;more than 50% of our assets are located in the United&#x00a0;States or (iii)&#x00a0;our business is administered principally in the United&#x00a0;States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">In this prospectus, we have taken advantage of certain of the reduced reporting requirements as a result of being an emerging growth company and a foreign private issuer. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold equity securities.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CONVENTIONS THAT APPLY TO THIS PROSPECTUS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except otherwise indicated or the context otherwise requires:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;CAGR&#x201d; refers to compound average growth rate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;China&#x201d; or the &#x201c;PRC&#x201d;, in each case, refers to the People&#x2019;s Republic of China, excluding, for the purpose of this prospectus only, Hong&#x00a0;Kong, Macau and Taiwan. The term &#x201c;Chinese&#x201d; has a correlative meaning for the purpose of this prospectus. When used in the case of laws and regulations, of &#x201c;China&#x201d; or &#x201c;the PRC&#x201d;, it refers to only such laws and regulations of mainland China;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;EIT&#x201d; refers to enterprise income tax;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">11</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;Hong&#x00a0;Kong&#x201d; refers to Hong&#x00a0;Kong Special Administrative Region in the PRC;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;HKD&#x201d; refers to the legal currency of Hong&#x00a0;Kong;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;mu&#x201d; refers to a Chinese unit of area, which equals to approximately 666.7 square meters;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;NTD&#x201d; refers to the legal currency of Taiwan;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;ordinary shares&#x201d; or &#x201c;shares&#x201d; prior to the completion of this offering refer to our ordinary shares of par value US$0.00001 per share, and upon and after the completion of this offering are to our ordinary shares;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;P value&#x201d; refers to a statistical measurement used to validate a hypothesis against observed data. The lower the P value, the greater the statistical significance of the observed difference. A P value of 0.05 or lower is generally considered statistically significant;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;R&amp;D&#x201d; refers to research and development;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;RMB&#x201d; and &#x201c;Renminbi&#x201d; refer to the legal currency of China;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;R value&#x201d; refers to the ratio of intrinsic clearance values of a probe substrate for an enzymatic pathway in the absence of the potential inducing drug versus in the presence of the potential inducing drug in vitro drug<FONT CLASS="nobreak">-drug</FONT> interaction study and was calculated using the following equation: </P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;text-align:center;margin-top:5pt;"><IMG ALT="" SRC="tformula_001.jpg" STYLE="width:176.64000000000001px;max-width:100%;"></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:8pt;">where <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">d</FONT> is a scaling factor that is assumed as 1; <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">EC</FONT><FONT CLASS="Subscript" STYLE="vertical-align:sub;font-size:58%;">50</FONT> is the concentration causing half maximal effect; <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">E</FONT><FONT CLASS="Subscript" STYLE="vertical-align:sub;font-size:58%;">max</FONT> is the maximum induction effect; [<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">I</FONT>] is the concentration of BDS component D in serum; <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">w</FONT><FONT CLASS="Italic-Subscript" STYLE="font-style:italic;font-weight:normal;vertical-align:sub;font-size:58%;">D</FONT> is the percentage of component D in BDS.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;SEC&#x201d; refers to the Securities and Exchange Commission;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;Taiwan&#x201d; refers to Taiwan, Republic of China.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;TFDA&#x201d; refers to the Food and Drug Administration, Ministry of Health and Welfare, the Republic of China;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;US$&#x201d; and &#x201c;U.S.&#x00a0;dollars&#x201d; refer to the legal currency of the United&#x00a0;States;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;U.S. FDA&#x201d; refers to the U.S.&#x00a0;Food and Drug Administration;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;U.S.&#x00a0;GAAP&#x201d; refers to generally accepted accounting principles in the United&#x00a0;States; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to Jyong Biotech Ltd., a Cayman Islands company and its subsidiaries.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise indicated, (a)&#x00a0;information in this prospectus assumes that the underwriters do not exercise their over<FONT CLASS="nobreak">-allotment</FONT> option to purchase additional ordinary shares, and (b)&#x00a0;references in this prospectus to this offering are to our offering of ordinary shares pursuant to this prospectus.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our reporting currency is U.S.&#x00a0;dollars. The functional currency of the Company&#x2019;s subsidiary located in Taiwan is NTD.&#x00a0;Unless otherwise noted, all translations from NTD to U.S.&#x00a0;dollars and from U.S.&#x00a0;dollars to NTD in this prospectus are made at a rate of NTD31.14 to US$1.00, the exchange rate in effect as of June<FONT CLASS="nobreak"> </FONT>30, 2023 as set forth in the H.10 statistical release of The Board of Governors of the Federal Reserve System. We make no representation that the NTD or U.S.&#x00a0;dollar amounts referred to in this prospectus could have been or could be converted into U.S.&#x00a0;dollars or NTD, as the case may be, at any particular rate or at all.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Internet site addresses in this prospectus are included for reference only and the information contained in any website, including our website, is not incorporated by reference into, and does not form part of, this prospectus.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">12</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MARKET AND INDUSTRY DATA</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">This prospectus contains estimates and information concerning our industry, including our market position and the size and growth rates of the markets in which we participate, that are based on industry publications and the reports. This prospectus contains statistical data and estimates published by Frost&#x00a0;&amp; Sullivan, an independent research firm, for which we paid a fee. This information involves a number of assumptions and limitations, and you are cautioned not to place undue reliance on these estimates. We have not independently verified the accuracy or completeness of the data contained in these industry reports. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the &#x201c;Risk Factors&#x201d; section. These and other factors could cause results to differ materially from those expressed in these publications and reports.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Industry publications, research, surveys, studies and forecasts generally state that the information they contain has been obtained from sources believed to be reliable. Forecasts and other forward<FONT CLASS="nobreak">-looking</FONT> information obtained from these sources are subject to the same qualifications and uncertainties as the other forward<FONT CLASS="nobreak">-looking</FONT> statements in this prospectus. These forecasts and forward<FONT CLASS="nobreak">-looking</FONT> information are subject to uncertainty and risk due to a variety of factors, including those described under &#x201c;Risk Factors.&#x201d; These and other factors could cause results to differ materially from those expressed in the forecasts or estimates from independent third parties and us.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RISK FACTORS SUMMARY</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">You should carefully consider the risks and uncertainties summarized below, the risks described under the &#x201c;Risk Factors&#x201d; section beginning on page 18. The risks described in &#x201c;Risk Factors&#x201d; in this prospectus may cause us to not realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our growth strategy. Some of the more significant risks include the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our business is highly dependent on the success of our core drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>. If we are unable to obtain marketing approval for or successfully commercialize MCS<FONT CLASS="nobreak">-2</FONT>, or if we experience significant delays in doing so, our business could be materially and adversely affected. (page 18)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We may allocate our limited resources to pursue a particular drug candidate, indication, or technology and fail to capitalize on existing or future drug candidates, indications or technologies that may later prove to be more profitable, or for which there is a greater likelihood of success. (page 19)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The U.S. FDA has rarely approved botanical drug products. If we are unable to obtain the U.S. FDA&#x2019;s approval for marketing our drug candidates, or if we experience significant delays in doing so, our business could be materially and adversely affected. (page 19)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The COVID<FONT CLASS="nobreak">-19</FONT> pandemic and any other pandemics could adversely impact our business including our ongoing and planned clinical trials and preclinical research. (page 20)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results. (page 22)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>All of our key drug candidates are in preclinical or clinical development. If we are unable to complete clinical development and obtain regulatory approval to ultimately commercialize our key drug candidates, or if we experience significant delays in doing so, our business, financial condition, results of operations and prospects will be materially harmed. (page 23)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>If we encounter delays or difficulties enrolling and retaining patients in our clinical trials, our clinical development progress and our receipt of necessary regulatory approvals could be delayed or otherwise materially adversely affected. (page 24)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>If clinical trials of our key drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates. (page 25)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our clinical trials are conducted in multiple jurisdictions, which may subject us to delays and expenses. (page 26)</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">13</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our drug candidates may be found to cause serious adverse, undesirable or unacceptable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, and/or result in significant negative consequences following regulatory approval, if any. (page 27)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The manufacture of our botanical drug products is a complex process which requires significant expertise and capital investment, and if we encounter problems in establishing our manufacturing capabilities for clinical or commercial scale or in the manufacture of our future products, our business could suffer. (page 28)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Changes in our drug candidates&#x2019; manufacturing or formulation may result in additional costs or delay. (page 28)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We have not yet obtained marketing approval for a drug candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for our drug candidates. (page 29)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Obtaining and maintaining regulatory approval of our drug candidates in one jurisdiction does not mean that we will be successful in obtaining or maintaining regulatory approval of our drug candidates in other jurisdictions. (page 29)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>If we are unable to identify a supplier capable of producing API<FONT CLASS="nobreak">-2</FONT> that is sufficiently comparable to API<FONT CLASS="nobreak">-1</FONT>, we will be required to repeat our clinical trials for MCS<FONT CLASS="nobreak">-2</FONT> and PCP, or to conduct other additional clinical trials as may be required by the U.S. FDA, which would significantly delay our product development and increase our costs.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Even if any of our drug candidates receives marketing approval, we or others may later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability, or that of any future collaborators, to market the product. (page 32)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, patient advocacy groups, third<FONT CLASS="nobreak">-party</FONT> payors and others in the medical community necessary for commercial success. (page 32)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We face substantial competition, rapid technological change and the possibility that our competitors may discover, develop or commercialize drugs before we do or more successfully than we do, or develop therapies that are similar, more advanced or more effective than ours, each of which may adversely affect our financial condition and our ability to successfully market or commercialize our drug candidate. (page 33)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Even if we are able to commercialize any approved drug candidates, reimbursement may be limited or unavailable in certain market segments for our drug candidates, and we may be subject to unfavorable pricing regulations, which could harm our business. (page 34)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The data and information that we gather in our research and development process could be inaccurate or incomplete, which may have negative influence on our business, reputation, financial condition and results of operations. (page 35)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The incidence and prevalence for target patient populations of our drug candidates are based on estimates and third<FONT CLASS="nobreak">-party</FONT> sources. The market opportunities for our drug candidates, if approved, may be smaller than we anticipate. (page 36)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We have been involved in legal proceedings in the ordinary course of our business, and are currently involved in active legal proceedings. Any adverse outcome of these legal proceedings could have a material adverse effect on our business, results of operations and financial condition. (page 37)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We face economic and political risks associated with doing business in Taiwan, particularly due to the geopolitical tension between Taiwan and PRC that could negatively affect our business and hence the value of your investment. (page 40)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We are required to comply with extensive regulations and hold a number of permits and licenses to carry on our business in Taiwan. Our ability to obtain and maintain these regulatory approvals is uncertain, and future government regulation may place additional burdens on our efforts to commercialize our drug candidates. (page 42)</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">14</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our future success depends on our ability to attract, retain and motivate senior management and qualified scientific employees. (page 43)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>If we do not achieve our projected development and commercialization goals in the timeframes we announced and expected, the commercialization of any of our drug candidates may be delayed and our business will be negatively influenced. (page 44)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Certain of our facilities were mortgaged. If the mortgagees enforce the mortgage, our business could be materially and adversely affected. (page 44)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>As we rely on third parties to conduct our clinical trials and provide other important services related to research and development, regulatory submissions, and commercialization, if we fail to maintain our relationships with these third parties or if they do not successfully carry out their contractual duties, comply with applicable laws, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed. (page 59)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>If we are unable to obtain and maintain patent and other intellectual property protection for our drug candidates, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, and our ability to successfully commercialize any product or technology may be adversely affected. (page 62)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non<FONT CLASS="nobreak">-compliance</FONT> with these requirements. (page 64)</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>If the TFDA, the U.S. FDA or comparable foreign regulatory authorities approve generic versions of any of our products that receive marketing approval, or such authorities do not grant our products appropriate periods of data exclusivity before approving generic versions of our products, the sales of our products could be materially and adversely affected. (page 64)</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">15</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T20"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">THE OFFERING</FONT></P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Offering Price per Ordinary Share</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">The assumed price range for this Offering is $7.50 to $8.50.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Ordinary Shares Offered by Us</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">2,352,941 ordinary shares (or 2,705,882 ordinary shares if the underwriters exercise in full their option to purchase additional ordinary shares).</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Ordinary Shares Outstanding Immediately Prior to the Completion of This Offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT><BR></FONT>73,361,000 ordinary shares.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Ordinary Shares Issued and Outstanding Immediately After This Offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT><BR></FONT>75,713,941 ordinary shares (or 76,066,882 ordinary shares if the underwriters exercise the option to purchase additional 352,941 ordinary shares in full).</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Over-Allotment Option</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">We have granted to the underwriters an option, exercisable for 45&#x00a0;days from the date of this prospectus, to purchase up to an aggregate of additional 352,941 ordinary shares at the initial public offering price, less underwriting discounts and commissions, solely for the purpose of covering over<FONT CLASS="nobreak">-allotments</FONT>.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Dividends</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">We do not expect to pay dividends in the foreseeable future.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Listing</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">We plan to have our ordinary shares listed on the Nasdaq Global Market under the symbol &#x201c;MENS.&#x201d; </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Transfer Agent</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Transhare Corporation</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Use of Proceeds</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">We estimate that we will receive net proceeds of approximately US$17,769 thousand from this offering, assuming an initial public offering price of US$8.50 per ordinary share, the upper end of the estimated range of the initial public offering price, after deducting estimated underwriter discounts, commissions and estimated offering expenses payable by us. We intend to primarily use our net proceeds from this offering for researching and developing new drugs and clinical trials. See &#x201c;Use of Proceeds&#x201d; for additional information.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Risk Factors</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Investing in these securities involves a high degree of risk. See &#x201c;Risk Factors&#x201d; and other information included in this prospectus for a discussion of the risks you should carefully consider before deciding to invest in our ordinary shares.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Lock-up</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Our directors and officers and holders of more than 5% of our outstanding shares as of the effective date of this registration statement will enter into customary lock<FONT CLASS="nobreak">-up</FONT> agreements in favor of the underwriters for a period of twelve (12)&#x00a0;months from the date of this offering. Our holders of less than 5% of our outstanding shares as of the effective date of this registration statement will enter into customary lock<FONT CLASS="nobreak">-up</FONT> agreements in favor of the underwriters for a period of six (6)&#x00a0;months from the closing of this offering.</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">16</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">We have agreed with the underwriters that, for a period of twelve (12)&#x00a0;months from the closing of this offering, we and any successors of us will not (a)&#x00a0;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of us or any securities convertible into or exercisable or exchangeable for shares of capital stock of us; (b)&#x00a0;file or caused to be filed any registration statement with the SEC relating to the offering of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock; or (c)&#x00a0;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our capital stock, whether any such transaction described in clause (a), (b)&#x00a0;or (c)&#x00a0;above is to be settled by delivery of shares of our capital stock or such other securities, in cash or otherwise. See &#x201c;Underwriting&#x201d; for more information.</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">17</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T19"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RISK FACTORS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Investing in the ordinary shares involves a high degree of risk. You should carefully consider the following</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> risks, as well as other information contained in this prospectus, before making an investment in our company. The risks discussed</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> below could materially and adversely affect our business, prospects, financial condition, results of operations,</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> cash flows, ability to pay dividends and the trading price of our ordinary shares. We may face additional risks and uncertainties</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> aside from the ones mentioned below. There may be risks and uncertainties that we are unaware of, or that we currently do not consider material,</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> that may become important factors that adversely affect our business in the future. Any of the following</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> risks and uncertainties could have a material adverse effect on our business, financial condition, results of operations</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> and ability to pay dividends. In such case, the market prices of the ordinary shares could decline and you may lose part</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> or all of your investment.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RISKS RELATED TO THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF OUR DRUG CANDIDATES</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our business is highly dependent on the success of our core drug candidate, MCS-2. If we are unable to obtain marketing approval for or successfully commercialize MCS-2, or if we experience significant delays in doing so, our business would expect to be materially and adversely affected.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We currently have no drug products that are approved for commercial sale. Compared with other companies that have multiple drug candidates in active development, our business and future success depends, in large parts, on our ability to obtain regulatory approval for, and then successfully commercialize our core drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>. If we cannot obtain approval for MCS<FONT CLASS="nobreak">-2</FONT>, which is the initial indication that we are currently exploring, we will have spent substantial time and financial resources without receiving a return on investment. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The success of MCS<FONT CLASS="nobreak">-2</FONT> will depend on several factors, including the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the successful completion of Phase I PK study and Phase III clinical trial to support marketing approval by the U.S. FDA and successfully addressing the deficiencies the U.S. FDA identified in our previous submissions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>timely receipt of marketing approvals from applicable regulatory authorities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the performance of our future collaborators, if any;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the extent of any required post<FONT CLASS="nobreak">-marketing</FONT> approval commitments to applicable regulatory authorities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>establishment of supply arrangements with third<FONT CLASS="nobreak">-party</FONT> raw materials suppliers;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in Taiwan, the U.S.&#x00a0;and internationally;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>protection of our rights in our intellectual property portfolio;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>successful launch of commercial sales following any marketing approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a continued acceptable safety profile following any marketing approval, and meeting all applicable post<FONT CLASS="nobreak">-market</FONT> commitments, obligations, and requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>commercial acceptance of our products, if approved, by patients, the medical community and third<FONT CLASS="nobreak">-party</FONT> payors; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to compete with other therapies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant delays or an inability to obtain regulatory approvals or commercialize MCS<FONT CLASS="nobreak">-2</FONT>. Even if regulatory approvals are obtained, we may not be able to successfully commercialize MCS<FONT CLASS="nobreak">-2</FONT> due to various factors beyond our control. Accordingly, we may not be able to generate sufficient revenue through the sale of MCS<FONT CLASS="nobreak">-2</FONT> to sustain our operations.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">18</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We may allocate our limited resources to pursue a particular drug candidate, indication, or technology and fail to capitalize on existing or future drug candidates, indications or technologies that may later prove to be more profitable, or for which there is a greater likelihood of success.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because we have limited financial and managerial resources, we intend to focus on developing drug candidates for specific indications that we identify as most likely to succeed, in terms of both their potential for marketing approval and commercialization. As a result, we may forgo or delay pursuit of opportunities with other drug candidates or for other indications or technologies that later may prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially viable drug candidates. In addition, if we do not accurately evaluate the commercial potential or target market for a particular drug candidate or technology, we may relinquish valuable rights to that drug candidate or technology through collaboration, licensing or other royalty arrangements when it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate or technology. For example, we are developing our core drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>, to initially treat BPH/LUTS.&#x00a0;We are also considering a number of additional indications for MCS<FONT CLASS="nobreak">-2</FONT>, including the potential to prevent prostate cancer. We cannot guarantee that the treatment of BPH/LUTS will be the most profitable indication for MCS<FONT CLASS="nobreak">-2</FONT> as opposed to other contemplated indications. This could result in us failing to capitalize on the true market potential of our core drug candidate in a timely manner or at all.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although a substantial amount of our efforts will focus on the continued clinical testing, potential approval, manufacturing and commercialization of our existing drug candidates, the success of our business depends, in part, upon our ability to identify, license, discover, develop, and commercialize additional drug candidates or new technologies. Research efforts to identify new drug candidates and technologies require substantial technical, financial, and human resources. Although we do not currently engage in such activities, we may in the future seek to expand our drug pipeline through in<FONT CLASS="nobreak">-licensing</FONT> arrangements. We may end up focusing our efforts and resources on potential drug candidates and technologies that ultimately prove to be unsuccessful. Our research and any future licensing efforts may fail to identify, discover or in<FONT CLASS="nobreak">-license</FONT> new drug candidates and technologies suitable for clinical development and commercialization for a number of reasons, including, but not limited to, the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our research or business development methodology or search criteria and process may be unsuccessful in identifying potential drug candidates and technologies, or potential drug candidates and technologies that are within our resources to license or acquire and develop;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our potential drug candidates and technologies may be shown to have adverse effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>it may take greater human, financial and/or research resources to identify additional therapeutic opportunities for our drug candidates or to develop more suitable potential drug candidates and technologies than what we possess, thereby limiting our ability to diversify and expand our drug portfolio.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, there can be no assurance that we will successfully identify and develop new drug candidates or technologies, or additional therapeutic opportunities for our drug candidates, whether through internal research or future licensing efforts, which could materially and adversely affect our future growth and prospects.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The U.S. FDA has rarely approved botanical drug products. If we are unable to obtain the U.S. FDA&#x2019;s approval for marketing our drug candidates, or if we experience significant delays in doing so, our business could be materially and adversely affected. </FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, only two botanical drug products have received the U.S. FDA&#x2019;s approval for marketing as prescription drugs: (i) Veregen which contains the drug substance sinecatechins, which is a partially purified fraction of the water extract of green tea leaves from <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Camellia sinensis (L.) O Kuntze</FONT> and is indicated for the treatment of genital and perianal warts, and (ii) Mytesi which is a proanthocyanidin oligomer indicated to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy and is derived from the red latex of <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Croton lechleri M&#x00fc;ll. Arg</FONT>. The U.S. FDA has not approved any botanical drug products since 2012.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">19</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The quality control of botanical drug products is very complex due to the variability of botanical raw material and the need to ensure that the therapeutic effect for botanical drug product batches is consistent. It is challenging to ensure batch<FONT CLASS="nobreak">-to-batch</FONT> consistency, which must be demonstrated to obtain U.S. FDA approval. Minor changes in API source or the manufacturing process can result in meaningful difference in clinical effects and may mean that earlier developed pharmacological, nonclinical and clinical data no longer apply to the changed product.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We cannot predict the time required to secure all appropriate regulatory approvals or the extent of testing and documentation that may be required by governmental authorities, in particular, to obtain the approval for a botanical drug product from the U.S. FDA. Any delays in obtaining, or failure to obtain, regulatory approvals would significantly delay the development of markets and products and would have a material adverse effect on our business, results of operations and financial condition.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The COVID-19 pandemic and the monkeypox outbreak would adversely impact our business including our ongoing and planned clinical trials and preclinical research.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Over two&#x00a0;years after the World Health Organization declared the COVID<FONT CLASS="nobreak">-19</FONT> a pandemic, it continues to impact worldwide economic activity and financial markets. Variants of COVID<FONT CLASS="nobreak">-19</FONT> have caused and may continue to cause waves of increased infections. As a result of measures imposed by the governments in affected regions, many commercial activities, businesses and schools were affected by quarantines and other measures intended to contain the pandemic and subsequent variants of the COVID<FONT CLASS="nobreak">-19</FONT> virus. The extent to which the COVID<FONT CLASS="nobreak">-19</FONT> pandemic ultimately impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of any outbreak, including current and subsequent variants of COVID<FONT CLASS="nobreak">-19</FONT>, travel restrictions and social distancing in Taiwan and other countries, business closures or business disruptions, and the effectiveness of actions taken in Taiwan and other countries to contain and treat the disease and to address its impact, including on financial markets or otherwise. Since early May&#x00a0;2022, cases of monkeypox have been reported from countries where the disease is not endemic, and continue to be reported in several endemic countries. Most confirmed cases with travel history reported travel to countries in Europe and North America, rather than West or Central Africa where the monkeypox virus is endemic. In July 2022, WHO declared the monkeypox outbreak a global health emergency. As the COVID<FONT CLASS="nobreak">-19</FONT> pandemic and the monkeypox outbreak continue, we may experience disruptions that could severely impact our business, current and planned clinical trials and preclinical research, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays or difficulties in enrolling and retaining subjects, including elderly subjects, who are at a higher risk of severe illness or death from COVID<FONT CLASS="nobreak">-19</FONT> and monkeypox, in our ongoing clinical trials and our future clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays or difficulties in clinical site initiation, including due to difficulties in staffing and recruiting at clinical sites;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>difficulties interpreting data from our clinical trials due to the possible effects of COVID<FONT CLASS="nobreak">-19</FONT> and monkeypox on subjects;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>limitations in resources, including our employees, that would otherwise be focused on the conduct of our business or our current or planned clinical trials or preclinical research, including because of sickness, the desire to avoid contact with large groups of people, or restrictions on movement or access to our facility as a result of government<FONT CLASS="nobreak">-imposed</FONT> &#x201c;shelter in place&#x201d; or similar working restrictions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>interruptions, difficulties or delays arising in our existing operations and company culture as a result of some or all of our employees working remotely, including those hired during the COVID<FONT CLASS="nobreak">-19</FONT> pandemic and the monkeypox outbreak;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays in receiving approval from regulatory authorities to initiate our clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>interruptions in our preclinical studies due to restricted or limited operations;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">20</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>interruptions or delays in the operations of the TFDA, the U.S. FDA or other foreign regulatory authorities, which may impact review and approval timelines;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays in receiving the supplies, materials and services needed to conduct clinical trials and preclinical research;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>changes in regulations as part of a response to the COVID<FONT CLASS="nobreak">-19</FONT> pandemic and the monkeypox outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs or require us to discontinue the clinical trial altogether;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>interruptions or delays to our development pipeline;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>refusal of the TFDA or the U.S. FDA to accept data from clinical trials in affected geographies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The COVID<FONT CLASS="nobreak">-19</FONT> pandemic and any other pandemic or outbreak may continue to pose a threat on our ability to effectively conduct our business operations as planned. There can be no assurance that we will avoid a material impact on our business from the spread of COVID<FONT CLASS="nobreak">-19</FONT> and monkeypox or its consequences, including disruption to our business and downturns in business sentiment generally or in our industry or due to shutdowns that may be requested or mandated by federal, state and local governmental authorities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Additionally, certain third parties with whom we engage or may engage, including collaborators, suppliers, clinical trial sites, regulators and other third parties are similarly adjusting their operations and assessing their capacity in light of the COVID<FONT CLASS="nobreak">-19</FONT> pandemic and the monkeypox outbreak. If these third parties experience shutdowns or continued business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. For example, as a result of the COVID<FONT CLASS="nobreak">-19</FONT> pandemic, there could be delays in the procurement of materials or manufacturing supply chains for one or more of our drug candidates, which could delay or otherwise impact our preclinical studies and our planned clinical trials. It is also likely that the disproportionate impact of the COVID<FONT CLASS="nobreak">-19</FONT> pandemic or the monkeypox outbreak on hospitals and clinical sites will have an impact on recruitment and retention for our planned clinical trials. We may also be required to make certain adjustments to the operation of clinical trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the TFDA and the U.S. FDA.&#x00a0;We may need to make further adjustments in the future that could impact the timing or enrollment of our clinical trials. Many of these adjustments are new and untested, may not be effective, may increase costs and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials. While we are currently continuing our clinical trials and preclinical studies, we may experience delays in the completion of our clinical trials, preclinical activities and subject enrollment, may need to suspend our clinical trials and may encounter other negative impacts to such trials due to the effects of the COVID<FONT CLASS="nobreak">-19</FONT> pandemic and the monkeypox outbreak.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Further, as a result of the COVID<FONT CLASS="nobreak">-19</FONT> pandemic and any other pandemic or outbreak, we may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the COVID<FONT CLASS="nobreak">-19</FONT> pandemic and the monkeypox outbreak, which may include using telemedicine visits, remote monitoring of subjects and clinical sites and measures to ensure that data from clinical trials that may be disrupted as a result of the COVID<FONT CLASS="nobreak">-19</FONT> pandemic or the monkeypox outbreak are collected pursuant to the study protocol and consistent with clinical research practices. Subjects who may miss scheduled appointments, any interruption in study drug supply, or other consequences that may result in incomplete data being generated during a clinical trial as a result of the pandemic must be adequately documented and justified. For example, in March&#x00a0;2020, the U.S.&#x00a0;FDA issued a guidance, which the U.S. FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the trial, and any disruption of the trial as a result of the COVID<FONT CLASS="nobreak">-19</FONT> pandemic; a list of all subjects affected by the COVID<FONT CLASS="nobreak">-19</FONT> pandemic related study disruption by unique subject identifier and by investigational site and a description of how the individual&#x2019;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the clinical trial. In June&#x00a0;2020, the U.S. FDA also issued a guidance on good manufacturing practice considerations for responding to COVID<FONT CLASS="nobreak">-19</FONT> infection in employees in drug product manufacturing, including recommendations for manufacturing controls to prevent contamination of drugs.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">21</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Since December 2022, many of the restrictive measures previously adopted by the PRC government at various levels to control the spread of the COVID<FONT CLASS="nobreak">-19</FONT> virus have been revoked or replaced with more flexible measures. As a result, there has recently been and may continue to be an increase in COVID<FONT CLASS="nobreak">-19</FONT> cases in China, which may lead to temporary interruptions to business operations. There remain significant uncertainties surrounding the COVID<FONT CLASS="nobreak">-19</FONT> outbreak, including with respect to the ultimate spread of the virus, the severity and duration of the pandemic and the further actions government authorities may take in response. While it is unknown how long these conditions will last and what the complete financial effect will be on us, we are closely monitoring the impact of COVID<FONT CLASS="nobreak">-19</FONT>. Our business, results of operations, financial condition and prospects could be materially adversely affected to the extent that COVID<FONT CLASS="nobreak">-19</FONT> harms the Chinese and global economy in general.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">To the extent the COVID<FONT CLASS="nobreak">-19</FONT> pandemic and the monkeypox outbreak adversely affect our business and financial results, it may also have the effect of heightening many of the other risks described in this section.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">There is a risk of failure for every drug candidate. Clinical testing is expensive, difficult to design and implement and can take many&#x00a0;years to complete, so its outcome is inherently uncertain. It is difficult to predict when or if any of our drug candidates will prove effective and safe in humans or will receive regulatory approval, and failure can occur at any time during the preclinical and clinical development process. Before obtaining regulatory approval from regulatory authorities for the commercialization of any drug candidate, our drug candidates must complete preclinical studies and then be subjected to extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The results of preclinical studies and clinical trials of our drug candidates may not be predictive of the results of later<FONT CLASS="nobreak">-stage</FONT> clinical trials. Drug candidates during later stages of clinical trials may fail to show the desired results in safety and efficacy despite having progressed through preclinical studies and initial to advanced clinical trials and despite the level of scientific rigor in the study, design and adequacy of execution. In some instances, there can be significant variability in safety and/or efficacy results among different studies of the same drug candidate due to numerous factors, including, but not limited to, differences in individual patient conditions, including genetic differences, and other compounding factors, such as other medications or pre<FONT CLASS="nobreak">-existing</FONT> medical conditions. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their drug candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their drug candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In the case of any studies we conduct, results may differ from earlier studies due to the larger number of clinical trial sites, foreign subjects and different languages involved in such studies. Clinical practices vary globally, and there is a lack of harmonization among the guidance provided by various regulatory bodies of different regions and countries with respect to the data that is required to receive marketing approval, which makes designing global studies increasingly complex. Differing regulatory approval requirements in different countries could make it more difficult for us to conduct unified global studies, which can lead to increased development costs and marketing delays or non<FONT CLASS="nobreak">-viability</FONT> of our clinical trials. In addition, regulatory authorities may determine that clinical trial results obtained in foreign subjects do not adequately represent the results that would be obtained in local patients and are thus not supportive of relevant approvals.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In particular, if we experience delays in the start or completion of, or termination of, any clinical trial of our key drug candidates, MCS<FONT CLASS="nobreak">-2</FONT>, PCP and IC, the commercial prospects of them may be harmed, and our ability to generate product revenues from our key drug candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down the development and approval process for our key drug candidates, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our key drug candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Investigation and development of botanical drug products is very complex due to the variability of botanical raw material and the need to ensure that the therapeutic effect for botanical drug product batches is consistent. Minor changes in API source or the manufacturing process can result in meaningful difference in clinical effects and may mean that earlier developed pharmacological, nonclinical and clinical data no longer apply to the changed product.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">22</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">All of our key drug candidates are in preclinical or clinical development. If we are unable to complete clinical development and obtain regulatory approval to ultimately commercialize our key drug candidates, or if we experience significant delays in doing so, our business, financial condition, results of operations and prospects will be materially harmed.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">All of our key drug candidates are still in development. Our ability to generate revenue from our key drug candidates is dependent on receipt of regulatory approval and successful commercialization of such products. We cannot guarantee that we will be able to obtain regulatory approvals for our existing drug candidates in a timely manner, or at all, and we may be unable to obtain successful commercialization of our key drug candidates even if we receive regulatory approval. Each of our key drug candidates will require additional preclinical and/or clinical development, regulatory approvals in multiple jurisdictions, development of commercial manufacturing supply and capacity, substantial investment and significant marketing efforts before we generate any revenue from product sales.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The success of our key drug candidates will depend on several factors, including, but not limited to, the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>hiring and maintaining sufficient experts and employees to oversee all development and regulatory activities and meeting of safety requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>for our botanical drug product candidates, the ability to obtain and maintain an adequate supply of the botanical raw material from which the drug products are derived and manufactured;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>successful completion of preclinical studies and clinical trials, including the successful enrollment in such clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>receipt of regulatory approvals from applicable regulatory authorities for planned and future clinical trials, drug registration, manufacturing and commercialization;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>successful completion of all studies required to obtain regulatory approval in the United&#x00a0;States, Taiwan, China, Europe and any other jurisdictions where we intend to market our key drug candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to establish manufacturing capabilities and capacities, whether internally or through third<FONT CLASS="nobreak">-party</FONT> cooperators, to the specifications of our key drug candidates for clinical supply;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>obtaining and maintaining patent, trade secret and other intellectual property protection and/or regulatory exclusivity for our key drug candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>launching commercial sales of our key drug candidates, if and when approved, whether alone or in collaboration with others;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>acceptance of the drug candidates, if and when approved, by patients, the medical community and third<FONT CLASS="nobreak">-party</FONT> payors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>obtaining and maintaining healthcare coverage and adequate reimbursement;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>effectively competing with other therapies and alternative drugs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>successfully enforcing and defending intellectual property rights and claims; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>maintaining a continued acceptable safety profile of the drug candidates following regulatory approval, and meeting all applicable post<FONT CLASS="nobreak">-market</FONT> commitments, obligations, and requirements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any significant delays in, or an inability to, obtain regulatory approval and ultimately achieve commercial success for our existing and future drug candidates in one or more jurisdictions would materially harm our business and we may not be able to generate enough revenues and cash flows to continue our operations could further materially harm our business. As a result, our financial condition, results of operations and prospects will be materially and adversely harmed.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">23</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we encounter delays or difficulties enrolling and retaining patients in our clinical trials, our clinical development progress and our receipt of necessary regulatory approvals could be delayed or otherwise adversely affected.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients that will remain in the study until its conclusion. We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these studies as required by the TFDA, the U.S. FDA, and any other applicable similar regulatory authorities, or if there are delays in the enrollment of eligible patients as a result of the competitive clinical enrollment environment. Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. The inability to enroll a sufficient number of patients who meet the applicable criteria for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. If patients are unwilling to enroll in our clinical trials because of restrictions on travel or healthcare institution policies, negative publicity from adverse events related to the pharmaceutical industry or for other reasons, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of our drug candidates may be delayed. As of the date of this prospectus, we have not encountered any delays or difficulties enrolling and retaining patients in our clinical trials, however, we cannot predict or guarantee that we will be successful at enrolling subjects in future clinical trials. Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment could result in increased development costs, delays in advancing our drug candidates, delays in testing the effectiveness of our drug candidates or termination of clinical trials altogether.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Patient enrollment for our clinical trials may be affected by other factors, including, but not limited to, the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>severity of the disease under investigation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>total size and nature of the relevant patient population;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>design and eligibility criteria for the clinical trial in question;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>perceived risks and benefits of the drug candidate under study;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our resources to facilitate timely enrollment in clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>patient referral practices of physicians;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>availability of competing therapies also undergoing clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our investigators&#x2019; or clinical trial sites&#x2019; efforts to screen and recruit eligible patients;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to maintain patients&#x2019; consents;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>ability to monitor patients adequately during and after treatment;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>proximity and availability of clinical trial sites for prospective patients; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the occurrence of any pandemic, epidemic or any other public health crises, including from the COVID<FONT CLASS="nobreak">-19</FONT> pandemic, the monkeypox outbreak, natural catastrophe or other disasters that may cause a delay in enrollment of patients in clinical trials.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">Additionally, our ability to successfully initiate, enroll and complete clinical trials in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>difficulty in establishing or managing relationships with our cooperators, including but not limited to research institutions, hospitals and physicians;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>different standards for the conduct of clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>absence in some countries of established groups with sufficient regulatory expertise for review of clinical trial protocols;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>inability to locate qualified local consultants, physicians and cooperators; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">24</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In addition, our clinical trials may compete with other clinical trials for drug candidates that are in the same therapeutic areas as our drug candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. For example, although we have not encountered any delays or difficulties in enrolling or retaining patients for our clinical trials in the past, we may in the future experience such delays or difficulties due to government orders and site policies on account of health epidemics, and some patients may be unwilling or unable to travel to study sites, enroll in our studies or comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. If we have difficulty enrolling a sufficient number of patients or finding additional clinical trial sites to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which could have an adverse effect on our business, financial condition, results of operations and prospects. In addition, it is possible that health pandemics may have an impact on the workforce of the third parties on which we rely, which could adversely impact our ability to conduct preclinical studies, enroll and retain patients in our clinical trials and conduct the clinical trials of our drug candidates on expected timeframes or to complete such studies, and our ability to ultimately obtain regulatory approval. As a result, the value of our Company could decline and our ability to obtain additional financing may be impaired.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The U.S. FDA has concluded that one of our four Phase III trials failed to demonstrate a statistically significant difference between MCS-2 with API-1 and placebo in the primary efficacy endpoint in the </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MCS-2-US-a</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> study. If our future clinical trials of our key drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development, regulatory approval, and commercialization of our drug candidates.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before obtaining regulatory approval for the sale of our drug candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. We may experience numerous unexpected events during, or as a result of clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our drug candidates, including, but not limited to, the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>regulators, institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective study site;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delay in reaching, or failure to reach, agreements on acceptable terms with prospective CROs and study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and study sites;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>manufacturing issues, including problems with manufacturing, supply quality, compliance with current good manufacturing practices, or obtaining sufficient quantities of a drug candidate from third parties for use in a clinical trial;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide to conduct additional clinical trials or abandon the development of such drug candidates, or regulators may require us to do so;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment may be insufficient or slower than we anticipate, or patients may drop out or fail to return for post<FONT CLASS="nobreak">-treatment</FONT> follow<FONT CLASS="nobreak">-up</FONT> at a higher rate than we anticipate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our third<FONT CLASS="nobreak">-party</FONT> contractors used in our clinical trials, including any clinical investigators, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from clinical trial protocol or dropout of clinical trials, which may require that we add new clinical trial sites or clinical investigators;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we might have to suspend or terminate clinical trials of our drug candidates for various reasons, including a finding of a lack of clinical response, serious adverse, undesirable or unacceptable side effects or other unexpected characteristics or a finding that participants are being exposed to unacceptable health risks;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">25</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or not rely on the results of clinical research for various reasons, including non<FONT CLASS="nobreak">-compliance</FONT> with regulatory requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the cost of clinical trials of our drug candidates may be greater than we anticipate; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently plan, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these studies or tests are not positive or are only modestly positive, or if they raise safety concerns, we may (i)&#x00a0;be delayed in obtaining regulatory approval for our drug candidates; (ii)&#x00a0;obtain approval for indications or patient populations that are not as broad as intended or desired; (iii)&#x00a0;not obtain regulatory approval at all; (iv)&#x00a0;have the drug removed from the market after obtaining regulatory approval; (v)&#x00a0;be subject to additional post<FONT CLASS="nobreak">-marketing</FONT> testing requirements; (vi)&#x00a0;be subject to restrictions on how the drug is distributed or used; or (vii)&#x00a0;be unable to obtain reimbursement for use of the drug. Many of the factors that cause a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our drug candidates. Further, the TFDA, the U.S. FDA or other regulatory authorities may disagree with our clinical trial design or our interpretation of data from clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We used one supplier for API<FONT CLASS="nobreak">-1</FONT>, which formed the basis for the NDA that has since been withdrawn by the Company. The supplier of API<FONT CLASS="nobreak">-1</FONT> sold a parcel of its land and is currently in the process of relocating and reconstructing its manufacturing facility. Consequently, API<FONT CLASS="nobreak">-1</FONT> is presently unavailable to us, and the supplier of API<FONT CLASS="nobreak">-1</FONT> withdrew its consent for us to reference their DMF on file with the U.S. FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S. FDA has determined that one of our four Phase III trials failed to demonstrate a statistically significant difference between MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-1</FONT> and placebo in the primary efficacy endpoint in the MCS<FONT CLASS="nobreak">-2-US-a</FONT> study. Given the current unavailability of API<FONT CLASS="nobreak">-1</FONT>, we requested a Type D meeting on December<FONT CLASS="nobreak"> </FONT>12, 2023, to propose conducting a new Phase III trial and Phase I PK study using API<FONT CLASS="nobreak">-2</FONT>. The U.S. FDA provided written responses on February<FONT CLASS="nobreak"> </FONT>23, 2024, with their comments on the Phase III trial and Phase I PK study design and requested that we provide the Statistical Analysis Plan for the Phase III study. We are currently finalizing the Phase III protocol and the Phase I PK study protocol from the synopsis to comply with the U.S. FDA requirements. If the CMC comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> is approved, we will request a Type B meeting (WRO) with the U.S. FDA to discuss our revised Phase III protocol, Statistical Analysis Plan, and PK study protocol.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We intend to conduct the two studies in the US in late 2024, with the completion targeted within one to two&#x00a0;years. The study budget cannot be determined at present and will need to be estimated after further comments from the U.S. FDA. The aforementioned completion timeline and study budget are additional to the originally allocated resources, necessitated by the failure of one of our four Phase III trials conducted in the United States and the lack of access to API<FONT CLASS="nobreak">-1</FONT> supplies.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our clinical trials are conducted in multiple jurisdictions, which may subject us to delays and expenses.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are currently conducting clinical trials, through third<FONT CLASS="nobreak">-party</FONT> CROs, in Taiwan and the U.S. There are risks inherent in conducting clinical trials in multiple jurisdictions, which may subject us to delays and expenses, such as:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>regulatory and administrative requirements of the jurisdiction where the study is conducted that could burden or limit our ability to conduct clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>differing and conflicting regulatory requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>foreign exchange fluctuations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>manufacturing, customs, shipment and storage requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>cultural differences in medical practice, patient consent, and clinical research; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the risk that the patient populations in such trials are not considered representative as compared to the patient population in the target markets where approval is being sought.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">26</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our drug candidates may cause serious adverse, undesirable or unacceptable side effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, and</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">or result in significant negative consequences following regulatory approval, if any.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As is the case with pharmaceuticals generally, it is likely that there may be serious adverse, undesirable or unacceptable side effects caused by our drug candidates that could cause us or regulatory authorities to interrupt, delay or halt clinical trials and may result in a more restrictive label, a delay or denial of regulatory approval by the TFDA, the U.S. FDA or other comparable regulatory authorities, or a significant change in our clinical trial protocols or even our development plan. Results of our future preclinical studies and clinical trials could reveal a high and unacceptable severity or prevalence of adverse events. In such an event, our studies could be suspended or terminated and the TFDA, the U.S. FDA or other comparable regulatory authorities could order us to cease further development of, or deny approval of, our drug candidates for any or all targeted indications. Adverse events related to our drug candidates may affect patient recruitment or the ability of enrolled subjects to complete the study and could result in potential liability claims. Serious or life<FONT CLASS="nobreak">-threatening</FONT> adverse events associated with any of our drug candidates or of a botanical constituent could be so rare in occurrence as to not be statistically likely to arise during clinical trials and may only arise after regulatory approval and marketing. Any of these occurrences may significantly influence our reputation, business, financial condition and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All identified serious adverse events have been determined to be &#x201c;not related&#x201d; to MCS<FONT CLASS="nobreak">-2</FONT>, with the exception of a pancreatitis event observed in the MCS<FONT CLASS="nobreak">-2-US-c</FONT> trial. In this instance, the pancreatitis lasted only three days, and the causality was assessed as &#x201c;possibly related&#x201d; but not &#x201c;definitely related,&#x201d; as the event was most likely attributable to Metformin, a medication used to treat diabetes mellitus.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, the identification of serious adverse, undesirable or unacceptable side effects caused by any of our future approved drug candidates may lead to potentially significant negative consequences, which include, but are not limited to, the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>suspension of our marketing of the drug candidate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>withdrawal or revocation by regulatory authorities of their approvals of or the licenses for the drug candidate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the requirement by regulatory authorities to conduct additional clinical trials, add additional warnings to, or otherwise change the label of the drug candidate, such as recommending or requiring additional pre<FONT CLASS="nobreak">-screening</FONT> testing prior to prescribing or administering the drug candidate or requiring a &#x201c;black box&#x201d; warning or contraindication, or to create a medication guide outlining the risks of such side effects for distribution to patients;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>restriction on the distribution of the drug candidate or imposition of burdensome implementation requirements on us through the establishment of a Risk Evaluation and Mitigation Strategy, or REMS, or similar strategy as may be required by the U.S. FDA or a comparable regulatory authority;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the requirement by regulatory authorities to conduct specific post<FONT CLASS="nobreak">-marketing</FONT> studies of the drug candidate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the requirement to change the way the drug candidate is distributed or administered;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>becoming subjected to regulatory investigations, government enforcement actions or litigation proceedings, and being held liable for harm caused to subjects or patients;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the product becoming less competitive;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>removal of drug candidates from the marketplace; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>harm to our reputation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any of these events could prevent us from achieving or maintaining market acceptance of any particular drug candidate that is approved and could significantly harm our business, results of operations and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, the use of our drug candidates in conjunction with other therapies, may result in unique adverse events that could be exacerbated compared with adverse events from the use of our drug candidates alone. Results of our studies could reveal a high and unacceptable severity or prevalence of adverse events. These types of adverse </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">27</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">events could be caused by our drug candidates and could cause us or regulatory authorities to interrupt, delay or halt clinical trials and may result in a more restrictive indication or the delay or denial of regulatory approval by the TFDA, the U.S. FDA or other comparable regulatory authority.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The manufacture of our drug products is a complex process which requires significant expertise and capital investment, and if we encounter problems in establishing our manufacturing capabilities for clinical or commercial scale or in the manufacture of our future products, our business could suffer.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, only two botanical drug products have received the U.S. FDA&#x2019;s approval for marketing as prescription drugs. The U.S. FDA has not approved any botanical drug products since 2012. The quality control of botanical drug products is very complex due to the variability of botanical raw material and the need to demonstrate that the therapeutic effect for the tested botanical drug product batches is the targeted constituent (or constituents in the aggregate). It is challenging to ensure batch<FONT CLASS="nobreak">-to-batch</FONT> consistency, which must be demonstrated to obtain U.S. FDA approval. Minor changes in geographical location of the API source or the manufacturing process can result in meaningful differences in clinical effects and may mean that earlier developed pharmacological, nonclinical and clinical data no longer apply to the changed product. If we are unable to obtain the U.S. FDA&#x2019;s approval for marketing our drug candidates, or if we experience significant delays in doing so, our business could be materially and adversely affected.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The manufacture of our drug products is a complex process, in part due to strict regulatory requirements and the inherent variability and sensitivities of the botanical nature of our drug products&#x2019; raw materials. If we are unable to identify an appropriate geographical location for growing our botanical raw materials to ensure consistency in the concentration of target constituents or if we are unable to identify an appropriate production site or suitable collaborators to develop our manufacturing infrastructure, or if we fail to do so in a timely manner, any of these may lead to significant delays in the clinical supply of our drug candidates as well as the commercial manufacturing of our drug candidates once regulatory and marketing approvals have been obtained. In turn, this could delay our clinical trials, negatively impact our ability to ultimately obtain regulatory approval and materially harm any future commercialization plans.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, problems may arise during the manufacturing process for a variety of reasons, including, but not limited to, required consistency of botanical raw materials, equipment malfunction, failure to follow specific protocols and procedures, problems with (including shortage of) raw materials, global supply chain issues, delays related to the construction of new facilities or expansion of any future growing or manufacturing facilities, including changes in growing or manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in the types of products produced, increases in the prices of raw materials, physical limitations that could inhibit continuous supply, man<FONT CLASS="nobreak">-made</FONT> or natural disasters and environmental factors. For example, although we have not experienced material supply disruptions due to the COVID<FONT CLASS="nobreak">-19</FONT> pandemic, we cannot guarantee that we will not experience supply disruptions in the future due to the COVID<FONT CLASS="nobreak">-19</FONT> pandemic or any other pandemics, epidemics or other public health crises, natural catastrophes or other disasters.&#x201d; If problems arise during the production of a batch of future products, that batch of future products may have to be discarded and we may experience product shortages or incur added expenses. This, as well as problems that may arise during the manufacturing process, could, among other things, lead to significant additional costs and/or delays, lost revenue, damage to customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before such product is released to the market, recall and product liability costs may also be incurred.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Changes in our drug candidates&#x2019; manufacturing or formulation may result in additional costs or delay.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As our drug candidates are developed through preclinical studies to late<FONT CLASS="nobreak">-stage</FONT> clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as raw materials testing and release, manufacturing methods and formulation, are altered in an effort to optimize processes, which may not pass regulatory inspections. If we engage in the scale<FONT CLASS="nobreak">-up</FONT> of manufacturing, we may encounter unexpected issues relating to the manufacturing process or the quality, purity and stability of the product, and we may be required to refine or alter our manufacturing processes to address these issues. Such changes may not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of preclinical studies and clinical trials. Such changes may also require additional testing, notification or approval by relevant regulatory authorities, including additional pharmacokinetics or pharmacodynamics trials. This could delay completion of preclinical studies and clinical trials; require us to conduct bridging clinical trials or studies, or to repeat one or more clinical trials; increase study or clinical trial costs; or delay approval of our product candidates and jeopardize our ability to commence product sales and generate revenue.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">28</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We have not yet obtained marketing approval for a drug candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for our drug candidates.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have not yet obtained marketing approval for a drug candidate. It is possible that the TFDA, the U.S.&#x00a0;FDA or other comparable regulatory authority may refuse to accept for review any NDAs that we submit for our drug candidates. It is also possible that the U.S. FDA may conclude, after review of our data, that our application for MCS<FONT CLASS="nobreak">-2</FONT> is insufficient or the data fails to achieve clinical endpoints to statistical significance when compared with placebo, and thus may delay the U.S. FDA&#x2019;s issuance of marketing approval of MCS<FONT CLASS="nobreak">-2</FONT>. If the TFDA, the U.S. FDA or other comparable regulatory authority does not accept or approve our NDAs for any of our drug candidates, it may require that we conduct additional clinical trials, preclinical studies or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other required trials or studies, approval of any NDA or application that we submit may be delayed by several&#x00a0;years or may require us to expend more resources than we have available. It is also possible that additional trials or studies, if performed and completed, may not be considered sufficient by the TFDA, the U.S. FDA or other comparable regulatory authority to approve our NDAs. Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our drug candidates, generating revenues and achieving and sustaining profitability.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Obtaining and maintaining regulatory approval of our drug candidates in one jurisdiction does not mean that we will be successful in obtaining or maintaining regulatory approval of our drug candidates in other jurisdictions.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Obtaining and maintaining regulatory approval of our drug candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the U.S. FDA grants marketing approval of a drug candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the drug candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in Taiwan or the U.S., including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may also submit marketing applications in other countries. Regulatory authorities have requirements for approval of drug candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our drug candidates will be harmed.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Potential </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Non-Acceptance</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> by the U.S.&#x00a0;FDA of API-1 and API-2 Comparability could materially and adversely affect our business, financial condition, and results of operations.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Active pharmaceutical ingredient<FONT CLASS="nobreak">-1</FONT>(API<FONT CLASS="nobreak">-1</FONT>), the raw material we used in the previous clinical trials for MCS<FONT CLASS="nobreak">-2</FONT>, is currently unavailable due to the supplier&#x2019;s relocation and withdrawal of their consent to reference their Drug Master File on file with the U.S.&#x00a0;FDA.&#x00a0;We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA. As of this date, the Company has not yet successfully demonstrated the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are currently in the process of providing the U.S.&#x00a0;Food and Drug Administration (FDA) with the necessary information to demonstrate the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. However, there is a risk that the FDA may determine that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are not sufficiently comparable and we would have to perform more clinical trials.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA&#x2019;s concerns primarily relate to potential differences in the sources and methods of producing API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, including, but not limited to, changes in agricultural sites, agricultural and collection practices, processing methods, and manufacturing techniques. Each of these factors could impact the quality, safety, and efficacy of the active pharmaceutical ingredients, leading to a requirement for additional data or even new clinical trials to establish comparability.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">29</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the FDA does not agree that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are sufficiently comparable, we could face significant consequences, including, but not limited to, regulatory delays and increased costs. We will be required to repeat the MCS<FONT CLASS="nobreak">-2</FONT> and PCP clinical trials using API<FONT CLASS="nobreak">-2</FONT>, or to conduct other additional clinical trials as may be required by the U.S. FDA. For further details, see the risk factor titled &#x201c;<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs</FONT>&#x201d; on page 31. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The approval process for our drug candidates could be delayed significantly, as we may be required to conduct additional studies or provide further data to address the FDA&#x2019;s concerns. The need for additional studies or data submissions could result in substantial, unanticipated costs, which could adversely affect our financial condition and operational results.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our ability to obtain FDA approval for our new drug application (NDA) may be delayed or denied due to concerns raised by the FDA regarding our clinical trial data and comparability of our active pharmaceutical ingredients.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S.&#x00a0;FDA has reviewed our proposed Phase&#x00a0;III protocol and Phase&#x00a0;I pharmacokinetic (PK) synopsis, as reflected in their written response dated February&#x00a0;23, 2024. The U.S.&#x00a0;FDA raised several concerns in this response that could impact our ability to obtain approval for our new drug application (NDA):</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(i)<FONT STYLE="width: 17px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The U.S. FDA questioned whether one new Phase III study with API<FONT CLASS="nobreak">-2</FONT> would be sufficient, as they believe results from two positive Phase III efficacy studies provide more convincing evidence of effectiveness than results from a single trial. Additionally, a single Phase III efficacy study could make it challenging to collect the amount of safety information required for a new molecular entity.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(ii)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The U.S. FDA noted its concern that Study MCS<FONT CLASS="nobreak">-2-US-a</FONT> did not demonstrate a statistically significant difference between the drug and placebo in the primary efficacy endpoint. They also expressed concerns regarding the treatment effect of questionable significance in Study MCS<FONT CLASS="nobreak">-2-TWN-a</FONT>.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(iii)<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT>The U.S. FDA was concerned that our study plan had not specified either the quantity or quality of the confirmatory evidence, and did not state a specific clinical circumstance, ethical or practical consideration, or unmet medical need that would preclude the conduct of a second adequate and well<FONT CLASS="nobreak">-controlled</FONT> efficacy study.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(iv)<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT>Additionally, regarding the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, the U.S. FDA commented that it will need more information on how we would demonstrate comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. They noted that their determination of whether our original Phase III studies with API<FONT CLASS="nobreak">-1</FONT> would be useful depends on the quality of support for a convincing link between products containing these APIs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In response to these concerns and upon U.S. FDA&#x2019;s recommendation, we are developing a comparability plan to provide the U.S.&#x00a0;FDA with convincing link and data between products containing API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. As of this date, the Company is still in the process of providing the information required by the U.S.&#x00a0;FDA and has not yet successfully demonstrated the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After our submission of our comparability plan and, if U.S. FDA agrees our data demonstrates comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be able to rely on trials that were previously conducted using API<FONT CLASS="nobreak">-1</FONT>, and we then will initiate the MCS<FONT CLASS="nobreak">-2</FONT> Phase III study and the PK study using API<FONT CLASS="nobreak">-2</FONT> simultaneously. As mentioned earlier, for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;(API<FONT CLASS="nobreak">-1</FONT>), we have conducted four Phase III clinical trials in the U.S. and Taiwan, including two pivotal trials (one in each location) and two open<FONT CLASS="nobreak">-label</FONT> extension studies (also one in each location) using API<FONT CLASS="nobreak">-1</FONT>. The U.S. FDA raised concerns about one pivotal Phase III trial in the U.S., which failed to demonstrate a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to-treat</FONT> population. Additionally, the FDA expressed concerns regarding the reproducibility of some reported efficacy results for Study MCS<FONT CLASS="nobreak">-2-TWN-a</FONT>. However, the U.S. FDA had no further comments on the two open<FONT CLASS="nobreak">-label</FONT> extension studies in the U.S. and Taiwan using API<FONT CLASS="nobreak">-1</FONT>. Therefore, if the FDA agrees that our data demonstrates comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will also need to conduct another pivotal Phase&#x00a0;III study using API<FONT CLASS="nobreak">-2</FONT>, and we will work with the FDA to address the reproducibility issue.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">30</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To address the U.S.&#x00a0;FDA&#x2019;s concern that Study MCS<FONT CLASS="nobreak">-2-</FONT><FONT CLASS="nobreak">US-a</FONT> did not demonstrate a statistically significant difference between the drug and placebo in the primary efficacy endpoint, we plan to conduct an additional Phase&#x00a0;III study, MCS<FONT CLASS="nobreak">-2-</FONT><FONT CLASS="nobreak">US-b</FONT>, using API<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regarding the U.S.&#x00a0;FDA&#x2019;s concerns about the reproducibility of the reported efficacy results for Study MCS<FONT CLASS="nobreak">-2-</FONT><FONT CLASS="nobreak">TWN-a</FONT>, we propose to re<FONT CLASS="nobreak">-analyze</FONT> the statistical results of the MCS<FONT CLASS="nobreak">-2-</FONT><FONT CLASS="nobreak">TWN-a</FONT> study data using Clinical Data Interchange Standards Consortium (CDISC) data sets that match the FDA&#x2019;s requested data format. Then, we will submit the reanalysis for further discussions with U.S. FDA about its concerns.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<FONT CLASS="nobreak"> </FONT>14, 2024, we asked U.S. FDA to provide a written response to our questions about obtaining U.S. FDA&#x2019;s review and comments on a newly proposed Phase III clinical trial protocol for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-2</FONT> and a pharmacokinetic (PK) study. On May&#x00a0;23, 2024, we received a denial notice from the U.S.&#x00a0;FDA, stating that it was premature to provide such a written response at this stage of drug development, however, the U.S. FDA would continue its review of the study design of PK study and Phase III clinical trial using API<FONT CLASS="nobreak">-2</FONT>. The U.S. FDA decided that until the company provides complete Chemistry, Manufacturing, and Controls (CMC) information on API<FONT CLASS="nobreak">-2</FONT> and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, the U.S.&#x00a0;FDA is not in a position to reach any agreement on protocols designed to establish the safety and efficacy of MCS<FONT CLASS="nobreak">-2</FONT>. We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA. If the U.S. FDA does not agree that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, we will continue to research additional API sources based on our own patent, to pursue additional outsourcing API vendors, and to follow U.S. FDA&#x2019;s guidance for demonstrating comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> to the U.S. FDA&#x2019;s satisfaction. In the event that we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be required to repeat the MCS<FONT CLASS="nobreak">-2</FONT> and PCP clinical trials using API<FONT CLASS="nobreak">-2</FONT>, or to conduct other additional clinical trials as may be required by the U.S. FDA. For further details, see the risk factor titled &#x201c;If we are unable to identify a supplier capable of producing API<FONT CLASS="nobreak">-2</FONT> that is sufficiently comparable to API<FONT CLASS="nobreak">-1</FONT>, we will be required to repeat our clinical trials for MCS<FONT CLASS="nobreak">-2</FONT> and PCP, which could significantly delay our product development efforts and result in increased costs&#x201d; on page 31.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There can be no assurance that the U.S.&#x00a0;FDA will agree with our comparability plan or that our additional studies will satisfactorily address the U.S.&#x00a0;FDA&#x2019;s concerns. Any failure to adequately address these concerns could significantly delay or prevent the approval of our NDA, which would materially and adversely affect our business, financial condition, and results of operations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">If we are unable to identify a supplier capable of producing API-2 that is sufficiently comparable to API-1, we will be required to repeat our clinical trials for MCS-2 and PCP, or to conduct other additional clinical trials as may be required by the U.S. FDA, which would significantly delay our product development and increase our costs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our clinical trials for MCS<FONT CLASS="nobreak">-2</FONT> and PCP have thus far utilized API<FONT CLASS="nobreak">-1</FONT>, an active pharmaceutical ingredient (API) produced by a supplier that is no longer available. We have transitioned to using API<FONT CLASS="nobreak">-2</FONT>, a new API produced by an alternative supplier, and are in the process of establishing comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. The U.S. FDA requires that we demonstrate that API<FONT CLASS="nobreak">-2</FONT> is sufficiently comparable to API<FONT CLASS="nobreak">-1</FONT> to rely on the results of our previous clinical trials using API<FONT CLASS="nobreak">-1</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If we are unable to successfully demonstrate this comparability, or if we are unable to identify another supplier capable of producing an API that meets the required standards, we may be required to repeat the clinical trials that we conducted using API<FONT CLASS="nobreak">-1</FONT> for both MCS<FONT CLASS="nobreak">-2</FONT> and PCP. This would encompass phases I, II, and III studies for MCS<FONT CLASS="nobreak">-2</FONT> using. API<FONT CLASS="nobreak">-2</FONT>, and phases I and II studies for PCP using API<FONT CLASS="nobreak">-2</FONT>, or to conduct other additional clinical trials as may be required by the U.S. FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This could result in significant delays in our product development timelines, increased costs, and could adversely affect our business, financial condition, and results of operations. Furthermore, we cannot guarantee that any future clinical trials using API<FONT CLASS="nobreak">-2</FONT> or any alternative API would yield results similar to those previously obtained using API<FONT CLASS="nobreak">-1</FONT>, which could further hinder our ability to obtain regulatory approval and bring our products to market.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">31</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Even if any of our drug candidates receives marketing approval, we or others may later discover that the product is less effective than previously believed or causes rare undesirable side effects that were not previously identified, which could compromise our ability, or that of any future collaborators, to market the product.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Clinical trials of our drug candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a drug candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a drug candidate, we, or others, discover that the product is less effective than previously believed or causes rare undesirable side effects that were not previously identified, any of the following adverse events could occur and may have material negative influence on our business and operations:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>regulatory authorities may withdraw their approval of our drug products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we, or any future collaborators, may be required to recall the product, change the way the product is administered or conduct additional clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>regulatory authorities may require the addition of labeling statements, such as recommending or requiring additional pre<FONT CLASS="nobreak">-screening</FONT> testing prior to prescribing or administering the drug candidate or requiring a &#x201c;black box&#x201d; warning or a contraindication;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we, or any future collaborators, could be sued and held liable for harm caused to patients;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the product may become less competitive; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>damages to our reputation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, patient advocacy groups, </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">third-party</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> payors and others in the medical community necessary for commercial success.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Even if our drug candidates receive regulatory approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, patient advocacy groups and others in the medical community. Efforts to educate physicians, patients, patient advocacy groups and third<FONT CLASS="nobreak">-party</FONT> payors on the benefits of our drug candidates may require significant resources and may not be successful, and physicians and patients may prefer other drugs or drug candidates to ours. If our drug candidates do not achieve an adequate level of acceptance, we may not generate significant revenue from sales of our drugs or drug candidates and may not become profitable.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The degree of market acceptance of our drug candidates, if and only when they are approved for commercial sale, will depend on a number of factors, including, but not limited to, the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the clinical indications for which our drug candidates are approved;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the degree to which physicians, hospitals, patient advocacy groups and patients consider our drug candidates as safe and effective treatments;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>whether our drug candidates have achieved the perceived advantages of our drug candidates over alternative treatments;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the prevalence and severity of any adverse effects;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>product labeling or package insert requirements of the TFDA, the U.S. FDA or other comparable regulatory authorities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>limitations or warnings or contraindications contained in the labeling approved by the TFDA, the U.S.&#x00a0;FDA or other comparable regulatory authorities;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">32</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>timing of market introduction of our drug candidates as well as competitive drugs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>cost of treatment in relation to alternative treatments;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>availability of adequate coverage and reimbursement from third<FONT CLASS="nobreak">-party</FONT> payors and government authorities in the United&#x00a0;States, Taiwan and/or any other jurisdictions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>willingness of patients to pay any out<FONT CLASS="nobreak">-of-pocket</FONT> expenses in the absence of coverage and reimbursement by third<FONT CLASS="nobreak">-party</FONT> payors and government authorities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>relative convenience and ease of administration, including as compared with alternative treatments and competitive therapies; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the effectiveness of our sales and marketing efforts.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We face substantial competition, rapid technological change and the possibility that our competitors may discover, develop or commercialize drugs before we do or more successfully than we do, or develop therapies that are similar, more advanced or more effective than ours, each of which may adversely affect our financial condition and our ability to successfully market or commercialize our drug candidate.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The development and commercialization of new drugs are highly competitive and the pharmaceutical industry is subject to rapid and significant technological change. We face competition with respect to our drug candidates and will face competition with respect to any drug candidates that we may seek to develop or commercialize in the future, from companies of all sizes around the world, including major and specialty pharmaceutical companies and generic drug companies. Potential competitors further include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our competitors may have significantly greater financial, technical, human and other resources, such as larger research and development staff and experienced marketing and manufacturing departments, and more experience in the development and regulatory approval process than we have. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated on our competitors. As a result, these companies may obtain regulatory approval from the TFDA, the U.S. FDA or other comparable regulatory authorities more rapidly than we are able to and may be more effective in selling and marketing their products as well. This may lead to potential increased competition from drugs that have already obtained approval in other jurisdictions. Smaller or early<FONT CLASS="nobreak">-stage</FONT> companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Our competitors also may also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our drug development programs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our competitors may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective, safer or less costly than any drug candidate that we may develop, or may achieve earlier patent protection, regulatory approval, product commercialization, and market penetration than we do. Additionally, technologies developed by our competitors may render our potential drug candidates uneconomical or obsolete, and we may not be successful in marketing our drug candidates against competitors. The availability of our competitors&#x2019; products could limit the demand, and the price we are able to charge, for any drug candidates that we may develop and commercialize.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">While certain of our employees have experience in launching and marketing drug candidates, we may not be able to effectively build and manage a sales network or benefit from the sales network of </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">third-party</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> collaborators.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are actively establishing a team for sales, marketing and distribution, which requires significant capital expenditures, management resources and time. We will have to compete with other biotechnology companies to recruit, hire, train and retain marketing and sales personnel. If we are unable to establish internal sales, marketing and commercial distribution capabilities for any or all of the drugs we develop or in particular regions or markets, we may pursue third<FONT CLASS="nobreak">-party</FONT> collaborative arrangements regarding the sales and marketing of our drug products into such regions or markets. However, there can be no assurance that we will be able to establish or maintain such </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">33</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">collaborative arrangements, or, if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend on the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our drug candidates ourselves. We will also face competition in our search for third parties to assist us with the sales and marketing efforts of our drug candidates, which may result in collaborative arrangements with less<FONT CLASS="nobreak">-than</FONT><FONT CLASS="nobreak">-optimal</FONT> terms.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There can be no assurance that we will be able to develop in<FONT CLASS="nobreak">-house</FONT> sales and commercial distribution capabilities or establish or maintain relationships with third<FONT CLASS="nobreak">-party</FONT> collaborators to successfully commercialize any product, and as a result, we may not be able to generate product sales revenue.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Even if we are able to commercialize any approved drug candidates, reimbursement may be limited or unavailable in certain market segments for our drug candidates, and we may be subject to unfavorable pricing regulations, which could harm our business.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The regulations that govern regulatory approvals, pricing and reimbursement for new therapeutic products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a drug product in a particular country, but then be subject to price regulations that delay our commercial launch of the drug and negatively impact the revenues we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain regulatory approval.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our ability to commercialize any drugs successfully also will depend in part on the extent to which reimbursement for these drugs and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third<FONT CLASS="nobreak">-party</FONT> payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the global healthcare industry is cost containment. Government authorities and these third<FONT CLASS="nobreak">-party</FONT> payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third<FONT CLASS="nobreak">-party</FONT> payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any drug for which we obtain regulatory approval. Obtaining reimbursement for certain of our drugs may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any drug candidate that we successfully develop.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There may be significant delays in obtaining reimbursement for approved drug candidates, and coverage may be more limited than the purposes for which the drug candidates are approved by the TFDA, the U.S. FDA or other comparable regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on payments allowed for lower cost drugs that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United&#x00a0;States or Taiwan. Our inability to promptly obtain coverage and profitable payment rates from both government<FONT CLASS="nobreak">-funded</FONT> and private payors for any future approved drug candidates could have a material adverse effect on our business, our operating results, and our overall financial condition.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">34</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Preliminary interim or &#x201c;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">top-line</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x201d; data that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, we may publish preliminary interim or &#x201c;top<FONT CLASS="nobreak">-line</FONT>&#x201d; data from clinical trials. Positive preliminary data from such interim analyses may not be predictive of such trial&#x2019;s subsequent or overall results. Preliminary data are subject to the risk that one or more of the outcomes may materially change as more data become available. Additionally, preliminary data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Therefore, positive preliminary results in any ongoing clinical trial may not be predictive of such results in the completed trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a result, preliminary data that we report may differ from future results from the same clinical trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to preliminary data could significantly harm our business prospects.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The data and information that we gather in our research and development process could be inaccurate or incomplete, which may have negative influence on our business, reputation, financial condition and results of operations.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We collect, aggregate, process, and analyze data and information from our preclinical studies and clinical trials. We also engage in substantial information gathering following the identification of a promising drug candidate. Because data in the healthcare industry is fragmented in origin, inconsistent in format, often incomplete and rapidly evolving, the overall quality of data collected or accessed in the healthcare industry is often subject to challenge, the degree or amount of data which is knowingly or unknowingly absent or omitted can be material, and we often discover data issues and errors when monitoring and auditing the quality of our data. If we make mistakes in the capture, input, or analysis of these data, our ability to advance the development of our drug candidates may be materially harmed and our business, prospects and reputation may suffer.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We also engage in the procurement of regulatory approvals necessary for the development and commercialization of our drug candidates, for which we manage and submit data to governmental entities. These processes and submissions are governed by complex data processing and validation policies and regulations. Notwithstanding such policies and regulations, interim, top<FONT CLASS="nobreak">-line</FONT> or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data, in which case we may be exposed to liability to a customer, court or government agency that concludes that our storage, handling, submission, delivery or display of health information or other data was wrongful or erroneous. Although we maintain insurance coverage for clinical trials this coverage may prove to be inadequate or could cease to be available to us on acceptable terms, if at all. Even unsuccessful claims could result in substantial costs and diversion of management time, attention, and resources. A claim brought against us that is uninsured or under<FONT CLASS="nobreak">-insured</FONT> could harm our business, financial condition and results of operations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, we rely on CROs and other third parties to monitor and manage data for some of our ongoing preclinical studies and clinical trials and control only certain aspects of their activities. If any of our CROs or other third parties do not perform to our standards in terms of data accuracy or completeness, data from those preclinical studies and clinical trials may be compromised as a result, and our reliance on these parties does not relieve us of our regulatory responsibilities. For a detailed discussion, see &#x201c;&#x2014;&#x00a0;Risks Related to Our Dependence on Third Parties &#x2014;&#x00a0;As we rely on third parties to conduct our clinical trials and provide other important services related to research and development, regulatory submissions, and commercialization, if we fail to maintain our relationships with these third parties or if they do not successfully carry out their contractual duties, comply with applicable laws, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.&#x201d;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">35</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The incidence and prevalence for target patient populations of our drug candidates are based on estimates and </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">third-party</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> sources. The market opportunities for our drug candidates, if approved, may be smaller than we anticipate.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We expect to initially seek approval of MCS<FONT CLASS="nobreak">-2</FONT> for the treatment of BPH/LUTS.&#x00a0;Our projections of the number of patients with BPH/LUTS and the portion of those patients that would benefit from treatment with MCS<FONT CLASS="nobreak">-2</FONT> are based on our beliefs and estimates, including the report by Frost&#x00a0;&amp; Sullivan, data published by third parties, including scientific literature, patient foundations and publicly available databases, and on internally generated data and assumptions. While we believe our market size information is generally reliable, such information is inherently imprecise, and relies on our and third parties&#x2019; projections, assumptions and estimates within our target market, which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. For more details, please refer to &#x201c;RISKS RELATED TO THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF OUR DRUG CANDIDATES &#x2014; Even if we are able to commercialize any approved drug candidates, reimbursement may be limited or unavailable in certain market segments for our drug candidates, and we may be subject to unfavorable pricing regulations, which could harm our business.&#x201d; If such third<FONT CLASS="nobreak">-party</FONT> or internally generated data prove to be inaccurate or we make errors in our projections, assumptions or estimates based on that data, our addressable target market opportunity and/or our future growth rate may be less than we currently estimate. Further, new sources may reveal a change in the estimated number of patients, and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future drug candidates may be limited. Accordingly, the information regarding the size of our addressable market opportunity included in this prospectus should not be taken as indicative of our future growth.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ultimate market opportunity for our drug candidates will depend on, among other things, the final labeling for such drug candidates as agreed with the TFDA, the U.S. FDA and any other applicable comparable foreign regulatory authorities, acceptance by the medical community and patient access, potential competition and drug pricing and reimbursement. Even if we obtain significant market share for any drug candidate, if the potential target populations deviate from our estimation, our business, financial condition, results of operations and prospects may be harmed.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Potential product liability claims or lawsuits could divert our resources, incur substantial liabilities and limit the commercialization of any drug products that we may develop.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We face an inherent risk of product liability claims as a result of the clinical testing of our drug candidates despite obtaining appropriate informed consents from our clinical trial participants. We will face an even greater risk if we or any future collaborators commercially sell any product that we or they may develop. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit the commercialization of our drug candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Regardless of the merits or eventual outcome, liability claims may result in significant negative consequences to our business and prospects, including, but not limited to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>significant negative media attention and reputational damage;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>withdrawal of clinical trial participants or clinical trial sites or investigators and inability to continue clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>significant costs to defend the related litigation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>substantial monetary awards to trial participants or patients;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the inability to commercialize any drug candidates that we may develop;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>initiation of investigations by regulators;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>loss of revenue;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>diversion of management&#x2019;s time and our resources; and</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">36</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a decline in the price of our ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We currently maintain liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or which is in excess of the limits of our insurance coverage. Our insurance policies also contain various exclusions, and we may be subject to particular liability claims for which we have no coverage. We will have to pay any amount awarded by a court or negotiated in a settlement that exceeds our coverage limitations or that is not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. In addition, if we cannot successfully defend ourselves against such claims, we may incur substantial liabilities and be required to suspend or delay our ongoing clinical trials.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Illegal and</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">or parallel imports and counterfeit pharmaceutical products may reduce demand for our future approved drug candidates and could have a negative impact on our reputation and business.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The illegal importation of competing products from countries where government price controls or other market dynamics result in lower prices may adversely affect the demand for our future approved drug candidates, if any, and, in turn, may adversely affect our sales and profitability in countries and regions where we plan to commercialize our products. Unapproved foreign imports of prescription drugs are illegal in most of the territories all over the world. However, illegal imports may continue to occur or even increase as the ability of patients and other customers to obtain these lower priced imports continues to grow. Furthermore, cross<FONT CLASS="nobreak">-border</FONT> imports from lower<FONT CLASS="nobreak">-priced</FONT> markets (which are known as parallel imports) into higher<FONT CLASS="nobreak">-priced</FONT> markets could harm sales of our future drug products and exert commercial pressure on pricing within one or more markets. In addition, government authorities may expand consumers&#x2019; ability to import lower priced versions of our future approved products or competing products from outside Taiwan, the U.S., China or other countries where we operate or expect to operate. Any future legislation or regulations that increase consumer access to lower priced medicines from outside Taiwan, the United&#x00a0;States, China or other countries where we may operate could have a material adverse effect on our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Certain products distributed or sold in the pharmaceutical market may be manufactured without proper licenses or approvals, or be fraudulently mislabeled with respect to their content or manufacturers. These products are generally referred to as counterfeit pharmaceutical products. The counterfeit pharmaceutical product control and enforcement system, particularly in developing markets may be inadequate to discourage or eliminate the manufacturing and sale of counterfeit pharmaceutical products imitating our products. Since counterfeit pharmaceutical products in many cases have very similar appearances compared with the authentic pharmaceutical products but are generally sold at lower prices, counterfeits of our products could quickly erode the demand for our future approved drug candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In addition, counterfeit pharmaceutical products are not expected to meet our rigorous manufacturing and testing standards. A patient who receives a counterfeit pharmaceutical product may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit pharmaceutical products sold under our brand name. In addition, thefts of inventory at warehouses, plants or while in<FONT CLASS="nobreak">-transit</FONT>, which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RISKS RELATED TO OUR BUSINESS AND INDUSTRY</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We have been involved in legal proceedings in the ordinary course of our business, and are currently involved in active legal proceedings. Any adverse outcome of these legal proceedings could have a material adverse effect on our business, results of operations and financial condition.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">As of the date of this prospectus, we are a party to a legal dispute against one of our shareholders, the Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership), or the Plaintiff, concerning a claim of redemption. The dispute arose out of a share purchase agreement entered into in May 2019&#x00a0;among (i)&#x00a0;the Plaintiff, (ii)&#x00a0;Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited and Sira View Corp. (collectively, the &#x201c;Transferring Shareholders&#x201d;), (iii)&#x00a0;Jyong Biotech Ltd., or &#x201c;Jyong,&#x201d; (iv)&#x00a0;Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd., our Taiwan subsidiary, and (iv)&#x00a0;our CEO, Ms. Fu Feng Kuo, under which the Plaintiff purchased 1,794,258<FONT CLASS="nobreak"> </FONT>shares of Jyong from the Transferring Shareholders at an aggregate price of RMB112,500,000. The Plaintiff filed a complaint to the Taizhou Intermediate People&#x2019;s Court and primarily claimed for a redemption of all shares of Jyong held by it, as well as confirmation of the Plaintiff&#x2019;s right to liquidate all equity interests in our PRC subsidiary, Innovative Biotech Co., Ltd., which was pledged to the Plaintiff by our Hong&#x00a0;Kong subsidiary, Top ShunXing Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Limited on July&#x00a0;22, 2019. This dispute went on trial on March<FONT CLASS="nobreak"> </FONT>16, 2023 and November<FONT CLASS="nobreak"> </FONT>29, 2023, respectively. On March<FONT CLASS="nobreak"> </FONT>25, 2024, the Taizhou Court entered </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">37</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:6.5pt;">into a judgement partially in favor of the Plaintiff, ordering, among other things, the Transferring Shareholders to pay the Redemption price of RMB112,500,000 and corresponding interests, and Jyong, HEB, and Ms. Fu Feng Kuo to be jointly liable for such obligation. The Taizhou Court also ruled that the Plaintiff is entitled to liquidate all equity interest in Innovative Biotech pledged to it in order to realize the payment of the aforementioned obligations. We filed an appeal against this judgement on April<FONT CLASS="nobreak"> </FONT>29, 2024 to the High People&#x2019;s Court of Zhejiang Province (the &#x201c;High Court&#x201d;). The High Court held a hearing for this case on August<FONT CLASS="nobreak"> </FONT>9, 2024, and later issued a judgement against us to sustain the ruling of the Taizhou Court. as of the date of this prospectus, our total potential liability under this judgement is USD 18,998,574.5. The judgment is final and not appealable, and the settlement agreement becomes legally binding upon execution by the parties. Under applicable Chinese law, Taizhou is entitled to initiate enforcement proceedings to recover the approximately RMB 131.6<FONT CLASS="nobreak"> </FONT>million (USD 19.0<FONT CLASS="nobreak"> </FONT>million) in cash, with Jyong, HEB, and Ms. Fu Feng Kuo jointly liable for such obligations. As of the date of this prospectus, no enforcement procedure has been initiated, and the Company is not required to make any payments toward the judgment at this time, as the enforcement procedure has not yet commenced. Under PRC&#x2019;s civil procedure, after a judgement from civil litigation enters into effect, the parties may, at any time before and during the enforcement procedure, and until such enforcement procedure is completed, choose to enter into a settlement agreement and file to the competent court to perform such agreement in lieu of enforcing the judgement. In the opinion of our legal counsel for this lawsuit, should we eventually fail to reach a settlement with the Plaintiff, this case is likely to result in an outcome unfavorable to us. We estimated the fair value of guarantee liabilities at the fair value of the shares at the inception of this guarantee and recorded guarantee liabilities of US$18.4<FONT CLASS="nobreak"> </FONT>million, US$18.8<FONT CLASS="nobreak"> </FONT>million, and US$19.0<FONT CLASS="nobreak"> </FONT>million, respectively, as of December<FONT CLASS="nobreak"> </FONT>31, 2022 and 2023, and June<FONT CLASS="nobreak"> </FONT>30, 2024. For more details about the legal dispute, please see &#x201c;Business&#x00a0;&#x2014;&#x00a0;Legal Proceedings&#x00a0;&#x2014;&#x00a0;Taizhou Investment Dispute.&#x201d; There are no insurance policies to cover related payment liabilities. The dispute may incur substantial costs of settlement or litigation and may result in an outcome adverse to our interests, which may in turn result in the loss of our PRC subsidiary and materially and adversely affect our business, financial conditions and results of operations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">In addition to the right of requesting redemption of the shares purchased, certain provisions of the share purchase agreement also stipulate that the Plaintiff shall enjoy various preferential rights and management authorities as a shareholder of Jyong. Specifically, section 7 of the share purchase agreement states that the Plaintiff shall be entitled to, among other things: (i) the right of anti<FONT CLASS="nobreak">-dilution</FONT> should Jyong engage in financing activities at a lower price per share; (ii) the right of first refusal when Jyong issues new shares or any existing shareholder transfers shares to a third party before &#x201c;Qualified Issuance and Listing&#x201d; (defined as Jyong&#x2019;s potential public filing of shares and listing on the main board of The Stock Exchange of Hong Kong Limited, or the HKEx, which never occurred); and (iii) the right to take prior to other shareholders in case of liquidation events. Section 8 stipulates that should Jyong fails to get listed on the HKEx by June<FONT CLASS="nobreak"> </FONT>30, 2020, then the execution of certain matters shall obtain a written consent from the Plaintiff, including but not limited to: (i) approving any plans for initial public offering or merger/acquisition of Jyong; (ii) amending Jyong&#x2019;s registered capital or issuing any securities that may increase Jyong&#x2019;s registered capital or dilute Plaintiff&#x2019;s shareholding; (iii) selling, transferring or licensing any important intellectual property rights of the group companies; and (iv) determining plan for issuing dividends or offsetting losses for Jyong.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">On November&#x00a0;23, 2022, the Bureau of Natural Resources and Planning in Taizhou (&#x201c;Taizhou Resources Bureau&#x201d;) issued a formal notice of reminder of default, requiring Innovative Biotech Co., Ltd. to pay liquidated damages of RMB13,080,170, with the amount of damages accruing from November<FONT CLASS="nobreak"> </FONT>24, 2022 to the date of actual construction to be calculated separately, due to its failure to commence and complete construction on a parcel of land which it acquired the use right in December&#x00a0;2019. This claim arose out of a land use right agreement entered into on November<FONT CLASS="nobreak"> </FONT>29, 2019 between Innovative Biotech Co., Ltd. and Taizhou Resources Bureau, under which the land use right for a parcel of state<FONT CLASS="nobreak">-owned</FONT> land, with an aggregated area of 26,680 square meters, was transferred to Innovative Biotech Co., Ltd. (the &#x201c;Land Use Right Agreement&#x201d;) for the construction of a pharmaceutical factory project (the &#x201c;Factory Project&#x201d;). According to the Land Use Right Agreement, the construction of the Factory Project shall commence on May<FONT CLASS="nobreak"> </FONT>28, 2020 and complete on November<FONT CLASS="nobreak"> </FONT>28, 2022. However, Innovative Biotech Co., Ltd. failed to commence and complete the construction on agreed schedule. As of the date of this prospectus, we have not paid the liquidated damages of RMB13,080,170 yet and we are actively negotiating with Taizhou Resources Bureau for a settlement of this dispute. Under the Land Use Right Agreement, in addition to the liquidated damages, Innovative Biotech Co., Ltd. is obliged to pay land idling fee if the land is left idle for more than one year but less than two&#x00a0;years, and Taizhou Resources Bureau has the right to take back the land use right if the land is left idle for more than two&#x00a0;years. On September<FONT CLASS="nobreak"> </FONT>26, 2024, the Taizhou Resources Bureau issued a notice regarding taking back the land use right without compensation, giving Innovative Biotech Co., Ltd. the right to file for an administrative hearing within five business days of receipt of notice. While the Company initially applied for the </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">38</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:6.5pt;">administrative hearing, it subsequently decided to relinquish the land use rights to the Taizhou Resources Bureau in accordance with the notice. As a result, the Company will no longer proceed with the hearing process. The claims and proceedings discussed above, and other potential claims or proceedings relating to this issue, could result in substantial costs and materially and adversely affect our business, financial conditions and results of operations. For details about the legal dispute, please also see &#x201c;Business&#x00a0;&#x2014; Legal Proceedings &#x2014; Taizhou Administrative Penalty&#x201d; and &#x201c;Business &#x2014; License and Collaboration Agreements &#x2014; Taizhou Collaboration Framework Agreement.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">Moreover, we are exposed to risks related to potential legal disputes arising from agreements and contracts entered into from time to time in our ordinary course of business. For instance, on December<FONT CLASS="nobreak"> </FONT>21, 2018, we entered into a collaboration framework agreement, or the 2018 Taizhou Agreement, with Taizhou High<FONT CLASS="nobreak">-tech</FONT> Industrial Park Management Committee, or the &#x201c;Taizhou High<FONT CLASS="nobreak">-tech</FONT> Committee,&#x201d; and Taizhou Infrastructure Investment Group Co., Ltd., pursuant to which Taizhou High<FONT CLASS="nobreak">-tech</FONT> Committee agreed to grant up to 40 mu (approximate 26,666.66 sq.m.) industrial land to us for the Factory Project with a favorable price of RMB400,000 per mu and 1,500 mu industry land to us subject to further negotiation. On September<FONT CLASS="nobreak"> </FONT>12, 2019, based on the 2018 Taizhou Agreement, we entered into an investment cooperation agreement with the Taizhou Circular Economic Industrial Concentration District Administrative Committee (the &#x201c;Taizhou Industry District Committee&#x201d;), the successor of the Taizhou High<FONT CLASS="nobreak">-tech</FONT> Committee, or the &#x201c;2019 Taizhou Agreement,&#x201d; which further specified details relating to the Factory Project with no material deviation from the 2018 Taizhou Agreement. According to the 2018 Taizhou Agreement and 2019 Taizhou Agreement, we are obligated to complete the construction of the Factory Project by 2022, which shall be ready for production by 2023. As of the date of this prospectus, the construction of the Factory Project has yet taken place due to travel restriction, quarantines and lock<FONT CLASS="nobreak">-downs</FONT> caused by COVID<FONT CLASS="nobreak">-19</FONT>. In addition, RMB30<FONT CLASS="nobreak"> </FONT>million of Innovative Biotech Co., Ltd.&#x2019;s registered capital shall be actually paid within one year of its registration. As of the date of this prospectus, only RMB16,562,000 of Innovative Biotech Co., Ltd.&#x2019;s registered capital has been paid. Furthermore, our PRC subsidiary shall pay a cash deposit of RMB 10,000 per mu after signing the &#x201c;standard parcel&#x201d; development and construction agreement, or the Construction Agreement, with the Taizhou Industry District Committee. As of the date of this prospectus, no such deposit has been paid since the Construction Agreement was signed. According to the 2018 Taizhou Agreement, failure to commence and conclude the construction of the Factory Project on schedule as agreed may entitle the Taizhou Municipality with the rights to replace the granted parcel, adjust or withdraw the preferential policies available under such agreement (including but not limited to the government subsidy of RMB12.0<FONT CLASS="nobreak"> </FONT>million innovative Biotech Co., Ltd. has already received), and take back the parcel with the original purchase price of RMB400,000 per mu. See also &#x201c;Business&#x00a0;&#x2014;&#x00a0;License and Collaboration Agreements&#x00a0;&#x2014;&#x00a0;Taizhou Collaboration Framework Agreement.&#x201d; </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On November<FONT CLASS="nobreak"> </FONT>29, 2019, our PRC subsidiary, Innovative Biotech Co. (&#x201c;IB&#x201d;) entered into the Construction Agreement with the Taizhou Industry District Committee. The Construction Agreement provided specifics regarding the Factory Project IB was required to meet, including but not limited to the period of construction, plot ratio, amount of investment and tax income per mu. The Construction Agreement stipulates that before the Factory Project meets the requirements of amount of investment and plot ratio under the Construction Agreement, IB and its shareholder shall not transfer the acquired parcel, directly or via transfer or pledge of equity, to a third party. Should IB breaches this agreement and causes the purpose of the Construction Agreement unable to be realized, the Taizhou Industry District Committee shall have the right to terminate the Construction Agreement and claim corresponding damages. The Taizhou Industry District Committee did not explicitly consent to the pledging of IB&#x2019;s shares to the Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership). However, as of the date of this prospectus, the Taizhou Industry District Committee has yet to raise any claims against IB based on the event discussed above. As of December<FONT CLASS="nobreak"> </FONT>31, 2022 and 2023, and June<FONT CLASS="nobreak"> </FONT>30, 2024, IB classified the liquidated damages and accrued interests of US$2.2<FONT CLASS="nobreak"> </FONT>million, US$3.0<FONT CLASS="nobreak"> </FONT>million, and US$2.7<FONT CLASS="nobreak"> </FONT>million as other current liabilities, respectively. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">On November<FONT CLASS="nobreak"> </FONT>29, 2022, the Taizhou Bay New District Administrative Committee (the &#x201c;Plaintiff&#x201d;), successor of the Taizhou Industry District Committee, filed a civil complaint to the Taizhou Intermediate People&#x2019;s Court (&#x201c;the Taizhou Court&#x201d;) against our PRC subsidiary, IB, claiming that IB has materially breached the 2019 Taizhou Agreement by failing to initiate and conclude the construction of the Factory Project in accordance with the schedule stipulated by the 2019 Taizhou Agreement and the Land Use Right Agreement. The Plaintiff requested the Taizhou Court to terminate the 2019 Taizhou Agreement, and to order IB to return the government subsidy of RMB 12.0<FONT CLASS="nobreak"> </FONT>million IB previously received under the 2019 Taizhou Agreement, and to pay corresponding interests calculated at the Loan Prime Rate published by the National Inter<FONT CLASS="nobreak">-bank</FONT> Funding Center. On December<FONT CLASS="nobreak"> </FONT>1, 2022, the Court issued an order of preliminary asset preservation, freezing the RMB 12.0<FONT CLASS="nobreak"> </FONT>million deposit in IB&#x2019;s bank account. This dispute went on trial on February<FONT CLASS="nobreak"> </FONT>13, 2023, and two hearings were held on May<FONT CLASS="nobreak"> </FONT>6, 2023 and August<FONT CLASS="nobreak"> </FONT>17, 2023 respectively. On September<FONT CLASS="nobreak"> </FONT>8, 2023, the Court entered into a judgement in favor of the Plaintiff, terminating the 2019 Taizhou Agreement and ordering IB to return the government subsidy of RMB12.0<FONT CLASS="nobreak"> </FONT>million </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">39</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;text-indent:0pt;margin-top:5pt;">and corresponding interest and expenses to the Plaintiff. On September<FONT CLASS="nobreak"> </FONT>14, 2023, we filed an appeal with the High People&#x2019;s Court of Zhejiang Province (the &#x201c;High Court&#x201d;) regarding each of the Court&#x2019;s rulings described above. The High Court held a hearing for this case on October<FONT CLASS="nobreak"> </FONT>24, 2023. On December<FONT CLASS="nobreak"> </FONT>12, 2023, the High Court issued a judgment against IB to affirm the Taizhou Court&#x2019;s ruling in its entirety. On January<FONT CLASS="nobreak"> </FONT>5, 2024, the Taizhou Court issued an order of enforcement, stipulating, among other things, freezing and assignment of IB&#x2019;s deposit in its bank account or withholding of IB&#x2019;s income up to RMB 12.0<FONT CLASS="nobreak"> </FONT>million and corresponding interests, and the seizure, attachment and freezing of IB&#x2019;s property valued at RMB 12.0<FONT CLASS="nobreak"> </FONT>million and corresponding interests, and restrictions on making certain high expenses by IB and related personnel. As of the date of this prospectus, the 40 mu (approximate 26,666.66 sq.m.) industrial land we acquired for the Factory Project have been seized by the Taizhou Court, and IB&#x2019;s RMB 11.1<FONT CLASS="nobreak"> </FONT>million deposit in its bank account has been transferred to the Plaintiff. On December<FONT CLASS="nobreak"> </FONT>27, 2023, we filed a petition for retrial to the Supreme People&#x2019;s Court of the People&#x2019;s Republic of China (the &#x201c;Supreme Court&#x201d;). The Supreme Court issued a decision to reject our petition for retrial on August<FONT CLASS="nobreak"> </FONT>21, 2024. As of December<FONT CLASS="nobreak"> </FONT>31, 2022 and 2023, and June<FONT CLASS="nobreak"> </FONT>30, 2024, IB accrued US$2.0<FONT CLASS="nobreak"> </FONT>million, US$2.0<FONT CLASS="nobreak"> </FONT>million, and US$0.4<FONT CLASS="nobreak"> </FONT>million of other current liabilities for the loss contingencies for this dispute, respectively. For more details about the legal dispute, please see &#x201c;Business &#x2014; Legal Proceedings &#x2014; Taizhou Government Subsidy Dispute.&#x201d; There are no insurance policies to cover related payment liabilities. This dispute has resulted in an outcome adverse to our interests, which may in turn result in financial loss and adversely affect our business, financial conditions and results of operations. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">We plan to use approximately 10.0% of the net proceeds of this initial public offering for (i) a possible settlement of the litigation with Taizhou Bay New District Administrative Committee, including the return of government subsidiary, litigation expenses and interest expenses, and (ii) commitments with Taizhou Resources Bureau, including liquidated damages and land idling fee. We may, in the future, be subject to allegations, claims and legal actions arising in the ordinary course of our business, which may include claims by shareholders and claims by third parties, including customers, suppliers, product consumers, business partners, or regulators. If any of these proceedings is determined adversely against us, or results in judgments, fines or settlements involving a payment of a material sum of money, it could materially and adversely affect our business, financial condition, and results of operations. In addition, negative publicity could adversely affect the reputation and brand of the operating entities. Even the successful defense of these proceedings may cause the operating entities to incur substantial legal costs and may divert management&#x2019;s attention and resources.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We face economic and political risks associated with doing business in Taiwan, particularly due to the geopolitical tension between Taiwan and PRC that could negatively affect our business and hence the value of your investment.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">Our performance is affected by global economic conditions as well as geopolitical issues and other conditions with global reach. Macroeconomic weakness and uncertainty make it more difficult for us to manage our operations and accurately forecast financial result. As a result of the invasion of Ukraine by Russia, the United&#x00a0;States, the European Union, the United Kingdom and other jurisdictions have imposed sanctions on certain Russian and Ukrainian persons and entities, including certain Russian banks, energy companies and defense companies, and have imposed restrictions on exports of various items to Russian and certain regions of Ukraine (including the self<FONT CLASS="nobreak">-proclaimed</FONT> Donetsk People&#x2019;s Republic and Luhansk People&#x2019;s Republic and Crimea). Moreover, on February&#x00a0;22, 2022, the Office of Foreign Assets Control of the United&#x00a0;States issued sanctions aimed at limiting Russia&#x2019;s ability to raise funds through sovereign debt. Such ongoing events between Ukraine and Russia could also increase China/Taiwan political tensions and U.S./China trade and other relations. These geopolitical issues have resulted in increasing global tensions and create uncertainty for global commerce. Any or all of these factors could negatively affect demand for our products and our business, financial condition and result of operations. In addition, new requirements or restrictions could come into effect which might increase the scrutiny on our business or result in one or more of our business activities being deemed to have violated sanctions. Our business and reputation could be adversely affected if the authorities of the United Nations, the United&#x00a0;States, the European Union, Taiwan or other jurisdictions were to determine that any of our activities constitutes a violation of the sanctions they impose or provides a basis for a sanction&#x2019;s designation of us.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">Further, our headquarters, R&amp;D center and material laboratory are located in Taiwan. Accordingly, our business, financial condition and results of operations and the market price of our ordinary shares may be affected by changes in governmental policies, taxation, growth rate, inflation rate or interest rates and by social instability and diplomatic and social developments in or affecting Taiwan. In particular, the unique political status of Taiwan and its internal political movement cause sustained tension between PRC and Taiwan. Past developments related to the interactions between PRC and Taiwan, especially in relation to trade activities such as bans on exports of goods from time to time, have on occasions depressed the transactions and business operations of certain Taiwanese companies </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">40</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:5.5pt;">and overall economic environment. We cannot predict whether there will be an escalation of the tensions between PRC and Taiwan which would lead to new bans or tariffs on exports or even conflict. Any conflict which threatens the military, political or economic stability in Taiwan could have a material adverse effect on our current or future business and financial condition and results of operations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;">We have engaged in transactions with related parties, and such transactions present possible conflicts of interest that could have an adverse effect on our business and results of operations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We have entered into a number of transactions with related parties, including our significant stockholders, directors and executive officers, and their relatives. For example, we have entered into several transactions with our Co<FONT CLASS="nobreak">-Founder</FONT> and Chief Executive Officer, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, including leases with landlord entities in which Ms. Kuo has or had a significant ownership interest. Also, From February 2021 to November 2021, the Company entered into several loan agreements with Nobel Consumer Corporation, which is managed by a related party of the Company. See &#x201c;Related Party Transactions&#x201d; on page 182. We may in the future enter into additional transactions with entities in which members of our board of directors and other related parties hold ownership interests.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Transactions such as loans and leases in which related parties hold ownership interests present potential conflicts of interest. The interests of the landlord entity and lender, along with their shareholders, may not align with the interests of our stockholders regarding the negotiation and certain other matters related to our lease or loan terms with that landlord entity or lender. We may have achieved more favorable terms if such transactions had not been entered into with related parties, and these transactions, individually or in the aggregate, may have an adverse effect on our business and results of operations, or may result in government enforcement actions or other litigation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;">We will need to obtain substantial additional financing for our outstanding liabilities due to legal proceedings and commitment, and bank loans, and if we fail to obtain additional financing, we may not be able to continue as a going concern. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The accompanying financial statements in this prospectus have been prepared in accordance with accounting principles generally accepted in the United States of America on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Accordingly, the financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should we be unable to continue as a going concern. We concluded that there is substantial doubt about our ability to continue as a going concern for a period of one year from the date that the unaudited interim consolidated financial statements included in this registration statement were issued. In addition, our independent registered public accounting firm has issued a report that included an explanatory paragraph referring to our significant net losses, working capital deficit and need to raise additional funds, which also raised substantial doubt about our ability to continue as a going concern as it noted.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As of the date of this prospectus, we have not generated revenue and we had a net working capital deficit of approximately US$12.4<FONT CLASS="nobreak"> </FONT>million and US$11.7<FONT CLASS="nobreak"> </FONT>million as of December<FONT CLASS="nobreak"> </FONT>31, 2023 and June<FONT CLASS="nobreak"> </FONT>30, 2024, respectively. This deficit included accrued expenses of approximately US$1.1<FONT CLASS="nobreak"> </FONT>million and US$0.9<FONT CLASS="nobreak"> </FONT>million, accounts payable of approximately US$2,000 and US$9,000, short<FONT CLASS="nobreak">-term</FONT> and long<FONT CLASS="nobreak">-term</FONT> loan from banks of approximately US$8.0<FONT CLASS="nobreak"> </FONT>million and US$7.5<FONT CLASS="nobreak"> </FONT>million which will be due within the next twelve months, other current liabilities of approximately US$5.0<FONT CLASS="nobreak"> </FONT>million and US$ 3.1<FONT CLASS="nobreak"> </FONT>million due to litigation with Taizhou Bay New District Administrative Committee and commitments with Taizhou Resources Bureau, and accrued interest owed under the loan agreement with related parties of approximately US$0.1<FONT CLASS="nobreak"> </FONT>million and US$0.1<FONT CLASS="nobreak"> </FONT>million, as of December<FONT CLASS="nobreak"> </FONT>31, 2023 and June<FONT CLASS="nobreak"> </FONT>30, 2024, respectively. As of the date of this prospectus, the Company&#x2019;s total potential liability under the judgment in the Taizhou Investment Dispute is approximately USD 18,998,574.50. The judgment is final and non<FONT CLASS="nobreak">-appealable</FONT>. Under applicable Chinese law, Taizhou is entitled to initiate enforcement proceedings to recover approximately RMB 131.6<FONT CLASS="nobreak"> </FONT>million (USD 19.0<FONT CLASS="nobreak"> </FONT>million) in cash, with Jyong, HEB, and Ms. Fu Feng Kuo jointly and severally liable for such obligations. As of the date of this prospectus, no enforcement procedure has been initiated, and the Company is not presently required to make any payments toward the judgment. The Company is engaged in ongoing discussions with the counterparty to reach a settlement; however, there can be no assurance that a settlement will be reached. In the event that a settlement is not concluded, Jyong, HEB, and Ms. Fu Feng Kuo may be required to jointly pay the full amount of approximately RMB 131.6<FONT CLASS="nobreak"> </FONT>million (USD 19.0<FONT CLASS="nobreak"> </FONT>million) in cash. We intend to use the net proceeds of this initial public offering to fund our future operations and debt obligations. If we are unable to complete the offering for a sufficient amount in a timely manner, we may need to seek other financing alternatives such as private financing of debt or equity or collaboration agreements. We will seek future funding based on the </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">41</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">requirements of our business operations until we obtain regulatory approvals to market and commercialize our drug candidates and generate sufficient revenue from them. We have the ability to exercise discretion and flexibility to deploy our capital resources used in research and development activities according to the amount and timing of our financing activities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We cannot guarantee that we are able to obtain future financing in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to: </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>significantly delay, scale back or discontinue the development or commercialization of our product candidates; </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>seek corporate partners for our product candidates when we would otherwise develop our product candidates on our own, or at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>relinquish or license on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves; or </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>significantly curtail or cease operations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing development and commercialization efforts, which will have a material and adverse effect on our business, operating results and prospects which could result in a loss of your investment.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We are required to comply with extensive regulations and hold a number of permits and licenses to carry on our business in Taiwan. Our ability to obtain and maintain these regulatory approvals is uncertain, and future government regulation may place additional burdens on our efforts to commercialize our drug candidates.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We are a Taiwan<FONT CLASS="nobreak">-based</FONT> biotechnology company which is subject to extensive government regulation and supervision in Taiwan. The regulatory framework addresses all aspects of operating in the pharmaceutical industry, including product development activities, clinical trials, registration, production, distribution, packaging, labelling, storage and shipment, advertising, licensing and post<FONT CLASS="nobreak">-approval</FONT> pharmacovigilance certification requirements and procedures, periodic renewal and reassessment processes, data security and data privacy protection requirements and compliance and environmental protection. Violation of applicable laws and regulations may materially and adversely affect our business. In particular, if we and our cooperators are unable to obtain or renew permits or licenses required for our operations, they will not be able to manufacture or distribute our drug candidates and we will not be able to engage in the commercialization and distribution of our drug candidates and our business may be adversely affected.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">The regulatory framework governing the pharmaceutical industry in Taiwan is subject to change and amendment from time to time. Any such change or amendment could materially and adversely impact our business, financial condition and prospects. The Taiwan government has introduced pharmaceutical laws and regulations in recent&#x00a0;years, especially imposing further obligations on the pharmaceutical manufacturers with respect to the management of drug safety surveillance. In addition, in order to align Taiwan laws and regulations with the global practice, the Taiwan government also requires the pharmaceutical manufacturers to comply with several global practice rules. In addition, the Taiwan government has also introduced reforms to the health care system in recent&#x00a0;years and may continue to do so, with an overall objective to expand basic medical insurance coverage and improve the quality and reliability of healthcare services. The specific regulatory changes under the various reform initiatives remain uncertain. The implementing measures to be issued may not be sufficiently effective to achieve the stated goals, and as a result, we may not be able to benefit from such reform to the extent we expect, if at all. Moreover, the various reform initiatives could give rise to regulatory developments, such as more burdensome administrative procedures, which may have an adverse effect on our business, financial condition and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">For further information regarding government regulation in Taiwan and other jurisdictions, see &#x201c;Regulations&#x201d; for more details.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Even if we receive regulatory approval for any of our drug candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense, and if we fail to comply with ongoing regulatory requirements or experience any unanticipated problems with any of our drug candidates, we may be subject to penalties.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">If the TFDA, the U.S. FDA or a comparable regulatory authority approves any of our drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">42</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:5.5pt;">promotion and record keeping for any such drug will be subject to extensive and ongoing regulatory requirements. These requirements may include submissions of safety and other post<FONT CLASS="nobreak">-marketing</FONT> information and reports, facility registration and drug listing requirements, and continued compliance with current good laboratory practices, or cGLPs and current good clinical practice, or GCPs. Any regulatory approvals that we receive for our drug candidates may also be subject to limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post<FONT CLASS="nobreak">-marketing</FONT> testing.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">Once a drug is approved by the TFDA, the U.S. FDA or a comparable regulatory authority for marketing, it is possible that there could be a subsequent discovery of previously unknown problems with the drug, including problems with manufacturing processes, or failure to comply with regulatory requirements. If any of the foregoing occurs with respect to our drug products, it may result in, among other things:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>restrictions on the marketing or manufacturing of the drug, withdrawal of the drug from the market or voluntary or mandatory drug recalls;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring mediation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, such as boxed warnings;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>imposition of a risk mitigation plan, or RMP, which may include distribution or use restrictions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>requirements to conduct additional post<FONT CLASS="nobreak">-market</FONT> clinical trials to assess the safety of the product;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>fines, warning letters or holds on clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>refusal by the TFDA, the U.S. FDA or comparable regulatory authorities to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of drug license approvals;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>product seizure or detention, or refusal to permit the import or export of products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>injunctions or the imposition of civil, administrative or criminal penalties; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>revocation of approval of such drug.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources and could generate negative publicity. Moreover, regulatory policies may change or additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are not able to maintain regulatory compliance, regulatory approval that has been obtained may be lost and we may not achieve or sustain profitability, which may harm our business, financial condition and prospects significantly.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our future success depends on our ability to attract, retain and motivate senior management and qualified scientific employees.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We are highly dependent on the expertise of the members of our research and development team, as well as the principal members of our management. We have entered into employment agreements with our executive officers, but each of them may terminate their employment with us at any time with or without prior written notice. In addition, we currently do not have &#x201c;key<FONT CLASS="nobreak">-man</FONT>&#x201d; insurance for any of our executive officers or other key personnel.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Recruiting, retaining and motivating qualified management, scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Further, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize drugs. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, our management will be required to devote significant time to compliance initiatives from our status as a public company, which may require us to recruit more management personnel.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">43</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Competition for skilled personnel is intense, particularly in the pharmaceutical industry. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. This competition may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous biotechnology companies for similar personnel. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed or may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we do not achieve our projected development and commercialization goals in the timeframes we announced and expected, the commercialization of any of our drug candidates may be delayed and our business will be negatively influenced.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">For planning purposes, we generally estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the regulatory submissions or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical trials, receipt of regulatory approval or the commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones to vary considerably from our estimates, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our available capital resources or capital constraints we experience;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the rate of progress, costs and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to identify and enroll patients who meet clinical trial eligibility criteria;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our receipt of approvals by the TFDA, the U.S. FDA and comparable regulatory authorities in other jurisdictions, and the timing thereof;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>other actions, decisions or rules issued by regulators;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to access sufficient, reliable and affordable supplies of materials used in the manufacture of our drug candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to manufacture and supply clinical trial materials to our clinical sites on a timely basis;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the efforts of our collaborators with respect to the commercialization of our products; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the securing of, costs related to, and timing issues associated with, commercial product manufacturing as well as sales and marketing activities.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>If we fail to achieve announced milestones in the timeframes we expected, the commercialization of any of our drug candidates may be delayed, and our business, results of operations, financial condition and prospects may be adversely affected.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Certain of our facilities were mortgaged. If the mortgagees enforce the mortgage, our business could be materially and adversely affected. </FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Some of our properties are mortgaged to commercial banks. We currently mortgage our titles of two constructions and two land parcels in Yilan County to Taiwan Cooperative Bank Suao Branch (&#x201c;Taiwan Cooperative Bank&#x201d;) to secure our long terms borrowings with a total amount of NTD88.2&#x00a0;million. The two constructions and two land parcels in Yilan County are currently used as our research and development center.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Taiwan Cooperative Bank may, at any time, reduce the loan amount or shorten the term of the loan to the Company, or deem it to be fully due, if any of the following circumstances apply to any of the debts owed by our Company to Taiwan Cooperative Bank, without prior notice or reminder from Taiwan Cooperative Bank: (1) when any debt is not paid off as agreed or when the principal is to be paid ; (2)when filing for settlement in accordance with the Bankruptcy Law, filing for declaration of bankruptcy, filing for company reorganization, being notified by the clearing house to refuse transactions, cessation of business, liquidation of debts; (3) when the original obligation </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">44</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">to provide guarantee is not provided according to the agreement; (4) when an heir is declared to have abandoned the inheritance after the person&#x2019;s death; (5) when the main property is confiscated due to criminal offenses; and (6) in addition to the above items, it is necessary for your bank to preserve its creditor&#x2019;s rights and the matters specifically stipulated in the contract. The copy of the mortgage agreement has been filed as exhibit 10.8.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In case the mortgagees enforce the mortgage, we may not be able to continue using our properties. Our business may be interrupted, and additional relocation costs may be incurred if we are required to relocate operations. Even if the mortgage is not enforced, such third<FONT CLASS="nobreak">-party</FONT> security rights may also limit our use of the collateral assets and adversely affect our operational efficiency. It could result in diversion of management attention and cause us to incur extra costs associated with addressing relevant issues. However, as of the date of this prospectus, we are not aware of any action, claim or investigation being conducted or threatened by mortgagees to enforce the mortgage.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">We are subject to risks relating to our leased properties.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We lease certain real properties in Taiwan and China from third parties primarily as office space and operation facilities. We may become involved in disputes with the property owners or third parties who otherwise have rights to or interests in our leased properties. We can provide no assurance that we will be able to find suitable replacement sites on terms acceptable to us on a timely basis, or at all, or that we will not be subject to material liability resulting from third parties&#x2019; challenges on our use of such properties. As a result, our business, financial condition and results of operations may be materially and adversely affected. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Furthermore, we have not registered any of our leasehold interests with the relevant Chinese governmental authorities as required by PRC law, which may expose us to potential fines if we fail to remediate after receiving any notice from the relevant Chinese governmental authorities. Failure to complete the lease registration will not affect the legal effectiveness of the lease agreements according to PRC law, but the real estate administrative authorities may require the parties to the lease agreements to complete lease registration within a prescribed period of time, and failure to do so may subject the parties to fines from RMB1,000 ($US138) to RMB10,000 ($US138) for each of such lease agreements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As of the date of this prospectus, we are current on our mortgage payments, no defaults have occurred, and we had not been subject to any actions, claims or investigations threatened against us or our lessors with respect to the defects in our leasehold interests which may have a material adverse impact on our business, financial condition and results of operation. However, if any of our leases is terminated as a result of challenges by third parties or governmental authorities for lack of title certificates or proof of authorization to lease, we do not expect to be subject to any fines or penalties, but we may be forced to relocate the affected offices, stores or warehouses and incur additional expenses relating to such relocation. We cannot guarantee that suitable alternative locations are readily available on commercially reasonable terms, or at all, and if we fail to relocate our operations in a timely manner, our operations may be interrupted.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our employees, consultants, collaborators and contract research organizations may engage in misconduct or other improper activities, including </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">non-compliance</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We are exposed to the risk that our employees, consultants, collaborators and contract research organizations may engage in fraud or other misconduct, including intentional failures to comply with the TFDA and the U.S. FDA regulations or similar regulations of comparable regulatory authorities, to provide accurate information to the TFDA, the U.S. FDA or comparable regulatory authorities, to comply with manufacturing standards we have established, to comply with healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable regulatory authorities, to report financial information or data accurately or to disclose unauthorized activities to us. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition and results of operations, including the imposition of significant fines or other sanctions.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">45</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We have limited insurance coverage, and any claims beyond our insurance coverage may result in our incurring substantial costs and a diversion of resources.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We maintain insurance policies that are required under applicable laws and regulations as well as insurance based on our assessment of our operational needs and industry practice. We also maintain liability insurance covering our clinical trials as well as certain other types of insurance. Our insurance coverage may be insufficient to cover any claim for product liability, damage to our fixed assets or employee injuries. Any liability or damage to, or caused by, our facilities or our personnel beyond our insurance coverage may result in our incurring substantial costs and a diversion of resources.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We also expect that operating as a public company will make it more expensive for us to obtain director and officer liability insurance, since we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as our executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may result in a substantial amount of payments, which would adversely affect our cash position and results of operations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our future success depends on our ability to promote our brand and protect our reputation. If we are unable to effectively promote our brand, our business may be materially and adversely affected.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">We believe that enhancing and maintaining awareness of our &#x201c;HEB&#x201d; brand is critical to achieving widespread acceptance of our drug candidates, especially MCS<FONT CLASS="nobreak">-2</FONT>, and attracting new customers. Successful promotion of our brand depends largely on the quality of the products we offer and the effectiveness of our branding and marketing efforts. We expect that our branding and marketing efforts will require us to incur significant expenses and devote substantial resources. We cannot guarantee that our sales and marketing efforts will be successful. Brand promotion activities may not lead to increased revenue in the near term, and, even if they do, any revenue increases may not offset the expenses we incur to promote our brand. Our failure to establish and promote our brand and any damage to our reputation will hinder our growth. In addition, our reputation may be undermined as a result of the negative publicity about our company or our industry in general. If our drug candidates do not perform to customers&#x2019; expectations, it may result in lower confidence in our products in general, which may in turn impair our operating results and our reputation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The tax laws of the jurisdictions in which we operate may adversely affect our business and our tax results.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">The tax laws applicable to our business activities are subject to change and uncertain interpretation. Our tax position could be adversely impacted by changes in tax rates, laws, practices, treaties or regulations or changes in the interpretation thereof by the authorities in jurisdictions in which we do business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">Moreover, we conduct operations through our subsidiaries in various tax jurisdictions pursuant to transfer pricing arrangements between us and our subsidiaries. While we believe that we operate in compliance with applicable transfer pricing laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable tax authorities. If tax authorities in any jurisdiction in which we operate were to successfully challenge our transfer prices as not reflecting arms&#x2019; length transactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect these revised transfer prices, which could result in a higher tax liability to us. Furthermore, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. Such circumstances could adversely affect our financial condition, results of operations and cash flows.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we, our CROs, consultants or any other collaborators fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">We and third parties, such as our CROs and consultants or any other collaborators, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">46</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;text-indent:0pt;margin-top:5pt;">We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">In addition, we may be required to incur substantial costs to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Although the audit report included in this prospectus is issued by an independent registered public accounting firm that is subject to inspections by the Public Company Accounting Oversight Board, or the PCAOB, and has been inspected by the PCAOB on a regular basis, there is no guarantee that future audit reports will be prepared by auditors or their international affiliates in jurisdictions where the PCAOB is able to fully inspect their work, and as such, future investors may be deprived of such inspections, which could result in limitations or restrictions to our access of the U.S.&#x00a0;capital markets.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">On April&#x00a0;21, 2020, SEC Chairman Jay Clayton and PCAOB Chairman William D.&#x00a0;Duhnke&#x00a0;III, along with other senior SEC staff, released a joint statement highlighting the risks associated with investing in companies based in or having substantial operations in emerging markets including China. The joint statement emphasized the risks associated with lack of access for the PCAOB to inspect auditors and audit work papers in China and higher risks of fraud in emerging markets.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May&#x00a0;18, 2020, Nasdaq filed three proposals with the SEC to (i)&#x00a0;apply minimum offering size requirement for companies primarily operating in &#x201c;Restrictive Market,&#x201d; (ii)&#x00a0;adopt a new requirement relating to the qualification of management or board of director for Restrictive Market companies, and (iii)&#x00a0;apply additional and more stringent criteria to an applicant or listed company based on the qualifications of the company&#x2019;s auditors.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May&#x00a0;20, 2020, the U.S.&#x00a0;Senate passed the HFCAA requiring a foreign company to certify it is not owned or controlled by a foreign government if the PCAOB is unable to audit specified reports because the company uses a foreign auditor not subject to PCAOB inspection. If the PCAOB is unable to inspect the company&#x2019;s auditors for three consecutive&#x00a0;years, the issuer&#x2019;s securities are prohibited from trading on a national exchange. On December&#x00a0;2, 2020, the U.S.&#x00a0;House of Representatives approved the HFCAA.&#x00a0;On December&#x00a0;18, 2020, the HFCAA was signed into law. On March&#x00a0;28, 2021, the SEC issued interim measures implementing the HFCAA which became effective on May&#x00a0;5, 2021. On December&#x00a0;2, 2021, the SEC adopted final amendments implementing congressionally mandated submission and disclosure requirements of the HFCAA, which sent into effect on January&#x00a0;10, 2022. On June&#x00a0;22, 2021, the U.S.&#x00a0;Senate passed the Accelerating Holding Foreign Companies Accountable Act. The bill, which was enacted, shortened the three<FONT CLASS="nobreak">-consecutive</FONT><FONT CLASS="nobreak">-year</FONT> compliance period under the HFCAA to two consecutive&#x00a0;years. As a result, the time period before our ordinary shares may be prohibited from trading or delisted will be reduced. On September&#x00a0;22, 2021, the PCAOB adopted a final rule implementing the HFCAA, which provides a framework for the PCAOB to use when determining, as contemplated under the HFCAA, whether the PCAOB is unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Inspections of an independent registered public accounting firm conducted by the PCAOB outside China have at times identified deficiencies in those auditors&#x2019; audit procedures and quality control procedures, which may be addressed as part of the inspection process to improve future audit quality. The recent joint statement by the SEC and PCAOB, proposed rule changes submitted by Nasdaq, and the Holding Foreign Companies Accountable Act, or HFCAA, all call for additional and more stringent criteria to be applied to emerging market companies, including companies based in China, upon assessing the qualification of their auditors, especially the non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;auditors who are not inspected by the PCAOB.&#x00a0;On August<FONT CLASS="nobreak"> </FONT>26, 2022, the PCAOB signed a Statement of Protocol with the China Securities Regulatory Commission and the PRC Ministry of Finance, which was the first step toward opening access for the PCAOB to inspect and investigate registered public accounting firms headquartered in mainland China and Hong&#x00a0;Kong completely, consistent with U.S.&#x00a0;Law. On December<FONT CLASS="nobreak"> </FONT>15, 2022, the PCAOB determined that it was able to secure complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and vacated its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB&#x2019;s access in the future, the PCAOB may consider the need to </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">47</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">issue a new determination. On December<FONT CLASS="nobreak"> </FONT>29, 2022, the Accelerating HFCAA was signed into law, which amended the HFCAA by requiring the SEC to prohibit an issuer&#x2019;s securities from trading on any U.S. stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years instead of three.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our auditor, WWC, P.C., headquartered in San Mateo, California, is independent registered public accounting firms with the PCAOB, are required under the laws of the United&#x00a0;States to undergo regular inspections by the PCAOB to assess their compliance with the laws of the United&#x00a0;States and professional standards. Therefore, it is not subject to the determinations announced by the PCAOB on December&#x00a0;16, 2021 as it is not on the list published by the PCAOB.&#x00a0;Although we have a subsidiary within the PRC, a jurisdiction where the PCAOB is currently unable to conduct inspections without the approval of the Chinese government authorities, our auditor, WWC, P.C., headquartered in San Mateo, California, has been inspected by the PCAOB on a regular basis. However, due to the recent developments in connection with the implementation of the HFCAA, we still cannot assure you whether the SEC, Nasdaq or other regulatory authorities would apply additional and more stringent criteria to us after considering the effectiveness of our auditor&#x2019;s audit procedures and quality control procedures, adequacy of personnel and training, or sufficiency of resources, geographic reach or experience as it relates to the audit of our financial statements. The requirement in the Accelerating HFCAA that the PCAOB be permitted to inspect the issuer&#x2019;s public accounting firm within two&#x00a0;years, may result in our delisting in the future if the PCAOB is unable to inspect our accounting firm at such future time.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our internal computer systems, or those used by our consultants or any other </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">third-party</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> cooperators may fail or suffer breakdowns, cyberattacks or information security breaches that could compromise the confidentiality, integrity and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial or proprietary information, and affect our reputation.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Despite the implementation of security measures, our internal computer systems or those used by our consultants or any other third<FONT CLASS="nobreak">-party</FONT> cooperators, may be vulnerable to damage from computer viruses and unauthorized access. As the cyber<FONT CLASS="nobreak">-threat</FONT> landscape evolves, attacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect. These risks are increased given the recent work from home arrangements because of the COVID<FONT CLASS="nobreak">-19</FONT> pandemic, the monkeypox outbreak and the threat of Russian cyberattacks in response to the war in Ukraine. Such attacks could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering, and/or other means. If a breakdown, cyberattack, or other information security breach were to occur and cause interruptions in our operations, it could result in a misappropriation of confidential information, including our intellectual property or financial information, and a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed, ongoing, or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third<FONT CLASS="nobreak">-party</FONT> research institution collaborators for research and development of our drug candidates and other third parties for the manufacture of our drug candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, financial, or proprietary information, including data related to our personnel, we could incur liability or risk disclosure of confidential, financial, or proprietary information, and the further development and commercialization of our drug candidates could be delayed. There can be no assurance that we and our business counterparties will be successful in efforts to detect, prevent, or fully recover systems or data from all breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data, which could result in financial, legal, business, or reputational harm to us.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which could include civil or criminal fines or penalties, private litigation, other liabilities, and</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products, could limit their use or adoption, and could otherwise negatively affect our operating results and business.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of personal information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Regulatory authorities in virtually every jurisdiction in which we operate have implemented and are considering a </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">48</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">number of legislative and regulatory proposals concerning personal data protection. Additionally, the interpretation and application of data protection laws in jurisdictions applicable to us are often uncertain and in flux. We therefore face uncertainty as to the exact interpretation of any such requirements, and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of new laws.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Since we are conducting clinical trials in the U.S., we are subject to laws and regulations that address privacy, personal information protection and data security at both the federal and state levels, including federal Health Insurance Portability and Accountability Act&#x00a0;of&#x00a0;1996, or HIPAA, as amended by the Health Information Technology and Clinical Health Act, and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Numerous laws and regulations, including security breach notification laws, health information privacy laws, and consumer protection laws, govern the collection, use, disclosure and protection of health<FONT CLASS="nobreak">-related</FONT> and other personal information. Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implementing all measures required by regulators or courts in their interpretation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We are also subject to laws and regulations that address personal information protection and data security in Taiwan, primarily including the Personal Data Protection Act (&#x201c;PDPA&#x201d;), under which we are generally required to give notice to and obtain consent from an individual before collecting, processing, or using any of the said individual&#x2019;s personal information, subject to certain exceptions, and are restricted from providing personal information beyond the authorized scope to third parties without an individual&#x2019;s prior consent. Personal data pertaining to a natural person&#x2019;s medical records, healthcare, genetics, sex life, physical examination and criminal records are classified as sensitive personal data, which shall be subject to certain stricter obligations. Any violation may lead to a fine ranging from NTD20,000 to NTD500,000, in some cases up to NTD1,000,000 depending on the violating scenario and be liable for any damages caused. Moreover, in the event that the violation is with the intention of obtaining unlawful gains, or with the intention of impairing other person&#x2019;s interests, thereby causing damage to others, such violation may lead to the imprisonment for no more than five years.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Regulatory authorities in Europe have implemented and are considering a number of legislative and regulatory proposals concerning data protection. For example, the General Data Protection Regulation (EU) 2016/ 679, or the GDPR, which became effective in May&#x00a0;2018, imposes a broad range of strict requirements on companies subject to the GDPR, such as us, including, but not limited to, requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside the European Economic Area (including to the U.S.), providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals&#x2019; requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals and recordkeeping. The GDPR substantially increases the penalties to which we could be subject in the event of any non<FONT CLASS="nobreak">-compliance</FONT>, including fines of up to &#x20ac;10.0&#x00a0;million or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to &#x20ac;20.0&#x00a0;million or up to 4% of our total worldwide annual turnover for more serious offenses. Given the new law, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law. National laws of member states of the European Union are in the process of being adapted to the requirements under the GDPR.&#x00a0;Because the GDPR specifically gives member states flexibility with respect to certain matters, national laws may partially deviate from the GDPR and impose different obligations from country to country, leading to additional complexity and uncertainty.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">We expect that we will continue to face uncertainty as to whether our efforts to comply with evolving obligations under global data protection, privacy and security laws will be sufficient. Any failure or perceived failure by us to comply with applicable laws and regulations could result in reputational damage or proceedings or actions against us by governmental entities, individuals or others. These proceedings or actions could subject us to significant civil or criminal penalties, damages, injunctive relief and negative publicity, result in the delayed or halted transfer or confiscation of certain personal information, require us to change our business practices, increase our costs and otherwise materially harm our business, prospects, financial condition and results of operations. In addition, our current and future relationships with customers, vendors, pharmaceutical collaborators and other third parties could be negatively affected by any proceedings or actions against us, or current or future data protection obligations imposed on them under applicable law. In addition, to the extent that any disruption or security breach </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">49</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:5.5pt;">were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur significant legal and financial exposure and reputational damage that could potentially have an adverse effect on the development of our drug candidates and our business.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Taiwan subsidiaries are subject to restrictions on paying dividend or making other payments to us, which may restrict our ability to satisfy its liquidity requirements.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">As an exempted company with limited liability incorporated under the laws of the Cayman Islands structured as a holding company, we may need dividends and other distributions on equity from our Taiwan subsidiaries to satisfy our liquidity requirements. Current Taiwan regulations permit our Taiwan subsidiaries to pay dividends to their respective shareholders only out of their accumulated profits, if any, which shall first make up previous losses and set aside at least 10% of its accumulated profits each year. These reserves are not distributable as cash dividends. Furthermore, if our Taiwan subsidiaries incur debt on their own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments to us. Any limitation on the ability of our Taiwan subsidiaries to distribute dividends or to make payments to us may restrict our ability to satisfy our liquidity requirements. In addition, the dividend payments by our Taiwan subsidiaries to us shall be subject to the withholding tax of 21% since January&#x00a0;1, 2018.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Taiwan laws and regulations of loans to and direct investment in Taiwan entities by offshore holding companies may delay or prevent us from using the proceeds of this offering to make loans or additional contributions to our Taiwan subsidiaries, which could materially and adversely affect our ability to fund and expand our business.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We are an offshore holding company conducting our operations substantially in Taiwan through our Taiwan subsidiaries. We may make loans to our Taiwan subsidiaries, or we may make additional capital contributions to our Taiwan subsidiaries, or we may establish new Taiwan subsidiaries and make capital contributions to these new Taiwan subsidiaries, or we may acquire offshore entities with business operations in Taiwan in an offshore transaction.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Most of these ways are subject to Taiwan regulations and approvals or registration. For example, investment, including lending long<FONT CLASS="nobreak">-term</FONT> loans, in Taiwan entities require Foreign Investment Approved from the Investment Commission, Ministry of Economic Affairs. Furthermore, foreign entities are prohibited from investing in some industries which are relating to national security and environmental protection, as specified in the negative list provided by Taiwan authority.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Taiwan subsidiaries are subject to foreign exchange control imposed by Taiwan authorities, which may affect the paying dividends, repatriating the interest or making other payments to us.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Currently Taiwan regulates only those foreign exchange transactions that involve the conversion of the NTD into foreign currencies. Pursuant to the relevant provisions of Taiwan Foreign Exchange Control Act, foreign exchange transactions by a company shall be submitted and such remittance shall be subject to the approval of the Central Bank of Taiwan where the&#x00a0;annual accumulated settlement amount of foreign exchange purchased or sold has exceeded USD50&#x00a0;million. Nevertheless, Taiwan government may impose further foreign exchange restrictions in certain emergency situations, where Taiwan government experiences extreme difficulty in stabilizing the balance of payments or where there are substantial disturbances in the financial and capital markets in Taiwan. If the dividend payments or other payments by our Taiwan subsidiaries and branches to us involves the currency conversion from NTD to US&#x00a0;Dollar, such conversion would be subject to the foregoing foreign exchange control imposed by Taiwan authority.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We have no experience operating as a public company.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We have no experience conducting our operations as a public company. After we become a public company, we may face enhanced administrative and compliance requirements, which may result in substantial costs. None our directors and executive officers have experience in operating a U.S.&#x00a0;public company, which makes our ability to comply with applicable laws, rules and regulations uncertain. Our failure to comply with all laws, rules and regulations applicable to U.S.&#x00a0;public companies could subject us or our management to regulatory scrutiny or sanction, which could harm our reputation and share price and result in a loss in your investment.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">50</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We are subject to changing laws and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">non-compliance</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are or will be subject to rules and regulations by various governing bodies, including, for example, once we become a public company, the U.S.&#x00a0;Securities and Exchange Commission, or the SEC, which is charged with the protection of investors and the oversight of companies whose securities are publicly traded as well as Nasdaq, and the various regulatory authorities in the Cayman Islands and Taiwan, and to new and evolving regulatory measures under applicable law. Our efforts to comply with new and changing laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention from revenue<FONT CLASS="nobreak">-generating</FONT> activities to compliance activities. Further, there could be unanticipated changes in existing regulatory requirements. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues from our drug candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our Company and our operating results will be adversely affected.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, because these laws, regulations and standards are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes, we may be subject to penalty and our business may be harmed.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We may be exposed to liabilities under the U.S.&#x00a0;Foreign Corrupt Practices Act, or the FCPA, and similar </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">anti-corruption</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">anti-bribery</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> laws of Taiwan and other countries in which we operate, as well as U.S.&#x00a0;and certain foreign export controls, trade sanctions and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our operations are subject to the FCPA and similar anti<FONT CLASS="nobreak">-bribery</FONT> or anti<FONT CLASS="nobreak">-corruption</FONT> laws, regulations or rules of Taiwan and other countries in which we operate. The FCPA and these other laws generally prohibit us, our officers, and our employees and intermediaries from, directly or indirectly, offering, authorizing or making improper payments to non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;government officials for the purpose of obtaining or retaining business or other advantage. We may engage third parties for preclinical studies or clinical trials outside of the United&#x00a0;States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government<FONT CLASS="nobreak">-affiliated</FONT> hospitals, universities and other organizations. As our business expands, the applicability of the FCPA and other anti<FONT CLASS="nobreak">-bribery</FONT> laws to our operations will increase. If our procedures and controls to monitor anti<FONT CLASS="nobreak">-bribery</FONT> compliance fail to protect us from reckless or criminal acts committed by our employees or agents or if we, or our employees, agents, contractors or other collaborators, fail to comply with applicable anti<FONT CLASS="nobreak">-bribery</FONT> laws, our reputation could be harmed and we could incur criminal or civil penalties, other sanctions and/or significant expenses, which could have a material adverse effect on our business, including our financial condition, results of operations, cash flows and prospects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, our products may be subject to U.S.&#x00a0;and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international or domestic sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S.&#x00a0;export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments and persons targeted by U.S.&#x00a0;sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons or products targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to, existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">51</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our operations are subject to the effects of a rising rate of inflation.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Taiwan has recently experienced historically high levels of inflation. The inflation rate of Taiwan inched up to 2.7% in December of 2022 from 2.4% in the previous month. The inflation rate in June 2022 was 3.6%, highest inflation rate since August of 2008. As of December 2023, the inflation rate in Taiwan stood at 2.7%. Although there was a decreasing trend in the inflation rate in January 2024, if the inflation rate continues to increase, for example due to increases in the costs of labor and supplies, it will affect our expenses, such as employee compensation and research and development charges. Research and development expenses account for a significant portion of our operating expenses. Such increased charges may not be readily recoverable during the period of time that we are bringing the drug candidates to market. Additionally, Taiwan is experiencing an acute workforce shortage, which in turn, has created a very competitive wage environment that may increase our operating costs. To the extent inflation results in rising interest rates and has other adverse effects on the market, it may adversely affect our consolidated financial condition and results of operations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our business may be exposed to foreign exchange risks.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We conduct clinical trials in multiple jurisdictions and thus we have expenses denominated in local currencies in multiple jurisdictions in connection with, among other things, our sponsored clinical trials, purchase of drug product for our clinical trials, process development and the prosecution and maintenance of our intellectual property portfolio. As a result, we are exposed to foreign currency exchange risk, as our results of operations and cash flows are subject to fluctuations in foreign currency exchange rates. In accordance with our business decisions, our exposure to this type of risk could change depending on:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the currencies chosen when agreements are signed, such as licensing agreements, or co<FONT CLASS="nobreak">-marketing</FONT> or co<FONT CLASS="nobreak">-development</FONT> agreements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the location of clinical trials on drug candidates; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our policy for insurance coverage.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, our business is conducted in Taiwan, and our books and records are maintained in NTD.&#x00a0;The financial statements that we file with the SEC and provide to our shareholders are presented in U.S.&#x00a0;dollars. Changes in the exchange rates between NTD and U.S.&#x00a0;dollars affect the value of our assets and the results of our operations, when presented in U.S.&#x00a0;dollars. The value of NTD against the U.S.&#x00a0;dollar and other currencies may fluctuate and is affected by, among other things, changes in the Taiwan&#x2019;s political and economic conditions and perceived changes in the economy of Taiwan and the United&#x00a0;States. Any significant revaluation of NTD may materially and adversely affect our cash flows, revenue, and financial condition. Further, our ordinary shares offered by this prospectus are offered in U.S.&#x00a0;dollars, we will need to convert the net proceeds we receive into NTD or other currencies in order to use the funds for our business. Changes in the conversion rate among the U.S.&#x00a0;dollar, NTD and other currencies will affect the amount of proceeds we will have available for our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into more hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by local exchange control regulations that restrict our ability to convert NTD into foreign currencies. See &#x201c;&#x2014; Our Taiwan subsidiaries are subject to restrictions on paying dividend or making other payments to us, which may restrict our ability to satisfy its liquidity requirements.&#x201d; As a result, fluctuations in exchange rates may have a material adverse effect on your investment.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">52</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We have recorded net cash outflow from operating activities since our inception and we expect to need to obtain additional financing to fund our operations. If we are unable to obtain such financing, we may be unable to complete the development and commercialization of our drug candidates.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since our inception, our operations have consumed substantial amounts of cash. The expenses used in our research and development activities were approximately US$1.3<FONT CLASS="nobreak"> </FONT>million, US$1.1<FONT CLASS="nobreak"> </FONT>million, and US$0.5<FONT CLASS="nobreak"> </FONT>million for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, and the six months ended June<FONT CLASS="nobreak"> </FONT>30, 2024, respectively. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We expect our expenses to increase in connection with our ongoing activities, particularly as we initiate new clinical trials of, initiate new research and preclinical development efforts for and seek marketing approval for, our drug candidates. In addition, if we obtain marketing approval for any of our drug candidates, we may incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of a future collaborator. Furthermore, following the completion of this offering, we expect to incur significant additional costs associated with operating as a public company. Accordingly, we expect to need to obtain substantial additional funding in connection with our continuing operations. Our financing to fund our operations may be adversely affected, delayed or fail to raise because of capital market environment, valuation of our company or the progress of our competitors. If we are unable to raise capital when needed or on attractive terms, we may be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The net proceeds of this offering and our existing cash on hand may not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of development of any of our drug candidates. We do not have any committed external source of funds. Accordingly, we may have to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. The incurrence of indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in our undertaking certain additional restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. However, adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a holder of our ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our existing cash on hand will not be sufficient to enable us to meet our short<FONT CLASS="nobreak">-term</FONT> obligations or long<FONT CLASS="nobreak">-term</FONT> plans, including commercialization of clinical pipeline products, if approved, or initiation or completion of future clinical trials. Our future funding requirements, both short<FONT CLASS="nobreak">-term</FONT> and long<FONT CLASS="nobreak">-term</FONT>, will depend on many factors, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the number of future drug candidates that we pursue and their development requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the scope, progress, timing, results and costs of discovering, researching and developing drug candidates, and conducting preclinical studies and clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the scope, prioritization and number of our research and development programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs, timing and outcome of regulatory review of our drug candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the cost of manufacturing our drug candidates and any products we commercialize, including costs associated with expanding our supply chain;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the cost and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our drug candidates for which we receive regulatory approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the cash received, if any, from commercial sales of any drug candidates for which we receive regulatory approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such collaborations and arrangements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the extent to which we acquire or in<FONT CLASS="nobreak">-license</FONT> other drug candidates and technologies;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">53</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our headcount growth and associated costs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs, timing and outcome of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property<FONT CLASS="nobreak">-related</FONT> claims;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>resources required to develop and implement policies and processes to promote ongoing compliance with applicable healthcare laws and regulations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the impact of COVID<FONT CLASS="nobreak">-19</FONT> or other pandemics on the initiation or completion of preclinical studies or clinical trials and the supply of our drug candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>costs required to ensure that our and any of our partners&#x2019; business arrangements with third parties comply with applicable healthcare laws and regulations; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs of operating as a public company.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We have no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have no history of commercializing pharmaceutical products. Our operations, to date, have been limited to financing and staffing our company, developing our biotechnology and conducting preclinical research and clinical trials for our drug candidates. We have not yet demonstrated an ability to successfully obtain marketing approvals for or commercialize our drug candidates or manufacture our drug candidates on a scale sufficient to supply the commercial markets. We currently have no drug candidates approved for commercial sale and have not generated any revenue from such sales. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history and/or approved products on the market.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Due to the fact that we have yet to commercialize a drug product, particularly in light of the rapidly evolving drug research and development industry in which we operate and the changing regulatory and market environments we encounter, may make it difficult to evaluate our prospects for future performance. As a result, any assessment of our future performance or viability is subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early<FONT CLASS="nobreak">-stage</FONT> companies in rapidly evolving fields as we seek to transition to a company capable of supporting commercial activities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We have incurred net losses since our inception and anticipate that we will continue to incur net losses for the foreseeable future and may not generate revenue that is significant or large enough to achieve profitability.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We have incurred significant annual net operating losses in every year since our inception. We may continue to incur net operating losses for at least the next several&#x00a0;years. Our net losses were approximately US$6.6<FONT CLASS="nobreak"> </FONT>million, US$4.3<FONT CLASS="nobreak"> </FONT>million, US$1.3<FONT CLASS="nobreak"> </FONT>million for the&#x00a0;years ended December<FONT CLASS="nobreak"> </FONT>31, 2022 and 2023, and the six months ended June<FONT CLASS="nobreak"> </FONT>30, 2024, respectively. As of December<FONT CLASS="nobreak"> </FONT>31, 2023 and June<FONT CLASS="nobreak"> </FONT>30, 2024, we had an accumulated deficit of approximately US$30.0&#x00a0;million and US$31.4<FONT CLASS="nobreak"> </FONT>million, respectively. In addition, we incurred negative cash flows in operating activities for the approximate amount of US$3.0<FONT CLASS="nobreak"> </FONT>million, US$2.6<FONT CLASS="nobreak"> </FONT>million, and US$2.8<FONT CLASS="nobreak"> </FONT>million for the years ended December<FONT CLASS="nobreak"> </FONT>31, 2022 and 2023, and the six months ended June<FONT CLASS="nobreak"> </FONT>30, 2024, respectively. We have not generated any revenues from product sales and may never have a drug candidate approved for commercialization. We have financed our operations to date primarily through bank loans. We have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and our clinical trials. Our net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#x2019; equity and working capital.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We anticipate that our expenses will increase substantially if and as we:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>continue to develop and conduct clinical trials with respect to our key drug candidates, PCP and IC;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>initiate and continue research, preclinical and clinical development efforts for any future drug candidates;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">54</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>seek regulatory approvals for our drug candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>commercialize our drug candidates once we have obtained marketing approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize various products for which we may obtain marketing approval, if any;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>hire additional clinical, operational, financial and administrative, quality control and scientific personnel;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>add operational, financial and management information systems and personnel, including personnel to support our product development and help us comply with our obligations as a public company;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>require the manufacture of larger quantities of drug candidates for clinical development and, potentially, commercialization;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>seek to identify additional drug candidates and technologies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>obtain, maintain, expand and protect our intellectual property portfolio;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>enforce and defend any intellectual property<FONT CLASS="nobreak">-related</FONT> claims;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>acquire or in<FONT CLASS="nobreak">-license</FONT> other drug candidates, intellectual property and technologies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>enter into out<FONT CLASS="nobreak">-licens</FONT><FONT CLASS="nobreak">ing</FONT> and co<FONT CLASS="nobreak">-development</FONT> collaborations consistent with our global strategy;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>add equipment and physical infrastructure to support our research and development</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>incur setbacks or delays to the initiation or completion of preclinical studies, drug development and/or clinical trials due to any pandemic; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>incur any disruption or delays to the supply of our drug candidates due to any pandemic.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We will likely need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In order to execute our business plans, we expect that we will need to significantly increase the number of our employees and consultants and the scope of our operations, particularly in the areas of research and development, regulatory affairs and business development. Our future financial performance and our ability to commercialize our drug candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To manage our anticipated future growth, we will need to continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations and have a material adverse effect on our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, we currently rely, and for the foreseeable future may continue to rely, in substantial part on certain academic organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these academic organizations, advisors and consultants will continue to be available to us on a timely basis when needed or that we can find qualified replacements. Furthermore, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by academic organizations, advisors or consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our drug candidates or otherwise advance our business. There can be no assurance that we will be able to maintain our existing relationships with these academic organizations, advisors and consultants or find other competent academic organizations, advisors and consultants on economically reasonable terms, if at all.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">55</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we fail to implement and maintain an effective system of internal </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">controls, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and investor </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">confidence and the market price of our shares may be materially and adversely affected. </FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are subject to the reporting requirements of the Exchange&#x00a0;Act&#x00a0;of&#x00a0;1934, or Exchange&#x00a0;Act, the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act&#x00a0;and the rules and regulations of the Nasdaq. Our independent registered public accounting firm has not conducted an audit of our internal control over financial reporting, as we are not required to provide a report of management&#x2019;s assessment on our internal control over financial reporting due to a transition period established by the rules of the SEC for newly public companies. However, in the course of auditing our consolidated financial statements for the financial statements included elsewhere in this prospectus, we and our independent registered public accounting firm identified eight material weaknesses in our internal control over financial reporting. As defined in standards established by the PCAOB, a &#x201c;material weakness&#x201d; is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness identified relates to: (i) lack of sufficient full<FONT CLASS="nobreak">-time</FONT> accounting personnel with U.S. GAAP experience and knowledge to prepare and review consolidated financial statements and related disclosures under U.S. GAAP and address complex U.S. GAAP accounting issue; (ii) lack of audit committee and qualified internal audit personnel to establish formal risk assessment process and internal control framework; (iii) lack of independent directors demonstrating independence from management in exercising oversight of the development and performance of internal control over financial reporting; (iv) no documentary evidence of proper review of related party transaction or approval for process to ensure the accuracy and completeness; (v) research and development expense were not properly accrued based on the service stage nor billing date; (vi) the patents with no alternative future uses were recognized as intangible asset in the bookkeeping; (vii) deferred tax asset was not recognized based on non<FONT CLASS="nobreak">-operating</FONT> loss and was not offset by appropriate allowance; and (viii) lack of sufficient IT policy and control procedures.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In response to the material weaknesses identified prior to this offering, we will implement a number of measures to address the material weakness identified, including but not limited to (i) working closely with external highly qualified accountants with relevant U.S. GAAP and SEC reporting experience and qualifications to strengthen the financial reporting function, establish a financial and system control framework, and arrange regular training programs on U.S. GAAP accounting for our accounting and financial reporting personnel; (ii) strengthening and improving the overall internal control function by employing an external consulting firm to assist us in assessing the compliance requirements of the Sarbanes Oxley Act; (iii) appointing independent directors to set up an Audit Committee to strengthen corporate governance; and (iv) making an internal control report to the Audit Committee every quarter to report the progress and improvement in internal control, which is well monitored by the Audit Committee.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, we cannot assure you that all these measures will be sufficient to address all the potential internal control issues for the financial reporting, and we cannot assure you that we will not identify additional material weaknesses or significant deficiencies in the future. In addition, if we are unable to meet the requirements of Section&#x00a0;404 of the Sarbanes<FONT CLASS="nobreak">-Oxl</FONT><FONT CLASS="nobreak">ey</FONT> Act, our ordinary shares may not be able to remain listed on the Nasdaq Global Market.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#x00a0;404 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act&#x00a0;of&#x00a0;2002 requires that we include a report of management on our internal control over financial reporting in our annual report on Form&#x00a0;20<FONT CLASS="nobreak">-F</FONT> beginning with our annual report beginning with our second annual report on Form&#x00a0;20<FONT CLASS="nobreak">-F</FONT>.&#x00a0;In addition, once we cease to be an &#x201c;emerging growth company&#x201d; as such term is defined under the JOBS Act, our independent registered public accounting firm must attest to and report on the effectiveness of our internal control over financial reporting. Our management may conclude that our internal control over financial reporting is not effective. Moreover, even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm, after conducting its own independent testing, may issue a report that is qualified if it is not satisfied with our internal controls or the level at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant requirements differently from us. In addition, as we are a public company, our reporting obligations may place a significant strain on our management, operational and financial resources and systems for the foreseeable future. We may be unable to timely complete our evaluation testing and any required remediation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the course of documenting and testing our internal control procedures, in order to satisfy the requirements of Section&#x00a0;404 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act&#x00a0;of&#x00a0;2002, we may identify other weaknesses and deficiencies in our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">56</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">control over financial reporting, as these standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting. If we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could in turn limit our access to capital markets, harm our results of operations and lead to a decline in the trading price of our shares. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations and civil or criminal sanctions. We may also be required to restate our financial statements from prior periods.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We currently have no operations in China although we have established a subsidiary in each of Hong&#x00a0;Kong and China. However, due to the extraterritorial reach (the </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">so-called</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> &#x201c;long arm provisions&#x201d;) under the current PRC laws and regulations, the Chinese government may exert substantial oversight and influence over the manner in which we must conduct our business and may intervene in or influence our operations at any time, which could result in a material change in our operations and significantly and adversely impact the value of our ordinary shares.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We currently have no operations in China although we have established a subsidiary in each of Hong&#x00a0;Kong and China. However, we may in the future expand our operations into China. The Chinese government has significant oversight and discretion over the conduct of our business and may intervene or influence our operations as the government deems appropriate to further regulatory, political and societal goals. The Chinese government has recently published new policies that significantly affected certain industries such as the education and internet industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding our industry that could require us to seek permission from Chinese authorities to continue to operate our business which adversely affect our business, financial condition and results of operations. Furthermore, recent statements made by the Chinese government have indicated an intent to increase the government&#x2019;s oversight and control over offerings of companies with significant operations in China that are to be conducted in foreign markets, as well as foreign investment in China<FONT CLASS="nobreak">-based</FONT> issuers. On February<FONT CLASS="nobreak"> </FONT>17, 2023, the CSRC issued the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, or the Trial Measures, which became effective on March<FONT CLASS="nobreak"> </FONT>31, 2023. We reasonably believed that the Trial Measures do not apply to us, and as of the date of this prospectus, we have not received any inquiry, notice, warning or sanctions regarding our planned overseas listing from the CSRC and any other PRC governmental authorities. Although as of the date of this prospectus, we do not expect to be materially affected by the foregoing statements or the Trial Measures, any such action, once taken by the Chinese government, could significantly limit or completely hinder our ability to offer or continue to offer ordinary shares to our investors, and could cause the value of our ordinary shares to significantly decline or become worthless.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Changes in the political and economic policies of the Chinese government or in relations between China and the United&#x00a0;States may materially and adversely affect our business, financial condition, results of operations and the market price of our ordinary shares.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If we, in the future, expand our operations into China, our financial condition and results of operations may be affected by economic, political and legal developments in China. The PRC economy differs from the economies of most developed countries in many respects, including the extent of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. Although the PRC government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets, and the establishment of improved corporate governance in business enterprises, a substantial portion of productive assets in China is still owned by the government. In addition, the PRC government continues to play a significant role in regulating industrial development by imposing industrial policies, and change of enforcement practice of such rules and policies can occur quickly with little advance notice. The PRC government also exercises significant control over China&#x2019;s economic growth by allocating resources, controlling payment of foreign currency<FONT CLASS="nobreak">-denominated</FONT> obligations, setting monetary policy, regulating financial services and institutions and providing preferential treatment to particular industries or companies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the PRC economy has experienced significant growth in the past four decades, growth has been uneven, both geographically and among various sectors of the economy. The PRC government has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">57</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the overall PRC economy, but may also have a negative effect on us. If we expand our operations into China, our business, financial condition and results of operations could be materially and adversely affected by government control over capital investments or changes in tax regulations that are applicable to us.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the business environment in China deteriorates from the perspective of domestic or international investment, or if relations between China and the United&#x00a0;States or other governments deteriorate, the Chinese government may intervene with our operations and our business in China in the future, and then the market price of our ordinary shares, may also be adversely affected.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of this offering to make loans or additional capital contributions to our PRC subsidiaries in China, which could materially and adversely affect our liquidity and our ability to fund and expand our business.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are an offshore holding company conducting our operations in Taiwan through our Taiwan subsidiaries. We currently have one subsidiary in China, namely Innovative Biotech Co., Ltd., which has no operations and generates no revenue as of the date of this prospectus. In the event that we elect to expand our operations into China in the future, we may make loans to our PRC subsidiary, or we may make additional capital contributions to our PRC subsidiary, or we may establish new PRC subsidiaries and make capital contributions to these new PRC subsidiaries, or we may acquire offshore entities with business operations in China in an offshore transaction.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Most of these ways are subject to PRC regulations and approvals or registration. For example, loans by us to our wholly owned PRC subsidiary to finance its activities cannot exceed statutory limits and must be registered with the local counterpart of SAFE.&#x00a0;If we decide to finance our wholly owned PRC subsidiary by means of capital contributions, these capital contributions are subject to registration with the State Administration for Market Regulation or its local branch, reporting of foreign investment information with the PRC Ministry of Commerce, or registration with other governmental authorities in China.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming the Administration of Foreign Exchange Settlement of Capital of Foreign<FONT CLASS="nobreak">-invested</FONT> Enterprises, or SAFE Circular<FONT CLASS="nobreak"> </FONT>19, effective June&#x00a0;2015, in replacement of the Circular on the Relevant Operating Issues Concerning the Improvement of the Administration of the Payment and Settlement of Foreign Currency Capital of Foreign<FONT CLASS="nobreak">-Invested</FONT> Enterprises, the Notice from the State Administration of Foreign Exchange on Relevant Issues Concerning Strengthening the Administration of Foreign Exchange Businesses, and the Circular on Further Clarification and Regulation of the Issues Concerning the Administration of Certain Capital Account Foreign Exchange Businesses. According to SAFE Circular<FONT CLASS="nobreak"> </FONT>19, the flow and use of the RMB capital converted from foreign currency<FONT CLASS="nobreak">-denominated</FONT> registered capital of a foreign<FONT CLASS="nobreak">-invested</FONT> company is regulated such that RMB capital may not be used for the issuance of RMB entrusted loans, the repayment of inter<FONT CLASS="nobreak">-enterprise</FONT> loans or the repayment of banks loans that have been transferred to a third party. Although SAFE Circular 19 allows RMB capital converted from foreign currency<FONT CLASS="nobreak">-denominated</FONT> registered capital of a foreign<FONT CLASS="nobreak">-invested</FONT> enterprise to be used for equity investments within China, it also reiterates the principle that RMB converted from the foreign currency<FONT CLASS="nobreak">-denominated</FONT> capital of a foreign<FONT CLASS="nobreak">-invested</FONT> company may not be directly or indirectly used for purposes beyond its business scope. Thus, it is unclear whether SAFE will permit such capital to be used for equity investments in China in actual practice. SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange Settlement Management Policy of Capital Account, or SAFE Circular<FONT CLASS="nobreak"> </FONT>16, effective on June&#x00a0;9, 2016, which reiterates some of the rules set forth in SAFE Circular<FONT CLASS="nobreak"> </FONT>19, but changes the prohibition against using RMB capital converted from foreign currency denominated registered capital of a foreign<FONT CLASS="nobreak">-invested</FONT> company to issue RMB entrusted loans to a prohibition against using such capital to issue loans to non<FONT CLASS="nobreak">-associated</FONT> enterprises. Violations of SAFE Circular 19 and SAFE Circular 16 could result in administrative penalties. SAFE Circular 19 and SAFE Circular 16 may significantly limit our ability to transfer any foreign currency we hold, including the net proceeds from this offering, to our PRC subsidiary, which may adversely affect our liquidity and our ability to fund and expand our business in China. On October&#x00a0;23, 2019, the SAFE promulgated the Notice for Further Advancing the Facilitation of Cross<FONT CLASS="nobreak">-border</FONT> Trade and Investment, or the SAFE Circular<FONT CLASS="nobreak"> </FONT>28, which, among other things, allows all foreign<FONT CLASS="nobreak">-invested</FONT> companies to use Renminbi converted from foreign currency<FONT CLASS="nobreak">-denominated</FONT> capital for equity investments in China, as long as the equity investment is genuine, does not violate applicable laws, and complies with the negative list on foreign investment. However, since the SAFE Circular 28 is newly promulgated, it is unclear how SAFE and competent banks will carry this out in practice.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">58</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies, we cannot assure you that we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, or at all, with respect to future loans to our PRC subsidiary or future capital contributions by us to our PRC subsidiary. As a result, uncertainties exist as to our ability to provide prompt financial support to our PRC subsidiary when needed. If we fail to complete such registrations or obtain such approvals, our ability to use the proceeds we expect to receive from this offering and to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIES</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As we rely on third parties to conduct our clinical trials and provide other important services related to research and development, regulatory submissions, and commercialization, if we fail to maintain our relationships with these third parties or if they do not successfully carry out their contractual duties, comply with applicable laws, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have relied on and plan to continue to rely on third<FONT CLASS="nobreak">-party</FONT> CROs to monitor and manage data for some of our ongoing clinical trials. We rely on these parties for the execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our CROs have the right to terminate their agreements with us in the event of an unrectified material breach. If any of our relationships with our third<FONT CLASS="nobreak">-party</FONT> CROs is terminated, we may not be able to (i)&#x00a0;enter into arrangements with alternative CROs or do so on commercially reasonable terms or (ii)&#x00a0;meet our desired clinical development timelines. In addition, there is a natural transition period when a new CRO commences work, and the new CRO may not provide the same type or level of services as the original provider and data from our clinical trials may be compromised as a result. There is also a need for relevant technology to be transferred to the new CRO, which may take time and further delay our development timelines.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except for remedies available to us under our agreements with our CROs, we cannot control whether or not our CROs devote sufficient time and resources to our ongoing clinical, nonclinical and preclinical studies. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols, the impacts of any pandemic on their operations, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results of operations and the commercial prospects for our drug candidates would be harmed and our costs could increase. In turn, our ability to generate revenues could be delayed or compromised.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We cannot guarantee that third parties perform duties complying with our standards or produce results in a timely manner. They may fail to perform at all. In addition, the use of third<FONT CLASS="nobreak">-party</FONT> service providers requires us to disclose our proprietary information to these third parties, which could increase the risk that such information will be misappropriated. We currently have a limited number of employees, which limits the internal resources we have available to identify and monitor our third<FONT CLASS="nobreak">-party</FONT> service providers. To the extent we are unable to identify and successfully manage the performance of third<FONT CLASS="nobreak">-party</FONT> service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future, and such challenges or delays could have a material adverse impact on our business, financial condition and prospects.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As we rely on third parties to conduct our preclinical studies and clinical trials, our business could be harmed if those third parties fail to comply with the applicable regulatory requirements.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We and our CROs are required to comply with cGCPs, cGLPs, and other regulatory regulations and guidelines enforced by the TFDA, the U.S. FDA, the International Conference on Harmonization, or ICH, and comparable foreign regulatory authorities for all of our drug candidates in clinical development. Regulatory authorities enforce </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">59</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">these cGCPs, cGLPs or other regulatory requirements through periodic inspections of study sponsors, investigators and study sites. If we or any of our CROs fail to comply with applicable cGCPs, cGLPs or other regulatory requirements, the relevant data generated in our preclinical studies and clinical trials may be deemed unreliable and the TFDA, the U.S. FDA or other comparable regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with cGCPs requirements. In addition, our clinical trials must be conducted with drug candidates or products produced under governmental requirements. Failure to comply with these regulations may require us to repeat preclinical studies and clinical trials, which would delay the regulatory approval process.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We are highly dependent on third parties to supply the drug raw materials, such as API, for our developing and manufacturing activities, and the lack of availability or significant increases in cost of such drug raw materials could adversely influence our business.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The development and manufacture of drug products are complex and require significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Currently, our drug raw materials for our developing and manufacturing activities are supplied by multi<FONT CLASS="nobreak">-source</FONT> suppliers. In addition, we believe that adequate alternative sources for such supplies exist. However, there is a risk that, if supplies are interrupted or if the costs of such drug materials were to significantly increase, our business would be materially harmed. For example, the COVID<FONT CLASS="nobreak">-19</FONT> pandemic, the monkeypox outbreak, geopolitical risk, wars and military conflicts could have an extensive impact on the production and supplies of active ingredients or other raw materials and result in a potential shortage of supply. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As mentioned elsewhere in this prospectus, our API<FONT CLASS="nobreak">-1</FONT> supplier withdrew their consent to reference their Drug Master File on file with the U.S. FDA due to the relocation and restructuring of their manufacturing facility. The API<FONT CLASS="nobreak">-1</FONT> we used to perform our clinical trials of MCS<FONT CLASS="nobreak">-2</FONT> is now unavailable to us, causing delays and additional expenses in the development of our drug candidates. As disclosed in the &#x201c;Use of Proceeds&#x201d; section, approximately 30.0% or US$8.7<FONT CLASS="nobreak"> </FONT>million will be allocated to fund the additional Phase III trials of MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-2</FONT>. The estimated time for completing the Phase III trials of MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-2</FONT> is approximately 1 to 2 years, depending on the processing and approval time from the U.S. FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have been conducting further research and development on MCS<FONT CLASS="nobreak">-2</FONT> and identified an additional source for the botanical drug substance API<FONT CLASS="nobreak">-2</FONT>. API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are similar drug substances covered by the same patent owned by us; however, because they are sourced from raw materials manufactured in different locations, the U.S.&#x00a0;FDA considers them to be different botanical drug substances. Therefore, we will conduct comparability study for API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. On June<FONT CLASS="nobreak"> </FONT>26, 2023, the U.S. FDA informed us that the information we provided on API<FONT CLASS="nobreak">-2</FONT> was not sufficient to demonstrate comparability with API<FONT CLASS="nobreak">-1</FONT>. In addition to current unavailability of API<FONT CLASS="nobreak">-1</FONT>, the U.S. FDA explained that we had not demonstrated a statistically significant difference between MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-1</FONT> and placebo in the primary efficacy endpoint in the MCS<FONT CLASS="nobreak">-2-US-a</FONT> study. The U.S. FDA stated that without new clinical information, any resubmission of the NDA for MCS<FONT CLASS="nobreak">-2</FONT> would be at risk of the U.S. FDA refusing to accept the application, a RTF action. We submitted a Type D WRO meeting request to the U.S. FDA on December<FONT CLASS="nobreak"> </FONT>12, 2023. We asked that the U.S. FDA provide a written response to questions focused on obtaining U.S. FDA review and comments on a new, proposed Phase III clinical trial protocol for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-2</FONT> and a PK study. We proposed to address CMC information for MCS<FONT CLASS="nobreak">-2</FONT> in a separate, future meeting. The U.S. FDA granted our WRO meeting request, and clarified that they viewed the meeting as a Type C meeting because it encompasses an entirely new drug development program, including Phase I PK study and Phase III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> made from API<FONT CLASS="nobreak">-2</FONT>, which the U.S. FDA characterizes as a new product with a new active pharmaceutical ingredient. We plan to schedule a special CMC meeting with the U.S. FDA in 2024 to discuss API<FONT CLASS="nobreak">-2</FONT>, providing comprehensive CMC information for U.S. FDA review and comments. We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA. This process does not indicate a &#x201c;shortage&#x201d; of API<FONT CLASS="nobreak">-2</FONT>. As of this date, the Company is still in the process of providing the information required by the U.S. FDA and has not yet successfully demonstrated the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. If the U.S.&#x00a0;FDA confirms that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable and deems the study results using API<FONT CLASS="nobreak">-2</FONT> acceptable, we will proceed to re<FONT CLASS="nobreak">-submit</FONT> our NDA.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">60</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, if we experience a shortage in supply of active ingredients or other raw materials, including API<FONT CLASS="nobreak">-2</FONT>, whether due to the aforementioned factors or otherwise, we could not supply adequate levels of our drug candidates. Identifying a suitable replacement and demonstrating its equivalence to API<FONT CLASS="nobreak">-2</FONT> could require extensive research and development efforts, potentially leading to additional costs and delays. Additionally, substituting the original ingredient with an alternative substance may necessitate conducting further clinical trials to assess the safety and efficacy of such new material. These additional trials could prolong the time to market for our products and increase regulatory scrutiny, further impacting our business operations and financial performance.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We expect to seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may form or seek strategic alliances, create collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our drug candidates and any future drug candidates that we may develop. Any of these relationships may require us to incur recurring or non<FONT CLASS="nobreak">-recurring</FONT> expenses and other charges, increase our near and long<FONT CLASS="nobreak">-term</FONT> expenditures, or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time<FONT CLASS="nobreak">-consuming</FONT> and complex. Moreover, we may not be successful in our efforts to establish a strategic collaboration or other alternative arrangements for our drug candidates because they may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our drug candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for the development and commercialization of a drug candidate, we can expect to relinquish some or all of the control over the future success of that drug candidate to the third party.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, collaborations involving our drug candidates are subject to additional risks, which include, but are not limited to, the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>collaborators may have significant discretion in determining the efforts and resources that they will apply to a collaboration;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>collaborators may not pursue the development and commercialization of our drug candidates or may elect not to continue or renew the development or commercialization programs based on clinical trial results, change in their strategic focus due to the acquisition of competitive drugs, increased competition, availability of funding, or other external factors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>collaborators may delay clinical trials, provide insufficient funding for a clinical trial, discontinue a clinical trial, repeat or conduct new clinical trials, or require a new formulation of a drug candidate for clinical testing;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our drug candidates or future drugs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>collaborators with marketing and distribution rights to one or more of our drug candidates or future drugs may not commit sufficient resources to their marketing and distribution;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>collaborators may not always be cooperative or responsive in providing their services in a clinical trial;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>disputes may arise between us and a collaborator that cause a delay or termination of the research, development or commercialization of our drug candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable drug candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>collaborators may self<FONT CLASS="nobreak">-own</FONT> intellectual property covering our drug candidates or future drugs that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we may not be able to receive agreed development fees, royalties or milestone payments we expected when seeking collaborations.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">61</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result, if we enter into collaboration agreements or license our drugs, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate these collaborations or licenses with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our drug candidates or bring them to market and generate product sales revenue, which would harm our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Negotiations of collaborations are complex and </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">time-consuming</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, and we may not able to find suitable collaborators and enter into agreements with them.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any collaboration agreements that we enter into in the future may contain restrictions on our ability cooperate with other potential collaborators. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the drug candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to obtain and maintain patent and other intellectual property protection for our drug candidates, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, and our ability to successfully commercialize any product or technology may be adversely affected.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our success depends, in large part, on our ability to protect our proprietary technology and drug candidates from competition by obtaining, maintaining, defending and enforcing our intellectual property rights, including patent rights. As of the date of this prospectus, our portfolio of self<FONT CLASS="nobreak">-own</FONT> patents consisted of 29 issued patents in 16 countries and regions. We seek to protect and intend to seek to protect the drug candidates and technology that we consider commercially important by filing patent applications globally, relying on trade secrets or pharmaceutical regulatory protection or employing a combination of these methods. This process is expensive and time<FONT CLASS="nobreak">-consuming</FONT>, and we may not be able to file and prosecute all necessary or desirable patent applications in all jurisdictions at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#x00a0;years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our self<FONT CLASS="nobreak">-own</FONT> pending and future patent applications may not result in patents being issued which protect our technology or drug candidates or which effectively prevent others from commercializing competitive technologies and drug candidates. The patent examination process may require us to narrow the scope of the claims of self<FONT CLASS="nobreak">-own</FONT> pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure that all of the potentially relevant prior art relating to our self<FONT CLASS="nobreak">-own</FONT> patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent application from being issued as a patent.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if patents do issue on any of these applications, there can be no assurance that a third party will not challenge their validity, enforceability, or scope, which may result in the patent claims being narrowed or invalidated, or that we will obtain sufficient claim scope in those patents to prevent a third party from competing successfully with our drug candidates. We may become involved in interference, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">inter partes </FONT>review, post grant review, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">ex parte</FONT> re<FONT CLASS="nobreak">-examination</FONT>, derivation, opposition or similar other proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">62</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">allow third parties to commercialize our technology or drug candidates and compete directly with us, or result in our inability to manufacture or commercialize drug candidates without infringing third<FONT CLASS="nobreak">-party</FONT> patent rights. Thus, even if our self<FONT CLASS="nobreak">-own</FONT> patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our competitors may be able to circumvent our self<FONT CLASS="nobreak">-own</FONT> patents by developing similar or alternative technologies or drug candidates in a non<FONT CLASS="nobreak">-infringing</FONT> manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our self<FONT CLASS="nobreak">-own</FONT> patents may be challenged in the courts or patent offices in the U.S., Taiwan and other countries. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and drug candidates, or limit the duration of the patent protection of our technology and drug candidates. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such assets might expire before or shortly after such assets are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drug candidates similar or identical to ours.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Changes in either the patent laws or interpretation of the patent laws in the U.S.&#x00a0;and other countries may diminish the value of our self<FONT CLASS="nobreak">-own</FONT> patents or narrow the scope of our patent protection. For instance, under the America Invents Act enacted in 2011, the U.S.&#x00a0;moved to this first<FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak">to-file</FONT> system in early 2013 from the previous system under which the first to make the claimed invention was entitled to the patent. Assuming the other requirements for patentability are met, the first to file a patent application is entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S.&#x00a0;and other jurisdictions are typically not published until 18&#x00a0;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our self<FONT CLASS="nobreak">-own</FONT> patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We enjoy only limited geographical protection with respect to certain patents and may not be able to protect our intellectual property rights throughout the world.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Filing and prosecuting patent applications and defending patents covering our drug candidates in all countries throughout the world could be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own drug candidates and, further, may export otherwise infringing drug candidates to territories, where we have patent protection, but enforcement rights are not as strong as those in the U.S.&#x00a0;These drug candidates may compete with our drug candidates, and our self<FONT CLASS="nobreak">-own</FONT> patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the U.S., and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, are not as favorable as other jurisdictions with regard to the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our self<FONT CLASS="nobreak">-own</FONT> patents or marketing of competing drug candidates in violation of our proprietary rights generally and specifically in certain jurisdictions. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our self<FONT CLASS="nobreak">-own</FONT> patent applications at risk of not issuing as patents, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our drug candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our drug candidates in all of our expected significant foreign markets. If we encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">63</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In those countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Enforcing our intellectual property rights against third parties may also cause such third parties to file other counterclaims against us, which could be costly to defend and could require us to pay substantial damages, cease the sale of certain drugs or enter into a license agreement and pay royalties (which may not be possible on commercially reasonable terms or at all).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">non-compliance</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> with these requirements.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and applications will be due to be paid to government patent agencies over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to patent agencies. The government agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non<FONT CLASS="nobreak">-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Terms of our future </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">self-own</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> patents may not be sufficient to effectively protect our drug candidates and business in certain jurisdictions.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In many countries where we file applications for patents, the term of an issued patent is generally 20&#x00a0;years from the earliest claimed filing date of a non<FONT CLASS="nobreak">-provisional</FONT> patent application in the applicable country. Although various extensions may be available, the life of a patent and the protection it affords are limited. Even if we obtain patents covering our drug candidates, we may still be open to competition from other companies, as well as generic medications once the patent life has expired for a drug. For example, while there are patent regulations in the PRC in respect of regulatory data protection of new drugs containing new chemical components, there are currently no other clear mechanisms providing patent term extension or patent linkages for other drugs in the PRC.&#x00a0;Therefore, it is possible that a lower<FONT CLASS="nobreak">-cost</FONT> generic drug can emerge onto the market much more quickly. For additional information regarding potential generic competition for our products in China, see &#x201c; &#x2014; The uncertainty of patent linkage, patent term extension and data and market exclusivity for our future drug products could increase the risk of early generic competition with our products in our primary sales markets.&#x201d; These factors may result in weaker protection for us against generic competition in jurisdictions similar to the PRC than could be available to us in other jurisdictions, such as the U.S.&#x00a0;In addition, patents which we expect to obtain in the PRC or similar jurisdictions may not be eligible to be extended for patent terms lost during clinical trials and the regulatory review process.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If we are unable to obtain patent term extensions or if such extensions are less than requested for, our competitors may obtain approval of competing products following our patent expirations and our business, financial condition, results of operations and prospects could be materially harmed as a result.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If the TFDA, the U.S. FDA or comparable foreign regulatory authorities approve generic versions of any of our products that receive marketing approval, or such authorities do not grant our products appropriate periods of data exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Once an NDA is approved, the drug candidate covered thereby becomes a &#x201c;reference<FONT CLASS="nobreak">-listed</FONT> drug&#x201d; in the U.S. FDA&#x2019;s publication, &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations,&#x201d; or the Orange Book. Manufacturers may seek approval of generic versions of reference<FONT CLASS="nobreak">-listed</FONT> drugs through submission of abbreviated </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">64</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">new drug applications, or ANDAs, in the U.S.&#x00a0;In support of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the applicant generally must show that its product has the same active ingredients, dosage form, strength, route of administration and conditions of use or labeling as the reference<FONT CLASS="nobreak">-listed</FONT> drug and that the generic version is bioequivalent to the reference<FONT CLASS="nobreak">-listed</FONT> drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference<FONT CLASS="nobreak">-listed</FONT> drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference<FONT CLASS="nobreak">-listed</FONT> drug may be typically lost to the generic product.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Competition that our products may face from generic versions of our products could negatively impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on our investments in those drug candidates.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The uncertainty of patent linkage, patent term extension and data and market exclusivity for our future drug products could increase the risk of early generic competition with our products in our primary sales markets.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the U.S., the Federal Food, Drug and Cosmetic Act, as amended by the Drug Price Competition and Patent Term Restoration Act, or the Hatch<FONT CLASS="nobreak">-Waxman</FONT> Act, provides the opportunity for patent<FONT CLASS="nobreak">-term</FONT> restoration, meaning a patent term extension of up to five&#x00a0;years to reflect patent term lost during certain portions of product development and the U.S. FDA regulatory review process. The Hatch<FONT CLASS="nobreak">-Waxman</FONT> Act also has a process for patent linkage, pursuant to which the U.S. FDA will stay approval of certain follow<FONT CLASS="nobreak">-on</FONT> applications during the pendency of litigation between the follow<FONT CLASS="nobreak">-on</FONT> applicant and the patent holder or licensee, generally for a period of 30&#x00a0;months. Finally, the Hatch<FONT CLASS="nobreak">-Waxman</FONT> Act provides for statutory exclusivities that can prevent submission or approval of certain follow<FONT CLASS="nobreak">-on</FONT> marketing applications. For example, federal law provides a five<FONT CLASS="nobreak">-year</FONT> period of exclusivity within the U.S.&#x00a0;to the first applicant to obtain approval of a new chemical entity and three&#x00a0;years of exclusivity protecting certain innovations to previously approved active ingredients where the applicant was required to conduct new clinical investigations to obtain approval for the modification. These provisions, designed to promote innovation, can prevent competing products from entering the market for a certain period of time after the U.S. FDA grants marketing approval for the innovative product.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Depending upon the timing, duration and specifics of any U.S. FDA marketing approval process for any drug candidates we may develop, one or more of our self<FONT CLASS="nobreak">-own</FONT> U.S.&#x00a0;patents, if issued, may be eligible for limited patent term extension under the Hatch<FONT CLASS="nobreak">-Waxman</FONT> Act. The Hatch<FONT CLASS="nobreak">-Waxman</FONT> Act permits a patent extension term of up to five&#x00a0;years as compensation for patent term lost during clinical trials and the U.S. FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#x00a0;years from the date of drug approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. The application for patent term extension is subject to approval by the U.S.&#x00a0;Patent and Trademark Office, or USPTO, in conjunction with the U.S. FDA.&#x00a0;However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Furthermore, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension for a given patent or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our drug will be shortened and our competitors may obtain earlier approval of competing drugs, and our ability to generate revenues could be materially and adversely affected.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In Taiwan, the Patent Act grants the patent holder of drugs for human purposes the right to extend the patent term. Pursuant to the Patent Act, the patent term might be extended up to five&#x00a0;years to reflect patent term lost during the clinical trial process and the Taiwan FDA regulatory review process. In addition, the Patent Act and the Pharmaceutical Affairs Act also provide the patent linkage process. As Taiwan adopts a double<FONT CLASS="nobreak">-track</FONT> examination system in terms of patent prosecution, including the examination of Taiwan Intellectual Property Office (&#x201c;TIPO&#x201d;) and the examination of the court, under the patent linkage process, the Taiwan FDA will stay approval of certain follow<FONT CLASS="nobreak">-on</FONT> applications during the pendency of the invalidation action and the pendency of litigation between the follow<FONT CLASS="nobreak">-on</FONT> applicant and the patent holder or licensee. The pendency of such litigation generally lasts for a period of&#x00a0;12<FONT CLASS="nobreak">-14</FONT>&#x00a0;months. Finally, the Pharmaceutical Affairs Act provides a five<FONT CLASS="nobreak">-year</FONT> period of exclusivity to the first applicant to exclusively hold the drug permit and a three<FONT CLASS="nobreak">-year</FONT> period of exclusivity to restrict other pharmaceutical firms who may apply for registration of the same drug from citing the application data submitted by the first applicant.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">65</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">For those drug candidates we may develop, one or more of our self<FONT CLASS="nobreak">-own</FONT> Taiwan patents, if issued, may be eligible for limited patent term extension under the Patent Act. The Patent Act provides that only one patent may be extended. The application for patent term extension is subject to approval by TIPO, in conjunction with the Taiwan FDA.&#x00a0;While the Patent Act explicitly provides that TIPO and the Taiwan FDA should take into consideration the impact on public health, we may not be granted the extension because of the authorities&#x2019; discretion. In addition, if we fail to apply within applicable deadlines, fail to apply prior to the expiration of relevant patents, or otherwise fail to satisfy applicable requirements, we may not be granted the extension as well.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Patent Act also provides that the extension term is restricted to be five&#x00a0;years as a maximum, implying that we may be granted a shorter extension period than we request. Furthermore, pursuant to the Patent Act, any person may file an invalidation action of the granted patent term extension to the authorities, together with documents of proof. If anyone files such invalidation action with respect to our patents, the permit of the extension period may be withdrawn by TIPO.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">If we are unable to obtain a patent term extension for a given patent, or the term of any such extension is less than we request, or our extension permit is withdrawn by TIPO, our competitors may compete with us in an earlier stage, and our ability to generate revenues could be materially and adversely affected.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patent rights. Obtaining and enforcing patents in the pharmaceutical market involves both technological and legal complexity, and is therefore costly, time<FONT CLASS="nobreak">-consuming</FONT>, and inherently uncertain. For instance, the America Invents Act includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation, which could increase the uncertainties and costs surrounding the prosecution of our owned, co<FONT CLASS="nobreak">-owned</FONT> and in<FONT CLASS="nobreak">-licensed</FONT> patent applications and the enforcement or defense of patents issuing from those patent applications, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Although we do not believe that our currently self<FONT CLASS="nobreak">-own</FONT> patents and any patents that may issue from our pending patent applications directed to our drug candidates, if issued in their currently pending forms, will be found invalid, we cannot predict how relevant regulatory authorities&#x2019; future decisions may impact the value of our patent rights. There could be similar changes in the laws of foreign jurisdictions that may impact the value of our patent rights or our other intellectual property rights.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We also may be subject to claims that our employees, consultants, or advisers have wrongfully used or disclosed alleged trade secrets of their former employers or claims asserting ownership of what we regard as our own intellectual property.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Many of our employees, consultants, and advisers, including our senior management, were previously employed at or contracted by other biotechnology or pharmaceutical companies. Some of these employees, consultants, and advisers, including members of our senior management, executed proprietary rights, non<FONT CLASS="nobreak">-disclosure</FONT> and non<FONT CLASS="nobreak">-competition</FONT> agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know<FONT CLASS="nobreak">-how</FONT> of others in their work for us, we may be subject to claims that we or these employees, consultants or advisors have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s former employer. We are not aware of any threatened or pending claims related to these matters or concerning the agreements with our senior management, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. In addition, while we typically require our employees, consultants and advisors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, and furthermore, the assignment of intellectual property rights may not be self<FONT CLASS="nobreak">-executing</FONT>, or the assignment agreements may be breached, each of which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs, be a distraction to our management and scientific personnel and have a material adverse effect on our business, financial condition, results of operations and prospects.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">66</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patent rights, trade secrets, or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or our patent rights, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our therapeutic programs and other proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Intellectual property litigation may lead to unfavorable publicity which may harm our reputation and any unfavorable outcome from such litigation could limit our research and development activities and</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">or our ability to commercialize our drug candidates.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the course of any intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our drug candidates, future drugs, programs or intellectual property could be diminished. Such announcements could also harm our reputation or the market for our drug candidates, which could have a material adverse effect on our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of intellectual property litigation, there can be no assurance that we would prevail, even if the case against us is weak or flawed. If third parties successfully assert their intellectual property rights against us, prohibitions against using certain technologies, or prohibitions against commercializing our drug candidates, could be imposed by a court or by a settlement agreement between us and a plaintiff. In addition, if we are unsuccessful in defending against allegations that we have infringed, misappropriated or otherwise violated the patent or other intellectual property rights of others, we may be forced to pay substantial damage awards to the plaintiff. It is possible that the necessary license will not be available to us on commercially acceptable terms, or at all. This may not be technically or commercially feasible, may render our products less competitive, or may delay or prevent the launch of our products to the market. Any of the foregoing could limit our research and development activities, our ability to commercialize one or more drug candidates, or both.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex intellectual property litigation longer than we could. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to conduct our clinical trials, continue our internal research activities, in<FONT CLASS="nobreak">-license</FONT> needed technology in the future, or enter into strategic collaborations that would help us bring our drug candidates to market.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, any future intellectual property litigation, interference or other administrative proceedings will result in additional expense and distraction of our personnel. An adverse outcome in such litigation or proceedings may expose us or any future strategic partners to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms, if at all, each of which could have a material adverse effect on our business.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Claims that our drug candidates or the sale or use of our future products infringe, misappropriate or otherwise violate the patents or other intellectual property rights of third parties could result in costly litigation or could require substantial time and money to resolve, even if litigation is avoided.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We cannot guarantee that our drug candidates or the sale or use of our future products do not and will not in the future infringe, misappropriate or otherwise violate third<FONT CLASS="nobreak">-party</FONT> patents or other intellectual property rights. Third parties might allege that we are infringing their patent rights or that we have misappropriated their trade secrets, or that we are otherwise violating their intellectual property rights, whether with respect to the manner in which we have conducted our research, or with respect to the use or manufacture of the compounds we have developed or are developing. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. Some claimants may have substantially greater resources than we have and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. Third parties might resort to litigation against us or other parties we have agreed to indemnify, which litigation could be based on either existing intellectual property or intellectual property that arises in the future.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">67</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is also possible that we failed to identify, or may in the future fail to identify, relevant patents or patent applications held by third parties that cover our drug candidates. Publication of discoveries in the scientific or patent literature often lags behind actual discoveries. Therefore, we cannot be certain that we were the first to invent, or the first to file patent applications on, our drug candidates or for their uses, or that our drug candidates will not infringe patents that are currently issued or that are issued in the future. In the event that a third party has also filed a patent application covering one of our drug candidates or a similar invention, our self<FONT CLASS="nobreak">-own</FONT> patent application may be regarded as a competing application and may not be issued in the end. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our products or their use.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a third party were to assert claims of patent infringement against us, even if we believe such third<FONT CLASS="nobreak">-party</FONT> claims are without merit, a court of competent jurisdiction could hold that these third<FONT CLASS="nobreak">-party</FONT> patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third<FONT CLASS="nobreak">-party</FONT> patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, or methods of treatment, prevention, or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. In addition, defending such claims would cause us to incur substantial expenses and could cause us to pay substantial damages, if we are found to be infringing a third party&#x2019;s patent rights. These damages potentially include increased damages and attorneys&#x2019; fees if we are found to have infringed such rights willfully. In order to avoid or settle potential claims with respect to any patent or other intellectual property rights of third parties, we may choose or be required to seek a license from a third party and be required to pay license fees or royalties or both, which could be substantial. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a drug candidate, or be forced, by court order or otherwise, to modify or cease some or all aspects of our business operations, if, as a result of actual or threatened patent or other intellectual property claims, we are unable to enter into licenses on acceptable terms. Further, we could be found liable for significant monetary damages as a result of claims of intellectual property infringement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Defending against claims of patent infringement, misappropriation of trade secrets or other violations of intellectual property rights is likely to be costly and time<FONT CLASS="nobreak">-consuming</FONT>, regardless of the outcome. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Thus, even if we were to ultimately prevail or settle at an early stage, such litigation could burden us with substantial unanticipated losses. Any claims of infringement, misappropriation or other violation of intellectual property made against us could have a material adverse effect on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Issued patents covering one or more of our drug candidates could be found invalid or unenforceable if challenged in court.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Despite measures we take to obtain and maintain patent and other intellectual property rights with respect to our drug candidates, our intellectual property rights could be challenged or invalidated. For example, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our drug candidates, the defendant could counterclaim that our self<FONT CLASS="nobreak">-own</FONT> patent is invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness, non<FONT CLASS="nobreak">-enablement</FONT>, lack of sufficient written description or obviousness<FONT CLASS="nobreak">-type</FONT> double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, the State Intellectual Property Office, or the SIPO, or the applicable foreign counterpart, or made a misleading statement, during prosecution. Although we believe that we have conducted our patent prosecution in accordance with a duty of candor and in good faith, the outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we could lose at least part, and perhaps all, of the patent protection on a drug candidate. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our self<FONT CLASS="nobreak">-own</FONT> patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. In addition, if </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">68</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the breadth or strength of protection provided by our self<FONT CLASS="nobreak">-own</FONT> patents is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize our current or future drug candidates. Any loss of patent protection could have a material adverse impact on one or more of our drug candidates and our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our competitive position may be adversely affected.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, we had 58 registered trademarks in 46 territories. We may not be able to obtain trademark protection in territories that we consider of significant importance to us. In addition, any of our trademarks or trade names, whether registered or unregistered, may be challenged, opposed, infringed, cancelled, circumvented or declared generic, or determined to be infringing on other marks, as applicable. We may not be able to protect our rights to these trademarks and trade names, which we will need to build name recognition by potential collaborators or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We expect to rely on trademarks as one means to distinguish any of our drug candidates that are approved for marketing from the products of our competitors. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to patents, we rely upon unpatented trade secrets, know<FONT CLASS="nobreak">-how</FONT> and continuing technological innovation to develop and maintain our competitive position. We seek to protect this trade secret and confidential information, in part, by entering into non<FONT CLASS="nobreak">-disclosure</FONT> and confidentiality agreements with parties that have access to them, such as our employees, collaborators, CROs, consultants and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, any of these parties may breach such agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time<FONT CLASS="nobreak">-consuming</FONT>, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us and our competitive position would be harmed. In addition, we face the risk of cybercrime. For instance, someone could hack our information networks and gain illicit access to our proprietary information, including our trade secrets. Even if we are successful in prosecuting such claims, any remedy awarded may be insufficient to fully compensate us for the improper disclosure or misappropriation.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">69</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. For instance:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our competitors may be able to make compounds that are similar to our drug candidates but that are not covered by the claims of our self<FONT CLASS="nobreak">-own</FONT> patents;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we might not have been the first to make the inventions covered by the issued patents or pending patent applications that we self<FONT CLASS="nobreak">-own</FONT>, which could result in the patents applied for not being issued or being invalidated after issuing;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we might not have been the first to file patent applications covering certain of our inventions, which could result in the patents applied for not being issued or being invalidated after issuing;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>it is possible that the pending and future self<FONT CLASS="nobreak">-own</FONT> patent applications will not lead to issued patents;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>issued self<FONT CLASS="nobreak">-own</FONT> patents may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors or other third parties;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we may obtain patents for certain compounds many&#x00a0;years before we receive regulatory approval for drugs containing such compounds, and because patents have a limited life, which may begin to run out prior to the commercial sale of the related drugs, the commercial value of our patents may be limited;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for commercialization in our major markets;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we may fail to develop additional proprietary technologies that are patentable;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we plan to sell our drug products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>third parties may gain unauthorized access to our intellectual property due to potential lapses in our information systems;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the patents of others may have an adverse effect on our business; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we may choose not to file a patent in order to maintain certain trade secrets or know<FONT CLASS="nobreak">-how</FONT>, and a third party may discover certain technologies containing such trade secrets or know<FONT CLASS="nobreak">-how</FONT> through independent research and development and/or subsequently file a patent covering such intellectual property.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RISKS RELATED TO OUR ORDINARY SHARES AND THIS OFFERING</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">An active trading market for our ordinary shares may not develop and the trading price for our ordinary shares may fluctuate significantly.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We plan to list our ordinary shares on the Nasdaq Global Market. Prior to the completion of this offering, there has been no public market for our ordinary shares, and we cannot assure you that a liquid public market for our ordinary shares will develop. If an active public market for our ordinary shares does not develop following the completion of this offering, the market price and liquidity of our ordinary shares may be materially and adversely affected. The initial public offering price for our ordinary shares will be determined by negotiation between us and the underwriters based upon several factors, and we can provide no assurance that the trading price of our ordinary shares after this offering will not decline below the initial public offering price. As a result, investors in our securities may experience a significant decrease in the value of their investment.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">70</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The trading price of our ordinary shares is likely to be volatile, which could result in substantial losses to investors.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Recently, there have been instances of extreme stock price run<FONT CLASS="nobreak">-ups</FONT> followed by rapid price declines and strong stock price volatility with a number of recent initial public offerings, especially among companies with relatively smaller public floats. As a relatively small<FONT CLASS="nobreak">-capitalization</FONT> company with relatively small public float, we may experience greater stock price volatility, extreme price run<FONT CLASS="nobreak">-ups</FONT>, lower trading volume and less liquidity than large<FONT CLASS="nobreak">-capitalization</FONT> companies. Such volatility, including any stock<FONT CLASS="nobreak">-run</FONT> up, may be unrelated to our actual or expected operating performance, financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the volatility and fluctuation of the trading price of our ordinary shares may happen because of broad market and industry factors, like the performance and fluctuation of the market prices of other companies with business operations located mainly in Taiwan that have listed their securities in the U.S.&#x00a0;A number of Taiwan companies have listed or are in the process of listing their securities on U.S.&#x00a0;stock markets. The securities of some of these companies have experienced significant volatility, including price declines in connection with their initial public offerings. The trading performances of these Taiwan companies&#x2019; securities after their offerings may affect the attitudes of investors toward Taiwan companies listed in the U.S.&#x00a0;in general and consequently may impact the trading performance of our ordinary shares, regardless of our actual operating performance.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to market and industry factors, the price and trading volume for our ordinary shares may be highly volatile for factors specific to our own operations, including the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>variations in our income, earnings and cash flow;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>announcements of new investments, acquisitions, strategic partnerships or joint ventures by us or our competitors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>announcements of new services and expansions by us or our competitors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>changes in financial estimates by securities analysts;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>detrimental adverse publicity about us, our services or our industry;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>additions or departures of key personnel;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>release of lock<FONT CLASS="nobreak">-up</FONT> or other transfer restrictions on our outstanding equity securities or sales of additional equity securities; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>potential litigation or regulatory investigations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any of these factors may result in large and sudden changes in the volume and price at which our ordinary shares will trade. Furthermore, the stock market in general experiences price and volume fluctuations that are often unrelated or disproportionate to the operating performance of companies like us. These broad market and industry fluctuations may adversely affect the market price of our ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, if the trading volumes of our ordinary shares are low, persons buying or selling in relatively small quantities may easily influence prices of our ordinary shares. This low volume of trades could also cause the price of our ordinary shares to fluctuate greatly, with large percentage changes in price occurring in any&#x00a0;trading day session. Holders of our ordinary shares may also not be able to readily liquidate their investment or may be forced to sell at depressed prices due to low volume trading. If high spreads between the bid and asked prices of our ordinary shares exist at the time of purchase, the stock would have to appreciate substantially on a relative percentage basis for an investor to recoup their investment. Broad market fluctuations and general economic and political conditions may also adversely affect the market price of our ordinary shares. As a result of this volatility, investors may experience losses on their investment in our ordinary shares. A decline in the market price of our ordinary shares also could adversely affect our ability to issue additional ordinary shares or other of our securities and our ability to obtain additional financing in the future. No assurance can be given that an active market in our ordinary shares will develop or be sustained. If an active market does not develop, holders of our ordinary shares may be unable to readily sell the shares they hold or may not be able to sell their shares at all.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">71</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the past, shareholders of public companies have often brought securities class action suits against those companies following periods of instability in the market price of their securities. If we were involved in a class action suit, it could divert a significant amount of our management&#x2019;s attention and other resources from our business and operations and require us to incur significant expenses to defend the suit, which could harm our results of operations. Any such class action suit, whether or not successful, could harm our reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial condition and results of operations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If securities or industry analysts do not publish research or reports about our business, or if they adversely change their recommendations regarding our ordinary shares, the market price for our ordinary shares and trading volume could decline.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The trading market for our ordinary shares will be influenced by research or reports that industry or securities analysts publish about our business. If one or more analysts who cover us downgrade our ordinary shares, the market price for our ordinary shares would likely decline. If one or more of these analysts cease to cover us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the market price or trading volume for our ordinary shares to decline.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We have broad discretion to determine how to use the net proceeds from this offering and may use them in ways that may not enhance our results of operations or the price of the ordinary shares.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although we currently intend to use the net proceeds from this offering in the manner described in the section titled &#x201c;Use of Proceeds&#x201d; in this prospectus, our management will have broad discretion over the use of net proceeds from this offering, and we could spend the net proceeds from this offering in ways the holders of the ordinary shares may not agree with or that do not yield a favorable return. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, our use of these proceeds may differ substantially from our current plans. The failure by our management to apply these funds effectively could have a material adverse effect on our business, financial condition and results of operation. You will not have the opportunity, as part of your investment decision, to assess whether the net proceeds from this offering are being used appropriately. You must rely on the judgment of our management regarding the application of the net proceeds of this offering.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The sale or availability for sale of substantial amounts of our ordinary shares could adversely affect their market price.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sales of substantial amounts of our ordinary shares in the public market after the completion of this offering, or the perception that these sales could occur, could adversely affect the market price of our ordinary shares and could materially impair our ability to raise capital through equity offerings in the future. The ordinary shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act&#x00a0;of&#x00a0;1933, as amended, or the Securities Act, and shares held by our existing shareholders may also be sold in the public market in the future subject to the restrictions in Rule&#x00a0;144 and Rule&#x00a0;701 under the Securities Act and the applicable lock<FONT CLASS="nobreak">-up</FONT> agreements. There will be [&#x2022;] ordinary shares outstanding immediately after this offering, or [&#x2022;] ordinary shares if the underwriters exercise their option to purchase additional ordinary shares in full. In connection with this offering, Our directors and officers and holders of more than 5% of our outstanding shares as of the effective date of this registration statement will enter into customary lock<FONT CLASS="nobreak">-up</FONT> agreements in favor of the underwriters for a period of twelve (12)&#x00a0;months from the date of this offering. Our holders of less than 5% of our outstanding shares as of the effective date of this registration statement will enter into customary lock<FONT CLASS="nobreak">-up</FONT> agreements in favor of the underwriters for a period of six (6)&#x00a0;months from the closing of this offering. Additionally, ordinary shares held by Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership) are subject to lock<FONT CLASS="nobreak">-up</FONT> for five (5) years from the closing date of this offering. We have agreed with the underwriters that, for a period of twelve (12)&#x00a0;months from the closing of this offering, we and any successors of us will not (a)&#x00a0;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of us or any securities convertible into or exercisable or exchangeable for shares of capital stock of us; (b)&#x00a0;file or caused to be filed any registration statement with the SEC relating to the offering of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock; or (c)&#x00a0;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our capital stock, whether any such transaction described in clause (a), (b)&#x00a0;or (c)&#x00a0;above is to be settled by delivery of </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">72</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">shares of our capital stock or such other securities, in cash or otherwise. However, the underwriters may release these securities from these restrictions at any time, subject to applicable regulations of the Financial Industry Regulatory Authority, Inc. We cannot predict what effect, if any, market sales of securities held by our significant shareholders or any other shareholder or the availability of these securities for future sale will have on the market price of our ordinary shares. See &#x201c;Underwriting&#x201d; and &#x201c;Shares Eligible for Future Sale&#x201d; for a more detailed description of the restrictions on selling our securities after this offering.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Because we do not expect to pay dividends in the foreseeable future after this offering, you must rely on price appreciation of our ordinary shares for return on your investment.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">We currently intend to retain most, if not all, of our available funds and any future earnings after this offering to fund the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an investment in our ordinary shares as a source for any future dividend income.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our board of directors has complete discretion as to whether to distribute dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on, among other things, our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiary, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in our ordinary shares will likely depend entirely upon any future price appreciation of our ordinary shares. There is no guarantee that our ordinary shares will appreciate in value after this offering or even maintain the price at which you purchased the ordinary shares. You may not realize a return on your investment in our ordinary shares and you may even lose your entire investment in our ordinary shares.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Because the initial public offering price is substantially higher than the pro forma net tangible book value per share, you will experience immediate and substantial dilution.</FONT></P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If you purchase ordinary shares in this offering, you will pay more for each ordinary share than the corresponding amount paid by existing shareholders for their ordinary shares. As a result, you will experience immediate and substantial dilution of approximately US$ per ordinary share. This number represents the difference between (1)&#x00a0;our pro forma net tangible book value deficit per ordinary share of US$0.23 as of June<FONT CLASS="nobreak"> </FONT>30, 2024, after giving effect to this offering and (2)&#x00a0;the assumed initial public offering price of US$8.50 per ordinary share, the upper end of the estimated initial public offering price range set forth on the front cover of this prospectus. See &#x201c;Dilution&#x201d; for a more complete description of how the value of your investment in our ordinary shares will be diluted upon the completion of this offering.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We may use these proceeds in ways with which you may not agree.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our management will have considerable discretion in deciding how to apply these proceeds. You will not have the opportunity to assess whether the proceeds are being used appropriately before you make your investment decision. You must rely on the judgment of our management regarding the application of the net proceeds of this offering. We cannot assure you that the net proceeds will be used in a manner that will improve our results of operations or increase our ordinary share price, nor that these net proceeds will be placed only in investments that generate income or appreciate in value.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">There can be no assurance that we will not be a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable year, which could subject U.S. investors in our ordinary shares or ordinary shares to significant adverse U.S. federal income tax consequences.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We will be classified as a passive foreign investment company, or PFIC, for United&#x00a0;States federal income tax purposes for any taxable year if either (a)&#x00a0;75% or more of our gross income for such year consists of certain types of &#x201c;passive&#x201d; income or (b)&#x00a0;50% or more of the value of our assets (generally determined on the basis of a quarterly average) during such year produce or are held for the production of passive income (the &#x201c;asset test&#x201d;). We will be treated as owning our proportionate share of the assets and earnings of any other corporation in which we own, directly or indirectly, more than 25% (by value) of the stock. Based upon our current and expected income and assets, including goodwill and other unbooked intangibles not reflected on our balance sheet (taking into account the expected proceeds from this offering) and projections as to the market price of our ordinary shares immediately following the offering, we do not expect to be classified as a PFIC for the current taxable year or the foreseeable future.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">73</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">While we do not expect to be classified as a PFIC, because the value of our assets for purposes of the asset test may be determined by reference to the market price of our ordinary shares, fluctuations in the market price of our ordinary shares may cause us to be classified as a PFIC for the current or subsequent taxable&#x00a0;years. The determination of whether we will be classified as a PFIC will also depend, in part, on the composition of our income and assets. In addition, the composition of our income and assets will also be affected by how, and how quickly, we use our liquid assets and the cash raised in this offering. If we determine not to deploy significant amounts of cash for active purposes, our risk of being a PFIC may substantially increase. It is also possible that the U.S.&#x00a0;Internal Revenue Service, or the IRS could challenge our classification of certain income and assets as non<FONT CLASS="nobreak">-passive</FONT>, which could result in our company being or becoming a PFIC for the current or future taxable&#x00a0;years. Because PFIC status is a factual determination made annually after the close of each taxable year, there can be no assurance that we will not be a PFIC for the current taxable year or any future taxable year.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">If we are a PFIC in any taxable year, a U.S.&#x00a0;Holder (as defined in &#x201c;Taxation&#x00a0;&#x2014;&#x00a0;U.S. Federal Income Tax Considerations&#x201d;) may incur significantly increased U.S.&#x00a0;income tax on gain recognized on the sale or other disposition of the ordinary shares and on the receipt of distributions on the ordinary shares to the extent such distribution is treated as an &#x201c;excess distribution&#x201d; under the U.S.&#x00a0;federal income tax rules, and such U.S.&#x00a0;Holder may be subject to burdensome reporting requirements. Further, if we are a PFIC for any year during which a U.S.&#x00a0;Holder holds our ordinary shares, we generally will continue to be treated as a PFIC for all succeeding&#x00a0;years during which such U.S.&#x00a0;Holder holds our ordinary shares, unless we were to cease to be a PFIC and the U.S.&#x00a0;Holder were to make a &#x201c;deemed sale&#x201d; election with respect to the ordinary shares. For more information see &#x201c;Taxation&#x00a0;&#x2014;&#x00a0;U.S. Federal Income Tax Considerations&#x00a0;&#x2014;&#x00a0;PFIC Rules.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our memorandum and articles of association contain </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">anti-takeover</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> provisions that could have a material adverse effect on the rights of holders of our ordinary shares.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We have adopted the second amended and restated memorandum and articles of association that will become effective immediately prior to the completion of this offering. Our new memorandum and articles of association contain provisions to limit the ability of others to acquire control of our company or cause us to engage in change<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-control</FONT> transactions. These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares at a premium over prevailing market prices by discouraging third parties from seeking to obtain control of our company in a tender offer or similar transaction. Our board of directors has the authority, without further action by our shareholders, to issue preferred shares in one or more series and to fix their designations, powers, preferences, privileges, and relative participating, optional or special rights and the qualifications, limitations or restrictions, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights associated with our ordinary shares. Preferred shares could be issued quickly with terms calculated to delay or prevent a change in control of our company or make removal of management more difficult. If our board of directors decides to issue preferred shares, the price of our ordinary shares may fall and the voting and other rights of the holders of our ordinary shares may be materially and adversely affected.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">You may face difficulties in protecting your interests, and your ability to protect your rights through U.S.&#x00a0;courts may be limited, because we are incorporated under Cayman Islands law.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We are an exempted company incorporated under the laws of the Cayman Islands. Our corporate affairs are governed by our memorandum and articles of association, the Companies Act (As Revised) of the Cayman Islands and the common law of the Cayman Islands. The rights of shareholders to take action against the directors, actions by minority shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from the common law of England, the decisions of whose courts are of persuasive authority, but are not binding, on a court in the Cayman Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedent in some jurisdictions in the U.S.&#x00a0;In particular, the Cayman Islands has a less developed body of securities laws than the U.S.&#x00a0;Some U.S.&#x00a0;states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies may not have standing to initiate a shareholder derivative action in a federal court of the U.S.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">74</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to obtain copies of lists of shareholders of these companies. Our directors have discretion under our articles of association to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but we are otherwise not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain corporate governance practices in the Cayman Islands, which is our home country, differ significantly from requirements for companies incorporated in other jurisdictions such as the U.S.&#x00a0;Currently, we plan to rely on home country practice with respect to any corporate governance matter and, our shareholders may be afforded less protection than they otherwise would under rules and regulations applicable to U.S.&#x00a0;domestic issuers.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result of all of the above, our public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as public shareholders of a company incorporated in the U.S.&#x00a0;For a discussion of significant differences between the provisions of the Companies Act (Revised) of the Cayman Islands and the laws applicable to companies incorporated in the U.S.&#x00a0;and their shareholders, see &#x201c;Description of Share Capital&#x00a0;&#x2014;&#x00a0;Differences in Corporate Law.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Certain judgments obtained against us by our shareholders may not be enforceable.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are a Cayman Islands company and substantially all of our assets are located outside of the U.S.&#x00a0;Substantially all of our current operations are conducted in Taiwan. In addition, all of our current directors and officers are nationals and residents of countries and regions other than the U.S.&#x00a0;Substantially all of the assets of these persons are located outside the U.S.&#x00a0;As a result, it may be difficult or impossible for you to bring an action against us or against these individuals in the U.S.&#x00a0;in the event that you believe that your rights have been infringed under the U.S.&#x00a0;federal securities laws or otherwise. Even if you are successful in bringing an action of this kind, the laws of the Cayman Islands, Taiwan, Singapore, Hong Kong and the PRC may render you unable to enforce a judgment against our assets or the assets of our directors and officers. For more information regarding the relevant laws of the Cayman Islands, Taiwan, Singapore, Hong Kong and the PRC, see &#x201c;Enforcement of Civil Liabilities.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We will incur increased costs as a result of being a public company.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon completion of this offering, we will become a public company and expect to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act&#x00a0;of&#x00a0;2002, as well as rules subsequently implemented by the SEC and the Nasdaq., impose various requirements on the corporate governance practices of public companies. We expect these rules and regulations to increase our legal and financial compliance costs and to make some corporate activities more time<FONT CLASS="nobreak">-consuming</FONT> and costly. For example, we expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. In addition, we will incur additional costs associated with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors or as executive officers. We are currently evaluating and monitoring developments with respect to these rules and regulations, and we cannot predict or estimate with any degree of certainty the amount of additional costs we may incur or the timing of such costs.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">The obligation to disclose information publicly may put us at a disadvantage to competitors that are private companies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Upon completion of this offering, we will be a publicly listed company in the United States. As a publicly listed company, we will be required to file annual reports with the Securities and Exchange Commission. In some cases, we will need to disclose material agreements or results of financial operations that we would not be required to disclose if we were a private company. Our competitors may have access to this information, which would otherwise be confidential. This may give them advantages in competing with our company. Similarly, as a U.S.<FONT CLASS="nobreak">-listed</FONT> public company, we will be governed by U.S. laws that some of our competitors are not required to follow. To the extent compliance with U.S. laws increases our expenses or decreases our competitiveness against such companies, our public listing could affect our results of operations.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">75</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We are a foreign private issuer within the meaning of the rules under the Exchange&#x00a0;Act, and as such we are exempt from certain provisions applicable to United&#x00a0;States domestic public companies.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Because we are a foreign private issuer under the Exchange&#x00a0;Act, we are exempt from certain provisions of the securities rules and regulations in the U.S.&#x00a0;that are applicable to U.S.&#x00a0;domestic issuers, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the rules under the Exchange&#x00a0;Act requiring the filing of quarterly reports on Form&#x00a0;10<FONT CLASS="nobreak">-Q</FONT> or current reports on Form&#x00a0;8<FONT CLASS="nobreak">-K</FONT> with the SEC;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the sections of the Exchange&#x00a0;Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange&#x00a0;Act;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the sections of the Exchange&#x00a0;Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the selective disclosure rules by issuers of material nonpublic information under Regulation&#x00a0;FD.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We will be required to file an annual report on Form&#x00a0;20<FONT CLASS="nobreak">-F</FONT> within four&#x00a0;months of the end of each fiscal year. In addition, we intend to publish our results on a quarterly basis through press releases, distributed pursuant to the rules and regulations of the Nasdaq. Press releases relating to financial results and material events will also be furnished to the SEC on Form&#x00a0;6<FONT CLASS="nobreak">-K</FONT>.&#x00a0;However, the information we are required to file with or furnish to the SEC will be less extensive and less timely than that required to be filed with the SEC by U.S.&#x00a0;domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you were you investing in a U.S.&#x00a0;domestic issuer.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Because we are a foreign private issuer and are exempt from certain Nasdaq corporate governance standards applicable to U.S. issuers, you will have less protection than you would have if we were a domestic issuer.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Nasdaq listing rules require listed companies to have, among other things, a majority of its board members be independent. As a foreign private issuer, however, we are permitted to, and we may follow home country practice in lieu of the above requirements, or we may choose to comply with the above requirement within one year of listing. The corporate governance practice in our home country, the Cayman Islands, does not require a majority of our board to consist of independent directors. Thus, although a director must act in the best interests of our Company, it is possible that fewer board members will be exercising independent judgment and the level of board oversight on the management of our Company may decrease as a result. Additionally, Nasdaq listing rules mandate that U.S. domestic issuers establish a compensation committee, a nominating and corporate governance committee, and an audit committee, each composed solely of independent directors. We, as a foreign private issuer, are not subject to these requirements. Nasdaq listing rules may require shareholder approval for certain corporate matters, such as requiring that shareholders be given the opportunity to vote on all equity compensation plans and material revisions to those plans, as well as certain ordinary share issuances. We intend to comply with the requirements of Nasdaq listing rules in determining whether shareholder approval is required on such matters, with regard to the requirement that a majority of our Board consists of independent directors and to appoint a nominating and corporate governance committee. We may, however, consider following home country practice in lieu of the requirements under Nasdaq listing rules with respect to certain corporate governance standards which may afford less protection to investors.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">We are an emerging growth company, and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares less attractive to investors.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company until the last&#x00a0;day of the fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five<FONT CLASS="nobreak">-year</FONT> period, including if we become a &#x201c;large accelerated filer,&#x201d; our annual gross revenues exceed US$1.235&#x00a0;billion or we issue more than US$1.0&#x00a0;billion of non<FONT CLASS="nobreak">-convertible</FONT> debt in any three<FONT CLASS="nobreak">-year</FONT> period, we will cease to be an emerging growth company prior to the end of such five<FONT CLASS="nobreak">-year</FONT> period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. We have taken advantage of reduced reporting burdens in this prospectus. In particular, in this prospectus, we have provided only two&#x00a0;years of audited consolidated financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">76</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">growth company. We cannot predict whether investors will find our ordinary shares less attractive if we rely on these exemptions. If some investors find our ordinary shares less attractive as a result, there may be a less active trading market for our ordinary shares and the trading price of our ordinary shares may be reduced or more volatile.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Nasdaq may apply additional and more stringent criteria for our initial and continued listing because we plan to have a small public offering and insiders will hold a large portion of the company&#x2019;s listed securities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Nasdaq Listing Rule 5101 provides Nasdaq with broad discretionary authority over the initial and continued listing of securities in Nasdaq and Nasdaq may use such discretion to deny initial listing, apply additional or more stringent criteria for the initial or continued listing of particular securities, or suspend or delist particular securities based on any event, condition, or circumstance that exists or occurs that makes initial or continued listing of the securities on Nasdaq inadvisable or unwarranted in the opinion of Nasdaq, even though the securities meet all enumerated criteria for initial or continued listing on Nasdaq. In addition, Nasdaq has used its discretion to deny initial or continued listing or to apply additional and more stringent criteria in the instances, including but not limited to: (i) where the company engaged an auditor that has not been subject to an inspection by the Public Company Accounting Oversight Board (&#x201c;PCAOB&#x201d;), an auditor that PCAOB cannot inspect, or an auditor that has not demonstrated sufficient resources, geographic reach, or experience to adequately perform the company&#x2019;s audit; (ii) where the company planned a small public offering, which would result in insiders holding a large portion of the company&#x2019;s listed securities. Nasdaq was concerned that the offering size was insufficient to establish the company&#x2019;s initial valuation, and there would not be sufficient liquidity to support a public market for the company; and (iii)&#x00a0;where the company did not demonstrate sufficient nexus to the U.S. capital market, including having no U.S.&#x00a0;shareholders, operations, or members of the board of directors or management. Our public offering will be relatively small, and our company&#x2019;s insiders will hold a large portion of the company&#x2019;s listed securities. Nasdaq might apply the additional and more stringent criteria for our initial and continued listing, which might cause delay or even denial of our listing application.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">If we cannot continue to satisfy the listing requirements and other rules of the Nasdaq Global Market, our securities may be delisted, which would negatively impact the price of our securities and your ability to sell them.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We plan to apply to have our ordinary shares listed on the Nasdaq Global Market upon consummation of this offering. It is a condition to the closing of this offering that our ordinary shares qualify for listing on a national securities exchange. As of the date of this prospectus, Nasdaq has not yet approved our application to list our ordinary shares. Following this offering, in order to maintain our listing on the Nasdaq Global Market, we will be required to comply with certain rules of the Nasdaq Global Market, including those regarding minimum stockholders&#x2019; equity, minimum share price, minimum market value of publicly held shares and various additional requirements. Even if we initially meet the listing requirements and other applicable rules of the Nasdaq Global Market, we may not be able to continue to satisfy these requirements and applicable rules. If we are unable to satisfy the Nasdaq Global Market criteria for maintaining our listing, our securities could be subject to delisting.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If the Nasdaq Global Market subsequently delists our securities from trading, we could face significant consequences, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a limited availability for market quotations for our securities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reduced liquidity with respect to our securities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a determination that our ordinary shares are a &#x201c;penny stock,&#x201d; which would require brokers trading in our ordinary shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our ordinary shares;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>limited amount of news and analyst coverage; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a decreased ability to issue additional securities or obtain additional financing in the future.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">77</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T18"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus contains forward<FONT CLASS="nobreak">-looking</FONT> statements that reflect our current expectations and views of future events. The forward<FONT CLASS="nobreak">-looking</FONT> statements are contained principally in the sections entitled &#x201c;Prospectus Summary,&#x201d; &#x201c;Risk Factors,&#x201d; &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; &#x201c;Business&#x201d; and &#x201c;Regulations.&#x201d; Known and unknown risks, uncertainties and other factors, including those listed under &#x201c;Risk Factors,&#x201d; may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward<FONT CLASS="nobreak">-looking</FONT> statements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You can identify some of these forward<FONT CLASS="nobreak">-looking</FONT> statements by words or phrases such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;expect,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;aim,&#x201d; &#x201c;estimate,&#x201d; &#x201c;intend,&#x201d; &#x201c;plan,&#x201d; &#x201c;believe,&#x201d; &#x201c;is/are likely to,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue&#x201d; or other similar expressions. We have based these forward<FONT CLASS="nobreak">-looking</FONT> statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward<FONT CLASS="nobreak">-looking</FONT> statements include statements relating to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our goals and strategies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our future business development, financial condition and results of operations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the expected growth of the pharmaceutical industry;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our expectations regarding demand for and market acceptance of our products and services;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our expectations regarding our bases of customers;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our plans to invest in our products and services;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>competition in our industry; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>relevant government policies and regulations relating to our industry.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These forward<FONT CLASS="nobreak">-looking</FONT> statements involve various risks and uncertainties. Although we believe that our expectations expressed in these forward<FONT CLASS="nobreak">-looking</FONT> statements are reasonable, our expectations may later be found to be incorrect. The forward<FONT CLASS="nobreak">-looking</FONT> statements made in this prospectus relate only to events or information as of the date on which the statements are made in this prospectus. Except as required by law, we undertake no obligation to update or revise publicly any forward<FONT CLASS="nobreak">-looking</FONT> statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should thoroughly read this prospectus and the documents that we refer to herein with the understanding that our actual future results may be materially different from and worse than what we expect. We qualify all of our forward<FONT CLASS="nobreak">-looking</FONT> statements by these cautionary statements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus contains certain data and information that we obtained from various government and private publications. Statistical data in these publications also include projections based on a number of assumptions. The pharmaceutical industry may not grow at the rate projected by market data, or at all. Failure of this industry to grow at the projected rate may have a material and adverse effect on our business and the market price of our ordinary shares. In addition, the competitive and rapidly changing nature of the pharmaceutical industry results in significant uncertainties for any projections or estimates relating to the growth prospects or future condition of our industry. Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the projections based on these assumptions. You should not place undue reliance on these forward<FONT CLASS="nobreak">-looking</FONT> statements.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">78</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T17"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">USE OF PROCEEDS</FONT></P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We estimate that we will receive net proceeds from this offering of approximately US$17,769 thousand, or approximately US$20,769 thousand if the underwriters exercise their over<FONT CLASS="nobreak">-allotment</FONT> option in full, after deducting underwriting discounts and the estimated offering expenses payable by us. These estimates are based upon an assumed initial public offering price of US$8.50 per ordinary share, the upper end of the price range shown on the front cover page of this prospectus. A US$1.00 increase (decrease) in the assumed initial public offering price of US$8.50 per ordinary share would increase (decrease) the net proceeds to us from this offering by US$1,358 thousand, assuming the underwriters do not exercise their over<FONT CLASS="nobreak">-allotment</FONT> option to purchase additional ordinary shares and the number of ordinary shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated expenses payable by us.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary purposes of this offering are to finance (i) our research and development of new drugs, (ii)&#x00a0;clinical trials of our drug candidates, and (iii) debt obligations due to litigation with Taizhou Bay New District Administrative Committee and commitments with Taizhou Resources Bureau. Assuming the offering size to be USD$20<FONT CLASS="nobreak"> </FONT>million, we plan to use the net proceeds from this offering as follows:</P>
		 <P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>approximately 40.0% to fund the additional Phase III trials of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and the new drug application of MCS<FONT CLASS="nobreak">-2</FONT>;</P>
		 <P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>approximately 25.0% to fund earlier phase trials if we are unable to demonstrate comparability;</P>
		 <P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>approximately 10.0% to fund the Phase II trial of PCP;</P>
		 <P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>approximately 5.0% to fund the Phase I clinical trial of IC;</P>
		 <P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>approximately 20.0% for general corporate purposes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing represents our current intentions based upon our present plans and business conditions to use and allocate the net proceeds of this offering. Our management will have flexibility and discretion in the application of net proceeds from this offering, and investors will be relying on the judgment of our management regarding the use of these net proceeds. See &#x201c;Risk Factors &#x2014; Risks Related to This Offering and Our Ordinary Shares&#x00a0;&#x2014;&#x00a0;We have broad discretion to determine how to use the net proceeds from this offering and may use them in ways that may not enhance our results of operations or the price of the ordinary shares.&#x201d; Due to the many variables inherent in the development of drug candidates, such as the size and timing of patient enrollment, evolving regulatory requirements and the associated costs, we cannot currently predict the stage of development that we will be able to achieve for the drug candidates in our pipeline with the net proceeds of this offering. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the results of the preclinical studies and clinical trials of our drug candidates, our operating costs and expenditures. If an unforeseen event occurs or business conditions change, we may use the proceeds of this offering differently than as described in this prospectus.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The expected net proceeds of this offering will not be sufficient for us to fund all our drug candidates through regulatory approval, and we will need to raise additional capital, approximately US$10<FONT CLASS="nobreak"> </FONT>million, to complete the development and commercialization of our drug candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In using the proceeds of this offering, we are permitted under PRC laws and regulations as an offshore holding company to provide funding to our PRC subsidiary only through loans or capital contributions. Subject to satisfaction of applicable government registration and approval requirements, we may extend inter<FONT CLASS="nobreak">-company</FONT> loans to our PRC subsidiary or make additional capital contributions to our PRC subsidiary to fund its capital expenditures or working capital in the future. We cannot assure you that we will be able to obtain these government registrations or approvals on a timely basis, if at all, which may delay or prevent us from providing the proceeds of this offering to our PRC subsidiary.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">79</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T16"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">DIVIDEND POLICY</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our board of directors has discretion on whether to distribute dividends, subject to certain restrictions under Cayman Islands law, namely that our Company may only pay dividends out of profits or share premium, and provided always that we are able to pay our debts as they become due in the ordinary course of business. Even if our board of directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the board of directors may deem relevant.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have never declared or paid dividends on our ordinary shares. We do not have any present plan to declare any cash dividends on our ordinary shares in the foreseeable future after this offering. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and grow our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are a holding company incorporated in the Cayman Islands. We have not received and do not have any present plan to receive dividends paid by our U.S., Taiwan, Singapore, Hong&#x00a0;Kong and PRC subsidiaries, but we have discretion as to whether such dividends are paid, subject to applicable statutory and contractual restrictions, including PRC regulations which may govern the ability of our PRC subsidiary to pay dividends to us.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">80</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T15"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CAPITALIZATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth our capitalization, as of June<FONT CLASS="nobreak"> </FONT>30, 2024 as follows:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>on an actual basis;</P>
		 <P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>on an adjusted basis to reflect the issuance and sale <FONT CLASS="CharOverride-1" STYLE="">of 2,352,941</FONT> ordinary shares in this offering at an assumed initial public offering price of US$8.50 per ordinary share, [add range] after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, assuming the underwriters do not exercise the over<FONT CLASS="nobreak">-allotment</FONT> option.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You should read this table together with the consolidated financial statements and related notes, and the sections titled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; that are included in this prospectus. </P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of June 30, 2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Actual</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Pro Forma <BR>As adjusted</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(in US$ thousand, except for share <BR>and per share data)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Long-term borrowings</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;font-style:normal;font-weight:bold;">(2)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,031</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,031</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Shareholders&#x2019; equity (deficit):</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary shares (par value of US$0.00001 per share; 5,000,000,000 <BR>ordinary shares authorized and 73,361,000 ordinary shares issued and outstanding as of June 30, 2024, respectively.)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,805</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">29,574</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Treasury shares, 1,794,258 shares as of June 30, 2024</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(16,366</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(16,366</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(31,387</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(31,387</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated other comprehensive income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,021</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,021</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total shareholders&#x2019; equity (deficit)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(34,926</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(17,157</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P> <P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Reflects the sale of ordinary shares in this offering at an assumed initial public offering price of US$8.50 per ordinary share, and after deducting the estimated underwriting discounts and estimated offering expenses payable by us, assuming that the option to purchase additional ordinary shares has not been exercised. The pro forma as adjusted information is for illustrative purposes only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing. Additional paid<FONT CLASS="nobreak">-in</FONT> capital includes the aggregate amount of issued and paid<FONT CLASS="nobreak">-in</FONT> capital of the entities now comprising our corporate group less consideration paid to acquire the relevant interest, if any. We estimate that net proceeds will be approximately US$17,769 thousand, assuming no exercise of the option to purchase additional ordinary shares. The net proceeds of US$17,769 thousand is calculated as follows: US$20,000 thousand gross offering proceeds, less underwriting discounts and commissions of US$1,400 thousand and estimated offering expenses of US$831 thousand. The pro forma as adjusted total shareholders&#x2019; equity deficit is the sum of the net proceeds of US$17,769&#x00a0;thousand and the actual shareholders&#x2019; deficit of US$34,926 thousand.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Long<FONT CLASS="nobreak">-term</FONT> borrowings consist of current portion of long<FONT CLASS="nobreak">-term</FONT> bank loans, long term loan from related parties, long<FONT CLASS="nobreak">-term</FONT> loan from third parties and long<FONT CLASS="nobreak">-term</FONT> bank loans, net of current portion.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">81</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T555"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">DILUTION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you invest in our ordinary shares, your interest will be diluted to the extent of the difference between the initial public offering price per ordinary share and our net tangible book value per ordinary share after this offering. Dilution results from the fact that the initial public offering price per ordinary share is substantially in excess of the book value per ordinary share attributable to the existing shareholders for our presently issued and outstanding ordinary shares.</P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our net tangible book value deficit as of June<FONT CLASS="nobreak"> </FONT>30, 2024 was approximately US$[34,926] thousand, or US$[0.48]&#x00a0;per&#x00a0;ordinary share as of that date. Net tangible book value represents the amount of our total consolidated tangible assets, less the amount of our total consolidated liabilities. Dilution is determined by subtracting net tangible&#x00a0;book value per ordinary share, after giving effect to the additional proceeds we will receive from this offering, from the assumed initial public offering price of US$8.50 per ordinary share, which is the upper end of the estimated offering price range set forth on the cover page of this prospectus after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Dilution is determined by subtracting net tangible book value per ordinary share on an as<FONT CLASS="nobreak">-converted</FONT> basis, after giving effect to the additional proceeds we will receive from this offering, from the initial public offering price of US$8.50 per ordinary share, which is the assumed initial public offering price set forth on the front cover of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Without taking into account any other changes in net tangible book value after June<FONT CLASS="nobreak"> </FONT>30, 2024, other than to give effect to the sale of the ordinary shares offered in this offering at the assumed initial public offering price of US$8.50 per ordinary share, the upper end of the estimated range of the offering price, after deduction of the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value deficit as of June<FONT CLASS="nobreak"> </FONT>30, 2024 would have been approximately US$17,157 thousand, or US$0.23 per ordinary share. This represents an immediate increase in net tangible book value of US$0.25 per ordinary share to the existing shareholders and an immediate dilution in net tangible book value of US$8.73 per ordinary share to investors purchasing ordinary shares in this offering. The following table illustrates such dilution:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Per <BR>Ordinary <BR>Share</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(US$)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Assumed initial public offering price per ordinary share</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.50</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net tangible book value deficit as per ordinary share of June 30, 2024</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.48</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pro forma net tangible book value deficit per ordinary share</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.23</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pro forma as adjusted net tangible book value deficit per ordinary share after giving effect this offering as of June 30, 2024</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.23</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amount of dilution in net tangible book value per ordinary share to new investors in this <BR>offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.73</P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A US$1.00 change in the assumed public offering price of US$8.50 per ordinary share would increase (decrease), in the case of an increase (decrease), our pro forma as adjusted net tangible book value after giving effect to this offering by approximately US$1,358 thousand, the pro forma as adjusted net tangible book value per ordinary share after giving effect to this offering by US$0.02 per ordinary share and the dilution in pro forma as adjusted net tangible book value per ordinary share to new investors in this offering by US$0.02 per ordinary share, assuming no change to the number of ordinary shares offered by us as set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and other offering expenses.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">82</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes, on a pro forma as adjusted basis as of June<FONT CLASS="nobreak"> </FONT>30, 2024, the differences between existing shareholders and the new investors with respect to the number of ordinary shares purchased from us in this offering, the total consideration paid and the average price per ordinary share and per ordinary share paid before deducting the underwriting discounts and commissions and estimated offering expenses. The total number of ordinary shares does not include ordinary shares issuable upon the exercise of the over<FONT CLASS="nobreak">-allotment</FONT> option granted to the underwriters.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 23.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="4" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Ordinary Shares Purchased</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="4" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total Consideration</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Average Price <BR>Per Ordinary <BR>Share <BR>(in US$)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 23.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Percent</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Amount <BR>(in US$ <BR>thousands)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Percent</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Existing shareholders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">73,361,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">97</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,806</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">37</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.16</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">New investors</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,352,941</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">63</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.50</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">75,713,941</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">100</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31,806</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">100</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The pro forma as adjusted information discussed above is illustrative only. Our net tangible book value following the completion of this offering is subject to adjustment based on the actual initial public offering price of our ordinary shares and other terms of this offering determined at pricing.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">83</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T14"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ENFORCEMENT OF CIVIL LIABILITIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are incorporated in the Cayman Islands to take advantage of certain benefits associated with being a Cayman Islands exempted company, such as:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>political and economic stability;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an effective judicial system;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a favorable tax system;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the absence of exchange control or currency restrictions; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the availability of professional and support services.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, certain disadvantages accompany incorporation in the Cayman Islands. These disadvantages include, but are not limited to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the Cayman Islands has a less developed body of securities laws as compared to the United&#x00a0;States and these securities laws provide significantly less protection to investors as compared to the United&#x00a0;States; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Cayman Islands companies may not have standing to sue before the federal courts of the United&#x00a0;States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Substantially all of our operations are conducted in Taiwan, and substantially all of our assets are located in Taiwan. All of our directors and executive officers are nationals or residents of jurisdictions other than the United&#x00a0;States and some of their assets are located outside the United&#x00a0;States. As a result, it may be difficult for a shareholder to effect service of process within the United&#x00a0;States upon these persons, or to enforce against us or them judgments obtained in United&#x00a0;States courts, including judgments predicated upon the civil liability provisions of the securities laws of the United&#x00a0;States or any state in the United&#x00a0;States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have appointed Cogency Global Inc. as our agent upon whom process may be served in any action brought against us under the securities laws of the United&#x00a0;States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Conyers Dill &amp; Pearman, our legal counsel as to Cayman Islands law, and KMPG Law Firm, our legal counsel as to Taiwan law have advised us, respectively, that there is uncertainty as to whether the courts of the Cayman Islands and Taiwan, respectively, would:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>recognize or enforce judgments of United&#x00a0;States courts obtained against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United&#x00a0;States or any state in the United&#x00a0;States; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>entertain original actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities laws of the United&#x00a0;States or any state in the United&#x00a0;States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Conyers Dill &amp; Pearman has informed us that although there is no statutory enforcement in the Cayman Islands of judgments obtained in the federal or state courts of the United&#x00a0;States, the courts of the Cayman Islands would recognize as a valid judgment, a final and conclusive judgment in personam obtained in the US Courts against our company under which a sum of money is payable (other than a sum of money payable in respect of multiple damages, taxes or other charges of a like nature or in respect of a fine or other penalty) or, in certain circumstances, an in personam judgment for non<FONT CLASS="nobreak">-monetary</FONT> relief, and would give a judgment based thereon provided that (a) such courts had proper jurisdiction over the parties subject to such judgment, (b) such courts did not contravene the rules of natural justice of the Cayman Islands, (c) such judgment was not obtained by fraud, (d) the enforcement of the judgment would not be contrary to the public policy of the Cayman Islands, (e) no new admissible evidence relevant to the action is submitted prior to the rendering of the judgment by the courts of the Cayman Islands, and (f) there is due compliance with the correct procedures under the laws of the Cayman Islands.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">84</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">KPMG Law Firm has advised us that any United&#x00a0;States judgments obtained against us will be enforced by courts in Taiwan without further review of the merits only if the court of Taiwan in which enforcement is sought is satisfied with the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the court rendering the judgment has jurisdiction over the subject matter according to the laws of Taiwan;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if the judgment was rendered by default by the court rendering the judgment, (i)&#x00a0;we were duly served within a reasonable period of time within the jurisdiction of such court in accordance with the laws and regulations of such jurisdiction, or (ii)&#x00a0;process was served on us with judicial assistance of Taiwan;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the judgment and the court procedures resulting in the judgment are not contrary to the public order or good morals of Taiwan; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>judgments of the courts of Taiwan are recognized in the jurisdiction of the court rendering the judgment on a reciprocal basis.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The recognition and enforcement of foreign judgments are subject to compliance with the PRC Civil Procedures Law and relevant civil procedure requirements in the PRC.&#x00a0;PRC courts may recognize and enforce foreign judgments in accordance with the requirements of PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made or on reciprocity between jurisdictions. China does not have any treaties or other form of reciprocity with the United&#x00a0;States or the Cayman Islands that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law, courts in the PRC will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC law or national sovereignty, security or public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United&#x00a0;States or in the Cayman Islands.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, there is no treaty between the U.S.&#x00a0;and Singapore providing for the reciprocal recognition and enforcement of judgments in civil and commercial matters and a final judgment for the payment of money rendered by any federal or state court in the U.S.&#x00a0;based on civil liability, whether or not predicated solely upon the federal securities laws, would, therefore, not be automatically enforceable in Singapore. In making a determination as to enforceability of a foreign judgment, the Singapore courts need to be satisfied that the foreign judgment was final and conclusive and on the merits of the case, given by a court of law of competent jurisdiction, and was expressed to be for a fixed sum of money. In general, a foreign judgment would be enforceable in Singapore unless procured by fraud, or if the proceedings in which such judgments were obtained were not conducted in accordance with principles of natural justice, or if the enforcement thereof would be contrary to the public policy of Singapore, or if the judgment would conflict with earlier judgments from Singapore or earlier foreign judgments recognized in Singapore, or if the judgment would amount to the direct or indirect enforcement of foreign penal, revenue or other public laws. The Singapore courts do not allow the enforcement of foreign judgments which amount to the direct or indirect enforcement of foreign penal, revenue or other public laws. It is uncertain as to whether a judgment of the courts of the U.S.&#x00a0;awarding such punitive damages would be regarded by the Singapore courts as being pursuant to foreign, penal, revenue or other public laws. Such determination has yet to be made by a Singapore court in a reported decision.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">85</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T13"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CORPORATE HISTORY AND STRUCTURE</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OUR CORPORATE HISTORY</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are a Cayman Islands exempted company incorporated on January&#x00a0;26, 2018 and primarily conduct our operations through our wholly owned subsidiaries in Taiwan. We commenced our commercial operations in July&#x00a0;2002 through Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd., which has been wholly owned by Jyong Biotech Ltd. since August&#x00a0;2018. In September&#x00a0;2019, we established Genvace Biotechnology Co., Ltd., a Taiwan subsidiary wholly owned by Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd. for the research and development of health products.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our Hong&#x00a0;Kong subsidiary, Top ShunXing Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Limited, was established in March&#x00a0;2019, with Jyong Biotech Ltd. as its sole shareholder. Top ShunXing Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Limited is a holding company and has no substantial operations in Hong&#x00a0;Kong, except that in October&#x00a0;2020, all intellectual properties of Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd. were transferred to Top ShunXing Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Limited for the sake of centralized management and that in August 2019, it borrowed approximately US$ 2.3&#x00a0;million from third parties to invest our PRC subsidiary via capital contribution.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our PRC subsidiary, Innovative Biotech Co., Ltd., was established in July&#x00a0;2019 pursuant to a collaboration framework agreement we entered with Taizhou Infrastructure Investment Group Co., Ltd. on December<FONT CLASS="nobreak"> </FONT>21, 2018. In September&#x00a0;2019, according to an investment cooperation agreement Innovative Biotech Co., Ltd. entered with the successor of the Taizhou High<FONT CLASS="nobreak">-tech</FONT> Industrial Park Management Committee, Innovative Biotech Co., Ltd. obtained the land use rights for a parcel of industrial land in Taizhou City, Zhejiang Province for the construction of manufacturing factory in the future. See &#x201c;Business&#x00a0;&#x2014;&#x00a0;License and Collaboration Agreements&#x00a0;&#x2014;&#x00a0;Taizhou Collaboration Framework Agreement&#x201d; for more details. We planned to construct a manufacturing factory in 2023 and the construction is expected to be completed in 2026. As of the date of this prospectus, the construction has not yet taken place.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In September&#x00a0;2022, we established our Singapore subsidiary, Jyong Biotech International Pte. Ltd., with Jyong Biotech Ltd. as its sole shareholder, primarily for holding all our intellectual properties which were transferred from Top ShunXing Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Limited in January 2023.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OUR CORPORATE STRUCTURE</FONT></P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following diagram sets forth our corporate structure prior to the initial offering:</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><IMG ALT="" SRC="tflow_001.jpg" STYLE="width:590.08px;max-width:100%;"></P>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>No single shareholder among &#x201c;other shareholders&#x201d; beneficially owns more than 5% of our ordinary shares.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">86</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following diagram illustrates our corporate structure, including our significant subsidiaries immediately upon the completion of this offering, assuming no exercise of the over<FONT CLASS="nobreak">-allotment</FONT> option granted to the underwriters, based on the assumed initial public offering price of US$8.50 per ordinary share.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><IMG ALT="" SRC="tflow_002.jpg" STYLE="width:584.96px;max-width:100%;"></P>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>No single shareholder among &#x201c;other shareholders&#x201d; beneficially owns more than 5% of our ordinary shares.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">87</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T666"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND<BR>RESULTS OF OPERATIONS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain&#x00a0;</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">&#x00a0;statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results and the timing of selected events could differ materially from those anticipated in these&#x00a0;</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">&#x00a0;statements as a result of several factors, including those set forth under &#x201c;Risk Factors&#x201d; and elsewhere in this prospectus. You should carefully read the &#x201c;Risk Factors&#x201d; section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our&#x00a0;</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">&#x00a0;statements.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OVERVIEW</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are a science<FONT CLASS="nobreak">-driven</FONT>&#x00a0;biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since our inception in 2002, we have built integrated capabilities that encompass all key functionalities of drug development, including early<FONT CLASS="nobreak">-stage</FONT>&#x00a0;drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging our strong research and development capabilities and proprietary platform, we have been developing a series of botanical drug candidates, including our primary botanical drug candidate of MCS<FONT CLASS="nobreak">-2</FONT>, another clinical<FONT CLASS="nobreak">-stage</FONT>&#x00a0;botanical drug candidate of PCP, and other preclinical<FONT CLASS="nobreak">-stage</FONT>&#x00a0;botanical drug candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our pipeline features three innovative and differentiated new drug candidates, and we are developing them for (i)&#x00a0;the treatment of benign prostate hyperplasia/lower urinary tract symptoms, or BPH/LUTS, (ii)&#x00a0;prostate cancer prevention (PCP), and (iii)&#x00a0;the treatment of interstitial cystitis, respectively.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;is our new botanical drug candidate developed for treatment of BPH/LUTS.&#x00a0;MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;is expected to be our core product in the future. MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;is a softgel capsule containing patented active pharmaceutical ingredients derived from botanical raw materials, specifically, Lycopersecum Esculentum. MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;contains, in the largest concentrations, five carotenoids including lycopene, phytoene, phytofluene, tocopherol and beta<FONT CLASS="nobreak">-carotene</FONT>. We developed MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;using chylomicron technology to improve its bioavailability. Chylomicron is a type of lipoprotein particles consisting of triglycerides and phospholipids.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">We have conducted four Phase&#x00a0;III clinical trials for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;in the U.S.&#x00a0;and Taiwan, including two pivotal trials (one in the US and one in Taiwan) and two open<FONT CLASS="nobreak">-label</FONT>&#x00a0;extension studies, using API<FONT CLASS="nobreak">-1</FONT>. Our pivotal Phase&#x00a0;III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;in the U.S.&#x00a0;failed to show a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-treat</FONT>&#x00a0;population.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">We resubmitted an NDA for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;using API<FONT CLASS="nobreak">-1</FONT>&#x00a0;to the US FDA on December&#x00a0;17, 2022, the US FDA accepted our NDA for review &#x201c;with issues identified.&#x201d; In the February&#x00a0;22, 2022 Filing Issues Identified letter, the US FDA identified, among other things, the lack of demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;and placebo for the primary efficacy endpoint in the MCS<FONT CLASS="nobreak">-2-</FONT><FONT CLASS="nobreak">US-a</FONT>&#x00a0;study. US FDA identified additional issues, including issues regarding pharmacology, toxicology, and our pharmacokinetic submission, statistical analyses, and the content and format of our proposed Prescribing Information. In a Mid<FONT CLASS="nobreak">-Cycle</FONT>&#x00a0;meeting and communication with the US FDA on May&#x00a0;24, 2022, the US FDA also identified the fact that API<FONT CLASS="nobreak">-1</FONT>, the botanical drug substance used in our clinical trials and that was the basis for our NDA, was not available. Based upon these observations, we voluntarily withdrew our NDA on November&#x00a0;30, 2022, to develop more information about API<FONT CLASS="nobreak">-2</FONT>&#x00a0;for the US FDA&#x2019;s review, to address the US FDA&#x2019;s concerns of a lack of demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;and placebo for the primary efficacy endpoint, and to resolve other issues the US FDA had previously identified (and discussed above). In the December&#x00a0;12, 2022 Acknowledge Withdrawal from the US FDA, the US FDA stated that &#x201c;this withdrawal will not prejudice any future decisions on filing&#x201d; if we decide to resubmit our NDA, and we can retain the application number (NDA 212872).</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">88</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">We have been conducting further research and development on MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;and identified an additional source for the botanical drug substance API<FONT CLASS="nobreak">-2</FONT>. API<FONT CLASS="nobreak">-1</FONT>&#x00a0;and API<FONT CLASS="nobreak">-2</FONT>&#x00a0;are similar drug substances covered by the same patent owned by us; however, because they are sourced from raw materials manufactured in different locations, the US FDA considers them to be different botanical drug substances.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">We submitted a meeting request to the US FDA on April&#x00a0;14, 2023 with our very preliminary comparative specifications of API<FONT CLASS="nobreak">-1</FONT>&#x00a0;and API<FONT CLASS="nobreak">-2</FONT>, and request that the agency provide a WRO to questions about our refiling of the NDA for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;using API<FONT CLASS="nobreak">-2</FONT>. The US FDA agreed to our request and responded in writing on June&#x00a0;26, 2023. The US FDA informed us that the information we provided on API<FONT CLASS="nobreak">-2</FONT>&#x00a0;was not sufficient to demonstrate comparability with API<FONT CLASS="nobreak">-1</FONT>. In addition to a lack of API source, US FDA explained that we had not demonstrated a statistically significant difference between MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;with API<FONT CLASS="nobreak">-1</FONT>&#x00a0;and placebo in the primary efficacy endpoint in the MCS<FONT CLASS="nobreak">-2-</FONT><FONT CLASS="nobreak">US-a</FONT>&#x00a0;study. The US FDA stated that without new clinical information, any resubmission of the NDA for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;would be at risk of the agency refusing to accept the application, a RTF action.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">We submitted a Type D WRO meeting request to the US FDA on December&#x00a0;12, 2023. We asked that the US FDA provide a written response to questions focused on obtaining US FDA review and comments on a new, proposed Phase&#x00a0;III clinical trial protocol for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;with API<FONT CLASS="nobreak">-2</FONT>&#x00a0;and a Phase&#x00a0;I pharmacokinetic study. We proposed to address chemistry and manufacturing controls for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;in a separate, future meeting. FDA granted our WRO meeting request but clarified that they viewed the meeting as a Type&#x00a0;C meeting because it encompasses an entirely new drug development program, including Phase&#x00a0;1 PK study and Phase&#x00a0;III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;made from API<FONT CLASS="nobreak">-2</FONT>, which the agency characterizes as a new product with a new active pharmaceutical ingredient.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">If our new Phase&#x00a0;1 PK and Phase&#x00a0;III studies are successful and we address the other deficiencies the US FDA has previously identified (including clinical, pharmacological, statistical, pharmaceutical manufacturing, validation, and other issues), we plan to resubmit our NDA for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;under the same NDA number to the US FDA.&#x00a0;The resubmission timeline is unclear at this point, depending on the comments from the US FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">BPH/LUTS is the most common urinary tract disease in the middle<FONT CLASS="nobreak">-aged</FONT>&#x00a0;male population.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">According to Frost&#x00a0;&amp; Sullivan, the global prevalence of BPH increased from 88.4&#x00a0;million in 2017 to 94.2&#x00a0;million in 2020, representing an increase of 6.5%.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">The global BPH drugs market increased from US$3.7&#x00a0;billion in 2017 to US$4.1&#x00a0;billion in 2020, representing a CAGR of 4.6%. We are establishing a strong sales and marketing team that is expected to consist of employees with experience in relevant areas and our target markets, and plan to work with both domestic and international business partners to seize the great market opportunities and to help more patients reduce their distress caused by BPH/LUTS and drug side effects caused by chemical drugs.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PCP:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>PCP is our new botanical drug candidate developed for the prevention of prostate cancer. PCP, like MCS<FONT CLASS="nobreak">-2</FONT>, contains patented active pharmaceutical ingredients derived from botanical raw materials, specifically,&#x00a0;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Lycopersecum esculentum</FONT>. PCP contains, in the largest concentrations, five carotenoids including lycopene, phytoene, phytofluene, tocopherol and beta<FONT CLASS="nobreak">-carotene</FONT>. PCP and MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;are essentially the same in terms of active ingredients, dosage form, strength and route of administration; however, they are different drug candidates targeting different indications. We are conducting phase&#x00a0;II clinical trials of PCP in Taiwan.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:48pt;text-indent:0pt;margin-top:8pt;">Prostate cancer begins when cells in the prostate gland start to grow out of control. In general, the more quickly prostate cells grow and divide, the more chances there are for mutations to occur. According to Frost&#x00a0;&amp; Sullivan, the global prevalence of prostate cancer increased from 10.0&#x00a0;million in 2017 to 11.2&#x00a0;million in 2020, representing a CAGR of 3.9%. The global prostate cancer market increased from US$9.7&#x00a0;billion in 2017 to US$12.6&#x00a0;billion in 2019, representing a CAGR of 9.1%. In addition, the prostate<FONT CLASS="nobreak">-specific</FONT>&#x00a0;antigen abnormal population, or PSA abnormal population, representing men over 40&#x00a0;years old with a prostate<FONT CLASS="nobreak">-specific</FONT>&#x00a0;antigen test value of 4.0 ng/ml or higher, is exposed to a high risk of prostate cancer. From 2015 to 2020, the total number of PSA abnormal populations in the U.S., Taiwan and China increased from 5.0&#x00a0;million to 5.3&#x00a0;million.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">89</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;font-style:normal;font-weight:bold;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">IC:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Interstitial Cystitis (IC) is our additional key new drug candidate which is composed of polysorbate loaded micelles as nanocarriers which can be used in the intravenous injection and intravesical instillation. The micelles enhance the bioavailability by prolonging the duration of stay in the bladder and increase the penetration of drug across the bladder wall. IC/BPS, refers to interstitial cystitis and bladder pain symptoms that is often associated with voiding symptomatology and other systemic chronic pain disorders.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">KEY FACTORS THAT AFFECT OPERATING RESULTS</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Costs and Expenses Structure</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our results of operations are significantly affected by our cost structure, which primarily consists of research and development expenses and general and administrative expenses.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development activities are central to our business operations. We believe our ability to successfully develop drug candidates will be the primary factor affecting our long<FONT CLASS="nobreak">-term</FONT>&#x00a0;competitiveness, as well as our future growth and development. Developing high<FONT CLASS="nobreak">-quality</FONT>&#x00a0;drug candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, and engaging in activities related to regulatory filings for our drug candidates. Clinical studies become increasingly more expensive from Phase&#x00a0;I/II and onwards due to an increase in the number of subjects enrolled in such studies. Research and development costs are expensed as incurred. Costs for certain activities, such as activities performed by third<FONT CLASS="nobreak">-party</FONT>&#x00a0;contractors relating to the manufacturing and preclinical studies and clinical trials of our drug candidates, are generally accrued based on our estimates of the actual services performed for a given period. These estimates are based on our evaluation of the progress to completion of specific tasks to be performed using information and data provided to us by our third<FONT CLASS="nobreak">-party</FONT>&#x00a0;contractors and vendors.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At this time, we cannot reasonably estimate the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, or the period, if any, in which material net cash inflows may commence from, any of our drug candidates. We expect research and development costs to continue to increase for the foreseeable future as we continue to support and advance the clinical trials of our drug candidates, including MCS<FONT CLASS="nobreak">-2</FONT>, PCP and IC.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our general and administrative expenses consist primarily of employee salaries and related benefit costs for personnel in executive, finance and administrative functions, professional fees for legal, audit and accounting services, and expenses for rental of facilities. We expect our employee salaries and related costs for personnel in executive to increase in the future to support our clinical program and research and development efforts, and the commercialization of our product candidates in the event approval is obtained. We also anticipate that our general and administrative expenses will increase as we operate as a public company.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Funding for Our Operations</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the periods presented, we have funded our operations primarily through loans from banks, related parties and third parties. However, if our business and our drug candidate pipeline continue to expand, we will require further funding through public or private offerings, debt financing, collaboration, and licensing arrangements or other sources. Any fluctuation in our ability to fund our operations will impact our development plan, operating plan and our results of operations. In the event of the successful development and commercialization of one or more of our drug candidates, we expect to fund our operations in part with revenue generated from sales of our commercialized drug products. In the event that we enter into out<FONT CLASS="nobreak">-license</FONT>&#x00a0;and/or collaboration arrangements with others, we expect to fund our operations in part with revenue received from such out<FONT CLASS="nobreak">-license</FONT>&#x00a0;and/or collaboration arrangements.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">90</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Ability to Commercialize and</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">or&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Out-License</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;Our Drug Candidates</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our business and results of operations depend on our ability to out<FONT CLASS="nobreak">-license</FONT>&#x00a0;our drug candidates or, in the event any of our drug candidates are approved for marketing by the respective regulatory authority in a country, commercialize such drug candidates. Our core drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>, is under further clinical development in the U.S.&#x00a0;If our new Phase&#x00a0;1 PK and Phase&#x00a0;III studies are successful and we address the other deficiencies the US FDA has previously identified (including clinical, pharmacological, statistical, pharmaceutical manufacturing, validation, and other issues), we plan to resubmit our NDA for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;under the same NDA number to the US FDA.&#x00a0;The resubmission timeline is unclear at this point, depending on the comments from the US FDA.&#x00a0;Although we currently do not have any product approved for commercial sale and have not generated revenue from product sales, we expect to generate revenue either from sales of a drug candidate if we obtain regulatory approval and successfully commercialize MCS<FONT CLASS="nobreak">-2</FONT>, or from out<FONT CLASS="nobreak">-licensing</FONT>&#x00a0;arrangements if we enter into an out<FONT CLASS="nobreak">-license</FONT>&#x00a0;and/or collaboration agreement for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;and other drug candidates.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Impact of the COVID-19 pandemic on our operations</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beginning in December&#x00a0;2019, the outbreak of the COVID<FONT CLASS="nobreak">-19</FONT>&#x00a0;pandemic created business interruptions for companies globally, including us. Although we have not been materially impacted by the COVID<FONT CLASS="nobreak">-19</FONT>&#x00a0;pandemic to date, other outbreaks may occur, or there could be a resurgence of the COVID<FONT CLASS="nobreak">-19</FONT>&#x00a0;pandemic, which could cause business disruptions in the future. Efforts to contain the spread of the COVID<FONT CLASS="nobreak">-19</FONT>&#x00a0;pandemic in Taiwan and the United&#x00a0;States have included quarantines, shelter<FONT CLASS="nobreak">-in</FONT><FONT CLASS="nobreak">-place</FONT>&#x00a0;orders and various other government restrictions in order to control the spread of this virus. We have been carefully monitoring the COVID<FONT CLASS="nobreak">-19</FONT>&#x00a0;pandemic and its potential impact on our business. We have taken important steps to ensure the workplace safety of our employees when working within our administrative offices, or when traveling to our clinical trial sites. To date, we have been able to continue our key business activities and advance our clinical programs. However, in the future, it is possible that our clinical development timelines and business plans could be adversely affected. We maintain regular communication with our vendors and clinical sites to appropriately plan for, and mitigate, the impact of the COVID<FONT CLASS="nobreak">-19</FONT>&#x00a0;pandemic on our operations. See &#x201c;Risk Factors&#x201d; for a further discussion of the potential adverse impact of COVID<FONT CLASS="nobreak">-19</FONT>&#x00a0;on our business, results of operations and financial condition.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">KEY COMPONENTS OF OUR RESULTS OF OPERATIONS</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Revenue</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, we have not generated any revenue. Our ability to generate revenue and to become profitable will depend upon the successful commercialization of, and/or our successful entry into out<FONT CLASS="nobreak">-license</FONT>&#x00a0;and/or collaboration arrangements in connection with, one or more of our drug candidates. Because of the numerous risks and uncertainties associated with product development and regulatory approval, and out<FONT CLASS="nobreak">-license</FONT>&#x00a0;and/or collaboration arrangements, we are unable to predict the amount or timing of product revenue or out<FONT CLASS="nobreak">-license</FONT>&#x00a0;and/or collaboration revenue.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Research and Development Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses consist of costs associated with planning and conducting clinical trials of our drug candidates. Our research and development expenses primarily consist of:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>payroll and other related costs of personnel engaged in research and development activities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>costs for preclinical testing of our technologies and clinical trials such as payments to CROs, investigators and clinical trial sites that conduct the clinical studies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>costs to develop our drug candidates, including raw materials and supplies, product testing, clinical trial equipment and its depreciation, and facility related expenses;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>costs incurred in seeking regulatory approval of our drug candidates; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>other research and development expenses.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">91</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Clinical trial costs are a significant component of our research and development expenses. Our current research and development activities primarily related to the clinical development of the following drug candidates:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">-2</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">.&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;is our drug candidate being developed for BPH/LUTS treatment. MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;has been subjected various stages of regulatory review by US FDA or TFDA.&#x00a0;We have conducted four Phase&#x00a0;III clinical trials for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;in the U.S.&#x00a0;and Taiwan, including two pivotal trials and two open<FONT CLASS="nobreak">-label</FONT>&#x00a0;extension studies, using API<FONT CLASS="nobreak">-1</FONT>. Our pivotal Phase&#x00a0;III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;in the U.S.&#x00a0;failed to show a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-treat</FONT>&#x00a0;population. In a communication with the US FDA on May<FONT CLASS="nobreak">&#x00a0;</FONT>24, 2022, the US FDA also identified the fact that API<FONT CLASS="nobreak">-1</FONT>, the botanical drug substance used in our clinical trials and that was the basis for our pending NDA, was not available. Based upon these observations, we voluntarily withdrew our pending NDA on November<FONT CLASS="nobreak">&#x00a0;</FONT>30, 2022, to develop more information about API<FONT CLASS="nobreak">-2</FONT>&#x00a0;for the US FDA&#x2019;s review, to address the US FDA&#x2019;s concerns of a lack of demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;and placebo for the primary efficacy endpoint, and to resolve other issues the US FDA had previously identified. We <FONT CLASS="CharOverride-2" STYLE="">submitted a Type D Written Response Only (WRO) meeting request to the US FDA on December</FONT><FONT CLASS="nobreak" STYLE="">&#x00a0;</FONT><FONT CLASS="CharOverride-2" STYLE="">12, 2023. We asked that the US FDA provide a written response to questions focused on obtaining US FDA review and comments on a new, proposed Phase&#x00a0;III clinical trial protocol for MCS</FONT><FONT CLASS="nobreak" STYLE="">-2</FONT><FONT CLASS="CharOverride-2" STYLE="">&#x00a0;with API</FONT><FONT CLASS="nobreak" STYLE="">-2</FONT><FONT CLASS="CharOverride-2" STYLE="">&#x00a0;and a pharmacokinetic study. We proposed to address chemistry and manufacturing controls (CMC) data for our proposed drug product in a separate, future meeting. US FDA granted our WRO meeting request but clarified that they viewed the meeting as a Type C meeting because it encompasses an entirely new drug development program, including Phase&#x00a0;1 PK study and Phase&#x00a0;III clinical trial for a new product with a new active pharmaceutical ingredient. On May</FONT><FONT CLASS="nobreak" STYLE=""> </FONT><FONT CLASS="CharOverride-2" STYLE="">23, 2024, we received a denial notice from the FDA, stating that it is premature for this stage of drug development, and until the company can provide complete Chemistry, Manufacturing, and Controls (CMC) information on the active pharmaceutical ingredient</FONT><FONT CLASS="nobreak" STYLE="">-2</FONT><FONT CLASS="CharOverride-2" STYLE=""> (API</FONT><FONT CLASS="nobreak" STYLE="">-2</FONT><FONT CLASS="CharOverride-2" STYLE="">) and a plan to establish comparability between API</FONT><FONT CLASS="nobreak" STYLE="">-1</FONT><FONT CLASS="CharOverride-2" STYLE=""> and API</FONT><FONT CLASS="nobreak" STYLE="">-2</FONT><FONT CLASS="CharOverride-2" STYLE="">, the U.S. FDA is unable to reach agreement on protocols designed to establish the safety and efficacy of MCS</FONT><FONT CLASS="nobreak" STYLE="">-2</FONT><FONT CLASS="CharOverride-2" STYLE="">. We have completed the CMC documentation on the active pharmaceutical ingredient</FONT><FONT CLASS="nobreak" STYLE="">-2</FONT><FONT CLASS="CharOverride-2" STYLE=""> (API</FONT><FONT CLASS="nobreak" STYLE="">-2</FONT><FONT CLASS="CharOverride-2" STYLE="">) and a plan to establish comparability between API</FONT><FONT CLASS="nobreak" STYLE="">-1</FONT><FONT CLASS="CharOverride-2" STYLE=""> and API</FONT><FONT CLASS="nobreak" STYLE="">-2</FONT><FONT CLASS="CharOverride-2" STYLE=""> and submitted it to the U.S. FDA on October</FONT><FONT CLASS="nobreak" STYLE=""> </FONT><FONT CLASS="CharOverride-2" STYLE="">16, 2024, and are awaiting feedback from the U.S. FDA.</FONT></P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">PCP.&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>PCP is our key drug candidate being developed for the prevention of prostate cancer. We received the investigation (IND) implication approval from the TFDA and are currently conducting ongoing Phase&#x00a0;II clinical trials initiated in November&#x00a0;2014.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We incurred research and development expenses of approximately US$1,290&#x00a0;thousand, US$1,071 thousand, US$538 thousand, and US$499 thousand for the year ended December&#x00a0;31, 2022 and 2023, and the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, representing approximately 46%, 38%, 49%, and 52% of our total operating expenses for those periods, respectively. Our research and development expenses may vary substantially from period to period according to the status of our research and development activities. The timing of expenses is impacted by the commencement of clinical trials and enrollment of patients in clinical trials. We expect our research and development expenses to continue to increase for the foreseeable future, as we advance our core drug candidates, MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;and key drug candidate, PCP, toward later stages and continue to expand our operations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">General and Administrative Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our general and administrative expenses consist primarily of employee salaries and related benefit costs for personnel in executive, finance and administrative functions. Other selling, general and administrative expenses include professional fees for legal, audit and accounting services, expenses for rental of facilities and litigation expenses. For the year ended December&#x00a0;31, 2022 and 2023, and the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, our general and administrative expenses amounted to approximately US$1,492 thousand, US$1,679 thousand, US$549 thousand, and US$431 thousand, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We anticipate that our general and administrative expenses will increase in the future to support ongoing and planned research and development of our core drug candidate and additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, investor relations activities and other administrative and professional services.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">92</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Selling and Marketing Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our selling and marketing expenses consist primarily of employee salaries and related benefit costs for personnel in selling and marketing functions. Other selling and marketing expenses include promotion costs. For the year ended December&#x00a0;31, 2022 and 2023, and the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, our selling and marketing expenses amounted to approximately US$47 thousand, US$47 thousand, US$22 thousand and US$21 thousand, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We anticipate that our selling and marketing expenses will increase in the future to support commercial activities for the potential commercialization of drug candidates.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Interest Income (Expenses)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest income consists primarily of interest income derived from our cash. Interest expense consists primarily of interest on borrowings under outstanding loan agreements and accrued interest incurred pursuant to loans due to related parties.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other Gains and Losses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other gains and losses consists primarily of government grants, foreign exchange gains and losses, contingent losses due to litigations, and non<FONT CLASS="nobreak">-operating</FONT>&#x00a0;gains or losses.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RESULTS OF OPERATIONS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth a summary of our consolidated results of operations for the period indicated. This information should be read together with our consolidated financial statements and related notes included elsewhere in this prospectus. The operating results in any period are not necessarily indicative of the results that may be expected for any future period.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years ended December&#x00a0;31,</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Six&#x00a0;months ended June&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="15" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(amounts in US$ and in thousands)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,290</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,071</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">538</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">499</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Selling and marketing</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,492</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,679</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">549</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">431</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total operating expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,829</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,797</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,109</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">951</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss from operations</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,829</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,797</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,109</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(951</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other incomes (expenses):</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">56</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(765</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(757</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(359</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(448</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other (losses) gains, net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,041</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(902</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(276</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total other expense, net</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,801</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,603</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(633</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(375</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss before income tax</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,630</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,400</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,742</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,326</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net loss</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,630</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,400</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,742</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,326</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">93</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Comparison of the Six&#x00a0;Months Ended June&#x00a0;30, 2023 to the Six&#x00a0;Months Ended June&#x00a0;30, 2024</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">The following table sets forth a summary of our consolidated results of operations for the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Six&#x00a0;months ended June&#x00a0;30,</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(amounts&#x00a0;in&#x00a0;US$&#x00a0;and&#x00a0;in&#x00a0;thousands)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">538</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">499</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(39</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Selling and marketing</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">549</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">431</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(118</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(21</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total operating expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,109</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">951</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(158</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(14</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss from operations</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,109</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(951</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">158</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other incomes (expenses):</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">200</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(359</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(448</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(89</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(25</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other (losses) gains, net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(276</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">343</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">124</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total other expense, net</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(633</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(375</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">258</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss before income tax</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,742</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,326</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">416</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net loss</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,742</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,326</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">416</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Revenue</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">We did not generate any revenue for the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Research and Development Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">Our research and development expenses decreased by 7% from approximately US$538 thousand for the six&#x00a0;months ended June&#x00a0;30, 2023, to approximately US$499 thousand for the six&#x00a0;months ended June&#x00a0;30, 2024. The decrease was primarily attributable to a decrease in contracted research expenses and clinical trial expenses relating to our Phase&#x00a0;II clinical trials for PCP and the preparation of the initial new drug application for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;for submission to the US FDA.&#x00a0;Additionally, there was a decrease in payroll and other headcount<FONT CLASS="nobreak">-related</FONT>&#x00a0;expense due to a reduction in the research and development office staff in our Taiwan subsidiary.&#x00a0;We anticipate research and development expenses to increase in the future as we plan to initiate further clinical trials for PCP in Taiwan and apply for the necessary approvals to conduct the same clinical trials for PCP in other relevant jurisdictions. Further, given the withdrawal of our NDA from US FDA review for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;with API<FONT CLASS="nobreak">-1</FONT>, we anticipate further drug substance and drug product development and additional clinical trials for that key drug candidate with API<FONT CLASS="nobreak">-2</FONT>. We have asked that the US FDA to provide a written response to questions focused on obtaining US FDA review and comments on a new, proposed Phase&#x00a0;III clinical trial protocol for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;with API<FONT CLASS="nobreak">-2</FONT>&#x00a0;and a pharmacokinetic study. On May<FONT CLASS="nobreak"> </FONT>23, 2024, we received a denial notice from the FDA, stating that it is premature for this stage of drug development, and until the company can provide complete Chemistry, Manufacturing, and Controls (CMC) information on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, the U.S. FDA is unable to reach agreement on protocols designed to establish the safety and efficacy of MCS<FONT CLASS="nobreak">-2</FONT>. We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a&#x00a0;percentage of our total research and development expenses for the&#x00a0;six&#x00a0;months ended June&#x00a0;30, 2023 and 2024:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 60.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Six&#x00a0;months ended June&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.08%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(in US$ thousands, except percentages)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">%</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contracted research expenses and clinical trial expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">159</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">30</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">135</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payroll</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">216</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">188</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">38</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">56</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">53</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Consultancy and professional service fees</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">104</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">117</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">538</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">100</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">499</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">100</FONT></P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">94</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">General and Administrative Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our general and administrative expenses decreased by approximately US$118 thousand from the six&#x00a0;months ended June&#x00a0;30, 2023, to the six&#x00a0;months ended June&#x00a0;30, 2024, which was primarily due to an US$90 thousand decrease in professional service expenses in connection with this offering and other consulting services and a US$6 thousand decrease in payroll and other headcount<FONT CLASS="nobreak">-related</FONT>&#x00a0;expense due to a decrease in headcount of the general and administrative office in the Taiwan subsidiary. We expect these costs to increase materially in the near future as we become a public company.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Interest Expense</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our interest expense increased by approximately US$89 thousand from the six&#x00a0;months ended June&#x00a0;30, 2023 to the six&#x00a0;months ended June&#x00a0;30, 2024, which was primarily due to an increase in the interest rate of bank loan, partially offset by a decrease in the short<FONT CLASS="nobreak">-term</FONT>&#x00a0;and long<FONT CLASS="nobreak">-term</FONT> borrowing for the six&#x00a0;months ended June&#x00a0;30, 2024.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Other Gain or Losses, net</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other gains and losses are primarily foreign exchange gains or losses, government grants, contingency loss due to litigations and other non<FONT CLASS="nobreak">-operating</FONT>&#x00a0;gains or losses. Other gains increased by approximately US$343 thousand from the six&#x00a0;months ended June&#x00a0;30, 2023 to the six&#x00a0;months ended December, 2024, primarily due to US345 thousand of initial loss contingencies related to the penalty be paid to Taizhou Resource Bureau, which was recognized in the first half of 2023.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Comparison of the Fiscal Year Ended December&#x00a0;31, 2022 to the Fiscal Year Ended December&#x00a0;31, 2023</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth a summary of our consolidated results of operations for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years ended December&#x00a0;31,</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(amounts&#x00a0;in&#x00a0;US$&#x00a0;and&#x00a0;in&#x00a0;thousands)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,290</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,071</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(219</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(17</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Selling and marketing</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,492</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,679</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">187</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total operating expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,829</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,797</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(32</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss from operations</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,829</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,797</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other incomes (expenses):</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">56</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">51</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,020</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(765</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(757</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other losses, net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,041</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(902</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,139</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total other expense, net</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,801</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,603</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,198</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss before income tax</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,630</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,400</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,230</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">34</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net loss</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,630</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,400</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,230</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">34</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Revenue</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We did not generate any revenue for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Research and Development Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our research and development expenses decreased by 17% from approximately US$1,290 thousand for the year ended December&#x00a0;31, 2022, to approximately US$1,071 thousand for the year ended December&#x00a0;31, 2023. The decrease was primarily attributable to a decrease in contracted research expenses and clinical trial expenses relating to our Phase&#x00a0;II clinical trials for PCP and the preparation of the initial new drug application for MCS<FONT CLASS="nobreak">-2</FONT> for submission to the US FDA.&#x00a0;We anticipate research and development expenses to increase in the future as we plan to </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">95</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">initiate further clinical trials for PCP in Taiwan and apply for the necessary approvals to conduct the same clinical trials for PCP in other relevant jurisdictions. Further, given the withdrawal of our NDA from US FDA review for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-1</FONT>, we anticipate further drug substance and drug product development and additional clinical trials for that key drug candidate with API<FONT CLASS="nobreak">-2</FONT>. We have asked that the US FDA to provide a written response to questions focused on obtaining US FDA review and comments on a new, proposed Phase&#x00a0;III clinical trial protocol for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-2</FONT> and a pharmacokinetic study. On May<FONT CLASS="nobreak"> </FONT>23, 2024, we received a denial notice from the FDA, stating that it is premature for this stage of drug development, and until the company can provide complete Chemistry, Manufacturing, and Controls (CMC) information on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, the U.S. FDA is unable to reach agreement on protocols designed to establish the safety and efficacy of MCS<FONT CLASS="nobreak">-2</FONT>. We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a&#x00a0;percentage of our total research and development expenses for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years ended December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.42%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.70%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(in US$ thousands, except percentages)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">%</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-19" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contracted research expenses and clinical trial expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">498</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">273</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payroll</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">437</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">34</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">453</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">113</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">110</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Consultancy and professional service fees</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">238</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">229</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,290</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">100</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,071</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">100</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">General and Administrative Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our general and administrative expenses increased by approximately US$187 thousand from the year ended December&#x00a0;31, 2022, to the year ended December&#x00a0;31, 2023, which was primarily due to an US$212 thousand increase in professional service expenses in connection with this offering and other consulting services and a US$10 thousand decrease in payroll and other headcount<FONT CLASS="nobreak">-related</FONT> expense due to a decrease in headcount of the general and administrative office in the Taiwan subsidiary. We expect these costs to increase materially in the near future as we become a public company.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Interest Expense</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our interest expense decreased by approximately US$8 thousand from the year ended December&#x00a0;31, 2022 to the year ended December&#x00a0;31, 2023, which was primarily due to a decrease in the loan benchmark interest rate of People&#x2019;s Bank of China for guarantee liabilities, partially offset by an increase in the short<FONT CLASS="nobreak">-term</FONT> borrowing for the year ended December&#x00a0;31, 2023.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Other Losses, net</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other gains and losses are primarily foreign exchange gains or losses, government grants, contingency loss due to litigations and other non<FONT CLASS="nobreak">-operating</FONT> gains or losses. Other losses decreased by approximately US$2,139 thousand from the year ended December&#x00a0;31, 2022 to the year ended December, 2023, primarily due to a decrease in loss contingencies related to the penalty be paid to Taizhou Resources Bureau, partially offset by a decrease in the foreign exchange gain and an increase in the litigation expenses.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LIQUIDITY AND CAPITAL RESOURCES</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Overview</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, we have not generated any revenues. We incurred net losses of approximately US$6,630 thousand, US$4,400 thousand, and US$1,326 thousand for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, and for the six&#x00a0;months ended June&#x00a0;30, 2024, respectively. Our primary use of cash is funding our research and </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">96</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">development expenses and professional services expenses. We used approximately US$2,971 thousand, US$2,601 thousand, and US$2,773 thousand in cash for our operating activities for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, and for the six&#x00a0;months ended June&#x00a0;30, 2024, respectively. In addition, we are involved in several legal proceedings and the outcomes may be unfavorable to us. One of legal proceedings was concluded on August&#x00a0;21, 2024 and we returned RMB 10,952 thousand (US$1,507 thousand) of government subsidy to the New District Administrative Committee in 2024 and the remaining subsidy and corresponding interest expenses shall be repaid in the future. As of December&#x00a0;31, 2022 and 2023, and June&#x00a0;30, 2024, we have accrued corresponding liabilities of approximately US$22,602 thousand, US$23,818 thousand, and US$22,360 thousand, respectively, and will need additional resources to pay the settlement in the future, including a portion of the net proceeds of this offering. We have financed our operations primarily through the issuance of our ordinary shares and loan from banks, third parties, and related parties. As of December&#x00a0;31, 2022 and 2023, and June&#x00a0;30, 2024 we had cash and cash equivalents of approximately thousand, US$718&#x00a0;thousand, US$177 thousand, and US$ 96 thousand, and time deposit with original maturities more than three&#x00a0;months of approximately US$94 thousand, nil, and nil respectively. Our cash consists primarily of bank deposits which are unrestricted as to withdrawal and use. Our ability to fund the operations is highly contingent on raising additional capital until we receive a regulatory approval that provides an ability to generate sufficient revenue, if ever. As such, we concluded that there is substantial doubt about our ability to continue as a going concern within one year after the issuance date of the consolidated financial statements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We intend to pursue this initial public offering to fund our future operations. If we are unable to complete the offering for a sufficient amount in a timely manner, we may need to pursue other financing alternatives such as private financing of debt or equity or collaboration agreements. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all. If we are unable to obtain sufficient funding from this initial public offering by August&#x00a0;2025, we may have to delay our development efforts, limit activities and reduce research and development costs, which could adversely affect our business and the consolidated financial statements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although we completed Phase&#x00a0;III clinical trials for our core drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>, and filed a new drug application for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;to the US FDA, the new drug application was subsequently withdrawn. We voluntarily withdrew our NDA on November&#x00a0;30, 2022, in order to develop more information about API<FONT CLASS="nobreak">-2</FONT>&#x00a0;for the US FDA&#x2019;s review and to address ongoing questions regarding demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;and placebo for the primary efficacy endpoint in a clinical study for MCS<FONT CLASS="nobreak">-2</FONT>, and to address other questions US FDA had previously identified in our NDA.&#x00a0;Respecting our other drug candidates, PCP is under Phase&#x00a0;II clinical trials and IC is under preclinical studies. We expect our expenses to increase substantially as compared to prior periods in connection with our ongoing activities, particularly as we continue the development of PCP and perform additional clinical trials and pursue regulatory approval for MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;and PCP.&#x00a0;Furthermore, upon the completion of this initial public offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we anticipate that we will need substantial additional funding in connection with our continuing operations. These factors raise substantial doubt about our ability to continue as a going concern. Our financial statements have been prepared assuming that we will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from our possible inability to continue as a going concern.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We expect that our expenses will continue to increase substantially and that we will continue to incur significant operating losses and negative operating cash flows as we fund both ongoing research and development activities and new activities as well as working capital needs. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect or on alternative uses. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development and commercialization of our drug candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the initial public offering, we may decide to enhance our liquidity position or increase our cash reserve for future operations and investments through additional financing. Our future capital requirements will depend on many factors, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the number and development requirements of the drug candidates we pursue;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the scope, progress, timing, results and costs of discovering, researching and developing drug candidates, and conducting preclinical studies and clinical trials;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">97</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the scope, prioritization and number of our research and development programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs, timing and outcome of regulatory review of our drug candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the cost of manufacturing our drug candidates and any products we commercialize, including costs associated with expanding our supply chain;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the cost and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our drug candidates for which we receive regulatory approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the cash received, if any, from commercial sales of any drug candidates for which we receive regulatory approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such collaborations and arrangements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the extent to which we acquire or in<FONT CLASS="nobreak">-license</FONT>&#x00a0;other drug candidates and technologies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our headcount growth and associated costs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs, timing and outcome of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property<FONT CLASS="nobreak">-related</FONT>&#x00a0;claims;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>resources required to develop and implement policies and processes to promote ongoing compliance with applicable healthcare laws and regulations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the impact of COVID<FONT CLASS="nobreak">-19</FONT>&#x00a0;or any other pandemic on the initiation or completion of preclinical studies or clinical trials and the supply of our drug candidates; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs of operating as a public company in the United&#x00a0;States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our shares. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to delay our future revenue streams or the development of drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. For additional information regarding the risks related to our need to obtain additional capital, see &#x201c;Risk Factors&#x00a0;&#x2014;&#x00a0;Risks Related to Our Business and Industry&#x00a0;&#x2014;&#x00a0;We have recorded net cash outflow from operating activities since our inception and we expect to need to obtain additional financing to fund our operations. If we are unable to obtain such financing, we may be unable to complete the development and commercialization of our drug candidates.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the key components of our cash flows for the period indicated.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years ended December&#x00a0;31,</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Six&#x00a0;months ended June&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="15" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(amounts in US$ and in thousands)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,971</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,601</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1.292</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,773</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by investing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,392</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,333</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,028</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">713</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,142</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-19" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effects of exchange rate changes on cash and restricted cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(31</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(54</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(72</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(12</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-19" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increases (decrease) in cash and restricted cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,723</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(532</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(556</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,643</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">98</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Operating Activities</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Net cash used in operating activities was approximately US$1,292&#x00a0;thousand for the six&#x00a0;months ended June&#x00a0;30, 2023 and consisted primarily of a net loss of approximately US$1,742 thousand, after non<FONT CLASS="nobreak">-cash</FONT>&#x00a0;add backs, offset primarily by a decrease in accrued expenses of approximately US$145&#x00a0;thousand, a decrease in operating lease liabilities US$65 thousand and an increase in other current liabilities US$360 thousand.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Net cash used in operating activities was approximately US$2,773 thousand for the six&#x00a0;months ended June&#x00a0;30, 2024, primarily due to a net loss of approximately US$1,326 thousand, after non<FONT CLASS="nobreak">-cash</FONT> adjustments, and a decrease in other current liabilities of approximately $1,542 thousand, mainly associated with the repayment of a government subsidy to the New District Administrative Committee.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Net cash used in operating activities was approximately US$2,971 thousand for the year ended December&#x00a0;31, 2022 and consisted primarily of a net loss of approximately US$6,630 thousand, after non<FONT CLASS="nobreak">-cash</FONT>&#x00a0;add backs, offset primarily by a decrease in prepayments and other current assets of approximately US$168 thousand, a decrease in accrued expenses of approximately US$187 thousand, a decrease in operating lease liabilities US$162 thousand, and an increase in other current liabilities US$3,134 thousand.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Net cash used in operating activities was approximately US$2,601 thousand for the year ended December&#x00a0;31, 2023 and consisted primarily of a net loss of approximately US$4,400 thousand, after non<FONT CLASS="nobreak">-cash</FONT>&#x00a0;add backs, offset primarily by an increase in accrued expenses of approximately US$254 thousand, a decrease in operating lease liabilities US$128 thousand, and an increase in other current liabilities US$878 thousand.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Investing Activities</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Net cash provided by investing activities during the six&#x00a0;months ended June&#x00a0;30, 2023 was approximately US$95 thousand, which resulted primarily from the proceeds from maturity of time deposits with original maturities more than three&#x00a0;months of approximately US$95 thousand.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No cash was provided by or used in investing activities during the six&#x00a0;months ended June&#x00a0;30, 2024.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Net cash provided by investing activities during the year ended December&#x00a0;31, 2022 was approximately US$1,392 thousand, which resulted primarily from the proceeds from maturity of time deposits with original maturities more than three&#x00a0;months of approximately US$1,930 thousand, partially offset by the purchase of time deposits with original maturities more than three&#x00a0;months of approximately US$292 thousand.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Net cash provided by investing activities during the year ended December&#x00a0;31, 2023 was approximately US$95 thousand, which resulted from the proceeds from maturity of time deposits with original maturities more than three&#x00a0;months.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Financing Activities</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Net cash provided by financing activities was approximately US$713 thousand for the six&#x00a0;months ended June&#x00a0;30, 2023, which consisted primarily of proceeds from short<FONT CLASS="nobreak">-term</FONT>&#x00a0;bank loans and loan from related parties of approximately US$2,461 thousand, partially offset by repayment of short<FONT CLASS="nobreak">-term</FONT>&#x00a0;and long<FONT CLASS="nobreak">-term</FONT>&#x00a0;bank loans of approximately US$1,549 thousand.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Net cash provided by financing activities was approximately US$1,142 thousand for the six&#x00a0;months ended June&#x00a0;30, 2024, which consisted primarily of proceeds from short<FONT CLASS="nobreak">-term</FONT>&#x00a0;bank loans and loan from related parties of approximately US$2,512 thousand, partially offset by repayment of short<FONT CLASS="nobreak">-term</FONT>&#x00a0;and long<FONT CLASS="nobreak">-term</FONT>&#x00a0;bank loans of approximately US$1,260 thousand.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Net cash provided by financing activities was approximately US$3,333 thousand for the year ended December&#x00a0;31, 2022, which consisted primarily of proceeds from short<FONT CLASS="nobreak">-term</FONT>&#x00a0;bank loans and loan from related parties of approximately US$12,277 thousand, partially offset by repayment of short<FONT CLASS="nobreak">-term</FONT>&#x00a0;and long<FONT CLASS="nobreak">-term</FONT>&#x00a0;bank loans of approximately US$8,668 thousand.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Net cash provided by financing activities was approximately US$2,028 thousand for the year ended December&#x00a0;31, 2023, which consisted primarily of proceeds from short<FONT CLASS="nobreak">-term</FONT>&#x00a0;bank loans and loan from related parties of approximately US$11,829 thousand, partially offset by repayment of short<FONT CLASS="nobreak">-term</FONT>, long<FONT CLASS="nobreak">-term</FONT>&#x00a0;bank loans and loan from related parties of approximately US$9,356 thousand.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">99</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CONTINGENCIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, we may have certain contingent liabilities that arise in the ordinary course of business activities. We accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of the date of this prospectus, we are not aware of any current pending legal matters or claims except for the litigation with Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership) and Taizhou Bay New Administrative Committee. See &#x201c;Business&#x00a0;&#x2014;&#x00a0;Legal Proceeding and Compliance&#x201d; below.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CONTRACTUAL OBLIGATIONS AND COMMITMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of normal business operations, we have agreements with contract service providers to assist in the performance of clinical trial activities. Such agreements are generally cancellable upon reasonable notice and payment of costs incurred. Upon such agreements, we need to pay expenditures related to clinical trial activities, which are based on actual costs incurred.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of June&#x00a0;30, 2024, the future minimum payments under certain of our contractual obligations and commitments were as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="14" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 69.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Payments Due In</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Less than<BR>1 year</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1-2 years</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">3-5 years</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Thereafter</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Contractual obligations</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating leases</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">242</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">166</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">76</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Short-term loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,144</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,144</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-19" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long-term loans (including the current portion)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,349</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">415</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">394</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">770</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">770</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loans from related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,001</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">819</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,353</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">829</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loans from third parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,517</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,354</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,163</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,253</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,898</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,823</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,762</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">770</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From July&#x00a0;1 to August&#x00a0;31, 2024, we borrowed an aggregate amount of NTD 5,000 thousand (US$154 thousand from a bank, which with a 2.185% interest rate and a maturity date of September&#x00a0;23, 2024 and an aggregate amount of US$162 thousand from related parties, which had a two<FONT CLASS="nobreak">-year</FONT>&#x00a0;term with a 2% interest rate per annum. See Note&#x00a0;17 to our consolidated financial statements included elsewhere in this prospectus for discussion of our other commitments as of June&#x00a0;30, 2024.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LICENSING AND OTHER ARRANGEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have entered into a royalty<FONT CLASS="nobreak">-bearing</FONT>&#x00a0;license agreement. Under the terms of this agreement described below, we have the right to collect certain milestone payments upon the achievement of specified commercial milestones.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Royalty-bearing</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;license agreement with Chhak Kamponngsaon Sez Co., Ltd.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#x00a0;2016, we entered into a licensing agreement with Chhak Kamponngsaon Sez Co., Ltd to grant an exclusive right to sell and market MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;in the Kingdom of Cambodia until April&#x00a0;2036 in exchange for an upfront payment of US$100 thousand, a certain amount in development milestone payments and a certain percent on net sells in royalty payments. We have no other performance obligation in addition to the license, and Chhak Kamponngsaon Sez Co., Ltd will be responsible for obtaining initial and all subsequent regulatory approvals of MCS<FONT CLASS="nobreak">-2</FONT>&#x00a0;in the Kingdom of Cambodia. We recognized the upfront payment of US$100 thousand as revenue in 2016 since we have no other performance obligation in addition to the licenses. See &#x201c;Business&#x00a0;&#x2014;&#x00a0;License and Collaboration Agreements&#x00a0;&#x2014;&#x00a0;Chhak License Agreement&#x201d; for more details. As of the date of this prospectus, we have not achieved any milestones.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">100</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OFF-BALANCE</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;SHEET ARRANGEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There are no off<FONT CLASS="nobreak">-balance</FONT>&#x00a0;sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to shareholders. We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties except for the guarantee mentioned in Note&#x00a0;17 of our audited consolidated financial statements included elsewhere in this prospectus. In addition, we have not entered into any derivative contracts that are indexed to our shares</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">and classified as shareholder&#x2019;s equity or that are not reflected in our consolidated financial statements included elsewhere in this prospectus. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or product development services with us.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">HOLDING COMPANY STRUCTURE</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are a holding company with no business operations of our own and a substantial portion of our assets are located in Taiwan. We conduct all of our operations through our five wholly<FONT CLASS="nobreak">-owned</FONT>&#x00a0;subsidiaries, including Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT>&#x00a0;Co., Ltd. and Genvace Biotechnology Co., Ltd. in Taiwan, Jyong Biotech International Pte. Ltd. in Singapore, Top ShunXing Bio<FONT CLASS="nobreak">-Tech</FONT>&#x00a0;Co., Limited in Hong&#x00a0;Kong, and Innovative Biotech Co., Ltd. in the PRC, among which Jyong holds the equity interests in its PRC subsidiary through its subsidiary incorporated in Hong&#x00a0;Kong. As a result, our ability to pay dividends and to service any debt we may incur overseas largely depends upon dividends paid by our subsidiaries. If our subsidiaries incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Jyong is not prohibited under the laws of the Cayman Islands to provide funding to our subsidiaries through capital contributions or loans, and there are currently no restrictions on transferring funds between our Cayman Islands holding company and subsidiaries in Singapore and Hong&#x00a0;Kong. Our ability to make loans and additional capital contribution to our Taiwan and PRC subsidiaries might be restricted by Taiwan and PRC laws and regulations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the normal course of our business, Jyong would evaluate the financial condition and capital needs of our subsidiaries periodically and then provide funding for their operations via equity investments and intercompany loans. As of December&#x00a0;31, 2023 and June<FONT CLASS="nobreak"> </FONT>30, 2024, we had provided US$14.5&#x00a0;million to our Hong&#x00a0;Kong subsidiary for acquiring the patent owned by our Taiwan subsidiary via intercompany loans, and we have also provided US$5,000 to our Hong&#x00a0;Kong subsidiary via capital contribution. Our Hong&#x00a0;Kong subsidiary borrowed approximately US$2.4&#x00a0;million from third parties to invest our PRC subsidiary via capital contribution. No other transfer of cash or other types of assets has been made between our Cayman Islands holding company and subsidiaries as of the date of this prospectus.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our subsidiaries outside China and Taiwan are permitted, under the respective laws of Singapore and Hong&#x00a0;Kong, to provide funding to Jyong through dividend distribution without restrictions on the amount of the funds. Under Taiwan laws and regulations, there are no restrictions on providing funding to Jyong through dividend distribution except for the withholding tax. Pursuant to the Taiwan Income Tax Act, a withholding tax rate of up to 21% will be applicable to dividends payable by Taiwanese companies to non<FONT CLASS="nobreak">-Taiwan</FONT><FONT CLASS="nobreak">-resident</FONT>&#x00a0;enterprises. Our PRC subsidiary has no operations and generates no revenue as of the date of this prospectus, but should it generate revenue in the future, its ability to distribute dividends to us will be limited by foreign exchange restrictions. In addition, restrictions on currency exchanges in China may limit our ability to freely convert Renminbi to fund any future business activities outside China or other payments in U.S.&#x00a0;dollars, and capital control measures imposed by the Chinese government may limit our ability to use capital from our PRC subsidiary for business purposes outside of China. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service<FONT CLASS="nobreak">-related</FONT>&#x00a0;foreign exchange transactions, cannot be made in currencies other than Renminbi without complying with certain procedural requirements of the State Administration of Foreign Exchange, or SAFE.&#x00a0;Specifically, approval from or registration with appropriate government authorities is required where Renminbi is to be converted into another currency and remitted out of China to pay capital </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">101</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">expenses, such as the repayment of loans denominated in currencies other than Renminbi. As a result, we may need to obtain SAFE approval to use cash generated from the operations of our PRC subsidiary to pay off its debt in a currency other than Renminbi owed to entities outside China, or to make other capital expenditure payments outside China in a currency other than Renminbi. On the other hand, the PRC Enterprise Tax Law (&#x201c;EIT Law&#x201d;) and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by Chinese companies to non<FONT CLASS="nobreak">-PRC</FONT><FONT CLASS="nobreak">-resident</FONT>&#x00a0;enterprises unless otherwise exempted or reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the non<FONT CLASS="nobreak">-PRC</FONT><FONT CLASS="nobreak">-resident</FONT>&#x00a0;enterprises are incorporated. As of the date of this prospectus, we have not received, nor do we have any present plan to receive dividends paid by our Singapore, Taiwan, Hong&#x00a0;Kong and PRC subsidiaries.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, we did not adopt any specific cash management policies and procedures in relation to how funds are transferred within/through our group. Our management monitors the cash position of each entity within our group regularly on a monthly basis. In the event that there is a need for cash or a potential short<FONT CLASS="nobreak">-term</FONT>&#x00a0;cashflow shortage, it would be reported to our chief financial officer and, subject to the approval by our board of directors, we will enter into an intercompany loan arrangement for relevant subsidiary. Other than the above, we did not adopt or maintain any cash management policies and procedures as of the date of this prospectus.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our Board of Directors has discretion as to whether to distribute dividends, subject to certain requirements of Cayman Islands law. As of the date of this prospectus, we have not paid and do not have any present plan to declare or pay any dividends in the foreseeable future. We currently intend to retain most of our available funds and any future earnings to fund the development and growth of our business. See &#x201c;Risk Factors&#x00a0;&#x2014;&#x00a0;Risks Related to Our Ordinary Shares and This Offering&#x00a0;&#x2014;&#x00a0;Because we do not expect to pay dividends in the foreseeable future after this offering, you must rely on price appreciation of our ordinary shares for return on your investment.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INFLATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Inflation generally affects us by increasing our cost of labor and research and development contracts. We do not believe that inflation has had a significant effect on our financial results during the periods presented. However, to the extent that the inflation the United&#x00a0;States has recently been experiencing results in rising interest rates and has other adverse effects on the market, it may adversely affect our future consolidated financial condition and results of operations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TAXATION</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cayman Islands</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciations and there is no taxation in the nature of inheritance tax or estate duty or withholding tax applicable to us or to any holder of our ordinary shares. There are no other taxes likely to be material to us levied by the Government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or after execution brought within the jurisdiction of the Cayman Islands. No stamp duty is payable in the Cayman Islands on transfers of shares of Cayman Islands companies except those which hold interests in land in the Cayman Islands. Save and except that the Cayman Islands is a party to a double tax treaty entered into with the United Kingdom in 2010, the Cayman Islands are not party to any double tax treaties that are applicable to any payments made to or by the Company. There are no exchange control regulations or currency restrictions in the Cayman Islands. Payments of dividends and capital in respect of ordinary shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of ordinary shares, nor will gains derived from the disposal of ordinary shares be subject to Cayman Islands income or corporation tax.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Taiwan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Entities incorporated in Taiwan are subject to corporate income tax rate of 20% and a 5% surtax on undistributed earnings. Effective from 2020, Taiwan&#x00a0;Statute for Industrial Innovation was amended, which extends the tax incentive by 10&#x00a0;years until December&#x00a0;31, 2029 for research and development (&#x201c;R&amp;D&#x201d;) expenditure. Under the tax incentive program, a company conducting qualifying R&amp;D activities may select one of the following incentives: (i)&#x00a0;up to 15% of qualifying R&amp;D expenses may be credited against corporate income tax payable in the </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">102</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">current year; or (ii)&#x00a0;up to 10% of qualifying R&amp;D expenses may be credited against corporate income tax payable in the year expenses incurred and carried forward for the next 2&#x00a0;years. In addition, if a company uses NTD 1&#x00a0;million or more of its undistributed earnings to construct or purchase buildings, software or hardware equipment, or technology for use in production or operation within 3&#x00a0;years from the year such earnings are derived, such investment amounts may be deducted from the undistributed earnings in calculation of the current year&#x2019;s undistributed earnings for assessment of surtax imposed on undistributed earnings from the year 2018. The alternative minimum tax (&#x201c;AMT&#x201d;) imposed under the Taiwan&#x00a0;Income Basic Tax Act is a supplemental income tax which applies if the amount of regular income tax calculated pursuant to the Taiwan&#x00a0;Income Tax Act and relevant laws and regulations is below the amount of basic tax prescribed under the Taiwan&#x00a0;Income Basic Tax Act. The taxable income for calculating AMT includes most income that is exempt from income tax under various legislations, such as capital gains from qualified securities and future transactions. The prevailing AMT rate for business entities is 12%.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our subsidiaries, Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT>&#x00a0;Co., Ltd. and Genvace Biotechnology Co., Ltd. which are both incorporated in Taiwan, and are subject to corporate income tax at a rate of 20% and surtax on undistributed earnings at a rate of 5%. Both entities have no taxable income for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, and the six months ended June<FONT CLASS="nobreak"> </FONT>30, 2024; therefore, no provision for income taxes has been provided.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Singapore</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Entities incorporated in Singapore are subject to corporate income tax rate of 17%. Our subsidiary, Jyong Biotech International Pte. Ltd., which was incorporated under the law of Singapore on September&#x00a0;29, 2022, and is subject to corporate income tax rate of 17%. The Singapore entity has no taxable income for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, and the six months ended June<FONT CLASS="nobreak"> </FONT>30, 2024.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Hong&#x00a0;Kong</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Entities incorporated in Hong&#x00a0;Kong are subject to profits tax in Hong&#x00a0;Kong at the rate of 16.5%. According to Tax (Amendment) (No. 3) Ordinance 2018 published by Hong&#x00a0;Kong government, effective April&#x00a0;1, 2018, under the two<FONT CLASS="nobreak">-tiered</FONT>&#x00a0;profits tax rates regime, the profits tax rate for the first HKD2&#x00a0;million of assessable profits will be lowered to 8.25% (half of the rate specified in Schedule&#x00a0;8 to the Inland Revenue Ordinance (IRO)) for corporations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our subsidiary, Top ShunXing Bio<FONT CLASS="nobreak">-Tech</FONT>&#x00a0;Co., Limited is subject to Hong&#x00a0;Kong profits tax at a tax rate of 8.25% for assessable profits on the first HKD2&#x00a0;million and 16.5% for any assessable profits in excess. No Hong&#x00a0;Kong profit tax was provided as there was no estimated assessable profit that was subject to Hong&#x00a0;Kong profits tax for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, and the six months ended June<FONT CLASS="nobreak"> </FONT>20, 2024.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PRC</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Enterprise Income Tax Laws of the PRC, or the EIT Laws, domestic enterprises and Foreign Investment Enterprises, or the FIEs, are usually subject to a unified 25% enterprise income tax rate, while preferential tax rates, tax holidays and tax exemption may be granted on case<FONT CLASS="nobreak">-by</FONT><FONT CLASS="nobreak">-case</FONT>&#x00a0;basis.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our PRC subsidiary, Innovative Biotech Co., Ltd., is subject to the statutory rate of 25%, in accordance with the EIT Law. No provision for PRC corporate income tax has been made for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, and the six months ended June<FONT CLASS="nobreak"> </FONT>30, 2024, as Innovative Biotech Co., Ltd. had no such assessable profit.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Interest and Credit Risk</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our interest rate risk arises primarily from bank borrowing bearing interest based on floating rates. We currently do not have any interest rate hedging policy and have not historically used any derivative financial instruments to manage our interest risk exposure. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, it is estimated that a general increase of 100 basis points in interest rate, with all other variables held constant, would have increased our pre<FONT CLASS="nobreak">-tax</FONT>&#x00a0;loss for the year by US$23 thousand and increased our pre<FONT CLASS="nobreak">-tax</FONT>&#x00a0;loss for the six&#x00a0;months by US$11 thousand, respectively.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">103</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our credit risk is primarily attributable to cash. We mainly place or invest cash with reputable financial institutions in the jurisdictions where we and our subsidiaries are located. We do not believe that our cash has significant risk of default or illiquidity, and we will continually monitor the credit worthiness of these financial institutions. While we believe our cash does not contain excessive risk, future investments may be subject to adverse changes in market value.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assets that potentially subject us to significant concentration of credit risk primarily consist of cash. We expect that there is no significant credit risk associated with our cash, which were held by reputable financial institutions in the jurisdictions where we and our subsidiaries are located. We believe that it is not exposed to unusual risks as these financial institutions have high credit quality.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Liquidity Risk</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We manage liquidity risk by monitoring and maintaining a level of cash deemed adequate to finance its operations and mitigate the effects of fluctuations in cash flows. In addition, management monitors the utilization of bank borrowings and ensures compliance with loan covenants.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Foreign Currency Exchange Rate Risk</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fluctuations in exchange rates may adversely affect our financial results. Our functional currency is the U.S.&#x00a0;dollar, but the functional currency for each of our foreign subsidiaries is the local currency. As a result, certain of our assets and liabilities which were not denominated in U.S.&#x00a0;dollar are sensitive to foreign currency exchange rate fluctuations. As of June&#x00a0;30, 2024, substantially all of our total assets and liabilities were denominated in the NTD and RMB.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our consolidated financial statements are prepared in accordance with U.S.&#x00a0;GAAP.&#x00a0;The preparation of our consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates. Our most critical accounting policies are summarized below. See Note&#x00a0;3 &#x201c;Summary of Significant Accounting Policies&#x201d; to our consolidated financial statements beginning on page F<FONT CLASS="nobreak">-33</FONT> of this prospectus for a description of our other significant accounting policies.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Research and Development Expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses primarily include (1)&#x00a0;payroll and other related costs of personnel engaged in research and development activities, (2)&#x00a0;costs related to preclinical testing of our technologies and clinical trials such as payments to CROs, investigators and clinical trial sites that conduct the clinical studies; (3)&#x00a0;costs to develop our drug candidates, including raw materials and supplies, product testing, clinical trial equipment and its depreciation, and facility related expenses, (4)&#x00a0;other research and development expenses. Research and development expenses are charged to expenses as incurred when these expenditures relate to the Company&#x2019;s research and development services and have no alternative future uses.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses resulting from obligations under contracts with vendors, consultants and CROs, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which the services are provided under such contracts. We reflect research and development expenses in our consolidated financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the preclinical or clinical study as measured by the timing of various aspects of the study or related activities and determine accrual estimates through review of the underlying contracts along with discussions with research and other key personnel as to the progress of studies, or other services being conducted. During the course of a study, we adjust our rate of expense recognition if actual results differ from our estimates. Estimates for accrued research and development expenses are classified as accrued expenses on the accompanying consolidated balance sheet.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">104</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Impairment of&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Long-lived</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;Assets</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We review our long<FONT CLASS="nobreak">-lived</FONT>&#x00a0;assets, including intangible assets with finite lives, for recoverability whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value which is generally an expected present value cash flow technique. Our estimates of future cash flows attributable to our assets require significant judgment based on our historical and anticipated results and are subject to many factors. Factors we consider important which could trigger an impairment review include significant negative industry or economic trends, under<FONT CLASS="nobreak">-performance</FONT>&#x00a0;of a drug candidate in relation to expectations, and significant changes in the manner of our use</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">of the acquired assets or the strategy for our overall business. If our assumptions are not correct, there could be an impairment loss in subsequent periods. For the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, and the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, no impairment loss of long<FONT CLASS="nobreak">-lived</FONT>&#x00a0;assets was recognized.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RECENT ISSUED ACCOUNTING PRONOUNCEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A list of recently issued accounting pronouncements that are relevant to us is included in Note&#x00a0;3 &#x201c;Summary of Significant Accounting Policies&#x00a0;&#x2014;&#x00a0;Recent Accounting Pronouncements&#x201d; of our consolidated financial statements beginning on page F<FONT CLASS="nobreak">-40</FONT>&#x00a0;of this prospectus.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INTERNAL CONTROL OF FINANCIAL REPORTING</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to this offering, although we have been a private company with limited accounting and financial reporting personnel, and other resources to address the internal controls. Our independent registered public accounting firm had not conducted an audit of our internal control over financial reporting. However, in connection with the audits of our consolidated financial statements for the&#x00a0;years ended and as of December&#x00a0;31, 2022 and 2023, we and our independent registered public accounting firm identified eight &#x201c;material weaknesses&#x201d; in our internal control over financial reporting, as defined in the standards established by the PCAOB, and other control deficiencies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A &#x201c;material weakness&#x201d; is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The material weaknesses identified are related to:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">i)<FONT STYLE="width: 23px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Lack of sufficient full<FONT CLASS="nobreak">-time</FONT>&#x00a0;accounting personnel with U.S.&#x00a0;GAAP experience and knowledge to prepare and review consolidated financial statements and related disclosures under U.S.&#x00a0;GAAP and address complex U.S.&#x00a0;GAAP accounting issues;</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">ii)<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Lack of audit committee and qualified internal audit personnel to establish formal risk assessment process and internal control framework;</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">iii)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Lack of independent directors demonstrating independence from management in exercising oversight of the development and performance of internal control over financial reporting;</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">iv)<FONT STYLE="width: 17px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>No documentary evidence of proper review of related party transaction or approval for process to ensure the accuracy and completeness;</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">v)<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Research and development expense were not properly accrued based on the service stage nor billing date;</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">vi)<FONT STYLE="width: 17px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The patents with no alternative future uses were recognized as intangible asset in the bookkeeping;</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">vii)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Deferred tax asset was not recognized based on non<FONT CLASS="nobreak">-operating</FONT>&#x00a0;loss and was not offset by appropriate allowance; and</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">viii)&#x00a0;&#x00a0;Lack of sufficient IT policy and control procedures.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">105</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In response to the material weaknesses identified prior to this offering, we will implement a number of measures to address the material weaknesses identified, including but not limited to: (i)&#x00a0;working closely with external highly qualified accountants with relevant U.S.&#x00a0;GAAP and SEC reporting experience and qualifications to strengthen the financial reporting function, establish a financial and system control framework, and arrange regular training programs on U.S.&#x00a0;GAAP accounting for our accounting and financial reporting personnel; (ii)&#x00a0;strengthening and improving the overall internal control function by employing an external consulting firm to assist us in assessing the compliance requirements of the Sarbanes Oxley Act; (iii)&#x00a0;appointing independent directors to set up an Audit Committee to strengthen corporate governance; and (iv)&#x00a0;making an internal control report to the Audit Committee every quarter to report the progress and improvement in internal control, which is well monitored by the Audit Committee.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We plan to adopt additional measures to im0prove our internal control over financial reporting, including, among others, creating U.S.&#x00a0;GAAP accounting policies and procedures manual, which will be maintained, reviewed and updated, on a regular basis, to the latest US GAAP accounting standards, and establishing an audit committee and strengthening corporate governance.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, we cannot assure you that all these measures will be sufficient to address all the potential internal control issues for the financial reporting, and we cannot assure you that we have identified all, or that we will not in the future have additional, potential internal control issues for the financial reporting. See &#x201c;Risk Factors&#x00a0;&#x2014;&#x00a0;Risks Related to Our Business and Industry&#x00a0;&#x2014;&#x00a0;If we fail to implement and maintain an effective system of internal controls, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and investor confidence and the market price of our shares may be materially and adversely affected.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a company with less than US$1.235&#x00a0;billion in revenues for our last fiscal year, we qualify as an &#x201c;emerging growth company&#x201d; pursuant to the JOBS Act as further explained on page&#x00a0;11. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation requirement under Section&#x00a0;404 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT>&#x00a0;Act of&#x00a0;2002, in the assessment of the emerging growth company&#x2019;s internal control over financial reporting.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">106</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T12"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INDUSTRY OVERVIEW</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Certain information, including statistics and estimates, set forth in this section and elsewhere</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> in this prospectus has been derived from an industry report commissioned by us and independently prepared by Frost&#x00a0;&amp; Sullivan in connection</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> with this offering. All the information and data presented in this section has been derived from Frost&#x00a0;&amp; Sulliva</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">n&#x2019;s industry report unless otherwise noted. Frost&#x00a0;&amp; Sullivan has advised us that</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> the statistical and graphical information contained herein is drawn from its database and other sources.</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> However, neither we nor any other party involved in this offering has independently verified such information</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">. Therefore,</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> investors are cautioned not to place any undue reliance on the information, including statistics and estimates, set forth</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> in this section or similar information included elsewhere in this prospectus.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OVERVIEW OF GLOBAL PHARMACEUTICAL MARKET</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As the world&#x2019;s population grows and ages more rapidly, people&#x2019;s demand for healthcare resources and the expenditure on healthcare increase. According to the World Bank, there were nearly 7,836.6&#x00a0;million people in 2021, representing a CAGR of 1.0% compared to that of 2017. The global aging population reached 747.5&#x00a0;million in 2021, representing an increase of nearly 15.0% compared to 650.3&#x00a0;million in 2017. The population of people over 55&#x00a0;years old, or pan<FONT CLASS="nobreak">-aging</FONT> people, reached 14374.6&#x00a0;million in 2020, representing a CAGR of 2.3% compared to 1,242.5&#x00a0;million in 2015. Consequently, the total global healthcare expenditure increased from US$7,180.5&#x00a0;billion in 2017 to US$7,872.1&#x00a0;billion in 2021, representing a CAGR of 2.3%. It is estimated that the global healthcare expenditure will be approximately US$8,877.1&#x00a0;billion in 2026.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As shown in the following diagram, under the combined influence of global growth of aging population, social healthcare expenditure, and R&amp;D investment in the pharmaceutical industry, the global pharmaceutical market has maintained stable growth. The global pharmaceuticals market reached a total of US$1,401.2&#x00a0;billion in 2021 and is expected to increase to US$1,791.1&#x00a0;billion by 2026, representing a CAGR of 5.1%.</P>
		<P CLASS="Text_ind_center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><IMG ALT="" SRC="tbar_001.jpg" STYLE="width:291.84000000000003px;max-width:100%;"></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:4pt;text-align:center;margin-top:4pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Source: Frost&#x00a0;&amp; Sullivan</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OVERVIEW OF GLOBAL BENIGN PROSTATIC HYPERPLASIA DRUGS INDUSTRY</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The prostate gland, or the prostate, is a male reproductive organ. The prostate is in front of the rectum. The urethra runs through the center of the prostate, from the bladder to the penis. As a man ages, the prostate tends to become larger. If the prostate gets too large, it can lead to health problems, such as BPH and LUTS.&#x00a0;When the prostate enlarges, it puts pressure on the bladder and urethra, the tube through which urine passes. This affects how </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">107</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">man urinates and may cause: (1)&#x00a0;dysuria; (2)&#x00a0;frequent urination; and (3)&#x00a0;urinary retention. The three most common forms of prostate disease are inflammation (prostatitis), non<FONT CLASS="nobreak">-cancerous</FONT> enlargement (BPH), and prostate cancer. As the prostate enlarges, the gland presses against and pinches the urethra. The bladder wall becomes thicker. Eventually, the bladder may weaken and lose the ability to empty, leaving some urine in the bladder. The narrowing of the urethra and urinary retention&#x00a0;&#x2014;&#x00a0;the inability to empty the bladder&#x00a0;&#x2014;&#x00a0;cause many of the problems associated with BPH.&#x00a0;Prostatitis is inflammation of the prostate gland. Prostate cancer is cancer that occurs in the prostate, which is one of the most common types of cancer.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Benign Prostatic Hyperplasia</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Treatment of BPH</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The prevailing treatments for BPH include lifestyle changes, medications, minimally invasive procedures and surgery. Data indicate that patients in the U.S.&#x00a0;choose medication as the primary method for BPH treatment and observation ranks as the second prevailing way. Common chemical drugs used to treat BPH include <FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT>1<FONT CLASS="nobreak">-blockers</FONT> or 5<FONT CLASS="nobreak">-alpha</FONT> reductase inhibitors.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Symbol-BoldItalic" STYLE="font-family:Times New Roman, serif;font-style:italic;font-weight:bold;">&#x03b1;</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">1</FONT><FONT CLASS="nobreak"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">-blockers</FONT></FONT> are highly expressed in the smooth muscle cells of the prostate gland, bladder neck, and urethra. When stimulated by <FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT><FONT CLASS="nobreak">-adrenergic</FONT> nerve fibers, these cells cause strong contractions, resulting in increased levels of urethral. Based on this physiological mechanism, <FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT>1<FONT CLASS="nobreak">-adrenergic</FONT> antagonists bind to <FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT>1<FONT CLASS="nobreak">-adrenoceptors</FONT> on the smooth muscle cells of the urethra and cause relaxation in smooth muscle tone, thereby reducing urethral resistance and relieving LUTS.&#x00a0;However, <FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT>1<FONT CLASS="nobreak">-blockers</FONT> are associated with four major side effects: cardiovascular events, ejaculatory dysfunction, intraoperative floppy iris syndrome and an increase in the risk of cardiac failure.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">5</FONT><FONT CLASS="nobreak"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">-alpha</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> reductase inhibitors</FONT> can inhibit the conversion of testosterone and reduce the levels of dihydrotestosterone, thereby shrinking an enlarged prostate and preventing the progression of disease into BPH. 5<FONT CLASS="nobreak">-alpha</FONT> reductase inhibitors nevertheless are also associated with a range of side effects, such as decreased libido, gynecomastia, and erectile dysfunction. The U.S. FDA had ever informed healthcare professionals that 5<FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT><FONT CLASS="nobreak">-reductase</FONT> Inhibitors might increase the risk of a more serious form of prostate cancer. Moreover, studies show that men with a benign prostatic hyperplasia diagnosis and exposed to both 5<FONT CLASS="nobreak">-alpha</FONT> reductase inhibitor and a<FONT CLASS="nobreak">-blocker</FONT> therapy had an increased association with cardiac failure.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">-2</FONT></FONT> is a new drug being developed for BPH/LUTS treatment. The table below shows a comparison of commonly used BPH drugs and MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-1</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-2</FONT> has not yet undergone clinical trials, and the Company plans to conduct additional Phase III trials and a Phase I PK study using API<FONT CLASS="nobreak">-2</FONT> in 2024. The API<FONT CLASS="nobreak">-1</FONT> supplier withdrew their consent to reference their DMF on file with the U.S. FDA due to the relocation and restructuring of the manufacturing facility. As API<FONT CLASS="nobreak">-1</FONT> is currently unavailable, we have no future plans for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-1</FONT> unless and until it again becomes available. We are continuing the development of MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-2</FONT> in consultation with the U.S. FDA. The U.S. FDA provided comments on our proposed Phase III study, and we are finalizing the protocol for resubmission to the U.S. FDA. In addition, we are in the process of finalizing the PK study protocol per the U.S. FDA&#x2019;s requirements and hope to satisfy the U.S. FDA of the comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. If the CMC comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> is approved, we will request a Type B meeting (WRO) with the U.S. FDA to discuss our revised Phase III protocol, Statistical Analysis Plan, and PK study protocol.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, once the API<FONT CLASS="nobreak">-1</FONT> supplier is able to provide the raw materials for API<FONT CLASS="nobreak">-1</FONT> after completing the relocation and restructuring of the new manufacturing facility, we will further discuss business cooperation with them within the next 5 years.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">108</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Global BPH Drugs Market</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The global prevalence of BPH increased from 88.4&#x00a0;million in 2017 to 94.2&#x00a0;million in 2020, representing an increase of 6.5%. The global BPH drugs market size increased from US$3.7&#x00a0;billion in 2017 to US$4.1&#x00a0;billion in 2020, which is expected to reach US$9.8&#x00a0;billion in 2026. The rapid increase in BPH drugs market is mainly attributable to: (1)&#x00a0;an increase in the number of older males due to global population aging; (2)&#x00a0;an increase of the rate of obesity worldwide; and (3)&#x00a0;an increase in patients&#x2019; awareness of medical care.</P>
		<P CLASS="Text_ind_center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><IMG ALT="" SRC="tbar_002.jpg" STYLE="width:518.4px;max-width:100%;"></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Source: Frost&#x00a0;&amp; Sullivan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The prevalence of BPH in the U.S.&#x00a0;reaches 4.7&#x00a0;million in 2020, representing an increase of nearly 6.8% compared to 4.4&#x00a0;million in 2017. The BPH drugs market size in the U.S.&#x00a0;increased from US$2.0&#x00a0;billion in 2017 to US$2.2&#x00a0;billion in 2020 and is expected to reach US$5.5&#x00a0;billion in 2026. The prevalence of BPH in China increased from 18.8&#x00a0;million in 2017 to 21.1&#x00a0;million in 2020. The BPH drugs market size in China indicated stable growth from 2017 and reached 0.5&#x00a0;billion in 2021, which is expected to reach US$1.2&#x00a0;billion in 2026.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Prostate Cancer Prevention</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Introduction to the Prevention of Prostate Cancer</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As men age, their risk for prostate cancer increases considerably. Approximately 60% of prostate cancer is diagnosed in men over the age of 65. Prostate cancer is one of the most heritable cancers. Approximately 58% of prostate cancer is driven by genetic factors. Early prevention of prostate cancer is very important. The prevailing methods to prevent prostate cancer include proper diet, regular medical check<FONT CLASS="nobreak">-ups</FONT>, maintenance of personal hygiene, herbal treatment, anti<FONT CLASS="nobreak">-androgen</FONT> therapy, and immunotherapy.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Proper diet.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The occurrence of prostate cancer is closely related to dietary structure. Medical studies have shown that a high<FONT CLASS="nobreak">-fat</FONT> diet is a recognized risk factor. Also, the incidence of prostate cancer is higher in areas with high calcium content in drinking water. Therefore, it is important to eat more vegetables and fruits in daily diet to reduce the occurrence of constipation and reduce the risk of congestion in the prostate. It is also important to note that men should not drink too much water.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Regular medical </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">check</FONT><FONT CLASS="nobreak"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">-ups</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">.&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Men over the age of 40 should have regular blood tests for prostate<FONT CLASS="nobreak">-specific</FONT> antibodies (PSA) for early detection of prostate cancer. Prostate cancer is characterized by a long latency period, and insidiousness, and is not easily distinguished from other diseases such as prostate enlargement so that most clinically diagnosed cases have metastatic disease.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Maintenance of personal hygiene.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The scrotum is stretchy and sweaty, and with poor ventilation and long foreskin, it is easy to hide dirt and bacteria often take advantage of it. Therefore, regular daily cleaning is necessary to prevent PC.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Anti</FONT><FONT CLASS="nobreak"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">-androgen</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> therapy.&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The main effect of anti<FONT CLASS="nobreak">-androgen</FONT> drugs is the blocking of androgenic cellular receivers in the prostate so that cancer cells cannot receive androgenic messages and do not continue to grow.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">109</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Immunotherapy.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Immune drugs are used to inhibit the growth of tumor cells by improving the body&#x2019;s immunity and resistance to disease, and it also protects cellular functions and reduces the damage caused by endocrine drugs and anti<FONT CLASS="nobreak">-cancer</FONT> drugs to the body.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Global PCP Drugs Market</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The global prevalence of prostate cancer increased from 10.0&#x00a0;million in 2017 to 11.2&#x00a0;million in 2020, representing a CAGR of 3.9%. The global prostate cancer market increased from US$9.7&#x00a0;billion in 2017 to US$12.6&#x00a0;billion in 2019, representing a CAGR of 9.1%, and is expected to reach US$23.1&#x00a0;billion in 2026. The rapid growth is primarily due to population aging and men&#x2019;s frequent intake of high<FONT CLASS="nobreak">-fat</FONT> foods. The prevalence of prostate cancer in the U.S.&#x00a0;increased from 3.4&#x00a0;million in 2017 to 3.7&#x00a0;million in 2019, representing a CAGR of 4.0%. The prostate cancer market in the U.S.&#x00a0;increased from US$4.9&#x00a0;billion in 2017 to US$5.9&#x00a0;billion in 2018, and is expected to reach US$11.0&#x00a0;billion in 2026. The prevalence of prostate cancer in China increased from 0.2&#x00a0;million in 2017 to 0.3&#x00a0;million in 2018, at a CAGR of 26.4%. The prostate cancer market in China increased from US$0.4&#x00a0;billion in 2017 to US$0.8&#x00a0;billion in 2019, at a CAGR of 20.9%, and is expected to reach US$3.8&#x00a0;billion in 2026.</P>
		<P CLASS="Text_ind_center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><IMG ALT="" SRC="tbar_003.jpg" STYLE="width:518.4px;max-width:100%;"></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Source: Frost&#x00a0;&amp; Sullivan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the prostate<FONT CLASS="nobreak">-specific</FONT> antigen abnormal population, or PSA abnormal population, representing men over 40&#x00a0;years old with a prostate<FONT CLASS="nobreak">-specific</FONT> antigen test value of 4.0 ng/ml or higher, is exposed to a high risk of prostate cancer. From 2015 to 2020, the total number of PSA abnormal populations in the U.S., Taiwan and China increased from 5.0&#x00a0;million to 5.3&#x00a0;million.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MARKET DRIVERS AND ENTRY BARRIERS OF BPH DRUGS INDUSTRY</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Market Drivers</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Innovation of BPH drugs.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Benefiting from the development of modern molecular biology and bioengineering technology, the innovation of BPH drugs has evolved dramatically. Research and activities conducted by various researchers, companies, and governments for the treatment of BPH, including clinical trials for efficacy and safety, are driving the BPH drugs market.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Increase in elderly male population.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The increment of incidence of BPH has a positive relationship with age and data shows that the prevalence rate of BPH is increasing dramatically for men over 50&#x00a0;years old. The hormones from the testis may be the main factor. BPH may occur when these hormone changes trigger prostate cell growth. In parallel with the increasing aging trend, the potential growing number of BPH patients is going to increase as well and drive the total market.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Increase in obese population.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The increment of incidence of BPH also has a positive relationship with body mass index, or BMI.&#x00a0;The number of obese people worldwide is increasing every year. Obesity increases intra<FONT CLASS="nobreak">-abdominal</FONT> pressure, which raises intravesical pressure, in turn worsening or causing BPH symptoms such as hesitancy, poor urine stream, and nocturia.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">110</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Entry Barriers</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Sales Network Barrier.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>There are high sales network barriers for new entrants to the pharmaceutical manufacturing industry. The breadth of the sales network determines whether the drug can cover all hospitals, and new entrants need to spend a lot of time and economic costs to build their own sales network. The coverage of the sales network determines whether it can effectively change doctors&#x2019; medication habits.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Brand Barrier.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Pharmaceuticals are directly related to public health, so people tend to be cautious when choosing drugs. The differences between the products of different pharmaceutical companies are mainly manifested in drug indications, drug delivery methods, drug efficacy, drug quality, drug packaging, drug prices, and after<FONT CLASS="nobreak">-sales</FONT> services. These differences enhance the uniqueness of each company&#x2019;s drugs and reduce the substitutability between products, thus making patients loyal to the drugs of specific companies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Capital Barrier.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The pharmaceutical industry is a knowledge<FONT CLASS="nobreak">-intensive</FONT>, high<FONT CLASS="nobreak">-technology</FONT> industry. Pharmacological research, clinical trials, review, and approval of drugs require a significant investment of capital, talent, equipment, and other resources.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">FUTURE TREND ANALYSIS</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Marketing-oriented</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> to </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">value-oriented</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Many pharmaceutical enterprises attach importance to the establishment of hospital sales channels and the maintenance of relationship with the doctors, and the marketing expense far exceeds the expenses in R&amp;D, innovation and technology promotion. This phenomenon has hindered the innovative development of the pharmaceutical industry. With the strengthening of national supervision over pharmaceutical enterprises and the guidance of innovation investment, pharmaceutical enterprises will return to their main business and focus on R&amp;D and production of drug products. BPH drugs enterprise with self<FONT CLASS="nobreak">-investigate</FONT> ability should gain an advantageous position in the competition.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Botanicals may be favored</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">With the increased marketing trend of natural products generally, we believe demand for new plant<FONT CLASS="nobreak">-derived</FONT> drugs (botanicals)) will increase as well. As of the date of this prospectus, only two botanical drug products have received the U.S. FDA&#x2019;s approval for marketing as prescription drugs: (i) Veregen which contains the drug substance sinecatechins, which is a partially purified fraction of the water extract of green tea leaves from <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Camellia sinensis (L.) O Kuntze </FONT>and is indicated for the treatment of genital and perianal warts, and (ii) Mytesi which is a proanthocyanidin oligomer indicated to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy and is derived from the red latex of <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Croton lechleri M&#x00fc;ll. Arg.</FONT> The U.S. FDA has not approved any botanical drug products since 2012. US.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"> The quality control of botanical drug products is very complex due to the variability of botanical raw material and the need to ensure that the therapeutic effect for botanical drug product batches is consistent. It is challenging to ensure batch<FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak">to-</FONT><FONT CLASS="nobreak">batch</FONT> consistency, which must be demonstrated to obtain U.S. FDA approval. Minor changes in API source or the manufacturing process can result in a meaningful difference in clinical effects and may mean that earlier developed pharmacological, nonclinical and clinical data no longer apply to the changed product.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Growing aging people as the market driver</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We believe that there will be more research, development, and investment in diseases that are highly prevalent in the elderly, such as benign prostatic hyperplasia. We also believe pharmaceutical and medical device companies will be attracted to the treatment of BPH and will increase their product development and further expand and capture the market.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">111</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T11"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">BUSINESS</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OUR MISSION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We endeavor to develop and supply first<FONT CLASS="nobreak">-class</FONT> innovative drugs to meet our customers&#x2019; health needs. We seek to be a valuable business organization that is held in high esteem by the public.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OVERVIEW</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are a science<FONT CLASS="nobreak">-driven</FONT> biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant<FONT CLASS="nobreak">-derived</FONT>) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since our inception in 2002, we have built integrated capabilities that encompass all key functionalities of drug development, including early<FONT CLASS="nobreak">-stage</FONT> drug discovery and development, clinical trials, regulatory affairs, manufacturing and commercialization. Leveraging our strong research and development capabilities and proprietary platform, we have been developing a series of botanical drug candidates, our primary botanical drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>, another clinical<FONT CLASS="nobreak">-stage</FONT> botanical drug candidate, and other preclinical<FONT CLASS="nobreak">-stage</FONT> botanical drug candidates. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We resubmitted a new drug application, or NDA, for MCS<FONT CLASS="nobreak">-2</FONT> with the U.S. FDA on December<FONT CLASS="nobreak"> </FONT>17, 2021, using Active Pharmaceutical Ingredient (API)<FONT CLASS="nobreak">-1</FONT>. We voluntarily withdrew our NDA on November<FONT CLASS="nobreak"> </FONT>30, 2022, in order to develop more information about API<FONT CLASS="nobreak">-2</FONT> for the U.S. FDA&#x2019;s review and to address ongoing questions regarding demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT> and placebo for the primary efficacy endpoint in a clinical study for MCS<FONT CLASS="nobreak">-2</FONT>, and to address other questions U.S. FDA had previously identified in our NDA regarding U.S.&#x00a0;FDA&#x2019;s questions related to the drug substance and product, validation of methods used for measuring the effect of MCS<FONT CLASS="nobreak">-2</FONT>, manufacturing, clinical and nonclinical testing, data, and statistical analyses, among others. In a June<FONT CLASS="nobreak"> </FONT>26, 2023 response to our meeting request regarding refiling the NDA for MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-2</FONT>, the U.S.&#x00a0;FDA informed us that the information we provided on API<FONT CLASS="nobreak">-2</FONT> was not yet sufficient to demonstrate comparability with API<FONT CLASS="nobreak">-1</FONT> since we only provided the preliminary comparative drug substance and drug product specifications between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, and also mentioned the statistically significant difference between MCS<FONT CLASS="nobreak">-2</FONT> and placebo in the primary efficacy endpoint in in Study MCS<FONT CLASS="nobreak">-2-US-a</FONT>, one of our Phase III pivotal studies. The U.S.FDA&#x2019;s conclusions at that time were that without new clinical information, any NDA resubmission for MCS<FONT CLASS="nobreak">-2</FONT> would be at risk of the U.S.&#x00a0;FDA refusing to accept the application, referred to as &#x201c;Refusal To File&#x201d; (RTF).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We submitted a Type D WRO meeting request to the U.S.&#x00a0;FDA on December<FONT CLASS="nobreak"> </FONT>12, 2023. We asked that the U.S. FDA provide a written response to questions focused on obtaining U.S.&#x00a0;FDA review and comments on a new, proposed Phase III clinical trial protocol for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-2</FONT> and a PK study. We proposed to address CMC data for our proposed drug product in a separate, future meeting. U.S.&#x00a0;FDA granted our WRO meeting request but clarified that they viewed the meeting as a Type C meeting because it encompasses an entirely new drug development program, including Phase I PK study and Phase III clinical trial for a new product with a new active pharmaceutical ingredient.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If our new Phase I PK and Phase III studies are successful and after addressing other U.S.FDA<FONT CLASS="nobreak">-identified</FONT> deficiencies summarized above, we plan to resubmit our NDA for MCS<FONT CLASS="nobreak">-2</FONT> under the same NDA number to the U.S.&#x00a0;FDA. The resubmission timeline is unclear at this point, depending on the comments from the U.S.&#x00a0;FDA. Another of our clinical<FONT CLASS="nobreak">-stage</FONT> key botanical drug candidates, PCP, is under phase II trials stage in Taiwan. Another drug candidate, IC, is under preclinical studies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event that we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, or we are unable to identify an active pharmaceutical ingredient that the FDA agrees is comparable to API<FONT CLASS="nobreak">-1</FONT>, we will be required to repeat the MCS<FONT CLASS="nobreak">-2</FONT> and PCP clinical trials using API<FONT CLASS="nobreak">-2</FONT>, or to conduct other additional clinical trials as may be required by the U.S. FDA. For further details, see the risk factor titled &#x201c;<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs</FONT>&#x201d; on page 31.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">112</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have not yet proven comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and the following chart illustrates and summarizes our API<FONT CLASS="nobreak">-2</FONT> current drug candidates&#x2019; status:</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"><IMG ALT="" SRC="ttimeline_002.jpg" STYLE="width:599.04px;max-width:100%;"></FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">Our pipeline features three innovative and differentiated new drug candidates, and we are developing them for (i) the treatment of benign prostate hyperplasia/lower urinary tract symptoms, or BPH/LUTS, (ii) prostate cancer prevention, and (iii) the treatment of interstitial cystitis, respectively.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>MCS<FONT CLASS="nobreak">-2</FONT> is our new botanical drug candidate developed for treatment of BPH/LUTS. MCS<FONT CLASS="nobreak">-2</FONT> is expected to be our core product in the future. MCS<FONT CLASS="nobreak">-2</FONT> is a softgel capsule containing patented active pharmaceutical ingredients derived from botanical raw materials, specifically, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Lycopersicon Esculentum</FONT>. MCS<FONT CLASS="nobreak">-2</FONT> contains, in the largest concentrations, five carotenoids including lycopene, phytoene, phytofluene, tocopherol and beta<FONT CLASS="nobreak">-carotene</FONT>. We developed MCS<FONT CLASS="nobreak">-2</FONT> using chylomicron technology to improve its bioavailability. Chylomicron is a type of lipoprotein particles consisting of triglycerides and phospholipids in human body. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:5pt;margin-top:5pt;">We&#x00a0;have conducted four Phase&#x00a0;III clinical trials for MCS<FONT CLASS="nobreak">-2</FONT> in the U.S. and Taiwan, including two pivotal trials (one in the US and one in Taiwan) and two open<FONT CLASS="nobreak">-label</FONT> extension studies, using API<FONT CLASS="nobreak">-1</FONT>. Our pivotal Phase III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> in the U.S. failed to show a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to-treat</FONT> population. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:5pt;margin-top:5pt;">We resubmitted an NDA for MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-1</FONT> to the U.S.&#x00a0;FDA on December<FONT CLASS="nobreak"> </FONT>17, 2021. On February<FONT CLASS="nobreak"> </FONT>22, 2022, the U.S.&#x00a0;FDA accepted our NDA for review &#x201c;with issues identified.&#x201d; In the February<FONT CLASS="nobreak"> </FONT>22, 2022 Filing Issues Identified letter, the U.S.&#x00a0;FDA identified, among other things, the lack of demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT> and placebo for the primary efficacy endpoint in the MCS<FONT CLASS="nobreak">-2-US-a</FONT> study. U.S.&#x00a0;FDA identified additional issues, including issues regarding pharmacology, toxicology, and our pharmacokinetic submission, statistical analyses, and the content and format of our proposed Prescribing Information. We used one supplier for API<FONT CLASS="nobreak">-1</FONT>, which was the basis for the NDA that has since been withdrawn by the Company. The supplier of API<FONT CLASS="nobreak">-1</FONT> sold a parcel of its land and is in the process of relocating and reconstructing its manufacturing facility, and as a result, API<FONT CLASS="nobreak">-1</FONT> is currently unavailable to us, and the supplier of API<FONT CLASS="nobreak">-1</FONT> withdrew its consent for us to reference their DMF on file with the U.S. FDA. This does not mean we would not be able to use API<FONT CLASS="nobreak">-1</FONT> in later studies or as a basis for additional filings with the U.S. FDA. The supplier&#x2019;s withdrawal of its consent to reference should not be interpreted as anything other than the supplier removing API<FONT CLASS="nobreak">-1</FONT> from availability for reference by us (or anyone else) in any submission to U.S. FDA. In a Mid<FONT CLASS="nobreak">-Cycle</FONT> meeting and communication with the U.S.&#x00a0;FDA on May<FONT CLASS="nobreak"> </FONT>24, 2022, the U.S.&#x00a0;FDA also identified the fact that API<FONT CLASS="nobreak">-1</FONT>, the botanical drug substance used in our clinical trials and that was the basis for our NDA, was currently not available. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:5pt;margin-top:5pt;">Based upon these observations, we voluntarily withdrew our NDA on November<FONT CLASS="nobreak"> </FONT>30, 2022, to develop more information about API<FONT CLASS="nobreak">-2</FONT> for the U.S.&#x00a0;FDA&#x2019;s review, to address the U.S.&#x00a0;FDA&#x2019;s concerns of a lack of demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT> and placebo for the primary efficacy endpoint, and to resolve other issues the U.S.&#x00a0;FDA had previously identified (and discussed above). </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:5pt;margin-top:5pt;">If we are able to satisfy U.S. FDA that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, that is if the U.S. FDA agrees with our data about the comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, then we may not need to conduct redundant studies using API<FONT CLASS="nobreak">-2</FONT>. If we are unable to demonstrate comparability, we would have to perform more clinical trials. We will work with API vendors to follow FDA guidance to demonstrate comparability. In the event that </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">113</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:5pt;margin-top:5pt;">we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be required to repeat the MCS<FONT CLASS="nobreak">-2</FONT> clinical trials using API<FONT CLASS="nobreak">-2</FONT>. For further details, see the risk factor titled &#x201c;If we are unable to identify a supplier capable of producing API<FONT CLASS="nobreak">-2</FONT> that is sufficiently comparable to API<FONT CLASS="nobreak">-1</FONT>, we may be required to repeat our clinical trials for MCS<FONT CLASS="nobreak">-2</FONT>, which could significantly delay our product development efforts and result in increased costs&#x201d; on page 31. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:5pt;margin-top:5pt;">Moreover, we are planning the CMC meeting with U.S. FDA, one purpose of which is to seek the U.S FDA&#x2019;s concurrence that API<FONT CLASS="nobreak">-2</FONT> is comparable to API<FONT CLASS="nobreak">-1</FONT>. Those plans are no more speculative than the fact that we are engaged in an ongoing drug approval process with the U.S. FDA. It is not uncommon to maintain redundant API sources for the same finished drug to minimize the risk of shortages.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:5pt;margin-top:5pt;">In the December<FONT CLASS="nobreak"> </FONT>12, 2022 Acknowledge Withdrawal from the U.S. FDA, the U.S. FDA stated that &#x201c;this withdrawal will not prejudice any future decisions on filing&#x201d; if we decide to resubmit our NDA, and we can retain the application number (NDA 212872). The retention of the NDA number signifies the U.S. FDA&#x2019;s acknowledgment that they have not declined to approve NDA 212872. Instead, we voluntarily withdrew it. Retaining the application number allows U.S. FDA to review prior submissions and data when the Company resubmits in the future.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:5pt;margin-top:5pt;">We have been conducting further research and development on MCS<FONT CLASS="nobreak">-2</FONT> and identified an additional source for the botanical drug substance API<FONT CLASS="nobreak">-2</FONT>. API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are similar drug substances covered by the same patent owned by us; however, because they are sourced from raw materials manufactured in different locations, the U.S. FDA considers them to be different botanical drug substances. Therefore, we will conduct a comparability study for API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:5pt;margin-top:5pt;">We submitted a meeting request to the U.S. FDA on April<FONT CLASS="nobreak"> </FONT>14, 2023 with our very preliminary comparative specifications of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, and request that the U.S. FDA provide a WRO to questions about our refiling of the NDA for MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-2</FONT>. The U.S. FDA agreed to our request and responded in writing on June<FONT CLASS="nobreak"> </FONT>26, 2023. The U.S. FDA informed us that the information we provided on API<FONT CLASS="nobreak">-2</FONT> was not sufficient to demonstrate comparability with API<FONT CLASS="nobreak">-1</FONT>. In addition to a lack of API source, U.S. FDA explained that we had not demonstrated a statistically significant difference between MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-1</FONT> and placebo in the primary efficacy endpoint in the MCS<FONT CLASS="nobreak">-2-US-a</FONT> study. The U.S.&#x00a0;FDA stated that without new clinical information, any resubmission of the NDA for MCS<FONT CLASS="nobreak">-2</FONT> would be at risk of the U.S. FDA refusing to accept the application, a RTF action. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:5pt;margin-top:5pt;">We submitted a Type D WRO meeting request to the U.S. FDA on December<FONT CLASS="nobreak"> </FONT>12, 2023. We asked that the U.S. FDA provide a written response to questions focused on obtaining U.S. FDA review and comments on a new, proposed Phase III clinical trial protocol for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-2</FONT> and a Phase I PK study. We proposed to address chemistry and manufacturing controls for MCS<FONT CLASS="nobreak">-2</FONT> in a separate, future meeting. U.S.&#x00a0;FDA granted our WRO meeting request but clarified that they viewed the meeting as a Type C meeting because it encompasses an entirely new drug development program, including Phase I PK study and Phase III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> made from API<FONT CLASS="nobreak">-2</FONT>, which the U.S. FDA characterizes as a new product with a new active pharmaceutical ingredient.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:7pt;margin-top:7pt;">We provided its proposed additional Phase III study protocol and Phase I PK study synopsis using API<FONT CLASS="nobreak">-2</FONT> on December<FONT CLASS="nobreak"> </FONT>12, 2023, for U.S. FDA to review and approve acceptability of the study design. The U.S. FDA sent us written responses on February<FONT CLASS="nobreak"> </FONT>23, 2024, which included comments on the revisions in the Phase III protocol and asked for the SAP (statistical analysis plan) for the Phase III protocol. U.S. FDA also asked the Company to develop the protocol for the PK study from the submitted synopsis. We are following the U.S. FDA&#x2019;s requirements in each respect. In addition, we will need to perform studies demonstrating that the source of API<FONT CLASS="nobreak">-2</FONT> is sufficiently similar botanical drug substance. We plan to request a meeting with U.S. FDA to discuss the U.S. FDA&#x2019;s concerns regarding the CMC data separately and by providing to U.S. FDA more analytical testing for the API<FONT CLASS="nobreak">-2</FONT> for the U.S. FDA to assess whether API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:8pt;">If our new Phase I PK and Phase III studies are successful and we address the other deficiencies the U.S. FDA has previously identified (including clinical, pharmacological, statistical, pharmaceutical manufacturing, validation, and other issues), we plan to resubmit our NDA for MCS<FONT CLASS="nobreak">-2</FONT> under the same NDA number to the U.S. FDA. The resubmission timeline is unclear at this point, depending on the comments from the U.S. FDA.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">114</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:8pt;">BPH/LUTS is the most common urinary tract disease in the middle<FONT CLASS="nobreak">-aged</FONT> male population. According to Frost&#x00a0;&amp; Sullivan, the global prevalence of BPH increased from 88.4&#x00a0;million in 2017 to 94.2&#x00a0;million in 2020, representing an increase of 6.5%. The global BPH drugs market increased from US$3.7&#x00a0;billion in 2017 to US$4.1&#x00a0;billion in 2020, representing a CAGR of 4.6%. We will set up internal sales and marketing departments, and plan to work with both domestic and international business partners to seize the great market opportunities and to help more patients reduce their distress caused by BPH/LUTS and drug side effects caused by chemical drugs.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PCP:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>PCP is our new botanical drug candidate developed for the prevention of prostate cancer. PCP, like MCS<FONT CLASS="nobreak">-2</FONT>, contains patented active pharmaceutical ingredients derived from botanical raw materials, specifically, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Lycopersecum Esculentum</FONT>. PCP contains, in the largest concentrations, five carotenoids including lycopene, phytoene, phytofluene, tocopherol and beta<FONT CLASS="nobreak">-carotene</FONT>. PCP and MCS<FONT CLASS="nobreak">-2</FONT> are essentially the same in terms of active ingredients, dosage form, strength and route of administration; however, they are different drug candidates targeting different indications. Our PCP Phase II study enrollment and treatment phase using API<FONT CLASS="nobreak">-1</FONT> is now in the source data verification (SDV) stage before drafting the clinical study report (CSR), which may take an additional year or more to complete. After completion of the SDV stage, we will conduct the necessary statistical analysis. While PCP is still in the SDV stage, we are working with the U.S. FDA to establish the comparability of the API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. To date, we have not had any discussions with the TFDA regarding the unavailability of API<FONT CLASS="nobreak">-1</FONT>. We will discuss the statistical results of the PCP using API<FONT CLASS="nobreak">-2</FONT> with Taiwan regulator and proceed with the Phase III PCP study if the U.S. FDA accepts such results and determines that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable. The PCP shall not proceed to Phase III until the U.S. FDA accepts the results and determines that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable. Based on our prior communications with the TFDA, the Chemistry, Manufacturing, and Controls (&#x201c;CMC&#x201d;) and study design for the product are consistent between the U.S. and Taiwan, encompassing two pivotal studies and two open<FONT CLASS="nobreak">-label</FONT> extension studies. The protocol for the Phase III clinical trials was approved by the U.S. FDA in December 2009 and subsequently approved by the TFDA in February 2010. Therefore, we believe the TFDA will give due consideration to the comments provided by the U.S. FDA.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:8pt;">We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA. As of this date, the Company is still in the process of providing the information required by the U.S. FDA and has not yet successfully demonstrated the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:8pt;">We are currently collaborating with a supplier to prepare the API<FONT CLASS="nobreak">-2</FONT> CMC documents required by the U.S. FDA. Should the FDA concur that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API<FONT CLASS="nobreak">-2</FONT>. If the U.S. FDA does not agree that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, we will continue to research additional API sources based on our own patent, to pursue additional outsourcing API vendors, and to follow U.S. FDA&#x2019;s guidance for demonstrating comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> to the U.S. FDA&#x2019;s satisfaction. In the event that we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be required to repeat the PCP clinical trials using API<FONT CLASS="nobreak">-2</FONT>. For further details, see the risk factor titled &#x201c;<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs</FONT>&#x201d; on page 31.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:48pt;margin-top:8pt;">Prostate cancer begins when cells in the prostate gland start to grow out of control. In general, the more quickly prostate cells grow and divide, the more chances there are for mutations to occur. According to Frost&#x00a0;&amp; Sullivan, the global prevalence of prostate cancer increased from 10.0&#x00a0;million in 2017 to 11.2&#x00a0;million in 2020, representing a CAGR of 3.9%. The global prostate cancer market increased from US$9.7&#x00a0;billion in 2017 to US$12.6&#x00a0;billion in 2019, representing a CAGR of 9.1%. In addition, the prostate<FONT CLASS="nobreak">-specific</FONT> antigen abnormal population, or PSA abnormal population, representing men over 40&#x00a0;years old with a prostate<FONT CLASS="nobreak">-specific</FONT> antigen test value of 4.0 ng/ml or higher, is exposed to a high risk of prostate cancer. From 2015 to 2020, the total number of PSA abnormal populations in the U.S., Taiwan and China increased from 5.0&#x00a0;million to 5.3&#x00a0;million.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">115</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;font-style:normal;font-weight:bold;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">IC:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Interstitial Cystitis (IC) is our additional key new drug candidate which is composed of polysorbate loaded micelles as nanocarriers which can be used in the intravenous injection and intravesical instillation. The micelles enhance the bioavailability by prolonging the duration of stay in the bladder and increase the penetration of drug across the bladder wall. IC/BPS, refers to interstitial cystitis and bladder pain symptoms that is often associated with voiding symptomatology and other systemic chronic pain disorders.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We incurred expenses in our research and development activities in the amount of approximately US$1.3<FONT CLASS="nobreak"> </FONT>million, US$1.1<FONT CLASS="nobreak"> </FONT>million, and US$0.5<FONT CLASS="nobreak"> </FONT>million for the years ended December&#x00a0;31, 2022 and 2023, and the six months ended June<FONT CLASS="nobreak"> </FONT>30, 2024, respectively. </P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OUR STRENGTHS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We believe the following strengths have contributed to our success and differentiate us from others:</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Innovative new drug (</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">plant-derived</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">) candidate developed for BPH</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LUTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our core drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>, is an innovative drug we have internally developed for the treatment of BPH/LUTS.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">BPH/LUTS is the most common urinary tract disease in the middle<FONT CLASS="nobreak">-aged</FONT> male population. It is often considered a normal part of aging due to the increase in dihydrotestosterone. To date, there is no effective cure for BPH/LUTS, while the currently available drugs to control the disease are either limited in efficacy or can cause significant side effects, such as postural hypotension, dizziness, headache, fainting, general weakness, nasal congestion, rapid heartbeat, drowsiness, indigestion, abdominal pain, diarrhea, nausea, sexual dysfunction, and ejaculation difficulties. As BPH/LUTS often occurs in middle<FONT CLASS="nobreak">-aged</FONT> male patients who usually require lifelong treatment to control the chronic disease conditions, the medical needs for safe and effective drugs are huge, which has been underserved in the long history of BPH/LUTS drug development.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We believe that MCS<FONT CLASS="nobreak">-2</FONT> has the potential to satisfy the growing treatment needs of BPH/LUTS patients. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We have conducted four Phase III clinical trials for MCS<FONT CLASS="nobreak">-2</FONT> in the U.S.&#x00a0;and Taiwan, including two pivotal trials (one in the US and one in Taiwan) and two open<FONT CLASS="nobreak">-label</FONT> extension studies, using API<FONT CLASS="nobreak">-1</FONT>. Our pivotal Phase III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> in the U.S.&#x00a0; failed to show a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to-treat</FONT> population. The U.S. FDA granted our WRO meeting request and is reviewing our new drug development program for API<FONT CLASS="nobreak">-2</FONT>, including Phase I PK study and Phase III clinical trial.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We believe there is a tremendous overall addressable market for MCS<FONT CLASS="nobreak">-2</FONT> and significant commercial potentials. In order to facilitate global registrations and commercial launches of MCS<FONT CLASS="nobreak">-2</FONT>, to which we own worldwide development and commercialization rights, we are actively seeking marketing approvals and formulating commercialization strategies for MCS<FONT CLASS="nobreak">-2</FONT> in targeted markets. Our management team has been aggressively seeking strategic cooperation opportunities with business partners and potential marketing teams around the world.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Diverse drug portfolio and pipeline drug candidates focusing on the treatment of urinary system diseases</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">Our pipeline currently consists of three compelling new drug candidates focusing on the treatment of urinary system diseases. Leveraging our strong research and development capabilities and proprietary platform, we have been developing a series of botanical drug candidates, our primary botanical drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>, another clinical<FONT CLASS="nobreak">-stage</FONT> botanical drug candidate, and other preclinical<FONT CLASS="nobreak">-stage</FONT> botanical drug candidates. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">MCS<FONT CLASS="nobreak">-2</FONT> is our new botanical drug candidate developed for treatment of BPH/LUTS. Another two key drug candidates, PCP and IC, are developed for prostate cancer prevention and the treatment of interstitial cystitis, respectively. We initiated phase&#x00a0;II clinical trials in Taiwan in November&#x00a0;2014 for PCP with 702 subjects and 20 medical centers being involved. Our new drug candidates either demonstrate the achievement of statistically significant endpoints in clinical trials or indicate great potentials to treat adaptive disease in preclinical studies. We believe each of our drug candidates has the potential to address significant medical needs in our target markets and for the treatment of urinary system diseases that have been historically underserved and lacked innovation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">In particular, the target users of MCS<FONT CLASS="nobreak">-2</FONT> and PCP can be highly overlapping. Since only a portion of BPH/LUTS patients, who are potential users of MCS<FONT CLASS="nobreak">-2</FONT>, will seek active treatment, the remaining part of them will likely be in need of pharmaceutical products to prevent BPH/LUTS and prostate cancer, considering that medical studies do show that BPH is associated with an increased risk of prostate cancer. If the follow<FONT CLASS="nobreak">-up</FONT> research and development, or R&amp;D, of PCP progresses smoothly, it would effectively synergize with MCS<FONT CLASS="nobreak">-2</FONT> and enable us to seize a larger market share in the future.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">116</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">We believe that we have created a diverse, balanced portfolio of new drug candidates specializing in the treatment of urinary system diseases, which represents significant market potentials and provides multiple avenues for value creation for us.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Leading R&amp;D capabilities and proprietary platform for innovative drugs</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We have built an innovative proprietary R&amp;D platform focused on the discovery, research and development of innovative drugs. Leveraging our leading proprietary R&amp;D platform, we are able to efficiently and swiftly develop a series of pharmaceutical products with cross<FONT CLASS="nobreak">-disciplinary</FONT> expertise that spans a variety of fields, such as chemistry, biology, pharmacology, toxicology, pharmacovigilance, and translational and clinical research. Our main R&amp;D center is located in New Taipei, Taiwan with a gross floor area (&#x201c;GFA&#x201d;) of approximately 1,029 sq.m. Furthermore, we actively seek and leverage cooperation opportunities with preeminent academic researchers and institutions to keep us updated with the front R&amp;D techniques, methods and information.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Utilizing our proprietary platform, our R&amp;D team has developed three innovative and differentiated drug candidates that specializing in the treatment of BPH/LUTS and interstitial cystitis, as well as prostate cancer prevention. We have conducted four Phase&#x00a0;III clinical trials for MCS<FONT CLASS="nobreak">-2</FONT> in the&#x00a0;U.S.&#x00a0;and Taiwan, including two pivotal trials (one in the US and one in Taiwan) and two open<FONT CLASS="nobreak">-label</FONT> extension studies, using API<FONT CLASS="nobreak">-1</FONT>. Our pivotal Phase III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> in the U.S. failed to show a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to-treat</FONT> population. The U.S. FDA granted our WRO meeting request and is reviewing our new drug development program for API<FONT CLASS="nobreak">-2</FONT>, including Phase I PK study and Phase III clinical trial.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As of the date of this prospectus, we have obtained 31 invention patents in 19 territories and 58 trademarks in 46 territories. We believe that our innovative proprietary R&amp;D platform has contributed to our success and will continue to do so.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Integrated </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">in-house</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> capabilities that well position us for pharmaceutical innovation from bench to bedside</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We have built fully integrated capabilities that encompass all the key functionalities of drug development, including early<FONT CLASS="nobreak">-stage</FONT> drug discovery and development, clinical trials, regulatory affairs, manufacturing and commercialization. The full integration of these functionalities provides us with the opportunity to potentially bring our drug candidates efficiently from bench to bedside. This integration may enable us to identify and address potential clinical, manufacturing, and commercial opportunities, as well as issues early in the development process. It&#x2019;s important to note that as of now, none of our drug candidates have received regulatory approval. However, this approach allows us to focus our efforts on drugs that have the potential to become clinically active, cost<FONT CLASS="nobreak">-effective</FONT>, and commercially viable. Besides, it also allows us to process product manufacturing, maintain consistent quality control and redeploy resources appropriately.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Leveraging rigorous trial design and trial operational excellence, we have achieved substantial progress in our innovative drug candidates. Led by Ms. Fu Feng Kuo, our founder and CEO, we have a team with approximately 15&#x00a0;employees, which supervises and manages our clinical trials and clinical activities, including clinical trial design, implementation and the collection and analysis of trial data. We maintain control and oversight over these key functions of clinical trials while partnering with reputable hospitals and contract research organizations, or CROs, for trial execution. We have established close relationships with 12 reputable hospitals and CROs in Taiwan to conduct MCS<FONT CLASS="nobreak">-2</FONT> studies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have built a seasoned team of regulatory affairs specialists with rich experience in communicating and cooperating with drug regulatory agencies in Taiwan and the U.S.&#x00a0;Leveraging our CEO&#x2019;s rich working experience in the pharmaceutical industry, we have substantial expertise in and familiarity with regulatory review requirements and processes, which enable us to communicate efficiently with regulatory authorities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have established one manufacturing facility in Taiwan. The GFA of our manufacturing facility, Yilan Letzer Pharmaceutical Factory, is approximately 1,944 sq.m. In addition, we have two new manufacturing facilities under planning in Yilan of Taiwan and Taizhou, Zhejiang Province of China which we believe will further enhance our production capacity in the future.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We intend to form a comprehensive internal sales and marketing mechanism conforming to the Code of Marketing Practices and the Good Distribution Practice drawn up by the International Research<FONT CLASS="nobreak">-Based</FONT> Pharmaceutical Manufacturers Association, a Taiwanese non<FONT CLASS="nobreak">-profit</FONT> organization established in 1992. In Taiwan, we are establishing a strong sales and marketing team that is expected to consist of employees with rich experience in relevant areas and our target markets. In other territories, we plan to cooperate with local pharmaceuticals </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">117</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and leverage their sales and marketing network. Our management team also brings us an average of 30&#x00a0;years of substantial operation, managerial and commercialization experience, resources and expertise that can be leveraged to accelerate the build<FONT CLASS="nobreak">-out</FONT> of our proprietary commercialization infrastructure.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Visionary and experienced management and R&amp;D team with extensive industry expertise</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">Our management team has extensive expertise in R&amp;D of innovative drugs gained from their enriching experience in well<FONT CLASS="nobreak">-known</FONT> companies and institutions in the pharmaceutical industry, as well as in<FONT CLASS="nobreak">-depth</FONT> knowledge and understanding of our target markets and the access to top<FONT CLASS="nobreak">-tier</FONT> hospitals and renowned medical experts, which we believe gives us an advantage in navigating the clinical development and regulatory approval process as well as the commercialization of our drug candidates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">Our founder and CEO, Ms. Kuo, brings over 20&#x00a0;years of experience in the discovery and development of innovative drugs (plant<FONT CLASS="nobreak">-derived</FONT>) to our Company. Over the&#x00a0;years, she has gained extensive experience in the discovery, preclinical studies, and clinical development of various drug products. She also led our conferences with regulatory authorities, joined meetings with CROs, assisted with the establishment of chemistry, manufacturing and controls data, or CMC data, monitored the execution of toxicology tests and clinical trials, and actively participated in the study of new drugs extraction technologies. She has full command of our key technologies and R&amp;D plans. Our CTO, Dr.&#x00a0;Fenglin Hsu is an expert in the research of natural medicinal chemistry, the R&amp;D of Chinese herbal medicine, and the management of biotechnology medicine R&amp;D.&#x00a0;Dr.&#x00a0;Hsu previously served as a professor at the School of Pharmacy and the director of the Institute of Pharmacology at Taipei Medical University. Our CSO, Ms. Angela Su has expertise in clinical pharmacy, pharmacotherapy, patient assessment and disease management. She previously served as the manager of the Pharmacy Department at a supermarket chain in the U.S.&#x00a0;Our R&amp;D team leader, Mr.&#x00a0;Albert Pu has expertise in the research on natural medicinal chemistry and formulation development and previously served as an inspector at the TFDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">We are proud of our R&amp;D team which has been contributing to our growth. As of the date of this prospectus, our R&amp;D team consisted of 15 employees, including three holding doctorate degrees and eight holding master&#x2019;s degrees. Members of our core R&amp;D team have an average of more than 15&#x00a0;years of experience in innovative drug development.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">Our success is, to a large extent, the product of our management&#x2019;s leadership and our R&amp;D team&#x2019;s expertise, which cover the full spectrum of the product development process, from preclinical studies through design and execution of clinical studies to regulatory approval.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OUR STRATEGIES</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To achieve our mission, we intend to execute the following strategies:</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Advance the clinical development of our core drug candidate MCS-2 to seek regulatory approval and achieve commercialization in our target markets.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In order to obtain regulatory approval and commercial rights for our core drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>, in the U.S. and Taiwan, we have designed regulatory strategies that we believe will enable us to leverage data generated in our clinical trials that account for considerations specific to our licensed territories, including local clinical practice and patient preferences, with the goal of obtaining regulatory approval and maximizing patient reach for MCS<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In terms of preparation for manufacturing and quality control for future commercialization, we have already built the Yilan Letzer Pharmaceutical Factory with an aggregate GFA of approximately 1,944 sq.m. We are currently planning for a mass production trial at Yilan Letzer Pharmaceutical Factory and have already purchased customized equipment to support future operations. In October&#x00a0;2021, we initiated the planning of the construction project to build another manufacturing facility in Yilan to produce MCS<FONT CLASS="nobreak">-2</FONT> softgels. We will further strengthen our seasoned commercialization team with extensive industry experience, which we believe will contribute to the marketing promotion of MCS<FONT CLASS="nobreak">-2</FONT>. We are also actively seeking commercial partnerships with pharmaceutical companies to maximize the commercial value of MCS<FONT CLASS="nobreak">-2</FONT>. As of June<FONT CLASS="nobreak"> </FONT>30, 2024, we have received several letters of intent and term sheets from renowned pharmaceutical companies. We are currently discussing licensing opportunity with a renowned pharmaceutical company in the U.S. We believe that these potential partners could bring significant strategic synergy with us in the pursuit of potential opportunities for strategic collaboration in order to gain reasonable commercial returns and expedite the practical use of MCS<FONT CLASS="nobreak">-2</FONT> globally.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">118</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Leverage differentiated approaches to advance our development of other drug candidates, such as PCP, IC and other new small molecule drugs, toward regulatory approvals. </FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We will continue to devote substantial resources to the clinical trials of PCP and IC, and the innovative development of other new small molecule drugs. We have adopted and will continue to leverage differentiated development approaches for these drug candidates, which are specifically tailored based on the different development stages that the various drug candidates are undergoing, in order to maximize the value of these drug candidates and obtain potential regulatory approvals in the U.S., Taiwan, China and other territories.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">PCP:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>in November&#x00a0;2014, we initiated a phase&#x00a0;II clinical trial of PCP in Taiwan, which is still in the process as of the date of this prospectus. As of December<FONT CLASS="nobreak"> </FONT>31, 2023, 702 subjects and 20 medical centers in Taiwan have been involved. A total of 185 serious adverse events (SAEs) occurred to date in the PCP Phase II clinical trial, and all of the 185 SAEs have been professionally judged by clinicians and they are not related to PCP. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table indicates the serious adverse events (SAEs) occurred to date in the PCP Phase&#x00a0;II clinical trial:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">System Organ Class</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Number</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Relationship</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Reproductive system and breast disorders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">35</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Not related</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Musculoskeletal and connective tissue disorders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">28</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Not related</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cardiac disorders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">25</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Not related</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Renal and urinary disorders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">25</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Not related</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gastrointestinal disorders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">18</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Not related</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Neoplasms benign, malignant and unspecified (incl cysts and polyps)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">16</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Not related</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Others</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">38</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Not related</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">185</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We intend to expedite our clinical development of PCP in Taiwan. We have pushed our CRO to add more personnel to manage the data and we are scheduled to complete all the SDV (Source Data Verification) by the end of 2024, after which we will perform the database lock and statistical analysis. Subsequently, the medical writer will draft the clinical study report (CSR) next year, which will not be affected by the currently unavailable API<FONT CLASS="nobreak">-1</FONT>. Once the CSR is available, we will discuss within the team and determine if this program should advance to Phase&#x00a0;III.&#x00a0;Should this program advances to Phase&#x00a0;III, we plan to cooperate with international pharmaceutical companies and proceed to multinational Phase&#x00a0;III clinical trials of PCP.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA. As of this date, the Company has not yet successfully demonstrated the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. If the U.S. FDA agrees about comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will discuss with the TFDA the conduct of the Phase III PCP study using API<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are currently collaborating with one supplier to prepare the CMC documents mandated by the U.S. FDA. Should the FDA concur that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API<FONT CLASS="nobreak">-2</FONT>. We will only be able to proceed with Phase III PCP study the after the U.S. FDA accepts such results and determines that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable. If there is any possibility that FDA does not agree that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, we will work with another supplier who is able to meet the comparability.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">IC:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>we are conducting the preclinical studies of IC. Phase&#x00a0;I clinical trials of IC are expected to be conducted in Taiwan.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;font-style:italic;font-weight:bold;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Preclinical new small molecule drugs:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>our R&amp;D team is developing several new small molecule drugs.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">119</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Establish and enhance integrated launch capabilities and strategically build commercial infrastructure customized to each of our drug candidates.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our commercial strategy aims to efficiently maximize patient reach for each of our future products. For our core drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>, we intend to keep building and then utilize a focused salesforce in the U.S., the EU and Asia (primarily Taiwan and mainland China) in order to promote our products, if approved. We believe we will be able to leverage the commercial infrastructure we create for our core product candidate to benefit our other product candidates. For example, in the U.S., Taiwan and mainland China, prescription drugs across our therapeutic areas are primarily sold through hospitals. As a result, we believe the hospital relationships we may establish will lay the groundwork for the future launch of programs across our portfolio. Our overall launch approach will focus on early integration of medical, regulatory and commercialization preparation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may continue to pursue a co<FONT CLASS="nobreak">-commercialization</FONT> strategy with strategic partners globally. In the past, we entered into a license agreement with a Cambodian corporation, Chhak Kamponngsaom Sez Co., Ltd., in 2016, which provides for the potential co<FONT CLASS="nobreak">-commercialization</FONT> of MCS<FONT CLASS="nobreak">-2</FONT> in Cambodia. As of June<FONT CLASS="nobreak"> </FONT>30, 2024, we received six&#x00a0;letters of intent from renowned pharmaceutical companies indicating their interest in the distribution rights and licensing rights of MCS<FONT CLASS="nobreak">-2</FONT> in the U.S., the EU and Greater China. We are currently discussing licensing opportunity with a renowned pharmaceutical company in the U.S.. We believe the co<FONT CLASS="nobreak">-commercialization</FONT> strategy with strategic partners would enable us to access their extensive sales network and established commercial organization globally.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Continue to deepen our pipeline in existing therapeutic areas with new drugs that fit with our expertise, portfolio and strategy.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We seek to anchor each therapeutic focus area with a competitive drug product and build around these core areas. We will encourage the innovation and growth of our in<FONT CLASS="nobreak">-house</FONT> talents and plan to recruit more high<FONT CLASS="nobreak">-quality</FONT> talents, which we believe will support our expanding research and development efforts to deepen our pipeline. We also intend to collaborate with outstanding partners, electing programs with a strong scientific basis and compelling clinical data to build out a broad and clinically validated pipeline. We intend to opportunistically seek out additional hospitals and CROs as partners based on our market assessments. We consider our existing portfolio of product candidates, as well as those of our strategic collaborations, to identify and pursue novel combination approaches. We intend to continue building our portfolio with innovative new drugs that have the potential to become new standards of care in our target markets.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OUR DRUG CANDIDATES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We discover and develop innovative drugs based on differentiated or clinically validated efficacy and safety. To complement our in<FONT CLASS="nobreak">-house</FONT> research and development efforts, we may also collaborate with third parties on the commercialization of our drug candidates through various arrangements. Please see &#x201c;&#x2014;&#x00a0;License and Collaboration Agreements&#x201d; for more details.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Drug Candidates</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">MCS-2</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">MCS<FONT CLASS="nobreak">-2</FONT> is our new drug candidate developed for BPH/LUTS treatment. MCS<FONT CLASS="nobreak">-2</FONT> is expected to be our core product in the future. We have conducted four phase&#x00a0;III clinical trials in the U.S.&#x00a0;and Taiwan, including two pivotal trials and two open<FONT CLASS="nobreak">-label</FONT> extension studies using API<FONT CLASS="nobreak">-1</FONT>. One of the Phase III clinical trials for MCS<FONT CLASS="nobreak">-2</FONT> in the U.S. failed to show a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to-treat</FONT> population. Therefore, we did not reach the endpoint of Phase III clinical trials for MCS<FONT CLASS="nobreak">-2</FONT>. We withdrew our NDA from U.S.&#x00a0;FDA review for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-1</FONT>. We have asked that the U.S.&#x00a0;FDA to provide a written response to questions focused on obtaining U.S.&#x00a0;FDA review and comments on a new, proposed Phase III clinical trial protocol for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-2</FONT> and a pharmacokinetic study. On May<FONT CLASS="nobreak"> </FONT>23, 2024, we received a denial notice from the FDA, stating that it is premature for this stage of drug development, and until the company can provide complete Chemistry, Manufacturing, and Controls (CMC) information on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, the U.S. FDA is unable to reach agreement on protocols designed to establish the safety and efficacy of MCS<FONT CLASS="nobreak">-2</FONT>. We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">120</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">BPH/LUTS is the most common urinary tract disease in the middle<FONT CLASS="nobreak">-aged</FONT> male population. According to Frost&#x00a0;&amp; Sullivan, in 2021, the global prevalence of BPH increased from 88.4&#x00a0;million in 2017 to 94.2&#x00a0;million in 2020, representing an increase of 6.5%. The global BPH drugs market increased from US$3.7&#x00a0;billion in 2017 to US$4.1&#x00a0;billion in 2020, representing a CAGR of 4.6%. We are establishing a strong sales and marketing team that is expected to consist of employees with rich experience in relevant areas and our target markets, and plan to work with both domestic and international business partners to seize the great market opportunity and to help more patients reduce their distress caused by BPH/LUTS and drug side effects caused by chemical drugs.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:12pt;margin-top:12pt;">Disease Overview</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">BPH is a histologic diagnosis that refers to the proliferation of glandular epithelial tissue, smooth muscle, and connective tissue within the prostatic transition zone. The exact etiology of BPH is unknown. BPH can lead to an enlargement of the prostate called benign prostatic enlargement, or BPE, which may eventually cause obstruction at the level of the bladder neck and in turn caused termed benign prostatic obstruction, or BPO.&#x00a0;Males&#x2019; LUTS may be caused by a variety of conditions including BPE and BPO.&#x00a0;Since when the entire prostate gland enlarges, the prostate tissue compresses the prostatic urethra and it then becomes more difficult for urine to pass through, so the urine builds up in the bladder and causes it to dilate. The stagnation of urine in the bladder also promotes bacterial growth and can lead to urinary tract infection. LUTS includes voiding or obstructive symptoms such as hesitancy, poor and/or intermittent stream, straining, prolonged micturition, feeling of incomplete bladder emptying, dribbling, and storage or irritative symptoms such as frequency, urgency, urge incontinence, and nocturia. BPH/LUTS is the most common urinary tract disease in the middle<FONT CLASS="nobreak">-aged</FONT> male population and the risk of BPH/LUTS in the male population increases with age.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:9pt;margin-top:9pt;">Current Standard Care</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Conservative management and surgical treatment are current standards of care for BPH/LUTS. Conservative management includes lifestyle changes and pharmacological management. Surgical treatment of symptomatic BPH may be classified into three general types: (i)&#x00a0;minimally invasive sinus surgery, or MIST, (ii)&#x00a0;simple prostatectomy, and (iii)&#x00a0;transurethral surgery. Although effects and benefits from surgical treatments can show up immediately, however, there are inherent risks of surgery, possibilities of recurrence, and post<FONT CLASS="nobreak">-operative</FONT> side effects, such as hematuria, pain, retrograde ejaculation, impotence and urinary incontinence. In general, pharmacological management is still the prevailing method of BPH/LUTS treatment. Patients are treated with surgery only if pharmacological management is ineffective. The treatment of BPH focuses on relieving the lower urinary tract symptoms. This can be done through 5<FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak"><FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT></FONT> reductase inhibitors, or 5<FONT CLASS="nobreak">-Ari</FONT>, and alpha<FONT CLASS="nobreak">-adrenergic</FONT> blockers, or <FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT><FONT CLASS="nobreak">-blockers</FONT>. However, neither 5<FONT CLASS="nobreak">-Ari</FONT> nor <FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT><FONT CLASS="nobreak">-blockers</FONT> can effectively cure BPH/LUTS.&#x00a0;Patients generally need to take such drugs for life, but long<FONT CLASS="nobreak">-term</FONT> use of these chemical drugs can lead to drug resistance and adverse effects such as cardiac failure. Due to drug<FONT CLASS="nobreak">-related</FONT> adverse effects, physicians and patients have great concerns over using medications, and thus some patients choose to watch and wait instead of taking any drugs to treat BPH/LUTS.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Mechanism of Action</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">MCS<FONT CLASS="nobreak">-2</FONT> has an antioxidant capacity and can reduce inflammatory cytokines (IL<FONT CLASS="nobreak">-6</FONT>). It may take effect by reducing oxidative stress and inflammation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Oxidative stress is an important contributing factor in the development of chronic diseases. It is an imbalance between the production of reactive oxygen species, or ROS, and antioxidant defense, can lead to oxidative damage, caused by deficiency in antioxidant defense processes, elevation in ROS due to presence of toxins and activation of ROS mediated by chronic infection and inflammation. Based on the Cellular Antioxidant Activity, or CAA, method, the results showed a dose<FONT CLASS="nobreak">-dependent</FONT> increase in CAA for MCS<FONT CLASS="nobreak">-2</FONT>. MCS<FONT CLASS="nobreak">-2</FONT> caused a concentration<FONT CLASS="nobreak">-dependent</FONT> increase in cellular antioxidant assay and thus exhibited antioxidant activity. The following table indicates the cellular antioxidant assay unit obtained for different concentrations of standard materials and MCS<FONT CLASS="nobreak">-2</FONT>:</P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 26.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Conc. (ppm)</P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Standard</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.29%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">MCS-2</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">CAA</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">CAA</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">14.23&#x00b1;0.00</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">9.14&#x00b1;2.58</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">26.75&#x00b1;0.00</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">17.26&#x00b1;0.78</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">34.04&#x00b1;0.00</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">27.20&#x00b1;6.59</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">36.12&#x00b1;0.27</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">29.76&#x00b1;5.90</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">5</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">38.90&#x00b1;0.17</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 2.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">37.88&#x00b1;1.48</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">121</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Chronically inflamed cells can release cytokines to functionally determine a constitutively active stroma and stimulate tumor growth and progression. Chronic inflammation in benign prostate biopsy specimens has been evident to be associated with high<FONT CLASS="nobreak">-grade</FONT> prostate tumors in adjacent areas. IL<FONT CLASS="nobreak">-6</FONT> is a prototypical cytokine with various biological effects on a wide variety of cells. IL<FONT CLASS="nobreak">-6</FONT> is therefore involved in the control of immune responses and inflammation. It is produced, participating in host defense against infections and tissue injuries. However, over production of IL<FONT CLASS="nobreak">-6</FONT> leads to severe disease complications. Accordingly, IL<FONT CLASS="nobreak">-6</FONT> blockade was expected to become a therapeutic strategy for the diseases characterized by IL<FONT CLASS="nobreak">-6</FONT> overproduction. Based on an important pro<FONT CLASS="nobreak">-inflammatory</FONT> cytokine, the IL<FONT CLASS="nobreak">-6</FONT> levels can be determined for the understanding of anti<FONT CLASS="nobreak">-inflammatory</FONT> activity of MCS<FONT CLASS="nobreak">-2</FONT>. MCS<FONT CLASS="nobreak">-2</FONT> is able to cause a concentration<FONT CLASS="nobreak">-dependent</FONT> inhibition of LPS<FONT CLASS="nobreak">-induced</FONT> IL<FONT CLASS="nobreak">-6</FONT> release in differentiated THP<FONT CLASS="nobreak">-1</FONT> cells, suggesting an anti<FONT CLASS="nobreak">-inflammatory</FONT> activity of MCS<FONT CLASS="nobreak">-2</FONT>. The following diagram indicates that MCS<FONT CLASS="nobreak">-2</FONT> has anti<FONT CLASS="nobreak">-inflammatory</FONT> activity:</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><IMG ALT="" SRC="tbar_005.jpg" STYLE="width:262.4px;max-width:100%;"></P>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">Notes:</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LPS means lipopolysaccharides which are large molecules consisting of a lipid and a polysaccharide that are bacterial toxins.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>BDS means botanical drug substance.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>BDP means botanical drug product.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LPS<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">#1</FONT> means 0.3 &#x00b5;g/ml LPS/0.1% DMSO.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LPS<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">#2</FONT> means 0.3 &#x00b5;g/ml LPS/0.1% DMSO and 0.004% soybean oil.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>* means <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">P</FONT> &lt; 0.05, ** means <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">P</FONT> &lt; 0.01 and *** means <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">P</FONT> &lt; 0.001 compared with LPS<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">#1</FONT>.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT># means <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">P</FONT> &lt; 0.05, ## means P <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">&lt;</FONT> 0.01 and ### means <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">P</FONT> &lt; 0.001 compared with LPS<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">#2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The purpose of this study is to evaluate the anti<FONT CLASS="nobreak">-inflammation</FONT> effect of BDS and BDP by measuring LPS<FONT CLASS="nobreak">-induced</FONT> IL<FONT CLASS="nobreak">-6</FONT> release. The data demonstrated that both BDS and BDP showed a concentration<FONT CLASS="nobreak">-dependent</FONT> inhibition of LPS<FONT CLASS="nobreak">-induced</FONT> IL<FONT CLASS="nobreak">-6</FONT> release. LPS is one of the main etiological factors in the pathogenesis of several diseases. LPS has been shown to stimulate host cells, including macrophages and fibroblasts, to produce cytokines. LPS can markedly increase the production of IL&#x00a0;6, IL&#x00a0;8 and TNF <FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT> in differentiated THP 1 cells. Therefore, based on an important pro<FONT CLASS="nobreak">-inflammatory</FONT> cytokine, the IL<FONT CLASS="nobreak">-6</FONT> levels stimulated by LPS can be determined for the understanding of anti<FONT CLASS="nobreak">-inflammatory</FONT> activity of the MCS<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Interleukin (IL)<FONT CLASS="nobreak">-6</FONT> is produced at the site of inflammation. IL<FONT CLASS="nobreak">-6</FONT> exerts stimulatory effects on T- and B<FONT CLASS="nobreak">-cells</FONT>, thus favoring chronic inflammatory responses. Although its expression is strictly controlled by transcriptional and posttranscriptional mechanisms, dysregulated continual synthesis of IL<FONT CLASS="nobreak">-6</FONT> plays a pathological effect on chronic inflammation and autoimmunity. BDS (25, 50 and 100&#x00a0;&#x00b5;g/ml) and BDP (35, 70 and 140&#x00a0;&#x00b5;g/ml) were used, respectively. The data demonstrated that both BDS and BDP showed a concentration<FONT CLASS="nobreak">-dependent</FONT> inhibition of LPS<FONT CLASS="nobreak">-induced</FONT> IL<FONT CLASS="nobreak">-6</FONT> release in differentiated THP<FONT CLASS="nobreak">-1</FONT> cells, suggesting an anti<FONT CLASS="nobreak">-inflammatory</FONT> activity of MCS<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="H5" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;">Clinical Data</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The data in the Clinical Data section for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> from page 122 to page 133, pertains to the clinical trials utilizing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> (&#x201c;MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> (API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)&#x201d;), which is currently unavailable. We will be conducting new studies using API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> (&#x201c;MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> (API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)&#x201d;). However, we must conduct API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> comparability studies first and if the FDA accepts such results and determines that API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> are comparable, only then we will be able to </FONT></P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">122</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">conduct the additional Phase I PK study and Phase III pivotal study using API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">. If the U.S. FDA does not agree that API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> are comparable, we will need to work with other API vendor to demonstrate the comparability that meet U.S. FDA&#x2019;s requirements.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Considering a variety of factors including the current unavailability of API<FONT CLASS="nobreak">-1</FONT>, we voluntarily withdrew our NDA on November<FONT CLASS="nobreak"> </FONT>30, 2022, in order to develop more information about API<FONT CLASS="nobreak">-2</FONT> for the U.S. FDA&#x2019;s review and to address ongoing questions regarding demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT> and placebo for the primary efficacy endpoint in a clinical study for MCS<FONT CLASS="nobreak">-2</FONT>, and to address other questions FDA had previously identified in our NDA regarding FDA&#x2019;s questions related to the drug substance and product, validation of methods used for measuring the effect of MCS<FONT CLASS="nobreak">-2</FONT>, manufacturing, clinical and nonclinical testing, data, and statistical analyses, among others.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The U.S. FDA has reviewed our proposed Phase III protocol and Phase I pharmacokinetic (PK) synopsis, as reflected in their written response dated February<FONT CLASS="nobreak"> </FONT>23, 2024. The U.S. FDA raised several concerns in this response:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;">(i)<FONT STYLE="width: 17px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The U.S. FDA questioned whether one new Phase III study with API<FONT CLASS="nobreak">-2</FONT> would be sufficient, as they believe results from two positive Phase III efficacy studies provide more convincing evidence of effectiveness than results from a single trial. Additionally, a single Phase III efficacy study could make it challenging to collect the amount of safety information required for a new molecular entity.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;">(ii) <FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT>The U.S. FDA noted its concern that Study MCS<FONT CLASS="nobreak">-2-US-a</FONT> did not demonstrate a statistically significant difference between the drug and placebo in the primary efficacy endpoint. They also expressed concerns regarding the treatment effect of questionable significance in Study MCS<FONT CLASS="nobreak">-2-TWN-a</FONT>.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;">(iii)<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT>The U.S. FDA was concerned that our study plan had not specified either the quantity or quality of the confirmatory evidence, and did not state a specific clinical circumstance, ethical or practical consideration, or unmet medical need that would preclude the conduct of a second adequate and well<FONT CLASS="nobreak">-controlled</FONT> efficacy study.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;">(iv)<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT>Additionally, regarding the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, the U.S. FDA commented that it will need more information on how we would demonstrate comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. They noted that their determination of whether our original Phase III studies with API<FONT CLASS="nobreak">-1</FONT> would be useful depends on the quality of support for a convincing link between products containing these APIs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In response to these concerns and upon U.S. FDA&#x2019;s recommendation, we are developing a comparability plan to provide the U.S. FDA with convincing data to link between products containing API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. As of this date, the Company is still in the process of providing the information required by the U.S. FDA and has not yet successfully demonstrated the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">After our submission of our comparability plan and, if U.S. FDA agrees our data demonstrates comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be able to rely on trials that were previously conducted using API<FONT CLASS="nobreak">-1</FONT>, and we then will initiate the MCS<FONT CLASS="nobreak">-2</FONT> Phase III study and the PK study using API<FONT CLASS="nobreak">-2</FONT> simultaneously. As mentioned earlier, for MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>), we have conducted four Phase III clinical trials in the U.S. and Taiwan, including two pivotal trials (one in each location) and two open<FONT CLASS="nobreak">-label</FONT> extension studies (also one in each location) using API<FONT CLASS="nobreak">-1</FONT>. The U.S. FDA raised concerns about one pivotal Phase III trial in the U.S., which failed to demonstrate a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to-treat</FONT> population. Additionally, the FDA expressed concerns regarding the reproducibility of some reported efficacy results for Study MCS<FONT CLASS="nobreak">-2-TWN-a</FONT>. However, the U.S. FDA had no further comments on the two open<FONT CLASS="nobreak">-label</FONT> extension studies in the U.S. and Taiwan using API<FONT CLASS="nobreak">-1</FONT>. Therefore, if the FDA agrees that our data demonstrates comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will also need to conduct another pivotal Phase III study using API<FONT CLASS="nobreak">-2</FONT>, and we will work with the FDA to address the reproducibility issue.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">To address the U.S. FDA&#x2019;s concern that Study MCS<FONT CLASS="nobreak">-2-US-a</FONT> did not demonstrate a statistically significant difference between the drug and placebo in the primary efficacy endpoint, we plan to conduct an additional Phase III study, MCS<FONT CLASS="nobreak">-2-US-b</FONT>, using API<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Regarding the U.S. FDA&#x2019;s concerns about the reproducibility of the reported efficacy results for Study MCS<FONT CLASS="nobreak">-2-TWN-a</FONT>, we propose to re<FONT CLASS="nobreak">-analyze</FONT> the statistical results of the MCS<FONT CLASS="nobreak">-2-TWN-a</FONT> study data using Clinical Data Interchange Standards Consortium (CDISC) data sets that match the FDA&#x2019;s requested data format. Then, we will submit the reanalysis for further discussions with U.S. FDA about its concerns.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">123</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On May<FONT CLASS="nobreak"> </FONT>14, 2024, we asked U.S. FDA to provide a written response to our questions about obtaining U.S. FDA&#x2019;s review and comments on a newly proposed Phase III clinical trial protocol for MCS<FONT CLASS="nobreak">-2</FONT> with API<FONT CLASS="nobreak">-2</FONT> and a pharmacokinetic (PK) study. On May<FONT CLASS="nobreak"> </FONT>23, 2024, we received a denial notice from the U.S. FDA, stating that it was premature to provide such a written response at this stage of drug development, however, the U.S. FDA would continue its review of the study design of PK study and Phase III clinical trial using API<FONT CLASS="nobreak">-2</FONT>. The U.S. FDA decided that until the company provides complete Chemistry, Manufacturing, and Controls (CMC) information on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) with a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, the U.S. FDA is not in a position to reach any agreement on protocols designed to establish the safety and efficacy of MCS<FONT CLASS="nobreak">-2</FONT>. We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA. If the U.S. FDA does not agree that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, we will continue to research additional API sources based on our own patent, to pursue additional outsourcing API vendors, and to follow U.S. FDA&#x2019;s guidance for demonstrating comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> to the U.S. FDA&#x2019;s satisfaction. In the event that we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be required to repeat the MCS<FONT CLASS="nobreak">-2</FONT> clinical trials using API<FONT CLASS="nobreak">-2</FONT>. For further details, see the risk factor titled &#x201c;<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs</FONT>&#x201d; on page 31.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, we are in the process of finalizing the PK study protocol per U.S. FDA requirements and hope to satisfy the U.S. FDA of the comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. If the CMC comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> is approved, we will request a Type B meeting (WRO) with the U.S. FDA to discuss our revised Phase III protocol, Statistical Analysis Plan, and PK study protocol.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Phase&#x00a0;I Clinical Studies</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Phase&#x00a0;I clinical studies of MCS<FONT CLASS="nobreak">-2</FONT> focused on pharmacokinetics and clinical drug<FONT CLASS="nobreak">-drug</FONT> interaction studies. <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The data in the Phase I Clinical Studies section, pertains to the clinical trials utilizing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, which is currently unavailable. We will be conducting new studies using API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> (&#x201c;MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> (API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)&#x201d;). However, we must conduct API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> comparability studies first and if the FDA accepts such results and determines that API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> are comparable, only then we will be able to conduct the additional Phase I PK study and Phase III pivotal study using API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">. If the U.S. FDA does not agree that API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> are comparable, we will need to work with other API vendor to demonstrate the comparability that meet U.S. FDA&#x2019;s requirements.</FONT></P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Pharmacokinetics</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The study of pharmacokinetics of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) was a randomized, balanced, single<FONT CLASS="nobreak">-dose</FONT>, two<FONT CLASS="nobreak">-treatment</FONT> (fed versus fasted) study in healthy male adult subjects. The study was designed to evaluate the pharmacokinetics, or PK, of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) when it was administered in the fed and fasted state. 47 subjects were randomized to receive a single dose either in the fed (24 subjects) or fasted (23 subjects) state, and the PK parameters were evaluated and compared for the two treatment groups. Relevant trials were conducted in U.S. and were initiated on April&#x00a0;22, 2015 and completed on April&#x00a0;24, 2017, with 23 subjects in fed group and 22 subjects in fasted group had completed the study. The above study of the pharmacokinetics of MCS<FONT CLASS="nobreak">-2</FONT> was conducted using API<FONT CLASS="nobreak">-1</FONT>, which is currently unavailable. We are continuing development of MCS<FONT CLASS="nobreak">-2</FONT> using API<FONT CLASS="nobreak">-2</FONT> in consultation with U.S. FDA. U.S. FDA provided comments on our proposed Phase III study, and we are finalizing the protocol for resubmission to the U.S. FDA. In addition, we are in the process of finalizing the PK study protocol per U.S. FDA requirements and hope to satisfy the U.S. FDA of the comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. If the CMC comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> is approved, we will request a Type B meeting (WRO) with the U.S. FDA to discuss our revised Phase III protocol, Statistical Analysis Plan, and PK study protocol.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As to the efficacy of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>), the study compared serum active ingredient levels of five major biomarkers PL, PF, PE, TC and BC (code names of our active ingredients to represent the content of each carotenoid in our pharmaceutical composition), in subjects taking MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) after a meal with those taking MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) on an empty stomach. It is found that the proportion of active ingredient absorbed after a meal was better than after an empty stomach. Subjects were randomized to two groups in order to obtain their pre<FONT CLASS="nobreak">-prandial</FONT> or postprandial </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">124</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">medication status. The results showed that the adverse effects were well tolerated irrespective of the timing of administration (postprandial or postprandial), although absorption rates were higher when MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) were taken after meals. The following figure indicates the concentration of active ingredients in serum:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Pharmacokinetics (Unit)</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Fed State</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Fasted State</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">AUC<FONT CLASS="CharOverride-4" STYLE="font-size:58%;vertical-align:sub;">0-72</FONT> (day*&#x00b5;mol/L)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.521</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.376</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">AUC<FONT CLASS="CharOverride-4" STYLE="font-size:58%;vertical-align:sub;">0-last</FONT> (day*&#x00b5;mol/L)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.457</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.236</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C<FONT CLASS="CharOverride-4" STYLE="font-size:58%;vertical-align:sub;">max</FONT> (day*&#x00b5;mol/L)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.306</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.217</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">t<FONT CLASS="CharOverride-4" STYLE="font-size:58%;vertical-align:sub;">1</FONT><FONT CLASS="CharOverride-4" STYLE="font-size:58%;vertical-align:sub;">/</FONT><FONT CLASS="CharOverride-4" STYLE="font-size:58%;vertical-align:sub;">2</FONT> (day)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.691</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.049</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">t<FONT CLASS="CharOverride-4" STYLE="font-size:58%;vertical-align:sub;">max</FONT> (day)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.133</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.724</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">Notes:</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>AUC<FONT CLASS="Subscript" STYLE="vertical-align:sub;font-size:58%;">0</FONT><FONT CLASS="nobreak"><FONT CLASS="Subscript" STYLE="vertical-align:sub;font-size:58%;">-72</FONT></FONT> means area under the serum concentration<FONT CLASS="nobreak">-time</FONT> curve, calculated from time zero to time 72 hours postdose by the linear trapezoidal rule (after correction for the baseline concentration).</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>AUC<FONT CLASS="Subscript" STYLE="vertical-align:sub;font-size:58%;">0</FONT><FONT CLASS="nobreak"><FONT CLASS="Subscript" STYLE="vertical-align:sub;font-size:58%;">-las</FONT></FONT><FONT CLASS="nobreak" STYLE="font-size:58%;vertical-align:sub;">t</FONT> means area under the serum concentration<FONT CLASS="nobreak">-time</FONT> curve, calculated from time zero to the last measurable concentration by the linear trapezoidal rule (after correction for the baseline concentration).</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>C<FONT CLASS="Subscript" STYLE="vertical-align:sub;font-size:58%;">max</FONT> means maximum (peak) serum drug concentration observed (after correction for baseline concentration).</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4) <FONT STYLE="width: 15px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>t<FONT CLASS="Subscript" STYLE="vertical-align:sub;font-size:58%;">1/2</FONT> means half<FONT CLASS="nobreak">-life</FONT> period.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>t<FONT CLASS="Subscript" STYLE="vertical-align:sub;font-size:58%;">max</FONT> means time of the maximum observed concentration.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As to the safety profile of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>), data indicated that MCS<FONT CLASS="nobreak">-2</FONT> was well<FONT CLASS="nobreak">-tolerated</FONT> among 47 subjects. 22 subjects, or 46.8%, of all subjects reported at least one treatment emergent adverse event, or TEAE, during the study. The fasted group has a higher TEAEs rate (60.9%) than the fed group (33.3%), but the rate of Aes was similar for the two groups. Overall, the most frequently reported TEAEs were headache (19.1%), upper respiratory tract infection (8.5%), back pain (4.3%) and nasopharyngitis (4.3%). The fasted group reported higher rate of headaches than the fed group. The two groups had similar rates for other TEAEs. No subject experiences serious, severe, or life<FONT CLASS="nobreak">-threatening</FONT> treatment emergent adverse events, or TEAEs. No TEAEs resulted discontinuation of the study and no death was caused. Other data such as the changes in blood pressure, heart rate, respiratory rate, weight and temperature were generally small and clinically insignificant.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Clinical </FONT><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Drug-Drug</FONT><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;"> Interaction</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The study of clinical drug<FONT CLASS="nobreak">-drug</FONT> interaction of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) was an open<FONT CLASS="nobreak">-label</FONT>, fixed<FONT CLASS="nobreak">-sequence</FONT>, drug<FONT CLASS="nobreak">-drug</FONT> interaction study to evaluate the effect of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) on the pharmacokinetics of 24 healthy male subjects. Relevant trials were initiated on May&#x00a0;20, 2018 and completed on September, 2018. A total of 24 subjects were enrolled in the study and 23 of them completed the study. One subject discontinued the study primarily due to a failure to meet compulsory criteria.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Midazolam is used to produce sleepiness or drowsiness and to relieve anxiety before surgery or certain procedures. Bupropion is indicated for the treatment of major depressive disorder, seasonal affective disorder, and as an aid to smoking cessation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Since our in vitro drug<FONT CLASS="nobreak">-drug</FONT> interaction study conducted in the U.S. concluded that our drug substance may be an inducer of CYP3A4 and CYP2B6 based on the calculated R values (&lt; 0.9). U.S. FDA suggested that we further investigate the potential drug<FONT CLASS="nobreak">-drug</FONT> interactions by conducting a clinical drug<FONT CLASS="nobreak">-drug</FONT> interaction study using a sensitive index substrate. The sensitive index substrate is midazolam for CYP3A4 and bupropion for CYP2B6, respectively. Therefore, we conducted such study to assess the effect of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) on the PK of midazolam and bupropion following U.S. FDA&#x2019;s suggestion in 2018. The coadministration of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) with midazolam and bupropion generally would not affect the efficacy of midazolam and bupropion, and concluded that MCS<FONT CLASS="nobreak">-2</FONT> is not an inducer of both midazolam (CYP3A4) and bupropion (CYP2B6).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary objective of this clinical drug<FONT CLASS="nobreak">-drug</FONT> interaction study was to assess the effect of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) on the PK of midazolam and bupropion in healthy male subjects. The results indicated that the peak exposure (Cmax) and the total exposure to midazolam were not significantly affected by the co<FONT CLASS="nobreak">-administration</FONT> of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>). The total and peak exposures of bupropion, midazolam, and their measured metabolites were not significantly altered after multiple daily doses of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>). The median time to peak concentration (Tmax) of bupropion, midazolam and their measured metabolites was not affected by multiple daily doses of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>). The safety data indicated that the administration of MCS<FONT CLASS="nobreak">-2</FONT> alone or the co<FONT CLASS="nobreak">-administration</FONT> of MCS<FONT CLASS="nobreak">-2</FONT>, midazolam and </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">125</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">bupropion was generally tolerated by healthy male subjects in this study. Seven of 24 subjects (29.2%) treated with midazolam, bupropion, and/or MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) experienced a total of 10 TEAEs. Six of 24 subjects (25.0%) treated with midazolam or bupropion experienced seven TEAEs. One of 24 subjects (4.2%) treated with MCS<FONT CLASS="nobreak">-2</FONT> alone experienced two TEAEs. One of 23 subjects treated with midazolam/bupropion and MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) experienced one TEAEs. The most frequently reported TEAEs were somnolence and others included headache, dry skin, macule, skin irritation and cough. However, 30% of TEAES were assessed as unrelated to the study. All TEAEs were assessed as mild in severity and fully recovered or resolved at the end of the study. No TEAEs resulted discontinuation of the study and no serious adverse effect, or SAE, or deaths were reported.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Overall summary and conclusions</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the Phase&#x00a0;I clinical studies, the administration of a single oral MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) was well<FONT CLASS="nobreak">-tolerated</FONT> in the fed and fasted state in healthy male subjects. Subjects absorbed active ingredients of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) better when they took MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) after meals. The administration of MCS<FONT CLASS="nobreak">-2</FONT> alone or the co<FONT CLASS="nobreak">-administration</FONT> of MCS<FONT CLASS="nobreak">-2</FONT>, midazolam and bupropion was generally tolerated by healthy male subjects in this study. The coadministration of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) with midazolam and bupropion generally would not affect the efficacy of midazolam and bupropion. Our Phase I trial was completed several years later than Phase II and Phase III trials per U.S. FDA&#x2019;s requirements. Since our in vitro drug<FONT CLASS="nobreak">-drug</FONT> interaction study conducted in the U.S. concluded that our drug substance may be an inducer of midazolam and bupropion based on the calculated R values (&lt; 0.9). The U.S. FDA suggested that we conduct additional Phase I studies on both PK and DDI using a sensitive index substrate. Therefore, we conducted such additional study to assess the effect of PCP on the PK of midazolam and bupropion following the U.S. FDA&#x2019;s suggestion in 2018 after we had previously completed Phase II and Phase III studies. The clinical DDI study concluded that MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) is neither an inducer of midazolam nor an inducer of bupropion.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Phase&#x00a0;II Clinical Studies</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The data in the Phase II Clinical Studies section, pertains to the clinical trials utilizing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, which is currently unavailable. We will be conducting new studies using API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> (&#x201c;MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> (API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)&#x201d;). However, we must conduct API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> comparability studies first and if the FDA accepts such results and determines that API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> are comparable, only then we will be able to conduct the additional Phase I PK study and Phase III pivotal study using API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">. If the U.S. FDA does not agree that API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> are comparable, we will need to work with other API vendor to demonstrate the comparability that meet U.S. FDA&#x2019;s requirements. In the event that we are unable to establish comparability between API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat the MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> clinical trials using API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">. For further details, see the risk factor titled &#x201c;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs&#x201d; on page 31.</FONT></P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Trial Design</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The phase&#x00a0;II clinical trial in Taiwan was initiated on March&#x00a0;21, 2004 and completed on August, 2006. The phase&#x00a0;II clinical study was a randomized exploratory intervention one with 65 subjects involved and 62 subjects completed the study. 32 subjects were administered 15&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) per&#x00a0;day and 29 of them completed the study. 33 subjects were administered 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> per&#x00a0;day and all of them completed the study.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Efficacy</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the results of phase&#x00a0;II clinical trials in Taiwan, the primary endpoint was the change in International Prostate Symptom Score system, or I<FONT CLASS="nobreak">-PSS</FONT>, which is a validated, reproducible scoring system that measures severity of lower urinary tract symptoms and responses to therapeutics, from Day one to Week 12. The mean (standard deviation [SD]) reductions in I<FONT CLASS="nobreak">-PSS</FONT> from baseline decreased from 11.31 [5.84] to 9.52 [4.98] after four weeks, and decreased to 9.14 [5.86] after 12 weeks in low<FONT CLASS="nobreak">-dose</FONT> group. Thus, for subjects who took one MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgel (15&#x00a0;mg) per&#x00a0;day, their&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> reduced by 15.8% and 19.2% after four and 12&#x00a0;weeks, respectively. In addition, the mean [SD] reductions in I<FONT CLASS="nobreak">-PSS</FONT> from Day one decreased from 12.30 [6.45] to 9.00 [4.98] at 4 weeks, and decreased to 7.55 [3.97] at 12 weeks in high<FONT CLASS="nobreak">-dose</FONT> group. Thus, for subjects who took two MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgels (30&#x00a0;mg) per&#x00a0;day, their&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> reduced by 26.8% and 38.6% after four and 12&#x00a0;weeks, respectively. The study result indicated that the 30 mg/day was the optimal dose. For subjects with moderate and severe BPH/LUTS, or to </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">126</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">say, for those whose I<FONT CLASS="nobreak">-PSS</FONT> larger than 10 points (inclusive), the I<FONT CLASS="nobreak">-PSS</FONT> decreased by 16.3% and 22.1% after 4 and 12 weeks of MCS<FONT CLASS="nobreak">-2</FONT> softgels (15 mg/day) treatment, and the I<FONT CLASS="nobreak">-PSS</FONT> decreased by 28.6% and 44.4%% after 4 and 12 weeks of MCS<FONT CLASS="nobreak">-2</FONT> softgels (30 mg/day) treatment.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Safety</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) were well tolerated by both groups of subjects. There were no adverse effects, or AEs, resulting in discontinuation of the study. And no unexpected or unanticipated events were reported. 14 subjects, or 20%, of all subjects reported AEs, but most of the AEs were reported by one subject. Only one kind of AE, influenza like syndrome, occurred with an incidence greater than 5%. One subject reported one SAE which was hospitalization. However, the subject reported hospitalization since it was a common practice in Taiwan to conduct transrectal ultrasound<FONT CLASS="nobreak">-guided</FONT> prostate biopsies under intravenous general anesthesia, which must be carried out in a hospital setting. In the U.S., transrectal ultrasound<FONT CLASS="nobreak">-guided</FONT> prostate biopsies are conducted in an outpatient setting. Therefore, should the subject locate in the U.S., it would not be hospitalized, and no SAE would be reported then.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Overall summary</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Both levels of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) administration, 15&#x00a0;mg/day and 30&#x00a0;mg/day, were well tolerated by the subjects. The incidences of AEs and SAEs were relatively low and common side effects of 5<FONT CLASS="nobreak">-Ari</FONT> and <FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT><FONT CLASS="nobreak">-blockers</FONT> were not reported during relevant trials, which showed an excellent tolerability profile of MCS<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Phase&#x00a0;III Clinical Studies</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The data in the Phase III Clinical Studies section, pertains to the clinical trials utilizing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, which is currently unavailable. We will be conducting new studies using API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> (&#x201c;MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> (API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)&#x201d;). However, we must conduct API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> comparability studies first and if the FDA accepts such results and determines that API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> are comparable, only then we will be able to conduct the additional Phase I PK study and Phase III pivotal study using API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">. If the U.S. FDA does not agree that API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> are comparable, we will need to work with other API vendor to demonstrate the comparability that meet U.S. FDA&#x2019;s requirements. In the event that we are unable to establish comparability between API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat the MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> clinical trials using API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">. For further details, see the risk factor titled &#x201c;If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs&#x201d; on page 31.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Phase&#x00a0;III clinical trials were approved by the U.S. FDA in December&#x00a0;2009 and approved by Taiwan TFDA in February&#x00a0;2010. We have conducted four Phase III clinical trials for MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) in the U.S. and Taiwan, including two pivotal trials (one in the US and one in Taiwan) and two open<FONT CLASS="nobreak">-label</FONT> extension studies (one in the US and one in Taiwan) using API<FONT CLASS="nobreak">-1</FONT>. Among four Phase III clinical trials, the U.S. FDA determined our pivotal Phase III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) in the U.S. failed to show a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to-treat</FONT> population. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, our API<FONT CLASS="nobreak">-1</FONT> supplier withdrew their consent to reference their DMF on file with the FDA, due to the relocation and restructuring of manufacturing facility. Considering a variety of factors, we voluntarily withdrew our NDA on November<FONT CLASS="nobreak"> </FONT>30, 2022, in order to develop more information about API<FONT CLASS="nobreak">-2</FONT> for the U.S. FDA&#x2019;s review and to address ongoing questions regarding demonstrated difference between MCS<FONT CLASS="nobreak">-2</FONT> and placebo for the primary efficacy endpoint in a clinical study for MCS<FONT CLASS="nobreak">-2</FONT>, and to address other questions FDA had previously identified in our NDA regarding FDA&#x2019;s questions related to the drug substance and product, validation of methods used for measuring the effect of MCS<FONT CLASS="nobreak">-2</FONT>, manufacturing, clinical and nonclinical testing, data, and statistical analyses, among others.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S. FDA provided written responses on February<FONT CLASS="nobreak"> </FONT>23, 2024. In the response, U.S. FDA questioned whether one new Phase III study with API<FONT CLASS="nobreak">-2</FONT> would be sufficient, noting again its concern that Study MCS<FONT CLASS="nobreak">-2-US-a</FONT> did not demonstrate a statistically significant difference between the drug and placebo in the primary efficacy endpoint and concerns regarding the treatment effect of questionable significance in the Study MCS<FONT CLASS="nobreak">-2-TWN-a</FONT>. The U.S. FDA also commented that it will need more information on how we would demonstrate comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and that its determination of whether our original Phase III studies with API<FONT CLASS="nobreak">-1</FONT> would have utility, based upon the quality of support, for a convincing link between products containing API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">127</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We followed the U.S. FDA&#x2019;s advice to amend the Phase III protocol and develop the Phase I PK protocol. On May<FONT CLASS="nobreak"> </FONT>14, 2024, we submitted a Type B meeting request to the FDA containing the amended protocols for their review and comments. On May<FONT CLASS="nobreak"> </FONT>23, 2024, we received a denial notice from the FDA, stating that it is premature for this stage of drug development, and until the company can provide complete Chemistry, Manufacturing, and Controls (CMC) information on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, the U.S. FDA is unable to reach agreement on protocols designed to establish the safety and efficacy of MCS<FONT CLASS="nobreak">-2</FONT>. We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If the comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> is accepted by the U.S. FDA, we plan to conduct additional Phase III pivotal study in the US using API<FONT CLASS="nobreak">-2</FONT> (MCS<FONT CLASS="nobreak">-2-US-b</FONT> study). If the comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> is not accepted by the U.S. FDA, we will need to work with other API vendor to demonstrate the comparability that meet U.S. FDA&#x2019;s requirements and would have to perform more clinical trials. In the event that we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be required to repeat the MCS<FONT CLASS="nobreak">-2</FONT> clinical trials using API<FONT CLASS="nobreak">-2</FONT>. For further details, see the risk factor titled &#x201c;<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs</FONT>&#x201d; on page 31.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">More details are indicated in the following tablet:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 16.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Short-term Clinical Studies</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 39.98%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Long-term Clinical Studies</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 16.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Location</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">USA</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Taiwan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">USA</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 20.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Taiwan</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 16.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Approved Date</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">November&#x00a0;17, 2009</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">February&#x00a0;1, 2010</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">November&#x00a0;17, 2009</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 20.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">February&#x00a0;1, 2010</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 16.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Date of the first subject randomized</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">September<FONT CLASS="nobreak"> </FONT>8, 2010</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">July<FONT CLASS="nobreak"> </FONT>5, 2010</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">December<FONT CLASS="nobreak"> </FONT>1, 2010</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 20.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">September<FONT CLASS="nobreak"> </FONT>27, 2010</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 16.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Study Type</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Phase&#x00a0;IIb/III</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Phase&#x00a0;III</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Open<FONT CLASS="nobreak">-label</FONT> Extension</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 20.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Open<FONT CLASS="nobreak">-label</FONT> Extension</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 16.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Objective</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Comparison Study of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) and placebo:</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">the efficacy and safety</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Comparison Study of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) and placebo:</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">the efficacy and safety</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Long<FONT CLASS="nobreak">-term</FONT> use of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>):</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">the safety</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 20.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Long<FONT CLASS="nobreak">-term</FONT> use of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>):</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">the safety</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 16.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Study Design</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Multi<FONT CLASS="nobreak">-center</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Double<FONT CLASS="nobreak">-Blind</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Randomized</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Placebo<FONT CLASS="nobreak">-controlled</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Multi<FONT CLASS="nobreak">-center</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Double<FONT CLASS="nobreak">-Blind</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Randomized</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Placebo<FONT CLASS="nobreak">-controlled</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Multi<FONT CLASS="nobreak">-center</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Open<FONT CLASS="nobreak">-Label</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Single arm</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 20.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Multi<FONT CLASS="nobreak">-center</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Open<FONT CLASS="nobreak">-Label</FONT></P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Single arm</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 16.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Study drug</FONT></P>
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Dosage</FONT></P>
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">administration</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Two MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgels</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Once daily</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oral</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Two MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>)<FONT CLASS="Superscript" STYLE="vertical-align:super;"> </FONT>softgels</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Once daily</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oral</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Two MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>)<FONT CLASS="Superscript" STYLE="vertical-align:super;"> </FONT>softgels</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Once daily</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oral</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 20.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Two MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>)<FONT CLASS="Superscript" STYLE="vertical-align:super;"> </FONT>softgels</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Once daily</P>
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oral</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 16.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Diagnosis</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">BPH</FONT><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">/</FONT><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">LUTS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">BPH</FONT><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">/</FONT><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">LUTS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">BPH</FONT><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">/</FONT><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">LUTS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 20.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">BPH</FONT><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">/</FONT><FONT CLASS="AllCaps" STYLE="font-variant:normal;text-transform:uppercase;">LUTS</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 16.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Treatment Periods</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">12&#x00a0;weeks</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 19.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">12&#x00a0;weeks</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">24&#x00a0;weeks/40&#x00a0;weeks</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 20.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">24&#x00a0;weeks/40&#x00a0;weeks</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The study completion dates included in the following table:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 47.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Last Subject Last Visit</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Clinical Study Report Date</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 47.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">MCS-2-US-a</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 24.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2013-04-09</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 25.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2017-06-21</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 47.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">MCS-2-US-c</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 24.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2014-03-28</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 25.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2017-06-22</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 47.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">MCS-2-TWN-a</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 24.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2014-03-28</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 25.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2017-01-20</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 47.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">MCS-2-TWN-c</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 24.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2014-03-28</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 25.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2017-01-20</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The primary objective of phase&#x00a0;III clinical trials is to investigate the clinical use of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>), by measuring the difference in the changes of&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> between MCS<FONT CLASS="nobreak">-2</FONT> group and placebo group after short term (12&#x00a0;weeks) and long<FONT CLASS="nobreak">-term</FONT> (40&#x00a0;weeks). The whole clinical studies were up to 52&#x00a0;weeks, or one year. Despite </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">128</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">the pivotal Phase III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) in the U.S. failing to demonstrate a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to-treat</FONT> population, the remaining data, including one phase III US open label extension study and two phase III studies conducted in Taiwan, still indicated that the overall results indicated that MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgels could reduce the I<FONT CLASS="nobreak">-PSS</FONT> total score. However, the U.S. FDA has expressed concerns regarding the reproducibility of some of the reported efficacy results for Study MCS<FONT CLASS="nobreak">-2</FONT>- TWN<FONT CLASS="nobreak">-a</FONT>. To address the U.S. FDA&#x2019;s concerns about the reproducibility of the reported efficacy results for Study MCS<FONT CLASS="nobreak">-2-TWN-a</FONT>, we propose to re<FONT CLASS="nobreak">-analyze</FONT> the statistical results of the MCS<FONT CLASS="nobreak">-2-TWN-a</FONT> study data using Clinical Data Interchange Standards Consortium (CDISC) data sets that match the FDA&#x2019;s requested data format. Then, we will submit the reanalysis for further discussions with U.S. FDA about its concerns.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As mentioned above, the data in the Phase I Clinical Studies section pertains to the clinical trials utilizing API<FONT CLASS="nobreak">-1</FONT>, which is currently unavailable. We will be conducting new studies using API<FONT CLASS="nobreak">-2</FONT> (&#x201c;MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>)&#x201d;). If we are unable to demonstrate comparability, we would have to work with other API vendors to follow FDA guidance to demonstrate comparability. In the event that we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be required to repeat the MCS<FONT CLASS="nobreak">-2</FONT> clinical trials using API<FONT CLASS="nobreak">-2</FONT>. For further details, see the risk factor titled &#x201c;<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs</FONT>&#x201d; on page 31.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Overview of clinical trials</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The phase&#x00a0;III clinical trials (pivotal studies) in the U.S.&#x00a0;and Taiwan primarily aimed to investigate whether daily treatment of two MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgels can improve LUTS in patients with BPH.&#x00a0;The phase&#x00a0;III clinical trials involved 546 subjects from two pivotal trials, including 274 subjects in the U.S.&#x00a0;and 272 subjects in Taiwan. Among the 546 subjects, 545 of them received more than one dose of MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>). 42 subjects received 15&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> per&#x00a0;day, 338 subjects received 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> per&#x00a0;day, and 165 subjects received 0&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) per&#x00a0;day.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">MCS-2<BR>(API-1)</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">MCS-2<BR>(API-1)</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Placebo</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Dosage</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">15&#x00a0;mg/day</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">30&#x00a0;mg/day</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">0&#x00a0;mg/day</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Randomized</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">42</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">338</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">166</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Received &#x2265; 1 Dose of Study Medication</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">42 (100%)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">338 (100%)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">165 (99.4%)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table indicates the demographics for phase&#x00a0;III pivotal clinical studies.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MCS-2<BR>(API-1)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MCS-2<BR>(API-1)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Placebo</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Dosage</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">15&#x00a0;mg/day</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">30&#x00a0;mg/day</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">0&#x00a0;mg/day</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Parameter</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Statistic</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">N=42</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">N=338</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">N=165</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Race, n (</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">%)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">American Indian/Alaskan Native</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">1 (2.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">1 (0.3)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">1 (0.6)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Asian</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">1 (2.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">184 (54.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">88 (53.3)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Black/African American</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">1 (2.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">18 (5.3)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">7 (4.2)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Caucasian</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">38 (90.5)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">129 (38.2)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">65 (39.4)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Other, Specify</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">1 (2.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">3 (0.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">2 (1.2)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Taiwan Aboriginal</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">0</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">3 (0.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">2 (1.2)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Age (Years)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">n</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">42</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">338</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">165</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mean (SD)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">62.2 (8.6)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">62.2 (8.3)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">61.3 (8.9)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Median</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">61.0</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">61.0</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">62.0</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.71%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Min<FONT CLASS="nobreak">-Max</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">43.0-78.0</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">44.0-86.0</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">40.0-82.0</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">129</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Efficacy</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The results of the treatment of LUTS caused by BPH were determined by the&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary endpoint was the change in&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> from Day 1 to Week 12. According to the US<FONT CLASS="nobreak">-a</FONT> Phase&#x00a0;III clinical trial, the mean (standard deviation [SD]) reductions in&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> from Day 1 to Week 12 in the MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) group were insignificant than that in the placebo group (<FONT CLASS="nobreak">-3</FONT>.36 [1.00] vs. <FONT CLASS="nobreak">-3</FONT>.42 [1.11], p=0.1204). According to the TWN<FONT CLASS="nobreak">-a</FONT> Phase&#x00a0;III clinical trial, the mean (standard deviation [SD]) reductions in&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> from Day 1 to Week 12 in the MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) group were significant than that in the placebo group (<FONT CLASS="nobreak">-4</FONT>.59 [4.58] vs. <FONT CLASS="nobreak">-2</FONT>.69 [4.01], p=0.0134).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Table 1: Summary of the primary endpoint for the two<FONT CLASS="nobreak">-Phase</FONT>&#x00a0;III studies and meta<FONT CLASS="nobreak">-analysis</FONT>.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Study</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Population</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="9" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 76.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change from Baseline in&#x00a0;I-PSS at Week 12</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">TWN-a/ITT</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Treatment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">N</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Baseline</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12 Weeks</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Change</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">MCS &#x2013; 2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">148</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">17.30</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12.72</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">-4.59</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Placebo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">68</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">16.22</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">13.53</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">-2.69</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">P-Value</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0.0134</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">US-a/ITT</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">MCS &#x2013; 2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">156</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">18.62</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">15.32</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">-3.36</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Placebo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">74</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">17.83</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">14.75</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">-3.42</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">P-Value</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0.12</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Phase&#x00a0;III open label extension studies, or OLEs, primarily aimed to evaluate the safety and tolerability of long<FONT CLASS="nobreak">-term</FONT> administration of two MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgels per&#x00a0;day. The phase&#x00a0;III OLEs involved a total of 361&#x00a0;subjects, including 181 subjects in the U.S.&#x00a0;and 180 subjects in Taiwan. Among those, 226 subjects received 30mg to 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) per&#x00a0;day and 107 subjects received 0&#x00a0;mg to 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) per&#x00a0;day.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the US<FONT CLASS="nobreak">-c</FONT> results of phase&#x00a0;III OLEs, all subjects, including 102 subjects receiving 30&#x00a0;mg to 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> per&#x00a0;day and 51 subjects receiving 0&#x00a0;mg to 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) per&#x00a0;day, were reported with significant decreases (P value &lt; 0.05) in the&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> at Day<FONT CLASS="nobreak"> </FONT>85, Day 169 and Day 281; and 28 subjects receiving 15&#x00a0;mg to 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) per&#x00a0;day, were reported with significant decreases (P value &lt; 0.05) in the&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> at Day 85 and Day 169. According to the results of TWN<FONT CLASS="nobreak">-c</FONT> phase&#x00a0;III OLEs, all subjects, including 124 subjects receiving 30&#x00a0;mg to 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> per&#x00a0;day and 56 subjects receiving 0&#x00a0;mg to 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) per&#x00a0;day, were reported with significant decreases (P value &lt; 0.05) in the&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> at Day<FONT CLASS="nobreak"> </FONT>85, Day 169 and Day 281. Despite the pivotal Phase&#x00a0;III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) in the U.S.&#x00a0;failing to demonstrate a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-treat</FONT> population, the remaining data, including one phase III US open label extension study and two phase III studies conducted in Taiwan, still indicated statistically significant improvements with MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) for up to one year, with no drug<FONT CLASS="nobreak">-related</FONT> serious adverse events reported.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table displays the summary for the two open label extension studies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Table 2: Summary for the two open label extension studies and meta<FONT CLASS="nobreak">-analysis</FONT>:</P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-29" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Study</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Population</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Post- <BR>baseline&#x00a0;Visit</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Treatment</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change from <BR>baseline in&#x00a0;<BR>I-PSS <BR>Mean (SD)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">P-Value</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">US</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ITT</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Day 281</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">30&#x00a0;mg</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">day to 30&#x00a0;mg</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">71</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-3.3&#x00a0;(7.01)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">0.0002</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">0&#x00a0;mg</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">day to 30&#x00a0;mg</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">21</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-5.1&#x00a0;(4.93)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">0.0001</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Taiwan</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ITT</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Day 281</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">30&#x00a0;mg</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">day to 30&#x00a0;mg</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">50</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-4.9&#x00a0;(5.9)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&lt;0.0001</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">0&#x00a0;mg</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">day to 30&#x00a0;mg</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">23</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-8.0&#x00a0;(4.6)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&lt;0.0001</FONT></P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">130</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Safety</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the results of US<FONT CLASS="nobreak">-a</FONT> phase&#x00a0;III clinical, 108 subjects, or 39.4% of the 274 subjects, reported AEs. The administration of 15&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) and 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) per&#x00a0;day for 12&#x00a0;weeks was indicated to be safe and well tolerated. The incidence of AEs and SAEs were lower in the MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) compared to the placebo. There were no death or premature un<FONT CLASS="nobreak">-blinding</FONT> during the study period. The statistics of AEs, related AEs, or SAEs, of relevant subjects are indicated in the following table:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Phase&#x00a0;III Clinical Trials</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">MCS-2 (API-1) <BR>15</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;mg</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">MCS-2 (API-1) <BR>30&#x00a0;mg</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Placebo</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=42 <BR>N (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=156 <BR>N (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=76 <BR>N (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=274 <BR>N (%)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Adverse Event (AE)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">16<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT>(38.1)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">59<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT>(37.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">33&#x00a0;(43.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">108&#x00a0;(39.4)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Related AE</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT>(14.3)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">21<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT>(13.5)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">14&#x00a0;(18.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">41&#x00a0;(15.0)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Serious Adverse Event (SAE)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT>(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT>(0.6)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2&#x00a0;(2.6)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#x00a0;(1.1)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The parameter of correlation of relevant subjects are indicated in the following table:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Parameter</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">15&#x00a0;mg <BR>N = 42 <BR>n (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">30&#x00a0;mg <BR>N = 156 <BR>n (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">0&#x00a0;mg <BR>N = 76 <BR>n (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total <BR>N = 274 <BR>n (%)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subjects with &#x2265; 1 TEAE</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">16<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT>(38.1)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">59&#x00a0;(37.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">33&#x00a0;(43.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">108&#x00a0;(39.4)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Definitely</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Probably</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6&#x00a0;(3.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#x00a0;(3.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">9&#x00a0;(3.3)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Possibly</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6&#x00a0;(14.3)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">15&#x00a0;(9.6)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">11&#x00a0;(14.5)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">32&#x00a0;(11.7)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Not Related</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">10&#x00a0;(23.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">38&#x00a0;(24.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">19&#x00a0;(25.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">67&#x00a0;(24.5)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the results of TWN<FONT CLASS="nobreak">-a</FONT> phase&#x00a0;III clinical trials, 106 subjects, or 39.1% of the 271 subjects, reported AEs. The administration of 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) per&#x00a0;day for 12&#x00a0;weeks was indicated to be safe and well tolerated. The incidence of AEs and SAEs were lower in the MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) compared to the placebo. There were no death or premature un<FONT CLASS="nobreak">-blinding</FONT> during the study period. The statistics of AEs, related AEs, or SAEs, of relevant subjects are indicated in the following table:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Phase&#x00a0;III Clinical Trials</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">MCS-2 (API-1) <BR>30&#x00a0;mg</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Placebo</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=182 <BR>N (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=89 <BR>N (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=271 <BR>N (%)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Adverse Event (AE)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">67&#x00a0;(36.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">39&#x00a0;(43.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">106&#x00a0;(39.1)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Related AE</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">9&#x00a0;(4.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6&#x00a0;(6.7)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">15&#x00a0;(5.5)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">5Serious Adverse Event (SAE)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2&#x00a0;(1.1)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2&#x00a0;(2.2)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">4&#x00a0;(1.5)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The parameter of correlation of relevant subjects are indicated in the following table:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Parameter</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">30&#x00a0;mg <BR>N = 182 <BR>n (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">0&#x00a0;mg <BR>N = 89 <BR>n (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total <BR>N = 271 <BR>n (%)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subjects with &#x2265; 1 TEAE</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">67&#x00a0;(36.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">39&#x00a0;(43.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">106&#x00a0;(39.1)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Definitely</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1&#x00a0;(1.1)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2&#x00a0;(0.7)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Probably</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1&#x00a0;(1.1)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2&#x00a0;(0.7)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Possibly</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">4&#x00a0;(2.2)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6&#x00a0;(6.7)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">10&#x00a0;(3.7)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Not Related</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">59&#x00a0;(32.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">33&#x00a0;(37.1)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">92&#x00a0;(33.9)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The results of phase&#x00a0;III clinical trials indicated that MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) has fewer AEs and SAEs than that of placebo.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">131</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">According to the US<FONT CLASS="nobreak">-c</FONT> results of phase&#x00a0;III OLEs, MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgels showed excellent tolerability. No life<FONT CLASS="nobreak">-threatening</FONT> adverse events occurred during 40/52&#x00a0;weeks of taking MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgels.</P>
		<TABLE CLASS="No-Table-Style TableOverride-2" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Phase&#x00a0;III Clinical Trials (Long-term)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">MCS-2 (API-1) <BR>0-30&#x00a0;mg</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">MCS-2 (API-1) <BR>15-30&#x00a0;mg</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">MCS-2 (API-1) <BR>30&#x00a0;mg to <BR>30&#x00a0;mg</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=51 <BR>N (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=28 <BR>N (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=102 <BR>N (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=181 <BR>N (%)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Adverse Event (AE)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">25&#x00a0;(49.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#x00a0;(17.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">42&#x00a0;(41.2)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">72&#x00a0;(39.8)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Related AE</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6&#x00a0;(11.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6&#x00a0;(5.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12&#x00a0;(6.6)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Serious Adverse Event (SAE)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#x00a0;(5.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6&#x00a0;(5.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">9&#x00a0;(5.0)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">The parameter of correlation of relevant subjects are indicated in the following table:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Parameter</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">15&#x00a0;mg&#x2013;30&#x00a0;mg <BR>N = 28 <BR>n (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">30&#x00a0;mg&#x2013;30&#x00a0;mg <BR>N = 102 <BR>n (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">0&#x00a0;mg&#x2013;30&#x00a0;mg <BR>N = 51 <BR>n (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total <BR>N = 181 <BR>n (%)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subjects with &#x2265; 1 TEAE</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#x00a0;(17.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">42&#x00a0;(41.2)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">25&#x00a0;(49.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">72&#x00a0;(39.8)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Definitely</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">l&#x00a0;(2.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1&#x00a0;(0.6)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Probably</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1&#x00a0;(1.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2&#x00a0;(3.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#x00a0;(1.7)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Possibly</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#x00a0;(4.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#x00a0;(5.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">8&#x00a0;(4.4)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Not Related</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#x00a0;(17.9)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">39&#x00a0;(38.2)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">21&#x00a0;(41.2)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">65&#x00a0;(35.9)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Most AEs were unrelated to MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) as illustrated in the table above. In the group taking 30&#x00a0;mg<FONT CLASS="nobreak">-30</FONT>&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>), the occurrence of related AEs was all less than 1%. There were no related AEs reported in the group taking 15&#x00a0;mg<FONT CLASS="nobreak">-30</FONT>&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the results of TWN<FONT CLASS="nobreak">-c</FONT> Phase&#x00a0;III OLEs, MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgels showed excellent tolerability. No life<FONT CLASS="nobreak">-threatening</FONT> adverse events occurred during 40/52&#x00a0;weeks of taking MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgels.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Phase&#x00a0;III Clinical Trials (Long-term)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">MCS-2 (API-1) <BR>0-30&#x00a0;mg</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">MCS-2 (API-1) <BR>30&#x00a0;mg to <BR>30&#x00a0;mg</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">day</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=56 <BR>N (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=124 <BR>N (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">N=180 <BR>N (%)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Adverse Event (AE)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">39&#x00a0;(69.6)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">71&#x00a0;(57.3)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">110&#x00a0;(61.1)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Related AE</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#x00a0;(5.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6&#x00a0;(4.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">9&#x00a0;(5.0)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Serious Adverse Event (SAE)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2&#x00a0;(3.6)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#x00a0;(4.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">7&#x00a0;(3.9)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The parameter of correlation of relevant subjects are indicated in the following table:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Parameter</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">30&#x00a0;mg&#x2013;30&#x00a0;mg <BR>N = 124 <BR>n (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">0&#x00a0;mg&#x2013;30&#x00a0;mg <BR>N = 56 <BR>n (%)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total <BR>N = 180 <BR>n (%)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subjects with &#x2265; 1 TEAE</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">71&#x00a0;(57.3)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">39&#x00a0;(69.6)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">110&#x00a0;(61.1)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Definitely</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1&#x00a0;(0.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1&#x00a0;(0.6)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Probably</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1&#x00a0;(0.8)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0&#x00a0;(0.0)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1&#x00a0;(0.6)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Possibly</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">4&#x00a0;(3.2)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#x00a0;(5.4)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">7&#x00a0;(3.9)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Not Related</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">69&#x00a0;(55.6)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">39&#x00a0;(69.6)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">108&#x00a0;(60.0)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Most AEs were unrelated to MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) as illustrated in the table above. In the group taking 30&#x00a0;mg<FONT CLASS="nobreak">-30</FONT>&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>), the occurrence of related AEs was all less than 1%. There were no related AEs reported in the group taking 15&#x00a0;mg<FONT CLASS="nobreak">-30</FONT>&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">All identified serious adverse events have been determined to be &#x201c;not related&#x201d; to MCS<FONT CLASS="nobreak">-2</FONT>, with the exception of a pancreatitis event observed in the MCS<FONT CLASS="nobreak">-2-US-c</FONT> trial. In this instance, the pancreatitis lasted only three days, and the causality was assessed as &#x201c;possibly related&#x201d; but not &#x201c;definitely related,&#x201d; as the event was most likely attributable to Metformin, a medication used to treat diabetes mellitus. </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">132</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Overall summary</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The data of phase&#x00a0;III clinical trials indicated that after taking MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgels for 12&#x00a0;weeks, patients&#x2019; LUTS caused by BPH were improved as shown by the&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> results. When compared to the placebo group, despite the pivotal Phase&#x00a0;III clinical trial for MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) in the U.S.&#x00a0;failing to demonstrate a difference between treatment groups for the primary efficacy endpoint in the intent<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-treat</FONT> population, the remaining MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) groups, including one phase&#x00a0;III US open label extension study and two phase&#x00a0;III studies conducted in Taiwan, still demonstrated a statistically significant improvement (P value &lt; 0.05) based on meta<FONT CLASS="nobreak">-analysis</FONT>. However, the U.S.&#x00a0;FDA has expressed concerns regarding the reproducibility of some of the reported efficacy results for Study MCS<FONT CLASS="nobreak">-2</FONT>- TWN<FONT CLASS="nobreak">-a</FONT>. In addition, when compared with the baseline, there were significant decreases (P value &lt; 0.05) in the&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> at Day<FONT CLASS="nobreak"> </FONT>85, Day 169 and Day 281, which indicated long<FONT CLASS="nobreak">-term</FONT> decreases in the&#x00a0;I<FONT CLASS="nobreak">-PSS</FONT> scores after taking MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) softgels for up to 52&#x00a0;weeks.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">There were no deaths reported for either the phase&#x00a0;III clinical trials or the open<FONT CLASS="nobreak">-label</FONT> extension studies. In the phase&#x00a0;III clinical trials, the incidence of AEs was slightly higher in the placebo group when compared to the 15&#x00a0;mg and 30&#x00a0;mg MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>) treatment groups, respectively. The majority of reported AEs were considered unrelated to MCS<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-1</FONT>).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As the U.S.&#x00a0;FDA issued new statistical analysis standards in December&#x00a0;2016, we have to retain an outsourcing statistical team to re<FONT CLASS="nobreak">-create</FONT> our study data programs, tabulation model and analysis data model database for its Phase&#x00a0;III studies and evaluation of integrated safety and efficacy, in order to match with U.S.&#x00a0;FDA&#x2019;s electronic submission gateway, which resulted in a delay in our NDA submission in late 2021. This NDA was later withdrawn on November&#x00a0;30, 2022, and we currently do not have an NDA on file with the U.S.&#x00a0;FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">However, the U.S.&#x00a0;FDA also had concerns regarding the reproducibility of some of the reported efficacy results for Study MCS<FONT CLASS="nobreak">-2-</FONT><FONT CLASS="nobreak">TWN-a</FONT>. On February&#x00a0;23, 2024, we received a written response from the U.S.&#x00a0;FDA.&#x00a0;In the response, the U.S.&#x00a0;FDA noted again its concern that Study MCS<FONT CLASS="nobreak">-2-</FONT><FONT CLASS="nobreak">US-a</FONT> did not demonstrate a statistically significant difference between the drug and placebo in the primary efficacy endpoint and concerns regarding the treatment effect of questionable significance in the Study MCS<FONT CLASS="nobreak">-2-</FONT><FONT CLASS="nobreak">TWN-a</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">If the comparability is accepted by the U.S.&#x00a0;FDA, we will conduct additional Phase&#x00a0;III trial and Phase&#x00a0;I PK study in the US using API<FONT CLASS="nobreak">-2</FONT> to support our NDA re<FONT CLASS="nobreak">-submission</FONT>. If our comparability is not accepted by the U.S.&#x00a0;FDA, we will need to work with other API vendor to demonstrate the comparability that meet U.S.&#x00a0;FDA&#x2019;s requirements and would have to perform more clinical trials. In the event that we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be required to repeat the MCS<FONT CLASS="nobreak">-2</FONT> clinical trials using API<FONT CLASS="nobreak">-2</FONT>. For further details, see the risk factor titled &#x201c;<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs</FONT>&#x201d; on page 31.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">PCP</FONT></P>
		<P CLASS="H5" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;">Disease Overview</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Prostate cancer begins when cells in the prostate gland start to grow out of control. On a basic level, prostate cancer is caused by changes in the DNA of a normal prostate cell. Most gene mutations related to prostate cancer seem to develop during a man&#x2019;s life rather than having been inherited. In general, the more quickly prostate cells grow and divide, the more chances there are for mutations to occur. Therefore, anything that speeds up this process may make prostate cancer more likely. Although researchers do not know exact causes of prostate cancer, they have found some risk factors that might cause prostate cells to become cancer cells. Primary risk factors include age, race/ethnicity, geography, family history and gene changes. Factors with less clear effects on prostate cancer risk include diet, obesity, smoking, chemical exposures, inflammation of the prostate, sexually transmitted infections, and vasectomy. According to Frost&#x00a0;&amp; Sullivan, the global prevalence of prostate cancer increased from 10.0&#x00a0;million in 2017 to 11.2&#x00a0;million in 2020, representing a CAGR of 3.9%. The global prostate cancer market increased from US$9.7&#x00a0;billion in 2017 to US$12.6&#x00a0;billion in 2019, representing a CAGR of 9.1%. In addition, the prostate<FONT CLASS="nobreak">-specific</FONT> antigen abnormal population, or PSA abnormal population, representing men over 40&#x00a0;years old with a prostate<FONT CLASS="nobreak">-specific</FONT> antigen test value of 4.0 ng/ml or higher, is exposed to a high risk of prostate cancer. From 2015 to 2020, the total number of PSA abnormal populations in the U.S., Taiwan and China increased from 5.0&#x00a0;million to 5.3&#x00a0;million.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">133</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H5" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;">Current Standard Care</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">According to the U.S.&#x00a0;National Cancer Institute, several protective factors may decrease the risk of prostate cancer. A 10<FONT CLASS="nobreak">-year</FONT> study showed that the risk of prostate cancer was lower in men who had enough folate in their diets. Folate is a kind of vitamin B that occurs naturally in some foods, such as green vegetables, beans and orange juice. However, the risk of prostate cancer was increased in men who took 1&#x00a0;mg supplements of folic acid. Although some studies have shown that finasteride or dutasteride may lower the risk for prostate cancer, U.S.&#x00a0;FDA made a safety announcement in June&#x00a0;2011 and informed that 5<FONT CLASS="nobreak">-Ari</FONT> may increase the risk of a more serious form of prostate cancer (high<FONT CLASS="nobreak">-grade</FONT> prostate cancer). Both finasteride or dutasteride may cause side effects such as impotence, decreased libido, ejaculation disorders, breast disorders, rash, asthenia, headache, hypotension, postural hypotension, peripheral edema, dizziness, somnolence, dyspnea, rhinitis, abnormal ejaculation, gynecomastia, dizziness, pruritus, urticaria, localized edema, serious skin reactions, angioedema, and sexual function abnormal. In addition, men with a benign prostatic hyperplasia diagnosis and exposed to 5<FONT CLASS="nobreak">-alpha</FONT> reductase inhibitor had an increased association with cardiac failure. Currently, there is no drug available to prevent prostate cancer.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">Mechanism of Action</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Similar to MCS<FONT CLASS="nobreak">-2</FONT>, PCP works through its mechanism of antioxidant and anti<FONT CLASS="nobreak">-inflammatory</FONT>. PCP contains several types of patented pharmaceutical ingredients that reduce oxidative stress and inflammatory cytokines (IL<FONT CLASS="nobreak">-6</FONT>), both of which are main causes of many chronic inflammatory diseases.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Antioxidant Activity</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Free radicals are highly reactive chemicals that have the potential to harm cells. They are formed naturally in the human body and play an important role in many normal cellular processes. At high concentrations, however, free radicals can be hazardous to the human body and damage all major components of cells, including DNA, proteins, and cell membranes. The damage to cells caused by free radicals, especially the damage to DNA, may play a role in the development of cancer and other health conditions. Elevated rates of reactive oxygen species, or ROS, have been detected in almost all cancers, where they promote many aspects of tumor development and progression. A challenge for novel therapeutic strategies will be the fine<FONT CLASS="nobreak">-tuning</FONT> of intracellular ROS signaling to effectively deprive cells of ROS<FONT CLASS="nobreak">-induced</FONT> tumor<FONT CLASS="nobreak">-promoting</FONT> events, towards tipping the balance to ROS<FONT CLASS="nobreak">-induced</FONT> apoptotic signaling.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Antioxidants are also known as &#x201c;free radical scavengers.&#x201d; Therapeutic antioxidants may prevent early events in tumor development. Antioxidants are chemicals that interact with and neutralize free radicals and thus prevent free radicals from causing damages. The pharmaceutical ingredients contained in PCP are potent antioxidants as they modify cell growth and induce apoptosis, and possess distinctive antioxidative properties including the protection of important biomolecules such as DNA from free radicals and thus could decrease incidence rates of cancers.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Anti-inflammatory</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> Activity</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Inflammation involves the induction of complex, coordinated chemical signals and associated physiological processes following an injury that promote the &#x201c;healing&#x201d; of damaged tissues. Early responses include increases in vascular permeability and activation, together with the directed migration of leukocytes (neutrophils, monocytes and eosinophils) towards the site of injury, where the groundwork is being laid for the formation of a new extracellular matrix. The directional migration is mediated by secreted chemokines (such as IL<FONT CLASS="nobreak">-6</FONT>) that form a concentration gradient towards the site of inflammation. The extracellular matrix provides the structure upon which cells (fibroblasts and endothelial cells) can migrate and proliferate, regenerating new tissues and a vascular network. In the later stage of the inflammatory response, the macrophages are the dominant cell type, orchestrating and directing the healing process. Normally, inflammation is a self<FONT CLASS="nobreak">-limiting</FONT> process due to the production of anti<FONT CLASS="nobreak">-inflammatory</FONT> cytokines, which buffer the effect of pro<FONT CLASS="nobreak">-inflammatory</FONT> cytokines. The cytokine/chemokine pattern persisting at the inflammatory site is important in the development of chronic diseases. The longer the inflammation persists, the higher the risk of associated carcinogenesis.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">IL<FONT CLASS="nobreak">-6</FONT> is a prototypical cytokine with various biological effects on a wide variety of cells, which involves in the control of immune responses and inflammation. However, over production of IL<FONT CLASS="nobreak">-6</FONT> lead to severe disease complications. Therefore, as illustrated in the diagram below, IL<FONT CLASS="nobreak">-6-mediated</FONT> inflammation could be </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">134</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">a therapeutic target for prostate cancer, since anti<FONT CLASS="nobreak">-IL</FONT><FONT CLASS="nobreak">-6</FONT> receptor antibody administration suppressed tumor growth. PCP contains several types of patented pharmaceutical ingredients that can reduce IL<FONT CLASS="nobreak">-6</FONT> and thus address inflammation issues.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><IMG ALT="" SRC="tbar_005.jpg" STYLE="width:262.4px;max-width:100%;"></P>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">Notes:</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LPS means lipopolysaccharides which are large molecules consisting of a lipid and a polysaccharide that are bacterial toxins.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>BDS means botanical drug substance.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>BDP means botanical drug product.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LPS<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">#1</FONT> means 0.3 <FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;font-family:Times New Roman PS Std, serif;font-style:normal;font-weight:normal;">&#x00b5;</FONT>g/ml LPS/0.1% DMSO.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LPS<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">#2</FONT> means 0.3 &#x00b5;g/ml LPS/0.1% DMSO and 0.004% soybean oil.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>* means <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">P</FONT> &lt; 0.05, ** means <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">P</FONT> &lt; 0.01 and *** means <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">P</FONT> &lt; 0.001 compared with LPS<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">#1</FONT>.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT># means <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">P</FONT> &lt; 0.05, ## means <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">P</FONT> &lt; 0.01 and ### means <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">P</FONT> &lt; 0.001 compared with LPS<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">#2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purpose of this study is to evaluate the anti<FONT CLASS="nobreak">-inflammation</FONT> effect of BDS and BDP by measuring LPS<FONT CLASS="nobreak">-induced</FONT> IL<FONT CLASS="nobreak">-6</FONT> release. The data demonstrated that both BDS and BDP showed a concentration<FONT CLASS="nobreak">-dependent</FONT> inhibition of LPS<FONT CLASS="nobreak">-induced</FONT> IL<FONT CLASS="nobreak">-6</FONT> release. LPS is one of the main etiological factors in the pathogenesis of several diseases. LPS has been shown to stimulate host cells, including macrophages and fibroblasts, to produce cytokines. LPS can markedly increase the production of IL<FONT CLASS="nobreak"> </FONT>6, IL 8 and TNF <FONT CLASS="Symbol" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT> in differentiated THP 1 cells. Therefore, based on an important pro<FONT CLASS="nobreak">-inflammatory</FONT> cytokine, the IL<FONT CLASS="nobreak">-6</FONT> levels stimulated by LPS can be determined for the understanding of anti<FONT CLASS="nobreak">-inflammatory</FONT> activity of the PCP.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interleukin (IL)<FONT CLASS="nobreak">-6</FONT> is produced at the site of inflammation. IL<FONT CLASS="nobreak">-6</FONT> exerts stimulatory effects on T- and B<FONT CLASS="nobreak">-cells</FONT>, thus favoring chronic inflammatory responses. Although its expression is strictly controlled by transcriptional and posttranscriptional mechanisms, dysregulated continual synthesis of IL<FONT CLASS="nobreak">-6</FONT> plays a pathological effect on chronic inflammation and autoimmunity. BDS (25, 50 and 100 &#x00b5;g/ml) and BDP (35, 70 and 140 &#x00b5;g/ml) were used, respectively. The data demonstrated that both BDS and BDP showed a concentration<FONT CLASS="nobreak">-dependent</FONT> inhibition of LPS<FONT CLASS="nobreak">-induced</FONT> IL<FONT CLASS="nobreak">-6</FONT> release in differentiated THP<FONT CLASS="nobreak">-1</FONT> cells, suggesting an anti<FONT CLASS="nobreak">-inflammatory</FONT> activity of PCP.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Clinical Data</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Phase&#x00a0;I Clinical Studies</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Phase&#x00a0;I clinical studies of PCP focused on pharmacokinetics and clinical drug<FONT CLASS="nobreak">-drug</FONT> interaction studies.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Pharmacokinetics</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The study of pharmacokinetics of PCP was a randomized, balanced, single<FONT CLASS="nobreak">-dose</FONT>, two<FONT CLASS="nobreak">-treatment</FONT> (fed versus fasted) study in healthy male adult volunteers. The study was designed to evaluate the PK of PCP when the product was administered in the fed and fasted state. A total of 47 subjects were randomized to receive a single dose either in the fed (24 subjects) or fasted (23 subjects) state, and the PK parameters were evaluated and compared for the 2 groups of subjects. Relevant trials were initiated on April&#x00a0;22, 2015 and completed on April&#x00a0;24, 2017, with 23 subjects in fed group and 22 subjects in fasted group had completed the study.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">135</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As to the efficacy of PCP, the study compared serum active ingredient levels of five major biomarkers,<BR>PL, PF, PE, TC and BC (drug codes for carotenoid chylomicrons), in subjects taking PCP after a meal with those taking PCP on an empty stomach, and found that the proportion of active ingredient absorbed after a meal was better than after an empty stomach. Subjects were randomized to two groups in order to obtain their pre<FONT CLASS="nobreak">-prandial</FONT> or postprandial medication status. The results showed that the adverse effects were well tolerated irrespective of the timing of administration (postprandial or postprandial), although absorption rates were higher when PCP were taken after meals.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As to the safety profile of PCP, data indicated that 22 subjects, or 46.8%, of all subjects reported at least one treatment emergent adverse event, or TEAE, during the study. The fasted group has a higher TEAEs rate (60.9%) than the fed group (33.3%), but the rate of Aes was similar for the two groups. Overall, the most frequently reported TEAEs were headache (19.1%), upper respiratory tract infection (8.5%), back pain (4.3%) and nasopharyngitis (4.3%). The fasted group reported higher rate of headaches than the fed group. The two groups had similar rates for other TEAEs. There were no serious, severe, or life<FONT CLASS="nobreak">-threatening</FONT> TEAEs and no deaths. No TEAEs resulted discontinuation of the study. Other data such as the changes in blood pressure, heart rate, respiratory rate, weight and temperature were generally small and clinically insignificant.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Clinical </FONT><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Drug-Drug</FONT><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;"> Interaction</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The study of clinical drug<FONT CLASS="nobreak">-drug</FONT> interaction of PCP was an open<FONT CLASS="nobreak">-label</FONT>, fixed<FONT CLASS="nobreak">-sequence</FONT>, drug<FONT CLASS="nobreak">-drug</FONT> interaction study to evaluate the effect of PCP on the pharmacokinetics of 24 healthy male subjects. Relevant trials were initiated on May&#x00a0;20, 2018 and completed on September, 2018. A total of 24 subjects were enrolled in the study and 23 of them completed the study. One subject discontinued the study primarily due to a failure to meet compulsory criteria.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Since our in vitro drug<FONT CLASS="nobreak">-drug</FONT> interaction study conducted in the U.S. concluded that our drug substance may be an inducer of CYP3A4 and CYP2B6 based on the calculated R values (&lt; 0.9). U.S. FDA suggested that we further investigate the potential drug<FONT CLASS="nobreak">-drug</FONT> interactions by conducting a clinical drug<FONT CLASS="nobreak">-drug</FONT> interaction study using a sensitive index substrate. The sensitive index of substrate is midazolam for CYP3A4 and bupropion for CYP2B6, respectively. Therefore, we conducted such study to assess the effect of PCP on the PK of midazolam and bupropion following U.S. FDA&#x2019;s suggestion in 2018. The coadministration of PCP with midazolam and bupropion generally would not affect the efficacy of midazolam and bupropion, and concluded that PCP is not an inducer of both midazolam (CYP3A4) and bupropion (CYP2B6).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The primary objective of this clinical drug<FONT CLASS="nobreak">-drug</FONT> interaction study was to assess the effect of PCP on the PK of midazolam and bupropion in healthy male subjects. The results indicated that the peak exposure (Cmax) and the total exposure to midazolam were not significantly affected by the co<FONT CLASS="nobreak">-administration</FONT> of PCP.&#x00a0;The total and peak exposures of bupropion, midazolam, and their measured metabolites were not significantly altered after multiple daily doses of PCP.&#x00a0;The median time to peak concentration (Tmax) of bupropion, midazolam and their measured metabolites was not affected by multiple daily doses of PCP.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The safety data Indicated that the administration of MCS<FONT CLASS="nobreak">-2</FONT> alone or the co<FONT CLASS="nobreak">-administration</FONT> of MCS<FONT CLASS="nobreak">-2</FONT>, midazolam and bupropion was generally tolerated by healthy male subjects in this study. Seven of 24 subjects (29.2%) treated with midazolam, bupropion, and/or PCP experienced a total of 10 TEAEs. Six of 24 subjects (25.0%) treated with midazolam or bupropion experienced seven TEAEs. One of 24 subjects (4.2%) treated with PCP alone experienced two TEAEs. One of 23 subjects treated with midazolam/bupropion and PCP experienced one TEAE.&#x00a0;The most frequently reported TEAEs were somnolence and others included headache, dry skin, macule, skin irritation and cough. However, 30% of TEAES were assessed as unrelated to the study. All TEAEs were assessed as mild in severity and fully recovered or resolved at the end of the study. No TEAE resulted discontinuation of the study and no SAEs or deaths were reported.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;">Overall summary and conclusions</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">According to the phase&#x00a0;I clinical studies, the administration of a single oral PCP was well<FONT CLASS="nobreak">-tolerated</FONT> among 24 subjects in both the fed and fasted states. Subjects absorbed active ingredients of PCP better when they took PCP after meals. The administration of MCS<FONT CLASS="nobreak">-2</FONT> alone or the co<FONT CLASS="nobreak">-administration</FONT> of MCS<FONT CLASS="nobreak">-2</FONT>, midazolam and bupropion was generally tolerated by healthy male subjects in this study. The coadministration of PCP with midazolam and bupropion generally would not affect the efficacy of midazolam and bupropion.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">136</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Phase&#x00a0;II Clinical Studies</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Phase&#x00a0;II clinical study of PCP was a double<FONT CLASS="nobreak">-blind</FONT>, randomized, placebo<FONT CLASS="nobreak">-controlled</FONT>, parallel one, with a group of 702 subjects for a two<FONT CLASS="nobreak">-year</FONT> treatment of three arms, i.e. 15&#x00a0;mg PCP per&#x00a0;day, 30&#x00a0;mg PCP per&#x00a0;day, and placebo. As approved by TFDA, phase&#x00a0;II clinical trials were initiated in November&#x00a0;2014. 20 medical centers in Taiwan were involved. The 702 subjects were men with high levels of prostate specific antigen, or PSA.&#x00a0;As of the data of this prospectus, phase&#x00a0;II clinical trials are still in process and the P value and conclusions as to the statistical significance are not available. Our PCP Phase II study enrollment and treatment phase using API<FONT CLASS="nobreak">-1</FONT> is now in the source data verification (SDV) stage, which may take an additional year or more to complete. After completion of the SDV stage, we will conduct the necessary statistical analysis. While PCP is still in the SDV stage, we are working with the U.S. FDA to establish the comparability of the API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. To date, we have not had any discussions with the TFDA regarding the unavailability of API<FONT CLASS="nobreak">-1</FONT>. We will discuss the statistical results of the PCP using API<FONT CLASS="nobreak">-2</FONT> with Taiwan regulator and proceed with the Phase III PCP study if the U.S. FDA accepts such results and determines that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable. The PCP shall not proceed to Phase III until the U.S. FDA accepts the results and determines that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable. Based on our prior communications with the TFDA, the Chemistry, Manufacturing, and Controls (&#x201c;CMC&#x201d;) and study design for the product are consistent between the U.S. and Taiwan, encompassing two pivotal studies and two open<FONT CLASS="nobreak">-label</FONT> extension studies. The protocol for the Phase III clinical trials was approved by the U.S. FDA in December 2009 and subsequently approved by the TFDA in February 2010. Therefore, we believe the TFDA will give due consideration to the comments provided by the U.S. FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We have completed the CMC documentation on the active pharmaceutical ingredient<FONT CLASS="nobreak">-2</FONT> (API<FONT CLASS="nobreak">-2</FONT>) and a plan to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and submitted it to the U.S. FDA on October<FONT CLASS="nobreak"> </FONT>16, 2024, and are awaiting feedback from the U.S. FDA. As of this date, the Company is still in the process of providing the information required by the U.S. FDA and has not yet successfully demonstrated the comparability of API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We are currently collaborating with a supplier to prepare the API<FONT CLASS="nobreak">-2</FONT> CMC documents required by the U.S. FDA. Should the FDA concur that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API<FONT CLASS="nobreak">-2</FONT>. If the U.S. FDA does not agree that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, we will continue to research additional API sources based on our own patent, to pursue additional outsourcing API vendors, and to follow U.S. FDA&#x2019;s guidance for demonstrating comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> to the U.S. FDA&#x2019;s satisfaction. If the U.S. FDA does not agree that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, we will continue to research additional API sources based on our own patent, to pursue additional outsourcing API vendors, and to follow U.S. FDA&#x2019;s guidance for demonstrating comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> to the U.S. FDA&#x2019;s satisfaction. In the event that we are unable to establish comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>, we will be required to repeat the PCP clinical trials using API<FONT CLASS="nobreak">-2</FONT>. For further details, see the risk factor titled &#x201c;<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">If we are unable to identify a supplier capable of producing API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> that is sufficiently comparable to API</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-1</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, we will be required to repeat our clinical trials for MCS</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-2</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> and PCP, which could significantly delay our product development efforts and result in increased costs</FONT>&#x201d; on page 31.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:11pt;margin-top:11pt;">Material Communications</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As of the date of this prospectus, we have not received any relevant regulatory authority&#x2019;s concerns or objections to our clinical development plans and no material unexpected or adverse changes have occurred since the date of issue of relevant regulations for PCP.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">IC</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:10pt;margin-top:10pt;">Disease Overview</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the definition adopted by American Urological Association, interstitial cystitis/bladder pain syndrome, or IC/BPS, refers to a bladder pain disorder that is often associated with voiding symptomatology and other systemic chronic pain disorders. The exact cause of IC/BPS is still not clear. Pain (including sensations of pressure and discomfort) is the hallmark symptom of IC/BPS.&#x00a0;The prototypical IC/BPS patient also may present with marked urinary urgency and frequency. IC/BPS is most commonly diagnosed in individuals over<FONT CLASS="nobreak"> </FONT>40, although the diagnosis may be delayed depending upon the index of suspicion for the disease, and the criteria used to diagnose it. IC/BPS&#x00a0;most often affects women and can have a long<FONT CLASS="nobreak">-lasting</FONT> impact on quality of life. Historically, IC/BPS in men has been considered relatively unusual with a female to male ratio of 10:1. However, uncontrolled clinical series over the past two decades have suggested the incidence of male IC/BPS may be higher than previously observed.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">137</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Current Standard Care</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Current standard care for IC/BPS include: (i)&#x00a0;behavioral/non<FONT CLASS="nobreak">-pharmacologic</FONT> treatments; (ii)&#x00a0;oral medications; (iii)&#x00a0;intravenous injection and intravesical instillations; (iv)&#x00a0;nerve stimulation; and (v)&#x00a0;surgeries including fulguration, resection, bladder and augmentation. Intravesical instillations refers to a procedure where the prescription medication is placed into patients&#x2019; bladders through a thin, flexible tube inserted through the urethra. Nerve stimulation techniques include transcutaneous electrical nerve stimulation, which may relieve pelvic pain and, in some cases, reduce urinary frequency; and sacral nerve stimulation, which may reduce urinary urgency but cannot relieve pains. Since surgery is irreversible and life<FONT CLASS="nobreak">-altering</FONT>, it is rarely used to treat IC/BPS.&#x00a0;While some patients have complete or near<FONT CLASS="nobreak">-complete</FONT> symptom resolution after surgery, others have poor outcomes including persistent pain (even if the bladder is removed), complications or new symptoms with lifelong significant bother. Among all the treatment categories stated above, intravenous injection and intravesical instillations are comparatively effective methods to treat IC/BPS.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:12pt;margin-top:12pt;">Clinical Data</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Preclinical Studies</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Data from our preclinical studies show that the micelles have favorable characteristics and stability. IC micelles with a target size of micromulsion under 100nm were developed for injection. We adopt a microemulsion technique of sonicating the mixture of substrate and surfactants and filtering through a sterilized 0.22<FONT CLASS="nobreak">-um</FONT> membrane filter to obtain micelle. As a result, the mixture passed through a sterilized 0.22<FONT CLASS="nobreak">-um</FONT> membrane filter to cut the bigger particles of micelle into the size of approximately 7.5 nm and 10.5 nm, respectively, with the narrow particle size distribution of low polydispersity of 0.033. The average size of micelle, based on the dynamic light scattering, or the DLS, and transmission electron microscopy analyses, is approximately 7.5 nm and 10.5 nm, respectively. The particle size distribution is narrow with low polydispersity of 0.033 being shown, indicating that a highly homogeneous microemulsion, the transparent or semi<FONT CLASS="nobreak">-transparent</FONT> thermodynamically stable emulsion formed by two immiscible liquids, oil and water in the presence of surfactant or co<FONT CLASS="nobreak">-surfactant</FONT>, has been successfully prepared. The zeta potential value of micelle implies a good stability of microemulsion. During the storage at 4&#x00b0;C or 25&#x00b0;C for three&#x00a0;months or the heating at 100&#x00b0;C for four&#x00a0;hours, only a minor difference in particle size (7.0&#x00a0;&#x2013;&#x00a0;7.5 nm) was shown for micelle by the DLS analysis, demonstrating a high stability of this microemulsion.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">COMMERCIALIZATION</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Commercialization strategies</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are establishing a strong sales and marketing team dedicated to the commercialization of our pipeline drug candidates, especially for the commercialization of MCS<FONT CLASS="nobreak">-2</FONT>. We expect our sales and marketing team in Taiwan to have employees with rich experience. We will also actively seek for cooperation with local pharmaceutical companies in other territories in order to benefit from their sales and marketing network. There will be a senior product manager who is familiar with MCS<FONT CLASS="nobreak">-2</FONT> and we expect he or she will be primarily responsible for strategies&#x2019; formulation. The head of our sales and marketing department, senior manager<FONT CLASS="nobreak">-level</FONT> personnel, most of the regional managers and the preliminary sales team are in place as of the date of this prospectus. In the U.S., we retained a local company to conduct the value research survey among urologists and payers and obtained positive feedbacks.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Leveraging the expertise and industry connections of our team, we will market the products primarily through a physician<FONT CLASS="nobreak">-targeted</FONT> marketing strategy, focusing on direct and interactive communication with key opinion leaders and physicians in the respective therapeutic areas to promote the differentiating clinical aspects of our products. Such marketing efforts are expected to commence several&#x00a0;months before the expected approval for the commercialization of a drug candidate. We will also actively organize academic conferences and seminars to publicize the clinical data and research results in relation of our drug candidates in order to raise our brand awareness and recognition. We are also pursuing licensing relationships with global pharmaceutical companies to promote and market our products worldwide.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Pricing Strategy</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We primarily consider two factors when formulating our pricing strategies: (i)&#x00a0;the overall impact of our drug candidates in the international market; and (ii)&#x00a0;the market positioning of our drug candidates. When considering the first factor, if our drug candidate is expected to be marketed internationally, we will fully consider the global market </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">138</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">price rather than the market price in a single region. When considering the second factor, we will evaluate the overall costs of production, market demand, targeted patients and competitive advantages in order to decide the proper position of our drug candidate.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We plan to position MCS<FONT CLASS="nobreak">-2</FONT> as a high<FONT CLASS="nobreak">-end</FONT> product in the BPH/LUTS pharmaceuticals market. In Taiwan, we expect to sell MCS<FONT CLASS="nobreak">-2</FONT> through our own marketing team and we have consulted with the Bureau of National Health Insurance Ministry of Health and Welfare, or Taiwan NHI, regarding the pricing of MCS<FONT CLASS="nobreak">-2</FONT>. Based on our preliminary communications, Taiwan NHI can determine the payment of new drugs developed in Taiwan by means of &#x201c;cost<FONT CLASS="nobreak">-plus</FONT> pricing&#x201d; or &#x201c;market reference price.&#x201d; Therefore, we expect that in the first two&#x00a0;years after the launch of MCS<FONT CLASS="nobreak">-2</FONT> in Taiwan, MCS<FONT CLASS="nobreak">-2</FONT> might not be immediately included in the reimbursement list and patients need to purchase it at their own costs. In other territories, since we plan to cooperate with local pharmaceutical companies for the sale of MCS<FONT CLASS="nobreak">-2</FONT>, we will make necessary adjustments depending on the pricing of comparable drugs and the local medical insurance payment level in each specified target market. In particular, our consultant in U.S. along with her commercial strategy team have conducted a price sensitivity analysis based on updated market predictions. We plan to collaborate with a renowned U.S. pharmaceutical company to distribute our MCS<FONT CLASS="nobreak">-2</FONT> in U.S. market.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LICENSE AND COLLABORATION AGREEMENTS</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Chhak License Agreement</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#x00a0;2016, we entered into a pharmaceutical license agreement with a Cambodian corporation, Chhak Kamponngsaom Sez Co., Ltd., or the &#x201c;Chhak License Agreement.&#x201d; Under the Chhak License Agreement, we granted Chhak Kamponngsaom Sez Co., Ltd., or Chhak, exclusive sale and marketing rights of MCS<FONT CLASS="nobreak">-2</FONT> in Cambodia, and Chhak agreed not to sub<FONT CLASS="nobreak">-license</FONT> any rights related to MCS<FONT CLASS="nobreak">-2</FONT> without our prior written consent. Chhak also agreed to use the best efforts to help us obtain necessary regulatory approvals for MCS<FONT CLASS="nobreak">-2</FONT> and to promote and enhance the sale of MCS<FONT CLASS="nobreak">-2</FONT> in Cambodia. We agreed to provide Chhak with information related to MCS<FONT CLASS="nobreak">-2</FONT> as may be known or possessed by us and as may be reasonably necessary for the sale and marketing of MCS<FONT CLASS="nobreak">-2</FONT> in Cambodia. We would be Chhak&#x2019;s sole manufacturer and supplier of MCS<FONT CLASS="nobreak">-2</FONT>. In addition, we owned all the intellectual property rights of MCS<FONT CLASS="nobreak">-2</FONT> or any improvements to MCS<FONT CLASS="nobreak">-2</FONT> and we both agreed to maintain the other party&#x2019;s confidential information in confidence.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Chhak License Agreement, Chhak should pay license fees with a total amount of US$0.25&#x00a0;million In addition, upon the regulatory approval of MCS<FONT CLASS="nobreak">-2</FONT> in Cambodia, Chhak should pay us a royalty of 25% of its net sales of MCS<FONT CLASS="nobreak">-2</FONT> every six&#x00a0;months. Chhak should also deliver to us a written report showing its computation of royalties due under this agreement. We reserved the rights to review Chhak&#x2019;s book, records and other supporting data as may be necessary to verify Chhak&#x2019;s computation of royalties.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We should indemnify and hold harmless Chhak, from and against any and all claims, losses, costs, damages, fees and expenses arising out of or in connection with intellectual property right infringement. Chhak agreed to indemnify, held harmless and defended us (including our directors, officers, employees and agents) from and against any and all losses we became legally obligated to pay due to any claim against Chhak (i)&#x00a0;arising out of Chhak&#x2019;s breach of this agreement; or (ii)&#x00a0;for any product liability, liability for death, illness, personal injury or other liabilities under any laws re regulations, to the extent that such claims are due to reasons caused by Chhak.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Chhak would have the right to terminate this agreement in its entirety by providing us with 60&#x00a0;days prior written notice. We would have the right to terminate this agreement if (i)&#x00a0;Chhak experienced a change of control; (ii)&#x00a0;the quantity of MCS<FONT CLASS="nobreak">-2</FONT> sold by Chhak was diverted to other markets; (iii)&#x00a0;we reasonably determined that Chhak was unable to maintain the quality of MCS<FONT CLASS="nobreak">-2</FONT>; (iv)&#x00a0;Chhak was in material breach of its duties of non<FONT CLASS="nobreak">-sublicensing</FONT> and confidentiality or violated the consensus that we were the sole manufacture and provider of MCS<FONT CLASS="nobreak">-2</FONT>, or (v)&#x00a0;Chhak became insolvent. We would not be held liable for any losses Chhak might incur if we terminated the agreement based on any of the aforementioned five reasons. In case either party breached the agreement, the non<FONT CLASS="nobreak">-breaching</FONT> party under the Chhak License Agreement would have the right of termination but should provide written notice to the breaching party to cure such breach, and no party should be relieved of any obligations incurred prior to such termination.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In case either party breached the agreement, the non<FONT CLASS="nobreak">-breaching</FONT> party under the Chhak License Agreement would be able to terminate this agreement but should provide a written notice to the breaching party who would be given a chance to cure such breach.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">139</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Taizhou Collaboration Framework Agreement</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December 21,&#x00a0;2018, we entered into a collaboration framework agreement, or the &#x201c;2018 Taizhou Agreement,&#x201d; with Taizhou High<FONT CLASS="nobreak">-tech</FONT> Industrial Park Management Committee, or the &#x201c;Taizhou High<FONT CLASS="nobreak">-tech</FONT> Committee,&#x201d; and Taizhou Infrastructure Investment Group Co., Ltd., pursuant to which Taizhou High<FONT CLASS="nobreak">-tech</FONT> Committee agreed to grant up to (i)&#x00a0;40&#x00a0;mu (approximate 26,666.66 sq.m.) industrial land to us with a favorable price of RMB0.4&#x00a0;million per mu, (ii) 20 mu commercial land to us with a favorable price of RMB4.08&#x00a0;million per mu and (iii) 1,500 mu industrial land to us subject to further negotiation. Under the 2018 Taizhou Agreement, we might also receive several government grants and subsidies when we met prerequisites as agreed. 2018 Taizhou Agreement does not specify the term and termination provision. We would conduct projects under the 2018 Taizhou Agreement primarily through our subsidiary in China, Innovative Biotech Co., Ltd., which was established in 2019 pursuant to the 2018 Taizhou Agreement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On September 12,&#x00a0;2019, based on the 2018 Taizhou Agreement, we entered into an investment cooperation agreement with the successor of the Taizhou High<FONT CLASS="nobreak">-tech</FONT> Committee, or the 2019 Taizhou Agreement, which further specified details relating to projects related to MCS<FONT CLASS="nobreak">-2</FONT> manufacturing facilities with no material deviation from the 2018 Taizhou Agreement. 2019 Taizhou Agreement does not specify the term and termination provision. In December 2019, under the terms and conditions of the Land Use Right Agreement with the Taizhou Resources Bureau, Innovative Biotech Co., Ltd. obtained the use right over 26,680 square meters of industrial land in Taizhou by paying a consideration of RMB16.5<FONT CLASS="nobreak"> </FONT>million with tax included. According to such Land Use Right Agreement, Innovative Biotech Co., Ltd. was obligated to commence construction of the Factory Project by May<FONT CLASS="nobreak"> </FONT>28, 2020, and conclude construction by November<FONT CLASS="nobreak"> </FONT>28, 2022, as well as to meet several requirements on the specifics of the construction, including, but not limited to, the amount of the total investment, investment amount per mu, proportion of land dedicated to non<FONT CLASS="nobreak">-production</FONT> facilities, plot ratio, and building density. As of the date of this prospectus, the 26,680 square meter industrial land we acquired for the factory project have been seized by the Taizhou Court. For risks associated with the legal proceeding, see more details under &#x201c;Risk Factors&#x00a0;&#x2014;&#x00a0;Risks Related to Our Business and Industry&#x00a0;&#x2014;&#x00a0;We have been involving in legal proceedings in the ordinary course of our business, and are currently involved in active legal proceedings.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MANUFACTURING AND QUALITY CONTROL</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are preparing for commercial<FONT CLASS="nobreak">-scale</FONT> manufacturing capabilities to ensure large scale delivery of high<FONT CLASS="nobreak">-quality</FONT> products. We have already built Yilan Letzer Pharmaceutical Factory with an aggregate GFA of approximately 1,944 sq.m. Our manufacturing team consists of three&#x00a0;employees as of the date of this prospectus. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have in<FONT CLASS="nobreak">-house</FONT> capabilities to manufacture our drug candidates, and we employ advanced technology to produce our core drug candidate MCS<FONT CLASS="nobreak">-2</FONT>. Yilan Letzer Pharmaceutical Factory intends to adopt PIC/S GMP standard of production and was authorized by TFDA to conduct drug manufacturing, packaging, laboratory operations, transportation, and storage. We expect our new manufacturing facilities in Yilan and Taizhou will be in compliance with PIC/S GMP standards and have sufficient capacity to meet our commercial manufacturing needs in the foreseeable future.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following flowchart indicates our general process of drug manufacturing we designed for future production:</P>
		<P CLASS="Text_ind_center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;"><IMG ALT="" SRC="tflow_003.jpg" STYLE="width:519.6800000000001px;max-width:100%;"></P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">140</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our Quality Assurance team performs the quality control function to oversee the quality of our facilities and our products, as well as the quality systems in research and development, manufacturing and commercialization of drug candidates and potential future commercial products. The tasks for quality control include (i)&#x00a0;ensuring quality control throughout the manufacturing process, including specification of the drug substance and the drug product, testing of raw materials, and product quality assessments; (ii)&#x00a0;establishing a quality assurance system across the entire business, including employee training programs, audits of various business segments and product manufacturing; and (iii)&#x00a0;validation of facilities and equipment, which includes laboratory tests to verify that a particular process, method, program, equipment or material works properly.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SUPPLIERS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We procure raw materials and equipment for the development and manufacture of our drug candidates from industry<FONT CLASS="nobreak">-leading</FONT> and highly reputable manufacturers and suppliers around the world. For the&#x00a0;years ended December<FONT CLASS="nobreak"> </FONT>31, 2022 and 2023 and the six months ended June<FONT CLASS="nobreak"> </FONT>30, 2024, our purchases from our five largest suppliers in the aggregate accounted for approximately 71.5%, 78.2%, and 79.5% of our total purchases, respectively. Our purchases mainly include raw materials, third<FONT CLASS="nobreak">-party</FONT> contracting services for research and development purposes, machines and equipment, clinical trials, project construction and administrative services. When choosing our suppliers, we consider their qualification and reputation, their response speed in general, and the proposed pricing. There are several raw material suppliers and third<FONT CLASS="nobreak">-party</FONT> contracting services we can choose from, providing alternatives if the suppliers that the company works with are unable to provide the material or service we need. However, the stability of the raw material supplier is critical to our business. We must assess the quality of the raw materials before selecting an outsourcing supplier. Changing suppliers and sourcing new materials will necessitate additional clinical studies and potentially regulatory approval, significantly impacting our business and potentially delaying our regulatory approval process. To initiate the additional Phase III and Phase I PK studies, it is necessary to first identify a supplier for the raw materials required to produce API<FONT CLASS="nobreak">-2</FONT>. We are currently collaborating with one supplier to prepare the CMC documents mandated by the U.S. FDA. Should the FDA concur that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API<FONT CLASS="nobreak">-2</FONT>. We will only be able to proceed with the Phase III PCP study after the U.S. FDA accepts such results and determines that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable. If there is any possibility that FDA does not agree that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are comparable, we will work with another supplier who is able to meet the comparability. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We used one supplier for API<FONT CLASS="nobreak">-1</FONT>, which was the basis for our now withdrawn NDA. The supplier of API<FONT CLASS="nobreak">-1</FONT> sold a parcel of its land and is in the process of relocating and reconstructing its manufacturing facility, and as a result, API<FONT CLASS="nobreak">-1</FONT> is currently not available to us and the supplier of API<FONT CLASS="nobreak">-1</FONT> withdrew its consent for us to reference their Drug Master File on file with the U.S. FDA. We have been conducting further research and development on MCS<FONT CLASS="nobreak">-2</FONT> and identified an additional source for the botanical drug substance API<FONT CLASS="nobreak">-2</FONT>. API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> are similar drug substances covered by the same patent owned by us; however, because they are sourced from raw materials manufactured in different locations, the U.S. FDA required us to do the comparability study. Only when FDA concur that API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> is comparable, we are able to conduct the Phase I PK study and Phase III clinical trial with this API<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The U.S. FDA provided written responses on February<FONT CLASS="nobreak"> </FONT>23, 2024. In the response, the U.S. FDA questioned whether one new Phase study with API<FONT CLASS="nobreak">-2</FONT> would be sufficient, noting again its concern that Study MCS<FONT CLASS="nobreak">-2-US-a</FONT> did not demonstrate a statistically significant difference between the drug and placebo in the primary efficacy endpoint and concerns regarding the treatment effect of questionable significance in the Study MCS<FONT CLASS="nobreak">-2-TWN-a</FONT>. The U.S. FDA also commented that it will need more information on how we would demonstrate comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT> and that its determination of whether our original Phase III studies with API<FONT CLASS="nobreak">-1</FONT> would have utility, based upon the quality of support, for a convincing link between products containing API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>. The U.S. FDA provided comments on our proposed Phase III study, and we are finalizing the protocol for submission to the U.S. FDA. In addition, we are in the process of finalizing the PK study protocol per U.S. FDA requirements and hope to satisfy the U.S. FDA of the comparability between API<FONT CLASS="nobreak">-1</FONT> and API<FONT CLASS="nobreak">-2</FONT>.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">COMPETITION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our industry is highly competitive, rapidly evolving and subject to significant change. Although we believe that our core competencies in the identification, research and development of innovative therapies and our management team&#x2019;s regulatory and commercialization expertise provide us with distinct competitive advantages, we face significant competition from companies of all sizes around the world, including major and specialty pharmaceutical companies, generic drug companies, academic institutions, government agencies and research institutions.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">141</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Many of our competitors have significantly greater resources, including greater access to capital, technical capabilities and human resources, as well as more experience in the development and regulatory approval process than we have. Mergers and acquisitions in our industry may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunities could be reduced or eliminated if our competitors develop or market novel therapies or other products that are more effective, safer or less costly than our current or future product candidates, or obtain regulatory approval for their products more rapidly than we may obtain approval for our product candidates.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OUR HONORS AND AWARDS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We have received numerous honors and a wealth of awards for our innovative drug development achievements. From 2004 to 2020, we were consecutively endorsed the Symbol of National Quality (SNQ) by the Institute for Biotechnology and Medicine Industry in Taiwan. As early as 2008, our core drug candidate, MCS<FONT CLASS="nobreak">-2</FONT>, was recorded in <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Physician&#x2019;s Desk Reference 2009 (63</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;font-size:58%;vertical-align:super;">rd</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> Edition)</FONT>, a widely used source of drug information by American physicians and patients. The following table sets forth significant honors and awards we have received over the&#x00a0;years:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Honor</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Award Name</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Issuing Authority</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Year</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">National Pharmaceutical Science and Technology Research and Development Award</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Food and Drug Administration, Department of Health, Taiwan</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2009</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-34" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Biotech and New Pharmaceuticals Company</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Ministry of Economic Affairs, Taiwan</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2010</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-35" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Taipei Biotechnology Award&#x00a0;&#x2013;&#x00a0;Invention and Creation Award</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Taipei Municipal Government, Taiwan</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2012</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-36" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:4pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">National Industrial Innovation Award</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:4pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Ministry of Economic Affairs, Taiwan</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:4pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:4pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2015</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-34" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Biotech and New Pharmaceuticals Company</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Ministry of Economic Affairs, Taiwan</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2015</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Drug Research and Development Science and Technology Award</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Department of Health and Ministry of Economic Affairs, Taiwan</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2016</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-35" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Drug Research and Development Science and Technology Award</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Department of Health and Ministry of Economic Affairs, Taiwan</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2017</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-34" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">National Invention and Creation Award</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Ministry of Economic Affairs, Taiwan</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2018</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INTELLECTUAL PROPERTY</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Intellectual property rights are important to the success of our business. We actively seek patent protection for our drug candidates in Taiwan and other major jurisdictions worldwide, and file additional patent applications, when appropriate, to cover improvements to our technologies. We rely on a combination of patents, trademarks and trade secrets as well as employee and third<FONT CLASS="nobreak">-party</FONT> confidentiality agreements to safeguard our intellectual property.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As of the date of this prospectus, we were not involved in any proceedings in respect of, and we had not received notice of any claims of infringement of, any intellectual property rights that may be threatened or pending, in which we may be a claimant or a respondent.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Patents</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">All of our patents are self<FONT CLASS="nobreak">-developed</FONT> based on our in<FONT CLASS="nobreak">-house</FONT> R&amp;D capabilities. We either own all material patents for each of our product candidates or have filed relevant patent applications with the authorities. The term of individual patents depends on the legal term for patents in the jurisdictions in which they are granted. The following table indicates our key invention patents which have all been granted as of the date of this prospectus: </P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Type</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Territory</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Period of Validity</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Taiwan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">May&#x00a0;1, 2016 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">South Korea</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">January&#x00a0;18, 2017 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Singapore</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">April&#x00a0;13, 2017 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT> (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">United States</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">January&#x00a0;10, 2017 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">142</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Type</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Territory</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Period of Validity</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(2)</FONT> (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">United States</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">March&#x00a0;28, 2017 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Japan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">June&#x00a0;30, 2017 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Malaysia</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">January&#x00a0;30, 2018 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Philippines</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">June&#x00a0;20, 2018 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Vietnam</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">December<FONT CLASS="nobreak"> </FONT>4, 2020 to December<FONT CLASS="nobreak"> </FONT>9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Russia</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">March&#x00a0;29, 2018 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Indonesia</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">July&#x00a0;10, 2018 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Saudi Arabia</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">September&#x00a0;16, 2018 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">China</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">December&#x00a0;18, 2018 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Canada</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">April&#x00a0;2, 2019 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Macao</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">May&#x00a0;9, 2019 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Israel</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">July&#x00a0;1, 2019 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Hong&#x00a0;Kong</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">January&#x00a0;17, 2020 to December&#x00a0;9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">India</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">February<FONT CLASS="nobreak"> </FONT>16, 2024 to December<FONT CLASS="nobreak"> </FONT>9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Thailand</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">August<FONT CLASS="nobreak"> </FONT>23, 2023 to December<FONT CLASS="nobreak"> </FONT>9, 2034</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-37" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Invention &#x2013; Composition of matter (medical grade ingredients)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">European</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">April<FONT CLASS="nobreak"> </FONT>10, 2024 to December<FONT CLASS="nobreak"> </FONT>9, 2034</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;margin-top:8pt;">Notes:</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The patent number is 9,539,219 B2, and the patent is pharmaceutical composition of carotenoid micelle. IC is covered by this patent with the compositions comprising a micelle and a carotenoid, suspended in an aqueous solution and suitable for intravenous administration.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The patent number is 9,603,811 B2, and the patent is pharmaceutical composition of carotenoid with chylomicron technology. MCS<FONT CLASS="nobreak">-2</FONT> and PCP are both covered by this patent for oral administration. This invention covers pharmaceutical compositions comprising carotenoid with chylomicron technology. The bioavailability of the carotenoid with chylomicron technology in the pharmaceutical composition is higher than the bioavailability of free carotenoid.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Trade secrets</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to patents, we also rely upon unpatented trade secrets and know<FONT CLASS="nobreak">-hows</FONT> and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary technology and information, in part, by entering into confidentiality agreements with our senior management and certain key members of our research and development team and other employees who have access to trade secrets or confidential information about our business.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Trademarks and domain names</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, we have 58 trademarks in 46 territories.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, we have registered the following domain names: hebiotech.com and healtheverbiotech.com.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">143</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LICENSES, PERMITS AND APPROVALS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, we have obtained all requisite licenses, permits and approvals from relevant authorities that are material to our pharmaceutical manufacturing operations. The table below sets forth the relevant details of the material licenses we hold for our operation in Taiwan:</P>
		<TABLE CLASS="No-Table-Style TableOverride-2" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 20.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">License</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">/</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Permit</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Holder</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Issuing <BR>Authority</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Issue Date</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Expiration <BR>Date</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-42" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 20.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pharmaceutical Manufacturing License</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd., Yilan Letzer Pharmaceutical Factory</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Department of Health, Taiwan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">October&#x00a0;23, 2014</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#x2014;<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 20.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Factory Registration Certificate</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd., Yilan Letzer Pharmaceutical Factory</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Yilan County Government, Taiwan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 14.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">August&#x00a0;31, 2018</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#x2014;<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>No specific expiration date. </P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EMPLOYEES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, we had 31 employees in total. The following table sets forth the number of our employees categorized by function as of the date of this prospectus: </P>
		<TABLE CLASS="No-Table-Style TableOverride-2" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Function</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">% of Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Management</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25.8</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Auditing Office</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.2</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Information Center</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.2</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">R&amp;D and Manufacturing Department</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">48.4</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financial and Accounting Department</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12.9</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Business Operation and Development Department</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.5</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">31</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">100.0</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We enter into individual employment contracts with our employees covering matters such as salaries, bonuses, employee benefits, workplace safety, confidentiality obligations, work product assignment clause and grounds for termination. We also enter into separate confidentiality and non<FONT CLASS="nobreak">-competition</FONT> agreements with our senior management and certain key members of our R&amp;D team and other employees who have access to trade secrets or confidential information about our business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To maintain the quality, knowledge and skill levels of our workforce, we provide continuing education and training programs, including internal and external training, for our employees to improve their technical, professional or management skills. We also provide training programs to our employees from time to time to ensure their awareness and compliance with our policies and procedures in various aspects.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We consider our relations with our employees to be good. As of the date of this prospectus, we have not experienced any strikes or labor disputes which had a material effect on our business.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">FACILITIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our headquarters is located in New Taipei, Taiwan. As of the date of this prospectus, the approximate GFA of our leased properties was approximately 1,964.8 sq.m. in aggregate. As of the same date, we owned two properties with approximately 1,944.88 sq.m. in aggregate in Yilan County, Taiwan, two parcels of land with approximately 4,000.2 sq.m. in aggregate in Yilan County, Taiwan. We believe our properties are sufficient for our current needs and that, should it be needed, suitable additional space will be available on commercially reasonable terms to accommodate any such expansion of our operations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LEGAL PROCEEDINGS AND COMPLIANCE</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In the ordinary course of our business, we are subject to legal or administrative proceedings from time to time. As of the date of this prospectus, we are a <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">party</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> </FONT>to a legal dispute with one of our shareholders concerning a claim of redemption, which may have material and adverse impact on our business, financial condition, or the results of operations.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">144</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Taizhou Investment Dispute</FONT> </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">On May&#x00a0;15, 2019, Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership), or the Plaintiff, entered into a share purchase agreement, or the Share Purchase Agreement, with (i)&#x00a0;Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited and Sira View Corp., collectively, the Transferring Shareholders, (ii)&#x00a0;Jyong Biotech Ltd., or &#x201c;Jyong,&#x201d; (iii)&#x00a0;our Taiwan subsidiary, Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd., or HEB, and (iv)&#x00a0;our CEO, Ms. Fu Feng Kuo, under which the Plaintiff purchased 1,794,258<FONT CLASS="nobreak"> </FONT>shares of Jyong from the Transferring Shareholders at an aggregate price of RMB112,500,000 (US$16,366 thousand), or the Share Purchase Transaction. Pursuant to the Share Purchase Agreement, on July&#x00a0;1, 2019, our Hong&#x00a0;Kong subsidiary, Top ShunXing Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Limited, or Top ShunXing, established our only PRC subsidiary, Innovative Biotech Co., Ltd., or Innovative Biotech, and later on July&#x00a0;22, 2019, Top ShunXing pledged 100% equity interests in Innovative Biotech to the Plaintiff as a guarantee for the performance of buyback shares obligation of the Transferring Shareholders, if Jyong would not accomplish the &#x201c;Qualified Issuance and Listing&#x201d; (defined as Jyong&#x2019;s potential public filing of shares and listing on the main board of the HKEx which never occurred) within 5 years after the closing of the Share Purchase Transaction, or any other redemption events occurred under the Share Purchase Agreement. Please also see &#x201c;Note 17 Commitments and Contingencies&#x00a0;&#x2014;&#x00a0;Commitment with the TaiZhou Company&#x201d; on pages F<FONT CLASS="nobreak">-50</FONT> and F<FONT CLASS="nobreak">-52</FONT> for more details. In August 2022, we sent a written notice to the Plaintiff by mail and informed that we were preparing for this initial public offering. However, as of the date of this prospectus, we have not received the Plaintiff&#x2019;s written consent as required under section 8 of the Share Purchase Agreement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">On November<FONT CLASS="nobreak"> </FONT>15, 2022, we received a complaint for civil suit filed by the Plaintiff to the Taizhou Intermediate People&#x2019;s Court, or the Taizhou Court, against the Transferring Shareholders, Jyong, HEB, Top ShunXing, Innovative Biotech and Ms. Fu Feng Kuo (collectively, the &#x201c;Defendants&#x201d;), requesting, among other claims: (i)&#x00a0;redemption by the Transferring Shareholders for all shares purchased by the Plaintiff under the Share Purchase Agreement for the original purchase price of RMB112,500,000 (US$16,366 thousand) and corresponding interests from July&#x00a0;29, 2019 to the date of actual payment calculated at the loan prime rate in China, or the Redemption; (ii)&#x00a0;the Taizhou Court to hold Jyong, HEB and Ms. Fu Feng Kuo jointly liable for the Redemption; (iii)&#x00a0;the Taizhou Court to confirm Plaintiff&#x2019;s right to liquidate all equity interest in Innovative Biotech held by Top ShunXing that was pledged to the Plaintiff; and (iv)&#x00a0;the&#x00a0;Taizhou Court to hold Innovative Biotech liable for the obligations of other Defendants within the scope of the benefits it received from the investment made under the Share Purchase Agreement. This dispute went on trial before the Taizhou Court on March<FONT CLASS="nobreak"> </FONT>16, 2023 and November<FONT CLASS="nobreak"> </FONT>29, 2023, respectively. We estimated the fair value of guarantee liabilities at the fair value of the shares at the inception of this guarantee and recorded guarantee liabilities of US$18.4<FONT CLASS="nobreak"> </FONT>million, US$18.8<FONT CLASS="nobreak"> </FONT>million, and US$19.0<FONT CLASS="nobreak"> </FONT>million as of December<FONT CLASS="nobreak"> </FONT>31, 2022 and 2023, and June<FONT CLASS="nobreak"> </FONT>30, 2024, respectively. On March<FONT CLASS="nobreak"> </FONT>25, 2024, the Taizhou Court entered into a judgement partially in favor of the Plaintiff, ordering, among other things, the Transferring Shareholders to pay the Redemption price of RMB112,500,000 and corresponding interests, and Jyong, HEB, and Ms. Fu Feng Kuo to be jointly liable for such obligation. The Taizhou Court also ruled that the Plaintiff is entitled to liquidate all equity interest in Innovative Biotech pledged to it in order to realize the payment of the aforementioned obligations. We filed an appeal against this judgement on April<FONT CLASS="nobreak"> </FONT>29, 2024 to the High People&#x2019;s Court of Zhejiang Province (the &#x201c;High Court&#x201d;). The High Court held a hearing for this case on August<FONT CLASS="nobreak"> </FONT>9, 2024, and later issued a judgement against us to sustain the ruling of the Taizhou Court. As of June<FONT CLASS="nobreak"> </FONT>30, 2024, our total potential liability under this judgement is approximately RMB131.6<FONT CLASS="nobreak"> </FONT>million (USD 19.0<FONT CLASS="nobreak"> </FONT>million).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">The judgment is final and non<FONT CLASS="nobreak">-appealable</FONT>, and the settlement agreement shall become legally binding upon execution by the parties. Pursuant to applicable Chinese law, Taizhou is entitled to initiate enforcement proceedings to recover approximately RMB 131.6<FONT CLASS="nobreak"> </FONT>million (USD 19.0<FONT CLASS="nobreak"> </FONT>million) in cash, with Jyong, HEB, and Ms. Fu Feng Kuo jointly liable for such obligations. As of the date of this prospectus, no enforcement procedure has been initiated, and the Company is not required to make any payments toward the judgment at this time, as the enforcement procedure has not yet commenced.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">Under PRC's civil procedure, after a judgement from civil litigation enters into effect, the parties may, at any time before and during the enforcement procedure, and until such enforcement procedure is completed, choose to enter into a settlement agreement and file to the competent court to perform such agreement in lieu of enforcing the judgement. We are actively negotiating with the Plaintiff for a settlement of this legal proceeding. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">The Company and Taizhou have mutually agreed to expedite the resolution of the dispute through negotiation. The key terms and conditions of the settlement are currently under discussion and pending confirmation by the relevant parties. The proposed resolution under negotiation involves a third party acquiring the shares held by Taizhou at a price equivalent to the share subscription cost, potentially including all or part of the accrued interest. It is anticipated that the contemplated transaction will be structured as a post<FONT CLASS="nobreak">-IPO</FONT> bulk trade, intended to be executed following the Company's listing and the expiration of the applicable lock<FONT CLASS="nobreak">-up</FONT> period. The Company affirms that no proceeds from the offering will be utilized for any payment related to the Taizhou dispute. However, </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">145</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;text-indent:0pt;margin-top:4pt;">there can be no assurance that a settlement will be reached. In the event that a settlement is not concluded, Jyong, HEB, and Ms. Fu Feng Kuo may be required to jointly pay the full amount of approximately RMB 131.6<FONT CLASS="nobreak"> </FONT>million (USD&#x00a0;19.0<FONT CLASS="nobreak"> </FONT>million) in cash.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">However, this dispute may still incur substantial costs of settlement or litigation, and may result in an outcome adverse to our interests. In the opinion of our legal counsel for this lawsuit, should we eventually fail to reach a settlement with the Plaintiff, this case is likely to result in an outcome unfavorable to us. For risks associated with the legal proceeding, see more details under &#x201c;Risk Factors&#x00a0;&#x2014;&#x00a0;Risks Related to Our Business and Industry&#x00a0;&#x2014;&#x00a0;We have been involving in legal proceedings in the ordinary course of our business, and are currently involved in active legal proceedings. Any adverse outcome of these legal proceedings could have a material adverse effect on our business, results of operations and financial condition.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Taizhou Administrative Penalty</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On November<FONT CLASS="nobreak"> </FONT>29, 2019, Innovative Biotech Co., Ltd., our PRC subsidiary, entered into the Land Use Right Agreement with Taizhou Resources Bureau. Under the terms and conditions of the Land Use Right Agreement, Innovative Biotech shall commence construction on the parcel granted by May&#x00a0;28, 2020 and complete the construction by November&#x00a0;28, 2022, otherwise, liquidated damages shall be paid to Taizhou Resources Bureau for each&#x00a0;day of delay, being 0.1% of the total amount of the land use right grant price of approximately RMB16.0<FONT CLASS="nobreak"> </FONT>million plus tax. On November&#x00a0;23, 2022, Taizhou Resources Bureau issued a formal notice of reminder of default, requiring Innovative Biotech to pay liquidated damages of RMB13,080,170, with the amount of damages accruing from November<FONT CLASS="nobreak"> </FONT>24, 2022 to the date of actual construction to be calculated separately. As of the date of this prospectus, we have not paid the liquidated damages of RMB13,080,170 (US$ 1,803.8 thousand) yet and we are actively negotiating with Taizhou Resources Bureau for a settlement of this dispute. In addition, under the Land Use Right Agreement, apart from the liquidated damages, Innovative Biotech is obliged to pay a land idling fee if the land is left idle for more than one year but less than two years, and Taizhou Resources Bureau has the right to take back the land use right if the land is left idle for more than two years. On September<FONT CLASS="nobreak"> </FONT>26, 2024, the Taizhou Resources Bureau issued a notice regarding taking back the land use right without compensation, giving Innovative Biotech Co., Ltd. the right to file for an administrative hearing within five business days of receipt of notice. While the Company initially applied for the administrative hearing, it subsequently decided to relinquish the land use rights to the Taizhou Resources Bureau in accordance with the notice. As a result, the Company will no longer proceed with the hearing process.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">According to the 2018 Taizhou Agreement and 2019 Taizhou Agreement, we were obligated to complete the construction of a pharmaceutical factory project, or the Factory Project, by 2022, which shall be ready for production by 2023. As of the date of this prospectus, the construction of the Factory Project has yet taken place due to travel restrictions, quarantines and lock<FONT CLASS="nobreak">-downs</FONT> caused by COVID<FONT CLASS="nobreak">-19</FONT>. In addition, RMB30<FONT CLASS="nobreak"> </FONT>million of Innovative Biotech Co., Ltd.&#x2019;s registered capital shall be actually paid within one year of its registration. As of the date of this prospectus, only RMB16,562,000 (US$2,284 thousand) of Innovative Biotech Co., Ltd.&#x2019;s registered capital has been paid. Furthermore, our PRC subsidiary shall pay cash deposit of RMB 10,000 (US$1.4 thousand) per mu after signing the &#x201c;standard parcel&#x201d; development and construction agreement, or the Construction Agreement, with the Taizhou Industry District Committee. As of the date of this prospectus, no such deposit has been paid after the Construction Agreement was signed. According to the 2018 Taizhou Agreement, failure to commence and conclude the construction of the Factory Project on schedule as agreed may entitle the Taizhou Municipality the rights to replace the granted parcel, adjust or withdraw the preferential policies available under such agreement (including but not limited to the government subsidy of RMB12.0<FONT CLASS="nobreak"> </FONT>million (US$1,654.9 thousand) Innovative Biotech Co., Ltd. has already received), and take back the parcel with the original purchase price of RMB400,000 (US$55.2 thousand) per mu. See also &#x201c;&#x2014; License and Collaboration Agreements &#x2014; Taizhou Collaboration Framework Agreement.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The claims and proceedings discussed above, and other potential claims or proceedings relating to this issue, may incur substantial costs of settlement or litigation, and may result in outcome adverse to our interests. For risks associated with the legal proceeding, see more details under &#x201c;Risk Factors&#x00a0;&#x2014;&#x00a0;Risks Related to Our Business and Industry&#x00a0;&#x2014;&#x00a0;We have been involving in legal proceedings in the ordinary course of our business, and are currently involved in active legal proceedings. Any adverse outcome of these legal proceedings could have a material adverse effect on our business, results of operations and financial condition.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On November<FONT CLASS="nobreak"> </FONT>29, 2019, our PRC subsidiary, Innovative Biotech Co. (&#x201c;IB&#x201d;) entered into the Construction Agreement with the Taizhou Industry District Committee. The Construction Agreement provided specifics regarding the Factory Project IB was required to meet, including but not limited to the period of construction, plot ratio, amount </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">146</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">of investment and tax income per mu. The Construction Agreement stipulates that before construction of the Factory Project meet the requirements of amount of investment and plot ratio under the Construction Agreement, IB and its shareholder shall not transfer the acquired parcel, directly or via transfer or pledge of equity, to a third party. Should IB breaches this agreement and causes the purpose of the Construction Agreement unable to be realized, the Taizhou Industry District Committee shall have the right to terminate the Construction Agreement and claim corresponding damages. The Taizhou Industry District Committee did not explicitly consent to the pledging of IB&#x2019;s shares to the Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership). However, as of the date of this prospectus, the Taizhou Industry District Committee has yet to raise any claims against IB based on the event discussed above. As of December<FONT CLASS="nobreak"> </FONT>31, 2022 and 2023, and June<FONT CLASS="nobreak"> </FONT>30, 2024, IB classified the liquidated damages and accrued interests of US$2.2<FONT CLASS="nobreak"> </FONT>million, US$3.0<FONT CLASS="nobreak"> </FONT>million, and US$2.7<FONT CLASS="nobreak"> </FONT>million as other current liabilities, respectively. </P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;">Taizhou Government Subsidy Dispute</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">On November<FONT CLASS="nobreak"> </FONT>29, 2022, the Taizhou Bay New District Administrative Committee (the &#x201c;Plaintiff&#x201d;), successor of the Taizhou Industry District Committee, filed a civil complaint to the Taizhou Intermediate People&#x2019;s Court (&#x201c;the Taizhou Court&#x201d;) against our PRC subsidiary, Innovative Biotech Co. (&#x201c;IB&#x201d;), claiming that IB has materially breached the 2019 Taizhou Agreement by failing to initiate and conclude the construction of the Factory Project in accordance with the schedule stipulated by the 2019 Taizhou Agreement and the Land Use Right Agreement. The Plaintiff requested the Taizhou Court to terminate the 2019 Taizhou Agreement, and to order IB to return the government subsidy of RMB 12.0<FONT CLASS="nobreak"> </FONT>million (US$1,654.9 thousand) IB previously received under the 2019 Taizhou Agreement, and to pay corresponding interests calculated at the Loan Prime Rate published by the National Inter<FONT CLASS="nobreak">-bank</FONT> Funding Center. On December<FONT CLASS="nobreak"> </FONT>1, 2022, the Taizhou Court issued an order of preliminary asset preservation, freezing the RMB 12.0<FONT CLASS="nobreak"> </FONT>million deposit in IB&#x2019;s bank account. This dispute went on trial on February<FONT CLASS="nobreak"> </FONT>13, 2023, and two hearings were held on May<FONT CLASS="nobreak"> </FONT>6, 2023 and August<FONT CLASS="nobreak"> </FONT>17, 2023, respectively. On September<FONT CLASS="nobreak"> </FONT>8, 2023, the Taizhou Court entered into a judgement in favor of the Plaintiff, terminating the 2019 Taizhou Agreement and ordering IB to return the government subsidy of RMB12.0<FONT CLASS="nobreak"> </FONT>million and corresponding interest and expenses to the Plaintiff. On September<FONT CLASS="nobreak"> </FONT>14, 2023, we filed an appeal with the High People&#x2019;s Court of Zhejiang Province (the &#x201c;High Court&#x201d;) regarding each of the Court&#x2019;s rulings described above. The High Court held a hearing for this case on October<FONT CLASS="nobreak"> </FONT>24, 2023. On December<FONT CLASS="nobreak"> </FONT>12, 2023, the High Court issued a judgment against IB to affirm the Taizhou Court&#x2019;s ruling in its entirety. On January<FONT CLASS="nobreak"> </FONT>5, 2024, the Taizhou Court issued an order of enforcement, stipulating, among other things, freezing and assignment of IB&#x2019;s deposit in its bank account or withholding of IB&#x2019;s income up to RMB 12.0<FONT CLASS="nobreak"> </FONT>million and corresponding interests, and the seizure, attachment and freezing of IB&#x2019;s property valued at RMB 12.0<FONT CLASS="nobreak"> </FONT>million and corresponding interests, and restrictions on making certain high expenses by IB and related personnel. As of the date of this prospectus, the 40 mu (approximate 26,680 sq.m.) industrial land we acquired for the Factory Project have been seized by the Taizhou Court, and IB&#x2019;s RMB 11.1<FONT CLASS="nobreak"> </FONT>million deposit in its bank account has been transferred to the Plaintiff. On December<FONT CLASS="nobreak"> </FONT>27, 2023, we filed a petition for retrial to the Supreme People&#x2019;s Court of the People&#x2019;s Republic of China (the &#x201c;Supreme Court&#x201d;). The Supreme Court issued a decision to reject our petition for retrial on August<FONT CLASS="nobreak"> </FONT>21, 2024. As of December<FONT CLASS="nobreak"> </FONT>31, 2022 and 2023, and June<FONT CLASS="nobreak"> </FONT>30, 2024, IB&#x00a0;accrued US$2.0<FONT CLASS="nobreak"> </FONT>million, US$2.0<FONT CLASS="nobreak"> </FONT>million, and US$0.4<FONT CLASS="nobreak"> </FONT>million of other current liabilities for the loss contingencies for this dispute, respectively. For risks associated with the legal proceeding, see more details under &#x201c;Risk Factors &#x2014; Risks Related to Our Business and Industry &#x2014; We have been involving in legal proceedings in the ordinary course of our business, and are currently involved in active legal proceedings.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">This dispute has resulted in an outcome adverse to our interests, which may in turn result in financial loss and adversely affect our business, financial conditions and results of operations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">Even though we are currently involved in the legal proceedings as aforementioned, we are committed to maintaining the highest standards of compliance with the laws and regulations applicable to our business in the future. Apart from the legal proceedings discussed above, we are not engaged in, nor are we aware of, any legal proceeding, investigation or claim which, in the opinion of our management, is likely to have a material adverse effect on our business, financial condition or results of operations. we may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business. Litigation or any other legal or administrative proceeding, regardless of the outcome, is likely to result in substantial costs and diversion of our resources, including our management&#x2019;s time and attention.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INSURANCE</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We maintain insurance policies that we consider to be in line with market practice and adequate for our business. We currently maintain insurance for adverse events in clinical trials as we estimate the risk exposure to be minimal. We currently do not maintain product liability insurance or key person insurance.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">147</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T10"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">REGULATIONS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are subject to a variety of U.S.&#x00a0;and Taiwan laws, rules and regulations across a number of aspects of our business. This section sets forth a summary of the most significant laws and regulations that are applicable to our current business activities within the territory of U.S.&#x00a0;and Taiwan.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">U.S.&#x00a0;Government Regulation and Product Approval</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S.&#x00a0;Food and Drug Administration, or the U.S. FDA, and other regulatory authorities in the United&#x00a0;States at federal, state and local levels extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post<FONT CLASS="nobreak">-approval</FONT> monitoring and post<FONT CLASS="nobreak">-approval</FONT> reporting of and for drug products. Along with third<FONT CLASS="nobreak">-party</FONT> contractors, we are required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The processes for obtaining regulatory approvals in the United&#x00a0;States and in foreign jurisdictions, along with subsequent compliance with applicable laws and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The failure to comply with applicable statutory and regulatory requirements may subject a sponsor, applicant or marketer to administrative or judicial enforcement actions. These actions could include the suspension or termination of clinical trials by the U.S. FDA, the U.S. FDA&#x2019;s refusal to approve pending applications or supplemental applications, withdrawal of an approval, &#x201c;Warning Letters&#x201d; (official messages from the U.S. FDA to a manufacturer or other organization providing notice that it has violated federal law) or &#x201c;Untitled Letters&#x201d; (initial correspondences from the U.S. FDA that cite violations that do not meet the threshold of regulatory significance for a Warning Letter and request correction of the violation), product recalls, product seizures, total or partial suspension of production or distribution, import detention, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the U.S. FDA, the Department of Justice, or the DOJ, or other governmental entities.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Review and Approval for Licensing Drugs</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S. FDA regulates drugs primarily under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the Public Health Service Act, and their associated implementing regulations. Our product candidates must be approved by the U.S. FDA through the new drug application, or the NDA, process before they may be legally marketed in the United&#x00a0;States. The process required by the U.S. FDA before a drug may be marketed in the United&#x00a0;States generally involves the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>completion of extensive preclinical studies, including preclinical laboratory tests, preclinical animal studies and formulation studies all performed in compliance with applicable regulations, including the current good laboratory practice, or the cGLP, regulations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>submission to the U.S. FDA of an investigational new drug application, or an IND, which must become effective before human clinical trials may begin and must be updated annually and when significant changes are made, such as initiating a new clinical trial;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>manufacture, labeling and distribution of an investigational drug in compliance with current good manufacturing practices, or cGMP;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>approval by an institutional review board, or IRB, or ethics committee at each clinical site before each clinical trial may be initiated and obtaining informed consent of all clinical trial participants;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>performance of adequate and well<FONT CLASS="nobreak">-controlled</FONT> human clinical trials in accordance with the U.S. FDA&#x2019;s current good clinical practices requirements, or cGCP, clinical trial registration, and other clinical trial related regulations, to provide substantial evidence of effectiveness and evidence of safety for the drug product&#x2019;s proposed indication;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">148</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>preparation of and submission to the U.S. FDA of an NDA after completion of all pivotal clinical trials requesting marketing approval for one or more proposed indications;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>satisfactory completion of an U.S. FDA Advisory Committee review, where appropriate or if applicable, as may be requested by the U.S. FDA to assist with its review;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>satisfactory completion of one or more U.S. FDA pre<FONT CLASS="nobreak">-approval</FONT> inspections of the manufacturing facility or facilities at which active pharmaceutical ingredient, or API, and finished drug product, or components thereof, are produced to assess compliance with cGMP and data integrity requirements to assure that the facilities, methods, and proposed chemistry, manufacturing, and controls, or CMC, are adequate to preserve the drug&#x2019;s identity, safety, quality, purity, potency and efficacy;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>satisfactory completion of U.S. FDA audits of selected preclinical and/or clinical investigation sites to assure compliance with cGLP and cGCP requirements and the integrity of the preclinical and/or clinical data;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>payment of user fees under the Prescription Drug User Fee Act, or, as amended, the PDUFA, for the relevant year;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>obtaining U.S. FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the United&#x00a0;States; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>compliance with all post<FONT CLASS="nobreak">-approval</FONT> requirements, including but not limited to, cGMP, CMC, post<FONT CLASS="nobreak">-market</FONT> reporting and pharmacovigilance, registration and listing, advertising and promotional requirements, the potential requirement to implement risk evaluation and mitigations strategies, or REMS, and the potential requirement to conduct post<FONT CLASS="nobreak">-approval</FONT> studies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to drug<FONT CLASS="nobreak">-specific</FONT> requirements, combinations of differently regulated articles, such a drug and device (e.g., a drug delivery system or companion diagnostic) could also result in various additional requirements to consider, such as device and combination product requirements of the FDCA and its implementing regulations with respect to investigation, marketing, and post<FONT CLASS="nobreak">-market</FONT> requirements. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The approval process for botanical drug products is similar to that of conventional chemical drugs. The standards for the safety and efficacy of a botanical drug are the same as those for a conventional chemical drug with the same indication. However, the quality control of botanical drugs is more complex than that of conventional chemical drugs due to the variability of botanical raw materials. Given botanicals&#x2019; chemical and biological complexity, efforts in characterizing the pharmacology, demonstrating therapeutic efficacy, and ensuring quality consistency remain scientific and regulatory challenges. For botanical drug products in particular, which may be heterogeneous in nature and may carry additional uncertainty about their active constituents in comparison to synthetic small<FONT CLASS="nobreak">-molecule</FONT> drug products, one of the critical issues during drug development is ensuring that the therapeutic effect for marketed drug product batches is consistent. The U.S. FDA has determined that therapeutic consistency can generally be supported by a &#x201c;totality of the evidence&#x201d; approach, which the U.S. FDA has outlined in a 2016 guidance for industry entitled Botanical Drug Development.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Development of data and other information sufficient to support an NDA approval requires substantial time, effort and financial resources and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all. From time to time, new legislation is enacted that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the U.S. FDA.&#x00a0;In addition to new legislation, U.S. FDA regulations and policies are often revised or interpreted by the U.S. FDA in ways that may significantly affect our business and our product candidates. It is impossible to predict whether further legislative changes will be enacted or whether U.S. FDA regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Preclinical Development</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The data required to support an NDA is generated in two distinct development stages: preclinical and clinical. For new chemical entities, or NCEs, the preclinical development stage generally involves synthesizing the active component, developing the formulation and determining the manufacturing process, evaluating purity and stability, </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">149</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">as well as carrying out non<FONT CLASS="nobreak">-human</FONT> toxicology, pharmacology and drug metabolism studies in the laboratory, which support subsequent clinical testing. The conduct of the preclinical studies must comply with federal regulations, including cGLPs. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol or protocols, to the U.S. FDA as part of its IND.&#x00a0;The central focus of an IND submission is on the general investigational plan and the protocol(s)&#x00a0;for human studies. An IND is a request for authorization from the U.S. FDA to administer an investigational product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s)&#x00a0;for human studies. An IND acts as an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial. Such authorization must be secured prior to interstate shipment. Any subsequent protocol amendments must be submitted to the U.S. FDA as part of the IND, and the U.S. FDA must allow these amendments to the IND to go into effect prior to their execution. Frequently, sponsors are also required to conduct additional animal studies after an IND is obtained and human clinical testing begins, and is often referred to as &#x2018;preclinical&#x2019; or &#x2018;nonclinical&#x2019; testing, even though it occurs in parallel with the clinical phase of development.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Clinical Development</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Human clinical trials subject to the U.S. FDA&#x2019;s jurisdiction may not begin until an IND is effective. The IND automatically becomes effective 30&#x00a0;days after receipt by the U.S. FDA, unless the U.S. FDA raises safety concerns or questions about the proposed clinical trial within the 30<FONT CLASS="nobreak">-day</FONT> time period. In such a case, the IND may be placed on clinical hold and the IND sponsor and the U.S. FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in U.S. FDA authorization to begin a clinical trial.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The U.S. FDA may also place a clinical hold or partial clinical hold on such study following commencement of a clinical trial under an IND.&#x00a0;A clinical hold is an order issued by the U.S. FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND.&#x00a0;For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30&#x00a0;days after the imposition of a clinical hold or partial clinical hold, the U.S. FDA will provide the sponsor with a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the U.S. FDA has notified the sponsor that the investigation may proceed. The U.S. FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the U.S. FDA that the investigation can proceed.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Clinical studies involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCP regulations. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Furthermore, an IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial before the clinical trial begins at that site, and must monitor the study until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or the DSMB.&#x00a0;DSMBs provide authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if a DSMB determines that there is an unacceptable safety risk for subjects or based on other grounds, such as no demonstration of efficacy. Other grounds for suspension or termination may be made based on evolving business objectives and/or competitive climate. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all U.S. FDA IND requirements must be met unless waived. When the foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study complies with cGCP regulations in order to use the study as support for an IND or application for marketing approval, including review and approval by an independent ethics committee and informed consent from subjects. If conducting a clinical study in a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;population, acceptance of clinical trial results by the U.S. FDA will depend, among other things, on whether the non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;population that enrolled in the study is sufficiently similar to the indicated U.S.&#x00a0;population that the results of the trial would fairly represent expected results in the U.S.&#x00a0;population. The same issue can also arise in multi<FONT CLASS="nobreak">-national</FONT> trials where non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;sites are enrolling subjects that will become part of the data submitted to the U.S. FDA.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">150</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of drug approval, clinical trials are typically conducted in the following sequential phases that may overlap or be combined:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Phase&#x00a0;I:&#x00a0;&#x00a0;&#x00a0;&#x00a0;The investigational product is initially introduced into a small number of healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses. These studies may also yield early evidence of effectiveness.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Phase&#x00a0;II:&#x00a0;&#x00a0;&#x00a0;&#x00a0;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Phase&#x00a0;III:&#x00a0;&#x00a0;&#x00a0;&#x00a0;The investigational product is administered to an expanded patient population generally at multiple geographically dispersed clinical trial sites to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety. These clinical trials are intended to generate sufficient data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval by the U.S. FDA and labeling of the drug product.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In some cases, the U.S. FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product, sometimes referred to as &#x201c;Phase&#x00a0;IV&#x201d; studies. Such post<FONT CLASS="nobreak">-approval</FONT> studies, when applicable, are conducted following initial approval, typically to develop additional data and information relating to the biological characteristics of the product and the treatment of patients in the intended therapeutic indication.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the U.S. FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the U.S.&#x00a0;FDA for any of the following: suspected serious and unexpected adverse reactions; findings from epidemiological studies, pooled analysis of multiple studies, animal or in vitro testing, or other clinical trials, whether or not conducted under an IND, and whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol or investigator brochure, which is a comprehensive document summarizing the body of information about an investigational product obtained during clinical and non<FONT CLASS="nobreak">-clinical</FONT> trials.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Each of Phase&#x00a0;I, Phase&#x00a0;II and Phase&#x00a0;III clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the U.S. FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with such IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, if a clinical trial is overseen by a Data Safety Monitoring Board, or DSMB, the DSMB will provide authorization for whether or not a study may move forward at designated check points based on access to certain data from the study.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Concurrent with clinical trials, companies must develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate, and cGMPs impose, among other things, extensive procedural, substantive and recordkeeping requirements to ensure and preserve the long<FONT CLASS="nobreak">-term</FONT> stability and quality of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. Any changes to the drug product during development, and especially after Phase&#x00a0;II, can raise questions with respect to impact of changes on study results, and whether results may be extrapolated to support approval of a final finished dosage form for which approval is sought.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the clinical development process, earlier phase drug results may be promising, but it cannot be assumed that subsequent phases of development will be successful. In fact, it is often the case that drugs with promising early phase data fail to ultimately show sufficient efficacy or safety to support approval in later phases of development.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">151</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">NDA Submission and Review</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following study completion, study results and data are analyzed to assess safety and efficacy. The results of preclinical studies and clinical trials are then submitted to the U.S. FDA as part of an NDA, along with relevant patent information, proposed labeling for the drug, information about the manufacturing process and facilities that will be used to ensure drug quality, results of analytical testing conducted on the chemistry of the drug and other relevant information. The NDA is a request for approval to market the drug and must contain adequate evidence of safety and substantial evidence of efficacy, which is demonstrated by extensive preclinical and clinical testing. Data may come from company<FONT CLASS="nobreak">-sponsored</FONT> clinical trials intended to test the safety and efficacy of a use of a drug, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational drug product to the satisfaction of the U.S. FDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the PDUFA, each NDA must generally be accompanied by a significant application user fee. The U.S. FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business which has fewer than 500 employees; in assessing whether an application qualifies as a &#x2018;first application&#x2019; and calculating the number of employees, affiliates of the small business making the NDA submission are considered. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non<FONT CLASS="nobreak">-orphan</FONT> indication.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S. FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA for filing. The U.S. FDA conducts a preliminary review of an NDA within 60&#x00a0;days of receipt and informs the sponsor by the 74<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT>&#x00a0;day after the U.S. FDA&#x2019;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the U.S. FDA begins an in<FONT CLASS="nobreak">-depth</FONT> review of the NDA.&#x00a0;Under the goals and policies agreed to by the U.S. FDA under PDUFA, the U.S. FDA has ten&#x00a0;months from the filing date in which to complete its initial review of a standard NDA and respond to the applicant, and six&#x00a0;months from the filing date for a &#x201c;priority review&#x201d; NDA.&#x00a0;The U.S. FDA does not always meet its PDUFA goal dates for standard and priority review NDAs, and the review process is often significantly extended by U.S. FDA requests for additional information or clarification.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the NDA submission is accepted for filing, the U.S. FDA reviews the NDA to determine, among other things, whether the proposed drug is safe and effective for its intended use, and whether the drug is being manufactured in accordance with cGMP to assure and preserve the drug&#x2019;s identity, strength, quality, purity and efficacy. The U.S. FDA may refer applications for novel drugs or product candidates that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee consists of a panel that includes clinicians and other experts who will review, evaluate and provide a recommendation as to whether the application should be approved and, if so, under what conditions. The U.S. FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and usually follows such recommendations. The U.S. FDA may re<FONT CLASS="nobreak">-analyze</FONT> the clinical trial data, which could result in extensive discussions between the U.S. FDA and us during the review process.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before approving an NDA, the U.S. FDA will also conduct a pre<FONT CLASS="nobreak">-approval</FONT> inspection of the manufacturing facilities for the new drug to determine whether they comply with cGMPs. The U.S. FDA will not approve the drug unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the drug within required specifications. In addition, before approving an NDA, the U.S. FDA may also audit data from clinical trials to ensure compliance with cGMP requirements. After the U.S. FDA evaluates the application, manufacturing process and manufacturing facilities where the drug product and/or its API will be produced, it may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A complete response letter indicates that the review cycle of the application is complete and the application is not ready for approval. A complete response letter usually describes all of the specific deficiencies in the NDA identified by the U.S. FDA.&#x00a0;The complete response letter may require additional clinical data and/or an additional pivotal clinical trial(s), and/or other significant, expensive and time<FONT CLASS="nobreak">-consuming</FONT> requirements related to preclinical studies or clinical trials or manufacturing. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">152</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">information is submitted, the U.S. FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the U.S. FDA may interpret data differently than we interpret the same data.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a drug receives marketing approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited. Further, the U.S. FDA may require that certain contraindications, warnings or precautions be included in the drug labeling or may condition the approval of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post<FONT CLASS="nobreak">-market</FONT> testing or clinical trials and surveillance to monitor the effects of approved drugs. For example, the U.S. FDA may require Phase&#x00a0;IV testing which involves clinical trials designed to further assess a drug&#x2019;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved drugs that have been commercialized. The U.S. FDA may also place other conditions on approvals including the requirement for a REMS to ensure that the benefits of a drug or biological product outweigh its risks. If the U.S. FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS and the U.S. FDA will not approve the NDA without a REMS that the U.S. FDA has determined is acceptable. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of a drug. Drug approvals may be withdrawn for non<FONT CLASS="nobreak">-compliance</FONT> with regulatory standards or if problems occur following initial marketing.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Post-Approval</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Requirements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any products manufactured or distributed pursuant to U.S. FDA approvals are subject to pervasive and continuing regulation by the U.S. FDA, including, among other things, requirements relating to monitoring, recordkeeping, registration and listing, periodic reporting, reporting of certain deviations and adverse experiences, providing the regulatory authorities with updated safety and efficacy information, drug sampling and distribution requirements, complying with applicable promotion and advertising requirements, and the provision and maintenance of data about each sale of prescription drugs to authorized trading partners in a secure and interoperable manner, and systems for the identification and management of suspect and illegitimate products. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to U.S.&#x00a0;FDA review and approval and may require the development and submission of data, including clinical data. There also are continuing user fee requirements, under which the U.S. FDA assesses an annual program fee for each product identified in an approved NDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">U.S. FDA regulations also require that approved products be manufactured in specific approved facilities and in accordance with cGMP.&#x00a0;We currently use contract manufacturing organizations, or CMOs, to manufacture the drugs used in our clinical trials and expect to rely on third parties for the production of commercial quantities of our products in accordance with cGMP regulations. NDA holders using CMOs, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP.&#x00a0;Drug manufacturers and their third<FONT CLASS="nobreak">-party</FONT> contractors are required to register their establishments with the U.S. FDA and certain state agencies. These establishments are subject to routine and periodic unannounced inspections by the U.S. FDA and certain state agencies for compliance with cGMP and data integrity requirements, which impose certain procedural and documentation requirements to assure quality of manufacturing and product. Any interference with U.S. FDA inspection activities at our company or at CMOs can result in substantial penalties. The U.S. FDA has increasingly observed cGMP violations involving data integrity during site inspections and investigating compliance with data integrity requirements is a significant focus of its oversight. Requirements with respect to data integrity include, among other things, controls to ensure data are complete and secure; requiring that activities are documented at the time of performance; audit trail functionality; requiring authorized access and limitations; validated computer systems; and the review of records for accuracy, completeness and compliance with established standards.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">153</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Post<FONT CLASS="nobreak">-approval</FONT> changes to the manufacturing process, including changes of the site of manufacture, are strictly regulated, and, depending on the significance of the change, may require U.S. FDA approval before being implemented. U.S. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third<FONT CLASS="nobreak">-party</FONT> CMOs that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP, data integrity, pharmacovigilance (<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">i.e.</FONT>, post<FONT CLASS="nobreak">-marketing</FONT> safety reporting obligations) and other aspects of regulatory compliance.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S. FDA may withdraw a product approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post<FONT CLASS="nobreak">-approval</FONT> studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS.&#x00a0;Other potential consequences include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>fines, Warning Letters, Untitled Letters or holds on post<FONT CLASS="nobreak">-approval</FONT> clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>refusal of the U.S. FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>product seizure or detention, or refusal of the U.S. FDA to permit the import or export of products that it believes present safety problems by issuing an Import Alert;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>permanent injunctions and consent decrees, including the imposition of civil or criminal penalties;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>adverse publicity;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>voluntary or mandatory product recall; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>recoupment of payment and damages for noncompliant drug products based on various legal theories, including a theory that reimbursement for noncompliant products violates federal and state false claims laws (e.g., the federal False Claims Act).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S. FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. A company can make only those claims relating to safety and efficacy, identity, strength, quality, purity and potency that are approved by the U.S. FDA and in accordance with the provisions of the approved label. Promotional claims relating to a product&#x2019;s safety or effectiveness are prohibited before the drug is approved. After approval, a product generally may not be promoted for uses that are not approved by the U.S. FDA, as reflected in the product&#x2019;s prescribing information. In the United&#x00a0;States, healthcare professionals are generally permitted to prescribe drugs for such uses not described in the drug&#x2019;s labeling, known as off<FONT CLASS="nobreak">-label</FONT> uses, because the U.S. FDA does not regulate the practice of medicine. However, U.S. FDA regulations impose rigorous restrictions on manufacturers&#x2019; communications, prohibiting the promotion of off<FONT CLASS="nobreak">-label</FONT> uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in non<FONT CLASS="nobreak">-promotional</FONT>, non<FONT CLASS="nobreak">-misleading</FONT> communication regarding off<FONT CLASS="nobreak">-label</FONT> information, such as distributing scientific or medical journal information in accordance with the U.S. FDA&#x2019;s good reprint practices or unsolicited request doctrine.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a company is found to have promoted off<FONT CLASS="nobreak">-label</FONT> uses, it may become subject to adverse public relations and administrative and judicial enforcement by the U.S. FDA, the DOJ or the Office of the Inspector General of the Department of Health and Human Services, as well as other federal and state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that such companies enter into consent decrees and permanent injunctions under which specified promotional conduct is changed or curtailed. Among other legal theories, penalties may be sought based on a theory that off<FONT CLASS="nobreak">-label</FONT> promotion causes submission of claims that for an unapproved use in violation of state and federal false claims laws.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">154</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other Regulatory Matters</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Manufacturing, sales, promotion and other activities following drug approval are also subject to regulation by numerous regulatory authorities in addition to the U.S. FDA, including, in the United&#x00a0;States, the Centers for Medicare&#x00a0;&amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Drug Enforcement Administration for controlled substances, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#x00a0;&amp; Health Administration, the Environmental Protection Agency and state and local governments. The activities of pharmaceutical manufacturers are subject to federal and state laws designed to prevent &#x201c;fraud and abuse&#x201d; in the healthcare industry. The laws generally limit financial interactions between manufacturers and health care providers or other participants in the healthcare industry, require disclosure to the government and public of such interactions, and govern various matters regarding reimbursement of healthcare products. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. Pharmaceutical manufacturers are also required to provide discounts or rebates under government healthcare programs or to certain government and private purchasers in order to obtain coverage under federal healthcare programs such as Medicaid. Participation in such programs may require tracking and reporting of certain drug prices. Manufacturers are subject to fines and other penalties if such prices are not reported accurately. Additionally, the handling of any controlled substances must comply with the U.S.&#x00a0;Controlled Substances Act and Controlled Substances Import and Export Act. Drugs must meet applicable child<FONT CLASS="nobreak">-resistant</FONT> packaging requirements under the U.S.&#x00a0;Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of prescription drugs and biologics are subject to the Drug Supply Chain Security Act, which requires manufacturers and other stakeholders to comply with product labeling, tracing, verification, detection and disposition of suspect and illegitimate products, notifications regarding illegitimate products, and products with a high risk of illegitimacy, and state permitting or licensing requirements. Manufacturers of prescription drugs must develop secure, electronic and interoperable recordkeeping systems that track transaction data at the package level when they sell prescription products to their authorized downstream customers and be able to produce those records when requested by U.S. FDA. In addition, the Prescription Drug Marketing Act and its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the Drug Supply Chain Security Act imposes requirements to ensure accountability in distribution and to identify, quarantine, investigate, and remove from the market prescription drug and biological products that may be counterfeit, stolen, contaminated, or otherwise harmful.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Hatch-Waxman</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> Protections</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Patent Term Restoration</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After approval, owners of relevant drug or biological product patents may apply for up to a five<FONT CLASS="nobreak">-year</FONT> patent extension to restore a portion of patent term lost during product development and U.S. FDA review of an NDA if approval of the application is the first permitted commercial marketing or use of a drug containing the API under the Hatch<FONT CLASS="nobreak">-Waxman</FONT> Act. The allowable patent term extension is calculated as one<FONT CLASS="nobreak">-half</FONT> of the product&#x2019;s testing phase, which is the time between IND and NDA submission, and all of the review phase, which is the time between NDA submission and approval, up to a maximum of five&#x00a0;years. The time can be shortened if the U.S. FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed more than 14&#x00a0;years from the date of U.S. FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60&#x00a0;days of approval. The US Patent and Trademark Office (US PTO), in consultation with the U.S. FDA, reviews and approves the application for patent term restoration.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post<FONT CLASS="nobreak">-approval</FONT> patent extension is reduced by one year. The director of the US PTO must determine that approval of the product candidate covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a product candidate for which an NDA has not been submitted.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">155</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Patent Listing and the Orange Book</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In seeking approval for a drug through an NDA, applicants are required to list with the U.S. FDA each drug substance, drug product, and method<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-use</FONT> patent whose claims cover the NDA drug product. Upon approval of the NDA, each of the patents listed in the application for the drug is published in the U.S. FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors as reference listed drugs, or RLDs, in support of approval of an abbreviated new drug application, or ANDA, or 505(b)(2)&#x00a0;NDA which relies upon the RLD&#x2019;s approval to support its own.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, nonclinical or clinical tests (beyond, potentially, bioequivalence studies) to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#x201c;generic equivalents&#x201d; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug under various state laws. A 505(b)(2)&#x00a0;NDA is generally used where there are one more difference from the RLD in terms of dosage form, labeling, or other properties, but where an applicant may nonetheless rely upon U.S. FDA&#x2019;s prior approval determinations with respect to the RLD to support safety and/or efficacy of the 505(b)(2)&#x00a0;NDA drug product.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An ANDA or 505(b)(2)&#x00a0;NDA applicant is required to certify to the U.S. FDA concerning any patents listed for the RLD in the U.S. FDA&#x2019;s Orange Book. Specifically, the applicant must certify that: (i)&#x00a0;the required patent information has not been filed; (ii)&#x00a0;the listed patent has expired; (iii)&#x00a0;the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv)&#x00a0;the listed patent is invalid or will not be infringed by the new product. An ANDA applicant may also elect to submit a section viii statement, certifying that its proposed ANDA label does not contain or carve out any language regarding the patented method<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-use</FONT>, rather than certify to a listed method<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-use</FONT> patent.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the applicant does not challenge the listed patents, the ANDA or 505(b)(2)&#x00a0;NDA will not be approved until all the listed patents claiming the referenced product have expired. A certification that the new product will not infringe the already approved product&#x2019;s listed patents, or that such patents are invalid, is called a Paragraph&#x00a0;IV certification. If the ANDA or 505(b)(2)&#x00a0;NDA applicant has provided a Paragraph&#x00a0;IV certification to the U.S. FDA, the applicant must also send notice of the Paragraph&#x00a0;IV certification to the NDA and patent holders once the ANDA or 505(b)(2)&#x00a0;NDA has been accepted for filing by the U.S. FDA.&#x00a0;The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#x00a0;IV certification. The filing of a patent infringement lawsuit within 45&#x00a0;days of the receipt of a Paragraph&#x00a0;IV certification automatically prevents the U.S. FDA from approving the ANDA or 505(b)(2)&#x00a0;NDA until the earlier of 30&#x00a0;months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2)&#x00a0;NDA applicant.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ANDA or 505(b)(2)&#x00a0;NDA also will not be approved until any applicable non<FONT CLASS="nobreak">-patent</FONT> market exclusivity listed in the Orange Book for the referenced product have expired.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Market Exclusivity</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon NDA approval of a new chemical entity (NCE), which is a drug that contains no active moiety that has been approved by the U.S. FDA in any other NDA, that drug receives five&#x00a0;years of marketing exclusivity during which time the U.S. FDA cannot receive any ANDA or 505(b)(2)&#x00a0;NDA seeking approval that uses the NDA as its RLD.&#x00a0;Certain changes to a drug, such as the addition of a new indication to the package insert, are associated with a three<FONT CLASS="nobreak">-year</FONT> period of exclusivity during which the U.S. FDA cannot approval an ANDA or 505(b)(2)&#x00a0;NDA seeking approval that uses the NDA as its RLD.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An ANDA or 505(b)(2)&#x00a0;NDA may be submitted one year before NCE exclusivity expires if a Paragraph&#x00a0;IV certification is filed. If there is no listed patent in the Orange Book, there may not be a Paragraph&#x00a0;IV certification, and, thus, no ANDA or 505(b)(2)&#x00a0;may be filed before the expiration of the exclusivity period.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Federal Food, Drug, and Cosmetic Act directs the U.S. FDA to meet with sponsors, pursuant to a sponsor&#x2019;s written request, for the purpose of reaching agreement on the design and size of clinical trials intended to form the primary basis of an efficacy claim in an NDA.&#x00a0;If an agreement is reached, the U.S. FDA will reduce the agreement to writing and make it part of the administrative record. This agreement is called a special protocol assessment, or </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">156</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an SPA.&#x00a0;While the U.S. FDA&#x2019;s guidance on SPAs states that documented SPAs should be considered binding on the review division, the U.S. FDA has latitude to change its assessment if certain exceptions apply. Exceptions include public health concerns emerging that were unrecognized at the time of the protocol assessment, identification of a substantial scientific issue essential to the safety or efficacy testing that later comes to light, a sponsor&#x2019;s failure to follow the protocol agreed upon, or the U.S. FDA&#x2019;s reliance on data, assumptions or information that are determined to be wrong.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An SPA request can be requested after a pre<FONT CLASS="nobreak">-Phase</FONT>&#x00a0;III meeting with the U.S. FDA.&#x00a0;It allows the U.S. FDA and sponsor to agree on the study design for a Phase&#x00a0;III study whose efficacy results will be the basis of an NDA.&#x00a0;There is no guarantee that we will request or be able to receive and maintain Fast Track designation, Breakthrough Therapy designation, Priority Review designation, Accelerated Approval designation or a Special Protocol Assessment for any of our product candidates.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Disclosure of Clinical Trial Information</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sponsors of clinical trials of certain U.S. FDA<FONT CLASS="nobreak">-regulated</FONT> products, including prescription drugs, are required to register and disclose certain clinical trial information on a public website maintained by the U.S.&#x00a0;National Institutes of Health. Information related to the product, patient population, phase of investigation, clinical trial sites and investigator, and other aspects of the clinical trial is made public as part of the registration. Sponsors are also obligated to disclose the results of these clinical trials after completion if the product candidate is ultimately approved, and disclosure of the results of these clinical trials will be delayed until such approval. Competitors may use this publicly<FONT CLASS="nobreak">-available</FONT> information to gain knowledge regarding the design and progress of in development programs.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">U.S.&#x00a0;Healthcare Regulation</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Pharmaceutical Coverage and Reimbursement</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United&#x00a0;States, sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third<FONT CLASS="nobreak">-party</FONT> payors. Third<FONT CLASS="nobreak">-party</FONT> payors include government authorities, managed care providers, private health insurers and other organizations. Third<FONT CLASS="nobreak">-party</FONT> payors establish the coverage and reimbursement policies for pharmaceutical products, and the marketability of any products for which we may receive regulatory approval for commercial sale depends on those payors&#x2019; coverage policies and reimbursement rates. Third<FONT CLASS="nobreak">-party</FONT> payors may limit coverage to specific products on an approved list, or formulary, which might not include one or more of our product candidates, if approved. Third<FONT CLASS="nobreak">-party</FONT> payors, together with regulators and others, are increasingly challenging the prices charged for pharmaceutical products and health services, in addition to their cost<FONT CLASS="nobreak">-effectiveness</FONT>, safety and efficacy. In addition, no uniform policy for coverage and reimbursement exists in the United&#x00a0;States. Third<FONT CLASS="nobreak">-party</FONT> payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement rates can vary significantly from payor to payor.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, obtaining coverage and adequate reimbursement is a time<FONT CLASS="nobreak">-consuming</FONT> and costly process. We may be required to provide scientific and clinical support for the use of any product to each third<FONT CLASS="nobreak">-party</FONT> payor separately with no assurance that approval will be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost<FONT CLASS="nobreak">-effectiveness</FONT> of our products. We cannot be certain that our product candidates will be considered cost<FONT CLASS="nobreak">-effective</FONT> by third<FONT CLASS="nobreak">-party</FONT> payors. This process could delay the market acceptance of any product candidates for which we may receive approval and could have a negative effect on our future revenues and operating results.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Other U.S.&#x00a0;Healthcare Laws and Compliance Requirements</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our business may be subject to healthcare fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business, particularly once third<FONT CLASS="nobreak">-party</FONT> reimbursement becomes available for one or more of our products. The healthcare fraud and abuse laws and regulations that may affect our ability to operate include, but are not limited to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The federal Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">157</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs, or other federal healthcare programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, which prohibits, among other things, knowingly presenting, or causing to be presented, claims for payment of government funds that are false or fraudulent, or knowingly making, or using or causing to be made or used, a false record or statement material to a false or fraudulent claim to avoid, decrease, or conceal an obligation to pay money to the federal government;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>HIPAA, which, among other things, prohibits executing a scheme to defraud any healthcare benefit program, including private third<FONT CLASS="nobreak">-party</FONT> payors, and prohibits (i)&#x00a0;knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation and (ii)&#x00a0;making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act&#x00a0;of&#x00a0;2009, or HITECH, and their respective implementing regulations, which impose requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, including health plans, healthcare clearinghouses and certain healthcare providers, and their business associates, individuals or entities that perform certain services on behalf of a covered entity that involve the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The federal Physician Payments Sunshine Act, being implemented as the Open Payments Program, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) to report annually to the CMS, information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in a company by physicians and their immediate family members. Beginning in 2022, applicable manufacturers will also be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse<FONT CLASS="nobreak">-midwives</FONT>; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>U.S.&#x00a0;state and local laws and regulations, such as state anti<FONT CLASS="nobreak">-kickback</FONT> and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non<FONT CLASS="nobreak">-governmental</FONT> third<FONT CLASS="nobreak">-party</FONT> payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that restrict the ability of manufacturers to offer co<FONT CLASS="nobreak">-pay</FONT> support to patients for certain prescription drugs; state laws that require drug manufacturers to report information related to clinical trials, or information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require drug manufacturers to report information on the pricing of certain drugs; state laws and local ordinances that require identification or licensing of sales representatives; state and local laws regarding the manufacturing and distribution of drugs; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not pre<FONT CLASS="nobreak">-empted</FONT> by HIPAA, thus complicating compliance efforts.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">158</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Even then, governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If governmental authorities find that our operations violate any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non<FONT CLASS="nobreak">-compliance</FONT> with these laws, and we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our operations and business. In addition, the approval and commercialization of any product candidate we develop outside the United&#x00a0;States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. The extent to which future legislation or regulations, if any, relating to health care fraud and abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on our business remains uncertain.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Healthcare Reform</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#x00a0;States there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post<FONT CLASS="nobreak">-approval</FONT> activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United&#x00a0;States, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, enacted in March&#x00a0;2010, has substantially changed healthcare financing and delivery by both governmental and private insurers. Among other things the Affordable Care Act included the following provisions:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a new Medicare Part&#x00a0;D coverage gap discount program, in which manufacturers must agree to offer 50% point<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-sale</FONT> discounts, which through subsequent legislative amendments, will be increased to 70%, starting in 2019, off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#x2019; outpatient drugs to be covered under Medicare Part&#x00a0;D;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>extension of manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>expansion of eligibility criteria for Medicaid programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>expansion of the entities eligible for discounts under the 340B Drug Discount Program;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a Patient<FONT CLASS="nobreak">-Centered</FONT> Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a licensure framework for follow<FONT CLASS="nobreak">-on</FONT> biological products.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. Various portions of the Affordable Care Act are currently undergoing legal and constitutional challenges in the United&#x00a0;States Supreme Court and members of Congress have introduced several </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">159</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">pieces of legislation aimed at significantly revising or repealing the Affordable Care Act. The implementation of the Affordable Care Act is ongoing, the law appears likely to continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. Litigation and legislation related to the Affordable Care Act are likely to continue, with unpredictable and uncertain results.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August&#x00a0;2, 2011, the Budget Control Act&#x00a0;of&#x00a0;2011 was signed into law, which, among other things, included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#x00a0;1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2030 unless additional Congressional action is taken. These reductions have been suspended from May&#x00a0;1, 2020 through December&#x00a0;31, 2020 due to the COVID<FONT CLASS="nobreak">-19</FONT> pandemic. The Consolidated Appropriations Act&#x00a0;of&#x00a0;2021, extended the suspension period to March&#x00a0;31, 2021. An Act to Prevent Across<FONT CLASS="nobreak">-the</FONT><FONT CLASS="nobreak">-Board</FONT> Direct Spending Cuts, and for Other Purposes, signed into law on April&#x00a0;14, 2021, has extended the suspension period to December&#x00a0;31, 2021. On January&#x00a0;2, 2013, the American Taxpayer Relief Act&#x00a0;of&#x00a0;2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#x00a0;years.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. For example, for the fiscal year of 2023, the U.S. Department of Health &amp; Human Services, or the HHS, proposes $127.3<FONT CLASS="nobreak"> </FONT>billion in discretionary funding and $1.7 trillion in mandatory funding, including Medicare and Medicaid. On March&#x00a0;10, 2020, the previous administration sent &#x201c;principles&#x201d; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part&#x00a0;D beneficiary out<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-pocket</FONT> pharmacy expenses, provide an option to cap Medicare Part&#x00a0;D beneficiary monthly out<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-pocket</FONT> expenses and place limits on pharmaceutical price increases. Further, the previous administration previously released a &#x201c;Blueprint&#x201d; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May&#x00a0;2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part&#x00a0;B drugs beginning January&#x00a0;1, 2020. This final rule codified CMS&#x2019;s policy change, which was effective as of January&#x00a0;1, 2019. Although a number of these and other measures may require additional authorization to become effective, Congress and the Biden administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. In addition, individual states in the United&#x00a0;States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, it is possible that additional governmental action is taken to address the COVID<FONT CLASS="nobreak">-19</FONT> pandemic. For example, on April&#x00a0;18, 2020, CMS announced that qualified health plan issuers under the ACA may suspend activities related to the collection and reporting of quality data that would have otherwise been reported between May and June&#x00a0;2020 given the challenges healthcare providers are facing responding to the ongoing COVID<FONT CLASS="nobreak">-19</FONT> pandemic.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, on May&#x00a0;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase&#x00a0;I clinical study and that are undergoing investigation for U.S. FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical studies and without obtaining U.S. FDA permission </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">160</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">under the U.S. FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. If we obtain approval to market a product candidate in the United&#x00a0;States, any healthcare reforms adverse to drug manufacturers, including but not limited to, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs, that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on our results of operations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TAIWAN REGULATION</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Company Establishment</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The establishment, operation and management of companies in Taiwan is governed by the Taiwan Company Act, which was latest amended on December&#x00a0;29, 2021. There are four types of companies in Taiwan: unlimited company, unlimited company with limited liability shareholders, limited company and company limited by shares. Unlimited company and unlimited company with limited liability shareholders are rarely used in practice; a company limited by shares is the most common form of business undertaken for foreign investors in Taiwan. The Taiwan Company Act applies to both Taiwan domestic companies and foreign<FONT CLASS="nobreak">-invested</FONT> companies, unless otherwise provided in the relevant foreign investment laws and regulations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Foreign Investment</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The principal regulations governing foreign investments in Taiwan are the Statute for Investment by Foreign Nationals, the Regulations for Verification of Investment by Overseas Chinese and Foreign Nationals, and the Regulations Governing Investment in Securities by Overseas Chinese and Foreign Nationals. In order to efficiently provide services and manage foreign investments, Taiwan government has specifically established the Investment Commission under the Ministry of Economic Affairs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All investments made by foreign nationals within the territory of Taiwan must comply with the provisions of the Statute for Investment by Foreign Nationals and receive permission from the Investment Commission. According to the administrative ordinance &#x201c;Negative List for Investment by Overseas Chinese and Foreign Nationals&#x201d; issued by the Investment Commission, Taiwan maintains a negative list of industries closed to foreign investment as the authorities determine that they relate to national security and environmental protection, including public utilities, power distribution, natural gas, postal service, telecommunications, mass media, and air and sea transportation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Merger and Acquisition</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The main laws and regulations governing merger and acquisition (&#x201c;M&amp;A) activities in Taiwan are the Business Merger and Acquisitions Act, the Company Act, the Securities and Exchange&#x00a0;Act and the Fair Trade Act.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The competent authority in charge of the regulations in relation to M&amp;A is the Ministry of Economic Affairs. The main regulatory body in charge of public M&amp;A transactions is the Securities Futures Bureau of the Financial Supervisory Commission, the government agency in charge of public companies. Other relevant regulatory bodies include the Fair Trade Commission, the authority in charge of antitrust clearance, and the Investment Commission, the authority in charge of reviewing foreign and PRC investments. If the M&amp;A target holds any special license, the transaction may also be subject to the review of the authority in charge of such special license.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except for certain specific sensitive activities, foreign investments are generally not restricted in Taiwan but are subject to the prior approval from the Investment Commission of Taiwan where a foreign investor seeks to acquire 10% or more of the shares of a Taiwan listed company. The approval must be obtained before the final completion of the transaction.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Drug Regulations</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Government Regulation and Competent Authority</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The legal structure of Taiwan consists of the constitution, laws, and regulations. Taiwan&#x2019;s Legislative Yuan established the Pharmaceutical Affairs Act in accordance with the Constitution to protect people&#x2019;s health and sanitation. The Pharmaceutical Affairs Act provides that the drugs are prohibited to be marketed for sale unless they </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">161</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">are approved by the Taiwan Food and Drug Administration (&#x201c;TFDA&#x201d;). In addition to the provisions regarding the licensing procedures, the Pharmaceutical Affairs Act also address the management of pharmaceutical companies, patent linkage of drugs, sales and manufacture of drugs, and drug advertisement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The TFDA is the competent authority for drug management in Taiwan. The TFDA is responsible for approving the license application required by the Pharmaceutical Affairs Act. In addition, the TFDA should continuously monitor and inspect the safety of the drugs from the development stage to the marketing and sales stage. Furthermore, it has the power to penalize those who violate the provisions in the Pharmaceutical Affairs Act.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Review and Approval for Licensing Drugs</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before a drug is permitted to sale as a product on the market, the pharmaceutical firm is required to obtain the following approvals or licenses:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Approval for the investigational new drug application (&#x201c;IND&#x201d;);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Drug license;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Drug manufacturing factory registration;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Drug manufacturing license;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Western pharmaceuticals distribution license;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Approval to publish or broadcast drug advertisement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The process required by the TFDA before a drug may be marketed in Taiwan generally involves the following steps:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Completion of the preclinical research which is incompliance with the Good Laboratory Practice (&#x201c;GLP&#x201d;);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Submission of the IND to the TFDA, which application should be approved before starting the clinical trial;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Completion of the clinical trial which is incompliance with the Regulations for Good Clinical Practice and the Guidance for Good Clinical Practice (collectively as &#x201c;GCP&#x201d;);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Starting from the stage of the clinical trial stage, the investigational drugs and the drug products should be in compliance with the Good Manufacturing Practice (&#x201c;GMP&#x201d;);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Submission of the NDA to the TFDA, along with the complete risk evaluation and mitigation strategy (&#x201c;REMS&#x201d;);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Register the drug manufacturing factory with the Ministry of Economic Affairs and comply with the Factory Management Act;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>After obtaining the approval of the NDA from the TFDA, the pharmaceutical firm should continuously report the adverse drug reactions (&#x201c;ADR&#x201d;) of the drugs to the TFDA, and counsel the obligations provided by the Regulations for the Management of Drug Safety Surveillance and the Good Pharmacovigilance Practices (&#x201c;GPvP&#x201d;);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>After the drug products are manufactured, the pharmaceutical firm shall distribute the products in compliance with the Good Distribution Practice (&#x201c;GDP&#x201d;); and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Every time when the pharmaceutical firm would like to publish or broadcast drug advertisement, it should obtain the TFDA&#x2019;s approval regarding the contents of the advertisement.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">162</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Preclinical Development</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a requirement to apply for the IND, the applicant shall submit the documents containing the drug characteristic data (non<FONT CLASS="nobreak">-clinical</FONT> and clinical trial data such as drug physical and chemical properties, toxic pharmacological effects, pharmacokinetics, etc.). In order to collect the data, the applicant shall conduct pre<FONT CLASS="nobreak">-clinical</FONT> research.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In order to encourage the pharmaceutical firms to develop new drugs, the TFDA has engaged a non<FONT CLASS="nobreak">-profit</FONT> organization, Center for Drug Evaluation (&#x201c;CDE&#x201d;), to involve in the whole process before the new drugs are approved to market in Taiwan. Anyone who intends to apply for the IND can reach out to the CDE for advice before he/she submits the application. When CDE receives the request, it will meet with the potential applicant and provide its advice from the preclinical research stage.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Different from the clinical trial which is human study, the preclinical research is animal testing or testing with the human biological samples in the laboratory. To perform an experiment which may be approved by the TFDA when applying for the IND, the researchers shall conduct the research in compliance with the GLP.&#x00a0;If the applicant for the IND fails to conduct the preclinical research in compliance with the GLP, the TFDA may reject the application for the IND.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Clinical Development</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The IND is valid subject to both the TFDA&#x2019;s and the Institutional Review Board (&#x201c;IRB&#x201d;)&#x2018;s approvals. After the sponsor submits the application documents to the TFDA, including the approval letter of the IRB, the TFDA will starts to examine the application. Depending on the TFDA&#x2019;s discretion, it may form a professional consulting committee, a committee formed by pharmaceutical and medical experts, to evaluate the feasibility of the clinical trial. In practice, if it is the first time for the drug to be applied on human studies, the TFDA is more likely to form the committee and come out with the decision after considering the committee&#x2019;s conclusion. Generally, the TFDA comes out with a decision whether to approve the application or not around&#x00a0;60<FONT CLASS="nobreak">-90</FONT>&#x00a0;days. Once the sponsor obtains the TFDA&#x2019;s approval, the sponsor is permitted to administer the investigational product to humans.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The clinical trials are typically conducted in the following three phases:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Phase&#x00a0;I:&#x00a0;&#x00a0;&#x00a0;&#x00a0;The purpose for Phase&#x00a0;I is mainly to understand the safe dose of the drug, the highest dose that can be tolerated by the human body. This phase is usually performed by experienced physicians in specific clinical trial wards. Pursuant to Regulations for Registration of Medicinal Products, there should be at least 10 valid Taiwanese subjects for a Phase&#x00a0;I clinical trial, such as pharmacokinetics study or pharmacodynamics study.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Phase&#x00a0;II:&#x00a0;&#x00a0;&#x00a0;&#x00a0;Through studying with a group of patients with high homogeneity, the efficacy and safety of the drug is able to be explored out. Phase&#x00a0;II is a clinical trial for a small number of patients, usually dozens of people. The outcome of the Phase&#x00a0;II clinical trial will be referred to evaluate how many subjects should be included in Phase&#x00a0;III.&#x00a0;Pursuant to Regulations for Registration of Medicinal Products, there should be at least 20 valid Taiwanese subjects for a phase&#x00a0;II clinical trial.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Phase&#x00a0;III:&#x00a0;&#x00a0;&#x00a0;&#x00a0;In this phase, a larger<FONT CLASS="nobreak">-scale</FONT> clinical trial will be conducted. The design is generally carried out in the form of random allocation, double<FONT CLASS="nobreak">-blind</FONT> and controlled trials, etc., mainly to verify the efficacy and safety of the drug, as a pre<FONT CLASS="nobreak">-marketing</FONT> trial. Pursuant to Regulations for Registration of Medicinal Products, there should be at least 80 valid Taiwanese subjects for a Phase&#x00a0;III pivotal trial; and the results have to show the similarity between Taiwan and other countries.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Though Regulations for Registration of Medicinal Products provides the standard number of the subjects, if the TFDA deems necessary, it has the power to request the investigator or the sponsor to include more subjects on grounds of the improvement in quality, safety or efficacy of the drug, the nation&#x2019;s welfare or special circumstances.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">163</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the whole process of the clinical trials, the clinical trials shall always comply with the GCP Rules. The obligations provided in the GCP Rules include the following four aspects:</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-2" STYLE="text-decoration:underline;">Alarm Reporting Requirements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any of the following events occurs, the investigator or the sponsor of the clinical trial shall report to the TFDA:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The investigator or the sponsor decides to suspend or terminate the clinical trial;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>If the clinical trial has a data safety monitoring board (&#x201c;DSMB&#x201d;), and the DSMB decides that certain issues should be reported to the TFDA;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>If the investigator has implemented the deviation or change of the protocol; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Any unexpected serious adverse reactions have occurred.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-2" STYLE="text-decoration:underline;">Submitting the Reports</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the GCP rules, the investigator or the sponsor is not required to provide periodic reports to the TFDA.&#x00a0;However, the TFDA is entitled to request the investigator or the sponsor to provide specific reports. For example, the TFDA may require the investigator or the sponsor to provide the safety reports or the report elaborating the trial status. Though the periodic reports are not a requirement, the sponsor is required to submit a clinical trial report upon the end of the clinical trial. Along with the clinical trial report, a risk management plan should also be submitted.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-2" STYLE="text-decoration:underline;">Complying with the GMP</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The GCP Rules provides that the manufacturing, handling and storage of the investigational product(s)&#x00a0;shall comply with the GMP.&#x00a0;Whether the product complies with the GMP is relevant to the quality of the products. Therefore, the GMP compliance requirement is required not only in the clinical trial stage, but also in the stage after the NDA is approved.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To verify whether the clinical trial complies with the GCP Rules, the TFDA has the power to inspect the sponsor and the trial site at any time. In practice, the TFDA does not inspect all of the clinical trials but focus only on those trials relating to human studies involving new drugs. If the TFDA requests to inspect, the sponsor and the trial site shall cooperate with the inspection without interruption.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-2" STYLE="text-decoration:underline;">Bridging Study Evaluation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the clinical trial is conducted outside Taiwan, the TFDA may accept the outcome from such foreign clinical trial as part of the NDA documents, provided that the applicant has completed the bridging study evaluation (&#x201c;BSE&#x201d;) in Taiwan.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A BSE is carried out through evaluating the data of pharmacokinetics/pharmacodynamics, efficacy, safety, and dosage to evaluate whether the foreign clinical trial data can be extrapolated to the corresponding population in Taiwan. The BSE data can be used to support new drug applications and to reduce duplicate clinical trials. An applicant should submit documents in accordance with the requirements set forth in the Guidelines on Bridging Studies, and verify whether the drug is regarded as requiring a BSE before submission.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the BSE requirement, if a foreign clinical trial is included in the NDA, the TFDA will also evaluate if the foreign clinical trial is in compliance with those laws and regulations which the domestic clinical trial shall comply, such as the GCP and GMP.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">NDA Submission and Review</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the clinical trial is completed, and the applicant has prepared the required documents, the applicant can submit the NDA to the TFDA.&#x00a0;The NDA review process conducted by the TFDA mainly focuses on three aspects.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">164</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The first aspect is to examine the safety and the efficacy of the drugs. At this stage, the TFDA focuses on (i)&#x00a0;if the chemical, manufacturing and regulatory data can show that the quality of the raw materials and preparations of the drug is well controlled, and has stable quality consistency between different batches; (i)&#x00a0;if the pharmacological and toxicological data of animals can support the mechanism of action of the drug and can fully evaluate the possible potential toxic reactions; (iii)&#x00a0;if the basic pharmacokinetics/pharmacodynamics of the drug can be understood from the pharmacokinetic/pharmacodynamic data of animals and humans The pharmacokinetic information of the drug in special groups and the interaction information with other drugs are helpful to evaluate the rationality of the dosage adjustment of the drug in special groups and in combination with other drugs; and (iv)&#x00a0;if the results of clinical trials can show that the drug has credible curative effect and acceptable safety in the group of declared indications, so as to support the rationality of the claimed usage and dosage.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The second aspect is to examine the quality of the drugs. At this stage, the TFDA will examine the chemistry, manufacturing and controls (&#x201c;CMC&#x201d;), and will perform the audit to examine if the clinical trial is in compliance with the GMP, GLP and GCP.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The third aspect is to examine the labeling of the drugs. At this stage, the TFDA will evaluate whether the direction of use shown on the labeling is appropriate and will not mislead the patients.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the TFDA receives the NDA, it will convene a filing meeting within 30&#x00a0;days to verify if the application is submitted along with all required documents. If the application lacks required documents, the TFDA will issue a notice before the 42<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT>&#x00a0;day to inform the applicant that the application is not qualified. On the other hand, if the application meets the requirements, the TFDA will not issue any notice to the applicant on the 42<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT>&#x00a0;day. The TFDA will then convene a review meeting before the 100<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT>&#x00a0;day. On the review meeting, if the examiners decide that the applicant should provide supplementary documents, the TFDA will issue a request letter to the applicant before the 120<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT>&#x00a0;day. If the applicant provides the supplementary documents on time, the TFDA will then convene another review meeting before the 210<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT>&#x00a0;day and will complete the review report before the 315<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT>&#x00a0;day. If the TFDA decides to approve the NDA, it will issue the approval letter before the 330<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT>&#x00a0;day. Generally, the applicant is able to obtain the drug license around the 360<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT>&#x00a0;day after the submission.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Post-Approval</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> Requirements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the TFDA approves the NDA, the new drug products are obligated to comply with several laws and regulations. The post<FONT CLASS="nobreak">-approval</FONT> requirements under the Pharmaceutical Affairs Act and its relative regulations mainly relating to four aspects:</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-2" STYLE="text-decoration:underline;">Manufacturing</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Pharmaceutical Affairs Act, the manufacturer of the drugs is prohibited from manufacturing prior to registering its manufacturing factory with the Ministry of Economic Affairs and obtaining the manufacturing License from the TFDA (&#x201c;Manufacturing License&#x201d;). In practice, the registration of the factory and the Manufacturing License will be issued by the respective authorities at almost the same time upon the approval of the NDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">When operating the factory, the manufacturers are required to continuously comply with applicable laws and regulations; otherwise, the Ministry of Economic Affair is entitled to de<FONT CLASS="nobreak">-register</FONT> the factory.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Manufacturing License is valid for two&#x00a0;years. When the two year period expires, the manufacturer shall apply for another Manufacturing License. As continuous compliance of the GMP is the requirement for the TFDA to issue the Manufacturing License, the manufacturer shall always comply with the GMP.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-2" STYLE="text-decoration:underline;">Distribution</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The manufacturer of pharmaceuticals is obliged to obtain a pharmaceuticals distribution license (&#x201c;Distribution License&#x201d;) before distributing the products. The requirement for the TFDA to issue the Distribution License is that the manufacturer shall comply with the GDP.&#x00a0;The Distribution License is valid for&#x00a0;3<FONT CLASS="nobreak">-5</FONT>&#x00a0;years, subject to the TFDA&#x2019;s discretion. If the manufacturer fails to comply with the GDP, the TFDA is entitled to reject the renewal of the Distribution License, leading to the suspension of the distributing of the drug products.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">165</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-2" STYLE="text-decoration:underline;">Advertisement</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In order to prevent pharmaceutical firms from conveying misleading information to the public, the Pharmaceutical Affairs Act provides that the pharmaceutical firm should obtain the approval of the TFDA before publishing or broadcasting drug advertisement. If the pharmaceutical firm fails to comply with the provision, the TFDA shall announce in the newspaper the name of the responsible person of the pharmaceutical firm, the name of the drug, and the act of violation. In the case of serious violation, the approval of the NDA may be revoked by the TFDA, along with the restriction that no application for use of the original name of the said drug shall be accepted within a period of two&#x00a0;years thereafter.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-2" STYLE="text-decoration:underline;">Drug Safety Surveillance</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In order to ensure the quality, efficacy and safety of drugs, and to reduce the incidence of adverse drug reactions, the pharmaceutical firm is required to survey the safety of the drugs and to report any serious adverse reactions caused by drugs to the TFDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Regulations for the Management of Drug Safety Surveillance (&#x201c;Surveillance Regulations&#x201d;) provides the main obligations which the pharmaceutical firm shall fulfil. Under the current Surveillance Regulations, in addition to reporting any serious adverse reactions within the period provided by the Regulations for Reporting Severe Adverse Reactions of Drugs, the pharmaceutical firm shall also submit drug safety update reports periodically during the first five&#x00a0;years after the pharmaceutical firm obtains the drug license.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Though such provisions are still in effect as of now, the TFDA has already promulgated the amendment of the Surveillance Regulations in April&#x00a0;2022, and the amendment will come into effect from January&#x00a0;1, 2023. Pursuant to the amendment, the TFDA extends the surveillance period from the first five&#x00a0;years upon the pharmaceutical firm obtaining the drug license to the whole effective period of the drug license. As long as the drug license is in effect, the pharmaceutical firm shall keep tracking the safety of the drugs. Pursuant to the amendment, the pharmaceutical firm shall have a pharmacovigilance plan as its internal policy. During the surveillance period, which is also the effective period of the drug license, the pharmaceutical firm shall follow its own pharmacovigilance plan and take mitigation measures, if necessary. In addition to keep submitting the periodic drug safety update reports during the first five&#x00a0;years just as current practice, the pharmaceutical firm shall also submit a drug safety summary report at the end of the first five&#x00a0;years of the surveillance period. For the remaining period of the surveillance period, the pharmaceutical firm should only keep implementing its pharmacovigilance plan without submitting the update reports to the TFDA.&#x00a0;However, if the TFDA considers necessary, it may request the pharmaceutical firm continues to collect the data and submit the periodic update for a designated period. Furthermore, the TFDA may provide such request more than once.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Intellectual Property Rights</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Patent Protection</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Taiwan Patent Act, amended on May&#x00a0;4, 2022, there are three types of patents in Taiwan: invention patents, utility model patents, and design patents. The respective patent terms are<FONT CLASS="nobreak"> </FONT>20,<FONT CLASS="nobreak"> </FONT>10, and 15&#x00a0;years, all calculated from the filing date of a patent application, while the patent rights are actionable from the issue date of the patent. An extension of patent term of a maximum of 5&#x00a0;years is possible for invention patents involving pharmaceuticals, agrichemicals, or manufacturing processes thereof to compensate for the regulatory delay caused by marketing authorization procedures.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In terms of the infringement disputes of a patent, the civil division of the Intellectual Property Court (&#x201c;IP Court&#x201d;) hears civil actions relating to patent infringement. If the defendant of an infringement action challenges the validity of the disputed patent as a defense, the civil division will deal with the infringement and validity issues simultaneously. However, any person who intends to invalidate the disputed patent in all aspects must file revocation proceedings (invalidation action) with the TIPO.&#x00a0;Decisions of the TIPO in an invalidation action can be appealed to the Ministry of Economic Affairs, and subsequently to the IP Court by way of filing an administrative lawsuit.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">166</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-2" STYLE="text-decoration:underline;">Patent Term Extension</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Patent Act, where a regulatory approval shall be obtained for the exploitation of an invention patent involving a pharmaceutical or agrichemical, or the manufacturing process thereof, if such regulatory approval is obtained after the publication of the concerned invention patent, the patentee may apply for one and only one extension of the patent term of said invention patent based on the first regulatory approval. The said regulatory approval is allowed to be used only once for seeking patent term extension.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The calculation of the extension period includes: (i)&#x00a0;the period of clinical trials conducted for obtaining a pharmaceutical license from the TFDA; and (ii)&#x00a0;the period for the NDA review process. The extension period approved shall not exceed the length of time when the patent cannot be exploited because of the filing of a request for the regulatory approval with the competent authorities in charge of the business. If the time needed to obtain the said regulatory approval exceeds five&#x00a0;years, the granted patent term extension shall still be five&#x00a0;years. When requesting for patent term extension, the request shall be submitted within three&#x00a0;months after obtaining the first regulatory approval; no request for patent term extension shall be filed within six&#x00a0;months prior to the expiry of the original patent term.</P>
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-2" STYLE="text-decoration:underline;">Patent Linkage System</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Taiwan has established the patent linkage system through the Patent Act and the Pharmaceutical Affairs Act in 2018. In order to reduce the patent search burden of generic drug manufacturers and achieve the goal of early listing of generic drugs, the first important procedure of the patent linkage system is to enable generic drug manufacturers to quickly grasp the patent status of the brand drug. That is to say, since the purpose of patent linkage system is to avoid patent infringement disputes of generic drugs on the market, the generic pharmaceutical firm should be able to know what patent rights the brand drug has. Therefore, after the brand drug manufacturer obtains the drug license, patent information of new drugs should be disclosed within the statutory period.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since the brand drug manufacturer is obliged to announce the patent rights of the new drug, there should be a corresponding procedure to require the generic pharmaceutical company to clarify and determine whether it will have a patent in the future within certain period. If the brand drug does not involve any patent rights or all patent rights have been extinguished, the TFDA should allow the generic drug to be marketed. In addition, if the brand drug is still protected by the patent right, and the generic pharmaceutical company has no intention of having an infringement dispute with the brand drug pharmaceutical company, then the TFDA should only allow the generic drug to be marketed after all patent rights have expired. On the other hand, if a generic drug intends to obtain the drug license earlier, it should avoid infringing on the patent right in the future.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As Taiwan adopts a double<FONT CLASS="nobreak">-track</FONT> examination system in terms of patent invalidation procedures, anyone who intends to invalidate a patent may take two kinds of measures; one is to submit the application of ground for patent invalidation to the Taiwan Intellectual Property Office (&#x201c;TIPO&#x201d;); the other one is to file a lawsuit. Subject to such double<FONT CLASS="nobreak">-track</FONT> examination system, if the generic drug manufacturer intends to obtain the drug license earlier, it may the following actions: </P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;">(i)<FONT STYLE="width: 17px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Engaging in patent avoidance designs;</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(ii)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Challenging the validity of the drug patent right through submitting the application of ground for patent invalidation to the TIPO;</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(iii)<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT>While the brand drug pharmaceutical firm files a patent infringement lawsuit against the generic drug pharmaceutical company, it may defend that the patent right of the brand drug has grounds for revocation; and</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(iv)<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT>Filing a lawsuit to request the court to confirm that the generic drug does not infringe the patent right.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before it is clarified whether the generic drug manufacturer has successfully avoided infringing the patent right or whether the patent right of the brand drug is invalid, patent infringement disputes may arise if the generic drug has been approved to obtain the drug license. Therefore, the Pharmaceutical Affairs Act provides that the drug license cannot be issued within 12&#x00a0;months, commencing from the date when the brand drug manufacturer receives the notice from the generic drug manufacturer regarding whether the drug patent is in doubt. With such provision, the brand drug manufacturer and the generic drug manufacturer have a certain period of time to clarify doubts through filing the application to the TIPO or filing the patent infringement lawsuit.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">167</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H6" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-2" STYLE="text-decoration:underline;">Market Exclusivity</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a supporting measure of the patent linkage system, the Pharmaceutical Affairs Act rewards generic drug manufacturers who take positive actions to achieve the legislative intention of promoting the early marketing of generic drugs. Such reward is that those generic drugs which meet the legal requirements have a 12<FONT CLASS="nobreak">-month</FONT> exclusive sales period. During this 12<FONT CLASS="nobreak">-month</FONT> exclusive period, only the brand drug and the generic drug exist on the market. Before the period expires, the TFDA will not approve other generic drugs for marketing, so that generic drugs that actively challenge the validity of the patent of the brand drug or engage in patent avoidance design may enjoy certain profits and rewards.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Copyright</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Taiwan Copyright Law provides that original copyrightable works shall enjoy exclusive rights automatically upon their completion, with no form of registration required. The competent authority for the application and registration of trademarks is the Taiwan Intellectual Property Office (&#x201c;TIPO&#x201d;) under the Ministry of Economic Affairs. A copyrighted work is protected throughout the author&#x2019;s lifetime and 50&#x00a0;years after.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a copyright holder, when enforcing a copyright, bears the burden of proving the copyright ownership (and sometimes even the creation time of the copyright, if such issue is being raised), relevant evidence of copyright ownership can be preserved by having the evidence notarized by a notary public. For important copyrighted work, it is recommendable to obtain a copyright certificate issued by a copyright owners&#x2019; organization to serve as prima facie evidence of the completion and ownership of the copyright. However, it is important to note that such private organizations do not and cannot conduct any substantive examination of the copyrightability of a work. Therefore, when a work&#x2019;s copyrightable is being challenged, only a court will have a final say over such dispute on a case<FONT CLASS="nobreak">-by</FONT><FONT CLASS="nobreak">-case</FONT> basis.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Trademarks</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Trademark rights in Taiwan are governed by the Trademark Act. The competent authority for the application and registration of trademarks is the TIPO.&#x00a0;Types of protection include trademarks, certification marks, collective membership marks and collective trademarks. The trademarks which are registered are protected for 10&#x00a0;years from publication in the Trademark Gazette. This term may be extended successively every 10&#x00a0;years via application for renewal.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Trade Secrets</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Taiwan Trade Secret Act mainly governs the following items: (1)&#x00a0;the required elements of a trade secret; (2)&#x00a0;ownership of a trade secret; (3)&#x00a0;the licensing of a trade secret; (4)&#x00a0;misappropriation of a trade secret; (5)&#x00a0;the civil remedy and criminal penalty for the misappropriation of a trade secret; (6)&#x00a0;the issuance of a protective order during criminal investigation. Pursuant to the Trade Secret Act, the information that can be protected under the Trade Secret Act is defined as any method, technique, process, formula, program, design, or other information that may be used in the course of production, sale or operation, and must meet the following requirements: (1)&#x00a0;secrecy; (2)&#x00a0;economic value; and (3)&#x00a0;reasonable measures to maintain secrecy. Under the Trade Secret Act, the types of misappropriation include acquisition, use and divulging of a trade secret by unlawful means. The Trade Secret Act provides civil remedies and criminal penalties for trade<FONT CLASS="nobreak">-secret</FONT> misappropriation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TFDA Expedited Programs</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The TFDA has developed five expedited programs to help to accelerate the application process, include abbreviated review program, priority review program, accelerated approval program, breakthrough therapy program, and pediatric and rare severe disease priority review voucher program. The TFDA is responsible for evaluating applications for designation. There are specific criteria for each expedited program. If a drug meets these criteria, it is eligible for expedited programs. At the time of NDA submission, the applicant should provide the designation letter.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the abbreviated review program, the qualifying criteria include that (i)&#x00a0;the drug should be New chemical entities (&#x201c;NCE&#x201d;); (ii)&#x00a0;the drug has been approved by two of the three regulatory agencies (U.S. FDA, EMA, or MHLW/PMDA); and (iii)&#x00a0;No ethnic difference in BSE.&#x00a0;Under the abbreviated review program, the review process may be completed within 180&#x00a0;days, commencing from the submission date of the NDA.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">168</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the priority review program, the drug should qualify two of the three qualifying criteria, including (i)&#x00a0;the drug is NCE or new administration routes or new therapeutic compounds; (ii)&#x00a0;the drug is intended to treat a serious condition and address an unmet medical need with major clinical advance; (iii)&#x00a0;the drug is intended to address a public health or an unmet medical need which is under priority counseling and grant for research from the government. The review process will be shorter than standard review; however, the evaluation will be under normal TFDA approval standards in safety, effectiveness, and quality. Under the priority review program, the review process may be completed within 240&#x00a0;days, commencing from the submission date of the NDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the accelerated approval program, the qualifying criteria include that (i)&#x00a0;the drug is NCE or new administration routes or new therapeutic compounds; (ii)&#x00a0;the drug shall meet one of the following criteria: (a)&#x00a0;A drug is intended to treat a serious condition and address unmet medical need; or (b)&#x00a0;A drug is intended to address an unmet medical need and granted as orphan drug in US, UK, Japan, Switzerland, Canada, France, Australia, Germany, Belgium, and Sweden; or (c)&#x00a0;A drug is not an orphan drug in Taiwan; however, it is intended to address an unmet medical need and with difficulties of manufacturing or importing. The drug in accelerated approval program may be approved on the basis of the effect on a surrogate endpoint to predict clinical benefit. It can shorten the time from R&amp;D to marketing. In principle, post<FONT CLASS="nobreak">-marketing</FONT> confirmatory trials are required to verify its clinical benefit. Under the accelerated approval program, the review process may be completed within 240&#x00a0;days, commencing from the submission date of the NDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the breakthrough therapy program, the qualifying criteria include that (i)&#x00a0;the drug is NCE or new administration routes or new therapeutic compounds; (ii)&#x00a0;preliminary clinical evidence indicates substantial improvement over available therapies on one or more clinically significant endpoints; (iii)&#x00a0;the applicant has conducted at least a clinical trial in Taiwan, especially clinical trials in the early phase. The applicant should report the implementation progress and the R&#x00a0;&amp; D plan to TFDA at least every 3&#x00a0;months after designation. If an applicant has any regulatory issue, they can request the consultation with TFDA.&#x00a0;Under the breakthrough therapy program, the review process may be completed within 240&#x00a0;days, commencing from the submission date of the NDA.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the pediatric and rare severe disease priority review voucher program, the qualifying criteria include that (i)&#x00a0;the drug is NCE or new administration routes or new therapeutic compounds; (ii)&#x00a0;the drug is intended to treat a serious condition; (iii)&#x00a0;the disease is mainly prevalent in pediatric population or the prevalence of the disease is less than five per ten thousand; (iv)&#x00a0;the drug is intended to address an unmet medical need. Under the pediatric and rare severe disease priority review voucher program, the review process may be completed within 240&#x00a0;days, commencing from the submission date of the NDA.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Taiwan Healthcare Regulation</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Drug Price Regulations</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Taiwan has been implementing a compulsory, universal, single<FONT CLASS="nobreak">-payer</FONT> national health insurance system since 1995, with the overall coverage reaching 99.9%. The benefit package is comprehensive, covering inpatient, outpatient, and dental services, traditional Chinese medicine, and so on. Most drugs including orphan drugs, target therapy drugs, and many expensive drugs are covered. In Taiwan, the National Health Insurance Agency (&#x201c;NHI&#x201d;), one of the departments of the Ministry of Health and Welfare, imposes direct price controls on drugs by fixing the reimbursement prices product by product. Every one or two&#x00a0;years, the NHI implements the price regulation to re<FONT CLASS="nobreak">-set</FONT> (usually decrease) the reimbursement price of each product. According to NHI&#x2019;s Principles on Drug Reimbursement Price Approval, a new drug is defined as a newly applied pharmaceutical product that owns a new chemical entity, new dosage form, new administrated route or new therapeutic effect compound to the listed items in the pharmaceutical benefit scheme. New drugs are further categorized as breakthrough, generic, and line extension based on drug innovation. Different reimbursement price policies are applied in accordance with how drugs are categorized based upon these definitions.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">National Health Insurance Reform</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Due to the Taiwan healthcare system&#x2019;s accessibility, Taiwan&#x2019;s healthcare expenditures have increased steadily over the&#x00a0;years, and there is currently a budget shortfall. During recent&#x00a0;years, there have been calls to reform Taiwan&#x2019;s National Health Insurance to avoid bankruptcy of the healthcare system.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">169</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a large portion of the healthcare expenditures arise from the drug reimbursement, one of the main targets in the reform plan is to utilize the healthcare budget more reasonably and to allocate more reimbursement on new drugs considering patients&#x2019; benefits.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In order to achieve such goal, the National Health Insurance Agency has taken some reform measures since 2018. The National Health Insurance Agency has adopted the mechanism of managed entry agreement to set up an upper limit of drug expenditures in order to mitigate the financial impact caused by new drugs on the National Health Insurance. Though under the managed entry agreement mechanism, the price of the new drugs is subject to limitation, the National Health Insurance Agency have increased its budgets on new drug reimbursement during 2020 to 2021, to achieve a balance between including more new drugs in the medical insurance coverage and the financial impact it may cause to the healthcare system.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Other Healthcare Compliance Requirements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Though Taiwan does not enact a special law for the management of the healthcare fraud, healthcare fraud shall be prosecuted under the Criminal Code. In order to establish a clearer standard for the pharmaceutical firms and the doctors to follow, the TFDA has published the Rule of the Relationship Between the Doctors and the Pharmaceutical Firms. Though such rule does not have mandatory enforcement, the court may refer to such rule as the standard to judge whether the behavior of doctors or pharmaceutical firms constitute fraud as defined in the Criminal Code.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Consumer Protection</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In Taiwan, the main regulation governing the consumer protection is the Consumer Protection Act. Pursuant to the Consumer Protection Act, a manufacture shall be liable for any damage caused by its products, unless it is able to prove that the products have met and complied with the contemporary technical and professional standards of reasonably expected safety requirements prior to the launching of such products into the market. Furthermore, if the products may endanger consumers&#x2019; lives, bodies, health or property, they shall be labelled in a conspicuous place with a warning and the methods for emergency handling of such danger. If an enterprise fails to perform its labelling obligations in this regard, it will be held liable for the damage caused thereby.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the Consumer Protection Act, Taiwan regulations also provide special liability regimes for medicinal products. Pursuant to the Drug Injury Relief Act, the pharmaceutical manufactures and importers are required to make contributions to the Drug Injury Relief Fund according to a certain percentage of their drug sales in the previous year. Under the Drug Relief Act, alleged victims or their heirs/legal guardians may apply for drug injury compensation for death, disability and serious illness. Violation of such provision may result in fines.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Personal Data Protection</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Personal Data Protection Act is the main law in Taiwan governing personal data protection. Under the Personal Data Protection Act, unless otherwise specified, a company is generally required to give notice to and obtain consent from an individual before collecting, processing, or using any of the said individual&#x2019;s personal information, subject to certain exceptions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Personal Data Protection Act, the personal data pertaining to a natural person&#x2019;s medical records, healthcare, genetics, sex life, physical examination and criminal records is classified as sensitive personal data, which shall be subject to certain stricter obligations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the Personal Data Protection Act, when conducting the clinical trial, the sponsor and the investigator shall also comply with other relative regulations or practices with regard to the protection of the subject&#x2019;s personal data, such as the Human Subjects Research Act and the Regulations on Human Trials.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Environmental Protection</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The bedrock of environmental protection in Taiwan is the Basic Environment Act. In addition to the Basic Environment Act, Taiwan regulations regulate each type of pollution by a different set of regulations, including the Soil and Groundwater Pollution Remediation Act, the Waste Disposal Act, the Air Pollution Control Act, the </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">170</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Water Pollution Control Act, and Toxic and Concerned Chemical Substances Control Act. The competent authority governing the environmental regulations is the Environmental Protection Agency (EPA). Failure to comply with such regulations may result in fines and other administrative sanctions.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Foreign Currency Exchange</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The principal regulation governing foreign currency exchange in Taiwan is the Foreign Exchange Regulation&#x00a0;Act, amended on April&#x00a0;29, 2009. Pursuant to the Foreign Exchange Regulation&#x00a0;Act, Taiwan Dollars amounting under the amount of NTD$500,000 are freely convertible no matter what transaction they are in relation with. On the other hand, the transactions involving NTD$500,000 or more or its equivalent in foreign currency shall fulfill certain obligations as provided in the Regulations Governing the Declaration of Foreign Exchange Receipts and Disbursements or Transactions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Regulations Governing the Declaration of Foreign Exchange Receipts and Disbursements or Transactions, for those foreign exchange transactions which amounts more than NTD$500,000 and relates to the sales of goods or provision of services, such transaction shall be declared through filing a declaration statement. For those foreign exchange transactions which are not related to the sales of goods or provision of services, ranging from NTD$500,000 to US$ 50&#x00a0;million, such transaction shall be declared through filing a declaration statement, and providing supporting documents, such as contracts or letters of approval, to the bank. For those foreign exchange transactions which are not related to the sales of goods or provision of services, amounting more than USD&#x00a0;50&#x00a0;million, such transaction shall be declared through filing a declaration statement, providing supporting documents to the bank, and obtaining the approval of the Central Bank of Taiwan.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Though Taiwan government has promulgated the Regulations Governing Foreign Exchange Control on July&#x00a0;2, 1997, pursuant to the Foreign Exchange Regulation&#x00a0;Act, the requirements for the government to implement those foreign exchange control measures should be subject to either of the following conditions: (1)&#x00a0;When the domestic or foreign economic disorder might endanger the stability of the domestic economy; and (2)&#x00a0;When Taiwan suffers a severe balance of payments deficit. From the past history, the Taiwan government only implemented these foreign exchange control measures once, in 1997 during the Asian Financial Crisis.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Dividend Distribution</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The principal regulations governing dividend distribution is the Company Act. Pursuant to the Company Act, a Taiwan company shall not pay dividends unless its losses have been covered and statutory reserve funds has been set aside, which should be 10% of the company&#x2019;s after<FONT CLASS="nobreak">-tax</FONT> net profits. However, in the event that the company&#x2019;s statutory reserve funds have reached the total amount of the company&#x2019;s capital, the company does not need to set aside any amounts for its statutory reserve funds. If the company has no net profits, in principle, it shall not pay dividends.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Employee Stock Incentive Plan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The principal regulations governing dividend distribution is the Company Act. Pursuant to the Company Act, a Taiwan company may choose to implement the employee stock incentive plan in 5 ways: (1)&#x00a0;employee stock compensation, (2)&#x00a0;employee stock option certificates, (3)&#x00a0;employee subscription of new shares using cash as consideration, (4)&#x00a0;treasury shares transferred to employees, (5)&#x00a0;employee restricted share units. After the amendment of the Company Act on August&#x00a0;1, 2018, transferring the company&#x2019;s stocks to the employees of the company&#x2019;s parent company or its subsidiaries under the employee stock incentive plan is also permitted by law.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Employment and Social Insurance</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The labor law in Taiwan is regulated mainly by the Labor Standards Act, amended in June&#x00a0;2020. The Labor Standards Act governs the terms and conditions of employment such as working&#x00a0;hours, holidays, rest periods, wages, overtime, leave, and termination of employment. According to Labor Standard Act, an employer is required to reach an agreement on salary with the employees, in which the agreed salary shall meet with the minimum amount set by the competent authority. Violations of the Labor Standards Act may result in fines and other administrative sanctions, and serious violations may result in criminal liabilities.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">171</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In order to protect workers&#x2019; safety and health and to prevent occupational accidents, employers in Taiwan are also required to comply with the Occupational Safety and Health Act. According to the Occupational Safety and Health Act, the employer shall arrange safety equipment to prevent any emergency. In addition, the employer shall provide safety education and training for employees which shall enable the employees to protect themselves when any accident occurs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Taiwan governmental authorities have passed a variety of laws and regulations regarding social insurance and employee&#x2019;s pension from time to time, including, among others, the Labor Insurance Act, the National Health Insurance Act, the Labor Pension Act, and the Employment Insurance Act. Pursuant to these laws and regulations, Taiwan companies must make contributions at specified levels for their employees to the relevant social insurance and pension funds. Failure to comply with such laws and regulations may result in various fines and legal sanctions.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Taxation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the Taiwan&#x00a0;Income Tax Act, a company incorporated in Taiwan is a Taiwan tax resident and will be subject to 20% corporate income tax on its worldwide income. A non<FONT CLASS="nobreak">-resident</FONT> company will be subject to 20% corporate income tax on its Taiwan<FONT CLASS="nobreak">-sourced</FONT> income. If a resident company does not distribute its financial earnings generated in a year to its shareholders by the end of the following year, a surtax of 5% would be imposed on the undistributed earnings.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective from 2020, the Taiwan&#x00a0;Statute for Industrial Innovation was amended, which extends the tax incentive by 10&#x00a0;years until December&#x00a0;31, 2029 for research and development (&#x201c;R&amp;D&#x201d;) expenditure. Under the tax incentive program, a company conducting qualifying R&amp;D activities may select one of the following incentives: (i)&#x00a0;up to 15% of qualifying R&amp;D expenses may be credited against corporate income tax payable in the current year; or (ii)&#x00a0;up to 10% of qualifying R&amp;D expenses may be credited against corporate income tax payable in the year expenses incurred and carried forward for the next 2&#x00a0;years. In addition, if a company uses NTD 1&#x00a0;million or more of its undistributed earnings to construct or purchase buildings, software or hardware equipment, or technology for use in production or operation within 3&#x00a0;years from the year such earnings are derived, such investment amounts may be deducted from the undistributed earnings in calculation of the current year&#x2019;s undistributed earnings for assessment of surtax imposed on undistributed earnings from the year 2018.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The alternative minimum tax (&#x201c;AMT&#x201d;) imposed under the Taiwan&#x00a0;Income Basic Tax Act is a supplemental income tax which applies if the amount of regular income tax calculated pursuant to the Taiwan&#x00a0;Income Tax Act and relevant laws and regulations is below the amount of basic tax prescribed under the Taiwan&#x00a0;Income Basic Tax Act. The taxable income for calculating AMT includes most income that is exempt from income tax under various legislations, such as capital gains from qualified securities and future transactions. The prevailing AMT rate for business entities is 12%.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the Taiwan&#x00a0;Income Tax Act, a withholding tax rate of 21% shall generally be applicable to dividends distributed to non<FONT CLASS="nobreak">-Taiwan</FONT> resident enterprise/individual investors. The withholding tax on the dividends may be reduced pursuant to a tax treaty between Taiwan and the jurisdictions in which the non<FONT CLASS="nobreak">-Taiwan</FONT> shareholders reside. Taiwan currently has a treaty network with 34 countries.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SINGAPORE</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Intellectual Property Rights</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Intellectual Property Office of Singapore administers the intellectual property legislative framework in Singapore, which includes copyrights, trademarks and patents. Singapore is a member of the main international conventions regulating intellectual property matters, and the WTO&#x2019;s Agreement on Trade Related Aspects of Intellectual Property Rights.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Copyright</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Copyright Act&#x00a0;2021 of Singapore, authors of protected works enjoy various exclusive rights, including the rights of reproduction and communication to the public. Generally, an author will automatically enjoy copyright protection as soon as he creates and expresses an original work in a tangible form. Authors and performers also have a distinct right to be identified whenever their works or performances are used in public unless exceptions </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">172</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">apply. For commissioned works, the copyright will be owned by the author by default, unless otherwise agreed by contract. On the other hand, employers by default own the copyright in all content created by their employees in the course of the employees&#x2019; employment, unless otherwise agreed by contract.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There is no need to file for registration to obtain copyright protection. Copyright works sent over the internet or stored on web servers are treated in the same manner as copyright material in other media. Online games and computer programs would qualify for such copyright protection, for example, as literary works, artistic works and/or cinematograph films.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Trademarks</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Singapore operates a first<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-file</FONT> system in respect of registered trademarks under the Trade Marks Act&#x00a0;1988 of Singapore, and the registered proprietor is granted a statutory monopoly of the trademark in Singapore in relation to the product or service for which it is registered. In the event of any trademark infringement, the registered proprietor will be able to rely on the registered trademark as proof of his right to the mark, and the infringement of a trademark may give rise to civil and criminal liabilities. Statutory protection of a registered trademark can last indefinitely, as long as the registration is renewed every 10&#x00a0;years.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Patents</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Patents Act&#x00a0;1994 of Singapore confers protection on patentable inventions on a first<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-file</FONT> basis in Singapore, provided that the invention satisfies the requirements of novelty, having an inventive step and industrial applicability. Patents are valid for 20&#x00a0;years from the date of filing, subject to the payment of annual renewal fees. During the life of the patent, the owner will have the exclusive right to exploit the invention that is the subject of the patent.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on Dividend Distributions</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The governing legislation for the distribution of dividends in Singapore is the Companies Act&#x00a0;1967 of Singapore, or the Companies Act. Under Section&#x00a0;403 of the Companies Act, a Singapore company is only allowed to pay dividends out of profits and there are certain restrictions on the use of profits for the purposes of dividend declaration. Firstly, any profits of a company applied towards the purchase of its shares pursuant to the share buyback provisions under the Companies Act cannot be payable as dividends to the shareholders. However, the foregoing restriction does not apply to any part of the proceeds received by the company from a sale or disposal of its treasury shares where the sums that were utilized to purchase those treasury shares initially came out of profits in the first place. Finally, any gains derived from the sale of treasury shares cannot be payable as dividends to the shareholders of the company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to complying with the Companies Act, the payment of dividends must also be in accordance with the company&#x2019;s constitution and the generally acceptable accounting principles in Singapore.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulations on </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Anti-money</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Laundering and Prevention of Terrorism Financing</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary anti<FONT CLASS="nobreak">-money</FONT> laundering legislation in Singapore is the Corruption, Drug Trafficking and Other Serious Crimes (Confiscation of Benefits) Act&#x00a0;1992 of Singapore, or CDSA, provides for the confiscation of benefits derived from, and to combat, corruption, drug dealing and other serious crimes. Generally, the CDSA criminalizes the concealment or transfer of the benefits of criminal conduct as well as the knowing assistance of the concealment, transfer or retention of such benefits.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Terrorism (Suppression of Financing) Act&#x00a0;2002 of Singapore, or TSOFA, is the primary legislation for the combating of terrorism financing. It was enacted to give effect to the International Convention for the Suppression of the Financing of Terrorism. Besides criminalizing the laundering of proceeds derived from drug dealing and other serious crimes and terrorism financing, the CDSA also requires suspicious transaction reports to be lodged with the Suspicious Transaction Reporting Office&#x00a0;and the TSOFA requires information about any property belonging to any terrorist or terrorist entity to be reported to the Commissioner of Police. If any person fails to lodge the requisite reports under the CDSA and the TSOFA, it may be subject to criminal liability.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">173</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INTERNATIONAL REGULATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to regulations in the United&#x00a0;States, the European Union and Taiwan, we will be subject to a variety of other regulations governing clinical trials and commercial sales and distribution of our products to the extent we choose to develop or sell any products outside of the United&#x00a0;States, Europe or Taiwan. The approval and reimbursement process varies from country to country and the time may be longer or shorter than that required to obtain U.S. FDA, EMA or NMPA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. In all cases the clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory requirements and the ethical principles having their origin in the Declaration of Helsinki.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Anti-Corruption</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Laws</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FCPA, the U.S.&#x00a0;domestic bribery statute contained in 18 U.S.C. &#x00a7;201, the U.S.&#x00a0;Travel Act, the USA PATRIOT Act, and possibly other state and national anti<FONT CLASS="nobreak">-bribery</FONT> and anti<FONT CLASS="nobreak">-money</FONT> laundering laws in countries in which we conduct activities, prohibit any U.S.&#x00a0;individual or business from paying, offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. This could become relevant in the conduct of international clinical trials where the sites for such studies may be a government<FONT CLASS="nobreak">-owned</FONT> hospital. The FCPA also obligates companies whose securities are listed in the United&#x00a0;States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United&#x00a0;States, can result in criminal and civil fines, imprisonment, disgorgement, oversight and debarment from government contracts.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the European Union, interactions between pharmaceutical companies and physicians are governed by strict laws, regulations, industry self<FONT CLASS="nobreak">-regulation</FONT> codes of conduct and physicians&#x2019; codes of professional conduct both at the European Union level and in the individual European Union member states. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti<FONT CLASS="nobreak">-bribery</FONT> laws of the European Union member states. Violation of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain European Union member states also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#x2019;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual European Union member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual European Union member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">174</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T9"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MANAGEMENT</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">DIRECTORS AND EXECUTIVE OFFICERS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth information regarding our executive officers and directors as of the date of this prospectus. Unless otherwise stated, the business address for our directors and executive officers is that of our principal executive offices at 23F<FONT CLASS="nobreak">-3</FONT>, No.<FONT CLASS="nobreak"> </FONT>95, Section&#x00a0;1, Xintai 5<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT> Road, Xizhi District, New Taipei City, Taiwan, 221.</P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 31.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Directors and Executive Officers</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Age</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Position</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 31.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">66</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Chairwoman&#x00a0;of&#x00a0;the&#x00a0;Board&#x00a0;of&#x00a0;Directors&#x00a0;and&#x00a0;Chief&#x00a0;Executive&#x00a0;Officer</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 31.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fenglin Hsu</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">75</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Director Nominee and Chief Technology Officer Nominee</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 31.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Hung-Shu Fan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">59</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Independent Director Nominee</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 31.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pang-Chief Chi</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">78</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Independent Director Nominee</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 31.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ming Tsan Hsu</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">66</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Independent Director Nominee</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 31.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Alfred Ying</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">59</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Chief Financial Officer Nominee</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 31.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Wanwen (Angela) Su<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">50</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Chief Science Officer Nominee</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Ms. Fu</FONT><FONT CLASS="nobreak"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">-Feng</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> Kuo</FONT> has been our director since December&#x00a0;2018. She currently serves as our chairwoman of the board of directors and chief executive officer. Ms. Kuo is the founder of Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd. She has also been serving as the Chairwoman and CEO of Genvace Biotechnology Co., Ltd. and Zhao Jian Fu Co., Ltd. since 2021 and 2011, respectively. Ms. Kuo has over 30&#x00a0;years of experience in the R&amp;D of botanical products and new drugs and used to own multiple global patents in compositions. Since the establishment of Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd., or HEB, in 2002, Ms. Kuo has painstakingly researched and established CMC data, led HEB&#x2019;s conferences with regulatory authorities, and highly participated in preclinical studies as well as clinical trials of new drug candidates, such as Phase&#x00a0;III clinical trials on MCS<FONT CLASS="nobreak">-2</FONT> in the U.S.&#x00a0;and Taiwan. Ms. Kuo had already initiated her research on natural medicine formulations before establishing HEB.&#x00a0;During her study in the U.S., Ms. Kuo focused on developing new drugs for the treatment of urinary system diseases, formulated a preliminary blueprint, and began to explore active ingredients from plants. From 1996 to 1997, Ms. Kuo previously served as the guest lecturer on special nutritional foods in various hospitals in Taiwan. From 1987 to 1996, Ms. Kuo established Panatoz Corporation, a company engaging in international trade of health care products and plant raw materials and served as the Chairwoman as well as the general manager. Ms.&#x00a0;Kuo received a master&#x2019;s degree in business management from Dominican University of California in 2000.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We believe Ms. Kuo is qualified to serve on the Board because of her substantial experience in executive leadership roles and her extensive knowledge of new drugs&#x2019; R&amp;D and corporate operations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Dr. Fenglin Hsu</FONT> will serve as our director and chief technology officer upon the effectiveness of our registration statement on Form&#x00a0;F<FONT CLASS="nobreak">-1</FONT> of which this prospectus is a part. Dr.&#x00a0;Hsu has been serving as the chief technology officer of Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd. since July&#x00a0;2021. He is an expert in the research of natural medicinal chemistry, the R&amp;D of Chinese herbal medicine, and the management of biotechnology medicine R&amp;D.&#x00a0;Prior to joining us, Dr. Hsu served as deputy editor<FONT CLASS="nobreak">-in-chief</FONT> for Journal of Food and Drug Analysis, the director and consultant of NatureWise Biotech &amp; Medicals Corporation from 2018 to 2021. Dr. Hsu served as the professor fellow for China Industrial &amp; Commercial Research Institute and deputy editor<FONT CLASS="nobreak">-in-chief</FONT> for Journal of Food and Drug Analysis from 2015 to 2018. Dr.&#x00a0;Hsu served as a professor at Taipei Medical College (currently known as Taipei Medical University) from 1993 to 2014, and was awarded an Honorary Professorship in 2015. From 1993 to 2003, Dr.&#x00a0;Hsu also served as the director of the Pharmacy Department of Taipei Medical College Hospital, where he engaged in drug management and clinical pharmacy. From 2000 to 2010, Dr.&#x00a0;Hsu served as the director of Graduate Institute of Pharmacognosy at Taipei Medical College where he was responsible for the daily management of the Institute. Dr.&#x00a0;Hsu received a Ph.D. in pharmaceutical sciences in 1985 and a master&#x2019;s degree in pharmaceutical sciences in 1982 from Kyushu University in Japan. Dr.&#x00a0;Hsu has been a qualified pharmacist in Taiwan since 1949.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;margin-top:7pt;margin-top:7pt;">We believe Dr.&#x00a0;Hsu is qualified to serve on the Board because of his extensive experience in the biotechnology field and his knowledge and expertise in drug development.</P>
		<P CLASS="Textfootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Textfootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">Note:</P>
		<P CLASS="Textfootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Ms. Wanwen Su was censured by The Stock Exchange of Hong Kong Limited, or the HKEx, for her breach of fiduciary duties and duties of skill, care and diligence to a standard at lease commensurate with the standard established by Hong Kong law on December 1, 2022. The HKEx directed Ms. Su to attend the 15 hours of training on regulatory and legal topics and Listing Rule compliance, as a prerequisite of any future appointment as a director of any company listed or to be listed on the HKEx.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">175</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Mr.&#x00a0;</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Hung</FONT><FONT CLASS="nobreak"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">-Shu</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> Fan</FONT> will serve as our independent director upon the effectiveness of our registration statement on Form&#x00a0;F<FONT CLASS="nobreak">-1</FONT> of which this prospectus is a part. Mr.&#x00a0;Fan has been serving as a professor in the Department of Accounting since 2010 and the associate dean of the College of Management at Fu Jen Catholic University in Taiwan since 2021. Mr.&#x00a0;Fan currently serves as an independent director of Taiwan Semiconductor Co., Ltd. (Taipei Exchange: 5425) and a director of Tigerair Taiwan Co., Ltd. (Taipei Exchange: 6757). From 2018 to 2021, Mr.&#x00a0;Fan served as a member of the Listing Review Committee of the Taiwan Stock Exchange and the OTC Listing Review Committee of The Taipei Exchange. From 2011 to 2021, Mr.&#x00a0;Fan served as a member of the CPA Examination Review Committee of the Ministry of Examination. From 1994 to 2010, he successively served as the lecturer, associate professor, and head of the Department of Accounting at Fu Jen Catholic University. From 2015 to 2017, Mr.&#x00a0;Fan worked as the director of TSC Venture Capital Co., Ltd. He also used to be the supervisor of Mega International Commercial Bank from 2016 to 2017, the independent supervisor of TSC Auto ID Technology Co., Ltd. from 2007 to 2010 and Para Light Co., Ltd. from 2004 to 2016, and the supervisor of Tidehold Development Co., Ltd. from 2002 to 2020. Mr.&#x00a0;Fan received a master&#x2019;s degree in business administration and a Ph.D. degree in accounting from National Taiwan University in 1989 and 1997, respectively. From 2009 to 2022, Mr.&#x00a0;Fan has been the moderator of 11 special research projects in accounting of the National Science and Technology Council. He was awarded the Special Outstanding Talent Award by the National Science and Technology Council in 2015 and 2017.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">We believe Mr.&#x00a0;Fan is qualified to serve on the Board due to his accounting background and lengthy experience in positions as a supervisor and independent director of publicly listed companies.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Mr.&#x00a0;</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Pang</FONT><FONT CLASS="nobreak"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">-Chief</FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> Chi</FONT> will serve as our independent director upon the effectiveness of our registration statement on Form&#x00a0;F<FONT CLASS="nobreak">-1</FONT> of which this prospectus is a part. Mr.&#x00a0;Chi is the chief of Chi&#x2019;s Surgical Urology Medical Clinic in Taiwan. He has over 50&#x00a0;years of experience in the medical field and has expertise in urology, surgery, and family medicine. Mr.&#x00a0;Chi has been serving as the physician<FONT CLASS="nobreak">-in</FONT><FONT CLASS="nobreak">-charge</FONT> of the urology department at Taipei Tzuchi Hospital since 2007. From 1974 to 1981, Mr.&#x00a0;Chi served as the director of the urology department at Zuoying Naval General Hospital. From 1981 to 1984, Mr.&#x00a0;Chi served as the director of both the medical department and the surgical department at Shuntian Hospital in Taiwan. Mr.&#x00a0;Chi received a bachelor&#x2019;s degree in medicine from National Defense Medical Center in 1971. During his&#x00a0;years of practice, Mr.&#x00a0;Chi has called on local doctors to conduct free clinics for disadvantaged groups and residents in undeveloped areas. He has also actively devoted himself to social medical welfare activities launched by the government in local communities. Mr.&#x00a0;Chi has received numerous awards in Taiwan, such as &#x201c;Outstanding Medical Staff&#x201d; in 2002, &#x201c;Eight Virtues Award&#x201d; in 2012, &#x201c;Medical Contribution Award&#x201d; in 2017, and &#x201c;National Medical Exemplary Award&#x201d; in 2021.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">We believe Mr.&#x00a0;Chi is qualified to serve on the Board because of his successful practice in the treatment of urinary system disease as well as other medical fields.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Mr.</FONT><FONT CLASS="nobreak"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> </FONT></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Ming Tsan Hsu</FONT> will serve as our independent director upon the effectiveness of our registration statement on Form F<FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak">1</FONT> of which this prospectus is a part. Mr.<FONT CLASS="nobreak"> </FONT>Hsu has been serving as the deputy chairman of the board of directors at Joyear Construction Co., Ltd. since April 2008 and the supervisor of Duennien Construction Co., Ltd since June 2008. From 2017 to 2018, Mr.<FONT CLASS="nobreak"> </FONT>Hsu previously served as the independent director of Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd. He served as the deputy general manager of Joyear Construction Co., Ltd. from 2003 to 2008 and Duennien Construction Co., Ltd. from 1989 to 2002. He served as the assistant manager of the Engineering Department at Chang Shen Construction Co., Ltd from 1988 to 1989, and the site director of Guang Ji Construction Co., Ltd. from 1982 to 1987. Mr.<FONT CLASS="nobreak"> </FONT>Hsu received a master&#x2019;s degree in business management from Dayeh University in Taiwan in 1999, a Ph.D. degree in management from Xi&#x2019;an Jiaotong University in China in 2009, and a Ph.D. degree in law from China University of Political Science and Law in 2015. He previously served as the deputy director of Taiwan Innovative Business Management Association from 2018 to 2014.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">We believe Mr.<FONT CLASS="nobreak"> </FONT>Hsu is qualified to serve on the Board because of his experience in corporate management, as well as his combined professional academic background in law and management.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Mr.&#x00a0;Alfred Ying</FONT> will serve as our chief financial officer upon the effectiveness of our registration statement on Form&#x00a0;F<FONT CLASS="nobreak">-1</FONT> of which this prospectus is a part. Mr.&#x00a0;Ying has over 20&#x00a0;years of experience in capital markets as well as extensive knowledge in corporate finance, capital raising, finance and accounting. Mr.&#x00a0;Ying has been serving as the chief financial officer of Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd. since July&#x00a0;2022 and he used to serve in this position from November&#x00a0;2018 to November&#x00a0;2020. Mr.&#x00a0;Ying previously worked as the chief strategy officer of BlueCity Holdings Limited from July&#x00a0;2021 to June&#x00a0;2022. He also served as the chief financial officer of iFresh, Inc. from May&#x00a0;2017 to March&#x00a0;2018, the director of investor relations at Safe<FONT CLASS="nobreak">-Run</FONT> Machinery (Suzhou) Co., Ltd. from December&#x00a0;2015 to November&#x00a0;2016, and the vice president of equity research at Piper Jaffray Asia Securities Limited from September&#x00a0;2011 to September&#x00a0;2014. Before joining Piper Jaffray, Mr.&#x00a0;Ying served as the vice president of investor relations and M&amp;A at Daphne International Holdings Limited from August&#x00a0;2007 to March&#x00a0;2011, and the research director of BNP Paribas Peregrine Securities (Taiwan) Co., Ltd. from October&#x00a0;2000 to December&#x00a0;2004. Mr.&#x00a0;Ying </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">176</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;text-indent:0pt;margin-top:5pt;">received a master&#x2019;s degree in business administration from the University of New South Wales in Australia in 1995, a master&#x2019;s degree in mechanical engineering from the National Chiao Tung University in Taiwan in 1989, and a bachelor&#x2019;s degree in mechanical engineering from the National Cheng Kung University in Taiwan in 1987.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Dr. Wanwen (Angela) Su</FONT> will serve as our chief science officer upon the effectiveness of our registration statement on Form&#x00a0;F<FONT CLASS="nobreak">-1</FONT> of which this prospectus is a part. Dr.&#x00a0;Su has been the chief science officer of Health Ever Bio<FONT CLASS="nobreak">-Tech</FONT> Co., Ltd. since December&#x00a0;2020. From 2007 to 2020, Dr.&#x00a0;Su served as the clinical assistant professor at Taipei Medical University. From 2008 to 2009, Dr.&#x00a0;Su served as the project manager of the Clinical Trials Center at Taipei Municipal Wan Fang Hospital, where she focused on managing clinical trials and coordination. Dr.&#x00a0;Su received a diploma in aromatherapy from the International Federation of Aromatherapists in 2019, a bachelor&#x2019;s degree of science in pharmacy from Northeastern University in 2004, and a Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Health Sciences in 1998. She has been an international clinical member and an international level 3 NAHA certified clinical aromatherapist of the National Association for Holistic Aromatherapy since 2020, and a registered full member of the International Federation of Aromatherapists since 2019. In 2005, Dr.&#x00a0;Su became a holistic health counselor certified by Institute for Integrative Nutrition and was recognized as an expert in the health field as a Holistic Health Practitioner. Dr.&#x00a0;Su has been a registered pharmacist in the state of Massachusetts since 1999 and a qualified pharmacist in Taiwan since 2008.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EMPLOYMENT AGREEMENTS AND INDEMNIFICATION AGREEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">We have entered into employment agreements with each of our executive officers. Under these agreements, each of our executive officers is employed for a specified time period. We may terminate employment for cause, at any time, without advance notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty to a felony or any crime involving moral turpitude, negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. We may also terminate an executive officer&#x2019;s employment without cause upon advance written notice. In such case of termination by us, we will provide severance payments to the executive officer as expressly required by applicable law of the jurisdiction where the executive officer is based. The executive officer may resign at any time with an advance written notice.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">Each executive officer has agreed to hold, both during and after the termination or expiry of his or her employment agreement, in strict confidence and not to use, except as required in the performance of his or her duties in connection with the employment or pursuant to applicable law, any of our confidential information or trade secrets, any confidential information or trade secrets of our clients or prospective clients, or the confidential or proprietary information of any third party received by us and for which we have confidential obligations. The executive officers have also agreed to disclose in confidence to us all inventions, designs and trade secrets which they conceive, develop or reduce to practice during the executive officer&#x2019;s employment with us and to assign all right, title and interest in them to us, and assist us in obtaining and enforcing patents, copyrights and other legal rights for these inventions, designs and trade secrets.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">In addition, each executive officer has agreed to be bound by non<FONT CLASS="nobreak">-competition</FONT> and non<FONT CLASS="nobreak">-solicitation</FONT> restrictions during the term of his or her employment and typically for two&#x00a0;years following the last date of employment. Specifically, each executive officer has agreed not to (i)&#x00a0;approach our suppliers, clients, customers or contacts or other persons or entities introduced to the executive officer in his or her capacity as a representative of us for the purpose of doing business with such persons or entities that will harm our business relationships with these persons or entities; (ii)&#x00a0;assume employment with or provide services to any of our competitors, or engage, whether as principal, partner, licensor or otherwise, any of our competitors, without our express consent; or (iii)&#x00a0;seek directly or indirectly, to solicit the services of any of our employees who is employed by us on or after the date of the executive officer&#x2019;s termination, or in the year preceding such termination, without our express consent.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">We will also enter into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being our director or officer.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CORPORATE GOVERNANCE</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Board of Directors</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">Our board of directors will consist of five directors, including two executive directors and three independent directors. The powers and duties of our directors include convening general meetings and reporting our board&#x2019;s work at our shareholders&#x2019; meetings, declaring dividends and distributions, determining our business and investment plans, appointing officers and determining the term of office of the officers, preparing our annual financial budgets and financial reports, formulating proposals for the increase or reduction of our authorized capital as well as exercising </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">177</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:5.5pt;">other powers, functions and duties as conferred by our articles of association. A director may exercise all the powers of our company to borrow money, mortgage its business, property and uncalled capital and issue debentures or other securities whenever money is borrowed or as security for any obligation of our company or of any third party. A director who is in any way, whether directly or indirectly, interested in a contract or proposed contract with our company is required to declare the nature of his interest at a meeting of our directors. A director may vote in respect of any contract or proposed contract or arrangement notwithstanding that he may be interested therein and if he does so his vote shall be counted and he may be counted in the quorum at any meeting of the directors at which any such contract or proposed contract or arrangement is considered. A general notice given to the directors by any director to the effect that he is a member or officer of any specified company or firm and is to be regarded as interested in any contract or arrangement with that company or firm or a specified person who is connected with him shall be deemed a sufficient declaration of interest for the purposes of voting on a resolution in respect to a contract or transaction in which he has an interest, provided that no such notice shall be effective unless either it is given at a meeting of the board of directors or the director takes reasonable steps to secure that it is brought up and read at the next board meeting after it is given.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;">None of our directors has a service contract with us that provides for benefits upon termination of service.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:6pt;margin-top:6pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Committees of the Board of Directors</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;">Prior to the completion of this offering, we intend to establish an audit committee, a compensation committee and a nominating and corporate governance committee under the board of directors. We intend to adopt a charter for each of the three committees prior to the completion of this offering. Each committee&#x2019;s members and functions are described below.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Audit Committee.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our audit committee will consist of Mr.&#x00a0;Hung<FONT CLASS="nobreak">-Shu</FONT> Fan, Mr.&#x00a0;Pang<FONT CLASS="nobreak">-Chief</FONT> Chi and Mr.<FONT CLASS="nobreak"> </FONT>Ming Tsan Hsu, and will be chaired by Mr.&#x00a0;Hung<FONT CLASS="nobreak">-Shu</FONT> Fan. Mr.&#x00a0;Hung<FONT CLASS="nobreak">-Shu</FONT> Fan, Mr.&#x00a0;Pang<FONT CLASS="nobreak">-Chief</FONT> Chi and Mr.<FONT CLASS="nobreak"> </FONT>Ming Tsan Hsu satisfy the &#x201c;independence&#x201d; requirements of Rule 5605(c)(2) of the Listing Rules of the Nasdaq and meet the independence standards under Rule&#x00a0;10A<FONT CLASS="nobreak">-3</FONT> under the Securities Exchange&#x00a0;Act&#x00a0;of&#x00a0;1934, as amended. We have determined that Mr.&#x00a0;Hung<FONT CLASS="nobreak">-Shu</FONT> Fan qualifies as an &#x201c;audit committee financial expert.&#x201d; The audit committee will oversee our accounting and financial reporting processes and the audits of the financial statements of our company. The audit committee will be responsible for, among other things:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>selecting the independent registered public accounting firm and pre<FONT CLASS="nobreak">-approving</FONT> all auditing and non<FONT CLASS="nobreak">-auditing</FONT> services permitted to be performed by the independent registered public accounting firm;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing with the independent registered public accounting firm any audit problems or difficulties and management&#x2019;s response;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing and approving all proposed related party transactions, as defined in Item&#x00a0;404 of Regulation <FONT CLASS="CharOverride-3" STYLE="">S</FONT><FONT CLASS="nobreak" STYLE="">-K</FONT><FONT CLASS="CharOverride-3" STYLE=""> under the Securities </FONT><FONT CLASS="CharOverride-3" STYLE="">Act;</FONT></P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>discussing the annual audited financial statements with management and the independent registered public accounting firm;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing major issues as to the adequacy of our internal controls and any special audit steps adopted in light of material control deficiencies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>annually reviewing and reassessing the adequacy of our audit committee charter;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>meeting separately and periodically with management and the independent registered public accounting firm; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reporting regularly to the board of directors.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Compensation Committee.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our compensation committee will consist of Mr.&#x00a0;Hung<FONT CLASS="nobreak">-Shu</FONT> Fan, Mr.&#x00a0;Pang<FONT CLASS="nobreak">-Chief</FONT>&#x00a0;Chi and Mr.<FONT CLASS="nobreak"> </FONT>Ming Tsan Hsu, and will be chaired by Mr.&#x00a0;Pang<FONT CLASS="nobreak">-Chief</FONT> Chi. Mr.&#x00a0;Hung<FONT CLASS="nobreak">-Shu</FONT>&#x00a0;Fan, Mr.&#x00a0;Pang<FONT CLASS="nobreak">-Chief</FONT> Chi and Mr.<FONT CLASS="nobreak"> </FONT>Ming Tsan Hsu satisfy the &#x201c;independence&#x201d; requirements of Rule 5605(c)(2) of the Listing Rules of the Nasdaq. The compensation committee will assist the board of directors in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers. Our executive officers may not be present at any committee meeting during which their compensation is deliberated upon. The compensation committee will be responsible for, among other things:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing the total compensation package for our executive officers and making recommendations to the board of directors with respect to it;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:3pt;margin-top:3pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>approving and overseeing the total compensation package for our executives other than the three most senior executives;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:3pt;margin-top:3pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing the compensation of our directors and making recommendations to the board of directors with respect to it; and</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">178</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:3pt;margin-top:3pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>periodically reviewing and approving any long<FONT CLASS="nobreak">-term</FONT> incentive compensation or equity plans, programs or similar arrangements, annual bonuses, and employee pension and welfare benefit plans.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our nominating and corporate governance committee will consist of Mr.&#x00a0;Hung<FONT CLASS="nobreak">-Shu</FONT> Fan, Mr.&#x00a0;Pang<FONT CLASS="nobreak">-Chief</FONT> Chi and Mr.<FONT CLASS="nobreak"> </FONT>Ming Tsan Hsu and will be chaired by Mr.<FONT CLASS="nobreak"> </FONT>Ming&#x00a0;Tsan Hsu. Mr.&#x00a0;Hung<FONT CLASS="nobreak">-Shu</FONT> Fan, Mr.&#x00a0;Pang<FONT CLASS="nobreak">-Chief</FONT> Chi and Mr.<FONT CLASS="nobreak"> </FONT>Ming Tsan Hsu satisfy the &#x201c;independence&#x201d; requirements of Rule 5605(c)(2) of the Listing Rules of the Nasdaq. The nominating and corporate governance committee will assist the board of directors in selecting individuals qualified to become our directors and in determining the composition of the board of directors and its committees. The nominating and corporate governance committee will be responsible for, among other things:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>recommending nominees to the board of directors for election or re<FONT CLASS="nobreak">-election</FONT> to the board of directors, or for appointment to fill any vacancy on the board of directors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing annually with the board of directors the current composition of the board of directors with regards to characteristics such as independence, age, skills, experience and availability of service to us;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>selecting and recommending to the board of directors the names of directors to serve as members of the audit committee and the compensation committee, as well as of the nominating and corporate governance committee itself; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:6pt;margin-top:6pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Duties of Directors</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Under Cayman Islands law, our directors have a fiduciary duty to our company act honestly, in good faith and with a view to our best interests. Our directors also owe to our company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands. In fulfilling their duty of care to us, our directors must ensure compliance with our memorandum and articles of association, as amended and restated from time to time. Our company has the right to seek damages if a duty owed by our directors is breached. In limited exceptional circumstances, a shareholder may have the right to seek damages in our name if a duty owed by our directors is breached. You should refer to &#x201c;Description of Share Capital&#x00a0;&#x2014;&#x00a0;Differences in Corporate Law&#x201d; for additional information on our standard of corporate governance under Cayman Islands law.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:6pt;margin-top:6pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Terms </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">of Directors and Officers</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our officers are elected by and serve at the discretion of the board of directors. Pursuant to our second amended and restated memorandum and articles of association, our board of directors has the power from time to time and at any time to appoint any person as a director to fill a casual vacancy on the board or as an addition to the existing board (subject to the maximum size limit, if any). Our directors are subject to retirement from office at least once every three years under our second amended and restated memorandum and articles of association. A director will be removed from office automatically if, among other thing, the director (i) becomes of unsound mind or dies; (ii) becomes bankrupt or makes any arrangement or composition with his creditors generally; (iii) is absent from meeting of the board for three consecutive meetings without special leave of absence form the board; (iv) resigns his office by notice in writing to our company; (v) is prohibited by law from being a director; and (vi) is removed from the office pursuant to any other provisions of our amended and restated memorandum and articles of association.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:6pt;margin-top:6pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Compensation of Directors and Executive Officers</FONT></P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">For the year ended December&#x00a0;31, 2022, 2023 and 2024, and the six months ended June<FONT CLASS="nobreak"> </FONT>30, 2024, we paid an aggregate of approximately US$373,803, US$405,198, $399,400, US$202,966 and $399,400 in cash to our executive officers and directors, respectively. We have not set aside or accrued any amount to provide pension, retirement or other similar benefits to our executive officers and directors. We did not grant any stock options or restricted stock units to our named executive officers or directors in 2022, 2023 and 2024, and six months ended June<FONT CLASS="nobreak"> </FONT>30, 2024. Our Taiwan subsidiaries are required by Taiwan laws to make contributions equal to certain percentages of its employee&#x2019;s salary for his or her labor insurance, medical insurance, employment service insurance, occupational accident insurance and labor pension. Our PRC subsidiary is required by the PRC law to make contributions equal to certain percentages of each employee&#x2019;s salary for his or her pension insurance, medical insurance, unemployment insurance and other statutory benefits and a housing provident fund. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">179</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T8"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PRINCIPAL SHAREHOLDERS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth information concerning the beneficial ownership of our ordinary shares as of the date of this prospectus by:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>each of our directors and executive officers; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>each person known to us to beneficially own more than 5% of our ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beneficial ownership is determined in accordance with the rules and regulations of the SEC.&#x00a0;In computing the number of ordinary shares beneficially owned by a person and the percentage ownership of that person, we have included ordinary shares that the person has the right to acquire within sixty (60)&#x00a0;days, including through the exercise of any option, warrant, or other right or the conversion of any other security. These ordinary shares, however, are not included in the computation of the percentage ownership of any other person. The percentage of beneficial ownership of our ordinary shares immediately after the completion of this offering is based on ordinary shares that will be issued and outstanding which includes (i)&#x00a0;73,361,000 ordinary shares outstanding as of the date of this prospectus; and (ii)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT> ordinary shares issued in connection with this offering, assuming the underwriters do not exercise their option to purchase additional ordinary shares. Unless otherwise noted, the business address for each of our directors and executive officers is 23F<FONT CLASS="nobreak">-3</FONT>, No.<FONT CLASS="nobreak"> </FONT>95, Section&#x00a0;1, Xintai 5<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT> Road, Xizhi District, New Taipei City, Taiwan, 221.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="4" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Ordinary&#x00a0;shares&#x00a0;beneficially&#x00a0;owned <BR>prior to this offering</FONT>&#x2020;</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 44.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Ordinary shares beneficially owned <BR>after this offering</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number of <BR>ordinary shares</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Percentage <BR>of beneficial <BR>ownership**</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number&#x00a0;of <BR>ordinary&#x00a0;shares</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Percentage <BR>of beneficial <BR>ownership</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Percentage of <BR>total voting <BR>power after this <BR>offering***</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Directors and Executive Officers**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,349,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">34.6</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,349,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fenglin Hsu</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Hung-Shu Fan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pang-Chief Chi</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ming Tsan Hsu</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Alfred Ying<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(2)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Wanwen (Angela) Su</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-17" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">All Directors and Executive Officers <BR>as a Group</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">25,353,500</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">34.6</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">%</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">25,353,500</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">%</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">%</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Principal Shareholders:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Perfect Minds Co., Ltd.<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,349,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">34.6</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,349,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Laxton Investments Company Limited<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(3)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,631,200</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10.4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,631,200</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linkage Gladden <BR>Enterprise Ltd.<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">4)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863,548</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9.4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863,548</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Honest Dynasty Ltd.<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(5)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,343,610</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,343,610</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Peak Valley International Co., Ltd.<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(6)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,098,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.0</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,098,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.69%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">Notes:</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#x2020;<FONT STYLE="width: 24px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Beneficial ownership information disclosed herein represents direct and indirect holdings of entities owned, controlled or otherwise affiliated with the applicable holder as determined in accordance with the rules and regulations of the SEC.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">*<FONT STYLE="width: 24px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents less than 1% of the total number of shares outstanding as of the date of this prospectus.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">**<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>For each person and group included in this table, percentage ownership is calculated by dividing the number of shares beneficially owned by such person or group by the sum of the total number of shares outstanding as of the date of this prospectus.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">***<FONT STYLE="width: 12px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>For each person or group included in this column, percentage of total voting power is calculated by dividing the voting power beneficially owned by such person or group by the voting power of all of our ordinary shares as a single class.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">180</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents 25,349,500 ordinary shares held of record by Perfect Minds Co., Ltd., a Seychelles company wholly owned by Ms. Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo. The registered address of Perfect Minds Co., Ltd. is No.4, Franky Building, Providence Industrial Estate, Mahe, Seychelles.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents 4,000 ordinary shares transferred from Pao<FONT CLASS="nobreak">-Min</FONT> Chen to Alfred Ying on September 1, 2022.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents 3,471,000 ordinary shares held of record by, Laxton Investments Company Limited (&#x201c;Laxton&#x201d;), a British Virgin Islands company wholly owned by Shuai Shao, and 4,160,200 ordinary shares mortgaged by Honest Dynasty Ltd. to Laxton in 2018. According to the Mortgage Agreement entered between Honest Dynasty Ltd. and Laxton on April 15, 2018 (&#x201c;2018 Mortgage Agreement&#x201d;), an event of default has occurred on December 31, 2018 and Laxton may, following an event of default, enforce all of the 4,160,200 mortgaged shares. On March 31, 2023, Laxton enforced all of the 4,160,200 mortgaged shares. The registered address of Laxton Investments Company Limited is Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands. </P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents 6,863,548 ordinary shares held of record by Linkage Gladden Enterprise Ltd., a Belize company wholly owned by I<FONT CLASS="nobreak">-Hsien</FONT> Huang. The registered address of Linkage Gladden Enterprise Ltd. is 25 Guzman Street Belama Phase&#x00a0;1, Belize City, Belize, C.A.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents 6,503,810 ordinary shares held of record by Honest Dynasty Ltd., a Seychelles company wholly owned by Wen<FONT CLASS="nobreak">-Tsai</FONT> Peng. The registered address of Honest Dynasty Ltd. is No. 4, Franky Building, Providence Industrial Estate, Mahe, Seychelles. According to the 2018 Mortgage Agreement, Honest Dynasty Ltd. mortgaged 4,160,200 ordinary shares to Laxton and on December 31, 2018, an event of default has occurred, thus Laxton may, following an event of default, enforce all such shares. On March 31, 2023, Laxton enforced all of the 4,160,200 mortgaged shares. The number of shares beneficially owned by Honest Dynasty Ltd. was 2,343,610, representing 3.2% of our 73,361,000 ordinary shares outstanding as of the date of this prospectus. </P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents 5,098,000 ordinary shares held of record by Peak Valley International Co., Ltd., a Seychelles company wholly owned by Chun<FONT CLASS="nobreak">-Ko</FONT> Chen. The registered address of Peak Valley International Co., Ltd. is No. 4, Franky Building, Providence Industrial Estate, Mahe, Seychelles.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, of our issued and outstanding ordinary shares are held by record holders in the United&#x00a0;States, representing approximately 0.01% of our total outstanding shares on an as<FONT CLASS="nobreak">-converted</FONT> basis. None of our shareholders has informed us that it is affiliated with a registered broker<FONT CLASS="nobreak">-dealer</FONT> or is in the business of underwriting securities. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company. See &#x201c;Description of Share Capital&#x00a0;&#x2014;&#x00a0;History of Securities Issuances&#x201d; for historical changes in our major shareholders.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">181</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T777"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RELATED PARTY TRANSACTIONS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before the completion of this offering, we intend to adopt an audit committee charter, which will require the committee to review all related<FONT CLASS="nobreak">-party</FONT> transactions on an ongoing basis and all such transactions be approved by the committee. Set forth below are material related<FONT CLASS="nobreak">-party</FONT> transactions in the&#x00a0;years ended December&#x00a0;31, 2022 and 2023.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TRANSACTIONS WITH RELATED PARTIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Set forth below are our material related party transactions that occurred during the fiscal&#x00a0;years ended December&#x00a0;31, 2022 and 2023. The &#x201c;related party transactions&#x201d; are transactions identified in accordance with the rules prescribed under Part&#x00a0;I, Item&#x00a0;7B of Form&#x00a0;20<FONT CLASS="nobreak">-F</FONT>.&#x00a0;Please see &#x201c;Note&#x00a0;15 Related Party Balances and Transactions&#x201d; from page F<FONT CLASS="nobreak">-21</FONT> to F<FONT CLASS="nobreak">-23</FONT> for more details.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-22" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:1pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 17.09%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">For the&#x00a0;years <BR>ended <BR>December&#x00a0;31,</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 18.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">For the six <BR>months ended <BR>June 30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:1pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Related Parties</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Nature</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:1pt;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 36.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">US$ thousand</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;font-size:9pt;">Rental Expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Panatoz Corporation</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Significantly influenced by <BR>Fu-Feng Kuo, CEO of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">76</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">83</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Zhao Jian Fu Co., Ltd.</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Significantly influenced by <BR>Fu-Feng Kuo, CEO of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">52</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">48</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 21.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Fu-Feng Kuo</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">CEO and Chairwoman of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">2</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">2</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">1</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-28" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:1pt;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 20.09%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">As of <BR>December&#x00a0;31,</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">As of <BR>June 30,<BR>2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:1pt;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Related Parties</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Nature</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:1pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:1pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 20.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">US$ thousand</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;font-size:9pt;">Loan from related parties</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Nobel Consumer Corporation</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Managed by Xue-Juan Chen, a related <BR>party of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">895</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">1,375</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,389</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Fu-Feng Kuo</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">CEO and Chairwoman of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">342</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">1,305</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,773</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Panatoz Corporation</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Significantly influenced by Fu-Feng Kuo, <BR>CEO of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">471</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,139</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Zhao Jian Fu Co., Ltd</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Significantly influenced by Fu-Feng Kuo, <BR>CEO of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">460</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-29" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-30" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;font-size:9pt;">Operating lease liabilities due to related parties (including current and n</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;font-size:9pt;">on-cu</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;font-size:9pt;">rrent)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Panatoz Corporation</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Significantly influenced by Fu-Feng Kuo, <BR>CEO of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">162</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">116</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Zhao Jian Fu Co., Ltd</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Significantly influenced by Fu-Feng Kuo, <BR>CEO of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">119</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">81</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Fu-Feng Kuo</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">CEO and Chairwoman of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">4</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">2</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">1</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-29" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;font-size:9pt;">Other non-current liabilities <BR>due to related parties</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Fu-Feng Kuo</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:6pt;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">CEO and Chairwoman of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">62</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">62</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">62</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">Ju-Ting Chen</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:6pt;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">The shareholder of the Company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">566</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">566</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-5" STYLE="font-size:9pt;">566</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">Notes:</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The balance of other non<FONT CLASS="nobreak">-current</FONT> liabilities due to related parties resulted from the transaction with Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo and Ju<FONT CLASS="nobreak">-Ting</FONT> Chen that they paid securities exchange tax and bridge loan fees on behalf of us during 2018 and 2019.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">182</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Nobel Consumer Corporation, Panatoz Corporation, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, and Ju<FONT CLASS="nobreak">-Ting</FONT> Chen provided guarantees of short<FONT CLASS="nobreak">-term</FONT> and long<FONT CLASS="nobreak">-term</FONT> loans from Shanghai Commercial&#x00a0;&amp; Savings Bank, Ltd. and long<FONT CLASS="nobreak">-term</FONT> loans from Taiwan Cooperative Bank to HEB.&#x00a0;As of December&#x00a0;31, 2022 and 2023, and June<FONT CLASS="nobreak"> </FONT>30, 2024, the amount of borrowing guaranteed were US$9,547 thousand, US$10,209 thousand, and US$9,239 thousand, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PRIVATE PLACEMENT</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">See &#x201c;Description of Share Capital&#x00a0;&#x2014;&#x00a0;History of Securities Issuances.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EMPLOYMENT AGREEMENTS AND INDEMNIFICATION AGREEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">See &#x201c;Management&#x00a0;&#x2014;&#x00a0;Employment Agreements and Indemnification Agreements.&#x201d;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">183</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T888"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">DESCRIPTION OF SHARE CAPITAL</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are a Cayman Islands exempted company and our affairs are governed by our memorandum and articles of association, as amended from time to time, and the Companies Act (As Revised) of the Cayman Islands, which we refer to as the Companies Act below, and the common law of Cayman Islands.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, our authorized share capital is US$50,000.00 divided into 5,000,000,000<FONT CLASS="nobreak"> </FONT>shares, par value of US$0.00001 each. As of the date of this prospectus, 73,361,000 ordinary shares are issued and outstanding.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately prior to the completion of this offering, we will have <FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT> ordinary shares issued and outstanding. All of our shares issued and outstanding prior to the completion of the offering are and will be fully paid, and all of our shares to be issued in the offering will be issued as fully paid.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Post-Offering</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Memorandum and Articles of Association</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have adopted the second amended and restated memorandum and articles of association, which will become effective and replace our current memorandum and articles of association in its entirety immediately prior to the completion of this offering. The following are summaries of certain material provisions of the post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association and of the Companies Act, insofar as they relate to the material terms of our ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Objects of Our Company.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Under our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association, the objects of our company are unrestricted, and we are capable of exercising all the functions of a natural person of full capacity irrespective of any question of corporate benefit, as provided by section 27(2)&#x00a0;of the Companies Act.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Ordinary Shares.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our ordinary shares are issued in registered form and are issued when registered in our register of members. We may not issue shares to bearer. Our shareholders who are non<FONT CLASS="nobreak">-residents</FONT> of the Cayman Islands may freely hold and vote their shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Dividends.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The holders of our ordinary shares are entitled to such dividends as may be declared by our board of directors. Our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association provide that dividends may be declared and paid out of the funds of our company lawfully available therefor. Under the laws of the Cayman Islands, our company may pay a dividend out of either profit or share premium account; provided that in no circumstances may a dividend be paid out of our share premium if this would result in our company being unable to pay its debts as they fall due in the ordinary course of business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Voting Rights.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Voting at any meeting of shareholders is by show of hands unless a poll is demanded. A poll may be demanded by:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the chairperson of such meeting;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>by at least three shareholders present in person or by proxy for the time being entitled to vote at the meeting;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>by shareholder(s)&#x00a0;present in person or by proxy representing not less than one<FONT CLASS="nobreak">-tenth</FONT> of the total voting rights of all shareholders having the right to vote at the meeting; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>by shareholder(s)&#x00a0;present in person or by proxy and holding shares in us conferring a right to vote at the meeting being shares on which an aggregate sum has been paid up equal to not less than one<FONT CLASS="nobreak">-tenth</FONT> of the total sum paid up on all shares conferring that right.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary shares cast at a meeting, while a special resolution requires the affirmative vote of no less than two<FONT CLASS="nobreak">-thirds</FONT> of the votes cast attaching to the issued and outstanding ordinary shares at a meeting. A special resolution will be required for important matters such as a change of name, making changes to our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association, a reduction of our share capital and the winding up of our company. Our shareholders may, among other things, divide or combine their shares by ordinary resolution.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">184</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">General Meetings of Shareholders.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholders&#x2019; annual general meetings. Our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association provide that we shall, if required by the Companies Act or our post<FONT CLASS="nobreak">-offering</FONT> articles of association, in each year hold a general meeting as its annual general meeting, and shall specify the meeting as such in the notices calling it, and the annual general meeting shall be held at such time and place as may be determined by our directors. General meetings, including annual general meetings, may be held at such times and in any location in the world as may be determined by the Board. A general meeting or any class meeting may also be held by means of such telephone, electronic or other communication facilities as to permit all persons participating in the meeting to communicate with each other, and participation in such a meeting constitutes presence at such meeting.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shareholders&#x2019; general meetings may be convened by the chairperson of our board of directors or by a majority of our board of directors. Advance notice of at least ten clear&#x00a0;days is required for the convening of our annual general shareholders&#x2019; meeting (if any) and any other general meeting of our shareholders. A quorum required for any general meeting of shareholders consists of, at the time when the meeting proceeds to business, two shareholders holding shares which carry in aggregate (or representing by proxy) not less than one<FONT CLASS="nobreak">-third</FONT> of all votes attaching to issued and outstanding shares in our company entitled to vote at such general meeting.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Companies Act does not provide shareholders with any right to requisition a general meeting or to put any proposal before a general meeting. However, these rights may be provided in a company&#x2019;s articles of association. Our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association provide that only a majority of the Board or the Chairman of the Board may call extraordinary general meetings.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Transfer of Ordinary Shares.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Subject to the restrictions set out below, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or in a form prescribed by Nasdaq or any other form approved by our board of directors. Notwithstanding the foregoing, ordinary shares may also be transferred in accordance with the applicable rules and regulations of Nasdaq.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share which is not fully paid up or on which we have a lien. Our board of directors may also decline to register any transfer of any ordinary share unless:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the instrument of transfer is in respect of only one class of ordinary shares;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the instrument of transfer is properly stamped, if required;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be transferred does not exceed four; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a fee of such maximum sum as the Nasdaq may determine to be payable or such lesser sum as our directors may from time to time require is paid to us in respect thereof.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If our directors refuse to register a transfer they shall, within two&#x00a0;months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The registration of transfers may, after compliance with any notice required in accordance with the rules of the Nasdaq, be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine; provided, however, that the registration of transfers shall not be suspended nor the register closed for more than 30&#x00a0;days in any year as our board may determine.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Liquidation.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>On the winding up of our company, if the assets available for distribution amongst our shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> </FONT>winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> </FONT>held by them at the commencement of the winding up, subject to a deduction from those shares in respect of<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> </FONT>which </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">185</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> </FONT>available for distribution are insufficient to repay all of the paid<FONT CLASS="nobreak">-up</FONT> capital, such assets will be distributed so<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> </FONT>that, as nearly as may be, the losses are borne by our shareholders in proportion to the par value of the shares<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> </FONT>held by them.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Calls on Shares and Forfeiture of Shares.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their shares in a notice served to such shareholders at least 14&#x00a0;days prior to the specified time and place of payment. The shares that have been called upon and remain unpaid are subject to forfeiture.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Redemption, Repurchase and Surrender of Shares.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders of these shares, on such terms and in such manner as may be determined by our board of directors. Our company may also repurchase any of our shares on such terms and in such manner as have been approved by our board of directors. Under the Companies Act, the redemption or repurchase of any share may be paid out of our company&#x2019;s profits, share premium or out of the proceeds of a new issue of shares made for the purpose of such redemption or repurchase, or out of capital if our company can, immediately following such payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a)&#x00a0;unless it is fully paid up, (b)&#x00a0;if such redemption or repurchase would result in there being no shares outstanding or (c)&#x00a0;if the company has commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Variations of Rights of Shares.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Whenever the capital of our company is divided into different classes the rights attached to any such class may, subject to any rights or restrictions for the time being attached to any class, only be varied with the sanction of a resolution passed by a majority of two<FONT CLASS="nobreak">-thirds</FONT> of the votes cast at a separate meeting of the holders of the shares of that class. The rights conferred upon the holders of the shares of any class issued with preferred or other rights shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation, allotment or issue of further shares ranking pari passu with such existing class of shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Issuance of Additional Shares.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association authorizes our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine, to the extent of available authorized but unissued shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association also authorizes our board of directors to establish from time to time one or more series of preference shares and to determine, with respect to any series of preference shares, the terms and rights of that series, including, among other things:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the designation of the series;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the number of shares of the series;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the dividend rights, dividend rates, conversion rights and voting rights; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the rights and terms of redemption and liquidation preferences.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our board of directors may issue preference shares without action by our shareholders to the extent of available authorized but unissued shares. Issuance of these shares may dilute the voting power of holders of ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Inspection of Books and Records.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Holders of our ordinary shares will have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association have provisions that provide our shareholders the right to inspect our register of shareholders without charge, and to receive our annual audited financial statements. See &#x201c;Where You Can Find Additional Information.&#x201d;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">186</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Anti</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-Takeover</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> Provisions.&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Some provisions of our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>authorize our board of directors to issue preference shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preference shares without any further vote or action by our shareholders; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>limit the ability of shareholders to requisition and convene general meetings of shareholders.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, under Cayman Islands law, our directors may only exercise the rights and powers granted to them under our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Exempted Company.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>does not have to file an annual return of its shareholders with the Registrar of Companies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>is not required to open its register of members for inspection;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>does not have to hold an annual general meeting;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>may issue shares with no par value;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20&#x00a0;years in the first instance);</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>may register as an exempted limited duration company; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>may register as a segregated portfolio company.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">&#x201c;Limited liability&#x201d; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on that shareholder&#x2019;s shares of the company (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift the corporate veil).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Differences in Corporate Law</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Companies Act is derived, to a large extent, from the older Companies Acts of England but does not follow recent English statutory enactments and accordingly there are significant differences between the Companies Act and the current Companies Act&#x00a0;of&#x00a0;England. In addition, the Companies Act differs from laws applicable to U.S.&#x00a0;corporations and their shareholders. Set forth below is a summary of certain significant differences between the provisions of the Companies Act applicable to us and the laws applicable to companies incorporated in the State of Delaware in the United&#x00a0;States and their shareholders.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Mergers and Similar Arrangements.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The Companies Act permits mergers and consolidations between Cayman Islands companies and between Cayman Islands companies and non<FONT CLASS="nobreak">-Cayman</FONT> Islands companies. For these purposes, (a)&#x00a0;&#x201c;merger&#x201d; means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving company, and (b)&#x00a0;a &#x201c;consolidation&#x201d; means the combination of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which must then be authorized by (a)&#x00a0;a special resolution of the shareholders of each constituent company, and (b)&#x00a0;such other authorization, if any, as may be specified in such constituent company&#x2019;s articles of association. The plan must be filed with the Registrar of Companies of the Cayman Islands together with a declaration as to the </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">187</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">solvency of the consolidated or surviving company, a list of the assets and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory procedures.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A merger between a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders of that Cayman subsidiary if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member agrees otherwise. For this purpose, a company is a &#x201c;parent&#x201d; of a subsidiary if it holds issued shares that together represent at least ninety percent (90%) of the votes at a general meeting of the subsidiary.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The consent of each holder of a fixed or floating security interest over a constituent company is required unless this requirement is waived by a court in the Cayman Islands.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Save in certain limited circumstances, a shareholder of a Cayman constituent company who dissents from the merger or consolidation is entitled to payment of the fair value of his shares (which, if not agreed between the parties, will be determined by the Cayman Islands court) upon dissenting to the merger or consolidation, provided the dissenting shareholder complies strictly with the procedures set out in the Companies Act. The exercise of dissenter rights will preclude the exercise by the dissenting shareholder of any other rights to which he or she might otherwise be entitled by virtue of holding shares, save for the right to seek relief on the grounds that the merger or consolidation is void or unlawful.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Separate from the statutory provisions relating to mergers and consolidations, the Companies Act also contains statutory provisions that facilitate the reconstruction and amalgamation of companies by way of schemes of arrangement, provided that the arrangement is approved by seventy<FONT CLASS="nobreak">-five</FONT> per cent in value of the members or class of members, as the case may be, with whom the arrangement is to be made and a majority in number of each class of creditors with whom the arrangement is to be made, and who must in addition represent seventy<FONT CLASS="nobreak">-five</FONT> per cent in value of each such class of creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction ought not to be approved, the court can be expected to approve the arrangement if it determines that:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the statutory provisions as to the required majority vote have been met;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the shareholders have been fairly represented at the meeting in question and the statutory majority are acting bona fide without coercion of the minority to promote interests adverse to those of the class;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the arrangement is such that may be reasonably approved by an intelligent and honest man of that class&#x00a0;acting in respect of his interest; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Companies Act also contains a statutory power of compulsory acquisition which may facilitate the &#x201c;squeeze out&#x201d; of a dissentient minority shareholder upon a tender offer. When a tender offer is made and accepted by holders of 90% of the shares affected within four&#x00a0;months, the offeror may, within a two<FONT CLASS="nobreak">-month</FONT> period commencing on the expiration of such four<FONT CLASS="nobreak">-month</FONT> period, require the holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If an arrangement and reconstruction by way of scheme of arrangement is thus approved and sanctioned, or if a tender offer is made and accepted, in accordance with the foregoing statutory procedures, a dissenting shareholder would have no rights comparable to appraisal rights, save that objectors to a takeover offer may apply to the Grand Court of the Cayman Islands for various orders that the Grand Court of the Cayman Islands has a broad discretion to make, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">188</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Companies Act also contains statutory provisions which provide that a company may present a petition to the Grand Court of the Cayman Islands for the appointment of a restructuring officer on the grounds that the company (a)&#x00a0;is or is likely to become unable to pay its debts within the meaning of section 93 of the Companies Act; and (b)&#x00a0;intends to present a compromise or arrangement to its creditors (or classes thereof) either, pursuant to the Companies Act, the law of a foreign country or by way of a consensual restructuring. The petition may be presented by a company acting by its directors, without a resolution of its members or an express power in its articles of association. On hearing such a petition, the Cayman Islands court may, among other things, make an order appointing a restructuring officer or make any other order as the court thinks fit.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Shareholders&#x2019; Suits.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>In principle, we will normally be the proper plaintiff and as a general rule a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely the rule in <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Foss v. Harbottle</FONT> and the exceptions thereto) so that a non<FONT CLASS="nobreak">-controlling</FONT> shareholder may be permitted to commence a class&#x00a0;action against or derivative actions in the name of the company to challenge actions where:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a company acts or proposes to act illegally or ultra vires;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the act complained of, although not ultra vires, could only be effected duly if authorized by more than a simple majority vote that has not been obtained; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>those who control the company are perpetrating a &#x201c;fraud on the minority.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our post<FONT CLASS="nobreak">-offering</FONT> articles of association contains a provision by which our shareholders waive any claim or right of action that they may have, both individually and on our behalf, against any director in relation to any action or failure to take action by such director in the performance of his or her duties with or for our Company, except in respect of any fraud, willful default or dishonesty of such director.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Indemnification of Directors and Executive Officers and Limitation of Liability.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Cayman Islands law does not limit the extent to which a company&#x2019;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association provide that that we shall indemnify our directors and officers, and their personal representatives, against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such persons, other than by reason of such person&#x2019;s dishonesty, willful default or fraud, in or about the conduct of our company&#x2019;s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning our company or its affairs in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, we have entered into indemnification agreements with our directors and executive officers that provide such persons with additional indemnification beyond that provided in our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Directors&#x2019; Fiduciary Duties.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director acts in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. This duty prohibits self<FONT CLASS="nobreak">-dealing</FONT> by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">189</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, the director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company and therefore it is considered that he owes the following duties to the company&#x00a0;&#x2014;&#x00a0;a duty to act in good faith in the best interests of the company, a duty not to make a personal profit based on his position as director (unless the company permits him to do so), a duty not to put himself in a position where the interests of the company conflict with his personal interest or his duty to a third party and a duty to exercise powers for the purpose for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Shareholder Action by Written Consent.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Under the Delaware General Corporation Law, a corporation may eliminate the right of shareholders to act by written consent by amendment to its certificate of incorporation. Cayman Islands law permits us to eliminate the right of shareholders to act by written consent and our post<FONT CLASS="nobreak">-offering</FONT> amended and restated articles of association provide that any action required or permitted to be taken at any general meetings may be taken upon the vote of shareholders at a general meeting duly noticed and convened in accordance with our post<FONT CLASS="nobreak">-offering</FONT> amended and restated articles of association and may not be taken by written consent of the shareholders without a meeting.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Shareholder Proposals.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Companies Act does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company&#x2019;s articles of association. Our post<FONT CLASS="nobreak">-offering</FONT> amended and restated articles of association provide that only a majority of the Board may call extraordinary general meetings. As an exempted Cayman Islands company, we are not obliged by law to call shareholders&#x2019; annual general meetings.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Cumulative Voting.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&#x2019;s certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder is entitled on a single director, which increases the shareholder&#x2019;s voting power with respect to electing such director. There are no prohibitions in relation to cumulative voting under the laws of the Cayman Islands but our post<FONT CLASS="nobreak">-offering</FONT> amended and restated articles of association do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Removal of Directors.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our post<FONT CLASS="nobreak">-offering</FONT> amended and restated articles of association, subject to certain restrictions as contained therein, directors may be removed with or without cause, by an ordinary resolution of our shareholders. An appointment of a director may be on terms that the director shall automatically retire from office (unless he has sooner vacated office) at the next or a subsequent annual general meeting or upon any specified event or after any specified period in a written agreement between the company and the director, if any; but no such term shall be implied in the absence of express provision. Under our post<FONT CLASS="nobreak">-offering</FONT> amended and restated articles of association, a director&#x2019;s office shall be vacated if the director (i)&#x00a0;becomes bankrupt or has a receiving order made against him or suspends payment or compounds with his creditors; (ii)&#x00a0;is found to be or becomes </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">190</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of unsound mind or dies; (iii)&#x00a0;resigns his office by notice in writing to the company; (iv)&#x00a0;without special leave of absence from our board of directors, is absent from three consecutive meetings of the board and the board resolves that his office be vacated; (v)&#x00a0;is prohibited by law from being a director or; (vi)&#x00a0;is removed from office pursuant to the laws of the Cayman Islands or any other provisions of our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Transactions with Interested Shareholders.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The Delaware General Corporation Law contains a business combination statute applicable to Delaware corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited from engaging in certain business combinations with an &#x201c;interested shareholder&#x201d; for three&#x00a0;years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target&#x2019;s outstanding voting share within the past three&#x00a0;years. This has the effect of limiting the ability of a potential acquirer to make a two<FONT CLASS="nobreak">-tiered</FONT> bid for the target in which all shareholders would not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with the target&#x2019;s board of directors.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cayman Islands law has no comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute. However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide that such transactions must be entered into bona fide in the best interests of the company and not with the effect of constituting a fraud on the minority shareholders.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Dissolution; Winding up.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&#x2019;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its members or, if the company is unable to pay its debts, by an ordinary resolution of its members. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Variation of Rights of Shares.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under our post<FONT CLASS="nobreak">-offering</FONT> amended and restated articles of association, if our share capital is divided into more than one class of shares, the rights attached to any such class may only be varied with the sanction of a resolution passed by a majority of two<FONT CLASS="nobreak">-thirds</FONT> of the votes cast at a separate meeting of the holders of the shares of that class.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Amendment of Governing Documents.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Under the Delaware General Corporation Law, a corporation&#x2019;s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under Cayman Islands law, our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association may only be amended with a special resolution of our shareholders.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Rights of </FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Non</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-resident</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> or Foreign Shareholders.&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>There are no limitations imposed by our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association on the rights of non<FONT CLASS="nobreak">-resident</FONT> or foreign shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions in our post<FONT CLASS="nobreak">-offering</FONT> memorandum and articles of association governing the ownership threshold above which shareholder ownership must be disclosed.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">History of Securities Issuances</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the past three years, we have not issued any securities.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">191</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T7"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SHARES ELIGIBLE FOR FUTURE SALE</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon completion of this offering, we will have <FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT> ordinary shares outstanding, or approximately &#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>% of our outstanding ordinary shares, assuming the underwriters do not exercise their option to purchase additional ordinary shares. All of the ordinary shares sold in this offering will be freely transferable by persons other than by our &#x201c;affiliates&#x201d; without restriction or further registration under the Securities Act. Sales of substantial amounts of our ordinary shares in the public market could adversely affect prevailing market prices of our ordinary shares. Prior to this offering, there has been no public market for our ordinary shares and we cannot assure you that a regular trading market will develop even if our ordinary shares are approved for listing on the Nasdaq Global Market.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LOCK-UP</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> AGREEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have agreed for a period of twelve (12)&#x00a0;months from the closing of this offering, we and any successors of us will not (a)&#x00a0;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of us or any securities convertible into or exercisable or exchangeable for shares of capital stock of us; (b)&#x00a0;file or caused to be filed any registration statement with the SEC relating to the offering of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock; or (c)&#x00a0;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our capital stock, whether any such transaction described in clause (a), (b)&#x00a0;or (c)&#x00a0;above is to be settled by delivery of shares of our capital stock or such other securities, in cash or otherwise.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, each of our directors, officers and holders of more than 5% of our outstanding shares as of the effective date of this registration statement will enter into customary &#x201c;lock<FONT CLASS="nobreak">-up</FONT>&#x201d; agreements in favor of the underwriters for a period of twelve (12)&#x00a0;months from the date of this offering. Our holders of less than 5% of our outstanding shares as of the effective date of this registration statement will enter into customary &#x201c;lock<FONT CLASS="nobreak">-up</FONT>&#x201d; agreements in favor of the underwriters for a period of six (6)&#x00a0;months from the closing of this offering. Additionally, ordinary shares held by Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership) are subject to lock<FONT CLASS="nobreak">-up</FONT> for five (5) years from the closing date of this offering.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The restrictions described in the preceding paragraphs will be automatically extended under certain circumstances. See &#x201c;Underwriting.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other than this offering, we are not aware of any plans by any significant shareholders to dispose of significant numbers of our ordinary shares. However, one or more existing shareholders or owners of securities may dispose of significant numbers of our ordinary shares in the future. We cannot predict what effect, if any, future sales of our ordinary shares, or the availability of ordinary shares for future sale, will have on the trading price of our ordinary shares from time to time. Sales of substantial amounts of our ordinary shares in the public market, or the perception that these sales could occur, could adversely affect the trading price of our ordinary shares.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">REGULATION S</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regulation&#x00a0;S under the Securities Act provides an exemption from registration requirements in the United&#x00a0;States for offers and sales of securities that occur outside the United&#x00a0;States. Rule&#x00a0;903 of Regulation&#x00a0;S provides the conditions to the exemption for a sale by an issuer, a distributor, their respective affiliates or anyone acting on their behalf, while Rule&#x00a0;904 of Regulation&#x00a0;S provides the conditions to the exemption for a resale by persons other than those covered by Rule&#x00a0;903. In each case, any sale must be completed in an offshore transaction, as that term is defined in Regulation&#x00a0;S, and no directed selling efforts, as that term is defined in Regulation&#x00a0;S, may be made in the United&#x00a0;States.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are a foreign issuer as defined in Regulation&#x00a0;S.&#x00a0;As a foreign issuer, securities that we sell outside the United&#x00a0;States pursuant to Regulation&#x00a0;S are not considered to be restricted securities under the Securities Act, and are freely tradable without registration or restrictions under the Securities Act, unless the securities are held by our affiliates. Generally, subject to certain limitations, holders of our restricted shares who are not our affiliates or who are our affiliates solely by virtue of their status as an officer or director of us may, under Regulation&#x00a0;S, resell their restricted shares in an &#x201c;offshore transaction&#x201d; if none of the seller, its affiliate nor any person acting on their behalf engages in directed selling efforts in the United&#x00a0;States and, in the case of a sale of our restricted shares by an officer </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">192</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">or director who is an affiliate of us solely by virtue of holding such position, no selling commission, fee or other remuneration is paid in connection with the offer or sale other than the usual and customary broker&#x2019;s commission that would be received by a person executing such transaction as agent. Additional restrictions are applicable to a holder of our restricted shares who will be an affiliate of us other than by virtue of his or her status as an officer or director of us.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are not claiming the potential exemption offered by Regulation&#x00a0;S in connection with the offering of newly issued shares outside the United&#x00a0;States and will register all of the newly issued shares under the Securities Act.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RULE 144</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All of our ordinary shares outstanding prior to this offering upon the completion of this offering are &#x201c;restricted shares&#x201d; as that term is defined in Rule&#x00a0;144 under the Securities Act and may be sold publicly in the United&#x00a0;States only if they are subject to an effective registration statement under the Securities Act or pursuant to an exemption from the registration requirement such as those provided by Rule&#x00a0;144 and Rule&#x00a0;701 promulgated under the Securities Act. In general, under Rule&#x00a0;144 as currently in effect, beginning ninety (90)&#x00a0;days after the date of this prospectus a person (or persons whose shares are aggregated) who has beneficially owned our restricted shares for at least six&#x00a0;months, is entitled to sell the restricted securities without registration under the Securities Act, subject to certain restrictions. Persons who are our affiliates may sell within any three&#x00a0;months period a number of restricted shares that does not exceed the greater of the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;% of our then total issued and outstanding ordinary shares, which will equal &#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0; ordinary shares immediately after this offering, assuming the underwriters do not exercise their option to purchase additional ordinary shares (or approximately ordinary shares if the underwriters in full their option to purchase additional ordinary shares); or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the average weekly trading volume of our ordinary shares, during the four calendar&#x00a0;weeks preceding the date on which notice of the sale is filed with the Securities and Exchange Commission.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sales under Rule&#x00a0;144 must be made through unsolicited transactions. They are also subject to other manner of sale provisions, notice requirements and the availability of current public information about us. Persons who are not our affiliates and have beneficially owned our restricted shares for more than six&#x00a0;months but not more than one&#x00a0;year may sell the restricted shares without registration under the Securities Act, subject to the availability of current public information about us. Persons who are not our affiliates and have beneficially owned our restricted shares for more than one year may freely sell the restricted shares without registration under the Securities Act. However, these shares would remain subject to lock<FONT CLASS="nobreak">-up</FONT> arrangements and would only become eligible for sale when the lock<FONT CLASS="nobreak">-up</FONT> period expires.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RULE 701</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, under Rule&#x00a0;701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases our ordinary shares from us in connection with a compensatory stock or option plan or other written agreement relating to compensation is eligible to resell such ordinary shares ninety (90)&#x00a0;days after we became a reporting company under the Exchange&#x00a0;Act in reliance on Rule&#x00a0;144, but without compliance with some of the restrictions, including the holding period, contained in Rule&#x00a0;144. However, these shares would remain subject to lock<FONT CLASS="nobreak">-up</FONT> arrangements and would only become eligible for sale when the lock<FONT CLASS="nobreak">-up</FONT> period expires.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">REGISTRATION RIGHTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this prospectus, we do not have registration rights arrangements with the holders of our ordinary shares or their transferees, but we may enter into registration rights agreements with certain holders of our ordinary shares or their transferees in the future, under which they will be entitled to request that we register their ordinary shares for resale under the Securities Act upon completion of this offering and following the expiration of the lock<FONT CLASS="nobreak">-up</FONT> agreements described above.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">193</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T6"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TAXATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following summary of the material Cayman Islands, Taiwan and U.S. federal income tax consequences of an investment in our ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this registration statement, all of which are subject to change. This summary does not deal with all possible tax consequences relating to an investment in our ordinary shares, such as the tax consequences under U.S.&#x00a0;state and local tax laws or under the tax laws of jurisdictions other than the Cayman Islands, Taiwan and the United&#x00a0;States. To the extent that the discussion relates to matters of Cayman Islands tax law, it represents the opinion of Conyers Dill &amp; Pearman, our special Cayman Islands counsel, and to the extent it relates to Taiwan tax law, it is the opinion of KPMG Law Firm, our Taiwan counsel.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TAIWAN TAXATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a general summary of the principal Taiwan tax consequences of the ownership and disposition of our ordinary shares by and to a non<FONT CLASS="nobreak">-resident</FONT> individual or non<FONT CLASS="nobreak">-resident</FONT> entity holder (referred to herein as a &#x201c;Non<FONT CLASS="nobreak">-Taiwan</FONT> Holder&#x201d;). As used in the preceding sentence, a &#x201c;non<FONT CLASS="nobreak">-resident</FONT> individual&#x201d; is generally a foreign national who owns our ordinary shares and is not physically present in Taiwan for 183&#x00a0;days or more during any calendar year, and a &#x201c;non<FONT CLASS="nobreak">-resident</FONT> entity&#x201d; is a corporation or a non<FONT CLASS="nobreak">-corporate</FONT> body that owns our ordinary shares and is organized under the laws of a jurisdiction other than Taiwan.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Holders should consult their tax advisors concerning the Taiwan tax consequences of holding our ordinary shares and the laws of any relevant taxing jurisdiction to which they are subject.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Capital gains from the sale or disposal of our ordinary shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sale or disposal of the ordinary shares of a Cayman Islands company is generally not regarded as the sale of Taiwan securities; thus, any gains generated therefrom by Non<FONT CLASS="nobreak">-Taiwan</FONT> Holders are not subject to Taiwan income tax.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Securities Transaction Tax</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sale of the ordinary shares of a Cayman Islands company by Non<FONT CLASS="nobreak">-Taiwan</FONT> Holders is generally not subject to Taiwan securities transaction tax.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CAYMAN ISLANDS TAXATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciations and there is no taxation in the nature of inheritance tax or estate duty or withholding tax applicable to us or to any holder of our ordinary shares. There are no other taxes likely to be material to us levied by the Government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or after execution brought within the jurisdiction of the Cayman Islands. No stamp duty is payable in the Cayman Islands on transfers of shares of Cayman Islands companies except those which hold interests in land in the Cayman Islands. Save and except that the Cayman Islands is a party to a double tax treaty entered into with the United Kingdom in 2010, the Cayman Islands are not party to any double tax treaties that are applicable to any payments made to or by the Company. There are no exchange control regulations or currency restrictions in the Cayman Islands.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Payments of dividends and capital in respect of ordinary shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of ordinary shares, nor will gains derived from the disposal of ordinary shares be subject to Cayman Islands income or corporation tax.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">U.S.&#x00a0;FEDERAL INCOME TAX CONSIDERATIONS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a discussion of the material U.S.&#x00a0;federal income tax considerations relevant to the acquisition, ownership, and disposition of our ordinary shares by U.S.&#x00a0;Holders (as defined below) that will hold our ordinary shares as &#x201c;capital assets&#x201d; (generally, property held for investment) under the U.S.&#x00a0;Internal Revenue Code of 1986, as amended, or the &#x201c;Code&#x201d;). This discussion is based upon applicable provisions of the Code, U.S.&#x00a0;Treasury regulations promulgated thereunder, pertinent judicial decisions, interpretive rulings of the U.S.&#x00a0;Internal Revenue Service, or the IRS, and such other authorities as we have considered relevant, all of which are subject to change, possibly </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">194</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">with retroactive effect. This discussion does not address all aspects of U.S.&#x00a0;federal income taxation that may be important to particular investors in light of their individual investment circumstances, including investors subject to special tax and/or reporting rules (for example, certain financial institutions; insurance companies; broker<FONT CLASS="nobreak">-dealers</FONT>; pension plans; regulated investment companies; real estate investment trusts; tax<FONT CLASS="nobreak">-exempt</FONT> organizations (including private foundations); holders who are not U.S.&#x00a0;Holders (as defined below); holders who own (directly, indirectly, or constructively) 10% or more of the voting power or value of our stock; investors that will hold their ordinary shares as part of a straddle, hedge, conversion, constructive sale, or other integrated transaction for U.S.&#x00a0;federal income tax purposes; investors that are traders in securities that have elected the mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> method of accounting; or investors that have a functional currency other than the U.S.&#x00a0;dollar), or holders that acquire ordinary shares through the exercise of options or other convertible instruments or in connection with the provision of services, all of whom may be subject to tax rules that differ significantly from those discussed below.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, this discussion does not address tax considerations relevant to U.S.&#x00a0;Holders under any non<FONT CLASS="nobreak">-U</FONT>.S., state or local tax laws, the Medicare tax on net investment income, the one<FONT CLASS="nobreak">-percent</FONT> excise tax on stock repurchases, estate or gift tax, or the alternative minimum tax. Each U.S.&#x00a0;Holder is urged to consult its tax advisors regarding the U.S.&#x00a0;federal, state, local, and non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;income and other tax considerations of an investment in ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The discussion below of U.S.&#x00a0;federal income tax consequences applies to you if you are a &#x201c;U.S.&#x00a0;Holder.&#x201d; You are a U.S.&#x00a0;Holder if you are a beneficial owner of our ordinary shares and you are: (i)&#x00a0;an individual who is a citizen or resident of the United&#x00a0;States for U.S.&#x00a0;federal income tax purposes; (ii)&#x00a0;a corporation, or other entity treated as a corporation for U.S.&#x00a0;federal income tax purposes, created in, or organized under the law of any state of the United&#x00a0;States, or the District of Columbia; (iii)&#x00a0;an estate the income of which is includible in gross income for U.S.&#x00a0;federal income tax purposes regardless of its source; or (iv)&#x00a0;a trust (A)&#x00a0;the administration of which is subject to the primary supervision of a U.S.&#x00a0;federal or state court and which has one or more U.S.&#x00a0;persons who have the authority to control all substantial decisions of the trust or (B)&#x00a0;that has otherwise validly elected to be treated as a U.S.&#x00a0;person under the Code.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a partner in a partnership (including any entity or arrangement treated or elects to be treated as a partnership for U.S.&#x00a0;federal income tax purposes) that holds our ordinary shares, your tax treatment generally will depend on your status and the activities of the partnership (or any such entity or arrangement treated as or elects to be treated as a partnership for U.S.&#x00a0;federal income tax purposes). Partners in a partnership (or any such entity or arrangement treated as or elects to be treated as a partnership for U.S.&#x00a0;federal income tax purposes) holding our ordinary shares should consult their tax advisors regarding the tax consequences of an investment in the ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are a corporation organized under the laws of the Cayman Islands. As such, we believe that we are properly classified as a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;corporation for U.S.&#x00a0;federal income tax purposes. Under certain provisions of the Code and U.S.&#x00a0;Treasury regulations, however, if pursuant to a plan (or a series of related transactions), a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;corporation (such as our company) acquires substantially all of the properties constituting a trade or business of a U.S.&#x00a0;corporation or partnership, and after the acquisition 80% or more of the stock (by vote or value) of the non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;corporation (excluding stock issued in a public offering related to the acquisition) is owned by former stockholder or partners of the U.S.&#x00a0;corporation or partnership by reason of their holding stock or a capital or profits interest in the U.S.&#x00a0;corporation or partnership, the non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;corporation will be considered a U.S.&#x00a0;corporation for U.S.&#x00a0;federal income tax purposes. You are urged to consult your tax advisor concerning the income tax consequences of purchasing, holding or disposing of ordinary shares if we were to be treated as a U.S.&#x00a0;corporation for U.S.&#x00a0;federal income tax purposes. The remainder of this discussion assumes that our company is treated as a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;corporation for U.S.&#x00a0;Federal income tax purposes.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Dividends</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the PFIC rules discussed below, any cash distributions (including the amount of any other tax withheld) paid on our ordinary shares out of our current or accumulated earnings and profits, as determined under U.S.&#x00a0;federal income tax principles, will generally be includible in your gross income as dividend income on the&#x00a0;day actually or constructively received by you. Because we do not intend to determine our earnings and profits under U.S.&#x00a0;federal income tax principles, any distribution paid will generally be treated as a dividend for U.S.&#x00a0;federal income tax purposes by us. Dividends received by corporations on our ordinary shares may be eligible for the dividends received deduction allowed to U.S.&#x00a0;corporations under the Code.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">195</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Considering that the U.S.&#x00a0;has not entered into an income tax treaty with Taiwan, in the event that we are deemed to be a Taiwan tax resident enterprise under Taiwan Tax Law, you may be subject to Taiwan withholding taxes on dividends paid on our ordinary shares, as described under &#x201c;&#x2014;&#x00a0;Taiwan Taxation.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A non<FONT CLASS="nobreak">-corporate</FONT> U.S.&#x00a0;Holder generally may be subject to tax at preferential tax rates applicable to &#x201c;qualified dividend income,&#x201d; provided that certain conditions are satisfied, including that (1)&#x00a0;our stock is readily tradable on an established securities market in the United&#x00a0;States, (2)&#x00a0;we are neither a PFIC nor treated as such with respect to a U.S.&#x00a0;Holder (as discussed below) for the taxable year in which the dividend was paid and the preceding taxable year, and (3)&#x00a0;certain holding period requirements are met. U.S.&#x00a0;holders are urged to consult their own tax advisors regarding the availability of the preferential rate for any dividends paid with respect to our ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For U.S.&#x00a0;foreign tax credit purposes, dividends generally will be treated as income from foreign sources and generally will constitute &#x201c;passive&#x201d; category income. Depending on your particular circumstances, you may be eligible, subject to a number of complex limitations, to claim a foreign tax credit in respect of any foreign withholding taxes imposed on dividends received on our ordinary shares. If you do not elect to claim a foreign tax credit for foreign tax withheld, you may instead claim a deduction, for U.S.&#x00a0;federal income tax purposes, for the foreign tax withheld, but only for a year in which you elect to do so for all creditable foreign income taxes. The rules governing the foreign tax credit are complex. You are urged to consult your tax advisor regarding the availability of the foreign tax credit under your particular circumstances.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Sale or Other Disposition of Ordinary Shares</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the PFIC rules discussed below, you generally will recognize capital gain or loss upon the sale or other disposition of our ordinary shares in an amount equal to the difference, if any, between the amount realized upon the disposition and your adjusted tax basis in such ordinary shares. Any capital gain or loss will be long<FONT CLASS="nobreak">-term</FONT> capital gain or loss if you have held the ordinary shares for more than one year, and will generally be U.S.<FONT CLASS="nobreak">-source</FONT> gain or loss for U.S.&#x00a0;foreign tax credit purposes. In the event that we are deemed to be a Taiwan tax resident enterprise under Taiwan Tax Law, gain from the disposition of the ordinary shares may be subject to tax in the PRC, as described under &#x201c;&#x2014;&#x00a0;Taiwan Taxation.&#x201d; If such income were treated as U.S.<FONT CLASS="nobreak">-source</FONT> income for foreign tax credit purposes, you might not be able to use the foreign tax credit arising from any tax imposed on the sale, exchange, or other taxable disposition of our ordinary shares unless such credit could be applied (subject to applicable limitations) against tax due on other income derived from foreign sources. The deductibility of a capital loss may be subject to limitations. You are urged to consult your tax advisor regarding the tax consequences if a foreign tax is imposed on a disposition of our ordinary shares, including the availability of the foreign tax credit under your particular circumstances.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PFIC Rules</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;corporation, such as our company, will be classified as a PFIC for U.S.&#x00a0;federal income tax purposes for any taxable year, if either (i)&#x00a0;75% or more of its gross income for such year consists of certain types of &#x201c;passive&#x201d; income or (ii)&#x00a0;50% or more of the value of its assets (determined on the basis of a quarterly average) during such year produce or are held for the production of passive income. Passive income generally includes dividends, interest, royalties, rents, annuities, net gains from the sale or exchange of property producing such income and net foreign currency gains. For this purpose, cash is categorized as a passive asset and the company&#x2019;s goodwill associated with active business activity is taken into account as an active asset. We will be treated as owning our proportionate share of the assets and income of any other corporation in which we own, directly or indirectly, more than 25% (by value) of the stock.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on the projected composition of our assets and income, we do not anticipate being classified as a PFIC for our taxable year ending December&#x00a0;31, 2023. While we do not anticipate being classified as a PFIC, because the value of our assets for purposes of the PFIC asset test will generally be determined by reference to the market price of our ordinary shares, fluctuations in the market price of our ordinary shares may cause us to become a PFIC for the current or any subsequent taxable year. The determination of whether we will become a PFIC will also depend, in part, on the composition of our income and assets, which will be affected by how, and how quickly, we use our liquid assets and the cash raised in this offering. Whether we are a PFIC is a factual determination and we must make a separate determination each taxable year as to whether we are a PFIC (after the close of each taxable year). Accordingly, we cannot assure you that we will not be classified as a PFIC for our taxable year ending December&#x00a0;31, </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">196</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">2023 or any future taxable year. If we are classified as a PFIC for any taxable year during which you hold our ordinary shares, we generally will continue to be treated as a PFIC, unless you make certain elections, for all succeeding&#x00a0;years during which you hold our ordinary shares even if we cease to qualify as a PFIC under the rules set forth above.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If we are a PFIC for any taxable year during which you hold our ordinary shares, you will be subject to special tax rules with respect to any &#x201c;excess distribution&#x201d; that you receive and any gain you realize from a sale or other disposition (including a pledge) of our ordinary shares, unless you make a &#x201c;mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT>&#x201d; election as discussed below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable&#x00a0;years or your holding period for the ordinary shares will be treated as an excess distribution. Under these special tax rules:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the excess distribution or gain will be allocated ratably over your holding period for the ordinary shares;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>amounts allocated to the current taxable year and any taxable&#x00a0;years in your holding period prior to the first taxable year in which we are classified as a PFIC (a &#x201c;pre<FONT CLASS="nobreak">-PFIC</FONT> year&#x201d;) will be taxable as ordinary income; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>amounts allocated to each prior taxable year, other than the current taxable year or a pre<FONT CLASS="nobreak">-PFIC</FONT> year, will be subject to tax at the highest tax rate in effect applicable to you for that year, and such amounts will be increased by an additional tax equal to interest on the resulting tax deemed deferred with respect to such&#x00a0;years.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If we are classified as a PFIC for any taxable year during which you hold our ordinary shares and any of our non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;subsidiaries is also a PFIC, you will be treated as owning a proportionate amount (by value) of the shares of each such non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;subsidiary classified as a PFIC for purposes of the application of these rules.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Alternatively, a U.S.&#x00a0;Holder of &#x201c;marketable stock&#x201d; (as defined below) in a PFIC may make a mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> election for such stock of a PFIC to elect out of the tax treatment discussed in the two preceding paragraphs. If you make a valid mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> election for the ordinary shares, you will include in income each year an amount equal to the excess, if any, of the fair market value of the ordinary shares as of the close of your taxable year over your adjusted basis in such ordinary shares. You will be allowed a deduction for the excess, if any, of the adjusted basis of the ordinary shares over their fair market value as of the close of the taxable year. However, deductions will be allowable only to the extent of any net mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> gains on the ordinary shares included in your income for prior taxable&#x00a0;years. Amounts included in your income under a mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> election, as well as gain on the actual sale or other disposition of the ordinary shares, will be treated as ordinary income. Ordinary loss treatment will also apply to the deductible portion of any mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> loss on the ordinary shares, as well as to any loss realized on the actual sale or disposition of the ordinary shares, to the extent that the amount of such loss does not exceed the net mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> gains previously included for such ordinary shares. Your basis in the ordinary shares will be adjusted to reflect any such income or loss amounts. If you make a mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> election, tax rules that apply to distributions by corporations which are not PFICs would apply to distributions by us (except that the preferential rates for qualified dividend income would not apply).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> election is available only for &#x201c;marketable stock&#x201d; which is stock that is traded in other than de minimis quantities on at least 15&#x00a0;days during each calendar quarter (&#x201c;regularly traded&#x201d;) on a qualified exchange or other market, as defined in applicable U.S.&#x00a0;Treasury regulations. We expect that the ordinary shares will be listed on the Nasdaq Global Market, which is a qualified exchange for these purposes. If the ordinary shares are regularly traded, and the ordinary shares qualify as &#x201c;marketable stock&#x201d; for purposes of the mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> rules, then the mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> election might be available to you if we were to become a PFIC.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because, as a technical matter, a mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> election cannot be made for any lower<FONT CLASS="nobreak">-tier</FONT> PFICs that we may own, you may continue to be subject to the PFIC rules with respect to your indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S.&#x00a0;federal income tax purposes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We do not currently intend to provide information necessary for U.S.&#x00a0;Holders to make qualified electing fund elections, which, if available, would result in tax treatment different from the general tax treatment for PFICs described above.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">197</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you own our ordinary shares during any taxable year that we are a PFIC, you must file an annual report with the IRS, subject to certain exceptions based on the value of the ordinary shares held. You are urged to consult your tax advisor concerning the U.S.&#x00a0;federal income tax consequences of purchasing, holding, and disposing of our ordinary shares if we are or become a PFIC, including the possibility of making a mark<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> election.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Information Reporting and Backup Withholding</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You may be required to submit to the IRS certain information with respect to your beneficial ownership of our ordinary shares, if such ordinary shares are not held on your behalf by certain financial institutions. Penalties also may be imposed if you are required to submit such information to the IRS and fail to do so.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Dividend payments with respect to ordinary shares and proceeds from the sale, exchange or redemption of ordinary shares may be subject to information reporting to the IRS and possible U.S.&#x00a0;backup withholding. Backup withholding will not apply, however, to a U.S.&#x00a0;Holder who furnishes a correct taxpayer identification number and makes any other required certification or who is otherwise exempt from backup withholding. U.S.&#x00a0;Holders who are required to establish their exempt status generally must provide such certification on IRS Form&#x00a0;W<FONT CLASS="nobreak">-9</FONT> or by otherwise establishing an exemption.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S.&#x00a0;Federal income tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the IRS and furnishing any required information. You are urged to consult your tax advisors regarding the application of the U.S.&#x00a0;information reporting and backup withholding rules.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S.&#x00a0;federal income tax discussion set forth above is included for general information only and may not be applicable depending upon a holder&#x2019;s particular situation. Holders are urged to consult their tax advisors with respect to the tax consequences to them of the acquisition, ownership and disposition of our ordinary shares and warrants, including the tax consequences under state, local, estate, foreign and other tax laws and tax treaties and the possible effects of changes in U.S.&#x00a0;or other tax laws.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">198</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T5"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">UNDERWRITING</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Joseph Stone Capital, LLC is acting as representative (the &#x201c;Representative&#x201d;) of each of the underwriters named below. We and the underwriters named below agree to enter into an underwriting agreement with respect to the ordinary shares being offered. Subject to certain conditions, each underwriter has severally agreed to purchase the number of ordinary shares indicated in the following table.</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						 <P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Underwriter</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number of <BR>Ordinary <BR>Shares</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joseph Stone Capital, LLC</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,328,921</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The underwriters and the Representative are collectively referred to as the &#x201c;underwriters&#x201d; and the &#x201c;Representative,&#x201d; respectively. The underwriters are offering the ordinary shares subject to their acceptance of the ordinary shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the underwriters to purchase the ordinary shares included in this offering are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. The underwriters are obligated, severally and not jointly, to purchase all the ordinary shares if any such ordinary shares are taken. However, the underwriters are not required to take or pay for the ordinary shares covered by the underwriters&#x2019; over<FONT CLASS="nobreak">-allotment</FONT> option described below.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The underwriters initially propose to offer part of the ordinary shares directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of US$<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT> per ordinary share under the initial public offering price. After the initial offering of the ordinary shares, the offering price and other selling terms may from time to time be varied by the representative.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OPTION TO PURCHASE ADDITIONAL ORDINARY SHARES</FONT></P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have granted to the underwriters an option, exercisable for 45&#x00a0;days after the date of this prospectus, to purchase up to an aggregate of 349,338 additional ordinary shares from us at the public offering price listed on the cover page of this prospectus, less underwriters discounts and commissions. To the extent the option is exercised, each underwriter will become severally obligated, subject to certain conditions, to purchase additional ordinary shares approximately proportionate to each underwriter&#x2019;s initial amount reflected in the table above.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">COMMISSIONS AND EXPENSES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#x2019; option to purchase additional ordinary shares.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Per ordinary <BR>shares</FONT></P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">No exercise</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Full exercise</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(US$)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Public offering price</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.50</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22,765,202</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Underwriting discounts and commissions paid by us</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;font-style:normal;font-weight:bold;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.60</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,400,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,606,955</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Proceeds, before expenses, to us</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.90</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,600,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,158,247</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">Note:</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents underwriting discounts equal to (i)&#x00a0;seven percent (7.0%) per ordinary share (or US$&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT> per share), for investors in this offering introduced by the underwriters.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will also pay to the Representative, by deduction from the net proceeds of the offering contemplated herein, a non<FONT CLASS="nobreak">-accountable</FONT> expense allowance equal to two and a quarter percent (2.25%) of the gross proceeds received by us from the sale of our ordinary shares.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">199</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We paid an advance (the &#x201c;Advance&#x201d;) expense deposit of US$35,000 to the Representative for its anticipated out<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-pocket</FONT> expenses. Any expense deposits will be returned to us to the extent the Representative&#x2019;s out<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-pocket</FONT> accountable expenses are not actually incurred in accordance with FINRA Rule&#x00a0;5110(g)(4)(A).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We have agreed to reimburse the Representative&#x2019;s accountable expenses in connection with the offering, up to US$160,000 (inclusive of the Advance), including, but not limited to, travel, communication, due diligence, and legal counsel fees and expenses.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Additionally, we have paid the Representative an advisory fee of $45,000 and shall pay an additional $30,000 advisory fee to the Representative once the SEC informs us that they have no further comments on this registration statement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We estimate that the total expenses of the offering payable by us, excluding the underwriting discounts and commissions and non<FONT CLASS="nobreak">-accountable</FONT> expense allowance, will be approximately US$&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;, including a maximum aggregate reimbursement of US$160,000 of Representative&#x2019;s accountable expenses.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LOCK-UP</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> AGREEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Our directors and officers and holders of more than 5% of our outstanding shares as of the effective date of this registration statement will enter into customary &#x201c;lock<FONT CLASS="nobreak">-up</FONT>&#x201d; agreements in favor of the underwriters for a period of twelve (12)&#x00a0;months from the date of this offering. Our holders of less than 5% of our outstanding shares as of the effective date of this registration statement will enter into customary &#x201c;lock<FONT CLASS="nobreak">-up</FONT>&#x201d; agreements in favor of the underwriters for a period of six (6)&#x00a0;months from the closing of this offering. Additionally, ordinary shares held by Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership) are subject to lock<FONT CLASS="nobreak">-up</FONT> for five (5) years from the closing date of this offering. We have agreed with the underwriters that, for a period of twelve (12)&#x00a0;months from the closing of this offering, we and any successors of us will not (a)&#x00a0;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of us or any securities convertible into or exercisable or exchangeable for shares of capital stock of us; (b)&#x00a0;file or caused to be filed any registration statement with the SEC relating to the offering of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock; or (c)&#x00a0;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our capital stock, whether any such transaction described in clause (a), (b)&#x00a0;or (c)&#x00a0;above is to be settled by delivery of shares of our capital stock or such other securities, in cash or otherwise.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the offering, the underwriters may purchase and sell ordinary shares in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of ordinary shares than they are required to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#x201c;covered short position&#x201d; is a short position that is not greater than the amount of additional ordinary shares for which the underwriters&#x2019; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional ordinary shares or purchasing ordinary shares in the open market. In determining the source of ordinary shares to cover the covered short position, the underwriters will consider, among other things, the price of ordinary shares available for purchase in the open market as compared as compared to the price at which they may purchase additional ordinary shares pursuant to the option described above. &#x201c;Naked&#x201d; short sales are any short sales that create a short position greater than the amount of additional ordinary shares for which the option described above may be exercised. The underwriters must cover any such naked short position by purchasing ordinary shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ordinary shares in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of the ordinary shares made by the underwriters in the open market prior to the completion of the offering.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representative has repurchased ordinary shares sold by or for the account of such underwriter in stabilizing or short covering transactions.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">200</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of our ordinary shares, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a result, the price of the ordinary shares may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on the New&#x00a0;York Stock Exchange, Nasdaq or relevant exchange, in the over<FONT CLASS="nobreak">-the</FONT><FONT CLASS="nobreak">-counter</FONT> market or otherwise.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act&#x00a0;of&#x00a0;1933. A prospectus in electronic format may be made available by e<FONT CLASS="nobreak">-mail</FONT> or on the websites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of ordinary shares for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#x2019; websites and any information contained in any other website maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PRICING OF THE OFFERING</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Ordinary shares sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover page of this prospectus. Any ordinary shares sold by the underwriters to securities dealers may be sold at a discount of up to US$<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT> per ordinary share from the initial public offering price. After the initial offering of the ordinary shares, the representative may change the offering price and the other selling terms. The offering of the ordinary shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#x2019; right to reject any order in whole or in part.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the offering, there has been no public market for the ordinary shares. The initial public offering price has been negotiated among us and the representative. Among the factors to be considered in determining the initial public offering price of the ordinary shares, in addition to prevailing market conditions, will be our historical performance, estimates of the business potential and earnings prospects of us, an assessment of our management and the consideration of the above factors in relation to market valuation of companies in related businesses.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RELATIONSHIPS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non<FONT CLASS="nobreak">-financial</FONT> activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with relationships with us, for which they received or will receive customary fees and expenses.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to our assets, securities and/or instruments (directly, as collateral securing other obligations or otherwise) and/or persons and entities with relationships with us. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">201</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SELLING RESTRICTIONS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No action may be taken in any jurisdiction other than the United&#x00a0;States that would permit a public offering of the ordinary shares or the possession, circulation or distribution of this prospectus in any jurisdiction where action for that purpose is required. Accordingly, the ordinary shares may not be offered or sold, directly or indirectly, and neither the prospectus nor any other offering material or advertisements in connection with the ordinary shares may be distributed or published in or from any country or jurisdiction except under circumstances that will result in compliance with any applicable laws, rules and regulations of any such country or jurisdiction.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">202</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T4"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EXPENSES RELATED TO THIS OFFERING</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Set forth below is an itemization of the total expenses, excluding underwriting discounts and commissions, expected to be incurred in connection with the offer and sale of the ordinary shares by us. With the exception of the SEC registration fee, Nasdaq listing fee and the Financial Industry Regulatory Authority Inc. filing fee, all amounts are estimates.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">SEC registration fee</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">US$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT>9,568.62</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Nasdaq listing fee</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,000.00</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financial Industry Regulatory Authority Inc. filing fee</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,746.76</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Printing and engraving expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal fees and expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">847,756.31</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounting fees and expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68,900.00</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transfer agent expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;&#x00a0;&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Miscellaneous</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">200.00</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">US$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">943,171.69</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will bear these expenses and the underwriting discounts and commissions incurred in connection with the offer and sale of the ordinary shares by us.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T3"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LEGAL MATTERS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">We are being represented by Sichenzia Ross Ference Carmel LLP with respect to certain legal matters as to United&#x00a0;States federal securities and New&#x00a0;York State law. The underwriters are represented by VCL Law LLP with respect to certain legal matters as to United&#x00a0;States federal securities and New&#x00a0;York State law. Certain legal matters related to Litigation in PRC will be passed to ZHEJIANG BONING LAW FIRM. The validity of the ordinary shares offered in this offering will be passed upon for us by Conyers Dill &amp; Pearman. Certain non<FONT CLASS="nobreak">-TFDA</FONT> related legal matters as to Taiwan laws of general application will be passed upon for us by KPMG Law Firm. Certain legal matters limited to the regulatory history of MCS<FONT CLASS="nobreak">-2</FONT> before the U.S. Food and Drug Administration (FDA) will be passed upon for us by Olsson Frank Weeda Terman Matz PC. Sichenzia Ross Ference Carmel LLP may rely upon Conyers Dill &amp; Pearman with respect to matters governed by Cayman Islands law, KPMG Law Firm with respect to matters governed by Taiwan law, and and Olsson Frank Weeda Terman Matz PC with respect to certain legalmatters related to the regulatory history of MCS<FONT CLASS="nobreak">-2</FONT> before the FDA.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">203</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><A NAME="T2"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EXPERTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">The consolidated financial statements of Jyong Biotech Ltd., as of December<FONT CLASS="nobreak"> </FONT>31, 2022 and 2023, and for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2022 and 2023 have been audited by WWC, P.C., an independent registered public accounting firm, as stated in their report appearing herein and elsewhere in the Registration Statement.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T1"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have filed with the SEC a registration statement on Form&#x00a0;F<FONT CLASS="nobreak">-1</FONT>, including relevant exhibits and schedules under the Securities Act with respect to underlying ordinary shares, to be sold in this offering. This prospectus, which constitutes a part of the registration statement, does not contain all of the information contained in the registration statement. You should read the registration statements on Form&#x00a0;F<FONT CLASS="nobreak">-1</FONT> and their exhibits and schedules for further information with respect to us and our ordinary shares.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately upon completion of this offering we will become subject to periodic reporting and other informational requirements of the Exchange&#x00a0;Act as applicable to foreign private issuers. Accordingly, we will be required to file reports, including annual reports on Form&#x00a0;20<FONT CLASS="nobreak">-F</FONT>, and other information with the SEC.&#x00a0;All information filed with the SEC can be inspected and copied at the public reference facilities maintained by the SEC at 100&#x00a0;F&#x00a0;Street, N.E., Washington, D.C. 20549. You can request copies of these documents, upon payment of a duplicating fee, by writing to the SEC.&#x00a0;Please call the SEC at&#x00a0;1<FONT CLASS="nobreak">-800-SEC-0330</FONT> for further information on the operation of the public reference rooms. You may also obtain additional information over the Internet at the SEC&#x2019;s website at&#x00a0;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">www.sec.gov</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a foreign private issuer, we are exempt under the Exchange&#x00a0;Act from, among other things, the rules prescribing the furnishing and content of proxy statements to shareholders, and our executive officers, directors and principal shareholders are exempt from the reporting and short<FONT CLASS="nobreak">-swing</FONT> profit recovery provisions contained in Section&#x00a0;16 of the Exchange&#x00a0;Act. In addition, we will not be required under the Exchange&#x00a0;Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S.&#x00a0;companies whose securities are registered under the Exchange&#x00a0;Act.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">204</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T25"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED<BR>FINANCIAL STATEMENTS<BR>TABLE OF CONTENTS</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CONTENTS</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PAGE(S)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T220">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB#1171)</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-2</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T221">UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2023 AND JUNE&#x00a0;30, 2024</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-3</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T222">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND&#x00a0;COMPREHENSIVE LOSS FOR THE SIX MONTHS ENDED JUNE&#x00a0;30, 2023 AND&#x00a0;2024</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-4</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T223">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#x2019; EQUITY FOR THE SIX MONTHS ENDED JUNE&#x00a0;30, 2023 AND&#x00a0;2024</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-5</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T224">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR&#x00a0;THE SIX MONTHS ENDED JUNE&#x00a0;30, 2023 AND&#x00a0;2024</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-6</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T225">NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL <BR>STATEMENTS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-7&#x00a0;&#x2013;&#x00a0;F-26</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">CONTENTS</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">PAGE(S)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T226">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB#1171)</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-27</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T227">AUDITED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2022 AND&#x00a0;2023</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-28</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T228">AUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE YEARS ENDED DECEMBER 31, 2022 AND&#x00a0;2023</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-29</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T229">AUDITED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#x2019; EQUITY FOR&#x00a0;THE YEARS ENDED DECEMBER 31, 2022 AND&#x00a0;2023</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-30</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T230">AUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2022 AND&#x00a0;2023</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-31</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 87.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T231">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-32&#x00a0;&#x2013;&#x00a0;F-53</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-1</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><IMG ALT="" SRC="twwc_header.jpg" STYLE="width:565.76px;max-width:100%;"></FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><A NAME="T220"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:24pt;margin-top:6pt;text-indent:-24pt;margin-top:6pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;">To:<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The Board of Directors and Shareholders of<BR>Jyong Biotech Ltd. and Subsidiaries</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:10pt;">Results of Review of Interim Financial Information</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;">We have reviewed the unaudited interim condensed consolidated balance sheet of Jyong Biotech Ltd. and its subsidiaries&#x00a0;(collectively the &#x201c;Group&#x201d;) as of June&#x00a0;30, 2024, and the related unaudited interim condensed consolidated statements of operations and comprehensive loss, changes in shareholders&#x2019; deficit, and cash flows for the </FONT><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;">six</FONT><FONT CLASS="nobreak" STYLE="font-size:10pt;">-month</FONT><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;"> periods ended June&#x00a0;30, 2023 and 2024, and the related notes (collectively referred to as the unaudited interim condensed consolidated financial statements). Based on our reviews, we are not aware of any material modifications that should be made to the accompanying interim financial statements for them to be in conformity with accounting principles generally accepted in the United&#x00a0;States of America.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;">We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United&#x00a0;States) (PCAOB), the consolidated balance sheet of the Company as of December&#x00a0;31, 2023, and the related consolidated statement of operations and comprehensive loss, changes in shareholders&#x2019; deficit and cash flows for the year then ended (not presented herein); and in our report dated May&#x00a0;8, 2024, except for Note&#x00a0;18 for which the date is October&#x00a0;4, 2024, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December&#x00a0;31, 2023, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:10pt;">Explanatory Paragraph&#x00a0;&#x2014;&#x00a0;Substantial Doubt about the Company&#x2019;s Ability to Continue as a Going Concern</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note&#x00a0;2 of the Company&#x2019;s audited consolidated financial statements as of December&#x00a0;31, 2023, and for the year then ended discloses that, the Company has a significant working capital deficiency, has incurred significant losses, and needs to raise additional funds to meet its obligations and sustain its operations. Our auditor&#x2019;s report on those financial statements includes an explanatory paragraph referring to the matters in Note&#x00a0;2 of those financial statements and indicating that these matters raised substantial doubt about the Company&#x2019;s ability to continue as a going concern. As indicated in Note&#x00a0;2 of the Company&#x2019;s unaudited interim condensed consolidated financial statements as of June&#x00a0;30, 2024 and for the six&#x00a0;months then ended, the Company was still has a significant working capital deficiency, has incurred significant losses, and needs to raise additional funds to meet its obligations and sustain its operations. The accompanying interim financial information does not include any adjustments that might result from the outcome of this uncertainty.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:10pt;">Basis for Review Results</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;">These interim consolidated financial statements are the responsibility of the Company&#x2019;s management. We conducted our review in accordance with the standards of the PCAOB.&#x00a0;A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#x00a0;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#x00a0;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;">/</FONT><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;">s</FONT><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;">/</FONT><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;"> WWC, P.C.<BR>WWC, P.C.<BR>Certified Public Accountants<BR>PCAOB ID No.1171</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:10pt;">We have served as our auditor since 2023.<BR>San Mateo, California<BR>October&#x00a0;4, 2024</FONT></P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-2</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><A NAME="T221"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS</FONT><BR>(in thousand US Dollars, except share and per share data)</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of <BR>December&#x00a0;31, <BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of <BR>June&#x00a0;30, <BR>2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Audited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ASSETS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Current Assets</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">177</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">96</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Restricted cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,565</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepayments and other current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">97</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">101</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total current assets</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,839</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">200</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,386</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,139</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating right-of-use assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">158</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">199</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred offering costs</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">721</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">831</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Restricted asset</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2,137</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2,065</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other non-current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">7</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total non-current assets</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6,409</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6,240</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TOTAL ASSETS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">8,248</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6,440</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Current liabilities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Short-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7,897</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7,100</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notes and accounts payable</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">9</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,127</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">876</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">55</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">95</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current portion of long-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">75</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">361</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liabilities due to related parties-current</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">130</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">161</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4,951</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,304</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current liabilities due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">21</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">28</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total current liabilities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">14,258</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">11,934</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long-term loan from related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,151</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4,761</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long-term loan from third parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,131</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,131</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long-term bank loans, net of current portion</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2,238</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,778</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liabilities due to related parties&#x00a0;&#x2013;&#x00a0;non-current</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">69</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">77</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other non-current liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">59</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">58</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other non-current liabilities due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">628</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">628</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Guarantee liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">18,787</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">18,999</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total non-current liabilities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">28,063</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">29,432</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TOTAL LIABILITIES</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">42,321</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">41,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Commitments and contingencies (Note&#x00a0;16)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Shareholders&#x2019; deficit</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary shares, $0.00001 par value; 5,000,000 thousand shares and 73,361 thousand shares issued and outstanding as of December&#x00a0;31, 2023&#x00a0;and June&#x00a0;30, 2024, respectively</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11,805</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11,805</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Treasury shares, 1,794 thousand shares as of December&#x00a0;31, 2023 and June&#x00a0;30, 2024</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(16,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(16,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(30,061</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(31,387</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated other comprehensive income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">548</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,021</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total shareholders&#x2019; deficit</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(34,073</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(34,926</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TOTAL LIABILITIES AND SHAREHOLDERS&#x2019; DEFICIT</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">8,248</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6,440</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-3</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T222"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<BR>AND COMPREHENSIVE LOSS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(in thousand US Dollars, except share data in thousands and per share data)</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">For the six&#x00a0;months ended <BR>June&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Operating expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(538</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(499</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Selling and marketing</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(22</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(21</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(549</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(431</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total operating expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(1,109</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(951</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss from operations</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(1,109</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(951</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other incomes (expenses):</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">6</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(359</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(448</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other (losses) gains, net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(276</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">67</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total other expenses, net</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(633</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(375</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss before income tax</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,742</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,326</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net loss</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(1,742</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(1,326</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other comprehensive income</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign currency translation adjustments, net of nil tax</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">124</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">473</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total comprehensive loss</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(1,618</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(853</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net loss per share:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and Diluted</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(0.02</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(0.02</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Weighted average shares outstanding (in thousands):</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and Diluted</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">71,567</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">71,567</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-4</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T223"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS<BR>OF CHANGES IN SHAREHOLDERS&#x2019; DEFICIT<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(In thousand US Dollars, except share data in thousands)</FONT></P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="4" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><BR><BR>Ordinary Shares</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.51%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Additional <BR>Paid-in <BR>Capital</P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Accumulated <BR>Other <BR>Comprehensive <BR>Income</P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Accumulated <BR>Deficit</P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Treasury <BR>Shares</P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.99%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Total <BR>Shareholders&#x2019; <BR>Deficit</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Shares</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Amount</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Balance as of January&#x00a0;1, 2023&#x00a0;(Audited)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">73,361</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11,805</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">590</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(25,661</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(16,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(29,631</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.32%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.77%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.64%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,742</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.22%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,742</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Foreign currency translation adjustment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">124</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">124</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Balance as of June&#x00a0;30, 2023&#x00a0;(Unaudited)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">73,361</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">11,805</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">714</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(27,403</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(16,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(31,249</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Balance as of January&#x00a0;1, 2024&#x00a0;(Audited)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">73,361</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11,805</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">548</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(30,061</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(16,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(34,073</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.32%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.77%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.64%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,326</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.22%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,326</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Foreign currency translation adjustment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">473</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">473</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Balance as of June&#x00a0;30, 2024&#x00a0;(Unaudited)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">73,361</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">11,805</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,021</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(31,387</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(16,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(34,926</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-5</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T224"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LTD.<BR>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(In thousand US Dollars)</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">For the six&#x00a0;months ended <BR>June&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from operating activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,742</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,326</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">65</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">62</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Noncash operating lease expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">89</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">85</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value changes in the guarantee liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">117</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">212</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in operating assets and liabilities:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepayments and other current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">5</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(4</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notes and accounts payable</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(145</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(251</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">6</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">40</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liabilities due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(65</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(62</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">360</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,542</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current liabilities due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">15</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other non-current liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net cash used in operating activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(1,292</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(2,773</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from investing activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from maturity of time deposits</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">95</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net cash provided by investing activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">95</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from financing activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payments of deferred offering costs</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(199</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(110</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from short-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,761</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">859</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Repayment of short-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,476</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,216</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds of loan from related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">700</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,653</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Repayments of long-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(73</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(44</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net cash provided by financing activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">713</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,142</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Effects of exchange rate changes on cash and restricted cash</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(72</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(12</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">NET DECREASE IN CASH AND RESTRICTED CASH</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(556</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,643</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CASH AND RESTRICTED CASH AT BEGINNING OF THE YEAR</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2,274</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,742</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CASH AND RESTRICTED CASH AT END OF THE PERIOD</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,718</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">99</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income taxes paid</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">104</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">110</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Reconciliation to amount on consolidated balance sheets</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">238</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">96</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Restricted cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,480</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">3</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">TOTAL CASH AND RESTRICTED CASH</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,718</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">99</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-6</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T225"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>ORGANIZATION AND BUSINESS OPERATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Health Ever Biotech Co., Ltd., (&#x201c;HEB&#x201d;) was incorporated under the laws of Taiwan in August&#x00a0;2002 to research and develop new drugs for today&#x2019;s great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. In January&#x00a0;2018, HEB incorporated Jyong Biotech Ltd., (&#x201c;Jyong&#x201d; or the &#x201c;Company&#x201d;) under the laws of the Cayman Islands and was reorganized into the Company&#x2019;s subsidiary in December&#x00a0;2018. After the reorganization, HEB was wholly owned by the Company in April&#x00a0;2019.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company and its subsidiaries&#x2019; (the &#x201c;Group&#x201d;) product candidates are led by &#x201c;Botreso&#x201d; (also known as&#x00a0;MCS<FONT CLASS="nobreak">-2</FONT>) and PCP.&#x00a0;Botreso is a drug candidate in the clinic, developed for unmet medical needs of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). The Group has completed four Phase&#x00a0;III clinical trials in Taiwan and the U.S.&#x00a0;and submitted a new drug application for Botreso to the U.S.&#x00a0;Food and Drug Administration (&#x201c;US FDA&#x201d;) for review in December&#x00a0;2021. &#x201c;PCP&#x201d; is the other key new drug candidate developed for the prevention of prostate cancer. Similar to MCS<FONT CLASS="nobreak">-2</FONT>, PCP works through its mechanism of antioxidant and anti<FONT CLASS="nobreak">-inflammatory</FONT>. PCP contains several types of patented medical<FONT CLASS="nobreak">-grade</FONT> active pharmaceutical ingredients that reduce oxidative stress and inflammatory cytokines (IL<FONT CLASS="nobreak">-6</FONT>), both of which are causes of many chronic inflammatory diseases. The Group is conducting phase&#x00a0;II clinical trials of PCP in Taiwan.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of June&#x00a0;30, 2024, the Company&#x2019;s subsidiaries are as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Subsidiaries</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Date of <BR>incorporation</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Place of <BR>incorporation</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Ownership</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Principal activities</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Health Ever Biotech Co., Ltd. (&#x201c;HEB&#x201d;)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">August&#x00a0;1, 2002</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Taiwan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">100% owned by the Company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Research, development, manufacturing</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Genvace Biotechnology (&#x201c;GB&#x201d;)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">September&#x00a0;14, 2021</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Taiwan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">100% owned by HEB</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Research and development</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Top ShunXing Bio-Tech Co., (&#x201c;TSB&#x201d;)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">March&#x00a0;4, 2019</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Hong&#x00a0;Kong</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">100% owned by the Company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Investment holding</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Innovative Biotech Co., (&#x201c;IB&#x201d;)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July&#x00a0;1, 2019</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">People&#x2019;s Republic of China (&#x201c;China&#x201d;)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">100% owned by TSB</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Research, development, manufacturing</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Jyong Biotech International Pte. Ltd.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">September&#x00a0;29, 2022</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Singapore</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">100% owned by the Company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Leasing of non<FONT CLASS="nobreak">-financial</FONT> intangible assets</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LIQUIDITY RISKS AND GOING CONCERN</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;)&#x00a0;2014<FONT CLASS="nobreak">-15</FONT>, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic&#x00a0;205<FONT CLASS="nobreak">-40</FONT>), the Group has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Group&#x2019;s ability to continue as a going concern within one year after the date that the unaudited interim condensed consolidated financial statements are issued.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of June&#x00a0;30, 2024 and as of August&#x00a0;31, 2024, the Group had cash of approximately $96 and $64, respectively. The Group has incurred recurring negative cash flows since inception and has funded its operations primarily from equity and debt financing. The Group had accumulated deficit of approximately $30,061 and $31,387 as of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, respectively and net losses of approximately $1,742 and $1,326 for the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024. In addition, the Group incurred negative cash flows in operating activities for the approximate amount of $1,292 and $2,773 for the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, respectively. The Group&#x2019;s ability to fund its operations is highly contingent on raising additional capital until a regulatory approval that provides an ability to generate sufficient revenue, if ever. As such, the Group&#x2019;s management concluded that there is substantial doubt about the Group&#x2019;s ability to continue as a going concern within one year after the issuance date of the unaudited interim condensed consolidated financial statements.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-7</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LIQUIDITY RISKS AND GOING CONCERN</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Group intends to pursue a public offering to fund future operations. If the Group is unable to complete a public offering for a sufficient amount in a timely manner, it would need to pursue other financing alternatives such as private financing of debt or equity or collaboration agreements. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Group, or at all. If the Group is unable to obtain sufficient funding by August&#x00a0;2025, it could be required to delay its development efforts, limit activities and reduce research and development costs, which could adversely affect its business and the unaudited interim condensed consolidated financial statements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The accompanying unaudited interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, unaudited interim condensed consolidated financial statements have been prepared on a basis that assumes the Group will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Basis of presentation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#x00a0;States of America (&#x201c;U.S.&#x00a0;GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;), regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S.&#x00a0;GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in these unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The accompany unaudited interim condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year ending December&#x00a0;31, 2024.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Principle of consolidation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated on consolidation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Use of estimates</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The preparation of unaudited interim condensed consolidated financial statements in conformity with U.S.&#x00a0;GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Significant accounting estimates reflected in the Group&#x2019;s unaudited interim condensed consolidated financial statements include, but are not limited to, useful lives for property and equipment, impairment of long<FONT CLASS="nobreak">-live</FONT> assets, determination of incremental borrowing rate for lease, research and development expense recognition, other contingency liabilities, and valuation allowance for deferred income tax assets. Management evaluates the estimates based on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Accordingly, actual results could differ from those estimates.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risk and uncertainties</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The product candidates developed by the Group require approvals from the US FDA or foreign regulatory agencies prior to commercial sales. There can be no assurance that the Group&#x2019;s current and future product candidates will receive the necessary approvals or be commercially successful. If the approval is denied or delayed, it will have a material adverse impact on the business and unaudited interim condensed consolidated financial statements of the Group.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-8</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Generally, the industry in which the Group operates subjects the Group to a number of other risks and uncertainties that can affect its operating results and financial condition. Such factors include, but are not limited to: the timing, costs and results of clinical trials and other development activities versus expectations; the ability to manufacture products successfully; competition from products sold or being developed by other companies; the price of, and demand for products once approved; the ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Emerging Growth Company Status</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group is an &#x201c;emerging growth company,&#x201d; as defined in Section&#x00a0;2(a)&#x00a0;of the Securities Act&#x00a0;of&#x00a0;1933, as amended, (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart The Company&#x2019;s Business Startups Act&#x00a0;of&#x00a0;2012, (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#x00a0;404 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, Section&#x00a0;102(b)(1)&#x00a0;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non<FONT CLASS="nobreak">-emerging</FONT> growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition periods which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company difficult because of the potential differences in accounting standards used.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Fair value measurements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group applies ASC&#x00a0;820, Fair Value Measurements and Disclosures. ASC&#x00a0;820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ASC&#x00a0;820 requires disclosures to be provided for fair value measurements. ASC&#x00a0;820 establishes a three<FONT CLASS="nobreak">-tier</FONT> fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Level&#x00a0;1&#x00a0;&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 85.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Observable inputs such as quoted prices for identical instruments in active markets;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Level&#x00a0;2&#x00a0;&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 85.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Level&#x00a0;3&#x00a0;&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 85.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ASC&#x00a0;820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#x00a0;market approach; (2)&#x00a0;income approach; and (3)&#x00a0;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-9</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of the Group&#x2019;s financial instruments, including cash, short<FONT CLASS="nobreak">-term</FONT> bank loans, notes and accounts payable, other current liabilities due to related parties, approximates fair value due to the short<FONT CLASS="nobreak">-term</FONT> maturity of the instruments. The Group&#x2019;s long<FONT CLASS="nobreak">-term</FONT> liabilities approximate their fair values as they contain interest rates that vary according to market interest rates.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash consists of cash and demand deposits placed with banks. All cash is unrestricted to withdrawal and use.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Restricted cash</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Restricted cash mainly consists of the bank deposits held as collateral for the credit of a business credit card and bank deposits with time deposits having original maturities of more than three&#x00a0;months, frozen by the order of the Taizhou Intermediate People&#x2019;s Court as asset preservation for the Taizhou Bay New District Administrative Committee. See litigation in Note&#x00a0;16 &#x2014;&#x00a0;Commitments and Contingencies for further detail.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Property and equipment</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and impairment if applicable. Significant additions, renewals and betterments are capitalized, while maintenance and repairs are expenses as incurred. Depreciation is computed on a straight<FONT CLASS="nobreak">-line</FONT> basis over estimated useful lives that range as follows:</P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Useful life</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Buildings</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">50 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Building improvements</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3 to 15 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Laboratory equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3 to 5 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Transportation equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Office equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2 to 8 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Other equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2 to 10 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Leasehold improvements</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">the shorter of the estimated useful life or the lease term, which is 3 to 5 years</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Retirements, sale and disposals of assets are recorded by removing the cost and accumulated depreciation with any resulting gain or loss reflected in the unaudited interim condensed consolidated statements of operations and comprehensive loss.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Leases</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group determines if an arrangement is a lease at inception. The Group classifies the lease as a finance lease if it meets certain criteria or as an operating lease when it does not. The Group leases several properties for offices, research and development centers, and manufacturing factories in mainland China and Taiwan, which are all classified as operating leases with fixed lease payments, as contractually stated in the lease agreements. The Group&#x2019;s leases do not contain any material residual value guarantees or material restrictive covenants.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the commencement date of a lease, the Group recognizes a lease liability for future fixed lease payments and a right<FONT CLASS="nobreak">-of-use</FONT> (&#x201c;ROU&#x201d;) asset representing the right to use the underlying asset during the lease term. The lease liability is initially measured as the present value of the future fixed lease payments that will be made over the lease term. The future fixed lease payments are discounted using the rate implicit in the lease, if available, or the incremental borrowing rate (&#x201c;IBR&#x201d;) based on the information available at the commencement date of the lease. The Group has elected not to record leases with an initial term of 12&#x00a0;months or less on the unaudited interim condensed consolidated balance sheets.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-10</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ROU asset is measured at the amount of the lease liability with adjustments, if applicable, for lease prepayments made prior to or at lease commencement, initial direct costs incurred by the Group and lease incentives. Under ASC&#x00a0;842, land use rights agreements are also considered to be operating lease contracts. The Group will evaluate the carrying value of ROU assets if there are indicators of impairment and review the recoverability of the related asset group. If the carrying value of the asset group is determined to not be recoverable and is in excess of the estimated fair value, the Group will record an impairment loss in other expenses in the unaudited interim condensed consolidated statements of operations. ROU assets for operating leases are included in operating lease right<FONT CLASS="nobreak">-of-use</FONT> assets in the unaudited interim condensed consolidated balance sheets.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Operating leases are included in operating lease right<FONT CLASS="nobreak">-of-use</FONT> assets and operating lease liabilities in the unaudited interim condensed consolidated balance sheets. Operating lease liabilities that become due within one year of the balance sheet date are classified as current operating lease liabilities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lease expense is recognized on a straight<FONT CLASS="nobreak">-line</FONT> basis over the lease term.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, IB, the Company&#x2019;s subsidiary, acquired land use rights from the Bureau of Natural Resources and Planning in Taizhou, China (&#x201c;Taizhou Resources Bureau&#x201d;) in December&#x00a0;2019 for 50&#x00a0;years and paid RMB&#x00a0;16,494 thousand ($2,528). All land in mainland China is owned by the China government. The China government may sell land use rights for a specified period of time. The purchase price of land use rights represents the operating lease prepayments for the rights to use the land in mainland China under ASC&#x00a0;842 and is recorded as operating ROU assets on the unaudited interim condensed consolidated balance sheets, which is amortized over the lease term.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Restricted asset</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Restricted asset mainly consists of the land use rights from the Taizhou Resources Bureau have been seized by the Taizhou Intermediate People&#x2019;s Court as asset preservation for the Taizhou Bay New District Administrative Committee. See Note&#x00a0;16 &#x2014;&#x00a0;Commitments and Contingencies for further detail.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Intangible assets</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Intangible assets consist of costs incurred to acquire computer software, which are considered finite live assets and recorded at cost less accumulated amortization and accumulated impairment. Amortization is recorded using the straight<FONT CLASS="nobreak">-line</FONT> basis over estimated useful lives that range from 3&#x00a0;years.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Impairment of </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">long-lived</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> assets</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group evaluates the recoverability of long<FONT CLASS="nobreak">-lived</FONT> assets, including finite<FONT CLASS="nobreak">-lived</FONT> intangible assets, whenever events or changes in circumstances indicate the carrying value may not be fully recoverable. When these events occur, the Group evaluates the recoverability of long<FONT CLASS="nobreak">-lived</FONT> assets by comparing the carrying amount of the assets to the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets when the market prices are not readily available. The adjusted carrying amount of the assets becomes a new cost basis and is depreciated over the assets&#x2019; remaining useful lives. No impairment loss was recorded for the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-11</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Deferred offering costs</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Deferred offering costs consist of underwriting, legal, accounting and other expenditures incurred through the balance sheet date that are directly related to the Company&#x2019;s initial public offering and that will be charged to shareholder&#x2019;s deficit upon the completion of the initial public offering. Should the initial public offering prove to be unsuccessful, the deferred offering costs, will be charged to operating expense in the consolidated statement of operations and comprehensive loss. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, the Company incurred $721 and $831 of offering costs, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Guarantee liabilities</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company provided a joint and several guarantee for the performance of buyback shares obligation of the certain shareholders who transferred some of their shares in the Company to others. The guarantee of buyback shares obligation falls within the scope of ASC&#x00a0;460<FONT CLASS="nobreak">-10-15-4</FONT>(b). The guarantee liability is recognized at the fair value at the inception of the guarantee and subsequently remeasured at each reporting period. Changes in the fair value of the guarantee liability are recorded as changes in guarantee liabilities in the unaudited interim condensed consolidated statements of operations and comprehensive loss. When the Company settles the guarantee liability through the performance of the guarantee by making requisite payments to buy back shares, the Company records a corresponding deduction to the guarantee liability. When the Company is released from the guarantee obligation due to the buyback of shares performed by certain shareholders, it is recognized as a reversal of the deduction to the guarantee liability. See Commitment with the Taizhou Company in Note&#x00a0;16 &#x2014;&#x00a0;Commitments and Contingencies for further detail.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss contingencies</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group is subject to certain legal proceedings and contingencies in addition to those related to guarantee liabilities discussed above in this Note, the outcome of which are subject to significant uncertainty. The Group accrues for estimated losses if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company uses judgment and evaluates whether a loss contingency arising from litigation or an unasserted claim should be disclosed or recorded. The outcome of legal proceedings and other contingencies is inherently uncertain and often difficult to estimate. Accrued legal contingencies are reported within other current liabilities or other non<FONT CLASS="nobreak">-current</FONT> liabilities in the consolidated balance sheets based on the period in which the Group expects the contingency to be settled.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Segment reporting</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with ASC&#x00a0;280, Segment Reporting, the Group&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) has been identified as the Chief Executive Officer. The Group&#x2019;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages its business as a single segment. The Group does not distinguish between markets for the purpose of making decisions about resource allocation and performance assessment. Hence, the Group has only one operating segment and one reportable segment. No geographical segments are presented as substantially all the Group&#x2019;s long<FONT CLASS="nobreak">-lived</FONT> assets are located in Asia.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Research and development expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses primarily include (1)&#x00a0;payroll and other related costs of personnel engaged in research and development activities, (2)&#x00a0;costs related to preclinical testing of the Group&#x2019;s technologies and clinical trials such as payments to contract research organizations (&#x201c;CRO&#x201d;), investigators and clinical trial sites that conduct the clinical studies, (3)&#x00a0;costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (4)&#x00a0;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the Group&#x2019;s research and development services and have no alternative future uses.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-12</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants and CROs, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which the services are provided under such contracts. The Group reflects research and development expenses in the unaudited interim condensed consolidated financial statements by matching those expenses with the period in which services and efforts are expended. The Group accounts for these expenses according to the progress of the preclinical or clinical study as measured by the timing of various aspects of the study or related activities and determines accrual estimates through reviewing the underlying contracts along with discussions with research and other key personnel as to the progress of studies, or other services being conducted. During the course of a study, the Group adjusts its expense recognition if actual results differ from its estimates.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Government Grants</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Government grants for the purpose of giving financial support to the Group with no future related costs or obligations are recognized as non<FONT CLASS="nobreak">-operating</FONT> income when received. The government grants with certain operating conditions are recorded as liabilities when received and will be recorded as non<FONT CLASS="nobreak">-operating</FONT> income when the conditions are met. No government grants from China government authority were received by IB, Jyong&#x2019;s subsidiary located in China, during the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Income tax</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The income tax expense for the interim period is accrued using the tax rate that would be applicable to expected total annual earnings, that is, the estimated average annual effective income tax rate applied to the pre<FONT CLASS="nobreak">-tax</FONT> income of the interim period.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Earnings (loss) per share</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic earnings (loss) per ordinary share is computed by dividing net income (loss) attributable to ordinary shareholders by weighted average number of ordinary shares outstanding during the period.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Diluted earnings (loss) per ordinary share reflects the potential dilution that could occur if securities were exercised or converted into ordinary shares. The Company did not have potential ordinary shares (e.g., stock options, non<FONT CLASS="nobreak">-vested</FONT> restricted shares and other securities), which could potentially convert into ordinary shares and dilute basic earnings (loss) per share in the future.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Foreign currency transactions</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The functional currency of the Company is the U.S.&#x00a0;dollar. The Company&#x2019;s subsidiaries determined their functional currency to be the local currency of the respective entities except for TSB which determined its functional currency to be the U.S.&#x00a0;dollar based on the criteria of ASC&#x00a0;830, Foreign Currency Matters. Gains or losses, resulting from the application of different foreign exchange rates when cash in foreign currency is converted into the entities&#x2019; functional currency, or when foreign currency receivable and payable are settled, are credited or charged to income in the period of conversion or settlement. At period<FONT CLASS="nobreak">-end</FONT>, the balances of foreign currency monetary assets and liabilities are recorded based on prevailing exchange rates and any resulting gains or losses are credited or charged to non<FONT CLASS="nobreak">-operating</FONT> income or loss.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Translation of foreign currency financial statements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reporting currency of the Group is the US dollar. Assets and liabilities are translated from each entity&#x2019;s functional currency to the reporting currency at the exchange rate on the balance sheet date. Equity amounts, except for the change in accumulated deficits, are translated at historical exchange rates at the date of entry to shareholders&#x2019; equity; the change in accumulated deficits uses historical exchange rates of each period&#x2019;s statement of </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-13</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">operations. Translation adjustments are reported as accumulative translation adjustments and are shown as a separate component of other comprehensive income in the unaudited interim condensed consolidated statements of changes in shareholders&#x2019; deficit.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Translation of amounts into USD has been made at the following exchange rates from Board of Governors of the Federal Reserve System:</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Balance sheet items, except for equity accounts</P>
		<TABLE CLASS="Basic-Table" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="Basic-Table _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">June&#x00a0;30, 2024</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">RMB7.2672 to $1; NTD32.4500 to $1</P>
					</TD>
				</TR>
				<TR CLASS="Basic-Table _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">December&#x00a0;31, 2023</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">RMB7.0999 to $1; NTD30.6200 to $1</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Statement of operations and comprehensive loss, and cash flows items</P>
		<TABLE CLASS="Basic-Table" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="Basic-Table _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">For the&#x00a0;six&#x00a0;months&#x00a0;ended&#x00a0;June&#x00a0;30, 2024</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">RMB7.2150 to $1; NTD31.8992 to $1</P>
					</TD>
				</TR>
				<TR CLASS="Basic-Table _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">For the&#x00a0;six&#x00a0;months&#x00a0;ended&#x00a0;June&#x00a0;30, 2023</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">RMB6.9283 to $1; NTD30.5542 to $1</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Comprehensive loss</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss consists of two components, net loss and other comprehensive income (loss). The foreign currency translation gain or loss resulting from translation of the unaudited interim condensed consolidated financial statements expressed in USD is reported in other comprehensive loss in the unaudited interim condensed consolidated statements of operations and comprehensive loss.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Concentration of risks</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Concentration of suppliers</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following suppliers accounted for 10% or more of research and development expenses for the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Six&#x00a0;months ended June&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Supplier</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">A</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">33</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">B</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">29</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">D</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<FONT STYLE="width: 24px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents less than 10% of research and development expenses for the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Concentration of credit risk</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject the Group to significant concentration of credit risk consist primarily of deposits and time deposits with original maturities more than three&#x00a0;months.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In China, the insurance coverage of each financial institution is RMB 500 thousand. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, the Group had RMB 10,586 thousand ($1,491) and nil, which was frozen by the order of the Taizhou Intermediate People&#x2019;s Court, in uninsured deposits at the financial institution incorporated in China, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In Taiwan, the insurance coverage of each financial institution is NTD 3,000 thousand. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, the Group had $6 and $3 in uninsured deposits at the financial institutions incorporated in Taiwan, respectively.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-14</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In Hong&#x00a0;Kong, the insurance coverage of each financial institution is HKD 500 thousand. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, all deposits at the financial institution incorporated in Hong&#x00a0;Kong were covered by the insurance, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While management believes that these financial institutions are of high credit quality, it also continually monitors their credit worthiness.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Recent accounting pronouncements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In October&#x00a0;2023, the FASB issued ASU&#x00a0;2023<FONT CLASS="nobreak">-06</FONT>, &#x201c;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative.&#x201d; This amendment incorporates certain U.S.&#x00a0;Securities and Exchange Commission (SEC) disclosure requirements into the FASB Accounting Standards Codification. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification Topics, allow users to more easily compare entities subject to the SEC&#x2019;s existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the Codification with the SEC&#x2019;s regulations. For entities subject to the SEC&#x2019;s existing disclosure requirements and for entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. For all other entities, the amendments will be effective two&#x00a0;years later. However, if by June&#x00a0;30, 2027, the SEC has not removed the related disclosure from its regulations, the amendments will be removed from the Codification and not become effective for any entity. The Company does not expect the adoption of ASU&#x00a0;2023<FONT CLASS="nobreak">-06</FONT> to have a material impact on its unaudited interim condensed consolidated financial statements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In November&#x00a0;2023, the FASB issued ASU&#x00a0;2023<FONT CLASS="nobreak">-07</FONT>, Segment Reporting (Topic&#x00a0;280) &#x2014;&#x00a0;Improvements to Reportable Segment Disclosures. The amendment requires entities to report a measure of segment profit or loss that the chief operating decision maker uses to assess segment performance and make decisions about allocating resources. The amendment also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosure under certain circumstances. The amendment does not change or remove those disclosure requirements and also does not change how an entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. This amendment is effective for the Group&#x2019;s consolidated financial statements issued for annual periods beginning after December&#x00a0;15, 2023. Early adoption is permitted. The Group adopted this standard on January&#x00a0;1, 2024. There was no material impact to the Group&#x2019;s consolidated financial statements upon adoption.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#x00a0;2023, the FASB issued ASU&#x00a0;2023<FONT CLASS="nobreak">-09</FONT>, Income Taxes (Topic&#x00a0;740) &#x2014;&#x00a0;Improvements to Income Tax Disclosures. The amendment requires that entities on an annual basis (1)&#x00a0;disclose specific categories in the rate reconciliation and (2)&#x00a0;provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate. The amendment also requires disclosure of, on an annual basis, the year<FONT CLASS="nobreak">-to-date</FONT> amount of income tax paid (net of refunds received) disaggregated by disaggregated by federal, state, and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). This amendment is effective for the Group&#x2019;s consolidated financial statements issued for annual periods beginning after December&#x00a0;15, 2024. Early adoption is permitted. The Group is currently evaluating the impact of adopting this amendment.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-15</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>CASH AND RESTRICTED CASH</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>December&#x00a0;31,<BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>June&#x00a0;30,<BR>2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Audited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash in hand</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deposits in banks</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">176</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">177</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">96</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deposits in banks frozen by the other of the Taizhou Intermediate People&#x2019;s Court (see Note&#x00a0;16 for further detail)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,562</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Collateral for the credit of a business credit card</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total restricted cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,565</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total cash and restricted cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,742</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">99</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">On February&#x00a0;22, 2024, the RMB 11,129 thousand ($1,542) of restricted cash, which was deposits in banks frozen by the Taizhou Intermediate People&#x2019;s Court, was transferred to New District Administrative Committee (see Note&#x00a0;16 for further detail).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">5.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>PROPERTY AND EQUIPMENT, NET</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consist of the following:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>December&#x00a0;31,<BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>June&#x00a0;30,<BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Audited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Land</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,020</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">962</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Buildings</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,499</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,358</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Buildings improvements</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">152</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">143</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Laboratory equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">793</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">749</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Office equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">120</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">113</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transportation equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Leasehold improvements</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">142</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Construction in progress</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">139</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">136</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,948</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,674</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: accumulated depreciation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,562</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,535</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,386</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,139</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Depreciation expenses recognized during the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024 were approximately $65 and $62, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">6.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LEASES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group leased facilities for office, research and development and manufacturing facilities in China and Taiwan. Most of the lease facilities in Taiwan were leased from the related parties. In December&#x00a0;2019, the land use right of gross value of RMB 16,494 thousand ($2,528) for 50&#x00a0;years was acquired from Taizhou Resource Bureau in China. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, the net carrying values of the acquired land use rights of Taizhou were RMB 15,175 thousand ($2,137) and RMB 15,010 thousand ($2,065), respectively. In January&#x00a0;2024, this land use right was seized by the Taizhou Intermediate People&#x2019;s Court due to the litigation with Taizhou Bay New District Administrative Committee and RMB15,010 thousand ($2,065) of operating right<FONT CLASS="nobreak">-of-use</FONT> assets regarding IB&#x2019;s land use right was reclassified as a restricted asset. See Notes 16 for the detail. In November&#x00a0;2023, </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-16</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">6.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LEASES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">February 2024 and May&#x00a0;2024, the Group renewed the lease agreement with the related party, Zhao Jian Fu Co., Ltd to lease an office in Taiwan, continuously. Lease terms vary based on the nature of operations and the market dynamics; however, all leased facilities are classified as operating leases with remaining lease terms between 0.50 to 1.92&#x00a0;years except for the land use rights acquired from the Bureau of Land and Resources in Taizhou, China with remaining lease terms of 45.5&#x00a0;years. See Note&#x00a0;15 for related party lease obligations due and related party lease costs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Supplemental information related to leases was as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Six&#x00a0;months ended June&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating fixed lease cost</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">92</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Supplemental cash flow information related to leases was as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Six&#x00a0;months ended June&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash paid for amounts included in measurement of lease liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">65</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-cash operating lease liabilities arising from obtaining operating right-of-use assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">113</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The maturities of lease liabilities&#x00a0;as of June&#x00a0;30, 2024 were as follows:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Amount</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024 (excluding the six&#x00a0;months ended June&#x00a0;30, 2024)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">103</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">124</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thereafter</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total lease payments</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">244</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed interest</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Present value of minimum operating lease payments</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">238</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Weighted<FONT CLASS="nobreak">-average</FONT> remaining lease terms and discount rates are as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>December&#x00a0;31,<BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>June&#x00a0;30,<BR>2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Audited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average remaining lease term</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1.78&#x00a0;years</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1.63&#x00a0;years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average discount rate</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2.89%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3.19%</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SHORT-TERM</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> BANK LOANS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table presents short<FONT CLASS="nobreak">-term</FONT> bank loan as of December&#x00a0;31, 2023 and June&#x00a0;30, 2024:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>December&#x00a0;31,<BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>June&#x00a0;30,<BR>2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Audited</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Unaudited</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shanghai Commercial&#x00a0;&amp; Savings Bank</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,630</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,256</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Taipei Fubon Bank</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,267</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">844</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,897</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,100</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-17</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SHORT-TERM</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> BANK LOANS</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="H7" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-4" STYLE="font-style:italic;font-weight:normal;text-decoration:underline;">Shanghai Commercial&#x00a0;&amp; Savings Bank loan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On September&#x00a0;23, 2023, HEB entered into an one<FONT CLASS="nobreak">-year</FONT>&#x00a0;loan agreement with Shanghai Commercial and Savings Bank, Ltd. This new loan agreement provided a credit limit of NTD 300,000 thousand with a variable interest rate and a maturity date of September&#x00a0;23, 2024. On October&#x00a0;2 and October&#x00a0;26, 2023, HEB borrowed an aggregate amount of NTD 203,000 thousand ($6,515) with the interest rate of 2.06%.&#x00a0;As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, the outstanding borrowing under this agreement was NTD 203,000 thousand ($6,630) and NTD&#x00a0;203,000 thousand ($6,256) with an interest rate of 2.06% and 2.19% per annum, respectively. The borrowing was guaranteed by Panatoz Corporation, Nobel Consumer Corporation, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, and Ju<FONT CLASS="nobreak">-Ting</FONT> Chen, related parties. No additional borrowing or repayment was made in the first half of 2024.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the subsequent period, HEB had borrowed an aggregate amount of NTD 5,000 thousand ($154) for this loan as of August&#x00a0;31, 2024.</P>
		<P CLASS="H7" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-4" STYLE="font-style:italic;font-weight:normal;text-decoration:underline;">Taipei Fubon Bank loan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#x00a0;6, 2023, HEB entered into a short<FONT CLASS="nobreak">-term</FONT>&#x00a0;loan agreement with Taipei Fubon Bank. This loan agreement provided a credit limit of NTD 38,800 thousand ($1,246) with a variable interest rate. This borrowing will be due on June&#x00a0;3, 2024 and the interest rate was 2.63% per annum.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2023, the outstanding borrowing under this agreement was NTD 38,800 thousand ($1,267).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January 22 and June<FONT CLASS="nobreak"> </FONT>3, 2024, HEB repaid an aggregate amount of NTD 38,800 thousand ($1,216) for this loan. On June&#x00a0;3, 2024, HEB entered into a short<FONT CLASS="nobreak">-term</FONT> loan agreement with Taipei Fubon Bank. This loan agreement provided a credit limit of NTD 27,400 thousand ($859) with a variable interest rate. This borrowing will be due on November&#x00a0;30, 2024 and the interest rate was 2.76% per annum.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of June&#x00a0;30, 2024, the outstanding borrowing under this agreement was NTD 27,400 thousand ($844). These borrowings were guaranteed by Zhao Jian Fu Co., Ltd. and Panatoz Corporation, the related parties.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">8.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accrued expenses and other current liabilities consist of the following:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>December&#x00a0;31,<BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>June&#x00a0;30,<BR>2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Audited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Clinical trial</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">287</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">317</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">282</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">312</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Professional service fees</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">346</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">156</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payroll</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">169</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">43</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,127</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">876</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">9.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LOANS FROM THIRD PARTIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On September&#x00a0;10, 2019, the Company entered into a loan facility with Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited (&#x201c;Medi<FONT CLASS="nobreak">-life</FONT>), a minority shareholder, for $600. This loan had a one<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. Before the maturity date, the Company renewed the loan agreement with Medi<FONT CLASS="nobreak">-life</FONT> to extend the maturity date to September&#x00a0;10, 2026. On December&#x00a0;3, 2020, the Company also entered into a new loan facility with Medi<FONT CLASS="nobreak">-life</FONT> for $100, which had a two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. Before the maturity date, the Company renewed the loan agreement with Medi<FONT CLASS="nobreak">-life</FONT> to extend the maturity date to December&#x00a0;2, 2026.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-18</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">9.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LOANS FROM THIRD PARTIES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#x00a0;5, 2019, TSB entered a loan facility with Medi<FONT CLASS="nobreak">-life</FONT> for RMB 16,003 thousand ($2,273), which had a two<FONT CLASS="nobreak">-y</FONT><FONT CLASS="nobreak">ear</FONT> term with a 2% interest rate per annum. On June&#x00a0;1, 2021, TSB repaid $250 to Medi<FONT CLASS="nobreak">-life</FONT>. Before the maturity date, TSB renewed the loan agreement with Medi<FONT CLASS="nobreak">-life</FONT> to extend the maturity date to May&#x00a0;31, 2025.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#x00a0;10, 2020 and December&#x00a0;7, 2020, TSB also entered two loan facilities with Medi<FONT CLASS="nobreak">-life</FONT> for an aggregate amount of $408, which had a two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. Before the maturity date, TSB renewed the loan agreement with Medi<FONT CLASS="nobreak">-life</FONT>, totaling $80 and $328, extending the maturity date to January&#x00a0;9, 2025 and December&#x00a0;6, 2026, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Loans from third parties were $3,131 and $3,131 as of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, and accrued interests were $271 and $303 as of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">10.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LONG-TERM</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> BANK LOANS</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>December&#x00a0;31,<BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>June&#x00a0;30,<BR>2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Audited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Secured bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,313</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,139</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(75</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(361</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,238</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,778</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 63.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>December&#x00a0;31,<BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>June&#x00a0;30,<BR>2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 63.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Audited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 63.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loan content</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 63.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Annual interest rate</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">2.59%~3.25%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">2.72%~3.38%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 63.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Maturity date</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">Due&#x00a0;by&#x00a0;June&#x00a0;2032</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">Due&#x00a0;by&#x00a0;June&#x00a0;2032</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H7" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-4" STYLE="font-style:italic;font-weight:normal;text-decoration:underline;">Taiwan Cooperative Bank loan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On June&#x00a0;5, 2014, HEB entered into a loan agreement with Taiwan Cooperative Bank for NTD 73,200 thousand. This loan had an 18<FONT CLASS="nobreak">-year</FONT> term with a variable interest rate per annum. HEB started repaying the principal from June&#x00a0;2015. HEB did not repay a loan payment from 2020 through March&#x00a0;2023 due to the COVID<FONT CLASS="nobreak">-19</FONT> emergency relief of suspension of loan payments provided by Taiwan Cooperative Bank. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, the outstanding loan was NTD 55,012 thousand ($1,797) and NTD 55,012 ($1,695) with an interest rate of 2.59% and 2.72% per annum, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#x00a0;20, 2019, HEB also entered into a new loan agreement with Taiwan Cooperative Bank for NTD&#x00a0;15,000 thousand. This loan had a 5<FONT CLASS="nobreak">-year</FONT> term with a variable interest rate per annum. HEB did not repay a loan payment from 2020 through March&#x00a0;2023 due to the COVID<FONT CLASS="nobreak">-19</FONT> emergency relief of suspension of loan payments provided by Taiwan Cooperative Bank. For the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, HEB repaid NTD 500 thousand ($16) and NTD 500 thousand ($16) for this loan, respectively. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, the outstanding loan was NTD 12,828 ($419) and NTD 12,328 ($380) with an interest rate of 2.60% and 2.88% per annum, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#x00a0;19, 2024, HEB reached an agreement with Taiwan Cooperative Bank to postpone the repayment of the principal. As a result, HEB will only pay the interest expense until it begins repaying the principal in March&#x00a0;2025.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-19</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">10.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LONG-TERM</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> BANK LOANS</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HEB provided land and buildings located in Yilan, Taiwan as collateral for these loans from Taiwan Cooperative Bank. These loans were also guaranteed by Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, CEO of the Company, and Ju<FONT CLASS="nobreak">-Ting</FONT> Chen, the shareholder of the Company. The carrying amount of pledged land, buildings, and building improvements was $3,072 and $2,872 as of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, respectively.</P>
		<P CLASS="H7" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-4" STYLE="font-style:italic;font-weight:normal;text-decoration:underline;">Shanghai Commercial&#x00a0;&amp; Savings Bank loan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#x00a0;25, 2020, HEB entered into a loan agreement with Shanghai Commercial&#x00a0;&amp; Saving Bank for NTD&#x00a0;16,000 thousand. This loan had a 5<FONT CLASS="nobreak">-year</FONT> term with a variable interest rate per annum. For the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, HEB repaid NTD 885 thousand ($29) and NTD 885 thousand ($28) for this loan, respectively. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, the outstanding loan was NTD 2,951 thousand ($96) and NTD 2,066 thousand ($64) with an interest rate of 3.25% and 3.38% per annum, respectively. This loan was also guaranteed by Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, CEO of the Company with the fixed asset located in Xinbei, Taiwan owned by Panatoz Corporation. In the subsequent period, HEB had repaid an aggregate amount of NTD 295 thousand ($9) for this loan as of August&#x00a0;31, 2024.</P>
		<P CLASS="H7" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-4" STYLE="font-style:italic;font-weight:normal;text-decoration:underline;">Chang Hwa Bank loan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On September&#x00a0;16, 2020, HEB entered into a secured loan agreement with Chang Hwa Bank for a loan amount of up to NTD 5,000 thousand. Loans under this agreement had a 3<FONT CLASS="nobreak">-year</FONT> term with a variable interest rate per annum. These loans were guaranteed by Small&#x00a0;&amp; Medium Enterprise Credit Guarantee Fund of Taiwan, a non<FONT CLASS="nobreak">-profit</FONT> organization to provide credit guarantees to small and medium enterprises which are promising but short of collateral necessary to obtain finance from contracted financial institutions. For the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, HEB repaid NTD 842 thousand ($28) and NTD 16 thousand ($1), respectively. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, the outstanding loan was NTD 16 thousand ($1) and nil, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>INCOME TAX</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No provision for income taxes has been required to be accrued because the Company and all of its subsidiaries are in cumulative loss positions for the periods presented.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company recorded a full valuation allowance against deferred tax assets of all its consolidated entities because all entities were in a cumulative loss position as of December&#x00a0;31, 2023 and June&#x00a0;30, 2024. No unrecognized tax benefits and related interest and penalties were recorded in the periods presented.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">12.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>ORDINARY SHARES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024 the Company was authorized to issue 5,000,000 thousand shares. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, 73,361 thousand shares were issued and outstanding, $0.00001 par value ordinary shares. Holders of the Company&#x2019;s ordinary shares are entitled to dividends, if and when, declared by the board of directors of the Company. The holder of each ordinary share is entitled to one vote. As of June&#x00a0;30, 2024, no dividends were declared.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">13.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LICENSE AGREEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#x00a0;2016, HEB entered into a licensing agreement with Chhak Kamponngsaon Sez Co., Ltd to grant an exclusive right to sell and market Botreso in the Kingdom of Cambodia until April&#x00a0;2036 in exchange for an upfront payment of $100 thousand, a certain amount in milestone payments for applying the regulatory approval of Botreso and obtaining the regulatory approval of Botreso in the Kingdom of Cambodia, and a certain percent on net sales in royalty payments. HEB has no other performance obligation in addition to the license, and Chhak Kamponngsaon Sez Co., Ltd is responsible for assisting HEB to obtain initial and all subsequent regulatory approvals of Botreso in the Kingdom of Cambodia. HEB recognized the upfront payment of $100 thousand as revenue in 2016 since HEB has no other performance obligation in addition to the licenses. As of October&#x00a0;4, 2024, HEB has not achieved any milestones.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-20</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">14.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>NET LOSS PER SHARE</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic and diluted net loss per share for the&#x00a0;six&#x00a0;months ended June&#x00a0;30, 2023 and 2024 are calculated as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Six&#x00a0;months ended June&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Unaudited</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Unaudited</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Numerator:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss attributable to ordinary shareholders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,742</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,326</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Denominator:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average number of ordinary shares outstanding &#x2013; basic and diluted (in thousands)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">71,567</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">71,567</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share &#x2013; basic and diluted</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.02</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.02</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">15.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>RELATED PARTY TRANSACTIONS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Intercompany balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated upon consolidation; therefore, those items are not disclosed in this note. The table below sets forth the major related parties and their relationships with the Group as of December&#x00a0;31, 2023 and June&#x00a0;30, 2024:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Name of related parties</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Relationship with the Group</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">CEO and Chairwoman of the Company</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Ju-Ting Chen</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The shareholder of the Company</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Xue-Juan Chen</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The fourth degree of kinship to CEO</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Alfred Ying</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">CFO</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Panatoz Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Significantly influenced by Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, CEO of the Company</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Zhao Jian Fu Co., Ltd.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Significantly influenced by Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, CEO of the Company</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-33" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Nobel Consumer Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Managed by Xue<FONT CLASS="nobreak">-Juan</FONT> Chen, a related party of the Company</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February&#x00a0;2021 to November&#x00a0;2021, the Company entered into several loan agreements with Nobel Consumer Corporation for an aggregate amount of $ 300, which had a 2<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. Before the maturity date, the Company renewed the loan agreements with Nobel Consumer Corporation to extend the maturity date to February, June, and November&#x00a0;2025. From March&#x00a0;2022 to December&#x00a0;2022, the Company entered additional loan agreements with Nobel Consumer Corporation and Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo for an aggregate amount of $595 and $342, respectively, which had two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. Before the maturity date, the Company renewed the loan agreements to extend the maturity date of the loans due on March&#x00a0;2026 to December&#x00a0;2026.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From January&#x00a0;2023 to December&#x00a0;2023, the Company and HEB entered additional loan agreements with Nobel Consumer Corporation, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, and Panatoz Corporation for an aggregate amount of $480, $1,083 and $446, respectively, which had two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. On September&#x00a0;8, 2023, the Company repaid amount of $120 to Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From January&#x00a0;2024 to June&#x00a0;2024, the Company and HEB entered additional loan agreements with Nobel Consumer Corporation, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, Panatoz Corporation, and Zhao Jian Fu Co., Ltd. for an aggregate amount of $14, $468, $693, and $460, respectively, which had two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. As of June&#x00a0;30, 2024, the accrued interest expenses to Nobel Consumer Corporation, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, Panatoz Corporation and Zhao&#x00a0;Jian Fu Co., Ltd. were $49, $34, $8, and $4 respectively.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-21</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">15.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>RELATED PARTY TRANSACTIONS</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the subsequent period, the Company and HEB borrowed an aggregate amount of $70 and $92 from Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo and Panatoz Corporation as of August&#x00a0;31, 2024, respectively. These new loans had a two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HEB leased the facilities for office, research and development, and manufacturing facilities in Taiwan from Panatoz Corporation, Zhao Jian Fu Co., Ltd., and Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, respectively. See Note&#x00a0;6.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During 2018 and 2019, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo and Ru<FONT CLASS="nobreak">-Ting</FONT> Chen paid securities exchange tax and bridge loan fees on behalf of the Company, respectively. As of December&#x00a0;31, 2023 and June&#x00a0;30, 2023, the aggregate balance of due to Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo and Ju<FONT CLASS="nobreak">-Ting</FONT> Chen were $628 and $628, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Nobel Consumer Corporation, Panatoz Corporation, Zhao Jian Fu Co., Ltd., Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, and Ju<FONT CLASS="nobreak">-Ting</FONT> Chen provided guarantees of short<FONT CLASS="nobreak">-term</FONT> and long<FONT CLASS="nobreak">-term</FONT> loans from Shanghai Commercial&#x00a0;&amp; Savings Bank, Ltd., short<FONT CLASS="nobreak">-term</FONT> loan from Taipei Fubon Bank loan, and long<FONT CLASS="nobreak">-term</FONT> loans from Taiwan Cooperative Bank to HEB.&#x00a0;As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, the amount of borrowing guaranteed were $10,209 and $9,239, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The related party balances and transactions were summarized as follows:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">(a)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Related party balances</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>December&#x00a0;31,<BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of <BR>June&#x00a0;30,<BR>2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Audited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loan from related parties</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Nobel Consumer Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,375</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,389</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,305</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,773</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Panatoz Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">471</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,139</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Zhao Jian Fu Co., Ltd.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">460</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,151</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,761</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-34" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Accrued expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Nobel Consumer Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">34</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Panatoz Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Zhao Jian Fu Co., Ltd.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Alfred Ying</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Operating lease liabilities due to related parties (including current and non-current)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Panatoz Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">116</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Zhao Jian Fu Co., Ltd.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">81</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">199</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">238</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-34" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other non-current liabilities due to related parties</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ju-Ting Chen</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">566</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">566</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-35" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">62</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">62</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-35" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">628</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">628</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-22</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">15.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>RELATED PARTY TRANSACTIONS</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">(b)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Related party transactions</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the&#x00a0;six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, related party transactions of rental expenses consisted of the following:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">Six&#x00a0;months ended June&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Zhao Jian Fu Co., Ltd.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Panatoz Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">64</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">16.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>COMMITMENTS AND CONTINGENCIES</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Clinical Research Organization (CRO)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group has agreements with contract service providers to assist in the performance of phase&#x00a0;II clinical trial activities for PCP, one of the Group&#x2019;s key drug candidates. One CRO is mainly responsible for the data management, biostatistical analysis, and clinical study report writing; while the other CRO is responsible for the subjects&#x2019; enrollment and serving as study coordinator (SC) at each study site. Such agreements are generally cancellable upon reasonable notice and payment of costs incurred.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Commitment and Litigation with the TaiZhou Company</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In May&#x00a0;2019, two of Jyong&#x2019;s shareholders, Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited and Sira View Corp. (collectively, the &#x201c;Transferring Shareholders&#x201d;), entered into a share purchase agreement (the &#x201c;Share Purchase Agreement) with Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership) (the &#x201c;Taizhou Company&#x201d;) to sell 1,794 thousand shares of Jyong&#x2019;s ordinary shares held by the Transferring Shareholders to the Taizhou Company at RMB 112,500 thousand ($16,366) (the &#x201c;Share Purchase Transaction&#x201d;). Under the Share Purchase Agreement, the Taizhou Company would have a right to request the Transferring Shareholders to repurchase the shares if Jyong would not accomplish the &#x201c;Qualified Issuance and Listing&#x201d; (defined as Jyong&#x2019;s public filing of shares and listing on the main board of the Stock Exchange of Hong&#x00a0;Kong Limited, or the HKEX) within 5&#x00a0;years after the closing of the Share Purchase Transaction, or any other commitments were breached, such as not changing the primary control<FONT CLASS="nobreak">-person</FONT> of Jyong, not changing the main operation of HEB, etc. and the repurchase payment is determined by the principal investment plus the interest based on the loan benchmark interest rate of People&#x2019;s Bank of China when the payment is made. In addition, Jyong provided the Taizhou Company a joint and several guarantee for the performance of the repurchase shares obligation of the Transferring Shareholders and pledged 100% of its equity interest in IB to the Taizhou Company as collateral pursuant to the Share Purchase Agreement. The above commitments and guarantees shall be automatically terminated after the Company completes the qualified issuance and listing.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of any liquidation, dissolution, bankruptcy or winding up of Jyong, either voluntary or involuntary, or any deemed liquidation event as defined in the agreement, the Taizhou Company is entitled to receive, prior to any distribution to the holders of ordinary shares, an amount per share equal to the original issue price, plus accrued interest. This right enjoyed by the Taizhou Company shall be automatically suspended when the Company submits its A1 application proof to go public on the main board of the HKEX, which never occurred. If the Company fails to pass the hearing procedure or withdraws the application, this right will automatically resume its validity and has retrospective rights to the rights and interests of the Taizhou Company during the period of expiration.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-23</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">16.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>COMMITMENTS AND CONTINGENCIES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On November&#x00a0;15, 2022, the Group received a complaint for civil suit filed by the Taizhou Company to the Taizhou Intermediate People&#x2019;s Court (the &#x201c;Taizhou Court&#x201d;) against the Transferring Shareholders, Jyong, HEB, TSB, IB and Ms. Kuo, Fu Feng (collectively, the &#x201c;Defendants&#x201d;), requesting, among other claims: (i)&#x00a0;redemption by the Transferring Shareholders for all shares purchased by the Taizhou Company under the Share Purchase Agreement for the original purchase price of RMB112,500 thousand ($16,366) and corresponding interests from July&#x00a0;29, 2019 to the date of actual payment calculated at the loan prime rate in China (the &#x201c;Redemption&#x201d;); (ii)&#x00a0;the Taizhou Court to hold Jyong, HEB and Ms. Kuo, Fu Feng jointly liable for the Redemption; (iii)&#x00a0;the Taizhou Court to confirm Taizhou Company&#x2019;s right to liquidate all equity interest in IB held by TSB that was pledged to the Taizhou Company; and (iv)&#x00a0;the Taizhou Court to hold IB for the obligations of other Defendants within the scope of the benefits it received from the investment made under the Share Purchase Agreement. The dispute went on trial in the Taizhou Court on March&#x00a0;16, 2023 and November&#x00a0;29, 2023, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#x00a0;25, 2024, the Taizhou Court issued a judgment partially in favor of the Taizhou Company, requiring Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited and Sira View Corp. to pay the redemption price of RMB 112,500 thousand ($16,366) and corresponding interests from August&#x00a0;20, 2019, to the date of actual payment calculated at the Loan Prime Rate published by the National Inter<FONT CLASS="nobreak">-bank</FONT> Funding Center in China, and Jyong, HEB, and Ms. Fu Feng Kuo to be jointly liable for such obligation. The Taizhou Court also ruled that the TaiZhou Company is entitled to liquidate all equity interest in Innovative Biotech pledged to it in order to realize the payment of the aforementioned obligations. Additionally, the lawyer service fees of RMB 420 thousand ($59) incurred by the Taizhou Company and litigation fees of RMB 684 thousand ($97) should be paid by Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited, Sira View Corp., Jyong, HEB, or Ms. Fu Feng Kuo. In April&#x00a0;2024, Nobel Consumer Corporation, the Company&#x2019;s related party, paid the litigation fees of RMB&#x00a0;684 thousand ($97) on behalf of Sira View Corp. Additionally, other than the guarantee liabilities under the Share Purchase Agreement as set forth below, the Company recognized an additional contingency liability of RMB 420 thousand ($59) for litigation fees in 2023, which will be due by the end of appeal process. The Company filed an appeal with the High People&#x2019;s Court of Zhejiang Province on April&#x00a0;29, 2024. The Defendants are actively negotiating with the Taizhou Company for a smooth settlement of this legal proceeding.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group considered the guarantee provided under this Share Purchase Agreement was accounted for as an equity transaction between Jyong and shareholders to buy back Jyong&#x2019;s shares. Therefore, the Group estimated the fair value of guarantee liabilities at the fair value of the shares at the inception of this guarantee and recorded $16,366 of guarantee liabilities and corresponding treasury shares at the inception date, as well as subsequently measured the fair value of guarantee liabilities determined by the interest expense which will be paid when repurchasing the shares under the Share Purchase Agreement and recognized interest expense for the fair value change of guarantee liabilities. The amount of interest expenses recognized were $217 and $267 for the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, and the amount of guarantee liabilities were $18,787 and $18,999 as of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, respectively. In addition, the negative net book value of IB&#x2019;s equity pledged was $1,194 and $1,169 as of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Commitments with Taizhou Resources Bureau</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On November&#x00a0;29, 2019, IB, our PRC subsidiary, entered into the land use right agreement with Taizhou Resources Bureau (the &#x201c;Land Use Right Agreement&#x201d;). Under the Land Use Right Agreement, IB shall commence construction on the industrial land granted by May&#x00a0;28, 2020 and complete the construction by November&#x00a0;28, 2022, otherwise, IB shall pay the liquidated damages to Taizhou Resources Bureau for each&#x00a0;day of delay, being 0.1% of the total amount of the land use right grant price of approximately RMB16,000 thousand plus tax.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On November&#x00a0;23, 2022, Taizhou Resources Bureau issued a formal notice of reminder of default, requiring IB to pay the liquidated damages of RMB13,080 thousand, with the amount of damages accruing from November&#x00a0;24, 2022 to the date of actual construction to be calculated separately. In addition, under the Land Use Right Agreement, apart from the liquidated damages, IB is obliged to pay a land idling fee if the land is left idle for more than one year </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-24</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">16.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>COMMITMENTS AND CONTINGENCIES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">but less than two&#x00a0;years, and Taizhou Resources Bureau has the right to take back the land use right if the land is left idle for more than two&#x00a0;years. IB submitted the application to the People&#x2019;s Government of Zhejiang Province (the &#x201c;Zhejiang Government&#x201d;) for seeking its approval for construction on March&#x00a0;18, 2023.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#x00a0;16, 2024, this industrial land acquired by IB was seized by the Taizhou Court due to the litigation with the Taizhou Bay New District Administrative Committee due to the litigation with the Taizhou Bay New District Administrative Committee. Therefore, IB is unable to start construction even after receiving the approval to proceed. IB considered that the contingent penalty would be estimated through January&#x00a0;16, 2024, since the delay in construction after this date was not caused by IB.&#x00a0;As of December&#x00a0;31, 2023, IB had accrued a sufficient contingent liability for penalties estimated through January&#x00a0;16, 2024 and no additional contingent loss needs to be accrued for the first half of 2024.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the issuance of unaudited interim condensed consolidated financial statements, IB has not received the Zhejiang Government&#x2019;s approval and did not pay the penalty of RMB13,080 thousand yet. IB accrued RMB&#x00a0;21,005 thousand ($2,959) and RMB 21,005 thousand ($2,890) of other liabilities for the liquidated damages as of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, and recorded RMB 2,450 thousand ($354) and nil of other loss for the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Litigation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, the Group may have certain contingent liabilities that arise in the ordinary course of business activities or may be a party to certain legal proceedings, as well as certain asserted and un<FONT CLASS="nobreak">-asserted</FONT> claims. The Group accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Amounts accrued, as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the unaudited interim condensed consolidated financial statements. As of the issuance of unaudited interim condensed consolidated financial statements, the Group is not aware of any current pending legal matters or claims except for the litigation with the Taizhou Company discussed above and as set forth below:</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Innovative Biotech Co. v. Taizhou Bay New District Administrative Committee.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>On November&#x00a0;29, 2022, the Taizhou Bay New District Administrative Committee (the &#x201c;Plaintiff&#x201d; or &#x201c;New District Administrative Committee&#x201d;), the successor of the Taizhou Industry District Committee, filed a civil complaint to the Taizhou Court (the &#x201c;Court&#x201d;) against the Company&#x2019;s PRC subsidiary, IB, claiming that IB has materially breached the Jyong Biotechnology Herbal Medicine Project Investment Cooperation Agreement (the &#x201c;2019 Taizhou Agreement&#x201d;) by failing to initiate and conclude the construction of the Factory Project in accordance with the schedule stipulated by the 2019 Taizhou agreement and the Land Use Right Agreement. The Plaintiff requested the Court to terminate the 2019 Taizhou Agreement, and to order IB to return the government subsidy of RMB12.0&#x00a0;million ($1,690) IB previously received under the 2019 Taizhou Agreement, and to pay corresponding interests calculated at the Loan Prime Rate published by the National Inter<FONT CLASS="nobreak">-bank</FONT> Funding Center. On December&#x00a0;1, 2022, the Court issued an order of preliminary asset preservation, freezing the RMB 10,708 thousand ($1,477) deposit in IB&#x2019;s bank account. This dispute went on trial on February&#x00a0;13, 2023, and two hearings were held on May&#x00a0;6, 2023 and August&#x00a0;17, 2023, respectively. On September&#x00a0;8, 2023, the Court entered into a judgement in favor of the Plaintiff, terminating the 2019 Taizhou Agreement and ordering IB to return the government subsidy of RMB12.0&#x00a0;million ($1,690) and corresponding interest and expenses to the Plaintiff. On September&#x00a0;14, 2023, IB filed an appeal with the High People&#x2019;s Court of Zhejiang Province (the &#x201c;High Court&#x201d;) regarding each of the Court&#x2019;s rulings described above. The High Court held a hearing for this case on October&#x00a0;24, 2023. On December&#x00a0;12, 2023, the High Court issued a judgment against IB to affirm the Taizhou Court&#x2019;s ruling in its entirety. In addition, IB is required to pay litigation fees of RMB 94 thousand ($13) to the Taizhou Administrative Committee, and security fees of RMB 5 thousand ($1) and execution fees of RMB 79 thousand ($11) to the High Court. IB filed a petition for retrial to the Supreme People&#x2019;s Court of the People&#x2019;s Republic of China (the &#x201c;Supreme Court&#x201d;) on December&#x00a0;27, 2023 and it was accepted by the Supreme Court on January&#x00a0;9, 2024.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-25</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">16.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>COMMITMENTS AND CONTINGENCIES</FONT><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#x00a0;5 and<FONT CLASS="nobreak"> </FONT>10, 2024, the Taizhou Court issued an order of enforcement, stipulating, among other things, freezing and assignment of IB&#x2019;s deposit in its bank account or withholding of IB&#x2019;s income up to RMB&#x00a0;12.0&#x00a0;million ($1,690) and corresponding interests, and the seizure, attachment and freezing of IB&#x2019;s property valued at RMB&#x00a0;12.0&#x00a0;million ($1,690) and corresponding interests, and restrictions on making certain high expenses by IB and related personnel. On January&#x00a0;16, 2024, the industrial land acquired by IB was seized by the Taizhou Court, and corresponding RMB15,010 thousand ($2,065) of operating right<FONT CLASS="nobreak">-of-use</FONT> assets as of June&#x00a0;30, 2024. On February&#x00a0;22, 2024, RMB 11,129 thousand ($1,567) of IB&#x2019;s bank deposit was transferred to the Taizhou Court to repay litigation fees, security fees, and execution fees, and to the New District Administrative Committee to return a government subsidy.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of June&#x00a0;30, 2024, IB returned RMB 10,952 thousand ($1,507) of government subsidy to the New District Administrative Committee and the remaining subsidy of RMB 1,048 thousand ($144) and corresponding interest expenses shall be repaid when IB has assets to pay in the future.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2023 and June&#x00a0;30, 2024, IB accrued an aggregate amount of RMB 14,293 thousand ($2,013) and RMB 3,003 thousand ($413) of other liabilities for this litigation and recorded an aggregate amount of RMB 99 thousand ($14) of other losses and RMB 161 thousand ($22) of other gains for reversing overestimated other liabilities for the six&#x00a0;months ended June&#x00a0;30, 2023 and 2024, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">17.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUBSEQUENT EVENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">For litigation with the TaiZhou Company, The High Court held a hearing on August&#x00a0;9, 2024. On September&#x00a0;12, 2024, the High Court issued a judgment rejecting the Company&#x2019;s petition and affirming the Taizhou Court&#x2019;s ruling in its entirety. As a result, Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited and Sira View Corp., the Transferring Shareholders, shall pay the redemption price of RMB 112,500 thousand ($16,366) and corresponding interests to buy back the Company&#x2019;s shares from the TaiZhou Company, and Jyong, HEB, and Ms. Fu Feng Kuo are jointly liable for this obligation. The Transferring Shareholders are planning to negotiate with the Taizhou Company for a settlement of this repurchase obligation in the fourth quarter of 2024. As of June&#x00a0;30, 2024, the Company accrued corresponding liabilities to cover the joint liability for the repurchase obligation (see Note&#x00a0;16 for further detail), and no additional liability was required as a result of the High Court&#x2019;s judgment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">For the commitment with the Taizhou Resources Bureau, on September<FONT CLASS="nobreak"> </FONT>26, 2024, the Taizhou Resource Bureaus issued a notification informing IB that it will take back the land use right from IB since the industrial land has been left idle for more than two years. However, IB has the right to request a hearing to explain the reasons for the delayed construction on the industrial land within the 5 business of receiving the notification (i.e. October<FONT CLASS="nobreak"> </FONT>10, 2024), and is planning to request a hearing by the deadline for submission. As of the issuance of consolidated financial statements, IB has not submitted the request and still retains control over the land use rights until the hearing reaches a conclusion. </P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">For litigation with New District Administrative Committee, on July&#x00a0;7, 2024, the Taizhou Court issued a ruling of execution, notifying IB that it had repaid RMB 10,952 thousand ($1,542) to the Taizhou Administrative Committee by enforcing the transfer of its bank deposit and the Taizhou Administrative Committee agreed to terminate the execution as IB had no available assets to repay the remaining government subsidy of RMB 1,048 thousand ($148) and corresponding interest expenses. On August&#x00a0;21, 2024, the Supreme Court issued a decision to reject IB&#x2019;s petition for retrial and this lawsuit was concluded. As a result, IB shall return government subsidy of RMB 12.0&#x00a0;million and corresponding interest expenses to the Taizhou Administrative Committee. As of the issuance of consolidated financial statements, IB returned RMB 10,952 thousand ($1,507) of government subsidy to the New District Administrative Committee and the remaining subsidy of RMB 1,048 thousand ($144) and corresponding interest expenses shall be repaid when IB has assets to pay in the future.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Group evaluated all events and transactions that occurred after June&#x00a0;30, 2024 up through October&#x00a0;4, 2024, which is the date that these consolidated financial statements are available to be issued, other than the events disclosed above, no other subsequent events have occurred that would require recognition or disclosure in the Company&#x2019;s consolidated financial statements.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-26</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><IMG ALT="" SRC="twwc_header.jpg" STYLE="width:565.76px;max-width:100%;"></FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><A NAME="T226"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-left:24pt;margin-top:6pt;text-indent:-24pt;margin-top:6pt;">To:<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The Board of Directors and Shareholders of<BR>Jyong Biotech Ltd. and Subsidiaries</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Opinion on the Financial Statements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We have audited the accompanying consolidated balance sheet of Jyong Biotech Ltd. and subsidiaries (collectively the &#x201c;Group&#x201d;) as of December&#x00a0;31, 2022 and 2023, and the related consolidated statement of operations and comprehensive loss, change in shareholders&#x2019; deficit, and cash flows for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#x00a0;31, 2022 and 2023, and the results of its operations and its cash flows for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, in conformity with accounting principles generally accepted in the United&#x00a0;States of America.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Emphasis of Matter&#x00a0;&#x2014;&#x00a0;Substantial Doubt about the Company&#x2019;s Ability to Continue as a Going Concern</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&#x00a0;2 to the consolidated financial statements, the Company has a significant working capital deficiency, has incurred significant losses, and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s evaluation of the events and conditions and management&#x2019;s plans regarding those matters are also described in Note&#x00a0;2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Basis for Opinion</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">These consolidated financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on our consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#x00a0;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#x00a0;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">We conducted our audit in accordance with the standards of the PCAOB.&#x00a0;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of our internal control over financial reporting. Accordingly, we express no such opinion.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">/s/ WWC, P.C.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">WWC, P.C.<BR>Certified Public Accountants<BR>PCAOB ID No.1171</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">We have served as our auditor since 2023.<BR>San Mateo, California<BR>May&#x00a0;8, 2024, except for Note&#x00a0;18 for which the date is October<FONT CLASS="nobreak"> </FONT>4, 2024</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-27</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><A NAME="T227"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>CONSOLIDATED BALANCE SHEETS<BR>(in thousand US Dollars, except share and per share data)</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ASSETS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Current Assets</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">718</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">177</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Restricted cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,556</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,565</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Short-term investment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">94</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepayments and other current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">95</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">97</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total current assets</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2,463</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,839</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,508</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,386</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating right-of-use assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2,491</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">158</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred offering costs</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">276</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">721</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Restricted asset</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2,137</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other non-current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">7</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">7</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total non-current assets</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6,282</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6,409</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TOTAL ASSETS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">8,745</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">8,248</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Current liabilities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Short-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7,169</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7,897</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notes and accounts payable</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">873</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,127</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">13</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">55</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current portion of long-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">479</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">75</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liabilities due to related parties-current</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">170</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">130</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4,195</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4,951</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current liabilities due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">4</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">21</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total current liabilities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">12,907</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">14,258</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long-term loan from related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,237</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,151</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long-term loan from third parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,131</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,131</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long-term bank loans, net of current portion</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,950</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2,238</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liabilities due to related parties&#x00a0;&#x2013;&#x00a0;non-current</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">115</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">69</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other non-current liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">59</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other non-current liabilities due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">628</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">628</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Guarantee liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">18,408</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">18,787</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total non-current liabilities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">25,469</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">28,063</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TOTAL LIABILITIES</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">38,376</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">42,321</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Commitments and contingencies (Note&#x00a0;17)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Shareholders&#x2019; deficit</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary shares, $0.00001 par value; 5,000,000 thousand shares and 73,361 thousand shares issued and outstanding as of December&#x00a0;31, 2022 and 2023, respectively</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11,805</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11,805</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Treasury shares, 1,794 thousand shares as of December&#x00a0;31, 2022 and 2023</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(16,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(16,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(25,661</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(30,061</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated other comprehensive income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">590</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">548</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total shareholders&#x2019; deficit</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(29,631</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(34,073</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TOTAL LIABILITIES AND SHAREHOLDERS&#x2019; DEFICIT</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">8,745</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">8,248</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of the consolidated financial statements.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-28</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><A NAME="T228"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS<BR>(in thousand US Dollars, except share data in thousands and per share data)</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">For the&#x00a0;years ended <BR>December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Operating expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,290</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(1,071</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Selling and marketing</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(47</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(47</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(1,492</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(1,679</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total operating expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(2,829</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(2,797</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss from operations</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(2,829</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(2,797</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other income (expense):</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">5</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">56</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(765</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(757</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other losses, net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(3,041</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(902</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total other expenses, net</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(3,801</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(1,603</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss before income tax</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(6,630</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(4,400</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net loss</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(6,630</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(4,400</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other comprehensive income</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign currency translation adjustments, net of nil tax</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">324</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(42</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total comprehensive loss</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(6,306</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(4,442</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net loss per share:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and Diluted</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(0.09</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(0.06</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Weighted average shares outstanding (in thousands):</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and Diluted</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">71,567</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">71,567</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of the consolidated financial statements.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-29</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><A NAME="T229"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#x2019; DEFICIT<BR>(In thousand US Dollars, except share data in thousands)</FONT></P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 22.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="4" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><BR><BR>Ordinary Shares</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Additional<BR>Paid-in<BR>Capital</FONT></P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Accumulated<BR>Other<BR>Comprehensive<BR>Income</FONT></P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Accumulated<BR>Deficit</FONT></P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Treasury<BR>Shares</FONT></P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total<BR>Shareholders&#x2019;<BR>Deficit</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 22.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Shares</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Amount</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 22.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of January&#x00a0;1, 2022</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">73,361</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11,805</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">266</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(19,031</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(16,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(23,325</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 22.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.78%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.17%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.11%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(6,630</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(6,630</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 22.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign currency translation adjustment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.78%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">324</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">324</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 22.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Balance as of December&#x00a0;31, 2022</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">73,361</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.78%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">11,805</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">590</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(25,661</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(16,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(29,631</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 22.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.78%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.17%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.11%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(4,400</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(4,400</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 22.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign currency translation adjustment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.78%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(42</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(42</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 22.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Balance as of December&#x00a0;31, 2023</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">73,361</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.78%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">11,805</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">548</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(30,061</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(16,366</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(34,073</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of the consolidated financial statements.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-30</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><A NAME="T230"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>CONSOLIDATED STATEMENTS OF CASH FLOWS<BR>(In thousand US Dollars)</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">For the&#x00a0;years ended <BR>December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from operating activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(6,630</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(4,400</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">123</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">127</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Noncash operating lease expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">187</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">175</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value changes in the guarantee liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">412</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">379</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in operating assets and liabilities:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepayments and other current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">168</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(2</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notes and accounts payable</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(28</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(2</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(187</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">254</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">10</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">42</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liabilities due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(162</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(128</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3,134</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">878</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current liabilities due to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">17</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other non-current liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">59</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net cash used in operating activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(2,971</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(2,601</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from investing activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Purchases of short-term investments</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(292</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from maturity of time deposits</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,930</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">95</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Purchase of property and equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(246</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net cash provided by investing activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,392</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">95</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from financing activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payments of deferred offering costs</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(276</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(445</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from short-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11,340</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">9,803</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Repayment of short-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(8,377</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(9,113</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds of loan from related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">937</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2,026</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Repayment of loan from related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(120</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Repayments of long-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(291</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(123</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net cash provided by financing activities</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">3,333</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2,028</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Effects of exchange rate changes on cash and restricted cash</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(31</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(54</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,723</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(532</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CASH AND RESTRICTED CASH AT BEGINNING OF THE PERIOD</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">551</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2,274</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CASH AND RESTRICTED CASH AT END OF THE PERIOD</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2,274</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,742</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income taxes paid</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">162</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">104</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Reconciliation to amount on consolidated balance sheets</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">718</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">177</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Restricted cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,556</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,565</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">TOTAL CASH AND RESTRICTED CASH</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2,274</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,742</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of the consolidated financial statements.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-31</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><A NAME="T231"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>ORGANIZATION AND BUSINESS OPERATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Health Ever Biotech Co., Ltd., (&#x201c;HEB&#x201d;) was incorporated under the laws of Taiwan in August&#x00a0;2002 to research and develop new drugs for today&#x2019;s great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. In January&#x00a0;2018, HEB incorporated Jyong Biotech Ltd., (&#x201c;Jyong&#x201d; or the &#x201c;Company&#x201d;) under the laws of the Cayman Islands and was reorganized into the Company&#x2019;s subsidiary in December&#x00a0;2018. After the reorganization, HEB was wholly owned by the Company in April&#x00a0;2019.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company and its subsidiaries&#x2019; (the &#x201c;Group&#x201d;) product candidates are led by &#x201c;Botreso&#x201d; (also known as MCS<FONT CLASS="nobreak">-2</FONT>) and PCP.&#x00a0;Botreso is a drug candidate in the clinic, developed for unmet medical needs of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). The Group has completed four Phase&#x00a0;III clinical trials in Taiwan and the U.S.&#x00a0;and submitted a new drug application for Botreso to the U.S.&#x00a0;Food and Drug Administration (&#x201c;US FDA&#x201d;) for review in December&#x00a0;2021. &#x201c;PCP&#x201d; is the other key new drug candidate developed for the prevention of prostate cancer. Similar to MCS<FONT CLASS="nobreak">-2</FONT>, PCP works through its mechanism of antioxidant and anti<FONT CLASS="nobreak">-inflammatory</FONT>. PCP contains several types of patented medical<FONT CLASS="nobreak">-grade</FONT> active pharmaceutical ingredients that reduce oxidative stress and inflammatory cytokines (IL<FONT CLASS="nobreak">-6</FONT>), both of which are causes of many chronic inflammatory diseases. The Group is conducting phase&#x00a0;II clinical trials of PCP in Taiwan.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">As of December&#x00a0;31, 2023, the Company&#x2019;s subsidiaries are as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Subsidiaries</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Date of <BR>incorporation</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Place of <BR>incorporation</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Ownership</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Principal activities</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Health Ever Biotech Co., Ltd. (&#x201c;HEB&#x201d;)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">August&#x00a0;1, 2002</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Taiwan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">100% owned by the Company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Research, development, manufacturing</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Genvace Biotechnology (&#x201c;GB&#x201d;)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">September&#x00a0;14, 2021</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Taiwan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">100% owned by HEB</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Research and development</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Top ShunXing Bio-Tech Co., (&#x201c;TSB&#x201d;)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">March&#x00a0;4, 2019</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Hong&#x00a0;Kong</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">100% owned by the Company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Investment holding</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Innovative Biotech Co., (&#x201c;IB&#x201d;)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July&#x00a0;1, 2019</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">People&#x2019;s Republic of China (&#x201c;China&#x201d;)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">100% owned by TSB</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Research, development, manufacturing</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 26.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Jyong Biotech International Pte. Ltd.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">September&#x00a0;29, 2022</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Singapore</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">100% owned by the Company</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 18.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Leasing of non<FONT CLASS="nobreak">-financial</FONT> intangible assets</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LIQUIDITY RISKS AND GOING CONCERN</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;)&#x00a0;2014<FONT CLASS="nobreak">-15</FONT>, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic&#x00a0;205<FONT CLASS="nobreak">-40</FONT>), the Group has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Group&#x2019;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2023 and as of April&#x00a0;15, 2024, the Group had cash of approximately $177 and $97, respectively. The Group has incurred recurring negative cash flows since inception and has funded its operations primarily from equity and debt financing. The Group had accumulated deficit of approximately $25,661 and $30,061 as of December&#x00a0;31, 2022 and 2023, respectively and net losses of approximately $6,630 and $4,400 for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023. In addition, the Group incurred negative cash flows in operating activities for the approximate amount of $2,971 and $2,601 for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, respectively. The Group&#x2019;s ability to fund its operations is highly contingent on raising additional capital until a regulatory approval that provides an ability to generate sufficient revenue, if ever. As such, the Group&#x2019;s management concluded that there is substantial doubt about the Group&#x2019;s ability to continue as a going concern within one year after the issuance date of the consolidated financial statements.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-32</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LIQUIDITY RISKS AND GOING CONCERN</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group intends to pursue a public offering to fund future operations. If the Group is unable to complete a public offering for a sufficient amount in a timely manner, it would need to pursue other financing alternatives such as private financing of debt or equity or collaboration agreements. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Group, or at all. If the Group is unable to obtain sufficient funding by April&#x00a0;2025, it could be required to delay its development efforts, limit activities and reduce research and development costs, which could adversely affect its business and the consolidated financial statements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Group will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Basis of presentation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#x00a0;States of America (&#x201c;U.S.&#x00a0;GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Principle of consolidation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated on consolidation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Use of estimates</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with U.S.&#x00a0;GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Significant accounting estimates reflected in the Group&#x2019;s consolidated financial statements include, but are not limited to, useful lives for property and equipment, impairment of long<FONT CLASS="nobreak">-live</FONT> assets, determination of incremental borrowing rate for lease, research and development expense recognition, other contingency liabilities, and valuation allowance for deferred income tax assets. Management evaluates the estimates based on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Accordingly, actual results could differ from those estimates.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risk and uncertainties</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The product candidates developed by the Group require approvals from the US FDA or foreign regulatory agencies prior to commercial sales. There can be no assurance that the Group&#x2019;s current and future product candidates will receive the necessary approvals or be commercially successful. If the approval is denied or delayed, it will have a material adverse impact on the business and consolidated financial statements of the Group.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Generally, the industry in which the Group operates subjects the Group to a number of other risks and uncertainties that can affect its operating results and financial condition. Such factors include, but are not limited to: the timing, costs and results of clinical trials and other development activities versus expectations; the ability to manufacture products successfully; competition from products sold or being developed by other companies; the price of, and demand for products once approved; the ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-33</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Emerging Growth Company Status</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group is an &#x201c;emerging growth company,&#x201d; as defined in Section&#x00a0;2(a)&#x00a0;of the Securities Act&#x00a0;of&#x00a0;1933, as amended, (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart The Company&#x2019;s Business Startups Act&#x00a0;of&#x00a0;2012, (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#x00a0;404 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, Section&#x00a0;102(b)(1)&#x00a0;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non<FONT CLASS="nobreak">-emerging</FONT> growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition periods which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company difficult because of the potential differences in accounting standards used.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Fair value measurements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group applies ASC&#x00a0;820, Fair Value Measurements and Disclosures. ASC&#x00a0;820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ASC&#x00a0;820 requires disclosures to be provided for fair value measurements. ASC&#x00a0;820 establishes a three<FONT CLASS="nobreak">-tier</FONT> fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Level&#x00a0;1&#x00a0;&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 85.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Observable inputs such as quoted prices for identical instruments in active markets;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Level&#x00a0;2&#x00a0;&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 85.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 8.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Level&#x00a0;3&#x00a0;&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 85.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ASC&#x00a0;820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#x00a0;market approach; (2)&#x00a0;income approach; and (3)&#x00a0;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of the Group&#x2019;s financial instruments, including cash, short<FONT CLASS="nobreak">-term</FONT> investment, short<FONT CLASS="nobreak">-term</FONT> bank loans, notes and accounts payable, other current liabilities due to related parties, approximates fair value due to the short<FONT CLASS="nobreak">-term</FONT> maturity of the instruments. The Group&#x2019;s long<FONT CLASS="nobreak">-term</FONT> liabilities approximate their fair values as they contain interest rates that vary according to market interest rates.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-34</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash consists of cash and demand deposits placed with banks. All cash is unrestricted to withdrawal and use.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Restricted cash</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Restricted cash mainly consists of the bank deposits held as collateral for the credit of a business credit card and bank deposits with time deposits having original maturities of more than three&#x00a0;months, frozen by the order of the Taizhou Intermediate People&#x2019;s Court as asset preservation for the Taizhou Bay New District Administrative Committee. See litigation in Note&#x00a0;17&#x00a0;&#x2014;&#x00a0;Commitments and Contingencies for further detail.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Short-term</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> investment</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Short<FONT CLASS="nobreak">-term</FONT> investments are time deposits with original maturities more than three&#x00a0;months. Short<FONT CLASS="nobreak">-term</FONT> investments are stated at cost, which approximates fair value. Interest earned is included in interest income.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Property and equipment</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and impairment if applicable. Significant additions, renewals and betterments are capitalized, while maintenance and repairs are expenses as incurred. Depreciation is computed on a straight<FONT CLASS="nobreak">-line</FONT> basis over estimated useful lives that range as follows:</P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Useful life</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Buildings</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">50&#x00a0;years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Building improvements</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">3&#x00a0;to&#x00a0;15 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Laboratory equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">3 to 5 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Transportation equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">5 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Office equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2 to 8 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Other equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2 to 10 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Leasehold improvements</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">the shorter of the estimated useful life or the lease term, which is 3 to 5 years</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Retirements, sale and disposals of assets are recorded by removing the cost and accumulated depreciation with any resulting gain or loss reflected in the consolidated statements of operations and comprehensive loss.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Leases</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From January&#x00a0;1, 2019, the Group adopted the ASC Topic&#x00a0;842, Leases (&#x201c;ASC&#x00a0;842&#x201d;). The Group adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application. The Group determines if an arrangement is a lease at inception. The Group classifies the lease as a finance lease if it meets certain criteria or as an operating lease when it does not. The Group leases several properties for offices, research and development centers, and manufacturing factories in mainland China and Taiwan, which are all classified as operating leases with fixed lease payments, as contractually stated in the lease agreements. The Group&#x2019;s leases do not contain any material residual value guarantees or material restrictive covenants.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the commencement date of a lease, the Group recognizes a lease liability for future fixed lease payments and a right<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-use</FONT> (&#x201c;ROU&#x201d;) asset representing the right to use the underlying asset during the lease term. The lease liability is initially measured as the present value of the future fixed lease payments that will be made over the lease term. The future fixed lease payments are discounted using the rate implicit in the lease, if available, or the incremental borrowing rate (&#x201c;IBR&#x201d;) based on the information available at the commencement date of the lease. The Group has elected not to record leases with an initial term of 12&#x00a0;months or less on the consolidated balance sheets.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-35</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ROU asset is measured at the amount of the lease liability with adjustments, if applicable, for lease prepayments made prior to or at lease commencement, initial direct costs incurred by the Group and lease incentives. Under ASC&#x00a0;842, land use rights agreements are also considered to be operating lease contracts. The Group will evaluate the carrying value of ROU assets if there are indicators of impairment and review the recoverability of the related asset group. If the carrying value of the asset group is determined to not be recoverable and is in excess of the estimated fair value, the Group will record an impairment loss in other expenses in the consolidated statements of operations. ROU assets for operating leases are included in operating lease right<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-use</FONT> assets in the consolidated balance sheets.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Operating leases are included in operating lease right<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-use</FONT> assets and operating lease liabilities in the consolidated balance sheets. Operating lease liabilities that become due within one year of the balance sheet date are classified as current operating lease liabilities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lease expense is recognized on a straight<FONT CLASS="nobreak">-line</FONT> basis over the lease term.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, IB, the Company&#x2019;s subsidiary, acquired land use rights from the Bureau of Natural Resources and Planning in Taizhou, China (&#x201c;Taizhou Resources Bureau&#x201d;) in December&#x00a0;2019 for 50&#x00a0;years and paid RMB 16,494 thousand ($2,528). All land in mainland China is owned by the&#x00a0;China government. The China government may sell land use rights for a specified period of time. The purchase price of land use rights represents the operating lease prepayments for the rights to use the land in&#x00a0;mainland China&#x00a0;under ASC&#x00a0;842 and is recorded as operating ROU assets on the consolidated balance sheets, which is amortized over the lease term.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Restricted asset</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Restricted asset mainly consists of the land use rights from the Taizhou Resources Bureau have been seized by the Taizhou Intermediate People&#x2019;s Court as asset preservation for the Taizhou Bay New District Administrative Committee. See Note&#x00a0;18&#x00a0;&#x2014;&#x00a0;Subsequent Events for further detail.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Intangible assets</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Intangible assets consist of costs incurred to acquire computer software, which are considered finite live assets and recorded at cost less accumulated amortization and accumulated impairment. Amortization is recorded using the straight<FONT CLASS="nobreak">-line</FONT> basis over estimated useful lives that range from 3&#x00a0;years.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Impairment of </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">long-lived</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> assets</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group evaluates the recoverability of long<FONT CLASS="nobreak">-lived</FONT> assets, including finite<FONT CLASS="nobreak">-lived</FONT> intangible assets, whenever events or changes in circumstances indicate the carrying value may not be fully recoverable. When these events occur, the Group evaluates the recoverability of long<FONT CLASS="nobreak">-lived</FONT> assets by comparing the carrying amount of the assets to the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets when the market prices are not readily available. The adjusted carrying amount of the assets becomes a new cost basis and is depreciated over the assets&#x2019; remaining useful lives. No impairment loss was recorded for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Deferred offering costs</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Deferred offering costs consist of underwriting, legal, accounting and other expenditures incurred through the balance sheet date that are directly related to the Company&#x2019;s initial public offering and that will be charged to shareholder&#x2019;s deficit upon the completion of the initial public offering. Should the initial public offering prove to </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-36</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">be unsuccessful, the deferred offering costs, will be charged to operating expense in the consolidated statement of operations and comprehensive loss. As of December&#x00a0;31, 2022 and 2023, the Company incurred $276 and $721 of offering costs, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Guarantee liabilities</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company provided a joint and several guarantee for the performance of buyback shares obligation of the certain shareholders who transferred some of their shares in the Company to others. The guarantee of buyback shares obligation falls within the scope of ASC&#x00a0;460<FONT CLASS="nobreak">-10-15-4</FONT>(b). The guarantee liability is recognized at the fair value at the inception of the guarantee and subsequently remeasured at each reporting period. Changes in the fair value of the guarantee liability are recorded as changes in guarantee liabilities in the consolidated statements of operations and comprehensive loss. When the Company settles the guarantee liability through the performance of the guarantee by making requisite payments to buy back shares, the Company records a corresponding deduction to the guarantee liability. When the Company is released from the guarantee obligation due to the buyback of shares performed by certain shareholders, it is recognized as a reversal of the deduction to the guarantee liability. See Commitment with the Taizhou Company in Note&#x00a0;17&#x00a0;&#x2014;&#x00a0;Commitments and Contingencies for further detail.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loss contingencies</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group is subject to certain legal proceedings and contingencies in addition to those related to guarantee liabilities discussed above in this Note, the outcome of which are subject to significant uncertainty. The Group accrues for estimated losses if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company uses judgment and evaluates whether a loss contingency arising from litigation or an unasserted claim should be disclosed or recorded. The outcome of legal proceedings and other contingencies is inherently uncertain and often difficult to estimate. Accrued legal contingencies are reported within other current liabilities or other non<FONT CLASS="nobreak">-current</FONT> liabilities in the consolidated balance sheets based on the period in which the Group expects the contingency to be settled.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Segment reporting</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with ASC&#x00a0;280, Segment Reporting, the Group&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) has been identified as the Chief Executive Officer. The Group&#x2019;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages its business as a single segment. The Group does not distinguish between markets for the purpose of making decisions about resource allocation and performance assessment. Hence, the Group has only one operating segment and one reportable segment. No geographical segments are presented as substantially all the Group&#x2019;s long<FONT CLASS="nobreak">-lived</FONT> assets are located in Asia.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Research and development expenses</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses primarily include (1)&#x00a0;payroll and other related costs of personnel engaged in research and development activities, (2)&#x00a0;costs related to preclinical testing of the Group&#x2019;s technologies and clinical trials such as payments to contract research organizations (&#x201c;CRO&#x201d;), investigators and clinical trial sites that conduct the clinical studies, (3)&#x00a0;costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (4)&#x00a0;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the Group&#x2019;s research and development services and have no alternative future uses.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-37</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants and CROs, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which the services are provided under such contracts. The Group reflects research and development expenses in the consolidated financial statements by matching those expenses with the period in which services and efforts are expended. The Group accounts for these expenses according to the progress of the preclinical or clinical study as measured by the timing of various aspects of the study or related activities and determines accrual estimates through reviewing the underlying contracts along with discussions with research and other key personnel as to the progress of studies, or other services being conducted. During the course of a study, the Group adjusts its expense recognition if actual results differ from its estimates.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Government Grants</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Government grants for the purpose of giving financial support to the Group with no future related costs or obligations are recognized as non<FONT CLASS="nobreak">-operating</FONT> income when received. The government grants with certain operating conditions are recorded as liabilities when received and will be recorded as non<FONT CLASS="nobreak">-operating</FONT> income when the conditions are met. During the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, IB, Jyong&#x2019;s subsidiary located in China, received RMB 24 thousand ($3) and nil of government grants, respectively, from China government authority and were recognized as non<FONT CLASS="nobreak">-operating</FONT> income since the required conditions were met.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Income tax</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group accounts for income taxes under the liability method in accordance with the regulations of the relevant tax jurisdictions. Under the liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and income tax bases of assets and liabilities and are measured using the enacted income tax rates expected to apply when the differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period including the enactment date. A valuation allowance is recorded if it is more likely than not that some portion or all of a deferred income tax assets will not be realized in the foreseeable future.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group evaluates its uncertain tax positions using the provisions of ASC&#x00a0;740<FONT CLASS="nobreak">-10</FONT>, Income Taxes, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the consolidated financial statements the benefit of a tax position which is &#x201c;more likely than not&#x201d; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#x2019;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For&#x00a0;years ended December&#x00a0;31, 2022 and 2023, the Company did not have any material interest or penalties associated with tax positions nor did the Company have any significant uncertain tax benefits.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Earnings (loss) per share</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic earnings (loss) per ordinary share is computed by dividing net income (loss) attributable to ordinary shareholders by weighted average number of ordinary shares outstanding during the period.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Diluted earnings (loss) per ordinary share reflects the potential dilution that could occur if securities were exercised or converted into ordinary shares. The Company did not have potential ordinary shares (e.g., stock options, non<FONT CLASS="nobreak">-vested</FONT> restricted shares and other securities), which could potentially convert into ordinary shares and dilute basic earnings (loss) per share in the future.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-38</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Foreign currency transactions</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The functional currency of the Company is the U.S.&#x00a0;dollar. The Company&#x2019;s subsidiaries determined their functional currency to be the local currency of the respective entities except for TSB which determined its functional currency to be the U.S.&#x00a0;dollar based on the criteria of ASC&#x00a0;830, Foreign Currency Matters. Gains or losses, resulting from the application of different foreign exchange rates when cash in foreign currency is converted into the entities&#x2019; functional currency, or when foreign currency receivable and payable are settled, are credited or charged to income in the period of conversion or settlement. At year<FONT CLASS="nobreak">-end</FONT>, the balances of foreign currency monetary assets and liabilities are recorded based on prevailing exchange rates and any resulting gains or losses are credited or charged to non<FONT CLASS="nobreak">-operating</FONT> income or loss.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Translation of foreign currency financial statements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reporting currency of the Group is the US dollar. Assets and liabilities are translated from each entity&#x2019;s functional currency to the reporting currency at the exchange rate on the balance sheet date. Equity amounts, except for the change in accumulated deficits, are translated at historical exchange rates at the date of entry to shareholders&#x2019; equity; the change in accumulated deficits uses historical exchange rates of each period&#x2019;s statement of operations. Translation adjustments are reported as accumulative translation adjustments and are shown as a separate component of other comprehensive income in the consolidated statements of changes in shareholders&#x2019; deficit.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Translation of amounts into USD has been made at the following exchange rates from Board of Governors of the Federal Reserve System:</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Balance sheet items, except for equity accounts</P>
		<TABLE CLASS="Basic-Table" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="Basic-Table _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">December&#x00a0;31, 2023</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">RMB7.0999 to $1; NTD30.6200 to $1</P>
					</TD>
				</TR>
				<TR CLASS="Basic-Table _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">December&#x00a0;31, 2022</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">RMB6.8972 to $1: NTD30.7300 to $1</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Statement of operations and comprehensive loss, and cash flows items</P>
		<TABLE CLASS="Basic-Table" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="Basic-Table _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">For&#x00a0;the&#x00a0;year&#x00a0;ended&#x00a0;December&#x00a0;31,&#x00a0;2023</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">RMB7.0809&#x00a0;to&#x00a0;$1;&#x00a0;NTD31.1525&#x00a0;to&#x00a0;$1</P>
					</TD>
				</TR>
				<TR CLASS="Basic-Table _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">For&#x00a0;the&#x00a0;year&#x00a0;ended&#x00a0;December&#x00a0;31,&#x00a0;2022</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">RMB6.7290&#x00a0;to&#x00a0;$1; NTD29.7963 to $1</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Comprehensive loss</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss consists of two components, net loss and other comprehensive income (loss). The foreign currency translation gain or loss resulting from translation of the consolidated financial statements expressed in USD is reported in other comprehensive loss in the consolidated statements of operations and comprehensive loss.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Concentration of risks</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Concentration of suppliers</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following suppliers accounted for 10% or more of research and development expenses for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years ended December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Supplier</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">A</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">B</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">D</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<FONT STYLE="width: 24px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents less than 10% of research and development expenses for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-39</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Concentration of credit risk</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject the Group to significant concentration of credit risk consist primarily of deposits and time deposits with original maturities more than three&#x00a0;months.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In China, the insurance coverage of each financial institution is RMB 500 thousand. As of December&#x00a0;31, 2022 and 2023, the Group had RMB 10,208 thousand ($1,480) and RMB 10,586 thousand ($1,491), which was frozen by the order of the Taizhou Intermediate People&#x2019;s Court, in uninsured deposits at the financial institution incorporated in China, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In Taiwan, the insurance coverage of each financial institution is NTD 3,000 thousand. As of December&#x00a0;31, 2022, the Group had NTD 13,507 thousand ($440), which included deposits held as collateral for the credit of a business credit card, and $26 in uninsured deposits at the financial institutions incorporated in Taiwan. As of December&#x00a0;31, 2023, the Group had $6 in uninsured deposits at the financial institutions incorporated in Taiwan.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In Hong&#x00a0;Kong, the insurance coverage of each financial institution is HKD 500 thousand. As of December&#x00a0;31, 2022 and 2023, all deposits at the financial institution incorporated in Hong&#x00a0;Kong were covered by the insurance, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While management believes that these financial institutions are of high credit quality, it also continually monitors their credit worthiness.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Recent accounting pronouncements</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In November&#x00a0;2021, the FASB issued ASU&#x00a0;2021<FONT CLASS="nobreak">-10</FONT>, Government Assistance (Topic&#x00a0;832)&#x00a0;&#x2014;&#x00a0;Disclosures by Business Entities about Government Assistance. The amendment requires business entities to disclose, in notes to their financial statements, information about certain types of government assistance they receive in order to increase transparency in financial reporting. This amendment is effective for the Group&#x2019;s consolidated financial statements issued for annual periods beginning after December&#x00a0;15, 2021. Early adoption is permitted. The Group adopted this standard on January&#x00a0;1, 2022. There was no material impact to the Group&#x2019;s consolidated financial statements upon adoption.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In October&#x00a0;2023, the FASB issued ASU&#x00a0;2023<FONT CLASS="nobreak">-06</FONT>, &#x201c;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative.&#x201d; This amendment incorporates certain U.S.&#x00a0;Securities and Exchange Commission (SEC) disclosure requirements into the FASB Accounting Standards Codification. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification Topics, allow users to more easily compare entities subject to the SEC&#x2019;s existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the Codification with the SEC&#x2019;s regulations. For entities subject to the SEC&#x2019;s existing disclosure requirements and for entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. For all other entities, the amendments will be effective two&#x00a0;years later. However, if by June&#x00a0;30, 2027, the SEC has not removed the related disclosure from its regulations, the amendments will be removed from the Codification and not become effective for any entity. The Company does not expect the adoption of ASU&#x00a0;2023<FONT CLASS="nobreak">-06</FONT> to have a material impact on its consolidated financial statements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In November&#x00a0;2023, the FASB issued ASU&#x00a0;2023<FONT CLASS="nobreak">-07</FONT>, Segment Reporting (Topic&#x00a0;280)&#x00a0;&#x2014;&#x00a0;Improvements to Reportable Segment Disclosures. The amendment requires entities to report a measure of segment profit or loss that the chief operating decision maker uses to assess segment performance and make decisions about allocating </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-40</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">resources. The amendment also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosure under certain circumstances. The amendment does not change or remove those disclosure requirements and also does not change how an entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. This amendment is effective for the Group&#x2019;s consolidated financial statements issued for annual periods beginning after December&#x00a0;15, 2023. Early adoption is permitted. The Group is currently evaluating the impact of adopting this amendment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#x00a0;2023, the FASB issued ASU&#x00a0;2023<FONT CLASS="nobreak">-09</FONT>, Income Taxes (Topic&#x00a0;740)&#x00a0;&#x2014;&#x00a0;Improvements to Income Tax Disclosures. The amendment requires that entities on an annual basis (1)&#x00a0;disclose specific categories in the rate reconciliation and (2)&#x00a0;provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate. The amendment also requires disclosure of, on an annual basis, the year<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-date</FONT> amount of income tax paid (net of refunds received) disaggregated by disaggregated by federal, state, and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). This amendment is effective for the Group&#x2019;s consolidated financial statements issued for annual periods beginning after December&#x00a0;15, 2024. Early adoption is permitted. The Group is currently evaluating the impact of adopting this amendment.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>CASH AND RESTRICTED CASH</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash in hand</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deposits in banks</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">715</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">176</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">718</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">177</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deposits in banks frozen by the Taizhou Intermediate People&#x2019;s Court (see&#x00a0;Note&#x00a0;17 for further detail)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,553</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,562</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Collateral for the credit of a business credit card</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total restricted cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,556</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,565</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total cash and restricted cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,274</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,742</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#x00a0;22, 2024, the RMB 11,086 thousand ($1,562) of restricted cash, which was deposits in banks frozen by the Taizhou Intermediate People&#x2019;s Court, was transferred to New District Administrative Committee (see Note&#x00a0;18 for further detail).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">5.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SHORT-TERM</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> INVESTMENT</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Short<FONT CLASS="nobreak">-term</FONT> investment consists of time deposits with original maturities over three&#x00a0;months to one year. For the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, the Group recorded the interest income of $3 and nil, respectively, from the short<FONT CLASS="nobreak">-term</FONT> investments in the consolidated statements of operations and comprehensive loss.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-41</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-bottom:10pt;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">6.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>PROPERTY AND EQUIPMENT, NET</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consist of the following:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Land</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,016</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,020</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Buildings</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,490</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,499</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Buildings improvements</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">151</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">152</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Laboratory equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">791</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">793</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Office equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">119</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">120</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transportation equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other equipment</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">51</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Leasehold improvements</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Construction in progress</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">144</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">139</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,935</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,948</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: accumulated depreciation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,427</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,562</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,508</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,386</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Depreciation expenses recognized during the&#x00a0;years ended December&#x00a0;31, 2022 and 2023 were approximately $123 and $127, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LEASES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group leased facilities for office, research and development and manufacturing facilities in China and Taiwan. Most of the lease facilities in Taiwan were leased from the related parties. In December&#x00a0;2019, the land use right of gross value of RMB 16,494 thousand ($2,528) for 50&#x00a0;years was acquired from Taizhou Resource Bureau in China. As of December&#x00a0;31, 2022 and 2023, the net carrying values of the acquired land use rights of Taizhou were RMB&#x00a0;15,505 thousand ($2,248) and RMB 15,175 thousand ($2,137), respectively. In January&#x00a0;2024, this land use right was seized by the Taizhou Intermediate People&#x2019;s Court due to the litigation with Taizhou Bay New District Administrative Committee and RMB15,175 thousand ($2,137) of operating right<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-use</FONT> assets regarding IB&#x2019;s land use right was reclassified as a restricted asset. See Notes 17 and 18 for the detail. In November&#x00a0;2023, the Group renewed the lease agreement with the related party, Zhao Jian Fu Co., Ltd to lease an office in Taiwan, continuously. Lease terms vary based on the nature of operations and the market dynamics; however, all leased facilities are classified as operating leases with remaining lease terms between 0.17 to 2.00&#x00a0;years except for the land use rights acquired from the Bureau of Land and Resources in Taizhou, China with remaining lease terms of 46&#x00a0;years. See Note&#x00a0;16 for related party lease obligations due and related party lease costs.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Supplemental information related to leases was as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years ended December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating fixed lease cost</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">194</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">180</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Supplemental cash flow information related to leases was as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years ended December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash paid for amounts included in measurement of lease liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">168</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-cash operating lease liabilities arising from obtaining operating right-of-use assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">124</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">43</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-42</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LEASES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The maturities of lease liabilities&#x00a0;as of December&#x00a0;31, 2023 were as follows:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years&#x00a0;ending <BR>December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">134</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thereafter</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total lease payments</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed interest</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Present value of minimum operating lease payments</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">199</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Weighted<FONT CLASS="nobreak">-average</FONT> remaining lease terms and discount rates are as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average remaining lease term</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2.26 years</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1.78 years</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average discount rate</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2.44%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2.89%</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">8.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SHORT-TERM</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> BANK LOANS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table presents short<FONT CLASS="nobreak">-term</FONT> bank loan as of December&#x00a0;31, 2022 and 2023:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shanghai Commercial&#x00a0;&amp; Savings Bank</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,906</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,630</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Taipei Fubon Bank</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,263</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,267</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,169</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,897</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H7" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="font-style:italic;font-weight:normal;text-decoration:underline;">Shanghai Commercial&#x00a0;&amp; Savings Bank loan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On September&#x00a0;10, 2021, HEB entered into a one<FONT CLASS="nobreak">-year</FONT> loan agreement with Shanghai Commercial&#x00a0;and Savings Bank, Ltd. This loan agreement provided a credit limit of NTD 200,000 thousand with a variable interest rate. As of December&#x00a0;31, 2022, the outstanding borrowing under this agreement was NTD 181,500 thousand ($5,906) with an interest rate of 1.81% per annum and a maturity date of September&#x00a0;23, 2023.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#x00a0;1, May&#x00a0;4, May&#x00a0;19, July&#x00a0;24, August&#x00a0;28, and August&#x00a0;31, 2023, HEB borrowed an aggregate amount of NTD 24,800 thousand ($796) with the interest rate of 2.06% per annum and a maturity date of September&#x00a0;23, 2023 under this agreement. On February&#x00a0;7 and October&#x00a0;2, 2023, HEB repaid an aggregate amount of NTD 206,300 thousand ($6,621).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On September&#x00a0;23, 2023, HEB entered into a new one<FONT CLASS="nobreak">-year</FONT> loan agreement with Shanghai Commercial and Savings Bank, Ltd. This new loan agreement provided a credit limit of NTD 300,000 thousand with a variable interest rate. On October&#x00a0;2 and October&#x00a0;26, 2023, HEB borrowed an aggregate amount of NTD 203,000 thousand ($6,515) with the interest rate of 2.06%. As of December&#x00a0;31, 2023, the outstanding borrowing under this agreement was NTD 203,000 thousand ($6,630) with an interest rate of 2.06% per annum and a maturity date of September&#x00a0;23, 2024. The borrowing was guaranteed by Panatoz Corporation, Nobel Consumer Corporation, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, and Ju<FONT CLASS="nobreak">-Ting</FONT> Chen, related parties.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-43</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">8.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SHORT-TERM</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> BANK LOANS</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="H7" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="font-style:italic;font-weight:normal;text-decoration:underline;">Taipei Fubon Bank loan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On December&#x00a0;16, 2021, HEB entered into a short<FONT CLASS="nobreak">-term</FONT> loan agreement with Taipei Fubon Bank. This loan agreement provided a credit limit of NTD 38,800 thousand ($1,399) with a variable interest rate. As of December&#x00a0;31, 2022, the outstanding borrowing under this agreement was NTD 38,800 thousand ($1,263) with an interest rate of 2.06% per annum and a maturity date of June&#x00a0;9, 2023. On June&#x00a0;9, 2023, HEB had repaid amount of NTD 38,800 thousand ($1,246).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On June&#x00a0;9, 2023, HEB entered into a short<FONT CLASS="nobreak">-term</FONT> loan agreement with Taipei Fubon Bank. This loan agreement provided a credit limit of NTD 38,800 thousand ($1,246) with a variable interest rate. This borrowing was due on December&#x00a0;6, 2023 and the interest rate was 2.62% per annum. On December&#x00a0;6, 2023, HEB repaid amount of NTD 38,800 thousand ($1,246).</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On December&#x00a0;6, 2023, HEB entered into a short<FONT CLASS="nobreak">-term</FONT> loan agreement with Taipei Fubon Bank. This loan agreement provided a credit limit of NTD 38,800 thousand ($1,246) with a variable interest rate. This borrowing will be due on June&#x00a0;3, 2024 and the interest rate was 2.63% per annum.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As of December&#x00a0;31, 2023, the outstanding borrowing under this agreement was NTD 38,800 thousand ($1,267). These borrowings were guaranteed by Zhao Jian Fu Co., Ltd. and Panatoz Corporation, the related parties. In subsequent period, HEB had repaid amount of NTD 11,400 thousand ($366) as of April&#x00a0;15, 2024.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">9.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accrued expenses and other current liabilities consist of the following:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Clinical trial</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">261</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">287</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">230</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">282</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Professional service fees</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">196</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">346</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payroll</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">163</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">169</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">43</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">873</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,127</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">10.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LOANS FROM THIRD PARTIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On September&#x00a0;10, 2019, the Company entered into a loan facility with Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited (&#x201c;Medi<FONT CLASS="nobreak">-life</FONT>), a minority shareholder, for $600. This loan had a one<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. Before the maturity date, the Company renewed the loan agreement with Medi<FONT CLASS="nobreak">-life</FONT> to extend the maturity date to September&#x00a0;10, 2026 On December&#x00a0;3, 2020, the Company also entered into a new loan facility with Medi<FONT CLASS="nobreak">-life</FONT> for $100, which had a two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. Before the maturity date, the Company renewed the loan agreement with Medi<FONT CLASS="nobreak">-life</FONT> to extend the maturity date to December&#x00a0;2, 2026.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On August&#x00a0;5, 2019, TSB entered a loan facility with Medi<FONT CLASS="nobreak">-life</FONT> for RMB 16,003 thousand ($2,273), which had a two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. On June&#x00a0;1, 2021, TSB repaid $250 to Medi<FONT CLASS="nobreak">-life</FONT>. Before the maturity date, TSB renewed the loan agreement with Medi<FONT CLASS="nobreak">-life</FONT> to extend the maturity date to May&#x00a0;31, 2025.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On January&#x00a0;10, 2020 and December&#x00a0;7, 2020, TSB also entered two loan facilities with Medi<FONT CLASS="nobreak">-life</FONT> for an aggregate amount of $408, which had a two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. Before the maturity date, TSB renewed the loan agreement with Medi<FONT CLASS="nobreak">-life</FONT>, totaling $80 and $328, extending the maturity date to January&#x00a0;9, 2025 and December&#x00a0;6, 2026, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Loans from third parties were $3,131 and $3,131 as of December&#x00a0;31, 2022 and 2023, and accrued interests were $209 and $271 as of December&#x00a0;31, 2022 and 2023, respectively.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-44</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-bottom:10pt;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LONG-TERM</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> BANK LOANS</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Secured bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,429</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,313</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(479</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(75</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long-term bank loans</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,950</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,238</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 63.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 63.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 63.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loan content</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 63.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Annual interest rate</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2.25%~3.00%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2.59%~3.25%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 63.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Maturity date</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Due&#x00a0;by&#x00a0;June&#x00a0;2032</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Due&#x00a0;by&#x00a0;June&#x00a0;2032</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H7" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="font-style:italic;font-weight:normal;text-decoration:underline;">Taiwan Cooperative Bank loan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On June&#x00a0;5, 2014, HEB entered into a loan agreement with Taiwan Cooperative Bank for NTD 73,200 thousand. This loan had an 18<FONT CLASS="nobreak">-year</FONT> term with a variable interest rate per annum. HEB started repaying the principal from June&#x00a0;2015. HEB did not repay a loan payment from 2020 through March&#x00a0;2023 due to the COVID<FONT CLASS="nobreak">-19</FONT> emergency relief of suspension of loan payments provided by Taiwan Cooperative Bank. As of December&#x00a0;31, 2022 and 2023, the outstanding loan was NTD 55,012 thousand ($1,790) and NTD 55,012 ($1,797) with an interest rate of 2.34% and 2.59% per annum, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#x00a0;20, 2019, HEB also entered into a new loan agreement with Taiwan Cooperative Bank for NTD 15,000 thousand. This loan had a 5<FONT CLASS="nobreak">-year</FONT> term with a variable interest rate per annum. HEB did not repay a loan payment from 2020 through March&#x00a0;2023 due to the COVID<FONT CLASS="nobreak">-19</FONT> emergency relief of suspension of loan payments provided by Taiwan Cooperative Bank. For the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, HEB repaid nil and NTD 500 thousand ($16) for this loan, respectively. As of December&#x00a0;31, 2022 and 2023, the outstanding loan was NTD 13,328 ($434) and NTD 12,828 ($419) with an interest rate of 2.35% and 2.60% per annum, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HEB provided land and buildings located in Yilan, Taiwan as collateral for these loans from Taiwan Cooperative Bank. These loans were also guaranteed by Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, CEO of the Company, and Ju<FONT CLASS="nobreak">-Ting</FONT> Chen, the shareholder of the Company. The carrying amount of pledged land, buildings, and building improvements was $3,116 and $3,072 as of December&#x00a0;31, 2022 and 2023, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the subsequent period, HEB negotiated with Taiwan Cooperative Bank to postpone the repayment of the principal and obtained the agreement from Taiwan Cooperative Bank on February&#x00a0;19, 2024. Additionally, HEB had repaid an aggregate amount of NTD 500 thousand ($16) for this loan as of April&#x00a0;15, 2024.</P>
		<P CLASS="H7" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="font-style:italic;font-weight:normal;text-decoration:underline;">Shanghai Commercial&#x00a0;&amp; Savings Bank loan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#x00a0;25, 2020, HEB entered into a loan agreement with Shanghai Commercial&#x00a0;&amp; Saving Bank for NTD 16,000 thousand. This loan had a 5<FONT CLASS="nobreak">-year</FONT> term with a variable interest rate per annum. For the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, HEB repaid NTD 7,012 thousand ($235) and NTD 1,770 thousand ($57) for this loan, respectively. As of December&#x00a0;31, 2022 and 2023, the outstanding loan was NTD 4,721 thousand ($154) and NTD 2,951 thousand ($96) with an interest rate of 3.13% and 3.25% per annum, respectively. This loan was also guaranteed by Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, CEO of the Company with the fixed asset located in Xinbei, Taiwan owned by Panatoz Corporation. In the subsequent period, HEB had repaid an aggregate amount of NTD 443 thousand ($14) for this loan as of April&#x00a0;15, 2024.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-45</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">11.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LONG-TERM</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> BANK LOANS</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="H7" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="font-style:italic;font-weight:normal;text-decoration:underline;">Chang Hwa Bank loan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On September&#x00a0;16, 2020, HEB entered into a secured loan agreement with Chang Hwa Bank for a loan amount of up to NTD 5,000 thousand. Loans under this agreement had a 3<FONT CLASS="nobreak">-year</FONT> term with a variable interest rate per annum. These loans were guaranteed by Small&#x00a0;&amp; Medium Enterprise Credit Guarantee Fund of Taiwan, a non<FONT CLASS="nobreak">-profit</FONT> organization to provide credit guarantees to small and medium enterprises which are promising but short of collateral necessary to obtain finance from contracted financial institutions. For the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, HEB repaid NTD 1,659 ($56) and NTD 1,566 thousand ($50). As of December&#x00a0;31, 2022 and 2023, the outstanding loan was NTD 1,583 thousand ($51) and NTD 16 thousand ($1) with an interest rate of 2.35% and 2.60% per annum, respectively. In the subsequent period, HEB had fully repaid the amount of NTD 16 thousand ($1) for this loan as of April&#x00a0;15, 2024.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">12.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>INCOME TAX</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group is subject to income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which each entity is domiciled.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Cayman Islands</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Taiwan</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HEB and GB are incorporated in Taiwan and are subject to corporate income tax at a rate of 20%. Both of them have no taxable income for all periods presented, therefore, no provision for income taxes is required.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Hong&#x00a0;Kong</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">TSB is incorporated in Hong&#x00a0;Kong and is subject to Hong&#x00a0;Kong profits tax on the taxable income as reported in the respective statutory financial statements adjusted in accordance with the relevant Hong&#x00a0;Kong tax laws. The applicable tax rate in Hong&#x00a0;Kong is 8.25% for assessable profits on the first HKD2&#x00a0;million and 16.5% for any assessable profits in excess.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">China</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">IB is incorporated in China and is subject to China statutory income tax rate of 25% on the assessable income in accordance with relevant PRC enterprise income tax legislation, interpretations and practices.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No provision for PRC corporate income tax has been made for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023 as IB had no such assessable profit for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Singapore</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Entities incorporated in Singapore are subject to corporate income tax rate of 17%. Jyong Biotech International Pte. Ltd., which was incorporated under the law of Singapore on September&#x00a0;29, 2022, and is subject to corporate income tax rate of 17%. No provision for Singapore corporate income tax has been made for the year ended December&#x00a0;31, 2022 and 2023 as Jyong Biotech International Pte. Ltd., had no such assessable profit.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company and its subsidiaries file separate income tax returns. The applicable statutory income tax rate in the Cayman Islands was zero for the Company for the&#x00a0;years being reported.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-46</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">12.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>INCOME TAX</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since the main operation of the Group is located in Taiwan, the Taiwan statutory income tax rate is used to reconcile the Group&#x2019;s effective income tax rate. Reconciliations of the differences between the Taiwan statutory income tax rate and the Group&#x2019;s effective income tax rate for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023 are as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years ended December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Statutory income tax rate</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-deductible expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.11</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.09</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in valuation allowances</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(19.89</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(19.91</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effective tax rate</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The deferred income tax assets and liabilities as of December&#x00a0;31, 2022 and 2023 consisted of the following:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred income tax assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,711</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,415</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development credits</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,603</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,843</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Others</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,318</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,258</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(18,318</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(18,258</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total net deferred income tax assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Realization of the net deferred income tax assets is dependent on factors including future reversals of existing taxable temporary differences and adequate future taxable income, exclusive of reversing deductible temporary differences and tax loss carry forwards. The Group evaluates the potential realization of deferred tax assets on an entity<FONT CLASS="nobreak">-by</FONT><FONT CLASS="nobreak">-entity</FONT> basis. As of December&#x00a0;31, 2022 and 2023, valuation allowances were provided against deferred tax assets in entities where it was determined it was more likely than not that the benefits of the deferred tax assets will not be realized.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2022 and 2023, HEB had Taiwan research and development credit carryforwards of approximately $10,603 and $10,641, respectively. The Act for the Development of Biotech and New Pharmaceuticals Industry in Taiwan provided HEB the research and development credit for a period of five&#x00a0;years from the time it is subject to the profit<FONT CLASS="nobreak">-seeking</FONT> enterprise income tax.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2023, the Group had net operating loss carryforward available to offset future taxable income, shown below by jurisdictions.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Jurisdiction</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Amount</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Expiring year</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Taiwan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37,002</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2024&#x00a0;&#x2013;&#x00a0;2033</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">China</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">59</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2026&#x00a0;&#x2013;&#x00a0;2027</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">13.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>ORDINARY SHARES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2022 and 2023 the Company was authorized to issue 5,000,000 thousand shares. As of December&#x00a0;31, 2022 and 2023, 73,361 thousand shares were issued and outstanding, $0.00001 par value ordinary shares. Holders of the Company&#x2019;s ordinary shares are entitled to dividends, if and when, declared by the board of directors of the Company. The holder of each ordinary share is entitled to one vote. As of December&#x00a0;31, 2023, no dividends were declared.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-47</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-bottom:10pt;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">14.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LICENSE AGREEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#x00a0;2016, HEB entered into a licensing agreement with Chhak Kamponngsaon Sez Co., Ltd to grant an exclusive right to sell and market Botreso in the Kingdom of Cambodia until April&#x00a0;2036 in exchange for an upfront payment of $100 thousand, a certain amount in milestone payments for applying the regulatory approval of Botreso and obtaining the regulatory approval of Botreso in the Kingdom of Cambodia, and a certain percent on net sales in royalty payments. HEB has no other performance obligation in addition to the license, and Chhak Kamponngsaon Sez Co., Ltd is responsible for assisting HEB to obtain initial and all subsequent regulatory approvals of Botreso in the Kingdom of Cambodia. HEB recognized the upfront payment of $100 thousand as revenue in 2016 since HEB has no other performance obligation in addition to the licenses. As of April&#x00a0;15, 2024, HEB has not achieved any milestones.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">15.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>NET LOSS PER SHARE</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic and diluted net loss per share for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023 are calculated as follows:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years ended December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Numerator:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss attributable to ordinary shareholders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,630</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,400</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Denominator:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average number of ordinary shares outstanding&#x00a0;&#x2013;&#x00a0;basic and diluted (in thousands)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">71,567</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">71,567</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share&#x00a0;&#x2013;&#x00a0;basic and diluted</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.09</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.06</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">16.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>RELATED PARTY TRANSACTIONS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Intercompany balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated upon consolidation; therefore, those items are not disclosed in this note. The table below sets forth the major related parties and their relationships with the Group as of December&#x00a0;31, 2022 and 2023:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Name of related parties</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Relationship with the Group</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">CEO and Chairwoman of the Company</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Ju-Ting Chen</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The shareholder of the Company</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Xue-Juan Chen</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The fourth degree of kinship to CEO</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Alfred Ying</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">CFO</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Panatoz Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Significantly influenced by Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, CEO of the Company</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Zhao Jian Fu Co., Ltd.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Significantly influenced by Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, CEO of the Company</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 39.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Nobel Consumer Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 59.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Managed by Xue<FONT CLASS="nobreak">-Juan</FONT> Chen, a related party of the Company</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February&#x00a0;2021 to November&#x00a0;2021, the Company entered into several loan agreements with Nobel Consumer Corporation for an aggregate amount of $ 300, which had a 2<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. Before the maturity date, the Company renewed the loan agreements with Nobel Consumer Corporation to extend the maturity date to February, June, and November&#x00a0;2025. From March&#x00a0;2022 to December&#x00a0;2022, the Company entered additional loan agreements with Nobel Consumer Corporation and Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo for an aggregate amount of $595 and $342, respectively, which had two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum. Before the maturity date, the Company renewed the loan agreements to extend the maturity date of the loans due on March&#x00a0;2026 to December&#x00a0;2026.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-48</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">16.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>RELATED PARTY TRANSACTIONS</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From January&#x00a0;2023 to December&#x00a0;2023, the Company and HEB entered additional loan agreements with Nobel Consumer Corporation, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, and Panatoz Corporation for an aggregate amount of $480, $1,083 and $463, respectively, which had two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2023, the accrued interest expenses to Nobel Consumer Corporation, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, and Panatoz Corporation were $35, $18, and $1, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the subsequent period, the Company and HEB borrowed an aggregate amount of $14, $470, $264, and $479 from Nobel Consumer Corporation, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, Panatoz Corporation, and Zhao Jian Fu Co., Ltd. as of April&#x00a0;15, 2024, respectively. These new loans had a two<FONT CLASS="nobreak">-year</FONT> term with a 2% interest rate per annum.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HEB leased the facilities for office, research and development, and manufacturing facilities in Taiwan from Panatoz Corporation, Zhao Jian Fu Co., Ltd., and Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, respectively. See Note&#x00a0;7.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During 2018 and 2019, Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo and Ru<FONT CLASS="nobreak">-Ting</FONT> Chen paid securities exchange tax and bridge loan fees on behalf of the Company, respectively. As of December&#x00a0;31, 2022 and 2023, the aggregate balance of due to Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo and Ju<FONT CLASS="nobreak">-Ting</FONT> Chen were $628 and $628, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Nobel Consumer Corporation, Panatoz Corporation, Zhao Jian Fu Co., Ltd., Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, and Ju<FONT CLASS="nobreak">-Ting</FONT> Chen provided guarantees of short<FONT CLASS="nobreak">-term</FONT> and long<FONT CLASS="nobreak">-term</FONT> loans from Shanghai Commercial&#x00a0;&amp; Savings Bank, Ltd., short<FONT CLASS="nobreak">-term</FONT> loan from Taipei Fubon Bank loan, and long<FONT CLASS="nobreak">-term</FONT> loans from Taiwan Cooperative Bank to HEB.&#x00a0;As of December&#x00a0;31, 2022 and 2023, the amount of borrowing guaranteed were $9,547 and $10,209, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The related party balances and transactions were summarized as follows:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">(a)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Related party balances</FONT></P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Loan from related party</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Nobel Consumer Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">895</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,375</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">342</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,305</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Panatoz Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">471</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,237</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,151</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-35" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Accrued expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Nobel Consumer Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Panatoz Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Zong-jie Ying</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-35" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Operating lease liabilities due to related parties (including current and non-current)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Panatoz Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">162</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">116</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Zhao Jian Fu Co., Ltd.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">119</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">81</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">285</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">199</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-35" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other non-current liabilities due to related parties</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ju-Ting Chen</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">566</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">566</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">62</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">62</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">628</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">628</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-49</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">16.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>RELATED PARTY TRANSACTIONS</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">(b)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Related party transactions</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the&#x00a0;years ended December, 2022 and 2023, related party transactions of rental expenses consisted of the following:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Years ended December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Zhao Jian Fu Co., Ltd.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">76</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">83</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Panatoz Corporation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">48</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">17.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>COMMITMENTS AND CONTINGENCIES</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Clinical Research Organization (CRO)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group has agreements with contract service providers to assist in the performance of phase&#x00a0;II clinical trial activities for PCP, one of the Group&#x2019;s key drug candidates. One CRO is mainly responsible for the data management, biostatistical analysis, and clinical study report writing; while the other CRO is responsible for the subjects&#x2019; enrollment and serving as study coordinator (SC) at each study site. Such agreements are generally cancellable upon reasonable notice and payment of costs incurred.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Commitment and Litigation with the TaiZhou Company</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In May&#x00a0;2019, two of Jyong&#x2019;s shareholders, Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited and Sira View Corp. (collectively, the &#x201c;Transferring Shareholders&#x201d;), entered into a share purchase agreement (the &#x201c;Share Purchase Agreement) with Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership) (the &#x201c;Taizhou Company&#x201d;) to sell 1,794 thousand shares of Jyong&#x2019;s ordinary shares held by the Transferring Shareholders to the Taizhou Company at RMB 112,500 thousand ($16,366) (the &#x201c;Share Purchase Transaction&#x201d;). Under the Share Purchase Agreement, the Taizhou Company would have a right to request the Transferring Shareholders to repurchase the shares if Jyong would not accomplish the &#x201c;Qualified Issuance and Listing&#x201d; (defined as Jyong&#x2019;s public filing of shares and listing on the main board of the Stock Exchange of Hong&#x00a0;Kong Limited, or the HKEX) within 5&#x00a0;years after the closing of the Share Purchase Transaction, or any other commitments were breached, such as not changing the primary control<FONT CLASS="nobreak">-person</FONT> of Jyong, not changing the main operation of HEB, etc. and the repurchase payment is determined by the principal investment plus the interest based on the loan benchmark interest rate of People&#x2019;s Bank of China when the payment is made. In addition, Jyong provided the Taizhou Company a joint and several guarantee for the performance of the repurchase shares obligation of the Transferring Shareholders and pledged 100% of its equity interest in IB to the Taizhou Company as collateral pursuant to the Share Purchase Agreement. The above commitments and guarantees shall be automatically terminated after the Company completes the qualified issuance and listing.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of any liquidation, dissolution, bankruptcy or winding up of Jyong, either voluntary or involuntary, or any deemed liquidation event as defined in the agreement, the Taizhou Company is entitled to receive, prior to any distribution to the holders of ordinary shares, an amount per share equal to the original issue price, plus accrued interest. This right enjoyed by the Taizhou Company shall be automatically suspended when the Company submits its A1 application proof to go public on the main board of the HKEX, which never occurred. If the Company fails to pass the hearing procedure or withdraws the application, this right will automatically resume its validity and has retrospective rights to the rights and interests of the Taizhou Company during the period of expiration.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On November&#x00a0;15, 2022, the Group received a complaint for civil suit filed by the Taizhou Company to the Taizhou Intermediate People&#x2019;s Court (the &#x201c;Taizhou Court&#x201d;) against the Transferring Shareholders, Jyong, HEB, TSB, IB and Ms. Kuo, Fu Feng (collectively, the &#x201c;Defendants&#x201d;), requesting, among other claims: (i)&#x00a0;redemption by the </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-50</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">17.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>COMMITMENTS AND CONTINGENCIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Transferring Shareholders for all shares purchased by the Taizhou Company under the Share Purchase Agreement for the original purchase price of RMB112,500 thousand ($16,366) and corresponding interests from July&#x00a0;29, 2019 to the date of actual payment calculated at the loan prime rate in China (the &#x201c;Redemption&#x201d;); (ii)&#x00a0;the Taizhou Court to hold Jyong, HEB and Ms. Kuo, Fu Feng jointly liable for the Redemption; (iii)&#x00a0;the Taizhou Court to confirm Taizhou Company&#x2019;s right to liquidate all equity interest in IB held by TSB that was pledged to the Taizhou Company; and (iv)&#x00a0;the Taizhou Court to hold IB for the obligations of other Defendants within the scope of the benefits it received from the investment made under the Share Purchase Agreement. The dispute went on trial in the Taizhou Court on March&#x00a0;16, 2023 and November&#x00a0;29, 2023, respectively. The Defendants are actively negotiating with the Taizhou Company for a smooth settlement of this legal proceeding. As of December&#x00a0;31, 2023, the Company accrue an additional contingency liabilities of RMB 420 thousand ($59) due to the judgement issued by the Taizhou Court on March&#x00a0;25, 2024 (see Note&#x00a0;18 for further detail) other than the guarantee liabilities under the Share Purchase Agreement as set forth below.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group considered the guarantee provided under this Share Purchase Agreement was accounted for as an equity transaction between Jyong and shareholders to buy back Jyong&#x2019;s shares. Therefore, the Group estimated the fair value of guarantee liabilities at the fair value of the shares at the inception of this guarantee and recorded $16,366 of guarantee liabilities and corresponding treasury shares at the inception date, as well as subsequently measured the fair value of guarantee liabilities determined by the interest expense which will be paid when repurchasing the shares under the Share Purchase Agreement and recognized interest expense for the fair value change of guarantee liabilities. The amount of interest expenses recognized were $536 and $438 for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, and the amount of guarantee liabilities were $18,408 and $18,787 as of December&#x00a0;31, 2022 and 2023, respectively. In addition, the negative net book value of IB&#x2019;s equity pledged was $251 and $1,194 as of December&#x00a0;31, 2022 and 2023, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Commitments with Taizhou Resources Bureau</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On November&#x00a0;29, 2019, IB, our PRC subsidiary, entered into the land use right agreement with Taizhou Resources Bureau (the &#x201c;Land Use Right Agreement&#x201d;). Under the Land Use Right Agreement, IB shall commence construction on the parcel granted by May&#x00a0;28, 2020 and complete the construction by November&#x00a0;28, 2022, otherwise, IB shall pay the liquidated damages to Taizhou Resources Bureau for each&#x00a0;day of delay, being 0.1% of the total amount of the land use right grant price of approximately RMB16,000 thousand plus tax.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On November&#x00a0;23, 2022, Taizhou Resources Bureau issued a formal notice of reminder of default, requiring IB to pay the liquidated damages of RMB13,080 thousand, with the amount of damages accruing from November&#x00a0;24, 2022 to the date of actual construction to be calculated separately. In addition, under the Land Use Right Agreement, apart from the liquidated damages, IB is obliged to pay a land idling fee if the land is left idle for more than one year but less than two&#x00a0;years, and Taizhou Resources Bureau has the right to take back the land use right if the land is left idle for more than two&#x00a0;years. IB submitted the application to the People&#x2019;s Government of Zhejiang Province (the &#x201c;Zhejiang Government&#x201d;) for seeking its approval for construction on March&#x00a0;18, 2023. As of the issuance of consolidated financial statements, IB has not received the Zhejiang Government&#x2019;s approval and did not pay the penalty of RMB13,080 thousand yet. IB accrued RMB 15,145 thousand ($2,196) and RMB 21,005 thousand ($2,959) of other liabilities for the liquidated damages as of December&#x00a0;31, 2022 and 2023, and recorded RMB 7,284 thousand ($1,083) and RMB 5,860 thousand ($828) of other loss for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Litigation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, the Group may have certain contingent liabilities that arise in the ordinary course of business activities or may be a party to certain legal proceedings, as well as certain asserted and un<FONT CLASS="nobreak">-asserted</FONT> claims. The Group accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Amounts accrued, as well as the total amount of reasonably </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-51</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">17.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>COMMITMENTS AND CONTINGENCIES </FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">(cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements. As of the issuance of consolidated financial statements, the Group is not aware of any current pending legal matters or claims except for the litigation with the Taizhou Company discussed above and as set forth below:</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Innovative Biotech Co. v. Taizhou Bay New District Administrative Committee.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>On November&#x00a0;29, 2022, the Taizhou Bay New District Administrative Committee (the &#x201c;Plaintiff&#x201d;), the successor of the Taizhou Industry District Committee, filed a civil complaint to the Taizhou Court (the &#x201c;Court&#x201d;) against the Company&#x2019;s PRC subsidiary, IB, claiming that IB has materially breached the Jyong Biotechnology Herbal Medicine Project Investment Cooperation Agreement (the &#x201c;2019 Taizhou Agreement&#x201d;) by failing to initiate and conclude the construction of the Factory Project in accordance with the schedule stipulated by the 2019 Taizhou agreement and the Land Use Right Agreement. The Plaintiff requested the Court to terminate the 2019 Taizhou Agreement, and to order IB to return the government subsidy of RMB12.0&#x00a0;million ($1,690) IB previously received under the 2019 Taizhou Agreement, and to pay corresponding interests calculated at the Loan Prime Rate published by the National Inter<FONT CLASS="nobreak">-bank</FONT> Funding Center. On December&#x00a0;1, 2022, the Court issued an order of preliminary asset preservation, freezing the RMB 10,708 thousand ($1,477) deposit in IB&#x2019;s bank account. This dispute went on trial on February&#x00a0;13, 2023, and two hearings were held on May&#x00a0;6, 2023 and August&#x00a0;17, 2023, respectively. On September&#x00a0;8, 2023, the Court entered into a judgement in favor of the Plaintiff, terminating the 2019 Taizhou Agreement and ordering IB to return the government subsidy of RMB12.0&#x00a0;million ($1,690) and corresponding interest and expenses to the Plaintiff. On September&#x00a0;14, 2023, IB filed an appeal with the High People&#x2019;s Court of Zhejiang Province (the &#x201c;High Court&#x201d;) regarding each of the Court&#x2019;s rulings described above. The High Court held a hearing for this case on October&#x00a0;24, 2023. On December&#x00a0;12, 2023, the High Court issued a judgment against IB to affirm the Taizhou Court&#x2019;s ruling in its entirety. In addition, IB is required to pay litigation fees of RMB 94 thousand ($13) to the Taizhou Administrative Committee, and security fees of RMB 5 thousand ($1) and execution fees of RMB 79 thousand ($11) to the High Court. IB filed a petition for retrial to the Supreme People&#x2019;s Court of the People&#x2019;s Republic of China (the &#x201c;Supreme Court&#x201d;) on December&#x00a0;27, 2023 and accepted by the Supreme Court on January&#x00a0;9, 2024.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2022 and 2023, IB accrued an aggregate amount of RMB 13,778 thousand ($1,998) and RMB 14,293 thousand ($2,013) of other liabilities for the loss contingencies and accrued expenses for this dispute and recorded an aggregate amount of RMB 13,778 thousand ($2,048) and RMB 609 thousand ($86) of other loss and litigation expenses for the&#x00a0;years ended December&#x00a0;31, 2022 and 2023, respectively.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">18.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUBSEQUENT EVENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For litigation with the TaiZhou Company, on March&#x00a0;25, 2024, the Taizhou Court issued a judgment partially in favor of the Taizhou Company, Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited and Sira View Corp. to pay the redemption price of RMB 112,500 thousand ($16,366) and corresponding interests from August&#x00a0;20, 2019, to the date of actual payment calculated at the Loan Prime Rate published by the National Inter<FONT CLASS="nobreak">-bank</FONT> Funding Center in China, and Jyong, HEB, and Ms. Fu Feng Kuo to be jointly liable for such obligation. The Taizhou Court also ruled that the TaiZhou Company is entitled to liquidate all equity interest in Innovative Biotech pledged to it in order to realize the payment of the aforementioned obligations. Additionally, the lawyer service fees of RMB 420 thousand ($59) incurred by the Taizhou Company and litigation fees of RMB 684 thousand ($97) should be paid by Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited, Sira View Corp., Jyong, HEB, or Ms. Fu Feng Kuo. As of the issuance of consolidated financial statements, Nobel Consumer Corporation, the Company&#x2019;s related party, paid the litigation fees of RMB 684 thousand ($97) on behalf of Sira View Corp. Additionally, the Company recognized an additional contingency liabilities for RMB&#x00a0;420 thousand ($59) of litigation fees, which will be due by the end of appeal process, in the consolidated financial statements on December&#x00a0;31, 2023. The Company filed an appeal with the High People&#x2019;s Court of Zhejiang Province (the &#x201c;High Court&#x201d;) on April&#x00a0;29, 2024. The High Court held a hearing on August&#x00a0;9, 2024. On September<FONT CLASS="nobreak"> </FONT>12, 2024, the High Court issued a judgment rejecting the Company&#x2019;s petition and affirming the Taizhou Court&#x2019;s ruling in its entirety. As a result, Medi<FONT CLASS="nobreak">-life</FONT> Co., Limited and Sira View Corp., the Transferring Shareholders, shall pay the redemption price of RMB 112,500 thousand ($16,366) and corresponding interests to </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-52</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LIMITED<BR>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>(Amounts in thousand US Dollars, except for number of shares, per share data, or otherwise stated)</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">18.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUBSEQUENT EVENTS</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">buy back the Company&#x2019;s shares from the TaiZhou Company, and Jyong, HEB, and Ms. Fu Feng Kuo are jointly liable for this obligation. The Transferring Shareholders are planning to negotiate with the Taizhou Company for a settlement of this repurchase obligation in the fourth quarter of 2024. As of December<FONT CLASS="nobreak"> </FONT>31, 2023, the Company accrued corresponding liabilities to cover the joint liability for the repurchase obligation (see Note 17 for further detail), and no additional liability was required as a result of the High Court&#x2019;s judgment.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the commitment with the Taizhou Resources Bureau, on September<FONT CLASS="nobreak"> </FONT>26, 2024, the Taizhou Resource Bureaus issued a notification informing IB that it will take back the land use right from IB since the industrial land has been left idle for more than two years. However, IB has the right to request a hearing to explain the reasons for the delayed construction on the industrial land within the 5 business of receiving the notification (i.e. October<FONT CLASS="nobreak"> </FONT>10, 2024), and is planning to request a hearing by the deadline for submission. As of the issuance of consolidated financial statements, IB has not submitted the request and still retains control over the land use rights until the hearing reaches a conclusion.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For litigation with New District Administrative Committee, on January&#x00a0;5 and<FONT CLASS="nobreak"> </FONT>10, 2024, the Taizhou Court issued an order of enforcement, stipulating, among other things, freezing and assignment of IB&#x2019;s deposit in its bank account or withholding of IB&#x2019;s income up to RMB 12.0&#x00a0;million ($1,690) and corresponding interests, and the seizure, attachment and freezing of IB&#x2019;s property valued at RMB 12.0&#x00a0;million ($1,690) and corresponding interests, and restrictions on making certain high expenses by IB and related personnel. On January&#x00a0;16, 2024, the 40 mu industrial land acquired by IB was seized by the Taizhou Court, and corresponding RMB15,175 thousand ($2,137) of operating right<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-use</FONT> assets as of December&#x00a0;31, 2023. On February&#x00a0;22, 2024, RMB 11,129 thousand ($1,567) of IB&#x2019;s deposit in its bank was transferred to the Taizhou Court to repay litigation fees, security fees, and execution fees and to New District Administrative Committee to return a government subsidy. On July&#x00a0;7, 2024, the Taizhou Court issued a ruling of execution, notifying IB that it had repaid RMB 10,952 thousand ($1,542) to the Taizhou Administrative Committee by enforcing the transfer of its bank deposit and the Taizhou Administrative Committee agreed to terminate the execution as IB had no available assets to repay the remaining government subsidy of RMB 1,048 thousand ($148) and corresponding interest expenses. On August&#x00a0;21, 2024, the Supreme Court issued a decision to reject IB&#x2019;s petition for retrial and this lawsuit was concluded. As a result, IB shall return government subsidy of RMB 12.0&#x00a0;million ($1,690) and corresponding interest expenses to the Taizhou Administrative Committee. As of the issuance of consolidated financial statements, IB returned RMB 10,952 thousand ($1,542) of government subsidy to the New District Administrative Committee and the remaining subsidy of RMB 1,048 thousand ($148) and corresponding interest expenses shall be repaid when IB has assets to pay in the future.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to ASC&#x00a0;855<FONT CLASS="nobreak">-10-25-1</FONT> and ASC&#x00a0;855<FONT CLASS="nobreak">-10-55-1</FONT>, the Company considered that seizing the land use right during the subsequent period provided additional evidence that the restriction on the land use right should exist as of the balance sheet date due to the judgment made by the High Court and the insufficient deposits in IB&#x2019;s bank to compensate the required payment, even though IB had filed a petition for retrial to the Supreme People&#x2019;s Court of the People&#x2019;s Republic of China (the &#x201c;Supreme Court&#x201d;) on December&#x00a0;27, 2023. As a result, in addition to accruing other liabilities for the litigation with the Taizhou Administrative Committee, the Company reclassified the seized land use right from a right of use asset to restricted assets in the consolidated financial statements on December&#x00a0;31, 2023.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Group evaluated all events and transactions that occurred after December&#x00a0;31, 2023 up through October&#x00a0;4, 2024, which is the date that these consolidated financial statements are available to be issued, other than the events disclosed above, no other subsequent events have occurred that would require recognition or disclosure in the Company&#x2019;s consolidated financial statements.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-53</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PART&#x00a0;II</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INFORMATION NOT REQUIRED IN PROSPECTUS</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ITEM 6.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>INDEMNIFICATION OF DIRECTORS AND OFFICERS.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cayman Islands law does not limit the extent to which a company&#x2019;s articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our second amended and restated memorandum and articles of association permit indemnification of officers and directors for losses, damages, costs and expenses incurred in their capacities as such unless such losses, damages or cost arise from dishonesty, willful default or fraud which may attach to such directors or officers.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the form of indemnification agreements filed as Exhibit 10.3 to this registration statement, we will agree to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being such a director or executive officer.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The form of underwriting agreement to be filed as Exhibit 1.1 to this registration statement will also provide for indemnification of us and our officers and directors.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ITEM 7.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>RECENT SALES OF UNREGISTERED SECURITIES.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">None.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ITEM 8.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>EXHIBITS AND FINANCIAL</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> STATEMENT SCHEDULES.</FONT></P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">a)<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Exhibits</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">See Exhibit Index beginning on page&#x00a0;II<FONT CLASS="nobreak">-3</FONT> of this registration statement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The agreements included as exhibits to this registration statement contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties were made solely for the benefit of the other parties to the applicable agreement and (i)&#x00a0;were not intended to be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii)&#x00a0;may have been qualified in such agreement by disclosure that was made to the other party in connection with the negotiation of the applicable agreement; (iii)&#x00a0;may apply contract standards of &#x201c;materiality&#x201d; that are different from &#x201c;materiality&#x201d; under the applicable securities laws; and (iv)&#x00a0;were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We acknowledge that, notwithstanding the inclusion of the foregoing cautionary statements, we are responsible for considering whether additional specific disclosure of material information regarding material contractual provisions is required to make the statements in this registration statement not misleading.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">b)<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Financial Statement Schedules</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the Consolidated Financial Statements or the Notes thereto.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-1</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ITEM 9.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>UNDERTAKINGS.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions described in Item&#x00a0;6, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The undersigned registrant hereby undertakes that:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(1)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#x00a0;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&#x00a0;424(b)(1)&#x00a0;or (4)&#x00a0;or 497(h)&#x00a0;under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(2)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>For the purpose of determining any liability under the Securities Act, each post<FONT CLASS="nobreak">-effective</FONT> amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(3)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>For the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule&#x00a0;424(b)&#x00a0;as part of a registration statement relating to an offering, other than registration statements relying on Rule&#x00a0;430B or other than prospectuses filed in reliance on Rule&#x00a0;430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(4)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>For the purpose of determining any liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(i)<FONT STYLE="width: 17px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#x00a0;424;</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(ii)<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(iii)<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT>The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(iv)<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT>Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-2</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">JYONG BIOTECH LTD.<BR>EXHIBIT INDEX</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">



						 <P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Exhibit&#x00a0;No.</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Description of Exhibit</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">1.1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="ea020069620ex1-1_jyong.htm">Form of Underwriting Agreement</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex3-1_jyongbio.htm">Memorandum and Articles of Association of the Registrant, as currently in effect</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.2<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex3-2_jyongbio.htm">Form of Amended and Restated Memorandum and Articles of Association of the Registrant, effective immediately prior to the completion of this offering</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.1<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex4-1_jyongbio.htm">Registrant&#x2019;s Specimen Certificate for Ordinary Shares</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1**</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024110278/ea020069618ex5-1_jyong.htm">Opinion of Conyers Dill &amp; Pearman regarding the validity of the ordinary shares being registered and certain other legal matters</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.2**</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024110278/ea020069618ex5-2_jyong.htm">Opinion of Olsson Frank Weeda Terman Matz PC regarding the regulatory history of MCS-2 before the U.S. Food and Drug Administration (FDA).</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="ea020069620ex5-3_jyong.htm">Opinion of ZHEJIANG BONING LAW FIRM regarding certain legal matters related to litigation in PRC</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">8.1<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex8-1_jyongbio.htm">Opinion of Conyers Dill &amp; Pearman regarding certain Cayman Islands tax matters</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.1<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex10-1_jyongbio.htm">Form of Employment Agreement between the Registrant and each of its executive officers</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.2<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex10-2_jyongbio.htm">Form of Director Agreement between the Registrant and each of its directors</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.3<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex10-3_jyongbio.htm">Form of Indemnification Agreement between the Registrant and each of its directors and executive directors</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.4<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex10-4_jyongbio.htm">English Translation of Share Purchase Agreement Among Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership), Medi-life Co., Limited, Sira View Corp., Jyong Biotech Ltd., Health Ever Bio-Tech Co., Ltd., and Ms. Fu Feng Kuo in May 2019</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.5<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex10-5_jyongbio.htm">English Translation of Supplementary Agreement to Share Purchase Agreement Among Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership), Medi-life Co., Limited, Sira View Corp., Jyong Biotech Ltd., Health Ever Bio-Tech Co., Ltd., and Ms. Fu Feng Kuo in July 2019</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.6<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex10-6_jyongbio.htm">English Translation of Agreement of Cooperation Framework among Taizhou High-tech Industrial Park Management Committee, Taizhou Infrastructure Investment Group Co., Ltd. and Jyong Biotech Ltd. for New Botanical Medicines Project dated December 21, 2018</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.7<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex10-7_jyongbio.htm">English Translation of Jyong Biotechnology Herbal Medicine Project Investment Cooperation Agreement dated September 12, 2019</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.8**</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024040670/ea020069603ex10-8_jyong.htm">Loan and Mortagage Agreement between Taiwan Cooperative Bank Suao Branch and Health Ever Bio-Tech Co., Ltd.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">15.1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="ea020069620ex15-1_jyong.htm">Letter of WWC, P.C., an independent registered public accounting firm</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">21.1<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex21-1_jyongbio.htm">Significant Subsidiaries of the Registrant</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="ea020069620ex23-1_jyong.htm">Consent of WWC, P.C.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.3</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024110278/ea020069618ex5-1_jyong.htm">Consent of Conyers Dill &amp; Pearman (included in Exhibit 5.1)</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.4<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex99-2_jyongbio.htm">Consent of KPMG Law Firm (included in Exhibit 99.2)</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.5</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="ea020069620ex5-3_jyong.htm">Consent of ZHEJIANG BONING LAW FIRM (included in Exhibit 5.3)</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">24.1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="#T001">Powers of Attorney (included on signature page in Part&#x00a0;II of the registration statement)</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.1<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex99-1_jyongbio.htm">Code of Business Conduct and Ethics of the Registrant</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.2<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex99-2_jyongbio.htm">Opinion of KPMG Law Firm regarding certain Taiwan law matters</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-color:#000000;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.3<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-color:#000000;border-right-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex99-3_jyongbio.htm">Consent of Frost&#x00a0;&amp; Sullivan</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-color:#000000;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.4<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-color:#000000;border-right-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex99-4_jyongbio.htm">Consent of Fenglin Hsu</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-color:#000000;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.5<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-color:#000000;border-right-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex99-5_jyongbio.htm">Consent of Hung-Shu Fan</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-color:#000000;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.6<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-color:#000000;border-right-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex99-6_jyongbio.htm">Consent of Pang-Chief Chi</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-color:#000000;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.7<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-color:#000000;border-right-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex99-7_jyongbio.htm">Consent of Ming Tsan Hsu</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-color:#000000;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.8<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-color:#000000;border-right-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex99-8_jyongbio.htm">Request for Waiver and Representation under Item 8.A.4 of Form 20-F</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-color:#000000;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">107<FONT CLASS="CharOverride-1" STYLE="font-size:9pt;">**</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-color:#000000;border-right-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1954488/000121390024020570/ea0200696ex-fee_jyongbio.htm">Filing Fee Table</A></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<FONT STYLE="width: 24px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>To be filed by amendment.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">**<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Previously Filed.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-3</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T001"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SIGNATURES</FONT></P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act&#x00a0;of&#x00a0;1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&#x00a0;F<FONT CLASS="nobreak">-1</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in 23F<FONT CLASS="nobreak">-3</FONT>, No.<FONT CLASS="nobreak"> </FONT>95, Section&#x00a0;1, Xintai 5<FONT CLASS="CharOverride-2" STYLE="font-size:58%;vertical-align:super;">th</FONT> Road, Xizhi District, New Taipei City, Taiwan, 221, on February<FONT CLASS="nobreak"> </FONT>6, 2025.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">KNOW ALL MEN BY THESE PRESENTS</FONT>, that each person whose signature appears below constitutes and appoints Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo, his true and lawful attorney<FONT CLASS="nobreak">-in-fact</FONT> and agent, with full power of substitution and revocation, for him and in his name, place and stead, in any and all capacities (until revoked in writing), to sign any and all amendments (including post<FONT CLASS="nobreak">-effective</FONT> amendments) to this registration statement and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney<FONT CLASS="nobreak">-in-fact</FONT> and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney<FONT CLASS="nobreak">-in-fact</FONT> and agent, or her substitute, may lawfully do or cause to be done by virtue hereof. This power<FONT CLASS="nobreak">-of-attorney</FONT> does not revoke any earlier powers<FONT CLASS="nobreak">-of-attorney</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" COLSPAN="3" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Jyong Biotech Ltd.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-style:none;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-style:none;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-style:none;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Fu-Feng Kuo</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name: Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title: Chief Executive Officer</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form F<FONT CLASS="nobreak">-1</FONT> has been signed by the following persons in the capacities and on the dates indicated.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:bold;">Signature</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:bold;">Title</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-3" STYLE="font-style:normal;font-weight:bold;">Date</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Chief Executive Officer, Chairwoman of the Board</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">February<FONT CLASS="nobreak"> </FONT>6, 2025</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name: Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Directors (principal executive officer)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">* </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">February<FONT CLASS="nobreak"> </FONT>6, 2025</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name: Fenglin Hsu</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">February<FONT CLASS="nobreak"> </FONT>6, 2025</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name: Hung<FONT CLASS="nobreak">-Shu</FONT> Fan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">February<FONT CLASS="nobreak"> </FONT>6, 2025</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name: Pang<FONT CLASS="nobreak">-Chief</FONT> Chi</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">February<FONT CLASS="nobreak"> </FONT>6, 2025</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name: Ming Tsan Hsu</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Chief Financial Officer </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">February<FONT CLASS="nobreak"> </FONT>6, 2025</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name: Alfred Ying</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">(principal financial and accounting officer)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>

		</TABLE>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-style:none;padding-left:0pt;vertical-align:top;width: 3.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">*By:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-style:none;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-style:none;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">/s/ Fu-Feng Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-style:none;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-style:none;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 68.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;vertical-align:top;width: 3.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name: Fu<FONT CLASS="nobreak">-Feng</FONT> Kuo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 68.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-top:10pt;vertical-align:top;width: 3.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 25.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Attorney<FONT CLASS="nobreak">-in-fact</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 68.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-4</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</FONT></P>
		 <P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Securities Act&#x00a0;of&#x00a0;1933, the undersigned, the duly authorized representative in the United&#x00a0;States of Jyong Biotech Ltd., has signed this Registration Statement or amendment thereto in New&#x00a0;York on February<FONT CLASS="nobreak"> </FONT>6, 2025.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" COLSPAN="5" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Authorized U.S.&#x00a0;Representative Cogency Global Inc.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-style:none;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-style:none;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" COLSPAN="3" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-style:none;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 44.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Colleen A. De Vries</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Colleen A. De Vries</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice<FONT CLASS="nobreak">-President</FONT> on behalf of Cogency Global Inc.</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-5</P>



</DIV></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea020069620ex1-1_jyong.htm
<DESCRIPTION>FORM OF UNDERWRITING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jyong Biotech Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 90%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">[</FONT></TD><TD STYLE="white-space: nowrap; text-align: justify; width: 5%">]<FONT STYLE="font-family: Times New Roman, Times, Serif">, 2025</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Joseph Stone Capital, LLC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">585 Stewart Ave., Suite L60-C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Garden City, NY 11530</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>As the representative of several underwriters
named on Schedule A hereto</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned, Jyong Biotech Ltd., a Cayman Islands exempted company
(the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this &ldquo;<B>Agreement</B>&rdquo;) with Joseph Stone Capital, LLC
(the &ldquo;<B>Representative</B>&rdquo;) to issue and sell to the underwriters named on Schedule A hereto (each, an &ldquo;<B>Underwriter</B>&rdquo;
and collectively, &ldquo;<B>Underwriters</B>&rdquo;) an aggregate of [&nbsp; &nbsp; &nbsp;] ordinary shares, par value $0.00001 per share (the &ldquo;Ordinary
Shares&rdquo;), of the Company (the &ldquo;<B>Firm Shares</B>&rdquo;). The Company also agrees to issue and sell to the Underwriters not
more than an additional [&nbsp; &nbsp; &nbsp;] Ordinary Shares (the &ldquo;<B>Option Shares</B>&rdquo;), if and to the extent that the Underwriters shall
have determined to exercise the right to purchase such shares of Option Shares granted to the Underwriters. The Firm Shares and the Option
Shares are hereinafter collectively referred to as the &ldquo;<B>Securities.</B>&rdquo; The offering and sale of securities contemplated
by this Agreement is referred to herein as the &ldquo;<B>Offering</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1. </B><U>Purchase and Sale of Securities.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)  <U>Purchase
of Firm Shares</U>. On the basis of the representations and warranties herein contained, but subject to the terms and conditions herein
set forth, the Company agrees to issue and sell to the Underwriters an aggregate of [&nbsp; &nbsp; &nbsp;] Firm Shares at a purchase price (net of underwriting
discounts) of $[&nbsp; &nbsp; &nbsp;] per share (the &ldquo;<B>Purchase Price</B>&rdquo;). The Underwriters agrees to purchase from the Company the Firm
Shares set forth opposite its name on&nbsp;<U>Schedule A</U>&nbsp;attached hereto and made a part hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)  <U>Delivery
of and Payment for Firm Shares</U>. Delivery of and payment for the Firm Shares shall be made at 10:00 A.M., Eastern time, on the [&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
] <FONT STYLE="font-family: Times New Roman, Times, Serif">Business Day following the effective date of the Registration Statement (&ldquo;<B>Effective
Date</B>&rdquo;) or at such time as shall be agreed upon by the Underwriters and the Company, at the offices of VCL Law LLP (the &ldquo;<B>Underwriters&rsquo;
Counsel</B>&rdquo;) or at such other place as shall be agreed upon by the Underwriters and the Company. The hour and date of delivery
of and payment for the Firm Shares is called the &ldquo;<B>Closing Date</B>.&rdquo; The closing of the payment of the purchase price for,
and delivery of certificates representing, the Firm Shares is referred to herein as the &ldquo;<B>Closing</B>.&rdquo; Payment for the
Firm Shares shall be made on the Closing Date by wire transfer in Federal (same day) funds upon delivery to the Underwriters of certificates
(in form and substance reasonably satisfactory to the Underwriters) representing the Firm Shares (or if uncertificated through the full
fast transfer facilities of the Depository Trust Company (the &ldquo;<B>DTC</B>&rdquo;)) for the account of the Underwriters. The Firm
Shares shall be registered in such names and in such denominations as the Underwriters may request in writing at least two (2) Business
Days prior to the Closing Date. If certificated, the Company will permit the Underwriters to examine and package the Firm Shares for delivery
at least one (1) full Business Day prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Shares except
upon tender of payment by the Underwriters for all the Firm Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) <U>Option
Shares</U>. The Company hereby agrees to issue and sell to the Underwriters the Option Shares, and the Underwriters shall have the option
to purchase, severally and not jointly, in whole or in part, the Option Shares from the Company (the &ldquo;<B>Over-Allotment Option</B>&rdquo;),
in each case, at a price per share equal to the Purchase Price less an amount per share equal to any dividends or distributions declared
by the Company and payable on the Firm Shares but not payable on the Option Shares (the &ldquo;<B>Over-Allotment Option Purchase Price</B>&rdquo;).
The Company and the Underwriters agree that the Underwriters may only exercise the Over-Allotment Option for the purpose of covering over-allotments
made in connection with the offering of the Firm Shares. The Underwriters may exercise the Over-Allotment Option at any time in whole,
or from time to time in part, on or before the 45th day from the Effective Date, by giving written notice to the Company (the &ldquo;<B>Over-Allotment
Exercise Notice</B>&rdquo;). Each exercise date must be at least one (1) business day after the written notice is given and may not be
earlier than the Closing Date nor later than ten (10) business days after the date of such notice. On each day, if any, that the Option
Shares are to be purchased, each Underwriter agrees, severally and not jointly, to purchase the number of the Option Shares (subject to
such adjustments to eliminate fractional shares as the Underwriters may determine) that bears the same proportion to the total number
of the Option Shares to be purchased on such additional closing date (&ldquo;<B>Additional Closing Date</B>&rdquo;) as the number of Firm
Shares set forth in Schedule A hereto opposite the name of such Underwriter bears to the total number of the Firm Shares. The Underwriters
may cancel any exercise of the Over-Allotment Option at any time prior to the Closing Date or any Additional Closing Date, as the case
may be, by giving written notice of such cancellation to the Company. The Over-Allotment Exercise Notice shall set forth: (i) the aggregate
number of Option Shares as to which the Over-Allotment Option is being exercised; (ii) the Over-Allotment Option Purchase Price; (iii)
the names and denominations in which the Option Shares are to be registered; and (iii) any Additional Closing Date. Payment for the Option
Shares shall be made, against delivery of the Option Shares to be purchased, by wire transfer in immediately available funds to the account(s)
specified by the Company to the Underwriters at least one (1) business day in advance of such payment at the office of VCL Law LLP on
any Additional Closing Date, or at such other place on the same or such other date and time, as shall be designated in writing by the
Underwriters. Delivery of the Option Shares shall be made through the facilities of DTC, unless the Underwriters shall otherwise instruct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>2.</B> &nbsp;<U>Representations
and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Applicable Time (as defined below)
and as of the Closing Date and the applicable Additional Closing Date, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<U>Filing of Registration
Statement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(i) &nbsp;<U>Pursuant
to the Act</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(A)  The
Company has filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a registration statement and an amendment
or amendments thereto, on Form F-1 (File No. 333- 277725), including any related prospectus or prospectuses, for the registration of the
Securities under the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;), which registration statement and amendment or
amendments have been prepared by the Company and conform, in all material respects, with the requirements of the Act and the rules and
regulations of the Commission under the Act (the &ldquo;<B>Regulations</B>&rdquo;). Except as the context may otherwise require, such
registration statement on file with the Commission at the time the registration statement becomes effective (including the prospectus,
financial statements, schedules, exhibits and all other documents filed as a part thereof or incorporated therein and all information
deemed to be a part thereof as of the Effective Date pursuant to paragraph (b) of Rule 430A of the Regulations), is referred to herein
as the &ldquo;<B>Registration Statement</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(B)  The
prospectus to be filed pursuant to Rule 424(b) under the Act after the execution and delivery of this Agreement by the parties hereto,
or, if no filing pursuant to Rule 424(b) under the Act is required, the prospectus relating to the Offering included in the Registration
Statement at the effective date of the Registration Statement, is hereinafter called the &ldquo;<B>Prospectus</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(C)  The
Registration Statement has been declared effective by the Commission on or prior to the date hereof. &ldquo;<B>Applicable Time</B>&rdquo;
means [&nbsp; &nbsp; &nbsp;] p.m. Eastern Time, on [&nbsp;&nbsp;&nbsp;&nbsp;]<FONT STYLE="font-family: Times New Roman, Times, Serif">, 2024, or such other time as agreed
to by the Company and the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii) <U>Registration under
the Exchange Act</U>. The Securities are registered pursuant to Section 12(b) of the Securities Exchange Act of 1934 (the &ldquo;<B>Exchange
Act</B>&rdquo;), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the
Securities under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such
registration except as described in the Registration Statement and Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(iii) <U>Listing on Nasdaq</U>.
The Securities have been approved for listing on the Nasdaq Global Market (&ldquo;<B>Nasdaq</B>&rdquo;) by the Closing Date and any Additional
Closing Date, subject to official notice of issuance, and the Company has taken no action designed to, or likely to have the effect of,
terminating the listing of the Securities on Nasdaq nor has the Company received any notification that Nasdaq is contemplating revoking
or withdrawing approval for listing of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)  <U>No
Stop Orders, etc</U>. Neither the Commission nor, to the best of the Company&rsquo;s knowledge, any state regulatory authority has issued
any order preventing or suspending the use of any preliminary prospectus (&ldquo;<B>Preliminary Prospectus</B>&rdquo;), the Prospectus
or the Registration Statement or has instituted or, to the best of the Company&rsquo;s knowledge, threatened to institute any proceedings
with respect to such an order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)  <U>Disclosures
in Registration Statement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i) &nbsp;<U>10b-5 Representation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(A)  The
Registration Statement, the Disclosure Materials, and the Prospectus and any post-effective amendments thereto will in all material respects
comply with the requirements of the Act and the Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(B)  The
Registration Statement, when it became effective, and any amendment or supplement thereto, did not contain and, at the Closing Date and
any Additional Closing Date, will not contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading,
and the Prospectus when filed with the Commission does not contain and, at the Closing Date and any Additional Closing Date, will not
contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading. The representation and warranty made
in this&nbsp;<U>Section 2(c)(i)(B)</U>&nbsp;does not apply to statements made or statements omitted in reliance upon and in conformity
with written information with respect to the Underwriters furnished to the Company by the Underwriters expressly for use in the Registration
Statement or Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree that such information provided
by or on behalf of any of the Underwriters consists solely of the Underwriters&rsquo; names (collectively, the &ldquo;<B>Underwriters&rsquo;
Information</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(C)  Any
issuer free writing prospectus(es) as defined in Rule 433 of the Regulations (the &ldquo;<B>Issuer Free Writing Prospectus</B>&rdquo;)
and Preliminary Prospectus(es), when taken together as a whole with the Prospectus (collectively, the &ldquo;<B>Disclosure Materials</B>&rdquo;),
do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The preceding sentence does not apply to statements in or
omissions from the Disclosure Materials based upon and in conformity with the Underwriters&rsquo; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii) <U>Prior Securities
Transactions</U>. No securities of the Company have been sold by the Company or by or on behalf of, or for the benefit of, any person
or persons controlling, controlled by, or under common control with the Company, except as disclosed in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)  <U>Changes
After Dates in Registration Statement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i) &nbsp;<U>No Material
Adverse Change</U>. Since the end of the period covered by the latest audited financial statements included in the Registration Statement,
the Disclosure Materials, and the Prospectus, and except as otherwise specifically stated therein: (A) there have been no events, individually
or in the aggregate, that have occurred that would have a material adverse effect on the assets, business, conditions, financial position,
results of operations or business prospects of the Company and its Subsidiaries (as defined below), taken as a whole, or the ability of
the Company to perform its obligations under this Agreements, including the issuance and sale of the Securities, or to consummate the
transactions contemplated in the Registration Statement, the Disclosure Materials, and the Prospectus (each of such effects and changes
a &ldquo;<B>Material Adverse Effect</B>&rdquo; and a &ldquo;<B>Material Adverse Change</B>,&rdquo; respectively); and (B) there have been
no material transactions entered into by the Company not in the ordinary course of business, other than as contemplated pursuant to this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii) <U>Recent Securities
Transactions, etc</U>. Since the end of the period covered by the latest audited financial statements or interim financial statements
included in the Registration Statement, the Disclosure Materials, and the Prospectus, and except as may otherwise be indicated or contemplated
herein or disclosed in the Registration Statement and the Prospectus, the Company has not, other than with respect to options to purchase
ordinary shares at an exercise price equal to the then fair market price of the ordinary shares, as determined by the Company&rsquo;s
board of directors, granted to employees, consultants or service providers: (A) issued any securities or incurred any material liability
or obligation, direct or contingent, for borrowed money other than in the ordinary course of business; or (B) declared or paid any dividend
or made any other distribution on or in respect to its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)  <U>Independent
Accountants</U>. To the best of the Company&rsquo;s knowledge, WWC, P.C., whose report is filed with the Commission as part of the Registration
Statement, are independent registered public accountants as required by the Act and the Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) <U>Financial
Statements, etc</U>. The financial statements, including the notes thereto and supporting schedules included in the Registration Statement,
the Disclosure Materials, and Prospectus fairly present the financial position and the results of operations of the Company at the dates
and for the periods to which they apply; and such financial statements have been prepared in conformity with United States generally accepted
accounting principles (&ldquo;<B>GAAP</B>&rdquo;), consistently applied throughout the periods involved except as disclosed therein; and
the supporting schedules included in the Registration Statement present fairly the information required to be stated therein. The Registration
Statement discloses all material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other
relationships of the Company with unconsolidated entities or other persons that may have a material current or future effect on the Company&rsquo;s
financial condition, changes in financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant
components of revenues or expenses. Except as disclosed in the Registration Statement, the Disclosure Materials, and the Prospectus, (i)
neither the Company nor any of its subsidiaries (each a &ldquo;<B>Subsidiary</B>&rdquo; and collectively, &ldquo;<B>Subsidiaries</B>&rdquo;),
has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the
ordinary course of business, (ii) the Company has not declared or paid any dividends or made any distribution of any kind with respect
to its capital stock; (iii) there has not been any change in the capital stock of the Company or any of its Subsidiaries or any grants
under any stock compensation plan and, (iv) there has not been any material adverse change in the Company&rsquo;s long-term or short-term
debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g) <U>Authorized
Capital; Options, etc</U>. The Company had the duly authorized, issued and outstanding capitalization as set forth in the Registration
Statement, the Disclosure Materials, and the Prospectus. Based on the assumptions stated in the Registration Statement, the Disclosure
Materials, and the Prospectus, the Company will have on the Closing Date and any Additional Closing Date the adjusted capitalization set
forth therein. Except as set forth in, or contemplated by, this Agreement, the Registration Statement, the Disclosure Materials, and the
Prospectus, on the Effective Date, the Closing Date, and any Additional Closing Date, there will be no options, warrants, or other rights
to purchase or otherwise acquire any authorized, but unissued share capital of the Company or any security convertible into share capital
of the Company, or any contracts or commitments to issue or sell shares or any such options, warrants, rights or convertible securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)  <U>Valid
Issuance of Securities, etc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i) &nbsp;<U>Outstanding
Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement have
been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission with respect
thereto, and are not subject to personal liability by reason of being such holders; and none of such securities were issued in violation
of the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii) <U>Securities Sold
Pursuant to this Agreement</U>. The Securities have been duly authorized for issuance and sale and, when issued and paid for, will be
validly issued, fully paid and non-assessable; the Securities are not and will not be subject to the preemptive rights of any holders
of any security of the Company or similar contractual rights granted by the Company; and all corporate action required to be taken for
the authorization, issuance and sale of the foregoing Securities has been duly and validly taken. The Securities conform in all material
respects to all statements with respect thereto contained in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(iii) <U>Issuance of Securities</U>.
Upon issuance of Securities, and subject to full payment thereof by the Underwriters in accordance with the terms thereof, such Securities
will be duly and validly issued, and the persons in whose names the Securities are registered will be entitled to the rights specified
in the Securities, and upon the sale and delivery of these Securities, and payment therefor, pursuant to this Agreement, the purchasers
will acquire good, marketable and valid title to such Securities, free and clear of all pledges, liens, security interests, charges, claims
or encumbrances of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i) &nbsp;<U>Registration
Rights of Third Parties</U>. Except as set forth in the Registration Statement, the Disclosure Materials, and the Prospectus, no holders
of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities of the Company have the
right to require the Company to register any such securities of the Company under the Act or to include any such securities in a registration
statement to be filed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(j) <U>Validity
and Binding Effect of This Agreement</U>. This Agreement has been duly and validly authorized by the Company, and, when executed and delivered,
will constitute, the valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except:
(i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights
generally; (ii) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities
laws; and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable
defenses and to the discretion of the court before which any proceeding therefore may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k)  <U>No
Conflicts.</U>&nbsp;The execution, delivery, and performance by the Company of this Agreement, the consummation by the Company of the
transactions herein and therein contemplated and the compliance by the Company with the terms hereof do not and will not, with or without
the giving of notice or the lapse of time or both: (i) result in a material breach of, or conflict with any of the terms and provisions
of, or constitute a material default under, or result in the creation, modification, termination or imposition of any lien, charge or
encumbrance upon any property or assets of the Company pursuant to the terms of any agreement or instrument to which the Company is a
party; (ii) result in any violation of the provisions of the Company&rsquo;s amended and restated memorandum and articles of association
or bylaws (as the same may be amended from time to time, the &ldquo;<B>Charter</B>&rdquo;); or (iii) violate any existing applicable law,
rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company
or any of its properties or business constituted as of the date hereof, except such violation or breach that would not reasonably be expected
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(l) <U>No
Defaults; Violations</U>. No default exists in the due performance and observance of any term, covenant or condition of any material license,
contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other material agreement or instrument evidencing
an obligation for borrowed money, or any other material agreement or instrument to which the Company is a party or by which the Company
may be bound or to which any of the properties or assets of the Company is subject, except for such defaults that would not, singly or
in the aggregate, result in a Material Adverse Effect to the Company and its Subsidiaries, taken as a whole, and that are not otherwise
disclosed in the Disclosure Materials. The Company is not in violation of any term or provision of its Charter, or in violation in any
respect of any franchise, license, permit, applicable law, rule, regulation, judgment or decree of any governmental agency or court, domestic
or foreign, having jurisdiction over the Company or any of its properties or businesses, except for such defaults that would not, singly
or in the aggregate, result in a Material Adverse Effect to the Company and its Subsidiaries, taken as a whole, and that are not otherwise
disclosed in the Disclosure Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(m) <U>Corporate
Power; Licenses; Consents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i) &nbsp;<U>Conduct of
Business</U>. Except as described in the Registration Statement, the Disclosure Materials, and the Prospectus, the Company has all requisite
corporate power and authority, and has all necessary authorizations, approvals, orders, licenses, certificates and permits of and from
all governmental regulatory officials and bodies that it needs as of the date hereof to conduct its business purpose as described in the
Prospectus except, any non-compliance, in each case, would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii) <U>Transactions Contemplated
Herein</U>. The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions and conditions
hereof and thereof, and all consents, authorizations, approvals and orders required in connection therewith have been obtained. No consent,
authorization or order of, and no filing with, any court, government agency or other body is required for the valid issuance, sale and
delivery of the Securities and the consummation by the Company of the transactions and agreements contemplated by this Agreement and as
contemplated by the Prospectus, except with respect to applicable federal and state securities laws and the rules and regulations of the
Financial Industry Regulatory Authority, Inc. (&ldquo;<B>FINRA</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(n)  <U>D&amp;O
Questionnaires</U>. All information contained in the questionnaires (the &ldquo;<B>Questionnaires</B>&rdquo;) completed by each of the
Company&rsquo;s directors and officers named in the section &ldquo;Management&rdquo; in the Prospectus and the beneficial owners of five
percent (5%) or greater of the Company&rsquo;s ordinary shares or securities convertible into ordinary shares immediately prior to the
Offering (the &ldquo;<B>Insiders</B>&rdquo;) as well as in the Lock-Up Agreement in the form attached hereto as&nbsp;<U>Annex IV</U>&nbsp;provided
to the Underwriters is true and correct in all respects and the Company has not become aware of any information which would cause the
information disclosed in the questionnaires completed by each Insider to become inaccurate and incorrect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(o)  <U>Litigation;
Governmental Proceedings</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding
pending or threatened against, or involving the Company or any executive officer or director that has not been disclosed in the Registration
Statement, the Disclosure Materials, and the Prospectus or in connection with the Company&rsquo;s listing application for the listing
of the Securities on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(p)  <U>Good
Standing</U>. The Company has been duly incorporated, is validly existing and is in good standing under the laws of the Cayman Islands
as of the date hereof, and is duly qualified to do business and is in good standing in each jurisdiction in which the conduct of business
requires such qualification, except where the failure to qualify would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(q)  <U>Transactions
Affecting Disclosure to FINRA</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i) &nbsp;<U>Finder&rsquo;s
Fees</U>. Except as described in the Registration Statement and the Prospectus, there are no claims, payments, arrangements, agreements
or understandings relating to the payment of a finder&rsquo;s, consulting or origination fee by the Company or any Insider with respect
to the sale of the Securities hereunder or any other arrangements, agreements or understandings of the Company or, to the best of the
Company&rsquo;s knowledge, any of its shareholders that may affect the Underwriters&rsquo; compensation, as determined by FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii) <U>Payments
Within Twelve (12) Months</U>. Except as described in the Registration Statement and the Prospectus, the Company has not made any direct
or indirect payments (in cash, securities or otherwise) to: (A) any person, as a finder&rsquo;s fee, consulting fee or otherwise, in consideration
of such person raising capital for the Company or introducing to the Company persons who raised or provided capital to the Company; (B)
to any FINRA member; or (C) to any person or entity that has any direct or indirect affiliation or association with any FINRA member,
within the twelve months prior to the Effective Date<FONT>, other than the prior payment of US$45,000
to the Underwriters</FONT></FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">, as provided hereunder in connection
with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(iii) <U>FINRA Affiliation</U>.
To the best of the Company&rsquo;s knowledge, and except as may have been previously disclosed in writing to the Underwriters, no Insider
or any beneficial owner of 10% or more of the Company&rsquo;s outstanding ordinary shares has any direct or indirect affiliation or association
with any FINRA member (as determined in accordance with the rules and regulations of FINRA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(r) <U>Foreign
Corrupt Practices Act</U>. Neither the Company nor any of Subsidiaries, nor any director or officer of the Company or any of its Subsidiaries
nor, to the best knowledge of the Company, any agent, employee, affiliate or other person associated with or acting on behalf of the Company
or any of its Subsidiaries has (i) made, offered, promised or authorized any unlawful contribution, gift, entertainment or other unlawful
expense (or taken any act in furtherance thereof), (ii) made, offered, promised or authorized any direct or indirect unlawful payment
or (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or the rules and regulations
thereunder, or any other applicable anti-corruption, anti-bribery or related law, statute or regulation (collectively, &ldquo;Anti-Corruption
Laws&rdquo;); the Company and its Subsidiaries have conducted their businesses in compliance with Anti-Corruption Laws and have instituted
and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws
and with the representations and warranties contained herein; neither the Company nor any of its Subsidiaries will use, directly or indirectly,
the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money,
or anything else of value, to any person in violation of Anti-Corruption Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(s) <U>Officers&rsquo;
Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to Underwriters or to Underwriters&rsquo;
Counsel shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(t) <U>Lock-Up
Period.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i) &nbsp;Each Insider
and their affiliated parties shall not offer, pledge, sell, contract to sell, grant, lend or otherwise transfer or dispose of, directly
or indirectly, any Securities or capital stock of the Company, including ordinary shares, or any securities convertible into or exercisable
or exchangeable for such Securities or capital stock without the consent of the Representative, with certain exceptions, pursuant to executed
lock-up agreements in the form attached hereto as Annex IV (the &ldquo;<B>Lock-Up Agreements</B>&rdquo;) for a period of twelve (12) months
from the date of commencement of sales of this Offering. Each of the beneficial owners of less than 5% of the Company&rsquo;s ordinary
shares or securities convertible into ordinary shares immediately prior to the Offering has agreed to enter into the Lock-Up Agreements
for a period of six (6) months from the date of commencement of sales of this Offering. The twelve months lock-up periods and the six
months lock-up periods are collectively referred to as the &ldquo;<B>Lock-Up Periods</B>.&rdquo; The parties subject to the Lock-Up Agreements
are collectively referred to as the &ldquo;<B>Lock-Up Parties</B>&rdquo;. The Representative may consent to an early release from the
applicable Lock-Up Period if, in its opinion, the market for the Securities would not be adversely impacted by sales and in cases of financial
emergency of a Lock-Up Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii) The Company, on behalf of
itself and any successor entity, has agreed that, without the prior written consent of the Representative, it will not, for a period of
twelve (12) months from the closing date of this Offering, (A) offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly
or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares
of capital stock of the Company; (B) file or cause to be filed any registration statement with the Commission relating to the offering
of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital
stock of the Company or (C) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of capital stock of the Company, whether any such transaction described in clause (A), (B) or (C) above is to
be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise. The restrictions contained
in this&nbsp;<U>Section 2(t)(ii)</U>&nbsp;shall not apply to (D) the Securities to be sold hereunder, (E) the issuance by the Company
of Securities upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof of, provided that
the Underwriters have been advised in writing of such issuance prior to the date hereof, (F) the issuance by the Company of option to
purchase or shares of Securities, capital stock or restricted stock of the Company under any stock compensation plan of the Company outstanding
on the date hereof, or (iv) any registration statement on Form S-8. For purposes of subclause (E) in this paragraph, the Underwriters
acknowledge that disclosure in the Registration Statement filed prior to the date hereof of any outstanding option or warrant shall be
deemed to constitute prior written notice to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(u)  <U>Subsidiaries</U>.
Exhibit 21.1 of the Registration Statement lists all the Subsidiaries and sets forth the ownership of all of the Subsidiaries. The Subsidiaries
are duly organized and in good standing under the laws of the place of organization or incorporation, and each such Subsidiary is in good
standing in each jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except
where the failure to qualify would not reasonably be expected to have a Material Adverse Effect. The Company&rsquo;s ownership and control
of each Subsidiary and each Subsidiary&rsquo;s ownership and control of other Subsidiary, is as described in the Registration Statement,
the Disclosure Materials and the Prospectus. The Company does not own or control, directly or indirectly, any corporation, association
or entity other than the Subsidiaries described in the Registration Statement, the Disclosure Materials and the Prospectus. Each of the
Company and its Subsidiaries has full corporate power and authority to own or lease, as the case may be, and to operate its properties
and conduct its business as described in the Registration Statement, the Disclosure Materials, and the Prospectus, and is duly qualified
to do business under the laws of each jurisdiction which requires such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(v)  <U>Related
Party Transactions</U>. Except as disclosed in the Registration Statement the Disclosure Materials, and the Prospectus, there are no business
relationships or related party transactions involving the Company or any other person required to be described in the Prospectus that
have not been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(w)  <U>Board
of Directors</U>. The Board of Directors of the Company is comprised of the persons set forth under the heading of the Prospectus captioned
&ldquo;Management.&rdquo; The qualifications of the persons serving as board members and the overall composition of the board comply with
the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder applicable to the Company and the rules of Nasdaq. At least one member
of the Board of Directors of the Company qualifies as an &ldquo;audit committee financial expert&rdquo; as such term is defined under
the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder and the rules of Nasdaq. In addition, at least a majority of the persons
serving on the Board of Directors qualify as &ldquo;independent&rdquo; as defined under the rules of the Commission and Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(x) <U>Sarbanes-Oxley
Compliance</U>. Except as described in the Registration Statement, the Disclosure Materials, and the Prospectus, the Company has taken
all necessary actions to ensure that, on the Effective Date, will be in material compliance with the provisions of the Sarbanes-Oxley
Act of 2002 applicable to it and has implemented or will implement such programs and taken reasonable steps to ensure the Company&rsquo;s
future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all the material provisions of the Sarbanes-Oxley
Act of 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(y)  <U>No
Investment Company Status</U>. The Company is not and, after giving effect to the Offering and sale of the Securities and the application
of the net proceeds thereof as described in the Registration Statement the Disclosure Materials, and the Prospectus, will not be, an &ldquo;investment
company&rdquo; as defined in the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(z) <U>No
Labor Disputes</U>. No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the best of the Company&rsquo;s
knowledge, is imminent, which would result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(aa)  &nbsp;<U>Intellectual
Property</U>. Except as described in the Registration Statement and the Prospectus, the Company and each of its Subsidiaries owns or possesses
or has valid rights to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service
mark registrations, copyrights, licenses, inventions, trade secrets and similar rights (&ldquo;<B>Intellectual Property</B>&rdquo;) necessary
for the conduct of the business of the Company and its Subsidiaries as currently carried on and as described in the Registration Statement
and the Prospectus, except for such Intellectual Property, the failure of which to own or possess, as the case may be, would not reasonably
be expected to result in a Material Adverse Effect. To the best of the Company&rsquo;s knowledge, no action or use by the Company or any
of its Subsidiaries will involve or give rise to any infringement of, or material license or similar fees for, any Intellectual Property
of others, that would reasonably be expected to have a Material Adverse Effect on the Company and the Subsidiaries, taken as a whole,
except as disclosed in the Registration Statement. Neither the Company nor any of its Subsidiaries has received any notice alleging any
such infringement or fee, except such infringement or fee that would not reasonably be expected to have a Material Adverse Effect on the
Company or the Subsidiaries, taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(bb)  &nbsp;<U>Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i)  &nbsp;Each of the
Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing authorities prior to the
date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and its Subsidiaries has paid all taxes
(as hereinafter defined) shown as due on such returns that were filed and has paid all material taxes imposed on or assessed against the
Company or such Subsidiary. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration
Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, for all periods to and including the dates of such
consolidated financial statements. Except as disclosed in writing to the Underwriters and to the knowledge of the Company, (A) no material
issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as
due from the Company or its Subsidiaries, and (B) no waivers of statutes of limitation with respect to the returns or collection of taxes
have been given by or requested from the Company or its Subsidiaries. The term &ldquo;<B>taxes</B>&rdquo; mean all federal, state, local,
foreign, and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service,
service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties
or other taxes, fees, assessments, or charges of any kind whatever, together with any interest and any penalties, additions to tax, or
additional amounts with respect thereto. The term &ldquo;<B>returns</B>&rdquo; means all returns, declarations, reports, statements, and
other documents required to be filed with relevant taxing authorities in respect to taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii)  &nbsp;Except as disclosed
in the Registration Statement, the Disclosure Materials, and Prospectus, no transaction, stamp, capital or other issuance, registration,
transaction, transfer or withholding taxes or duties are payable in the People&rsquo;s Republic of China (the &ldquo;<B>PRC</B>&rdquo;),
the Republic of China (the &ldquo;<B>ROC</B>&rdquo;) or the Cayman Islands to any PRC, ROC, or Cayman Islands taxing authority in connection
with (A) the issuance, sale and delivery of the Securities to or for the account of the purchasers, and (B) the purchase from the Company
and the sale and delivery of the Securities to purchasers thereof</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(cc)  &nbsp;<U>Data</U>.
The statistical, industry-related and market-related data included in the Registration Statement the Disclosure Materials, and the Prospectus
are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, and such data
agree with the sources from which they are derived. The Company has obtained the written consent to the use of such data from such sources
to the extent necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(dd)  The
Company&rsquo;s Board of Directors has validly appointed an audit committee whose composition satisfies the requirements of the rules
and regulations of Nasdaq and the Board of Directors and/or audit committee has adopted a charter that satisfies the requirements of the
rules and regulations of Nasdaq. Except as described in the Registration Statement the Disclosure Materials, and the Prospectus, neither
the Board of Directors nor the audit committee has been informed, nor is any director of the Company aware, of any significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the Company&rsquo;s ability to record, process, summarize and report financial information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ee)  &nbsp;Neither
the Company nor the Subsidiaries has, prior to the date hereof, made any offer or sale of any securities which are required to be &ldquo;integrated&rdquo;
pursuant to the Act or the Regulations with the offer and sale of the Underwriters pursuant to the Registration Statement. Except as disclosed
in the Registration Statement, neither the Company nor the Subsidiaries has sold or issued any ordinary shares or any securities convertible
into, exercisable or exchangeable for ordinary shares, or other equity securities, or any rights to acquire any ordinary shares or other
equity securities of the Company, during the six-month period preceding the date of the Prospectus, including but not limited to any sales
pursuant to Rule 144A or Regulation D or S under the Act, other than ordinary shares issued pursuant to employee benefit plans, qualified
stock option plans or the employee compensation plans or pursuant to outstanding options, rights or warrants as described in the Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ff)  &nbsp;<U>Money
Laundering</U>. The operations of the Company and the Subsidiaries are and have been conducted at all times in all material respects in
compliance with applicable financial recordkeeping and reporting requirements of money laundering statutes and the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively,
the &ldquo;<B>Money Laundering Laws</B>&rdquo;) and no action, suit or proceeding by or before any court or governmental agency, authority
or body or any arbitrator involving the Company, or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to
the best of the Company&rsquo;s knowledge, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(gg)  &nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any of its Subsidiaries, nor any director or officer of the Company or any of its
Subsidiaries nor, to the knowledge of the Company, any agent, employee, affiliate or other person associated with or acting on behalf
of the Company or any of its Subsidiaries is (A) currently the subject or the target of any sanctions administered or enforced by the
U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;OFAC&rdquo;),
or the U.S. Department of State and including, without limitation, the designation as a &ldquo;specially designated national&rdquo; or
&ldquo;blocked person,&rdquo; the European Union, His Majesty&rsquo;s Treasury, the United Nations Security Council, or other relevant
sanctions authority (collectively, &ldquo;Sanctions&rdquo;), (B) located, organized, or resident in a country or territory that is the
subject or target of comprehensive Sanctions (a &ldquo;Sanctioned Jurisdiction&rdquo;), and the Company will not directly or indirectly
use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture
partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding,
is the subject or the target of Sanctions or with a Sanctioned Jurisdiction (ii) in any other manner that will result in a violation by
any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions;
neither the Company nor any of its Subsidiaries is engaged in, or has, at any time in the past five years, engaged in, any dealings or
transactions with or involving any individual or entity that was or is, as applicable, at the time of such dealing or transaction, the
subject or target of Sanctions or with any Sanctioned Jurisdiction; the Company and its Subsidiaries have instituted, and maintain, policies
and procedures designed to promote and achieve continued compliance with Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(hh)  &nbsp;<U>No
Immunity</U>. None of the Company, its Subsidiaries, or any of its or their properties or assets has any immunity from the jurisdiction
of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution
or otherwise) under the laws of the Cayman Islands, PRC, ROC, New York or United States federal law; and, to the extent that the Company,
its Subsidiaries, or any of their respective properties, assets or revenues may have or may hereafter become entitled to any such right
of immunity in any such court in which proceedings may at any time be commenced, each of the Company and its Subsidiaries waives or will
waive such right to the extent permitted by law and has consented to such relief and enforcement under New York law as provided under
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)  &nbsp;<U>Free
Transferability of Dividends or Distributions</U>. Except as disclosed in the Disclosure Materials, Registration Statement and Prospectus
all dividends and other distributions declared and payable on the Ordinary Shares may under current Cayman Islands, PRC and ROC law and
regulations be paid to the holders of Securities in United States dollars and may be converted into foreign currency that may be transferred
out of the Cayman Islands, PRC and ROC in accordance with, and all such payments made to holders thereof or therein who are non-residents
of the Cayman Islands, PRC or ROC, will not be subject to income, withholding or other taxes under, the laws and regulations of the Cayman
Islands, PRC and ROC, or any political subdivision or taxing authority thereof or therein and will otherwise be free and clear of any
other tax, duty, withholding or deduction in the Cayman Islands, PRC and ROC or any political subdivision or taxing authority thereof
or therein and without the necessity of obtaining any governmental authorization in the Cayman Islands, PRC and ROC or any political subdivision
or taxing authority thereof or therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(jj)  &nbsp;<U>Not
a PFIC</U>. Except as disclosed in the Disclosure Materials, Registration Statement and Prospectus, the Company does not expect that it
will be treated as a Passive Foreign Investment Company (&ldquo;<B>PFIC</B>&rdquo;) within the meaning of Section 1297 of the United States
Internal Revenue Code of 1986, as amended, for its current taxable year. The Company has no plan or intention to operate in such a manner
that would reasonably be expected to result in the Company becoming a PFIC in future taxable years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(kk)  <U>PRC
Representation and Warranties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i) &nbsp;<U>Organization</U>.
All Subsidiaries established in the PRC <FONT STYLE="color: #231F20">are duly organized under the laws of the PRC and possess all necessary
business licenses, approvals, permits or other authorizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii) <U>Dividends and Distributions</U>.
Except as disclosed in the Disclosure Materials, Registration Statement and the Prospectus, no Subsidiary of the Company is currently
prohibited or restricted, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such
Subsidiary&rsquo;s capital stock, from repaying to the Company any loans or advances to such Subsidiary from the Company or from transferring
any of such Subsidiary&rsquo;s property or assets to the Company or any other Subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(iii) <U>Compliance with
SAFE Regulations</U>. The Company has taken all reasonable steps to cause all of the Company&rsquo;s shareholders and option holders who
are residents or citizens of the PRC, to comply with any applicable rules and regulations of the State Administration of Foreign Exchange
(<B>SAFE</B>) relating to such shareholders&rsquo; and option holders&rsquo; shareholding with the Company (the &ldquo;<B>SAFE Rules and
Regulations</B>&rdquo;), including, without limitation, taking reasonable steps to require each shareholder or option holder that is,
or is directly or indirectly owned or controlled by, a resident or citizen of the PRC to complete any registration and other procedures
required under applicable SAFE Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(iv) &nbsp;<U>M&amp;A and
China Securities Regulatory Commission Rules</U>. The Company is aware of and has been advised as to the content of the Rules on Mergers
and Acquisitions of Domestic Enterprises by Foreign Investors jointly promulgated by the Ministry of Commerce, the State Assets Supervision
and Administration Commission, the State Tax Administration, the State Administration of Industry and Commerce, the China Securities Regulatory
Commission (&ldquo;<B>CSRC&rdquo;</B>) and SAFE on August 8, 2006 and amended on June 22, 2009 (the &ldquo;<B>M&amp;A Rules</B>&rdquo;),
in particular the relevant provisions thereof that purport to require offshore special purpose vehicles formed for the purpose of obtaining
a stock exchange listing outside of the PRC and controlled directly or indirectly by companies or natural persons of the PRC, to obtain
the approval of the CSRC prior to the listing and trading of their securities on a stock exchange located outside of the PRC; the Company
has received legal advice specifically with respect to the M&amp;A Rules from its PRC counsel and based on such legal advice, the Company
confirms with the Underwriters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(A) Except
as disclosed in the Disclosure Materials, Registration Statement and the Prospectus, the issuance and sale of the Securities, the listing
and trading of the Securities on Nasdaq and the consummation of the transactions contemplated by this Agreement are not and will not be,
as of the date hereof or on the Closing Date, affected by the M&amp;A Rules or any official clarifications, guidance, interpretations
or implementation rules in connection with or related to the M&amp;A Rules, including the guidance and notices issued by the CSRC on September
8 and September 21, 2006, as amended (collectively, the &ldquo;<B>M&amp;A Rules and Related Clarifications</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(B) Except
as disclosed in the Disclosure Materials, Registration Statement and the Prospectus, as of the date hereof, the M&amp;A Rules and Related
Classifications did not and do not require the Company to obtain the approval of the CSRC prior to the issuance and sale of the Securities,
the listing and trading of the Securities on Nasdaq, or the consummation of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(v) &nbsp;<U>Securities
Offering and Listing Rules</U>. The Company represents and warrants to the Underwriters that this Offering or the listing of the Company&rsquo;s
securities on Nasdaq is not subject to the Trial Administrative Measures of the Overseas Securities Offering and Listing by Domestic Companies
(the &ldquo;Trial Measures&rdquo;) and related regulations, rules or guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ll)  <U>Foreign
Private Issuer Status</U>. The Company is a &ldquo;foreign private issuer&rdquo; within the meaning of Rule 405 under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(mm) <U>Choice
of Law</U>. Except as disclosed in the Registration Statement, the Disclosure Materials, and the Prospectus, the choice of law provision
set forth in this Agreement constitutes a legal and valid choice of law under the laws of the Cayman Islands, PRC and ROC. The Company
has the power to submit, and pursuant&nbsp;<U>to Section 14</U>&nbsp;of this Agreement, has legally, validly, effectively and submitted,
to the personal jurisdiction of each of the New York Courts, and the Company has the power to designate, appoint and authorize, and pursuant
to&nbsp;<U>Section 14</U>&nbsp;of this Agreement, has legally, validly, effectively and irrevocably designated, appointed an authorized
agent for service of process in any action arising out of or relating to this Agreement, or the Securities in any New York Court, and
service of process effected on such authorized agent will be effective to confer valid personal jurisdiction over the Company as provided
in&nbsp;<U>Section 14</U>&nbsp;of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(nn)  &nbsp;<U>Recognition
of Judgments</U>.&nbsp;Except as described under the section &ldquo;Enforceability of Civil Liabilities&rdquo; in the Registration Statement
and the Prospectus, the courts of the Cayman Islands, PRC and ROC would recognize as a valid judgment any final monetary judgment obtained
against the Company in the courts of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(oo)  &nbsp;<U>MD&amp;A</U>.
The section entitled &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</I>&rdquo;
in the Preliminary Prospectus included in the Disclosure Materials and the Prospectus accurately and fully describes in all material respects
(i) accounting policies that the Company believes are the most important in the portrayal of the Company&rsquo;s financial condition and
results of operations and that require management&rsquo;s most difficult, subjective or complex judgments (&ldquo;<B>Critical Accounting
Policies</B>&rdquo;); (ii) judgments and uncertainties affecting the application of the Critical Accounting Policies; and (iii) the likelihood
that materially different amounts would be reported under different conditions or using different assumptions and an explanation thereof;
and the Company&rsquo;s management have reviewed and agreed with the selection, application and disclosure of the Critical Accounting
Policies as described in the Disclosure Materials and the Prospectus and have consulted with its independent accountants with regard to
such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(pp)  &nbsp;<U>Scheme
or Arrangement with Shareholders</U>. Neither the Company nor any of its Subsidiary or affiliates is a party to any scheme or arrangement
through which shareholders or potential shareholders are being loaned, given or otherwise having money made available for the purchase
of shares whether before, in or after the Offering. Neither the Company nor any of its Subsidiaries or affiliates is aware of any such
scheme or arrangement, regardless of whether it is a party to a formal agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(qq)  &nbsp;<U>Dividends
and Distributions</U>. Except as disclosed in the Registration Statement, the Disclosure Materials, and the Prospectus, no Subsidiaries
of the Company is currently prohibited or restricted, directly or indirectly, from paying any dividends to the Company, from making any
other distribution on such Subsidiary&rsquo;s capital stock, from repaying to the Company any loans or advances to such subsidiary from
the Company or from transferring any of such Subsidiary&rsquo;s property or assets to the Company or any other Subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3.</B> &nbsp;<U>Offering</U>.
Upon authorization of the release of the Securities by the Underwriters, the Underwriters propose to offer the Securities for sale to
the public upon the terms and conditions set forth in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4.</B> &nbsp;<U>Covenants
of the Company</U>. The Company acknowledges, covenants and agrees with the Underwriters that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)  The
Registration Statement and any amendments thereto have been declared effective, and if Rule 430A is used or the filing of the Prospectus
is otherwise required under Rule 424(b), the Company will file the Prospectus (properly completed if Rule 430A has been used) pursuant
to Rule 424(b) within the prescribed time period and will provide evidence satisfactory to the Underwriters of such timely filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)  During
the period beginning on the date hereof and ending on the later of the Closing Date or such date as, in the reasonable opinion of Underwriters&rsquo;
Counsel, the Prospectus is no longer required by law to be delivered (or in lieu thereof the notice referred to in Rule 173(a) under the
Act is no longer required to be provided) in connection with sales by an underwriter or dealer (the &ldquo;<B>Prospectus Delivery Period</B>&rdquo;),
prior to amending or supplementing the Registration Statement, the Disclosure Materials or the Prospectus, the Company shall furnish to
the Underwriters and Underwriters&rsquo; Counsel for review a copy of each such proposed amendment or supplement, and the Company shall
not file any such proposed amendment or supplement to which the Underwriters reasonably object within 36 hours of delivery thereof to
Underwriters&rsquo; Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) After
the date of this Agreement, the Company shall promptly advise the Underwriters in writing of: (i) the receipt of any comments of, or requests
for additional or supplemental information from, the Commission; (ii) the time and date of any filing of any post-effective amendment
to the Registration Statement or any amendment or supplement to any prospectus, the Disclosure Materials, or the Prospectus; (iii) the
time and date that any post-effective amendment to the Registration Statement becomes effective; and (iv) the issuance by the Commission
of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or of any order preventing
or suspending its use or the use of any prospectus, the Disclosure Materials, the Prospectus, or the initiation of any proceedings to
remove, suspend or terminate from listing the Shares from any securities exchange upon which the Shares are listed for trading, or of
the threatening of initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time,
the Company will use its reasonable efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company
agrees that it shall comply with the provisions of Rules 424(b), 430A and 430B, as applicable, under the Act and will use its reasonable
efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the Commission
(without reliance on Rule 424(b)(8) or Rule 164(b)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)  (i)
During the Prospectus Delivery Period, the Company will comply with all requirements imposed upon it by the Act, as now and hereafter
amended, and by the Regulations, as from time to time in force, so far as necessary to permit the continuance of sales of or dealings
in the Securities as contemplated by the provisions hereof, the Registration Statement, Disclosure Materials, and the Prospectus. If during
such period any event or development occurs as a result of which the Prospectus (or if the Prospectus is not yet available to prospective
purchasers, the Disclosure Materials) would include an untrue statement of a material fact or omit to state a material fact necessary
to make the statements therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary
or appropriate in the opinion of the Company or its counsel or the Underwriters or Underwriters&rsquo; Counsel to amend the Registration
Statement or supplement the Prospectus (or if the Prospectus is not yet available to prospective purchasers, the Disclosure Materials)
to comply with the Act, the Company will promptly notify the Underwriters and will promptly amend the Registration Statement or supplement
the Prospectus (or if the Prospectus is not yet available to prospective purchasers, the Disclosure Materials) or file such document (at
the expense of the Company) so as to correct such statement or omission or effect such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii)  If
at any time following the issuance of an Issuer Free Writing Prospectus there occurs an event or development as a result of which such
Issuer Free Writing Prospectus would conflict with the information contained in the Registration Statement or the Prospectus or would
include an untrue statement of a material fact or would omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances there existing, not misleading, the Company will promptly notify the Underwriters and will promptly
amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or
omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iii) The
Company shall use commercially reasonable efforts to continually comply with the PRC laws and regulations governing the Company&rsquo;s
listing on an exchange not in the PRC, rectify or cure any non-compliance, and implement and maintain content control and other measures
in continuing compliance with PRC laws and regulations after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)  The
Company will deliver to the Underwriters and Underwriters&rsquo; Counsel a copy of the Registration Statement, as initially filed, and
all amendments thereto, including all consents and exhibits filed therewith, and will maintain in the Company&rsquo;s files manually signed
copies of such documents for at least three (3) years after the date of filing thereof. The Company will promptly deliver to each of the
Underwriters such number of copies of any Preliminary Prospectus, the Prospectus, the Registration Statement, and all amendments of and
supplements to such documents, if any, and all documents which are exhibits to the Registration Statement and any Preliminary Prospectus
or Prospectus or any amendment thereof or supplement thereto, as the Underwriters may reasonably request. Prior to 10:00 A.M., Eastern
Time, on the Business Day next succeeding the date of this Agreement, and from time to time thereafter, the Company will furnish to the
Underwriters copies of the Prospectus in such quantities as the Underwriters may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)  The
Company consents to the use and delivery of the Preliminary Prospectus by the Underwriters in accordance with Rule 430 and Section 5(b)
of the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)  If
the Company elects to rely on Rule 462(b) under the Act, the Company shall both file a Rule 462(b) Registration Statement with the Commission
in compliance with Rule 462(b) by the earlier of: (i) 10:00 P.M., Eastern Time, on the date of this Agreement, and (ii) the time that
confirmations are given or sent, as specified by Rule 462(b)(2), and pay the applicable fees in accordance with Rule 111 of the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h) The
Company will use its best efforts, in cooperation with the Underwriters, at or prior to the time of effectiveness of the Registration
Statement, to qualify the Securities for offering and sale under the securities laws relating to the offering or sale of the Securities
of such jurisdictions as the Underwriters may designate and to maintain such qualifications in effect for so long as required for the
distribution thereof; except that in no event shall the Company be obligated in connection therewith to qualify as a foreign corporation
or to execute a general consent to service of process or to subject itself to taxation if it is otherwise not so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)  The
Company will make generally available (which includes filings pursuant to the Exchange Act made publicly through the Electronic Data Gathering,
Analysis and Retrieval (&ldquo;<B>EDGAR</B>&rdquo;) system) to its security holders as soon as practicable, but in any event not later
than 15 months after the end of the Company&rsquo;s current fiscal quarter, an earnings statement (which need not be audited) covering
a 12-month period that shall satisfy the provisions of Section 11(a) of the Act and Rule 158 of the Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(j) Except
with respect to (i) securities of the Company which may be issued in connection with an acquisition of another entity (or the assets thereof),
(ii) the issuance of securities of the Company intended to provide the Company with proceeds to acquire another entity (or the assets
thereof), or (iii) the issuance of securities under the Company&rsquo;s stock option plans with exercise or conversion prices at fair
market value (as defined in such plans) in effect from time to time, during the three (3) months following the Closing Date, the Company
or any successor to the Company shall not undertake any public or private offerings of any equity securities of the Company (including
equity-linked securities) without the prior written consent of the Representative, which shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k)  Starting
from the commencement of sales of this Offering, any of the entities and individuals listed on&nbsp;<U>Schedule B</U>&nbsp;hereto, without
the prior written consent of the Representative, shall not sell or otherwise dispose of any securities of the Company, whether publicly
or in a private placement, during their respective lock-up period in the lock-up agreements that are in effect. The Company will deliver
to the Representative the agreements of the Lock-Up Parties to the foregoing effect on the date of this Agreement, which agreements shall
be substantially in the form attached hereto as&nbsp;<U>Annex IV.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)  The
Company will not issue press releases or engage in any other publicity without the Representative&rsquo; prior written consent, for a
period ending at 5:00 P.M., Eastern time, on the first Business Day following the forty-fifth (45th) day following the Closing Date, other
than normal and customary releases issued in the ordinary course of the Company&rsquo;s business, or as required by law.</FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(m)  &nbsp;The
Company will apply the net proceeds from the sale of the Securities as set forth under the caption &ldquo;Use of Proceeds&rdquo; in the
Prospectus. Without the prior written consent of the Representative, except as disclosed in the Registration Statement, the Disclosure
Materials, and the Prospectus, no proceeds of the Offering will be used to pay outstanding loans from officers, directors or shareholders
or to pay any accrued salaries or bonuses to any employees or former employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(n) The
Company will use its best efforts to effect and maintain the listing of the Shares on the Nasdaq for at least three (3) years after the
Effective Date, unless such listing is terminated as a result of a transaction approved by the holders of a majority of the voting securities
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(o) The
Company will use its best efforts to do and perform all things required to be done or performed under this Agreement by the Company prior
to the Closing Date and any Additional Closing Date, and to satisfy all conditions precedent to the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(p) The
Company will not take, and will cause its Subsidiaries not to take, directly or indirectly, any action which constitutes or is designed
to cause or result in, or which could reasonably be expected to constitute, cause or result in, the stabilization or manipulation of the
price of any security to facilitate the sale or resale of any of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(q) The
Company shall cause to be prepared and delivered to the Underwriters, at its expense, within one (1) Business Day from the date of this
Agreement, an Electronic Prospectus to be used by the Underwriters in connection with the Offering. As used herein, the term &ldquo;Electronic
Prospectus&rdquo; means a form of prospectus, and any amendment or supplement thereto, that meets each of the following conditions: (i)
it shall be encoded in an electronic format, satisfactory to the Underwriters, that may be transmitted electronically by the Underwriters
to offerees and purchasers of the Securities for at least the period during which a Prospectus relating to the Securities is required
to be delivered under the Act or the Exchange Act; (ii) it shall disclose the same information as the paper prospectus and prospectus
filed pursuant to EDGAR, except to the extent that graphic and image material cannot be disseminated electronically, in which case such
graphic and image material shall be replaced in the electronic prospectus with a fair and accurate narrative description or tabular representation
of such material, as appropriate; and (iii) it shall be in or convertible into a paper format or an electronic format, satisfactory to
the Underwriters, that will allow recipients thereof to store and have continuously ready access to the prospectus at any future time,
without charge to such recipients (other than any fee charged for subscription to the Internet as a whole and for online time).</FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>5.</B> &nbsp;<U>Representations
and Warranties of the Underwriters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Underwriters represent and agree that, unless
they obtain the prior written consent of the Company, they have not made and will not make any offer relating to the Securities that would
constitute a &ldquo;free writing prospectus,&rdquo; as defined in Rule 405 under the Act, required to be filed with the Commission;&nbsp;<I>provided&nbsp;</I>that
the prior written consent of the parties hereto shall be deemed to have been given in respect of the free writing prospectuses. Any such
free writing prospectus consented to by the Underwriters is herein referred to as a &ldquo;Permitted Free Writing Prospectus.&rdquo; The
Underwriters represent that they have treated or agree that they will treat each Permitted Free Writing Prospectus as an &ldquo;issuer
free writing prospectus,&rdquo; as defined in Rule 433, and have complied and will comply with the requirements of Rule 433 applicable
to any Permitted Free Writing Prospectus, including timely Commission filing where required, legending and record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>6. </B><U>Consideration;
Payment of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)  In
consideration of the services to be provided for hereunder, the Company shall pay to the Underwriters or their respective designees their
pro rata portion (based on the Securities purchased) of the following compensation with respect to the Securities which they are offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) an
underwriting discount equal to seven percent (7%) of the aggregate gross proceeds raised in the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii)  a
non-accountable expense allowance of two and a quarter percent (2.25%) of the gross proceeds of the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iii) an
advisory fee of $75,000 of which $45,000 has been paid as of the date of this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iv) an
accountable expense allowance of up to $160,000, including, among other things, all reasonable fees and expenses of the Underwriters&rsquo;
outside legal counsel; any reasonable costs and expenses incurred in conducting background checks of the Company&rsquo;s officers and
directors by a background search firm acceptable to the Underwriters; the costs associated with bound volumes and mementos in such quantities
as the Underwriters may reasonably request; and expenses related to book building, prospectus tracking, and compliance software services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) The
Underwriters reserve the right to reduce any item of compensation or adjust the terms thereof as specified herein in the event that a
determination shall be made by FINRA to the effect that the Underwriters&rsquo; aggregate compensation is in excess of FINRA Rules or
that the terms thereof require adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) Whether
or not the transactions contemplated by this Agreement, the Registration Statement and the Prospectus are consummated, or this Agreement
is terminated, the Company hereby agrees to bear the following costs and expenses incident to the Offering, and the Underwriters shall
not receive any such payment, directly or indirectly, as compensation to this Offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) &nbsp;all
expenses in connection with the preparation, printing, formatting for EDGAR and filing of the Registration Statement, any Preliminary
Prospectus, the Prospectus, the underwriting documents, and any and all amendments and supplements thereto and the mailing and delivering
of copies thereof to the Underwriters and dealers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii) all
fees and expenses in connection with filings with FINRA&rsquo;s Public Offering System;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iii)  all
fees, disbursements and expenses of the Company&rsquo;s counsel and accountants in connection with the registration of the Securities
under the Act and the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iv) all
reasonable expenses in connection with the qualifications of the Securities for offering and sale under state or foreign securities or
blue sky laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(v)  all
fees and expenses in connection with listing the Securities on a national securities exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(vi) all
reasonable travel expenses of the Company&rsquo;s officers, directors and employees and any other expense of the Company incurred in connection
with attending or hosting meetings with prospective purchasers of the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(vii)  &nbsp;all
the road show expenses incurred by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(viii)  any
stock transfer taxes or other taxes incurred in connection with this Agreement or the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ix)  the
cost of preparing, printing, and delivering certificates representing the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(x) the
cost and charges of any transfer agent or registrar for the Securities, the public relations firm, and post-Closing advertising of the
Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(xi)  the
cost and charges of the background checks of the Insiders and any translation costs; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(xii) the
cost associated with bound volumes of the public offering materials as well as commemorative mementos and lucite tombstones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)  It
is understood, however, that except as provided in this&nbsp;<U>Section 6</U>, and&nbsp;<U>Sections 8</U>,&nbsp;<U>9</U>&nbsp;and&nbsp;<U>11(d)</U>&nbsp;hereof,
the Underwriters will pay all of their own costs and expenses. Notwithstanding anything to the contrary in this&nbsp;<U>Section 6</U>,
in the event that this Agreement is terminated pursuant to&nbsp;<U>Section 11(b)</U>&nbsp;hereof, or subsequent to a Material Adverse
Change, the Company will pay, less any advances previously paid, representing an advance to be applied towards the accountable expenses
allowance (the &ldquo;<B>Advances</B>&rdquo;), all documented out-of-pocket expenses of the Underwriters (including but not limited to
fees and disbursements of Underwriters&rsquo; Counsel and reasonable and accountable travel) incurred in connection herewith which shall
be limited to expenses which are actually incurred as allowed under FINRA Rule 5110 and in any event, the aggregate amount of such expenses
to be reimbursed by the Company shall not exceed $160,000, including the Advances. To the extent that the Underwriters&rsquo; out-of-pocket
expenses are less than the Advances, the Underwriters will return to the Company that portion of the Advances not offset by actual expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>7.</B> &nbsp;<U>Conditions
of Underwriters&rsquo; Obligations</U>. The obligations of the Underwriters to purchase and pay for the Firm Shares as provided herein
shall be subject to: (i) the accuracy of the representations and warranties of the Company herein contained, as of the date hereof and
as of the Closing Date, (ii) the absence from any certificates, opinions, written statements or letters furnished to the Underwriters
or to Underwriters&rsquo; Counsel pursuant to this&nbsp;<U>Section 7</U>&nbsp;of any misstatement or omission, (iii) the performance by
the Company of its obligations hereunder, and (iv) each of the following additional conditions. For purposes of this&nbsp;<U>Section 7</U>,
the terms &ldquo;Closing Date&rdquo; and &ldquo;Closing&rdquo; shall refer to the Closing Date for the Firm Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) The
Registration Statement shall have become effective and all necessary regulatory and listing approvals shall have been received not later
than 4:00 P.M., Eastern Time, on the date of this Agreement, or at such later time and date as shall have been consented to in writing
by the Underwriters. If the Company shall have elected to rely upon Rule 430A under the Act, the Prospectus shall have been filed with
the Commission in a timely fashion in accordance with the terms thereof and a form of the Prospectus containing information relating to
the description of the Securities and the method of distribution and similar matters shall have been filed with the Commission pursuant
to Rule 424(b) within the applicable time period; and, at or prior to the Closing Date and the actual time of the Closing, no stop order
suspending the effectiveness of the Registration Statement or any part thereof, or any amendment thereof, nor suspending or preventing
the use of the Disclosure Materials, the Prospectus shall have been issued; no proceedings for the issuance of such an order shall have
been initiated or threatened; all requests of the Commission for additional information (to be included in the Registration Statement,
the Disclosure Materials, the Prospectus) shall have been complied with to the Underwriters&rsquo; satisfaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) The
Underwriters shall not have reasonably determined, and advised the Company, that the Registration Statement, the Disclosure Materials,
or the Prospectus, or any amendment thereof or supplement thereto, or any Issuer Free Writing Prospectus, contains an untrue statement
of fact which, in the Underwriters&rsquo; reasonable opinion, is material, or omits to state a fact which, in the Underwriters&rsquo;
reasonable opinion, is material and is required to be stated therein or necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) The
Underwriters shall have received, in form satisfactory to the Underwriters and Underwriters&rsquo; counsel of (i) favorable legal opinions
from Conyers Dill &amp; Pearman, Cayman Islands counsel to the Company dated as of the Closing Date and addressed to the Underwriters,
(ii) favorable legal opinions and negative assurance letter from Sichenzia Ross Ference Carmel LLP, U.S. legal counsel for the Company,
dated as of the Closing Date and addressed to the Underwriters, (iii) favorable legal opinions from KPMG Law Firm, ROC legal counsel to
the Company, dated as of the Closing Date, and (iv) favorable legal opinions from Zhejiang Boning Law Firm, PRC legal counsel to the Company,
regarding the litigation matter referenced in the Registration Statement, dated as of the Closing Date. A copy of such opinion shall have
been provided to the Underwriters with consent from such counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) The
Underwriters shall have received certificates of each of the Chief Executive Officer and Chief Financial Officer of the Company (the &ldquo;<B>Officers&rsquo;
Certificate</B>&rdquo;), substantially in the form attached hereto as&nbsp;<U>Annex I</U>&nbsp;and dated as of the Closing Date, to the
effect that: (i) the conditions set forth in subsection (a) of this&nbsp;<U>Section 7</U>&nbsp;have been satisfied, (ii) as of the date
hereof and as of the Closing Date, the representations and warranties of the Company set forth in&nbsp;<U>Section 2</U>&nbsp;hereof are
accurate, (iii) as of the Closing Date, all agreements, conditions and obligations of the Company to be performed or complied with hereunder
on or prior thereto have been duly performed or complied with, (iv) the Company has not sustained any material loss or interference with
its businesses, whether or not covered by insurance, or from any labor dispute or any legal or governmental proceeding, (v) no stop order
suspending the effectiveness of the Registration Statement or any amendment thereof has been issued and no proceedings therefor have been
initiated or threatened by the Commission, (vi) there are no pro forma or as adjusted financial statements that are required to be included
in the Registration Statement, the Disclosure Materials, and the Prospectus pursuant to the Regulations which are not so included, (vii)
subsequent to the respective dates as of which information is given in the Registration Statement and the Prospectus, there has not been
any Material Adverse Change or any development involving a prospective Material Adverse Change, whether or not arising from transactions
in the ordinary course of business, and (viii) any other conditions deemed necessary for the closing of this Offering by the Underwriters&rsquo;
Counsel have been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)  At
each of the Closing Date, the Underwriters shall have received a certificate of the Company signed by the Chief Executive Officer of the
Company (the &ldquo;<B>CEO&rsquo;s Certificate</B>&rdquo;), substantially in the form attached hereto as&nbsp;<U>Annex II</U>&nbsp;and
dated the Closing Date, certifying: (i) that each of the Charter and Bylaws is true and complete, has not been modified and is in full
force and effect; (ii) that the resolutions of the Company&rsquo;s Board of Directors relating to the Offering are in full force and effect
and have not been modified; (iii) the good standing of the Company; (iv) as to the incumbency of the officers of the Company. The documents
referred to in such certificate shall be attached to such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) On
the date of this Agreement and on the Closing Date, the Underwriters shall have received a &ldquo;comfort&rdquo; letter from WWC, P.C.
(the &ldquo;<B>Auditor Comfort Letter</B>&rdquo;) as of each such date, addressed to the Underwriters and in form and substance satisfactory
to the Underwriters and Underwriters&rsquo; Counsel, confirming that they are independent certified public accountants with respect to
the Company within the meaning of the Act and all applicable Regulations, and stating, as of such date (or, with respect to matters involving
changes or developments since the respective dates as of which specified financial information is given in the Prospectus, as of a date
not more than two (2) business days prior to such date), the conclusions and findings of such firm with respect to the financial information
and other matters relating to the Registration Statement covered by such letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)  On
the date of this Agreement and on the Closing Date, the Company shall have furnished to the Underwriters, a certificate on behalf of the
Company, dated the respective dates of delivery thereof and addressed to the Underwriters, of its Chief Financial Officer with respect
to certain financial date contained in the Registration Statement and Prospectus (the &ldquo;<B>CFO Certificate</B>&rdquo;), providing
&ldquo;management comfort&rdquo; with respect to such information, in form and substance reasonably satisfactory to the Underwriters,
substantially in the form attached hereto as&nbsp;<U>Annex III</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)  Subsequent
to the execution and delivery of this Agreement and prior to the Closing Date or, if earlier, the dates as of which information is given
in the Registration Statement (exclusive of any amendment thereof) and the Prospectus (exclusive of any supplement thereto), there shall
not have been any change in the capital stock or long-term debt of the Company or any change or development involving a change, whether
or not arising from transactions in the ordinary course of business, in the business, condition (financial or otherwise), results of operations,
shareholders&rsquo; equity, properties or prospects of the Company, taken as a whole, including but not limited to the occurrence of any
fire, flood, storm, explosion, accident, act of war or terrorism or other calamity, the effect of which, in any such case described above,
is, in the reasonable judgment of the Underwriters, so material and adverse as to make it impracticable or inadvisable to proceed with
the sale of Securities or Offering as contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)  The
Representative shall have received a lock-up agreement from each of the Lock-Up Parties, duly executed by the applicable Lock-Up Party,
in each case substantially in the form attached as&nbsp;<U>Annex IV</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(j)  The
Securities are registered under the Exchange Act and, as of the Closing Date, the Securities shall be listed and admitted and authorized
for trading on the Nasdaq and satisfactory evidence of such action shall have been provided to the Underwriters. The Company shall have
taken no action designed to terminate, or likely to have the effect of terminating, the registration of the Securities under the Exchange
Act or delisting or suspending the Securities from trading on the Nasdaq, nor will the Company have received any information suggesting
that the Commission or the Nasdaq is contemplating terminating such registration or listing. The Firm Shares shall be DTC eligible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k)  FINRA
shall have confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting terms and
arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(l) No
action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state
or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance or sale of the Securities; and
no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance
or sale of the Securities or materially and adversely affect or potentially materially and adversely affect the business or operations
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(m)  &nbsp;The
Company shall have furnished the Underwriters and Underwriters&rsquo; Counsel with such other certificates, opinions or documents as they
may have reasonably requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>8.</B> <U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)  The
Company agrees to indemnify and hold harmless (to the fullest extent permitted by applicable law) the Underwriters and each person, if
any, who controls the Underwriters within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, against any losses,
liabilities, claims, damages and expenses whatsoever, as incurred (including but not limited to reasonable attorneys&rsquo; fees and any
and all reasonable expenses whatsoever, incurred in investigating, preparing or defending against any litigation, commenced or threatened,
or any claim whatsoever, and any and all amounts paid in settlement of any claim or litigation), joint or several, to which they or any
of them may become subject under the Act, the Exchange Act or otherwise (including in settlement of any litigation if such settlement
is effected with the written consent of the Company), insofar as such losses, liabilities, claims, damages or expenses (or actions in
respect thereof) arise out of or are based upon: (i) an untrue statement or alleged untrue statement of a material fact contained in (A)
the Registration Statement, including the information deemed to be a part of the Registration Statement at the time of effectiveness and
at any subsequent time pursuant to Rules 430A and 430B of the Regulations, any Preliminary Prospectus, the Disclosure Materials, the Prospectus,
or any amendment or supplement to any of them or (B) any Issuer Free Writing Prospectus or any materials or information provided to investors
by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (&ldquo;<B>Marketing Materials</B>&ldquo;),
including any road show or investor presentations made to investors by the Company (whether in person or electronically), or arise out
of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading and will reimburse such indemnified party for any legal or other expenses reasonably incurred by
it in connection with investigations or defending against such losses, liabilities, claims, damages or expenses (or actions in respect
thereof); or (ii) in whole or in part upon any inaccuracy in the representations and warranties of the Company contained herein; or (iii)
in whole or in part upon any failure of the Company to perform its obligations hereunder;&nbsp;<I>provided, however</I>, that the Company
shall not be liable in any such case to the extent that any such loss, liability, claim, damage or expense (or action in respect thereof)
arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration
Statement, any Preliminary Prospectus, the Disclosure Materials, the Prospectus, or any such amendment or supplement to any of them, or
any Issuer Free Writing Prospectus or any Marketing Materials in reliance upon and in conformity with the Underwriters&rsquo; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)  The
Underwriters agree to indemnify and hold harmless the Company, each of the directors of the Company, each of the officers of the Company
who shall have signed the Registration Statement, and each other person, if any, who controls the Company within the meaning of Section
15 of the Act or Section 20 of the Exchange Act, against any losses, liabilities, claims, damages and expenses whatsoever, as incurred
(including but not limited to reasonable attorneys&rsquo; fees and any and all reasonable expenses whatsoever, incurred in investigating,
preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, and any and all amounts paid in settlement
of any claim or litigation), joint or several, to which they or any of them may become subject under the Act, the Exchange Act or otherwise
(including in settlement of any litigation if such settlement is effected with the written consent of the Underwriters), insofar as such
losses, liabilities, claims, damages or expenses (or actions in respect thereof) arise out of or are based upon an untrue statement or
alleged untrue statement of a material fact contained in the Registration Statement, at the time of effectiveness and at any subsequent
time pursuant to Rules 430A and 430B of the Regulations, any Preliminary Prospectus, the Disclosure Materials, the Prospectus, any amendment
or supplement to any of them or any Marketing Materials, or arise out of or are based upon the omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse such indemnified
party for any legal or other expenses reasonably incurred by it in connection with investigating or defending against such losses, liabilities,
claims, damages or expenses (or actions in respect thereof), in each case to the extent, but only to the extent, that any such loss, liability,
claim, damage or expense (or action in respect thereof) arises out of or is based upon any such untrue statement or alleged untrue statement
or omission or alleged omission made in the Underwriters&rsquo; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)  Promptly
after receipt by an indemnified party under subsection (a) or (b) above of notice of any claim or the commencement of any action, such
indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify each
party against whom indemnification is to be sought in writing thereof (but the failure so to notify an indemnifying party shall not relieve
the indemnifying party from any liability which it may have under this&nbsp;Section 8&nbsp;to the extent that it is not materially prejudiced
as a result thereof ). In case any such claim or action is brought against any indemnified party, and it so notifies an indemnifying party
thereof, the indemnifying party will be entitled to participate at its own expense in the defense of such action, and to the extent it
may elect by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party,
to assume the defense thereof with counsel satisfactory to such indemnified party. Notwithstanding the foregoing, the indemnified party
or parties shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be
at the expense of such indemnified party or parties unless: (i) the employment of such counsel shall have been authorized in writing by
one of the indemnifying parties in connection with the defense of such action; (ii) the indemnifying parties have not employed counsel
to have charge of the defense of such action within a reasonable time after notice of the claim or the commencement of the action; (iii)
the indemnifying party does not diligently defend the action after assumption of the defense; or (iv) such indemnified party or parties
shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party, or
any of them, in conducting the defense of any such action or there may be legal defenses available to it or them which are different from
or additional to those available to any of the indemnifying parties (in which case the indemnifying parties shall not have the right to
direct the defense of such action on behalf of the indemnified party or parties), in any of which events such fees and expenses shall
be borne by the indemnifying parties and shall be paid as incurred. It is understood that the indemnifying party shall not, in respect
of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable
for the fees and expenses of more than one separate firm (in addition to any local counsel) of the indemnified party or parties unless
such separate representations are required under applicable ethics rules that govern the representations of the indemnified party or parties
by such legal counsel. In the case of any separate firm for the Underwriters and such control persons and affiliates of any Underwriters,
such firm shall be designated in writing by the Underwriters. In the case of more than one separate firm (in addition to any local counsel)
for the Company, and such directors, officers and control persons of the Company, such firm shall be designated in writing by the Company.
No indemnifying party shall, without the prior written consent of the indemnified parties, effect any settlement or compromise of, or
consent to the entry of judgment with respect to, any pending or threatened claim, investigation, action or proceeding in respect of which
indemnity or contribution may be or could have been sought by an indemnified party under this&nbsp;Section 8&nbsp;or&nbsp;Section 9&nbsp;hereof
(whether or not the indemnified party is an actual or potential party thereto), unless (v) such settlement, compromise or judgment (A)
includes an unconditional release of the indemnified party from all liability arising out of such claim, investigation, action or proceeding
and (B) does not include a statement as to or an admission of fault, culpability or any failure to act, by or on behalf of the indemnified
party, and (vi) the indemnifying party confirms in writing its indemnification obligations hereunder with respect to such settlement,
compromise or judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>9. </B><U>Contribution</U>.
In order to provide for contribution in circumstances in which the indemnification provided for in&nbsp;Section 8&nbsp;is for any reason
held to be unavailable from any indemnifying party or is insufficient to hold harmless a party indemnified thereunder, the Company and
the Underwriters shall contribute to the aggregate losses, claims, damages, liabilities and expenses of the nature contemplated by such
indemnification provision (including any investigation, legal and other expenses incurred in connection with, and any amount paid in settlement
of, any action, suit or proceeding or any claims asserted, but after deducting in the case of losses, claims, damages, liabilities and
expenses suffered by the Company, any contribution received by the Company from persons, other than the Underwriters, who may also be
liable for contribution, including persons who control the Company within the meaning of Section 15 of the Act or Section 20 of the Exchange
Act, officers of the Company who signed the Registration Statement and directors of the Company), as incurred, to which the Company and
one or more of the Underwriters may be subject, in such proportions as is appropriate to reflect the relative benefits received by the
Company on the one hand and the Underwriters on the other hand from the Offering and sale of the Securities or, if such allocation is
not permitted by applicable law, in such proportions as are appropriate to reflect not only the relative benefits referred to above but
also the relative fault of the Company and the Underwriters in connection with the statements or omissions which resulted in such losses,
claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the
Company and the Underwriters shall be deemed to be in the same proportion as (i) the total proceeds from the Offering (net of underwriting
discount and commission but before deducting expenses) received by the Company bears to (ii) the underwriting discount and commissions
received by the Underwriters, in each case as set forth in the table on the cover page of the Prospectus. The relative fault of the Company
and the Underwriters shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or the Underwriters and
the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this&nbsp;Section 9&nbsp;were
determined by&nbsp;pro rata&nbsp;allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method
of allocation which does not take account of the equitable considerations referred to above in this&nbsp;Section 9. The aggregate amount
of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this&nbsp;Section 9&nbsp;shall
be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending
against any litigation, or any investigation or proceeding by any judicial, regulatory or other legal or governmental agency or body,
commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission.
Notwithstanding the provisions of this&nbsp;Section 9: (iii) no Underwriter shall be required to contribute any amount in excess of the
underwriting discounts applicable to the Securities underwritten by it and distributed to the public and (iv) no Person guilty of fraudulent
misrepresentation (within the meaning of Section 12(f) of the Act) shall be entitled to contribution from any Person who was not guilty
of fraudulent misrepresentation (within the meaning of Section 12(f) of the Act). For purposes of this&nbsp;Section 9, each Person, if
any, who controls an Underwriter within the meaning of Section 15 of the Act or Section 20 of the Exchange Act shall have the same rights
to contribution as such Underwriter, and each Person, if any, who controls the Company within the meaning of Section 15 of the Act or
Section 20 of the Exchange Act, each officer of the Company who shall have signed the Registration Statement and each director of the
Company shall have the same rights to contribution as the Company, subject in each case to clauses (iii) and (iv) of the immediately preceding
sentence. Any party entitled to contribution will, promptly after receipt of notice of commencement of any action, suit or proceeding
against such party in respect of which a claim for contribution may be made against another party or parties, notify each party or parties
from whom contribution may be sought, but the omission to so notify such party or parties shall not relieve the party or parties from
whom contribution may be sought from any obligation it or they may have under this&nbsp;Section 9&nbsp;or otherwise. As used herein, a
&ldquo;Person&rdquo; refers to an individual or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>10.</B> <U>Survival
of Representations and Agreements</U>. All representations, warranties, covenants and agreements of the Company and the Underwriters contained
in this Agreement or in certificates of officers of the Company submitted pursuant hereto, including, without limitation, the agreements
contained in&nbsp;Sections 6,&nbsp;14&nbsp;and&nbsp;15, the indemnity agreements contained in&nbsp;Section 8&nbsp;and the contribution
agreements contained in&nbsp;Section 9, shall remain operative and in full force and effect regardless of any investigation made by or
on behalf of the Underwriters or any controlling Person thereof or by or on behalf of the Company, any of its officers or directors or
any controlling Person thereof, and shall survive delivery of and payment for the Securities to and by the Underwriters. The representations
and warranties contained in&nbsp;Section 2&nbsp;and the covenants and agreements contained in&nbsp;Sections 4, 6, 8, 9, 14 and 15 shall
survive any termination of this Agreement, including termination pursuant to&nbsp;Sections 11. For the avoidance of doubt, in the event
of termination the Underwriters will receive out-of-pocket accountable expenses actually incurred subject to the limit in&nbsp;Section
11(d)&nbsp;below, in compliance with FINRA Rules5110(g)(5)(A), 5110(g)(5)(B)(i) and 5110(g)(5)(B)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>11.</B> <U>Effective
Date of Agreement; Termination; Defaulting Underwriters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)  This
Agreement shall become effective upon the later of: (i) receipt by the Underwriters and the Company of notification of the effectiveness
of the Registration Statement or (ii) the execution of this Agreement. Notwithstanding any termination of this Agreement, the provisions
of this&nbsp;Section 12 and of Sections 1, 4, 6, 8, 9, 14 and 15 shall remain in full force and effect at all times after the execution
hereof to the extent they are in compliance with FINRA Rule 5110(g)(5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)  The
Underwriters shall have the right to terminate this Agreement at any time prior to the consummation of the Closing if: (i) any domestic
or international event or act or occurrence has materially disrupted, or in the reasonable opinion of the Underwriters will in the immediate
future materially disrupt, the market for the Company&rsquo;s securities or securities in general; or (ii) trading on the New York Stock
Exchange or the Nasdaq Stock Market has been suspended or made subject to material limitations, or minimum or maximum prices for trading
have been fixed, or maximum ranges for prices for securities have been required, on the NYSE or the Nasdaq Stock Market or by order of
the Commission, FINRA or any other governmental authority having jurisdiction; or (iii) a banking moratorium has been declared by any
state or federal authority or any material disruption in commercial banking or securities settlement or clearance services has occurred;
or (iv) (A) there has occurred any outbreak or escalation of hostilities or acts of terrorism involving the United States or there is
a declaration of a national emergency or war by the United States or (B) there has been any other calamity or crisis or any change in
political, financial or economic conditions, if the effect of any such event in (A) or (B), in the reasonable judgment of the Underwriters,
is so material and adverse that such event makes it impracticable or inadvisable to proceed with the offering, sale and delivery of the
Firm Shares on the terms and in the manner contemplated by the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)  Any
notice of termination pursuant to this&nbsp;Section 11&nbsp;shall be in writing and delivered in accordance with&nbsp;Section 12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)  If,
on the Closing Date or any Additional Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse to purchase
the Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of the Shares which such defaulting
Underwriter or Underwriters agreed but failed or refused to purchase is not more than one-tenth (10%) of the aggregate number of the Shares
to be purchased on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set
forth opposite their respective names in Schedule I bears to the aggregate number of Firm Shares set forth opposite the names of all such
non-defaulting Underwriters, or in such other proportions as the Underwriters may specify, to purchase the Shares which such defaulting
Underwriter or Underwriters agreed but failed or refused to purchase on such date; provided that, in no event shall the number of Shares
that any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 11(d) by an amount in excess
of one-ninth (1/9) of such number of Shares without the written consent of such Underwriter. If, on the Closing Date, any Underwriter
or Underwriters shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default
occurs is more than one-tenth (10%) of the aggregate number of Firm Shares to be purchased on such date, and arrangements satisfactory
to the Underwriters and the Company for the purchase of such Firm Shares are not made within thirty six (36) hours after such default,
this Agreement shall terminate without liability on the part of any non-defaulting Underwriter or the Company. In any such case, either
the Underwriters or the Company shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order
that the required changes, if any, in the Registration Statement, in the Pricing Disclosure Package, in the Final Prospectus or in any
other documents or arrangements may be effected. If, on an Additional Closing Date, any Underwriter or Underwriters shall fail or refuse
to purchase Option Shares and the aggregate number of Option Shares with respect to which such default occurs is more than one-tenth (10%)
of the aggregate number of Option Shares to be purchased on such Additional Closing Date, the non-defaulting Underwriters shall have the
option to (i) terminate their obligation hereunder to purchase the Option Shares to be sold on such Additional Closing Date or (ii) purchase
not less than the number of Option Shares that such non-defaulting Underwriters would have been obligated to purchase in the absence of
such default. Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default
of such Underwriter under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)  If
this Agreement shall be terminated pursuant to any of the provisions hereof (other than pursuant to&nbsp;Section 11(b)&nbsp;hereof), or
if the sale of the Securities provided for herein is not consummated because any condition to the obligations of the Underwriters set
forth herein is not satisfied or because of any refusal, inability or failure on the part of the Company to perform any agreement herein
or comply with any provision hereof, the Company will, subject to demand by the Underwriters, reimburse the Underwriters for only those
documented out-of-pocket expenses (including the reasonable fees and expenses of their counsel), actually incurred by the Underwriters
in connection herewith as allowed under FINRA Rule 5110 less any amounts previously paid by the Company);&nbsp;<I>provided, however,</I>&nbsp;that
all such expenses, including the costs and expenses set forth in&nbsp;Section 6(c)&nbsp;which were actually paid, shall not exceed accountable
expenses actually incurred in the aggregate, including any advances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12.</B> <U>Notices</U>.
All communications hereunder, except as may be otherwise specifically provided herein, shall be in writing, and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)  if
sent to the Representative, shall be mailed or delivered, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Joseph Stone Capital, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">585 Stewart Ave., Suite L60-C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Garden City, NY 11530</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Attention: Cathy Cao</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">with a copy to Underwriters&rsquo;
Counsel at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">VCL Law LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1945 Old Gallows Rd., Suite
260</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Vienna, VA 22182</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Attention: Fang Liu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)  if
sent to the Company, shall be mailed, delivered, or emailed, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Jyong Biotech Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23F-3, No. 95, Section 1,
Xintai 5th Road, Xizhi District, New Taipei City, Taiwan, 221</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Attn: Fu-Feng kuo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">with a copy to the Company&rsquo;s
Counsel at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sichenzia Ross Ference Carmel
LLP,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1185 Avenue of the Americas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">31st Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New York, NY 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Attention: Ross Carmel, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>13.</B> <U>Parties;
Limitation of Relationship</U>. This Agreement shall inure solely to the benefit of, and shall be binding upon, the Underwriters, the
Company and the controlling Persons, directors, officers, employees and agents referred to in&nbsp;Sections 8&nbsp;and&nbsp;9&nbsp;hereof,
and their respective successors and assigns, and no other Person shall have or be construed to have any legal or equitable right, remedy
or claim under or in respect of or by virtue of this Agreement or any provision herein contained. This Agreement and all conditions and
provisions hereof are intended to be for the sole and exclusive benefit of the parties hereto and such Persons and their respective successors
and assigns, and not for the benefit of any other Person. The term &ldquo;successors and assigns&rdquo; shall not include a purchaser,
in its capacity as such, of Securities from the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>14.</B> <U>Governing
Law</U>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York. Each of the parties
hereto hereby submits to the exclusive jurisdiction of the Federal and state courts in the Borough of Manhattan in The City of New York
(each, a &ldquo;New York Court&rdquo;) in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby. Each of the parties hereto irrevocably waives any objection to the laying of venue of any suit or proceeding arising out of or
relating to this Agreement or the transactions contemplated hereby in the New York Courts, and irrevocably waives and agrees not to plead
or claim in any such court that any such suit or proceeding in any such court has been brought in an inconvenient forum. The Company irrevocably
appoints Cogency Global Inc. as its authorized agent (the &ldquo;<B>Authorized Agent</B>&rdquo;) in the Borough of Manhattan in The City
of New York upon which process may be served in any such suit or proceeding, and agrees that service of process in any manner permitted
by applicable law upon such agent shall be deemed in every respect effective service of process in any manner permitted by applicable
law upon the Company in any such suit or proceeding. The Company further agrees to take any and all actions as may be necessary to maintain
such designation and appointment of such agent in full force and effect for a period of three years from the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>15.</B> <U>Entire
Agreement</U>. This Agreement, together with the schedules and annexes attached hereto and as the same may be amended from time to time
in accordance with the terms hereof, contains the entire agreement among the parties hereto relating to the subject matter hereof and
there are no other or further agreements outstanding not specifically mentioned herein. This Agreement supersedes any prior agreements
or understandings among or between the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>16.</B> <U>Severability</U>.
If any term or provision of this Agreement or the performance thereof shall be invalid or unenforceable to any extent, such invalidity
or unenforceability shall not affect or render invalid or unenforceable any other provision of this Agreement and this Agreement shall
be valid and enforceable to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>17.</B> <U>Amendment</U>.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>18.</B> <U>Waiver,
etc.</U>&nbsp;The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed
or construed to be a waiver of any such provision, nor to in any way affect the validity of this Agreement or any provision hereof or
the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance
or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by
the party or parties against whom or which enforcement of such waiver may be sought; and no waiver of any such breach, non-compliance
or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment. The
parties to this Agreement hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury
in any legal suit, action or proceeding arising out of or relating to this Agreement, the Registration Statement, the Disclosure Materials,
the Prospectus, the offering of the Shares or the transactions contemplated hereby</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>19.</B> <U>No
Fiduciary Relationship</U>. The Company hereby acknowledges that the Underwriters are acting solely as Underwriters in connection with
the offering of the Company&rsquo;s Securities. The Company further acknowledges that the Underwriters are acting pursuant to a contractual
relationship created solely by this Agreement entered into on an arm&rsquo;s-length basis and in no event do the parties intend that the
Underwriters act or be responsible as a fiduciary to the Company, its management, shareholders, creditors or any other person in connection
with any activity that the Underwriters may undertake or have undertaken in furtherance of the offering of the Company&rsquo;s Securities,
either before or after the date hereof. The Underwriters hereby expressly disclaim any fiduciary or similar obligations to the Company,
either in connection with the transactions contemplated by this Agreement or any matters leading up to such transactions, and the Company
hereby confirms its understanding and agreement to that effect. The Company hereby further confirms its understanding that the Underwriters
have not assumed an advisory or fiduciary responsibility in favor of the Company with respect to the Offering contemplated hereby or the
process leading thereto, including, without limitation, any negotiation related to the pricing of the Securities; and the Company has
consulted its own legal and financial advisors to the extent it has deemed appropriate in connection with this Agreement and the Offering.
The Company and the Underwriters agree that they are each responsible for making their own independent judgments with respect to any such
transactions, and that any opinions or views expressed by the Underwriters to the Company regarding such transactions, including but not
limited to any opinions or views with respect to the price or market for the Company&rsquo;s securities, do not constitute advice or recommendations
to the Company. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against
the Underwriters with respect to any breach or alleged breach of any fiduciary or similar duty to the Company in connection with the transactions
contemplated by this Agreement or any matters leading up to such transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>20.</B> <U>Counterparts</U>.
This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all such counterparts
shall together constitute one and the same instrument. Delivery of a signed counterpart of this Agreement by facsimile or other electronic
transmission shall constitute valid and sufficient delivery thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>21.</B> <U>Headings</U>.
The headings herein are inserted for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation
of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>22.</B>  &nbsp;<U>Time
is of the Essence</U>. Time shall be of the essence of this Agreement. As used herein, the term &ldquo;Business Day&rdquo; shall mean
any day other than a Saturday, Sunday or any day on which any of the major U.S. stock exchanges are not open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If the foregoing correctly sets forth your understanding,
please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement among us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><B>Jyong Biotech Ltd.</B> <B>&nbsp;</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 31%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accepted on behalf of itself and as the representative
of the several underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4"><B>Joseph Stone Capital, LLC.</B> <B>&nbsp;</B></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 31%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Signature Page to Underwriting Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Underwriters</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Closing<BR>
 Securities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Closing<BR>
 Securities<BR> if the <BR> Maximum <BR> Over-Allotment<BR> Option is<BR>
 Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Closing<BR> Purchase<BR>
 Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Joseph Stone Capital, LLC</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Lock-Up Parties</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="border-right: Black 0pt solid; border-bottom: Black 0pt solid; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 1.5pt; width: 100%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 1.5pt; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 1.5pt; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 1.5pt; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 1.5pt; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 1.5pt; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 1.5pt; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 1.5pt; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border: Black 1pt solid; padding: 1.5pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Annex I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JYONG BIOTECH INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OFFICERS&rsquo; CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[&nbsp; &nbsp; &nbsp;], 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned, Fu-Feng Kuo, Chief Executive Officer, and Alfred Ying,
Chief Financial Officer, of Jyong Biotech Ltd., a Cayman Islands exempted company (the &ldquo;<B>Company&rdquo;</B>), pursuant to Section
7(d) of the Underwriting Agreement, dated as of [&nbsp;&nbsp; &nbsp;], 2024 by&nbsp;<FONT STYLE="color: #212121">and between the Company and Joseph Stone
Capital, LLC </FONT>thereto (the &ldquo;<B>Underwriting Agreement</B>&rdquo;), do hereby certify, each in her or his capacity as an officer
of the Company, and not individually and without personal liability, on behalf of the Company, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such officer has carefully examined the Registration Statement, the Disclosure Materials, any Permitted Free Writing Prospectus and the Prospectus and, in his or her opinion, the Registration Statement and each amendment thereto, as of [&nbsp; &nbsp; &nbsp;] p.m. ET, [&nbsp; &nbsp; &nbsp;], 2024 (the &ldquo;<B>Applicable Time</B>&rdquo;) and as of the Closing Date did not include any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and the Disclosure Materials, as of the Applicable Time and as of the Closing Date, any Permitted Free Writing Prospectus as of its date and as of the Closing Date, the Prospectus and each amendment or supplement thereto, as of the respective date thereof and as of the Closing Date, did not include any untrue statement of a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances in which they were made, not misleading.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to the respective dates as of which information is given in the Registration Statement, the Disclosure Materials, or the Prospectus, there has not been any Material Adverse Changes or any development involving a prospective Material Adverse Change, whether or not arising from transactions in the ordinary course of business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the best of his or her knowledge after reasonable investigation, as of the Closing Date, the representations and warranties of the Company in the Underwriting Agreement are true and correct in all material respects (except for those representations and warranties qualified as to materiality, which shall be true and correct in all respects and except for those representations and warranties which refer to facts existing at a specific date, which shall be true and correct as of such date) and the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied under the Underwriting Agreement at or prior to the Closing Date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the best of his or her knowledge after reasonable investigation, as of the Closing Date, the Company has not sustained any material loss or interference with its businesses, whether or not covered by insurance, or from any labor dispute or any legal or governmental proceeding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no pro forma or as adjusted financial statements that are required to be included in the Registration Statement and the Prospectus pursuant to the Regulations which are not so included.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No stop order or other order suspending the effectiveness of the Registration Statement or any part thereof or any amendment thereof or the qualification of the Securities for offering or sale, nor suspending or preventing the use of the Disclosure Materials, any Permitted Free Writing Prospectus and the Prospectus, has been issued, and no proceeding for that purpose has been instituted or, to the best of his knowledge, is contemplated by the Commission or any state or regulatory body.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Capitalized terms used herein but not defined herein
shall have the meanings ascribed to them in the Underwriting Agreement. This certificate may be executed in one or more counterparts,
all of which together shall be deemed to be one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, I have, on behalf of
the Company, signed this certificate as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp; </FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fu-Feng Kuo</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alfred Ying</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page of Officers&rsquo; Certificate]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Annex II</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JYONG BIOTECH LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECRETARY&rsquo;S CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[&nbsp; &nbsp; &nbsp;], 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned, [&nbsp; &nbsp; &nbsp;], hereby certifies that he/she
is the duly elected, qualified, and acting chief executive officer of Jyong Biotech Ltd., a Cayman Islands exempted company (the &ldquo;<B>Company</B>&rdquo;),
and that as such he/she is authorized to execute and deliver this certificate in the name and on behalf of the Company. Pursuant to Section
7(e) of the Underwriting Agreement, dated as of [&nbsp; &nbsp; &nbsp;], 2024, by and between the Company and Joseph Stone Capital, LLC (the &ldquo;<B>Underwriting
Agreement</B>&rdquo;), the undersigned further certifies in his/her capacity as chief executive officer of the Company and without personal
liability, on behalf of the Company, the items set forth below. Capitalized terms used herein but not defined herein shall have the meanings
ascribed to them in the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached hereto as&nbsp;<U>Exhibit A</U>&nbsp;are true and complete copies of the resolutions adopted by the Board of Directors of the Company (the &ldquo;<B>Board</B>&rdquo;) either at a meeting or meetings properly held or by the unanimous written consent of each member of the Company&rsquo;s Board and any committee of or designated by the Company&rsquo;s Board relating to the public offering contemplated by the Underwriting Agreement: all of such resolutions were duly adopted, have not been amended, modified or rescinded and remain in full force and effect; and such resolutions are the only resolutions adopted by the Board or by any committee of or designated by the Board relating to the public offering contemplated by the Underwriting Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached hereto as&nbsp;<U>Exhibit B</U>&nbsp;is a true, correct, and complete copy of the Certificate of Incorporation of the Company, together with any and all amendments thereto. No action has been taken to further amend, modify, or repeal such charter documents, which remain in full force and effect in the attached form as of the date hereof. No action has been taken by the Company, its shareholders, directors or officers in contemplation of the filing of any such amendment or other document or in contemplation of the liquidation or dissolution of the Company prior to the consummation of the transactions contemplated by the Underwriting Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached hereto as&nbsp;<U>Exhibit C</U>&nbsp;is a true, correct, and complete copy of the memorandum and articles of association of the Company and any and all amendments thereto. No action has been taken to further amend, modify, or repeal such memorandum and articles of association, which remain in full force and effect in the attached form as of the date hereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached hereto as&nbsp;<U>Exhibit D</U>&nbsp;is a true and complete copy of a Certificate of Good Standing, dated&nbsp;[&nbsp; &nbsp; &nbsp;]<FONT STYLE="text-transform: uppercase">, 2024</FONT>, by the Registrar of Companies in the Cayman Islands, relating to the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each person listed below has been duly elected or appointed to the positions indicated opposite its name and is duly authorized to sign the Underwriting Agreement and each of the documents in connection therewith on behalf of the Company, and the signature appearing opposite such person&rsquo;s name below is its genuine signature.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 37%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fu-Feng Kuo</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alfred Ying</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This certificate may be executed
in one or more counterparts, all of which together shall be deemed to be one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the undersigned has
signed this certificate as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp; &nbsp; &nbsp;]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 189.35pt; text-indent: 27.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page of CEO&rsquo; Certificate]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Annex III</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JYONG BIOTECH LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHIEF FINANCIAL OFFICER&rsquo;S CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[&nbsp; &nbsp; &nbsp;], 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned, Alfred Ying, hereby certifies
that he is the duly elected, qualified, and acting Chief Financial Officer, of Jyong Biotech Ltd., a Cayman Islands exempted company (the
&ldquo;<B>Company</B>&rdquo;), and that as such he is authorized to execute and deliver this certificate in the name and on behalf of
the Company. Pursuant to Section 7(g) of the Underwriting Agreement, dated as of [&nbsp; &nbsp; &nbsp;], 2024 by and between the Company and Joseph Stone
Capital, LLC, the undersigned further certifies<FONT STYLE="color: #212121">, solely in the capacity as an officer of the Company for
and on behalf of the Company</FONT>&nbsp;as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I am the Chief Financial Officer of the Company and have been duly appointed to such position as of the date hereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I am providing this certificate in connection with the offering of the securities described in the Registration Statement, the Disclosure Materials and the Prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212121">3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212121">I am familiar with the accounting, operations, records systems and internal controls of the Company and have participated in the preparation of the Registration Statement and the Prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212121">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212121">4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company Financial Statements present fairly, in all material respects, the financial condition of the Company and its Subsidiaries and their results of operations for the periods presented in the Registration Statement and the Prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212121">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212121">I have reviewed the disclosure in the Registration Statement and the Prospectus, the financial and operating information and data identified and circled by VCL Law LLP in the Registration Statement and the Prospectus dated [&nbsp; &nbsp; &nbsp;], 2024 attached hereto as&nbsp;<U>Exhibit A</U>, and to the best of my knowledge such information is correct,</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;complete and accurate in all material respects.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Capitalized terms used herein but not defined herein
shall have the meanings ascribed to them in the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the undersigned has
signed this certificate as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jyong Biotech Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp; </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alfred Ying</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page of CFO&rsquo;s Certificate]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Annex IV</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[&nbsp; &nbsp; &nbsp;], 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Joseph Stone Capital, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">585 Stewart Ave., Suite L60-C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Garden City, NY 11530</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands Joseph Stone Capital,
LLC (the &ldquo;<B>Underwriter</B>&rdquo;) propose to enter into an Underwriting Agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;)
with Jyong Biotech Ltd., a Cayman Islands exempted company (the &ldquo;<B>Company</B>&rdquo;), providing for the initial public offering
in the United States (the &ldquo;<B>Offering</B>&rdquo;) of a certain number of ordinary shares, par value $0.00001 per share, of the
Company. For purposes of this letter agreement, &ldquo;Shares&rdquo; shall mean the Ordinary Shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To induce the Underwriter to continue its efforts
in connection with the Offering, the undersigned hereby agrees that, without the prior written consent of the Underwriter, the undersigned
will not, during the period commencing on the date hereof and ending [<FONT>one hundred and eighty (180)
days</FONT>] from the date of commencement of sales of this Offering (the &ldquo;<B>Lock-Up Period</B>&rdquo;), (1) offer, pledge, announce
the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, make any short sale, or otherwise transfer or dispose of, directly or indirectly, any Shares
or any securities convertible into or exercisable or exchangeable for or represent the right to receive Shares, whether now owned or hereafter
acquired by the undersigned (collectively, the &ldquo;<B>Lock-Up Securities</B>&rdquo;); (2) enter into any swap or other agreement that
transfers to another, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction
described in clause (1) above or this clause (2) is to be settled by delivery of Shares or such other securities, in cash or otherwise;
(3) make any written demand for or exercise any right with respect to the registration of any Shares or any security convertible into
or exercisable or exchangeable for Shares; or (4) publicly disclose the intention to do any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the foregoing, and subject to
the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of the Underwriters in connection
with, if applicable, (a) transactions relating to Lock-Up Securities acquired in open market transactions after the completion of the
Initial Public Offering; (b) transfers of Lock-Up Securities as a&nbsp;<I>bona fide</I>&nbsp;gift, by will or intestacy or to a family
member or trust for the benefit of the undersigned and/or one or more family members (for purposes of this lock-up agreement, &ldquo;family
member&rdquo; means any relationship by blood, marriage or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities
to a charity or educational institution or other not-for-profit organization; (d) if the undersigned, directly or indirectly, controls
a corporation, partnership, limited liability company or other business entity, any transfers of Lock-Up Securities to any such corporation,
partnership, limited liability company or other business entity, or any shareholder, partner or member of, or owner of similar equity
interests in, the same, as the case may be; (e) the exercise of warrants, the conversion of convertible securities or the exercise of
stock options granted pursuant to the Company&rsquo;s stock option/incentive plans or otherwise outstanding on the date hereof (including
any exercise effected by the delivery of Shares held by the undersigned);&nbsp;<I>provided</I>, that the restrictions of this lock-up
agreement shall apply to Shares upon such exercise or conversion; (f) a sale or surrender to the Company of any options or Shares of the
Company underlying options in order to pay the exercise price or taxes associated with the exercise of options; or (g) transfers or distributions
pursuant to any&nbsp;<I>bona fide</I>&nbsp;third-party tender offer, merger, acquisition, consolidation or other similar transaction made
to all holders of the Company&rsquo;s Shares involving a Change of Control of the Company, provided that in the event that such tender
offer, merger, acquisition, consolidation or other such transaction is not completed, the Lock-Up Securities held by the undersigned shall
remain subject to the provisions of this lock-up agreement;&nbsp;<U>provided</U>&nbsp;that in the case of any transfer pursuant to the
foregoing clauses (b), (c) or (d), (i) any such transfer shall not involve a disposition for value, (ii) each transferee shall sign and
deliver to the Underwriters a lock-up agreement substantially in the form of this lock-up agreement and (iii) no filing under Section
16(a) of the U.S. Securities Exchange Act of 1934, as amended shall be required or shall be voluntarily made (collectively, &ldquo;<B>Permitted
Transfers</B>&rdquo;). For purposes of this paragraph, the term &ldquo;Change of Control&rdquo; shall mean any transaction or series of
related transactions pursuant to which any &ldquo;person&rdquo; or &ldquo;group&rdquo; (as such terms are used in Sections 13(d) and 14(d)
of the Exchange Act) becomes the &ldquo;beneficial owner&rdquo; (as such term is defined in Rules 13d-3 and 13d-5 under the Exchange Act),
directly or indirectly, of more than 50% of the total voting power of the Shares of the Company on a fully diluted basis. The undersigned
also agrees and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar against the
transfer of the undersigned&rsquo;s Lock-Up Securities except in compliance with this lock-up agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned agrees that, prior to engaging
in any transaction or taking any other action that is subject to the terms of this lock-up agreement (for the avoidance of doubt, excluding
any transaction or other action in connection with a Permitted Transfer) during the period from the date hereof to and including the 15
days following the expiration of the initial Lock-Up Period, the undersigned will give notice thereof to the Company and will not consummate
any such transaction or take any such action unless it has received written confirmation from the Company that the Lock-Up Period has
expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned agrees that (i) the foregoing
restrictions shall be equally applicable to any issuer-directed or &ldquo;friends and family&rdquo; Shares that the undersigned may purchase
in the Initial Public Offering, (ii) at least three (3) business days before the effective date of any release or waiver of the foregoing
restrictions in connection with a transfer of Lock-Up Securities, the Underwriters will notify the Company of the impending release or
waiver. Any release or waiver granted by the Underwriters hereunder to any such officer or director shall only be effective two (2) business
days after the publication date of a press release by the Company for such release or waiver. The provisions of this paragraph will not
apply if (a) the release or waiver is effected solely to permit a transfer of Lock-Up Securities not for consideration or in connection
with any other Permitted Transfer and (b) the transferee has agreed in writing to be bound by a lock-up agreement substantially in the
form of this lock-up agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned agrees that except as set forth
in this Lock-Up Agreement, there are no and will not have any other agreement or arrangement, either verbal or in writing, with any other
individuals or entities, including but not limited to shareholders, friends and family, and other third parties, to circumvent or has
an effect of circumventing the obligations set forth in this Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No provision in this agreement shall be deemed
to restrict or prohibit the exercise, exchange or conversion by the undersigned of any securities exercisable or exchangeable for or convertible
into Shares, as applicable;&nbsp;<U>provided</U>&nbsp;that the undersigned does not transfer the Shares acquired on such exercise, exchange
or conversion during the Lock-Up Period, unless in connection with a Permitted Transfer or in a transfer otherwise permitted pursuant
to the terms of this lock-up agreement. In addition, no provision herein shall be deemed to restrict or prohibit the entry into or modification
of a so-called &ldquo;10b5-1&rdquo; plan at any time (other than the entry into or modification of such a plan in such a manner as to
cause the sale of any Lock-Up Securities within the Lock-Up Period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands that the Company and
the Underwriter are relying upon this lock-up agreement in proceeding toward consummation of the Offering. The undersigned further understands
that this lock-up agreement is irrevocable and shall be binding upon the undersigned&rsquo;s heirs, legal representative, successors and
assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands that, if the Underwriting
Agreement does not become effective, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall
terminate or be terminated prior to payment for and delivery of the Shares to be sold thereunder, then this lock-up agreement shall be
void and of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Whether or not the Offering actually occurs depends
on a number of factors, including market conditions. The Offering will only be made pursuant to an Underwriting Agreement, the terms of
which are subject to negotiation between the Company and the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This lock-up agreement shall be governed by and
construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof. Delivery of
a signed copy of this lock-up agreement by facsimile or e-mail/.pdf transmission shall be effective as the delivery of the original hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">[<B>SIGNATURE PAGE TO FOLLOW</B>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Very truly yours,</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">By: &nbsp; </TD>
    <TD STYLE="width: 53%; border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page of Lock-up Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">34</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.3
<SEQUENCE>3
<FILENAME>ea020069620ex5-3_jyong.htm
<DESCRIPTION>OPINION OF ZHEJIANG BONING LAW FIRM REGARDING CERTAIN LEGAL MATTERS RELATED TO LITIGATION IN PRC
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Exhibit 5.3</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img src="ex5-3_001.jpg" alt="" style="height: 376px; width: 850px"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Jyong Biotech Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">c/o Health Ever Bio-Tech Co., Ltd</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">23F-3, No.95, Sec.1, Xintai
5th Rd., Xizhi District.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">New Taipei City, Taiwan 221416</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Dear Sir/Madam,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Re: PRC Legal Opinion on Jyong Biotech
Ltd&#8217;s Certain PRC Litigation Related Legal Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">We have
acted in the capacity of licensed legal counsel for the People&#8217;s Republic of China (the &#8220;PRC&#8221; or &#8220;China,&#8221; for the
purposes of this legal opinion, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and Taiwan)
to provide an opinion on the disclosure of litigation matters in connection with the Company&#8217;s registration statement on Form F-1 (File
No. 333-277725), as amended (the &#8220;Registration Statement&#8221;), filed with the U.S. Securities and Exchange Commission. The base
of this legal opinion is limited to litigations that have been filed in the courts of the PRC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>SECTION I: DOCUMENTS REVIEWED
AS THE BASIS FOR THIS LEGAL OPINION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">For the purpose
of delivering this opinion, I have reviewed the copies of the following documents:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">Civil Ruling of Taizhou Intermediate Court of Zhejiang Province</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><i>Ruling Registry No.: (2022) Zhejiang
Province 10 Civil First Instance 1126 (Original Copy in Chinese)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><i>&nbsp;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">Civil Ruling of High Court of Zhejiang Province</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><i>Ruling Registry No.: (2023) Zhejiang Province Civil Final 1150 (Original  Copy in Chinese)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><i>&nbsp;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">Civil Enforcement Ruling of Taizhou Intermediate Court of Zhejiang
Province</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><i>Ruling Registry No.: (2024)
Zhejiang 10 Enforcement 16 (Original Copy in Chinese)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">Civil Enforcement Ruling of Taizhou Intermediate Court of Zhejiang
Province</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><i>Ruling Registry No.: (2024) Zhejiang 10 Enforcement
16-1 (Original Copy in Chinese)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><i>&nbsp;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">Civil Ruling of the Supreme Court of People&#8217;s Republic
of China</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><i>Ruling Registry No.: (2024)
Supreme Court Civil Re-Trial 673 (Original Copy in Chinese)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><i>&nbsp;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">6.</td><td style="text-align: left">Share Purchase Agreement executed between the Company and Taizhou
City Optimization and Upgrade Investment Partnership (Limited Partnership)</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><i>(Original Copy in Chinese)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><i>&nbsp;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">7.</td><td style="text-align: left">Civil Compliant as filed by Taizhou City Optimization and Upgrade
Investment Partnership (Limited Partnership)</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><i>(Original Copy in Chinese)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">8.</td><td style="text-align: justify">Civil Ruling of Taizhou Intermediate Court of Zhejiang Province</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><i>Ruling Registry No.: (2022)
Zhejiang Province 10 Civil First Instance 990 (Original Copy in Chinese)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">9.</td><td style="text-align: justify">Civil Ruling of High Court of Zhejiang Province</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><i>Ruling Registry No.: (2023)
Zhejiang Province Civil Final 692 (Original Copy in Chinese)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>SECTION II: ASSUMPTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">We have assumed the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">1.   The
genuineness and authenticity of all signatures /stamps and the conformity to the originals of all copies (whether or not certified) reviewed
by me and the authenticity and completeness of the originals from which such copies were taken;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">2. That there is no
provision of the law of any jurisdiction, other than the People&#8217;s Republic of China, which would have implication in relation
to the opinions expressed herein;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>SECTION III:</b> QUALIFICATIONS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">We have
made no investigation of and express no opinion in relation to the laws of any jurisdiction other than the People&#8217;s Republic of China.
This opinion shall be governed and construed in accordance with the laws of People&#8217;s Republic of China and is limited to and is given
on the basis of the currently effective laws and practices in the People&#8217;s Republic of China.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>SECTION IV: OPINION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">On the basis
of the documents reviewed and subject to the foregoing assumptions, we hereby deliver the opinion as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt">The statements in the Registration Statement,
as amended, filed with U.S. Securities and Exchange Commission, regarding litigations in People&#8217;s <font style="font-family: Times New Roman, Times, Serif">Republic
of China relating to: 1) Taizhou Investment Dispute and ; 2) Taizhou Administrative Penalty; 3) Taizhou Government Subsidy Dispute,
are true and accurate in all material aspects, and are fairly disclosed and correctly set forth therein, and nothing has been
omitted from such statements which would make the same misleading in any material aspects. Based on our review, nothing has come to
our attention that would lead us to believe that the litigation related disclosure in the Registration Statement, or any amendment
or supplement thereto, contains any untrue statement of a material fact or omits to state any material fact required to be stated
therein, or necessary to make the statements therein not misleading. Furthermore, nothing has come to our attention to suggest that,
in light of the circumstances under which they were made, the Registration Statement or any amendment or supplement thereto (except
as noted above) contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements
therein not misleading.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">We hereby
consent to the use of this opinion in, and the filing hereof as an exhibit to, the Registration Statement, and to the reference to our
name in such Registration Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Yours faithfully,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 40%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ ZHEJIANG BONING LAW FIRM</font></td>
    <td style="width: 60%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><img src="ex5-3_002.jpg" alt=""></td>
    <td>&nbsp;</td></tr>
  </table>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->



</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>4
<FILENAME>ea020069620ex15-1_jyong.htm
<DESCRIPTION>LETTER OF WWC, P.C., AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex15-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Shareholders of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jyong Biotech Ltd. and its subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LETTER IN LIEU OF CONSENT FOR REVIEW REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We have reviewed, in accordance with the standards
of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial statements of
Jyong Biotech Ltd. and its subsidiaries for the six-month periods ended&nbsp;June 30, 2023 and 2024, as indicated in our report dated&nbsp;October
4, 2024; because we did not perform an audit, we expressed no opinion on that information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We also are aware that the aforementioned report,
pursuant to Rule 436(c) under the Securities Act of 1933, is not considered a part of the Registration Statement prepared or certified
by an accountant or a report prepared or certified by an accountant within the meaning of Sections 7 and 11 of that Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><IMG SRC="ex15-1_002.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Mateo, California</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WWC, P.C.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 6, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified Public Accountants</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCAOB ID No. 1171</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ea020069620ex23-1_jyong.htm
<DESCRIPTION>CONSENT OF WWC, P.C
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="ex23-1_001.jpg" ALT="" STYLE="width: 673px; height: 115px"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Consent of Independent Registered Public Accounting
Firm</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We hereby consent to the inclusion of our report
dated May 8, 2024, except for Note 18 for which the date is October 4, 2024&nbsp;in Amendment No. 9 to the Registration Statement on Form
F-1(No. 333-277725), under the Securities Act of 1933 with respect to the consolidated balance sheets of Jyong Biotech Ltd. and its subsidiaries(collectively
the &ldquo;Group&rdquo;) as of December 31, 2022 and 2023, and related consolidated statements of operations and comprehensive loss, change
in shareholders&rsquo; deficit and cash flows, for the years ended December 31, 2022 and 2023, and the related notes included herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the reference to our firm under
the heading &ldquo;Experts&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><IMG SRC="ex23-1_003.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">San Mateo, California</TD>
    <TD STYLE="width: 40%; text-align: justify">WWC, P.C.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">February 6, 2025</FONT></TD>
    <TD STYLE="text-align: justify">Certified Public Accountants</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">PCAOB ID: 1171</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex23-1_002.jpg" ALT="" STYLE="width: 731px; height: 51px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %A QX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WZBBL*[\3
MQVEU+;G2=9E,9QOAL79&^C="* -VBN=_X2Y.VA:\?^W!J8?&!'_,M^(3]+(?
M_%4 =+17,_\ "9'&?^$:\1?^ 7_V5 \8L?\ F6O$(_[<A_\ %4 =-17-?\)>
M_;PSXA/_ &Z+_P#%4G_"7R?]"QXA_P# 1?\ XN@#IJ*YG_A,).WA?Q%_X"+_
M /%TG_"83?\ 0K>(?_ 9/_BZ .GHKF?^$OF_Z%;Q!_X#)_\ %T'Q?,/^96\0
M?^ R?_%T =-17,'QA<?]"IX@_P# >/\ ^+I/^$PN?^A3\0?]^(__ (N@#J*6
MN7'BZY)_Y%/Q /\ MA'_ /'*=_PEEWC(\)Z\?^V40_\ :E '2T5RS^+[U.1X
M/U\_1(?_ (Y0GB^^<<>#]>_[Y@_^.5+DD^7J!U-%<S_PE6H'IX0US\H!_P"U
M*:WBK5!]WP9KC?\  K?_ ..U0'445RG_  ENK_\ 0CZ[_P!_+;_X[0/%NK$_
M\B/KH^KVW_QV@#JZ*Y7_ (2O6.W@?6_^_MK_ /':/^$JUG_H1];_ ._UK_\
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M7#Q_S+/_ )'I0OQ!QRWAK\IZ8'74E<GM^(/][PU^4](4^(/:3PT/^ 3_ .-
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M444 %%%-VG?G-3)M6L@'444F1ZTVTMP%HHHI@%%%% !11G%% !1110 4444
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MSY6]&=&-PT:U-R6ZV/HNBD4Y%+7O'RPTMCM6#XQ\4+X0\/2:O)8W%XD;!62
M#Y0?XF/8>]=!BN?\5^*/#_AJQC'B&YCBM[LF)4>,OY@QR, 'C!YJ(J5]6!5\
M'>/]#\;0N=.E=+F)0TMM*,.H/?T(]Q6/\1OB<O@/4-,M!IQNVO SL?,V!5!
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M_P#P'7_XJN(U#3[2/]IBWM5MK<6IF3]SY8"?ZGT^M>_#0M( XTNR'_;!?\*
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M=:^G;!B^GVS,<EHD))^@H>V@%C(QD]*X/Q;\6_#'A>)T6[2_O@/EMK5@W/\
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MJ:5.9K60D!BI4@@X((-:E>-_L^WVJ2>&;BREL0FE0R,UO=@\R.3\RX]J]DH
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MKL#TKRKX32^%)=0U$^'?#6IZ1*84,CWFXB1<G&TECWKU6@#YSU# _:JC&?\
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MXN:3+?\ AF.[@5V>REWG9G(4\$C'IP:[YIHE^](H^IJ-Y;2XC:-I(G1AM(W
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M!VA^$;+[-H]DD.?ORGYI)#[L>3].E;U%% ')>//!<OC33K>UAUF[TQX9"^Z
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M#.H&V^%6I:=-Y#;;R6WVK"?[Q.>U.PCZ&BN[>:V%S%/') 5W"5'!4CUSTQ5
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MR;B,!3M;WR?_ -76O2(OB);ZYH&N:'K%J=(\0Q6,X>SG; D_=GF-NX/IU^M
M'H-AK&FZK:-=Z??VUU;*2K2PRAU!')!(XK*?Q[X2C8AO$NE @X(^UI_C7E?P
MI<CX&^)V48.ZZQD_],5IWP#T'2-6\(:C-J.E6EU*M^4$D\*N0OEIP"1TZ_G0
M!Z>?B'X.&?\ BIM*X_Z>D_QK5TG7M)UV&2;2=1MKV*-MCO;R!PI]#BO-M4DN
M].N;U8/A'97%I;N^VX$D"AT&<-C;D9 SBMOX4^*;#Q9HE]=V&A6^D1Q7/E-%
M!C#G:#DX4>N* .^H)Q110!E:/XFT;7[B\@TN_BNI+-]DZIGY#DC!_(_E6K7B
MWP, 'B+QP .E\ /IODKVF@ KF]:\?^%?#UZ;/5=:MK>Y RT62S+]0H./QKI*
M^<+C7K3PU^T-KM_>V%U>1;2GE6T0E?)1.<$CCK0!ZP?B_P" @/\ D8H/^_<G
M_P 36GH7C[POXEO#9Z3J\-S<A=WE %6([D!@,_A7'?\ "X/#X^4>$M?Z?] Y
M?_BJX?P=J]OK?[11U"VM9[6*=),0W$?ENF(<<CMTH ]O\0>,]"\+SVD&L7HM
MY+LD0KL9MV" >@]Q^=2:YXLT7PY/90:K>BWDOGV6ZE2=YR!V''WAUKQW]H0_
M\5!X3'J9?_0XZT?CD NO^"7/W1>G(/3&^.@#T[Q+XPT3PC%;RZU=FW2X8I&?
M+9LD#)Z XK<5@RAAT/(KQ+]HH?\ $L\.?]?CC]!7M</^H3_='\J 'UE>(/$6
ME^%]*?4M7N1;VJL%W;2Q+'H !R36K7DG[0O_ "(-J?\ I_3_ -!>@#8_X75X
M.*[EGOW'7Y;&7I^5'_"Z?" &2VI#G_GQD_PK'T'XLV%GX>TVV'ACQ),8;6*,
MO%8[E8A ,@YY'O6@/C%;=!X,\6'G'&GC_P"*IB.Z?6;2/0&UMS(+-;;[424.
MX)MW=/7':J?A7Q=I/C+39=0T>25[>.8PL9(RAW  \ ^S"J_B:X%_\.=6N1#)
M")M+ED\N5=KIF,G##L1FN$_9U!7P%?Y7'_$R?_T7'4WU8SIM3^*V@Z3J=S83
MVFKO-;RM$YBLF921W![BJ1^-'AP '^S]=_\  !O\:I^*/C3;^%-9N=/O?#>I
M@12%$G.U4E _B4GJ#2:=\8;O6+=9]-\$ZM=QMT:&1&_/'2F(Z?PK\1M \87U
MQ8Z:]PEW;IO>&XB*-MX!(^A(!I_BSX@Z)X/GM;?43<R7-UDQ06T1=R!WQ]>*
MX;X?:)KUQ\5]<\6:AH\VF6=W 52*XQNW$IP/^^3GZU3^)&5^.?@DCN8^A_Z:
M&I;=T,Z";X[>%[>58;BQUF*9_NQO:;6;TP"U3GXV^&8IXH[NSUFS$C!1)<61
M51GUYS7 ?&O(^+?AC R=D'X_OS6W^T(/^)/IQ)POVN+/''W9:;>P'M:L&4,.
MAY%+45M_Q[18Z;!_*I:8!1110 444M !1244 %%%% !112T )1110 4444 %
M%%% !1110 52U>W^U:1>6Y&?,A=?S%7:,5,E=-#3LTSY<T?PEKFL!(K#3;B1
M>TK+LC4_[QXKJ_BU820W.B+=;3,;'9*4&1N4C)_7]:]W P,"N/\ &_@D^,)+
M ?:A;I;LQ=@,L0<< =.W>N*>&Y86CJSV(9DYUXSGHE<^;0&5B 6 & <#J.:N
M0Z;>SQ@PV-[)CDF.WD8CWX!KZ1T+P%X?T *]M9++<#DW$_SN3]3T_"NEVBB.
M#T]YG15SG7]W'[SY.FT+6QAUTK4MK=6:TE'?C^&JD\$T "3VUPA R#)&RX/T
M-?7F!37BCE7;(BNOHPR*IX./1F<<YGU@OO/D*)65RRLRY Y5B"/QJUY]W,CQ
MRSW#+M(VM,S=N.,U],7W@KPWJ((N='M23U9$V'\UQ7/S_"#PQ+(S)]NAST5+
M@X'Y@UE+"U=DSICG%)_%%K\3P  AL'[QX/4Y-6].L;Z^NHK.Q@DGF<@*D:$X
MY[^GUKW2W^#_ (6BD#S+>7.#G$LY _\ '<5V&FZ/IVD0"'3[.&V3N(T S]3W
MHC@Y-^^R*V;PM:G&_J8/@/P@OA72F$S*]_<8:=E^Z,#A1[#)KK***]",5%61
M\_4G*I)RENPKF_'5AK^I^%KFT\-W:6NH.0 [';E/X@&_A)'>NDHJB#YRT+X4
M^.-&OOM[Z)X?O[O=N$FH3O+@^NT$ _B#7H*3_& (%73O"T:@  !Y,?SKTRB@
M#@_'?AO7?&'PX32MMHFK2&%Y@)"L093EL'!.,]*W_"&C3:+X0TG2[U8C<VML
MD4ACY7(&.#BMZB@#DOB+X<N_$_@>_P!(TY81=3[-GF':O#ACR/8&L*^^'^HZ
MC\%[;P@\]O%J,,,8WY)CW(^[&<9P1[5Z510!X_HNC_%K0=%L]*M(?"S6]K&(
MD,ID+$#U(Q5_9\8O^>7A+\I:]0HH YV<^+!X-3[.NE_\)'L7<&W_ &?=GG'?
M&*Y//QGQT\*_^1:].HH \7\5>#OB?XVTN/2]8E\.1VPE$N^ R!E(R.X/K72^
M._ %]XC^'6F^&M/N8%FM&@S+/D*PC0KV!ZY%>ATN* /,_&GP\U3Q'\.M&\.V
MMS:I=6/E;Y)"VP[$*G&!FM33/A5X1@TJSBO?#VG2W<<")-((\[W"@,?Q.:[>
MEH \S\9?"#0]5\.2VOA_2M.T_42Z,EQL*X /(X]15C7/ >H:C\(;3PC#/;B\
M@A@C9V)",4()YQGG'I7HE)0!F>']-?2O#>G:;,RN]M:QPN5Z$JH!KS_QK\&;
M+7/M,^A7;:5/=,#<P#)MYL="4'0CU%>J44 <7KO@7^V/AY:^&%O!%):QPJDY
M3(+(,9(]#S6)IOACXEZ1IEOIUKXBT@VUM&L4(\C:551@9RC9XQ7I]% 'D^M^
M!O'_ (GTIM+UGQ)IDEI(P9PMKR"#D=%&?KQ]*]&\/Z1'H'A^PTF*1I([2!80
M[#!; QFM*B@!*Q/%VAR>)?"NHZ/%<+;O=Q>6)67<%Y!Z?A6Y24 >7:+X$\?:
M!I4&F:?XULXK.W!$<9TU6P"23R3GJ33]5\%_$'6-,N-.O?&UH]M<H8Y473E7
M*GKR.?Y5Z?13N!Q6@?#Z#1OAS/X2>\>5;B*5)9PN.7SD@=@..*P="^'GC7PU
MI2:7I/C:WBLXV9E1M,1B"3D\DD]37J5%(#@&\,?$!T9&\=PX88XTN/I^=6O!
MWP^C\)>$K_1DOFN)KYI'EG*;0&90O"^@ KMJ* .+^&_@:3P%H]W82:@M[Y]Q
MYP<1>7M^55QC)_NU:\8^ M&\9VFV^B,5X@/DWD/RR1GZ]Q[&NJHH X;P9\.H
M?"'A34=$2^>Y-\SM)*T84#*[1@?04[P?X 'A3P5>^'3J)NA=&0F;RMFW>H7I
MD^GK7;T4 <A\._!'_"!Z!-I?VXW@DN6F$GE[, A1C&3Z5-XR\ :'XUM=FI0%
M;I%Q#=Q?+)'^/<>QKJ:2@#C?"7P]LO"_@Z[\._:I;F.[,AFE*A2=Z[>!SC %
M<]HWPDU/PW!-:Z%XWU"RLY)#(8EMD;G &<GV _*O4Z* //9/A]XBFC:.7XA:
MPR."K 11C(/4=*V_ W@>P\":/+I]C//.)IC-))-C); '8=, 5T]% "TAHHH
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M*** "BBB@ HHH- !24M% !1110 E+12<T +1124 +1110 F*6BB@ I.U%+0
M4444 %)2T4 %)2TE !12TT$9I-I +2TE+3 2BBEH *2BB@!:2BB@ HHIK#(X
MJ9.RN ZB@=**H HHHH **** "BBB@ HHHH ***0G% "T444 %%%% !1110 4
M444 %%%% "TE%% "T4E% !2TE+0 E%%% !2TE% "TE%% "T4E% !1110 M)1
M10 4444 %%%% "TE%% !2TE+0 44E% "T4G6EH **** "BBB@ HHHH 2BEHQ
M0 4444 %%%)0 M%%% !24M% "4N:2EH **** "DQ2T4 %%%% !1110 4444
M)2TE+0 E+124 +1124 +24N*3% !1BBBBP!BEI** "CM110 444A&:3 6B@4
M4( HHQ13 *0'-*1D48I:W ****8!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%+0 4E+24 '2B@C(Q2 8%3=W\@%HHHJ@"B@44 %%%% !2TE%
M "TE%+0 4E+10 E+110 E%+10 4G>EI*  T44M !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !244M !1110 4444 %%%% !1110 4=Z**
M "BBB@ HHHH ***2@ HHHH 6DHHH 6BBDH ***6@ I*6B@!*,444 %%%% !1
MFEI* "CM110 4444 %%%% !1110 M)110 4M)10 4444 %%%% !1110 4444
M %%%% !1110 M)2T4 %)VI:2@ HI:2@!<TE%% !1110 4444 %!HHH ****
M"BEI* "BBB@!:*2EH 2BBB@ HHI: "BBB@ HHHH *3O110 N:*** "BBB@ H
MHHH **** "BBB@ HHHH 2EHHH **2EH **** "BBB@ HHHH **** "BBB@ I
M*6B@!***6@ I*** "BEHH 2BEHH 2BEHH 2BBEH 2EI** "BBB@!:*2B@ HH
MHH **** "BBB@ HHHH **6DH **** "BBEH 2BBB@ I:2EH 2EI*6@!****
M%HHI#0 M)SGVI:2@!:*2B@ -+244 +2444 %+24M "4M)10 M%)10 =J***
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M$+7[9;:CY9FW#:/G8#K70?$F]\3IXLTD3R06PTNQGU"">*+='//&A9B$8D@
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M *7%)2T )2T44 )1110 4444 %%%+S0 E%%% !1110 4444 +2444 %+244
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M(!4JP )!! (."*Y#Q]J_B[PU;W>JVFK:2EEN2.UM)+-WFD<X 0$, 23GMTH
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MWCC=8%6([<LN3RWKBO6G19$*.H93P01D&J]KIMC9,S6EG;V[/]XQ1*A/UP*
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MFS2R1>$K:"*R2'0[W7Y6LKB^MC)%8VW\+>6>Q.[ ;BO>MBXP5&/I2E01@]*
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M;M-NK2:X7S !B-LM@]ZY?Q=X!\5:I<:[;Q:/9ZDU]<&2WU.XOB&@B."(EC/
MQSSTKV";7M(M]233IM3LX[U^5MWG42-]%SFIM0U*RTFR>]U"ZAM;6/&^:9PJ
MKDX&2?<@4 8^A+K]M=I8WMK:)ID%E"L4R2$RM*% 8$=,<&NBJCJ&L:;I5@+Z
M_OK>UM3C$TT@53GIR:?I^IV.K6@NM.O(+NW8X$D$@=<^F10!;HHHH *6DHH
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M9QWWA#Q!:_:YUMX6FBC :1N@^_4FM?$Y-,U/4H+70-1U&STKB_O+<KLA;&2
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MSZJP!'Z&O(8-;TWPS!\1M+UN[CMKV[N[BY@B?@S)+$-FS^]SQQ7H_@6SGL/
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MZ9?17%FC,K3+D*"!D]?2@9ROA#X8Z=X<N]7EN%6[2\G8Q1RLTB"'Y2H96X+
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M-NKW.H1*EU;:-;B) V[RPQR^#WY.,UZ')8VDM]#>R6T374*LD<Q4;D5NH![
MX%<WK'A"6Y\9Z=XGTN[6UO(5^SW:.I9+FW)R5/H1U!H \62'5U^&1O&BLSX4
M.L"Y\[_E],?GX!Q]W.<=\UU^O'6O&?Q!N+S1DT][3PF0!#?.VV:9@6+ +Z8
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M0RB, ?/%MQ\I8G/(K-\^ST/QM9^)-2\,WD?AZYTE8K*(6>_["V>4*#A=W/\
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M/,,FU=Y&"V.<>F:%147:JA1Z 4ZB@!OEIM5=HVKT&.E#(K8W*#@Y&1T-.H%
M#0BABP4;CU..M"QHN,*!CI@4ZB@!"BL,$ _44U8D0DHBJ3U(&,T^B@!@B0$'
M:N1T..:?110 A4$@D=*,#.>]+10 44M% "8S12T4 -[TM%+22L E%+13 **2
MB@!:2EI* "EI*6@!**6B@ HHHH **** "BBB@ HHHH **** $Q112T %%%%
M"44M)0 M%%)0 4M)2T %)12T %%%% "44M% "44M% "4444 %%+29H ****
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MSC/A1%^NI)_1: .EI*YXZIXHQQX:ML^^I ?^TZ0:IXJP?^*;L@1ZZIU_\A4
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M** "BBB@!:2BB@!>U HHH 2EHHH #2444 **.]%%  :2BB@!12&BB@ HHHH
M****  T444 %':BB@ HHHH *6BB@!**** "BBB@ HHHH **** "BBB@ HHHH
? **** "E%%% "4=J** %[4E%% !1110 M%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-3_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-3_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #. 00# 2(  A$! Q$!_\0
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M;T'Y'_&@8OEY[_I_]>CR\=_T_P#KTF\^@_7_ !I=YY^[Q]<GZ<T 'E^_Z?\
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MZ_8^&]-\>ZB\>D^#O"%S9> -7'Q8\>7=UI%IX+\*S&.?7-,N]<L)Z_*O0_\
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M +%_C'5-1\+ZYXGT.XU;7_!=M\,=(N=;T'Q'KVF:CK.G>)!'J=]:RRF7]J_
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MOX>N+?Q+\"?CG\-+VY\<ZEXEOO$&J^.M ^+?P;\-^,/ OVFUU*!KGP_8>&/
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MN)Q*E0RK^U,P<\+3SC"8^C2H8:%;$QEB,KH1>'2A2K9A7IS53^T>5GV'8&D
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M/O&OB2RE\+Z%\7)+JT\-:B=.%U_PD_B+1+2TMM*L+[3X-7MI?PI\"?"CXS_
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M@VS\._$G7OA;JM[/:K']G\7>"-3MH)FLI'59M3T^&YE-O)=VTG(>+?&/PR\
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MJ2">PTO3U\/K<_$5-6'_  B]K'I,5S9:%)%)96E]=ZC>0HLU],Q^G<'S0<<
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M=3Y>!BECLU:JTW.56E)1C[TZ35.48*K#G3L[1J0MRQG!M*2:E;^O?%^OEL_
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MM;:)(5[EL$8.#Z G'/\ GTK^;3QC\6/VK_\ @F?IGQ;_ &M?VA/V8/A;XD^
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MOQQX>\17173KS7?&6H^'?$]O+%9VFG)KMO:Z9-<:M8^+'AS]DK]IW5? %_\
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MZOS;WUW%91B]:V:FDWV^;2_K\?F.33E%ZKSM8[[]H'X+:?\ \%7/BCI'BO\
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M=O9P>$/BE::7XE2W>W\8WUG5J.FJ=_/1?><Z][;7T/Z?_A!\4?#/QO\ A/\
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M1&@O6N6^S5[1\&OBII'QK^%W@CXKZ%X=\=^$M'\>:#9^(=.\-?$WP?K'P_\
M'VB6]VSA;+Q5X-U^&WUCP_JJ>66EL+Z%)%C,<J%XI(W;^;_5OVE/ GQ/_P""
MV%U^T5\--0UCQ/X8^'?_  0P^-EUXJM_"R+J'BOPMKUE^U-IVJ1^'+BUT^YD
M$'B>9-"OIM*@M;I7OHXH+^PFDLIH+I_R]\#?ML_MD_&#1?\ @G?\&=;U']I+
M]HWX/^(OV*](^+?Q'\%?#WXXQ?!;XG?M)?&#PKX%^&J:SX$M_CUX%O-3^,GB
MM?"<?Q!L_'_CGP7]OT?QMJ>HI<WFIM+X/TJZF'H.<'R*,G/G=ER7FOM>\VO=
M2;BXK5^]9>9_(L.!^)/:9YAL3EN(R_'\/XBA@<PR[,*-3"XR.95\QPN61RWD
MK3H4Z&+5?&4)_P"VU<-AZE*:='$U'*+7]YX Y<R#D$\MD  MN(&,C/1N2,KT
MSFOSS^,O_!2;X6_#/XU>+OV=OAY\&_VE?VJ?C1\-?#WAKQ3\6?!'[,GPUTWQ
MFWPFT7QG!-=^#G\>^(O%WBWP%X4T[5O%=A:7FHZ#X:T[7=5\37NG6DM\VD0V
MC1RO\K?\$;[3]IZTL?VF9_BW<ZO:?LY^(_%OP^\4?LJ_#CQW^T/=?M)_%WX*
M:9K/A2^_X6?\*?'_ (V\1VMKX[L;31O$%MHNJ>%M \>/=^(=%M=7U#3KF[86
MH5.=\6_L[Z!\7/VV_P!JKXQ_\$Y/V]+G]FS]KSPW)\+_  1^V;\(=9^&.@?%
M;X1?$37O"GA&.]^$NI?$3X?^+$\*>)K*Z7PAJ;Z$GQ"^&7C.WBN--BN=-CG?
M5M-O(VIIM1U35M.C:/F:]&OA,17PF)HSP^)PU:IA\30K1<:E&M1J3I5:56#N
MX3IU*<X3C>5I1=G)6E+]1/V3OVMO@Y^V;\*6^+OP5U#Q)-H5AXL\3?#[Q1X?
M\;>%-:\#>.O GQ#\%7J:;XP\!^-?"7B"VM=3T/Q-X;OY([;4;1EGMF\R&XLK
MR[M)X;A_IG(4L"Z]>/F]\=_4X%?RY?#3]O[XQ_'[X@_\$^KWXAZ9X9^"OB7X
M7_\ !7/]H_\ 8P_:+N?@7XWUM_V?OC;XH\(?LG_&&[TWQ!I%T\NGKK?ACQOX
M_P!4\.7.E^'?%IUR\T[QQI,<+WTVKVD;1=9^VS\>?'NE^-?^#@VV\!_%[QQI
M5U\$O^"7WP7\3>#+;PQ\0/$-FOPJ^(UQ\/?VIM<O=?\ "4.E:TL7@;QG=6]K
MX3U2]U70DT?6[S[%HEU=3RI;6,U3RR[/U=OQM9?AT(]HD[.R6RMW_#N?TQY'
MJ.XZCJ.H_#O2_P"?_P!7H/8<5_-7HGP(NOV7=,_X) ?M+>%OCA^T;XN^.?[0
M_P </V?/A'^TMXQ^(WQY^*/CK1/CIX5^-/[.WQ$\2^)++Q9\.?%?BG5_AUI4
M6B^(_#NAZGX)/A;PQH,_AMM+MX8+F=C,\_\ 2I2+33VU"L3Q)X:\/>,?#^M^
M%/%NAZ3XF\+^)=(U+0/$7AW7K"UU71-=T/6+.;3]6T?5]+OHI[+4=,U*PN)[
M*_L;N&6VNK6>6WGC>*1U.W2Y/ ].GXT#/GGX/_LE?LN?L](R? ;]G/X'?!G?
MGS)/AA\+/!/@:>4,B(PFN?#>B:=<3;ECC#>;*^[8N<X!KQ3]H3X*>(/ VMZK
M^U#^SQ>:%X2^+>C6T5_\2/"^KZN/#WPZ^/'A'2H/)O-(^(%Q)#+8Z1XJT721
M)<>#?B&MNNI:1>VEKIFKSWOAN>YM(_O"O-OBU\(_ 'QQ^'_B3X7?$_0O^$E\
M#>+;2.R\0:(=0U/3%U"UANH+V.%[S2+RPOHT6YMH9&2*Y1)0GE3K)"SQM,TW
M"7*HN:3=-R;5JBC)0?,E)QU:NU&3M=6:;3^HX,SY\.<0X#%UL15IY+BJU+ <
M3X2."HYOA\TX;Q6(H+.,OQ>1XO%X'!9Q2JX6-6K0P>)QF!<,PH8#&X3,\IQ^
M#PF9X7\@'T_XN?M"7EY^UQ^SS\ +?POX%\=^ [*Q^,WP0^,4MG97O[8'A_4K
M"TCGFLM$LKW5/"_AW6O!6CV^HV7@/Q[KL(NOB%)J,>F7RV/@Z'3[V_\ I7]B
MCPQ^R,_[-?CBQ\ ZMJ'CGPA?-KVE?&RW^-L5AJ7Q(T:32]/N+>^^''QB2^TR
MSO"W@+0Q)X?L]+UJ*>&RT:UB%G/<VT@N9OO'2M'\&_!SX<Z5H=C(F@^!OASX
M1LM)LI=6U2:XCTCPSX5TJ*TMFO\ 5]5GFNIULM.LX_M%_J%U-/(L3SW$TDA9
MC^7_ , _ /P4^-'A_P#:8_;3^*^E#P;\-/VD8==T :'-K^J^"?#M_P# SP.9
M_"UGXG\=:=H.H:+::KXM\:SZ3J7B)]:U:*3Q)I6C:IIWAJ"]58KF&?F]BU5H
MR:I5:TZ-=U%-6A&3IP56M2A[_LJ56K%4ZU.,)1FI.<7"<JJJ?O;XUI<;<)\5
M9>\-Q+PAP9P]Q-P5@.#,7PE+'YKG.<.'$%?#<*\(\11S#'0Q_%/%.7<-/,\[
MX;S^CF."S3(*V78+(L=0S7A9<*QX<W?^"=5YJO@/]GOQM\8/$/Q$O=)_93U?
M4O%/B[X ^!/'*7%]KWPG^#FC:OK4&E7%[XVO[^74KW0M?T:QM=8T3PM>V<LO
MA6PDMM.MM0NQ(88?S+^.7Q;U3_@I7\9]$\*?#77[VWU6T^(J>#O@]\*=7TR=
MYO#?PN/AZ2?XD?M)?$W06NX'TA8K]X-(\-)>^5J$-D\6A)!!JVL7-F^'\?OV
M@F_:%A^$O['?[*>B>+;+X86LVD^$/AS\/56;4KWQGIVCW-I-'XK\?WMY>7\V
MF^"=!MDL-0TV+Q#<0(@:ZNM:8W]K!IUG^XW[#G[%GA?]DOP'<K>SZ=XL^+WB
MV8W?CWX@0V)MVN@)Y)[#PSH0GDFGL?"^AI*8[.V1X1?7;W.JW5O%/=>3!YL(
MU<73I8&DX5,%3II8W%OFJ0JU74C4>'PBFW)4XRYHTTW*-*@Z<=H4Z;_H+B&K
MDG@ ^(_'#C&C/#^.W'N88RKX4<!3P65X?'\+\*4YXC*:/$W'M"&$KX:MG6:X
M"CEU7BC-:$\-F^:YVLRR_"8VKCLUXPSC#?0O[/\ \#?!/[/'PK\*?"WP+:F/
M2O#UCMN]2N!&=4\1ZU<N;C6/$NN7$4<:W>L:U?/+>7MQM"[F2&%8[>*&*/VJ
MD' 'T_S_ )_*EKW$HQ48Q2C&*48Q2248Q5HQ25DDDDDE9+HD?YTYIFF8YYF>
M8YUF^-Q&8YKF^-Q699EF&+J2JXK&X[&UZF)Q6*KU)-N=6M6K3G+:,5RTZ<:=
M*E2ITF_-NR,8P!C..<G)Z'MBG44UF"X!ZGI_GI]/7MFF>?9*[U^_0&;;CC.:
M=2 YYP?QQ_C2T FGMJ%%)SN']W'/3KS^/I3B2<9[=*!@1@]C]**2B@#SCXH?
M#+P-\9?A[XV^%7Q-T"W\5_#[XC>%==\$^-/#5Y/J%G:Z]X6\3:;<:1KNCSW>
MEW=AJ=M#J.G75Q:S2V-]:W2)(6AGC8!A1\5_!_X8_$'X4ZU\#/&_@K0?%7PD
M\0^"V^'NN^ ]?LO[4\/ZKX+DTQ=%?0;ZWNWEEGMCIJ);K+)*;J-DCN8KE+J-
M)EY#]I)OVF8_AK=?\,EP?!&Y^, UK1OL*?M!S>/(/APN@-,RZ\]TWPW1_$TF
MJI;;6TJ--MF\^X73+'S7Y"_LJ_M.?\%E/CS\<OCS\.?$/AO_ ()H:+X7_97_
M &C/"GP0^-5YH4G[4#^(M<L=1^'_ ,,?BWK>K?#5+W5;G3VNT\#?$BSLM'/B
MBVL+=O%-C>0W=J^EPBZN-I.^EO/1I?F<L8R6JY7&[T3>K[VU?J[V/TI^(?\
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MUG!:Z7H5S#':O=Z)/++9VON?AS]O/5OB)_P4R^$7[-7PI\1?#7QY^S#\5?\
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MIFBZC':Q:/::AI5G%-/I]W)']8?M'^*O"GB#_@K9_P $N]'T'Q)H.KZIX?\
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MXB,9*48UZ5.M3IUHQDE)1K4ZL5)*2BFDU^FX(& 5 / &>_8GD9]^>34F .@
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M30Y;.>6:1I;=P[AFW9.VKW3V?IJ8Q=U:6COMO&WGMJ?D'^TS^TSXU\:_$/\
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M7?"_PK_P6V_;G_:UTWXU?%GQA^SI\)/^"3WQ>G^#GP7UC]GKQ%I'PD_:,O\
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M\ >)?B3IO[2FA_#SP1K7[4GPX^&'CGX??!GQ[XWOO$MOIOAZR\7V\MQ=Z#J
MT2:X^Q^'M<U=+,>(M0T_1;S7_P"SEDCLI6*10UYQ^P+^Q9X-_80_9[M_@EX2
MO+75+K5O'WQ#^+/CC5]-M-7TW1=2^(/Q2\37GBCQ,?#FDZ_XA\6ZWI'A?2Y+
MJVT#PQIVL^*?$FM0Z#I&G-KGB#6]:DU#5;R&_NZ>12Y_3O?5?)&-^V__ ,%
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BH+J]M;&,27=Q' A.T-(P4$^G-9X\1V3W)@@$MP>S0 .&^F#F@#
M7HJ!+E7M3<&.5% )*LA#<>W6LYO$^EI_K'N4_P!^SF'_ ++0!L44@8%0PZ$9
MI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHIDTT5O$TLTB1QK]YW; 'U)H 9=W<%C;/<7,JQ0IRSMT%<_<^*].N5
MDAM[VR>-A@2+?K$WX9'%4K[7;B>[W1F*-$RJFWU>$!AGJ58=:LZ?/<:E+Y8D
MNP!]Z03VLP3TS@$T@&6-I/J$F8=0U$0'(,T.HQS*I]/NFNFAMDA1!@.Z@#S&
M W-[D@=:\]O_ !U=Z3K=W;6T5K-:QN54;-A)'4Y'7G-.7XH2X^;2D/TF_P#K
M5G[6!I[*1Z/5*^TNUU$J;F,N4!VXD9<9^A%<2/B?@C=I7'?$W_UJZ'0?%UIK
MD%S(8S:FV&YQ(P(V_P![--5(RT3$X26K1572KK1YEGBDLUD.54K:W$O'T$AK
M:LM2+11QW/F/<$X+1V<J)[?>!Q^)KG+#5V\2>+6^S&>*RMH7C\R(G$N3W/\
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M'6+&XT<Z;/I;K%-&]P)&WDL", #@;3S1\2/B&OP]LK"Z?3A>K=2-'M$XC92
M#D#!R/Y<>M ';T5E>&M8/B#PWI^KF%8/MD(F$:R>8%!Z#=@9.*X/4?BSJ5KJ
M_B&RL_"IO8=!RUW.E\  G8@;>O<CM@^E 'J-%87@[Q'_ ,)9X6LM;%LML+H,
MPB$HDV@,1R<#GCIVKD/$/Q;&A?$*+PE_9"322RPQK<&\"*/,Q]X;3C&>F?3U
MH ],HJGJUZVF:/>WZQK(;:!Y@COL#;5)P6[=.M<[X'\:R^+?#<NO7>F#2K %
MC%)+<!PZKG<QX&T CO[T ==17EQ^*^IZ_>S0>!_"=SK-O"^Q[Z:000D^Q/7\
M2#[4VX^)_B7PXPE\7^![FTL,@->64XG5/<@=/Q(H ]3HK/T36;3Q!H]OJEAY
MIM;@%HFDC*%ESC.#S@XX]JT* "BN2^(/C23P+H46K#3/MT!F$4@$XC*9'!Z'
M/2L%?B'XQ=0R_#/42K#(/VM?_B: /2Z*X/PW\38=7\1CP[K&BWNA:NZ%X8+K
ME9@!D[6XYX/;L>:[R@ HKC?&7Q&TSPC<V^G"WN-2UFYY@T^T&78=B?0?F?:L
M+_A,_B9Y/VH_#F/R.OE?V@OFX^G_ -;- 'I]%<1X1^)FG>*]2?2#IVH:?J\*
MLT]I<0G]T!CDMTQR!S@^U=O0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 9'BC58M$\,ZCJ<\'GQ6\)=H@VW?VQGMUKQD?&7
M1^_A&3_P-/\ A7J/Q-C:7X;:ZJ#)^S;OR()_E7R?DGO28T?5/@KQMI&MZ; (
MX?[.FER5MY'W Y/9N]=GUKYT\%NIM]&R>/,0'\'KZ+K.G-RO<N<4K6$&>]+1
M16IF0+96RWK7@A07+)L:0#DKZ5/110 @50Q8 9/4XZTM%% '/^);(W+6[I:K
M,PR"6M3/@?3>N/UK _LB0C']E6Y_WM'S_P"U:[^BE8"&T+&TA+C#;!D;=N#C
MTR<?3-3444P/']2'_"$_'VQU ?)IWB:'[/+V43C 'XY"?]]&F:KI\'Q(^-%U
MIERHETC0+!XI!U!GE&/S&?SCK=^-.BRZKX&%Q9P3RZG8W4<]H+>)I'W9P1@<
MXP<_@*B^"NE7=IX8O]3U6&YCU?4KZ2:[^TQ&-\]N".1R3_P(^E &-\+O$Q\-
M>"/$FCZNV+CPO++E2?O1\E0/JP8?B*U_@YH!_P"$$NM3U1!)=>(9I+JYW#[R
M-D 'V(+'_@5<'\7/#6JGXAS'1[;438ZQ;PKJ;6UJ[H,..X')PBG'M[U]!65K
M#8V-O:6R;(((UCC7T4# 'Y"@#R7X2Z@/"EUXK\':E+M719GNX6;O;GDGZ8VM
M_P #KBSX7N/%_P .?$_CUXR-4N+\WUFP^\D,1((!^A;_ +X%;7QNT/5X_%5O
MJ7AVSOI9[_3WM+[[-;NX,><<D#J1QC_9%>Q^'=(M--\(Z=I,49-K':)$5=<%
M@5YW ]"<G(]Z /,O&WC637?@SI L"&U'Q&8[((O7?G$H_,;?^!5-\6K9O"7P
M2M=$L"RPAX+*1UXRN"6)^I7GZUR/P]\*ZE!\5+:QO[74O["TBXNI=-:>U=8R
MQ/!R1@9P&SZJ/6O</&/ABV\8>%KW1;EO+$ZYCE R8W!RK?G^F: +'AK2K/1?
M#6G:?8(BVT,"!=O\7&2WU)Y_&KU[9V^HV-Q97<2RVUQ&T4L;=&5A@C\C7D6@
M>-O$?P_LX] \9^'M1N8+4>5;:G81^<KQC@!NG08YSGU%3ZS\3]9\36DND^"/
M#&KR75PIC^W747DI #P6!SU'8DC'O0!ZS!!%:V\5O!&L<,2!$11@*H& !^%2
M5R=K?Z]X6^'C7OB*,:IJ=C#F06.2TP& .H^]ZG'8FM/PIXBA\6>&+'7+>!X(
M[I"PB<Y*D,5(SWY!H X;X_\ _),V_P"OV'^M2VWQ+UU+6%%^''B%@$4!@HP>
M/I2?'6WNK_P)'86-C=W=S+=HRI;0-)@*"23@<=:]#TN43Z39RA)$#PHVV1"K
M#@<$'D'VH \MLM+\3>.OB7I/B35=!DT+3-'1O*CGD#2S,<]NPR1VZ#OFO7:*
MYFR\7->>.K[PR=&OXEM81+]N=/W,F=O /_ N/H: ."^%$4>L_$/QOX@OAOU&
M*\^S1!^6ACRPP/3A5'_ 37L=>0Z]X>\1^!/'=UXQ\*6)U/3M1YU+34/S[LY+
M*._/.1D@D\8-7S\;=*^SX7PYXC-YC_CV^Q<Y^N>G^<4 >B0Z990:G<ZC%;(M
MY<HB33#[SJF=H_#)JW7FO@NZ^(.M>*KG7=6LXM+T*=!$FFW#L95 SAU&.&R>
M<XR#TX%=+HWBYM7\6ZOH1T:^MAIV,7<RXCFYQ\OUZCU'I0!TM%%% &!>>+;2
MWO9;2UL=1U*6!@D_V&W\Q8FQG#,2!G'8$D>E6/\ A)]&33%U&YOXK*V:0Q;K
MW]QAQU4A\8/!X]JQ--OKKPI'<:9>Z/J-S']JEE@N[& SK,LCL_S!>58;L'(Q
MQD'FH/%L^I:AI&E7D=AJ-E)%J&_$5JMW,D?ER .8QD<Y QSC- '0)XN\-RV<
MMXFO::UK"RI),+I"B,W0%LX!.*%\6^''L7O5U[36M(W$;SBZ0HK'H"<X!-<K
M<&_UC0+&WLX;W[?!J,#/=7^DF$$;F.XQC;E5'!P16KH6DZA'XDOI]<^SSSK
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M]I^,_P#H7K+_ ,#!1_:?C/\ Z%ZR_P# P4>WCV?W,/9ONOO.JHKE?[3\9_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex15-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P )4# 2(  A$! Q$!_\0
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:3-O."H)(&W..I/.,U8HH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !\ L$# 2(  A$! Q$!_\0
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MHH **** "BBB@ HJHVJ:>DK1/>VRR(<,C2J"#[C-3Q3Q3IOAE21.FY&!'Z4
M244P31,<+(A^C"GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^"!W'F.^M"9E'J 1^F:$P.PHJ.">&YB$L$J2QGHR,&!_$5)3 **** "BBB@
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MVLQ.3E>A_*O8/ GQ>U/4KS[+KMO!)  -UW"-A3/3*]#^&*\+C1I) BKN=C@
M=<U[1\-O" FN8HG3,46)KE_5NR_Y]ZRE)K1;FL8IZL]R1PZ*ZD%6&01W%.I
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MI_X"_P#UZZ^BCDK?SK[O^"'-#^7\3D/^%C:3_P ^6J?^ O\ ]>C_ (6-I/\
MSY:I_P" O_UZZ^BCDK?SK[O^"'-#^7\3D/\ A8VD_P#/EJG_ ("__7H_X6-I
M/_/EJG_@+_\ 7KKZ*.2M_.ON_P""'-#^7\3D/^%C:3_SY:I_X"__ %Z/^%C:
M3_SY:I_X"_\ UZZ^BCDK?SK[O^"'-#^7\3D/^%C:3_SY:I_X"_\ UZ/^%C:3
M_P ^6J?^ O\ ]>NOHHY*W\Z^[_@AS0_E_$Y#_A8VD_\ /EJG_@+_ /7H_P"%
MC:3_ ,^6J?\ @+_]>NOHHY*W\Z^[_@AS0_E_$Y#_ (6-I/\ SY:I_P" O_UZ
M/^%C:3_SY:I_X"__ %ZZ^BCDK?SK[O\ @AS0_E_$Y#_A8VD_\^6J?^ O_P!>
MC_A8VD_\^6J?^ O_ ->NOHHY*W\Z^[_@AS0_E_$Y#_A8VD_\^6J?^ O_ ->C
M_A8VD_\ /EJG_@+_ /7KKZ*.2M_.ON_X(<T/Y?Q.0_X6-I/_ #Y:I_X"_P#U
MZ/\ A8VD_P#/EJG_ ("__7KKZ*.2M_.ON_X(<T/Y?Q.0_P"%C:3_ ,^6J?\
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M:I_X"_\ UZ/^%C:3_P ^6J?^ O\ ]>NOHHY*W\Z^[_@AS0_E_$Y#_A8VD_\
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M^7\2CI&JP:UIZWMO'-'&S%0LR;6X..E7J**W5[:F;M?0****8@HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex23-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z ND# 2(  A$! Q$!_\0
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MHH **** "LJ[L-3FN6DMM8-O$<8B^SJ^/Q)K5HJ913W&G8P_[+UO_H8#_P"
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MR];_ .A@/_@&G^-']EZW_P!# ?\ P#3_ !K<HH]G'^FPYF8?]EZW_P!# ?\
MP#3_ !H_LO6_^A@/_@&G^-;E)D9QGFCV<?Z;#F9B?V7K?_0P'_P#3_&C^R];
M_P"A@/\ X!I_C6WD>M+1[./]-AS,P_[+UO\ Z& _^ :?XT?V7K?_ $,!_P#
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M/\:/[+UO_H8#_P" :?XUN9HR,9H]G'^FPYF8?]EZW_T,!_\  -/\:/[+UO\
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M_C1_9>M_]# ?_ -/\:W**/9Q_IL.9F'_ &7K?_0P'_P#3_&C^R];_P"A@/\
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M'TJQ10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex23-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P )4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD_'&H3QKH^D6[
M1HVJWHMY'E@691'M);Y6X)SMZ^]=97&^+XEG\6>#8V;&+Z1QC_9C)_I0!V5<
MQX^U?5-!\+OJNE*C/;31O,K@'=%G##]1SVYKHQ<0&Y:V$T9N%02&+<-P4D@-
MCK@D$9]C7/?$&Z@M/ 6LM<<K);F%1C)+/\JX'<Y(/X4 6/$VN7&D:?:2:?:Q
MWEU>74=M!&TFU26R<D@'@ $UN"N,N([FW\<^%=.>Z:2."RN)'&T8D=45-V.Q
MPQP1R,D9P3GM* &12QSQB2*1)$/1D.0?QJEJ>M66DM;QW#.UQ<L5@MXD+RRX
M&6*J.2 .3[?A7)>#;7_A'O&FO^&[0.^E1QQ7=N!*9!;%L@QG.=I)R0#S@9YS
M5KPUGQ!XJU;Q',6,-I*^FV",N $4CS)!ZEFX!] 10!V=%%% &?KNJQ:'H-]J
MDQ0+;0M( [;0S ?*N?4G 'N:\\N++Q)X:\/VWC%-4O=1O]HN-1L99#Y)B?#,
MJ+SLV=,CL"< <5M_%V1D^&NI*$+!VA4D?PCS5.?T _&KOB?5+#3OA[="\G1#
M-I_E1QYRSNZ;5 '4Y)_F>@- '1V-Y%J.GVU[ 28;B)9H\]=K $?H:+V^MM.M
MC<74HCC!"C@DLQZ*H'+,3P% ))X K%\#V$VD>"]'L+J9I+E+8.P?AEW'=MQG
MHNX+^';I65"TOBCXC3%G4:7X=(58L[A/<NOWB.GR#@=P>>_ !UUA?VNJ64=Y
M93+-;R9VNO?!P1[$$$$=B*LT5&)XC.8!*AF"AS'N&X*>,XZXH DHHHH ****
M "N#^),ATN7P[XA^S7$R:;?CS?LZY98W4AOS(4<D D@=Z[RB@#SJ'PGK6JW'
M_"7I>FQ\02R^9;Q3AC%%;;<+ Z>N.21T8GOS6I::!XDU;4X+GQ7>Z<;2TD6:
M"QTY&V-*N=KNSC=QD_*.,X/;GL:* .6\6:/J$^HZ-KNC1";4--F8&!I @FA<
M8=<D=>F/Q[XK'T_P[XXL)&U*'6;-[V_8M>VMYNDAAY.TQ;0#E5XQG!]>!7H-
M% &+X<T#^P[69I[C[7J5W(9KR[*E3*_;C)VJHP !P *Y73]0\6>%4ETH>$Y-
M2M_MTQM;JWN44,DCM(-P.=O4\G Z#KU]$HH R]'OM5OHF?4M'&FG PAN5E)_
M[Y&/UK$\>7\UE+X76WN6A>;7;:-PCX+QD,&!'<<C/X5U]8=WX?>^\66&LW%X
M3!I\3BVM53&)7X9V;//R\ 8XH S_ (EV%UJ?P\U:ULH'GN&6-UC3J0LBLV!W
M.%/'4]JT[/P]I33VFJ3:;;G4DA1?/>,%UPH'?H1TK9HH H-HU@^N+K1@/]H+
M!]F$V]O]7G=MVYQU.<XS7 V%[XB\&ZYK5BOA>[U.'4M3EO;:XM6^0"0CAV(P
MN,#KCOU'->FT4 4M,N+^YMO,U"QCLI2>(DG\WCW( &?IFI5L;<:@U^$(N6B$
:3-O."H)(&W..I/.,U8HH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tjyong_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tjyong_logo.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  W     $  0#<     0 !_^X $T%D;V)E &2      04  DE$_]L
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MS]]ZCD[DNYDMMM3ZB\!H<SQ_\?M'7^?0EVWEJ[NL:= K\6#7RX:^B2]C=_\
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MVSA<Q-JKZTH:_#_J^7EQ&YWYTW+G?F/=.:-WF+7]P[,*Z11,#PP(XU4BE 2
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MX'1HR;"_LEZ$'2:S.77$P(Z0R5=;55*TM#2QD7JZVK!*W.K_ (!\F][?YO\
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M?RJ/@G$CH>F"\,G$PJ]\]D5<,M_[)^YW>/\ >/?K>26/=/$!.H'5Y>0J.(/
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MMTO?KC%_C)703\NVG^#H8_BY_E/RC^.+K_G1W]TO$+W^A[#VQ&Y(("^E"?\
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M6 C7-8J;'R?JFAC!MQRK*Q%BR !JL$<^\M>9=@M>;>5-RV61>^6+17/$D4-
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M_?#:&VG:>45/Q?K@_D(?Z1ZC_P"[5OL>Y<]<_31-59$MR.(_WZ/-1Y]6>?S
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MC_B^;]W"!6[AJVJM1^\H\>YBQ])/]31T<-^?>*6]7LFY[K-'$:6(/;\P,\"
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MFJ2E\N=W/7@">:FHQ]W]K24BA;T/WH'^3T_/^:O[C'>;B+>;G3.?TP:#C^7
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M[&XJ@P]#3XW'4E-1T%'&(Z6GIXO!!"O] +\?Z_LK::*8G-?V]9)"0BM.G)K
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M?Q;<%:TF1KE+I_F34?;CFP'LXM[4QM\-!ZG.>ITV_EBRVZDL(S3SK7T\W/\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ttimeline_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ttimeline_002.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M -DTW_;3U[_A]SYV?\=NGO\ T7DG_P!<??OZVWGJG^\_[/7O^#>YR_WWMO\
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M -%Y)_\ 7'W[^MMYZI_O/^SU[_@WN<O]][;_ -DTW_;3U[_A]SYV?\=NGO\
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MY)_]<??OZVWGJG^\_P"SU[_@WN<O]][;_P!DTW_;3U[_ (?<^=G_ !VZ>_\
M1>2?_7'W[^MMYZI_O/\ L]>_X-[G+_?>V_\ 9--_VT]>_P"'W/G9_P =NGO_
M $7DG_UQ]^_K;>>J?[S_ +/7O^#>YR_WWMO_ &33?]M/7O\ A]SYV?\ ';I[
M_P!%Y)_]<??OZVWGJG^\_P"SU[_@WN<O]][;_P!DTW_;3U[_ (?<^=G_ !VZ
M>_\ 1>2?_7'W[^MMYZI_O/\ L]>_X-[G+_?>V_\ 9--_VT]>_P"'W/G9_P =
MNGO_ $7DG_UQ]^_K;>>J?[S_ +/7O^#>YR_WWMO_ &33?]M/7O\ A]SYV?\
M';I[_P!%Y)_]<??OZVWGJG^\_P"SU[_@WN<O]][;_P!DTW_;3U[_ (?<^=G_
M !VZ>_\ 1>2?_7'W[^MMYZI_O/\ L]>_X-[G+_?>V_\ 9--_VT]>_P"'W/G9
M_P =NGO_ $7DG_UQ]^_K;>>J?[S_ +/7O^#>YR_WWMO_ &33?]M/7O\ A]SY
MV?\ ';I[_P!%Y)_]<??OZVWGJG^\_P"SU[_@WN<O]][;_P!DTW_;3U[_ (?<
M^=G_ !VZ>_\ 1>2?_7'W[^MMYZI_O/\ L]>_X-[G+_?>V_\ 9--_VT]>_P"'
MW/G9_P =NGO_ $7DG_UQ]^_K;>>J?[S_ +/7O^#>YR_WWMO_ &33?]M/7O\
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M_P"#>YR_WWMO_9--_P!M/7O^'W/G9_QVZ>_]%Y)_]<??OZVWGJG^\_[/7O\
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M_P!M/7O^'W/G9_QVZ>_]%Y)_]<??OZVWGJG^\_[/7O\ @WN<O]][;_V33?\
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MY)_]<??OZVWGJG^\_P"SU[_@WN<O]][;_P!DTW_;3U[_ (?<^=G_ !VZ>_\
M1>2?_7'W[^MMYZI_O/\ L]>_X-[G+_?>V_\ 9--_VT]>_P"'W/G9_P =NGO_
M $7DG_UQ]^_K;>>J?[S_ +/7O^#>YR_WWMO_ &33?]M/7O\ A]SYV?\ ';I[
M_P!%Y)_]<??OZVWGJG^\_P"SU[_@WN<O]][;_P!DTW_;3U[_ (?<^=G_ !VZ
M>_\ 1>2?_7'W[^MMYZI_O/\ L]>_X-[G+_?>V_\ 9--_VT]>_P"'W/G9_P =
MNGO_ $7DG_UQ]^_K;>>J?[S_ +/7O^#>YR_WWMO_ &33?]M/7O\ A]SYV?\
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MW/G9_P =NGO_ $7DG_UQ]^_K;>>J?[S_ +/7O^#>YR_WWMO_ &33?]M/7O\
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MTW_;3U[_ (?<^=G_ !VZ>_\ 1>2?_7'W[^MMYZI_O/\ L]>_X-[G+_?>V_\
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M_P &]SE_OO;?^R:;_MIZ]_P^Y\[/^.W3W_HO)/\ ZX^_?UMO/5/]Y_V>O?\
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M>U?]+*Q_[2HNCK_SD/\ MY!\C/\ RD/_ +P>U_9MS-_N=+_M/^K:=2M][/\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0P_'C_ )G_ -&_^)AZS_\
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=##\>/^9_]&_\
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MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NKF?Y$?\
MV79#_P"(>[#_ .MF.]B;E+_<P?Z1O\G687W(?^5RD_Z5MS_U>MNJ9O89ZP]Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>ZNX_F>?]D2?RB?_%?]X_\ NGZ\]BK?O]Q+/_FFW^"/K,O[RG_*G\C_
M /2JE_[1=JZI']A7K#3KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[JT?^4G\OML?$CY.&N['R<F)ZM[3VW)L+=V5,7EAQM0U5!4XO+5
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MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NKL/^Z$W_EX'_7'V)/^65_U$?\
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M_P#W=47M1:?VJ?Z=?\(Z&WMI_P K'M7_ $LK'_M*BZ.O_.0_[>0?(S_RD/\
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MO?NO=>]^Z]U[W[KW7O?NO=7<?S//^R)/Y1/_ (K_ +Q_]T_7GL5;]_N)9_\
M--O\$?69?WE/^5/Y'_Z54O\ VB[5U2/["O6&G7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U<S_ "1O^9__ "1_\4H[A_\
M=UM/V)N5O[67_F@_^%.LPON5_P#*Q[E_THKS_M*L>J9O89ZP]Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NMJ[>W\@?HV7I;*Y?JSLWN.L[E
M.Q!F=K4F[<Y@GP=9EHZ1)Q33TU-MZGK:>DJY_P!I6&1=J<2*[M/H(>0)>3XC
M#JC9_$TU%2NDFE:4"@Y^W'SZZ>[U]QG8CMDK[;>;@;WP&: 3RVWT[3A*J'$=
MFKA&;!(8E0:]U*&DO^7?\5]G_)_Y;X'H;N$[SVYA%Q>]*_<-#@9HMOY2.JV?
M3R2FAF-;1U1IAYXS'4(:=9E 9%>*2SJ%=FL%O[D0R:@.ZM,'M!/F#YC..L/O
MN_>UMI[C\T_N7>1<1)'%/)+&A$,OB6[*#&_B1L5%25< *XR RG/0QS_!3JF3
M^:J_P=AW'OVGZH?=XQ0SRY"@DSRTIVE_>,HM4V.-!Y?/>%9&QK 1V+(S@DJO
MW3'^\/I*MHU4KC533J]*?RZ%<OLCM3^Z!Y,66Z6Q,M!('C-RJG;OK:!VB*8?
MM!,9[.-6SU8?VC_+&_E'=*[Z7K+M;Y==S]?;YDH*+)KA=T;ZVYCPM/DPYIYY
M*AMBBD2*3QO8M4*+@@D'V=7&Q;;:OX<DTBMQH2OG\_#I_/J>N8ONS>U_*5V+
M'<]\O;6<HKB.>\L8SH:H#5:P H2I%:TJ".BE?.C^3[7_ !YZOJ?D+T!V8>Y^
MF,=0TF6SL5;%3RY.BH*YE6/*4]9CBV.S&-LZ-++'%3M$A$@CEB#R(6[MRV;*
M/QX6\2/!/J :4.,$?,4IZ4J>HQ]ZONDGD;;7WS8+MKVRB0231RZ#,D7G*LD0
M6.1 #5NU"J@L"PX5O_#OX^U'RD^2G4W1JU&1H<;O7<JIN?*8I%-128?#0RU^
M7J(&DCEACJ$Q]-4"%I8WC$YC#JX.DDFVV?U\Z0_Q')]%&3^= :=8[>T'(!]S
MN8K+9BSI'/(3/)&*M'!$K22$$AE5BJE49@5#LM0>!NK_ )C'\H7HOH;XS[@[
MP^.N3[$KLYUMEL5_?3$9[<5)NJFJ,5-/]C7SZ8J*FFIJV@JI::61EE,20)4*
M].#IDB%&]\MQ6,!FA+DJ1J!((I6A.%&:D5\J5QUF1[__ '4]DY2Y=FWCE\7*
MS695YXWE\=)8-021CJ */'4.2ITZ5<%"2&76]]@KKG;U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=78?R:?^Y[/_ !3_ 'Q_T7[$G+O_ !(_
MYYY/\G6;WW,O^=A_Z5@_ZS=4G^PWUA#U[W[KW7O?NO=>]^Z]UN>_RJM_[>Z<
M_E==;=B9J*DH\+1;ZW/_ 'FKRJTX2'.[[DP\]?4. "_V5),KDL2?' J#A5 D
MWE^X6SV]9&P QU'[9--?R'^#KL-]U_<XMA]N+"ZDHJ"6Y\1L  /N4T18G^BI
MJ2?):=4P_P \3XY8_IGY74/8VV,/18?:'?FVCNH4^/A%+"N>VZ\='G D2JJ(
M9UDQM9(5/KFJY7(!-R&.:K$6ESK4460:L8&H8;_(3\SUA]]]/D./E?F6+<[=
M%2+<X3(P7%;J K',=-*#4KQ,:?$[.2*FIMA_E ]8[<^+_P 0-G=Q;LQ5-!V%
M\K.U=I83"M50Q05CXO.Y-,5A:2*4J)&@^TCR69">0AX9-6D,MO8AY;A7;[82
MN.Z9U4>M"=('^%OLZRH^ZARG#[>\I6^XW"!;K=[F-@6">(89)/"@4,,E/##7
M 4DTUL: U'5:'\\3:.:WI_,'Z^V;L_#29?=F^.I.JMN8'$4*(DU?D\]G,W04
M4"EBBM-/*U/"I=P/T@L%'!'S7&9;U545+(@ 'F22!UC7]\_:9]ZYZL;*T3Q)
M[FPLX8D&D&2:6\NXT6K$"K$JH)( Q4@=,&#_ )!_S>RV'3)U^=Z%VS6M LK;
M=SF_,I45BLRW,3/C=OY#'ZU/I)%<4O\ 1RO/NJ<H7;K4F-3Z%C7^2D?SZ+K;
M[CG.$\8=I]KC)%=#W%P7'R)CLW6OV,1\^J\-_?#KO3K#Y(;6^*^^MO4.W^T]
MZ[IV9M;:WW.36;&5IW_7QX[%U\%?$LBOCIZF0JTHCUQE)4DC66-XP22[;+!.
M+=Q1RP45X'4: U]#_JSU _,'M!O7*_,4'+%ZD<=W<S6\4#:ZP2"ZE$,<@<*3
MX9>H)TZAI8%:BG1Y\%_(W^;6<WQNO9A?J7$4VT\?AZN;>V7W9DHL+6SYF(S+
M08^6'"3UU164\6AI]6/2"+R1@S%F ]FR<JW;NR=@TT[B3I-<T% 37\NIKMON
M4\XW%U+;:]O18DC;QVGG\&1GU'0FFU:0L@ +UC51J6C$U M _E.[>R>T?Y;O
MS;VIFHXHLQMCMKY);>RT4$PJ$6IPNP]N4TZI(OI=1+$X##@CD?7V?<OH8]ON
M%/$-*#]HC7K)C[J>UR['R5OME/3Q+?=-S@DTFJZXK"TC:AQ454T/F.J-OC=_
M+5^2'R>ZFW#W?LP[ VEUGMZ?,PON;LO<\VUH:H;=B\M?-2-'15:M2TEF22>1
MHH5D21-9:*32%+'9)[^,RKI5%KW.=(-,FF. \SP_GUA5[=?=NYA]R]K?>;-K
M2"U5I%$EW-)%X@B^-ET0RC0I!4LQ4:E8>1Z8/B1_+R^2_P T(LKENH]NX2@V
M9A*YL3E.PM\9@X#$)6JL4AHHVA@K*ZKJ5AF21Q3T,RQ(5\K1M)$LE-MV:?=*
MF("@-"S&B@^GF2?L'1;[6?=_YC]W4>?;(XH[9"4-U=2&*$R+I)1="2R,U&J2
ML944(9@U 1*^4_\ *@^6GQ,V14=E;TQVR=\[!QC0C<6Y^K<]5YV+%BJDCBBD
MKZ?(8[$UT<$DLBIYDI)(4:PE=-2:E&X\O7&VKK<*R^;(20/MJ ?Y4Z$7N1]U
MKFGVSL6W*Z6VN;>/,TEE+)(85) U.LL,#Z:FA958+Q:@SU;C_*J_EG;&SWQU
MS_9GR*ZNZM[&E[CQ>W]U=.U>1DFS-5C\?44=6I2J5X88Z.:6=X)"L;S7 &I@
MRZ0(N7MA62%I)U5M8!2I)(%#^SRZRS^[)]WRP/+QO]_LK"\:_$5S9LZ>,\4$
MD((5O$C 1JFI"EAD=U1045_,+X,=U?"++['P_<55LBNF[!QN:R6WZG9&=J,W
M%IP$M/%4I/\ <T-!)'(IJH"+1,K!N&N& "FY;3+M142Z>X$C2:\/R'KU@_[M
M^R.[^S+VR;J]J_U:RM$;:220#P3&&#>)#"0?U5I0$'.<=$V]EG4/=>]^Z]U[
MW[KW1G/B1_S-3=?_ (K'\V/_ 'S._?:_;?[0_P#-*?\ ZL2=2-[6_P#)3F_Z
M5','_=AW+J[C_A1=_P ?+\3O^U'W)_[D;:]BKG;XH?L?_"O69?W_ #^UV/\
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M*5--247][$R5'F:VMEPSXZ:3*B&I\VJHFK(6DJ4 BC^U6-VUNV\Q68>SAB%
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M],"3<L[=<,H\0;BB@TR%DM+AF \Z$QK^P5Z.O\_/D1T-\"*/8OR$KND<7O\
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M7'>AFC0RHQ5)C#%K46#Z$U Z18DY+17\:H!_L^(K_'UC)]P:".;]^EU5J#;
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M"M0';XC+TW_-YZ[^0>T:$1]?_('9';%7FEI80L-#NG'X@O7H2I("YB BN0D
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MMOY>NBH88<S+3S3UU?49.AQC_>-#2-#!100U.MI6*R/(L:^W=HV0[$[7%RZ
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M!70 $'RTG!IQH1Y^1KQIT(>1+?;_ +POME#R]!<B"X@MK:UE':[PS6+1Z&9
M:F.01*:BF&(!# ]5<]Z?RUMH_ [;WQ^["^1?;VSMZ;GW-\D>L,-O#K7:\+U&
M-CV9$E=6[BKB*V*GRN32-Z*GIS(*"GA59]#J\DJ:""\V1=G6-YW5B9%!1:D:
M!4L<T)X <!Q\Z]8T\V_=ULO9*':-QWZ]AN)9MYL8KFW11]*MC222X)$BB24
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M_P!][;_V33?]M/7O^'W/G9_QVZ>_]%Y)_P#7'W[^MMYZI_O/^SU[_@WN<O\
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M_P"#>YR_WWMO_9--_P!M/7O^'W/G9_QVZ>_]%Y)_]<??OZVWGJG^\_[/7O\
M@WN<O]][;_V33?\ ;3U8E\X/YG_R?Z ZK^#V\=@2]?#+_(#XW;6[1W^,UM)L
ME%_%,MCL/53&B05<1IJ<RUT]HRSV&D:N"2=;MO\ <6<<#(5K)$KM5:Y(!Q^W
MJ?O>/[R/,/(>T<NWUBMF9-UVQ+NY$L,C*)6AM9#X869"JUF;!+&E,X-:[?\
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MTW_;3U[_ (?<^=G_ !VZ>_\ 1>2?_7'W[^MMYZI_O/\ L]>_X-[G+_?>V_\
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MU[_@WN<O]][;_P!DTW_;3U[_ (?<^=G_ !VZ>_\ 1>2?_7'W[^MMYZI_O/\
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M..R\M'7S4PH\HE3!E,MB8DAJ8:7'-&T4K,'CD#H0ZLM^7M^3:5=)0Q5B&&D
MD&E#6I'$ ?LZ=^[5]Y7;_9_;[K;-WANYHI)Q<6YM5BD*,R!)%833P!5/AHRZ
M2:DO4<#T5W_9U\=N3^8_0?-7?F+W'4;2I.YJ#>*;>Q$$%5E(=O[="T6*HHHJ
MBNCI'KJ?%4](DB_?1P/.LA5T1A8O.YB2]^J<&GB!J"E=(H ./$ #SZCZ/WKB
MO?<1><;Y)C;K=F188PIF6U2-H(5"O-HUA I<"0(7UE2 0.A]^2G\R_9>]OYA
M/3GS1Z9V7NYL)U;M';FW:G:O8]+0X&LK?MI<Y'DHT..K\Q!"D]!F72"8S,R2
MC6T-E 99?[XLMXEU$IH@ H] 32M>!;B#@_RZ&O/WWCK'=N?=NYOVJWN#%96R
M0/#="**1ZM=K)I\*6=1^G<]A+?$,BG$X?<W\P[^59V%V+AOEG7=!]L]A_)#;
MN)P0V[MC<L?\%Q1K\#SCYLH$R]5BI#C3^B5:.IU:8V\#NB/$976];?.XN/"=
MI0!0&@6HX$T8C'V'[/28^:_?SVPWJ^AYIEL;N[W6".,00R(Z*KH69/$!F-N3
M$6)#@2$&A4,54@M?S2_F6]'_ "*^5_PR[ZV-M#M;&[6^.F]ML;HWGBMV8;$8
M_(5<6#W)BLS)'BTH\W7T\TCT]#*B^>IIQY"@)"DLJ/=-]BO;F&9 X$; L"!4
MT8-BC'T\Z=1=[P?>,V3G_F/E[>+*"^2':;M)[A)XX%D=5NK6<B(1W,JDZ86'
M>R"I&:5( K^:A\W^KOG%VCUKO+JG;F_MNX796PJK;%?'V%CL=BZJ6IJLA/5E
MH8L;D\K%X%C=!J:H5BVH>, !F1\P;K'NTJO&& 5=/=0&M2?(GU]>@9]YGWJV
MOWGO+*?:X;J)+:&6-_JDB1F:1U8:1%-.* +Q)!KY="_\#_YD/3'Q:^&7?7QW
MWUM#L_-[V[-W%V9F]LY/:>+Q57BHUWKM7$X.FCKIZS,457 T55CI'D,5#4 1
M.I74]T]J=JWN*PM)(&5BSER" -/<@45J0>(]#T*_8?[P^S>UO*]_LE_!>R3W
M-Q<S1- D#0@36EO H=I+B-@0T))HC=I!%3CI2_"W^:/U#U]\4MX?$3YB['[)
M[2ZZJJ/);?V=4[)H,9G:B+"Y]7>;&51R^8Q?A_AE4?-CIHGD:#4L:K$E-![O
MM>_1Q6[6UTK.APNFA(!\LE>!R#G\J#HS]G_O.;5R_P L2\L<UVUW>0:7AA,"
M12DVL@-8G\>XAIX9)\(K4*FE0%""KU\3?YH/Q[V]T#G?AG\N^L-X=I_'VEK\
MAB.OL]%14N2R(P#Y%J_'T6?HUR-&T53BYA%+3U>.KGEIR(H8(E^VCG>VW;]#
M' ;6Y1GCR%(XZ2:@'(X<00<<!PZ,/;#[RO+UKLTG*7--K/=;8KM%9S/''*_T
M8D+Q)<QK(M)(:+HD@+$'2%53&'9#]R=Y?R>=K=1=E;8^.7QH[%S_ &GOK9N=
MV_MK>F^FJJZFP-77P-#35T39G<&0:"HI97$R-2XWR,1I:H0:0&;F[VU(V6")
MR[ @,QPM?/+'(^S\^BCF[G7VCV;:KRVY?VJ>>\NK6:*&>9)9%M961E1P;VX=
MD96;4#"A8Z<L*+TC/Y4'\Q'9OP@W)V5MSM;![ER_6G:,>W*U\GM2GAR-7B<G
MMG[N..;[.:6F%125M/6LLY6H\L9@A,<4FIQ[IR]O2[2SB0$J]/AI4$5\B1ZY
M\^@_]UWW]L_:":[L]V65K.[,<@DB4.UO/&&4DIAF616 8@DJ8UHAU,0!_P#,
M$[4^$_96Z=@1_"OJ;(=:;<P>-W+-OBNK\/\ P,9.MSU13S4ZPP/7U\HAH$CG
M5=7A1/+XX8A$BDH]WN+6=E^E0H!757S)-?5L#\OLIT$_O \U<F\R7%HG)]F+
M:.)9S<R+ +=9GE:,H "Q8B/2_$*!JH@H.J]?91UCQU[W[KW7O?NO=&<^)'_,
MU-U_^*Q_-C_WS._?:_;?[0_\TI_^K$G4C>UO_)3F_P"E1S!_W8=RZNX_X47?
M\?+\3O\ M1]R?^Y&VO8JYV^*'['_ ,*]9E_?\_M=C_TNX_X;'K6K]@;KG=U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3YA-S[EVS)42[;W#G-ORU2
M)'52X3+5&*:18R2JR-!)&75220"2 3Q[VK%>!(^SHTVS>[W92QL[B> O0,89
M9(BP%:5T,M:5-*\*]-=75U5?55-=75-16UM;435=965<S5$LLM0Q>2661R7D
MDD<EF9B2Q))))]Z)KT@GG>Z=I969W=BSNQ+,S,:EF)J2234DY)R>G>'=>Z:?
M#2[<I]R9^#;T^OSX&',5$5$_E8.VJE600-J<!C=.3R>?>]1I2N/3RZ,8]_OX
M;8V:7-PL!J# )I!"0QJ:H&TFIR<9/3![UT4]/N*W3N;!4M;0X3<6=P]%DE*Y
M&CQ67J,?%4 J4M/'#(B2C0S+Z@>"1]#[V&(X>?'Y]&MAOU]M2-%:W$\*/\:1
M321J^*=P1@#C&?+'3+'))#)'+%(\4L3K)%+&Q1E9#=65A8A@0""#<'WKHMCD
M:%@Z$JRD$$$@@@U!!&00>!Z4.;WEN_<L,--N/=6Y,_3TTIGIX,WG*K*I&Y&D
MNBSRR*K%21< &W'NS.7XDG[3T;;ES'N&\H([RZN)U4ZE6:>250U"*@.S &A(
MKQIU>3_+]^?7Q/VA\/NP/A9\IX=[;,VWNR?>B2[YV9C9\FE;C][K&*B&8T*3
MU])D8&#*C?93T\D 59"NDQR"O9]XMXK9[6XU*&U=RCR:GI4U],$4X_/-;V']
M]^5MKY2GY1YF\:VC<7*&>)))%GANB2P)@5Y$D&ME^ J5"G56J]#?T)\J?Y3_
M /+GQ_8>[OC5O_O7Y"]@[SQ-+B?LL_A*K$ZH:282P4HGKMO;6HJ6G64AYIC2
MU-1PWB5@5B]J[3<-NV34]NTDK,*9%/GYJM/F:$^G0MY#]S_:[V#M[N?8+O<-
MRN+@(&62*5794/:H,MK91*JEBS,07XTU=J]:[G8/8&>['[*WOVIF)%I=S[\W
MSN7L#*RX]WA$=?NBOFR,[0,6,B!*B=BAUEA8&]^?8+FE,[M(W%F+'[2:GK '
M?^89]_W2YW9OTYKFZFNSH)&B2:5ICI/$:6;!XXKQZ9<YNO=.Y_M?[R[DS^X?
ML?/]E_',Q49;P_<Z/)XON))/'Y/''JTVU:5O>PM5G+\23]IZ3;GOM]O6GZRX
MGGT5T>-+)+HU4KIULU*Z16G&@KP'3![KT5=>]^Z]U>-_)^^4GP^^(6,[M[)[
MTWQD,-VMN5,5M;9^!H]DY;<#MA<:GWE2:>LH*"HI89,ED'@21)ZB(***-OH]
M_8JY;O[;;?$DF/>0%4!2>WB<@4R:<?3K-?[IWN7RE[66^X7N]7;17L[I%%&+
M:XE_Q:)==5:&%P#)(Y#!F']FIIYFG_M_LO.=R]J=B]L;D:8YSL;>FX]XY"*:
MK:N\+9^KEJ5I4E95)AI$D6&(!%58HT5410% ;N)S<R-(W%F+'\S7K$SG'F:;
MG+=;O=;C5KN[B6<JSF0H)'+*@8@56-2$7  50     Y]L]!OKWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[H8?CQ_S/\ Z-_\3#UG_P"[JB]J+3^U3_3K_A'0
MV]M/^5CVK_I96/\ VE1='7_G(?\ ;R#Y&?\ E(?_ '@]K^S;F;_<Z7_:?]6T
MZE;[V?\ T\'=?^H'_NVV?58_LAZQSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NLL$\U--#4TTTM/44\L<\$\$AB='B(971E(965@"""""+C
MW[IR*5X'62-BK*0RLI(96!J"",@@Y!&0>G',Y[.[BJUK]P9K+9VN2%*9:W,Y
M&;*2B.,LRQB2=W<(K,Q"WL"20.3[V6+9.>E>X[K=;Q();N:6=PH4/-(\C!02
M0*N6- 233A4GUZLY_E1?-[KGX4=R[SS/:V S5?LSLG:E#MBMW%MND3)5N)EQ
MU6M3#.:5WB:HH9;N*A8I#,NF)XXY2OC)]R]NJ;5*6D!*L-)(XC-:^6/7S_P=
M9)?=<]Y]M]H-SNCNJ2?3WL4<9GB76T#1.S E!ED8.=6FK JM%;-#\[2W_P#R
M4>K_ )!/\N<!WOWWNCL6/=^<[#Q_7U3MC-2T5/E\Q-//+,GFVKCY9KRS2/$D
M^XI8P7/E+#2J&\<NU6\WU(DD9M18+0TU5)_@'Y=WV]3MM/,?L]RYS$_-<&YW
M\EVTTURMNT%V84GF+%V4&QC8DZV(#S,HU'&%TU.?S#?F!'\VOD97]NXW;U=M
M;:>*VK@]A[(PN7ECFKH\9A):NK\E:87D@6IJ*_(5TI2)V2-72,/(4,CA[>=R
M_>LYEI0 !5'GI%3GYU)/\OGUBK[_ /NQ'[Q;^=T@B>&".WBM8$ET^+X<;22%
MG"LRAB\SFBL0!3)-3T1KV5=0EU[W[KW7O?NO=>]^Z]U[W[KW5V'_ '0F_P#+
MP/\ KC[$G_+*_P"HC_GSK-[_ ,$;_P!3/_M:ZI/]AOK"'KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[ITP^<S6WJS^(8#,93!UXB> 5
MV'R$N,FT2VU)Y871]+6%QJL;"_O8)7(QTNV_=+G:)/%M)I87H5UQ2/&^DTJ*
MH5-#05%:8ZAU=755]54UU=4U%;6UM1-5UE95S-42RRU#%Y)99')>221R69F)
M+$DDDGWHFO2:>=[IVEE9G=V+.[$LS,QJ68FI))-23DG)ZC^_=-=>]^Z]T_YS
M=>Z=S_:_WEW)G]P_8^?[+^.9BHRWA^YT>3Q?<22>/R>./5IMJTK>]A:S.7XD
MG[3T:[GOM]O6GZRXGGT5T>-+)+HU4KIULU*Z16G&@KP'7#";GW+MF2HEVWN'
M.;?EJD2.JEPF6J,4TBQDE5D:"2,NJDD@$D GCWI6*\"1]G6MLWN]V4L;.XG@
M+T#&&62(L!6E=#+6E32O"O3-)))-))++(\LLKM)++(Q=F9S=F9C<EB2223<G
MWKHNDD:9B[DLS$DDDDDDU)).22>)ZGXG-9C 5J9+!9;)X7(QI)''7XFOEQTR
MK*+.HEA='"L." UB.#[V"5R.E6W[G<[3)XUK+)#)0C7%(T;T/$:D(-#YBO6"
MNKZ[*5E1D,G6U>1KZN5IZNNKJAZN:5W^KR2R%G=C^26)/O1->FKN[EOY&FG=
MY)&-6>1B[L?4LQ))^T]1/?ND_2DI-Y;OQ^(FV_0;JW)18&IBJH*C"4F<JJ:D
MD2N!69'IDE6%EF#,'!0AP2&O?W8.0* FGI7HY@YCW"UMS:175PD#!E,*SR+$
M5>NH% P4AJG4*4-37I-^Z]$W7O?NO=>]^Z]THL)N_=FV8ZB+;>Z-Q;?BJG22
MJBPF;J<4LC1@A6D6"6,.R@D D$@'CW97*<"1]G1QMO,.X;,I2SN;B!6-6$,T
MD08@4J0C*":>9Z3ONO1/U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U<S_(C
M_P"R[(?_ !#W8?\ ULQWL3<I?[F#_2-_DZS"^Y#_ ,KE)_TK;G_J];=4S>PS
MUA[U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=+#%]A[_P )AY=O87?.\,1@)]0FP>+W-6X^C?4SN=5-%.D+7:20FZ?5
MF/U)]W$C*-()H>(J:=""RYLW7;8/IK:\NXH<_I1W$R1Y))[%<+DDDXXDGSZ1
M_NG0?Z][]U[J?B\KE,'7093"Y+(8C)TOE^VR.+K),?/'YD:-]$T3)(FN-W5K
M,+JQ4\$CWL$KD8Z565_/MDJSVTDD4BUTR1NT;K4%31E((J"0:'()' ]>RF5R
MF<KI\IFLED,ODZKQ?<Y'*5DF0GD\*+&FN:5GD?1&B*MV-E4*. ![\26R<]>O
M;^?<Y6GN9))9&IJDD=I':@"BK,230  5.  . Z@>]=)>O>_=>Z][]U[KWOW7
MNO>_=>ZGXO*Y3!UT&4PN2R&(R=+Y?MLCBZR3'SQ^9&C?1-$R2)KC=U:S"ZL5
M/!(][!*Y&.E5E?S[9*L]M))%(M=,D;M&ZU!4T92"*@D&AR"1P/7LIE<IG*Z?
M*9K)9#+Y.J\7W.1RE9)D)Y/"BQIKFE9Y'T1HBK=C95"C@ >_$ELG/7KV_GW.
M5I[F2261J:I)':1VH HJS$DT  %3@ #@.G"'=>Z:?#2[<I]R9^#;T^OSX&',
M5$5$_E8.VJE600-J<!C=.3R>??M1I2N/3RZ61[_?PVQLTN;A8#4& 32"$AC4
MU0-I-3DXR>F#WKHIZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NKN/YGG_9$G\HG_ ,5_WC_[I^O/8JW[_<2S_P":;?X(^LR_O*?\J?R/_P!*
MJ7_M%VKJD?V%>L-.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[JYGLS_ +<9_'C_ ,77S?\ [JM\^Q--_P D
MF/\ YKG_ (Z_687-7_3E=F_Z7LO_ !W=>J9O89ZP]Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NKF?YIO_ #(#^5?_ .*4;$_]TNVO8FY@_LK7_F@O^!>LPOO,?\JY
MR5_THHO^T7;^J9O89ZP]Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>ZN9_DC?\ ,_\ Y(_^*4=P_P#NZVG[$W*W]K+_ ,T'
M_P *=9A?<K_Y6/<O^E%>?]I5CU3-[#/6'O7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5V'\FG_N>S
M_P 4_P!\?]%^Q)R[_P 2/^>>3_)UF]]S+_G8?^E8/^LW5)_L-]80]>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T9SXD?\ ,U-U_P#BL?S8
M_P#?,[]]K]M_M#_S2G_ZL2=2-[6_\E.;_I4<P?\ =AW+J[C_ (47?\?+\3O^
MU'W)_P"Y&VO8JYV^*'['_P *]9E_?\_M=C_TNX_X;'K6K]@;KG=U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=##\>/^9_]&_^)AZS_P#=U1>U
M%I_:I_IU_P (Z&WMI_RL>U?]+*Q_[2HNCK_SD/\ MY!\C/\ RD/_ +P>U_9M
MS-_N=+_M/^K:=2M][/\ Z>#NO_4#_P!VVSZK']D/6.?7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW5V'_=";_P O _ZX^Q)_RRO^HC_GSK-[_P $
M;_U,_P#M:ZI/]AOK"'KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NKF?Y$?_9=D/_B'NP_^MF.]B;E+_<P?Z1O\G687W(?^5RD_
MZ5MS_P!7K;JF;V&>L/>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NKN/YGG_9$G\HG_ ,5_WC_[I^O/8JW[_<2S
M_P":;?X(^LR_O*?\J?R/_P!*J7_M%VKJD?V%>L-.O>_=>Z][]U[KWOW7NO>_
M=>Z][]U[HR5#\-?E]E*&CR>,^*GR2R.-R-+3UV/R%#T;N>K@G@JT$D4T,L>+
M:.6*6-E9'5BK*002"#[7+MERPJ(I2#D$1M0C]G4AQ^T7-DRATV7=F5@""-MO
M"""*@@B&A!' ]!'OKK7L;J_+)@>S-@;VZ[SDD1GCPV^MJU^T:MD4Z2XI\A!3
MS% W%PEK\>TTL+P'3(K*?1@0?V'H+[YRSN7+#B+<K2YM'8$JES!+ S 8) E1
M"0*YIT:WMO\ E\?(#ICXT]<?*S=O]QZCJ[LVAV/D\-%A-R25F4IH.P\><EBY
M*ZDEI*>)!+!H#K#4SM&[J'4 .RF%SL\UK MPVG0^FE#GN%144].I3YH]@=]Y
M2Y;MN:;@VKV=TEM(JQ2L9XTNXQ)&75XD7\2J0CN0S#&D%@1SV5=0CU[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0S9SXZ]\;9ZPP_=.X>H.Q,)U/N
MT7\&[!R>U*RCQ=0N4_X"2I5/$(_!5W'V\I(BGN/$[W%U#6<J()&1PAX,5(4U
M^=*9\O7H:WWMQOVV;5'O=Q87,=C+IT7+1,(R)/@;U"/4:'("O5=).H5!GVGZ
M!77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U<SV9_VXS^/'_BZ^;_ /=5OGV)IO\
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MKW5W'\SS_LB3^43_ .*_[Q_]T_7GL5;]_N)9_P#--O\ !'UF7]Y3_E3^1_\
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MN>WP1(0.V(DG@ $ST<[G[<W'NK[9[-LUO*D!DV_97>:0%ECCBM878Z006.*
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M;+);SQ6T,D,S!9+AVDU&2=L*LCF0Y)%#I!-!UKB^P9USGZVKOF-_VXEZ#_\
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M?A\/%.FO%J=>Z\_F;/L/X [D^##=)KEAG\%OO!Q]H+V.<>81O;)U&2\APO\
M 9_*:9JAH[#+)Y  UT^GOT.^^#9FTT5J&&O5_$:\-/\ EZ]R[]Y3]P<CR<F?
MN[Q/$@O(/K/J]&GZN6635X/TK5T>+2GBC52M5KU55[#_ %B[U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U<S_--_P"9 ?RK_P#Q2C8G_NEVU[$W,']E:_\
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M -&^^_[))_\ K7U[_19V=_S[C?G_ *"&0_\ J?W[PV]#^P]>_J-O?_1OOO\
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M.LL_N9<M[CM'-[RW=K<P(=NN%#S02QJ6,MN0*NJBI )IQP?3JGK_ $6=G?\
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M_00R'_U/[]X;>A_8>O?U&WO_ *-]]_V23_\ 6OKW^BSL[_GW&_/_ $$,A_\
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MC???]DD__6OKW^BSL[_GW&_/_00R'_U/[]X;>A_8>O?U&WO_ *-]]_V23_\
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M_H(9#_ZG]^\-O0_L/7OZC;W_ -&^^_[))_\ K7U[_19V=_S[C?G_ *"&0_\
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M#^P]>_J-O?\ T;[[_LDG_P"M?5PO9&R-Z3?R2>@,!#M'=$N=I/F=F:VJPD>
MJWJXX6Q6]@)I*81&9(B9([,4"^M>?4+B69#^ZHQ0_P!N?+^B_66?,_+>XR^S
MNT6BVMR9TWN5WA$$IE5"NY]S(%U =RY(IW#U'5/7^BSL[_GW&_/_ $$,A_\
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M_H(9#_ZG]^\-O0_L/7OZC;W_ -&^^_[))_\ K7U[_19V=_S[C?G_ *"&0_\
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M_00R'_U/[]X;>A_8>O?U&WO_ *-]]_V23_\ 6OKW^BSL[_GW&_/_ $$,A_\
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MC???]DD__6OKW^BSL[_GW&_/_00R'_U/[]X;>A_8>O?U&WO_ *-]]_V23_\
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M$,A_]3^PMX;>A_8>L0_ZC;W_ -&^^_[))_\ K7U[_19V=_S[C?G_ *"&0_\
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M?_57OW]5=K_Y0[7_ +)XO^@.O?USWC_E/O/^RJ?_ *#Z]_IE[?\ ^?K=D_\
MH<Y3_P"JO?OZJ[7_ ,H=K_V3Q?\ 0'7OZY[Q_P I]Y_V53_]!]>_TR]O_P#/
MUNR?_0YRG_U5[]_57:_^4.U_[)XO^@.O?USWC_E/O/\ LJG_ .@^O?Z9>W_^
M?K=D_P#H<Y3_ .JO?OZJ[7_RAVO_ &3Q?] =>_KGO'_*?>?]E4__ $'U[_3+
MV_\ \_6[)_\ 0YRG_P!5>_?U5VO_ )0[7_LGB_Z Z]_7/>/^4^\_[*I_^@^O
M?Z9>W_\ GZW9/_H<Y3_ZJ]^_JKM?_*':_P#9/%_T!U[^N>\?\I]Y_P!E4_\
MT'U[_3+V_P#\_6[)_P#0YRG_ -5>_?U5VO\ Y0[7_LGB_P"@.O?USWC_ )3[
MS_LJG_Z#Z]_IE[?_ .?K=D_^ASE/_JKW[^JNU_\ *':_]D\7_0'7OZY[Q_RG
MWG_95/\ ]!]>_P!,O;__ #];LG_T.<I_]5>_?U5VO_E#M?\ LGB_Z Z]_7/>
M/^4^\_[*I_\ H/KW^F7M_P#Y^MV3_P"ASE/_ *J]^_JKM?\ RAVO_9/%_P!
M=>_KGO'_ "GWG_95/_T'U[_3+V__ ,_6[)_]#G*?_57OW]5=K_Y0[7_LGB_Z
M Z]_7/>/^4^\_P"RJ?\ Z#Z]_IE[?_Y^MV3_ .ASE/\ ZJ]^_JKM?_*':_\
M9/%_T!U[^N>\?\I]Y_V53_\ 0?7O],O;_P#S];LG_P!#G*?_ %5[]_57:_\
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M *'.4_\ JKW[^JNU_P#*':_]D\7_ $!U[^N>\?\ *?>?]E4__0?7O],O;_\
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M-/\ ]>_=M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\
M]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?
MM Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]
MU[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3
MEV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_
MSMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3
M_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]
M-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\
M]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?
MM Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]
MU[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]T)59
MV=O"'JK%;I2OIQF:K=DF*FJ#00E3 L-2X41Z- .J-.;7X^O/NH45IU[H-?\
M3EV-_P [:D_\]-/_ ->_=M Z]U[_ $Y=C?\ .VI/_/33_P#7OW[0.O=>_P!.
M78W_ #MJ3_STT_\ U[]^T#KW7O\ 3EV-_P [:D_\]-/_ ->_?M Z]U[_ $Y=
MC?\ .VI/_/33_P#7OW[0.O=>_P!.78W_ #MJ3_STT_\ U[]^T#KW7O\ 3EV-
M_P [:D_\]-/_ ->_?M Z]U[_ $Y=C?\ .VI/_/33_P#7OW[0.O=>_P!.78W_
M #MJ3_STT_\ U[]^T#KW7O\ 3EV-_P [:D_\]-/_ ->_?M Z]U[_ $Y=C?\
M.VI/_/33_P#7OW[0.O=>_P!.78W_ #MJ3_STT_\ U[]^T#KW7O\ 3EV-_P [
M:D_\]-/_ ->_?M Z]U[_ $Y=C?\ .VI/_/33_P#7OW[0.O=>_P!.78W_ #MJ
M3_STT_\ U[]^T#KW7O\ 3EV-_P [:D_\]-/_ ->_?M Z]U[_ $Y=C?\ .VI/
M_/33_P#7OW[0.O=>_P!.78W_ #MJ3_STT_\ U[]^T#KW7O\ 3EV-_P [:D_\
M]-/_ ->_?M Z]U[_ $Y=C?\ .VI/_/33_P#7OW[0.O=>_P!.78W_ #MJ3_ST
MT_\ U[]^T#KW7O\ 3EV-_P [:D_\]-/_ ->_?M Z]U[_ $Y=C?\ .VI/_/33
M_P#7OW[0.O=>_P!.78W_ #MJ3_STT_\ U[]^T#KW7O\ 3EV-_P [:D_\]-/_
M ->_?M Z]U[_ $Y=C?\ .VI/_/33_P#7OW[0.O=>_P!.78W_ #MJ3_STT_\
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M-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\ ]>_?M Z]U[_3EV-_SMJ3_P ]-/\
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H7>K/\
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M=>]^Z]U7W\KO^9B8;_PR\=_[G9'WES[!_P#)'F_Y[)/^K%OU@]]Y?_DNP?\
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MS\*.M,1VCW_MW$;CQ='F]M87%9[<N>Q.0@%3#/%14Y@@21&!5D%=54C,&!#
M%?S[R&]V-_EY>V666!VCED>.*-U-&4LVHD$9KH1AC[>L7_97EN'F??XHKA%D
MABCEFEC=0RN%70H(."-<B'/I3HWN+Z]Z:W/\^\IU[1]=;5396TMEU%)/MZ#%
M1P4$^1I*..HEJ'IDM%(\;5AB.I+:H@VDE5;W&%QO>Z[?R8EZUU-X\UP")2Y,
MBQ%RH4,<@'1JP>#4KDCJ7[;E_9MSY\DV]+. 6]O:D&(1J(FF"*Y8H.TD>+IR
M.*UI4 ]+3YG_ !2Z\J.J:WL3I_:.$P.;V%4U51GJ+:M(M+%5XZDD:'(!X(BL
M0J,;(AF9](811SHVHZ-)7[5>X]ZFY+8[I-))'< "-IF+%)2 R4)J=,@.FG"I
M4BF:F_O+[5[?+M3;AM%O%%+:DM(L"A5DA4E9*JM!JC(U5I72K#.* I_+CZOZ
M[[(;N-M^[,V]NXX9.OTQ/\?QL>2%.,I_&_N/$) 0AE^V@U$"_H%C]?8L]].8
M;[8OH?HYY8=?U.OPW*ZM'@::TXTU']O0)^[KRUM_,/[P-];PW'A_2Z/%17T:
M_J=5-0-*Z%K]@ZK@W%!#2[@SM-3QK%3TV9R<$$2"P5(9W55'^"J ![G6P<R0
M1LQJ3&A)]25!ZQUW.-8;F5%% LL@ '  .0!TS>U?2'KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H>.ENY*KKK(?PO+-/5[0R,RFJ@4
MF5Z.1^#4P+^0?]VH.7 #+ZU :*O<OVX3G&'Q[?2EW&.UC0"91^!CZ_P,>!P<
M&HFGVC]UY.1)_IKHL]C*W>HJ6@8_Z(@\Q_&HR1D=PHUR'8=;29'KGI6OH*B&
MKHJS;5;44M53N)$D26''%65AP00?>%\UO):2/%*I5T8JRL*%6!(((]0>L^+6
MZCO8UFA971U#HZFJLK"H((X@@] O[IT_U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=#/D/^9$X+_P /V;_W
M'K/=!\77N@8]WZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=#/VM_Q9.JO_#"Q7_6
MF#W1>)Z]T#'N_7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NAGZ1_XO>Z__#"SO_6ZD]T?AU[H&/=^O=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=#1TY_S4#_PP\Q_T3[JWE]O7N@7]VZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW0N]6?\ >S?\ Q'&X?^A/=6\OMZ]U*[Z_YF!4?]JK
M&?\ 0K>])PZ]T#'N_7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[IUP7_ !>\-_VM<?\ ];D]Z/#KW2][I_YF9N7_ ,@W_NOI?>DX=>Z"WW;K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0T?\ -"/_ "?/_C?W
M7S_+KW0+^[=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[JOOY7?\ ,Q,-_P"&7CO_ '.R/O+GV#_Y(\W_ #V2?]6+?K![[R__
M "78/^>"+_M(NNBQ^YOZQXZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z6/7?_ #,#8O\ X>.V?_<V#V5;[_N#
M<?\ -"7_ *MMT=\M?\E*T_YZ8/\ JZO5L/\ -)_X]CJ#_M?;L_\ <>B]XW_=
MY_W(O?\ FG#_ ,>?K*K[SW^XEA_S6F_XXG1#_AGO8[%^1_6U;)/X*'/9639V
M1#'2KINJ-J2 ,?PJ5KTLE_H"@N0+^YB]U-I_?&Q72 5:-!.OJ#"0Y_XP&'Y]
M05[-;W^X^8[1R:+*YMW]")@44?\ .0H?R].K!^YNFOX]\_>E\R*-9<3N'$X_
M>66E"<?<]9>=SYAP'0BGQ$?)-_($9=(YA/E;FGZ/DN^BU4>-V@0?T;O2,?/N
ME/RI4&O607.')WU_/NW3Z:QRQK<2$?QV6HU/J,0K\ZT(IT9S8G;U-O/Y&]\=
M1U,B56/VIMO98QM-(P97"12#,#1^5$^1I(FX^JFY(*6 &\<LMM6Q[?N:X::6
M?41Q&1X6?6D3$?;]O4E[)S:N\<P[GM+96WAMM )XU5O%QZ RHI^=:^715O@M
MU@G5>^/DWG<XAI*#869GV)25\XN?ML--55M9(6*CT-318R4$-Z@UV LMY%]W
M^8?ZQ6>U0Q9:XC%PRC^-U2-1]NHR+\J?;U%WLARO_5:^WF:8:4MI3:HQXZ(V
M>5C6G IX3?.N?+HN_P (MT5>]_F)G-XUY?[S=-#V)N"H61M95LO*)]%QQ9->
MD        #V-_=O;EVCE>.U3X86MHQ3ST*5K^=*]1[[)[HV]\WS7CUU3I=RF
MIJ1XCJU/RK0?(8Z/+UAV_0T_RI[^Z W&],V,W%E*;<FT:6LTM')438>A.7H
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MXVI/_*3!_P!75ZMA_FDLO]VNH$U+K_CN[&TWYM]O1"]OK:_O&_[O(_QB]/\
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MF_O"V\O)=PE>>=B\DC%G9N+,34G_ %8' =9_6-C#MD*6]NBQQQJ$1%%%55%
M!_J^WH?NT/\ CQ.G?^U!D?\ K5CO:->)Z5] =[OU[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z&?(?\R)P
M7_A^S?\ N/6>Z#XNO= Q[OU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z&?M;_BR=
M5?\ AA8K_K3![HO$]>Z!CW?KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW0S](_P#%[W7_ .&%G?\ K=2>Z/PZ]T#'N_7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NAHZ<_P":@?\ AAYC_HGW5O+[>O= O[MU[KWOW7NO>_=>
MZ][]U[K6+_G33X7%_P TC^1=G.R*9)NL*7OO>=%#/64LU52P9VOS>Q5H'FT@
MPH1D!AY02>%A:24&*(^Z-Q'7NKVOEMCOEUE.GZNF^$F?Z/VYWJ-P8.6@K_D+
M3Y:HVT<8KN,C',,)25M>*IHRA@*P%=:V<A3?W8_+KW5'G3WSJ_FI=3_S;?B[
M_+N^;>5^'6ZL+WWU7OKM?(9CX\;9W+>GQ^)P._:K'1QU^<.*DAKQE]E/YT.*
MGA-)* DOF<F"M36G7NA0_F2?]OEOY&__ &O?EO\ ^\_A_>SQ'7N@E^>VU</\
MX?YY/PK^#O;\<6?^-?1_0VY?E1NWK#)U4PQNY]P5<N7I:.')47GIZ>OAHOX=
MB2JM'5 TDN4I&04];5@:.3U[JRO^95\$?C?\BO@YWQU]G.I>N,37;0ZAWQNO
MJC<>+VA2XBHVUG-F8BJJ\/6XZ6@2DJ*>"">"..>GBF2*II6EI9D>&1D.V&.O
M=5I?'ON_?GR!_P"$Q/9N^^R\K59_>..^&'RMZ\KMP5U5/6U%=3=8C<V!QE15
M35#RS3U9Q6/HDJ)6E<S3I)*2I<HFA\/7NC(_R.?@E\:^K?@/T1VY#UYA=[]K
M_(KJ;9>^>S.Q.Q,;3;PRD\>2HHA18*DGK(9/L=OX>CCIZ:EHH0D6B)9)1)*2
M_O:B@Z]T5K^7GLC&_"O^>[\^OAAU/B:/:OQQ[;Z$VC\E]E=?82OJ#C\+DJ-]
MMQ3I34,K?;T$4E9G]PQI%!=(Z2/'P1Z(8DA@T,$]>Z/9V]\M/Y5GQ#^3W96#
M&R\9OWYH]CF'=/;&W.B.B\KW]OR9:2BI5@&:J,3C\E+BXHZ&2C:*AGKJ94AD
MCF6G6.42-LD#KW5:/PZ[(ZJWS_PH9W5O#H;J'M7X^[6[-^!&8R?8NQ>S>G\C
MT)697.8[<5%')EWV_7P4K34\\-'CM-6(=,U3#4-J,HF)T./7NC9?S)/^WRW\
MC?\ [7ORW_\ >?P_O9XCKW6P;[MU[KWOW7NO>_=>Z][]U[H7>K/^ /9O_B.-
MP_\ 0GNK>7V]>ZE=]?\ ,P*C_M58S_H5O>DX=>Z!CW?KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW5!GQL_GQ]==Y?S!]]_!'>70VX.H8L?VOW%TIU/W/7
M[Y_O/C]T[CZ;K9(*S&34*X&@BPU35TD8GA49>NTO-2TTA62J@9ZALTZ]U8[_
M #$OF%_L@_PY[@^6?^CO_2O_ **/]'_^_ _O=_<7[_\ OUNG";:_XNO\,S/V
MOVO\9^Y_XMLWE\/A_;\GE39-.O=&@ZTWDO8W7'7_ &$F/;$)OO9.U-Y)BFJO
MOC2C<]!!7"G,PCB$QA$^C7XDUZ=6A;V&QGKW2V]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW0%_)[NZD^-/QS[S^0M=MZHW;1])]4[[[1J-KTF17$29%=DXVHR!HDJW
MAJ%IFJ?!X_*8)!'JU>-[:3XXZ]U3+U5_-H_F4=P=<[%[HV3_ "2]Y[DZAW_@
M\+N_ [MVS\WMI9:JJL-F0DB5M%AY]KT5?43- Q>.FD2"1VLCF*Y9:ZCZ=>Z/
ME\$OYG/0OSOJ=[;)VU@^PNF._P#JMBG:GQO[PV\=E[NPH$OA^X:A=V^ZHA(T
M2O(EI(&EA2KAIY)8T;8:O7NK'/>^O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3K@O^+WAO^UKC_\ K<GO1X=>Z7O=
M/_,S-R_^0;_W7TOO2<.O=!;[MU[KWOW7NO>_=>Z!CY'UE7COCQWUD,?55-#7
MT/3':-915M'.U--#-38.N>.6*1"KQR1NJLK*P96 (((]Z/#KW7R[?AYE.U/A
MEM?X]?S0>N,]N&CPFQ_F;E.ANR\1A*U*7[S'XS!;9W1_!7C<+'4P;HPU1NBF
MG2670AI()$\<H6561C/7NOI]]K_(WKKJGXR[X^562RL5=UAL[IW*]T1Y*E82
M?>XREQ396D6FTD^27(1F&.!5),DDJ*MRP]O5IU[KYBF3P?<N]>U?AY\_.X=R
M92OWY\T?F5O_ ')CJUJVHD_R;J;<^S*9:VAEGEFJJ>F@R^4RF.I834N*6GQ<
M$41557VR?7KW6Z;_ ,*'_P"9GO\ ^!7QTV+UST3FY-L=]?)');BQF$WI2 /5
M;=V]LU:-LUDZ+7#+"F3J9<A04=*[E6B66IJ8/WZ9&1QS3KW5>7QS_P"$N^VN
M\NF-L=R_-3Y-=_'Y)=K[=Q&^=U46 R&*RXQ-1N&CBGCQ^8K\S39NMSN2HE>.
M.JGCR$,1D1HH2\:I.^@E>O='7^5-'\M?Y0_\DCO#;]#\C,SW'VOM#?D.T>LN
M],S)75N6Q>UNU=R8ZAIB5R,U9)293&4596PTP6MJ(*25X)*>0K'' FS51U[J
MKC^69_(Q^%O\QWXD[6^4F\?F-\A-U?)'=61W!4=GS['WK@7&VMQ4==-X:+,T
M68P64W%+D8J9:2I:HFS-.:U)8ZNE*4\L+MH+4=>ZW)?C)U-N;HCX]].=,[R[
M(R_<&Z>LNOMN;,SO:.>AJ*>MSU1@J=8),G4QU5=DZE)JDKJ99,A4,/H97^OM
MP=>Z&ZI2>2GGCIIEIZEX94IZAX?N!&[*0CF/4NL*UB5U"]K7%[^_=>ZT[^T?
M^$R&Z.R>J^R>[/E+\]>S.U/EO)M+<FZZG=4^,_C^VXZO&P3UZ8Z5\O*^;J\:
MLWF198I<>L22:XJ! GA=O1U[I(_\)+_D3W5NV;Y/_'G=6[MQ;KZ?Z^VOUYO;
M86)SV3?)P[<KLM5U]#54>+,VN6FHLI!%%*U*DHIHI:-I888Y:FI>7R'KW6Z)
M[<Z]U[W[KW7O?NO=>]^Z]T-'_-"/_)\_^-_=?/\ +KW0+^[=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7QV[_.)^:?<W9WR.V=\4/Y3><^0VR_
MCCWSO_H'<'8,7S)VUUL:C)["K)*:21L5E]L&6G^YB5)U2.JJ41)%4S%PP%=1
M].O='1^#/\S7;'RY[)[.^.'9'2O87Q2^7G2^'Q^X>QOCWV=6TN9F_AU;]K&^
M5P&7I5@BSF(AJ*RDC:I%%3:EJ:69(VBJ$;WX-7KW01?,/^:-WKT9\U-O_!WX
MT?!'*?+_ +1R_0U'W]7/2_(C$])"FQE1EJ_%2QQIEL#D:>H^WDHXV=S7Q.?.
MJI"P1W'B:&G7NFCJ/^<-F*#Y#]8?%KY\?#;L_P" ?:W>4L]'TIE]V;\Q?;NS
MMQ5R5$%+%B:;=>*I<?3)EYZBIIHA3BED6*:>EBJ)87K*,5'M7KU[HTOR6^=D
M_P ?/F=\$_B3%UC%NR/YFY+N&BJ]^2;O.$;;J]6XVCKD:/&C&58RC5SU>E@U
M=2"%8[CR%_1LGKW5AGO?7NJZ_P"6Q\\ZC^8'UGWCV#4]70]4R=-?*+M#XXKB
MH-Y-O5<BG7E%@ZY,N9FQ>*-(U4N:$;4OCF"& R"H82^./2G5U[H8_G5\F<3\
M.?B%\@ODIE6H6EZKZWSN9VU0Y&J6BBKL]7**';N-:5DET?Q+.U6/IKB*0CRW
M"/;2?$TZ]U61A/D]WO\ RS?Y*.S/E9\B?[]?*+OREP&Q^Q-_XCM'L:;&5S5_
MR(W11LF*?*/19AJ&DVU29Z""*EBI7B3[3[:$4\3+XM5H.O=7D[3SO]Z-K;:W
M+]K]C_>+;^&SOV7G^Y\/\6IHZCQ>31'Y/'Y-.KQKJM?2+V%NO=$2K/G9/2_S
M.<5_+L_T81/39+XJ2_)4]N?WR*NCIG*C$##_ ,"_A95DTTYE^Z_BX-V"?;V7
M4VJYIU[H_F6KQBL5D\HT1F7&X^LKVA5M!<4<;2%0;&Q;3:]C;^GO?7NJ;?C+
M_-&[[^7?\O:F^9?Q]^#=1VCVG5=JYOKV'XWXOY XW:^NCP=6(JC+#=68P5+2
MA8*>2-VISB];O<(UC=:AJ]>Z*UV'_.G_ )@O5';W2W0W8'\F/,;=[9^0\^ZJ
M?IO9\WSOVM729M]D015.46*JI=G3T-)]I!/$Q^[JH ^JT>M@0-:B/+KW5@WQ
MR^;'R[W37]GYOYL_R^*KX(=*]8]3[G[0R7=>X_E/M;N;'D[2DII:NAJJ'$8W
M'5="B8I\A7&K;R0)'121R:7DBU6KZ]>Z*!M;^;1\]/D+@I.Y?A9_*0WSWE\8
M*NLKX=F]H[]^3.U.D,KN*GPU5-35%=CMMY*FJL@M),T++ \:U6H@DC4#$NM5
M> Z]U<C\;^Z)_D)TKLCMZKZQ[)Z9R&[(,U'E>K^WMNR;6W%A:W;F2K,36TF0
MHY.0!54,ST\R_MU5*\-5$3%,A][!KU[H;_>^O=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=5]_*[_F8F&_\,O'?^YV1]Y<^P?\ R1YO^>R3_JQ;]8/?>7_Y
M+L'_ #P1?]I%UT6/W-_6/'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW0L]3=5Y7LO-+&%FH]N4$J'-Y<+;2/KX("05>ID'T%B$4ZW%M
M*M'_ #_SY!R5;5P]Q(#X,7KY:VH:A!^UCVCS(D[VQ]M;GW!NZ=R6D;#ZB?\
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MR<.O=7T^[=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUG?YS/_93^Q/\
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M@$:D8885!\P0P!&WK\6/DULGY2]8T&^MKRQT.;HU@Q^]]HRSK)4XG(%3JC<
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M-R?LEWN=NJ/)!&'59-10DNJYTLIIW>1'4*^UW*D'/&_6FU732)%<.ZNT142
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M$16L5Q<2*"336T4L2 L%/:%K2M":5ZF^?[M?)_)\,(YAW>6*:56 )GMK6-V
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M66IDR%9NJ&D2".,%FD,P4+R3;W;2.O=)_P#G^[!V)UE_)%W3UUU1B:/$=8[
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MGIE5']-"E!+)&)([-+02:C$ADUEIC+"\WW;.4Y9O%%M*JU!,2W$PC/"HRQ<
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M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H:.G/^:@?^&'F/\
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M*?V)_P"(%VO_ .]#NGWT$^ZC_P J[<?]+&;_ +1K/KF[]\+_ )6:V_Z5D/\
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MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T+O5G_ 'LW_ ,1QN'_H3W5O+[>O=/\
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MNING_GF\_P#^>>H_Z]^_5'7NO?W4W3_SS>?_ ///4?\ 7OWZHZ]U[^ZFZ?\
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MO/\ _GGJ/^O?OU1U[KW]U-T_\\WG_P#SSU'_ %[]^J.O=>_NING_ )YO/_\
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M %E54+1DE6L& /!_H?=%.3U[H&?[J;I_YYO/_P#GGJ/^O?N]1U[KW]U-T_\
M/-Y__P \]1_U[]^J.O=>_NING_GF\_\ ^>>H_P"O?OU1U[KW]U-T_P#/-Y__
M ,\]1_U[]^J.O=>_NING_GF\_P#^>>H_Z]^_5'7NO?W4W3_SS>?_ ///4?\
M7OWZHZ]U[^ZFZ?\ GF\__P">>H_Z]^_5'7NO?W4W3_SS>?\ _//4?]>_?JCK
MW7O[J;I_YYO/_P#GGJ/^O?OU1U[KW]U-T_\ /-Y__P \]1_U[]^J.O=>_NIN
MG_GF\_\ ^>>H_P"O?OU1U[KW]U-T_P#/-Y__ ,\]1_U[]^J.O=>_NING_GF\
M_P#^>>H_Z]^_5'7NO?W4W3_SS>?_ ///4?\ 7OWZHZ]U[^ZFZ?\ GF\__P">
M>H_Z]^_5'7NO?W4W3_SS>?\ _//4?]>_?JCKW7O[J;I_YYO/_P#GGJ/^O?OU
M1U[KW]U-T_\ /-Y__P \]1_U[]^J.O=>_NING_GF\_\ ^>>H_P"O?OU1U[KW
M]U-T_P#/-Y__ ,\]1_U[]^J.O=>_NING_GF\_P#^>>H_Z]^_5'7NO?W4W3_S
MS>?_ ///4?\ 7OWZHZ]U[^ZFZ?\ GF\__P">>H_Z]^_5'7NO?W4W3_SS>?\
M_//4?]>_?JCKW0NU^"SC=*87'KALJU?'O>6HDHEQTQF6,T]6-9CT:PEV4:BM
MKD<\^Z YZ]T$7]U-T_\ /-Y__P \]1_U[]WJ.O=>_NING_GF\_\ ^>>H_P"O
M?OU1U[KW]U-T_P#/-Y__ ,\]1_U[]^J.O=>_NING_GF\_P#^>>H_Z]^_5'7N
MO?W4W3_SS>?_ ///4?\ 7OWZHZ]U[^ZFZ?\ GF\__P">>H_Z]^_5'7NO?W4W
M3_SS>?\ _//4?]>_?JCKW7O[J;I_YYO/_P#GGJ/^O?OU1U[KW]U-T_\ /-Y_
M_P \]1_U[]^J.O=>_NING_GF\_\ ^>>H_P"O?OU1U[KW]U-T_P#/-Y__ ,\]
M1_U[]^J.O=>_NING_GF\_P#^>>H_Z]^_5'7NO?W4W3_SS>?_ ///4?\ 7OWZ
MHZ]U[^ZFZ?\ GF\__P">>H_Z]^_5'7NO?W4W3_SS>?\ _//4?]>_?JCKW7O[
MJ;I_YYO/_P#GGJ/^O?OU1U[KW]U-T_\ /-Y__P \]1_U[]^J.O=>_NING_GF
M\_\ ^>>H_P"O?OU1U[KW]U-T_P#/-Y__ ,\]1_U[]^J.O=>_NING_GF\_P#^
M>>H_Z]^_5'7NO?W4W3_SS>?_ ///4?\ 7OWZHZ]U[^ZFZ?\ GF\__P">>H_Z
M]^_5'7NO?W4W3_SS>?\ _//4?]>_?JCKW7O[J;I_YYO/_P#GGJ/^O?OU1U[K
MW]U-T_\ /-Y__P \]1_U[]^J.O=>_NING_GF\_\ ^>>H_P"O?OU1U[KW]U-T
M_P#/-Y__ ,\]1_U[]^J.O="[V=@LY5X;K*.DPV5JGI-D8RGJDI\=-,8I$BA!
M20*A*."#=38C^GNBG)Z]T$7]U-T_\\WG_P#SSU'_ %[]WJ.O=>_NING_ )YO
M/_\ GGJ/^O?OU1U[KW]U-T_\\WG_ /SSU'_7OWZHZ]U[^ZFZ?^>;S_\ YYZC
M_KW[]4=>Z]_=3=/_ #S>?_\ //4?]>_?JCKW7O[J;I_YYO/_ /GGJ/\ KW[]
M4=>Z]_=3=/\ SS>?_P#//4?]>_?JCKW7O[J;I_YYO/\ _GGJ/^O?OU1U[KW]
MU-T_\\WG_P#SSU'_ %[]^J.O=>_NING_ )YO/_\ GGJ/^O?OU1U[KW]U-T_\
M\WG_ /SSU'_7OWZHZ]U[^ZFZ?^>;S_\ YYZC_KW[]4=>Z]_=3=/_ #S>?_\
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MYO/_ /GGJ/\ KW[]4=>Z]_=3=/\ SS>?_P#//4?]>_?JCKW7O[J;I_YYO/\
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MJ/\ Z,]^UGKV@=>_O;N+_G9R_P#4J/\ Z,]^UGKV@=>_O;N+_G9R_P#4J/\
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M^_?\%]9_]&V;_LH3_K7U[_@+;G_HZQ?]DC_]M'7O^&".R/\ O(O9'_H#5_\
M]6^_?\%]9_\ 1MF_[*$_ZU]>_P" MN?^CK%_V2/_ -M'7O\ A@CLC_O(O9'_
M * U?_\ 5OOW_!?6?_1MF_[*$_ZU]>_X"VY_Z.L7_9(__;1U[_A@CLC_ +R+
MV1_Z U?_ /5OOW_!?6?_ $;9O^RA/^M?7O\ @+;G_HZQ?]DC_P#;1U[_ (8(
M[(_[R+V1_P"@-7__ %;[]_P7UG_T;9O^RA/^M?7O^ MN?^CK%_V2/_VT=>_X
M8([(_P"\B]D?^@-7_P#U;[]_P7UG_P!&V;_LH3_K7U[_ ("VY_Z.L7_9(_\
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MZ.L7_9(__;1U[_A@CLC_ +R+V1_Z U?_ /5OOW_!?6?_ $;9O^RA/^M?7O\
M@+;G_HZQ?]DC_P#;1U[_ (8([(_[R+V1_P"@-7__ %;[]_P7UG_T;9O^RA/^
MM?7O^ MN?^CK%_V2/_VT=>_X8([(_P"\B]D?^@-7_P#U;[]_P7UG_P!&V;_L
MH3_K7U[_ ("VY_Z.L7_9(_\ VT=>_P"&".R/^\B]D?\ H#5__P!6^_?\%]9_
M]&V;_LH3_K7U[_@+;G_HZQ?]DC_]M'7O^&".R/\ O(O9'_H#5_\ ]6^_?\%]
M9_\ 1MF_[*$_ZU]>_P" MN?^CK%_V2/_ -M'7O\ A@CLC_O(O9'_ * U?_\
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MY?\ J5'_ -&>_:SU[0.O?WMW%_SLY?\ J5'_ -&>_:SU[0.O?WMW%_SLY?\
MJ5'_ -&>_:SU[0.O?WMW%_SLY?\ J5'_ -&>_:SU[0.O?WMW%_SLY?\ J5'_
M -&>_:SU[0.O?WMW%_SLY?\ J5'_ -&>_:SU[0.O?WMW%_SLY?\ J5'_ -&>
M_:SU[0.O?WMW%_SLY?\ J5'_ -&>_:SU[0.O?WMW%_SLY?\ J5'_ -&>_:SU
M[0.O?WMW%_SLY?\ J5'_ -&>_:SU[0.O?WMW%_SLY?\ J5'_ -&>_:SU[0.O
M?WMW%_SLY?\ J5'_ -&>_:SU[0.O?WMW%_SLY?\ J5'_ -&>_:SU[0.O?WMW
M%_SLY?\ J5'_ -&>_:SU[0.O?WMW%_SLY?\ J5'_ -&>_:SU[0.O?WMW%_SL
MY?\ J5'_ -&>_:SU[0.O?WMW%_SLY?\ J5'_ -&>_:SU[0.O?WMW%_SLY?\
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MOVL]>T#KW][=Q?\ .SE_ZE1_]&>_:SU[0.O?WMW%_P [.7_J5'_T9[]K/7M
MZ]_>W<7_ #LY?^I4?_1GOVL]>T#KW][=Q?\ .SE_ZE1_]&>_:SU[0.O?WMW%
M_P [.7_J5'_T9[]K/7M Z]_>W<7_ #LY?^I4?_1GOVL]>T#KW][=Q?\ .SE_
MZE1_]&>_:SU[0.O?WMW%_P [.7_J5'_T9[]K/7M Z]_>W<7_ #LY?^I4?_1G
MOVL]>T#KW][=Q?\ .SE_ZE1_]&>_:SU[0.O?WMW%_P [.7_J5'_T9[]K/7M
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M_J5'_P!&>_:SU[0.O?WMW%_SLY?^I4?_ $9[]K/7M Z]_>W<7_.SE_ZE1_\
M1GOVL]>T#KW][=Q?\[.7_J5'_P!&>_:SU[0.O?WMW%_SLY?^I4?_ $9[]K/7
MM Z]_>W<7_.SE_ZE1_\ 1GOVL]>T#KW][=Q?\[.7_J5'_P!&>_:SU[0.O?WM
MW%_SLY?^I4?_ $9[]K/7M Z]_>W<7_.SE_ZE1_\ 1GOVL]>T#KW][=Q?\[.7
M_J5'_P!&>_:SU[0.O?WMW%_SLY?^I4?_ $9[]K/7M Z]_>W<7_.SE_ZE1_\
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M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NEEL_\ Y?\
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TLMU?\
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M .RB+_H+KW^G?IC_ )^AL?\ ]"*F_P"OGOW]0-[_ .4&Z_YPO_FZ]_KD<O\
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M /0BIO\ KY[]_4#>_P#E!NO^<+_YNO?ZY'+_ /T<;/\ [*(O^@NO?Z=^F/\
MGZ&Q_P#T(J;_ *^>_?U WO\ Y0;K_G"_^;KW^N1R_P#]'&S_ .RB+_H+KW^G
M?IC_ )^AL?\ ]"*F_P"OGOW]0-[_ .4&Z_YPO_FZ]_KD<O\ _1QL_P#LHB_Z
M"Z]_IWZ8_P"?H;'_ /0BIO\ KY[]_4#>_P#E!NO^<+_YNO?ZY'+_ /T<;/\
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M *^>_?U WO\ Y0;K_G"_^;KW^N1R_P#]'&S_ .RB+_H+KW^G?IC_ )^AL?\
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MZL?_ .%&_P#QZO\ *L_\:V?%S_W&SWNJ^?V=;?AT@/\ A0?A]^_'[O3^5_\
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MMW(U.&IS-+4BCDD0JA,;/&CR>]@ ]5J1QZL/[:^>FVMO_P M3=O\QKJ3;O\
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MU[KWOW7NK!NF_GAV_MJDZVZMHMO=<3X#&2[9V=3UM9A\F]::42Q4P=Y(\O%
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M._G64/3FX:?:7:]5\R_YB$/7>YZO*1X./'YA^N]HB@JVKI@8:+P5/C<5#V2
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I9;/_ .7_ /\
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MOF,*:Y)5B%4\P0!W)0% SA?>2/.'+'[XV27;;=02(D6$$@=T.ED%30"N@+7
MSF@KUBGR-S?^X^88=UNF(5II&N"H)[9PZN:"I(&O53)P* FG5AORM^8/2F[>
ME-X;/ZIW<V;W1O:KQ5#D%@VSE,1II4D@:KFDER%#2Q,9*6D2FL&9]+BP&G4L
M)^W7MCNNV[M#=;C#X<4 =EK+$]7HVD 1R.<,Y?R%1\Z'('W2]W=FW79;BTVN
MX\2>X*(U(9DHFI=9)EB091-'$FAQPJ"._#+LK9/4_=E'N[?^:_@&WHMM[@H)
M,A_#JO*VFK4C$2>*B@J9SJ*GD1:1^2/<M^Z>PW?,>TFVLH_$D,L;:=2)VJ34
MUD91_/J$O9OF6RY4WD7=_)X47@2IKT2/W-IH*1J[9IZ4Z1OR7WWM_?\ WWO_
M 'ULG*35V!RV6Q=5A<LE-/C'<4%#20>58YTAJ(B)86TZHT;@&P]FG(6SS;-L
MUO9W:!9$1Q(E5<#5([4)4LIPV:$CHG]RM]M]^WZZOK%RT3O&T<@#H3HBC6H#
M!6%&4TJ ?/JU_J3Y_=+5O7.W9>T-VU.W]_46,CHMQ8_^[.4R8J:B@70:J":B
MHZBGTU@42:6E0H[,A 50YQRYD]F=UAOI1M\(DMV<M$WBQ+I5C720[JU5K2H!
MJ!7B:=94<J^_.RS[?"VYSF*Z5 LR>#.X9U%"RF.-UH]-5"0030\*]4;9FLBR
M.8RN0@618:[)5U9"LH"L%JI6=0P!8!@&%[,1?Z$^\N+6(P1(AXJBJ:<*@ =8
M2W\XNIY)5K1Y'85XT9B16E<YZ;?;_23KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KDB/(ZQQJSN[*B(BEB2QL  .22?H/>B0HJ< <3
MUM5+D  DDT &22>K=/C/\4CUQAMN=I;^I]>]=P4M74X+ U$0(Q%.XC"2R@W/
M\1GCD-QQ]NC:#^Z7T8D^[/N<=\9MML&_Q932613_ &[+Y _[[!_WLBOPTKFW
M[+>T8Y;1=UW%:W;+6*)A_N,K#B?^&D<?X 2O&O1RO<#=9&=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2RJ
M/^/%H?\ M?/_ -:YO=S\/5!\72-]TZOU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=+
M+=7_  "VM_VH:7_H1/=VX#JB\3TC?=.K]>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=++97_ W*_P#:AKO^AXO=TX]4?ATC
M?=.K]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=++9_P#R_P#_ +4-9_Q'NR^?V=5;R^WI&^Z]6Z][
M]U[KWOW7NO>_=>Z)-\>OYD'P2^6'8.8ZJ^./RFZA[@[$P6*K\]7[2V;N5:ZK
M:AQ4\=-4UE*KI&E=2P2S0AY:9YD421N6T.K'=*=:# ]'9]ZZWT4OY/?._P"'
MOPP?:47RE^0O6_2=5OM<I)L_'[SS!IZK(1X0PBKFIZ6".>I:GIVG@5Y3$(P[
MJFO4P'OU*]:) Z-#A<SB=QX?$[AP.1H\Q@\]C*#,X7+8^=:JGJJ3*1)/35,$
MJ$I)#/"Z.C*2&5@0;'W[K?3G[]U[KWOW7NO>_=>Z(E\Z?GOUY\#,=\<\EV%L
MS>>\HODC\ENN_C'MB/9AH0U!E>QHZR2FR-?]]54P./IQ1.)1$9)KLNB-N;;
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z651_QXM#_P!KY_\
MK7-[N?AZH/BZ1ONG5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I9;J_X!;6_[4-+_
M -")[NW =47B>D;[IU?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[I9;*_X&Y7_ +4-=_T/%[NG'JC\.D;[IU?KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[I9;/_ .7_ /\ :AK/^(]V7S^SJK>7V](WW7JW7O?NO=>]^Z]U[W[K
MW5*?\B'^6IW%_*R^(G8WQ][NWKUIOO=F\/DGO?N+'9?JNMRE?CH\9GMN[3P=
M)!,^7Q>(J5K]>W9YI46F>*,3(B3RE6;W9C7JJBG1.NQ/^$_];O?^=O@?YB2[
MPZ['Q4JMU[2[]["Z6R%9D6S5;V3L3&55+C9Z;&0XA,(^(_BZ8_,RU55F):IZ
MF;)4WVOAJ%<>U8IUK3FO5FO\XKX5=H_S"?Y??<WQ2Z9W!L';'8O8>6ZMR&#S
M/9V3R.&PL:[(W5ALW5K5U.*Q>:KHVDH\?.L/CQLH:8QJ_C1FD32FAZLPJ.G/
MY:_R]L=\Q?Y:63^ V_-WQ;5RN2Z=ZMV?1[_P=)+F*?'[BZH7$U>.R24LCT,M
M=CAE<3%Y8'>"2>D>1 T,K*Z>!IUHBHIU7QU?\5_Y_6;ZOV_\0>YOE#\%^K.@
M-O;)QG5V4^2_0VTMY;D[@R>W\'!%CE%%'F'QNU<5G,AB8VCDR0H ]%.140Q5
M,JZFW4=:H>'1T_Y2'P+[0_E_?R]]N?$'M3=FPMW;VV]G^Y:H;FZ_J\C5XJ:E
MW]F<A78Y[Y''XZKCG6EJH?N(OMG2*76D4TZ*LK:)KUM13J9_)E^#O;'\NSX#
M];_%GNO</7FZ.P=G[K[,SN3S'5N6R6;PTD.\\Y69.E6"HRV)PE:TD<%0BRA\
M>BK(&",Z@,?,:GKRBG33_-B^!W;GSMP?PLQW4>Y.N-N5/QQ^<O2_R8WL>Q\M
MD\0E7@.NX<G'74F*;&8C+M-EY&K(?!%.E-3N YDJXB%#>!IUYA7I/?S;?Y8&
M7^>.UNKNV_CQO[&="?/+XQ;KQ>]?C5WS5RS8^GA>DJDGJ,%GIZ2@R54^$J6!
MGCT4%2T%4@_8FI:FNI:K8-.O,*](KYE?RS_D%\N\%\//E%ANW>M_C;_-)^)6
M)CJ,/VWU_CZ[?6Q\C4YBG$>=P-5!DJ''Y2IVW7R/5FG:7'>:ECK*R%J>=)W#
M>!IUX@G[>@WI]I?\*8^P(HMD;J[9_E0]!82KI*W'Y7NKJC978'8^YZ,2PND=
M=B\'N7R;<K:Y)=#I'504U,!=G5](@?V/GU[/5N'R7^.=+\G_ (G=Q_%W>V[L
MC2Q]R],;FZISN^\9CX:>ICJ-QXQZ)LM'1DM '2I85'V^K00#%J .H5&.MD5'
M55G\K/XO_P XOXD5'5'QO^2W;?POWU\*.A-F[DV7L_.=>X;<<W8F:H<>DU/M
M2BJFJJ+&X7'4N+ADI_(XCFJ!#2QTKRULDLE=[L2#UH CJ^CW7JW7O?NO=>]^
MZ]TK=K?YC<O_ (;F0_WKW9?/[.JMY?;UEWW_ ,?!)_U"TW^]'WM^/6DX=(WW
M3J_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U*H?^!M'_ -15
M/_T./>QQZT>'3]O/_CY<E_U1_P#N/%[V_'K2<.DO[KU;KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[I9?\P+_P"1[_KG[MY?GU7S_+I&^Z]6Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU%/F_\4L?\R/^%(6SNH<GWM\D_CQ3
M1?RP,=NW_2!\5NSTZDW0S87>N=B% V5DQV44XRI^Z+3P?;7D>*%M:Z+&X-!^
M?5#D]7*?%'^3?\./BEVQC?D- .XOD7\E</B)<)B/D5\L>UJ[O#=='!4+41R&
M@GJTIL9C9WAJZJ(STF+@F$4TT2N$FF62I->MA0.B)?S%X8I_Y^W\BM)HHYD7
M!_,N8)*@D >GVG/)&P!!&I'564_4, 18@>]C@>M'XNA2_P"%->W]T[A_DU_)
MV/:]#DLBN(SG2.X-RTF,BDJ'_A6'WK@9:J>2*(,STU&_AJ)F(T0Q1-/(52)F
M'EX];?AT^]+_  O^:_9/4'5O8/7/\[WO_([ WMU[L[=.RZW ?&[IO(44F+SF
M/IZFA-+/%MN2.6 4\D81ED8$ <GWJORZT ?7I9=.?R;]C=-_RY/EM_+_ *_N
M;??=&+^4V;[GWUDM];\QF-Q$^+SO:6+QL$,F,H**$X^BI<=F<3396.-8B@KI
M:B4*H<(NRU37K>F@IUKPQ_+'L[Y>_P GOX3?RFJS*U6*^77;7S-H?Y;?>V'H
MLJU)E<'M3XK9.ARV>RCF26H7(1XC;!VA!D98JF:DJ=5<BLQU4?NU*&O5*U%.
MK,/^%'W7D77/Q?\ Y96-V9GZOI[IOH_Y_?&?!Y+L#%8RCR5+L;%8'$Y/&8?<
M$]+7Q/B!38&"%O&:Z,41D,5/,"E0$:J];?H\FX_Y;/SGW_M+/;4W#_.E^1N?
MVAO;;F4V]G*#_9:NH1#6XW<E-)35,/E@VVC^*II9G77'(K:6NC V/O5>K4/K
MT'WRB^(F#^!O_"?'Y0?$O;6_]V]GX+I[XD=_XW&;VWP(4R55'N6JS.;$4D=/
M^S#34!R9I*2)+B*D@@BN=%SNM3UHB@Z.[_*,55_E;_R]0H"C_9.OCVU@+<MM
MC'$G_7)))_Q]Z/'JR\.JZ_\ A.+14N-Z8_F58ZA@CI:&@_G#_,>BHZ:(66.*
MEQ6QDC11^%1% '^ ][;R^SJJ<.EM_P )U<MB\C\*^\:.@R%'6U> ^??S Q.;
MIJ:H69Z2JFST-<E/4*I)AF:BK:.<(P#&*:*2VEU)T>O)PZ"[^8E_V_X_D6?^
M&_\ -'_WD*CWL<#UX_%TR?R^\CB]G_\ "@_^='L[?SQX;LCLO9?Q=WOU32YM
MS2U.7VQMS 4\&2J<3Y-(K:.FDJ\-'*8=8B>$QM9H)0GCP'7AQ/6#_A4BU#N[
MX5_'+HC;7^4?(+O'YQ=%;4^.E/0RF&NI-P&/+4XRT$L+??4D=.E:M&U12Q33
MI-D*=%C(E9T\G'KS]*'_ (4*JK;H_DWJP#*W\VOXTJRL+@@U#W!'Y!]^7S^S
MKS<1U8/_ #HZ*EK_ .5#\_X*R".HAC^,?9=:D<@N!+C:,U$#_P#!HIXHW7_:
ME'O2\>MOPZ$_^5S_ -NS/Y=?_BBGQ&_]]_M_WX\>MCAT>OWKK?7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]T3'Y _%/L/O[L?$9K9V9V9C:6BV=2866/<V1KJ.0RT
M-97U+LHI<=6*8RE5& 2X.H,"H !,\>UWN=8<EV$EI=1W#N]P\H,21LNEHXDH
M2\J&M4/E2E,^F./N_P"T6Y<_;E%>V<MLB);)"1,\JOK669R0$AD%*2#SK6N/
M,EE_V0[M[_GH^M__ #[Y/_ZS^Y&_U_\ 9O\ ?-[_ ,XX/^VCJ+/^!HWW_?\
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M!_VT=>_X&C??]_V'_.6X_P"V7KW^R'=O?\]'UO\ ^??)_P#UG]^_U_\ 9O\
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M_.6X_P"V7KW^R'=O?\]'UO\ ^??)_P#UG]^_U_\ 9O\ ?-[_ ,XX/^VCKW_
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MANK1HMJCGCF?M\298P(U(-2NB62K^0J !QR13H5\F?=QGL[U9MYDMY8$[A%
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M[]U[KWOW7NO>_=>Z][]U[J50_P# VC_ZBJ?_ *''O8X]:/#I^WG_ ,?+DO\
MJC_]QXO>WX]:3ATE_=>K=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=++_F!?_(]_P!<_=O+\^J^?Y=(WW7JW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=++8G_'P1_\ 4+4_[T/=TX]4?ATC?=.K
M]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=+?<__%BV?_U 5'_0M/[NW =47B>D1[IU?KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z651_QXM#
M_P!KY_\ K7-[N?AZH/BZ1ONG5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I9;J_X!
M;6_[4-+_ -")[NW =47B>D;[IU?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[I9;*_X&Y7_ +4-=_T/%[NG'JC\.D;[IU?K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[I9;/_ .7_ /\ :AK/^(]V7S^SJK>7V](WW7JW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=*W:W^8W+_P"&YD/]Z]V7
MS^SJK>7V]9=]_P#'P2?]0M-_O1][?CUI.'2-]TZOU[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=2J'_@;1_P#453_]#CWL<>M'AT_;S_X^7)?]
M4?\ [CQ>]OQZTG#I+^Z]6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z67_,"_\ D>_ZY^[>7Y]5\_RZ1ONO5NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z66Q/\ CX(_^H6I_P!Z'NZ<>J/PZ1ON
MG5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NEON?\ XL6S_P#J J/^A:?W=N ZHO$](CW3J_7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TLJC
M_CQ:'_M?/_UKF]W/P]4'Q=(WW3J_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TLMU?
M\ MK?]J&E_Z$3W=N ZHO$](WW3J_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2RV5_P-RO_:AKO^AXO=TX]4?ATC?=.K]>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=++9__ "__ /M0UG_$>[+Y_9U5O+[>D;[KU;KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NE;M;_,;E_\-S(?[U[LOG]G
M56\OMZR[[_X^"3_J%IO]Z/O;\>M)PZ1ONG5^O>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[J50_\#:/_J*I_P#H<>]CCUH\.G[>?_'RY+_JC_\
M<>+WM^/6DX=)?W7JW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2
MR_Y@7_R/?]<_=O+\^J^?Y=(WW7JW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=++8G_'P1_P#4+4_[T/=TX]4?ATC?=.K]>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=+?<__ !8MG_\ 4!4?]"T_N[<!U1>)Z1'NG5^O>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I95'_'BT/\
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M/?O"'^H=>J>O?Z=J+_GW>!_ZGI_]2>_>$/\ 4.O5/7O].U%_S[O _P#4]/\
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MKT@O].U%_P ^[P/_ %/3_P"I/>_"'^H=>J>O?Z=J+_GW>!_ZGI_]2>_>$/\
M4.O5/7O].U%_S[O _P#4]/\ ZD]^\(?ZAUZIZ]_IVHO^?=X'_J>G_P!2>_>$
M/]0Z]4]>_P!.U%_S[O _]3T_^I/?O"'^H=>J>O?Z=J+_ )]W@?\ J>G_ -2>
M_>$/]0Z]4]>_T[47_/N\#_U/3_ZD]^\(?ZAUZIZ]_IVHO^?=X'_J>G_U)[]X
M0_U#KU3U[_3M1?\ /N\#_P!3T_\ J3W[PA_J'7JGKW^G:B_Y]W@?^IZ?_4GO
MWA#_ %#KU3U[_3M1?\^[P/\ U/3_ .I/?O"'^H=>J>O?Z=J+_GW>!_ZGI_\
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M/?O"'^H=>J>O?Z=J+_GW>!_ZGI_]2>_>$/\ 4.O5/7O].U%_S[O _P#4]/\
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MW@?^IZ?_ %)[]X0_U#KU3U[_ $[47_/N\#_U/3_ZD]^\(?ZAUZIZ]_IVHO\
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M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IUP7_%[PW_:UQ_\
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M_P#0+C_^K_?O^!AYH]+7_LH_Z$Z]_P %/RC_ +]N?^R9^O?\.[?$C_5=G?\
MH%Q__5_OW_ P\T>EK_V4?]"=>_X*?E'_ '[<_P#9,_7O^'=OB1_JNSO_ $"X
M_P#ZO]^_X&'FCTM?^RC_ *$Z]_P4_*/^_;G_ +)GZ]_P[M\2/]5V=_Z!<?\
M]7^_?\##S1Z6O_91_P!"=>_X*?E'_?MS_P!DS]>_X=V^)'^J[._] N/_ .K_
M '[_ (&'FCTM?^RC_H3KW_!3\H_[]N?^R9^O?\.[?$C_ %79W_H%Q_\ U?[]
M_P ##S1Z6O\ V4?]"=>_X*?E'_?MS_V3/U[_ (=V^)'^J[._] N/_P"K_?O^
M!AYH]+7_ +*/^A.O?\%/RC_OVY_[)GZ]_P .[?$C_5=G?^@7'_\ 5_OW_ P\
MT>EK_P!E'_0G7O\ @I^4?]^W/_9,_7O^'=OB1_JNSO\ T"X__J_W[_@8>:/2
MU_[*/^A.O?\ !3\H_P"_;G_LF?H>_CW\Z^@?DONO([(ZZR>X:?<V/Q#YM,;N
MC#+A6JJ>!U28TA$\RS/ 71G2X8(VL!E5RH+YW]G-[]O[9;N_2,Q,_AZXI/$"
M,02-7:*:J&AX5%.-*C?D7WFV'W%N7M-ME<RHGB%)8VC+(" 2NKXM)(K3A4'H
MX_N+.I5Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[H<>T/\ CQ.G?^U!D?\ K5CO=%XGKW0'>[]>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NAGR'_ #(G!?\ A^S?^X]9[H/BZ]T#'N_7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[H9^UO^+)U5_X86*_ZTP>Z+Q/7N@8]WZ]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T,_2/_%[W7_X86=_ZW4GN
MC\.O= Q[OU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[H:.G/^:@?^&'F/^B?=6\OMZ]T"_NW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z5.S_\ B[5?_AK;
MY_\ =)D/>CU[I+>]]>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z=<%_P 7O#?]K7'_ /6Y/>CPZ]TO>Z?^9F;E_P#(-_[KZ7WI.'7N
M@M]VZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T-'_ #0C_P G
MS_XW]U\_RZ]T"_NW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>ZUAOYPW_95F$_\ $.;1_P#=EF_?0W[K'_*MR?\ /=-_U:M^
MN;GWNO\ E9X?^E=!_P!I%UU51[R3ZQ:Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z6G778&ZNJM\;9[$V1DWQ&Z=I96#+8>N0:P'BNKQRI<"2"H
MB:2*:,G3)$[HW#'V4;]L=MS+9S6%XFN&9"CKYT.00?)E(#*?)@#Y='?+?,5U
MRG?0[C9-HF@<.AI4<""I&*JRDJP\U)'6Y%\:^_MJ_)3J/;7:&V&CIY,A#]CN
M;!>;S28O*T2J*VAE-@Q$;L'A<JOE@>*72 ]ARIY^Y*N>0=TEVZYJ=!U124H)
MH6KH<?:,,,Z6#+Y==>?;_G>U]PMJAW.T-!(*21UJT,RX>-N'PG@:#4I5A@CH
M>O8,Z&G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW0X]H?\>)T[_VH,C_UJQWNB\3U[H#O=^O=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0S
MY#_F1."_\/V;_P!QZSW0?%U[H&/=^O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0S
M]K?\63JK_P ,+%?]:8/=%XGKW0,>[]>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z&?I'_ (O>Z_\ PPL[_P!;J3W1^'7N
M@8]WZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]T-'3G_ #4#_P ,/,?]$^ZMY?;U[H%_=NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TJ=G_ /%VJ_\ PUM\
M_P#NDR'O1Z]TEO>^O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=.N"_XO>&_P"UKC_^MR>]'AU[I>]T_P#,S-R_^0;_ -U]+[TG#KW0
M6^[=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z&C_FA'_D^?\
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MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0S](_P#%[W7_ .&%G?\
MK=2>Z/PZ]T#'N_7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NAHZ<_P":@?\ AAYC_HGW5O+[>O=
MO[MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NE3L_P#X
MNU7_ .&MOG_W29#WH]>Z2WO?7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NG7!?\7O#?]K7'_\ 6Y/>CPZ]TO>Z?^9F;E_\@W_NOI?>
MDX=>Z"WW;KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0T?\T(_
M\GS_ .-_=?/\NO= O[MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NM8;^<-_V59A/_$.;1_]V6;]]#?NL?\ *MR?\]TW_5JW
MZYN?>Z_Y6>'_ *5T'_:1==54>\D^L6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z-W\"NI]C]Y_,#H?J7LG%SYK8V^-Y-B-R8JFR51B'G@6BJYM"U
M-))#40GR1(=4<JMQ:]B?8 ]T]]NN6>7[V_LV"30Q!HV*JX4F1%^%PRG!/$'J
M2?:#EZTYKYDL=OOD,D$TD@D0,Z:@L,CCN1E894'!'1I_YQ?Q8Z5^(OR;V/UO
MT3MJMVKM#.=%;8WQD<=7;AK]RLV1R6?W/033+/D:BIG1&IL92+XQ)H!4L%!9
MB05]W[G;<>?-FFO-TD$LJ7LD*L(XXZ1K!;N!2-5'Q2-FE<_+H:_>,Y&VSD#?
M(+/:HC#"]C%,RF226LC3W*$UE=V^&-12M,5ID]"+_)@^''0'S"[![OP/?FTJ
M_=N+V7LW:N7V]3T.Z,EM@PSY2MJ(9G9\;54KRAHXU 5V91]0 ?9-]XGW!W7D
M"VLI-JF$332RK(3'%)4(B$?VB/3)/"G1_P#=J]N-G]PY[]-W@,P@CMS$!+-%
MI,C2AO[)TK72.-:>71>]C?".E[W_ )E'9/P_Z\J:O:>PMN=]]U[;ES+LV:FP
M^U>LLSDX3(6J)-=35"CI(*:%I'/DJ98C*2I<^Q9NGN2W*_)UOO\ = 2SR65F
MX7X!+<W$,;?A% NIBY I15('ET#]F]KTYNYUNN7[75#;0WUZK,#K:&TMIY%P
M7-6:@6-2=1U,&8$5ZN9[G^/7\B7X;;MQ71??&V=X9?L3^[N,R6;SM7N+?N>J
MH*?*&]-59%MN5M'C:>HJ!$91%28\2",@M"L4J"3'GEWFSW-]P8&W+:Y(U@\1
ME1 EC&I91E5\=&<@:J5=B*\"2#3)+F7D[VL]NIUVW=HG\<Q([,S[C(VACAF-
MNVA6)0FB*#3R"M0T._/[KCXO]9]_R8OXA;^A[!Z9SNS-M;KQU9#N%-SC'UF7
M-0M5BONM*U(-,L,,ABJU%7#YO'-=E#')WVIWC>]ZVK7O\!@NTFDB(,9B,B*%
M*OIX9+$53L.FHZQ5]XMDV+8MW$?+LZSVDD$<HT3"=8Y&9U:,-4M@*K:7)<:J
M'%.B2^Y*ZBKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K8A_E/_ "]7=> B
M^,F_LD#N7:M!4575N0JY>:W$T2ZYL1J=B7J<6NJ2!1]:(,@55I"6P5^\M[7?
MNR<\PV2?HS,!=J!_9SL:"7 PLG!C_OS-:R #H/\ =<]V!O5J.7+Y_P!>W0FS
M8X\6V0#].M<O%^$8K%2@_38FZ_WB3UF#U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=#CVA_QXG3O_:@R/\ UJQWNB\3
MU[H#O=^O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW0SY#_ )D3@O\ P_9O_<>L]T'Q=>Z!CW?KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]T,_:W_%DZJ_\,+%?]:8/=%XGKW0,>[]>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z&?I'_B][
MK_\ #"SO_6ZD]T?AU[H&/=^O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=#1TY_S4#_PP\Q_T3[JW
ME]O7N@7]VZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2
MIV?_ ,7:K_\ #6WS_P"Z3(>]'KW26][Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]TZX+_ (O>&_[6N/\ ^MR>]'AU[I>]T_\ ,S-R
M_P#D&_\ =?2^])PZ]T%ONW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NAH_P":$?\ D^?_ !O[KY_EU[H%_=NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK#?SAO^RK,)_P"(<VC_ .[+-^^A
MOW6/^5;D_P">Z;_JU;]<W/O=?\K/#_TKH/\ M(NNJJ/>2?6+77O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=6!?RK?^WA'Q:_\ $B2?^ZVO]Q1[X_\
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MWOW7NO>_=>Z][]U[KWOW7NG7!?\ %[PW_:UQ_P#UN3WH\.O=+WNG_F9FY?\
MR#?^Z^E]Z3AU[H+?=NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=#1_P T(_\ )\_^-_=?/\NO= O[MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NM8;^<-_V59A/_ !#FT?\ W99OWT-^ZQ_R
MK<G_ #W3?]6K?KFY][K_ )6>'_I70?\ :1==54>\D^L6NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z,W\,>Y<-\?/E5T-W)N2)I=L[%['P.2W.T<4
ME0\6,JW-)D:B**(-)-/2T51/-%&H)DD14_M>P7[B\NR<V;'>[?"?U)H'$?
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=#1TY_P U _\
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MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T,_2/\ Q>]U_P#AA9W_ *W4GNC\.O=
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MV=UM4KD\5BMU9;,Y3!8RN@K$2IH*BBP]911FBD4-0@"D*QF$QIY<#KW1<?\
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M]C]=05\Q5I*N3:N.@I*BNF*1Q(T]=41RU$I6*-3)(Q5$6RBX%.O=%[_FH_\
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M'.G^^ME_WJ^_S=>_JER#_OSF#]FW=>_V0[X=?\]I\E_^I>UO^O'OW]>.=/\
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M6(CRQH[*)@"ZJQ!(!]ZIU[H=8XXX8XX88TBBB18XHHU"*JH+*JJ+ *    +
M>]]>ZY^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NG7!?\7O#?]K7'_P#6Y/>C
MPZ]TO>Z?^9F;E_\ (-_[KZ7WI.'7N@M]VZ]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]T-'_-"/_)\_^-_=?/\ +KW0+^[=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JN_Y2_\S*IO_#7Q?_6Z
MJ]Y>>QO_ "16_P">F7_CD76#?WC?^2^G_/'#_P!7)^BW^YDZ@/KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NAMZ,[+;K_=209"<KMG/-%1
MYA6/IA>Y$-6/Z>%F(?\ K$S<%E2T9^Z')8YML2T*UN8 7B]7'XH_]L!5?Z0&
M0">I>]G?< \D[D(YVI:7)"35X1MP27Y:2:-_0)-"57JS)65U5T961E#*RG4"
M&Y!!'!!'O"P@J:'!'$== 00PJ,@\#UW[UUOKWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z''M#_CQ.G?^U!D?^M6.]T7
MB>O= =[OU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z&?(?\R)P7_A^S?^X]9[H/BZ]T#'N_7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[H9^UO^+)U5_X86*_ZTP>Z+Q/7N@8]WZ]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T,_2/_ !>]
MU_\ AA9W_K=2>Z/PZ]T#'N_7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NAHZ<_YJ!_X8>8_Z)]U;
MR^WKW0+^[=>Z][]U[KWOW7NO>_=>Z^?7\#/C%F?D7_PGE^5.YM@_?4W<WQ=^
M=N\/E'U!E\.*DU]/D.J=A]>U&16B%*PEDJIL')D_MXS'*K5:4S"/R)')&T!4
M=>ZW!/CC_,!ZW[4_EM[0_F![LR%-C]J8_H/*]F]KPXXFM-!E>NJ.HCW3C84B
MA6666GS&.KZ>G1:97G_:,<7[B*7 <5Z]UJZ=O]3;MF_X3]_.'YR]P4DJ=Z?S
M%/D!U?\ (?<TM;,M=-1[:D['Q$.T,/#4DO*V+IJ*6KJZ"(N%IZ2OA@2&'Q%!
M2F*]>ZVW=E[%W)V=\%NN^O-H=C[BZ@W+O/XS]=[=P_9^T84GRN"ER>W:"+^)
M8T2/&BUU.K,T#E[1R:7L=-C<<.O=4Z]T?R7?Y:6V=I9[(;C^2G:F$^7>$V?E
M6VS\G.S/F)D#OF'+T-'-]M6S0U.6IJ$H9Y#Y((<9%>*5XXV1G#^ZE0.O=&N_
MDK?(WMKY.?RI>J^T>Y]TUN\NQZ/%=L[+R&],@Y:OR$&Q,KD\?CJJNF%C/7I0
MPTT<M0?W)WC\\K/-)([;7(Z]U2)_*(_EZ[[_ )IWPDV3N#YW=Z=N9SXP=>9;
ML#9O0?3>R-_U.&DR^2FS];D\[O'>-?.:^?*UU+7U/\+Q,$FA*2EHF=(D\TDE
M755U#KW5@O\ .]V7A>F.@?Y1W7=/N+.97;O5'\PCXA;+AW9OW.#*Y*IHMBX7
M*4*Y'-9*41"IKIH*435=2ZH))3)*P6Y LV*?;U[IQW!OCLS^>#WSD.O>C.P-
MU]6?RN/CCV%%C^U.[>O=RUNT\[W!NG Q13R[;V[5TLE/44FU*'SQF>M'$X:.
MH@9Y)*8TVOC^SKW3+_-5^1M$ORT^('\K3$_*;%_!CX\9?K-NW/DOW-+V9!U'
M7_W3VRU5C]M[.PV[,G6THH9LK+@JR&H'W1FJ$FIC(\L$5525GB?+KW1%?F'U
M?_+3^#'3FX/ES_*8^?'56QOEIU1F]J[RK-B;6^<F-[?B[*HADHJ?+XO.[>K-
MS9.;-S&CKZZL6*&(>1DF18@\JRQ:-!PZ]U9-_-)ZJZE^>_\ *A7YS9G)=J;:
MSF!^$F4[TZ]VQM7L:LVSBO)V9M[%YYJ'<6(HZBHH<J:26.*%XY)'TVEC,CBQ
M&V&H5Z]TJ?Y-_P#+AZ*ZXZ ^%7S!P>\?D%5]G[A^-FPMS5FWLUWEG,CM1:CL
M3:\45=&FV?,F-:DA6MF-+3RQR0TTBPS1()H()(_*M,]>ZOT]WZ]U[W[KW7O?
MNO=*G9__ !=JO_PUM\_^Z3(>]'KW26][Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]TZX+_B]X;_M:X_\ ZW)[T>'7NE[W3_S,S<O_
M )!O_=?2^])PZ]T%ONW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NAH_YH1_Y/G_QO[KY_EU[H%_=NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U7?\I?^9E4W_AKXO_K=5>\O/8W_ )(K?\],
MO_'(NL&_O&_\E]/^>.'_ *N3]%O]S)U ?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]T:/XQ]4=-=IY#=U-W!VC3=9T^&H\1/@IJG<6+VZ*QZQYUJ%#Y1620PK'$=*
M>H:[GCW'W/W,>Z<O)"VV6ANB[.) (I9= 4+IQ%D5J>/IU)_MIRKLW,[W"[O>
MBS$:QF(F:"'Q"Q?5F8$'308&<YZ/IB/Y>OQQW!@IMT8'NG<>;VS3+6/4;BQ&
MXL%DJ&-<>"U07JX:1Z=! H)D)D&@ EK>X=N?>K?+*86\UC%'*=-(WBN%D.KA
M16<-GRQGRZG2T]@>7=P@-S!N$TD(U$RQS6SQC3\576(KVTSG'GT'X^'GQ'K\
MUM;![;^1,FY\CN+/QX48[ ;YVWFJH">EJI(WCIZ6"65@:B*%&.C2H<D_CV='
MW.YE@BEFGVT1+''KU26]TB8= 06=@.!)X^71$OM%RE<S0P6VZF9Y9/#T175G
M(^4<@A40DY4 XP#T4[Y:_'W'_'?L+$[9P62RV8V_G-L4F<Q^1S)A,WE\]13U
M$#&"*%#XS%&PM&/3(O)-_<C>VW.C\[63SS*B21RF-E35III5E/<6.:D<>(/4
M5>Z_(,?M_?QV\#R212PB17DTZM6IE9>U5&* \.##HR'QD^"FT^Z>H\=V+NW=
M.[,%6YW)9N+$4N%6D$'VV+F:D65Q44\LCLU3#47M(@*A0+'U$#<_>[MSRKN3
M6-M%#(L:QER^O5J===!I8 =K+Y'/[.I$]M?9"SYQVE-PNYIXVE>0(L?AA=",
M8P3K1B265O,8I]O5=F7VOEL3NW)[+D@>?.8S<=;M=Z6);,]715+4AC4-8W:9
M; '_ &/N;K;<([FV2[!I&\2RU/DC('K^P]8^7>U2VMX]E35*DS04'G(KF.@K
MZD=',^7'Q7V'\<MK;$J\/NW<6;W3NG(U=+54.5-)]OX<53(U7/3K%!#,H2HG
MIE4,SC2]B=0%XM]MO<.\YXN+A988HXHE!#)KU:G8A0U68956.*9'IU,7NQ[7
MV'MY:VSP3S23S.5*R&/3I1*NRA44X9E&2<'.>C+4G\M+9F9Z]Q^7P_86Z8]W
MY3:U#E*/^(4U&<<:RLIDF6.2&.$5*4[2-IN*EW13J]9&D@23WXN[6]:.6VA,
M*2LC:2_B:%8K4$MI+4%?A )QCJ1X_NX6-U8+)%=3B=X5=2PC\+Q&0-0J$U!:
MFGQ$@9SU5_LO84^;[:VGU?N,5F#JLOV+@=A9Y45&J*.2OR<6/J@%;4AFIV>3
M@W74O-Q[G_==X6TVV;<(-,@2VDN(^.EPL1D7T-&H/G0]8R[-L37F[0;9<ZHR
M]W%:RTIKC+3+$_J*K4^HJ.AR^7WQ[VU\=MY[8VYMC-YS-T>>VRV;FFSWVYEC
MD6JF@**:>&%"A6-3RE[WY(]A+VSYUN.=K66>XCCC:.70!'JH04#9U,QKGUZ'
M'NW[?VWM]=P06LDLBRPF0F702"'*XT*HICTZ*1[DGJ)NO>_=>Z][]U[KWOW7
MNO>_=>Z/S\;.S_X]B?[C9FHU9C!T^K#S2GFHHH[#QW_,E+<#^IB*VOH<^\4_
M>;DC]U7'[TME_2G:DP'!)CG5]DG'Y/7^(#K-3V$]P_WW:_N>[:L]NM86/&6
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M>Z][]U[KG'')-)'##&\LLKK'%%&I=F9S9551<EB2  !<GW5W$8+,0  2230
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MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5W_ "E_YF53?^&OB_\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0T?\
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M>J]M1O;Z^ZU/7NIW\+Z&_P">CWS_ -2(?_J#WZK=>Z]_"^AO^>CWS_U(A_\
MJ#WZK=>Z]_"^AO\ GH]\_P#4B'_Z@]^JW7NO?POH;_GH]\_]2(?_ *@]^JW7
MNO?POH;_ )Z/?/\ U(A_^H/?JMU[KW\+Z&_YZ/?/_4B'_P"H/?JMU[KW\+Z&
M_P">CWS_ -2(?_J#WZK=>Z]_"^AO^>CWS_U(A_\ J#WZK=>Z]_"^AO\ GH]\
M_P#4B'_Z@]^JW7NO?POH;_GH]\_]2(?_ *@]^JW7NO?POH;_ )Z/?/\ U(A_
M^H/?JMU[KW\+Z&_YZ/?/_4B'_P"H/?JMU[KW\+Z&_P">CWS_ -2(?_J#WZK=
M>Z]_"^AO^>CWS_U(A_\ J#WZK=>Z]_"^AO\ GH]\_P#4B'_Z@]^JW7NO?POH
M;_GH]\_]2(?_ *@]^JW7NO?POH;_ )Z/?/\ U(A_^H/?JMU[KW\+Z&_YZ/?/
M_4B'_P"H/?JMU[KW\+Z&_P">CWS_ -2(?_J#WZK=>Z]_"^AO^>CWS_U(A_\
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M'OG_ *D0_P#U![]5NO=>_A?0W_/1[Y_ZD0__ %![]5NO=>_A?0W_ #T>^?\
MJ1#_ /4'OU6Z]U[^%]#?\]'OG_J1#_\ 4'OU6Z]U[^%]#?\ /1[Y_P"I$/\
M]0>_5;KW7OX7T-_ST>^?^I$/_P!0>_5;KW7OX7T-_P ]'OG_ *D0_P#U![]5
MNO=>_A?0W_/1[Y_ZD0__ %![]5NO=>_A?0W_ #T>^?\ J1#_ /4'OU6Z]U[^
M%]#?\]'OG_J1#_\ 4'OU6Z]U[^%]#?\ /1[Y_P"I$/\ ]0>_5;KW7OX7T-_S
MT>^?^I$/_P!0>_5;KW7OX7T-_P ]'OG_ *D0_P#U![]5NO=>_A?0W_/1[Y_Z
MD0__ %![]5NO=>_A?0W_ #T>^?\ J1#_ /4'OU6Z]U[^%]#?\]'OG_J1#_\
M4'OU6Z]U[^%]#?\ /1[Y_P"I$/\ ]0>_5;KW5:WRSVKU[7=ITLNWNRL/AL>-
MI8E'I]YT&;EJO(L]668'%8"KI_"RE0MY-=PVH :2<J?9C<)K;:&5+6>4?4R'
M5&UL%^"+'ZMQ$U1_I:9X\>L-/?[;(+S?$>2[MX#])$-$JW98CQ)L_H6LRT-:
M?%7!J *5*]_<S;G_ #]KK[_SV[J_^QGW+?[XN/\ E!NO][LO^VSJ$/W#:_\
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M>^?^I$/_ -0>_5;KW7OX7T-_ST>^?^I$/_U![]5NO=>_A?0W_/1[Y_ZD0_\
MU![]5NO=>_A?0W_/1[Y_ZD0__4'OU6Z]U[^%]#?\]'OG_J1#_P#4'OU6Z]U[
M^%]#?\]'OG_J1#_]0>_5;KW7OX7T-_ST>^?^I$/_ -0>_5;KW7OX7T-_ST>^
M?^I$/_U![]5NO=>_A?0W_/1[Y_ZD0_\ U![]5NO=>_A?0W_/1[Y_ZD0__4'O
MU6Z]U[^%]#?\]'OG_J1#_P#4'OU6Z]T).]*7K*?;.P(L_DMTT>(I\75IMJHH
MXX6DGA*4FMIQ]O+9@HA(_;C_ %-P?Q45SU[H-OX7T-_ST>^?^I$/_P!0>[5;
MKW7OX7T-_P ]'OG_ *D0_P#U![]5NO=>_A?0W_/1[Y_ZD0__ %![]5NO=>_A
M?0W_ #T>^?\ J1#_ /4'OU6Z]U[^%]#?\]'OG_J1#_\ 4'OU6Z]U[^%]#?\
M/1[Y_P"I$/\ ]0>_5;KW7OX7T-_ST>^?^I$/_P!0>_5;KW7OX7T-_P ]'OG_
M *D0_P#U![]5NO=>_A?0W_/1[Y_ZD0__ %![]5NO=>_A?0W_ #T>^?\ J1#_
M /4'OU6Z]U[^%]#?\]'OG_J1#_\ 4'OU6Z]U[^%]#?\ /1[Y_P"I$/\ ]0>_
M5;KW7OX7T-_ST>^?^I$/_P!0>_5;KW7OX7T-_P ]'OG_ *D0_P#U![]5NO=>
M_A?0W_/1[Y_ZD0__ %![]5NO=>_A?0W_ #T>^?\ J1#_ /4'OU6Z]U[^%]#?
M\]'OG_J1#_\ 4'OU6Z]U[^%]#?\ /1[Y_P"I$/\ ]0>_5;KW7OX7T-_ST>^?
M^I$/_P!0>_5;KW7OX7T-_P ]'OG_ *D0_P#U![]5NO=>_A?0W_/1[Y_ZD0__
M %![]5NO=>_A?0W_ #T>^?\ J1#_ /4'OU6Z]U[^%]#?\]'OG_J1#_\ 4'OU
M6Z]U[^%]#?\ /1[Y_P"I$/\ ]0>_5;KW0AU=)U<>LL92S93=2[27<\DM)D5C
MA^Y:L\50#&R_;G]O093?P#D#U?@US7KW0>?POH;_ )Z/?/\ U(A_^H/=JMU[
MKW\+Z&_YZ/?/_4B'_P"H/?JMU[KW\+Z&_P">CWS_ -2(?_J#WZK=>Z]_"^AO
M^>CWS_U(A_\ J#WZK=>Z]_"^AO\ GH]\_P#4B'_Z@]^JW7NO?POH;_GH]\_]
M2(?_ *@]^JW7NO?POH;_ )Z/?/\ U(A_^H/?JMU[KW\+Z&_YZ/?/_4B'_P"H
M/?JMU[KW\+Z&_P">CWS_ -2(?_J#WZK=>Z]_"^AO^>CWS_U(A_\ J#WZK=>Z
M]_"^AO\ GH]\_P#4B'_Z@]^JW7NO?POH;_GH]\_]2(?_ *@]^JW7NO?POH;_
M )Z/?/\ U(A_^H/?JMU[KW\+Z&_YZ/?/_4B'_P"H/?JMU[KW\+Z&_P">CWS_
M -2(?_J#WZK=>Z]_"^AO^>CWS_U(A_\ J#WZK=>Z]_"^AO\ GH]\_P#4B'_Z
M@]^JW7NO?POH;_GH]\_]2(?_ *@]^JW7NO?POH;_ )Z/?/\ U(A_^H/?JMU[
MKW\+Z&_YZ/?/_4B'_P"H/?JMU[KW\+Z&_P">CWS_ -2(?_J#WZK=>Z]_"^AO
M^>CWS_U(A_\ J#WZK=>Z]_"^AO\ GH]\_P#4B'_Z@]^JW7NO?POH;_GH]\_]
M2(?_ *@]^JW7NO?POH;_ )Z/?/\ U(A_^H/?JMU[KW\+Z&_YZ/?/_4B'_P"H
M/?JMU[KW\+Z&_P">CWS_ -2(?_J#WZK=>Z$/?%)U=/C=D+N'*;JHZ6#;%%%M
M^2BCA9IJ-8X_')-_D\MI&4*2-*<D^D?BHKGKW0>?POH;_GH]\_\ 4B'_ .H/
M=JMU[KW\+Z&_YZ/?/_4B'_Z@]^JW7NO?POH;_GH]\_\ 4B'_ .H/?JMU[KW\
M+Z&_YZ/?/_4B'_Z@]^JW7NO?POH;_GH]\_\ 4B'_ .H/?JMU[KW\+Z&_YZ/?
M/_4B'_Z@]^JW7NO?POH;_GH]\_\ 4B'_ .H/?JMU[KW\+Z&_YZ/?/_4B'_Z@
M]^JW7NO?POH;_GH]\_\ 4B'_ .H/?JMU[KW\+Z&_YZ/?/_4B'_Z@]^JW7NO?
MPOH;_GH]\_\ 4B'_ .H/?JMU[KW\+Z&_YZ/?/_4B'_Z@]^JW7NO?POH;_GH]
M\_\ 4B'_ .H/?JMU[KW\+Z&_YZ/?/_4B'_Z@]^JW7NO?POH;_GH]\_\ 4B'_
M .H/?JMU[KW\+Z&_YZ/?/_4B'_Z@]^JW7NO?POH;_GH]\_\ 4B'_ .H/?JMU
M[KW\+Z&_YZ/?/_4B'_Z@]^JW7NO?POH;_GH]\_\ 4B'_ .H/?JMU[KW\+Z&_
MYZ/?/_4B'_Z@]^JW7NO?POH;_GH]\_\ 4B'_ .H/?JMU[KW\+Z&_YZ/?/_4B
M'_Z@]^JW7NA#ZXI.KJ;)9QMJY3=60JI-L9.+(QY".%%2C:2#S2)_D\%Y%81@
M#4W!/I/XJU?/KW0>?POH;_GH]\_]2(?_ *@]VJW7NO?POH;_ )Z/?/\ U(A_
M^H/?JMU[KW\+Z&_YZ/?/_4B'_P"H/?JMU[KW\+Z&_P">CWS_ -2(?_J#WZK=
M>Z]_"^AO^>CWS_U(A_\ J#WZK=>Z]_"^AO\ GH]\_P#4B'_Z@]^JW7NO?POH
M;_GH]\_]2(?_ *@]^JW7NO?POH;_ )Z/?/\ U(A_^H/?JMU[KW\+Z&_YZ/?/
M_4B'_P"H/?JMU[KW\+Z&_P">CWS_ -2(?_J#WZK=>Z]_"^AO^>CWS_U(A_\
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F>WE+4'![F61:B&(**=\;5K5,+42_N)2F9DY_6%N&'I.B3U[K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tflow_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tflow_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M^_=>Z]_PZQ_PH6_[Y_\ _P!F@Q/_ $;[]U[KW_#K'_"A;_OG_P#_ &:#$_\
M1OOW7NO?\.L?\*%O^^?_ /\ 9H,3_P!&^_=>Z]_PZQ_PH6_[Y_\ _P!F@Q/_
M $;[]U[KW_#K'_"A;_OG_P#_ &:#$_\ 1OOW7NO?\.L?\*%O^^?_ /\ 9H,3
M_P!&^_=>Z]_PZQ_PH6_[Y_\ _P!F@Q/_ $;[]U[KW_#K'_"A;_OG_P#_ &:#
M$_\ 1OOW7NO?\.L?\*%O^^?_ /\ 9H,3_P!&^_=>Z]_PZQ_PH6_[Y_\ _P!F
M@Q/_ $;[]U[KW_#K'_"A;_OG_P#_ &:#$_\ 1OOW7NO?\.L?\*%O^^?_ /\
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M /T:?77_ -JKW[KW7O\ H"I_E9?\_P#/G_\ ^C3ZZ_\ M5>_=>Z]_P! 5/\
M*R_Y_P"?/_\ ]&GUU_\ :J]^Z]U[_H"I_E9?\_\ /G__ .C3ZZ_^U5[]U[KW
M_0%3_*R_Y_Y\_P#_ -&GUU_]JKW[KW7O^@*G^5E_S_SY_P#_ *-/KK_[57OW
M7NO?] 5/\K+_ )_Y\_\ _P!&GUU_]JKW[KW7O^@*G^5E_P _\^?_ /Z-/KK_
M .U5[]U[KW_0%3_*R_Y_Y\__ /T:?77_ -JKW[KW7O\ H"I_E9?\_P#/G_\
M^C3ZZ_\ M5>_=>Z]_P! 5/\ *R_Y_P"?/_\ ]&GUU_\ :J]^Z]U[_H"I_E9?
M\_\ /G__ .C3ZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -&GUU_]JKW[KW7O^@*G
M^5E_S_SY_P#_ *-/KK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!&GUU_]JKW[KW7
MO^@*G^5E_P _\^?_ /Z-/KK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T:?77_ -JK
MW[KW7O\ H"I_E9?\_P#/G_\ ^C3ZZ_\ M5>_=>Z]_P! 5/\ *R_Y_P"?/_\
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M]=?_ &JO?NO=>_Z J?Y67_/_ #Y__P#HT^NO_M5>_=>Z]_T!4_RLO^?^?/\
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M^/DC]M;;R^VLHU5LPTU5$WCIJNKBG0X_(4.J8&/5+Y (E"B_NO='!_[:\_\
MP5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %
M2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\
M%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_
M /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\
MP5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %
M2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\
M%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_
M /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\
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MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7;_X55_\
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MW7NO>_=>Z][]U[K5W_X5]?\ ;G/<W_BQ71G_ %OR'OW7NMF+97_'F[2_\-G
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M<F]X:&1]M8/>NZ:O9.*J:FX"QUV5H</N"KHH+%B9(L-5O<!1'ZM2^Z]U2O\
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MM3);MV?L3#]3X=,QE\EE:#%5N,J\MEJJ&5%QU!_%J"!Q'55%36Q) L4_NO=
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M9H9"/7<^Z]T?'W[KW6H%_P )Q/\ MZ;_ ,*</_%_\=_[\7O_ -^Z]T=O<?\
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M5?S9:FGH_P">U_PGGK*R>&EI*7._."IJJJIE6"...#;&#9Y)'8A41%!+,2
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M4TF3VG@,)55V(W5!0T5.M#F*>5XII9ZJEJHXX6AF]U[H,/\ A2!_Q]W\DO\
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M*GKGH3X?=>ZKR_E>_P#<2Y_/6_\ #%Z1_P#<+;?OW7NA=_X4@?\ 'W?R2_\
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MW77_  F]97W9_.R96#*W\XKY1LK*;@@U*$$$?4'W[KW7?\J/_M_'_P *'_\
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M[\RT-+A!V)M#<\DU9D]O5*QDB3<F!GAKPJ-,97CHZVGBAAH:3%FJ]U[I9_\
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M5+__  F]97W9_.R96#*W\XKY1LK*;@@U*$$$?4'W[KW7?\J/_M_'_P *'_\
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M<<F2K64 L8*-)X3(0ITZUXNP]^Z]UMEQ2Q3Q1SP21S0S1I+#-$XD5UD *LK
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M^6G;=@BI]MY/-Q96*2+)QQY6HKJ6LJ(!DA%/70>;W7NA?_G3;$ZI^1G\X/\
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MX"_ SK[^7%\.=B?$3X^YDST&Q(]RUZ;\WMA/XM4Y;,;KKZC(5>7S-)1UN/\
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M.Q\9\9-O?'[*=65WP?H\?.NW,AN#(5$TG]Y:N1LDV/DG59:>5)1AER,4M+'
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M[M]]^_=>ZVKO?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ!?,C_N,D_E._^* =C?\
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MGEJY:]JC<=%F]^9+'9^I-;/4S>7(4E1())ZA@UYYM?NO=*VK_E<_"^M^6?\
ML\\^R.UA\JABTP"]M4_RL[:HYUQ4<?B&%7%P[X3!K@2+L<6,8,>TI:=J8S,T
MA]U[KON'^5U\+N^_DCU[\NNT]B=H[@^1'4LZ3=7=C8[Y3=K[0?;H\TLTL.%Q
MF%WOCL-C:2J:>9*JG@QT<%7"[054<T#&/W[KW1[\A@\5EL'7;:RU%'E<'D\3
M4X/)X_)LV02II*V%J>:&H,S.\ZS0LRR%V9G!.HDDGW[KW0<]"]'=;?&CI;J[
MX_=/8)ML]7=.[(V]U]L7!R5LV3D@QVVJ=*:G$]54/)4552ZIKFGED:2:5GD=
MBS$^_=>Z"?YC?!?XH?/WJY>G/EQTSMKN+8]+D&S.$@R\M7B,AB:YHG@^^PV8
MQM11Y;%59B=D:2EK(O*A,<HDC)0^Z]T#OP-_E0_ S^6I2[L'Q!Z)QO7F>WVM
M-#O'?&7W#E=^YZO@H])BHVR^<K:^KIL<CHLGV=*\%*9OWFA,I+^_=>Z757_+
MY^.4?>O9'R9V?3]I]6]Z=PK11]J[ZZL[OW;LI-Q+BZ*CQM&<Q@J;+_W9KYZ"
M@H:>"DJ9L*U51QA_M9X6D=C[KW0_=,=$=4_'W9DNP^IMIP;:P-;FLQN?.S5&
M0J]Q9'+Y?<<GFR.9SN8R=169;.9C(2^JIKJ^MJ*J8@>25@J@>Z]T4SXZ?RIO
M@7\2][]M]B?'?HM.K-U]TUV1R.[Z[;/86Z::.DFS*Z:V3;5*V;:EVA+6"RSR
MX2&@FEC6.%Y&@AABC]U[IT^*'\L3X9?"#<78^Z?C'L+LGKO,]P9FKW+VC)7_
M ";[2[$@SV5KA5";,9.BW1O/-455F9365#-D'IS6&1A(9_(B,ONO=1>G/Y7/
MPNZ"^1?8/RRZJV1VMM_Y!]LU$=1VCV'D?E9VUO!]Q_;RQ3019S'9O?&1Q&5I
MJ0PQ)2P5./D@I8%%/3QQ0?M^_=>ZQ5W\K+X59+Y8P_.6LV-VQ)\JJ;'-@Z3M
MQ/E?VY3U,&,>*2$X:#'1[Y3"P8(K-*3BX\:N/\CO+]MY69S[KW4_YU_ROO@W
M_,DV_MW!_,#HG!]FUFS5JTV7O*DRV1V9N#$)D'22>"ASF&JZ'(+1SO&C24DD
M\E)(X#O S@,/=>Z??B!_+C^&_P #.G\_T?\ $_IZGZ?V5NVLFR6[J_;V[,X^
MX<K53!E%37;JFR4FY)9H$=DIB,HHI(R8Z00IZ??NO=,?Q3_EB_#3X1Y/LS+_
M !CV+V9US6=R93(;@[/6J^3W:>_X,UE<LLJU.:K*3<V],S2MGIA/(6RBPKD"
MVE_N=2(5]U[K%T+_ "O_ (8?&7O[LSY0]+;#[,VOWIW/42U?;F]\K\H.U-]C
M<TLDYJ4DSN+W#O7*X;*/2RL_VK5&.D-(CR14IABD=&]U[KGV'_*[^"G:ORTP
M/SAWUT)A\S\EL#B:+"G?<>YLYB:?)P8J.&*B7/X*CR=/@-Q_8QT].(!D\95K
M&8:=P-=-3-#[KW2BJ_Y?/QRC[U[(^3.SZ?M/JWO3N%:*/M7?75G=^[=E)N)<
M714>-HSF,%39?^[-?/04%#3P4E3-A6JJ.,/]K/"TCL?=>Z,!TMT5U7\>MG/L
M7J3:D.V,'5YO+[ISE1-D:S<.2R^7W#)YLCFLYF,G45F6S>9R$WKJ:ZNK:BJF
M('DE(50/=>Z%OW[KW6KO_P *^O\ MSGN;_Q8KHS_ *WY#W[KW6S%LK_CS=I?
M^&S@?_<6+W[KW2F]^Z]U[W[KW7O?NO=>]^Z]UJH_SIO^WWW_  G-_P#$R?(;
M_H?9'OW7NMJ[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW17>X/@]\*_D+G*;<_?OQ ^+O>.Y*)*F.CW#W
M!\?]I]EUT2UA1IEBJ\UB:VHC$K1QEPL@#%5+7TBWNO=#CL3KSK_J[;E'L[K+
M8VSNNMHXX*,?M;8FV:+:.-@"(D0$-#CX*>EBM''&@TQ"RHJ_10![KW2HK:*C
MR5'5X[(TE-7X^OIIZ*NH:V!*J&:&J0QRPS12!DDBD1F5E92K*2""#[]U[HI/
M3O\ +[^"_P >NR,KW#T3\0/C=U!VGF4R4-=V#USTW@=HY;QYDJU9#!6T5##/
M205;(K310/''*P!=6//OW7NA([\^+OQM^56W,1M#Y+]"]0]^[7V_E_[P8# ]
MO]>8KL*EH:XQ/ :RBBRE+4K2U+0221M)$$=HV9"2I(]^Z]UQSOQ9^,^YZSJ#
M(;B^/G2N;K/C]4O5]%39/K#"UG]SI7C2+7ME9*)EP;"..(+]F(=)CC9;,B$>
MZ]TC>PO@E\(.W-_P]L=K_#;XJ=G=IT\U#40=E]A?'G:.]-P))BYFJ:9TS.2P
M]3D5>GJ'>6(BI!CD8NA#$GW[KW4GM_X/?"SY!Y7"YSOSX@_%WN_-[;P\.W=N
MYCM_H#:?95508^GL8Z&BJ,UB:V:EHT(&F&)UC7\*/?NO=&&VUMC;6R\#B]K;
M.V]@]I[8PE*M%A=N;:Q-/@J"CA0DB&EHZ6.*GIX@6)"QQJMR3;GW[KW3Y[]U
M[I&[XZ[V)V7C<3A^P=H[?WGBL#O#9?8&%Q^X\7%E8:7.==92ES6!RL"3*RQU
M^(RU%25=+,H#PSPQR(0R@^_=>Z67OW7N@([\^+OQM^56W,1M#Y+]"]0]^[7V
M_E_[P8# ]O\ 7F*["I:&N,3P&LHHLI2U*TM2T$DD;21!':-F0DJ2/?NO=<<[
M\6?C/N>LZ@R&XOCYTKFZSX_5+U?14V3ZPPM9_<Z5XTBU[962B9<&PCCB"_9B
M'28XV6S(A'NO=)[NCX4_#7Y(9V@W1\B/B5\9>^MS8JD>@QFXNZ.AMJ]I5U-!
M)HU0P5><Q5=40PMXX[HD@4Z5X](M[KW4KM'X;_$/O# ;5VIW5\5OC?V_M;8D
M$=-LC;7:/1VV.P,?AHXD>-8\51Y;%U=/CD5)'4+3QQ@*S "Q/OW7NA1V1U1U
M;UGL.@ZLZXZUV!U_UABL7)A,7UQLC9V.VI@::BFC\3T<&'H*:GQ\-*T1*&)*
M<1E?25MQ[]U[HO\ T[_+[^"_QZ[(RO</1/Q ^-W4':>93)0UW8/7/3>!VCEO
M'F2K5D,%;14,,])!5LBM-% \<<K %U8\^_=>Z*9\[_YSOQA_EY_([ICXQ=U]
M9?*;=N_N^]BY+>W6^2Z4Z1F[.QM?)CZZHH%P5*::NAR.1W#+/3W:BH,=5M2Q
M3T<U:U+%64[R>Z]T8_X)=7[_ -M[$['[P[LVLVS._?EOVIF>^^S=GU-5]]5;
M<HJFCH<%LG9]7)'7Y&C^_P!I[$PNW,?DOL:G["7,QY2LI5*U;22>Z]T>/W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW6JC_P *3_\ LH/^0O\ ^-3NI/\ W=[6]^Z]UM7>_=>Z][]U[KWO
MW7NO>_=>ZU4?^$H/_9/G\R3_ ,:G?(+_ -TFU??NO=;5WOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND=V
M%U[L;MG8N[NL>S=IX'??7F_MO97:>]-F;HQL68QV3QN<A>GJZ*LI9E:.:">%
MV5E9?H;BQ /OW7NJQ?C=\"?DA\"=N_Z&OAO\E-G[B^*>/J\S5]=]$_+#86:[
M*RFQDRDL<ZXG:^^,/N;$9"HVQ!(:LPXW+8FOJ8#*/#E$B0P/[KW2HPO\NW-]
MM?(?KCY5?/+M[$_)/L+HZIRF0^._3VS>O6ZPZNV+7Y.5[[AH]N5^7W+E=P;R
M6F%/"N9RN<E6G\9DQV/Q[L"ONO="]_,C^#.S/YD/PR[E^'>^]UYC8F'[6H=N
M246],%1KDJC%Y+9F7H,YBZS[226".LABK\=3^:G:>,30ET$D;%77W7NBH;E_
MER_+[L3^7?V5\,.TOY@.'W]V=W%TU)\?=Z]Z[A^+T:XFCVI+1U.,>+ [&PN]
M]OTE)N"HQE94)59BKS%9)4S^&7[6*GIH**/W7NAA^,GPG^0?QJ_EZ[7^#V.^
M2_4FZMQ]==0_Z%>NNYJSXOY;%TU/B:>AJL?2SY?:Z=I3ME,C!!+3DR0;BQ\,
MC1,33@2VC]U[I$_ROOY8V8^ 'P;D^ G:_<VQ/E7TQ3#LS%XTMT+4]1U$^'[<
MK*W(9K$YR*7>^[:7+0S5.4R2*\4-%:FE2%TD:,RR>Z]U6IU-_("^9_P\WKGM
MD_R^OYQO=7QD^%NZMVUVYIOC[G.FL-W1D<!!F:MIZ['[:S.?KYJ.B>:*218J
M],3#4)+HJ*Q,C.))9/=>ZMR^17P!R78O\OSL7X#=$=O8SJ##]K==;WZTWUVS
MVCUU7?('-9"#M3[IMUYVK6/=FSY*S=F?J<ADJRHR5373(U=4O4/2R "/W[KW
M2X_ES_%'M+X0?%+J?XK]B=X[/[\Q/2.S<)U]U_O/;G2E3TK5G$X#S1TT66I9
M=X[NIZZICIFI8EF@-&"(F>2.1Y;I[KW1ZO?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4[?\*!/^W,_P#,
M&_\ $%5/_NUQGOW7NOC(>_=>Z^_Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NM5'L_P#[B^OCI_XRQSG_ +M]]^_=>ZVKO?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]TF\9L[:N'SV=W3C-OXFCW-N?[-=P[ABHT^]K$QZZ*>&>J(,[T]."WBB+^*,
MLY1%+N3[KW2D]^Z]U[W[KW7O?NO=>]^Z]UKM_P#"JO\ [<>?+'_PYOCA_P"_
M)VI[]U[JYKX@?]DE_%W_ ,5UZ3_]YK&>_=>Z,5[]U[KWOW7NO>_=>Z][]U[K
M4"_X3B?]O3?^%.'_ (O_ ([_ -^+W_[]U[K;]]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=$X[:_EW? 3OO>;]B]W_"7XG=N[_G>-JS>W9'Q[VGO/
M+5(B9W5*S(9#%5%561!Y)&$<\LB:G8Z;L2?=>Z-9MS;.V]G86@VWM';^$VMM
MW%0_;XO ;<Q4&#HJ:,$GQT]+31Q00I<DZ4C N?I[]U[I[]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]UJH]G_]Q?7QT_\ &6.<_P#=OOOW[KW6U=[]U[KWOW7NO>_=>Z][]U[K
MWOW7NM0+YD?]QDG\IW_Q0#L;_P!T7R6]^Z]UM^^_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNM7?_A7U_P!N<]S?^+%=&?\ 6_(>_=>ZV8ME?\>;M+_PV<#_ .XL7OW7NE-[
M]U[KWOW7NO>_=>Z][]U[K51_G3?]OOO^$YO_ (F3Y#?]#[(]^Z]UM7>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZQ/!!+)#+)#%
M)+3.[T\CQAVC9U*,4)%U)1F4D$7!(^A]^Z]UE]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JC_P
MI/\ ^R@_Y"__ (U.ZD_]W>UO?NO=;5WOW7NO>_=>Z][]U[KWOW7NM5'_ (2@
M_P#9/G\R3_QJ=\@O_=)M7W[KW6U=[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
MQRRQ0123SR1PPPQO+--*XC5%C!+,S$@*J@$DDV Y/OW7NDCD.Q-A8C953V3F
M=Y[7PG7E%C'S=7OO.9RFPV'BH5-A7ODJJ2*C6AD&EHZ@S>&2-DDC=HW5C[KW
M3QG-Q8';--2UNXLOC\)0UF2H,/3UV4J5H8#59600TL#32%8HY*J=DAA#.OEG
MDC@CU2RQHWNO=/7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JG;_A0)_VYG_F
M#?\ B"JG_P!VN,]^Z]U\9#W[KW7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]UJH]G_]Q?7QT_\ &6.<_P#=OOOW[KW6U=[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KB[%$=E1I65698T*AF(%PHU%5N?H+L!_4@<^_=>ZI<[0_
MG:=5]4_S ]@_RSLU\.OFYFOE!VGC:'<?7.-VUANJJW"Y;"U-'E*^?.0Y:H[8
MI4I\;04F#SDE3]U#3U,8H*@"G<F$2^Z]U<EAJ^JR>,I*^MPN3V[55",TV%S,
MM'/4P%690LKX^KKJ,LP 8>*KD%B+D-=1[KW3G[]U[J%C\ECLM21U^*KZ+)T,
MKSQQ5N/JDK8F:ED:*55DC9D)CE1T8 W5U938@CW[KW31N_/5VV-M9?/8S:>Y
M-]9#&TOGH]H;0;')DLA(S*BT]&V7R&)QB2L6OJJLE30JH+22HH)]^Z]U6Y_*
MT_F:XK^9YLCY';[P_1.]^@:7X_\ R5W1\<*C:O9.X*/+9VHK-G8;"9#(5&4H
M\?":/#55/7Y6IHFHXLED5 I1/]W>8P0^Z]U:/[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NM=O_ (55_P#;CSY8_P#AS?'#_P!^3M3W[KW5S7Q _P"R2_B[
M_P"*Z])_^\UC/?NO=&*]^Z]U[W[KW7O?NO=>]^Z]UJ!?\)Q/^WIO_"G#_P 7
M_P =_P"_%[_]^Z]UM^^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NN+J71U5VB9E95D0*64D6##4&6X^HNI']01Q[]U[K4D^4_P I/YA>
M#_X42?&7^6%UW_,%[DZZ^-GR1Z"S7;^7;%=)=);@SN#K<!M?L?)?9X?)9GJS
M(AZ&HK=C4+N*Z"LF"U=4B3*OV_A]U[JXS?/PG^>D^S-UP];?SD?EABNPI-O9
M=-D9+>WQP^-NXL/!E3 _V$F4H*'I7%5E70+4^,SQ09*EE>/4(YXV(8>Z]U8+
MTM5[XK^G.IJ[LY*F/LJMZSV'5]A)6T4&-F7.5.*I7RPFIZ:.*FIY17M4:HXH
MDC1KJBJH 'NO="9[]U[IEW)N3;^S=NYW=V[,UC-N;7VOA\EN#<>X,U6QXZCH
M:'#PO45=755$K+%!3TT$<DDDCL%1%+$@#W[KW02?&3O_ &A\J>@>J?D9U]'4
MIL/N3:-#OS93UL<L,LV)S9=\=4R13PT\\#U5)XIC%) DD1?QN-2$^_=>Z'7W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7WY7=0;\[_\ C;W5TKU?W9N[XX=A
M]F=>[@VCL_O78:S-F-KU^6B*09:@^VK<;5":G;\T^2I*E5+&GJJ:81S)[KW2
MA^/G7&[>GNB^HNJM^]J[H[SWKUWUUM+9NZ^X][1K%E]SU^WJ*&FJLWD5$DY%
M7D9HWFDUU$TEVO+//)JE?W7NAA]^Z]U[W[KW7O?NO=>]^Z]UJS?\*@_FK\X/
MY<OQQZ+^1GPY^5F\>I\MO7OR#J#<^Q*GJSK;L'"ST>7VYF\S'61-N39.6S%/
M6TL^""+IRIA>.IEUQ%DB9/=>ZV2NI=C;RZ_V?B<!OONC?G>NXZ/&8RERF^^P
M,#M3;5965-)&5J*O[/:&W=MXNG^[D)<Q)1E(P%6.UF+^Z]T)S,JJ68A54%F9
MC8 #ZDG\ >_=>Z+C\8/E#UC\M]B[K[-Z>RM-N+8&W^W.T^H\7NFAJ#54N5J>
MHLO/@<G743F*(24+Y2CK4IY4,D51#&E3!+)#-&Q]U[HP62IZJLQU?24.0FQ-
M;54553T>5IX(JJ2FEGC98ZA(ITD@D>%R'"R1LC$ .K*2#[KW6N)_*8[>^36X
M/YMW\['H#O7Y/=L?(G9GQURWQ>PO4,'8<N.P]+A\?O:#=N;DBI,%M^AQ&W*2
MMT5E-2U-;2XBGGKHZ.F-1<0PQQ>Z]ULD>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K51[/\ ^XOKXZ?^,L<Y_P"[???O
MW7NMJ[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:@7S(_[C)/Y3O\ XH!V-_[HODM[
M]U[K;]]^Z]U[W[KW7O?NO=$>^;WS]Z/^"6U-E5O8L.Z]^=H]O[I@V!T%\>^J
ML7'N?>F^=P5NE8<9@<6\].GB1Y(ONJVIG@HJ-71JB=6>-']U[I.;:[ _F=;A
MVK)N[)?&CX>[&S-4E?6XCI[<WRFW5DLA'$-1HZ7,;GQ/6==BJ'(2KI^X^RQ.
M4IJ=KI%/5C]SW[KW2?\ B3_,!S?R6^57RR^*F\OC+VW\<M[?$_9W1>=SZ]I3
MX>OBSLO<%3NY?O\ ;==A,EDJ++;7-+@*%Z'(!X9II9:VFJZ.BJ:*2#W[KW5D
MGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>ZJO_FX?S#>R_Y7_P 4]S_+O _'39WR$Z\V%G=DX??&
M#R/?M7TYEZ>/?>4I\+2U./A38>ZZ2O$>2K:%94DK*5A%))*NHQ>-_=>Z,%\#
MOD=W!\N/C+TC\ENR^D]A]'8OOOJG9?<>S=H[5[PK>YZN#$=CT%+E\(,C43[)
MVC3PU<^*K()9XX?.M/*W@#RV:1?=>Z.=[]U[HCGQYW_\[]R_*+YC[2^1G1_5
M/7WQ6V/N+8%+\-.S]G;H.4SV[L?DL<\N>GS]%_%LAX'HZWQ(A;&X@HS/ D%=
M&@KW]U[H\?OW7NO>_=>Z][]U[HCGS+W_ /._8^X/BO3?"KH_JGN3;^[_ )#;
M9VS\JZ[LW=!VW)MGKRKBE;)YW"VRV+,N1IW4:2L&4<-HC7%5"S//2^Z]T<#=
MN[MM[$V_7[JW=EJ;![?Q9I!79.KU%$-?/%30+9%=W>:HFBC154LSNJJ"2/?N
MO=*/W[KW7O?NO=>]^Z]U2_\ SQ/YB_R4_EA?#O<'R>Z(Z*ZF[:Q^$S.V-KYW
M-]G=B9+#)A:O?%1-C\;6#;6-QT<^XJ*+(-0I4QQ[IQ4X6<>(LJRRP^Z]U</M
MS(SY?;V"RU2L25.4PV+R-0D"E4#UL"2N$#,S! S&P+$V^I/U]^Z]T\^_=>Z]
M[]U[K5W_ .%?7_;G/<W_ (L5T9_UOR'OW7NMF+97_'F[2_\ #9P/_N+%[]U[
MI3>_=>Z][]U[KWOW7NO>_=>ZU4?YTW_;[[_A.;_XF3Y#?]#[(]^Z]UM7>_=>
MZ][]U[KWOW7NO>_=>Z9=PX"AW/B*O"9*?-4U'6H$FFV]N3([1JU -_V<AB:J
MBKZ<_P",52A_%[>_=>ZU"/\ A/U5]P=H?S+?YW&QNV_E+\Q>Y.O/A'\FWZ2^
M/VR^W?F!V5V'C\5B:W?79N/C-10Y+<\]#EZM,?LG%0FHKZ>HFT^72P^YJ/)[
MKW6X6]13QS0TTD\*5%2)6IX'E57D$ !<HI.I@@9=5@;7%_K[]U[K#39''ULU
M73T=?15<]!*(*Z"FJDG>%S?T2JC%HW])X8 \'^GOW7NB/?)CYY]4_'GY%?#K
MXI5&6QF8[T^8/:=9M7:VR(:A*BJH-O;9P^6S&9W+70K412T] AQD=!32%7\U
M;5($BDB@JW@]U[H]OOW7NH%#E,9D_/\ PW(T&0^UE,%5]C61U?C<?5)/&S:'
M']#8^_=>ZDS5%/3F$3SPP&HF6GIQ-*L6N1P2(TU$:G(5B%%R0#QQ[]U[K'35
MU%6-4I25E+5/1U#4M8E-4).8I4L6CD"DF.0 BZM8C^GOW7NHTV:P]/1PY"HR
MV,@H*B1(J>NFKXHH7:2^E4E9PC,VEK ,2;'^GOW7NG/W[KW393YK#UE=48RD
MRV,JLE2"1JK'T]?%//$(F",9(E<R(%9E!NHL2 >2/?NO=%2^>/S3Z>_E^_%C
MMGY2=U9RDQFV^N]M9&KP6#:IBCK=P9R6&3^#[=Q,,LT JLGEZQ8X8D$BJBEY
MYGBIX994]U[H<L;%%V_TS00[C-3CH>T>L:6+/';M;-B9H%WMBE%5]C4J[3TT
MD0J7\,@D,D;!6#%A?W[KW0"? 3X8=3_R^_BQUS\3>D]U[_WIUWU9+NBGQ.X.
MS=SP;KS$DV=RM9D:R.HGHZ2@H85@JZJ:-*>FH*>&%5""(/K9O=>Z-SD<OBL/
M$D^6R>/Q<,LGBCFR-;'1*S6)TJTK*"U@38&]@3[]U[IP]^Z]U%:NHE^[U5E*
MO\/4/7ZJA!X%*>0&;G]H&/U7:WIY^G/OW7NNZ2LI,A315E!54U;23@M#54DZ
MU,;A25)5T+*P!!'!^H(]^Z]U%R6:P^&6)LOEL9BEG+K V2KXJ$.8[:@AE==1
M6XO;Z7%_?NO=9LE0ID\=7XV2HK:2/(4550R56-K),=4Q+5QM&9*>HB*RP3H&
MNDB,&1@&4@@'W[KW6KM_)LV[5;(_G5_S]>OCO?L[?6#V/F_B'C-IUO;/9.:[
M7RE%C\]1[PSO\+CS&?K*_)R8^BK<O6"EBEJG,43!2SMJ=O=>ZVEO?NO=:[7;
MOS=[P^?7\S7>G\K'X8=DYWH_IWXO;:IMX_/SY6;#AI*C<JU-7+2I2=<[)K*V
M*:#!Y2KEF:"NR\=//54QAKTI/MYZ!GG]U[JS+&?RX?CG@=O8K$[;SGR7V_N#
M"KCIL?V90_,3M2JW.:O&2I41UE=EJW=]4V8:6HC5ZFFR,57CZQ+TU91ST;-3
MGW7N@J_EL=;_ "UZ9W5\Y^L_ESW]NCY+9F/Y0X_??2W:^[<!AMKU==L#=FQ]
MIT6$BEQVWZ'&X>CJ<?6X3+4%8M)04T-37TE5D5IXC7,#[KW5G%7E\505%)25
MV3Q]%5Y"014%+5UL=-).S,JA84=@TC%F464$W('U(]^Z]TX>_=>Z][]U[KWO
MW7NN+H)$>-BP5U9&*.T3686-F4AE/]"""/J#?W[KW6F5\I)NU*+_ (50?"SX
M:X7Y4?-S;?Q?[LZ!R'=/8W2VVOFWVK@L+69K:&V.T\G (8*?=R/08VIJ]EX-
MJFBI9(::8+4*8P*F;5[KW6Y)AL32X+&4F)HI<G/2T2-'#+F<U6;BJ2'9G/EK
M<A/55D[78V,L[D"R@A0 /=>Z*E\\?FGT]_+]^+';/RD[JSE)C-M]=[:R-7@L
M&U3%'6[@SDL,G\'V[B899H!59/+UBQPQ()%5%+SS/%3PRRI[KW1D]@;@JMV;
M$V5NJNAIZ>MW+M+;>X*RGI RQ)+F:.&ID2(.SN(U>0A=3L; 7)//OW7N@/\
MEWLS;G:?Q^[AZYRF_-][)KLAUGOFOI<AU1VGE.I]QP/38BO\-11Y+!UM%DXU
M@D_=TB0P2-$JU$<T(>)O=>ZJ'_X2U9C+[A_DJ?&7/Y_*9'.9[.;Y^3F8S>;S
M%=+DZNLJ\GV9NR>IJJJIG9YJBIJ)G>2661V>1V9F8L2??NO=;"OOW7NO>_=>
MZ][]U[KWOW7NO>_=>ZU4?^%)_P#V4'_(7_\ &IW4G_N[VM[]U[K:N]^Z]U[W
M[KW7O?NO=>]^Z]UJH_\ "4'_ +)\_F2?^-3OD%_[I-J^_=>ZVKO?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW53_5GSV[S^8_9'=V)^#G2/7.<Z'^/?9^\.C-U
M_)+Y#=AYG8&/W/O/8GV\>9QFQ<!AMM9FORV$PM9-)2U><JZRAII:J-X\;!7Q
M*]0GNO=2>EOY@_=.XOG'@/@%\B/B%G>B>UZKX^;Z^0<O9VW>PJ?M;KG<.,VA
MDMM8?3LK<9Q^!R]?40Y#.RID:3*;7Q=9C_%3NT,U/74E3-[KW01;6_F2_)6N
M_G6?\-C;]Z/Z>V)U='\2MS?)C%]@8#?N7['SN:@;*8_&8=M4N-VWC]O^&HCS
MD5=0G'Y8R.E/)39)(U83>Z]U=I[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI
M+_FW_P R7Y*_R^=S?#*AZRZ/Z>WAU[\I?EKT[\9\MV9OK?N7JZ_#S[\R%/)5
MK%M''XW'13_<8:',"DKFW?:GK(8WJ,;40GQR^Z]U=I[]U[KWOW7NO>_=>ZK_
M /YF_P K.ZOA+\..Y_E#TMTSL;NNNZ7V3F-_;IV[OGLZIZVBAQ>!:!JNII?M
ML)EVRM1!3/43_:-/CQ(D#*E7YGBBD]U[H2/@+WWO#Y4?"'XE?)7L'&[:P^^N
M^?CSU)VUN_$[-HZK'XFFR6_<)1Y*L@QL%=69&LAHHYZAUA2>OJ)5C"AYI&!8
M^Z]T(WR2WYVOUATGV)O_ *5ZVVIVSV%M#:FXMR8?8V\^Q)>K:"M.!H*JL,3Y
M>'"YYX997@2*-30!'>1?+/3QAYD]U[HE?\FOYU]A_P R7^7[U/\ ,+M#:&S-
MA;L[.W5W/1MM+8*UW\.HJ#8^\<Y@L5"),C5UE3458QN.I?NI]<4<]3Y9H::E
MB=*>+W7NK1O?NO=>]^Z]U[W[KW7O?NO=58_.ON+-UGRP_EN_!S"RTZX'Y7]H
M]U]A=XP22)>LV#\5=HR[@K,+*CR1^6BW#NW);.HJVG D^]QIKZ6:"6@DKC'[
MKW20_GV;+VCN_P#E#_/B?=&VL)GZG;'QRW]N/;E5E<;%6RT%?BXHZB"KHY74
MR4T\<L,9UQLI(&EKJ2#[KW5L>Y-N8'>.W<[M+=.)H<]MG<^'R6W]PX3)P"II
MJRBS$+T]533QMP\,\$CHZGZJ2/?NO=5G?RE/DMN#Y =%=Z["WIFJO<^_/A-\
MV/E5\$=V;IK?N)ILFGQVW&]/MZNGJZIY)\C6S;/R&W/O:UR'JJX5,TBK(SJ/
M=>ZM+]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5.W_  H$_P"W,_\ ,&_\054_^[7&
M>_=>Z^,A[]U[K[_'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
MU4>S_P#N+Z^.G_C+'.?^[???OW7NMJ[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=:;7RI_[C.OY:O_ (I1OO\ ]XCO[W[KW6Y+[]U[JM;^;?WW\H?C)\!?
MDEWA\3MM=<Y7L3K/J/L/?.0W-V5NFIPE/M[&;3Q5375F8QV.IL3DO[P9JGAA
M<T-!/-0TDE0$>IJQ$AAF]U[HM?\ (S[8^2^X/Y</Q6S_ ,B.O.L=I]4T'Q6Z
M_P!V;:[WB^2N3[-W#N/72BIK<KNW"978VWX-NSS4YEK*F8;MS7[OD625N9S[
MKW0Y]1?.3Y&?*_K/,_(KXB_%S9N\/CE+D9UZ>W!W1W3DNG-S=DXS;V2J:/+9
MS;6 BV5G*7$X:M@I7?;51F,O2OG79'JH,)C9(,E4>Z]U5#_PE+WK_I)Z)_F7
M=B_W<W'L[^_W\U3Y#;U_NCO"@_A67Q7]Z</M>N_AN4I=3?;9&A\_AJ8M1\<R
M.ES:_OW7NMJCW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:[?\ PJK_ .W'
MGRQ_\.;XX?\ OR=J>_=>ZN:^('_9)?Q=_P#%=>D__>:QGOW7NC%>_=>Z][]U
M[KWOW7NO>_=>ZU O^$XG_;TW_A3A_P"+_P"._P#?B]_^_=>ZV_??NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:2'\P>O[@QG_"O
M;^7M7=";5ZUWMVS!\*-R_P!U-L=O[_RG5VW:KR;6[U2N_B.=PNVMX9*A\.-:
MLE@\.W:OS5,<-/)X(I7JH?=>ZOV[![3_ )KV/W3T/C^Q?CK\/MD=.[@^172&
M$[>[ Z)^5^\.W,_C,-D=QX^)(X,-N#J;8,$E/D\DU!0U<J9&H:*CJ9R:?23+
M%[KW2P_G--W#@/Y;_P L>U^COD9V[\<-^]&=&=J]P8K/=1KMN*?+2;&P5;6Q
MXG)56<V[FZ^BQ\TD2L9L-68G)+(J%*]8O)%)[KW5571/P\^0/SJ_DN?'OM[L
M7^8;\R>O^VIOA!MS>74^2Z8[BRO6]%C\_C=O5M72[@WC5T50-T=@9?*5DD+Y
M5LEN):7PQ1Q8NDQU5]UD*WW7N@E':^Y/YH'_  E*WI\B/DSN/?F5[1VE\3?D
M]FMP97;&_P#*;#AW%N#XZS[EQ.)RVX:? U.,I\Y!6'!4-=5XZLAEQ\U8TC2T
MTH6-A[KW5BG\C3J+KCX_?RKOBO\ )"HWYWSD!N#X7; WAOG"[_\ D5O?LS:^
M,I<+BAE*I]M[1W#N"OVQM58DBD"IB<=0QK%^S81 */=>Z"OHGL7:W\QGXJ;>
M^0OR*J_YCF%W;\B\/E-_=<P_%RG[IZ>PVP=NY^M>?:E!MR;8=118K.Y2AQ,.
M.ER.9KVR;9'(R5P@:GP\M/C*?W7NE!_*XK?YH':7P&[^Z1^=V\_D7T5WMTSO
MC>&UNG/EH=E;:V_N[>6S8:62IPF;GH-SX+<V*%=&\<U/4O/CFR!IQ3&>H%>9
MJR;W7NJU/Y3'QN^:G\VC^4CT!VEV#_-'^8O0?8NV_D!V[N[;6^.JM]/G*W/S
M8W=U6:R;?DN2$65S45/$L]#A\5!G:?"X^!4GJ:+(EXZ2D]U[H;Z]_G/6_P#"
MA??_ ,)L!_,)^0==U;G/Y:]?V73YS>B;9:IVE_>C<N!QN2R.UMNX+;6%V15;
MJ4T BQN2RVW*I\?'7U4TGWQA6EJO=>Z!SMG'_+S^0;_,A^#60Q_S1^77S5^
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M(;_H?9'OW7NMJ[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:@7_"<3_MZ;_P *</\
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MD<%AZ7;&UJ^JI)Z/;6&IJ"J>IRE=!JSE0)3%BI,;]G/7CW7NB"=(4W1O7?\
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M\QGXZ?)WX-_,#?7RK[?^<797=.W_ ))8SK.HR.S=Z[1W!'AL5ML57968R$>
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M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIV_X4"?]N9_Y@W_ (@JI_\
M=KC/?NO=?&0]^Z]U]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=:J/9__<7U\=/_ !ECG/\ W;[[]^Z]UM7>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZUV_^%5?_;CSY8_^'-\</_?D[4]^Z]U<U\0/^R2_
MB[_XKKTG_P"\UC/?NO=&*]^Z]U[W[KW7O?NO=>]^Z]UJ!?\ "<3_ +>F_P#"
MG#_Q?_'?^_%[_P#?NO=;?OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K51[/_P"XOKXZ?^,L<Y_[M]]^
M_=>ZVKO?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ!?,C_ +C)/Y3O_B@'8W_NB^2W
MOW7NMOWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=%?W5\(?A=OKLJ@[FWO\ $/XO[Q[@Q4U+48OM?=70.U-P[EII*&22
M:!Z?.U>)FRD+PS32NA2J!1W=E(9B3[KW1F*2DI:"EIJ&AIJ>BHJ*GAI*.CI(
M5IHHHJ90D<44:!4CCC10JJH 4    >_=>ZD>_=>Z][]U[KWOW7NO>_=>Z!7)
M?&WX\9CN?%?([+]%=/Y3Y!8/;Z;4PW>&0ZWP]9NVDQD;NZ4%/N&2C;+0TD;2
M2E(EJPB>20* )'U>Z]T-7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[K5W_P"%?7_;G/<W_BQ71G_6_(>_=>ZV8ME?\>;M+_PV<#_[BQ>_=>Z4WOW7
MNO>_=>Z][]U[KWOW7NM5'^=-_P!OOO\ A.;_ .)D^0W_ $/LCW[KW6U=[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[K51_X4G_]E!_R%_\ QJ=U)_[N]K>_=>ZVKO?NO=>]^Z]U
M[W[KW7O?NO=:J/\ PE!_[)\_F2?^-3OD%_[I-J^_=>ZVKO?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW5.W_  H$_P"W,_\ ,&_\054_^[7&>_=>Z^,A[]U[K[_'OW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4>S_P#N+Z^.G_C+'.?^[???
MOW7NMJ[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6NW_ ,*J
M_P#MQY\L?_#F^.'_ +\G:GOW7NKFOB!_V27\7?\ Q77I/_WFL9[]U[HQ7OW7
MNO>_=>Z][]U[KWOW7NM0+_A.)_V]-_X4X?\ B_\ CO\ WXO?_OW7NMOWW[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]UJH]G_]Q?7QT_\ &6.<_P#=OOOW[KW6U=[]U[KWOW7NO>_=>Z][
M]U[KWOW7NM0+YD?]QDG\IW_Q0#L;_P!T7R6]^Z]UM^^_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NM7?_A7U_P!N<]S?^+%=&?\ 6_(>_=>ZV8ME?\>;M+_PV<#_ .XL7OW7
MNE-[]U[KWOW7NO>_=>Z][]U[K51_G3?]OOO^$YO_ (F3Y#?]#[(]^Z]UM7>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>ZU4?^%)_P#V4'_(7_\ &IW4G_N[VM[]U[K:N]^Z]U[W
M[KW7O?NO=>]^Z]UJH_\ "4'_ +)\_F2?^-3OD%_[I-J^_=>ZVKO?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW5.W_"@3_MS/_,&_\054_P#NUQGOW7NOC(>_=>Z^_P >_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K51[/_P"XOKXZ?^,L<Y_[
MM]]^_=>ZVKO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:[?_
M  JK_P"W'GRQ_P##F^.'_OR=J>_=>ZN:^('_ &27\7?_ !77I/\ ]YK&>_=>
MZ,5[]U[KWOW7NO>_=>Z][]U[K4"_X3B?]O3?^%.'_B_^._\ ?B]_^_=>ZV_?
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW6JCV?\ ]Q?7QT_\98YS_P!V^^_?NO=;5WOW7NO>_=>Z][]U
M[KWOW7NO>_=>ZU OF1_W&2?RG?\ Q0#L;_W1?);W[KW6W[[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZU=_^%?7_;G/<W_BQ71G_6_(>_=>ZV8ME?\ 'F[2_P##9P/_ +BQ
M>_=>Z4WOW7NO>_=>Z][]U[KWOW7NM5'^=-_V^^_X3F_^)D^0W_0^R/?NO=;5
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NM5'_ (4G_P#90?\ (7_\:G=2?^[O:WOW7NMJ[W[K
MW7O?NO=>]^Z]U[W[KW6G[_PE[[TZ2ZNZ/_F,X3LSN+JOKK,U_P#,_P#D!E*'
M$[Z["Q&T:J:EDQ&V8EJ8J?(5E/+) 98I4$BH4+HZWNI ]U[K9X_V;_XE_P#>
M47QU_P#1V;:_^N?OW7NO?[-_\2_^\HOCK_Z.S;7_ -<_?NO=>_V;_P")?_>4
M7QU_]'9MK_ZY^_=>Z]_LW_Q+_P"\HOCK_P"CLVU_]<_?NO=>_P!F_P#B7_WE
M%\=?_1V;:_\ KG[]U[KW^S?_ !+_ .\HOCK_ .CLVU_]<_?NO=>_V;_XE_\
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M)?\ WE%\=?\ T=FVO_KG[]U[KW^S?_$O_O*+XZ_^CLVU_P#7/W[KW7O]F_\
MB7_WE%\=?_1V;:_^N?OW7NO?[-_\2_\ O*+XZ_\ H[-M?_7/W[KW7O\ 9O\
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M /\ T:?77_VJO?NO=>_Z J?Y67_/_/G_ /\ HT^NO_M5>_=>Z]_T!4_RLO\
MG_GS_P#_ $:?77_VJO?NO=>_Z J?Y67_ #_SY_\ _HT^NO\ [57OW7NO?] 5
M/\K+_G_GS_\ _1I]=?\ VJO?NO=>_P"@*G^5E_S_ ,^?_P#Z-/KK_P"U5[]U
M[KW_ $!4_P K+_G_ )\__P#T:?77_P!JKW[KW7O^@*G^5E_S_P ^?_\ Z-/K
MK_[57OW7NO?] 5/\K+_G_GS_ /\ T:?77_VJO?NO=>_Z J?Y67_/_/G_ /\
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M77_VJO?NO=>_Z J?Y67_ #_SY_\ _HT^NO\ [57OW7NO?] 5/\K+_G_GS_\
M_1I]=?\ VJO?NO=>_P"@*G^5E_S_ ,^?_P#Z-/KK_P"U5[]U[KW_ $!4_P K
M+_G_ )\__P#T:?77_P!JKW[KW7O^@*G^5E_S_P ^?_\ Z-/KK_[57OW7NO?]
M 5/\K+_G_GS_ /\ T:?77_VJO?NO=>_Z J?Y67_/_/G_ /\ HT^NO_M5>_=>
MZ]_T!4_RLO\ G_GS_P#_ $:?77_VJO?NO=>_Z J?Y67_ #_SY_\ _HT^NO\
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M -^Z]U[_ *!Q/YIO_?3A\_\ _P ]W8O_ -O_ -^Z]U[_ *!Q/YIO_?3A\_\
M_P ]W8O_ -O_ -^Z]U[_ *!Q/YIO_?3A\_\ _P ]W8O_ -O_ -^Z]U[_ *!Q
M/YIO_?3A\_\ _P ]W8O_ -O_ -^Z]U[_ *!Q/YIO_?3A\_\ _P ]W8O_ -O_
M -^Z]U[_ *!Q/YIO_?3A\_\ _P ]W8O_ -O_ -^Z]U[_ *!Q/YIO_?3A\_\
M_P ]W8O_ -O_ -^Z]U[_ *!Q/YIO_?3A\_\ _P ]W8O_ -O_ -^Z]U[_ *!Q
M/YIO_?3A\_\ _P ]W8O_ -O_ -^Z]U[_ *!Q/YIO_?3A\_\ _P ]W8O_ -O_
M -^Z]U[_ *!Q/YIO_?3A\_\ _P ]W8O_ -O_ -^Z]U[_ *!Q/YIO_?3A\_\
M_P ]W8O_ -O_ -^Z]U[_ *!Q/YIO_?3A\_\ _P ]W8O_ -O_ -^Z]U[_ *!Q
M/YIO_?3A\_\ _P ]W8O_ -O_ -^Z]U[_ *!Q/YIO_?3A\_\ _P ]W8O_ -O_
M -^Z]U[_ *!Q/YIO_?3A\_\ _P ]W8O_ -O_ -^Z]U[_ *!Q/YIO_?3A\_\
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M]=?_ &JO?NO=>_Z J?Y67_/_ #Y__P#HT^NO_M5>_=>Z]_T!4_RLO^?^?/\
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MO_M5>_=>Z]_T!4_RLO\ G_GS_P#_ $:?77_VJO?NO=>_Z J?Y67_ #_SY_\
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MUU_]JKW[KW7O^@*G^5E_S_SY_P#_ *-/KK_[57OW7NO?] 5/\K+_ )_Y\_\
M_P!&GUU_]JKW[KW7O^@*G^5E_P _\^?_ /Z-/KK_ .U5[]U[KW_0%3_*R_Y_
MY\__ /T:?77_ -JKW[KW7O\ H"I_E9?\_P#/G_\ ^C3ZZ_\ M5>_=>Z]_P!
M5/\ *R_Y_P"?/_\ ]&GUU_\ :J]^Z]U[_H"I_E9?\_\ /G__ .C3ZZ_^U5[]
MU[KW_0%3_*R_Y_Y\_P#_ -&GUU_]JKW[KW7O^@*G^5E_S_SY_P#_ *-/KK_[
M57OW7NO?] 5/\K+_ )_Y\_\ _P!&GUU_]JKW[KW7O^@*G^5E_P _\^?_ /Z-
M/KK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T:?77_ -JKW[KW7O\ H"I_E9?\_P#/
MG_\ ^C3ZZ_\ M5>_=>Z]_P! 5/\ *R_Y_P"?/_\ ]&GUU_\ :J]^Z]U[_H"I
M_E9?\_\ /G__ .C3ZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -&GUU_]JKW[KW7O
M^@*G^5E_S_SY_P#_ *-/KK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!&GUU_]JKW
M[KW7O^@*G^5E_P _\^?_ /Z-/KK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T:?77_
M -JKW[KW0H]'?\)!/Y:O0/=73_>^SN[_ )R9+=W2G:/7_;>U<=N;LK8-9C:C
M)=<9:DS-#!D(:7K.BJI:&6JHHEG2&L@E:(LL<T3D.ONO=;5GOW7NO>_=>Z][
M]U[KWOW7NM?K=7_"7K^2OO7=&Y-Y;E^+6Y<AN+=N?S&YL_7K\ANQ*,3UN>J)
M*JJF$,&Z(X8A)/+(VB.-46^E%50 /=>Z8/\ H%4_D>?]XG;F_P#2C^R?_LK]
M^Z]U[_H%4_D>?]XG;F_]*/[)_P#LK]^Z]U[_ *!5/Y'G_>)VYO\ TH_LG_[*
M_?NO=>_Z!5/Y'G_>)VYO_2C^R?\ [*_?NO=>_P"@53^1Y_WB=N;_ -*/[)_^
MROW[KW7O^@53^1Y_WB=N;_TH_LG_ .ROW[KW7O\ H%4_D>?]XG;F_P#2C^R?
M_LK]^Z]U[_H%4_D>?]XG;F_]*/[)_P#LK]^Z]U[_ *!5/Y'G_>)VYO\ TH_L
MG_[*_?NO=>_Z!5/Y'G_>)VYO_2C^R?\ [*_?NO=>_P"@53^1Y_WB=N;_ -*/
M[)_^ROW[KW7O^@53^1Y_WB=N;_TH_LG_ .ROW[KW7O\ H%4_D>?]XG;F_P#2
MC^R?_LK]^Z]U[_H%4_D>?]XG;F_]*/[)_P#LK]^Z]U[_ *!5/Y'G_>)VYO\
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MG;F_]*/[)_\ LK]^Z]U[_H%4_D>?]XG;F_\ 2C^R?_LK]^Z]U[_H%4_D>?\
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M:NPJ/'1I).E51)C:1JO).)_+'E,FRO&M"^+EF]U[JTKL-&^5_<51T;2I//\
M'CI'.8/-?(7+4U8L=-NC==#]KE<)URIB<RU&+Q<;T68W.A"0U DQ.%<U=/5Y
MRDA]U[JL'_A.G_QY?\WG_P ;K?/S_P!Q-D>_=>ZV)O?NO=:LG?76?\^K^6_N
MOY'_ #/Z,[AZ'_F&]';Q[3WAW_V[\-JOI6/JO==-B9T@I_M]H9O&+6Y?.UVW
MML4&-H(/N\C4U+T.*IDI<575&FDD]U[JXOK#Y#1_S/OY;]-WA\+NT)>E\O\
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MSDVC2UM;1;<[*Z+W)OBGH:62K;^"T.Y*2*25UCBD*PTV0GQTTKL8TCCC9V<
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M67>.E88DCJ)Z+,UI#5%56._NO=6C=D],_$WK7^^7R*W]UCL3%OMW=*=\[MW
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MWF__ +*??NO=>_Z!L/D'_P![Z/YIW_HV\W_]E/OW7NO?] V'R#_[WT?S3O\
MT;>;_P#LI]^Z]U[_ *!L/D'_ -[Z/YIW_HV\W_\ 93[]U[KW_0-A\@_^]]'\
MT[_T;>;_ /LI]^Z]U[_H&P^0?_>^C^:=_P"C;S?_ -E/OW7NO?\ 0-A\@_\
MO?1_-._]&WF__LI]^Z]U[_H&P^0?_>^C^:=_Z-O-_P#V4^_=>Z]_T#8?(/\
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MO-__ &4^_=>Z]_T#8?(/_O?1_-._]&WF_P#[*??NO=>_Z!L/D'_WOH_FG?\
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MW0K?] V'R#_[WT?S3O\ T;>;_P#LI]^Z]U[_ *!L/D'_ -[Z/YIW_HV\W_\
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M^0?_ 'OH_FG?^C;S?_V4^_=>Z]_T#8?(/_O?1_-._P#1MYO_ .RGW[KW7O\
MH&P^0?\ WOH_FG?^C;S?_P!E/OW7NO?] V'R#_[WT?S3O_1MYO\ ^RGW[KW7
MO^@;#Y!_][Z/YIW_ *-O-_\ V4^_=>Z]_P! V'R#_P"]]'\T[_T;>;_^RGW[
MKW7O^@;#Y!_][Z/YIW_HV\W_ /93[]U[KW_0-A\@_P#O?1_-._\ 1MYO_P"R
MGW[KW7O^@;#Y!_\ >^C^:=_Z-O-__93[]U[KW_0-A\@_^]]'\T[_ -&WF_\
M[*??NO=>_P"@;#Y!_P#>^C^:=_Z-O-__ &4^_=>Z]_T#8?(/_O?1_-._]&WF
M_P#[*??NO=>_Z!L/D'_WOH_FG?\ HV\W_P#93[]U[KW_ $#8?(/_ +WT?S3O
M_1MYO_[*??NO=>_Z!L/D'_WOH_FG?^C;S?\ ]E/OW7NO?] V'R#_ .]]'\T[
M_P!&WF__ +*??NO=>_Z!L/D'_P![Z/YIW_HV\W_]E/OW7NO?] V'R#_[WT?S
M3O\ T;>;_P#LI]^Z]U[_ *!L/D'_ -[Z/YIW_HV\W_\ 93[]U[KW_0-A\@_^
M]]'\T[_T;>;_ /LI]^Z]U[_H&P^0?_>^C^:=_P"C;S?_ -E/OW7NO?\ 0-A\
M@_\ O?1_-._]&WF__LI]^Z]U[_H&P^0?_>^C^:=_Z-O-_P#V4^_=>Z]_T#8?
M(/\ [WT?S3O_ $;>;_\ LI]^Z]U[_H&P^0?_ 'OH_FG?^C;S?_V4^_=>Z]_T
M#8?(/_O?1_-._P#1MYO_ .RGW[KW7O\ H&P^0?\ WOH_FG?^C;S?_P!E/OW7
MNO?] V'R#_[WT?S3O_1MYO\ ^RGW[KW7O^@;#Y!_][Z/YIW_ *-O-_\ V4^_
M=>Z]_P! V'R#_P"]]'\T[_T;>;_^RGW[KW7O^@;#Y!_][Z/YIW_HV\W_ /93
M[]U[KW_0-A\@_P#O?1_-._\ 1MYO_P"RGW[KW7O^@;#Y!_\ >^C^:=_Z-O-_
M_93[]U[I/9#_ (2VYO>^[NJLWWE_-U^>?R"VOU5V9MKM/%;#[ASTV_: Y/:;
MO)23T\>8SF0IZ&IN[1/4)2/*::2>!"GF+K[KW6V?[]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5'^75_W$[_SR/_$-_&3_ -YS
M9/OW7NMJ[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJH_RZO\ N)W_
M )Y'_B&_C)_[SFR??NO=;5WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[K51_EU?]Q._\\C_ ,0W\9/_ 'G-D^_=>ZVKO?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<7=(T>21UCCC5G=W8*%"BY))X  ^I
M]^Z]T%_^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U
M[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^
MG+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3
M_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'
M5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\
MZ,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$
M_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U
M7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U
M[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^
MG+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3
M_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'
M5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\
MZ,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$_P#U7[]U[KW^G+I3_G\'5O\ Z,#$
M_P#U7[]U[K5M_EZ]E]<4'_"EW^=MN.N[ V31;>S/3_QJAP^>J]UT%-15;TVW
M=EK(M-5/.L$[1LCA@DC%2I!L0??NO=;27^G+I3_G\'5O_HP,3_\ 5?OW7NO?
MZ<NE/^?P=6_^C Q/_P!5^_=>Z]_IRZ4_Y_!U;_Z,#$__ %7[]U[KW^G+I3_G
M\'5O_HP,3_\ 5?OW7NO?Z<NE/^?P=6_^C Q/_P!5^_=>Z]_IRZ4_Y_!U;_Z,
M#$__ %7[]U[KW^G+I3_G\'5O_HP,3_\ 5?OW7NO?Z<NE/^?P=6_^C Q/_P!5
M^_=>Z]_IRZ4_Y_!U;_Z,#$__ %7[]U[KW^G+I3_G\'5O_HP,3_\ 5?OW7NO?
MZ<NE/^?P=6_^C Q/_P!5^_=>Z]_IRZ4_Y_!U;_Z,#$__ %7[]U[KW^G+I3_G
M\'5O_HP,3_\ 5?OW7NO?Z<NE/^?P=6_^C Q/_P!5^_=>Z]_IRZ4_Y_!U;_Z,
M#$__ %7[]U[KW^G+I3_G\'5O_HP,3_\ 5?OW7NO?Z<NE/^?P=6_^C Q/_P!5
M^_=>Z]_IRZ4_Y_!U;_Z,#$__ %7[]U[KW^G+I3_G\'5O_HP,3_\ 5?OW7NO?
MZ<NE/^?P=6_^C Q/_P!5^_=>Z]_IRZ4_Y_!U;_Z,#$__ %7[]U[KW^G+I3_G
M\'5O_HP,3_\ 5?OW7NO?Z<NE/^?P=6_^C Q/_P!5^_=>Z]_IRZ4_Y_!U;_Z,
M#$__ %7[]U[KW^G+I3_G\'5O_HP,3_\ 5?OW7NO?Z<NE/^?P=6_^C Q/_P!5
M^_=>ZYQ]W=,32)%%V[UA++*ZQQQQ[^Q3LS.;!5 JR222  !<GW[KW0G^_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZK=_G%N\?\I_^9$T;NC'X1_)="R,5.F7:.55A<?AE)!'
MY!(/!]^Z]UK=?RD?^$W?\J;Y;?RW?B+\D.[.HNPL[VKVYU9#NG>^7Q7=6X]O
M4\]8]?70%XJ*DKHZ:G7QP1C3&@6XO:Y/OW7NK%_^@3'^2I_SXOM+_P!*#W9_
M]<??NO=>_P"@3'^2I_SXOM+_ -*#W9_]<??NO=>_Z!,?Y*G_ #XOM+_TH/=G
M_P!<??NO=>_Z!,?Y*G_/B^TO_2@]V?\ UQ]^Z]U[_H$Q_DJ?\^+[2_\ 2@]V
M?_7'W[KW7O\ H$Q_DJ?\^+[2_P#2@]V?_7'W[KW7O^@3'^2I_P ^+[2_]*#W
M9_\ 7'W[KW7O^@3'^2I_SXOM+_TH/=G_ -<??NO=>_Z!,?Y*G_/B^TO_ $H/
M=G_UQ]^Z]U[_ *!,?Y*G_/B^TO\ TH/=G_UQ]^Z]U[_H$Q_DJ?\ /B^TO_2@
M]V?_ %Q]^Z]U[_H$Q_DJ?\^+[2_]*#W9_P#7'W[KW7O^@3'^2I_SXOM+_P!*
M#W9_]<??NO=>_P"@3'^2I_SXOM+_ -*#W9_]<??NO=>_Z!,?Y*G_ #XOM+_T
MH/=G_P!<??NO=>_Z!,?Y*G_/B^TO_2@]V?\ UQ]^Z]U[_H$Q_DJ?\^+[2_\
M2@]V?_7'W[KW7O\ H$Q_DJ?\^+[2_P#2@]V?_7'W[KW7O^@3'^2I_P ^+[2_
M]*#W9_\ 7'W[KW7O^@3'^2I_SXOM+_TH/=G_ -<??NO=>_Z!,?Y*G_/B^TO_
M $H/=G_UQ]^Z]U[_ *!,?Y*G_/B^TO\ TH/=G_UQ]^Z]U[_H$Q_DJ?\ /B^T
MO_2@]V?_ %Q]^Z]U[_H$Q_DJ?\^+[2_]*#W9_P#7'W[KW7O^@3'^2I_SXOM+
M_P!*#W9_]<??NO=>_P"@3'^2I_SXOM+_ -*#W9_]<??NO=>_Z!,?Y*G_ #XO
MM+_TH/=G_P!<??NO=>_Z!,?Y*G_/B^TO_2@]V?\ UQ]^Z]U[_H$Q_DJ?\^+[
M2_\ 2@]V?_7'W[KW7O\ H$Q_DJ?\^+[2_P#2@]V?_7'W[KW7O^@3'^2I_P ^
M+[2_]*#W9_\ 7'W[KW7O^@3'^2I_SXOM+_TH/=G_ -<??NO=>_Z!,?Y*G_/B
M^TO_ $H/=G_UQ]^Z]U[_ *!,?Y*G_/B^TO\ TH/=G_UQ]^Z]U[_H$Q_DJ?\
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6U_.._[=._S(?\ Q2;Y*?\
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M[KW6AHS*O_"X*[,%![15;L;<O\<0 /\ 7)( _P ??NO=(O\ G&?]Q<7P/_\
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MR,U7X>CI=]5^#W'LR"',U4%(*VGIGQDTD&.JZ1'KJZ375S>Z]U:3_*L^)/\
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MZ"S&UZ#M&/./GNOO]+^\,OM&GJL_!/3R9+';3KLY4[?H\G215$JX^J&/:;%
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MI0;$Z<ZTZ_ZFV/BHXH<7LWK/9N.V)BJ9($6-$I\=BZ:EHX52-550D( 4 #@
M>_=>Z$#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3+N'/T.V,15YO)0
M9JIHZ) \T.WMMY'=U6P)M^SC\32UM?4'_"*F<_FUO?NO=5"=9_\ "@+^4YW%
MWCAOC3UM\D=Z;G[]SVZLKL?'=20_$WN;'YS^+X'[@Y#'U%%6=>T\E%4X\4E6
M:I:CQ?;"&4S^,1O;W7NKB<?70Y.AI<A3)61P5D$=1#'D,?48F<+*+@2TU5%#
M4P2 ?5)8D=3PR@\>_=>ZE.XC1Y&#%45G8(C2M91<V5068_T !)^@%_?NO=5C
M];?SC_Y=7;/S B^ NS.]=Q-\O9<]O/;/^A/=?Q\[,Z[KTK=@8?(9_*135NXM
MG8K$0+#AL965<4LF16*KA6,TCSF> 2^Z]U9U[]U[KWOW7NO>_=>Z][]U[KWO
MW7NBQ_*[YB= _"3K'(=S_)3<F[]D]68:-I\_O?;W3N].V*'&1">EIA-EGV?M
M[/MB8'GK:=(Y:Q(8Y"6\;,(I2GNO=8OB#\SOC5\\^FZ3Y ?%#LC_ $J]1UVX
M<[M2EW;_ '/S^QM=?MIT2M@^PW)BL/DU\#2(-9HA&][QNP!M[KW1H??NO= ]
MOSOGK'J_>NQ]C=B9V?9E;V34+B]D;BW!B:J@P%?E)95AAP0W T/\'I=P5A=6
MHL=4UD-7D%\AQ\54:>I$/NO=##[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUV_^%5?_;CSY8_^'-\</_?D[4]^
MZ]U<U\0/^R2_B[_XKKTG_P"\UC/?NO=&*]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5M?SCO^W3O\
MR'_Q2;Y*?^\GE/?NO= W_P )^_\ MS/_ "^?_$%4W_NUR?OW7NKB??NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJG?\*+
M/G'O$]L_!G^3UTINC(;:WG_,.[?ZOVQ\A-Q;4R,E%FL7UOO;=E#MO[*EEIY$
MFH8]S5!RXJ:G@"@Q=;3O^U4R,ONO=6X_S,?E=M'^5%_+,[C[RZ]VKA,9!T9U
MKMSK_HS8M'C_ !8Z+,9Z>BVWM:C^WB32N/H:JKIIIU](--3RB^HB_NO=:NW_
M  D*^/C?*+L?YH?S8/DWFI^[?D;7]H4_46S]^;[$F9R..R.1QM-G-UYB)Y)3
M21U60I,EM^@I&BHXGQU%3U-'1O%25<D'OW7NMZC=NT=K;^VON#9.]]NX7=VS
M]V8>OV_N?:^X\;#F*#(4.5C:&II*REG1X:BGGB=D='0JRD@CW[KW5=/QCZ>Z
M)_DW?!#?&V=\;\P&Q_C7T+OCY$]L4.Y<A/,T&$VIV1O7-[EQ&*DU1>>IK<=3
MYFEQD4<22RU=0D20^6695/NO=%-[N_GO[+Z,^)/6_P _MP_#/Y+93X6=HY_;
ME!M[N##YW8=?7Q8K>%4U-B-Q5^VJ;==1D*#&971JIXYY(ZZ-Y*>FKZ2AJY3!
M'[KW5@FX/GEUU7_!RG^?G0&Q^Q?E5T[D.LF[APVW^E\?1'<E?@:.FFJJ^2BQ
M.<K<.TV3QJT\\=1C#*N0%1%+2I3O4IXC[KW1./Y3O\\/X_\ \X'.]T8GX]=-
M]W["HNAJ'859OK+]P+MG$*Q[).:7%QT%-B-PYBJJKG 5_G<Q1I#>'4Q,H ]U
M[HY72'S-RW=_>ORKZ(QWQN[=VED_B3F-I[2WMOG<V;VI)@,OGM\;7Q.\<;A<
M#4T&?K:VIJOX!G<1/5/44%-#2&KBCED\A*K[KW53O4?_  IL^'_;'RS[+^%5
M/\?/EKA>^^N=P=E[#IMHT^RL!OF?<>Z>LLJ<-4[9VW#MS<>5GK*VIJHZF9:N
MHBI,51X^EJ\IE,A08ZDJ*F/W7NE#T=_PI'^(^^_DYVW\/^_NE_D;\/N_^J\?
MD)HNO.W]J4.[,GGLCCH8:C^[6 QVSJ_<&0R^ZLA!4028O&45)4RY<2(F.:HF
M>.)_=>Z4NQ_^%"'Q_J/YA>V?Y<7?_P ;/DY\1.X>PLGAL)UEG._\)@<3B\W6
M;R(_NU!$^+S>2:+^\SLE-0.IF0Y$G&3M#6H\2^Z]U8+\L/YBO1OQ1[:Z$^-^
M3I-P]H?*+Y/YB;$]'_'_ &!68:BS&3AHO(:O+UU;G\KA<+AL+1QT]4S5%5D4
MEJ6@FI\;35U8@IC[KW13]I_SMNE*#^8;0?RRODETSVS\6?D?NVAPE;U35[\K
M,'N[;.ZVW)!4U./@QF<P&1KDAEKTI9XJ;[J"!):V.2@UK6>**;W7NA*_FL?S
M;.I_Y1W7G7/;/>W3/<_8O779.\UZ[QN?ZA_NW7O29J6AK\E%1UE'FL_AJD+-
M0XVKD6:))8P4T.R,5#>Z]T17O?\ X4O?'+I7XX]+?+BA^(?S4[&^.';-)LR'
M(]P;=Z]Q&'P.#S6],4F7CVP^3RN;HZ3-9K'Q&>FK9<9-4XBGR5-5XK^*OD:2
MKI8/=>ZOF^/??/6GRBZ/ZK^1'3F:FW#U?W)LG!;^V1EJJ@EQ4\E#GX5FC6HI
M9U6:FJH26CFB<:HY4=#?3?W[KW0Q^_=>Z^6Y_*<_[B\,O_XNO_-"_P#>8[?]
M^Z]U]!3YM_S(>H?A3OSXS=)Y;;&[^V?D1\O^R*?K?H;I38-1C,?79"2*:EBR
M&6R&1S5=CL7B<-C/O*?RSS51DD=PE/#-IF:+W7NEETS\RZ[LGY'[M^*V^OCQ
MW!TAVILGJJ/M_)UF]FPV:V[D\1D<M%B*&?;>>PN1KZ7,K-.:G[A&2EJJ%H5C
MJZ6-IXBWNO=:2O4__<<-E?\ Q)?='_P-N=]^Z]UN;=O_ ,R/J'8?RVVS\"^M
M-L[F[_\ E[G]CUW9^8ZFV'F]O[=BVWMN@C20Y?<N7W%E\51TGW FIA3T-(*_
M*3)40U/V"T)DJX_=>Z+_ /#G^=1T!\J/F3W-_+WW?UKVI\9_F)TO4YX9#J7M
MM,5D8LU3[9BIYZZIP.9P5?D<;6^.EJH:R.)Y8I:B@;[VG26&.H,'NO=!!\U_
M^%!WQA^ ?S<V'\'?D-TOWSA=W]BS=;UV [2Q/]T\AM./"]FYFHPE)GZZI?<T
M.4HZ"CJ:.M>L1\5]Q%% [I#+=-?NO=)/>G_"C7XV]2?,CIKXE=]?%_YD?'VA
M^0M1M1>G>Z>Y.KJ796*RE'OFK?'8C+U&$J,B-TXK&U>35::1:S$0Y&@=PV3Q
MU"JR^/W7NKDOE?\ *SHSX3=";_\ DK\CMZT^P^INN*"FJ\]F7II,C42S9*>.
MDHJ#'T<"O45V1KZN:&"G@B0L[N"=**[K[KW6L)_,L_FW1_,'^2'\KNUZSX0_
M+?H+XZ?(/INLP'1GR [0QVT\OB<Q79#<%#C\93Y/#[:W-FMU;9I\W4Q.F.R>
M1P46$JF,(3*?Y70FJ]U[I=_\):>V^O>A/Y#>7[K[9W)1[/ZSZI[3^2N_M][G
MKD>6.BQ>US35=9.8XE>:9DAB;1%'&\LKZ8XT9V53[KW5DVT/YR-#N_XJ[)^;
M]'\+/DT/BYVADQC=@;_Q];M#<5>(LKGVV[A\MN';^/W%493 8+*5X356>*K-
M"C"2OAIXBLC>Z]U8?\Q?C7L_Y@_%[O+XU;WCD3#=O=<;FVE2Y:D$2UF)R5;3
M.<3F\;+/%-'3Y3"9-:2MHYC$WBJ8(W*L 0?=>ZI/_P"$S'\S/L#Y\_"_<W5G
MR&R.3KOE5\,=T8WJ+M>LW(DM-F,IBJ^.I_NWF<Q#46J5RS#'93&US2J)9:O&
M2U,UI9W ]U[K9%]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW6NW_PJK_[<>?+'_PYOCA_[\G:GOW7NKFOB!_V27\7?_%=
M>D__ 'FL9[]U[HQ7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JMK^<=_VZ=_F0_P#BDWR4_P#>3RGO
MW7N@;_X3]_\ ;F?^7S_X@JF_]VN3]^Z]U<3[]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM";^9#_'?^@PO^7C_%O%]A_=
MSXZ_W7\>N_V.K=_D\FOTZ_XG_$?T>G3IOZ]?OW7NK^/^%*OQQ[!^37\GCY1[
M3ZOQ%9N'>.P4V+W53[=QWW,D];0=4YFDR>;C@@IB6JIX,&F2J(H&BD$LD**B
M";Q.GNO=4S_\(C>WMH9'XJ?,OH2'(H-_;.^0>V^WLAB'@DC8X?LK;E!A:.IC
ME8>*8+6[4KDD5"6AU1&2PGBO[KW6[S[]U[JOO^9S@/A/V)\!_DAC/GIF:.#X
MAT^UI*_MK-4&6JJ>HI'V/E:>HI#C9<8)JU\[1[@H*1*2F@BEFEKT2D,$K,T+
M>Z]UI??.#<6+W[_PF;W7EOAOUI%\>OY86SNY<1MWH':W:V6K.T.SM_S#M6!<
MGNS+9,9"/$[,Q46ZSNB)<3'3YBJK&B@F6NQ5-$:*J]U[K9#_ .$N\44_\B/X
M/03QQS0S1_)R*:&5!(KK)W#V$&5E((96!(((L1P??NO=:M_5&Z=O?\)Q/^%(
MG96PMZY4;$^$'R>P^3F@F:JFIL5B]D=S5DV3VQD6H:.!H-.R]VXNJPJS/3@T
M^/CR#B6.*>8M[KW6_?\ #[9NX=N]+T&[]^86? =J=YY_.]^]JXBN6G-709CM
M%TK8<%5R4R)#/)M+"##[>CE&LO3XF$M+,UY7]U[K0Q_D(*K?\*D/YAY958IN
M7^8BR$B]B>S:47']#8D?ZQ(_/OW7NE#+##/_ ,+@0D\4<R+VI#,J2H) 'I_C
MFLD;@$$:HY%5E/U5@"+$ ^_=>ZY_\*! */\ X5!_ROZJD I:EJC^7I5M4TW[
M$AEA[CSJ)*76S&15CC :]P%4 V46]U[JZ[^>)+_*VZZ^<?P.[;[CZ>WW\AOY
MI-=N_JG:?PPZ0ZY[+J^MZ;-9'&;RAEV7-OG)A)Z##[=H]Y9%A#4-3S5509:M
M$HJ^GIYUI_=>ZU__ .:E0=U4/_"HS^5T_?\ N3KW<?9&1[A_ERY6NCZLVQ7;
M7P>,I*WMZ9J'#48R>1R60R3XVF"13Y*>2G.0J/+51X_&PR14%/[KW5O7_"V'
M_MW-\8__ !=?;?\ [PN^??NO=%V_FP0PP?\ "0OX&)!%'"C=8_ "9DB01@O4
M8**21R  -4DC,S'ZLQ)-R2??NO=7F?\ "9/<F;W7_(W^"64W!7-D:^EP?>6V
MX*AX8X"M%LSL_>V'QD&F)(U(I<;0TD(8J7<1AY&>1F=O=>ZOB]^Z]U\MS^4Y
M_P!Q>&7_ /%U_P":%_[S';_OW7NMH7_A2G_*&[F_F,;>Z7[U^(.^(J?Y<?$7
M";FW#MSJF'=,>V<EG\/EJVBKH*G U@E@EQ>X,=E,67Q\\E1#3SREH?/#.D3C
MW7NBJ?\ "<[^<WW]\K/DME_@C_,4ZUKW^972O5/8%#UIWENS9K[(W:</15>W
MIMT[.WEC:J*EJ8,S)-C,/7?<K20FJ7'E:Z$54,=15>Z]T0'J?_N.&RO_ (DO
MNC_X&W.^_=>ZN'^8%1_+@ZP_GR=%Y7X\=,9SO3^=7VTE)%2XENT\EL;KS:=%
M_<O)XVNW?OJ2&&L6;)T'7-'DIXL30TD]15T]+3-,E!+54M=)[KW5(/Q>QO8&
M(_X6EXS'=K;KVWOCL>FWMW"-Z;KV=M";8.)K<A)\;L^\\F,PM3E,Y4XW'JS:
M*>"?,UTZ1*OFJYY=<K>Z]TKO^%"4,-1_PIV_EAT]1%'/!/'_ "_(9X)D$J.D
MO<FX%9'5@5964D$$6(X/OW7NFK_A:AN3-[,^:?P"WAMJN;%[CVITMN;<FW\F
MD,=0:>MP6[(ZJDG$<R20R&&>*-PKQLC6LRLI(/NO=6/?\+9\_NVB^"_Q-V_C
MI:J'9>>^4]55[I\-8T,<M;A-J9DXF&:$2*)E,=3DY%U1LJ/$INK%=7NO=&M^
M07\)_P"@1# _P71]G_PT[\9O-HUV^[_NWM3[_P#SGJO]]]S>WIO?1Z-/OW7N
MBW_\)Z/C_LOY6?\ ";;MKXV=@[M.PMI]X[S^3?6=?O-:J"C.,FW9+14E#6*U
M21 [0U\E*PB<@3FT-[R#W[KW5!>Q>^/YF/\ PF<[IR_PV^876\_R'_ER]KY7
M/8S/[#RU!+G]E;OVYO))J;,U^P,S5!:?"[@EI'DDR&$J)%1Y"1D*-!54^4/N
MO=?3\V?NK"[ZVEM?>^VZDUNW=X[=PFZL#6,AC,M%N&FBJZ64J>5,D$T;6_%[
M>_=>ZT0?^$F<V17^9?\ SC8,4M3_ '/DSDLU2U5XO(*B#?\ N=<6)=)OY#2R
M9'5H&BX-R/1?W7NM^#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=:[?\ PJK_ .W'GRQ_\.;XX?\ OR=J>_=>ZN:^('_9
M)?Q=_P#%=>D__>:QGOW7NC%>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJVOYQW_;IW^9#_P"*3?)3
M_P!Y/*>_=>Z!O_A/W_VYG_E\_P#B"J;_ -VN3]^Z]U<3[]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM47_A1I\*-]8_M;
MX/\ \X_HG9^X-X[Y_EX]K]<;D^0&T=B42U&>S'6^R=S4VY6J:-%,3UJ8&<9>
M.III)A$:'+5<\I6GIYR?=>ZVD=H;LVEV7LO;6^-GY?%[LV/OS;6)W-MK.8Z9
M,A1Y'&;DIDJ:6IA<:DEIZJFF1E/(96]^Z]UKR[N_X3W8?H_Y<5OSG_E5?)S+
M_ KNC<%7D9.P>J\EUS!W%U?N.DS<LM1D,;+MM<G@:S$4E;5M3S&.')5%-2M
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6NW_P *J_\
MMQY\L?\ PYOCA_[\G:GOW7NKFOB!_P!DE_%W_P 5UZ3_ />:QGOW7NC%>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NJVOYQW_;IW^9#_XI-\E/_>3RGOW7NBL_R$.W.J,%_)X^ F(S
M?9W7N'RM!T?305V,RN],;CZB%QE,D=$L,U2DD;6(-F4&Q]^Z]U;S_IRZ4_Y_
M!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_
M .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C
MQ/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\
M]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_
M=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]
M_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ
M4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_
M!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_
M .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C
MQ/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\
M]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_
M=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]
M_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ
M4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_
M!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_
M .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C
MQ/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\
M]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_
M=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]
M_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ
M4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_
M!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_
M .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C
MQ/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\ ]5^_=>Z]_IRZ4_Y_!U;_ .C Q/\
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MN/OW7NO?] F/\E3_ )\7VE_Z4'NS_P"N/OW7NO?] F/\E3_GQ?:7_I0>[/\
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M/]^Z]U[_ (?"_E"_][%?BE_Z->@_Z/\ ?NO=>_X?"_E"_P#>Q7XI?^C7H/\
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M^'POY0O_ 'L5^*7_ *->@_Z/]^Z]U[_A\+^4+_WL5^*7_HUZ#_H_W[KW7O\
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M:]!_T?[]U[KW_#X7\H7_ +V*_%+_ -&O0?\ 1_OW7NO?\/A?RA?^]BOQ2_\
M1KT'_1_OW7NO?\/A?RA?^]BOQ2_]&O0?]'^_=>Z]_P /A?RA?^]BOQ2_]&O0
M?]'^_=>Z]_P^%_*%_P"]BOQ2_P#1KT'_ $?[]U[KW_#X7\H7_O8K\4O_ $:]
M!_T?[]U[KW_#X7\H7_O8K\4O_1KT'_1_OW7NO?\ #X7\H7_O8K\4O_1KT'_1
M_OW7NO?\/A?RA?\ O8K\4O\ T:]!_P!'^_=>Z]_P^%_*%_[V*_%+_P!&O0?]
M'^_=>Z]_P^%_*%_[V*_%+_T:]!_T?[]U[KW_  ^%_*%_[V*_%+_T:]!_T?[]
MU[KW_#X7\H7_ +V*_%+_ -&O0?\ 1_OW7NO?\/A?RA?^]BOQ2_\ 1KT'_1_O
MW7NO?\/A?RA?^]BOQ2_]&O0?]'^_=>Z]_P /A?RA?^]BOQ2_]&O0?]'^_=>Z
M]_P^%_*%_P"]BOQ2_P#1KT'_ $?[]U[KW_#X7\H7_O8K\4O_ $:]!_T?[]U[
MKW_#X7\H7_O8K\4O_1KT'_1_OW7NO?\ #X7\H7_O8K\4O_1KT'_1_OW7NO?\
M/A?RA?\ O8K\4O\ T:]!_P!'^_=>Z]_P^%_*%_[V*_%+_P!&O0?]'^_=>Z]_
MP^%_*%_[V*_%+_T:]!_T?[]U[KW_  ^%_*%_[V*_%+_T:]!_T?[]U[KW_#X7
M\H7_ +V*_%+_ -&O0?\ 1_OW7NO?\/A?RA?^]BOQ2_\ 1KT'_1_OW7NO?\/A
M?RA?^]BOQ2_]&O0?]'^_=>Z]_P /A?RA?^]BOQ2_]&O0?]'^_=>Z]_P^%_*%
M_P"]BOQ2_P#1KT'_ $?[]U[KW_#X7\H7_O8K\4O_ $:]!_T?[]U[KW_#X7\H
M7_O8K\4O_1KT'_1_OW7NO?\ #X7\H7_O8K\4O_1KT'_1_OW7NO?\/A?RA?\
MO8K\4O\ T:]!_P!'^_=>Z]_P^%_*%_[V*_%+_P!&O0?]'^_=>Z]_P^%_*%_[
MV*_%+_T:]!_T?[]U[KW_  ^%_*%_[V*_%+_T:]!_T?[]U[KW_#X7\H7_ +V*
M_%+_ -&O0?\ 1_OW7NO?\/A?RA?^]BOQ2_\ 1KT'_1_OW7NO?\/A?RA?^]BO
MQ2_]&O0?]'^_=>Z]_P /A?RA?^]BOQ2_]&O0?]'^_=>Z]_P^%_*%_P"]BOQ2
M_P#1KT'_ $?[]U[KW_#X7\H7_O8K\4O_ $:]!_T?[]U[KW_#X7\H7_O8K\4O
M_1KT'_1_OW7NO?\ #X7\H7_O8K\4O_1KT'_1_OW7NO?\/A?RA?\ O8K\4O\
MT:]!_P!'^_=>Z]_P^%_*%_[V*_%+_P!&O0?]'^_=>Z]_P^%_*%_[V*_%+_T:
M]!_T?[]U[KW_  ^%_*%_[V*_%+_T:]!_T?[]U[KW_#X7\H7_ +V*_%+_ -&O
M0?\ 1_OW7NO?\/A?RA?^]BOQ2_\ 1KT'_1_OW7NO?\/A?RA?^]BOQ2_]&O0?
M]'^_=>Z]_P /A?RA?^]BOQ2_]&O0?]'^_=>Z]_P^%_*%_P"]BOQ2_P#1KT'_
M $?[]U[KW_#X7\H7_O8K\4O_ $:]!_T?[]U[KW_#X7\H7_O8K\4O_1KT'_1_
MOW7NO?\ #X7\H7_O8K\4O_1KT'_1_OW7NO?\/A?RA?\ O8K\4O\ T:]!_P!'
M^_=>Z]_P^%_*%_[V*_%+_P!&O0?]'^_=>Z]_P^%_*%_[V*_%+_T:]!_T?[]U
M[KW_  ^%_*%_[V*_%+_T:]!_T?[]U[KW_#X7\H7_ +V*_%+_ -&O0?\ 1_OW
M7NO?\/A?RA?^]BOQ2_\ 1KT'_1_OW7NO?\/A?RA?^]BOQ2_]&O0?]'^_=>Z]
M_P /A?RA?^]BOQ2_]&O0?]'^_=>Z]_P^%_*%_P"]BOQ2_P#1KT'_ $?[]U[K
MW_#X7\H7_O8K\4O_ $:]!_T?[]U[KW_#X7\H7_O8K\4O_1KT'_1_OW7NO?\
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M]ZZOBE_Z*B@_Z,]^Z]U[_ACW^4+_ -ZZOBE_Z*B@_P"C/?NO=>_X8]_E"_\
M>NKXI?\ HJ*#_HSW[KW7O^&/?Y0O_>NKXI?^BHH/^C/?NO=>_P"&/?Y0O_>N
MKXI?^BHH/^C/?NO=>_X8]_E"_P#>NKXI?^BHH/\ HSW[KW7O^&/?Y0O_ 'KJ
M^*7_ **B@_Z,]^Z]U[_ACW^4+_WKJ^*7_HJ*#_HSW[KW7O\ ACW^4+_WKJ^*
M7_HJ*#_HSW[KW7O^&/?Y0O\ WKJ^*7_HJ*#_ *,]^Z]U[_ACW^4+_P!ZZOBE
M_P"BHH/^C/?NO=>_X8]_E"_]ZZOBE_Z*B@_Z,]^Z]U[_ (8]_E"_]ZZOBE_Z
M*B@_Z,]^Z]U[_ACW^4+_ -ZZOBE_Z*B@_P"C/?NO=>_X8]_E"_\ >NKXI?\
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M+_WKJ^*7_HJ*#_HSW[KW7O\ ACW^4+_WKJ^*7_HJ*#_HSW[KW7O^&/?Y0O\
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M^C/?NO=>_P"&/?Y0O_>NKXI?^BHH/^C/?NO=>_X8]_E"_P#>NKXI?^BHH/\
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M^&/?Y0O_ 'KJ^*7_ **B@_Z,]^Z]U[_ACW^4+_WKJ^*7_HJ*#_HSW[KW7O\
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M;O?NO=>_Z"SOY*G_ #_3M+_TGS=G_P!;O?NO=>_Z"SOY*G_/].TO_2?-V?\
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MNO=>_P"@L[^2I_S_ $[2_P#2?-V?_6[W[KW7O^@L[^2I_P _T[2_])\W9_\
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MNO=>_P"@L[^2I_S_ $[2_P#2?-V?_6[W[KW7O^@L[^2I_P _T[2_])\W9_\
M6[W[KW7O^@L[^2I_S_3M+_TGS=G_ -;O?NO=>_Z"SOY*G_/].TO_ $GS=G_U
MN]^Z]U[_ *"SOY*G_/\ 3M+_ -)\W9_];O?NO=>_Z"SOY*G_ #_3M+_TGS=G
M_P!;O?NO=>_Z"SOY*G_/].TO_2?-V?\ UN]^Z]U[_H+._DJ?\_T[2_\ 2?-V
M?_6[W[KW7O\ H+._DJ?\_P!.TO\ TGS=G_UN]^Z]U[_H+._DJ?\ /].TO_2?
M-V?_ %N]^Z]U[_H+._DJ?\_T[2_])\W9_P#6[W[KW7O^@L[^2I_S_3M+_P!)
M\W9_];O?NO=>_P"@L[^2I_S_ $[2_P#2?-V?_6[W[KW7O^@L[^2I_P _T[2_
M])\W9_\ 6[W[KW7O^@L[^2I_S_3M+_TGS=G_ -;O?NO=>_Z"SOY*G_/].TO_
M $GS=G_UN]^Z]U[_ *"SOY*G_/\ 3M+_ -)\W9_];O?NO=>_Z"SOY*G_ #_3
MM+_TGS=G_P!;O?NO=>_Z"SOY*G_/].TO_2?-V?\ UN]^Z]U[_H+._DJ?\_T[
M2_\ 2?-V?_6[W[KW7O\ H+._DJ?\_P!.TO\ TGS=G_UN]^Z]T(_3O_"GO^3]
MWGVSUGTKL3O+L&7?7;F_-I]:;)ILMT5NO&4T^8WQ708S%TTU4V,:.F2IKJF"
M+S2:8HM>N9XXE=U]U[K8)]^Z]UIG_P#",OKCKS>'\K_O?)[MV'LS=&1@^>O:
M%#!D-Q;7H<W.D$77O5TBPK+4P2R+$LDLC! VD,[$"[$GW7NMM[_0;TI_SY_J
MW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD
M]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O
M2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]
M%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?N
MO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_
MSY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?X
MG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7
MO]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?
MZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^
MI/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0
M;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?
M_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W
M[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*
M?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7
M^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]
MU[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/
MG^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?
M_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_
MT&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_J
MW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD
M]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O
M2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]
M%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?N
MO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_
MSY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?X
MG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7
MO]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?
MZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0;TI_SY_JW_T7^)_^
MI/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW7O]!O2G_/G^K?_1?XG_ZD]^Z]U[_0
M;TI_SY_JW_T7^)_^I/?NO=>_T&]*?\^?ZM_]%_B?_J3W[KW6L-NW:VV=H_\
M"NOX[XO:FW<%MC&2?RNL_628[;V(I\+ TTN5WPK2F&FCBC,C+&@+%=1"J";
M>_=>ZVR_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]UJ1_\)U-@;#WE\B?Y[U3N_9.T=U5%%_-)[>@HY]R;;H\X\229S=#
M,D354,K1JS $A2 3R??NO=;17^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/
M]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\
M3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[
M]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H
M-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/
M]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\
M3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[
M]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H
M-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/
M]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\
M3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[
M]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H
M-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/
M]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\
M3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[
M]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H
M-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/
M]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\
M3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[
M]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H
M-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/
M]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\
M3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[
M]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H
M-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/
M]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\
M3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H-Z4_Y\_U;_Z+_$__ %)[
M]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/]6_^B_Q/_P!2>_=>Z]_H
M-Z4_Y\_U;_Z+_$__ %)[]U[KW^@WI3_GS_5O_HO\3_\ 4GOW7NO?Z#>E/^?/
M]6_^B_Q/_P!2>_=>ZU<?^%3?777VS^B/Y<60VEL39NUJ^I_FB_'ZCJ*W;FV*
M+"320MAMT.8GDIH(G:,NB,5+%=2J;7 ]^Z]UMP>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4X[MVYM[=7_"NGX[XC<^
M!PVX\5)_*VR\[XS/8N#,4[/!F-]E',-0DD99#RITW!^GOW7NMG7_ $&]*?\
M/G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K
M?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?
MXG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_Z
MD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z
M]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_
M $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]
M*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\
M/G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K
M?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?
MXG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_Z
MD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z
M]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_
M $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]
M*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\
M/G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K
M?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?
MXG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_Z
MD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z
M]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_
M $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]
M*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\
M/G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K
M?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?
MXG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_Z
MD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z
M]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_
M $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]
M*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\
M/G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K
M?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?
MXG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_Z
MD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z
M]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_
M $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]
M*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\ /G^K?_1?XG_ZD]^Z]U[_ $&]*?\
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MJ3JG:B5)2KK*C'8C(YW+5XC2*9EH<3B\9,\TKB.'S2TM,95FJH%?W7NJ/_\
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M/(4&1HMMXO(UV2J:>:D=9*>EE4%&*R)[KW5#7\YK<'\R3^67_+I[ ^677/\
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M&DQ.SJ>.DIJRIPVV)< ,C6SS ST5)$T%9[KW0Z?SO:7YB?$#KO\ E+0=;?S
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M?BC_ .'1\CO_ 'X^ZO?NO=;$WOW7NM-/^1#W%V5U-WE_//J-@_%+O/Y-??\
M\U#N):FDZ4W1UGM^>A89C=3!JQ>Q>P=A0M"?&BZJ2>JEU2I:$J)&3W7NC?\
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MM_=>ZL=_G=5'R!^+/RA_E_?SGOC=L'/?(7JCXP8GL7J?Y4; ZT$>>KJOKKN
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M%/2T-9+++3B2-$AD9F 4^_=>ZV/>A^Q=@=L=.];;_P"L-Z[5[#V/N/9>VJ_
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MOW7NO>_=>Z][]U[JEG^8KU+_ #+,%\JOC?\ -;X,8+JOY+;8Z)ZQ[1Z^W?\
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M/_PRI%9C?XWB*?*_;S"W[L'GCD\4G ]2V;@<^_=>Z?%554*H"JH"JJBP 'T
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M[]U[K51_X4G_ /90?\A?_P :G=2?^[O:WOW7NMJ[W[KW6H%_PBI_[=9=^?\
MB_\ VG_[[KJKW[KW6W[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU9-W1GK[_A7+U5D-S>>@HN^?Y7
M&>V_UM65<PB@R&1VKE\O79"@HVG:-9JJDH-O5M3-34WEFCB9:F2-89&D7W7N
MMIOW[KW6J'_PFIR^)J/D9_/LPU/E,=/F*'^:!V9EZ[%0UL<M3#29K.[OBHZJ
M6!6,L=/5RT-<D,C*$E>GG5&8Q2!?=>Z-]_PJ._[<4?.;_P MF_\ ?Q=?>_=>
MZ"D=2]A]Z?\ "5+9/575&+R&>["W9_*>ZIBVSM_$M:JR,N)V=BJ^3'4RZX_)
M/7T]+-3QQZOW6D$=FU:3[KW1PO\ A/YWQL'O[^4#\&LOL3,4N2?K7I#:?16]
M*"-P)\=G>F*=,!7TE7%J9X9)110U<.JWEI:FGJ%'CF3W[KW1#?Y6?5>2R/\
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M><SFYNV>R/[V;NRF'Q&3HH,AD(<<TD%#AL&F1J,=Y:;"X7&X:"IGB$=)%)*
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ML]:KY/=I[_@S65RRRK4YJLI-S;TS-*V>F$\A;*+"N0+:7^YU(A7W7NL/0_\
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M +T+_P T[_T4F;_^Q;W[KW7O^@D_Y!_]Z%_YIW_HI,W_ /8M[]U[KW_02?\
M(/\ [T+_ ,T[_P!%)F__ +%O?NO=>_Z"3_D'_P!Z%_YIW_HI,W_]BWOW7NO?
M]!)_R#_[T+_S3O\ T4F;_P#L6]^Z]U[_ *"3_D'_ -Z%_P":=_Z*3-__ &+>
M_=>Z]_T$G_(/_O0O_-._]%)F_P#[%O?NO=>_Z"3_ )!_]Z%_YIW_ **3-_\
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M^0?_ 'H7_FG?^BDS?_V+>_=>Z]_T$G_(/_O0O_-._P#129O_ .Q;W[KW7O\
MH)/^0?\ WH7_ )IW_HI,W_\ 8M[]U[KW_02?\@_^]"_\T[_T4F;_ /L6]^Z]
MU[_H)/\ D'_WH7_FG?\ HI,W_P#8M[]U[KW_ $$G_(/_ +T+_P T[_T4F;_^
MQ;W[KW7O^@D_Y!_]Z%_YIW_HI,W_ /8M[]U[KW_02?\ (/\ [T+_ ,T[_P!%
M)F__ +%O?NO=>_Z"3_D'_P!Z%_YIW_HI,W_]BWOW7NO?]!)_R#_[T+_S3O\
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M2_\ 2?-V?_6[W[KW7O\ H+._DJ?\_P!.TO\ TGS=G_UN]^Z]U[_H+._DJ?\
M/].TO_2?-V?_ %N]^Z]U[_H+._DJ?\_T[2_])\W9_P#6[W[KW7O^@L[^2I_S
M_3M+_P!)\W9_];O?NO=>_P"@L[^2I_S_ $[2_P#2?-V?_6[W[KW7O^@L[^2I
M_P _T[2_])\W9_\ 6[W[KW7O^@L[^2I_S_3M+_TGS=G_ -;O?NO=>_Z"SOY*
MG_/].TO_ $GS=G_UN]^Z]U[_ *"SOY*G_/\ 3M+_ -)\W9_];O?NO=>_Z"SO
MY*G_ #_3M+_TGS=G_P!;O?NO=>_Z"SOY*G_/].TO_2?-V?\ UN]^Z]U[_H+.
M_DJ?\_T[2_\ 2?-V?_6[W[KW7O\ H+._DJ?\_P!.TO\ TGS=G_UN]^Z]U[_H
M+._DJ?\ /].TO_2?-V?_ %N]^Z]U[_H+._DJ?\_T[2_])\W9_P#6[W[KW7O^
M@L[^2I_S_3M+_P!)\W9_];O?NO=>_P"@L[^2I_S_ $[2_P#2?-V?_6[W[KW7
MO^@L[^2I_P _T[2_])\W9_\ 6[W[KW7O^@L[^2I_S_3M+_TGS=G_ -;O?NO=
M>_Z"SOY*G_/].TO_ $GS=G_UN]^Z]U[_ *"SOY*G_/\ 3M+_ -)\W9_];O?N
MO=>_Z"SOY*G_ #_3M+_TGS=G_P!;O?NO=>_Z"SOY*G_/].TO_2?-V?\ UN]^
MZ]U[_H+._DJ?\_T[2_\ 2?-V?_6[W[KW7O\ H+._DJ?\_P!.TO\ TGS=G_UN
M]^Z]U[_H+._DJ?\ /].TO_2?-V?_ %N]^Z]U[_H+._DJ?\_T[2_])\W9_P#6
M[W[KW7O^@L[^2I_S_3M+_P!)\W9_];O?NO=>_P"@L[^2I_S_ $[2_P#2?-V?
M_6[W[KW7O^@L[^2I_P _T[2_])\W9_\ 6[W[KW7O^@L[^2I_S_3M+_TGS=G_
M -;O?NO=>_Z"SOY*G_/].TO_ $GS=G_UN]^Z]U[_ *"SOY*G_/\ 3M+_ -)\
MW9_];O?NO=>_Z"SOY*G_ #_3M+_TGS=G_P!;O?NO=>_Z"SOY*G_/].TO_2?-
MV?\ UN]^Z]U[_H+._DJ?\_T[2_\ 2?-V?_6[W[KW7O\ H+._DJ?\_P!.TO\
MTGS=G_UN]^Z]U[_H+._DJ?\ /].TO_2?-V?_ %N]^Z]U[_H+._DJ?\_T[2_]
M)\W9_P#6[W[KW7O^@L[^2I_S_3M+_P!)\W9_];O?NO=>_P"@L[^2I_S_ $[2
M_P#2?-V?_6[W[KW7O^@L[^2I_P _T[2_])\W9_\ 6[W[KW7O^@L[^2I_S_3M
M+_TGS=G_ -;O?NO=>_Z"SOY*G_/].TO_ $GS=G_UN]^Z]U[_ *"SOY*G_/\
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M[KWOW7NO>_=>Z][]U[KWOW7NJ ?^%1W_ &XH^<W_ );-_P"_BZ^]^Z]T?_\
ME._]NLOY:?\ XH!\-_\ WW6W/?NO='_]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=:@7PW_ .XR3^;%_P"* =<_^Z+XT^_=>ZV_??NO=>]^Z]U[
MW[KW7O?NO=>]^Z]T$&U_D!TCO?M3?'2&S.U=B[M[<ZRP^(SW8_7VVMQTV<R>
M I=P2RPT+YFGIGE.,DK'@F\,508Y95C=T0HI8>Z]T*.3R>-PF.K\QF<A0XC$
M8NCJ,AD\IDZN.@IJ:GI$,DL\\\K)%##$BLSN[!54$D@#W[KW0!]:?+7XY=P;
MGQFS.O.V-MY[<^X=NY+>6S\-*E5@Y=PX3#/1I69S;'\1IZ1-SX.D;(XX39'$
MM6447WE(9)U%5!Y/=>Z%[?._-E=8[2SV_>Q=V;=V-LG:^/FRNXMV;KS$&!Q]
M%3TX]4U35U+QPQ(. "SBY(47) /NO=!_U=\C.E>YLUG]K]>;\Q^6WAM7%8;/
M[CV-E*"MVCGZ+&[CEJX,;E:C YFEQ^8BQ&2GH*^*CKC1?:54E+4QT\TCT\H3
MW7ND_P!C_+?XX]1[HR>SNQ>U]O;8S>WJ';&4WB:J&KJJ+;M+O:J-%A:K=.5I
MJ:;%[5ILO5AHJ*7+UE%'5N"(&DL;>Z]T8M65E#*0RL RLIN"#]"#^0??NO=(
M[;?8.S-WY[?.VML9^CS>9ZTSM!M??=+CUDF3&9/)8^DRT6.J)]'V_P!\,;7T
M%3) LK2PPU-.\R()XM?NO=++W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_P *
MCO\ MQ1\YO\ RV;_ -_%U][]U[H__P#*=_[=9?RT_P#Q0#X;_P#ONMN>_=>Z
M/_[]U[KWOW7NO>_=>Z36\-Y[0Z]VSFMZ[]W3MW9.SMMT%1E=P[KW;FJ;;N-H
M:6D4M+45E;5R0TU-#&H)9Y)%4#ZGW[KW35UCV=L#N?8&T^U.J]V8???7.^\/
M3[AV;O+;U1][09.@K;^"MHI[!:BDJ%&J*5;I*A62-F1E8^Z]TP]I]Y=4=*PX
M!^R]YX_;U;NW(U&)VAM^*EJL_F,S54<$E5/3X?"8V"LR^6EIJ6*6>9:2BF,,
M"/-+HB1F'NO=/'67:W6_<^U(=\=5;VV[OW:DN4SF!DS.V\DF0C@R.UZN;'Y7
M&5B*?+193%9"GJ*2NHJB.*JHZJ*6FJ88IHW1?=>Z"_LWY>_&KIO.YS;G9?;^
MU=K93:6"I]T[\-2U16TNV,35K/)%EMVU])!/0;2Q,L5+52)6YBIH:5HX)Y!*
M4AD9?=>Z'N?.X2FPDVY:G,8JGVY3XJ3.S[@GR$,5$E%%":AZQZMG$"TJP R&
M4R",1C66T\^_=>Z!/JGY3] =W9Q=L]8]E8G<>X*C:%'V)B<--05VWJC*;;R%
M0:2GW+A(LG2439W;4]2!%'EL>*G'22,BI4DN@;W7NA:WKO3:?7&T-S[_ -^;
M@Q>T]E[,P64W-NK<V;JEH:2@H,+"]15551*W"10PQNS'ZV%@";#W[KW3Y05L
M&2H:/(TPJ%IJ^DIZVG%71S8Z4)5('02T]1'%402:6&J.6))$-U=58$#W7NI?
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4"^&__<9)_-B_\4 ZY_\ =%\:
M??NO=;?OOW7NO>_=>Z][]U[KWOW7NL4\$%5!-35,,5135$4D%13SQB5'24%7
M1T8%61E)!!!!!L??NO=4"?#+KW8O77\^[^:[0["VCM[9N/SWQ5^!FY,MC=LX
MJ'"TTU=/#N6DDJOMJ=8X$EE@HZ97*1KK*:VN[,S>Z]T@_P#A0]WI74%)_+,^
M"U'F8*#"_P Q#^8ET!TSW#A/O_M),WUWB-QX*'<^%=8Y%J'QF2KLYM^#(:8I
M(I*21Z.H!CK-$GNO=+C_ (4;[HKOCM_+]V;\TNN*6+&=L_!#Y._'+NSJ&LH*
MZ7!")LCG:?9N7PTGVRVEP^=V[N/(XZMI'7P24\MRA>*(>_=>Z"+^8-\BD[Z_
MG$?R-?@@:RFDZI[!_P!)GSI[4Z]K:M91DZGJ_:&XLYUNV4ID<F>DQ.<VSF*R
M"*>G-/-D*>"=3Y:%6B]U[H1?YV':%=\2_E#_ "<_F+LNGFCWC+\X,;\+M\BD
MRDU ,OL#Y74#)GL36P(K0UT5)7;?QF3HQ,#]O7TD3Q:?+*P]U[HH&\4RVQOC
M/_PJRZ^^0-;'6=P;]WWW[O7KW$UM)]A6Y?9_>74V/VYTFV)H6F:;)0/7XX8&
MDJ*>-UJ\MC:NDCU5<$U+#[KW5RO2>\._>BOY?_P6Z0W2JYKYR[^^.W3/4M'2
M;@I),_!C]TX':%!_>7<^YTA>FDEP>SQ%-5923S0_?50IL7!.M=E:+7[KW1\.
ME.H=M=&=;X#KG;$E7D(\:<AE-P;FRRPG)9[-[CJ9<AG-Q9B6".&.HS&>RM35
MUU;,(U$E1/(555TJ/=>Z%;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_PJ._[
M<4?.;_RV;_W\77WOW7NC_P#\IW_MUE_+3_\ % /AO_[[K;GOW7NC_P#OW7NO
M>_=>Z][]U[HHGSTZVZ_[0^&_RAV[V+LO;.]L+)\=^\%6@W+AH,LL9J=L9-&D
M@,R,]-/I_3+$R2(0&1U8 CW7NBX?R1?^W1/\NC_Q4OI__P!U</OW7NB#?RY.
MZY?F'_/+_G*=A;@R5%N/$?!O ?'CX:]#4XJA7Q[>HL_4[IJ-^Q42J\T$%;F-
MW[/8Y&5/'4,M)24=0"*-$C]U[I+5ORAH_@I_/1_F$=>:(Z+I#NK^6=0?S(NP
M,?59YJ>@H=Y?'>.KVWE,Q'#4&.CQW\=VK@J=,E(DL:2R8^DJ)F+F1E]U[H;/
M^$X-17]W?RI]L?);MK[/>/;'S<[B^4G<_?VY<C":N3.Y*KWSN':(CJ_-K8T5
M)@]NX_'TE+K:&EH((::$)$@1?=>ZJ5Z@W1\ANZOY /\ .>^#72L>Y,WO+X(=
M\?*+X=]-P4@K.P<KD^L>N<_0Y%MLTZ./XA75D>S7S^!H57RS?;K1"..211"?
M=>ZLT['KI^Z_YJW\A#?/Q7S=!N'K_9?Q%^8W9G=>X]IY2+,X\=9]G;/V5CMF
M+6U--)50RTN6W+#'_#P9+33TTD\,D@I96C]U[JU'/1+\L.\3L[0*KXY_&3>^
M/K]_QUN,%12;T[(VX:7(XC#P22ZH:K!]>5!@R&0*1.LNYEQM*D\4V RM++[K
MW1Y??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:@7PW_[C)/YL7_B@
M'7/_ +HOC3[]U[K;]]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5%OQFEC'\_S^:'"9
M$$TGPW^!<J1%P&987W8'8+]2JET!-K LM_J/?NO= 3_PH1Z[R>W=Y?RB_G31
M4_VFW/A5_,KZ(F[BWHM5!1C [#[PW!@,5GZRIDG=5&.K*[&8.@G**[JU5"]E
MC621/=>Z77_"F+;.?[C_ )9Z_%7KQ*+)]N_,3Y.?&#H/J# 3&5S79?(;KH<\
MSVIUFG2CH,=@JVLK:A::9::C@FF= BEU]U[H(OF_TY7?'3^>'_(O^55S1=99
MW8W='\OKL7?DU33T<<V3R&S-SUO7N#K1(ZN7S&9R.5J*0116,U)*C.K/$DGN
MO=+O^>SUOG?DOW__ "7OBGL1Z:HWMG?YBVUODKG:6TCR4&R_B_BZC([LS4IB
M2?[>"FILK!!"\L(AFKZBCI3-$THU>Z]U?+V94]3[.P&5[?[5IMF8W"]5X/)[
MPK]][JQM)(<+1;?B>KJ*R.LGC:2E6!$=[QNIO^GU$>_=>Z*+MB'L+"=>]_?.
M+?VT*NB[JS74N^,EU3UAFRU7+M/9NS:.JRFW]M2Q1+JAS6XJFEI\KN)8]3C(
M3PXKRU-/A:&4^Z]U0'2_(CN_H?X$?\)__F?MWLK?N\/D'\ROG?\ %GK+Y0;G
MWKNO(;A7>^#^:F/W=D-U8O)4!J!1I3XZK@Q[;=@IJ:*EP(HJ2GQU-%1QFE?W
M7NMP'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_PJ._[<4?.;_P MF_\ ?Q=?
M>_=>Z/\ _P IW_MUE_+3_P#% /AO_P"^ZVY[]U[H_P#[]U[KWOW7NO>_=>Z+
MU\N/^R4?DY_XKUW1_P"\WDO?NO=$W_D@RQS?RA_Y=+Q2)*H^)W4<1:-PX#0X
MV-'6XOZD=65A]000>1[]U[H@?\KGKW)?%_\ G6?SR^B-Q0+M[%_(C+_&[YR]
M*85ZN#1E\5V(^\(=Y[@HX5=YR/[W5_V-67"E:BEN$$<D;R>Z]T'&^OC#5_-[
M^?9_, R=-'CLET]U-_*)I_@IV972+*T$FZ_E*V2R\&"DD5'IYG@VQDJJJKD6
MHCGIDGQX:$K4B3W[KW1HO^$U^;SN(_E#=*=1]ES-BNUOBOV+\F?COW5MW+5]
M-+4;>S76G86YG;#5S02/!$^+Q%7C([^1E,2I('=&#GW7ND%_PG"ZPW'0=#?-
M[Y1Y5(X]I?.?^8W\H_D=TXT<4L K-G9'+#&XK+^.:-66+*U=%DYJ8I+/%-0_
M:5,<S"?CW7NK9.]]P'8;8CI/XZX3:>V?D'\B)LC'C<IAL10X]L#@\&]-!N7L
M/*0I#_EL6UJ?)P+1131O'79NLQ>-D>*&LFGA]U[JOWYX19/I3?G\H'X0]3Y;
M>.Q^B.\OE]D-L=RS[:W)6XG*;@Q'56TMP;T_@F8SE,\60GAW=N*ECK<\PJXY
M\RL573UCSTE=D(9_=>ZS_P O3O#L9?YI'\Y7X1U.7K\MT'\8=R_#+L7HW%9B
MMJ<O4;=?Y+==Q9W<V$I:JHEE*8*3,TTE9048TK1/-5I$6AD1(?=>ZO"]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:@7PW_ .XR3^;%_P"* =<_^Z+XT^_=
M>ZV_??NO=>]^Z]U[W[KW7O?NO=<702(\;%@KJR,4=HFLPL;,I#*?Z$$$?4&_
MOW7NB1[&_EU_%#KCY0;U^9NT=I]G4/R2['PN+VWOOL7(?)?L[<2Y;&X,TIHL
M;787);QJ]OSX^B^RIQ3TS8KP0A66*-1)(']U[HV&_M@;([5V3NOK;LO:6WM^
M=?[ZP.3VMO+9>[<3!GL9E,=F8F@JZ*NHZE)(*FFJ(G971T*D'Z>_=>Z!#K?X
M@=(=8;FVGO#$8[>^Z-P]>;<J-H]9Y'M3M;<_;[[9QM8)$G@P']Y\ME1C)JFG
MD%-45D5J^IHXX*.HJI::GABC]U[H2^Y>E.K/D'L#*]7]R;,Q>^MD9>JQ&2FQ
M.1>>CDIZ[;M5%7XS)XZNI):?(8G,8JOIZ>JH,A155/6T-5%%4TD\,\:2+[KW
M28ZS^-O5G5>[,OV#AJ3=.Y>Q\Y@<;M.N[&[,WYFNTLZF(Q(B\.(I,EGZ[(5&
M.Q9EA2HFI:1H(*FL+UU4DU9)).WNO=*WLSJC:_;=/M'&;S?)5NWMI[XV[V!)
MM>&>*.@RM=L^4UF(CR\;P22U5'CLJE'D8H4FB5JRCI6F\L*/#)[KW0E.B2H\
M<B+)'(K))&ZAU97%B"#P01P0??NO=$&V!_+4^+G6^6Z9. P6Z)]A?&SL#>7:
M?QMZ7R^Y6K]H["S^^OXC][D-N8WPI4QI3)E\G'BZ.KKJN@P4-0\&#I<="L<:
M>Z]T?OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_PJ._[<4?.;_RV;_W\77WO
MW7NC_P#\IW_MUE_+3_\ % /AO_[[K;GOW7NC_P#OW7NO>_=>Z][]U[H*^Z.F
M-@_('K?=?4O9]/NFOV'OC!Y7;6ZL5M+L;<?5]168_.4\E+64<F3VMEL-E5IZ
MFFEDCD1*U0R,0>#[]U[I#_%OXG]&?##J7 =%_'3;FY]F=3[4AEI=K;,S_:N[
M>TX,9!-45%4U-CIMW9S.U=#2^>JG8005"0BX4(%1 ONO=.7:_P :>H>Y-W;"
M[&W;@LIC^S^KDS--U_VEL?=64Z]W'C*/<O@_BF*CR^%JZ*LJ<'E32TK5F+JI
M)\=4RT]-/-2O/34\L7NO=*GJ+ICK?HO:LFS^LMO'!XRMRU?N+.U]=E:W<V5R
M^5RVG[S,9W-92HK,OG,Q6%$\]=7UM153:5#RL%4#W7N@:W?\'_CIO+=W9&]*
MG;&Z-MY+ND8<]W8SKSL[<O6V*WH^"CIJ>GGW3B,%EL?C<Q6/04E/05-5-3&I
MK\6BXJOFJL:JTJ^Z]T:'!8+";7PF(VUMK$8S;^W=OXRAPN"P6%H8L91T5'C(
MEAIJ6EIH52&GIZ>%$2.-$5$10J@  >_=>Z1&V^J-K[;['[![7C?)9;?/8U)M
MC"Y/,YF>*I:BP^SHIACL'C%B@A%+BH*NLR=:8V\DLE975,LLSKX4A]U[I)_(
M#XW=5?)?;FT<#V=B:Z6LZX['VCW#U=O#;V3DP&<VONO8DKRXO/X/(P_N4E;
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ!?#?_N,D_FQ?^* =<_\
MNB^-/OW7NMOWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5 /\
MPJ._[<4?.;_RV;_W\77WOW7NC_\ \IW_ +=9?RT__% /AO\ ^^ZVY[]U[H__
M +]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU OAO_W&2?S8O_%
M.N?_ '1?&GW[KW6W[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MJ@'_ (5'?]N*/G-_Y;-_[^+K[W[KW1__ .4[_P!NLOY:?_B@'PW_ /?=;<]^
MZ]T?_P!^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:@7PW_[C)/Y
ML7_B@'7/_NB^-/OW7NMOWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW5 /_  J._P"W%'SF_P#+9O\ W\77WOW7NC__ ,IW_MUE_+3_ /% /AO_
M .^ZVY[]U[H__OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4"^&
M_P#W&2?S8O\ Q0#KG_W1?&GW[KW6W[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[K2PZ?\ FO\ \**_Y@GR7_F#;;^$':WP5V)U
M-\1?E[VG\?:+"]S;+K,;7"DVWFLM1XDQ3TV$W!)7.<?CD-3-+/$6G9BD2QD*
MGNO=&A_T8?\ "OK_ +R+_E8_^>/+_P#V">_=>Z]_HP_X5]?]Y%_RL?\ SQY?
M_P"P3W[KW7O]&'_"OK_O(O\ E8_^>/+_ /V">_=>Z]_HP_X5]?\ >1?\K'_S
MQY?_ .P3W[KW7O\ 1A_PKZ_[R+_E8_\ GCR__P!@GOW7NO?Z,/\ A7U_WD7_
M "L?_/'E_P#[!/?NO=>_T8?\*^O^\B_Y6/\ YX\O_P#8)[]U[KW^C#_A7U_W
MD7_*Q_\ /'E__L$]^Z]U[_1A_P *^O\ O(O^5C_YX\O_ /8)[]U[KW^C#_A7
MU_WD7_*Q_P#/'E__ +!/?NO=>_T8?\*^O^\B_P"5C_YX\O\ _8)[]U[KW^C#
M_A7U_P!Y%_RL?_/'E_\ [!/?NO=>_P!&'_"OK_O(O^5C_P">/+__ &">_=>Z
M]_HP_P"%?7_>1?\ *Q_\\>7_ /L$]^Z]U[_1A_PKZ_[R+_E8_P#GCR__ -@G
MOW7NO?Z,/^%?7_>1?\K'_P \>7_^P3W[KW7O]&'_  KZ_P"\B_Y6/_GCR_\
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MOK_O(O\ E8_^>/+_ /V">_=>Z]_HP_X5]?\ >1?\K'_SQY?_ .P3W[KW7O\
M1A_PKZ_[R+_E8_\ GCR__P!@GOW7NO?Z,/\ A7U_WD7_ "L?_/'E_P#[!/?N
MO=>_T8?\*^O^\B_Y6/\ YX\O_P#8)[]U[KW^C#_A7U_WD7_*Q_\ /'E__L$]
M^Z]U[_1A_P *^O\ O(O^5C_YX\O_ /8)[]U[KW^C#_A7U_WD7_*Q_P#/'E__
M +!/?NO=>_T8?\*^O^\B_P"5C_YX\O\ _8)[]U[KW^C#_A7U_P!Y%_RL?_/'
ME_\ [!/?NO=>_P!&'_"OK_O(O^5C_P">/+__ &">_=>Z]_HP_P"%?7_>1?\
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M /V">_=>Z]_HP_X5]?\ >1?\K'_SQY?_ .P3W[KW7O\ 1A_PKZ_[R+_E8_\
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M /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\
MOG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *
M%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ
M_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_
M  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U
M[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T
M;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H
M,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__
M /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\
MOG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *
M%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ
M_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_
M  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U
M[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T
M;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H
M,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__
M /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\
MOG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *
M%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ
M_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_
M  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U
M[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T
M;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H
M,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__
M /9H,3_T;[]U[KW_  ZQ_P *%O\ OG__ /9H,3_T;[]U[KW_  ZQ_P *%O\
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M$;3S&Z(:[<N=KZRAI*#$T%?5U]165,-$L'WC& >Z]T33NO\ FY=<_%/?W3V
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M=>Z$[M+MWJGH[9F6[&[H[*V'U-L# PM49G>O9&[:#96*I54%KSU^1GIJ:,D
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M66CWSUJ'RFW'AGA5YZ8UM7":":6-&=::LGTJQ.D^Z]T0OX-?-VO_ )JGP:^
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4 _\
M"H[_ +<4?.;_ ,MF_P#?Q=?>_=>Z/_\ RG?^W67\M/\ \4 ^&_\ [[K;GOW7
MNC_^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7;_X55_]N//E
MC_X<WQP_]^3M3W[KW5S7Q _[)+^+O_BNO2?_ +S6,]^Z]T8KW[KW7O?NO=>]
M^Z]U[W[KW0/_ "%Q.X<_T%WA@MHK4/NS-=/]EXG;"4C,LIR.1PM;#1"(J"PD
M-2\6D@$WM87]^Z]UJB?\(H=RX:J_EL_)39\%9&^X,%\X=X;ER= "-45'NS87
M7]+03$7OIGGPN14<6O$UB;&WNO=;:7;NT=Y[XZ]W-MOK[M+=O36\LAB<C%MW
ML'96*VYFJZ@JY*>9*:5:;=6!W+A9HXYWBD99L3*&T!?TEE;W7NM8S_A.Q_,%
M^;'S!_E[?+OYS_,CY*;H[TSW3G9?:>Q=I]=?Z,.O>O,-3T?4NQ-O[M>JOM;:
M&!RM37Y*HW"T,GFRS0)'2P>**-FF>3W7NC:_RF*KY'=X?RX>H^VJGK;XI]N2
M_+_:^<[C[UW?V1VEN6LR.[,[V)65AS,>?IGV3E83#BV!P]'C_OJBEQ>,H*3%
MT96CHX$7W7NN/\NK^3]E/A_\&_DW\+/EQD>E/E)\<-U]D[V[5Z2Z@S>UJCL+
M#;/QV;BDKOX*J;KI)S4OC<K#%7TE7XQ*M=)45JB*ID9V]U[HG/\ PET^)_QQ
M[9_E!=);][>Z<V#V]N>MW+\C]E4=9VMMRE[$BQF&R>\*TU^+PM)EXZNEPU'E
M9J2FGR"T<,+9":&G>L:?[6E$'NO="Q_PESA_NI\:?G_\?L7/5R=6?'+^:'\I
M>HNG]O9.LDRIQ.W*"'!318M)ZAI)IX!53U=0S2L\CS5,\CNQ?CW7NF#^7_C,
M-_+ _G?_ #0_EW28['[5Z%_F&8,?.[X@LE)'B:2/<-!]W%O;9^/8E5GE@CI\
ME54]%"3]CC,7 WBCCJ4+>Z]U<S\:,%0]R=T_)WY?R15%,=W9 ?%'I/./25M#
M40[)^..1R])DLA3T^0BBCB.<['R&\:B*J@IC#E,318"K6HJZ5:-D]U[JL;XO
M=.])_'[^7M\COY?W25;NS^973Q2?*^'Y+=];DH,;MO:U5G^QJO.U6>H-V[LK
MZJOI\]N7&EQ19"'$G<&5IZN*.3)P8U9HQ%[KW1-/Y9GR[[8^._\ PDG3Y)[7
MS-1DNT>C.COE-C.M\[N*>;<#4<^)[ W3B=NNRU,S:Z;;\=511TM-J$$5+1P4
MR1^%!'[]U[JYGX<?#OHSLO\ DZ=2_%_)9%=\]<_*'X<X6?MWLW&,HR>[\Q\D
M-L19+=._)ZZ:2NGJ-P9[+Y>KRPK:BJJIUJ7B=YY3&K'W7NB,?-CK_*_R@/Y*
M76OQ,Z=[N[+W;1U?<73?Q5Q_=79N\)L!G<9MCY ;_OFECS6$C@JL#!BMLUN1
MQ6-J:&!Y\33+324B>2FBT^Z]T8WY[_R\.[?G1\%=Z?!2NZ?^%G5>R,CMG;N%
MZMSNWM\;HKUV35;.JZ.KQ-=A<=!LC%B,4C44<301UM/'44[RTTQ>"62-_=>Z
MLN^'767</2WQ:Z&ZB[^[(HNX.X>L^M-L[&WWVC0+4*F>J]L0"C3*/]VJU35%
M7310/.\MW><R.S.6UGW7NBV?SD?^W3G\R'_Q2CY(_P#O*9/W[KW54O\ )6^)
M/R@WS_*7^%>X=A_S0/E=TM@=R])15>!Z[VEU#T1N?$8-*FNR""EH:K<?4F7W
M+/3(X9U-3N":<%B%G4!=/NO=$(Z+W'G/Y*7\[#;_ %W\_</1?,#L/^9CDL1M
M+I7^9Y7RY"EWE2Q[ER]+@J/9F6VO-D,A@\/CJ7*MA(*Q\)38^.*GJ:.5C54D
M(IJ#W7NCA?\ "CCJ'JNC[_\ Y*_=U'UWLRB[@R7\U_XP;$RO9M%MVEH\Y68:
M7(TU2,96Y**):JMHHI\?2/#%/+(L!3]D('D#>Z]T8C_A1'\B=W; V-_+_P#B
MM@<A4X39OSQ^?/1O07>N5H:V7&5$^PILM0'<.$AJH)H)J09O[NCAJ)5;FC6J
M@]/GU+[KW5A_\S#X5=6?*K^7AW]\;9=J[8P%-B^F-RUW2570X2*BBVCN/K_&
MRUFU,GAXZ8TIH!B<C1T=DIY8 U.)*?4(I&!]U[K4^^3'R=[%^:/_  CBF[S[
MTJJ?=G<6%S/5O5&<W_6P?<5^4BZM[EQ&"Q^0JJF9IJB3(5>)IJ/[^8RWJJS[
MBI*IYM"^Z]U?S_-<[LS?QF_E3;"EZQK:+KS-=\;J^'_QQS6]<1E*C8<N-P_<
MV4P^-W%7)F<2%R.)J#M\Y6"+(TR255"\XJZ9#-$A'NO=*7Y[_P O#NWYT?!7
M>GP4KNG_ (6=5[(R.V=NX7JW.[>WQNBO79-5LZKHZO$UV%QT&R,6(Q2-11Q-
M!'6T\=13O+33%X)9(W]U[HG'\PQ^\.FOC9_)9_EK?(_O/%[M?Y2?*_H/XR?,
M+MNE2KB3?FUNN/MYZW;,TE14T=6(^QI(\1B\F9C(:E*BI@G2J@J)H:CW7NK5
M_P"95_*ZZ7_F5]$=8=([RWAOWHR3I+M79?;O3_8O1L]'MG-;<R6R:2KH*6/%
M224\D-)3BDK"$6*-#!-!23PE7IH[>Z]U57_PISQ2UO6W\IK"29#*Q+5_S=OB
MIBI,I1US45<HGH-PPFHBJ8@CPU2WUK*@4K)9UL0/?NO=!W_PIG^*GQR^/G\J
M/,=X](=,=>=6]S= _(+I+LGJWM?9^V*3&;DHL]N+>%,V2R]3G/$V4RN1R=57
M5-96U%?55,U;7M]]5/-57E/NO=+[_A55U1U7V%_)D[.[XWAUEU]G.Y.NI^@)
M.O.SLAL^@K,]@8M_;UVM2YFDPV7F@DR6.HLG3SO'500521U"A/,KE%(]U[I?
M_P U;X(_$NH_D<?+'<E9T?L;(]@47Q8H^\Y>V<GB(\EO&JW9L7"8JNQ^;K=U
MSJ^>JJI!BZ*C*O7F+^%Q+B5C7&*E*ONO=$F^:'S$[8K_ .4M_(!Z8S>Y\C+_
M ,.0;U^ 73WR<WH*^7'5^5VADL5MQ]U4#5D$T$M//N66KI5K9T(UTWWD5D$X
M*^Z]UL#_ ,S#X5=6?*K^7AW]\;9=J[8P%-B^F-RUW2570X2*BBVCN/K_ !LM
M9M3)X>.F-*: 8G(T='9*>6 -3B2GU"*1@?=>Z)-_).^5_:WS,_D9];=P=WYF
M7<_:&/ZI[UZNW-N^I>26HS"]4U6;P>-R==)+)++/DZG$T= :Z=Y"U36">ILG
MET+[KW5;O\I?Y)[N^'__  DPRGR4Z^BI9-_=3=:?,+<&Q9*Z#[J"#-578.Z:
M'%5<\.N/S045?54]1)'K7R)&R @M[]U[J['^3AUIL3*_RFOB-+G,%B=X5'R)
M^/.S^WN]LCN:ECW%-NS<G=N-CR^Z,CN"6I$K92IKZVNJ(Y/N"^B%(Z90D,,<
M:>Z]U69_(%SF_P#X[_-+^;Y_*PJ-Q3;C^/OP_P"\=L=A?&+'UDU14R[8V]WG
M-F,E_=B"6HJJD_PRBH1A##$NA4K!D:@B];XXO=>Z6?\ PGAW+FZS>W\X_9/R
M-J)/]G,I/YF?;6Y>Y,/O2HUYT[.SF%P=)LF3P5;M6-M$0T.93!NJG'?P\Q+C
MV-*8Q[]U[H"/^$Y_P[Z9I>__ .:=\E:3X[=3S[7VC_,V^3^VO@_\@VZZQLN4
MAVU!D,_@<O#LW<1H5J1MG^&3TM"C4%6:-GER5*H5OND;W7NE55[.VS_)^_X4
M!XWL/'X/%;/^''\ZG;$/7^4R%!C(,5C-L=X;'J$J*."69(*:FH*;>$M;++!&
MU1+49#+YO(RK&E/C[I[KW5OFU<!A/DK_ #--Z]PUF'H<IM/^7CU?D/CAUOGI
MZ>=BO8OR9I\!NOL1J8S4R4[_ ,$V;CNN:-*FFJ9M,V5R]%*8IJ>6,>Z]U9U[
M]U[K2/\ Y;2U>VO^%?W\UW%[VEC7.9[XY]@MMI:H#6\.7R73>9QBPZU1M0VZ
MEQI4GQ*UBR78^Z]UNX>_=>Z#[MK?2]7]5]F=EO0MDTZ[Z^WGOI\:CB,U VEC
MJG(& ,;!3**?3>_%[^_=>ZHX_P"$W&ZZ_P"0O\N2#YD]I'';H^0GR^[L[_W_
M -\;WFIQ//7U&%W9E\#BL4IE>:6GPF&PN.HZ?'X_R>"FA+E$US2R2>Z]T5;X
M-#<OP<_X48_-KX"];5M)0_$7Y2?'.A^<NS^IJ*&2GH=I;LFJL109:;#P?<O2
MT-/F*Y]QR5<,%+$LBMBT542@'E]U[K:Q]^Z]U[W[KW7O?NO=:;7_  HP_P"W
MP/\ PFN_\77P'_OT.G/?NO=;DOOW7NJR_P"<WC<=7?RH?YBT];0459/0?"[Y
M(U%#-54L=0\$G]U<D=<+.I,;W5>5(/ YX]^Z]U7-\?OD76?"'_A,=U5\LMA8
M7;R=C]7?RXMDYS9U;78F*:)\_E<52X_"2UZJT$E72PYBLHI9HC.IE1&0,&8$
M>Z]T>;^3ETQL&B_E5?%>JS&,QV^LQ\J/CYLKY _(O<FZI3O"LWGNGY)82FW!
MNJOW+65QGGRU353Y2:DD2H=T@IH8J")4I:>*)/=>ZK#_ .$J6P=L=4](?S-.
MKMDT4N-V9UM_-9^16P=HXZ>LER+T^,V?B-L8Z@@>HG>2>=XJ2FB4R22-(Y&I
MV+$D^Z]UM1^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5W^:Q_W$+?\ "?\
M_P#+H/\ W4K[]U[K:B]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ!?#?\ [C)/YL7_
M (H!US_[HOC3[]U[K;]]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]UJH_\ ";#_ +*#_GT?^-3NV_\ W=[I]^Z]UM7>_=>Z][]U
M[KWOW7NB<_/+XY=I_+GXM=W?&7K7N79O1T'??5^]NGMY;WW1TY5]R3087L:A
MFQ.8&.H:?>&T8H:V;%U59%#--/.D,DBS&&3Q^-O=>Z+'_*M_EY=W?RR_B!@?
MAY_LT'7'>6T.O:O?==U9NBK^-63Z]KJ!]_9BLSU3'EHD[-S5/EJ:+*9'(.B4
MZXQS'(B-*71I9/=>Z1'\L'^6'WI_+KSORWR>=^6G6G?%%\N.]=\?)?<])3_%
M?)=5U&+WAO[R-6/257^E/<<<^!$I@9:&2D%2%C9?XB#)K3W7NH_PU_E@]_\
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M;%Q%=3T6.V=B:/>%+7Y6FVYATQ\%/54\%-1XK(9>GKZTQ9"J:?(U'NO=6Z?
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MK3_./XX]<= ;6V-\@<YM/XIUVQMT+GZK=&R*(2BFS.7C3+YB-9Y56EE2H5J
MS&HFIVQ=(U$9*CW7NK#/?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJN_S6/^XA;_A/
M_P#^70?^ZE??NO=;47OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM2;Y7?RI/YQFR?YQ
M7R>_F??RTNX_ASMM?DMT]U[U3D,;W]-F9JZ@H-N8+8V,R5&U!#MC,4,C5&1V
M%C:N"KCK%<13/3M"I5GD]U[I5_Z,/^%?7_>1?\K'_P \>7_^P3W[KW7O]&'_
M  KZ_P"\B_Y6/_GCR_\ ]@GOW7NO?Z,/^%?7_>1?\K'_ ,\>7_\ L$]^Z]U[
M_1A_PKZ_[R+_ )6/_GCR_P#]@GOW7NO?Z,/^%?7_ 'D7_*Q_\\>7_P#L$]^Z
M]U[_ $8?\*^O^\B_Y6/_ )X\O_\ 8)[]U[KW^C#_ (5]?]Y%_P K'_SQY?\
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M@Q/_ $;[]U[KW_#K'_"A;_OG_P#_ &:#$_\ 1OOW7NO?\.L?\*%O^^?_ /\
M9H,3_P!&^_=>Z]_PZQ_PH6_[Y_\ _P!F@Q/_ $;[]U[KW_#K'_"A;_OG_P#_
M &:#$_\ 1OOW7NO?\.L?\*%O^^?_ /\ 9H,3_P!&^_=>Z]_PZQ_PH6_[Y_\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:KO\
M-8_[B%O^$_\ _P"70?\ NI7W[KW6U%[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU
M4?\ A-A_V4'_ #Z/_&IW;?\ [N]T^_=>ZVKO?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$J^0WQ4J-Z]S]2?+OIC(8
M?:'RHZ,V[NK86(R><UP8;>6R-]34M7G.O=VR4\%360XFKR%!C\CC<E3035>#
MR]+#6Q4]=1393$Y/W7NC@X2NKLGA\;D,GA:W;F1K**GJ*W Y&II:R>DEE4%Z
M>66BGJ:25XVN"T50Z-:ZL1[]U[IT]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]T2CY*?''*_,'+;<ZI[7HJ;%_%+:N[MI;_W]LULB*JN['RFQ:Z'+87"
M9*&G9H*+8M#E:7'UU=!+.U7FZFF2@J*6EQ<<YRONO='65550J@*J@*JJ+  ?
M0 ?@#W[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[I,[U_P"/-W;_ .&SGO\ W%E]^Z]UK._\)!?^W.>V?_%BN\_^M^/]
M^Z]UM$>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>ZUV_\ A57_ -N//EC_ .'-\</_ 'Y.U/?N
MO=7-?$#_ +)+^+O_ (KKTG_[S6,]^Z]T8KW[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1,/G#\
M0:#Y=]:;1H,+NH]9=Y=(=G[-[]^-'<D&.?*OMC>O7DYFH9:RDBJ*.;);=S-,
M]5BL]C5K(/XCAZVKIEF@F:&HA]U[H?NHMY[SWGM&GG[(Z^K^LNQ,1+_!]Z[6
M:K.>QJUU,HUU.!S2Q0P9O!UBE9Z.I$4%2(9$AR-%C\C'54-/[KW0H^_=>Z][
M]U[J'58['U[TLE=04=9)0U"5=%)54J5#0RQD%9(BZDQR*0"&6Q%OK[]U[K*:
M6E-4M::: UJ0/2I5F%3*(I&5VC$EM8C9T5BM[$@$BX'OW7NL_OW7NO>_=>ZC
MTE)2T%+34-#34]%145/#24='20K31114RA(XHHT"I''&BA550 H    ]^Z]U
MZFI*6BC:&CIJ>DA>HJZMXJ:%8%,M?*\\\I5  9)IY)))&M=W9G8EF)/NO=8Z
MK'8^O>EDKJ"CK)*&H2KHI*JE2H:&6,@K)$74F.12 0RV(M]??NO=932TIJEK
M330&M2!Z5*LPJ91%(RNT8DMK$;.BL5O8D D7 ]^Z]UG]^Z]U[W[KW5>/?'Q]
MS?S7[>Z@Q'9&&RFV_BC\;^T\%W95;9S< H:OLO?&P];[8BJJ"0?<TFQ]HY*1
MLDZU<<,V:S-+0/%!_"*,5&4]U[JP[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:KO\
M-8_[B%O^$_\ _P"70?\ NI7W[KW6U%[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU
M4?\ A-A_V4'_ #Z/_&IW;?\ [N]T^_=>ZVKO?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW29WK_P >;NW_ ,-G/?\
MN++[]U[K6=_X2"_]N<]L_P#BQ7>?_6_'^_=>ZVB/?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M:[?_  JK_P"W'GRQ_P##F^.'_OR=J>_=>ZN:^('_ &27\7?_ !77I/\ ]YK&
M>_=>Z,5[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>ZU7?YK'_<0M_PG_\ _+H/_=2OOW7NMJ+W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]UH5_"[I/^;CA_EI_-HK/Y/GS"^ .[M@[@^?G<&;[P
MQO;.SM^XG+83<>1SN=GAPU0NX.MX:22IQ\<M533R8K(9''R2PF2&LEC>-V]U
M[JR;_1A_PKZ_[R+_ )6/_GCR_P#]@GOW7NO?Z,/^%?7_ 'D7_*Q_\\>7_P#L
M$]^Z]U[_ $8?\*^O^\B_Y6/_ )X\O_\ 8)[]U[KW^C#_ (5]?]Y%_P K'_SQ
MY?\ ^P3W[KW7O]&'_"OK_O(O^5C_ .>/+_\ V">_=>Z]_HP_X5]?]Y%_RL?_
M #QY?_[!/?NO=>_T8?\ "OK_ +R+_E8_^>/+_P#V">_=>Z]_HP_X5]?]Y%_R
ML?\ SQY?_P"P3W[KW7O]&'_"OK_O(O\ E8_^>/+_ /V">_=>Z]_HP_X5]?\
M>1?\K'_SQY?_ .P3W[KW7O\ 1A_PKZ_[R+_E8_\ GCR__P!@GOW7NO?Z,/\
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M_P#[!/?NO=>_T8?\*^O^\B_Y6/\ YX\O_P#8)[]U[KW^C#_A7U_WD7_*Q_\
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M7NO?Z,/^%?7_ 'D7_*Q_\\>7_P#L$]^Z]U[_ $8?\*^O^\B_Y6/_ )X\O_\
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M$NM/_K][]U[KW^S\?\*0O^]"O5O_ *<2ZT_^OWOW7NO?[/Q_PI"_[T*]6_\
MIQ+K3_Z_>_=>Z]_L_'_"D+_O0KU;_P"G$NM/_K][]U[KW^S\?\*0O^]"O5O_
M *<2ZT_^OWOW7NO?[/Q_PI"_[T*]6_\ IQ+K3_Z_>_=>Z]_L_'_"D+_O0KU;
M_P"G$NM/_K][]U[KW^S\?\*0O^]"O5O_ *<2ZT_^OWOW7NO?[/Q_PI"_[T*]
M6_\ IQ+K3_Z_>_=>Z]_L_'_"D+_O0KU;_P"G$NM/_K][]U[KW^S\?\*0O^]"
MO5O_ *<2ZT_^OWOW7NO?[/Q_PI"_[T*]6_\ IQ+K3_Z_>_=>Z]_L_'_"D+_O
M0KU;_P"G$NM/_K][]U[KW^S\?\*0O^]"O5O_ *<2ZT_^OWOW7NO?[/Q_PI"_
M[T*]6_\ IQ+K3_Z_>_=>Z]_L_'_"D+_O0KU;_P"G$NM/_K][]U[KW^S\?\*0
MO^]"O5O_ *<2ZT_^OWOW7NO?[/Q_PI"_[T*]6_\ IQ+K3_Z_>_=>Z]_L_'_"
MD+_O0KU;_P"G$NM/_K][]U[KW^S\?\*0O^]"O5O_ *<2ZT_^OWOW7NO?[/Q_
MPI"_[T*]6_\ IQ+K3_Z_>_=>Z]_L_'_"D+_O0KU;_P"G$NM/_K][]U[KW^S\
M?\*0O^]"O5O_ *<2ZT_^OWOW7NO?[/Q_PI"_[T*]6_\ IQ+K3_Z_>_=>Z]_L
M_'_"D+_O0KU;_P"G$NM/_K][]U[KW^S\?\*0O^]"O5O_ *<2ZT_^OWOW7NO?
M[/Q_PI"_[T*]6_\ IQ+K3_Z_>_=>Z]_L_'_"D+_O0KU;_P"G$NM/_K][]U[K
MW^S\?\*0O^]"O5O_ *<2ZT_^OWOW7NO?[/Q_PI"_[T*]6_\ IQ+K3_Z_>_=>
MZ]_L_'_"D+_O0KU;_P"G$NM/_K][]U[KW^S\?\*0O^]"O5O_ *<2ZT_^OWOW
M7NO?[/Q_PI"_[T*]6_\ IQ+K3_Z_>_=>Z]_L_'_"D+_O0KU;_P"G$NM/_K][
M]U[KW^S\?\*0O^]"O5O_ *<2ZT_^OWOW7NO?[/Q_PI"_[T*]6_\ IQ+K3_Z_
M>_=>Z]_L_'_"D+_O0KU;_P"G$NM/_K][]U[KW^S\?\*0O^]"O5O_ *<2ZT_^
MOWOW7NO?[/Q_PI"_[T*]6_\ IQ+K3_Z_>_=>Z]_L_'_"D+_O0KU;_P"G$NM/
M_K][]U[KW^S\?\*0O^]"O5O_ *<2ZT_^OWOW7NO?[/Q_PI"_[T*]6_\ IQ+K
M3_Z_>_=>Z]_L_'_"D+_O0KU;_P"G$NM/_K][]U[KW^S\?\*0O^]"O5O_ *<2
MZT_^OWOW7NO?[/Q_PI"_[T*]6_\ IQ+K3_Z_>_=>Z]_L_'_"D+_O0KU;_P"G
M$NM/_K][]U[KW^S\?\*0O^]"O5O_ *<2ZT_^OWOW7NO?[/Q_PI"_[T*]6_\
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)=>Z][]U[K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tformula_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tformula_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MC_O!G_V9GYA__=!>_=>Z]_T"X_R*/^\&?_9F?F'_ /=!>_=>Z]_T"X_R*/\
MO!G_ -F9^8?_ -T%[]U[KW_0+C_(H_[P9_\ 9F?F'_\ =!>_=>Z]_P! N/\
M(H_[P9_]F9^8?_W07OW7NO?] N/\BC_O!G_V9GYA_P#W07OW7NO?] N/\BC_
M +P9_P#9F?F'_P#=!>_=>Z]_T"X_R*/^\&?_ &9GYA__ '07OW7NO?\ 0+C_
M "*/^\&?_9F?F'_]T%[]U[KW_0+C_(H_[P9_]F9^8?\ ]T%[]U[KW_0+C_(H
M_P"\&?\ V9GYA_\ W07OW7NO?] N/\BC_O!G_P!F9^8?_P!T%[]U[KW_ $"X
M_P BC_O!G_V9GYA__=!>_=>Z]_T"X_R*/^\&?_9F?F'_ /=!>_=>Z]_T"X_R
M*/\ O!G_ -F9^8?_ -T%[]U[KW_0+C_(H_[P9_\ 9F?F'_\ =!>_=>Z]_P!
MN/\ (H_[P9_]F9^8?_W07OW7NO?] N/\BC_O!G_V9GYA_P#W07OW7NO?] N/
M\BC_ +P9_P#9F?F'_P#=!>_=>Z]_T"X_R*/^\&?_ &9GYA__ '07OW7NO?\
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M>_=>Z]_T"X_R*/\ O!G_ -F9^8?_ -T%[]U[KW_0+C_(H_[P9_\ 9F?F'_\
M=!>_=>Z]_P! N/\ (H_[P9_]F9^8?_W07OW7NO?] N/\BC_O!G_V9GYA_P#W
M07OW7NO?] N/\BC_ +P9_P#9F?F'_P#=!>_=>Z]_T"X_R*/^\&?_ &9GYA__
M '07OW7NO?\ 0+C_ "*/^\&?_9F?F'_]T%[]U[KW_0+C_(H_[P9_]F9^8?\
M]T%[]U[KW_0+C_(H_P"\&?\ V9GYA_\ W07OW7NO?] N/\BC_O!G_P!F9^8?
M_P!T%[]U[KW_ $"X_P BC_O!G_V9GYA__=!>_=>Z]_T"X_R*/^\&?_9F?F'_
M /=!>_=>Z]_T"X_R*/\ O!G_ -F9^8?_ -T%[]U[KW_0+C_(H_[P9_\ 9F?F
M'_\ =!>_=>ZK8_G!_P#">_\ E!_%K^6;\Q/D'T1\1O[B]O=5]3S[EV'N[_3Y
M\GMS_P "S:;@P5"M;_ -X]T[AVQE+4M9(OCK:*HA]5]-P"/=>ZLG_P"$N/\
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M=>]^Z]U[W[KW7O?NO=>]^Z]U3M_PH$_[<S_S!O\ Q!53_P"]5MGW[KW0%?\
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MM_TF_P"G3H[<W<W]Z/O/[L_W+_NM_=WLCK[^[?\ !/M<M]]YON_O/NZ?1XO
MWD]U[HEO^@_^?+_WGU\ /_2'>R__ +I#W[KW7O\ 0?\ SY?^\^O@!_Z0[V7_
M /=(>_=>Z]_H/_GR_P#>?7P _P#2'>R__ND/?NO=>_T'_P ^7_O/KX ?^D.]
ME_\ W2'OW7NO?Z#_ .?+_P!Y]? #_P!(=[+_ /ND/?NO=>_T'_SY?^\^O@!_
MZ0[V7_\ =(>_=>Z]_H/_ )\O_>?7P _](=[+_P#ND/?NO=>_T'_SY?\ O/KX
M ?\ I#O9?_W2'OW7NO?Z#_Y\O_>?7P _](=[+_\ ND/?NO=>_P!!_P#/E_[S
MZ^ '_I#O9?\ ]TA[]U[KW^@_^?+_ -Y]? #_ -(=[+_^Z0]^Z]U[_0?_ #Y?
M^\^O@!_Z0[V7_P#=(>_=>Z]_H/\ Y\O_ 'GU\ /_ $AWLO\ ^Z0]^Z]U[_0?
M_/E_[SZ^ '_I#O9?_P!TA[]U[KW^@_\ GR_]Y]? #_TAWLO_ .Z0]^Z]U[_0
M?_/E_P"\^O@!_P"D.]E__=(>_=>Z]_H/_GR_]Y]? #_TAWLO_P"Z0]^Z]U[_
M $'_ ,^7_O/KX ?^D.]E_P#W2'OW7NO?Z#_Y\O\ WGU\ /\ TAWLO_[I#W[K
MW7O]!_\ /E_[SZ^ '_I#O9?_ -TA[]U[KW^@_P#GR_\ >?7P _\ 2'>R_P#[
MI#W[KW7O]!_\^7_O/KX ?^D.]E__ '2'OW7NO?Z#_P"?+_WGU\ /_2'>R_\
M[I#W[KW7O]!_\^7_ +SZ^ '_ *0[V7_]TA[]U[KW^@_^?+_WGU\ /_2'>R__
M +I#W[KW7O\ 0?\ SY?^\^O@!_Z0[V7_ /=(>_=>Z]_H/_GR_P#>?7P _P#2
M'>R__ND/?NO=>_T'_P ^7_O/KX ?^D.]E_\ W2'OW7NO?Z#_ .?+_P!Y]? #
M_P!(=[+_ /ND/?NO=>_T'_SY?^\^O@!_Z0[V7_\ =(>_=>Z]_H/_ )\O_>?7
MP _](=[+_P#ND/?NO=>_T'_SY?\ O/KX ?\ I#O9?_W2'OW7NO?Z#_Y\O_>?
M7P _](=[+_\ ND/?NO=>_P!!_P#/E_[SZ^ '_I#O9?\ ]TA[]U[KW^@_^?+_
M -Y]? #_ -(=[+_^Z0]^Z]U[_0?_ #Y?^\^O@!_Z0[V7_P#=(>_=>Z]_H/\
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M;\_E\_+OXN86GVSD<]%V/WK4?'>;9E;D*&NQ5)!M6F7JCO;LS<@SV3AR,E1
M9<?'1^&CFUSI(8DD]U[H:OD[W[7?&CJ7=O<*=&]R][838FW,[N[=>WND&ZAE
MW?C-M;9HURF<RL.,[=[<ZBH,R:+$1U%4M)05=57SI2R1PP23O!#-[KW5;_\
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MHS+(1I74RK<\D#GW[KW5&'5/QH[R_F1=^8+Y=_S ^N\WU3\;.D]ZU65^$_P
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MHZBV1L3<M5MK)UF.R&0P%1F=N8;'U\V(K:_$4DTM.SF)Y::-B"44CW7NC?\
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M";_TI3J?_P"RCW[KW7O^'COY3O\ WLA^$W_I2G4__P!E'OW7NO?\/'?RG?\
MO9#\)O\ TI3J?_[*/?NO=>_X>._E._\ >R'X3?\ I2G4_P#]E'OW7NO?\/'?
MRG?^]D/PF_\ 2E.I_P#[*/?NO=>_X>._E._][(?A-_Z4IU/_ /91[]U[KW_#
MQW\IW_O9#\)O_2E.I_\ [*/?NO=>_P"'COY3O_>R'X3?^E*=3_\ V4>_=>Z]
M_P /'?RG?^]D/PF_]*4ZG_\ LH]^Z]U[_AX[^4[_ -[(?A-_Z4IU/_\ 91[]
MU[KW_#QW\IW_ +V0_";_ -*4ZG_^RCW[KW7O^'COY3O_ 'LA^$W_ *4IU/\
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M=L9>GI:F>@GDQ.<P=56XJOAIZREDA<PRNJ2QLALRD#W7NE/[]U[K4Q_DT_\
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MKW7O^@@3^3/_ -[!NBO_ #IW5_\ 8S[]U[KW_00)_)G_ .]@W17_ )T[J_\
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CEX&?<39?<67;<6 JUH*!:O 4M.9S3TLC^N1193S[]U[K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tflow_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tflow_002.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MWMS_ .S;W[KW7O\ AQ7_ (4[_P#>C?IO_P!*;VY_]FWOW7NO?\.*_P#"G?\
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M_P#TIO;G_P!FWOW7NO?\.*_\*=_^]&_3?_I3>W/_ +-O?NO=>_X<5_X4[_\
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M#_[WT?S3O_1MYO\ ^RGW[KW7O^@;#Y!_][Z/YIW_ *-O-_\ V4^_=>Z]_P!
MV'R#_P"]]'\T[_T;>;_^RGW[KW7O^@;#Y!_][Z/YIW_HV\W_ /93[]U[KW_0
M-A\@_P#O?1_-._\ 1MYO_P"RGW[KW7O^@;#Y!_\ >^C^:=_Z-O-__93[]U[K
MW_0-A\@_^]]'\T[_ -&WF_\ [*??NO=>_P"@;#Y!_P#>^C^:=_Z-O-__ &4^
M_=>Z]_T#8?(/_O?1_-._]&WF_P#[*??NO=>_Z!L/D'_WOH_FG?\ HV\W_P#9
M3[]U[KW_ $#8?(/_ +WT?S3O_1MYO_[*??NO=>_Z!L/D'_WOH_FG?^C;S?\
M]E/OW7NO?] V'R#_ .]]'\T[_P!&WF__ +*??NO=>_Z!L/D'_P![Z/YIW_HV
M\W_]E/OW7NO?] V'R#_[WT?S3O\ T;>;_P#LI]^Z]U[_ *!L/D'_ -[Z/YIW
M_HV\W_\ 93[]U[KW_0-A\@_^]]'\T[_T;>;_ /LI]^Z]U[_H&P^0?_>^C^:=
M_P"C;S?_ -E/OW7NO?\ 0-A\@_\ O?1_-._]&WF__LI]^Z]U[_H&P^0?_>^C
M^:=_Z-O-_P#V4^_=>Z]_T#8?(/\ [WT?S3O_ $;>;_\ LI]^Z]U[_H&P^0?_
M 'OH_FG?^C;S?_V4^_=>Z]_T#8?(/_O?1_-._P#1MYO_ .RGW[KW7O\ H&P^
M0?\ WOH_FG?^C;S?_P!E/OW7NO?] V'R#_[WT?S3O_1MYO\ ^RGW[KW7O^@;
M#Y!_][Z/YIW_ *-O-_\ V4^_=>Z]_P! V'R#_P"]]'\T[_T;>;_^RGW[KW7O
M^@;#Y!_][Z/YIW_HV\W_ /93[]U[H,NZ_P#A/9\C>J^FNV^SZ'^>Q_-&RU=U
MQUEOS?E'BZON#.P15,NT,55Y".GE=-T%TCF>G",R@D DCGW[KW5B/_"9SM#L
MSN3^3;\8NP^W^Q-]=J[_ ,WN+Y 19G?/9&[<AOG,5:XKL'<U)2K59/*5%56U
M"TU+!##$'G81Q1I&ED10/=>ZOJ]^Z]U[W[KW6E!_/Z^'/67S_P#YYW\I'XA=
MQYW?>VNM>Y.C>]<?N?-]9Y/'X;.0)M6GW'GJ<T%3E<7F:")GK,53I(9<9.#"
MTBJ$<K(GNO=#%_T!4_RLO^?^?/\ _P#1I]=?_:J]^Z]U[_H"I_E9?\_\^?\
M_P"C3ZZ_^U5[]U[KW_0%3_*R_P"?^?/_ /\ 1I]=?_:J]^Z]U[_H"I_E9?\
M/_/G_P#^C3ZZ_P#M5>_=>Z]_T!4_RLO^?^?/_P#]&GUU_P#:J]^Z]U[_ * J
M?Y67_/\ SY__ /HT^NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /1I]=?_ &JO
M?NO=>_Z J?Y67_/_ #Y__P#HT^NO_M5>_=>Z]_T!4_RLO^?^?/\ _P#1I]=?
M_:J]^Z]U[_H"I_E9?\_\^?\ _P"C3ZZ_^U5[]U[KW_0%3_*R_P"?^?/_ /\
M1I]=?_:J]^Z]U[_H"I_E9?\ /_/G_P#^C3ZZ_P#M5>_=>Z]_T!4_RLO^?^?/
M_P#]&GUU_P#:J]^Z]U[_ * J?Y67_/\ SY__ /HT^NO_ +57OW7NO?\ 0%3_
M "LO^?\ GS__ /1I]=?_ &JO?NO=>_Z J?Y67_/_ #Y__P#HT^NO_M5>_=>Z
M]_T!4_RLO^?^?/\ _P#1I]=?_:J]^Z]U[_H"I_E9?\_\^?\ _P"C3ZZ_^U5[
M]U[KW_0%3_*R_P"?^?/_ /\ 1I]=?_:J]^Z]U[_H"I_E9?\ /_/G_P#^C3ZZ
M_P#M5>_=>Z]_T!4_RLO^?^?/_P#]&GUU_P#:J]^Z]U[_ * J?Y67_/\ SY__
M /HT^NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /1I]=?_ &JO?NO=>_Z J?Y6
M7_/_ #Y__P#HT^NO_M5>_=>Z]_T!4_RLO^?^?/\ _P#1I]=?_:J]^Z]U[_H"
MI_E9?\_\^?\ _P"C3ZZ_^U5[]U[KW_0%3_*R_P"?^?/_ /\ 1I]=?_:J]^Z]
MU[_H"I_E9?\ /_/G_P#^C3ZZ_P#M5>_=>Z]_T!4_RLO^?^?/_P#]&GUU_P#:
MJ]^Z]U[_ * J?Y67_/\ SY__ /HT^NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__
M /1I]=?_ &JO?NO=>_Z J?Y67_/_ #Y__P#HT^NO_M5>_=>Z9]P_\(N?Y7&)
MP&<RM-WU\^GJ,9A\GD($G[1Z[9"]'"\BAPO5BL5+*+@,#;Z$?7W[KW1C?^$@
MO_;G/;/_ (L5WG_UOQ_OW7NMHCW[KW7O?NO=?,D_X3T_\)Z?A?\ S9?A?V=\
MB_D7V=\G]E[VV7\G]Z=*8O%]*;TVIMS%28K;FU-E9V"HJ(,[LK<=6^0>KW'7
M([I7)"84@58%=9))?=>ZO>_Z J?Y67_/_/G_ /\ HT^NO_M5>_=>Z]_T!4_R
MLO\ G_GS_P#_ $:?77_VJO?NO=>_Z J?Y67_ #_SY_\ _HT^NO\ [57OW7NO
M?] 5/\K+_G_GS_\ _1I]=?\ VJO?NO=>_P"@*G^5E_S_ ,^?_P#Z-/KK_P"U
M5[]U[KW_ $!4_P K+_G_ )\__P#T:?77_P!JKW[KW7O^@*G^5E_S_P ^?_\
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MO=>_Z J?Y67_ #_SY_\ _HT^NO\ [57OW7NO?] 5/\K+_G_GS_\ _1I]=?\
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M^Z]U[_H&P^0?_>^C^:=_Z-O-_P#V4^_=>Z]_T#8?(/\ [WT?S3O_ $;>;_\
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M /\ T:?77_VJO?NO=>_Z J?Y67_/_/G_ /\ HT^NO_M5>_=>Z]_T!4_RLO\
MG_GS_P#_ $:?77_VJO?NO=>_Z J?Y67_ #_SY_\ _HT^NO\ [57OW7NO?] 5
M/\K+_G_GS_\ _1I]=?\ VJO?NO=>_P"@*G^5E_S_ ,^?_P#Z-/KK_P"U5[]U
M[KW_ $!4_P K+_G_ )\__P#T:?77_P!JKW[KW7O^@*G^5E_S_P ^?_\ Z-/K
MK_[57OW7NO?] 5/\K+_G_GS_ /\ T:?77_VJO?NO=>_Z J?Y67_/_/G_ /\
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M77_VJO?NO=>_Z J?Y67_ #_SY_\ _HT^NO\ [57OW7NO?] 5/\K+_G_GS_\
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M?NO=:[?_  JK_P"W'GRQ_P##F^.'_OR=J>_=>ZN:^('_ &27\7?_ !77I/\
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MNO=>]^Z]U[W[KW7O?NO=)G>O_'F[M_\ #9SW_N++[]U[K6=_X2"_]N<]L_\
MBQ7>?_6_'^_=>ZVB/?NO=>]^Z]UJ!?\ "*G_ +=9=^?^+_\ :?\ [[KJKW[K
MW6W[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[K51_X4G_\ 90?\A?\ \:G=2?\ N[VM[]U[K:N]^Z]U[W[KW7O?NO=:
MKO\ -8_[B%O^$_\ _P"70?\ NI7W[KW6U%[]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H+>\O\ F2G<'_B+
M>P/_ '4U?OW7NJ ?^$F/_;E3HO\ \2E\@_\ WK,C[]U[K90]^Z]U[W[KW7O?
MNO=>]^Z]UJH]G_\ <7U\=/\ QECG/_=OOOW[KW6U=[]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4"_X4=_]O3?^$Q__ (O_ )'_
M -^+T![]U[H6_P#A3[_W1W_\:M="_P#73W[KW6U%[]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7;_X55_\ ;CSY8_\ AS?'#_WY
M.U/?NO=7-?$#_LDOXN_^*Z])_P#O-8SW[KW1BO?NO=>]^Z]U[W[KW6JC_+J_
M[B=_YY'_ (AOXR?^\YLGW[KW6U=[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HNOR_
M_P"R2_E%_P"*Z]V?^\UD_?NO=4R_\)5/^W'GQ._\.;Y'_P#OR=U^_=>ZV)/?
MNO=>]^Z]UJH_S%?^XG?^1O\ ^(;^3?\ [SF]O?NO=;5WOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z3.]?^/-W;_X;.>_]
MQ9??NO=:SO\ PD%_[<Y[9_\ %BN\_P#K?C_?NO=;1'OW7NO>_=>ZU O^$5/_
M &ZR[\_\7_[3_P#?==5>_=>ZV_??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J/_"D__LH/^0O_ .-3NI/_ '=[6]^Z
M]UM7>_=>Z][]U[KWOW7NM5W^:Q_W$+?\)_\ _P N@_\ =2OOW7NMJ+W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW06]Y?\ ,E.X/_$6]@?^ZFK]^Z]U0#_PDQ_[<J=%_P#B4OD'_P"]9D??
MNO=;*'OW7NO>_=>Z][]U[KWOW7NM5'L__N+Z^.G_ (RQSG_NWWW[]U[K:N]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ!?\*._
M^WIO_"8__P 7_P C_P"_%Z ]^Z]T+?\ PI]_[H[_ /C5KH7_ *Z>_=>ZVHO?
MNO=>]^Z]U[W[KW7O?NO=)[=.:R6W\)6Y7$[1W#OFOI8GD@VUM:IQ-)75)168
M)#)F\IA\:K,0%'FR$2ZF%V"ZF'NO=4I?&G^>CL_Y>?Z4Y>@?Y='\RG?%#T=V
M5E>HNX*^'9/4-!_ -P8!D7(XZHI)^YH\C75%"L@>2/'T59(R@B%)7LI]U[H\
M?PE_F0_$C^8)B]]R?''L.LR.\>ILW)MKN#J#?6V*_KC>>T<C%45-*U)N';67
M@ILC0O\ =4=7")/&\!F@FA$IEAE1/=>Z/7[]U[KWOW7NO>_=>Z+!W=\GMN]4
M=D=1]$8##CL#Y ]\4V^\GUCUG#G(=NH^,ZSI(JO.YW,Y&2*J.)P>/^ZH:=JD
M453)+65=-304\LDC:/=>Z+I\-?G[OCY#]\_(/XI=Z_$OL[XM_(/XX8K:&X]S
MK6YE>SMA;BQ6^&G6@R>R=\QXS!'.TQ$2^45& Q\L;L\/C-12UT5+[KW5E7OW
M7NO>_=>Z][]U[J%3Y+'5E5D*&DKZ*JK<3-!3Y6CIZJ.>6FDJHDGB2HC5B\+R
M021R*' +(RN 58$^Z]U(GD>*":6."6JDBBDD2F@**\A0$A$,KQQAW(L-<BK<
M^IE%R/=>ZI]Q_P#.K^.5+_,AVY_*V[/Z:^3/1GR2WKCJC*;%R_9^W=FS[2S4
M)QM7EJ)J#-;:WQN.<_Q6EH*U:7S8Z$&IA:CG,%44A;W7NKA_?NO=53?S(OYP
MGQ>_EA[G^/'7W<NU>ZNTNTOE!N:NVQU1U=T'MG";GS$[T-1047W59_']Q;9Q
MM'25&1RE#24Y;(F6>>1_%$T5/52P^Z]T:'Y*_(SM7I#XC]I?(O87Q)[E[N[4
MV'LQ-R;=^*.V,CA9-VYNKDEI8CCH9\'6[GH&>D2HEGJ?X><I5-!33C'462JC
M34M3[KW0Z=1;US?9/5'6?8FYNO\ <_4^X]^; V?O'/=7;U\/\8VY6;FQ]/6U
M."ROV[O!_$<3-,]+4:&*^:)[6^@]U[H1/?NO=>]^Z]T5GYH?**G^&7QM[8^2
M^3ZA[2[HVWTYLG</86\-L=2# G)4^'VG3O69/)R?W@S>#I?LL;11SU53X9YZ
MD4\,K04M1(JQ/[KW4OX8?).A^8GQ2Z ^4V,VG5;$QO??5^U^S\?LZNRZ9Z?'
M0;I@%1%2S5D=/2QU$L<;*'98$75< $ $^Z]T9OW[KW7O?NO=>]^Z]U[W[KW7
MO?NO=:[?_"JO_MQY\L?_  YOCA_[\G:GOW7NKFOB!_V27\7?_%=>D_\ WFL9
M[]U[HQ7OW7NO>_=>Z][]U[K51_EU?]Q._P#/(_\ $-_&3_WG-D^_=>ZVKO?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]UKQ?S$?Y@/\ ,5^,?\RC^7S\,NC9?A_G>M_G
MIG=VXBCW-V3T+O;-9O:R=<34<V<F>3$]J8NBS07$UT<T(&/H LD;"5C&VM/=
M>ZV =MT^Y:7"T,&[\M@\YN&.(#)93;>WJC:M%*_^J@H*K*9F>G7_ &ELE,?]
MJ]^Z]T _S"VS\HMY?&;N+:_PL[*Z^Z?^4F:VH]'TUV5VIMMMV8'$Y0U$#//7
M40I:]27HEJHH)I,7D(:6IDAJI\;DH89*"H]U[H4.HL?V;B>J.L\7W7N#;&[.
MX\=L#9]#VMNG96)EP.'R6Y*3'T\>;KL513L\U)CJO)+4RT\3MJCA9%8 BP]U
M[H1/?NO=5V?S6.[OD7\9O@7\E?D;\9<_UE@^P>B^J-W=HE.S^N\AV-2UE-M&
M 5512TT%!N# BBJWIDJ&CJI_O8(G5/+12QERONO=+W^6YW)V!\B/Y?WPO[Y[
M7R\&?[-[C^,O3'96_LW2XNFPD55E]YX&AKZ^>.CHHH*2ECDJ9Y"L4,*1H"%5
M0![]U[HZWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJR/G9_,;H/BUV
M7T'\5>FNLJSY&?-_Y6Y#,T?1_1M!GX]JXVBQNW(FERN\M\9UH:L[=V?B(TD:
M6:.AJZZL,4T6/HZ@P5+T_NO="1A>L_YBTF'.7W+\LOC33[UEDK*U-J[?^(N7
MJ-K4_D=FI\>\M5V8FX:Z&&,I'+6+D*.2=P9TI:93]L/=>Z;OAK\@?D_VGVC\
MK>I_E3TSM#I[=_06[>N\3LZ;KO=U1OG ;KV]O?%U%=1[MQ5?6X[%9"&+(5-/
M64TM!44;/05%%+!]S4-K9?=>ZK\^/_S9^:6X/^% /R)_E]=Q=@=69GX[=8_
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MD@#W[KW0>=,=N[([]ZFZY[MZTR3YGKSM;9V!W[LC,/&(ON\7N>G2KH:H*K.
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M_P#;HS&2P2;@P%#18_/XS"5T_@Q]544U16)X'%16UBLOC]U[HOG;WRD^7?\
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MZ][]U[KWOW7NO>_=>ZU O^%'?_;TW_A,?_XO_D?_ 'XO0'OW7NA;_P"%/O\
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MI>XJ?#8#%56?6B:KGQ<1J:>KE<U,,2I!"\TCI"DDL?NO=7H[J_G=_P HO9^
MK]QY/^8I\3:^BQU%45TM'M7N+$[TKY%IHS(4I\9B)ZW(5$S!;)%'3,[N0BJ6
M('OW7NJ_/YLGRSVAW1_PGP^4GR$W=N+![ P/RKZ8JMR_'C:VZLE3X.OKMN[U
MS.-&R8:>GG%/55>8SVW_ .&YBJI42=Z.?(3TJ2RTM+'.WNO=!MW!W;TW2_\
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MW>]]@_&/^?MLWY.="Q]O;:W%\8N@<UN3JS"YOK/>^.SM74=K0X<WWG/'233
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H+>\O\
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MN";'-44S9NM:JS/@JJR!:]8:NHCD]U[HV/OW7NO>_=>Z][]U[KWOW7NM=O\
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MYK)^_=>ZIE_X2J?]N//B=_X<WR/_ /?D[K]^Z]UL2>_=>Z][]U[K51_F*_\
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M8<#CW[KW4#&;=V_A)JVHPV"P^(GR4B39&?&8R"@>H>-0BO,T2(TK*BJH+$D
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MK*W([<VEMG 9#) C(UV$P-+BIJC4YD/GE@BC>6[DMZF/JY^OOW7NE-[]U[K
ME+2Q5$]7'301U54D$=34I"J22+3:O&LC@:G$>M]().G4;6N??NO=9_?NO=>]
M^Z]TTY? X//PPT^=PN)S=/3SQ54$&7QT.21)8&5TD19D=5D1U5E8 $$ @W ]
M^Z]T[>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[H+>\O^9*=P?\ B+>P/_=35^_=>ZH!_P"$F/\
MVY4Z+_\ $I?(/_WK,C[]U[K90]^Z]U[W[KW7O?NO=>]^Z]UJH]G_ /<7U\=/
M_&6.<_\ =OOOW[KW6U=[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[K4"_P"%'?\ V]-_X3'_ /B_^1_]^+T![]U[H6_^%/O_ '1W
M_P#&K70O_73W[KW6U%[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[K7;_ .%5?_;CSY8_^'-\</\ WY.U/?NO=7-?$#_LDOXN_P#B
MNO2?_O-8SW[KW1BO?NO=>]^Z]U[W[KW6JC_+J_[B=_YY'_B&_C)_[SFR??NO
M=;5WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J'D,A08FAJLGE:ZCQF-H8)*J
MNR&0J4HX(8H1=Y)99&6..-1R69@ .2??NO=$9R7\U#^6'ALC7X?,?S'?@;BL
MMBJVJQN4Q>2^7W7M#44U10R-%/3U$$NX5EAGAE5D='4,C JP!!'OW7NE%L'^
M9!_+O[6WEM[KKJ[YZ?"_LGL'=V1CQ&U-B;!^4>Q]XYG*5<H9DI<=B\=G:FNK
M:AE5B(X8'<@$A>#[]U[HZ'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NBR](?,GXP_)'LSY#=.=&]R;5[([+^*.^*/K?Y![3P'W
M7GVUFZY:G10U,D]/#3U16:AR%-++1S5$,-;1UM!-(E;1U,$7NO=&:]^Z]U[W
M[KW7O?NO=>]^Z]T6'N3YM_##XZ9RCVQ\@_EU\8>B=RY&":JQ^WNY._-J=85T
M\5.4$DD-)F\M0U$L:&2/4RQD#4MR-0O[KW0T[![*ZZ[6V]2[NZNW]LKLG:E:
M%:BW/L'=5#O''3!@&!BK<=/4TT@*D$:93P;^_=>Z6OOW7NO>_=>Z1O8'8O7_
M %/L_/=A=I;YVAUML':N.J<ON;>V_-R4>T<3CJ6B1I)JFNR.0FIZ.E@BC5F9
MY9E55!)( ]^Z]T@/CQ\E>BOECUM3]P_'+LO;W;G5]9G]R;9Q^^MJ--/C:JLV
MC5R4&02CJ)H85K(8*N&2,3P^2GETEH99%]7OW7NAQ]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]T77Y?_P#9)?RB_P#%=>[/_>:R?OW7NJ9?^$JG_;CS
MXG?^'-\C_P#WY.Z_?NO=;$GOW7NO>_=>ZU4?YBO_ '$[_P C?_Q#?R;_ /><
MWM[]U[K:N]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW29WK_QYN[?_  V<]_[BR^_=>ZUG?^$@O_;G/;/_ (L5WG_UOQ_O
MW7NMHCW[KW7O?NO=:@7_  BI_P"W67?G_B__ &G_ .^ZZJ]^Z]UM^^_=>Z][
M]U[KWOW7NH>0KH<90U60J4K)(*."2HFCQ^/J,M.5B%R(J:EBFJ9Y"/HD43NQ
MX52>/?NO=5P=8_S=O@7W%\F-W?#CKOLGM3.?)S8%-E:_?73E3\2>X-O97#4N
M&>CCGK<K_$]A4=+CZ -D<=XZJ>H2GF%72F&61:F O[KW5E?OW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)1V%\]>E^M/G
M'T%_+^W!M_MRH[K^1W5_87;.Q-QX;K>KR6T(,?UN)VK:;*;B#K!39"1*2I98
MHH9TI[4RY"6B?*8A<A[KW1U_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5=W4
M_P#- ^,'=OSL[$_EX=?)VS5=_P#4_3.7[P[!EW1U/ENNL-C\7C,EM?&Q4ZS[
MBBQ63KZO(G=N.J:.6BQ-3CIZ6.HE^_4BG2H]U[JQ'W[KW08]Q]U=1_'KKO<7
M;?>79&S.I^L]I4AK-Q;WWYGZ?;>.I4YTJ]14NBM-*PTQ0IJEF<B.)'=@I]U[
MHL&!_F&]+;APT6[Z/K?Y<T_7=550P478V2^&'9]!C9HJFMCH(\@*>3:PS4.'
M:603'(S8F*ACH@^2EJ(\>IJA[KW0U_'_ .5?QW^55#O[+_'/M[8W<^!ZSWK'
MUWN_<O7>?I]U8RGS+8G&9J2@3(4;RTD]13467HQ4)',S4]1Y::<1SPR1K[KW
M1@O?NO=>]^Z]U[W[KW7O?NO=!EV_V]LKHS8&XNSNP_[X)L_:>*R&;W!5;)ZT
MW+VO64])BH7J*FH_A&U,1FLO+'##&[L8J![ 'W[KW17/AM_,M^''\P'"Y#='
MQ%["WUVYM#%YFJV[7;V3X\=D[&P25]%%%/-1?QS<NT<-B7JH8IX6>):PNHD3
M4 6%_=>Z/A[]U[KWOW7NO>_=>Z(/@/YDOQEW3\YZC^7=@:GLZ?Y(XWK#-=O9
MK'9GJ7.[*P]+@\/+1PK5Q9?/4>+@S$-9+6JE//B4R%(TD51%)4QRT\J+[KW1
M^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJH_\*3_ /LH/^0O_P"-3NI/_=WM;W[K
MW6U=[]U[KWOW7NO>_=>ZU7?YK'_<0M_PG_\ _+H/_=2OOW7NMJ+W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]T3"I_F+_ NBW;D-CUGS"^.E)N3$[RI>N,K2U/
M;&&@@IMQ5[1+!M^HKWJACX<[,\\*)CWJA5N\B(L)=E!]U[HR47:G6<VV=Q[U
M7?\ LY=F;0J*^EW1O";<=)3XJ@?%)')5?=9&25:.%:994\K-,%C)*N0P8#W7
MN@B^,GS*^+_S-Q'8>X_BSW1M#O+;'5F_Y>L-Y[MV#+493#Q9N'&8W,/24.6,
M"8[,Q)C\O0.:K'5572!Y&@,_W$,\4?NO=&:]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW2"[-[4ZRZ6V5G.R>X.PME=6=>[9I9*[<.^.PMT46SL3111@L7JLAD)J>EA
M%E-M4HO]!<^_=>Z0WQN^3717R\ZHQ7>?QO[#QG:G4N=SN\]N8/?.$H*Z@HZV
MJV!EZW!93[3[^EI):FEAR>/JXXJJ.)J6K1%J*2:>FEBF?W7NAV]^Z]U[W[KW
M3!NG=>U]C;>R^[MZ[DP&S]J8"CDR.>W/NG,4^W\=14\5M<]76U<D--30K<7>
M255%^3[]U[H"/B_\Q?C)\T]J[YWU\5^X=K=W[)ZY[*RG4.Z]X[*%558I-P8;
M%X?-5-%19":GAI,O%%C<]BI?NZ":IHF:9H5J#/!411>Z]T,G8'8O7_4^S\]V
M%VEOG:'6VP=JXZIR^YM[;\W)1[1Q..I:)&DFJ:[(Y":GHZ6"*-69GEF554$D
M@#W[KW2 ^/'R5Z*^6/6U/W#\<NR]O=N=7UF?W)MG'[ZVHTT^-JJS:-7)09!*
M.HFAA6LA@JX9(Q/#Y*>726AED7U>_=>Z''W[KW7O?NO=>]^Z]U[W[KW16NV?
MD!!A>].G_BGL:MI#W/W#M;?W:57-54$V1CV_L3JJ?%4.>W')&D9IY*R7,[@V
M]BL;!4311O55[UC+508ZHHY_=>Z"OYL_(OM[XY9?X=T^P:'8>4VWWE\Q>BOC
MAV#7[OIJVNR<>/[+FKFJJK%14<M#14]6D.-9!+-YX[U!*TR&%3)[KW0L_*3O
M*I^,.R8N_-Q56-?I/963P5/WFF1$5#)A,!G*^"AGW?35SRPHE+MLU:UF6@F6
M42XN&>:E,-33>*M]U[HSD4L4\4<\$D<T,T:2PS1.)%=9 "K*P)#*P(((-B.1
M[]U[K)[]U[KWOW7NO>_=>Z][]U[H+>\O^9*=P?\ B+>P/_=35^_=>ZH!_P"$
MF/\ VY4Z+_\ $I?(/_WK,C[]U[K90]^Z]U[W[KW7O?NO=>]^Z]UJH]G_ /<7
MU\=/_&6.<_\ =OOOW[KW6U=[]U[KWOW7NO>_=>Z][]U[KWOW7N@>[V[^Z=^,
MW7&5[:[TW[A>N]A8BKQ>+ES.7,L[U-=GITI<=C,=14T<]?E<MDJJ2."CH:.F
MGJZJ9EB@AD<A??NO=%$SO\U7XB=?8:AW/WKD.YOB_M#+X'^\6%WQ\H?CGOGH
M7 5,+&)4I6SVXL#18>@S,QGB$.(KZVDRTVH^*A?1)H]U[J1\Z?YH?Q=_EX_'
MK'?)3Y KVY4;#SV-Q%9MJEZXZAS.^)ZVHW%325.-QTN0B@BVUA*[(B-HZ89G
M/XV"64:!/P2/=>ZL%Q61@R^+QN6IEE2FRE!1Y&G2=0KA*V-94#A690X5A<!B
M+_0GZ^_=>ZG^_=>Z][]U[KWOW7NO>_=>Z][]U[JO3YB?S./C+\'^Q/C]U/W+
M#VY5[^^37;^P.E.I\9LSJ3,9;'567[ RV,Q49J-SU<./VE3IC?XK!5UM.<\V
M16B266FH:F0)"_NO=6%^_=>Z][]U[KWOW7NJ[OYC'\T#XP?RO.IH>W_DTG;,
M^#R-;#A]O8WK'J?+;VDR&0JXJN:FQJY;Q4FUL97U:4-48(\KN''^41LR,45F
M'NO=6(^_=>Z)'\\/Y@WQQ_EQ=,5W>_R9K>Q<=L2CJZ/&)4[!ZHW!V,6K,FS1
MT=-4U6+H)L3AC6S@0039;)8^EDJ'B@%1YI8D?W7NC@;8S]'NS;6WMTXZ*IAQ
M^Y<'B<_0PUJ)',D.9IXZB)9EC>1%E5)%#!9&4-<!F')]U[I\]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:@7_"CO_MZ;_PF/_\ %_\
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7;_ .%5?_;CSY8_^'-\</\
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M[BP5-2;<E6#<-349:GACH'9(Y E:[2!:5S'+$X$I4Z75OHP)]U[KJ'=&V:G
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M<'E=@8[)1IDVR4&RV9*6CIJRHG=2-(DABE)'B%_=>Z(O_,\P>(W#_P *$O\
MA/[C]P8VAS=%%BOF-F4ILG0I/']YMS:YR-!5>*12$GI*^EIJB$VU131(ZV9
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MYK)^_=>ZIE_X2J?]N//B=_X<WR/_ /?D[K]^Z]UL2>_=>Z][]U[K51_F*_\
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MA"]]5/ 8_=>Z37_"@_X,_'#JK^4=V=\V-H[&BC^9O1&5^*?96Q_ECE*I\CV
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MZ][]U[KWOW7NO>_=>Z][]U[H+>\O^9*=P?\ B+>P/_=35^_=>ZH!_P"$F/\
MVY4Z+_\ $I?(/_WK,C[]U[K90]^Z]U[W[KW7O?NO=>]^Z]UJH]G_ /<7U\=/
M_&6.<_\ =OOOW[KW6U=[]U[KWOW7NO>_=>Z][]U[KWOW7NB6_+'X)=-?,C='
M1&[^T\QV=@=P_&W<VX=^]09_JKL3)=99/$;BSL=#3)F8LCBIH:B62FH::KIO
MM9S-0U$-;.E733@1A?=>Z!OM+^7=O7Y!["_T(_([YT?)KMWX^9?&5> [,ZRA
MPFP>J*S?.+JZ<TTF*W9N;9FT,!FOX?5(S&KBPDN#-7<QRL8&>%_=>Z[^=/\
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M_A)C_P!N5.B__$I?(/\ ]ZS(^_=>ZV4/?NO=>]^Z]U[W[KW7O?NO=:J/9_\
MW%]?'3_QECG/_=OOOW[KW6U=[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[K4"_X4=_\ ;TW_ (3'_P#B_P#D?_?B] >_=>Z%O_A3
M[_W1W_\ &K70O_73W[KW6U%[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[K7;_P"%5?\ VX\^6/\ X<WQP_\ ?D[4]^Z]U<U\0/\
MLDOXN_\ BNO2?_O-8SW[KW1BO?NO=>]^Z]U[W[KW6JC_ "ZO^XG?^>1_XAOX
MR?\ O.;)]^Z]UM7>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+K\O_P#LDOY1?^*Z
M]V?^\UD_?NO=4R_\)5/^W'GQ._\ #F^1_P#[\G=?OW7NMB3W[KW7O?NO=:J/
M\Q7_ +B=_P"1O_XAOY-_^\YO;W[KW6U=[]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDSO7_CS=V_\ ALY[_P!Q9??NO=:S
MO_"07_MSGMG_ ,6*[S_ZWX_W[KW6T1[]U[KWOW7NM0+_ (14_P#;K+OS_P 7
M_P"T_P#WW757OW7NMOWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW6JC_P *3_\ LH/^0O\ ^-3NI/\ W=[6]^Z]UM7>
M_=>Z][]U[KWOW7NM5W^:Q_W$+?\ "?\ _P#+H/\ W4K[]U[K:B]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]T%O>7_,E.X/_$6]@?\ NIJ_?NO=4 _\),?^W*G1?_B4OD'_ .]9D??NO=;*
M'OW7NO>_=>Z][]U[KWOW7NM5'L__ +B^OCI_XRQSG_NWWW[]U[K:N]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ!?\*._^WIO_
M  F/_P#%_P#(_P#OQ>@/?NO="W_PI]_[H[_^-6NA?^NGOW7NMJ+W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6NW_P *J_\ MQY\
ML?\ PYOCA_[\G:GOW7NKFOB!_P!DE_%W_P 5UZ3_ />:QGOW7NC%>_=>Z][]
MU[KWOW7NM5'^75_W$[_SR/\ Q#?QD_\ ><V3[]U[K:N]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]T77Y?_P#9)?RB_P#%=>[/_>:R?OW7NJ9?^$JG_;CSXG?^'-\C
M_P#WY.Z_?NO=;$GOW7NO>_=>ZU4?YBO_ '$[_P C?_Q#?R;_ /><WM[]U[K:
MN]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW29WK_QYN[?_  V<]_[BR^_=>ZUG?^$@O_;G/;/_ (L5WG_UOQ_OW7NMHCW[
MKW7O?NO=:@7_  BI_P"W67?G_B__ &G_ .^ZZJ]^Z]UM^^_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4?^%)__ &4'
M_(7_ /&IW4G_ +N]K>_=>ZVKO?NO=>]^Z]U[W[KW6J[_ #6/^XA;_A/_ /\
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M .\HOCK_ .CLVU_]<_?NO=>_V;_XE_\ >47QU_\ 1V;:_P#KG[]U[KW^S?\
MQ+_[RB^.O_H[-M?_ %S]^Z]U[_9O_B7_ -Y1?'7_ -'9MK_ZY^_=>Z]_LW_Q
M+_[RB^.O_H[-M?\ US]^Z]U[_9O_ (E_]Y1?'7_T=FVO_KG[]U[K4V_X4*=\
M=';V_F;_ /";G/[-[EZIW;@MB?.ZOS&]\WMCL3$9ZDPU(W8'1$PJLK4TM9+#
MCJ8PT=7)Y:AXTT03-JTQ.5]U[JUC^?O_ "^_E]\]NMOAXOPP/52=I_&CY6;<
M^0ZOV]N.?;V+_P!^=057V*G[>DJY:HG(M3>2$",-")/W5-K^Z]T5C_MKS_\
M!4O_ *W_ '[KW7O^VO/_ ,%2_P#K?]^Z]U[_ +:\_P#P5+_ZW_?NO=>_[:\_
M_!4O_K?]^Z]U[_MKS_\ !4O_ *W_ '[KW7O^VO/_ ,%2_P#K?]^Z]U[_ +:\
M_P#P5+_ZW_?NO=>_[:\__!4O_K?]^Z]U[_MKS_\ !4O_ *W_ '[KW7O^VO/_
M ,%2_P#K?]^Z]U[_ +:\_P#P5+_ZW_?NO=>_[:\__!4O_K?]^Z]U[_MKS_\
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MJ7_UO^_=>Z]_VUY_^"I?_6_[]U[KW_;7G_X*E_\ 6_[]U[KW_;7G_P""I?\
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M\!N^?Y;/\OC$?&7Y''93=DX[M[LS>DS[ W%)NC'-1;MDHY*0I52TE%(90(I
MZ&G&DC@L"#[]U[J['W[KW7O?NO=:+O\ +A_EK_\ "F7^5KT?NKX_?&&3^7-)
ML'>':N<[CR[=D;HS.[*[^,;@Q&#PE0(JF&AH$2D^RV]C],9A)$GE;60X5?=>
MZL _[:\__!4O_K?]^Z]U[_MKS_\ !4O_ *W_ '[KW7O^VO/_ ,%2_P#K?]^Z
M]U[_ +:\_P#P5+_ZW_?NO=>_[:\__!4O_K?]^Z]U[_MKS_\ !4O_ *W_ '[K
MW7O^VO/_ ,%2_P#K?]^Z]U[_ +:\_P#P5+_ZW_?NO=>_[:\__!4O_K?]^Z]U
M[_MKS_\ !4O_ *W_ '[KW7O^VO/_ ,%2_P#K?]^Z]U[_ +:\_P#P5+_ZW_?N
MO=>_[:\__!4O_K?]^Z]U[_MKS_\ !4O_ *W_ '[KW7O^VO/_ ,%2_P#K?]^Z
M]U[_ +:\_P#P5+_ZW_?NO=>_[:\__!4O_K?]^Z]U[_MKS_\ !4O_ *W_ '[K
MW7O^VO/_ ,%2_P#K?]^Z]U[_ +:\_P#P5+_ZW_?NO=>_[:\__!4O_K?]^Z]U
M[_MKS_\ !4O_ *W_ '[KW1&?D;_,)_X4Z?%SY*_$/XI=G)_+?;M/YM;AW;MC
MI=MM[;S66Q@J=EG&BL_C%8]93O01WRM+XV2GGU>NX72+^Z]T>;_MKS_\%2_^
MM_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4
MO_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_
M .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\
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M]=?_ &JO?NO=>_Z J?Y67_/_ #Y__P#HT^NO_M5>_=>Z]_T!4_RLO^?^?/\
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MV3_]E?OW7NO?] JG\CS_ +Q.W-_Z4?V3_P#97[]U[KW_ $"J?R//^\3MS?\
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MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5'^=-_P!OOO\
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MCZ.:HF3%XN?,U3QP N8X*:DBFJJB0V],443NS6"J2??NO=:P&Q/GO\.?D_\
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M6N_M; _SXNJ.V_D5OW:/Q@_ET=E9/N/M?/YB#LS?'R%W?MO,S[2VY5U=+L7
M2T%+@:ZFQE%M[ 21H*2GJY(6R%3D\BS/5Y&KFE]U[JJ_^25O#^8N?YQG\XLU
MW3'QCB?<_P B_C$OSG%)VAFJC^ZJ10;^&-/7H?'1#<7F23)FH->U(8O% 8UE
M+LGOW7NKBMQYK#_S'OYI_P PO@1\A=L09_X??!KHKX_9O+=#;HQ:MB.S-Y?)
M*DESU/NC-7D+9G [(QU)!28NA*)3T^X'J,I,)JVAQ4E%[KW1'/A/T3W'_)9_
MF^=9_P N_JW?>[.U/Y;'\PC9/R"[:Z$ZXW-556Y*_J3<?3-!_'\Y3?>S3.8\
M!4++34<=4UWKY\C0+5*V1I:FOR'NO=;1.\^L.J]\U6*SG8?7G7^\*W:K-6X/
M,;SVECMP2XTPLLQFI*BNIYGHRKQJY>-TL5#7N 1[KW1.^AFB^7/:U!\RJZMH
M<UT3LZCS& ^$F/IP\U-D:;.0O19_MAF8^"HDW33F3';9GC1A#MDU%?35#1[I
MJ8(?=>ZH+VK\F.]?E)\#/Y\?SOW'VOV#LOO3X;?*?Y@]:_$O(;!WADMNX[8^
M"^'6V]O9W;=)18:.K.'KY<S65=4=Q25U!4C-+,]/5HU#'34=/[KW6RE\'._,
MK\J?AG\5/DKGL-3;=SW?/Q[ZB[:SV"HIS504E=OS!4.2K*>"0I&7@BJ:B58V
M,:DH%)53<#W7NC3>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K51[/\ ^XOKXZ?^,L<Y_P"[???O
MW7NMJ[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5<_)7^57U'
MW=\I=I_.7K/N'N[X@_+O;&TZC8.9[Q^/%;MI:C<FWG2)4Q&ZL/N[;>Z=OYJE
MI?MJ;PM-C!(JPPI(\D<$"Q>Z]U3Q\+?CQD_G+_/.WW_,%AWMVWVS\5?Y>'6V
M4^,/0W=W9^YUSE-V'V;D8,OC-Z9O;M/CH,5MRGP^ AS68Q]5_!\'2XJ:OAHJ
MBGC:I6I:/W7NMLWW[KW6L)_+1VA7="_\*#OYX/66\VIL?FOD+LKXT?*'JJ&H
MR,/FR^V(?XE1Y/(4=.I\KTV-SF>7'U#,JF*>-5(998I']U[K)_,&V15_(C_A
M1E_)PZTVRXR,_P 6^D/D3\M>U:;SL%Q6 RT\>%PM<XC.H-7[FQ-%1J#969X]
M=TN#[KW6R7OW>VV^M-C;T['WED8<1M#K_:>XM[;JRU1(D4=+C=J4<U?75#M(
MR(J04L$KDLZJ I)('/OW7NJYOY0.Q=R8WX;8COKL3%5.)[>^<?8?87SB[1I,
MCCQCJVEG^15;_%-N8>MCTJXGVSL=-K84AU4J,>%$<2@1K[KW5@N\^L.J]\U6
M*SG8?7G7^\*W:K-6X/,;SVECMP2XTPLLQFI*BNIYGHRKQJY>-TL5#7N 1[KW
M1.^AFB^7/:U!\RJZMH<UT3LZCS& ^$F/IP\U-D:;.0O19_MAF8^"HDW33F3'
M;9GC1A#MDU%?35#1[IJ8(?=>ZH+VK\F.]?E)\#/Y\?SOW'VOV#LOO3X;?*?Y
M@]:_$O(;!WADMNX[8^"^'6V]O9W;=)18:.K.'KY<S65=4=Q25U!4C-+,]/5H
MU#'34=/[KW6RE\'._,K\J?AG\5/DKGL-3;=SW?/Q[ZB[:SV"HIS504E=OS!4
M.2K*>"0I&7@BJ:B58V,:DH%)53<#W7NC3>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z"WO+_F2G<'_B+>P/_=35^_=>ZH!_X28_]N5.B_\
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU7?\
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MYDOS^Z(J>Y*G#UF[NI-M;PV-VKLJEEQ5.E*9,!MWLK8F]\?@&E@C0'[6%=)
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M/OW7NO?[)O\ \+)/^]L7P _]%S@O_N:??NO=>_V3?_A9)_WMB^ '_HN<%_\
M<T^_=>Z]_LF__"R3_O;%\ /_ $7."_\ N:??NO=>_P!DW_X62?\ >V+X ?\
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MR3_O;%\ /_1<X+_[FGW[KW7O]DW_ .%DG_>V+X ?^BYP7_W-/OW7NO?[)O\
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MO?[)O_PLD_[VQ? #_P!%S@O_ +FGW[KW7O\ 9-_^%DG_ 'MB^ '_ *+G!?\
MW-/OW7NO?[)O_P +)/\ O;%\ /\ T7."_P#N:??NO=>_V3?_ (62?][8O@!_
MZ+G!?_<T^_=>Z]_LF_\ PLD_[VQ? #_T7."_^YI]^Z]U[_9-_P#A9)_WMB^
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MW[KW7O\ 9-_^%DG_ 'MB^ '_ *+G!?\ W-/OW7NO?[)O_P +)/\ O;%\ /\
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M]%S@O_N:??NO=>_V3?\ X62?][8O@!_Z+G!?_<T^_=>Z]_LF_P#PLD_[VQ?
M#_T7."_^YI]^Z]U[_9-_^%DG_>V+X ?^BYP7_P!S3[]U[KW^R;_\+)/^]L7P
M _\ 1<X+_P"YI]^Z]U[_ &3?_A9)_P![8O@!_P"BYP7_ -S3[]U[KW^R;_\
M"R3_ +VQ? #_ -%S@O\ [FGW[KW7O]DW_P"%DG_>V+X ?^BYP7_W-/OW7NO?
M[)O_ ,+)/^]L7P _]%S@O_N:??NO=>_V3?\ X62?][8O@!_Z+G!?_<T^_=>Z
M]_LF_P#PLD_[VQ? #_T7."_^YI]^Z]U[_9-_^%DG_>V+X ?^BYP7_P!S3[]U
M[KW^R;_\+)/^]L7P _\ 1<X+_P"YI]^Z]U[_ &3?_A9)_P![8O@!_P"BYP7_
M -S3[]U[KW^R;_\ "R3_ +VQ? #_ -%S@O\ [FGW[KW7O]DW_P"%DG_>V+X
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M]%S@O_N:??NO=>_V3?\ X62?][8O@!_Z+G!?_<T^_=>Z]_LF_P#PLD_[VQ?
M#_T7."_^YI]^Z]U[_9-_^%DG_>V+X ?^BYP7_P!S3[]U[KW^R;_\+)/^]L7P
M _\ 1<X+_P"YI]^Z]U[_ &3?_A9)_P![8O@!_P"BYP7_ -S3[]U[KW^R;_\
M"R3_ +VQ? #_ -%S@O\ [FGW[KW7O]DW_P"%DG_>V+X ?^BYP7_W-/OW7NO?
M[)O_ ,+)/^]L7P _]%S@O_N:??NO=>_V3?\ X62?][8O@!_Z+G!?_<T^_=>Z
M]_LF_P#PLD_[VQ? #_T7."_^YI]^Z]U[_9-_^%DG_>V+X ?^BYP7_P!S3[]U
M[KW^R;_\+)/^]L7P _\ 1<X+_P"YI]^Z]U[_ &3?_A9)_P![8O@!_P"BYP7_
M -S3[]U[KW^R;_\ "R3_ +VQ? #_ -%S@O\ [FGW[KW7O]DW_P"%DG_>V+X
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M]%S@O_N:??NO=>_V3?\ X62?][8O@!_Z+G!?_<T^_=>Z]_LF_P#PLD_[VQ?
M#_T7."_^YI]^Z]U[_9-_^%DG_>V+X ?^BYP7_P!S3[]U[KW^R;_\+)/^]L7P
M _\ 1<X+_P"YI]^Z]U[_ &3?_A9)_P![8O@!_P"BYP7_ -S3[]U[KW^R;_\
M"R3_ +VQ? #_ -%S@O\ [FGW[KW7O]DW_P"%DG_>V+X ?^BYP7_W-/OW7NO?
M[)O_ ,+)/^]L7P _]%S@O_N:??NO=>_V3?\ X62?][8O@!_Z+G!?_<T^_=>Z
M]_LF_P#PLD_[VQ? #_T7."_^YI]^Z]U[_9-_^%DG_>V+X ?^BYP7_P!S3[]U
M[KW^R;_\+)/^]L7P _\ 1<X+_P"YI]^Z]U[_ &3?_A9)_P![8O@!_P"BYP7_
M -S3[]U[KW^R;_\ "R3_ +VQ? #_ -%S@O\ [FGW[KW7O]DW_P"%DG_>V+X
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M+_TGS=G_ -;O?NO=>_Z"SOY*G_/].TO_ $GS=G_UN]^Z]U[_ *"SOY*G_/\
M3M+_ -)\W9_];O?NO=>_Z"SOY*G_ #_3M+_TGS=G_P!;O?NO=>_Z"SOY*G_/
M].TO_2?-V?\ UN]^Z]U[_H+._DJ?\_T[2_\ 2?-V?_6[W[KW7O\ H+._DJ?\
M_P!.TO\ TGS=G_UN]^Z]U[_H+._DJ?\ /].TO_2?-V?_ %N]^Z]U[_H+._DJ
M?\_T[2_])\W9_P#6[W[KW7O^@L[^2I_S_3M+_P!)\W9_];O?NO=>_P"@L[^2
MI_S_ $[2_P#2?-V?_6[W[KW7O^@L[^2I_P _T[2_])\W9_\ 6[W[KW7O^@L[
M^2I_S_3M+_TGS=G_ -;O?NO=>_Z"SOY*G_/].TO_ $GS=G_UN]^Z]U[_ *"S
MOY*G_/\ 3M+_ -)\W9_];O?NO=>_Z"SOY*G_ #_3M+_TGS=G_P!;O?NO=>_Z
M"SOY*G_/].TO_2?-V?\ UN]^Z]U[_H+._DJ?\_T[2_\ 2?-V?_6[W[KW7O\
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MIXY8_)%(Z-I<:D9E-P2/?NO=6>?RG?\ MUE_+3_\4 ^&_P#[[K;GOW7NC_\
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[K4"_X4=_]O3?^$Q__ (O_ )'_ -^+T![]U[K;]]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_PJ._[<4?.;
M_P MF_\ ?Q=?>_=>Z/\ _P IW_MUE_+3_P#% /AO_P"^ZVY[]U[H_P#[]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZU O\ A1W_ -O3?^$Q_P#XO_D?_?B] >_=>ZV_??NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=0<GCJ?+4%5C:J2NB
MIZN/Q2R8S*5.%G )!O%54<T%5 W'ZHYD;\7L3[]U[KYS7:W<ORAP7_"I6D^"
M&,^;7SRI/BGD?E1U3CY^HX/F_P!J1T0QV\MHX;=-;B8Y_P"]IK8\:^1KIT6%
M:D".F(IXRD2JH]U[KZ%;[XZNV%IVKE>Q=LXBMQB+Y*#=_8<=7D4%7^^IJ)<K
M72U\FM9 R&61O05"G0% ]U[IWJ.Q.OZ3"T&Y:K?6SJ;;F5GEI<9GZC<]%#15
M,L#2+)'!5-.()I$:*4,J2$@HX(NIM[KW3Q'N/;TV#.YX<[AI=MBBER)W#'E(
M'H13P EYS5AS3^% K%G\FD $D\'W[KW2+V#W5TWVM49&EZN[:ZR[)JL.-66I
MM@[\Q6\9*4:@MZE,=5U+0#4RCUA>2!]3[]U[I^S_ &#L+:=9%CMT[WVAMK(3
M4R5L-#G]RT6&F>&1WC698JB:-VB9XY%#!=)96 -U-O=>Z9,SW-T_MS*;6P>X
M>U^M<#FM\Q4DVRL1F=]8O%U682OMX'Q=//5)+D%GU#QF!) ]QIO?W[KW0B5-
M33T=//65D\-+24L,M35553*L$<<<"EGDD=B%1$4$LQ(  ))M[]U[H*-L?(+H
M7>V0RN)V9W=U#N[*8%Q'G,;MCLG#9^HHF8*0M7#25LLE.2'3B15_4O\ 4>_=
M>Z%*AR%!DZ9*S&UM)D*20NL=50U*5<;&,E6 >-F4E2"#SP>/?NO=57_SM*;.
M8K^6'\S>SME]C=R=5=C=0]";[[&Z^WOTOW3NOIG)4.5VI3?>TDS5.V,QBFK(
M?)"%D@JO-!)&SHT9#>_=>ZUL/^$U'7/:_P#-"^&/R@WO\I_G9_,LR_96U.\I
M^M]B]@;1_F(]O[2JL/0U&V<17H\%!3;O&%K)X:VKFE4UN,J0U]#@H H]U[IK
M_D3?S?\ YSC^;9VY_*?^5';^[_EUL&E["^2?6VP^WMV8:DDS>#R'QP;/3G)Y
M#)0)%4387/46 GA9*N2KDAR%10I!(B2S:O=>ZN$^1GQ&^;?;'\[+XO?+WIK^
M8ULK9OPZZ_QVT=O]D_&JF[NR5!5U38#^*)E<%3;,I!4;<W"^ZJBKACFJZR:G
MJZ0/KB62;'4*M[KW6P_N/<VV]G86OW)N[<&$VMMW%0_<93/[CRL&#HJ:,$#R
M5%54R100I<@:GD N?K[]U[I/;![3ZP[6QU3E^KNQ]A]DXFBG6FK,IL'=^/WC
M3Q2/JM'+/CJBIBC<Z6LK,";'C@^_=>ZJ5_F[?SB.F_Y;&W^N.LZ/-X#<ORL^
M0&\=F;+ZOZWDKXR<1CMUY>EQF0WGGETRBDQ6'IIZB6ECF5?XE6Q)2H1 M744
MWNO=7$;?W5M?=E--6[5W)@-S4=-/]K45>W\Q3YF*.72'\;R4TDBI)I93I)!L
M0;6(]^Z]TDZ#N;I_*;XK.LL9VOUKD>R<>\\=?U]0;ZQ=7G(&I06E6;$QU35\
M1C56+!J<:0"38 ^_=>Z7]=7T.+HJO)9.LI,=CJ"GFJZZOKJA*2&&*G4M)+++
M(52.-%!+,S   DD#W[KW0=[![MZ8[7JLG0]6]N]8=DUN%19<Q1[!W]BMXRTB
MNVA6J8\=5U+P*7](+A03Q]??NO=:1'\W?Y'?*#H?_A3#_+CZ.ZE^5GRHV1T=
MW5V3\"-Q]C]*X7Y);WAVCDG[ [:K<)G*27;;9U\.,7E<;0105% E&M%)$7C-
M/H=U;W7NMX/#=N]3[BWGF.N-O]G]>9WL/;M/]UN#8>&WKC<GFJ&+44\E9BX*
MEZZECU@KJD@47!%[^_=>Z$/W[KW6G1_PKV[2[P^+WQO^,G=_QK^2/RA^/_8&
MY^_<EUYN6JZ9^3&^NM<?7XJMVYD,CX:G"XC/TF':6&JQE.T4RT*S(&E4/IE<
M'W7NKI/Y'&%W/6?RP_AMVKV-VOW5W-VGV_TCM_LK?N_.Y^Z]W=N5M96[\8Y%
M@O\ >7-Y6*DCI(6IZ>)*:.&-$B)1%,TVOW7NK<_?NO=4CYG^=%T%N3^:WUI_
M+4ZEWCLW/OMS9W;>]/DWVA/GJ:'%X;([0Q=L1LRBJI2*6IRK5=2U3DY$J!]D
MU+!06EFGK$I/=>ZN-S&_-C;>VLV^=P;SVG@]E)34]8^\,QN*CQF+$-656*4Y
M">9*01RLRA&\VEB0 3<>_=>ZT+_^%:?RW[@Z)WU\(.V?@U\W?D=UY@._MH]Z
M?WTK_CI\R=[4&U,L>N*K::8N>BQN"W2=MTDT"YFO666@I(6J-:?<F4Q1E?=>
MZW^_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U0#_ ,*CO^W%'SF_\MF_]_%U][]U[H__ /*=_P"W67\M/_Q0#X;_ /ON
MMN>_=>Z/_P"_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NM0+_A1W_V]-_X3'_\ B_\ D?\ WXO0'OW7
MNMOWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3
M=-E\33Y*CPU1E,=!F,C!55./Q4U;%%4SQT6GS20P,PEE2'6FME4A-0U$7'OW
M7NOFS]V_]QJ.%_\ %K?C]_[ZW;7OW7NKW_\ A7!_+NQ_R;^ K?+;8NVZ.7NG
MX:Y)-WYO)4.)ADKLGL#-,M+N.AFJ3+!((,)+)29I68S"*"CKHXH==49$]U[H
M2/Y?'R=ZW_FR_P F?X<]&;EQ.V-X[I[*W#L7XC?(_:E9M['Y*"BA^.4--F]Y
MY.MQU)X*?$C<>S,)3/0U$4,"T.1W'BS#$&\43>Z]U7S_ ,*V/D-ONBW=_+U_
MEG;$SF2ZTZ'^0^XJ'+]S4&Q1'@&R.,I=P8;;V!P\/B_R=,;C/+DJIJ-Z1Z:2
MH7'R%&%*$]^Z]TY?\*K\IE?Y?FX_Y6'S9^(;XSI7MWI+?_9/6F)39^+&$HLM
M@*2EVYEJ/ YR.ADI'R. @.)J:=Z!W\4U/D*I6*L58>Z]UE_X6*Y[!=H_RL_@
MKW/3XBFILAO+Y%]?9[%5+IKGIJ#L#KK=&5EHQ(RJYC9XJ0L"HNT2FP-Q[]U[
MJKK^=W\1?CUU?_PG[_DU?(?:O7&)7OSL'9WQ#Q6\^Z,M+-FMS9'%[SZ9R&=D
MP=5EJF22IEP6,JZ6BBQ5 S&FQ=)30TE"D$*LK>Z]T>/^?)\A_EWN[_A.)_*[
M[ V[NG?$FV.]>M/C5#\Q=WX)I1/EVSG7E//2C/U5'%$L&'S^X$GFJHW6.FGK
M314K%M:1R^Z]U#_X4]]0]';7_E*?RCJ[H;8VQZ[.8#?O3^Q^CJK;6SL;FJFM
MVYN/KVKK9:.D@BH77(T>6R-!M^>>F\#PUE08FE@D=P/?NO=;H?PTZ;V;T-\8
M>E^N=D=0;.Z%H*/8N"SV=ZGV%@8MLXK#YW=T"93<-/34,*I%3ELW5USR!5%Y
M&=B+D^_=>Z*C_.Z_[=$_S%__ !4ON#_W5S>_=>ZU*O\ A+%T;\N>\/Y;7S8V
MU\6?F;'\1,WD_D+58>CW%3]%8KMBJ3(U&T,)IK$JLED:9J)#$Z1_L0>:%E^X
MBEUC0?=>Z8_Y#_RP^./\N#^9MO+^7)\J?B'M+9GSCWGVONKXWYOY[8[LC*;S
MJ]RYW(9!I\73U])NFLK)L31;]J8<4\4V(K4.1R570&IQD2R TGNO="?_ #$-
ML8+;O_"Q#X#5V&QU+CZC=^/^/&Y]PO2P)!]S7&/=&.-3)H5=<KTN/I59FNS:
M!<_2WNO="U_.3[ZWE\FO^%%_\LC^7!O',9*+XM=9]C?'KMO='7%.RK0[EW+D
MLA69]I\U YFI\C0+C<;CL='%+3AH(I\GX65JOR+[KW6'^=EW7N?^6M_PH!_E
ML?)/X^Y"/9-!\@.O>MNJ?D1U]A*1L5AMT8*BWMD,'72Y6CHGACK\B,)N!4HI
M98G^RJ<;05$:N8VC;W7NB_?\*S>ENG,/_,9_E<;@Q'4W6>*SW>.\,D>Z\WC=
MAXJAK-X?PO<^R,73?WIJ8J59MP?;XQFHXOOWG\=*33I:(E/?NO=7W?SP=];-
M_E&_R?ODGN+X#=1=1?%?<W9>ZMG=?8RHZ'ZRP_4U-0Y'M2II,3EMQ)2[>I,9
M#_'XMN4=3!1UY4ST\Z4<H9A3)'[]U[JI3._&3NKY(_\ ">CX0;'^#GP^[HR/
MR_VS2_'WY0]9?(/&5^R]BU/]\LQ7?QC=VZZ3=%?O2GS1K<F,IF"9JB))*IG0
MR1(5C6/W7NH7\^OYF_)/./\ R/O@O\D<7)U%3?*C)=!=B?S#]@4.7IW@R%8^
M;VM@\OM2JK,?D%HJG;]+6U.Y9JNF%4])4M]@XJ--+J;W7NKP.[_Y,%;O+^;]
M\4_YH'2/=]!T/A>ENOL9UYVQTYM?98I!N>@VXN7BIJ2"HH9Z*EAI,A0Y."BK
M(ZFFG5(:*F>G&M$$?NO=:S'_  H)VK1;Z_X4_?RN]DY*OSV*QV\6_E[;5R&4
MVKG:G:^4IH-P]S9^DEJ,;DZ*2*LQU?#',ST]5!*DU/*$EB9712/=>Z3/\S_8
MW7W\OO\ X5"?RVQ\/MC[=Z P^\:[X:UF^MO]98^+;=)F!VQV/G=K;K%9"L<L
M#R[AV^OVM9,83)*Q-4Q-63.?=>Z^CA[]U[K2W_X6U_\ 9"GQ(_\ %M)?_>.W
M#[]U[J_[^2+_ -NB?Y='_BI?3_\ [JX??NO=659#,[9?,T>Q\ID</)G-R[?W
M'F:':U=/%)/78S;TN.H\K4)2.2U11TDV9Q<-2V@HC5E.DEC,@;W7NOGF_%[X
MC?%'<'_"MOY3?&[/?&+X]9OX[[>VMOZHP'0F7Z6VWDMET,E'L7;59"]'M:;&
MO@Z9XJN>>=&CH5*S222*0[LQ]U[H:_YR^2HOD-_/K_E9_P HZ'&8#8GP<Z=R
M'QVK,C\?MI[?7![5R:9K)-E:_$U.WZ">AQ#8P[8P>.PV.C%(%Q4517/3HZ3R
M0/[KW16_^%G_ ,>.DNC^T/@GG>G.L]H=6R=D;8^0=1O3$; P=/M'%UU7M%MB
M4-)DI,501P8\94X]Z>CGK5IQ4U%)1X^FGD>&@I$B]U[KZ1?OW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH!_X5'?]N*/G
M-_Y;-_[^+K[W[KW1_P#^4[_VZR_EI_\ B@'PW_\ ?=;<]^Z]T?\ ]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=:@7_  H[_P"WIO\ PF/_ /%_\C_[\7H#W[KW6W[[]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K6'_F'_P L[Y'9O^=9
M\%OYKW7^*W]WKT;T?@Z/:/:W275>Y,7A=Y82?!4FY$Q^7P5-N',87$9? 5];
MFJ$YJBAR,60:EIZM:>GKWJHXH_=>Z*=\4/Y0?RU^1/\ /N[4_G$_)'K'*_&#
MI#;G9=3NOICJ?L/-[>W)O'<<N"V?3;.PU37T6W<CF,=@J&&*$5S^>N:L$T4<
M$<;J36^_=>ZW!MX[1VUV!M'=6PMYX:AW%L_>VW,YM'=>W\I *FFK\;N2EEHJ
MZCJ(VNLD%52S2QR*19D8@\'W[KW6K=_PG _E([I_EW]G_P Q3/;ZSV5W)A\%
M\CMV?'[XX5-=E(<I32[3V\N.R61W+"(8XH8,MN0';5!EQ%2T^FLVXU,XECIH
M#'[KW0[_ /"@S^3]VG_,5VS\>OD/\5*K::_+[X>[M.YMA;1WW7G$XC=N)GKJ
M#)38.>M::""BK:;(8VFJ*.2:2*"0/54TT],)TJ8/=>Z*Y_-;_EW_ "N_GO=]
M_P OG9^?Z%[5^'7Q@^/--O[>?R?W5W5N;:S5U56]G/M@S[:VMB-K[HW"V9R^
M/I-N5=-'E9%@QL'\2>6*IG*24TGNO="/_P *>/@3\Q_GK\4_C1\8/@[\8L_V
MW/U]W)C^T,[GX>S-A=?8?$8W:NV\WMZDQ3-N[>&#RE57SG,121_;XZHIU@@D
M,U4DQ2*3W7NBA_S9/Y:W\QCY<?R3OY57PFZ9^'>[\KW[\;,#T#1=U;?S'<G5
M>"I,-+T?UI6;(JU7)5&_4H<E_%,C5+449HIJ@"E5C5?;3VA/NO=#]\W^X/F]
M_+9_X3Q_$G;-#\3LCDM\]4[,^.?Q[^8&SMRS[7[)BP6S=FX'[?=&363#3[QP
M3X[,5.-I\7%DI8ZA<:M>*V:E62.,>_=>ZJUZI_X4Z?R9NN-P=-YO&?RI.RMO
MUOQ^VS'@>C<Y'-M7L6LV0E?#!!7TVT!G,DG\!CDAB$;U-#44L]7&B+.BAB%]
MU[K>&^''RYZ8^=GQLZM^57Q_S-?F>K>V</69+!MF:#^$Y"DJ,/65&-R>,R5+
MKE%/D,9DJ.KI9U262(R1%X)9H'CE?W7NBT?S?=@=X=U?R\?E5\?OCUT9O#O+
MM/OCIO=_5NU<+MK=NSMET])4[OA^S6LR5=O#<VW*>.CI4D>63P-43,$T)$S,
M/?NO=:^'\@;X[?S6/Y0OQG^0_3W;/\J?N'M;=W8_:J=I[&JNN_E/T'18YW7!
M4.*_A^6J,EV=3U./7SX^-_N*>AKSHE;_ "?5&%D]U[IN^#/_  GK^8W9G\UG
M/_S:/YGNY.J=JYR#O67Y$;"^//6>Y&[(JTSM#-+/MBBR>76@H<918K8W@P:T
M34TM?4U[T"&H>ET&2J]U[IT^:7P'_F3]Q_\ "BCXV?S$]C_!_?.=^*_Q_P K
MTMM*MW,O<_4>&RF0QNT#DCE<Q1XBL[(2M>"*?-5+PQ3Q4E5-# %--'*PU^Z]
MT<W^:[_*C[RWW_,/^$7\WWX>[.HNR>V_C=NSK>F[_P#CED<YCMO93=.U-H5\
MT\E3MBOR>4Q^ &Z*3$U^4HEIZS*TU+.WV4J5+?;/#5>Z]T%_R%_E=?(+^:A_
M.L^-7SF[@ZOWQ\</AA\,>ONJ*/!;7[:SF&;<V^-T=;;ES6[T7'8';V>S:8;$
M2Y/+8^FKZVMJ:::II\9XJ:"9)HJB'W7NL7_"E?\ E9?-3YL;[^#_ ,G_ (6[
M'VWW+NOXF;BS]3N/IG([LQ^R,CD$R>8V]EZ*LH*W,5N/QE1!%+AYHZN%JV&H
M5'1Z9:ABR)[KW5H?\P#X4=K_ ,U_^6AW9\<>Z=L[;^.7;'9E/A-X]3[:BW5'
MOX[5S>Q)J#)X6EW+FZ"&;'U[5V2I*NGR,F,I7BIL=7-%2/5U%.*J;W7NJ>_Y
M-*_\* _@MU7M3^77VM_+GV'O_K?KW=FY,/UQ\M-_?+/!;;P6U-NYJKJZ[568
M[%1[GSV\,92UDE2^-HJ.#&UT=//38^H%#3Q">F]U[H9?^%&O\C[NG^9IT%T-
MV!T#NFEWU\L_BWMW<6!.'W;68S8\78.)W)!139"!9_%38K%Y]<GC8Y\>LE11
MXVU7605,L0:">#W7NC=_RR>]/YW/;&U-@]6_.?X5=<_&!>M<9MG'=A?)_<'=
MF(W[EM[+MRH2*HIL+U_@OXC'CLIE:2E9*W*UNY4H89*DUN/H:KBCB]U[JH;^
M:Q_+=_F0_)O^?A\-_G;TQ\+]Z[M^-?Q3WI\/EW'O"7N?J?;E5G*/HOL"IWAF
MJ_!XG)]A4F4,#T=>T%,E?24%3)/"X:GCC,<LGNO=-_\ .&_ED?S'_E5_/#^(
M7S?Z(^'.[][_ !Z^.3_$D;JW*W<W56V:S(#I_?5?NW--B\7E]_4%<WCH\@M/
M$*F&F\M3%)I_9,<S^Z]UNST4\M51TE5/15.-GJ::">;'5KPR34[S(&:"9J>:
MHIVEB)*L8IY(RP.B1ULQ]U[K5:_X5$_!OYR?S'^C/CWT/\./BMN[MC(=?=SY
M+M'=>]ZKM/K?K[#PTL."K,5!20)N3>N)R]15U$V29Q;%K$B0/JEU/&&]U[HT
MO\MGL?\ F&?$+X(?&+XP=N_RE?E!N/L+H?JK"=:9C.]??(7XXUN'K5VQY(*.
M>EER'=.,K 'HQ3B0242E9 ]BXLQ]U[H8O@E5_P RCN;YW_*#Y%_-_P"*DOQ&
MZ2P_36P.FOB+UM5]V[,[BJY:6HSV6RNZ<QE)=GYO+PP9K+&EVZU6LJQ4\$4%
M'1T4E8:>JJYO=>ZJ:W+_ "U_YBOQE_X4<;F_F8=)_'S;7R?^.G?V*W#B\Q5X
M_M_!=65.USN#9M!@Y%S,>:J?O0*7*8R&834&,R8GHF=4A2M:.G]^Z]UF_G:_
MRD_G)OSYK?"G^;=\)=I[=[G^1OQS;I27O#HG;F[8>M4SM3TSG!FH*W 568JH
MO+CLG#4UV*R-)/D&J#CHZ;PP5;O4QM[KW18/Y^'\NS^;/_.;W'\(=W=:_">D
MZ7PVQMO=WXW-;)[([SV949C;1W)+M>1<CNK(T.;FQ)7-38Z:/'8_"G+5-/34
MHJ\G+35%>V-QONO=7;_SHL;_ #C]\?!CJ.K_ ):\%5UW\GHNS-M5G>>S^OMY
M;<J\K)A&H,A3RTN%S.?I:/'2TR9A\=55#1R450:=- +1"HA?W7NK7OAYCOD/
MB/BI\>,7\M<OBL_\F\=T]L&B[WS>%-*:>KW138Z!,O4*:&GI:$R2U8D:4TM-
M%3&4N:=%AT#W[KW1D/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW5 /\ PJ._[<4?.;_RV;_W\77WOW7NC_\ \IW_ +=9?RT__% /AO\
M^^ZVY[]U[H__ +]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU O^%'?_;TW_A,?_P"+_P"1_P#?B] >
M_=>ZV_??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW5+_ ,W?Y?/S'[G_ )@WQ!^<GQB^8=/U9A?CQL[.;&WE\=.Q
M8]QY+9V;CSTV4^XR[X[;V6Q1KZ^IILLD=33U<RQ3?PK%A9HA'(3[KW5JO4'6
M>-Z?Z[V[L'&Y"KS<F*7)9#/;FR5-3TE7F<SN:LJ,IG<[71TL<-,M?F\S65U=
M4B*)(_/42>-%2RCW7NA+]^Z]U[W[KW7O?NO=>]^Z]U6G_,E^!N\_G#@OCC6=
M>]WQ=1[S^,GR*V#\B=O8'=^R5[0V3NNIV+50U,>%WEMQJW'&OHM40DI:B.J6
M?'U-JJF J$BEB]U[I2;WZA^579VPMT]<9?8'P;V9%O#;N2VUDMX38;.]QP11
M9>(TU1+_ '2K<-MJFK#X9)'2&?<7B#JJ2B:,M[]U[H4/@E\,.I?Y?'Q2Z@^(
MO2+9RIZ_ZCPN1HZ7,;GKAD<ED\AN.OJ\OF<M7RJJ1BHR>6KZVI,44<=/3K(M
M/31Q4\44:^Z]T;CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW5 /_"H[_MQ1\YO_ "V;_P!_%U][]U[H_P#_ "G?^W67\M/_ ,4
M^&__ +[K;GOW7NC_ /OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4"_P"%'?\ V]-_X3'_ /B_^1_]
M^+T![]U[K;]]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW11OG3\U>E?Y?'Q@[.^5??63J:78_7&)$M-A,487R>=RV0)BQ
M> P\4\L,4V4RM45BB#RI%&NN>>2.GAED3W7ND'T!VIVKL;XNYGY=_/C?^TNM
MJC*=>U7=>^=B8>*+%[4ZQVU!2S9:+"BOD1\GGLMB\6\4>6RM3,%KZ^*1L=CL
M;3-'1^_=>ZH&^'O\R?\ F#_SZOD;W1C/AGV&OP _EQ]$5N)P&XN\,;L##[_[
M3W;D\E]Q+38_%2;CILGMW M6TT:5,^G$S38RF$(>>JFKEB@]U[JW7MOXX?S&
M_CATMV-O?X;?.?L;Y4]P;>VWD\]MCI?Y^=>[%WY@\[/B89ISB\=E>M-K]4;B
MQ64K["*FEJ<O74(F\:2TT2.\\?NO=&L_ET]I=C]W_ SX>]Q]P2RS=K=H_'+J
M3?W9#S8YL0PS>ZL+25N30TC^NE\=9-,OA;U1 :&Y4^_=>Z.;[]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN+J71U5VB9E
M95D0*64D6##4&6X^HNI']01Q[]U[K0R_G/\ \S[^:M\0/YQ74GP>^-GSLWAM
MWJ;O6F^.,]#0;HZ(Z>W-4X6H[DST^WJR&CR%3UP]3-2Q-2BHB-4:B5'E=6>2
M-44>Z]UO5[2P>3VY@<?A\QO+<F_LA1P10U.ZMVTN(HZ^K:-%4RU$>"Q6%Q:R
M2,I=A!C84U,0J*FE5]U[I1.I='57:)F5E61 I9218,-09;CZBZD?U!''OW7N
MM/7X;?S%_P"8)DO^%)?R$_EK]K?*K.=P_%CKC&]K9;:VT]R=1==;9KE2+;^*
MS^(BJ,QMG9V"R<[XK^*> -]THJ%B#SK(S'W[KW6X9[]U[KWOW7NO>_=>Z][]
MU[KWOW7NM7'_ (5$_-SYK_RZOC7T+\B?AM\GMV=.YS=_>]%TUNC91ZRZZ["P
M=91Y7;N?S0R/^_IV9F\Q3Y*"?"PQ(8<NE*8990]*TGCD3W7NKS_Y>W:6^^\?
M@+\'NZ^TL[_>CLWN#X@?&GM+L7<O\,H\)_$<[V!LO"Y;+UWV6.IZ3'TGW>0J
MZB7PTM)#3Q:]$,4<:J@]U[HW_OW7NJB-]_.3-_![YO\ 2'Q/^5.YES_17S3?
M-8SXD?(G-T]/B:S%;VP55$*SK/>D]/#28N9:^#(XG^Z^4"1UM?(\V.KXZJJA
M_B-1[KW5N_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZH!_X5'?\ ;BCYS?\ ELW_ +^+K[W[KW1__P"4[_VZR_EI_P#B
M@'PW_P#?=;<]^Z]T?_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ!?\*._P#MZ;_PF/\ _%_\C_[\
M7H#W[KW6W[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NM'W_A5WOZK[!^:'\FGX89VJ:KZ@W[WUB]_=D[.EHH*FFRDVX-
MU[:VICY:C[B&9)#1XNJW+ D9!B9:^;SQR@QZ/=>ZL[_X5A[LW?M?^2UWK3[5
MJ:RCI-V]D]%[3WE44-0U,PP]9N6CJI8G9&5C#4UM'0P2IRLD<C1N"C,/?NO=
M%@_X1@4.SH/Y5O:];MZIJZK<E?\ -3M#^_JUE-'#]O6TNTMB)1TU*Z@/-1#%
M&AG#.3:IGJT7A;#W7NMN;W[KW5*W\\K8_P#,IS_P(GZT_E)8Q,3W%N+?FV]K
M;T79&Z,5UEN"@V/74F27(ML_)9"MQ-#B<E_$?X2DE3%705=/0M5/1%*C3-%[
MKW6IG_PH,^5-7\,MX_RONY_A!V+B^C?EEMC:_:.-^7L?QS[-SN_]IG>&PZ/K
MFN.U<OFZB63";UDPN1S6XHJR"M-1D6HZRGDS5/$*ZC#^Z]ULU_\ "@?XR]R?
M(G^69OCN_P".&_\ L_K+Y,?'K9F/[OP>3ZAW_N+8-5FL%MZ 5NZMOSQ8"I27
M)!L1)7U>/@EAE(KZ>&*-X%J)Y/?NO=$M_DE_-W!?+/\ D,[KPNXIO[Z_(WK'
M+;A^,^[(\_N7-KDL_OKL_(4^-ZTS%;FVJZO/)59F3.[:IYLI!5F6"II*R6E%
M/'3)#%[KW0R_\* .M)?AU_(6WOC^FM_]H[>W[T"WQSP>UNYJ/LG.4V[ZBIRV
M[]L87-Y.OW$E>,M5UF>IIJ@UIEJV64R6TA4C5?=>ZIBP/Q_W)\C/^$I6%^;_
M &Y\F?E1NGY#=2;.[MW_ -3[IF[]W31TV(39O<V<H)J.LQU/EH:/<<^0IZ*I
M09'+Q5E?0QSPT]!/3TU%3P^_=>Z$KH38W:7SQ_X3)]B_+OY4?*/Y)[_[7^.G
M1/R=K^AI<%V_G^NZ/&#H"?*-BZK<E/@\G1IO[.3C&I3-D=P"M>GH5@BI88:L
MY&NR?NO='V_X3?\ RN^9_P GOY%7>]7M+<E/V7\JN@]]?(KHOXV;B[AW!+G8
M\AE,1L[;VZ-H0YZNK&$LM)1Y?=*40$]25%)3Q(\\<0_;]U[JL#YB0=\=(_R#
MN\,A_,6R]7LK^<=MOMS$=H[!W=A^^:_L;L^';>ZNT]K0#<6=JMJY.NH-D888
MK<.<P=!21U5/@(Z-<13TWBRU9'1)[KW6PU_) [M[/^<O\C7IK?WR<W=E.R]^
M;DV5WCL;<.]LA.:?*5L'6>YMP87#5U161%99,Q2T>+H&-=<5$E3"*N1VJ"\C
M>Z]UK"_\)C]G=J?S)>L/YGNROE3\N/F'N_KG9.R_CO)2;1Q?R0W3@YI<EN:'
ML>2ER/\ &X<E_&H(\;_"'OCHJU,9DGGC?+4E<**C6'W7NCV_\(N/EUWMW1U[
M\XNANWNR]Z]E;7Z@S?1.^^KY=\;DR&[JG%#LN+=5#G,?3U>1K:EZ;&.^WL1/
M3T<,:0QU$E?.?W*EK^Z]UO#>_=>Z^;;_ ,*(?^XF'X+_ /EA7_OQ<A[]U[J_
M_P#X5=_(7Y+?''X5= ;QZ9I][2=/5'RFV/'\IX]D9K);4;);9QD,]91;9S.<
MQ 7(87;VYLE"E'55,51 9)C249=_NA3S>Z]TO?Y0_P C?@?_ # >Y^OOEC\&
M>R-W=0Y+KCHOL+JWY#_R^]U=E9B&BP5;OFNV[D,;NW$;1FJ:C;\TM-/B:J@?
M.8JEIXJZGK52M>*MIOL_?NO=5$?$?_N-$^7W_AH=C?\ OO=J^_=>ZMQ[[P/S
MO7^<ONCLWYI4?5]%_)#V1T%E<#M3-[\[RH-@[5H,OGL1B:L9;)[<7*05NZ=_
M2[LH:W&TL62QKT5)A:N6;&RBM"+6>Z]U4;_PG;^6/;R?SQ?YE7PJVMV9V'D_
MAEB<U\NMW=2=/]@U>;K$VW!U;V=C\+MB/%T6Y2,SMTTV RDE+4T,L4$C:8EK
M8!4TR>/W7N@]_G?[[[VV%_PI(^ '1_1OR.[RZ'V?WON+X-5NYL5USV#D*+$Q
M9?L?M3*8*OS']VY9Y-O5\\T%+325$%9C9Z:M=&6LBFCDD1O=>Z3WSOW-OW^6
M%_PIG^!^SOCKW=\C)>N^]\I\5ZONG:79W?6Z^VZ?.1=][YS>S-T1U46;S$HJ
MHI<9&M514\\CTM#DDBJ*6*%(88HO=>ZL1_X5A?/[Y)=/4_P]^ WQ8['S/3N[
M_E]N/+U78O8VWMP3[8K?X.M;0[=Q6#^_HZ::OHL;E,GE:BIKYZ.1*H1X^*!1
M+#45$4GNO=$I_P"%7GP2Z7^''\NKXJ0]&93M'#8$_)79NR=U[4W/VKG^P<9G
M*[%;-WI44^ZJRESV0R4=+NEF;)+65U"*5\DE:5R0JA0XW[/W7NAD_FL_(7Y+
M?''_ (3N_P E3>/3-/O:3IZHZE_E_P ?RGCV1FLEM1LEMG&=:8*LHMLYG.8@
M+D,+M[<V2A2CJJF*H@,DQI*,N_W0IYO=>ZL\_E#_ "-^!_\ ,![GZ^^6/P9[
M(W=U#DNN.B^PNK?D/_+[W5V5F(:+!5N^:[;N0QN[<1M&:IJ-OS2TT^)JJ!\Y
MBJ6GBKJ>M5*UXJVF^S]^Z]T63_A9WC<O3?RU?CMV#MJ/-4FX^O?GCUADJ3=&
M ,]/48>*MV7O_36BKI[2T%LI!B5CG\L>FI,"JWE:,>_=>ZV0?@=WEEODW\)/
MB-\B-P49Q^XN[OC;TKVCN.A\HJ!%DMZ[=Q]?D(TD"IY(EK)YPCF-"Z:6*(24
M'NO=&P]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U0#_P *CO\ MQ1\YO\ RV;_ -_%U][]U[H__P#*=_[=9?RT_P#Q0#X;_P#O
MNMN>_=>Z/_[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>ZU O^%'?_;TW_A,?_XO_D?_ 'XO0'OW7NMO
MWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=:7'_"LKIK-;%[._E;_ ,R&/$UN4ZU^+WR+P&U.[*C&8>>ODQ]#7;@P.YL+
M6U,M-%-)#0M-@\S2%Y$T"LJZ.",F>K2.3W7NMJ3Y??%[J3YY_%+N#XP]J*F3
MZR[ZZ^J]O29K&0TN2FH9:Q8ZS#;AQ1J8JBE.2PN2BH<E02O$Z+4T\+E646/N
MO=:B?\I+K?YV_P#"=/N/O7XS_+'XU=R?('X*]V[JBWOL;Y4_$?K3,=\4F$SF
M"HVI1D<WMG 4E=N;%T.<P]/1P5J34)DHJVCITI/XC2S2U:>Z]ULTX;^8Q@N]
M:"LP7PVZ-^1G<7851 L./R';?QM[&^*.R\5-5"54K-P;H[&VGMM9*&E:(M/3
MX6DR^3D%D@HF+ZE]U[JM'_A2M3?S*V_EG[1V?\)<1VCV)OG<>^=J;6^4=?\
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M'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\
M]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\
M_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H
M'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\
M]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\
M_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H
M'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\
M]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\
M_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H
M'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\
M]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\
M_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H
M'$_FF_\ ?3A\_P#_ ,]W8O\ ]O\ ]^Z]U[_H'$_FF_\ ?3A\_P#_ ,]W8O\
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M[)_^Q3W[KW7O^@JO^1Y_WECN;_TG#LG_ .Q3W[KW7O\ H*K_ )'G_>6.YO\
MTG#LG_[%/?NO=>_Z"J_Y'G_>6.YO_2<.R?\ [%/?NO=>_P"@JO\ D>?]Y8[F
M_P#2<.R?_L4]^Z]U[_H*K_D>?]Y8[F_])P[)_P#L4]^Z]U[_ *"J_P"1Y_WE
MCN;_ -)P[)_^Q3W[KW7O^@JO^1Y_WECN;_TG#LG_ .Q3W[KW7O\ H*K_ )'G
M_>6.YO\ TG#LG_[%/?NO=>_Z"J_Y'G_>6.YO_2<.R?\ [%/?NO=>_P"@JO\
MD>?]Y8[F_P#2<.R?_L4]^Z]U[_H*K_D>?]Y8[F_])P[)_P#L4]^Z]U[_ *"J
M_P"1Y_WECN;_ -)P[)_^Q3W[KW7O^@JO^1Y_WECN;_TG#LG_ .Q3W[KW7O\
MH*K_ )'G_>6.YO\ TG#LG_[%/?NO=>_Z"J_Y'G_>6.YO_2<.R?\ [%/?NO=>
M_P"@JO\ D>?]Y8[F_P#2<.R?_L4]^Z]U[_H*K_D>?]Y8[F_])P[)_P#L4]^Z
M]U[_ *"J_P"1Y_WECN;_ -)P[)_^Q3W[KW7O^@JO^1Y_WECN;_TG#LG_ .Q3
MW[KW7O\ H*K_ )'G_>6.YO\ TG#LG_[%/?NO=>_Z"J_Y'G_>6.YO_2<.R?\
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M_90/B7_WB[\=?_1)[:_^MGOW7NO?[*!\2_\ O%WXZ_\ HD]M?_6SW[KW7O\
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MGOW7NO?[*!\2_P#O%WXZ_P#HD]M?_6SW[KW7O]E ^)?_ 'B[\=?_ $2>VO\
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M_HD]M?\ UL]^Z]U[_90/B7_WB[\=?_1)[:_^MGOW7NO?[*!\2_\ O%WXZ_\
MHD]M?_6SW[KW7O\ 90/B7_WB[\=?_1)[:_\ K9[]U[KW^R@?$O\ [Q=^.O\
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M %L]^Z]U[_90/B7_ -XN_'7_ -$GMK_ZV>_=>Z]_LH'Q+_[Q=^.O_HD]M?\
MUL]^Z]U[_90/B7_WB[\=?_1)[:_^MGOW7NO?[*!\2_\ O%WXZ_\ HD]M?_6S
MW[KW7O\ 90/B7_WB[\=?_1)[:_\ K9[]U[KW^R@?$O\ [Q=^.O\ Z)/;7_UL
M]^Z]U[_90/B7_P!XN_'7_P!$GMK_ .MGOW7NO?[*!\2_^\7?CK_Z)/;7_P!;
M/?NO=>_V4#XE_P#>+OQU_P#1)[:_^MGOW7NO?[*!\2_^\7?CK_Z)/;7_ -;/
M?NO=>_V4#XE_]XN_'7_T2>VO_K9[]U[KW^R@?$O_ +Q=^.O_ *)/;7_UL]^Z
M]U[_ &4#XE_]XN_'7_T2>VO_ *V>_=>Z]_LH'Q+_ .\7?CK_ .B3VU_];/?N
MO=>_V4#XE_\ >+OQU_\ 1)[:_P#K9[]U[KW^R@?$O_O%WXZ_^B3VU_\ 6SW[
MKW7O]E ^)?\ WB[\=?\ T2>VO_K9[]U[KW^R@?$O_O%WXZ_^B3VU_P#6SW[K
MW7O]E ^)?_>+OQU_]$GMK_ZV>_=>Z]_LH'Q+_P"\7?CK_P"B3VU_];/?NO=>
M_P!E ^)?_>+OQU_]$GMK_P"MGOW7NO?[*!\2_P#O%WXZ_P#HD]M?_6SW[KW7
MO]E ^)?_ 'B[\=?_ $2>VO\ ZV>_=>Z]_LH'Q+_[Q=^.O_HD]M?_ %L]^Z]U
M[_90/B7_ -XN_'7_ -$GMK_ZV>_=>Z]_LH'Q+_[Q=^.O_HD]M?\ UL]^Z]U[
M_90/B7_WB[\=?_1)[:_^MGOW7NO?[*!\2_\ O%WXZ_\ HD]M?_6SW[KW7O\
M90/B7_WB[\=?_1)[:_\ K9[]U[KW^R@?$O\ [Q=^.O\ Z)/;7_UL]^Z]U[_9
M0/B7_P!XN_'7_P!$GMK_ .MGOW7NO?[*!\2_^\7?CK_Z)/;7_P!;/?NO=>_V
M4#XE_P#>+OQU_P#1)[:_^MGOW7NO?[*!\2_^\7?CK_Z)/;7_ -;/?NO=>_V4
M#XE_]XN_'7_T2>VO_K9[]U[KW^R@?$O_ +Q=^.O_ *)/;7_UL]^Z]U[_ &4#
MXE_]XN_'7_T2>VO_ *V>_=>Z]_LH'Q+_ .\7?CK_ .B3VU_];/?NO=>_V4#X
ME_\ >+OQU_\ 1)[:_P#K9[]U[K69_FT]1]4=4_SN_P#A/#%U=UCU[UM'G.Y^
M^Y,U'L'9>-V<M8V/;9HIVJACJ:F%08!-,(S)JT:WTVU-?W7NMO#W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=:J/\ .F_[???\)S?_ !,GR&_Z'V1[]U[K:N]^
MZ]U[W[KW7O?NO=>]^Z]U'JUJGI:E*&:GIJUZ>9:.HJZ9JV*.5E(C>6%):=Y8
MU>Q9%GC+ %1(A.H>Z]U1+_+][_\ D]O#^<!_.1^,W=W>&5[5ZV^,^(^$4_2N
MWGVYC-J4&#I^Z-I5^YLC'34N.IH7EEDDJZ>*2>JJ*JH=8$!G*@#W[KW0K]P?
M+K='<'\V/KG^5KUMN//;'VOLKXH[L^97RFWIM6N&$R]?CI,WC-K[8V;A\K%(
MM?AS-6Y2/)96JI%BK#2M10T59 7K"/=>Z?>H/E#NSI_^:%V'_+2[(W#N?>FT
M][_&';'R\^*N^-WR2YG(T^/H\S7[9W?LK(9N56GS4N+K:*ER=%45DTV06DK)
M8:R>98Z:1O=>Z#;X/_([<O\ -,['^>?8=+V'V1US\>/C/\J-W_#/H#!=9;LF
MV%5U>7Z=Q6*J]R;ZR]7CYO/F#D\AFZ;^%4%:7Q<6.BB^[QLM7+4D>Z]T4W>G
M\X;NSK_^4C_,T[FKL4<Y\T/Y;/<?:/Q!WED:?9Z14V2SV)W9C]J[8[#_ (/:
M*E&+K,7F\?G*R*/_ "0?;5I@4T@B4^Z]T<S:O:W9GQZ_F0_#SXPP]D;[[0ZO
M^7GPZ[K[)WQ2=G;NJ]\Y#&[TZ'J-K5"[CQE16S2R8:AW#1[AKJ>KQ=*(L2LT
M-*^.HZ'PSK4>Z]T>/MK<6Z>U^UL%\<^M=Q;AVIC-N-MSL7Y&]A[7FDQE3C\*
MM1Y\1LW&Y.*2.6BSN\IJ5S5RT^JIQ^WX:R59*"MR>$K??NO=&Z]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5=_/"_[=
M"_S%?_%4NU__ ' ?W[KW7OY'O_;H7^75_P"*I=4?^X">_=>ZM1]^Z]U[W[KW
M7O?NO=>]^Z]U0KB._?E1A?\ A1!0_$7>/>U;NOXYYC^5KE_DQ@^J<7M/';4Q
M=#N&M['7;!JF:&.?*ULL5+BYO$:S+5*QK4.(U0D^_=>Z,7_-H^<V[/AWUQ\;
M^O.HI*.F^0_SC^6G27PVZ4SN2Q\&6I-O5?;F5AI,GNJKI*ET@JDP>/9_MH7$
MD;Y&HH?N(9*05('NO=(/YB]Z[I_EE]B_"#L.;L'M#L;X[_(CY,;3^(/R%Q79
M&XJSL6;&Y;N+&Y*7:V_:&MJO+/@DI,YB11Y&BI3!AY*;(#P45/4Q0:_=>Z<.
MX/EUNCN#^;'US_*UZVW'GMC[7V5\4=V?,KY3;TVK7#"9>OQTF;QFU]L;-P^5
MBD6OPYFK<I'DLK54BQ5AI6HH:*L@+UA'NO=/O4'RAW9T_P#S0NP_Y:79&X=S
M[TVGO?XP[8^7GQ5WQN^27,Y&GQ]'F:_;.[]E9#-RJT^:EQ=;14N3HJBLFFR"
MTE9+#63S+'32-[KW55.P_P"8=\B=W?RU>J/YN#;QW_B.R=Y?S!L7UUE>B=PY
MFIH-N+UONGNJ?J]=C2;1^X.*BSF/P,L59_%D@_C*YB!Y9:V6@5Z%O=>ZV0_D
M+VKN#K_;N#VMUO0TF;[O[9R\FR.H,)7T<F0HX:Z2%YJS<&9CBFIW3;FUZ%9<
MAD6^YA:9(XL=32'(5]##-[KW0D]:;-J>O=A;4V77[PW9V#DMO8:EH<MOK?.2
M_BN6S%98O69*ND 2&.:LJ7EE\%/##24RLM-1T]/210P1^Z]TN/?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW6JC_.F_P"WWW_"<W_Q,GR&_P"A]D>_=>ZVKO?NO=>]^Z]U[W[KW7O?NO=$
M%_FA[T[NZN_E_?,;N'H#M"'J;L7I?XP]\]O[?W0FT*'=U2M7UEMG(9NF2G3*
M+4XZ'R&AD1C-C:FY="GB*$M[KW4O^5UV3OKN3^7!\%NV>S]S9+>G8_97Q3Z,
MWQOK=V9=9*K)9;<^W:"LKZZH**B>6IJ9I';2BJ"UE4"P'NO=$W^#_P CMR_S
M3.Q_GGV'2]A]D=<_'CXS_*C=_P ,^@,%UENR;8575Y?IW%8JKW)OK+U>/F\^
M8.3R&;IOX505I?%Q8Z*+[O&RU<M21[KW3;\:/YK9QOP=^??;WR<I:O+]N_RL
M>S_DMTE\@(\+AX]M2[NJ>A)*F3;^:Q=(PBHJ63?6,_AC1JC)1I6S2F(I1^,C
MW7NDAB>ROEKE/Y0U!_- I>TMW9'Y8U_Q6@^=M'UQC,C45.Q:G!U.%&^X>MZ?
M9R-+CVHJC:Y7&)D1 ^X?O&%6,BTO[)]U[J7W+_,;R/?F[_Y(FQNCZO>NS^H?
MYJ66[*["[!WGMV:;!Y.@VSU/UV=V2;23-4TD%;@\KELO7T=/)544D58*;'9$
M4E13R:91[KW1G/Y=G>_8V[^Z_P"8[\7M];DR>^\%\,OE#MS8G5&^-PY*3/9>
M;;':6S,%NZCP^8RDKO49>NV]69*NHUK*AFK)*04L=;+4544M3-[KW1E^KMQ;
MI[Y[?S/;N-W%N'$?'[K==R===68"@FDQ-+O3-+.M-N#>5?HD#Y+!8R6FDQ6W
MHI$2FGE7*YGQUL,^!K*;W7NC=>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K51_G3?]OOO
M^$YO_B9/D-_T/LCW[KW6U=[]U[KWOW7NO>_=>Z][]U[KWOW7NM=G^7W_ -Q!
M?_"@O_PU_P"5Y_[Z@>_=>Z3OQ>PV4V1_PIW_ )G5+NS<+SU'=?P1^+G:_56!
MJYYG:/;NREV_M+*BD60M&E/!N.AJY9%CT+Y:TOI,C2N?=>ZE?(M<EO3_ (4]
M_P O';^T<_6T55TM_+N^1W;';.)IL4M7%5;=[!R&:VMB::>I>2,4RMN,TE26
MC$DH>E@C>-8JKRK[KW47_A+5ALILC^77VMU#NS<+[C[+Z/\ G=\KNJ.V:NIG
MFJ*I=Q;<R5#)7&L>H+3M45*5,%2S.[LPG!=B^JWNO=(#^5/U!LWY3_)C_A2+
MC>QH/](GQC[S^<.1^-F9V%E<6:&CFK^LL-EL/O9H:U)DJVEJAE<5$KHD7@%'
M35=).SSWB]U[JV+>G2NQ/C!N';G?=!6;Y^1GRKFZ[H/B7\5:#MO/XQ)8TSA7
M(-@Z.7!X+&1T>/JWQ$>6W-F9Z*NR*XO$RU#S2QT<=,WNO=!SE^U-P_&'O_XE
M? KJY,+N3Y!?,$=]?(KY ?(3?6#K,S1Q4_6%%CYMRYL8NGR-'4UN5S>8R>$P
M^ Q[Y:+'X'#0)$6FIL5C\57>Z]T,O\NWYMGYH[(^0=/N#$87!]L_$WY=?(+X
M9=TT>V(ZN'$U6?Z&S#42YK$1US35,&-SV+FQU?'325=6U%)--0M6534QJ)/=
M>ZL&]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M57?SPO\ MT+_ #%?_%4NU_\ W ?W[KW7OY'O_;H7^75_XJEU1_[@)[]U[JU'
MW[KW7O?NO=>]^Z]U[W[KW6NSG_\ N*PV1_XPIJ__ '^&8]^Z]TG?YV.&RF(_
MF*?\)[>WLEN%\-UIMCYW;YZHS])//-'2U&XN[<;@(]J&1%/@:H+X/+4T#.A9
M35N$9$>6_NO=2O\ A3\N2W!\$OCYU)M3/UNV^SN]_P"8C\0^I^H\IC<4N;G@
MW%ELCDJZBJ8Z:22&&1J1,?-,JRS1Q22)' TBF53[]U[J+\7L-E-D?\*=_P"9
MU2[LW"\]1W7\$?BYVOU5@:N>9VCV[LI=O[2RHI%D+1I3P;CH:N618]"^6M+Z
M3(TKGW7NI7R+7);T_P"%/?\ +QV_M'/UM%5=+?R[OD=VQVSB:;%+5Q56W>P<
MAFMK8FFGJ7DC%,K;C-)4EHQ)*'I8(WC6*J\J^Z]U9!NCX$?%'K[;&1S.\LWN
M; ?&_K?O#<_S7RG2N7S&-I]B8W=M-7U&ZZO<4T0Q(SGV5!N%ZO.Q8ULZV+BR
M3&=*$B."*+W7N@)^0OR0W#\2_C[V?_,A[.ZJJMS=Y]B5_7/1OQEZ3RV1J,9_
M ,1V]NC'8/96#RTWAG.%K<[E\G1YW>4U-1252+%3X=%R38#%F7W7NAGZM^9^
M\<7_ #$]V_RW>\9MC9_L@_#O8GS-ZV[$Z\VODMDT>1Q&2W/E=F[EPU;B:_*[
M@^UJ<3FL?2U5%,N99JF@KA!+#Y\?-5UGNO=66^_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5'^=-_P!O
MOO\ A.;_ .)D^0W_ $/LCW[KW6U=[]U[KWOW7NO>_=>Z][]U[H@'\V+_ +=9
M?S+/_% /F1_[[K<?OW7NDO\ R;O^W3G\M[_Q2CXW?^\IC/?NO=5O?\):L-E-
MD?RZ^UNH=V;A?<?9?1_SN^5W5';-74SS5%4NXMN9*ADKC6/4%IVJ*E*F"I9G
M=V83@NQ?5;W7NJ7N\=A[_P"[OB%_PK^WWUIN_,#9-=\OMF8'%T<&/?'1Q5?P
M]S5#F.R_%5Q3+45,>4PD,=%-&T2TYIH(Y T\-7*B^Z]UM0Y+L_9&,_DJUW<;
MYN&KZ[H?Y7U1V*=P4$;U:RXB#JDY$5,$:KY)3)2C5&@76Y(0+J-O?NO=$W_D
MQ?#_ !78O\FO^5*>XLON5>T.F-MQ_(?I+L_;]/0X'-;<??\ 6;EJ</'1+4P9
M7'U-"VR=S#$3Q5='/#7T;"::GCJ#'X/=>Z.A4=$[8V!G=V_%#H;([FGW]\G-
MUY;OSYO=\Y7/_:[HCV_NE?X149%\CB*;&PT.YMUPXJ/;NW8Z"GQT6)QU%D,G
M0)')A8H*GW7NB^]D?S =_=?8C^9G2_&7K;JS;G3/\GCIK!397:N[-O9"$[TR
MNT-C2[]R^V,!+C*^@I-HX/#;1@H,=1U;8_)RRY6I,YHH\=CDBS/NO=6Q?'ON
MS9_R4Z'Z8^0W7SU3[&[QZMV'VSM+[Z%J>=<?V!C*;*4L=1&RJT=1%#5*DBE0
M5=6! M[]U[H8/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J/\ .F_[???\)S?_ !,GR&_Z'V1[
M]U[K:N]^Z]U[W[KW7O?NO=>]^Z]UBG$[03+32115+12"GEGA-0BN0=#/&KQ,
MZ*UB5$J%AP&6]Q[KW55/QG_EW]M= _S"_G!\[LU\D]@[]@^<5-T=0[QZHH?C
MK7[-?"0_'W!KMW!+C,^W8F669Y<:&^\:?"'S3E98E@53$WNO=#]\@OAZ>R._
M^COEYU%O+$]5?)OHS$;EZ[I]U9[9[;YPVY]A=@3TU1N#96Y,;!DL-6O3255)
M39#$U]+E8*C$9:&.I,=?039#%5_NO=3^@?B-'UGWCW9\J^T-Y4_:?R5[WQ&T
M-C9K=N.VU_<W#[>V9UT]7-@-E[9Q35F2J(,;2UF0R-=75E7D:JNRF1JI9Y9*
M>CBQ^.H/=>Z#S&_"W?\ TOWA\CNW_B-VQL3JC%_+6JIM\]R==]B=2U/96-IN
MPZ&BIL2O8.W7Q^Y=M2TM5D\3301YO$U1J:7*55+0UU/48J<9/^+>Z]T._P 1
MOBMU[\.>EL9TYU]6YS<'EW)O'L/?^_MV2P3YK=6[>R\E49G<^Z,R])!2T8R&
M;R]743O%34L%)2QF.DHZ>"D@AA3W7NGK!=09>M[XW/WEV)E,=FJO$87^X'1>
MV:%6FI=M8/(+35&=R!>6"&23<>Z<C# M;*-4-/CL?C:*DTL<E45_NO= O\B/
MB5E.P?DS\7_F3UEE<#1]T?&/#=Q[%@VUO&IJ\?A=S;7[PHJ*#*XJLKJ*"MJL
M3645?BL96T5;'C:Q5:.HIYJ65*A9(/=>ZB_ +X0X?X3;)[TBEW%3[Q[0^4OR
MG[R^8G>VZ,?02XF@FW7WKDQ6U5%B*2>>IEIL/AZ*&AH:8/-KF\$E9(D4M3)&
MONO='R]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=57?SPO^W0O\Q7_ ,52[7_]P']^Z]U[^1[_ -NA?Y=7_BJ75'_N GOW7NK4
M??NO=>]^Z]U[W[KW7O?NO=5/UW\N[N"M_FLXG^9S_LR_7B'$_$UOAY'T>WQO
MR#J=N2;DJ=V-7#<@['1AESEZE[2'!M *;]K[<O:8>Z]T;KYC?$KKSYH]*5O3
MV_Z[,[;JL?NK9O9O678^UA3?QG:&\NLZ^+*[9W5AOO(*FC:OP^2@C?PU%-+3
M54#3T=5%)35$J-[KW00O\.>P>WNY/CIW-\O.UMD=IU7Q4DJ]W]3=?]5]5U?5
M>WI-_9;%SX:JW_EH<GN7=62J*RCQE9D8,+BER0HL4:VIJ:B7+5JT%3C_ '7N
ME/\ (+X>GLCO_H[Y>=1;RQ/57R;Z,Q&Y>NZ?=6>V>V^<-N?878$]-4;@V5N3
M&P9+#5KTTE524V0Q-?2Y6"HQ&6ACJ3'7T$V0Q5?[KW4_H'XC1]9]X]V?*OM#
M>5/VG\E>]\1M#8V:W;CMM?W-P^WMF==/5S8#9>V<4U9DJB#&TM9D,C75U95Y
M&JKLID:J6>62GHXL?CJ#W7NA.[?Z@R_<F[.L\5N+*8Z/I'9^:7?^]=EHK3U&
MZ,YMJ:"?;./R*O 84VYB*]/XM/$DWFK<C28R*7300UM/7^Z]T'_SL^(NW_G!
M\:MW] YO<=7LO(9#/=?[]V-O>CHOXF^&W+U/GL=N7;^0>D,U.*VEBRF+ITJJ
M<SQF>E>:))8I&25/=>Z"7JWX3YV3Y\[L_F-]Y939\G=-1\5-I?#CKW9?7,^0
MKL-AMKX;<F0W=F,E/79&&BJ*_+;@SE;"40XZ)<91TPI4J*UIYJ@^Z]U8U[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>ZU4?YTW_;[[_A.;_P")D^0W_0^R/?NO=;5WOW7NO>_=>Z][]U[K
MWOW7NBL?-?X_[Q^5OQ6[^^,VT.RMO]3'Y ].]E=+9[?&>ZYG[/-#C>T<1582
MOJ*3&P[BVT&JXZ*MJ?$9*XHLI1V1@A1_=>Z;?@I\;MW_  _^)_1'Q>W9V;MW
MMQ>@^K]E]3;?WQM_K6IZM-;CMB44>.HIJS&U&Y=T 5CTL$'F>.N2-I [I$BL
M$3W7N@GQOPMW_P!+]X?([M_XC=L;$ZHQ?RUJJ;?/<G7?8G4M3V5C:;L.AHJ;
M$KV#MU\?N7;4M+59/$TT$>;Q-4:FERE52T-=3U&*G&3_ (M[KW0N?&WX8]/?
M&SXY5WQKQ-)6]@;6WC4=CY[N3/\ 8*4V2R&^,]W355E?O/.;B2G@IJ&2IW)7
M9"M>>GIZ2"CIX72CI*>"D@AA3W7NB=TG\L;>J?% _P N^N^1T=1\&(9'V+3;
M>I^N):7L.3JO6DB]5U6\6S\N.>B$!EQ#;@AVU!F&VYXJ$:,VK[FE]U[JUS&8
M2AVIMC'[<V?A\7CL;MK TF$VMM^)SBJ*"##TZP4-&K10SFFI8HXXHP4IY#'&
M+K&]@I]U[H).@>GJSJK;N>R6[\U3;R[A[.W%4[][CW[!2?9ID,O61QP045!&
M0)*? ;>QL-'BL13N3)'CZ2%ZIYZZ:LJJCW7NJ]N[OY:N\]RUG\R3!],]@;/V
MML?^:AU]CMF=Y2[RQ]=DJ[:&1GV?-L'-[AVS34UZ?-OF-L/3VQ]758Y*7)0_
M>+6S0RFB7W7NK*.A>E]D_''I#I_X_=;4U71]?=(]9;'ZHV53U]4:ZH&+V!C:
M;%T1J9V]4]2U/2QM+*WJDD+.W+'W[KW0L^_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4?YTW_;
M[[_A.;_XF3Y#?]#[(]^Z]UM7>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJN_GA?]NA?YBO_ (JEVO\ ^X#^
M_=>Z]_(]_P"W0O\ +J_\52ZH_P#<!/?NO=6H^_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5'
M^=-_V^^_X3F_^)D^0W_0^R/?NO=;5WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM''^7]_,R_X
M4H_S6.JNPOD=\1,-_+JV]U-MKNK=G4PP79^(S>*R-'6X?&X7._:HT=55?>TU
M/C=Q8R,53&)YI5E)A2PO[KW1[/\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[
MKW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?
M]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_
MW[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\
M?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[
MKW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?
M]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_
MW[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\
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M /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\
MP5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %
M2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\
M%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_
M /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\
MP5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %
M2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\
M%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_
M /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\
MP5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %
M2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]TR;FW!_P
MKDVGMO<&ZLK_ ,-6'%[:P>6W!DA2QYZ:7[?#025,WC0E0TGCC;2"PN;"X^OO
MW7NK.OY$_P Z>Z/YC/\ +AZK^4GR I=F4O:.Z=X=K;<SG]P<+-MW&21;+W!7
M8^CDBHYZNM>&0TD,(D_RE@SAG 0-I'NO=7!^_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTPMD?S,/Y^_SF^<_\S#H+^7_BO@IB
M.N/@7\F=S=*5-/WAA<O0U\E!%N/>&W\)4BLIZN=:ZIK%V7D:BJ_R>!8'EC2,
M.INONO=&;_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^
MM_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4
MO_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_
M .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\
MK?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^
MM_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4
MO_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_
M .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\
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MW[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\
M?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[
MKW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_W[KW7O\ MKS_ /!4O_K?
M]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\ ?NO=>_[:\_\ P5+_ .M_
MW[KW7O\ MKS_ /!4O_K?]^Z]U[_MKS_\%2_^M_W[KW7O^VO/_P %2_\ K?\
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M>?\ X*E_];_OW7NO?]M>?_@J7_UO^_=>Z]_VUY_^"I?_ %O^_=>Z]_VUY_\
M@J7_ -;_ +]U[KW_ &UY_P#@J7_UO^_=>Z]_VUY_^"I?_6_[]U[KW_;7G_X*
ME_\ 6_[]U[KW_;7G_P""I?\ UO\ OW7NO?\ ;7G_ ."I?_6_[]U[KW_;7G_X
M*E_];_OW7NO?]M>?_@J7_P!;_OW7NO?]M>?_ (*E_P#6_P"_=>Z]_P!M>?\
MX*E_];_OW7NO?]M>?_@J7_UO^_=>Z]_VUY_^"I?_ %O^_=>Z]_VUY_\ @J7_
M -;_ +]U[KW_ &UY_P#@J7_UO^_=>Z]_VUY_^"I?_6_[]U[KW_;7G_X*E_\
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M]U[H_'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5'_ (4G_P#90?\
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MK:6>7W7NML+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JC_P *3_\
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M7W7N@![C_FC8;XR[B^(\7R=^.';?4'7?S,[1VWTEUYVA'G]L[[H\!NS?E/\
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M*H2LIJ/W7NCI? OX#9;XX]Z?-_YA]K93;U=\B?GIV=M7>&^MO[(R-9E,!MC
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M_P _C_A/4NH:@/YA3%;\@-L.A )']#8V_P!8^_=>Z$;^<3_V7A_(0_\ %_\
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M7PN:Q'Q$Z^QM725>-P&0FIJJEJ8=O)-3U%/,B21R1NKHZJRL& /OW7NJ[_\
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MV/Y5@"#^" 1S[]U[H[W\D7_MT3_+H_\ %2^G_P#W5P^_=>ZLBWO_ ,>7N_\
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M8FHK>Z]T3'_A*A'&G\C_ .*K(B(TVZ_D;)*RJ%+,.QMT(&8C]1TJHN>; #Z
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MTGN[M6BJ,WF3**+#/-MC#984^4KO!+]M33!)*G21 )&! ]U[II^9'\R;XM?
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MF,/E:./(TM72Y&.JAJ*:IIYE>*>GGB=TDC=&1T8JP*DCW[KW0#_)7XM=_?\
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M33CFH\ON*! X5$DJ95#JU0#[]U[J5A/^XMG>/_C'2E_][_%>_=>Z4V^41/\
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M]X0[!VL^4HI\SBJ0M]C/7'/8C$460IY(J"CS"K5>/W7NJZO^$]__ '#1Y_\
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MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!;WE_S)3N#_ ,1;V!_[J:OW[KW5 /\
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MO>OIGAE1<)3YVBHY:G"4GFJ*BU.^XI<]7DQ^)#'5TU,(EBHJ=(_=>ZQ_"_\
MEM=3_"[Y&_/OY#["DIVR_P XN\,'VQ58:DI)Z"#!4U'AJ8U^/BB:JFI&GRF[
MZS=&7J*B"EIFECK:*EF648^%Q[KW0$=X?RO^[,E_,@I/YCGQ)^9<GQOWGOCI
M["=%?(SK7=_2T/=N"W5A-M54,^/JZ&!]P8 8G-4<4*)#42I6B)U1T4025U)7
M>Z]U#Z0_E*[VZ)_F9]Y_/O;GS7[6S>T?DIUQU+A.\^F]S;,PE=DMQ[DZ=IL;
M0XO*S;LACISC,)]KC+OA\;A*.+_*ZFCBG@Q24]!%[KW3OB_Y97=5!_-JS_\
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M93ST=9!#54E5#+355+4Q+/')'.I5XY$8%71U)#*0002"+>_=>Z:-L[8V_LS
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MGW"?_95[]U[KW_05]\?/^];?\T[_ -)]PG_V5>_=>Z]_T%??'S_O6W_-._\
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MW%_]K[W[KW7O^@H[^11_WG-_[+-W%_\ :^]^Z]U[_H*._D4?]YS?^RS=Q?\
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M_99NXO\ [7WOW7NO?]!1W\BC_O.;_P!EF[B_^U][]U[KW_04=_(H_P"\YO\
MV6;N+_[7WOW7NO?]!1W\BC_O.;_V6;N+_P"U][]U[KW_ $%'?R*/^\YO_99N
MXO\ [7WOW7NO?]!1W\BC_O.;_P!EF[B_^U][]U[KW_04=_(H_P"\YO\ V6;N
M+_[7WOW7NO?]!1W\BC_O.;_V6;N+_P"U][]U[KW_ $%'?R*/^\YO_99NXO\
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MC?KK_P"QSW[KW7O^&G?Y67_>M/X ?^D;]=?_ &.>_=>Z]_PT[_*R_P"]:?P
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M?Y67_>M/X ?^D;]=?_8Y[]U[KW_#3O\ *R_[UI_ #_TC?KK_ .QSW[KW7O\
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M?P _](WZZ_\ L<]^Z]U[_AIW^5E_WK3^ '_I&_77_P!CGOW7NO?\-._RLO\
MO6G\ /\ TC?KK_['/?NO=>_X:=_E9?\ >M/X ?\ I&_77_V.>_=>Z]_PT[_*
MR_[UI_ #_P!(WZZ_^QSW[KW7O^&G?Y67_>M/X ?^D;]=?_8Y[]U[KW_#3O\
M*R_[UI_ #_TC?KK_ .QSW[KW7O\ AIW^5E_WK3^ '_I&_77_ -CGOW7NO?\
M#3O\K+_O6G\ /_2-^NO_ +'/?NO=>_X:=_E9?]ZT_@!_Z1OUU_\ 8Y[]U[KW
M_#3O\K+_ +UI_ #_ -(WZZ_^QSW[KW7O^&G?Y67_ 'K3^ '_ *1OUU_]CGOW
M7NO?\-._RLO^]:?P _\ 2-^NO_L<]^Z]U[_AIW^5E_WK3^ '_I&_77_V.>_=
M>Z]_PT[_ "LO^]:?P _](WZZ_P#L<]^Z]U[_ (:=_E9?]ZT_@!_Z1OUU_P#8
MY[]U[KW_  T[_*R_[UI_ #_TC?KK_P"QSW[KW7O^&G?Y67_>M/X ?^D;]=?_
M &.>_=>Z]_PT[_*R_P"]:?P _P#2-^NO_L<]^Z]U[_AIW^5E_P!ZT_@!_P"D
M;]=?_8Y[]U[KW_#3O\K+_O6G\ /_ $C?KK_['/?NO=>_X:=_E9?]ZT_@!_Z1
MOUU_]CGOW7NO?\-._P K+_O6G\ /_2-^NO\ ['/?NO=>_P"&G?Y67_>M/X ?
M^D;]=?\ V.>_=>Z'SI#XD_%3XRRYN?XW?&7X^?'V;<T<$6Y)ND.F-N=4-D%I
M3>):YL#C: U:QGE1*7"GD6]^Z]T8/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T77Y?_\
M9)?RB_\ %=>[/_>:R?OW7NJ9?^$JG_;CSXG?^'-\C_\ WY.Z_?NO=;$GOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[K51_G3?]OOO^$YO_ (F3Y#?]#[(]^Z]UM7>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+K\O_ /LDOY1?^*Z]V?\
MO-9/W[KW5,O_  E4_P"W'GQ._P##F^1__OR=U^_=>ZV)/?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW6JC_.F_[???\)S?_$R?(;_H?9'OW7NMJ[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW1=?E__ -DE_*+_ ,5U[L_]YK)^_=>ZIE_X
M2J?]N//B=_X<WR/_ /?D[K]^Z]UL2>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5'^=-_P!O
MOO\ A.;_ .)D^0W_ $/LCW[KW6U=[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[HNOR_P#^R2_E%_XKKW9_[S63]^Z]U3+_ ,)5/^W'GQ._
M\.;Y'_\ OR=U^_=>ZV)/?NO=>]^Z]U[W[KW7O?NO=4;_ /"B#O7Y0_%G^5K\
MBODC\7>\*GI7>75[]/Q_Q'";1QV9R53#O_?&WMKUL<-=E(ZZ&B'VV;#(\%!'
M4QM&S)5 LH3W7NKC:/=./V]UE2[UW5DOM<5@]B0;IW)F*LM+XZ?&8\5=94R$
M!G;1&DCM8$FQX)]^Z]U3'_+[[;[R_FF?"?<OSSQO;/8_2NYN[]X]]/\ #O:6
MV<VF.Q.R\#UCN',;4VXFXL#%+-A]VY3(U^"GJLR<NM;"?.T&-^RA2)_?NO=%
MNS?\\;<W9G\M/X!=O]68*EV)\N_YAGRAZH^!^+P^4PPJZ/8V^LYN([<WMG)\
M?DFC\U)@FI:F7'03B6]16XP5D4M.M6![KW1S?F+WKNG^67V+\(.PYNP>T.QO
MCO\ (CY,;3^(/R%Q79&XJSL6;&Y;N+&Y*7:V_:&MJO+/@DI,YB11Y&BI3!AY
M*;(#P45/4Q0:_=>Z0F9[W[4^4'\PS^9Q\6!V!VCTML7X(?&3XXYOJC*[$W+4
M=>?>[R[YP.X-SU&\*NLII0N?QN&AI<7CX<=D8ZC#&>FR7WE!5,4:/W7NC:_
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T77Y?_ /9)?RB_\5U[L_\
M>:R?OW7NJ9?^$JG_ &X\^)W_ (<WR/\ _?D[K]^Z]UL2>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NM5'^=-_V^^_X3F_^)D^0W_0^R/?NO=;5WOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NBZ_+__ +)+^47_ (KKW9_[S63]^Z]U3+_P
ME4_[<>?$[_PYOD?_ ._)W7[]U[K8D]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J/\Z;_M]]
M_P )S?\ Q,GR&_Z'V1[]U[K:N]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]T77Y?\ _9)?RB_\5U[L_P#>:R?OW7NJ9?\ A*I_VX\^)W_A
MS?(__P!^3NOW[KW6Q)[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>ZKB^0W\W?^6E\4>U<_P!'?(?YC].]6]M[5I<)6;FV#GLI4U&0QR;D
MHX,C0"MBHZ6I%++58^JI:J.*1ED-//#-H\<T;-[KW0)_]! G\F?_ +V#=%?^
M=.5_^MGOW7NO?]! G\F?_O8-T5_YTY7_ .MGOW7NO?\ 00)_)G_[V#=%?^=.
M5_\ K9[]U[KW_00)_)G_ .]@W17_ )TY7_ZV>_=>Z]_T$"?R9_\ O8-T5_YT
MY7_ZV>_=>Z]_T$"?R9_^]@W17_G3E?\ ZV>_=>Z]_P!! G\F?_O8-T5_YTY7
M_P"MGOW7NO?]! G\F?\ [V#=%?\ G3E?_K9[]U[KW_00)_)G_P"]@W17_G3E
M?_K9[]U[KW_00)_)G_[V#=%?^=.5_P#K9[]U[KW_ $$"?R9_^]@W17_G3E?_
M *V>_=>Z]_T$"?R9_P#O8-T5_P"=.5_^MGOW7NO?]! G\F?_ +V#=%?^=.5_
M^MGOW7NO?]! G\F?_O8-T5_YTY7_ .MGOW7NO?\ 00)_)G_[V#=%?^=.5_\
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M"?R9_P#O8-T5_P"=.5_^MGOW7NO?]! G\F?_ +V#=%?^=.5_^MGOW7NO?]!
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M +RB^.O_ *.S;7_US]^Z]U[_ &;_ .)?_>47QU_]'9MK_P"N?OW7NO?[-_\
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M_=>Z]_LW_P 2_P#O*+XZ_P#H[-M?_7/W[KW7O]F_^)?_ 'E%\=?_ $=FVO\
MZY^_=>Z]_LW_ ,2_^\HOCK_Z.S;7_P!<_?NO=>_V;_XE_P#>47QU_P#1V;:_
M^N?OW7NO?[-_\2_^\HOCK_Z.S;7_ -<_?NO=>_V;_P")?_>47QU_]'9MK_ZY
M^_=>Z]_LW_Q+_P"\HOCK_P"CLVU_]<_?NO=>_P!F_P#B7_WE%\=?_1V;:_\
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M9MK_ .N?OW7NO?[-_P#$O_O*+XZ_^CLVU_\ 7/W[KW7O]F_^)?\ WE%\=?\
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M6]\)O_2:]I__ %K]^Z]U[_AG'^4[_P!ZWOA-_P"DU[3_ /K7[]U[KW_#./\
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MOW[KW7O^@53^1Y_WB=N;_P!*/[)_^ROW[KW7O^@53^1Y_P!XG;F_]*/[)_\
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MG;F_]*/[)_\ LK]^Z]U[_H%4_D>?]XG;F_\ 2C^R?_LK]^Z]U[_H%4_D>?\
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M/[)_^ROW[KW7O^@53^1Y_P!XG;F_]*/[)_\ LK]^Z]U[_H%4_D>?]XG;F_\
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M\D]H4F\>[,I\3=P9+<66WGN/#=:5V&/\&P.Z<SFJ"ER%?EZ*9:G49*W*>-&
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M6_-I;<WGA/NHC#+]INBCAKJ;R(;%)/#.FI3R#<>_=>Z5OOW7NO>_=>ZUV?\
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MMJ[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)G>O_ !YN[?\
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M2K*3=DF16<TF3R_WD&.<318^QCQ3/XDJ4\MYXV@]U[HZ_P#-9^>>XOA;U_\
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M7_[0'OW7NO?]!'?\TW_OF/\ G_\ ^?'L7_[0'OW7NO?]!'?\TW_OF/\ G_\
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z3.]?^/-W;_X;.>_]Q9??NO=:SO\
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MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW29WK_P >;NW_ ,-G/?\
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M]XZ?RL?_ #^9?_[._?NO=>_TG_\ "OK_ +QT_E8_^?S+_P#V=^_=>Z]_I/\
M^%?7_>.G\K'_ ,_F7_\ L[]^Z]U[_2?_ ,*^O^\=/Y6/_G\R_P#]G?OW7NO?
MZ3_^%?7_ 'CI_*Q_\_F7_P#L[]^Z]U[_ $G_ /"OK_O'3^5C_P"?S+__ &=^
M_=>Z]_I/_P"%?7_>.G\K'_S^9?\ ^SOW[KW7O])__"OK_O'3^5C_ .?S+_\
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MW7NO?Z3_ /A7U_WCI_*Q_P#/YE__ +._?NO=>_TG_P#"OK_O'3^5C_Y_,O\
M_9W[]U[KW^D__A7U_P!XZ?RL?_/YE_\ [._?NO=>_P!)_P#PKZ_[QT_E8_\
MG\R__P!G?OW7NO?Z3_\ A7U_WCI_*Q_\_F7_ /L[]^Z]U[_2?_PKZ_[QT_E8
M_P#G\R__ -G?OW7NO?Z3_P#A7U_WCI_*Q_\ /YE__L[]^Z]U[_2?_P *^O\
MO'3^5C_Y_,O_ /9W[]U[KW^D_P#X5]?]XZ?RL?\ S^9?_P"SOW[KW7O])_\
MPKZ_[QT_E8_^?S+_ /V=^_=>Z]_I/_X5]?\ >.G\K'_S^9?_ .SOW[KW7O\
M2?\ \*^O^\=/Y6/_ )_,O_\ 9W[]U[KW^D__ (5]?]XZ?RL?_/YE_P#[._?N
MO=>_TG_\*^O^\=/Y6/\ Y_,O_P#9W[]U[JK;YX2?SBNR?EU_)^@_FUQ?!7X_
M;!P/\Q#I;,=.UW3(W;G:[-9NGW!M^2LQ<B8N7>:QR3TT<$=*U6N.I?N)4\];
M%")9(O=>ZW]_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
7?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tbar_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tbar_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M:>4V]1;7J\GF,_C&Q&/KI\C30IALC)0I*M5404[$R"/41I%KVY]C;W.Y+@Y
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M1ZDUC[8K=Z=E=%U/<% ?F[NCY0YW,YC<>W=^[*VIV!E>K(9L=NN6BBVSAI\
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M5$SA4)H0&#:11E!H1@R;NWL;LG,'LW9^T.^W+2I90P)'=I&(Y%FMQ1)TC9I
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MYGLC.=W;;HL3G,AGMK4.-R%)F5I:M,EF!-C<QX)()):UC2T$5-2K30I' )9
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M^XB\ 7$D:V\4,.*I# C.HK05-0/B*J"S$HZA^"^3Q?3_ ,B.JL5W14XV;O\
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M//LF/O=\7UY*)I6B?8([NVM'0?PZI\CDQ"HDK C(Q 8&QN/=S_:@GT_R=5_
M>C3?*O8^SMAQ?#Z79NVL/MB3;_RMZ?VKA7P=!2X]J' 9=<W_ !3%*\$(9H:@
M8V+S*S'65U.6-[T0DZJ^AZL0!2GKT?.KRV*H*K'T-=D\?1UV6EF@Q5'5UE-3
MU63FIXO//#CZ>:1'F9$];K&&(7DV'MOJ_4\D $D@  DDFP ')))]^Z]T0W=L
M\GS)WG#L';PU?&OKO=-'D.Q]X >2B[=W7M^=*JCZ^VHY!2?$T=0BR9:N&I9'
MC2.$@!)9'!V"OF?Y=4^(T\NI64:+;_\ ,3VQ6Y)XZ2DWM\6LGM?;DDA$25^=
MPG839_(8NFU6#2QT=-YRB\Z6!]^_T+\_\G6_Q_EUGS#Q;A_F";/AQ16J?K[X
M\YZIW5-$I>/&2[DW+X,/C:N95*I42I4+4QPN0QB;6!:Y]^&(C\SUK\?3=\V/
M^/I^&W_BVO5W_NQ7WZ/\7V'K;>7V]'>SN;QFVL)E]Q9NKBH,-@<97YC*UT[!
M8:/'8REEK*VJE8_14CA9C_K>V^K=$Z^&6(R>Z\;V)\EMU4<M+N7Y!;IDS&&I
M*JYJ,)UEMPRX78F&YDE _9ADF9TTB5&A:W /MR3%$'EU1<]WKT*]!'\K!V '
MRE7\>VZL_O!5DT]!CNQT[ _NJ:B<4*BLJ,H^._B B\9E/@\)<,% 4@BO93SK
MUONKTC^]^T=RYK,/\=^D7BK.V=UXM_[S[F&N7#=,;-R"""JW;N&: BV0EBF8
M8>@#+))(5E:R",2[4#XFX?X>O,?PCCT!7R6ZWVWT;TW\4,-@%--L?IKY)=/Y
M7.Y*I\<;18R.LS<F:W+E98U1%>HK:\S5#V5?)4\6%A[LA+,Q/$@]::B@?;T(
MGSFE@R^U.DMDT+I5;BWM\A>LH,!00CS3SP8ZLJ:W*918XP[?;4L3H:B8#3&L
MJEB ?>H^)/H#UY^%.A;[T[JK-AG#]?\ 7>*BWEWCOY)J;8VT%>]-C*>SQ56^
M=XRQ\TF&H""\LCE3.R>&(_YQXJJM<G '6R:8''HNW;G1DG4GP2[EV=0Y*?<F
M[<EA\EO[L'=3P:*K=6ZZO-8G.[RSLT:+<1^#'O%&&N5@@3620S&ZMJD!ZT11
M.@N[9Z_P/5_Q:P?R&ZW[>[83L/'8/KG/;6W-ENS]Q9ZEW1/G:W TYVW4;7JJ
MP8Z:FDIJZ9$H:>CB"+%9D:*.1#M26?21C[.M<%J./0@_)_;=5V'\A_@[@,IF
M=U['K<_1=V29#*;&SE1MO=&$JTV-MK)55/B,W'%++ 2\#4\K!=31.Z\%KC2&
MB,>/#K9R1T<[JWJN'JRBRU%#V!VIOY<M54]4:GM+>];O:MQQIXGB\&)JJZ&)
MH(GUZI(Q<,R@\'ZMDUZL!3H5/>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(KL#KG8_:FV:S9W86V
ML;NK;=<\<LV-R4<EHZB(.L-;15=/)!/35""1A'44TL4JAF"N 3?8)!J.M$ \
M>@GZZ^)W175^Y:;>6VMH3U.ZL? ]+B,]N?<6X]W5^#I'CEA^WP9W)E<DE):.
M9XQ) B2:'9"Y5B#LNQ%#UH*!T\]I?&[I_N/,8W<F^-L3S[GQ%&,;C]SX//9_
M:^?AQJRSSC'29/;N2QLDL >JD98YC(%,C%=)8W\&9<#K94'CTK.LNHNNNG<!
M-MGKG:]'MS%5=7+D,@(YJS(5^6R$RA):_,9;*U-=554I"A=<\TA"C2ME 'O1
M8MD]>  X= 11? OXI4,BM%U9Y:=)S4+C*W>O85?AA*9?-=L-6[KGI6 ;Z(\3
M+_A[MXC^O6M"]&KPF#PVVL3C\#MW$X[!8/$TT=%C,1B**GQV-Q])$+1TU'14
MD<4<:#\*B@>Z5KD]6Z1':?3_ %YW5@*#;/9.!?/X?%YRCW)C88<OG,'4T.<H
M*>MI*3(4V1V_DL54*Z1Y"90/+I]=R+A2-JQ7(ZT0#QZ16P/BWT5UEN./>&T]
MBQINJ".2*DW#GL]N?>&6Q\<L)IY1C*S=V:S;4I:-F1FI_&Q5F4G2Q!V78BAZ
M\% R.A(PG7&S]N[DW[NW$8N2ES_9D^'J=Z5QR.3G_BTN Q/\#Q31T]162Q4W
MBICX[4J0ZOU-=K$:J2*>G7J>?21/Q_ZH;J:@Z0.VI3UGC)*&6CV__'=P"2-\
M=N%-TTA;,#*"M?371B8AJ@@_H/H]/O>HUU>?7J"E.ECE^O=I9W>NS^PLIC'J
M=V["I-Q46ULF*_(PIC:;==+346=1L?!5QTTQFBI$4-/%(4M="IY]ZJ:4Z]3S
MZ!S>7Q!Z!WUN?+[MSFS:N'*[ED\NZXL!NK=FU\5NV0^0O+N3#[>S>-IJIW,S
MM+(T8>4L?*SW/NP=A@=:*@FO0F;BZ=ZWW1UY3]4Y3:])'U]2+@TI-M8F>MP5
M%2Q[<R5'EL1%3OA:F@E18JB@BD*JX#E3KU7-ZZC75Y];H*4Z==[]<[.[%3:J
M;QQ'\7796],%V%MD"NR- <;N[;1JCA<K?&U=(9?#]Y+>";R1/JLZ,+>_ D<.
MO4KT$F[NG\QV#\BNMNR-Q"AI]D=*;=SU3LVF@J3)E<]OS>WAHLO5Y&)$40T6
M/I,12M A<M)4/JXC1E>P:BD#SZU0EJ^0Z,)E,919K&9'#Y.#[G&Y:@J\9D*;
MR30_<45?3R4M7!YJ>2*1-<<K+J1E87N"#8^Z=6Z*-3_ 7XKTD*4]+U]F::GC
MU>."G[-[3AA36S.VB*/>BJ+LQ)L/J2?=_$?_ % =5T+T+V]?CUU'V%M#:6R-
MV;6.1PNPJ?'T^S*B/,YVBW!MI<70TV.HY,9NBBR=/D0_BHX1*SU+^8Q(TWD9
M01H,0:CK94$4Z=.J^D^M>EZ#*4/7FW%Q#9VK2OSV4J\AD\WGL[61B00S9;.Y
MNLR%5/XQ,_B1I=":VT*I9K^+%N/7@ .'09;O^&?QXWWN*OW5NK9^<RF<R.:J
M-PS51[([,I88<S4SM4RUV.H:/=]/!2-K8LBTL<*IP$55  V)&&!_@'6M*]"2
M>D.N#U35=*-B<G)UU64E90U.(GW5NJIKYJ3(9:7-UD$FY*G-39,K)43N2IJR
M-#&+_->CWK4:ZO/K=!2G0D8C$XW XG%X+#T<./Q&%QU%B<504X*P4.-QU-%1
MT-' &+$)%%"J*"3PH]U.<GK?3C[]U[HK6Z?A=\<=Y[KW#O;/[&R,^Y=U5YR>
M?R-%OWL/#C(5I729WH\1NJA@3\V6.-%%S8"Y]W#L!3_-U72O2^VY\>^H=K==
M[@ZHQFT5J.O]TU=76YW;V>S.X-SQ5U36T^/III36[BRN4J8RHQ5.\/BFC\4D
M0EBT2>OWK42:^?6Z"E.D_P!;_%;H_JC<<&[MH;2J5W'0T,F+P^5S^Y=S;KJ-
MOXR6-X7H-O\ ]Y<OE%HT,<C1%H CE&*%RK$'Q=B*$]:"@9'6'L7XF]"]K[PJ
M-^[XV;6Y/=E7CZ/%U.7HMY[XP#S4% @2EIVIMO[DQ<("A1>T8+6!:Y%_?@[
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M &?# _\ >-7R]_\ 1-T?_P!F'OWA_P!(?MZ]J^1Z]_L^&!_[QJ^7O_HFZ/\
M^S#W[P_Z0_;U[5\CU[_9\,#_ -XU?+W_ -$W1_\ V8>_>'_2'[>O:OD>O?[/
MA@?^\:OE[_Z)NC_^S#W[P_Z0_;U[5\CU[_9\,#_WC5\O?_1-T?\ ]F'OWA_T
MA^WKVKY'KW^SX8'_ +QJ^7O_ *)NC_\ LP]^\/\ I#]O7M7R/7O]GPP/_>-7
MR]_]$W1__9A[]X?](?MZ]J^1Z]_L^&!_[QJ^7O\ Z)NC_P#LP]^\/^D/V]>U
M?(]>_P!GPP/_ 'C5\O?_ $3='_\ 9A[]X?\ 2'[>O:OD>O?[/A@?^\:OE[_Z
M)NC_ /LP]^\/^D/V]>U?(]>_V?# _P#>-7R]_P#1-T?_ -F'OWA_TA^WKVKY
M'KW^SX8'_O&KY>_^B;H__LP]^\/^D/V]>U?(]>_V?# _]XU?+W_T3='_ /9A
M[]X?](?MZ]J^1Z]_L^&!_P"\:OE[_P"B;H__ +,/?O#_ *0_;U[5\CU[_9\,
M#_WC5\O?_1-T?_V8>_>'_2'[>O:OD>O?[/A@?^\:OE[_ .B;H_\ [,/?O#_I
M#]O7M7R/7O\ 9\,#_P!XU?+W_P!$W1__ &8>_>'_ $A^WKVKY'KW^SX8'_O&
MKY>_^B;H_P#[,/?O#_I#]O7M7R/7O]GPP/\ WC5\O?\ T3='_P#9A[]X?](?
MMZ]J^1Z]_L^&!_[QJ^7O_HFZ/_[,/?O#_I#]O7M7R/7O]GPP/_>-7R]_]$W1
M_P#V8>_>'_2'[>O:OD>O?[/A@?\ O&KY>_\ HFZ/_P"S#W[P_P"D/V]>U?(]
M>_V?# _]XU?+W_T3='_]F'OWA_TA^WKVKY'KW^SX8'_O&KY>_P#HFZ/_ .S#
MW[P_Z0_;U[5\CU[_ &?# _\ >-7R]_\ 1-T?_P!F'OWA_P!(?MZ]J^1Z]_L^
M&!_[QJ^7O_HFZ/\ ^S#W[P_Z0_;U[5\CU[_9\,#_ -XU?+W_ -$W1_\ V8>_
M>'_2'[>O:OD>O?[/A@?^\:OE[_Z)NC_^S#W[P_Z0_;U[5\CU[_9\,#_WC5\O
M?_1-T?\ ]F'OWA_TA^WKVKY'KW^SX8'_ +QJ^7O_ *)NC_\ LP]^\/\ I#]O
M7M7R/7O]GPP/_>-7R]_]$W1__9A[]X?](?MZ]J^1Z]_L^&!_[QJ^7O\ Z)NC
M_P#LP]^\/^D/V]>U?(]>_P!GPP/_ 'C5\O?_ $3='_\ 9A[]X?\ 2'[>O:OD
M>O?[/A@?^\:OE[_Z)NC_ /LP]^\/^D/V]>U?(]>_V?# _P#>-7R]_P#1-T?_
M -F'OWA_TA^WKVKY'KW^SX8'_O&KY>_^B;H__LP]^\/^D/V]>U?(]>_V?# _
M]XU?+W_T3='_ /9A[]X?](?MZ]J^1Z]_L^&!_P"\:OE[_P"B;H__ +,/?O#_
M *0_;U[5\CU[_9\,#_WC5\O?_1-T?_V8>_>'_2'[>O:OD>O?[/A@?^\:OE[_
M .B;H_\ [,/?O#_I#]O7M7R/7O\ 9\,#_P!XU?+W_P!$W1__ &8>_>'_ $A^
MWKVKY'KW^SX8'_O&KY>_^B;H_P#[,/?O#_I#]O7M7R/7O]GPP/\ WC5\O?\
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M^&!_[QJ^7O\ Z)NC_P#LP]^\/^D/V]>U?(]>_P!GPP/_ 'C5\O?_ $3='_\
M9A[]X?\ 2'[>O:OD>O?[/A@?^\:OE[_Z)NC_ /LP]^\/^D/V]>U?(]>_V?#
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M/?O#_I#]O7M7R/7O]GPP/_>-7R]_]$W1_P#V8>_>'_2'[>O:OD>O?[/A@?\
MO&KY>_\ HFZ/_P"S#W[P_P"D/V]>U?(]>_V?# _]XU?+W_T3='_]F'OWA_TA
M^WKVKY'KW^SX8'_O&KY>_P#HFZ/_ .S#W[P_Z0_;U[5\CU[_ &?# _\ >-7R
M]_\ 1-T?_P!F'OWA_P!(?MZ]J^1Z]_L^&!_[QJ^7O_HFZ/\ ^S#W[P_Z0_;U
M[5\CU[_9\,#_ -XU?+W_ -$W1_\ V8>_>'_2'[>O:OD>O?[/A@?^\:OE[_Z)
MNC_^S#W[P_Z0_;U[5\CU[_9\,#_WC5\O?_1-T?\ ]F'OWA_TA^WKVKY'KW^S
MX8'_ +QJ^7O_ *)NC_\ LP]^\/\ I#]O7M7R/7O]GPP/_>-7R]_]$W1__9A[
M]X?](?MZ]J^1Z]_L^&!_[QJ^7O\ Z)NC_P#LP]^\/^D/V]>U?(]>_P!GPP/_
M 'C5\O?_ $3='_\ 9A[]X?\ 2'[>O:OD>O?[/A@?^\:OE[_Z)NC_ /LP]^\/
M^D/V]>U?(]>_V?# _P#>-7R]_P#1-T?_ -F'OWA_TA^WKVKY'KW^SX8'_O&K
MY>_^B;H__LP]^\/^D/V]>U?(]>_V?# _]XU?+W_T3='_ /9A[]X?](?MZ]J^
M1Z]_L^&!_P"\:OE[_P"B;H__ +,/?O#_ *0_;U[5\CU[_9\,#_WC5\O?_1-T
M?_V8>_>'_2'[>O:OD>O?[/A@?^\:OE[_ .B;H_\ [,/?O#_I#]O7M7R/7O\
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M]U[KWOW7NJL?D1_,4[KZHWWV=M;IK^6?\R_D[M3I5X8NR.U=GGIWK?9-1/\
MW>QVZLE2=2TG;78^U,SO=Z*CRL25$NW\544QJQ+115$E33U$<7NO=&X^'GRR
MZ=^<WQKZI^5?0F5R&6ZL[?P55F=O/F*./&YW&U6*S.2VUN/;NX,=#55J09#&
M9/"UF/K8HYID$U,_CDDC*NWNO=(7YL_-_KOX1;+ZYS6Z=F=D=K]A=W]J8'HW
MH7I3J'!4F>[#[:[9W-CLOEL5MK%?Q;)87&XZDCI<%5561S.7KJ&AHX8B\TP9
MHT?W7N@+^/O\R?,]@?)K"?#[Y+?#_O/X5]\[]Z[W7VKT]A^T-U=*]E;.[;V=
ML.MQM%O>/:^_>C^Q=_4,65Q0S%+4U>+K/ X@E\JNP%C[KW29SG\VK8>&[$W#
M".@>XLC\:-G?+K"?!K=WRYHLGU>_7.(^0^;W-@^NVQ]/LAM\KNJKV_0;OW'2
M;0RFX(<08X,GY@(9*2"6J7W7NC6]O_+*AV!\C_C_ /%/8FQJ_M;N3N<YG>VZ
ML5CLU%@</TI\>-G20T6\^\^P<S)B\P$A_B.1H<'MW#+''/F,E6&*&6"FI*ZK
MI?=>Z-[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[JOC^8K_,&VK_+PZ_Z/WAGNGNT.]-Q?(CY+];_%+JWKKJ:79=-N
M7-]J=JXG=V3V?2SUN_-S[3H(*>HDVA)1"5ZKB>JAU!8O)+'[KW4[XJ?+WOKY
M![\SFTNTOY>7R>^). Q.T:O<='V)W7N3H'+;7SF8I\SA,93[+QU'U?VUOC)B
MOJ(,I45T<LE"M*L6.F62>.5Z>.;W7NC\^_=>ZIVVY_.N^+G8/SO^/'P:ZGVM
MVSV3)\CIN[L=LKY)8C:AQ/QRR>>Z$ZWR_9>^\3LO?&X9\8^ZHZ2GQ'V-3D]N
M4^0H(JNIAA^ZD/F\/NO=&Y^4WS%I_CQOGHCIC9O4&^/D%W]\C\AV .LNIMB9
MS8>UIQM7JC;M)N3LGL+=V[.Q=R[9QV-PN*7+XNA>;R5$\U;F**GA@?R.\7NO
M=);8/\QOX_;J^%&Z_G/NT;KZIZSZTC[.Q?;6T]ZXNCJ.PNO.PNF]YYWK?L/J
MVJPVU<CN&GRF;AW#MV?$8R##55>F2FEIOLGE^YBO[KW1F^@]^[^[1Z;Z\[&[
M/ZGK^B]\;VVY2[DS7468W+1;MSVP$RLDM5B=O[ES>-QV+IFRL=%)3-E::F26
M*EJWFI8ZBJ2%:J;W7NA>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T&G=
M'_,G>V/_ !&F^_\ WELK[]U[K5V_X3[]XS_&3_A,[N'Y(4N(.?JN@=C?.KNB
MDP6F5ES-7UAG>S-ZTN*E,()2.HDPJQ22&RHKEV954L/=>Z(-\9_A+VG\^?Y+
M_:?\W[N'^83\T=M?-_=VPOEGW_L/>V!^36YNI^E^HY?C_O/LG;V(VI1;1P!Q
ME!A\#6)T^W\1J:>2 4=/6^2#Q&F6_NO=0OGYV9OW^9=_PDMZT^='>W8O:F+[
MGZ<?:]+N.CVAN;'[>V#WWN#%?,#:/Q?K]P=S;7I-O1PY>&:DI$W-2TM+_#4H
M\[&DT9>&'Q2>Z]U;Q_+G^,?47PS_ )$U#VGO3YS_ "DZLV;\D/@]\?N[.Q>\
M>Q>TZ3=5?\4XMY]!;/EGPWQ?IZ3:./DP..QTFY6I=LXA8\Q4K.U)%$U3,$C?
MW7NJ#.X.[.H?CWWO_*X^0?\ +8[8_G%8P=O_ #!Z+ZZ[)[:^83?)0_&[Y9=3
M;[KL=2U-5'G>Y\;28?<==64-9)'34V,$$*T-3-5P4R304]5#[KW5X/\ -2_[
MB$?^$_?_ )=E_P"\-3>_=>ZVE/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=59_S U_G!9!,_@OY=V&^"PV5E.N(J:?<_?N^^Y\'WCCM\5%;GH]PP;"P6
MV>O<[M0 XX4"X/(9G)>.*OED>LI)*6%5E]U[H.?Y"^Y/CG-_+<ZMZF^-VT]_
M]=XGXQ;Q[/\ CCVWUKVQE-IYKM#87R$V%O+(9/N3%;[R>QIY\3-65^4W.V=A
MEHE@C>ER],X@@U>%/=>Z0G\\:DVEN38OQ)V-L;.]@XG^8-E?DMCMT_RVH^L(
M-L5N<7OW9&U<U6;HSV^\?OFOQ>$EV#CMN9.MDWN<C.FFBE04RRU;00R>Z]T4
M[XK;H^3NTOYL/31_G/[?V?1_+KL+H[M'KK^7;O3XT.9_@_\ W<QF-VKNSY%;
M9QL>Z:M]XTO:>4@QL%56S9R/^&28FC,&-\#LL<_NO=+'YB?#C<7Q9ZN[PS._
M_D+M'*_ /,?.?;?SQQ_QRP'3N;JOEMV1\A,]W;@^[-N_$CJ[M7(]PI@JNEWW
MVS2XPXTR;6CKH(,G/CQ/'&%R--[KW2-ZC^5W:_PNS_S;[X[;^,U7\C._ME8G
MK;OC^:SW+M#MC:6VZ#XP[%SG7F;[%ZF^*7QWVEGJ'+U>\J?JS8U51U^3HON]
MKTU7+FZW-0SSU^3:C/NO=;->#S6-W'A</N'#5*UN(SV+Q^:Q58BNBU>-RE)#
M74-2J2*K 213JP# $7Y'OW7NG3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U5S_-0^ W9/SXV)\5<=U%W-M+H_L7XJ?-CI;Y
MF[2W1O?KK)=G[9RNX.E,/OR# [<RNU\5O+8DSP35VZZ:HG*Y"/5%2R0@JTHD
M3W7NB[]2?-7YN?'?^8IT5_+R^?\ 6_'/MJE^7W6O<&^OC!\A?COLWL#JROJ-
MT]&8.#=F_>L^T.J=U;F['IZ9OX+!5Y2DS%'FXX;I%2F.668^'W7NKSO?NO=:
MX/SOQF.PW_"@K_A/CB</CZ+%8O';#_F8T>/QN-I(*''T-)!\5<A'!2T='2QQ
M1Q1HJA41%50!8"WOW7NK._E[\3.W.V.Y_C%\HOC=VMU_U;W[\95[<VI01]O=
M=[F[/ZM[!ZE[WQ>T:/LC96X<!M#L?K'(4=:M7U[@<IB<O2U\I@EQ[0RTTT-0
M^CW7NM??9,46PJSJW 5E-7_+'H+HWY][IP76V(P,VV^N=O?S'_YRW?7:>_NW
M>P][86++[ASM!@^J.BZNIW*:%:Z;-R?Q;;T]6O\ $*K;U/45WNO=;'/PU^7.
M0^3])W5M3?O5%9T5WW\:>T:3I_OCJB3>6-[(PFWMVY3K[9G:&!RFR>QL5B=N
MQYS"9/#;\H*JAKI<7B:@DR1U%%3R)I/NO='2]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]TFMZ;=_O?L[=FT_O/X=_>C;.=V[_ !#[?[O['^-XNJQOWGVO
MGIO+XON=?C\D>K3;4M[CW7NJWOY97\LK;W\OG^7YB/@'N[LFF^1VTXI.W:7<
M^ZJWK\];4>[-O=O9[/93-;?J]GKO;?YAB6FS\M%(XRDOE4%],>K0/=>ZJ'H_
M^$X/R8V+U[OOX:=)_P WWNOK#^6+V1F]T2YWXIKT;L7<78.+V/OJK;);VZXP
M??&2W+]W'1Y*=I1/)'C::"2.MJ%JZ"L>6JDK/=>ZN0[1_E6_&GL#^6+F/Y5.
M%I<OL;X]3]2X3K';E?C31Y'<VW\AM?<&+WSMSL"H>JAAAKLJFY,-3Y^N>58Q
M5U1E9]/E)'NO=$HZE_DD=BUW\L+NC^6%\T_G/N_Y2]9[UVKUIU]TMNC!]2;?
MZAK?CQL/I2HV]F>JL+MW'4FZ=VOF#097:F/JYWR=8SS4U,F.>1H ']^Z]T73
M(_\ "?GY;=P;>^'>"^5_\W'>G=>-^"_<_3?8/0^S\7\4NMMA=>)L_J2NH'_@
MF\\5MW?%)ELMN"KH<128F@W)79NI&.I8YM5%7SU=1.WNO=6C?*G^6I_LS/\
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M40AHX*5)H] F]^Z]T"'>W\KGL/N[K_X#[UG^8F\,!_,!_E\8K)R=9?-";K;
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M]W-LGL3!X6HJ,742NL0K*4SHCNB3>-I8@_NO='[=UC1Y'.E(T9W-B;*@+,;
M$_0?CW[KW5(^P_\ A0-\ NU-OXG>'5N ^:/9FR]P5%93[?WIU_\  WY9;PVG
MGCC\K5X.N?"YS =55\-2(:R@GII5B9G26%XG42(R#W7NK&_DE\N^HOBW)UGB
M=_P]@[GWQW-N/,[5ZGZNZCZWWCVSV;O[*;:V[6[MW3+@]G[)Q65J%HL5C:!Z
MO)9*K^VI*</$DDPEG@CD]U[K+UW\Q/CEV=\:*CY>[?[*QF-^/^+VUO/=.ZM\
M[RH\KL;^X-#UK69K&=DT'86#W90XBOPF0V]6;<R%%F<?D::"HI:BBEBDC#+S
M[KW2^Z%[AQ?R!Z=Z][JP6T-_[%V_V9MVFW;MW;7:6WH=I;\IMN9.2:3;^1W!
MM>/)91\>V0HQ!D8*.JDCJHH*N)*N"FJA-31>Z]T+GOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM-'^=%0T'R;_X42_R
M7_A+W7A*C.?&BAV9D^]JK;V2K,M'L_?/859G^W*N7!9G'0P/2U?@_P! F IY
MHF\A>GS4M/-X:>I9G]U[K;MRG4W5F<RW7V>S/6VP\KG.I<A+ENK,QD=HX"LR
MG6^4GV[F=HSY#8E?44$DN)F?%;BK\:TE T!--630$^.1U/NO=:3/7'0/SK^2
MG\^G^>1UE\,OF/A/@YB:N7X\Y+N#N>EZHINWNT:F&DZ_Q46Q-G=?8+*;AVG2
M4-/6RU.3FS&5&0@JX!24J4NH2S#W[KW1@OA3_.7^6O0W\J3^;/VA\O\ >.$^
M0_R+_E?_ "*WC\>=M;\R& &*A[!SV=WG@>JNM6WK%MF#'I5TT.[<U*DE1!%2
M3'&K$D\GD1JIO=>ZK)W)_.@[L^.7Q<^-7SLVG_.PH_E_\KLWG>LM[?*/^7-N
M78^P=M]82;([$2LRVZ>I]CPX3K6*MP66VHF;I\7D,G!72ZIJ2:KB7Q0Q4<GN
MO=7,?+KY$_S,.Z/YY,_\O3X<?+?'?&?JOM+^7EMGM;)[CWAUIM[LN?IJIFWX
M:S<'9W76S:F/'');KJ8,52;>AI,EF:>@@I<K6UB$5E/3,?=>Z)W\1<I_/A^2
M7RE^??\ *:F_FJ;3V;0?"W<&W,QG?F;6?'7$[M^1&[,3OK$TLG7FR-JX:+<V
MW:"@Q==3TTN1S-95Y&KRV/J3X*:OK:>0I'[KW5G/\A[YS?+[Y*?!#YF8+Y?[
MXH]]?)?X4]]]^= 93M/'T>%@GW-+L7:=)G<;D*U<1@\%15,V/R%764,%4M!"
M:BEI*:2H5YVE=_=>ZJ^V[_/-^6_0/_":'K?YP;W[%?M7YD]W?(3?_P =>O.R
M=XX#;%0N%R\N\NS<E3[IR.V\5A\9CZA<-MWKNN2C26D:%JHTHJ5E1F1_=>ZO
MQ^&OPE_F7?&O>4.]>]_YJ&Y?EEM7<72^ZJ/L/K+M7I_8>WL#M?O>MIL%5[:W
MWUUNW;]-+7TV"QDE'74L^(E:"*6*?[AE,@6.+W7NM9/Y_P#\QOMOX9]3+WKT
M3_PHZQOS&^9?7G8&U*7?/QDVYU;TG6?'GL#!U>[XJ;=>V]L;8V=A9XJ"FQEY
M&J:_^+UM9-10O%%+22R1SQ^Z]U:;_P *.-PR[NV3_)$W7/31T<VY_P"9_P#%
M;<,U'%(TL5)+FL3+DI*:.5U4LL9J2H8@$@7(]^Z]UM>^_=>ZU2/^$WV/H,KW
M;_/JQV4H:/)8^K_FF]P0U=#7TT-91U41WGV23%44M0DB.IL/2RD>_=>Z*]\8
ML)MKX8_\*7_YH70GQ5JL=LKJ+LGX%5O>6_NKMFXW%X_:_7G<.'VKU=O/!UU'
MC<?2>.CDIY]\Y#)4L $,4:[ODC$93P >Z]T+W_"?W<_\WO\ F!]?_&7YX?(W
MY_H/CKU_G^V]@93X]T766U:K/?)R&@R_9=#-O[LW?&&3;7\'K,5E=S8_&XVA
MI:*KADHMITTA6&:KJ99_=>Z-O_)A^9?R;^1G6G\WK.]V=M9SL'+?'?YP?);J
M_IBKR^.V[ VQ-A[%P$E9M3;F/BQ>&H(YXJ.4:EDK5J97^DCN./?NO=%G^&'\
MSKYN)_PF4[4_F)9K.Y'Y$_+;8N)[PK\7N/<N'VZ33TF"[GFV1'O',8+#T. H
M9Z':.$GFSU73+"GGI\1(C:V<ZO=>Z('0_)/Y9]G][?RJ^D?C!_PH"[/^2F]_
MG#0Y"O\ E;@>I]F?&C>^<^.,]!USMO<U;N&+;VU]@Y*';-#2UE16453@MRR4
MU6HHWG34?N#'[KW6^O[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[HH7S7^675/P8^.O87?'8-(^2EID&*V+UOMS'KD=
M]=Y=P[FC7#]?=2["VW1H:C+9[<.0--CJ6GB21@K&64I!#(Z>Z]T6C^2A\.^Q
MO@C_ "T/C7\=>X*C'OVOB,7O/?O8V-P]!CL7B-K[M[>["W5VGDMDXZ@P[-1H
MF#_O<N)D:C$=/)+1R2P1Q1.D2>Z]T>+Y%;X[1ZTZJSV_>E/CWE?E#VCM^HPR
M[7Z<P&_>N>K\YN-,OF\;B,[4X[??:N6P6$H?L*"MJ,A,*JKB,\=*T$6N:2-&
M]U[K7]^#>_-V=K_SO^V>[_G-TIO#X1?,S<?PA@Z-^,WQ8S<N$[%VMO7XQ;/[
M9C[&W[VO2?)/KW*Y7:VY=PG+Y2AAK-OTJT=5BJ:%U_RR%#4+[KW6'Y'_ !,[
M_P#C]T[\DNO.U)^B]L_R^Z#^88W\SG=WRE3L?=U=WOA>NZ7Y$8;Y?[OZ.QOQ
MVQ?3ZQ93=M;N[ IM/;5?1[KF6IH\I3,*26OB3'U'NO=/O27S5VAT+W+WY\P_
MFSU/\@LC\B]Y;'Z_W'W/'L#KL[_ZT_E7_"/<HW#N;H/J;MO<+YC$-197)TN'
MDWEV1%M:BW#7+DJ])*Z)</C,?4Q>Z]ULJ45929&CI,A05,%90U]-!645932)
M-355)51)/35-/-&65TD1U9&4D$$$>_=>ZD^_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHM1!1,\-950TK28_S3T]541Q%Z'7
M \51-#/(+Q7C=E=E*W4D'@GW[KW5 /Q/I(_F]_.A[\_F/=7O&_Q9^-GQ1;^7
M1UQV'!A**/&?(WM^'N&3M?N3>VPMVQ&.?*;8VG4:=JI5'[BCJ,E'5-02*(*I
MJCW7NM@*IC::GGB4@-+#+&I:X4,Z,H)(!XY_I[]U[K4P^(F=_F=?R#?Y:O7V
MPOD'\,>C?D#\8?BE2=E[H[=[(^.ORBR-9W=@]B[W[7WMV?G]ZX_JGL/I[96+
MR,6&.^3'-1T^XDD>GI'J&>%=8C]U[JVSY#;![9[T[6_E[_S)?A#CNJ.]X.N>
ML^V*.GZ_[&[+R/4^W^R^@/F)L[JK<='OW8?8V'ZV[5%-F,=+UW@ZREIJG'K3
M5E#75D1J89/$7]U[JF# 1G9NW(_BU\AILEO/XY]._-+=G;WS9V[T'A-R[ZQ?
MRI_F&_++O;.=]=,?RS>@J&LQ> GW9MK9<F^*++=BY&K3$T=3-BJ2CR24=(^;
MHZ/W7NMF/XJ?+3KGY9[5WGE=F[<[#ZYW=U5O>7K#N#IKM_;5'M#M7J'L&GV[
MM_=G]TMZ83%9C<F/+R8O=..KJ2MQ.3RE!4P5224M7,MR/=>Z-+[]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JD7^<7_*
M(RO\QV/X_P#=71'=]9\9?FM\1]U5&[?C]W.E)69/ 1_=U^(S%7MG=N+HG:3P
M&MP%)4TM;'#5F B>.2EJJ>IF@;W7NDK\->F_^% >4[RZJW-_,$^5'PLPO0G5
ME5D\ANGKOXN;$W3D]\?(>NJ=C;CVSC*3?>Y=W[4VC382AI,CEJ3.DX5$%1/1
M^!J.*'QE?=>Z$CX6?RZ^[/CC_-*_FA?-W>^Z.K,KU3\V/]"'^BO;^U<WNVN[
M"P'^C3;DV'SO^D#%9?9&#QM+Y99 U)_#LME=2\R>(^GW[KW1.OC_ /R(MY_Z
M"OYTGQU^4V^^M*O8W\SCY0=@=U]:9?JJLW+NK,=;X?)[TS&_^MLYO#&;RV;L
MF 9O#9<XO(O044]=3&2A*)7$$./=>ZR?$[XV?\*./C5LGI'XBT_;?\JK(?&'
MHC$[,ZKV]W?4;9^1^4^0U;T;U[1X_;FV**#:<B8_;*YL87&T]((ZJGEAAE0E
MJRL""2H]U[HX/_#=?=G_  ^G_P .<_WHZL_T"_[(]_LM']TOXWNW_2[_ '[_
M +Y?WB_BW\!_N1_!OX1X/3Y_X_\ <:^/M=/J]^Z]U[X6?RZ^[/CC_-*_FA?-
MW>^Z.K,KU3\V/]"'^BO;^U<WNVN["P'^C3;DV'SO^D#%9?9&#QM+Y99 U)_#
MLME=2\R>(^GW[KW20_E<_P LOOCX2["_F7;6[5W;U'N#(?,KY9=]=[]83=?9
M[>65H\%M#M+#/CMOX[?DFX]A;4>ER4+M>LAQ\>4A1>8ZB4\>_=>Z(5M/_A.O
MV%O;^0SM;^55\@.T^K<1WSUUW%NOO7KCM;K:;=V]>L]O[\JMZ[SR6WWJUW/M
M3KW*5%/4X'?63P^1TT$+0&O:6'[CQ*LGNO=&TZ&^)_\ .[[RV!W#T?\ S,OD
M_P#%#;_36[OBGVU\=<//\0<'V!6]L;RWMVGLF38=/W;OK>.^L+M2*DK,#3S3
MUM%38J&"&MJZV1JBE@6"$M[KW53FX?Y$?\YC?'\LC)?RH:SM[^69U]\?NM]P
MTVX.N]Y;,VGW=3]F=^U.-[)EWQAJ?N;/?W:FHMN>.;(5&3K<GBL'FZVIJ(:6
MA<M#]U75'NO=72?S1OY9??'S:V%_+1VMU5NWJ/;^0^&ORRZ%[W[/F[!SV\L5
M1YW:'5N&3';@QVPY-N;"W6]5DIG6]'#D(\7"Z\R5$1X]^Z]U>7[]U[K47Z3_
M )6/\^;X7_(/YS[G^%OR%_EK[;Z=^:'RO["^0-?E.W:/O?=_:FTL;O/=VX\K
MC'H-O4/4L>%_B&/H=QLK44N1JZ:>>!;U"1N2ONO=6'_RY/Y,^0^%M#\M.[NZ
MOD'EOEM\^?F?@]QXOM_Y%[PP[;8Q-/C\E35;8K9>T<)%49V:AQ,=2U(U48F6
M-H\?104M%24M#2TJ>Z]T-?\ )"^!7<'\M7^7EUC\2^]-R=;;K[&V5N_M//Y3
M-=39C=&=V344>^-^YK=.)BQ^2WAL[8E>\L=/DD2H63&Q*L@8(TB@.?=>ZJ>Z
M[_DW?S:_C1\B?FSUY\3?F;\=.O?@7\]NZ-Y=S=C[PW1LG/[D^4O44O851GYM
MX8WJ;;IVW'@9,O44N5APR93)YF:F6"EAKX:2EK(Y(*GW7NBW_,/XA[T_E-?\
M)5^\/B)\BM\3;BWPN\<A@L?NOXR9W<(P.1K.T?D32;QV71;FRV\-I;8J8L'4
MP".CW51R4:K-#--04\\KSQ2M[KW0!1?+3N_^4JGP4[4Z>WQ_)N^96Z/E_P!A
M=-=.;YZV^$WQFZYZO^5W96U=SX2D>*OQO9'7>_\ $09E::>KIL319+,T>,@;
M(9.@\],$J)Q#[KW6^Y[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[K70[\^'/\W_ '7_ #(=Q?,/;&*_EQ=[]7]6X^+;
MGP=V!\B.U/DGM$_'>AR^*6G[![$.R^O^E-S8RIWKG7?[.;/35]=)244 IZ%J
M>.>5![KW5H^S7_F0YSXF=S1=FT/P[V#\VJK!]C4?0\G5VX^W=\?'3&YJ39].
MG5F6[$R6]]E;;SS!<X\S9B*CQ=0B4B1&%:B0O&?=>Z1>],7_ #5L1\=_C7DN
ML=R?##>'RFVQMG!P_*O9O9U)VGMOI/M7<-7@,5!N>?J;L39>(K<QMQZ+(PU5
M1CI:W;.1AJHI1%/2TITO'[KW1>>DOA?\P>[/G3U3_,!_F%GXV;-W+\8.M^SN
MN/BOT-\:<OOSL3%[6K>ZL7A\1V9VGV+VQV-M;84]5EJC'T=3AJ+%8S"0TT%+
M.TK54LKNGOW7NC)]]_&#LGY2_+#I:H[8.W(/A3\;?X-W7@^OJ;,UU=G.^_E5
M0Y*M78>1[+P*4E)2P[6Z]BITSF)H)IJ[^(YZJI*R6*G7"P?=>Z]T2;Y6_P N
MKYA;UWW_ #)=K?'S<GQ[EZ/_ )KNPMC;2[CW7VYN'?V+[*^-.<PG1>.^-6]-
MR]<;%VQL#<6.WQ2Y3;&%H:R@QF1W%L]Z+)0S,:R:FFCC@]U[J\;:&VZ/9NT]
MK[0QTL\^/VIMW";;H9JHHU3-1X/&TV+I9:AHU13(R4JER !<FP'OW7NE%[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJD_F\
M?';YZ_*KX[;?Z0^#>_NE=B4V\M\T%+\DXNW-Z]F=;UN_>AXZ>23<G5^S=_\
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M ?\ WJX^''_I>+?_ &L??NO=>_V9S_A0'_WJX^''_I>+?_:Q]^Z]U[_9G/\
MA0'_ -ZN/AQ_Z7BW_P!K'W[KW7O]F<_X4!_]ZN/AQ_Z7BW_VL??NO=>_V9S_
M (4!_P#>KCX<?^EXM_\ :Q]^Z]U[_9G/^% ?_>KCX<?^EXM_]K'W[KW7O]F<
M_P"% ?\ WJX^''_I>+?_ &L??NO=>_V9S_A0'_WJX^''_I>+?_:Q]^Z]U[_9
MG/\ A0'_ -ZN/AQ_Z7BW_P!K'W[KW7O]F<_X4!_]ZN/AQ_Z7BW_VL??NO=>_
MV9S_ (4!_P#>KCX<?^EXM_\ :Q]^Z]U[_9G/^% ?_>KCX<?^EXM_]K'W[KW7
MO]F<_P"% ?\ WJX^''_I>+?_ &L??NO=>_V9S_A0'_WJX^''_I>+?_:Q]^Z]
MU[_9G/\ A0'_ -ZN/AQ_Z7BW_P!K'W[KW7O]F<_X4!_]ZN/AQ_Z7BW_VL??N
MO=>_V9S_ (4!_P#>KCX<?^EXM_\ :Q]^Z]U[_9G/^% ?_>KCX<?^EXM_]K'W
M[KW7O]F<_P"% ?\ WJX^''_I>+?_ &L??NO=>_V9S_A0'_WJX^''_I>+?_:Q
M]^Z]U[_9G/\ A0'_ -ZN/AQ_Z7BW_P!K'W[KW7O]F<_X4!_]ZN/AQ_Z7BW_V
ML??NO=>_V9S_ (4!_P#>KCX<?^EXM_\ :Q]^Z]U[_9G/^% ?_>KCX<?^EXM_
M]K'W[KW7O]F<_P"% ?\ WJX^''_I>+?_ &L??NO=>_V9S_A0'_WJX^''_I>+
M?_:Q]^Z]U[_9G/\ A0'_ -ZN/AQ_Z7BW_P!K'W[KW7O]F<_X4!_]ZN/AQ_Z7
MBW_VL??NO=>_V9S_ (4!_P#>KCX<?^EXM_\ :Q]^Z]U[_9G/^% ?_>KCX<?^
MEXM_]K'W[KW7O]F<_P"% ?\ WJX^''_I>+?_ &L??NO=>_V9S_A0'_WJX^''
M_I>+?_:Q]^Z]U[_9G/\ A0'_ -ZN/AQ_Z7BW_P!K'W[KW7O]F<_X4!_]ZN/A
MQ_Z7BW_VL??NO=>_V9S_ (4!_P#>KCX<?^EXM_\ :Q]^Z]U[_9G/^% ?_>KC
MX<?^EXM_]K'W[KW7O]F<_P"% ?\ WJX^''_I>+?_ &L??NO=>_V9S_A0'_WJ
MX^''_I>+?_:Q]^Z]U[_9G/\ A0'_ -ZN/AQ_Z7BW_P!K'W[KW7O]F<_X4!_]
MZN/AQ_Z7BW_VL??NO=>_V9S_ (4!_P#>KCX<?^EXM_\ :Q]^Z]U[_9G/^% ?
M_>KCX<?^EXM_]K'W[KW7O]F<_P"% ?\ WJX^''_I>+?_ &L??NO=>_V9S_A0
M'_WJX^''_I>+?_:Q]^Z]U[_9G/\ A0'_ -ZN/AQ_Z7BW_P!K'W[KW7O]F<_X
M4!_]ZN/AQ_Z7BW_VL??NO=>_V9S_ (4!_P#>KCX<?^EXM_\ :Q]^Z]U[_9G/
M^% ?_>KCX<?^EXM_]K'W[KW7O]F<_P"% ?\ WJX^''_I>+?_ &L??NO=>_V9
MS_A0'_WJX^''_I>+?_:Q]^Z]U[_9G/\ A0'_ -ZN/AQ_Z7BW_P!K'W[KW7O]
MF<_X4!_]ZN/AQ_Z7BW_VL??NO=>_V9S_ (4!_P#>KCX<?^EXM_\ :Q]^Z]U[
M_9G/^% ?_>KCX<?^EXM_]K'W[KW7O]F<_P"% ?\ WJX^''_I>+?_ &L??NO=
M>_V9S_A0'_WJX^''_I>+?_:Q]^Z]U[_9G/\ A0'_ -ZN/AQ_Z7BW_P!K'W[K
MW7O]F<_X4!_]ZN/AQ_Z7BW_VL??NO=>_V9S_ (4!_P#>KCX<?^EXM_\ :Q]^
MZ]U[_9G/^% ?_>KCX<?^EXM_]K'W[KW7O]F<_P"% ?\ WJX^''_I>+?_ &L?
M?NO=>_V9S_A0'_WJX^''_I>+?_:Q]^Z]U[_9G/\ A0'_ -ZN/AQ_Z7BW_P!K
M'W[KW7O]F<_X4!_]ZN/AQ_Z7BW_VL??NO=>_V9S_ (4!_P#>KCX<?^EXM_\
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MKCX<?^EXM_\ :Q]^Z]U[_9G/^% ?_>KCX<?^EXM_]K'W[KW7O]F<_P"% ?\
MWJX^''_I>+?_ &L??NO=>_V9S_A0'_WJX^''_I>+?_:Q]^Z]U[_9G/\ A0'_
M -ZN/AQ_Z7BW_P!K'W[KW7O]F<_X4!_]ZN/AQ_Z7BW_VL??NO=>_V9S_ (4!
M_P#>KCX<?^EXM_\ :Q]^Z]U[_9G/^% ?_>KCX<?^EXM_]K'W[KW7O]F<_P"%
M ?\ WJX^''_I>+?_ &L??NO=>_V9S_A0'_WJX^''_I>+?_:Q]^Z]U[_9G/\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
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M253Y>62BJ*NC>*KF]U[H_79/\X.+X(?R OBO\^\MU1UD>S^W.INEML=7=-[
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M']X=S[<T[;Z@WMN!_/M:>@IZC*Z,;C)C_#JPY -BZ[_-5:Q2M"S"-K;TD_\
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MG%U.\,9LQ=@]R1564BQ$L>>J>J=XT^SZ,9C#4F;C3)[JDQRT=.T"58IZQ9)
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M7?=N8\F8W)AA_=CJ#>NXM,NV<@F.GKY/X9C)]-'5L_EQM4?VZJ(&6$L@O[\
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M-=C]M0092@W;D(\75]9;KI=PT:;/HYZRIILG@IJ!:BGJ*X4YCQ$$B*];(RI
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M?PJJVW2R':O5N[MRK6-N;%Y;*P38ML5CZC[F*D7$-#DI(M2TL\\$,Q5YHP=
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M3?)CX>_'6394F>;Y997O3%0[O3<*XU=B2]*]55':!EEP)PE<<DN22E>CXK:
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M.3*4<K4U/%#@JH_PZ+RU\IIY9<A*R(K^[CVW8=N6T@B$ES;RB61HT=F7QYE
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MD?B&I_I-))(WY @?*N>G[6SDMT99IY)RWF^@4'H B(/V@GY]!WG/Y>W3&?\
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M)0:02:%E8#&I"IH!4X'1.OE%\$\?T?\ $'XC_&'H[KONCM+X^=+_ "JA[)[
MJNN\S0S?*/8&RLYN3M;?LV?Z<RVW9>OIXJBDS78G\(J:C#@92+ 5%3#"M1.\
MU1[.]MYADO\ >+S=MPECBN9K?0FM:P2.JQ)256$@-534-7;X@4F@QT67>SQV
MFW6^WVD;O!'-J;2:2HK&1JQLI0BC/I-.[PRP%2>L/QWV#W/V#\BI:+IW._S$
M^OOAEN#HKM;:O>%5\S]Y]Q8_?M3V/NV*AP?7U5\<'[USF1WW@<QB$CJJ^HS2
MQP8]%\8I_)52:EKN=Q:0;=6_6SDOEEC,7TRQ:!&H8OXW@J(F#$J ,M@UH,&U
MC#/)=#Z0W"VIC</X[2:RY*A?#\4F12H#$G"Y!%3D'JZB^"V$V#V_MCO7L[OG
MOCY/=F=;[=W;L_J#/]Z9/KR4=6[:WS%AJ?=PP&/ZUZ[Z[IZC)Y.'!P4]=ELA
M%53O"OC3Q!I-9'>;\]Q9O86EO%:0RLK2+%XGZC)JTZC))(:#4: $"N37'1E;
M;6L-PMU<327$B!E1I-'8K:=0 1$&=(R03Z>?1Z?9#T:]>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2.SW7?7^Z:U<EN?8VS
MMQY%8(Z5<AGMLX7+UJTL32/%3+59"BJ)!&K2N5358%B0.3[-;+?=[VV'Z?;K
MR>WC)+:8Y9$6IH":*P%<#/RZ)-PY:Y<W><76Z[?;74H 77+!%(VD5(74ZL:"
MIQPR>F7_ $+]._\ /I^M/_0$VM_]:O:O^MG-7_1SN_\ LHF_Z#Z0_P!1N2?^
MC/8_]DD'_6OKW^A?IW_GT_6G_H";6_\ K5[]_6SFK_HYW?\ V43?]!]>_J-R
M3_T9['_LD@_ZU]>_T+]._P#/I^M/_0$VM_\ 6KW[^MG-7_1SN_\ LHF_Z#Z]
M_4;DG_HSV/\ V20?]:^EE@MN;>VM0G&;9P.%V[C3/)4G'X+%T.(H34RJBRU!
MI,?!3QZV$:AGTW(47/ ]E5Y?WVXS?4;A-)/)0#5([.U!P&IB33/#H[V_;-MV
MFW^DVJWBMHJEM$4:QI4\3I0 5-,FG3S[2=+NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[H$>_F^04NQX,5\:H^M:3L3/YVEPU1N_M:7-5.UNNMMU
M&/RE1D]\)M7 1Q5&?K::6EIJ:BPOWV+CEDJQ+/5I#!)'*ML/W>)]6Y:S&HKI
MCH&<U%%U-4*#FK4:E/A->D]S]48M-GI#G%7J0N#G2*:OLJ/MZ*[_ "I>[>VO
MD5\#NF.WN]-X1[^[3W'G.\,9N?=L6W=N[3BS"[*^07:FQ,$\>WMJ8[%4%,L.
M-VS1TX6&$,PBURO+,TDKG'-]C9;;S!-9[='X4*K"5746IK@C<]S$DY8G_  ,
M=%O+US=7FU)/>/XDFJ52U M=$KH,# PH_P I)ST9?Y%]<]T=H; AVYT1\BLM
M\8=\1;AQV4?L?$=8]>=M35.$IJ7(09#;%1M3LJ@KZ#Q53U<,WW47BGC>E0*_
MC>5'*MMN;*TN?%O[87<="-#.\8KBC:HR#CTX9Z,+R"XN(?#MIC U0=2JC&GI
M1PPS]G54O5-1\_\ :'\RKK+XV;B^?^<^3'66SNF]S]X_)O#9;XP?'_JV@P6%
MS[5VS.E]HTNY=D;8^]_B.6RZ564>.GK:>2.DQ!9E>*8CV+KL\NS\KS;E'MJV
MLTDJQ0,L\SDE:/,Q5W(HJE5R.+^HZ#T"[O%OL=F;UIXDC:28-%$N&JL0#(BF
MI(8X/!<\>E;L3<_S0^<6Z?F)O#J7Y83?&7;GQP^3G;?QGZ6ZYVIU7UCO;&;G
MW5T?!C<3G=U]ZY7?^ W#7UM'F,G7O]OC<'683[>B9)&=JK0Z)[F'9=@CLH+R
MS%T]S!'/*[22(566K*L(1E (6E2X?NKBF"[#)N6[/<36]S].L,KQ(JHC F/M
M)EU D@L#0*5[:9KP$+J/>GR@_F)_#/XP=^=+?*3(?"_?&<P^[*?MZDVMTEU9
MW-A=S[TVIN.NZXW9C:.A[8HLLV/I<?G=CY23'R454_DAJ],KU(2&4)[R#:^6
MM[NMOOK07T:E?#+221D(P#HU8F6I*,M01@^0R.G[>6\WK;(+JWG:U<U#A41^
M]24=?U%; 930CCZGH//@]N'YLU_SP^2W579_S-RWRE^/GQOZZVAM'=63S'Q]
MZ5Z?67Y)=@R4&[H]NX2NZZVW1553'M_;<,;Y!A721?<9E(I(@\2M[5;\NQ#E
MZUNK2P6TN;IW9=,TLGZ"52I$C$#4]:8K1/0])]K_ 'I^^+B&>[:X@@15.J.-
M/UFHU 45?A2E>(JWJ.KA]VUFY,=M7<V0V;A*#<V[Z';^9K-J[<RN9;;F+W!N
M2FQM3/@\)DMPKCLN:"GJZI(H)JT4E48$D,OADTZ&!<0C:55F8JA(U$"I KD@
M5%2!Y5%?4="5RX0F,5:AH": GR!-#3[:'JL'X)=Q_+G=/S _F ='?*CL;8.]
M'Z3P_P 2-P;(V]UALBEVIL?K]^Z=I=K;HW/M_!96OCJ,]F(T&%QL#5^;K)6D
M:D:6"GHEF>'V*M^LMGBV+;K_ &J)XS.URKM(^IG\(Q!20**OQ'"C%:$M2O1#
MMESN+[M>6E](KB-860*ND+K\6HJ22?A&2?L ZM>]A'H0=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1<^U.Y<YL+<T>
M#QV*Q-93OBZ6O,U;]YYA)4354;(/!4Q+I @%N+\GV-.7^6;7=[$W4TCJ0Y6B
MTI@ ^8/KT$=\YBN-JO!;11JP*AJFM<DCR/RZ#;_9FMU_\Z#;W^VR7_U;[//Z
MB[?_ +^D_P",_P";HG_KI>_[Y3_C7^?KW^S-;K_YT&WO]MDO_JWW[^HNW_[^
MD_XS_FZ]_72]_P!\I_QK_/U[_9FMU_\ .@V]_MLE_P#5OOW]1=O_ -_2?\9_
MS=>_KI>_[Y3_ (U_GZ,9U7O6OWYMA\YD:2DHZA<I5T(AHO-X?'3Q4TBO^_+*
MVH^<WYMQ[!6_[7%M%_\ 20L6&D-5J5R3Z >G0NV3<9=TLOJI5"G4105IBGK]
MO7NT>Y>H.CMO4^[NZNU>MNG]J5>4I\'2;G[1WSMCK_;U5FZNGJZREP]/FMV9
M3$TSU4L5!/+'3K*9&2&1@I5&(+K2QO=PE\"PA>=Z5TQHSM0<31033/'HQN+J
MVLX_&NY%B2M-3L%%3P%6('6/J_NOION_#U.X>ENVNLNWL!1SBEJ\YU?OS:N_
M\/2U+-.BT]3D]J97+0HY:FD 1G!O&PMZ3;UW8WMA)X-]"\+_ ,,B,A_8P!Z]
M;W5M=Q^+:2+*OJC!A^T$CITZ_P"SNN^UL1D<_P!9[VVQOS"8C<>>VAE,MM3,
MT.<Q]!NG:]<^,W%@*JKQ\TZ)5T51&8JB$D,C"Q'NEQ;7%JXCN4:-BH8!@02K
M"JFA\B,@^8ZM%-%.I>%@X!*D@@BJFA&/,$4/SZ7/MCIWKWOW7NBR5WS7^&N,
MWI7];Y+Y;?&3']B8K-5NV\IL*N[ZZKI-Z8W<6-GEI<C@*_:U1NN.NAK:>2!X
MYJ62!949&5E!!'LU&Q;VUL+Q;.<PD!@_A2:"IX$-II0^M>D'[TVP7!M3<Q>*
M#31XB:ZCB--:U_+HS*.DB))&ZR1R*KHZ,&1T8!E=&4D$$&X(]E72_KE[]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MN@6[U^1?1OQDVCCM^]_]H;2ZFV;E]QTFT<9N/>61&,Q=;N:OQF7S-'A(*AD>
M]1)2X"MG5+<I3.?Q[76&V;ANLQM]MA>=U4L50%B%! )H/*I _/I+=WMG81B:
M]E6)": N0H)H32I\Z _LZJ:_D._)+H;>'PQZN^/6UNU]EY_NW8]1\CMZ[LZT
MQ>8AJ]TX/:65^4_960QNXJV@CO\ Y)-!O?$2QS*S*5R,!O\ N#V,/<':]QM]
M[DW&>!T@=;=%D*D*6%M&"H/J"K8^1].@]RG?V4VW"TAF1I5:=B@8%@IG<AJ
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MT%!0QSU,-%20HD232SU%145,5-2TM/'+-/-*D,,;R.JE':VMS>W"VMHADD?
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MB8H*:F@B5$2-$0*B*      /8JYM),6TDY)L(O\ J[/T1;"*3;@!_P I;_\
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MU63ESK9=Z_[NH@I6I'15C1SJD9$FYQ6WT4^WP"&XM&UM)J+^*XDUHQ0B@TT
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M2:A00H )( %3@4%23Q)/0P^T?2GKWOW7NO>_=>Z][]U[JI#^</\ \R%ZV_\
M$NT?_O&[N]Y/_=5_Y7;</^>%O^K\'6$?W[?^G8[5_P!+2/\ [1+OK76]YX]<
MJ^O>_=>Z][]U[KWOW7NO>_=>Z][]U[K<E^+_ /V33\>/_$&=2_\ O [?]\H?
M<7_IX.^_]+&]_P"TF7KO5[/?].DY6_Z5&V_]H4/0Y^P;U(W7O?NO=>]^Z]U[
MW[KW6LC_ #7/^RL*G_Q'>S?][ROOH;]V;_IV8_YZI_\ !'UR+^^S_P!/G7_I
M7VO_ !^?JM7WD'UB'U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=;;/P&_[) Z-_\
M#8K_ /WI<Y[Y@^]?_3T]Y_YK+_U:CZ[A_=P_Z<=RW_SR_P#623HW_N+>IMZ]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I/[MQ.6S
MVU=S8+ [EK]EYS-;?S.)PV\<518O)93:>6R.-J:/';EQN.SE'D**HJ*":9*J
M&&LIYX'>(++&\992Y$ZQRJ[J'52"5-0& .02"#0\,$'TZJZED*J2I((!%*CY
MBM1CY]4T_P N;J+#='_S%OYK?7N%W+O[><=#MOX!Y;);N[/WCE]][XW+GMQ]
M=]WYW.YK.[AS$KLTE155\KK3T\=/30*5BIH(841 -N8[R2^Y6VB>143OO %C
M144 -   %'\S4GB23T&=HMDM=^W"-"S52V)+,6))\:N6)_8* >0'5VWL"]"C
MK4EZ+ZW^ _462^4&4_F9?"[L#$9_='SE^0N8POR#[>^)/=-1U+3=<;U["T=>
MU&4[GBV8<0E#5U,E5-35CU$D BJDE:=83J28+^ZYEO$LTY7OU*):0 PQ740D
MUI$-8$/B:BPID 5J.%>H[M(-CMS<-OEI1VN)CXDELY32TAT$RF,K3/$F@'G3
MH[O\SWK39W9'S7_E_=D=I_&KM#Y4_%G;G6'R6&_Z7JKHK?\ \AL)#D-VX78Q
MZ[J*S']<8'</B-360PU5'.[PK)'32.C.J,"1<J75S;;%N5M8W:6EV\EOHUSI
M 2%,NNA=EK0&A'S'1KOT%O+NUG->6[7%NJ3 Z8FF 9O#TU"*U*T-#]O1Z_A-
M1?R_.TOCOVAUW\1-B;1P'3.X=R;SVCWCT[#LW<77.9Q&],_MG'[/WOMSLOK[
M<]'A<KCJ^IQ>.IZ.7SPQ"6&%6@D=1K]A_?6YBMMQBN-ZE=YU56BD+B0% 2R-
M'(I92 23@FAKY]&^U#9YK-XMLC5(BS!T"&,AJ ,'0A2#2G$9%/*G52GSK_E-
M_P O>GWY\6/B7\??C9MC9?<7R4[6@R>YMY8G=O9.0S'6_P <>HOMMX]S[QIJ
M3+;MRM(L]=%'1;=H#5)&'FR[>)O)'P,=@YSYF$%WO&X7;R0VL=%4A://+5(E
M.!PRYXX3Y]!W=^6MC=X-MM;9$DG<%F%05BCHTC#/GA/]O7RZV=:2EIZ&EIJ&
MDB$-+1T\-+30J6*Q4]/&L,,0+EB0JH!<DGCW%A))J>)Z'0Q@=4!?S//A'\7.
MG?CEO;M_K?9.Y9/G)O'LW:E/\;>W*??&[\_\A]S?)+>N_J2MVGAMN;MSF:KY
MC2KYJMYL8/#04^-IYPL<"1AUD#E7?-TN]RCLKN0?N]$)GC*J(! B4=F10!6@
M%&^(O3)8]!/?=KLH;)[JW0F\)_1>I,OBLU5 8DG34Y7X M:@+7J_'!IE(\+B
M(\W+'/FDQ>/3+SQ",1391:2)<A+&(8X4"M*'("(@L> !Q[ #:=1T\*X^SH5K
M72-7'IT]UZWU[W[KW7O?NO= AWM\A>M?CEMO$[L[/K\GC\-F\XFWJ";%XFJS
M$SY.2@K<DD<E/2 LJ^+'RG6>+@#ZD>QAR9R-S#S[N$NV<N1I)-#'XK!W6,:
MRI4%L<6&.H_]Q?<WE'VLVF'>^<IG@MYYA C)$\I,A1Y "J D#3&QKPQ3SZ*S
M_P .F?$3_GIMW_\ H#YO_HSW(_\ P.'NE_RC0_\ 91'_ )^H=_X,7V*_Z.$_
M_9'<?] =>_X=,^(G_/3;O_\ 0'S?_1GOW_ X>Z7_ "C0_P#91'_GZ]_P8OL5
M_P!'"?\ [([C_H#KW_#IGQ$_YZ;=_P#Z ^;_ .C/?O\ @</=+_E&A_[*(_\
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M7^*_8O9&V:,YGM/-)C.L>C-K1#76;M[O[,KH]I=:X.C@UQ>0BOR*ULZ:X_\
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M#^_\-+_NJ?\ ?.Z]_P /0_\ @-O_ +&+_P#19[]_P)7_ (<'_9C_ -OG7O\
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MJ_/XO:';NQMQ=?[DR.U:K'4.Y*'#;FQL^+KZG!UF7Q6<I8JI(Z@F%ZBCJ4#
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M;D:FMP$=945&#^TRE!%#/.\D\=1Z55RRW6XL+2YM+=5'U2JCN=6L(&#%5(8
M!B!JJ"2!0$9K2YL8KJX@N)2?T&+*N-)8J5#-BM5!-*$#-2#BAD?99TMZ][]U
M[KWOW7NO>_=>ZKJ_FF?]DB;F_P##OV/_ .[M/<[_ '</^GI6W_-&X_ZMGK%W
M[XO_ $XK</\ FO9_]I"=:OGOHSUQQZ][]U[KWOW7NO>_=>Z][]U[KWOW7NMB
MG^3Q_P R%[)_\2[6?^\;M'W@=]ZK_E=MO_YX5_ZOS]=5/N)?].QW7_I:2?\
M:):=6W^\8.LW.O>_=>Z][]U[KWOW7NJD/YP__,A>MO\ Q+M'_P"\;N[WD_\
M=5_Y7;</^>%O^K\'6$?W[?\ IV.U?]+2/_M$N^M=;WGCURKZ][]U[KWOW7NO
M>_=>Z][]U[KWOW7NKS/Y+W_<R7_E'?\ YJ?O#?[VO_.O_P#4=_VI]=&/N _\
M[;_U*_\ O(]7F>\-^NC'7O?NO=>]^Z]U[W[KW52'\X?_ )D+UM_XEVC_ />-
MW=[R?^ZK_P KMN'_ #PM_P!7X.L(_OV_].QVK_I:1_\ :)=]:ZWO/'KE7U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=;DOQ?_ .R:?CQ_X@SJ7_W@=O\ OE#[B_\
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M=I/"M+*&6>9]+-HBA1I)'TH&9M*J3106-* $XZ)M_P .3_"O_G]'_L.NV/\
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M;6S92?;$U*]3FQ0R1G(!2T 19XQ!<[[M5KS^^Y1@"#Q9DDD1_$#K*'0RKQ&
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M#P;6.2-(Z "2.2/]GB*I/S/KQZ.I[)>C'KWOW7NO>_=>Z SY0?\ 9-/R'_\
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M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5P'\G/\ YG'VO_XC.G_]ZG$^\5_O6?\
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M1ZO,]X;]=&.O>_=>Z][]U[KWOW7NJD/YP_\ S(7K;_Q+M'_[QN[O>3_W5?\
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MUHZ]_P /*;]_Y\EM#_T*\S_];??O^!/V;_H\3?\ .!/^@^O?\'QOO_3-P?\
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M^##8#'4V*QD-=G<_792OK9E@I$66KK:FHJ)F!DFEDD9G(<EE>:5II*:G)8T
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M5//! 61':,NH84W'>MQW1%BNG'AH25C1$CC!(H2$C55J:9-*_/JUGMMG8DO
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MFR,66_O+D?NLA%55(I<=]OX6J$8V^XM=DY>MYMY@%]!>O(\4!.@1^$ZH\HE
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M-:US6O4'LGX7_&OMCJ7KCI3>?7$=3L;IS';?QO43XC<V[]M[RZPCVMM^':V
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MW&+;[\QR^,DCJT:,FGPR@(96>2H.O!J,BE#QZM%]A;H\ZI_ZD_F']I=T?/\
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M *OS]=5/N)?].QW7_I:2?]HEIU;?[Q@ZS<Z][]U[KWOW7NO>_=>ZJ0_G#_\
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M_1HHM/BJ'1B'!4M%510E&8"I'%:TZ.KV:6[L95VI@[ZO#)5A5<@24)J-2BM
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MZ-V[_P#9/9?][#KW_#P/QI_YX?O/_P!!K8/_ -LSW[_@6/<'_E,V[_G+<_\
M;)U[_@ZO:3_HW;O_ -D]E_WL.O?\/ _&G_GA^\__ $&M@_\ VS/?O^!8]P?^
M4S;O^<MS_P!LG7O^#J]I/^C=N_\ V3V7_>PZ]_P\#\:?^>'[S_\ 0:V#_P#;
M,]^_X%CW!_Y3-N_YRW/_ &R=>_X.KVD_Z-V[_P#9/9?][#KW_#P/QI_YX?O/
M_P!!K8/_ -LSW[_@6/<'_E,V[_G+<_\ ;)U[_@ZO:3_HW;O_ -D]E_WL.O?\
M/ _&G_GA^\__ $&M@_\ VS/?O^!8]P?^4S;O^<MS_P!LG7O^#J]I/^C=N_\
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MU[KWOW7NK@/Y.?\ S./M?_Q&=/\ ^]3B?>*_WK/^55VS_GK;_JR_6>/W#/\
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M/_M$N^M=;WGCURKZ][]U[KWOW7NO>_=>Z][]U[KWOW7NKS/Y+W_<R7_E'?\
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M=CNO_2TD_P"T2TZMO]XP=9N=>]^Z]U[W[KW7O?NO=5(?SA_^9"];?^)=H_\
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MKWOW7NJD/YP__,A>MO\ Q+M'_P"\;N[WD_\ =5_Y7;</^>%O^K\'6$?W[?\
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M9'^:Y_V5A4_^([V;_O>5]]#?NS?].S'_ #U3_P""/KD7]]G_ *?.O_2OM?\
MC\_5:OO(/K$/KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZV]OA1_V2?T+_P"([PW^
M]2^^6GNY_P!/,WO_ )ZI/\/7=3V$_P"G,<L_]*^W_P".#HT7N.NI<Z][]U[K
MWOW7NO>_=>ZU-_YAO_99/=W_ &MML?\ O";6]]-?8G_IT^S_ .DF_P"TF;KB
MC]ZC_I_G,/\ I[;_ +0K;HE_N6^L?>O>_=>Z][]U[KWOW7NO>_=>Z4^R?^/S
MVC_X<^ _]VM)[+=Y_P"2/=_\T9?^.-T?\J?\K3MO_/5;_P#5Y.MW'WR!Z^A'
MKWOW7NO>_=>Z][]U[KWOW7NM*OM[_F;/:'_B1-Z_^]+D_?7'E3_E5MM_YY;?
M_JRG7S_^X?\ RO\ OG_2PO?^TF3H._9_T#^O>_=>Z][]U[KWOW7NO>_=>Z,U
M\,O^RJ^@_P#Q)FV__<L>X[]V_P#IVF]_\\DO^#J9?N\_]/LY:_Y[8_\  W6W
M][Y9]=R^O>_=>Z][]U[KWOW7NFG/_P#%BS7_ &J<C_[AS>U-G_N9%_IU_P"/
M#I+??[A3?Z1_^.GK1]]]A^OG9Z][]U[KWOW7NO>_=>Z][]U[KWOW7NCH?R\O
M^RR>D?\ M;;G_P#>$W3[B3WV_P"G3[Q_I(?^TF'K(+[J_P#T_P Y>_T]S_VA
M7/6V1[YE==KNO>_=>Z][]U[KWOW7N@,^4'_9-/R'_P#$&=M?^\#N#V,O;K_I
MX.Q?]+&R_P"TF+J.?>'_ *=)S3_TJ-R_[0INM-KWU>ZX*]>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW5P'\G/_F<?:_\ XC.G_P#>IQ/O%?[UG_*J[9_SUM_U9?K/
M'[AG_*Y[[_SQ1?\ 5\=;#'O!?KI_U[W[KW7O?NO=>]^Z]U75_-,_[)$W-_X=
M^Q__ '=I[G?[N'_3TK;_ )HW'_5L]8N_?%_Z<5N'_->S_P"TA.M7SWT9ZXX]
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6Q3_ ">/^9"]D_\ B7:S_P!XW:/O [[U
M7_*[;?\ \\*_]7Y^NJGW$O\ IV.Z_P#2TD_[1+3JV_WC!UFYU[W[KW7O?NO=
M>]^Z]U4A_.'_ .9"];?^)=H__>-W=[R?^ZK_ ,KMN'_/"W_5^#K"/[]O_3L=
MJ_Z6D?\ VB7?6NM[SQZY5]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5YG\E[_N9+
M_P H[_\ -3]X;_>U_P"=?_ZCO^U/KHQ]P'_G;?\ J5_]Y'J\SWAOUT8Z][]U
M[KWOW7NB1[L_F(_$_9.Z=R[,W'V!DZ+<.T=P9G;&=HX]D;TJXZ3,X#(U.*RE
M,E52X*:*41STCJ)(W96M=200?<O[9[$^YN[[;;[M86*/!=11S1L;BW75'(H=
M#I:0$5# T(!'GUCYO7WI/9/E_>+O8-UW5X[JQFEMYD%I>,%EA=HY%U+ 5-&4
MBH)!X@D=5J?S'/EYT/\ (7J?96UNJMV5N?S6&[#I]P9"FJ=L[CPB0XN/;>X<
M<TZU&9Q=#&Y\N0B70K%O5>U@3[R"]@_:[G7D;F>[W+F6U6"&6U,2D3125<RQ
M-2D;L1A3DBG6)?WKO?+VT]S^1K#9>2[]KJY@OTG=3;W$-(Q;W$9;5-$@/=(H
MH#7-:4!ZIN]Y7]8#=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6R3T7_,1^)^R>DN
MG=F;C[ R=%N':/5?7NV,[1Q[(WI5QTF9P&TL1BLI3)54N"FBE$<](ZB2-V5K
M74D$'W@!SE[$^YN[\X;KNUA8H\%U>74T;&XMUU1R3NZ'2T@(J&!H0"//KK/[
M<?>D]D^7_;S8=@W7=7CNK';K*WF06EXP66&VBCD74L!4T92*@D'B"1T;SI/Y
M;=%?(;.9?;O5.ZJW<&5P6*7-9."IVUN+")!CWJX*%9EGS6,H4<F2H5=",QYO
M:WN+>;_;#G/D6SBON9K98(IG\-")8I*L%+4I&[$8'$]3G[?>]?MS[HWUQMW)
M-\UW-:QB20&"XATH6T@UFC0'/D*GHR?L =2MU[W[KW6FIA]K;$W=VCOG&]@]
MHX_J7"P9#<U=2[CR6T]U;Q@K<I'N**"'")C-H45?4QO)%4S3B=T$2BF*,=;H
M#U?N=RWK:^6K*XV+;6W28I"IB2:& JAB),FN=E4@$!=(-3JKP!ZX-P;+RQOO
M/F[6G->])L5NLMTZSO:W%V'D%QI$/AVRLX)5F;41I&BARPZ,E\R/]%'>7=%7
MV+TCV]0]E;I[/W)UYM'&]9T6Q=_;<R]++3;*PNSH:X9[=N#PE#,LU=@X8DA5
MDD_RY#8K'(P /M1_6;DWE)=AYPVIMOMMNBNIWNVN;:5&!N))ROA022.*)(23
MD=A\R!U*GOV.1_<GW ?FKVYWU=WOMYN+*UCV];.\MY%(M8K57^HN8XHVU20J
MH7!_4!X*QZ8H.I?C#US\N]U]<=H=J9"IZ3ZZJ=,^X%Q.6R%7N[<>,Q^&;(;+
MK6V5C,U-21KD:FMI:JJ@@8B.A= 8Y9%=5;\S^XN_^UMMO_+FVJN\7XQ%K1%@
MB=I--POU#H&)C",JEN+@T*@@H(^2/9OE+WVON5.<MYD;EW:2/UO#DE:YN$2$
MO:2&TCD9 )6D1V5*@1%:J[ B5\J<MU?V;-E-_P")^2^SMUU^ H,3M[KOIO:?
M4'9^S<)M_:--D::CI=N;?K]P8+'4-/'0TU1+52RSLKSM$P #/&BM^VEKS'RZ
MD>R77+T]LD[/+=7\U]:3R2SE"QEE6*1G8NP"@"H4$$X!)4>]VX\E<YO-S/8<
MX6][):I'!8;5;[5?VL,%L)%400R31I&HC1F=F:AD*D "J*%;N7,_'?Y-;4Z3
MW)V+WK-U#O7JOK#;G5W8N'SFT-V;MK]UX39U5+#B=Q;0R>'IZV&:LJX\A)YH
M)PLBNYD<.D;2.5;?:<^>W>Y[QM^P;*-TL]RNY;RUDCGA@6&2=07BG1RI"*5%
M",$"@(+  ^W:^]IO>/9.7=XYMYE;8]QV7;X+"_BFMKBYDN8K9J)-;2(&5I'U
ML2"&8%M3*0A++?+?+#JCNW=7R:Z^W[F<WUQU+W'M_KG!]:[FFQ>3SL.R:OIZ
M<2;6K=P;;PLM1.R9-KR5AIO(4TQQL&51)&3VOMES/R?MO+N^[)#'?[IM4MU)
M=PATC-PM\*3+'+( *QC":J5J2,FA$E_[X\C^X^]\X<J\T74VU;'OL%C#M]P8
MY)5M7VUBT,DUO$6:DS'4Y7@%5&P R@AVEO?JWK+X[?[+9U5V G;&4W/V6O8G
M9.^\=M_+8#;5.F'Q46(P6T]O)FDIZBJ59(15S5?C,9(M&Q#608\M[/S+S'SY
M_K@\S6/[LBMK3Z6TMVE224^(Y>2:7PZJN"5"U!]1BICCG;F/DKDOVG/M!R1N
MO[\GO=P^MO[Q('AMU$2+'%;P>)1GRBN7&I30T/=10DRNS/CQ%V%L'!8KN;/5
M'7V<V+05V_-]/L3+RU>R-_56,S9J\+#MF6GQD^0HZ6LIZ#R24S-KBJ)!%*[)
MJ]BFUW?GQMAOKVZVF);^&X9;:V%P@6XM@\=)#,"ZH[(7H&I1E%5 -.@)?\O>
MTJ<V[9MFW\P3MM-Q9J]Y>FSE+VEZT<]8Q;E(VDC618JZ*U5V"N2*@R6W<[T9
M\:^J>]\7M_OFC[RW%W=UK)L3 ;/VIL_=F P>(I\U*[+O3==;N:FI8H:V@2-O
M!0HKU,;R:74+)K2/KZRYS]P>9MEN;[9&V:#9[OZB6>:>&21S'3_%X5B))1S2
MK_ 0*@U%#+VU[E[:^T'(_,MAM7,Z\R77,>WFT@M;:UN(8HA,& NKEINU9(P3
M2+^U4X9:-53:?R7O^YDO_*.__-3]QG][7_G7_P#J._[4^IA^X#_SMO\ U*_^
M\CU>9[PWZZ,=>]^Z]U[W[KW5#O\ .;_XOOQ^_P"U3V1_[F;*]YH_=,_W#WS_
M $]I_P =N.N;OW^_]S>5O])N'_'K/JDGWE_USQZ][]U[KWOW7NO>_=>Z][]U
M[KWOW7NMR7XO_P#9-/QX_P#$&=2_^\#M_P!\H?<7_IX.^_\ 2QO?^TF7KO5[
M/?\ 3I.5O^E1MO\ VA0]#G[!O4C=>]^Z]U[W[KW7O?NO=:R/\US_ +*PJ?\
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MZ3FG_I4;E_VA3=:;7OJ]UP5Z][]U[KWOW7NO>_=>Z][]U[KWOW7NK@/Y.?\
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MI.:?^E1N7_:%-UIM>^KW7!7KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZN _DY_\
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MP3W?+4>]2W,<6[6TCRBYN$N84M54EI9&6,J$HI+D**UKT$'PTS.Q.L,IV/\
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M[EO_ )Y?^LDG1O\ W%O4V]>]^Z]U[W[KW7O?NO=4._SF_P#B^_'[_M4]D?\
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M[<YMSKK+[7VWANL<3N>(5&$IJBKS.-S$E?FXH8S,\1*4BB0*Z.-+F%++FGW
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M.X;@D2H*(FFUN@Z1X'8CZE2F-(&DD4)V7O?/GKK1U[W[KW7O?NO=5(?SA_\
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M;W_SU2?X>NZGL)_TYCEG_I7V_P#QP=&B]QUU+G7O?NO=>]^Z]U[W[KW6IO\
MS#?^RR>[O^UMMC_WA-K>^FOL3_TZ?9_])-_VDS=<4?O4?]/\YA_T]M_VA6W1
M+_<M]8^]>]^Z]U[W[KW7O?NO=>]^Z]TI]D_\?GM'_P .? ?^[6D]EN\_\D>[
M_P":,O\ QQNC_E3_ )6G;?\ GJM_^KR=;N/OD#U]"/7O?NO=>]^Z]U[W[KW7
MO?NO=:5?;W_,V>T/_$B;U_\ >ER?OKCRI_RJVV_\\MO_ -64Z^?_ -P_^5_W
MS_I87O\ VDR=!W[/^@?U[W[KW7O?NO=>]^Z]U[W[KW1FOAE_V57T'_XDS;?_
M +ECW'?NW_T[3>_^>27_  =3+]WG_I]G+7_/;'_@;K;^]\L^NY?7O?NO=>]^
MZ]U[W[KW33G_ /BQ9K_M4Y'_ -PYO:FS_P!S(O\ 3K_QX=);[_<*;_2/_P =
M/6C[[[#]?.SU[W[KW7O?NO=>]^Z]U[W[KW7O?NO='0_EY?\ 99/2/_:VW/\
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M.QW5I9V[W!DED0!$#6EPBZC4\68#[3ULH^^?W76'KWOW7NO>_=>ZJ0_G#_\
M,A>MO_$NT?\ [QN[O>3_ -U7_E=MP_YX6_ZOP=81_?M_Z=CM7_2TC_[1+OK7
M6]YX]<J^O>_=>Z][]U[KWOW7NO>_=>Z][]U[K<E^+_\ V33\>/\ Q!G4O_O
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MU[KWOW7NO>_=>Z][]U[KWOW7NMO;X4?]DG]"_P#B.\-_O4OOEI[N?]/,WO\
MYZI/\/7=3V$_Z<QRS_TK[?\ XX.C1>XZZESKWOW7NO>_=>Z][]U[K4W_ )AO
M_99/=W_:VVQ_[PFUO?37V)_Z=/L_^DF_[29NN*/WJ/\ I_G,/^GMO^T*VZ)?
M[EOK'WKWOW7NO>_=>Z][]U[KWOW7NE/LG_C\]H_^'/@/_=K2>RW>?^2/=_\
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M_2PO?^TF3H._9_T#^O>_=>Z][]U[KWOW7NO>_=>Z,U\,O^RJ^@__ !)FV_\
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MR_\ :-:=<H?OU?\ 3V]N_P"E1;_]INX=%I/SW^4YHFQAW_MPXYZ@5;X\]/\
M2AHGJQ"U.*IJ0]=^,R"-V365OI)%[&WN0?\ 63]MO&^H^AE\0#3J^NO]6FM:
M5^JK2N:>O44G[SOO883;'=HO#)U:?W;M6G52FK3]%2M,5XTQTA]W=NX!OCOU
MQT%LRCR0I*+>&8[;[,S.7@2G;+=D9''OMC$T> IX\ED E!CL/$E.TK>)JF9V
MD\,.D^0XVOE:^'/FX<[[NZ:G@2RM(T-=%JK>,[2DHM7DE)8#(1134U<!W?\
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MN'_'K/JDGWE_USQZ][]U[KWOW7NO>_=>Z][]U[KWOW7NMR7XO_\ 9-/QX_\
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M[KW7O?NO=>]^Z]U4A_.'_P"9"];?^)=H_P#WC=W>\G_NJ_\ *[;A_P \+?\
M5^#K"/[]O_3L=J_Z6D?_ &B7?6NM[SQZY5]>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW6Y+\7_P#LFGX\?^(,ZE_]X';_ +Y0^XO_ $\'??\ I8WO_:3+UWJ]GO\
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MQRW>WC:1W(=YC]M[+>]Z/,FVW]WM5])&L4LMI(J>-$I%%E5D<%@,*PH5QQ
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M7_IQ6X?\U[/_ +2$ZU?/?1GKCCU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=;%/\
M)X_YD+V3_P")=K/_ 'C=H^\#OO5?\KMM_P#SPK_U?GZZJ?<2_P"G8[K_ -+2
M3_M$M.K;_>,'6;G7O?NO=>]^Z]U[W[KW52'\X?\ YD+UM_XEVC_]XW=WO)_[
MJO\ RNVX?\\+?]7X.L(_OV_].QVK_I:1_P#:)=]:ZWO/'KE7U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=7F?R7O^YDO_ "CO_P U/WAO][7_ )U__J._[4^NC'W
M?^=M_P"I7_WD>KS/>&_71CKWOW7NO>_=>Z][]U[JI#^</_S(7K;_ ,2[1_\
MO&[N]Y/_ '5?^5VW#_GA;_J_!UA']^W_ *=CM7_2TC_[1+OK76]YX]<J^O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[K<E^+__ &33\>/_ !!G4O\ [P.W_?*'W%_Z
M>#OO_2QO?^TF7KO5[/?].DY6_P"E1MO_ &A0]#G[!O4C=>]^Z]U[W[KW7O?N
MO=:R/\US_LK"I_\ $=[-_P![ROOH;]V;_IV8_P">J?\ P1]<B_OL_P#3YU_Z
M5]K_ ,?GZK5]Y!]8A]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6VS\!O^R0.C?\
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M*VZ)?[EOK'WKWOW7NO>_=>Z][]U[KWOW7NE/LG_C\]H_^'/@/_=K2>RW>?\
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M):N6?(5,=%0TJ3N(*:,%5%FT1QC4>"?<A;58;3RCL%MM43K#:V<<<2M(P7
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M"R@T&22P ]:D J_;[VVY@]Q[VYM]H>"UM[&$SW5W=R&&TM8A6CS2A7(U$$*
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M>A<.8B3\>FIP%5JCH8[5]VW>MYC.W;?S!LTN^&,RIM27FNZ95B,KQEE3PUF
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ME\M53QS.OC3--*ME-R@!X)/L;^W/*<//'.=GRM<3-;I=>+615#%?#@EF%%)
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MZOYIG_9(FYO_  []C_\ N[3W._W</^GI6W_-&X_ZMGK%W[XO_3BMP_YKV?\
MVD)UJ^>^C/7''KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZV*?Y/'_,A>R?\ Q+M9
M_P"\;M'W@=]ZK_E=MO\ ^>%?^K\_753[B7_3L=U_Z6DG_:):=6W^\8.LW.O>
M_=>Z][]U[KWOW7NJD/YP_P#S(7K;_P 2[1_^\;N[WD_]U7_E=MP_YX6_ZOP=
M81_?M_Z=CM7_ $M(_P#M$N^M=;WGCURKZ][]U[KWOW7NO>_=>Z][]U[KWOW7
MNKS/Y+W_ ',E_P"4=_\ FI^\-_O:_P#.O_\ 4=_VI]=&/N _\[;_ -2O_O(]
M7F>\-^NC'7O?NO=>]^Z]U[W[KW52'\X?_F0O6W_B7:/_ -XW=WO)_P"ZK_RN
MVX?\\+?]7X.L(_OV_P#3L=J_Z6D?_:)=]:ZWO/'KE7U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=;DOQ?_P"R:?CQ_P"(,ZE_]X';_OE#[B_]/!WW_I8WO_:3+UWJ
M]GO^G2<K?]*C;?\ M"AZ'/V#>I&Z][]U[KWOW7NO>_=>ZUD?YKG_ &5A4_\
MB.]F_P"]Y7WT-^[-_P!.S'_/5/\ X(^N1?WV?^GSK_TK[7_C\_5:OO(/K$/K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>ZVV?@-_V2!T;_ .&Q7_\ O2YSWS!]Z_\
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MU=96^S/O7LGO3M]]N.R6<]HEC(D;"<QU8NI8%?#9A0 >?1M/<9=31T&?=/\
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MV)9F9F))8DDDDDDFIZ'MG9VFW6D6W[?$D$$"+'''&JI''&BA41$4!555 "J
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M]U[W[KW7O?NO=>]^Z]UL4_R>/^9"]D_^)=K/_>-VC[P.^]5_RNVW_P#/"O\
MU?GZZJ?<2_Z=CNO_ $M)/^T2TZMO]XP=9N=>]^Z]U[W[KW7O?NO=5(?SA_\
MF0O6W_B7:/\ ]XW=WO)_[JO_ "NVX?\ /"W_ %?@ZPC^_;_T[':O^EI'_P!H
MEWUKK>\\>N5?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U>9_)>_[F2_\H[_\U/WA
MO][7_G7_ /J._P"U/KHQ]P'_ )VW_J5_]Y'J\SWAOUT8Z][]U[KWOW7NO>_=
M>ZJ0_G#_ /,A>MO_ !+M'_[QN[O>3_W5?^5VW#_GA;_J_!UA']^W_IV.U?\
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M;+M\TMW++>>"+J]O91X?CS+#5 (X_P!..A)T$!OA'6QE\!O^R0.C?_#8K_\
MWI<Y[P+]Z_\ IZ>\_P#-9?\ JU'UU6^[A_TX[EO_ )Y?^LDG1O\ W%O4V]>]
M^Z]TTY__ (L6:_[5.1_]PYO:FS_W,B_TZ_\ 'ATEOO\ <*;_ $C_ /'3UH^^
M^P_7SL]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1T/Y>7_99/2/_ &MMS_\ O";I
M]Q)[[?\ 3I]X_P!)#_VDP]9!?=7_ .G^<O?Z>Y_[0KGK;(]\RNNUW7O?NO=>
M]^Z]U[W[KW0&?*#_ +)I^0__ (@SMK_W@=P>QE[=?]/!V+_I8V7_ &DQ=1S[
MP_\ 3I.:?^E1N7_:%-UIM>^KW7!7KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZN _
MDY_\SC[7_P#$9T__ +U.)]XK_>L_Y57;/^>MO^K+]9X_<,_Y7/??^>*+_J^.
MMACW@OUT_P"O>_=>Z][]U[KWOW7NJZOYIG_9(FYO_#OV/_[NT]SO]W#_ *>E
M;?\ -&X_ZMGK%W[XO_3BMP_YKV?_ &D)UJ^>^C/7''KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZV*?Y/'_,A>R?_ !+M9_[QNT?>!WWJO^5VV_\ YX5_ZOS]=5/N
M)?\ 3L=U_P"EI)_VB6G5M_O&#K-SKWOW7NO>_=>Z][]U[JI#^</_ ,R%ZV_\
M2[1_^\;N[WD_]U7_ )7;</\ GA;_ *OP=81_?M_Z=CM7_2TC_P"T2[ZUUO>>
M/7*OKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZO,_DO?]S)?^4=_^:G[PW^]K_P Z
M_P#]1W_:GUT8^X#_ ,[;_P!2O_O(]7F>\-^NC'7O?NO=>]^Z]U[W[KW52'\X
M?_F0O6W_ (EVC_\ >-W=[R?^ZK_RNVX?\\+?]7X.L(_OV_\ 3L=J_P"EI'_V
MB7?6NM[SQZY5]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6Y+\7_^R:?CQ_X@SJ7_
M -X';_OE#[B_]/!WW_I8WO\ VDR]=ZO9[_ITG*W_ $J-M_[0H>AS]@WJ1NO>
M_=>Z][]U[KWOW7NM9'^:Y_V5A4_^([V;_O>5]]#?NS?].S'_ #U3_P""/KD7
M]]G_ *?.O_2OM?\ C\_5:OO(/K$/KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZVV?
M@-_V2!T;_P"&Q7_^]+G/?,'WK_Z>GO/_ #67_JU'UW#^[A_TX[EO_GE_ZR2=
M&_\ <6]3;U[W[KW7O?NO=>]^Z]U53_,"Z;VWW)V=U5#O?<.4VSL+K;IWO;MG
M?.0P-)!6[@EVSM"KZZBJZ' P52RQ?=2RY6$(TB2*JACH8V'O)/V0YLW#E/EW
M<WV:!+B]W"^VZRMUD8K$)9UNBK2$4.D!#6A!K3(ZPV^\SR!LW/\ S;LD7,MW
M)9[9M.V;SN5V\*AYC!:MMX98@P8:B95-2K8!P3U4EO/J?HC??16\^Z^@3V)M
MVJZDS^TL+V+LGL;*8+/2U&"WC4OAMO;OPN5P>-QVEYJY!#4TTB: 2YC**J++
MD_M',W.NR\YVG*'/'TMPNZ1SR6MQ:I)&!) /$E@D21FP$RK UX5J22,(^8^2
M/:_F7VUW#W$]KC?6C['-:PWUI?212EH;EO"AN8GB44+2893VX;2% 4,^9WJ/
MXW?'W%;.PGR A[;WIVKO79F-W;G-N==9?:^V\-UCB=SQ"HPE-45>9QN8DK\W
M%#&9GB)2D42!71QI<HK+FGW YZN;N\Y&-E:;99W#0QRW232R7;PFDA"HR!(2
M30'^TQ4$9 --RY#]H?:JRL-M]U%W/<-[W&S2YE@L9+>&+;TN,Q M(',EPH4F
MA)BSW*1I)0G072G7'9M3WEO?<N2WQ'U3TKM:MWH^%V^N&3L;<F+GRD])@:'[
MFIIZ^@I62*'RY*I$4R1V.A=)UH=<[\X;_P NQ[-L^WQVYW/=YEM_$E\3Z6)P
M@,C4!5VJ32-:@GSS@AGVN]N>3^<Y^9>9-VFO%V/EVW>Z\*'PA?SQ%W\%"Q5X
MD(1"96 (!^&@[@Y]T]2]//T;M#Y$],Q[]VM@MQ=CY;K3)["[#K,?EZM,AC<"
MN:3/[4SE!C\8:G'A86AJ6D6<K42>,.OC9/:?E#FCFM><KKD/FTVUS-;VJ7:7
M-JK(-+R>'X<T;,VE\U6FFJ"M#4'I5[C<B^W[>W%C[L>WBWME:W=_)8/97Q20
MATA,HFMIE52T8T%7)+_J-I#*4*] CT1U<_=7<&P.K%R\>!7>>?@Q<^7DB^X^
MPI%AGK*V:&G+QB2;PTKB",LH:0JI8 D@8\Z\R#E#E6^YD,1F-I&7" TU,2%4
M$YH*L-1\A4]1O[8\E_ZXG/NU\E^/],+^;0TM*E$56D<J/-M*$*#@L17'1N*[
MHOXU[]V]\@</U;2]T;.WM\<]I;JW77;A["R&W\KMK><.U,VF,R&)RM%C,'BV
MQF0J2CQXRG292QUZTE,3VBV#G/W"V6_V.[YD:PN[/?YH85BMEE26W,T>M71G
MD?Q$6H,C$&F*%=0ZGJ\]L_9_F7:N:-MY+3=K#<N4;:ZN))[UH9+>[^FE*/'*
ML<:>%(^DB%04)R2KZ& V$OB__P!DT_'C_P 09U+_ .\#M_W@W[B_]/!WW_I8
MWO\ VDR]=-?9[_ITG*W_ $J-M_[0H>AS]@WJ1NO>_=>Z][]U[K2MZQVML3=V
M?J\;V#VCC^I<+!B*BNI=QY+:>ZMXP5N4CK<?!#A$QFT**OJ8WDBJ9IQ.Z")1
M3%&.MT!ZX\Q;EO6UV2W&Q;:VZ3%PIB2:& JA5B9-<[*I ("Z0:G57@#U\_G)
MNR\L;[NDEIS7O2;%;K$SK.]K<78>0.BB'P[96<$JS-J(TC10Y8=&Y^9'^BCO
M+NBK[%Z1[>H>RMT]G[DZ\VCC>LZ+8N_MN9>EEIME879T-<,]NW!X2AF6:NP<
M,20JR2?Y<AL5CD81?[4?UFY-Y278><-J;;[;;HKJ=[MKFVE1@;B2<KX4$DCB
MB2$DY'8?,@=3G[]CD?W)]P'YJ]N=]7=[[>;BRM8]O6SO+>12+6*U5_J+F.*-
MM4D*J%P?U >"L>G7:>5Z@^+/R;[XZ;RN\\_N3I3=^P=S=&;GWGCX155V*J=P
MX;"RY/.3X;#OIJI,/E*>KH&2#]P)Y2H8EHG2;G;<U>Y/MWLO-EK:16^\6MS%
MN,,#'2KK%)($C$DGPB6,I)5L$Z:TP09;%?<@^R_O'S-R!?;A/=<N7]E/M%Q<
MIWO&\T,)DE>.'#M!*)8:*-2@M0$ZE+-7;GZ9^//1W<77O6O;E+W5V!WM#M7
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M]G0X]M>4X.>^?-JY0N9FMX]PG6%I%4,R!JY"D@$X\^KH/^&:=F?\_P!-S_\
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MZOYIG_9(FYO_  []C_\ N[3W._W</^GI6W_-&X_ZMGK%W[XO_3BMP_YKV?\
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M]GO^G2<K?]*C;?\ M"AZ'/V#>I&Z][]U[KWOW7NO>_=>ZUD?YKG_ &5A4_\
MB.]F_P"]Y7WT-^[-_P!.S'_/5/\ X(^N1?WV?^GSK_TK[7_C\_5:OO(/K$/K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>ZVV?@-_V2!T;_ .&Q7_\ O2YSWS!]Z_\
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MY2LA6EI8Z=70QI^X >6-AY.B]L=QGW^]FM-YVDWL2@WTT3V\T<DLD2P6PEC
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ME7-+2P4DDC/2Q0/&L3,60*23[5VNS;/96TUG96D,,-PSM*B1(B2-(*2-(JJ
MQ8"C%@2PP:]%]]S-S'N=];[GN6X7-Q<VBQI!++/+)+"D3%HDBD9BR*C$E I
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M>]^Z]U[W[KW7O?NO=>]^Z]T9KX9?]E5]!_\ B3-M_P#N6/<=^[?_ $[3>_\
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M>_=>Z][]U[KWOW7NO>_=>Z][]U[K<E^+_P#V33\>/_$&=2_^\#M_WRA]Q?\
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M#_Y7_?/^EA>_]I,G0=^S_H']>]^Z]U[W[KW7O?NO=>]^Z]T9KX9?]E5]!_\
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M *OS]=5/N)?].QW7_I:2?]HEIU;?[Q@ZS<Z][]U[KWOW7NO>_=>ZJ0_G#_\
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MVW_.>+_H+KW]0N>?^C+?_P#9'<?]:^O?Z,>R?^?>[X_]!//?_4'OW]9.7?\
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M[KW7O?NO=>]^Z]U[W[KW7O?NO=7F?R7O^YDO_*.__-3]X;_>U_YU_P#ZCO\
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M=>Z][]U[JQ3IS_F6FU/^H.J_]V5;[A7F?_DNW'VK_P <7J7N7?\ DBP?8?\
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MG-/_ $J-R_[0INM-KWU>ZX*]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5P'\G/\
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M'HZZ][]U[KWOW7NO>_=>ZH=_G-_\7WX_?]JGLC_W,V5[S1^Z9_N'OG^GM/\
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M3K'G[T?+>]\V>S][L?+UN;FZEFM2L8*J2$F5F-795% "<GY#/6NO_LK???\
MS[NO_P#/MMS_ .O'O.__ %S.1O\ HX+_ +Q+_P!:^N7'_ _^\'_1ED_YS6W_
M %NZ]_LK???_ #[NO_\ /MMS_P"O'OW^N9R-_P!'!?\ >)?^M?7O^!_]X/\
MHRR?\YK;_K=U[_96^^_^?=U__GVVY_\ 7CW[_7,Y&_Z."_[Q+_UKZ]_P/_O!
M_P!&63_G-;?];NO?[*WWW_S[NO\ _/MMS_Z\>_?ZYG(W_1P7_>)?^M?7O^!_
M]X/^C+)_SFMO^MW7O]E;[[_Y]W7_ /GVVY_]>/?O]<SD;_HX+_O$O_6OKW_
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M^P;U(W7O?NO=>]^Z]U[W[KW6LC_-<_[*PJ?_ !'>S?\ >\K[Z&_=F_Z=F/\
MGJG_ ,$?7(O[[/\ T^=?^E?:_P#'Y^JU?>0?6(?7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]UM[?"C_LD_H7_ ,1WAO\ >I??+3W<_P"GF;W_ ,]4G^'KNI["?].8
MY9_Z5]O_ ,<'1HO<==2YU[W[KW7O?NO=>]^Z]UJ;_P PW_LLGN[_ +6VV/\
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M^>27_!U,OW>?^GV<M?\ /;'_ (&ZV_O?+/KN7U[W[KW7O?NO=>]^Z]TTY_\
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M -,O^'HAGN7NHKZ][]U[KWOW7NO>_=>Z][]U[KWOW7NCI?&G_CT\[_X<3_\
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M?NO=>]^Z]U[W[KW5BG3G_,M-J?\ 4'5?^[*M]PKS/_R7;C[5_P".+U+W+O\
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M]4G^'KNI["?].8Y9_P"E?;_\<'1HO<==2YU[W[KW7O?NO=>]^Z]UJ;_S#?\
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MO?ZV?MO_ -,_MO\ V0VO_6KKW^AWJ+_GUG7'_H#[9_\ K7[]_6[FO_HYW?\
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MWZ][]U[KWOW7NO>_=>Z][]U[KWOW7NK--A?\>-LO_P -/;G_ +IZ/W!&\?\
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M+N(G #K_ ,>'2:]!:SE514E&_P".GK3;_P! '=7_ #[+=_\ YZ9_^*>^K?\
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ME[J*^O>_=>Z][]U[KWOW7NO>_=>Z][]U[HZ7QI_X]/._^'$__NMH/<7<]?\
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M9#T==>]^Z]U[W[KW7O?NO=4._P YO_B^_'[_ +5/9'_N9LKWFC]TS_</?/\
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M>&T@O!M\J5%55I*MJ#$"I4 Z: G *DD>=>#"O+)#X\9X@D+04(S0'SK3B00
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M7GW_ )3_ /JA;_\ 6GKW_ Y>S/\ T9O^SN^_[:>O?[*3\?/^??\ _KU[V_\
MLD]^_P!=7GW_ )3_ /JA;_\ 6GKW_ Y>S/\ T9O^SN^_[:>O?[*3\?/^??\
M_KU[V_\ LD]^_P!=7GW_ )3_ /JA;_\ 6GKW_ Y>S/\ T9O^SN^_[:>O?[*3
M\?/^??\ _KU[V_\ LD]^_P!=7GW_ )3_ /JA;_\ 6GKW_ Y>S/\ T9O^SN^_
M[:>A0Z4^-'2>UNVNN]Q8'99Q^9P^[,17XZM&X]V57V]5!5(T<GV];G:F)_\
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MC'>P1T,.O>_=>Z][]U[KWOW7NBX_);_CT\%_X<2?^ZVO]C?D7_DHS?\ -/\
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M4*?_ )PR?] ]>_N]G_\ G1YC_P ]E;_UX]^_>.W_ ._X_P#>U_S]>_<&^_\
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M:FP^X/DYW?B^W<SU,,[4=7;'V1UM!UEUUMC<6X,9_ <AOC*T-3N;>5?ELO\
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MR^XL?N3?O<M119""&6/&UM3AZ6@V]^G[BEIWJW0"2'V.9_\ %K?Z(_&6#/\
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MXGD5HE5$2_XU8I K*K1,QHS!:A].06(&"#45KD4KGIT_IS-(0:,%& 6R"QR
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M4D;JXR5,:A(U:02*A"B6\$<;U+RK&1ZA\_9I5OYTZ\SLGPJ6^S3C_>F7K/\
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M[KW7O?NO=>]^Z]T)W37_ #,S:O\ U%5O_NJK_9#S/_R0KC[%_P"/KT=\N?\
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MU-.U?\DNV_YI1_\ '!TK/9=TOZ][]U[KWOW7NO>_=>Z(=\@_^9BU'_:HQ?\
MUKE]R[R9_P D0?Z=_P#)U%W-W_)7/^D7_+T"'L5]!CKWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZL?ZI_YEUM'_M41?\ 6R3W"',/_);N?].?\G4Q['_R2+?_ $@Z
M$'V3=&O7O?NO=>]^Z]U[W[KW5=O<O_,S-U?]15%_[JJ#W-7+'_)"M_L;_C[=
M1%S'_P EJ?[5_P".+T&/L^Z).O>_=>Z][]U[KWOW7NO>_=>ZF8[_ (N%#_U&
M4W_6Y/;<W]DWV'_!TY#_ &J_:/\ #U:I[Q[ZG3KWOW7NO>_=>Z][]U[KWOW7
MNJMMP?\ %^S?_:WR7_N9-[G^S_W#B_TB_P#'1U"%Y_N9+_IV_P"/'IH]J>DW
M7O?NO=>]^Z]U[W[KW7O?NO=+CK3_ )F!L_\ \.#&_P#N0GLJWS_DCW/_ #3?
M_ >C/9?^2M;_ /-1?\/5E'N#.IEZ][]U[KWOW7NO>_=>ZBUW_ *L_P"H6H_Z
MU/[<A_M5^T?X>J2?V;?8?\'55/O(3J"NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MH3NFO^9F;5_ZBJW_ -U5?[(>9_\ DA7'V+_Q]>COES_DM0?:W_'&ZL2]PKU+
MO7O?NO=>]^Z]U[W[KW23W[_QXV]/_#3W'_[IZSV8[/\ \E:U_P":T?\ Q]>D
M&Z_\DNY_YI2?\</59?N=^H6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NC(?&C_CZ
ML_\ ^&__ /)&B]@CGK_DG0_\U/\ GUNACR9_N=+_ ,T_^?AT=#W%W4C]>]^Z
M]U[W[KW7O?NO= E\@?\ F7-5_P!K7%?];F]BKDW_ )+:_P"D?_!T&^:_^2._
M^F7_  ]$,]R]U%?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T=+XT_P#'IYW_ ,.)
M_P#W6T'N+N>O^2C#_P T_P#GYNI(Y,_Y)\O_ #4_Y]7HQWL$=##KWOW7NO>_
M=>Z][]U[HN/R6_X]/!?^'$G_ +K:_P!C?D7_ )*,W_-/_GY>@?SG_P D^+_F
MI_SZW1+?<H]1OU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=&P^,'_ #''_DM?_+![
MCOG[_B)_S=_ZQ]#SDG_B5_S;_P"LG1L/<=]#SKWOW7NO>_=>Z][]U[HN/R6_
MX]/!?^'$G_NMK_8WY%_Y*,W_ #3_ .?EZ!_.?_)/B_YJ?\^MT2WW*/4;]>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW5FFPO\ CQME_P#AI[<_]T]'[@C>/^2M=?\
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M_,8_]$SUI_\ ;L]^_>>P?]'*W_;)_P!:^O?N?>_^4*7_ (Q_T'U[_9G.X_\
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M#I3JR*I\E.KJY*4W>U6MCJX]=_\  >QUR^=GVK;A:7&YVK,&8U5I2,_;$/\
M!T#-\@W7<[[ZJ"QG"Z0.X1@XKZ2'H.O]F<[C_P"];O\ ,8_]$SUI_P#;L]G?
M[SV#_HY6_P"V3_K7T3_N?>_^4*7_ (Q_T'U[_9G.X_\ O6[_ #&/_1,]:?\
MV[/?OWGL'_1RM_VR?]:^O?N?>_\ E"E_XQ_T'U[_ &9SN/\ [UN_S&/_ $3/
M6G_V[/?OWGL'_1RM_P!LG_6OKW[GWO\ Y0I?^,?]!]>_V9SN/_O6[_,8_P#1
M,]:?_;L]^_>>P?\ 1RM_VR?]:^O?N?>_^4*7_C'_ $'U[_9G.X_^];O\QC_T
M3/6G_P!NSW[]Y[!_T<K?]LG_ %KZ]^Y][_Y0I?\ C'_0?7O]F<[C_P"];O\
M,8_]$SUI_P#;L]^_>>P?]'*W_;)_UKZ]^Y][_P"4*7_C'_0?1L]D_P Q3>FV
M]J8+!5W\LO\ F>2U>,H4I:B2DZ-Z@>F>16=B87F^0D#$>K^TBG_#W'6Z['97
MVXS7<6ZV061J@%YJ_G2 _P"'H?;=N5W9V,5K+M]R610#00T_*LPZ5/\ PY?N
MG_O6/_-$_P#1%=.?_=%>R_\ JS;?]':Q_P![G_[9^EO[[N/^C?=?[S#_ -;^
MO?\ #E^Z?^]8_P#-$_\ 1%=.?_=%>_?U9MO^CM8_[W/_ -L_7OWW<?\ 1ONO
M]YA_ZW]>_P"'+]T_]ZQ_YHG_ *(KIS_[HKW[^K-M_P!':Q_WN?\ [9^O?ONX
M_P"C?=?[S#_UOZ]_PY?NG_O6/_-$_P#1%=.?_=%>_?U9MO\ H[6/^]S_ /;/
MU[]]W'_1ONO]YA_ZW]%4W_\ +SM;=6[\UN#'_P MC^9%#1Y*:GD@BK>E>KHZ
ME%BHJ:F82I!WG4(#JA)%G;BW^M[D+9YMEV_;8K.;<[4L@()5I2,L3BL0]?3H
M"[M9[O?[A)=PV,P5R* ^'7"@9I(?3UZ1W^S.=Q_]ZW?YC'_HF>M/_MV>S/\
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MQ_T;[K_>8?\ K?U[_AR_=/\ WK'_ )HG_HBNG/\ [HKW[^K-M_T=K'_>Y_\
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M_P#;L]^_>>P?]'*W_;)_UKZ]^Y][_P"4*7_C'_0?7O\ 9G.X_P#O6[_,8_\
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M<OW3_P!ZQ_YHG_HBNG/_ +HKW[^K-M_T=K'_ 'N?_MGZ]^^[C_HWW7^\P_\
M6_KW_#E^Z?\ O6/_ #1/_1%=.?\ W17OW]6;;_H[6/\ O<__ &S]>_?=Q_T;
M[K_>8?\ K?U[_AR_=/\ WK'_ )HG_HBNG/\ [HKW[^K-M_T=K'_>Y_\ MGZ]
M^^[C_HWW7^\P_P#6_K#4_P RO=<U//$O\LC^:&&EAEC4MT7TX%#.C*"2/D2>
M.?Z>[IRW;*X8[M8X(/QS_P#;/U5]YN&4J-ONLC^&'_K=T2G_ &9SN/\ [UN_
MS&/_ $3/6G_V[/<I?O/8/^CE;_MD_P"M?4;?N?>_^4*7_C'_ $'U[_9G.X_^
M];O\QC_T3/6G_P!NSW[]Y[!_T<K?]LG_ %KZ]^Y][_Y0I?\ C'_0?7O]F<[C
M_P"];O\ ,8_]$SUI_P#;L]^_>>P?]'*W_;)_UKZ]^Y][_P"4*7_C'_0?7O\
M9G.X_P#O6[_,8_\ 1,]:?_;L]^_>>P?]'*W_ &R?]:^O?N?>_P#E"E_XQ_T'
MU[_9G.X_^];O\QC_ -$SUI_]NSW[]Y[!_P!'*W_;)_UKZ]^Y][_Y0I?^,?\
M0?7O]F<[C_[UN_S&/_1,]:?_ &[/?OWGL'_1RM_VR?\ 6OKW[GWO_E"E_P",
M?]!]+'8'R\[6VKN_"[@R'\MC^9%-1XV:HDGBHNE>KI*EUEHJFF41)/WG3H3J
MF!-W7B_^M[+-XFV7<-MELX=SM0S@ %FE PP.:1'T].C':;/=[#<([N:QF*H3
M4#PZY4C%9!Z^O1J_^'+]T_\ >L?^:)_Z(KIS_P"Z*]Q[_5FV_P"CM8_[W/\
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M (Q_T'U[_9G.X_\ O6[_ #&/_1,]:?\ V[/?OWGL'_1RM_VR?]:^O?N?>_\
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MC=;-E"L**\Q.1\X!_AZ*-[O+W<K!K6"PN0Q*GN$0&#7RF/\ @Z+/_LSG<?\
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M&EYB:U!\X5].B'F">_W6U2"WL+A2KZCJ$0%*$>4I]>B^?[,YW'_WK=_F,?\
MHF>M/_MV>QG^\]@_Z.5O^V3_ *U]!+]S[W_RA2_\8_Z#Z]_LSG<?_>MW^8Q_
MZ)GK3_[=GOW[SV#_ *.5O^V3_K7U[]S[W_RA2_\ &/\ H/KW^S.=Q_\ >MW^
M8Q_Z)GK3_P"W9[]^\]@_Z.5O^V3_ *U]>_<^]_\ *%+_ ,8_Z#Z]_LSG<?\
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M//$BEO:NRLWOIQ CHF"2TC!%  J22?Y 5). ">F+BX6VB\5PS9  52S$DT%
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M7KSLCLJFDI4:\,AGJ:>4.O\ FM!5RBW"RBL9%2*YBN0PKJB,E!G@?$CC-?/
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MF/1I^5*::8I2F*=)^7M/]6(?$_WVVNO\56UZOG6NJN:UKGHPW\OGL_:G2/\
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M5\0(1@HH15!'Q$%N!'15MT,LD\^[R JUPJ*B$4*QIJ*:@<AF+DD&E 0*5!J
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M^Y$C%/R_/H1VHNUBI>LCO4Y12BT\L,SG^?0P>T?2CKWOW7NO>_=>Z][]U[I
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M'&<4/5HKW<;3=8=MW!DF6X1V1XXV0J8])8."\@H0V#49QFHZ*#\?L;\OZ_\
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M6_Q&GVYFTW?M+>^.K<343)')6X^KQTT<WA0-Z00379=WFV._7<;>-)'0, )
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M)<OA,)G\?23O4-XT@1I$D,X^:[Q!'*\$#W,*JL=PR,9E""B<'",R@ *S(S
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M&&S4TM1+E\)A,_CZ2=ZAO&D"-(DBV/FN\01RO! ]S"JK'<,C&90@HG!PC,H
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MFI*<BB&3I/MIEIAX@0"VH_VGF"3:K.>Q%M#/'<%=?B"2I"Y"UCEC.FN:&HJ
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MF)Q6/QDF;SDU/4YO,/04D-*^4S%124M#%)55!B\U0\4,*-([%40$* N[:W+
M 5)-!P'R''H]44 %:T]>G3W7K?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
E=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tbar_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tbar_002.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M.-=1 IY@P7L$]2+U[W[KW7O?NO=8*JIBHZ6IK)RPAI:>:IF*C4=,"EFL/R;
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M[9$C1]4K++B#:O:?E_;+Q]OMK^\W.,SL]X@EBCBT12:50@@$"5 "*&NLDD4
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M'_2[F_X_/TU?SB/^9$=:?^);IO\ W39;VL^ZQ_R6;O\ YXC_ -7X>BC[\_\
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MC2%F]DO.?(VV[%S[M]G!#&+:Z^FF>W*@Q O++$RA6J-)\+5I^$:B   !T?\
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MD\2)]_\ >3F7=>2>7MVAN&AOY-W^EED&N&*[$?BA#*L= T;@)XH4:68,55<
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MR;-O+\Q7L#62W/T<4+R*\\EOKF8W<P822!]7A(E61$56*L:J7[N#M[=7=O\
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MG0LL4<P6K5)T^)I%23CB>/66'L7SA<\^\I[=NMX=4\L3I,Y"J9)+>>6V9Z(
MHUF+50 #. .'1*>Q_P#M[QT#_P"(DS/_ +HMZ^Y;V#_IU^Y?\]L?_:18=0#S
M;_T^[9?^E9+_ -HN[=-'\U/%X_;.2^./:VU\=3Q]KXSL>.@PU;1.*2KK(<9X
M:VG@<I:29:>N2$1L2?"9W MYN5'W<+A]P3=-LN6/T3VA:16&I$9JQEA7 +(6
MJ/Q:0?P],_?"M(]IDV+>K.,?O*+<4CA93IDE1:2A#3+ 2*@4FNC60*:S7/\
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MY/\ =,>#M]_N^VI:Q,FN[ABDEOIHHV!T'Q(8T!=1I9ZJXXZF-27?LGXT_(?
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M /V]]A-VY0Y%W;EB>>T>ZOY+MX9(WF\!1/;6\"ZV:!7!K"2VF-J BFKHI_R
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M1&H1G J8R11CBGGUD5[*<C77MMRQ9;+>O%)/;?4:W@+M$3-=3SC29$C8T64
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M9Z+%1O D4T\,(J*=BXD4SA08W 8V%_*M P^SK9/ ]''V!OW*;V;+#(]<;[V
MN,% 86WK2T5+]V:SS:A3"CK:S5X/$ODU:;>1+7YLV13SZL#7H1O=>M]>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$Y^!W_9-V
MUO\ M=;M_P#=A/[<E^(_ZO+JJ<.H&Q<0=P?(?YIX$54E"<W@.J<0*V(:GA_B
M6W:B'RJ+B[1Z]0Y'(^H][.%7\_\ #UKB3TD.M>RV^/VV,#T=\A=@2[;P%!//
M@,)V/14"YO;.3CJ9WFC>L<*?M9I#)J?R(QO>69( &MMEUFH_9Y]>!TX/2\R3
MK)\[-LNC*Z/\:YG1T(8$-G:\@@C@@CW7\'Y_Y.M^?Y=-ORHQE#LG=O1/<>W:
M1,?O./M_;.QLG6X^+P29#&;EBJVJ:6J*%34#13,B:[E1*^DB_OR9!'RKUIN(
M/1VO;?5^JUNH>T,CL3</RDH:#J/LGLIJOOOLFK+;/PE/DJ,$U$D?VM2\E0)E
M=PMV5*.;T,"%8G3[>9:TR. ZH#2OV]-FS]\UO57PEW1NG8&X,;_>S#[R\^1Q
M;8II4P57G,W1QSX>2CKX596IJ>6Q+0!=;L\18!9#XC4U#_JQUH8'1ANV?^RK
M/B9_U"]X_P#NA7W5?A/Y?X>K'B.L'4,C1?)'YC2I;7&_2LBW%^4P=<1_O(]^
M;X1^?^'KPXGI*[;^1.\:'XF;([/KX<;N'LO>N;J]F[=IYJ5,923Y.OS>1H*,
MRPTWA58H:6E,CK'H,AC(U(7+KLH-5/+_ &.M5QU+["SOR#Z"V]0=I;K[0PO9
M^U<;E\)3[]VBVPZ/:_V])FIXZ5YL564K&HED@GFC5%G!#7UN+ Q^] !\ 4Z]
MD=/V^=\]QY?Y"IT_UON' 8##9'J3'[UK,YF<)'EY,:/XI-2SUE)3D1FLJI :
M2*.&:80*&>1E)7WX ::GUZV2:TZ?^E-[=CIV/VATYV;GL?O/*;&I=LYW";UH
M<)%MUZVBW'$S%*FCIS]O%+ X0#QCDF2[, I]Z8"@(Z\#Y=&?]TZMTWS8S%25
M]/FJC'X]\ICZ6JI:3+34D;5$$-64::..=E\D<4IC0NH<*VE2P-A;W7NBA=)-
M2[P[S[Y[HVQ30IL.JI,-LC$9*GB\$>:K=MHK9"OB(],T44L8A2< K*K75B5<
M>W&P .J+DUZF?"J@I<IT+#N?)4]-6Y;LC<V^=P[MJ)X$E-9/59*JI)//JU&1
M&B@ TO<69N+,;^EP:>G7D&.DW\5MJX3=O3'9G5VXZ*:OV?M[N??6T*;&??ST
MJO0XRHH<@D'DA>*;PM432"1/(1(I=7U*[+[\YH0?D.O**BG3ST7B,5@?DO\
M*C#8/&T.(Q&.H^DJ7'XS&4J4,$,<>$DTI%%&JHBC^@4#WYS51^?^'K8XGHQG
M:>_\;U;U[NO?N5*&GVYB9ZN"G=M/GJ9+14E,#<>JIJGAC'/&J_T'NBC4:=;)
MIT$/0.#H>GNF:?='96;QF!SV],A-V!V#N#<==%B47([QD1DAJ)JAHTC>)'IX
M=!>WFUZ>7YLW<<?EUI<#H9L-NWK?LZAS&.P&X]F;_P 9%#%2Y^AQ64HMT0+'
MD1($CJXHGGC"3B.6RR+9PK6!L?=2"O6^/1:_E)#C]Z9/J#I3;M-2U.^,GOO
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M/_GMMH_^A)1_]?O?J'KU1U[_ $@;#_Y[;:/_ *$E'_U^]^H>O5'7O](&P_\
MGMMH_P#H24?_ %^]^H>O5'7O](&P_P#GMMH_^A)1_P#7[WZAZ]4=>_T@;#_Y
M[;:/_H24?_7[WZAZ]4=>_P!(&P_^>VVC_P"A)1_]?O?J'KU1U[_2!L/_ )[;
M:/\ Z$E'_P!?O?J'KU1U[_2!L/\ Y[;:/_H24?\ U^]^H>O5'7O](&P_^>VV
MC_Z$E'_U^]^H>O5'7O\ 2!L/_GMMH_\ H24?_7[WZAZ]4=>_T@;#_P">VVC_
M .A)1_\ 7[WZAZ]4=>_T@;#_ .>VVC_Z$E'_ -?O?J'KU1U[_2!L/_GMMH_^
MA)1_]?O?J'KU1U[_ $@;#_Y[;:/_ *$E'_U^]^H>O5'7O](&P_\ GMMH_P#H
M24?_ %^]^H>O5'7O](&P_P#GMMH_^A)1_P#7[WZAZ]4=>_T@;#_Y[;:/_H24
M?_7[WZAZ]4=>_P!(&P_^>VVC_P"A)1_]?O?J'KU1U[_2!L/_ )[;:/\ Z$E'
M_P!?O?J'KU1U[_2!L/\ Y[;:/_H24?\ U^]^H>O5'7O](&P_^>VVC_Z$E'_U
M^]^H>O5'7O\ 2!L/_GMMH_\ H24?_7[WZAZ]4=>_T@;#_P">VVC_ .A)1_\
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M/_H24?\ U^]^H>O5'7O](&P_^>VVC_Z$E'_U^]^H>O5'7O\ 2!L/_GMMH_\
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M/_GMMH_^A)1_]?O?J'KU1U[_ $@;#_Y[;:/_ *$E'_U^]^H>O5'7O](&P_\
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M#8?_ #VVT?\ T)*/_K][]0]>J.O?Z0-A_P#/;;1_]"2C_P"OWOU#UZHZ]_I
MV'_SVVT?_0DH_P#K][]0]>J.O?Z0-A_\]MM'_P!"2C_Z_>_4/7JCKW^D#8?_
M #VVT?\ T)*/_K][]0]>J.O?Z0-A_P#/;;1_]"2C_P"OWOU#UZHZ]_I V'_S
MVVT?_0DH_P#K][]0]>J.O?Z0-A_\]MM'_P!"2C_Z_>_4/7JCKW^D#8?_ #VV
MT?\ T)*/_K][]0]>J.O?Z0-A_P#/;;1_]"2C_P"OWOU#UZHZ]_I V'_SVVT?
M_0DH_P#K][]0]>J.O?Z0-A_\]MM'_P!"2C_Z_>_4/7JCKW^D#8?_ #VVT?\
MT)*/_K][]0]>J.O?Z0-A_P#/;;1_]"2C_P"OWOU#UZHZ]_I V'_SVVT?_0DH
M_P#K][]0]>J.O?Z0-A_\]MM'_P!"2C_Z_>_4/7JCKW^D#8?_ #VVT?\ T)*/
M_K][]0]>J.O?Z0-A_P#/;;1_]"2C_P"OWOU#UZHZ]_I V'_SVVT?_0DH_P#K
M][]0]>J.O?Z0-A_\]MM'_P!"2C_Z_>_4/7JCKW^D#8?_ #VVT?\ T)*/_K][
M]0]>J.O?Z0-A_P#/;;1_]"2C_P"OWOU#UZHZ]_I V'_SVVT?_0DH_P#K][]0
M]>J.O?Z0-A_\]MM'_P!"2C_Z_>_4/7JCKW^D#8?_ #VVT?\ T)*/_K][]0]>
MJ.O?Z0-A_P#/;;1_]"2C_P"OWOU#UZHZ]_I V'_SVVT?_0DH_P#K][]0]>J.
MO?Z0-A_\]MM'_P!"2C_Z_>_4/7JCKW^D#8?_ #VVT?\ T)*/_K][]0]>J.O?
MZ0-A_P#/;;1_]"2C_P"OWOU#UZHZ]_I V'_SVVT?_0DH_P#K][]0]>J.O?Z0
M-A_\]MM'_P!"2C_Z_>_4/7JCKW^D#8?_ #VVT?\ T)*/_K][]0]>J.O?Z0-A
M_P#/;;1_]"2C_P"OWOU#UZHZ]_I V'_SVVT?_0DH_P#K][]0]>J.O?Z0-A_\
M]MM'_P!"2C_Z_>_4/7JCKW^D#8?_ #VVT?\ T)*/_K][]0]>J.O?Z0-A_P#/
M;;1_]"2C_P"OWOU#UZHZ]_I V'_SVVT?_0DH_P#K][]0]>J.O?Z0-A_\]MM'
M_P!"2C_Z_>_4/7JCKW^D#8?_ #VVT?\ T)*/_K][]0]>J.O?Z0-A_P#/;;1_
M]"2C_P"OWOU#UZHZ]_I V'_SVVT?_0DH_P#K][]0]>J.O?Z0-A_\]MM'_P!"
M2C_Z_>_4/7JCKW^D#8?_ #VVT?\ T)*/_K][]0]>J.O?Z0-A_P#/;;1_]"2C
M_P"OWOU#UZHZ]_I V'_SVVT?_0DH_P#K][]0]>J.N<>_-CS21Q1;SVI++*ZQ
MQ11[BHW9F<V5543$EB2  !<GWZAZ]4=*OWKK?21_T?[#_P">)VC_ .@W1_\
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M/_H-T?\ UY]^J>O4'7O]'^P_^>)VC_Z#='_UY]^J>O4'7O\ 1_L/_GB=H_\
MH-T?_7GWZIZ]0=>_T?[#_P">)VC_ .@W1_\ 7GWZIZ]0=>_T?[#_ .>)VC_Z
M#='_ ->??JGKU!U[_1_L/_GB=H_^@W1_]>??JGKU!U[_ $?[#_YXG:/_ *#=
M'_UY]^J>O4'7O]'^P_\ GB=H_P#H-T?_ %Y]^J>O4'7O]'^P_P#GB=H_^@W1
M_P#7GWZIZ]0=>_T?[#_YXG:/_H-T?_7GWZIZ]0=>_P!'^P_^>)VC_P"@W1_]
M>??JGKU!U[_1_L/_ )XG:/\ Z#='_P!>??JGKU!U[_1_L/\ YXG:/_H-T?\
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M_H-T?_7GWZIZ]0=>_P!'^P_^>)VC_P"@W1_]>??JGKU!U[_1_L/_ )XG:/\
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M/_GB=H_^@W1_]>??JGKU!U[_ $?[#_YXG:/_ *#='_UY]^J>O4'7O]'^P_\
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MY]^J>O4'7O\ 1_L/_GB=H_\ H-T?_7GWZIZ]0=>_T?[#_P">)VC_ .@W1_\
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M/_H-T?\ UY]^J>O4'7O]'^P_^>)VC_Z#='_UY]^J>O4'7O\ 1_L/_GB=H_\
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MY9;/[WJ*G-XJKQR4N%&$V[7UE>BU=#-DZ@U)B$2&D$1;7-&K>Z]TB/B7_/\
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M]L?MC*5F1'EG G>E%-'JEF0'W7NMQWX#]Q?.#NKJW=>Y/GC\/<!\+NT,;O\
MK,)M3KG;_=^![XCR6!BQV.GAS;Y/;U354=(\N0J,C2_:R2B912B5E"2QEO=>
MZ/+[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUDO\ A6Q\DMY?'O\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K2:Z6_DS?\
M"@CX\_-?Y!?.S:_>W\J7NCY"=W9/)4U/VM\A:CL_<^1P>(EJ:GQT.V:*+9\D
M>V*6>@DI*5Z6+(UOV])2P44%6T(F>I]U[H__ ,U/Y2O\PK^8M\//C]G?D?WM
M\6^O/YIGQ [WW!W?\=>W^B=OYJIV! /-CJB@PU8V=PW\:I5JJK#8:KJJE<-5
MI'54-.31UL*M$?=>ZE?&_P#E=?S'N_\ ^8'T5_,(_F\]R_&+/9GXB;4W!@?C
M7T/\3L)FEPD66W)%HJ-RYBOSM-25*U(,CR&F3[I9*B"BECDHHJ8T]1[KW2%_
MG;?RU_YT?\SI>TOCCU?VO_+MVQ\%LQO+K/>O6V,["KM_;<["AJ=G8JC:K7+U
MF,VGG\/XWW!)EGB$#OKHS3:C%)KC7W7NK?\ ^79LK^9)UUTCN/:O\PW=7Q)W
MOV9@*[&X?J"3XMG<U!A5P&%Q%+3019VHW#AZ"L&2DR$<QDDIZ&2-8"C*&>\8
M]U[HC?\ )I_E0=^?"KN/YQ_,?YL]E];=M_,+YJ]G29O+9;JO.YC=>#P.VH*N
MJR<>)Q^0W!@L!E@:BNK8X9*?[,4E/0XK$4]*%$+@^Z]U?W[]U[K4N_FR_P G
M;^:Q\U_YDW6?RZZ:[=^">]/CY\?L;M6KZ ^.GRVK]\RX;&YBFQZC+U^;V[A-
MM9K%9FJGSO\ ET-4,C3ZXH,?1U-(\5$YJ_=>ZM(^*G2'\U_LO;WR&ZC_ )N&
MZ_@/V)T1VUTWG>KL)M?XC8S=T-9,-\P5.,SL6;_O5A<=3&@FPU3+%$D)E)=V
M\B!0+^Z]U1QMW^1S_.UZI^,/9G\ISJ+YE?#R'^6KV+NW=,=+VSNW9V=J>T\5
MM'?=6,EFL##B*;&QX1_OZYJPU$1S#O,:J=H,I00RK24ONO='=_FN_P EGY;_
M "!_ET_$;^6__+G[UZIZ@Z.Z0QM+MGN/"=V;CW'M27>&/VK0T28)ILEMG"9_
MSJ,HN3K\A0U&+$-55STM2D\1HO%/[KW0F_ [XV?S\/CGN3X^]1]D[C_E!;/^
M$G6,^)V]NGKKXU[>[%QVX(=NXR*0&FP"Y;;=)CCD)Y]#2S5=6K2L\T\LCS,6
M;W7N@/\ YVW\M?\ G1_S.E[2^./5_:_\NW;'P6S&\NL]Z];8SL*NW]MSL*&I
MV=BJ-JM<O68S:>?P_C?<$F6>(0.^NC--J,4FN-?=>Z.ULWXE?S/.Z/Y97S%^
M'GSM[)^&];W1V]TIV!T5T3NGXZ0;KBVUCL3N3:!PE%-N:3-8:AR3U:9.21YV
MI,?*HI@K1JTA,8]U[JL;X1?R_?\ A3+\ /C!UC\1^A^[?Y/,W5/4W]]/[JR[
MZE[4W#E3_?S<.6W-7?=5D.R:**:V2S-8(M-,FB'QH=14NWNO=;=U**H4M,*U
MH'K1!"*MZ5&CB,H4>0QJ[.ZQE[Z0S$@6!)//OW7NL_OW7NO>_=>Z][]U[KWO
MW7NM./Y$_P FW^=?NW^;-V3_ #*>M.Z?Y;G:PQ&8SV(^*6V/E75]B9B'8>VV
MFC.$%#MW';4R&-QVX<72K,CU<&8J(9JNIK,E'#3U%1$M+[KW1WN_/Y77\PG^
M9_\ R_.\?BM_-2[;^'N/[@F[)V3V7\6^Q?B5MK<F5Q&W<ALRCK(349VFW/C\
M16S2UZ9'(T$OVANE!53%)/*=!]U[HN&U_P"4=_-W^:7:WPLI/YO7R,^).?\
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M7:OQ>ZVV!\FJS=E)345-MK$[QVPJ)C]L;7RE/54";:W5XH+5M(T-1 K>%HU
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MY#G<&=OP46/CIW>@J*-3D#%/)]^&IO=>Z/1\"NM_YY>PNV=KX?YP;T_EAO\
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M7NO>_=>ZI<_T'_SY?^\^O@!_Z0[N;_[9'OW7NO?Z#_Y\O_>?7P _](=W-_\
M;(]^Z]U[_0?_ #Y?^\^O@!_Z0[N;_P"V1[]U[KW^@_\ GR_]Y]? #_TAW<W_
M -LCW[KW7O\ 0?\ SY?^\^O@!_Z0[N;_ .V1[]U[KW^@_P#GR_\ >?7P _\
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MO_>?7P _](=W-_\ ;(]^Z]U[_0?_ #Y?^\^O@!_Z0[N;_P"V1[]U[KW^@_\
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MOW7NO?Z#_P"?+_WGU\ /_2'=S?\ VR/?NO=>_P!!_P#/E_[SZ^ '_I#NYO\
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M_P"D.[F_^V1[]U[KW^@_^?+_ -Y]? #_ -(=W-_]LCW[KW7O]!_\^7_O/KX
M?^D.[F_^V1[]U[KW^@_^?+_WGU\ /_2'=S?_ &R/?NO=>_T'_P ^7_O/KX ?
M^D.[F_\ MD>_=>Z]_H/_ )\O_>?7P _](=W-_P#;(]^Z]U[_ $'_ ,^7_O/K
MX ?^D.[F_P#MD>_=>Z]_H/\ Y\O_ 'GU\ /_ $AW<W_VR/?NO=>_T'_SY?\
MO/KX ?\ I#NYO_MD>_=>Z]_H/_GR_P#>?7P _P#2'=S?_;(]^Z]U[_0?_/E_
M[SZ^ '_I#NYO_MD>_=>Z]_H/_GR_]Y]? #_TAW<W_P!LCW[KW7O]!_\ /E_[
MSZ^ '_I#NYO_ +9'OW7NO?Z#_P"?+_WGU\ /_2'=S?\ VR/?NO=>_P!!_P#/
ME_[SZ^ '_I#NYO\ [9'OW7NO?Z#_ .?+_P!Y]? #_P!(=W-_]LCW[KW7O]!_
M\^7_ +SZ^ '_ *0[N;_[9'OW7NO?Z#_Y\O\ WGU\ /\ TAW<W_VR/?NO=>_T
M'_SY?^\^O@!_Z0[N;_[9'OW7NO?Z#_Y\O_>?7P _](=W-_\ ;(]^Z]U[_0?_
M #Y?^\^O@!_Z0[N;_P"V1[]U[KW^@_\ GR_]Y]? #_TAW<W_ -LCW[KW7O\
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MCW[KW7O]!_\ /E_[SZ^ '_I#NYO_ +9'OW7NO?Z#_P"?+_WGU\ /_2'=S?\
MVR/?NO=>_P!!_P#/E_[SZ^ '_I#NYO\ [9'OW7NO?Z#_ .?+_P!Y]? #_P!(
M=W-_]LCW[KW7O]!_\^7_ +SZ^ '_ *0[N;_[9'OW7NO?Z#_Y\O\ WGU\ /\
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M_/E_[SZ^ '_I#NYO_MD>_=>Z]_H/_GR_]Y]? #_TAW<W_P!LCW[KW7O]!_\
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M](=W-_\ ;(]^Z]U[_0?_ #Y?^\^O@!_Z0[N;_P"V1[]U[KW^@_\ GR_]Y]?
M#_TAW<W_ -LCW[KW7O\ 0?\ SY?^\^O@!_Z0[N;_ .V1[]U[KW^@_P#GR_\
M>?7P _\ 2'=S?_;(]^Z]U[_0?_/E_P"\^O@!_P"D.[F_^V1[]U[KW^@_^?+_
M -Y]? #_ -(=W-_]LCW[KW7O]!_\^7_O/KX ?^D.[F_^V1[]U[KW^@_^?+_W
MGU\ /_2'=S?_ &R/?NO=>_T'_P ^7_O/KX ?^D.[F_\ MD>_=>Z]_H/_ )\O
M_>?7P _](=W-_P#;(]^Z]U[_ $'_ ,^7_O/KX ?^D.[F_P#MD>_=>Z]_H/\
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M+5XZJQU<V/Q"8FCQ4R&HBPZ48\F.BIJ<UC5DT]6]-'1O[KW12\7\"Z+^:/\
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MO5BI]U[I=?RTOY*&,_EQ[A_F&[@H_E+OWO\ R/S]K]HY;.YWLG8M#B\QB*W
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M)14=+Y/L#BX*=:FE]U[JSW^=3V)B_@U_PH1_E._S)ODM3YC;OQ>V_P#&S/\
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M41V"B655#R!0!;4QM[]U[J=[]U[KWOW7NO>_=>ZII_EM_P K+=OPU^4?S_\
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M*/JOK/K#8CS4.:RW7?6.R>MYMTQXM<=+61[0QU+0F4*7FEAAG>F$HA-1($)
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MAI:Q)8/=>ZO_ .XN^^B_COM==\?(#NGJ;HO93UL..3=_<78V'ZRQ9J*E@L<
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M::+Y/^87BO\ A55_-.F_EJ;=^,&Y.]I_C;MNEW32_+&?/P;>AVI+B.DC75-
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MUC^+GP.^)7R^_P"%)'\V'K'Y+;-A[*ZVZ7P'3^].ONB=R;HJ3MO(Y3#[:P&
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M3W-V)U))A,3_ !DPI12YEJ?:F5GJ*))#-31>%IE4R:5]U[K/\Z_E[OGXD_\
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M4Z![KW6M#\S>A]E0?SQOFIWM_,<^'/\ ,"CZ4W=U7U?L_P"+?:O\O7K;=/\
M!]S4>(IZ%*VMWMN/K^:GS.0W,%Q\-/%3SUH\%-2+#74OAIL+-[]U[H[_ /)U
M^%ORC^1'QS_FH=#_ "RR_P Y-A_R[/E5N*NZ\^&NS?EKN61>X<)M7)?W@Q^=
MR2Q[GH<I58**KH&V\M)%64DU++-3RUD%(RS2U=?[KW5SF\/Y1WQGWO\ RNZ3
M^4IF]U=SCXVT6R-C;%AW=1[GP\&]/!U]N7'[LQ]4<F=OOA36?Q;&4QE/]WO
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M0*S:=7C5PM94T^#:7)03_P 5CA1F2:+1_P !UD8!0LG()N>![]UNO2'RF_\
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M4=8R9)5?FI"EW%H^3H/]1[UUNO28Q^^-^5;[F6LZFRV.7#8^NJL(\FY**?\
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M!Z]:J?3I45VX=R4V%VMD:795;7Y+-5F$I\YA8\K3POBH\C$7J9I96_;J%H9
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M65Q4$%56B<P?;SY&AHX<A3SK33M'44DD\#JNI9"K*6.-VV&[V+0+N,QF1=2
ME22/F%)((KD&A'IT6;9O-MO <VSAPC:6(# 5^1( (]"*@^1Z,Q[)^C/KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZXNZ1H\DCK''&K.[
MNP4*%%R23P !]3[]U[I';5['Z\WU/D:;9._-F;QJ<0R+EJ?:NZ*'<+TID+*H
MJ$I)YF@+,K :PMR"/P?;TMO)#36K+7AJ!%?LJ.J)*LGPD&G&A!Z6?MGJ_2$W
M'VCUEL_+46!W;V+L3:V=R2PMCL+N/=V/PE74"H?QQF&FJ:B*:4/)Z5TH=3<"
MYX]OQVTDH+(C,!Q(4D#]@Z;:54-"0#Z$@'I=^V.G.O>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN)= RH64,]]"E@"=/)L/J;>
M_=>ZY>_=>ZXHZ2*'1E=3>S(P8&W'U''OW7NL<M33P/%'-/##).VB!)95C+FX
M%D!(+&Y' _J/Z^]@5Z]7K-[UU[KB[I&C22,J1HK.[NP4 *+DDG@ #ZGW[KW7
M"">"IB6:FFBJ(6+JLL$@E4F-BK ,I()5@0>>""#R/>R*<>O5KUE]ZZ]U[W[K
MW3!NO;.)WIM;<NSL\E9)@]V8#,;9S28[)U.$J&I,]3R4M2(*VCE@K*28PROH
MF@GCFB:SQ.CJK!R&4P.KK2JD,*@$5!J*@@@CY$$'SZI+&)5*-6C @T)!H13!
M!!'VC(ZI<ZQZCZQZ-_G3[:ZVZ@V+MKKK8N!_E8S+B]L[5QD>+ID:;M&4RSR!
M!KJ*JH?US5$KO//(3)+([DL9#O+Z;<>76FG=I';<\LQ))_Q8>OD/(< ,#H#6
MMI%8[\(H45$&WX50 !_C-?+U\SYGJU;MCX^].=SYK8.ZNU=AX;?V2ZDK<UG]
M@4FYO+E,=0Y'*1TZG)'%22'&5>0IA2Q_:5%122RT1:1J1X7ED9@19;G/8*Z0
MN4$H"N5PS**]NKB%-<@$!L5K0="^ZL(;PHTJ!S&2R:LA6_BH<:A3!I49I2IZ
MKB_DBYO$;:_E2]';CW!D:3#X';Z=[9O-Y;(3"F@I:3%;TW-/4U,\C66.&"&-
MW=B;*JDGZ>Q?[D1M+ODZJ"2?!  XDF&, =!?D%PFSPL30#Q22?(":3JM_P":
M6$R_R&^,G9?\Q+L#&UE$G;?<'QUZ\^*6V<Q"T<N!ZNP6\**6GRGAD57ILCOS
M(!LK4@AF%(*"-)/&63V)MAD&U7B;5$?[**Y>Y8?CN3 X*_-8AV#^EK/GT2[N
MAW&V;<7&));9;<'\$ G0AOD93WG^CH'EUM4^X:ZD_JM[Y[;XW7V!5; ^!W3N
M9K<-VI\I:;*G?^[<0Y6HV?UA@9(HMW;B+A76&KR,4HP^+\@42UE6VAU>&X%?
M+5NEJ'W*<!H[8C0IX2W#5,:?,"FM_P"BM//H.[[.\^BPA)$DX.IA@QP+0.]?
M(FH1?Z35\CT O\LG8VU.LOE9_,_Z[V+A:/;FS=D=J_'[:VU\%CT\<-+0X3:$
ME/30I]2=$4:W9B68W9B6)),N;KE[RRV^64EG>*=F8\23.Q)Z1<MP);75['&
MJK+"JJ,  0( .KF_8"Z%_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U3/_/)SV7Q'Q.ZMQ60RF5P/1.^?EU\?-A?+G.XG)U&$:FZPW+6
MU<>?%364DD5334-76KB:6H:-B7CG,+(R2O8=>WT2R7LC  S);3O:J0&K<JH*
M4!!!(&IA7S /$=!3G!RMJ@)I$T\*7!J5I S4;(((!-%/R)Z)I\M3\$_C-\AO
MY97:GP(R/QEV1V[N;Y?]4]';NVQ\=L_@Z$[DZU[LCFH,Y-F\=MNJ5,M20S)B
MC2UU9#/XZN>GE5W;2"?;'^\=ZM=PAW+ZAXDM9)E:8.?#N(2&72T@.DD:@5!%
M5J.BK=A9[5/9RV0A21[A(B(M*ZX900U0A&H Z2":T:A^W9C]Q/U('6HAN3>'
MPH^+.]?G3TA_,G^/>V^W_F/W/V_V+V)TUOK=.S*'L:HWYM[M>=:/9&.P6[*T
M5"["7$^"""2"KK,52XR.))8GD,:+[FF*'<=XBM;C:IVBM88HTE57,8@DC6LK
M,BT,FJI:JAR]2#Z=1K))9;;)/#N$2O/+([1LR"0S([4C578$)IH%TL5"T!X9
MZV)_Y>W47:70WPI^-_47=6XHMT=G;&ZTQ6*W5DH<I_'$B>62:HIL<E:'D2L3
M#T4U-0+,DC12BF#Q,T;*3&/,E[#N-_//;KIC>1B@I3'K3RKQIY5IT-]FMI+.
MTBBF.IU10QK7('KYTX5\^CD>R3HSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NM>GLKH7=_4_\ -3_E>;N[0[QWUWSV?VAE_F/5[FS>
MXXXMOX+&4^V]E0''8G:>VJ5I*3 XND^_J6;]^IJZN5O-5U4SB,1RG9;E'>['
MN4<,*0QQBS"A>YV+3&K2.<LQH/11P51FL<WEB]KO%@\LKRNYNB2V$4"$45$&
M% J?5C^)C04MW^3/0^\?D#B]L[0HN\]]]/\ 6$,N:JNU\'U>D6#SNZ:9DI_L
ML0FY2S5>!Q1*U8R HH!5UD4J0QU5*JR&4![3N4>V%I#"DLF!&9.Y(SFK:.#M
MPTZNT<2K8H--RL7OP$$KQIDN(^UW&*+KXJ.-=-&.*,OF23^1=)%3?RNOC[42
M$1QQUW=,\[A2>(M[[CNQ !)(5?Z$\6]B;W+SO=Q]D/\ U9CZ#WM]C:(/^;O_
M %>DZ+9\(_B/T9_,KZ-WG\S/EOMK.=J[_P#D5V%VN=CU6<W=D:)MD[8VWF:W
M"X7#;9@H:N&DQ;8[[!Y?,L3RRRZ7F>7U%S/F/>[KD^Y7;[%A$D$<6O2J_K2L
MBNS.6!+5U4H< 8 '2#8MJM^:+=KZ[4R-,\NC6Q_2C5V15320%H%J2,DY)/1Q
M?Y1/:>^NP/BWN38_9>\,IV!O;XU=^=N_&G+[TSIDDKLC%UM54\N/EJY) 6FF
MCQF1HH?(9)798U,TLD_E8D//-E':WBRPH(TN((;A47X5\1<@>@U*<8^0 IT<
M\HW;W%JT<CF1X)I8&=OB;PVQ7U.DKG-?,DUZ"+^:7%CH.Y/AWE_D?C-W9K^7
MK19OL*G^15+@17SX:EW!6T<";-K]YT^*D6NFV]#6^6S,CT<4NL50)EACE6\F
MU-O=+:%1?$1_3UH'* GQ!$6P'I3AW$?#Y])>:*":W-R&-I6034J4#T'AF0+G
M16O'M!IJ\NDW\"-F==P?.GNG>WP8I*G#_ (=(XO:>[&P.4KGV7F^U*?,0S-6
M[/IJLO3S#&;?04]=543"D\\CI9WD#^W^9KB4[;%'N6;[QBRZ@/&2VT<)",]S
MY4-W4%<#IG88(Q?R26&+/P@K:2?":XU<8QPPF&*]I)ID@]7D^XYZ'/7O?NO=
M-&X*W*8S YO)83"2[ES6/Q&2K<1MR&O@Q3Y"JI(7DIZ)*JI9::F:JE5(A+*P
MCC+:W(4$^[QJ&8!CI!(!:A-!7C09-/EU5R5!(%30T'"I],]4(RU_\Q-_Y@5-
M\U%_EJ;N_@\7Q.;XV/L$_*+K85/G.ZI-R?Q85_\ %3$8=#"#P?;!M5Y/+;T&
M3@NU?NK]W?O!-7U7U&OZ>YI3PO#TT\.M?.O4>ZMQ_>?UWT3Z?IO T^-;UKXG
MB5_M*4\NK:N_^U>_>O-K[1R'3GQ7SWR%SFXC4P;JVUB.VML=<28(?;QNCRU.
M>J(:?(:YGDBM3,UC&7)"LI($VRRMKMV$]PL 7*LT<CZ\^D:DCUST,MPNI[9
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MJ@?,F@'20ZK[WZ2[SH<EDNE^WNL^V:##5,='F*OKC?&,WHE)+*NM(ZIL=4U
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MV*ZYKNEW&Q0217"1EF5A2)TC5&62I&G32M3BG#SZKR[NUORU;M87;&.2!Y
MP-949V962E=6JM*#((H1PZ&_X:[N@^ W\O7L[Y5_)_:6[=DMVQW=OGY.;[V-
MB,&^4S>+'>N<QN+Q%'444IH_'5I2?PN2H20PFG1F694EC>,%N_0'F?=([&R9
M9/"ACMHW+ (W@1DL0<X)U4XU\N/2_9IEV#;I+RZ5H_$E>X=0"67QG 4$4!J
M5KPIY\.DM\[>Q]B5'R\^+%1\OQE*/^7'N#I?*;OHSN#$Y"IVCD.RZBM-1BZ/
M?M+2PRT\E/2844TV/I<BCTS5C2DHZQU&AWEJUD^@N/H,WZRJO:5\5;?20QB)
M-:EL,5R%IZ]4WZX3ZR$7N+(Q,W<#X9GU#2)<4H%RH;!;Y@=-/Q8R_2^7_F5U
M64_EV523_&'.=-[JR'RUBZ\Q]11]<KNW[B$;=EP\;)#BJ?=,J>,U(Q\8C-#J
M.G4]4POO27$>TA=U!%PLJBV\0_XQX5&UAOQ&,'X=7XN&*=5VIX'W(MMQ!@,;
M&X\/^P\6JZ"M.W6175I\J5SU?5[C;H==>]^Z]U[W[KW3+E-QX'"2119?+X_&
MR3HTD*5E2L!95-B5#$7 /O5:=;I7IK_O]LK_ )ZG!_\ GQC_ .CO?JCKU#U[
M^_VRO^>IP?\ Y\8_^CO?JCKU#U[^_P!LK_GJ<'_Y\8_^CO?JCKU#U[^_VRO^
M>IP?_GQC_P"CO?JCKU#U[^_VRO\ GJ<'_P"?&/\ Z.]^J.O4/2M5E=592&5@
M&5@;@@\@CWOK77?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[H(:GNW9M+45%++'F?)33RP2::%"-4+%38^87%Q_3W36.K:3U@_TZ
M;)_XYYO_ ,X$_P"OWOVL=>T'KW^G39/_ !SS?_G G_7[W[6.O:#U[_3ILG_C
MGF__ #@3_K][]K'7M!Z]_ITV3_QSS?\ YP)_U^]^UCKV@]#+[OU7KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM?/LOXN]=_'/\
MFD_RMLKMO);UWIV%VGG_ )IYWM7MCLS=$V[MP[AJL3L>C2B^\J7$5+2T>.CJ
MJB.CHJ*CI:*ECD<0P*7=FE*RWB7==DW)7"(D:V:QQ1J%1 9C6@XDF@U,Q+-0
M5)H.HZO-LCV_>+!EU,\ANS)([%G<B$4J3P J:*H"BIH!4]&%_F0TU)W!\JOY
M:?P_W;2-E>I.YNV.W.SNT-MS3R+29F'X];?AS&,Q.1@C(%=C:BJJI9)Z>6\+
M-%"S(Q4&,JY2K8V6X;A&:2PQ11QM3*&XDT,RGR8 4!&<G/1GS+2\N[&RD%8Y
M9)9'%<,((]05AYJ202#C J#TB/G!USUO\8OES_+/[\Z<V5M_K+<.[ODMBOBU
MO>#KK!4FTZ;-X#N6G^RAI<M242TL-;%C*A#-3F0-X6/D"N\5.$?Y;N9MXL=P
MM)W,BK;FY3Q"6*/"P)*DUH6!(-./"M*]-;]#%M=Y974:Z&:<6S: %UI,K !@
M*5"L 17AQ K3H[?R4Z-^"77^Q>W_ )*]W_%SXU[E_NIMS<?8F^=U;HZ-VOGL
MIDI<; TS>:MJ\5/55F0KI5CAC+N\DLTB*-3,![#VT;GN=S)%9VUS<+J98T19
MI%5:FG ,  .)\AT=;GMVWPI)=7$$#:5+N[1(S'2/4J23B@Z!+^4'\?GZ<^*-
M/V)G=IX+9._OE+NS,_(K=6T]M82';>/PU+OPB7;^#Q^.IXH(<?0XW"?:%*98
M(_MY9IHM(T@ PY[W3]X7QB5V=+95MU=CJ9S'AF))-2S5-:FHITBY/V[Z&S#E
M C3L9V11I":\JH%!32M!2G&O1\>W>@>F._:;:-!W3UOM?L[%;&W0F]-M8+>5
M!_&\=#DXJ2JH4JIL=*30US1TU;4JB55/-&A?R*@D5'4-6.YW&V%C;R-&770Q
M0Z6*U#4J,C(' C]G1]>6$&X!1.BR!6U*&&H!J$5H<'!/'JJC8_6_5V'_ )S!
MB^,&R]K[(PW6'Q/R='\L!UMCZ?;>&;*;WR22;4Q61H*".*B&>:GA6MN8A-)2
MQHSL? ![&EQ=SOR^/K'9S)= VOB$LVE%(D92V=%2%XTU5^?06@MX5WH_3*JZ
M+<BXT4"ZG8&,,!C50,:TKIIY4ZNV]Q[T->O>_=>Z][]U[K :6F8EFIX&9B2S
M&)223]23;Z^]U/6J#KFT,3HL;Q1LBVTHR!@-(L+ BPL/?J]>IUTD$$1U1PQ1
ML18LD80V_I<#WZM>O4IU'J,;CJNII*RJH**IK*!G>AJJBECFDA,@LQB=E+1D
MC@E2+^]AB!0$YX]>(!SU*DCCF1HI8TEC<:7CD4.I']"#<$>ZUIUOKA4TU/60
M2TM73P55-,NB:GJ8EG1P?PR,"K#_  (][!ID=:(KUCHZ&BQU/'1X^DI:&DA&
MF*EHZ=*6-1_140*JC_6'OQ8MDYZ\!3AU*]ZZWU[W[KW7O?NO=%9^0/\ Q>-O
M?]JVJ_ZVCVW)TY'T7WVWTYU[W[KW7O?NO=>]^Z]U[W[KW5C]'_P#I/\ J&@_
MZ%'M1TGZD^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NJZLU_Q><M_P!K.O\ ^MK^V#QZ?'#IL]ZZWU[W[KW7O?NO=>]^Z]U91[4=
M)^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ
M=OE1_,%^2'5?<O26U>NOCFFV^E-X?,CJWXJ;I[D[O@J*&?/5>]:ZK@R#[*V_
M25U%7''45/CZIHLY7.:.JD,0HZ.J@+3@>['RM:7]O,\L^J5+26Y6*&A"! "/
M$<@BI+#L7(%=3*<= W>.8;FRFA2.&D;W45NTDN-6LD'PU!!H*'O:@)II5@:@
M[7S3^4%)\1NALYVNFU:G?V[:O.[8V#UGU]1UJ8V3.[EWU5I0XG'?<276"$RN
M\T[V9EIX93&KR:48.<O[.=\N5@U"-=+/)(02$C12S&@XX% /,D<.CW>MS_=%
MN9@I=JJB(" 7=V"J*GADY/D*G/#HD>\/E5\^/B5G>E-Z?,K:GQBW/T-V[V/M
M?JC>-?T!3[EQ67V)E=^NR8NLKY\Y7U5%F,)!*K0U<T<-.^H*T7K>**<16^S;
M9OBS1V#7"311M*@G,96=8Q5@ B@J],@58>1]023;IN&TM$]XL+122+&QA#AH
M6<T4DNQ#+7!-%/F!Y='"[XKOGED]^4^V_C%A?C7M/8-!MRBR>5[-[YJL]NNI
MK\E62U2/B<9M[;TV/DI8:2**FDEKJO(D2&;QP4S&-G]D.VKMJ1E[PW#.6($<
M.A % '<7<-4G("A?*I;RZ.+\W[N%M1"J@ EY=;DMGM"(4H.!U%OEI\^D/_+_
M /ECV3\E]M]U;5[OV5M/97>/QM[FW%TCVA%U]7U&0V]D*W JC+DL,:QY:R"D
MJ+R 0SS22*$#LX,GBC4\S[+#M#Q/;.SPW$*S1ZP!(JL2-+4P2*<1@])^7]UE
MW-)%G54EAE:*30249E .I:YH:X!R//H2_G#\HD^'GQPWGW?%M5M[9K%UVV=L
M[4VR]>,33U.6WKD*?%X_[VK*O]K00SU*RU#A2WC1D3UNI"/EW9_W[=I;:M (
M9F:E2%12YH/,T&!Z]*M[W/\ <]LT^G60555K0%G8(*GR%6R?3HG6]_DW\[OB
MGOSXUU7RFHOBQV#U9\BN[=C?'S(TG1N,W+M#.;:S_9!F_AM33MG<IDX,_BJ=
MH:@51%-35!2)&C13(1[/[;9]MWN*X%E]3')!"\X,QC=)(XZ:@="*48U%,L/(
MGHFN=TOMHD@-UX#QS2I#^D'1XWDKI/>[!UP:_"?,#RZM[]@7H7]>]^Z]U[W[
MKW6NU\H/DWN+?/SN^"7=FW/AM\^:[8WQ7R_R@H>RJA?B=N)II_\ 29@*/"XR
M;#*B-%7P-54TCNYFBM#I= Y8+[E;9-H6WVN]MWNK(/<BV,8-U%_H<A=@V<&A
M_;CJ.-WW(S;E:3K;W12W-P)"+>7\:!!I[<BHXCRST9WYM8?LG>5=\#/YA/3?
M2O;&\\I\;-V;GW/O+HJ;;,FWM\2;/[JQ$..SJ0[?J#]Q+N'%Q4L13':Q([2N
ME](9E)>798H!>[5<31H+A559M0:$2POJ2KC&AJFK<!@]&V^QR3&UW*&*1S S
M,T5"LIBE32U%.=:X(4T)R./2>W!N/>/\Q3Y3?$BMVCT?W=UC\=?BKO\ R??W
M8'87?'6E7U<^7W-B*7[7;.#V_CLD\=96O254E1-6U(IS#"@L)%D6-:B\44?*
MUE<AYH9)[E! B0R++IC+:G9V2H%0 %%:FO"G"LDC\PW5N4BE2&!S,[RQM'JD
M"E450]&--1)-*"@H:]"9_,:V'V)\G^P_BU\+L)LK>57TIV-V'#VO\H^P*;;E
M6V"I]J]1R1Y&DVW598(M)'6[BRL421Q+/]S&\-/-H,3L?:7E2ZBV:*YW!G43
M1Q^%;)J&LRR@J7"\:(M34BF:<>E',=O)NDD%D$8Q._B3OIJ@CBHP0GU=J  9
MH">'5CO9FZZWK3JW?N]=N[)S6_,CL/8NY=RX/KK:%/JR&8FVU035--A\;$D<
MG^55SPI3P*L+G6ZA8W-E(4LX!=S)&SJ@=U4N_P *!B 6/R%:GH1W,IMHG=5+
ME59@B_$VD$Z1\S2@ZKC^67S*^2VV_AKU9V7T9\7.[Z?NOOZGPV-DVY2=8Y3L
MK(=;1YF#S5V5SN%H*(5M35X^#4*2GEHX(Y:G1]R%"&FF%6Q[!:3[A)#<W$/A
M0:CJ,JQK<:30*C,: ,>)J:#(]>@[N^]7$%E'-!!+XDND:?#9V@U"I9U45.D>
M7F: ])/X!]L]1]61;<Z&V-\8/GYB-V=D[CRFY^S^_>^?C%F]J)N#<N2@EJ\E
MN'=6?JY98Z9JR2)DA5F,4&J*GC^I=G^9K&XO-5S+<616-0L<,-S&_AQ@@*B(
MIJ0*Y\SDGIK8+R"VI;QPW09R6>66WD76Y%2SLP J:8\AA1Y#JXCV!.A?U[W[
MKW7O?NO=(O>F]\?LBEHJO(4E95I75$E/&M&$)!C742VMT%K?T]Z)IUL"O0=_
MZ?MM?\Z;.?[:G_Z_>ZZQU;0>O?Z?MM?\Z;.?[:G_ .OWOVL=>T'KW^G[;7_.
MFSG^VI_^OWOVL=>T'KW^G[;7_.FSG^VI_P#K][]K'7M!Z]_I^VU_SILY_MJ?
M_K][]K'7M!Z&G%9"++8O&Y6%)(X<G04>0BCEMJ5:R-9%5K$C4 P!L2+_ )]W
M&>J''4_W[KW7O?NO=>]^Z]T5GY _\7C;W_:MJO\ K:/;<G3D?1??;?3G7O?N
MO=>]^Z]U[W[KW7O?NO=6/T?_  #I/^H:#_H4>U'2?J3[]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKJS7_%YRW_:SK_^MK^V#QZ?
M'#IL]ZZWU[W[KW7O?NO=>]^Z]U91[4=)^O>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@OYN__ /^7+_XU+^*'_0N?]CWD/CN
M'_2MNO\ GSH%\Y_\0?\ I86W_/\ U@_G#JU)M?X%;FK8I'VML_\ F5_%W<&[
MZCCPTU#"<S$U34%OVTB#RK'K?TAI54_K]^Y"8:[U/Q/MURJ#S+40T'SH*_EU
MOG-25LVIA;^V9CY 585/YD#\^LG\\:!\Q\$J_9>,K31[Q[#[OZ'V5U]XIC#/
M)FLCN*EG@2ET,LK5"4]-52@1W<+&S #22*^W+"+<Q*PJD<,[R>F@1,#7RI4@
M9QGJ_/*F7;S&IH[RP(AK0ZS*E*>=10G&<='A^273?>W;M'@*;I7Y7;M^,;XZ
MDS]/G7VOUEMKL,95LI]J*229L[2RU-$<>(:C1]G4T[2?<,7>\<94.;3?VUB6
M-Q;)<5*TU22)II6M/#8 UJ.(-*8\^CW<;.>[ \&=X*5KI2-]5:4KXBM2E/*G
M'/ET0?\ E1U$_3V\OE]\'-V8+;M?VK\=NP]J;ZW]WAMJ3)3-V%+WOCVR\.X<
MY_%:W)5<&XV@AB6M05K4UV"4J(D+EA/SLOU\=KN2%A%<1ND<+:?T! VC0NE5
M&C/;BO\ %D]![E)OHWN+!@#) ZM)*M?UC,NO6VHL=>.[)'#308!B/YGW8O6>
MS?BW7;([*ZKQO=I^0^_=D_'K8'5V9RS;>I,GN;L*=WQ#U.3B1ZC%QXR2BDKE
MJX%%1#+31FG>*8I*A3R?:SSW@E@D,/@(\[RJ-12.,=U%- U:Z=)P:T.*]&7,
M]Q#%:^',@E\9TA2-CI#22'MJ:$K2FK4,BE1FG58>?Z,^0O\ +SW1\5/D+\K>
MVJ3YP].==9[:W5'\%ST>5Q-=U?E.QJU,?2;EVI!4Y"NBW6*&-XZ'[C*1-EA%
MXOM6I@6, OCW*TYH2YM;*+Z.5U:6JE66Y6-=11Z*OAUIJ 2B5X@T!Z#;6-SR
M^\%Q=R_51JRQT(*M TC! Z59M=*A27J],@Y(ZV2_<3]2-U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7[Y _\
M6;;_ /VLZG_K5[H_#JZ<>BL>VNG>O>_=>Z][]U[KWOW7NO>_=>ZL#V9_QY^T
M_P#PVL%_[BQ>WQPZ8/'I2^]]:Z][]U[KWOW7NBL_('_B\;>_[5M5_P!;1[;D
MZ<CZ+[[;Z<Z][]U[KWOW7NO>_=>Z][]U[JQ^C_X!TG_4-!_T*/:CI/U)]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5U9K_B\Y;_
M +6=?_UM?VP>/3XX=-GO76^O>_=>Z][]U[KWOW7NK*/:CI/U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4J_S8_D?\\^B
M>F^YNR.@J/8W2W5/3D'6<TG<.?:@W[N3=-=OC,X/&O0[=P-135N*P^*QK9:1
M*VLRL,E342P-%0TT<3"L,A\B[1MFZ7,,-UKEDE,GZ2U2.-41VJ[@AF8Z<*E
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M^+-M_P#[6=3_ -:O='X=73CT5CVUT[U[W[KW7O?NO=>]^Z]U[W[KW5@>S/\
MCS]I_P#AM8+_ -Q8O;XX=,'CTI?>^M=>]^Z]U[W[KW16?D#_ ,7C;W_:MJO^
MMH]MR=.1]%]]M].=>]^Z]U[W[KW7O?NO=>]^Z]U8_1_\ Z3_ *AH/^A1[4=)
M^I/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JNK-
M?\7G+?\ :SK_ /K:_M@\>GQPZ;/>NM]>]^Z]U[W[KW7O?NO=64>U'2?KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>ZK-WG_-#ZNPV<[,INN>BOD_\@MD=*YS+;:[<[=Z2ZTI-R;:PM?MTK_%:
M5:RMR^.J<K+B(BTM8:"DJ4BB"N'=6# 76_)\TBQF::W@>90T44TA61U;X30(
MP4-P765KT&YN9HD9Q%%/,L1*R21(&1&'$992Q7ST!J?;T/>\/F-L3$_'/9GR
M=ZRZ[[O^2VPM_P >W:K:^"^./7$G86XIZ;<22L*M\--4XZ>GAHGA:*L$KI+2
MS?M21APRJ6V^P2R7;64TD-NZ%@S7$@2,%?+4 PSY4P?(]+9]YCCM5NXDEG1@
MI584+N0WGI)4X\ZY'1.LA_.)Z_VWF-CXKL+X2_S&^J*3L+?FV.MMN;D[3^-=
M'L?&29?=T_@HJ7[NLW,@DF>TC^*%)9VCCD:.)RA'L0CD"61':*\L)?#C:1EB
MN"[:$%2:"/\ F:"O$]$?]=8U=%DM;V/Q'6-6D@"+J<T&2_\ @J?EU;Y[ 70S
MZK([1_FA[ ZREWYF4^,_S(WUU/U?G,M@=_=Z[-Z53^ZU%)MNLDHLK4PSY7*X
MO(Y'&XJ:*4U-;2XV6D5$=XYI54GV+['DZ6]T+]1:)+( T<+S?J-J%5':K*K-
MY*S!JX('09O.9X[/6W@7+1QDAY5B[%H:,>YE9E7B652M,@FAZL%Z\[ VAVML
M3:'9>P,U3[CV3OS;N)W7M;.4JO&E50YN%)Z>4)(J2QLT;C4CHKHUT=592 %[
MJVDLI&AE!5T8JRGR930CH06\Z74:RQG4KJ&4C@014'I9>V.GNO>_=>Z][]U[
MJI/^>=_VZZ^2O_41TM_[W^UO8[]M/^2W;_\ -[_JQ+T#/<'_ ))$_P#S:_ZO
M1]2_YRVT\WO'^5K\A\?@*1ZZMQ6VNLMV5-/&+D4.SMS8#)Y*;_@M-CZ6IG;_
M &F,^Z>WMPMMO5NSF@+2(/\ 3/&Z+^TD#IWGF!KC:9U05(5&_))$<_L"D]/O
M\PSN3K_)?RK>ZNQJ'-XROVUVS\?J+#["GH*H5ZY&K[8I::BPU/0^/R/52RS5
MT1"HK,%1W;2L;LK'*MA*N]0Q%2&BGJX.-(B8LQ-:4H%/3_,=Y&^U32 @K) 0
MA&=1E72M*<:EA3HH/0^RZ[XZ?S+/@YM/L#QX=]Q_R@MD?'3;,^5E6A>IW/U!
MDJ*OR^-C1B-=9!04@E:,7.ES877V?[E=C=]GO)(LTW5KAP,Z8YD95/V%C3HD
ML+4[7NMJCF@.VB!"30L\3JS#[:9_;Z=#]WA34G8W\Y?X/8C;LOW^4^.O0'R(
M[1[%6A3[E:"B[.Q\FV,0E:Z@K3R5%5.[QQLXD*E'T!)%9BK;7-GL%XS8%Q/;
MQ)7S,1,K4]:"E?+/1E?H+K>;4*<P0SR/3R$@$:U^W-//'5E6Y!T]W[U'O';F
M2W!M7?O479FW-R];[HK=O[NBGH:VCW5%+ALA0QY3&U2F&>7[F2GU0523QS,!
M&R2A;!&%I]LG1U#)+&RR+5<AE(<&C#Y5R*$?+H33)%N$+(Q#1NK(U&P0P*D5
M4_.F#7\^J,?YA/Q'Z>_EY_&Z'Y)?#/<G:G1W=W7&^.K\5U]MW&=T[KWE0;K_
M (UEJ#%S;9K,#G<QE(,A1G&2SU'VU-#&Q6D"$&$,ON2.5M\FYKO/I-Q6*6&1
M)3(QAB1HZ(SZPZ(I!U"E22,^O0#YBVF/ENT^IL3+'+&\81!+*ZR5=4T%'=@1
M0\  <"AZV&<545E7B\;59"D^PKZF@HZBNH=?D\,TT:M+%J_/C<LM_P V]Q8P
M ) R*X/4B@U&>I_NO6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[H&N]/\ CR8_^UW0?]"3>Z/PZLG'HGGMKI[KWOW7
MNO>_=>Z][]U[KWOW7NCT=6?\>!MO_J%J/_<B;V\G#I@\>A ]VZUU[W[KW7O?
MNO=%^^0/_%FV_P#]K.I_ZU>Z/PZNG'HK'MKIWKWOW7NO>_=>Z][]U[KWOW7N
MK ]F?\>?M/\ \-K!?^XL7M\<.F#QZ4OO?6NO>_=>Z][]U[HK/R!_XO&WO^U;
M5?\ 6T>VY.G(^B^^V^G.O>_=>Z][]U[KWOW7NO>_=>ZL?H_^ =)_U#0?]"CV
MHZ3]2??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5
M=6:_XO.6_P"UG7_];7]L'CT^.'39[UUOKWOW7NO>_=>Z][]U[JRCVHZ3]>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MUQ==:,FIEU*RZD.DC4+7!_!'X]^Z]U0?\*-\][? 'JNJ^%_8/P;^5?<N?VQV
M!VA5['[6Z=VQ@MW;4W/BMU96?(4E?F-P9'.XJEPU7.*T1RQ52M(L::F74DD4
M<F<PV]MS1-^\8KRVA#)$'BE,BR1NJ!2%58W+ ::@KZ_94 [)-<<O1?0O;7$I
M5Y2DL8C9)%9RP+,TB:6[L@^E1T/7\CS[N/X!;4I),9)A<50=M=[T>W,,]?%E
M1242;JR3"E2J@)@J%@JFJD\L?HD96=/2P)+/<4UW1S743% 6:A&H^"F:'(J*
M&AX=&'(XT[<HII DG 6H.D>,^*C!IPJ,=0MPSCYC?S3=O;.B5LATK_+>VQ3[
M[W43=J6N[3[6@ P=,RE!',=O8:*2KCE65FIJU)8652Q]VB'[AV5I.$M^VA?5
M;:(]QXXUO04(RHKUJ0_OC=0G^AV2ZV]#<2CM'"AT)4U!P6ZN%]@3H7]5)?S%
M.P?GS-UKWQUETG\4,#N?JO<>SJ[:5;W1A^U\?NG<28'=.+B@W%78[KVJI\,U
M7E*&&IR4-)3?WB<SR0Q3:"LGB WY5M=K$T,US<LLBMJ\(Q,L9=6)0&52Y"D@
M:CX> 2/*O02YBN-P\*6.W@5D9=/B"0-(%8 ,1$RJ"14T'B9H/6G1I_Y?5=TS
M6_"[XYI\?MTY3>G4V*ZUP^WML;CSU*,?D*A]N&2AR'\1I5+)2U\62IZQ*B!&
M:.*562)WB5'8FYH2X3<)_JU"2F1F=1E1J[A0^8H10^8Z->7V@:RA^F8O$(U5
M&/$A>W/H:@U'D<='&]D/1QU[W[KW7O?NO=$8^0/\MSX=?*/>>3W]WEUEG=Y[
MDS./Q&,RDD7;N\]L4<T."55I%;%XC<%#C T01#J6C#,RAW+/ZO8CVKFR_P!D
M01VTBH 21^E"S MQ[GC9OY]$6Y<MV>[L6N$9B0 1XLJJ0,CM5U7^70K]&?$C
MH'XX[%W7UIU1LFKQNQM\5=56;JV[NG>6=[*AK#6T:8^:*0[ER66D6EEHXUB>
MG1U@9=6J,EF)0[EO=SNTJS3L"Z@!65$CI0EO]#5!6IX\?GTLL-J@VV,Q1 Z6
M-2&=Y*U '&1F-*#APZ 387\J[X,=;;YP&_ML=+O]]L_<<N[]C[:SV_=Q[IV[
M@LI/.]4:_$;;R66JL)15*5,C2PE:&U-(%>F$+*I!I=<Y[E>1M&\N'4([*D:R
M.H%*,ZH'84%#4Y\Z]%]ORK86KATB^%BZ*7=HT8FM51F**:FHH!3RIT8?Y%?%
M?H?Y6[9P^U>]-ATV\*/;.9AW%M/*TV5KML97#Y"G9&6LQ67Q5319.@F+11%_
M#5*LNA!*KJH *MJWJYV1R]L^@LI5A165U/DRL"I'VC[.C'<=J@W9 DZZ@I#*
M:E65AD%64A@?L(Z:_CS\/OCS\6Z'=5-TSL%,%DM^3TM3OO=F<SV2WMG,T]$C
MI!_$LUF:NOR51% LDOBA-2((C)(T42&1RU]TWVZWDK]0]0E0BJJHB5XZ50*H
MK3)I4^?5=OVBWVO5X*4+T+L69W>G#4SEF-/*IH/+J%LWX5_&/8?QZS'Q4V[U
M7C(^@<^^;DS/7F3S&3SL%0=P5GW]27JZVMJ,@#]T$>(K5@PE(_"4T+:UQS!>
M75T+UY#XXTTD 52-(TC"@#A\L^?5;?9;6VMC:)&/!.JJ$E@=1+'XB3Q/KCRZ
M"SK+^65\-.JM[[=[$PG6>:W+NS9<\-1L2O[.[-W/VM%@GICJB?$4>X<QDJ.B
MEA<!HYEIS-$P!CD4^UEWS=?WL;1-(JJ_QB.**+7_ *8QHI(^1-/ETFMN6[.U
M=9 C,R_ 9)))='^E$CL ?F,]'X]AKH]Z][]U[KWOW7N@X[<=X^O=P/&[QNO\
M*LZ,4(O74PX(Y^GNK\.K+QZ)1]]6_P#*Y5?^=#_\5]L].T'7OOJW_E<JO_.A
M_P#BOOW7J#KWWU;_ ,KE5_YT/_Q7W[KU!U[[ZM_Y7*K_ ,Z'_P"*^_=>H.O?
M?5O_ "N57_G0_P#Q7W[KU!T<7I:2278U.\LCR/\ Q'(C5(Q<\,/R;GV\G#II
MN/0L^[=5Z][]U[KWOW7N@:[T_P"/)C_[7=!_T)-[H_#JR<>B>>VNGNO>_=>Z
M][]U[KWOW7NO>_=>Z/1U9_QX&V_^H6H_]R)O;R<.F#QZ$#W;K77O?NO=>]^Z
M]T7[Y _\6;;_ /VLZG_K5[H_#JZ<>BL>VNG>O>_=>Z][]U[KWOW7NO>_=>ZL
M#V9_QY^T_P#PVL%_[BQ>WQPZ8/'I2^]]:Z][]U[KWOW7NBL_('_B\;>_[5M5
M_P!;1[;DZ<CZ+[[;Z<Z][]U[KWOW7NO>_=>Z][]U[JQ^C_X!TG_4-!_T*/:C
MI/U)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5U
M9K_B\Y;_ +6=?_UM?VP>/3XX=-GO76^O>_=>Z][]U[KWOW7NK*/:CI/U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=5=?*/O3O?>GS$ZH^!?QT["QG2.:W'TSN#Y"=N]T56SZ3?
M.2H-NT.3?"X_';<Q^35\6V1KLC!.L\U3%(((626)?(A608[/MMM;V$FYW:&9
M5F6"*(,45I"NLERO=I"TH 14XK3H+[GN$T]['M]LXC8Q--))I#,J!M "!@5U
M$UJ34 >5>H7QX[@^1?4GS:W5\'OD?VG#W[C-S='0?(/HWN:HV)C.O\J::AR\
MF)S&W\U2X808RIJ*:4K-330T<3>"-FF),\<4%MUL+2^VY=QM(_!*S>!-"'9U
MJ4UJZEZL :$$%CGAPZUM]Y<VE\UC<OXH,7C12E%1J!]+*VBBDBH((48X]%9_
MF9?.[Y)[(WSEMO\ Q)WC0[+V3\:=S=0XSY)[ZFVMB]UC)Y_NW+4-)A]E8\Y6
MCK::*2@P[5>1RDL*>:(S4=.9(')$ASRCRY9W$0:^0N]PDQMTU,NE(49FE.D@
MFK *@.#1C0TZ+.9=[N89--HP5(7A$[:0VIIG55C&H$"BDLY&15 *5/5_'N,^
MAYU5)VUVW\DOD1\TMY_#SXU]QXWX[[.^/W6FS=^]]=N4.QL9V3N"HS'9)-1@
M]LXRAS44V*H(#BU2MGJI(I)G#^-$55!D&EE8VFU;>E_=Q&=YY'2"(NT<82.@
M9V*$,QU'2 "!@DD\.@K=WESN-ZUG;2"%88T>:0*KR:I*Z4 <%5[1J)()((
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M2II4DT%308Z-/[)>C;KWOW7NO>_=>Z;LODZ?"XNORU4DTE-CJ2:LG2G57<K
MI8A S(I8@<78#_'WXXZ\,]!#_I\V?_SK=R_^<=+_ /5GNFL=7T'KW^GS9_\
MSK=R_P#G'2__ %9[]K'7M!Z]_I\V?_SK=R_^<=+_ /5GOVL=>T'KW^GS9_\
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M %J]T?AU=./16/;73O7O?NO=>]^Z]U[W[KW7O?NO=6![,_X\_:?_ (;6"_\
M<6+V^.'3!X]*7WOK77O?NO=>]^Z]T5GY _\ %XV]_P!JVJ_ZVCVW)TY'T7WV
MWTYU[W[KW7O?NO=>]^Z]U[W[KW5C]'_P#I/^H:#_ *%'M1TGZD^_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM9N3?WP
MWW-\K?G+A_YQE5LV@WQ@.VMQ;4^+VS/D)35Z;5I>HVI:=<)E]BK-$,,<SF6,
MLV3KJ)SETJ%C0R0&,QK*HMKZ&SM&V+Q"K1!KAX*>*;G4=2R:3JTJ  BMV$5(
M!J3T S/:R7%PN[: 1(1"LW]GX&D:634-)8DG45[@: F@'0T_!3Y6XSXF_!KY
M-=_=VY?N2O\ A3U?\E=U8?X@[FWUB,GN3=-?UKG\IB\3MPTR9-DRE9@_XI7M
M%BYJYXYEI 4?QQ0PQJ@Y@V9MZW"WMK81?520*;E8RJQBX569_AHH;2H+A<:J
MTS7I5M6Y#:[.:><R> DS"%I-3.8BRJO&K%=1(4G.FE<=#=_,Z_F:[:^*>W.H
M^J]E[TV_UUV_\G\?)5;/[:[)P=;/MS9&W@J&OW9EJ:"FGJ<A7TT4A3'XM(&:
M:M*?=:(%T3%_*?*C[TTLS(TD5O37'&1XDKDT5%KP!IW-Y+4BIZ6;_OZ;6(X@
MZI)-72[UT(H%2S>M/)?-B!@5/2K_ )8_=7\NZ':\GQG^''R!Q?=F_P#'X_<7
M<G:VX<A#E)-Q[GR>:KJ.+<&\<[69&@I165U?D\A2+):5O"DD$$2B&)=+7-=A
MNA?ZN_@:)"5BC% (XU53HC4 F@"J:>M"34D].;#=6(7Z>TE61AJD<ZM3N21J
M=OF6;/D*@"@H.K8O8.Z$77O?NO=>]^Z]U[W[KW7O?NO=5U9K_B\Y;_M9U_\
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M3)Y">KR63KI5CC4S557+($1(U81HBJFW/=KC>)/%N7+L %' !5' *J@*H'H
M!T_8;;!M:>' @0$ECQ)9CQ+$DEB?4DGH;_9=TNZ][]U[KWOW7NO>_=>ZH@W;
MW!LKX1?S1?D[WK\LJ;>&#ZM[VZ?Z2V[\?^Z*;K7-[\Q>+3:E/%1YS:2SX+'Y
M2KHJK)9D)6>$4X65O&\EC)"7DF"QDYCV:WM;'09899VGB,B(SZLK)1V4$*HT
MUKC]O0#FO$V+=)[B\U^'+'"L,@C=U334-'5%8@LQ# 4S7[.GC^7YVALWL/\
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M?]E-M_UMZ]_P7?(/_1P?_LBO?^V?KW_#G'PV_P"?DY;_ - #/?\ UO\ ?O\
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MU>?I,>S+H@Z][]U[KWOW7NO>_=>ZM9_D_?\ 92V^/_$&;E_]W^V?>-/WI_\
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M4>U'2?KWOW7NO>_=>Z][]U[KWOW7NM:K^;A_V5%AO_$1;4_]V.9]] _NO_\
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MNO=6&_RNO^RO]G?^&QOK_P!UDWN"?O'?\JM/_P UK?\ ZNCK*O[F?_*\0?\
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MU[KWOW7NCT=6?\>!MO\ ZA:C_P!R)O;R<.F#QZ$#W;K77O?NO=>]^Z]T7[Y
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M^\/_ "MV]_\ 2WW+_M-FZ SV,NHYZ][]U[KWOW7NO>_=>ZL-_E=?]E?[._\
M#8WU_P"ZR;W!/WCO^56G_P":UO\ ]71UE7]S/_E>(/\ GEN_^K?6T7[YR]=A
M>O>_=>Z][]U[KWOW7NM([>W_ !^>[O\ PY\__P"Y<OOK]LW^X<'_ #1B_P".
M+U\]W-?_ "5+S_GJN/\ J\_28]F71!U[W[KW7O?NO=>]^Z]U:S_)^_[*6WQ_
MX@S<O_N_VS[QI^]/_P J];_]+&+_ +1KOK-+[BO_ "MUW_TJ+C_M-V_K8_\
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M?\>?M/\ \-K!?^XL7M\<.F#QZ4OO?6NO>_=>Z][]U[HK/R!_XO&WO^U;5?\
M6T>VY.G(^B^^V^G.O>_=>Z][]U[KWOW7NO>_=>ZL?H_^ =)_U#0?]"CVHZ3]
M2??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4>L)
M%)5$$@BGG((X^BGW[KW5>7\:S/\ SMLG_P"=\O\ T?[8J>GZ#KW\:S/_ #ML
MG_YWR_\ 1_OU3UZ@Z]_&LS_SMLG_ .=\O_1_OU3UZ@Z]_&LS_P [;)_^=\O_
M $?[]4]>H.O?QK,_\[;)_P#G?+_T?[]4]>H.C2]$U=55[=R[U=3453KFBJO4
M3-,0/!"; L20+^W$STVXH>AP]WZIU[W[KW7O?NO=1JS_ (!U?_4-/_T*??NO
M=5P>T_2CKWOW7NO>_=>Z][]U[KWOW7NK%L-_Q9\5_P!JVA_ZU+[4=)^G+W[K
MW7O?NO=>]^Z]U[W[KW5=6:_XO.6_[6=?_P!;7]L'CT^.'39[UUOKWOW7NO>_
M=>Z][]U[JRCVHZ3]>]^Z]U[W[KW7O?NO=>]^Z]UK5?S</^RHL-_XB+:G_NQS
M/OH']U__ )5R3_GNF_ZM6_7)?[\?_*X0?]*NV_[2+SJKSWD;UAOU[W[KW7O?
MNO=>]^Z]T+OQ^_YGUTE_XEWK;_W<T7L+<\_\D3</^>&[_P"K$G0\]K/^5GV?
M_I:;?_VEP];G?ODQUWTZ][]U[KWOW7NO>_=>ZU-_YAO_ &63W=_VMML?^Z'%
M>^FOL3_RJ>W_ .DF_P"TF;KBC]ZC_E?MV_T]M_VA6W1+_<M]8^]>]^Z]U[W[
MKW7O?NO=&W^"'_97?1?_ (=\G_N%5^XN]ZO^56W'_FB/^KD?4[?=E_Y7O:/^
M:\G_ &CS=;</OF!UVZZ][]U[KWOW7NO>_=>ZTVOE!_V4M\A__$Y]M?\ N_R'
MOJ][=?\ *O;7_P!*ZR_[1HNN"OO#_P K=O?_ $M]R_[39N@,]C+J.>O>_=>Z
M][]U[KWOW7NK#?Y77_97^SO_  V-]?\ NLF]P3]X[_E5I_\ FM;_ /5T=95_
M<S_Y7B#_ )Y;O_JWUM%^^<O787KWOW7NO>_=>Z][]U[K2.WM_P ?GN[_ ,.?
M/_\ N7+[Z_;-_N'!_P T8O\ CB]?/=S7_P E2\_YZKC_ *O/TF/9ET0=>]^Z
M]U[W[KW7O?NO=6L_R?O^REM\?^(,W+_[O]L^\:?O3_\ *O6__2QB_P"T:[ZS
M2^XK_P K==_]*BX_[3=OZV/_ '@+UU>Z][]U[KWOW7NFW,_\6?*_]JVN_P"M
M3>_=>ZKI]I^E'7O?NO=>]^Z]U[W[KW7O?NO=&+^/?_ S='_4-BO^AI_;D?3<
MG1G?;G3?7O?NO=>]^Z]TD=_?\>5NG_M1Y'_K6WO1X=;''H@OMCI_KWOW7NO>
M_=>Z][]U[KWOW7NC8= _\>UF?^UX?_<>'VZG#II^/0\>[]4Z][]U[KWOW7N@
MU[?_ .9=[A_\A/\ [G4WNK\.K)QZ)#[9Z>Z][]U[KWOW7NO>_=>Z][]U[HYG
M27_'B4__ &LLC_T,/;R<.F7X]"Y[MU7KWOW7NO>_=>Z!KO3_ (\F/_M=T'_0
MDWNC\.K)QZ)Y[:Z>Z][]U[KWOW7NO>_=>Z][]U[H]'5G_'@;;_ZA:C_W(F]O
M)PZ8/'H0/=NM=>]^Z]U[W[KW1?OD#_Q9MO\ _:SJ?^M7NC\.KIQZ*Q[:Z=Z]
M[]U[KWOW7NO>_=>Z][]U[JP/9G_'G[3_ /#:P7_N+%[?'#I@\>E+[WUKKWOW
M7NO>_=>Z*S\@?^+QM[_M6U7_ %M'MN3IR/HOOMOISKWOW7NO>_=>Z][]U[KW
MOW7NK'Z/_@'2?]0T'_0H]J.D_4GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U&K/^ =7_U#3_\ 0I]^Z]U7![3]*.O>_=>Z][]U
M[KWOW7NO>_=>Z-AT#_Q[69_[7A_]QX?;J<.FGX]#Q[OU3KWOW7NO>_=>ZC5G
M_ .K_P"H:?\ Z%/OW7NJX/:?I1U[W[KW7O?NO=>]^Z]U[W[KW5BV&_XL^*_[
M5M#_ -:E]J.D_3E[]U[KWOW7NO>_=>Z][]U[JNK-?\7G+?\ :SK_ /K:_M@\
M>GQPZ;/>NM]>]^Z]U[W[KW7O?NO=64>U'2?KWOW7NO>_=>Z][]U[KWOW7NM:
MK^;A_P!E18;_ ,1%M3_W8YGWT#^Z_P#\JY)_SW3?]6K?KDO]^/\ Y7"#_I5V
MW_:1>=5>>\C>L-^O>_=>Z][]U[KWOW7NA=^/W_,^NDO_ !+O6W_NYHO86YY_
MY(FX?\\-W_U8DZ'GM9_RL^S_ /2TV_\ [2X>MSOWR8Z[Z=>]^Z]U[W[KW7O?
MNO=:F_\ ,-_[+)[N_P"UMMC_ -T.*]]-?8G_ )5/;_\ 23?]I,W7%'[U'_*_
M;M_I[;_M"MNB7^Y;ZQ]Z][]U[KWOW7NO>_=>Z-O\$/\ LKOHO_P[Y/\ W"J_
M<7>]7_*K;C_S1'_5R/J=ONR_\KWM'_->3_M'FZVX??,#KMUU[W[KW7O?NO=>
M]^Z]UIM?*#_LI;Y#_P#B<^VO_=_D/?5[VZ_Y5[:_^E=9?]HT77!7WA_Y6[>_
M^EON7_:;-T!GL9=1SU[W[KW7O?NO=>]^Z]U8;_*Z_P"RO]G?^&QOK_W63>X)
M^\=_RJT__-:W_P"KHZRK^YG_ ,KQ!_SRW?\ U;ZVB_?.7KL+U[W[KW7O?NO=
M>]^Z]UI';V_X_/=W_ASY_P#]RY??7[9O]PX/^:,7_'%Z^>[FO_DJ7G_/5<?]
M7GZ3'LRZ(.O>_=>Z][]U[KWOW7NK6?Y/W_92V^/_ !!FY?\ W?[9]XT_>G_Y
M5ZW_ .EC%_VC7?6:7W%?^5NN_P#I47'_ &F[?UL?^\!>NKW7O?NO=>]^Z]TV
MYG_BSY7_ +5M=_UJ;W[KW5=/M/THZ][]U[KWOW7NO>_=>Z][]U[HQ?Q[_P"!
MFZ/^H;%?]#3^W(^FY.C.^W.F^O>_=>Z][]U[I([^_P"/*W3_ -J/(_\ 6MO>
MCPZV./1!?;'3_7O?NO=>]^Z]U[W[KW7O?NO=&PZ!_P"/:S/_ &O#_P"X\/MU
M.'33\>AX]WZIU[W[KW7O?NO=!KV__P R[W#_ .0G_P!SJ;W5^'5DX]$A]L]/
M=>]^Z]U[W[KW7O?NO=>]^Z]T<SI+_CQ*?_M99'_H8>WDX=,OQZ%SW;JO7O?N
MO=>]^Z]T#7>G_'DQ_P#:[H/^A)O='X=63CT3SVUT]U[W[KW7O?NO=>]^Z]U[
MW[KW1Z.K/^/ VW_U"U'_ +D3>WDX=,'CT('NW6NO>_=>Z][]U[HOWR!_XLVW
M_P#M9U/_ %J]T?AU=./16/;73O7O?NO=>]^Z]U[W[KW7O?NO=6![,_X\_:?_
M (;6"_\ <6+V^.'3!X]*7WOK77O?NO=>]^Z]T5GY _\ %XV]_P!JVJ_ZVCVW
M)TY'T7WVWTYU[W[KW7O?NO=>]^Z]U[W[KW5C]'_P#I/^H:#_ *%'M1TGZD^_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHU9_P
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M SV,NHYZ][]U[KWOW7NO>_=>ZL-_E=?]E?[._P##8WU_[K)O<$_>._Y5:?\
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M_M=T'_0DWNC\.K)QZ)Y[:Z>Z][]U[KWOW7NO>_=>Z][]U[H]'5G_ !X&V_\
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MROV[?Z>V_P"T*VZ)?[EOK'WKWOW7NO>_=>Z][]U[HV_P0_[*[Z+_ /#OD_\
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M4QTM%08Z@I4DJ:ZMJ9I!IBB0MH5Y&TQQNRF&U[7-O$P@MUU.03DA0 H))))
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M *AI_P#H4^_=>ZK@]I^E'7O?NO=>]^Z]U[W[KW7O?NO=6+8;_BSXK_M6T/\
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MS+H@Z][]U[KWOW7NO>_=>ZM9_D_?]E+;X_\ $&;E_P#=_MGWC3]Z?_E7K?\
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MAN_^K$G0\]K/^5GV?_I:;?\ ]I</6YW[Y,==].O>_=>Z][]U[KWOW7NM3?\
MF&_]ED]W?]K;;'_NAQ7OIK[$_P#*I[?_ *2;_M)FZXH_>H_Y7[=O]/;?]H5M
MT2_W+?6/O7O?NO=>]^Z]U[W[KW1M_@A_V5WT7_X=\G_N%5^XN]ZO^56W'_FB
M/^KD?4[?=E_Y7O:/^:\G_:/-UMP^^8'7;KKWOW7NO>_=>Z][]U[K3:^4'_92
MWR'_ /$Y]M?^[_(>^KWMU_RKVU_]*ZR_[1HNN"OO#_RMV]_]+?<O^TV;H#/8
MRZCGKWOW7NO>_=>Z][]U[JPW^5U_V5_L[_PV-]?^ZR;W!/WCO^56G_YK6_\
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MUC[U[W[KW7O?NO=>]^Z]T;?X(?\ 97?1?_AWR?\ N%5^XN]ZO^56W'_FB/\
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M[W[KW6FU\H/^REOD/_XG/MK_ -W^0]]7O;K_ )5[:_\ I767_:-%UP5]X?\
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MW7O?NO=&PZ!_X]K,_P#:\/\ [CP^W4X=-/QZ'CW?JG7O?NO=>]^Z]T&O;_\
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MK4_^>NH_Z]^_:QU[0>O?Z9M@?\[6I_\ /74?]>_?M8Z]H/7O],VP/^=K4_\
MGKJ/^O?OVL=>T'I7[;W9@]V05-3@ZF2IBI)4@G:2FDIK,XU 6D52>/Z>]@UZ
MT13I2>]]:Z][]U[KWOW7NO>_=>Z(?V5_Q_>YO^UD_P#T*OME^/3R<.D/[KU;
MKWOW7NO>_=>Z][]U[HW/0?\ QY^2_P##EK/_ '%H_;J<.FGX]#?[OU3KWOW7
MNO>_=>Z][]U[JOS>?_'X;L_\.7._^Y4OM@\>GQPZ37O76^O>_=>Z][]U[KWO
MW7NC*?'G_F+_ /R ?_'OMR/IN3HRGMSIOKWOW7NO>_=>ZC5G_ .K_P"H:?\
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M==NNO>_=>Z][]U[KWOW7NM-KY0?]E+?(?_Q.?;7_ +O\A[ZO>W7_ "KVU_\
M2NLO^T:+K@K[P_\ *W;W_P!+?<O^TV;H#/8RZCGKWOW7NO>_=>Z][]U[JPW^
M5U_V5_L[_P -C?7_ +K)O<$_>._Y5:?_ )K6_P#U='65?W,_^5X@_P">6[_Z
MM];1?OG+UV%Z][]U[KWOW7NO>_=>ZTCM[?\ 'Y[N_P##GS__ +ER^^OVS?[A
MP?\ -&+_ (XO7SW<U_\ )4O/^>JX_P"KS])CV9=$'7O?NO=>]^Z]U[W[KW5K
M/\G[_LI;?'_B#-R_^[_;/O&G[T__ "KUO_TL8O\ M&N^LTON*_\ *W7?_2HN
M/^TW;^MC_P!X"]=7NO>_=>Z][]U[IMS/_%GRO_:MKO\ K4WOW7NJZ?:?I1U[
MW[KW7O?NO=>]^Z]U[W[KW1B_CW_P,W1_U#8K_H:?VY'TW)T9WVYTWU[W[KW7
MO?NO=)'?W_'E;I_[4>1_ZUM[T>'6QQZ(+[8Z?Z][]U[KWOW7NO>_=>Z][]U[
MHV'0/_'M9G_M>'_W'A]NIPZ:?CT/'N_5.O>_=>Z][]U[H->W_P#F7>X?_(3_
M .YU-[J_#JR<>B0^V>GNO>_=>Z][]U[KWOW7NO>_=>Z.9TE_QXE/_P!K+(_]
M##V\G#IE^/0N>[=5Z][]U[KWOW7N@:[T_P"/)C_[7=!_T)-[H_#JR<>B>>VN
MGNO>_=>Z][]U[KWOW7NO>_=>Z/1U9_QX&V_^H6H_]R)O;R<.F#QZ$#W;K77O
M?NO=>]^Z]T7[Y _\6;;_ /VLZG_K5[H_#JZ<>BL>VNG>O>_=>Z][]U[KWOW7
MNO>_=>ZL#V9_QY^T_P#PVL%_[BQ>WQPZ8/'I2^]]:Z][]U[KWOW7NBL_('_B
M\;>_[5M5_P!;1[;DZ<CZ+[[;Z<Z][]U[KWOW7NO>_=>Z][]U[JQ^C_X!TG_4
M-!_T*/:CI/U)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<)98X8Y)II$AAA1Y9997$:JL
M8NS,QL%50"22; >_=>ZK2B_G"_RYIMX8G9R?)#%G^/;H79>%WRVQ=T1[.J\F
MX:U+3[V;"#:4PNC@S+F3 &5E,MU( K/)&Z"-I/ /:NMDUQ^*J^IBU^(./\/#
M/#HA',]B7">*.YM*OI?PF;T$FG03CR;CCCU9>K!@&4AE8!E93<$'Z$'\@^PI
MT?=5V?([^;%\ /B5VAD>F/D'WY_H_P"RL3B\/F<AMO\ T6;UW7XZ;/PBHI)/
MO,)MS)4#^6$AM*U19?HZJW'L4[3R5N>^P^/:PZXR2NKQ(ER..'=3_+H@W+F>
MQVB3P;B70] U-$C8/#*HP\O7I=?%+^8Q\-?F[G-W;;^,'<:]FYO8F*QV<W50
M_P"C_=.RS2TN5F>""4/N'"8F.H#S1LI6%Y&7@NJ@@E-O?*U_RZ$:\B\,.2%.
MN-ZE:$_ [4X^=.G]KW^TWHL+:364H6[76E:T^-5]#PZ.U[#_ $<=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=4G_ #KZ._D_X_?':>_?G_V'LC,]F[OV8-Q4>U>V>^ZX
MYO#X**B.-ACV!M*GRU/4XZ"IGQE1)&^-Q;3U6169FFED&E![R[?;X8XTVQ)!
M&KT+10C2SUU?JOI(:FH8=J*M, =!3>;7:M;M?-&69:Z99>Y5II_34M5:Z>*
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M\-V?^'+G?_<J7VP>/3XX=)KWKK?7O?NO=>]^Z]U[W[KW1E/CS_S%_P#Y /\
MX]]N1]-R=&4]N=-]>]^Z]U[W[KW4:L_X!U?_ %#3_P#0I]^Z]U7![3]*.O>_
M=>Z][]U[KWOW7NO>_=>Z-AT#_P >UF?^UX?_ ''A]NIPZ:?CT/'N_5.O>_=>
MZ][]U[J-6?\  .K_ .H:?_H4^_=>ZK@]I^E'7O?NO=>]^Z]U[W[KW7O?NO=6
M+8;_ (L^*_[5M#_UJ7VHZ3].7OW7NO>_=>Z][]U[KWOW7NJZLU_Q><M_VLZ_
M_K:_M@\>GQPZ;/>NM]>]^Z]U[W[KW7O?NO=64>U'2?KWOW7NO>_=>Z][]U[K
MWOW7NM:K^;A_V5%AO_$1;4_]V.9]] _NO_\ *N2?\]TW_5JWZY+_ 'X_^5P@
M_P"E7;?]I%YU5Y[R-ZPWZ][]U[KWOW7NO>_=>Z%WX_?\SZZ2_P#$N];?^[FB
M]A;GG_DB;A_SPW?_ %8DZ'GM9_RL^S_]+3;_ /M+AZW._?)CKOIU[W[KW7O?
MNO=>]^Z]UJ;_ ,PW_LLGN[_M;;8_]T.*]]-?8G_E4]O_ -)-_P!I,W7%'[U'
M_*_;M_I[;_M"MNB7^Y;ZQ]Z][]U[KWOW7NO>_=>Z-O\ !#_LKOHO_P .^3_W
M"J_<7>]7_*K;C_S1'_5R/J=ONR_\KWM'_->3_M'FZVX??,#KMUU[W[KW7O?N
MO=>]^Z]UIM?*#_LI;Y#_ /B<^VO_ '?Y#WU>]NO^5>VO_I767_:-%UP5]X?^
M5NWO_I;[E_VFS= 9[&74<]>]^Z]U[W[KW7O?NO=6&_RNO^RO]G?^&QOK_P!U
MDWN"?O'?\JM/_P UK?\ ZNCK*O[F?_*\0?\ /+=_]6^MHOWSEZ["]>]^Z]U[
MW[KW7O?NO=:1V]O^/SW=_P"'/G__ '+E]]?MF_W#@_YHQ?\ '%Z^>[FO_DJ7
MG_/5<?\ 5Y^DQ[,NB#KWOW7NO>_=>Z][]U[JUG^3]_V4MOC_ ,09N7_W?[9]
MXT_>G_Y5ZW_Z6,7_ &C7?6:7W%?^5NN_^E1<?]INW];'_O 7KJ]U[W[KW7O?
MNO=-N9_XL^5_[5M=_P!:F]^Z]U73[3]*.O>_=>Z][]U[KWOW7NO>_=>Z,7\>
M_P#@9NC_ *AL5_T-/[<CZ;DZ,[[<Z;Z][]U[KWOW7NDCO[_CRMT_]J/(_P#6
MMO>CPZV./1!?;'3_ %[W[KW7O?NO=>]^Z]U[W[KW1L.@?^/:S/\ VO#_ .X\
M/MU.'33\>AX]WZIU[W[KW7O?NO=!KV__ ,R[W#_Y"?\ W.IO=7X=63CT2'VS
MT]U[W[KW7O?NO=>]^Z]U[W[KW1S.DO\ CQ*?_M99'_H8>WDX=,OQZ%SW;JO7
MO?NO=>]^Z]T#7>G_ !Y,?_:[H/\ H2;W1^'5DX]$\]M=/=>]^Z]U[W[KW7O?
MNO=>]^Z]T>CJS_CP-M_]0M1_[D3>WDX=,'CT('NW6NO>_=>Z][]U[HOWR!_X
MLVW_ /M9U/\ UJ]T?AU=./16/;73O7O?NO=>]^Z]U[W[KW7O?NO=6![,_P"/
M/VG_ .&U@O\ W%B]OCATP>/2E][ZUU[W[KW7O?NO=%9^0/\ Q>-O?]JVJ_ZV
MCVW)TY'T7WVWTYU[W[KW7O?NO=>]^Z]U[W[KW5C]'_P#I/\ J&@_Z%'M1TGZ
MD^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NL4T,-3#+3U$4513U$4D,\$T8E1TE!5D=6!5
ME920018C@^]@TZ]UK:?S;OD3/O?XX;P^%[?$#N?X\=.[D[(VGUAF_E?W!U+#
M'UAM#";+W%331[EQB[/J-PUZTE6,;%'BS48[%QJE5').].H=!*7)6V"UNDOQ
M<Q32HC2+;12$7$KLA&@^*J+7N[])<FA"AN@)S1>FXMVM#!)&C,$,\B*88U#5
MU_ILY QVE@H!(+%>MB'KVFQ%'L'8])M_.P[HP-+L_;5-A-S4]5'71Y&C@HH%
MIJY)X6>*9*N$)*KHQ1PX9200?<8SDEVU"AU&HX4-<C\NAQ'0**&HH*'UQUDW
MYO?:_6>R-X=C;WR]+M_9FPML9W>.Z\Y72"*&CQVVJ66LK:F1B0 D-/#(Y_UO
M>[>W>ZD6*,%F=@JJ,DLQH /M)ZU-*L",[D!5!9B<  "I)^P=56_RC-G;CWYL
MCNK^8!V;B:G&]G_/CLJJ[+PV/R<:_<XCKS:AEQ?7^%U!Y0(DQ"-5JR2%9HJJ
M!W&M>!?SI,MK)%MD1K'9IX9(K1IV[I6R!^+M_P!KT'>6D:XC>^D!#W+:P#2J
MPCMC7!/X>[CQ8]6^^P5T)NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JNSO+Y0?-7
M;.^=_P"W?CG_ "]LUW7M+K>GC%;O_?O?N$Z/AW%5O04]>U+L_'SX[-UV5CB$
MYIWJZI*" U<;PPF4*S@3;=M5A-&C75X(F<_ D#S&,:BM9#J0#A4!=9IDTX=$
ME[?W<;,+>V\0*/B>58PYI6B#2Y/H2V@5X5&0-'PK^6FR?FW\=ME?(78N#S^U
M,?N>;-XC,[0W1&J5^(RVUJR:@R6/J&2R2^"I@<QRJJ^2)HW:.)V:)$._;-)L
M%T]K(58K0AE-596 92/M!'2K:MR3=H%G0$!J@JPHRLI*D'Y@@]/7RN^4?7/Q
M Z<R_<79$.X,O3193#[4V?LG9N*;/9W<VXMTR_;X?;N"H$(:LRF3J+K&EPJH
MLDTC+%$[!O9MHEWN<01:02"S.YTI&BBK.Q/!5&3^P9ZMN6XQ[7$9I*D @!5&
MIG9C154#B2<#^>.@4Z.[^^=6^-_;-Q_<WP)P_3/5F\(\W-7;WQWRDP?868VX
M*:BJ:S'#/;=CPV.#FOEAAHY!C<K7/2U,Z&1&IUEFC7W^W;?!&Q@NVED6G:;=
MD23(!T/K8XK4:U6H!X&@*:TO+R5P);<(C5[A,&9<$C4NA1G@=+-0D<14@_GL
M.=''7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4A\B_G!_*>?>O:/5?S%J.J\1OSK
MR"MVYN?;7R$Z.J:^KKL73O-X*C!35F#K5SN*JVEJ'I#CIYW9C(RQ))J]C':N
M7]X9(Y[%92KFJM!(**WHVEAH88KJIY>70=O]XVY6>&[:,%11EE7XE/IJ'<#_
M $:YJ.->@C_E4;FW#\=_@Q\H.X^R\+V5M?XO;-[J^2?<7Q?V1NO!Y!MQ8OI[
M;D0R&(I:7%Y K7Q4\L=)7R4%+,5+A_,C_;U$+^U_.,2;GN%O!"8VG:&WCN'5
MET/=-AB64Z:Y 8CSK7(/2/EMWLK2:24.(EEF>%2K:UMURHTD!O(E1QI2F*=&
M,^07R0_EQ=X_$WI;L3Y?Q[9'QO\ DBF&S?7)[IV971PQUE71R5=(]1544-4-
MNY 4GG\=4:^G!4R1Q5+"32Y5MNV;IM][+%9:_J(-0?P6&J@.DTR-0KQ !^SH
MQO;VQN[5)+G1X,H4KXJ]N1J%:CM/I6G59GQB^-?PP[<^>OQBW1_+AZ0P>W/B
MW\/Z#LSL+MWY)8_;>7JZ+=VZ]V8PX';FT,+NC<<TN7STN#9ZO)5TD4U31P^F
M-Y(ZEX2XMW?=K^TVZX3=9F:XNC&D=N7 ,4:L)'D:-!I350*H.DG) H.@YMVW
M6D]["VWQ*(8 [/,%J)'93&J*[&K4J68C4 0 37K9R]Q/U('7O?NO=>]^Z]U[
MW[KW4')U,E%C<A61!&EI*&KJ8UD!*EH(V8!@""02.;$?Z_MZWC$LBJ>!8 T^
M9 Z9N9##&SCBJL17A4 GK7._X>!^2W_/#]&?^@UG_P#[)O>>G_ L<O?\I&X_
M\Y;;_MDZY3_\'5S=_P HFT?]D][_ -[#KW_#P/R6_P">'Z,_]!K/_P#V3>_?
M\"QR]_RD;C_SEMO^V3KW_!U<W?\ *)M'_9/>_P#>PZ]_P\#\EO\ GA^C/_0:
MS_\ ]DWOW_ L<O?\I&X_\Y;;_MDZ]_P=7-W_ "B;1_V3WO\ WL.O?\/ _);_
M )X?HS_T&L__ /9-[]_P+'+W_*1N/_.6V_[9.O?\'5S=_P HFT?]D][_ -[#
MKW_#P/R6_P">'Z,_]!K/_P#V3>_?\"QR]_RD;C_SEMO^V3KW_!U<W?\ *)M'
M_9/>_P#>PZ.5\&?GUW#\FNY<AUWOS;?6F)PM)L7-[GCJMHX?*4%4:C&U6/@C
M1GK,S7Q&$I5R%@( Q(6S@ @Q/[R>R>U>WFTK?V4MV\C7,<)$\D+)I=)6)I'!
M&:U04S3CCJ??NX_>7WWW?WZ3:]R@L(HDLI;@-;17"2:XY8$ )ENIETTE-1IK
M4#(R#;K[Q=ZSAZ][]U[KWOW7NO>_=>Z)IW=_Q_4__:LQW_0K>VGX].IPZ"+W
M3J_7O?NO=>]^Z]U[W[KW1I_C]_Q9MP?]K.F_ZU>W4X=-/QZ,#[OU3KWOW7NO
M>_=>Z][]U[HA_97_ !_>YO\ M9/_ -"K[9?CT\G#I#^Z]6Z][]U[KWOW7NO>
M_=>Z-ST'_P >?DO_  Y:S_W%H_;J<.FGX]#?[OU3KWOW7NO>_=>Z][]U[JOS
M>?\ Q^&[/_#ESO\ [E2^V#QZ?'#I->]=;Z][]U[KWOW7NO>_=>Z,I\>?^8O_
M /(!_P#'OMR/IN3HRGMSIOKWOW7NO>_=>ZC5G_ .K_ZAI_\ H4^_=>ZK@]I^
ME'7O?NO=>]^Z]U[W[KW7O?NO=&PZ!_X]K,_]KP_^X\/MU.'33\>AX]WZIU[W
M[KW7O?NO=1JS_@'5_P#4-/\ ]"GW[KW5<'M/THZ][]U[KWOW7NO>_=>Z][]U
M[JQ;#?\ %GQ7_:MH?^M2^U'2?IR]^Z]U[W[KW7O?NO=>]^Z]U75FO^+SEO\
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M=NNO>_=>Z][]U[KWOW7NM-KY0?\ 92WR'_\ $Y]M?^[_ "'OJ][=?\J]M?\
MTKK+_M&BZX*^\/\ RMV]_P#2WW+_ +39N@,]C+J.>O>_=>Z][]U[KWOW7NK#
M?Y77_97^SO\ PV-]?^ZR;W!/WCO^56G_ .:UO_U='65?W,_^5X@_YY;O_JWU
MM%^^<O787KWOW7NO>_=>Z][]U[K2.WM_Q^>[O_#GS_\ [ER^^OVS?[AP?\T8
MO^.+U\]W-?\ R5+S_GJN/^KS])CV9=$'7O?NO=>]^Z]U[W[KW5K/\G[_ +*6
MWQ_X@S<O_N_VS[QI^]/_ ,J];_\ 2QB_[1KOK-+[BO\ RMUW_P!*BX_[3=OZ
MV/\ W@+UU>Z][]U[KWOW7NFW,_\ %GRO_:MKO^M3>_=>ZKI]I^E'7O?NO=>]
M^Z]U[W[KW7O?NO=&+^/?_ S='_4-BO\ H:?VY'TW)T9WVYTWU[W[KW7O?NO=
M)'?W_'E;I_[4>1_ZUM[T>'6QQZ(+[8Z?Z][]U[KWOW7NO>_=>Z][]U[HV'0/
M_'M9G_M>'_W'A]NIPZ:?CT/'N_5.O>_=>Z][]U[H->W_ /F7>X?_ "$_^YU-
M[J_#JR<>B0^V>GNO>_=>Z][]U[KWOW7NO>_=>Z.9TE_QXE/_ -K+(_\ 0P]O
M)PZ9?CT+GNW5>O>_=>Z][]U[H&N]/^/)C_[7=!_T)-[H_#JR<>B>>VNGNO>_
M=>Z][]U[KWOW7NO>_=>Z/1U9_P >!MO_ *A:C_W(F]O)PZ8/'H0/=NM=>]^Z
M]U[W[KW1?OD#_P 6;;__ &LZG_K5[H_#JZ<>BL>VNG>O>_=>Z][]U[KWOW7N
MO>_=>ZL#V9_QY^T__#:P7_N+%[?'#I@\>E+[WUKKWOW7NO>_=>Z*S\@?^+QM
M[_M6U7_6T>VY.G(^B^^V^G.O>_=>Z][]U[KWOW7NO>_=>ZL?H_\ @'2?]0T'
M_0H]J.D_4GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,6Z-RX39FV=Q;PW+6_PW;FU,%E]RY_(_
M;2UGV]%@J>2JJIO#3QRSR^*"*1M$<3R-;2BLQ *W;MOFW:XBM;==<LTB11+5
M5U22,$458A15B!4D <20.BW>-VM]@M)[^[?PX+:&6>9]+-HBA1I';2@9FTJI
M-%!8TH 3CHFW_#D_PK_Y_1_[#K=G_P!8O<K_ / _\W?\H'_9U9?]M/4"_P#!
M9^WW_1U_[,=R_P"V/KW_  Y/\*_^?T?^PZW9_P#6+W[_ ('_ )N_Y0/^SJR_
M[:>O?\%G[??]'7_LQW+_ +8^O?\ #D_PK_Y_1_[#K=G_ -8O?O\ @?\ F[_E
M _[.K+_MIZ]_P6?M]_T=?^S'<O\ MCZ]_P .3_"O_G]'_L.MV?\ UB]^_P"!
M_P";O^4#_LZLO^VGKW_!9^WW_1U_[,=R_P"V/KW_  Y/\*_^?T?^PZW9_P#6
M+W[_ ('_ )N_Y0/^SJR_[:>O?\%G[??]'7_LQW+_ +8^AGZ:^4717R!K\WB^
MHM\_WMKMN4=)7YF#^[.8P/ABKG:.)]63Q]$DFIT861F(M<@"Q]A+FSVYWGD=
M(Y-TM_ 65F6,^+!)J*@$C]&60B@(XTZD#D'WAY<]SY)HMBN_J6MU1IA]/=0Z
M%D+!36XAB!J5/PU(IFG0_P#L$=29U[W[KW7O?NO=>]^Z]U[W[KW5;?9WQJ_F
M!3;_ -^9KH7^8;C=B=>;\RE9E,?L7M3XQX7MVJVG+DFU3?W=S R^(EJ:.,Z?
MMJ+(TU1%  0)'5@JB>SW/;5C1;FS9W3!>.X:(2#RUJ4DH?4J5KZ>?1)<V5Z7
M8P7*JK<%>$2%#_1(=,?)@:>M,!5]%_!2C^.'Q9[BZ)ZJ[BWQ1]L]W5/;>^-Z
M_)W-T5+7;AJ-]]MTTD51O TE,:.E6>@G^U>EIHY(PB4\8:=IVEJ7;W'F$[K>
M17$T2&.(1(D +!!#$12.I+&A%:GU)/RZO9;.-OMWAB=@\AD=I2%+F22M7H !
M48H*4H .DWV[\!,QWK\3^CNDNQ_D/O:M^0/Q^S77G9'7ORUHL% ^:I]\==!_
MMMR2XJKJJF&KBJ/+,E11S5[>:-AJJ/*JRARQYB7;KR6XBA00S"1'MBQT&&3\
M&H $4Q1@,$5IY=4NMG-[;1Q22MXL91UG  82I^*AJ,YJO @D=)KKWX']V;H[
M_P"I_D3\U/E/!\BL[\?8,[-T=UUL/J*GZ3VQBLON.G:BK-S9.FBRV8J<YFI*
M(JD DFAIJ%M34\5V9B[<\PV\-M):V%OX(FT^,[R>-(RJ=013H0*M<F@JV*FF
M.FX=GEDG2>[F\0Q5\-$3PXU9A0L1J<LU#05-!F@KGJT+V$^C_KWOW7NO>_=>
MZ][]U[HNWRY_[)=^0/\ XB+?G_NNG]COVO\ ^5CVS_GNMO\ JZO47^]O_*G[
MW_TJ[[_M'DZT\/?57K@_U[W[KW7O?NO=>]^Z]U[W[KW6Q3_)X_YD+V3_ .)=
MK/\ W38CW@=]ZK_DMVO_ #PK_P!7Y^NJGW$O^58OO^EI)_VB6G5M_O&#K-SK
MWOW7NO>_=>Z:<_\ \6+-?]JG(_\ 6E_:FS_MH_\ 3K_QX=);[^PD_P!(_P#Q
MT]:/OOL/U\[/7O?NO=>]^Z]U[W[KW7O?NO=6A_RC_P#LJ+,_^(BW7_[L<-[Q
MR^]!_P JY'_SW0_]6KCK,C[CG_*X3_\ 2KN?^TBSZV5??/SKK1U[W[KW7O?N
MO=>]^Z]T33N[_C^I_P#M68[_ *%;VT_'IU.'01>Z=7Z][]U[KWOW7NO>_=>Z
M-/\ '[_BS;@_[6=-_P!:O;J<.FGX]&!]WZIU[W[KW7O?NO=>]^Z]T0_LK_C^
M]S?]K)_^A5]LOQZ>3ATA_=>K=>]^Z]U[W[KW7O?NO=&YZ#_X\_)?^'+6?^XM
M'[=3ATT_'H;_ '?JG7O?NO=>]^Z]U[W[KW5?F\_^/PW9_P"'+G?_ '*E]L'C
MT^.'2:]ZZWU[W[KW7O?NO=>]^Z]T93X\_P#,7_\ D _^/?;D?3<G1E/;G3?7
MO?NO=>]^Z]U&K/\ @'5_]0T__0I]^Z]U7![3]*.O>_=>Z][]U[KWOW7NO>_=
M>Z-AT#_Q[69_[7A_]QX?;J<.FGX]#Q[OU3KWOW7NO>_=>ZC5G_ .K_ZAI_\
MH4^_=>ZK@]I^E'7O?NO=>]^Z]U[W[KW7O?NO=6+8;_BSXK_M6T/_ %J7VHZ3
M].7OW7NO>_=>Z][]U[KWOW7NJZLU_P 7G+?]K.O_ .MK^V#QZ?'#IL]ZZWU[
MW[KW7O?NO=>]^Z]U91[4=)^O>_=>Z][]U[KWOW7NO>_=>ZUJOYN'_946&_\
M$1;4_P#=CF??0/[K_P#RKDG_ #W3?]6K?KDO]^/_ )7"#_I5VW_:1>=5>>\C
M>L-^O>_=>Z][]U[KWOW7NA=^/W_,^NDO_$N];?\ NYHO86YY_P"2)N'_ #PW
M?_5B3H>>UG_*S[/_ -+3;_\ M+AZW._?)CKOIU[W[KW7O?NO=>]^Z]UJ;_S#
M?^RR>[O^UMMC_P!T.*]]-?8G_E4]O_TDW_:3-UQ1^]1_ROV[?Z>V_P"T*VZ)
M?[EOK'WKWOW7NO>_=>Z][]U[HV_P0_[*[Z+_ /#OD_\ <*K]Q=[U?\JMN/\
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M]7GZ3'LRZ(.O>_=>Z][]U[KWOW7NK6?Y/W_92V^/_$&;E_\ =_MGWC3]Z?\
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M6;G7O?NO=>]^Z]TTY_\ XL6:_P"U3D?^M+^U-G_;1_Z=?^/#I+??V$G^D?\
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MPZ!_X]K,_P#:\/\ [CP^W4X=-/QZ'CW?JG7O?NO=>]^Z]U&K/^ =7_U#3_\
M0I]^Z]U7![3]*.O>_=>Z][]U[KWOW7NO>_=>ZL6PW_%GQ7_:MH?^M2^U'2?I
MR]^Z]U[W[KW7O?NO=>]^Z]U75FO^+SEO^UG7_P#6U_;!X]/CATV>]=;Z][]U
M[KWOW7NO>_=>ZLH]J.D_7O?NO=>]^Z]U[W[KW7O?NO=:U7\W#_LJ+#?^(BVI
M_P"[',^^@?W7_P#E7)/^>Z;_ *M6_7)?[\?_ "N$'_2KMO\ M(O.JO/>1O6&
M_7O?NO=>]^Z]U[W[KW0N_'[_ )GUTE_XEWK;_P!W-%["W//_ "1-P_YX;O\
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MJCO?_2HW+_M"FZTVO?5[K@KU[W[KW7O?NO=>]^Z]U[W[KW5SO\FO_C_>[?\
MPT-J?^YM3[Q*^]A_N'M__-:?_CB== ON#_[G;Q_S0M/^KD_5_?O"3KI=U[W[
MKW7O?NO=!GW3_P R<[9_\1GOS_W557L0<I_\E6R_YZ[?_J\G08YV_P"2-?\
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M]^Z]T&?=/_,G.V?_ !&>_/\ W557L0<I_P#)5LO^>NW_ .KR=!CG;_DC7_\
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MO3_CR8_^UW0?]"3>Z/PZLG'HGGMKI[KWOW7NO>_=>Z][]U[KWOW7NCT=6?\
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M!_VLZ;_K5[=3ATT_'HP/N_5.O>_=>Z][]U[KWOW7NB']E?\ '][F_P"UD_\
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M[]U[KWOW7NC*?'G_ )B__P @'_Q[[<CZ;DZ,I[<Z;Z][]U[KWOW7NHU9_P
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M SV,NHYZ][]U[KWOW7NO>_=>ZL-_E=?]E?[._P##8WU_[K)O<$_>._Y5:?\
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M_M=T'_0DWNC\.K)QZ)Y[:Z>Z][]U[KWOW7NO>_=>Z][]U[H]'5G_ !X&V_\
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M7#KY]NO>_=>Z][]U[KWOW7NO>_=>ZV$/Y./_ #*;MW_Q(F-_]UL/O!C[UO\
MR5++_GE;_J\W74C[A_\ R0-Q_P"E@/\ M&BZN(]XK=9T=>]^Z]U[W[KW1=OE
MS_V2[\@?_$1;\_\ ==/['?M?_P K'MG_ #W6W_5U>HO][?\ E3][_P"E7??]
MH\G6GA[ZJ]<'^O>_=>Z][]U[KWOW7NO>_=>ZV*?Y/'_,A>R?_$NUG_NFQ'O
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MK#?Y77_97^SO_#8WU_[K)O<$_>._Y5:?_FM;_P#5T=95_<S_ .5X@_YY;O\
MZM];1?OG+UV%Z][]U[KWOW7NO>_=>ZTCM[?\?GN[_P .?/\ _N7+[Z_;-_N'
M!_S1B_XXO7SW<U_\E2\_YZKC_J\_28]F71!U[W[KW7O?NO=>]^Z]U:S_ "?O
M^REM\?\ B#-R_P#N_P!L^\:?O3_\J];_ /2QB_[1KOK-+[BO_*W7?_2HN/\
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MKU[W[KW7O?NO=>]^Z]U[W[KW5SO\FO\ X_WNW_PT-J?^YM3[Q*^]A_N'M_\
MS6G_ ..)UT"^X/\ [G;Q_P T+3_JY/U?W[PDZZ7=>]^Z]U[W[KW09]T_\R<[
M9_\ $9[\_P#=55>Q!RG_ ,E6R_YZ[?\ ZO)T&.=O^2-?_P#/%=?]6).M+/WU
MPZ^?;KWOW7NO>_=>Z][]U[KWOW7NMA#^3C_S*;MW_P 2)C?_ '6P^\&/O6_\
ME2R_YY6_ZO-UU(^X?_R0-Q_Z6 _[1HNKB/>*W6='7O?NO=>]^Z]T7;Y<_P#9
M+OR!_P#$1;\_]UT_L=^U_P#RL>V?\]UM_P!75ZB_WM_Y4_>_^E7??]H\G6GA
M[ZJ]<'^O>_=>Z][]U[KWOW7NO>_=>ZV*?Y/'_,A>R?\ Q+M9_P"Z;$>\#OO5
M?\ENU_YX5_ZOS]=5/N)?\JQ??]+23_M$M.K;_>,'6;G7O?NO=>]^Z]TTY_\
MXL6:_P"U3D?^M+^U-G_;1_Z=?^/#I+??V$G^D?\ XZ>M'WWV'Z^=GKWOW7NO
M>_=>Z][]U[KWOW7NK0_Y1_\ V5%F?_$1;K_]V.&]XY?>@_Y5R/\ Y[H?^K5Q
MUF1]QS_E<)_^E7<_]I%GULJ^^?G76CKWOW7NO>_=>Z][]U[HFG=W_']3_P#:
MLQW_ $*WMI^/3J<.@B]TZOU[W[KW7O?NO=>]^Z]T:?X_?\6;<'_:SIO^M7MU
M.'33\>C ^[]4Z][]U[KWOW7NO>_=>Z(?V5_Q_>YO^UD__0J^V7X]/)PZ0_NO
M5NO>_=>Z][]U[KWOW7NC<]!_\>?DO_#EK/\ W%H_;J<.FGX]#?[OU3KWOW7N
MO>_=>Z][]U[JOS>?_'X;L_\ #ESO_N5+[8/'I\<.DU[UUOKWOW7NO>_=>Z][
M]U[HRGQY_P"8O_\ (!_\>^W(^FY.C*>W.F^O>_=>Z][]U[J-6?\  .K_ .H:
M?_H4^_=>ZK@]I^E'7O?NO=>]^Z]U[W[KW7O?NO=&PZ!_X]K,_P#:\/\ [CP^
MW4X=-/QZ'CW?JG7O?NO=>]^Z]U&K/^ =7_U#3_\ 0I]^Z]U7![3]*.O>_=>Z
M][]U[KWOW7NO>_=>ZL6PW_%GQ7_:MH?^M2^U'2?IR]^Z]U[W[KW7O?NO=>]^
MZ]U75FO^+SEO^UG7_P#6U_;!X]/CATV>]=;Z][]U[KWOW7NO>_=>ZLH]J.D_
M7O?NO=>]^Z]U[W[KW7O?NO=:U7\W#_LJ+#?^(BVI_P"[',^^@?W7_P#E7)/^
M>Z;_ *M6_7)?[\?_ "N$'_2KMO\ M(O.JO/>1O6&_7O?NO=>]^Z]U[W[KW0N
M_'[_ )GUTE_XEWK;_P!W-%["W//_ "1-P_YX;O\ ZL2=#SVL_P"5GV?_ *6F
MW_\ :7#UN=^^3'7?3KWOW7NO>_=>Z][]U[K4W_F&_P#99/=W_:VVQ_[H<5[Z
M:^Q/_*I[?_I)O^TF;KBC]ZC_ )7[=O\ 3VW_ &A6W1+_ '+?6/O7O?NO=>]^
MZ]U[W[KW1M_@A_V5WT7_ .'?)_[A5?N+O>K_ )5;<?\ FB/^KD?4[?=E_P"5
M[VC_ )KR?]H\W6W#[Y@==NNO>_=>Z][]U[KWOW7NM-KY0?\ 92WR'_\ $Y]M
M?^[_ "'OJ][=?\J]M?\ TKK+_M&BZX*^\/\ RMV]_P#2WW+_ +39N@,]C+J.
M>O>_=>Z][]U[KWOW7NK#?Y77_97^SO\ PV-]?^ZR;W!/WCO^56G_ .:UO_U=
M'65?W,_^5X@_YY;O_JWUM%^^<O787KWOW7NO>_=>Z][]U[K2.WM_Q^>[O_#G
MS_\ [ER^^OVS?[AP?\T8O^.+U\]W-?\ R5+S_GJN/^KS])CV9=$'7O?NO=>]
M^Z]U[W[KW5K/\G[_ +*6WQ_X@S<O_N_VS[QI^]/_ ,J];_\ 2QB_[1KOK-+[
MBO\ RMUW_P!*BX_[3=OZV/\ W@+UU>Z][]U[KWOW7NFW,_\ %GRO_:MKO^M3
M>_=>ZKI]I^E'7O?NO=>]^Z]U[W[KW7O?NO=&+^/?_ S='_4-BO\ H:?VY'TW
M)T9WVYTWU[W[KW7O?NO=)'?W_'E;I_[4>1_ZUM[T>'6QQZ(+[8Z?Z][]U[KW
MOW7NO>_=>Z][]U[HV'0/_'M9G_M>'_W'A]NIPZ:?CT/'N_5.O>_=>Z][]U[H
M->W_ /F7>X?_ "$_^YU-[J_#JR<>B0^V>GNO>_=>Z][]U[KWOW7NO>_=>Z.9
MTE_QXE/_ -K+(_\ 0P]O)PZ9?CT+GNW5>O>_=>Z][]U[H&N]/^/)C_[7=!_T
M)-[H_#JR<>B>>VNGNO>_=>Z][]U[KWOW7NO>_=>Z/1U9_P >!MO_ *A:C_W(
MF]O)PZ8/'H0/=NM=>]^Z]U[W[KW1?OD#_P 6;;__ &LZG_K5[H_#JZ<>BL>V
MNG>O>_=>Z][]U[KWOW7NO>_=>ZL#V9_QY^T__#:P7_N+%[?'#I@\>E+[WUKK
MWOW7NO>_=>Z*S\@?^+QM[_M6U7_6T>VY.G(^B^^V^G.O>_=>Z][]U[KWOW7N
MO>_=>ZL?H_\ @'2?]0T'_0H]J.D_4GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= 9\H/^R:?D/_
M .(,[:_]T&0]C+VZ_P"5AVO_ *6-E_VDQ=1S[P_\JCO?_2HW+_M"FZTVO?5[
MK@KU[W[KW7O?NO=>]^Z]U[W[KW5SO\FO_C_>[?\ PT-J?^YM3[Q*^]A_N'M_
M_-:?_CB== ON#_[G;Q_S0M/^KD_5_?O"3KI=U[W[KW7O?NO=!GW3_P R<[9_
M\1GOS_W557L0<I_\E6R_YZ[?_J\G08YV_P"2-?\ _/%=?]6).M+/WUPZ^?;K
MWOW7NO>_=>Z][]U[KWOW7NMA#^3C_P RF[=_\2)C?_=;#[P8^];_ ,E2R_YY
M6_ZO-UU(^X?_ ,D#<?\ I8#_ +1HNKB/>*W6='7O?NO=>]^Z]T7;Y<_]DN_(
M'_Q$6_/_ '73^QW[7_\ *Q[9_P ]UM_U=7J+_>W_ )4_>_\ I5WW_:/)UIX>
M^JO7!_KWOW7NO>_=>Z][]U[KWOW7NMBG^3Q_S(7LG_Q+M9_[IL1[P.^]5_R6
M[7_GA7_J_/UU4^XE_P JQ??]+23_ +1+3JV_WC!UFYU[W[KW7O?NO=-.?_XL
M6:_[5.1_ZTO[4V?]M'_IU_X\.DM]_82?Z1_^.GK1]]]A^OG9Z][]U[KWOW7N
MO>_=>Z][]U[JT/\ E'_]E19G_P 1%NO_ -V.&]XY?>@_Y5R/_GNA_P"K5QUF
M1]QS_E<)_P#I5W/_ &D6?6RK[Y^==:.O>_=>Z][]U[KWOW7NB:=W?\?U/_VK
M,=_T*WMI^/3J<.@B]TZOU[W[KW7O?NO=>]^Z]T:?X_?\6;<'_:SIO^M7MU.'
M33\>C ^[]4Z][]U[KWOW7NO>_=>Z(?V5_P ?WN;_ +63_P#0J^V7X]/)PZ0_
MNO5NO>_=>Z][]U[KWOW7NC<]!_\ 'GY+_P .6L_]Q:/VZG#II^/0W^[]4Z][
M]U[KWOW7NO>_=>ZK\WG_ ,?ANS_PY<[_ .Y4OM@\>GQPZ37O76^O>_=>Z][]
MU[KWOW7NC*?'G_F+_P#R ?\ Q[[<CZ;DZ,I[<Z;Z][]U[KWOW7NHU9_P#J_^
MH:?_ *%/OW7NJX/:?I1U[W[KW7O?NO=>]^Z]U[W[KW1L.@?^/:S/_:\/_N/#
M[=3ATT_'H>/=^J=>]^Z]U[W[KW4:L_X!U?\ U#3_ /0I]^Z]U7![3]*.O>_=
M>Z][]U[KWOW7NO>_=>ZL6PW_ !9\5_VK:'_K4OM1TGZ<O?NO=>]^Z]U[W[KW
M7O?NO=5U9K_B\Y;_ +6=?_UM?VP>/3XX=-GO76^O>_=>Z][]U[KWOW7NK*/:
MCI/U[W[KW7O?NO=>]^Z]U[W[KW6M5_-P_P"RHL-_XB+:G_NQS/OH']U__E7)
M/^>Z;_JU;]<E_OQ_\KA!_P!*NV_[2+SJKSWD;UAOU[W[KW7O?NO=>]^Z]T+O
MQ^_YGUTE_P")=ZV_]W-%["W//_)$W#_GAN_^K$G0\]K/^5GV?_I:;?\ ]I</
M6YW[Y,==].O>_=>Z][]U[KWOW7NM3?\ F&_]ED]W?]K;;'_NAQ7OIK[$_P#*
MI[?_ *2;_M)FZXH_>H_Y7[=O]/;?]H5MT2_W+?6/O7O?NO=>]^Z]U[W[KW1M
M_@A_V5WT7_X=\G_N%5^XN]ZO^56W'_FB/^KD?4[?=E_Y7O:/^:\G_:/-UMP^
M^8'7;KKWOW7NO>_=>Z][]U[K3:^4'_92WR'_ /$Y]M?^[_(>^KWMU_RKVU_]
M*ZR_[1HNN"OO#_RMV]_]+?<O^TV;H#/8RZCGKWOW7NO>_=>Z][]U[JPW^5U_
MV5_L[_PV-]?^ZR;W!/WCO^56G_YK6_\ U='65?W,_P#E>(/^>6[_ .K?6T7[
MYR]=A>O>_=>Z][]U[KWOW7NM([>W_'Y[N_\ #GS_ /[ER^^OVS?[AP?\T8O^
M.+U\]W-?_)4O/^>JX_ZO/TF/9ET0=>]^Z]U[W[KW7O?NO=6L_P G[_LI;?'_
M (@S<O\ [O\ ;/O&G[T__*O6_P#TL8O^T:[ZS2^XK_RMUW_TJ+C_ +3=OZV/
M_> O75[KWOW7NO>_=>Z;<S_Q9\K_ -JVN_ZU-[]U[JNGVGZ4=>]^Z]U[W[KW
M7O?NO=>]^Z]T8OX]_P# S='_ %#8K_H:?VY'TW)T9WVYTWU[W[KW7O?NO=)'
M?W_'E;I_[4>1_P"M;>]'AUL<>B"^V.G^O>_=>Z][]U[KWOW7NO>_=>Z-AT#_
M ,>UF?\ M>'_ -QX?;J<.FGX]#Q[OU3KWOW7NO>_=>Z#7M__ )EWN'_R$_\
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MO^KS==2/N'_\D#<?^E@/^T:+JXCWBMUG1U[W[KW7O?NO=%V^7/\ V2[\@?\
MQ$6_/_==/['?M?\ \K'MG_/=;?\ 5U>HO][?^5/WO_I5WW_:/)UIX>^JO7!_
MKWOW7NO>_=>Z][]U[KWOW7NMBG^3Q_S(7LG_ ,2[6?\ NFQ'O [[U7_);M?^
M>%?^K\_753[B7_*L7W_2TD_[1+3JV_WC!UFYU[W[KW7O?NO=-.?_ .+%FO\
MM4Y'_K2_M39_VT?^G7_CPZ2WW]A)_I'_ ..GK1]]]A^OG9Z][]U[KWOW7NO>
M_=>Z][]U[JT/^4?_ -E19G_Q$6Z__=CAO>.7WH/^5<C_ .>Z'_JU<=9D?<<_
MY7"?_I5W/_:19];*OOGYUUHZ][]U[KWOW7NO>_=>Z)IW=_Q_4_\ VK,=_P!"
MM[:?CTZG#H(O=.K]>]^Z]U[W[KW7O?NO=&G^/W_%FW!_VLZ;_K5[=3ATT_'H
MP/N_5.O>_=>Z][]U[KWOW7NB']E?\?WN;_M9/_T*OME^/3R<.D/[KU;KWOW7
MNO>_=>Z][]U[HW/0?_'GY+_PY:S_ -Q:/VZG#II^/0W^[]4Z][]U[KWOW7NO
M>_=>ZK\WG_Q^&[/_  Y<[_[E2^V#QZ?'#I->]=;Z][]U[KWOW7NO>_=>Z,I\
M>?\ F+__ " ?_'OMR/IN3HRGMSIOKWOW7NO>_=>ZC5G_  #J_P#J&G_Z%/OW
M7NJX/:?I1U[W[KW7O?NO=>]^Z]U[W[KW1L.@?^/:S/\ VO#_ .X\/MU.'33\
M>AX]WZIU[W[KW7O?NO=1JS_@'5_]0T__ $*??NO=5P>T_2CKWOW7NO>_=>Z]
M[]U[KWOW7NK%L-_Q9\5_VK:'_K4OM1TGZ<O?NO=>]^Z]U[W[KW7O?NO=5U9K
M_B\Y;_M9U_\ UM?VP>/3XX=-GO76^O>_=>Z][]U[KWOW7NK*/:CI/U[W[KW7
MO?NO=>]^Z]U[W[KW6M5_-P_[*BPW_B(MJ?\ NQS/OH']U_\ Y5R3_GNF_P"K
M5OUR7^_'_P KA!_TJ[;_ +2+SJKSWD;UAOU[W[KW7O?NO=>]^Z]T+OQ^_P"9
M]=)?^)=ZV_\ =S1>PMSS_P D3</^>&[_ .K$G0\]K/\ E9]G_P"EIM__ &EP
M];G?ODQUWTZ][]U[KWOW7NO>_=>ZU-_YAO\ V63W=_VMML?^Z'%>^FOL3_RJ
M>W_Z2;_M)FZXH_>H_P"5^W;_ $]M_P!H5MT2_P!RWUC[U[W[KW7O?NO=>]^Z
M]T;?X(?]E=]%_P#AWR?^X57[B[WJ_P"56W'_ )HC_JY'U.WW9?\ E>]H_P":
M\G_:/-UMP^^8'7;KKWOW7NO>_=>Z][]U[K3:^4'_ &4M\A__ !.?;7_N_P A
M[ZO>W7_*O;7_ -*ZR_[1HNN"OO#_ ,K=O?\ TM]R_P"TV;H#/8RZCGKWOW7N
MO>_=>Z][]U[JPW^5U_V5_L[_ ,-C?7_NLF]P3]X[_E5I_P#FM;_]71UE7]S/
M_E>(/^>6[_ZM];1?OG+UV%Z][]U[KWOW7NO>_=>ZTCM[?\?GN[_PY\__ .Y<
MOOK]LW^X<'_-&+_CB]?/=S7_ ,E2\_YZKC_J\_28]F71!U[W[KW7O?NO=>]^
MZ]U:S_)^_P"REM\?^(,W+_[O]L^\:?O3_P#*O6__ $L8O^T:[ZS2^XK_ ,K=
M=_\ 2HN/^TW;^MC_ -X"]=7NO>_=>Z][]U[IMS/_ !9\K_VK:[_K4WOW7NJZ
M?:?I1U[W[KW7O?NO=>]^Z]U[W[KW1B_CW_P,W1_U#8K_ *&G]N1]-R=&=]N=
M-]>]^Z]U[W[KW21W]_QY6Z?^U'D?^M;>]'AUL<>B"^V.G^O>_=>Z][]U[KWO
MW7NO>_=>Z-AT#_Q[69_[7A_]QX?;J<.FGX]#Q[OU3KWOW7NO>_=>Z#7M_P#Y
MEWN'_P A/_N=3>ZOPZLG'HD/MGI[KWOW7NO>_=>Z][]U[KWOW7NCF=)?\>)3
M_P#:RR/_ $,/;R<.F7X]"Y[MU7KWOW7NO>_=>Z!KO3_CR8_^UW0?]"3>Z/PZ
MLG'HGGMKI[KWOW7NO>_=>Z][]U[KWOW7NCT=6?\ '@;;_P"H6H_]R)O;R<.F
M#QZ$#W;K77O?NO=>]^Z]T7[Y _\ %FV__P!K.I_ZU>Z/PZNG'HK'MKIWKWOW
M7NO>_=>Z][]U[KWOW7NK ]F?\>?M/_PVL%_[BQ>WQPZ8/'I2^]]:Z][]U[KW
MOW7NBL_('_B\;>_[5M5_UM'MN3IR/HOOMOISKWOW7NO>_=>Z][]U[KWOW7NK
M'Z/_ (!TG_4-!_T*/:CI/U)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0&?*#_LFGY#_P#B#.VO
M_=!D/8R]NO\ E8=K_P"EC9?]I,74<^\/_*H[W_TJ-R_[0INM-KWU>ZX*]>]^
MZ]U[W[KW7O?NO=>]^Z]U<[_)K_X_WNW_ ,-#:G_N;4^\2OO8?[A[?_S6G_XX
MG70+[@_^YV\?\T+3_JY/U?W[PDZZ7=>]^Z]U[W[KW09]T_\ ,G.V?_$9[\_]
MU55[$'*?_)5LO^>NW_ZO)T&.=O\ DC7_ /SQ77_5B3K2S]]<.OGVZ][]U[KW
MOW7NO>_=>Z][]U[K80_DX_\ ,INW?_$B8W_W6P^\&/O6_P#)4LO^>5O^KS==
M2/N'_P#) W'_ *6 _P"T:+JXCWBMUG1U[W[KW7O?NO=%V^7/_9+OR!_\1%OS
M_P!UT_L=^U__ "L>V?\ /=;?]75ZB_WM_P"5/WO_ *5=]_VCR=:>'OJKUP?Z
M][]U[KWOW7NO>_=>Z][]U[K8I_D\?\R%[)_\2[6?^Z;$>\#OO5?\ENU_YX5_
MZOS]=5/N)?\ *L7W_2TD_P"T2TZMO]XP=9N=>]^Z]U[W[KW33G_^+%FO^U3D
M?^M+^U-G_;1_Z=?^/#I+??V$G^D?_CIZT???8?KYV>O>_=>Z][]U[KWOW7NO
M>_=>ZM#_ )1__9469_\ $1;K_P#=CAO>.7WH/^5<C_Y[H?\ JU<=9D?<<_Y7
M"?\ Z5=S_P!I%GULJ^^?G76CKWOW7NO>_=>Z][]U[HFG=W_']3_]JS'?]"M[
M:?CTZG#H(O=.K]>]^Z]U[W[KW7O?NO=&G^/W_%FW!_VLZ;_K5[=3ATT_'HP/
MN_5.O>_=>Z][]U[KWOW7NB']E?\ '][F_P"UD_\ T*OME^/3R<.D/[KU;KWO
MW7NO>_=>Z][]U[HW/0?_ !Y^2_\ #EK/_<6C]NIPZ:?CT-_N_5.O>_=>Z][]
MU[KWOW7NJ_-Y_P#'X;L_\.7._P#N5+[8/'I\<.DU[UUOKWOW7NO>_=>Z][]U
M[HRGQY_YB_\ \@'_ ,>^W(^FY.C*>W.F^O>_=>Z][]U[J-6?\ ZO_J&G_P"A
M3[]U[JN#VGZ4=>]^Z]U[W[KW7O?NO=>]^Z]T;#H'_CVLS_VO#_[CP^W4X=-/
MQZ'CW?JG7O?NO=>]^Z]U&K/^ =7_ -0T_P#T*??NO=5P>T_2CKWOW7NO>_=>
MZ][]U[KWOW7NK%L-_P 6?%?]JVA_ZU+[4=)^G+W[KW7O?NO=>]^Z]U[W[KW5
M=6:_XO.6_P"UG7_];7]L'CT^.'39[UUOKWOW7NO>_=>Z][]U[JRCVHZ3]>]^
MZ]U[W[KW7O?NO=>]^Z]UK5?S</\ LJ+#?^(BVI_[L<S[Z!_=?_Y5R3_GNF_Z
MM6_7)?[\?_*X0?\ 2KMO^TB\ZJ\]Y&]8;]>]^Z]U[W[KW7O?NO="[\?O^9]=
M)?\ B7>MO_=S1>PMSS_R1-P_YX;O_JQ)T//:S_E9]G_Z6FW_ /:7#UN=^^3'
M7?3KWOW7NO>_=>Z][]U[K4W_ )AO_99/=W_:VVQ_[H<5[Z:^Q/\ RJ>W_P"D
MF_[29NN*/WJ/^5^W;_3VW_:%;=$O]RWUC[U[W[KW7O?NO=>]^Z]T;?X(?]E=
M]%_^'?)_[A5?N+O>K_E5MQ_YHC_JY'U.WW9?^5[VC_FO)_VCS=;</OF!UVZZ
M][]U[KWOW7NO>_=>ZTVOE!_V4M\A_P#Q.?;7_N_R'OJ][=?\J]M?_2NLO^T:
M+K@K[P_\K=O?_2WW+_M-FZ SV,NHYZ][]U[KWOW7NO>_=>ZL-_E=?]E?[._\
M-C?7_NLF]P3]X[_E5I_^:UO_ -71UE7]S/\ Y7B#_GEN_P#JWUM%^^<O787K
MWOW7NO>_=>Z][]U[K2.WM_Q^>[O_  Y\_P#^Y<OOK]LW^X<'_-&+_CB]?/=S
M7_R5+S_GJN/^KS])CV9=$'7O?NO=>]^Z]U[W[KW5K/\ )^_[*6WQ_P"(,W+_
M .[_ &S[QI^]/_RKUO\ ]+&+_M&N^LTON*_\K==_]*BX_P"TW;^MC_W@+UU>
MZ][]U[KWOW7NFW,_\6?*_P#:MKO^M3>_=>ZKI]I^E'7O?NO=>]^Z]U[W[KW7
MO?NO=&+^/?\ P,W1_P!0V*_Z&G]N1]-R=&=]N=-]>]^Z]U[W[KW21W]_QY6Z
M?^U'D?\ K6WO1X=;''H@OMCI_KWOW7NO>_=>Z][]U[KWOW7NC8= _P#'M9G_
M +7A_P#<>'VZG#II^/0\>[]4Z][]U[KWOW7N@U[?_P"9=[A_\A/_ +G4WNK\
M.K)QZ)#[9Z>Z][]U[KWOW7NO>_=>Z][]U[HYG27_ !XE/_VLLC_T,/;R<.F7
MX]"Y[MU7KWOW7NO>_=>Z!KO3_CR8_P#M=T'_ $)-[H_#JR<>B>>VNGNO>_=>
MZ][]U[KWOW7NO>_=>Z/1U9_QX&V_^H6H_P#<B;V\G#I@\>A ]VZUU[W[KW7O
M?NO=%^^0/_%FV_\ ]K.I_P"M7NC\.KIQZ*Q[:Z=Z][]U[KWOW7NO>_=>Z][]
MU[JP/9G_ !Y^T_\ PVL%_P"XL7M\<.F#QZ4OO?6NO>_=>Z][]U[HK/R!_P"+
MQM[_ +5M5_UM'MN3IR/HOOMOISKWOW7NO>_=>Z][]U[KWOW7NK'Z/_@'2?\
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M7NC8= _\>UF?^UX?_<>'VZG#II^/0\>[]4Z][]U[KWOW7N@U[?\ ^9=[A_\
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MR!_XO&WO^U;5?];1[;DZ<CZ+[[;Z<Z][]U[KWOW7NO>_=>Z][]U[JQ^C_P"
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MW7NO>_=>ZV$/Y./_ #*;MW_Q(F-_]UL/O!C[UO\ R5++_GE;_J\W74C[A_\
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M *UM[T>'6QQZ(+[8Z?Z][]U[KWOW7NO>_=>Z][]U[HV'0/\ Q[69_P"UX?\
MW'A]NIPZ:?CT/'N_5.O>_=>Z][]U[H->W_\ F7>X?_(3_P"YU-[J_#JR<>B0
M^V>GNO>_=>Z][]U[KWOW7NO>_=>Z.9TE_P >)3_]K+(_]##V\G#IE^/0N>[=
M5Z][]U[KWOW7N@:[T_X\F/\ [7=!_P!"3>Z/PZLG'HGGMKI[KWOW7NO>_=>Z
M][]U[KWOW7NCT=6?\>!MO_J%J/\ W(F]O)PZ8/'H0/=NM=>]^Z]U[W[KW1?O
MD#_Q9MO_ /:SJ?\ K5[H_#JZ<>BL>VNG>O>_=>Z][]U[KWOW7NO>_=>ZL#V9
M_P >?M/_ ,-K!?\ N+%[?'#I@\>E+[WUKKWOW7NO>_=>Z*S\@?\ B\;>_P"U
M;5?];1[;DZ<CZ+[[;Z<Z][]U[KWOW7NO>_=>Z][]U[JQ^C_X!TG_ %#0?]"C
MVHZ3]2??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]T!GR@_[)I^0__B#.VO\ W09#V,O;K_E8=K_Z
M6-E_VDQ=1S[P_P#*H[W_ -*C<O\ M"FZTVO?5[K@KU[W[KW7O?NO=>]^Z]U[
MW[KW5SO\FO\ X_WNW_PT-J?^YM3[Q*^]A_N'M_\ S6G_ ..)UT"^X/\ [G;Q
M_P T+3_JY/U?W[PDZZ7=>]^Z]U[W[KW09]T_\R<[9_\ $9[\_P#=55>Q!RG_
M ,E6R_YZ[?\ ZO)T&.=O^2-?_P#/%=?]6).M+/WUPZ^?;KWOW7NO>_=>Z][]
MU[KWOW7NMA#^3C_S*;MW_P 2)C?_ '6P^\&/O6_\E2R_YY6_ZO-UU(^X?_R0
M-Q_Z6 _[1HNKB/>*W6='7O?NO=>]^Z]T7;Y<_P#9+OR!_P#$1;\_]UT_L=^U
M_P#RL>V?\]UM_P!75ZB_WM_Y4_>_^E7??]H\G6GA[ZJ]<'^O>_=>Z][]U[KW
MOW7NO>_=>ZV*?Y/'_,A>R?\ Q+M9_P"Z;$>\#OO5?\ENU_YX5_ZOS]=5/N)?
M\JQ??]+23_M$M.K;_>,'6;G7O?NO=>]^Z]TTY_\ XL6:_P"U3D?^M+^U-G_;
M1_Z=?^/#I+??V$G^D?\ XZ>M'WWV'Z^=GKWOW7NO>_=>Z][]U[KWOW7NK0_Y
M1_\ V5%F?_$1;K_]V.&]XY?>@_Y5R/\ Y[H?^K5QUF1]QS_E<)_^E7<_]I%G
MULJ^^?G76CKWOW7NO>_=>Z][]U[HFG=W_']3_P#:LQW_ $*WMI^/3J<.@B]T
MZOU[W[KW7O?NO=>]^Z]T:?X_?\6;<'_:SIO^M7MU.'33\>C ^[]4Z][]U[KW
MOW7NO>_=>Z(?V5_Q_>YO^UD__0J^V7X]/)PZ0_NO5NO>_=>Z][]U[KWOW7NC
M<]!_\>?DO_#EK/\ W%H_;J<.FGX]#?[OU3KWOW7NO>_=>Z][]U[JOS>?_'X;
ML_\ #ESO_N5+[8/'I\<.DU[UUOKWOW7NO>_=>Z][]U[HRGQY_P"8O_\ (!_\
M>^W(^FY.C*>W.F^O>_=>Z][]U[J-6?\  .K_ .H:?_H4^_=>ZK@]I^E'7O?N
MO=>]^Z]U[W[KW7O?NO=&PZ!_X]K,_P#:\/\ [CP^W4X=-/QZ'CW?JG7O?NO=
M>]^Z]U&K/^ =7_U#3_\ 0I]^Z]U7![3]*.O>_=>Z][]U[KWOW7NO>_=>ZL6P
MW_%GQ7_:MH?^M2^U'2?IR]^Z]U[W[KW7O?NO=>]^Z]U75FO^+SEO^UG7_P#6
MU_;!X]/CATV>]=;Z][]U[KWOW7NO>_=>ZLH]J.D_7O?NO=>]^Z]U[W[KW7O?
MNO=:U7\W#_LJ+#?^(BVI_P"[',^^@?W7_P#E7)/^>Z;_ *M6_7)?[\?_ "N$
M'_2KMO\ M(O.JO/>1O6&_7O?NO=>]^Z]U[W[KW0N_'[_ )GUTE_XEWK;_P!W
M-%["W//_ "1-P_YX;O\ ZL2=#SVL_P"5GV?_ *6FW_\ :7#UN=^^3'7?3KWO
MW7NO>_=>Z][]U[K4W_F&_P#99/=W_:VVQ_[H<5[Z:^Q/_*I[?_I)O^TF;KBC
M]ZC_ )7[=O\ 3VW_ &A6W1+_ '+?6/O7O?NO=>]^Z]U[W[KW1M_@A_V5WT7_
M .'?)_[A5?N+O>K_ )5;<?\ FB/^KD?4[?=E_P"5[VC_ )KR?]H\W6W#[Y@=
M=NNO>_=>Z][]U[KWOW7NM-KY0?\ 92WR'_\ $Y]M?^[_ "'OJ][=?\J]M?\
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M7NMA#^3C_P RF[=_\2)C?_=;#[P8^];_ ,E2R_YY6_ZO-UU(^X?_ ,D#<?\
MI8#_ +1HNKB/>*W6='7O?NO=>]^Z]T7;Y<_]DN_('_Q$6_/_ '73^QW[7_\
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M<S_Q9\K_ -JVN_ZU-[]U[JNGVGZ4=>]^Z]U[W[KW7O?NO=>]^Z]T8OX]_P#
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M:+JXCWBMUG1U[W[KW7O?NO=%V^7/_9+OR!_\1%OS_P!UT_L=^U__ "L>V?\
M/=;?]75ZB_WM_P"5/WO_ *5=]_VCR=:>'OJKUP?Z][]U[KWOW7NO>_=>Z][]
MU[K8I_D\?\R%[)_\2[6?^Z;$>\#OO5?\ENU_YX5_ZOS]=5/N)?\ *L7W_2TD
M_P"T2TZMO]XP=9N=>]^Z]U[W[KW33G_^+%FO^U3D?^M+^U-G_;1_Z=?^/#I+
M??V$G^D?_CIZT???8?KYV>O>_=>Z][]U[KWOW7NO>_=>ZM#_ )1__9469_\
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M$'7O?NO=>]^Z]U[W[KW5K/\ )^_[*6WQ_P"(,W+_ .[_ &S[QI^]/_RKUO\
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M'_XZ>M'WWV'Z^=GKWOW7NO>_=>Z][]U[KWOW7NK0_P"4?_V5%F?_ !$6Z_\
MW8X;WCE]Z#_E7(_^>Z'_ *M7'69'W'/^5PG_ .E7<_\ :19];*OOGYUUHZ][
M]U[KWOW7NO>_=>Z)IW=_Q_4__:LQW_0K>VGX].IPZ"+W3J_7O?NO=>]^Z]U[
MW[KW1I_C]_Q9MP?]K.F_ZU>W4X=-/QZ,#[OU3KWOW7NO>_=>Z][]U[HA_97_
M !_>YO\ M9/_ -"K[9?CT\G#I#^Z]6Z][]U[KWOW7NO>_=>Z-ST'_P >?DO_
M  Y:S_W%H_;J<.FGX]#?[OU3KWOW7NO>_=>Z][]U[JOS>?\ Q^&[/_#ESO\
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M6;G7O?NO=>]^Z]TTY_\ XL6:_P"U3D?^M+^U-G_;1_Z=?^/#I+??V$G^D?\
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MPZ!_X]K,_P#:\/\ [CP^W4X=-/QZ'CW?JG7O?NO=>]^Z]U&K/^ =7_U#3_\
M0I]^Z]U7![3]*.O>_=>Z][]U[KWOW7NO>_=>ZL6PW_%GQ7_:MH?^M2^U'2?I
MR]^Z]U[W[KW7O?NO=>]^Z]U75FO^+SEO^UG7_P#6U_;!X]/CATV>]=;Z][]U
M[KWOW7NO>_=>ZLH]J.D_7O?NO=>]^Z]U[W[KW7O?NO=:U7\W#_LJ+#?^(BVI
M_P"[',^^@?W7_P#E7)/^>Z;_ *M6_7)?[\?_ "N$'_2KMO\ M(O.JO/>1O6&
M_7O?NO=>]^Z]U[W[KW0N_'[_ )GUTE_XEWK;_P!W-%["W//_ "1-P_YX;O\
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MJCO?_2HW+_M"FZTVO?5[K@KU[W[KW7O?NO=>]^Z]U[W[KW5SO\FO_C_>[?\
MPT-J?^YM3[Q*^]A_N'M__-:?_CB== ON#_[G;Q_S0M/^KD_5_?O"3KI=U[W[
MKW7O?NO=!GW3_P R<[9_\1GOS_W557L0<I_\E6R_YZ[?_J\G08YV_P"2-?\
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MI@_X?Y_E)_\ >6/_ + GLO\ ^PWV[_K9;Y_RC?\ 5:W_ .MO3?\ 7C:_]_\
M_5.;_K7U1_\ S%/YG7P=[V[ZQF].JN[O[T[:I^N=O8&;)?Z-=WX.U70UN3EE
MB\.2P%'4'3'40G4(BAU6#$A@,PO8>9>3-E>TW,^#*;J60)F3L:.%0:Q:UR5.
M*UQPX=<\?O5<B;K[D\R1;ALL'U$"V$,+2>+##25)KERNF>2)L"13733.#4&A
M#?\ 9TOC/_S\K_USL_\ _6KW-7]<]M_W]_U3E_Z ZQI_UA.;/^4'_LZL_P#M
MHZ]_LZ7QG_Y^5_ZYV?\ _K5[]_7/;?\ ?W_5.7_H#KW^L)S9_P H/_9U9_\
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M]>_KQM?^_P#_ *IS?]:^M:/OCY[_ !-WGWCW+O#;7:_\2VYNOM;L3<N R/\
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M^MO7OZ\;7_O_ /ZIS?\ 6OKW_#_/\I/_ +RQ_P#8$]E__8;[]_K9;Y_RC?\
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M_7C:_P#?_P#U3F_ZU]>_X?Y_E)_]Y8_^P)[+_P#L-]^_ULM\_P"4;_JM;_\
M6WKW]>-K_P!__P#5.;_K7U"R?\_/^4O48W(4\/ROURST-7#$G^@KLM;M+&RJ
M+G9H N2/J;>_?ZV6^?\ *-_U6M_^MO7OZ\;7_O\ _P"J<W_6OHEW_#S7\M?_
M +R0_P#8/[]_^Q;VS_K8;[_RC?\ 5:W_ .MO3W]>]J_W_P#]4IO^M?7O^'FO
MY:__ 'DA_P"P?W[_ /8M[]_K8;[_ ,HW_5:W_P"MO7OZ][5_O_\ ZI3?]:^O
M?\/-?RU_^\D/_8/[]_\ L6]^_P!;#??^4;_JM;_];>O?U[VK_?\ _P!4IO\
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M<W_6OI8?\/\ /\I/_O+'_P!@3V7_ /8;[W_K9;Y_RC?]5K?_ *V]:_KQM?\
MO_\ ZIS?]:^O?\/\_P I/_O+'_V!/9?_ -AOOW^MEOG_ "C?]5K?_K;U[^O&
MU_[_ /\ JG-_UKZ]_P /\_RD_P#O+'_V!/9?_P!AOOW^MEOG_*-_U6M_^MO7
MOZ\;7_O_ /ZIS?\ 6OH'NX?YZ'\K'=.,P]/@?E']]-2UT\TZ?Z$NQ:72KQZ0
M;S;1C!N?Z$GW5_;'?#_Q&_ZK6_\ UMZLG/.U#_1_^J<W_6OH O\ AYK^6O\
M]Y(?^P?W[_\ 8M[;_P!;#??^4;_JM;_];>G/Z][5_O\ _P"J4W_6OKW_  \U
M_+7_ .\D/_8/[]_^Q;W[_6PWW_E&_P"JUO\ ];>O?U[VK_?_ /U2F_ZU]>_X
M>:_EK_\ >2'_ +!_?O\ ]BWOW^MAOO\ RC?]5K?_ *V]>_KWM7^__P#JE-_U
MKZ]_P\U_+7_[R0_]@_OW_P"Q;W[_ %L-]_Y1O^JUO_UMZ]_7O:O]_P#_ %2F
M_P"M?7O^'FOY:_\ WDA_[!_?O_V+>_?ZV&^_\HW_ %6M_P#K;U[^O>U?[_\
M^J4W_6OHX6V?Y]O\IS'[;V]05GRM\-70X/$T=5%_H+[*DTR4U/&CKJ79S*VE
ME(N&(/U!(]NCVRWS_E&_ZK6__6WIH\\[7_O_ /ZIS?\ 6OI\_P"'^?Y2?_>6
M/_L">R__ +#?>_\ 6RWS_E&_ZK6__6WK7]>-K_W_ /\ 5.;_ *U]>_X?Y_E)
M_P#>6/\ [ GLO_[#??O];+?/^4;_ *K6_P#UMZ]_7C:_]_\ _5.;_K7U[_A_
MG^4G_P!Y8_\ L">R_P#[#??O];+?/^4;_JM;_P#6WKW]>-K_ -__ /5.;_K7
MT ?</\\3^5SNG)8:HP/R?^_BI*&HAJ'_ -"O8=+I9Y P%IMI1DW'] 1[H_MC
MOA_XC?\ 5:W_ .MO5TYZVH?Z/_U2F_ZU] [_ ,/-?RU_^\D/_8/[]_\ L6]T
M_P!;#??^4;_JM;_];>K_ ->]J_W_ /\ 5*;_ *U]>_X>:_EK_P#>2'_L']^_
M_8M[]_K8;[_RC?\ 5:W_ .MO7OZ][5_O_P#ZI3?]:^O?\/-?RU_^\D/_ &#^
M_?\ [%O?O];#??\ E&_ZK6__ %MZ]_7O:O\ ?_\ U2F_ZU]>_P"'FOY:_P#W
MDA_[!_?O_P!BWOW^MAOO_*-_U6M_^MO7OZ][5_O_ /ZI3?\ 6OKW_#S7\M?_
M +R0_P#8/[]_^Q;W[_6PWW_E&_ZK6_\ UMZ]_7O:O]__ /5*;_K7T=>F_G[?
MRE8Z:GC?Y86=((D8?Z">RS8JH!'&S;?7V]_K9;Y_RC?]5K?_ *V],_UXVO\
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M?Z\6R?[]_P"JEO\ ];^O?\"9S=_!!^VX_P"V;KW][Z[_ )]9\A/_ $G#??\
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M^DX;[_\ L>]^_P!>+9/]^_\ 52W_ .M_7O\ @3.;OX(/VW'_ &S=>_O?7?\
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M?\;M^ (/^_.F+K?X98W4+/4JP'^+3\2"/]]]:SO][Z[_ )]9\A/_ $G#??\
M]CWOH3_KQ;)_OW_JI;_];^N1O_ F<W?P0?MN/^V;KW][Z[_GUGR$_P#2<-]_
M_8][]_KQ;)_OW_JI;_\ 6_KW_ F<W?P0?MN/^V;KW][Z[_GUGR$_])PWW_\
M8][]_KQ;)_OW_JI;_P#6_KW_  )G-W\$'[;C_MFZ]_>^N_Y]9\A/_2<-]_\
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M_4J[_CM?^RNW_P"MG5?ZQP?PS_\ 9-/_ -:^O?\ #Q'Q<_Y]S\Q?_2/-^?\
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MG7OZS6_\-Q_V33_]:^O?\.-]+?\ /LOEE_Z2;OO_ .LWOW]1[S^.U_[*[?\
MZV=>_K-;_P -Q_V33_\ 6OKW_#C?2W_/LOEE_P"DF[[_ /K-[]_4>\_CM?\
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MU_PXWTM_S[+Y9?\ I)N^_P#ZS>VOZCWG\=K_ -E=O_ULZ=_K-;_PW'_9-/\
M]:^O?\.-]+?\^R^67_I)N^__ *S>_?U'O/X[7_LKM_\ K9U[^LUO_#<?]DT_
M_6OKW_#C?2W_ #[+Y9?^DF[[_P#K-[]_4>\_CM?^RNW_ .MG7OZS6_\ #<?]
MDT__ %KZ]_PXWTM_S[+Y9?\ I)N^_P#ZS>_?U'O/X[7_ +*[?_K9U[^LUO\
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M^+TM//&G7/S%U20RHM_A[OP<NI _Y<_OW]2KO^.U_P"RNW_ZV=>_K'!_#/\
M]DT__6OHG7_#C?2W_/LOEE_Z2;OO_P"LWMK^H]Y_':_]E=O_ -;.G?ZS6_\
M#<?]DT__ %KZ]_PXWTM_S[+Y9?\ I)N^_P#ZS>_?U'O/X[7_ +*[?_K9U[^L
MUO\ PW'_ &33_P#6OKW_  XWTM_S[+Y9?^DF[[_^LWOW]1[S^.U_[*[?_K9U
M[^LUO_#<?]DT_P#UKZ]_PXWTM_S[+Y9?^DF[[_\ K-[]_4>\_CM?^RNW_P"M
MG7OZS6_\-Q_V33_]:^O?\.-]+?\ /LOEE_Z2;OO_ .LWOW]1[S^.U_[*[?\
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M7\R+I*JR-?4Q=9?+,Q5%;53QEOB9OM3IFD9A<?P;@V(]MGD>\/X[7_LKM_\
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M[=_J5=_QVO\ V5V__6SIK^L<'\,__9-/_P!:^O?\/$?%S_GW/S%_](\WY_\
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M"X((X((^A]ZZ]U[6FOQZEUZ=>C4+VO:]OK:_Y]^Z]UYW2-&DD94C16=W=@H
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M2+P%B01R T1M?;5BP^)B:\34= [>.6; Q37$X?6 \GC-(YDC(JPT&M%"GX5
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MN*A^/LM13=TS]+[H@ZN?'S0T=2,PV+D%$M'+.R4\-8TEEII)'6..<QLS*H)
M#VAH%O83=?V/BIXM:D:-0K6F:4XTS3H9[H)C:RBV_M?"?PZ4^/2=-*XK7A7'
MKUK59#:7Q#WY\8^E=L_"_;.\<+_-IFW!UU2++#6[BV_V+@=XX"KH9-^YK?M1
M7,[T^!A@_B[SS5RM12>6!*= 4*12Y'/?6MY*^XLK;9IDQ1&MWB(;PEA QK)T
MTTT84)/GU&LD-G<VL:V *[A5*$EEN$D!'B-,34Z::JZZJV M:CK;AIA4+3P"
MJ:-ZH0Q"I>%2J&0*-90'D*6O8'FWN#S\NI:'6;WKK?7O?NO=1ZN U5+4TPGJ
M*4U-/- *FD<12Q^92NN-B&"R)>ZDJ;$ V/O8-#7K1%>M>;^87_+S^)'Q<^(O
M8OR'V$.S=O\ RCV)5[7S?7GR'JNVMP[CWSF=W93)45#2K5551D'AR%1EO,\4
M\<-"@2(R24\<12XE+E;FJ^WB^CM)?#:V?4LD'AQK L0!8T 4:=-*@UX@5)ZC
MSF+EVSVRS>YCUK<)1HY_$=IFE)"J"23JU5TD4I0X Z%OO+'9KY??-CXJ?!_O
M6IW O66U?B#)\K_D5UYB,Q-MBCW5GJRN@VY18G+O02PU,V/Q632HJ6I8YT@D
M,UG\FA?&@VPC8MMN-RMPOB-="U@D(#-$@4R,RZ@0&84 :E10TITMW#_=ON$%
MA,6T+;FXF0'2LC%A&JM3)4&I*\#BM>N>Q^M]H? K^:-TITET/_$-C_'_ .9G
M2W:-5D^EH,E6Y/"T6\>G(&RQSN,BJI:HT$]5AH#!+&CQ1/ZV<NQIXXMW%W)S
M-LTUQ<T>>TFBI,0 YAFJNEB*:@&R*U(KB@K74-O'R_ND4$%4BNHI/T170)8J
M-J49TDK4&E :9J:=!9_,SZ%W?M_N#X5=X]C=X[Z[+R6YOYH7QLVEU_UTT<6U
M]H[3VSD*W+UD5%186G:49'.RBAHA79FLJ)*B?QF.GBHZ=FA9=R;N4<L%Y;Q0
MI&%VVY9Y/BEED 05+'@HJ=** !YZB*](>:[%XYK2>25W+;A;JJ?#'&E6- HX
ML:"K,2?X=()'1O/YP?8^]=A_&GKS![9W;F>N=J]P?)?I?ION;LS;V6_@%;M_
M9N\:BK?,5]/7BQH3(:2FII)[@+%/(C>ES[(>1+2.ZNY&=1(T5O-+#&PU+),B
MC2I'GQ)IYTZ.^<+J2WMD5"462>**613I,<3M1F!\O):^5:]%4^6_QRZ#_EZ;
MB^&OR.^(V)QW3VYG^3'574W8>#P>\LA-!O?9G9!J:+*0Y*BJLC,N;JZ8O#/#
M4LDLD3R-5.S-%"T9SL>[W/-"7=I?DRK]-++&65:PRQ@,"I"]@-*$"@(QY]%F
M[;9!R^UM<V86)OJ(HY &($L<A*$,-7<1JU FI!SUL"^XQZ'W7O?NO=>]^Z]T
MC.Q=EP]C;#WAL&IW%NS:5-O+;F7VU4;GV'FSMO-4$>9@>!ZK%Y!4D>BKH5<M
M#.J%HG =>0/;]K<&UD64*K:&#:7&I&H:T8'B#YCSZ9N(?J(VC)9=2E:J=+"H
MI4$<#Z'RZH+^:WPE^.WPKD^*O:/P^V_NGJWY1[@^574W7FU:[;^_\[N&OW?3
M;MK6DW!0[@ARF2K1DJ&>FB:>LE9% ;0DKK!*4,F<O\Q7?, N8+]EEMUMI9&#
M(BK$46B%-*KI()"@#UX5Z 6\[';;*8)K-6CG-Q&@*LY:4.U7#ZBVH:06).13
MC3HR/RUQ%%\M?YB_1WP7W_7;AE^/^S?CENOY4]M["Q&<J=NT>[:J?.#;>"QF
M7FHY8*RHQ^,J(VJFITF2*4S6E\A0>,JV1CL>TS;G$%\9[A+:)R S1#09'9:@
M@%A0 TJ*&E.C#=@-VW*+;Y"WA+ UQ(@-%E.L1JK4R5!J2O XK7I%;2ZPVA\%
M/YGG3O1/0T^7Z^Z ^:O1_:[9+I_'96LKL5CMY=14SY3^\&'6K>K_ (=55&&A
M,+JC1Q,0[/Y&-/'$HGO).9=GEN;FDD]I-%28@!VAF)70U*:@&R*U(KB@KTU#
M;1[!ND4$!*1744OZ0KH$L5&U+QTDJ2#2@-*FIIT%/\PO^7G\2/BY\1>Q?D/L
M(=F[?^4>Q*O:^;Z\^0]5VUN'<>^<SN[*9*BH:5:JJJ,@\.0J,MYGBGCAH4"1
M&22GCB*7"WE;FJ^WB^CM)?#:V?4LD'AQK L0!8T 4:=-*@UX@5)Z1\Q<NV>V
M6;W,>M;A*-'/XCM,TI(5022=6JNDBE*' '1@/G+N#L#M/<G\MOX1[MS^Y]GC
MY:Y[.YWY)2[1RC;7JZ[$=);9I,UGMMFMI66>DILU7592;[:1'*4YC\BQN5D*
M^6H8[.._W)%5_I558 XU!7FD**]#@E0"16HJ0:8P9;_,]S)9V#,R_4,QE*'2
M2D,>MDJ,@,2*TH: BN<AOW+T-U5_+@^7'P-[)^+6)J>GMB?('NNE^+/>/6>"
MRV1K\)N)-^TYBVW7U-)55%8L61Q61\CK4(JR/=/)*D0J/,LV_<I^;;&]AO#X
MSP0FYAD8#7'X;#6 0!VLIX'&,"M*);VPAY:N[26U'A)-+]/+&M=$FM3H)&0&
M5A\0%<Y-*]7T^XTZ'G7O?NO=1ZN U5+4TPGJ*4U-/- *FD<12Q^92NN-B&"R
M)>ZDJ;$ V/O8-#7K1%>M>;^87_+S^)'Q<^(O8OR'V$.S=O\ RCV)5[7S?7GR
M'JNVMP[CWSF=W93)45#2K5551D'AR%1EO,\4\<-"@2(R24\<12XE+E;FJ^WB
M^CM)?#:V?4LD'AQK L0!8T 4:=-*@UX@5)ZCSF+EVSVRS>YCUK<)1HY_$=IF
ME)"J"23JU5TD4I0X Z,!\Y=P=@=I[D_EM_"/=N?W/L\?+7/9W._)*7:.4;:]
M778CI+;-)FL]MLUM*RSTE-FJZK*3?;2(Y2G,?D6-RLA7RU#'9QW^Y(JO]*JK
M '&H*\TA17H<$J 2*U%2#3&#+?YGN9+.P9F7ZAF,I0Z24ACULE1D!B16E#0$
M5SD-^Y>ANJOY<'RX^!O9/Q:Q-3T]L3Y ]UTOQ9[QZSP66R-?A-Q)OVG,6VZ^
MII*JHK%BR.*R/D=:A%61[IY)4B%1YEFW[E/S;8WL-X?&>"$W,,C :X_#8:P"
M .UE/ XQ@5I1+>V$/+5W:2VH\))I?IY8UKHDUJ=!(R RL/B KG)I7H4_F#_+
M3^$='U%\EOD/VS3[_P KVA1[:[&[67O[=7;6<KMP8*MQRUF5Q,6#/W\&,HJ3
M#U30T^,H(\?XO&L-.ZS-9BAV'F_<O'M[6 H(RR1> L2".0&B-K[:L6'Q,37B
M:CI7O'+-@8IKB</K >3QFD<R1D58:#6BA3\*@4\J'HQ?Q7I_D5VY_+?Z'ARG
M9^6ZR[]WOTIL22J[7S>V(=YY.CCKFIW_ (E)05TL4-3F*O V*2U3.(ZR9:JH
MAG*/!(5;T;2QW:;3&)($FDI&&*J:$XJM3I#>G%10$<09;4+B[VV'4Y29HDJY
M4,P) J:-C53UP#D@\.B>?RU^K*'I?^8C_-0ZWHMV;ZWZ-N4/PQ>JWOV;N-]W
M9_*5>?VGD\E7UV3R$B1^:HJJZKGDTI%'#$I2&"*.&..-1#S?>&_VG;)2J)J-
MY1(UT(H$JJ !Z  <:D\2223T0<KVHL]SW",,[T^D[G;4[$Q,22?F3P% .
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M;K]]LF$R!&9:Z?$0.H)!%=+5!(K45!H0#3I)>V:W\9B<N%-*Z&*,0"#34I!
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MO\Q7?, N8+]EEMUMI9&#(BK$46B%-*KI()"@#UX5Z0[SL=MLI@FLU:.<W$:
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M\0GH_+/5PB9W2:T<I BA4"?F>Z?=-ML[JZ"FYD:9=8 5Y84*JK. !6AJ :9
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MH0#3I)>V:W\9B<N%-*Z&*,0"#34I! -*&A%14=4O;[^*_2/PI^?O\OW$_"G
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M1VUR1/(+Z0VD  &[-S5?\OJR6<OAJY#,-$;U(%/QHW\NA5NW+EEOC*UU'K*
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M7-2Q1PJNX!$CC! "BW)R22S,222S$DGT  "3;[(V._%6D>5C8EF>0@DL;@#
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M96.E2Q!.E *:105R:\>K6%E#S/<W4UTID6*=K>*-SV((U74P4&FIF).HU-*
M4X=")_+EJM][-S'\POX,[<['RE2OQ7[-H\;\>MS;ZII][R[;V_W/AJROVOCZ
MA*B:"3+T& J:&5EA>O5Y4UQ:Z>%H%1)S6L=PMCN31@?4QDSJE$\22%]+L* A
M2X(R%I7-":]*N6V>!KNP60GZ>0>$7JVB.5-2 U(+!2"!5JT%*@4Z"/H#I&NZ
M,_G4/@-P=K]C]W[RW+_+<R>^=[=D]H9.*MK:[*Y7L>&DE^RHZ:.&@PF(IZ:B
MIX:/'4<*04L2V!DD>660QW/<!N/+FI8HX57< B1Q@@!1;DY))9F)))9B23Z
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M7^8KOF 7,%^RRVZVTLC!D15B*+1"FE5TD$A0!Z\*](=YV.VV4P36:M'.;B-
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MS5R*<>C5^R3HVZ1G8NRX>QMA[PV#4[BW9M*FWEMS+[:J-S[#S9VWFJ"/,P/
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M[IHI<Y/N')4M%/3R9*>BH$^RA2>1H8C'K2.[,\A?%<R<K[1;W%M1)KR28F8
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M>=PAJ4U2PRRP^21$>3RZ%>1F85V=YNNW['8-M*R$L;KQ?"A66M)B%+51Z<"
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M#34]/'2RND\LSM$H\OCCF6;!LUUR?-+?WR^"(8I5CU%:RS.IC54H>[XB2PJ
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MYO*U*02531TV*A>>=Q%$KRR%(HV(5$9VM95)('N\:&5@HXD@#[3CJK,$!)X
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M-SG2WBIKD8(M305)ID]);V[2PA>>2NE%+-05- *\.M?+XU_/_P"%':'<-/\
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M1LCG:F:I?]RJ,=9.U/%+)=VIX(0Q)%_;',V[_OR]EN *(3IC6E L2#2@H,#
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MS1P30-GFJZB2ECE"#0PFDE^V=*ADN_6S7;V&S0LKR0IH:C H)YWULNH$@Z<
MD>8IQQTJV:=;=;S=)59$E?6M5(<PPIH5M) (U4) IP(Z*O\ &OY__"CM#N&G
M^<'S,^2VP</W#28W-;?^//0L&.SF;QO5VW<V2D[O/#B'IZ[>><I[?Q*O1K1P
ML*2+0B^*$ZW?E?<K* [;86\ABJ&GF[0;F1>'XL1*?@7S/<<]%6V\PV%Y,+^\
MGB$E"(8JDBW1N/EF1A\;>0[1BM36_*+>^ ^*W\R/H#YS]@39:C^-7;'Q=S'Q
M@WGV;0X:IRV-VWD)<^NY<%6YEJ:.6HI*#,R5%/31RF#0CQL\A5%D*DVRP/O>
MT3;9#0SQW(N4C) :1?#,;A:X)6E:5J1PZ,]UE7:-SBW"6HA> V[O2JQMX@="
MU,@,32O &E:=9MB;[VG\\?YF?4/?'1TD^\OCY\,NFNR\74=R)BJS'8C*;T[G
MC;%R87"3U5- ,DV.PNJ:IFB9XHB_C;27A::MS;2<M;1+;7'9/=RQGP:@NL,-
M6U, 3IU,0 #0FE>KP3Q[_N<=Q!WQ6T4@\4 Z&EFHNE32C:54ZB"0*TX]76>X
M^Z&G7O?NO=!;W=W!L[X_]2=A=T]@29&/9O6NU\GNO<'\(H&RE4T&-2_BIX$M
MY)IG*(FIDC#,&D>.,,ZK-OL9-SG2WBIKD8(M305)ID]);V[2PA>>2NE%+-05
M- *\.M?+XU_/_P"%':'<-/\ .#YF?);8.'[AI,;FMO\ QYZ%@QV<S>-ZNV[F
MR4G=YX<0]/7;SSE/;^)5Z-:.%A21:$7Q0RAN_*^Y64!VVPMY#%4-/-V@W,B\
M/Q8B4_ OF>XYZC_;>8;"\F%_>3Q"2A$,521;HW'RS(P^-O(=HQ6IK?E%O? ?
M%;^9'T!\Y^P)LM1_&KMCXNYCXP;S[-H<-4Y;&[;R$N?7<N"K<RU-'+44E!F9
M*BGIHY3!H1XV>0JBR%2;98'WO:)MLAH9X[D7*1D@-(OAF-PM<$K2M*U(X=&>
MZRKM&YQ;A+40O ;=WI58V\0.A:F0&)I7@#2M.LVQ-][3^>/\S/J'OCHZ2?>7
MQ\^&7379>+J.Y$Q59CL1E-Z=SQMBY,+A)ZJF@&2;'875-4S1,\41?QMI+PM-
M6YMI.6MHEMKCLGNY8SX-076&&K:F )TZF( !H32O5X)X]_W..X@[XK:*0>*
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MFV)OO:?SQ_F9]0]\='23[R^/GPRZ:[+Q=1W(F*K,=B,IO3N>-L7)A<)/54T
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MTL5748JDKZ:.GBF6%_N62T-W26*)/O<3;5MMMM3$>.TSW$L893X98".-6()
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M+319ZKIZV6KE2%'F2".J:H1B87T"\02[!LMU;;A57G>$V\#,"ZE6)=]-24!
M K0$TIT&#)'O6ZVUQ9$,D*3">500K!E 1-5*.0U32I"\>/081]__ !-^._\
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MP*LI'U!%C[\#3AUXBO7"EI*6AIX:.BIJ>CI*=!%3TM+"M/&BK]%1$ 55']
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MHJHB(H4 *+  #@ #Z#WKK?6'[2E_Y5J?_J2O_%/>ZGK5!UG "@*H"JH 50+
M ?0 >]=;ZBT5!0XV$T^.HJ2@IS)),8**F2E37,=3OI0*NIV))-KD\GWLL6XY
MZT!3AUE>GIY&+O!"[&UV>)6)MQ]2+^_5Z]3K(B)&H1%5%%[*BA0+\_0<>]=;
(ZY>_=>Z__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tbar_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tbar_003.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M-+]T:9-4J+-Z*EHV,3QB-/[A\LV'*LNS;S>6%O:/+/HW';T,<EN55A5E12Z
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M4]!+2U6&$ZTDBS/2UD:7@+(GBE?SR DL^X.^[!R#>R<O0[-:S110HLMQ(/\
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M2(B!IZ8LP'W#R)S''O!97^W"**_V>QV\B1O#N;",)#,E#V'22"PP>[2X ^$
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M":X -*LP/I)DUZ@OGR-^<N5]^YVG4UW+>+:WL]7%;&T+HE,L1JHJN"1W0U
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ML+H;Y8=3P+UE134VVMI=J[<(JH(Z:GE5HI7=/)1Y&.B#*[(!2UT4*B1X99@
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MVWYL7QY>:)=N+/H$$&W1SB.(#67+/.=3%JJ N0NFNHDGHA\'\NG?,/RD;?\
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MVAO3K/<&3[>Z>SNSJNFVC!D<4E+E<S)A_'%'3U%*X_A='3XL1+.U4U3+Z6>
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M WUO'XX4^S\!D</'N7=>$QV8RV<RU!CY8ON$$51%#0+55<$;J9!#3:#(7'J
M'L,;U>\BM'/-9P;J9Y%<Q0R/ EO#(P.G*EG*JQ!I5ZTIPZ&W+6W>YZ3VUON5
MSL0M8GC$]Q#'=R7=Q$C+J&EPD0>1006 0*6) ) '3_7?&W>]5\X\/\F4RVU5
MV)C>N)=H2XAJVK_BS54E-50ZU@%#]G]O>H4ZC7Z[ _M_3VAAY]LX^3Y.7RDW
MU#W8G#Z4\$(&0TU>)KU=O#13Y]&=Q[77\WN#%S8)+?Z2/;C:&/5)]293XF0O
MA:-'>,^)7^CTQ4GQ(S]?\MOD3W/NO);9KNK.\.EY.J?X!15M7_%U&1Q^V\?6
M&HC>C2DCA>/#U>EHZV1_W(KH/5I72^YT,/+&V;3;+*MYM]_]9XK*G@]LEU(F
MDARQ(,ZU!0#!SPJ46WLI<3<[;US!>O;OM^Z[7^[_  %:3ZBCPV,,FL&,(%(M
M7H5D8]RX&>@=ZH^,GSAZ2QW^AG8';_5%-TE%N>HR>/W;6XBIFW'28^OJ/N*N
MFIZ7[,TL<]2QEU:JF70TC/#4Q'2J"CF;W!Y0YO?][7ME>G<#"$:%706KRJNE
M69M>HJN."K4* R-DD&\D^T_/_M[&-AVW<MM&T+<-)'</%(=PB@>3Q'14$8CU
M.2U2SM3661U[544.Y?C+W3C_ )#_ .S1?&7=.PL9OG,[8@VGOK:79%-5C'9.
MGI4IX4D\]#').28J.@#)>$J:6-UGY:,A[E3W!VF?8_ZN\PPW+VZ3&:WFM2GB
MPL2Q(I(0O%WSW?&05X'H5\]>TV^VW,W];^4KBRCO);86MY;7Z2_3W$:Z &U0
M@OJI%&*=O]FI#C*DP71=!\G(Y-S93Y&9[JF=J\8Q-K;8ZKQM='3T(A-0:J2H
MJ\B!4S/,'@54U2*@CU"2[,"".<9N7F$4>PQW@TZ_&EO'C+25TZ0JQ=H HQ)P
M37ACJ2_;VWYL7QY>:)=N+/H$$&W1SB.(#67+/.=3%JJ N0NFNHDGID^6?QCV
M_P#*?K$['R>4?;V<Q&2CS^T=RQTQK125D4<D3+-")(C-2U$,CI*GD!!T2+ZX
MU!5^V?N%/[<;C]9&@EC=#'/$3IUQDAL&AHRD @T]0<$]%WO/[2VOO%LYVV>0
MPRQR":VG"ZO"F567N74NI&5BK+4<0P[E'1:MG=2_S(?%M_8N[^]^JL5LG"U.
M.AR&]MOXZ;+;AK:#&2):F#3XNE3RSPJ$>9GBF^K/-*Q8N/MUYEY"K)>6NW7C
MW$@8K;RNJ6L<C@]W;*YHI-0M"OD%44I%^P<G^Z8\"PW#=MM2TB=/$NX(I);Z
M:&-AV=\,: NHTL^'''4QJ3 IOBO\H>L.\.^=X=(;KZ:DVE\B<S/EL_N#LF@R
M>1S.#%?49"JFBQU/2+'32^"3(RB%99WAF6.G6>-/$7*B3W'Y=YBV?;K7=X;X
M3[9&$BCM6B2"XTK$@,C/5AJ$0U%5#*2Y4G53I%![/\W<G\Q;O?\ +]SMAM=[
ME\6>:_2XDNK34\[L(4BT(P4SMH#OI8"-7 T:BM/C5\7>]OC=\;>Q>L]J[YZ\
MA[3S'9M3O;9>Y9*2LR^(%*T>!IVILE!/1Q5$;UM+BZR&7PQRFG%0LD,KR(""
MGW ]Q=FY^W^UW"YM[DV:6@MYX@R)-KK<MJC*NRD(TRLNHKKTD,H!Z._:7V@Y
MA]J.5;W:;.[LOKY;]KNUG*2R6WAZ;1-$JLB,#(ENZMHU>'K!1F*],G7'Q?[]
MW5\G=I_)CY!U72^V\GL+"5^*Q&W^EZ#(1G*35]-7TQJ<I/7KY+QID'(;[B9I
M-"Q^.&,$R*]^]Q-EVWEZ;E_8Q?RI<R*[R7[1?HJKQMIC6+&3&/PJ!4FK'@BY
M6]I.9-YYMMN;.9VVJ&2RA>*&':DG'U#2)-&6F><:NT3&E&:M *( =;%LSXS?
M+CXQYS?N&^,&Y^D,YU1OG<U9NB@V[VM39:EJ,/45R)$?",8@601P1P1!S.ZR
M)!&6ID:^I;NON#RQ[A0VTO,46X1WEO"L+2V9A99U4DY\4U%26:E 06/>1P+]
MD]I^=/::XO(.3Y]HEVZ\N'N4@W);E7M9' 4A/IA1@%55!+&H1>P&I-@G56/[
M-QFQL/2]P;@VWN7L+7D)\]D]HXU\5CO\IJ)7@@I8Y0DK1TU.T47D>-'D*EF6
MY),(<R3[?<7CMM<<L5MVB-)W#RX4!BQ7%6:IH"0*T!ZR5Y1M]UM=OB3>IH)[
MSO,SVT;1P59V*J@<EJ(I"ZFH6I4@$]$R[P^+W=--\AJ?Y1?&+=6QL1OS*;<A
MVMOG:_8M/4?89&""&*F29)J6">4MX*:@#1DPL#2HZ5!!:%I7Y0]Q-IDV,\N\
MPPW#VR2F:WFM2OB1,6+$$.RBE6>A[OC(*\&$%>X'M'OT/,R\W\HW%G%>20"V
MO+>^5_ N(PH4-JB1FU 1Q CL_LU(>E49_P#CG\8NSMN]Q;R^2WR'WAMO<_;V
M[<$FV,?A=DT\T6(Q% IIQIA>HCAEDE,5+!&H$(6,&9FDJ))C(J+GOW"V^^VJ
M#E_8H)8;*&0S-)<%3/-+W9(4L *N3QSV@! M"9>V'M/NVV;Y=<U\SW,%QN=S
M"+9(K0.+6V@!3M4R!68D1K^$:>^I<MJ"F^%WQVWK\<]J]F83>V5VOE:S>G:>
M;WOC'VK65=;%'29&FI88XYVJZ*A9:D- ^I41T TD2,20"_W8YZM.>[BTEM$F
M1;>SCMW\944ET9R2NB20::,*$D'C@=&OL5[97_MA:;A!?R6\C7>YSWD9MVD9
M5BE2)5#&2*(AZH:@ J!2C'R5WS#Z4W3\@^@MV]6;-R& Q>X<[7;8JJ*LW/4U
M%'1*,+DJ6LE$LE+2ULZEHH7"::9KOI!T@E@6>UG-MMR/O<.Y7:R/%&LP98@K
M2?J1.@H'>,<6%:L,5X\.CCWRY!O/<WEFZV:P>&.>9K=D:=G6(>%<12MJ,<<K
M"JH:40YH#09 L=.[.R/7G4?5FP,O4457EMC=<[(V=E*O&N\E/+4;9QE+13R4
M[2QQ2M"\L#%"\2,5(+*IN &N:=UCWW=+R^B#*EQ=7$Z*U P665Y &H2*@-FA
M(KP)Z&7(VQ2\K[)M^V3,K26EC:6LC)4HSV\$<3%=04Z24)%0#3B <=%MKOC;
MO>J^<>'^3*9;:J[$QO7$NT)<0U;5_P 6:JDIJJ'6L H?L_M[U"G4:_78']OZ
M>QY#S[9Q\GR<OE)OJ'NQ.'TIX(0,AIJ\37J[>&BGSZC&X]KK^;W!BYL$EO\
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M42DJTD*L7;V4\\^X^T;WRY:[#MD%U$+6Z$B-<&-]402X%69&KXC--J*A-*Y
M8B@Z//;3V>W[ESG&]YJWFZLIVOK'P9$M4FCT3M):'2J2*P,2);!5<R:W)!9
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M9*M8ZFID\RSR,[QW&L(&95!$7<W3[--<*-DBN8X%C 8W3HTLDFIB6HE544(
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M6US2S^/6T<,"1.8<Q^XVQ[?L$NQ<MV]RBW4@DN9KK1KH"ITC0[U/8J^2JM:
MLQ8%')_M#S/NW-4/-/.-W9R26,+0V5M8>+X(9E=2[>*D=/[5V\V9M-2JQA"$
MFS_A+\J^N=D=P_'[9.]^DEZ=[4R6X,A7;^W'C<KD=U/!EZ.&C%(T42142-+%
M J2%C,(C)// XD<1^Q/NONYRWOUW8[W=V]_]=9I$JVT3PI9AD=GU G4YH6)
M&G51584%>@5L7L#SCRM8;IRS87FU?NO<9+AVO+B.YEW(K-$D6@JNB($J@#,2
MU*O(G<0@$W+_  L[0KO@+MCXKT^X-@CL##9J;)U>9FR>13#,DVY,AF=,=0N+
M>M+"GJT3G'J#(&%PMF(>MO=G;HN=I>9&BN?IG0*(PD1GJ+2.#*^,$^)"?C./
MGCH4W?L+N\WMI#R8LUG];')K:4O,+7.X27= P@,GP.%_LA5AY#/5AFP,!5[4
MV)LK:U?+3SUVVMI;<P%9/2,S1/+AJ.&GD>(NJ.8V>,E2R*;6NH/'N#=YO5W*
M\GN$!"RS2R*&I4!W9@#0D5H<T)ZR>V#;WVFPMK60@M#;PQ,5KI+1QJA(J :$
MC%0#3RZ*1UK\9-\[-^;/=/R3R>8VG4;([%V.NV<'B*&LK),K%.3MLL]7#)0Q
M4D<0.&J0#'6RL=<9TB[!)/W_ -PK/=>4;#8(TF%Q:W'BR.RH(2O^-84B0L3^
MNO%%&#GA6$>5O:3<-C]P-UYLEEMS:7MFMO#$C2FX5Z6-2ZF)4"_XJU-,C$U7
M R 8'Y"=>9KMCI+LWK;;E5BZ+.;TVGDL#BZO-32TU)'-6 !6J)((*F9(Q;DI
M [?T4^P/R1OD7+6[VE_.':."=)'$8!<JIJ=(9E!/VL!\^I/]R>6Y^<=@W#:K
M5HUENK6:"-I2RQJ\BE06**[!<YHK'Y'I'](=%U&ROC#MKH#L2;%9EHMC9[96
M[),!42STD\&XFK%J%IY*FGIY65J>K*W>F4WOZ;?4UYOYP7=N89=[L0\=;B.X
MA\0*'5H]!4L%9A74E<,?MZ).0/;]MAY3M^6]T,<NFS>TN?"+-$ZRAU<*71&(
M*N1E1]G1&MM?%+YS=6[!W'\>.M.TNFI^F,[49VDQ^Z\[29"DS^/QVZ2WWT<4
M4-')#'4.))V \L]I)2T=1#<"&8=P]R>3N8[V+?=PL[\7\8C9H8VB-M)+#302
M6<$J**."X6A1LZL>]H]G?<+DW;9N6-HW#:CM4K3+'<SI.M]!!<$F0*L<937W
M.15G[FJ'04"&(Q_0??'Q_P"GNK>N/B[N+K#-#:=-NB/L+&]QXBL6ES]3N>:G
MJ/O8GQS&II#22_>JE/\ <"-J>5%D>5X5+ 6?G39N=MUO+_F**[C\8PFV>Q>/
M7;+"K+H(E&E]0T$O2H920 &-).MO;GF+VUV+;]JY/GL)/IEG%VFZ1S>'=O.Z
MR>(K6[:XRC&2D=2I1P&)* E-_'7X8[DV5MKY)3=LYG9XW/\ )V@RN*W)MWK.
MAGQ^$Q%+E(<K$T5")4II7<C+2\>-1$$"I+*2TK+^>_=>#=KC:EVQ)_!VED>&
M6[96N)G1H6J]"P _1'F=5:D+A05^U_L5<[#:[X^^26QN-_5TN8+!'CM+>)UN
M$*Q:@C$D7+$F@TT #,:NP1=<_"KY-TO079GQ;W]V!UA2]59' Y#^X&4VO%75
M637+MGL?FZ>2N:6CIE7%R&EJXZB(%Y@*G2C.J*0*-^]VN7I=[M.8[*VNS>+(
MOU*3&,0^#]-);L$H['Q!K4HV%[*D GH$<J^PG-<'+-]R=N=[8+MSPR"REMA,
M;D7!O(KM3+K1%\$Z'61!J>DE U #TCM_?"3YD]O](=?=,;OW7\==M;>Z@.#H
M]G4&W(,VLF17%4;4!K<I7M23".H2F>1E$% @J9I)'G6-M#^S79?=WE3E;>+G
M=K6'<Y9+WQ&G:4V](B[B31&@=:J6 J6<Z% "UR.B'F7V YZYYY=L]@O[G9((
M=M,"VJ0+=UG$41@\2:5D:C!&) 2("1V)?3@]&Z^;7QDWSW[3]2;KZLS>W,+V
M3TSO";<VW6W7)/%12I6/0SR*QA@JAY4J<90NH>G9&570L@8DQA[1^X5GR4U[
M;;E'+):7T BE\$*9%*B101J9,%97!HP()!H:=39[^>TM_P"Y";;>[/+!%?[7
M=?46YN2XA8,T3L#H63.N")A52"%*U&HGH/>ROBY\C]\U?1_?E!OGK'"?+#JN
M@S6,S4T%!6+MG)4-=69"2FHD?[=ZR(04-?-3R7IB)FGG*O%Z)/9WL'N+L.SK
MN&RO;W<FS7C1O&"T?U<4BI$&>FH(=3QAAW=H5:ALCH.<U^T7-',4FT\R1W6W
MP\Q[<DJ2,L<W[ON(I'F*Q5*M* L<K(3I.HO(1HJ"#"=*T7S#GW969CY!9KI"
MAVDF$J*3';2ZJQV3GFDKI):<QU=15Y,L\4<<23C1'-(':3E4TK8$<VR\K);+
M%L<>X--X@9IKQH0HC :JJL- 225R0* <34]25R%!SP]V\W,TNTK;B(K';[;'
M<EFE+)1WDN#4  ,-*UU%JFE!T(G??2VV?D%U7N?JS=4M11T&X(()*3*T:AYJ
M*LQ\BSTE9$I90YAF12R%@)(R\;$*Y/LBY+YLN.2-RAW*V 9HB:HWPR(P*LIX
MTJ":'R-",CH3>XO(EG[E;/<;->EECG44=?CBD1@Z.O"I5E!H<,*J<$]$$V/T
M%_,;ZYVU1=.[6[RZ?BZYQ,(PVW][5N*J*[-8[&1C3'%34\N,9/)%'Z8HY:B;
MQ A(ZE41"DU;QSKR'OUPVZW&WWQNG/B2VZNJV\LIR2S"4&A.6*JNK)*$DUQR
MY=]N/='E:T38K3=MK%C$!%!>/#(]Y!;@44)&T.BJC"J[OI% )* 4$/OKXM]W
MY;M_HOY ]/[IV)N7L/J39%/LG(XGMV.L3'5[00Y!#E@*%7E^\F?)U+NOFC*.
MD$D<NJ,JQ'R5[B[/:[5N&Q[K#<16M[<&X5[(H98ZM$?"_4(&D"%0#0U!8%:&
MH$ON5[1;_?[[M/,^PW%I->[=:_2O%N0E%O+V3J9@( 6\1C<,6%5R(V#52C-O
M3_Q&[TVU\@.Y>]>T-Z=9[@R?;W3V=V=5TVT8,CBDI<KF9,/XXHZ>HI7'\+HZ
M?%B)9VJFJ9?2SP!BQ+_-7N=L^X['8[+MT%W$EE>QSJ9S$Y>%!/4EE8?J,TU2
MH4(N0&I3I+R+[+<P;/S3N7,N[W5C.^X[;);.MLL\0CN)&M:*JR*WZ*);!0Y<
MR/6K(#7I4]"_$_L'J[X;]H_'C<.<V;5[SWSANUL=C<KAJZMJ<9$^^L4U!2&>
M:?'TU6%BD(:;31L57] <\$OYS]RK'F+FNTWV".<06\EF[)(L8F(MYA(U LCK
M4C"U<9XTZ-/;GV:W+E+D.^Y6NI;9KJZAW&-)(FE:W4WD+1(69X8WH"06I&:#
MA7I.)\%,KN/X,[0^+V]=R8&EWSLS)YK<^&W1@C4Y/&PY.IR^8KJ8_OP4=3+
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M>OB2QT-)>TC5GB.L9_?CVCWSW!W+9MUV.:RBFVJ9YP+UIE1I!+;31T\&&4L
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MJIJF7TL\ 8L2JYJ]SMGW'8['9=N@NXDLKV.=3.8G+PH)ZDLK#]1FFJ5"A%R
MU*=(>1?9;F#9^:=RYEW>ZL9WW';9+9UMEGB$=Q(UK15616_11+8*'+F1ZU9
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M/X/7Y?RO0JC2BU!2U3)I61#=PH-^";&WE4MPZ\33I!;5^6GQ]WMN+$[4VSV
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M<?%F'DKH(JW<&,HI9ZB2F=OMZBH1E_;DFA=XB6:/0S,3HG22!UZE>D!\&_\
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M-TEV/US%\3Y=@;3/9AZ1@WPNYZ2DW!1;:,T^Z(:,EX9,C+&!"U2*HK97955
MRC5<;#!JUQ7KU"*=&>Z]WQVAN?,5=#O?I7(=;8R'&R5=-FJK?6)W0LTZ2Q(M
M*(*!C*C-&\DGD;T 1E3RR^Z$ <#7JP)Z&#W7K?7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TQ;HV_1[LVSN+:V1+KC]RX++[?KFC +"
M',T\E-*5OQ?1(UK^]@TZT<]$^V%D_DGT[M"@ZL'2%-V,=K4\N'VIOG#;\Q^$
MH:NEC=OM6K*:K/W-*T$94./JX72H!_<9PA6-:TZJ"1CI<=;=<]H=0=0[DEPU
M/MC=O<&Z]X9'L;<>.K:R7'8Z>MW!44YK:.FJ19HRM%"5A=_VON#J?]HF^F(8
M_+AUL @=!_OS%=V?(EMG;-SW3B]3[<P>\\)NS<VZL]N_';EE48,N?ML5%1@R
M/-,)' G*B.WI;2&-_ A,UKUHU;I^[-V[VQ@?DI@.W]C]93]CX*GZA.QZJFI-
MVXS;,D=5)E*VK8DU\JLRK%+$1IB(8L1J!4@^!!6A-,UZV:UKU*CV)VYW3O[8
MVZNW=N8?K;8_6N97=.!V!0;CBW;75^6I@/M:K(5E.BT:04A&I$CNQ+2(VI7U
MKZH6M,U\^O4)X]&VJT>2DJHXU+N]/,B("!<LI %R0!<_U('MOJW5?/4]-\H.
MH>F,9U;%TO0YW)24&;CVOG:'>M!2IC)-P55542)FX9);,]+-423(U-,\<L12
M+4DH8^W7TL:UZH*@4Z5-9\?MV;8ZR^+.P<!2KN"IZT[JV3O7>M;!6PT\4$$-
M375V3J(S420O+##/5LL:HAE= O[=R1[]KJ2?4=>I@="W!L?=*_*ZL[';%,NS
M'Z%CV9'F35P$-DCGHZW[<0"4U/%,A8N81'^-6H@>ZU[:?/\ R=;IGHNNXNCN
MTJ_H#Y(;,I=K/)N7L#Y"9W>FU<8<M0(:G&5N3PTT=4935""$-%23MHDD60!>
M4N0#<.*@^@ZU3!^WH<.W=C[_ ,5VOLCO;K7;])O3)X';F1V-NS9<N4BP=168
MRNEDJ(9:*JJ/\G6:EJ)9'97(UC2JWNQ%%(I0];(-:CJ!@=K=D]J=R[*[6W]L
MS_1IMGJ_$;BI]G[:KLW39O)5U=NR(4U3551HF>"FIHZ=5"QLYD\B@V9'.G=0
MHH,UZ\*D]*GXZ;'W3L>D[B3=.*;%2;J[Z[#WG@D:K@JS-C<T*):6H_R>641^
M4PR>ARL@ ]2BXOIS6GV#KP%/V])#JJFW!T#\>-\9;>^/I<+E-NY+LK=L%%75
ML57&XJ*B>:@5Y*2653]V_B555]9UA;!B![\W<<?+KP[1T8#K//;BW3L#:&Y-
MVX>+ ;CSF"H,IE<-"KQK3R5J"01A)6>5"$924=BZ$E6]0(]U.#UL=%@^1.&[
MJWKOC!;<H>K*_?'26(2CS.:Q.&WOB]L29ZNC.N.ER#UE0DR8ZED52T*P$3,-
M1D_08G$( XYZJU3TK,_@]^]\=6]@]8;PZCDZ?IJS;]!#M:LJ]W8S<M.]5CID
MJ*2,18PEZ:&FFI:;5Z;&,E4!(L:@Z36M>M\<=!YN"'Y)=H]<4W2&9ZI@V94Y
M*DQ&W=[]H56[J#)8\4./DB^YJL?1P.]5-/7Q066(C]KR%79>)$L-*FM?RZKD
MBG1D]X9+>'7FV]LX7K7JZM['IJ2ACP;4=-NS';7:BIL7!'%3N[5Q19_(H*VC
M7TZ;FP(]T&>)IU?APZ!+XDXOM[KW9>W^JM]]25>V\9@H-Q5AWJV\\3E(Y9<C
M7RU<=/\ 84DTU0A(J677K9?V[FVH 6DHQJ#U5:C'2OW5L#=^_P#Y%;)S>=Q#
M4W574^#J,_@JF:MII5R6X\J51'^V25IU3'PA'1Y(DT31$H2LGO0-!\S_ (.M
MD5/1A<O@L)N"GCI,]AL5FZ6*85$5-E\?#DHUD5642*DR.H<*[#4!>Q(O8GW2
MM.K4KT7OOK$]GX;8$6U_CQLFA@JMQ9.2GW'6;<J\;M:>@HY8U$]11+/+1P&M
MJ%41+-J9H@ 0NK0\=TH3GJI^737TO6]@[.I]L=>4OQGR>P=F4[215VXZCLS!
MYYXV=&>2MJXJ9A4UE34S >1E&HEK@!%"C;9S7_#UH5'ETG*'!]M]$]B]I5NS
M.LI.T]A=I;D??%"F'W-18"KQN6R(M6PU4=<RAZ>IE.I9([K&B+JY8JOJA@*F
ME.O4(/2BZYV1VGU[L?MOL&? XG-]V]EYK(;P79]/E8DHZ9U7Q8W%&M=HHYA1
M1,YD?S*KDF-9/]W-XD$@>0Z\ 1GH+.IAWUUTN;SN:^->?WGV1O"K-=O+?-?V
MMMNFEJ2I_9I*6'S2?9XZD32L4"N0+:CQH5-M0^>/L/7A4>70O=P;-["7?G5G
M=W7NVX=R;@V909K![JV)-FH,3-68[<4(U)3UDI%-YZ&8R. SZ9&TE;V*M53@
M@];(\^H.TMJ]D=B=W8;N3?NS5ZVP.QMIY/;^SMLUF;ILYDJNHW#<5-;5M1.]
M/30I"S1K"7,FH!CP3;Q( H.O4)->D#L&D[XZ>W;W:,=T/6[ZQ&_.WMV[XPV:
MHNQ<'@E-+F)V: &"IF:8,8]+'4J%22I7BYLU&IGRIUH5'ET<G9^6S^<VYC<K
MNC:TVRL[5K5&OVQ49:GSKTIAFDCC!JZ0FGE\L21RC0?2'T'U*?;9ZL.E-[UU
MOKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7ND-_I-Z]_P">SVY_Y]8O^CO>Z'K51U[_ $F]>_\
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MU[_2;U[_ ,]GMS_SZQ?]'>_4/7JCKW^DWKW_ )[/;G_GUB_Z.]^H>O5'7O\
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M/_/K%_T=[]0]>J.O?Z3>O?\ GL]N?^?6+_H[WZAZ]4=>_P!)O7O_ #V>W/\
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M-Z]_Y[/;G_GUB_Z.]^H>O5'7O])O7O\ SV>W/_/K%_T=[]0]>J.O?Z3>O?\
MGL]N?^?6+_H[WZAZ]4=>_P!)O7O_ #V>W/\ SZQ?]'>_4/7JCKW^DWKW_GL]
MN?\ GUB_Z.]^H>O5'4[&[ZV;F:V'&XK<V%R%?4^3P4=)D(YY'\*-(VE58DZ4
M5F/] "??J=>KTJ_>NM])W^Z&T_\ GE]N_P#GDIO^O7O=3UJ@Z]_=#:?_ #R^
MW?\ SR4W_7KWZIZ]0=>_NAM/_GE]N_\ GDIO^O7OU3UZ@Z]_=#:?_/+[=_\
M/)3?]>O?JGKU!U[^Z&T_^>7V[_YY*;_KU[]4]>H.O?W0VG_SR^W?_/)3?]>O
M?JGKU!U[^Z&T_P#GE]N_^>2F_P"O7OU3UZ@Z]_=#:?\ SR^W?_/)3?\ 7KWZ
MIZ]0=>_NAM/_ )Y?;O\ YY*;_KU[]4]>H.O?W0VG_P \OMW_ ,\E-_UZ]^J>
MO4'7O[H;3_YY?;O_ )Y*;_KU[]4]>H.O?W0VG_SR^W?_ #R4W_7KWZIZ]0=>
M_NAM/_GE]N_^>2F_Z]>_5/7J#KW]T-I_\\OMW_SR4W_7KWZIZ]0=>_NAM/\
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MVG_SR^W?_/)3?]>O?JGKU!U[^Z&T_P#GE]N_^>2F_P"O7OU3UZ@Z]_=#:?\
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M .>7V[_YY*;_ *]>_5/7J#KW]T-I_P#/+[=_\\E-_P!>O?JGKU!U[^Z&T_\
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M ,\OMW_SR4W_ %Z]^J>O4'7O[H;3_P">7V[_ .>2F_Z]>_5/7J#KW]T-I_\
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M>2F_Z]>_5/7J#KW]T-I_\\OMW_SR4W_7KWZIZ]0=>_NAM/\ YY?;O_GDIO\
MKU[]4]>H.O?W0VG_ ,\OMW_SR4W_ %Z]^J>O4'7O[H;3_P">7V[_ .>2F_Z]
M>_5/7J#KW]T-I_\ /+[=_P#/)3?]>O?JGKU!U[^Z&T_^>7V[_P">2F_Z]>_5
M/7J#KW]T-I_\\OMW_P \E-_UZ]^J>O4'7O[H;3_YY?;O_GDIO^O7OU3UZ@Z]
M_=#:?_/+[=_\\E-_UZ]^J>O4'7O[H;3_ .>7V[_YY*;_ *]>_5/7J#KW]T-I
M_P#/+[=_\\E-_P!>O?JGKU!U[^Z&T_\ GE]N_P#GDIO^O7OU3UZ@Z]_=#:?_
M #R^W?\ SR4W_7KWZIZ]0=>_NAM/_GE]N_\ GDIO^O7OU3UZ@Z>:.BH\? M+
M04E+0TJ%BE-1P)31@N;DA$"J"223QR>?>NM]2??NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1:R@H<C :;(4=)7TQ97-/64Z52$
MI]"4<,MQ^#;CW[KU*],_]T-I_P#/+[=_\\E-_P!>O>ZGK5!U[^Z&T_\ GE]N
M_P#GDIO^O7OU3UZ@Z]_=#:?_ #R^W?\ SR4W_7KWZIZ]0=>_NAM/_GE]N_\
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MW?\ SR4W_7KWZIZ]0=>_NAM/_GE]N_\ GDIO^O7OU3UZ@Z]_=#:?_/+[=_\
M/)3?]>O?JGKU!U[^Z&T_^>7V[_YY*;_KU[]4]>H.O?W0VG_SR^W?_/)3?]>O
M?JGKU!U[^Z&T_P#GE]N_^>2F_P"O7OU3UZ@Z]_=#:?\ SR^W?_/)3?\ 7KWZ
MIZ]0=>_NAM/_ )Y?;O\ YY*;_KU[]4]>H.O?W0VG_P \OMW_ ,\E-_UZ]^J>
MO4'7O[H;3_YY?;O_ )Y*;_KU[]4]>H.O?W0VG_SR^W?_ #R4W_7KWZIZ]0=>
M_NAM/_GE]N_^>2F_Z]>_5/7J#KW]T-I_\\OMW_SR4W_7KWZIZ]0=>_NAM/\
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MVG_SR^W?_/)3?]>O?JGKU!U[^Z&T_P#GE]N_^>2F_P"O7OU3UZ@Z]_=#:?\
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M .>7V[_YY*;_ *]>_5/7J#KW]T-I_P#/+[=_\\E-_P!>O?JGKU!U[^Z&T_\
MGE]N_P#GDIO^O7OU3UZ@ZDTFW-O4%1'5T.!PM%51:_%4TF+@II%\BE6TND:L
MNI6(-CR"1]#[]7KU.GGWKK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4W=Z_P#"
M@;^3Y\<.X:OHGM3YM;"I.R,3E7P6Y*'9FT]T]IX[$5L-144<U'E\[M?!9C!X
M^MHZVFE@K*6;(K4T+V-;%3QWD'NO=6?83N_J'<W3=-\AMM]C[1W!T?6["G[1
MH^TL)F8LKA9=O4M&^0ERT5; TD<E''1QR2LRDE0K @,I ]U[HL'P=_F<?!G^
M9%CNP\G\+>^L;W1!U16[>H.PJ:/9.YNOZS&/NU*N3&O+0;JPN#KI::M%!6B*
MHBIY(&>GFC\GDC=1[KW0\?(SY1_'?XB=<U/;7R:[DV!TCUU35L.,7='8&X(<
M)#45=0CR145%&Y-1D*^6.*5DIJ:&6=U1V6,A6(]U[JM'X]_\*'OY.WR>[1P_
M3?57S-VS_I W/E:3"[1Q?8/7V[^HJ;+U>1JH**CI<?D]U;?P^+EKJZJJ8(Z:
MC:L2LG9OVJ=M#Z?=>Z&SYI_SEOY:W\O+LK!=/_,'Y,474G96Y-HTF_,3M.+J
M[>W8L[8BOJJJC@K9GVIMK.04D<]315:1K/+$\AAD*(54GW[KW0U_$'^8G\(_
MGOB<IEOB'\DNM^[C@<;B\QN+ [=KY\7G,92YO4*6?*[>RM/09[&1S.CH#58Z
M&TBM$;2*RCW7NCH^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;,UF,=M[#Y;/YBH^SQ&#QE?F
M,I5^&2H\5-C(GGGD\<2O*^B)&;2B,QM95)('OW7NM7_,?\*Y_P"6+A-\;?H*
MSKSYF1]);HR\V%P'RGGZ%BH-DUST9TU530QU.:AW16T=#*LT-0(MNM6I/%(J
MT3H!(?=>ZNK^8_\ ,?\ B+\%/C!0_+OOSL^CHNG=QQ[8'7M7M2$;FR&ZZC>E
M/][BJ3;-#%(C92>LH!)5@K(D,5'%-5SRQ4\4DB^Z]T2;X-_S\?B#\V?D'2?%
M"JZU^3?Q-^1FX=OU>[>N^JOEWU7!U97;JQM%%/4R3X!Z;*Y6&HE6DI*N?PS/
M!)+%3U+TOW*4\S)[KW2Y_F4_ST_Y??\ *TGHML]_[]W#OGMZN_AM0G0?1>/Q
MN^=X4]'D_5'D,C1UV6PV,P]&8OW$.0RU++41^JDBJ/I[]U[HQ7S:_F)]6_!;
MXT[,^4&^^IOD9V[M7?FY=E[6P&Q?COUI!V7NCS[XQE=EZ>>IH),KC:&DHJ:C
MQ]1]S42Y-8DE,4$;2RSPH_NO=4]8K_A5[\'Y]^]9; W5\/\ ^9AU?7=L;]VU
MUWM;.=G_ !XVKM/'&NW16T]%$TDK]ARU$D-.]2DDPIJ6HG6($QPR-I1O=>ZV
M@_?NO=4K?S%_Y[7Q#_EO]H1=$;ZV%\D>]>]1L3'=I9?J_P".W4QWA48G;.2E
MJH(\_ELCDZ[#8F#&K/2/%(8*VIGBDDA\L$<<AD7W7NC&?RW?YJ/Q*_FF]+;C
M[K^,NX-S4M!L3-0[=[+V/V9@XMI9_;=954HK8$RD$-77X]Z:IIM;PU='DJJC
MD,4\:S^:GJ(XO=>ZK%WU_P *HOY<NS]];HHL)U_\N^TN@=A;X;KG?GS-ZMZ.
M3=/5N,RHJ8Z;0<X<O!75E,6FIGCEIL7*U5%44\M!'61SQLWNO=':^;?\[KX3
M?"+8_0F[LQ/VO\ALM\J-DU'8_P <=A_%[KR7M')[NP5'#0U4V6QT\M1C<-'1
M4]%D(*J3SY6.?[999(H)6C*'W7NL_P#*]_G6?#?^;#_I$P70"]F[#[4ZEIJ/
M(]@]-=U;5IMJYZCHJZIDHDR-.<?D,MC*ZB6LB,,IAR!GI9'A6LIZ8U$ D]U[
MI(_+#^?E_+O^)/R<ZM^'N>WQNKN+Y ]E=I[2ZCR6R>A,9B][#:63WG7TV-I&
MW?7UN9Q%!C!'55<(GI8*BKRD*W=\?:U_=>Z/'\\_FYT]_+K^+?9'RY[XH-\9
M;K/K%MKP9G$]<86EW!FJJ?>.6HL+04]#2UU?BZ-Y):ZOIU+3Y"")$+.\@"^_
M=>ZJQ^.7_"BKHCY-]C=(["V5_+^_FO[>P_?F[.OML;-[?WK\2L91[+IX.S*F
MEI\9G<EG<=O/*+#MPK6P5$N0AIZB*.D)J?5$"WOW7NM@_P!^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW6M!\B?^%5'\NSX]]I;OV W6/S&[5VGUKV-F.I>SN\>MND*:
M+9^%W'MZMEH,AB'KMPYS UU76T$L0DE2''%9()(I*-ZHOH'NO=7#9C^8G\/<
M#\(8/YBF5[DPE'\2:SKJ@[,H.RZBEJ:8U%'E76GI:&'&RQ)D7SM3D77'QXS[
M85IR)^R\(J 4'NO=5A?&;_A2I\$OD5WMU7T5G^M/EA\9:CY"U]/C_C7V9\FN
MGJ;KW:>_7R3PQX\8'+4V9R9/\5DJ:-:.2:GBIY7J:6$SI45$4#>Z]T-O\Q?^
M>U\0_P"6_P!H1=$;ZV%\D>]>]1L3'=I9?J_X[=3'>%1B=LY*6J@CS^6R.3KL
M-B8,:L](\4A@K:F>*22'RP1QR&1?=>Z'W^7C_-F^&W\S'H/>?R%Z WCE]N;7
MZNK7Q_<&W>X,?3;"RNTI$HOXB)<W_EM9BDH'HEEE2OILI4T+"&H3[@2TU1'%
M[KW0-_%?^>M\"?FO\W]T?!7XP[@W_P!L[TVGU]N/L.L[DP&W*!.OJJ#:E114
MM=1XW,3Y>++Y"JCDKX-$T& ?'S+J:&ND %_=>Z4W\S7^<E\:/Y5VX/C[L[N[
MK;Y'=L[X^3>5W+ANJ=D?'#K_ !6_LI5U&V)\32RQ-3Y7<.WQ)/4UF;QU/2T]
M-)45-1-+I2'@GW[KW63X$?S=.OOG]VMNGJ3:_P -_P"83\<,KM;KVO[&?=7R
MX^.-/U%@*ZGQN2QF,DQ^/RE+N'-)-F#)E8)DI7CB,E-%4RHS"!P/=>ZM3S68
MQVWL/EL_F*C[/$8/&5^8RE7X9*CQ4V,B>>>3QQ*\KZ(D9M*(S&UE4D@>_=>Z
MU?\ ,?\ "N?^6+A-\;?H*SKSYF1]);HR\V%P'RGGZ%BH-DUST9TU530QU.:A
MW16T=#*LT-0(MNM6I/%(JT3H!(?=>ZM<^=W\W#X<?R^^J>HNSNU-S[E[%KOD
M3+00?'/JOHO!Q]B[KWV<K3TU332[<Q@JJ2*HHY5KL<@JIJN&G\U;1P"1IZJ"
M-_=>Z0G\NK^=#\3_ .8_OOL7I38FW>ZNA?DEU1B8=Q;X^-WR;V%'UINZ#%S-
M3I_%::CAKLC3U=#&];0B4"I6I@%53//31QU$+R>Z]T1+Y$_\*J/Y=GQ[[2W?
ML!NL?F-VKM/K7L;,=2]G=X];=(4T6S\+N/;U;+09#$/7;ASF!KJNMH)8A)*D
M..*R02124;U1?0/=>ZO V?\ ,WXS;X^)V*^<6%[9V[%\6\KUA+W .V,QYL+1
M4V!I(7EJJBMAJ8HZNCJ*)HIH:BEDIUJ8:F-Z9XA.IC]^Z]U5#T/_ ,*'?CC\
MD>Y>K^O^J?AW_,?S?47<?8FVNK]@?+N;XK3TG6=3D=VY"+&457/F6RIKJ/"-
M6RK%+5S8Q7IFU/4T\4"2S)[KW0E?S /Y[WQ<_EY_*#8OP]WQT9\Q._>^.PNM
MJ;M3 ;/^+74>'[-F;%U4V7B4>"OW3@JVHJECP65GDCI:.H$-- TTSQK[]U[H
MRW\OC^93LK^8A3=KS[2^,/S2^-4O4<^R8<G1?,/HV+IF7+KOI<JT$NWS3YK-
M0Y..C.(G6M'EC>F,U+J0K4(WOW7NK'??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW25WSOK976.SMS=A]D;NVUL'8.R\+D-R;PWKO+.4VVL5B\?B8VF
MJJ[(9"LEAI:.DIXE9Y)9941%!+,![]U[JH[JO_A0G_)T[H[LHOC[U]\V]C9#
ML?+[CCVAM]<ULO=FSL)D\I-6&@CH\;N?,X"@VW6O451B2E>/*M#6B6-J&2I1
MM0]U[H_OR\^9GQH^!W35?\@?ECVA1]2=28[/X':T^Z:K;N9W<[Y'<TC145)3
MXS 8[*Y:KFE*2.1!02>.*.6>71#%)(ONO=*OXV?)7H[Y?])[%^1?QO[ QO:/
M3'95%D:_9F]L705V(2J3$5M3CJQ)*/)TM#D:*II*^CJJ>>GJJ.&>&:)XY(U9
M2/?NO=%T^:?\TKX!_P O."A7Y>?)?8O5&>RV-CR^%V)XJ_>FYJVEFF-/'54V
MVL!1Y3./1R5"O&*HT"TJLDA>95CD9/=>Z37PD_F[_P NG^8GF,KM;XC?)K:G
M9>^,'CZW+97KK)8/-==;B2CQII!4UT.$W-C<1D:['T[UU(DE9203TJ22")IA
M(K*ONO=%T[(_X45?R:.HNX-X=#=B?-3"[=[/V!OO*=:;RP[=-=C9.BQ^:P=8
MV/K:2HSM%L^IP(2BK$DBJ*A<F::%DD,DRB-RONO=6H=&=_\ 2/R;ZXPW;_QZ
M[5V)W+UCGY:VFQ.^.N]QTVY\?+-C9#%4TQGII'$552R@I-!)HFA?TR(K<>_=
M>Z%[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T0C^81_,
MA^-O\M#JK;':GR*?L3))V!O&/KGK#875&PJKL#<.YMQ55)4UE-A,52QM3T25
MM7'2R)"U;D:.G>4I&9PS#W[KW1+/Y<7_  H#^$W\R;N[<7QEV+MGOGH?Y$X#
M%9O.P=2?(S8=%LZOR5)MP1/7MCIL9ELS2FKHH)DEFHJJ6EK/$LTT,$T%/-,G
MNO=.'SG_ )]?Q"^$7?5;\6H.N_DI\L?D3MO;=%O/L;JCXA]7P=K5^U,36I',
MM7N*2?*8RGH9!3U%',T"RR3115='+4+!%50R/[KW1J?BU_-3^#GRY^(>7^</
M7'=FWMM= ;.?*47:&X.TZJGZ^J-GU^$C@EJL9N:*KG,./KDBJZ1XPE3-%5)4
M4\E'-4)/$S^Z]T%/\O'^<_\ #C^:!V[\BNIOBBG:N=C^-T&UJS/]D[LVA1[8
MV[GJ?=U174U+4[;8Y:?.3PK+CZ@.<A@\<2NAXUD5@??NO= G\VOY^GQX^#/R
M,WG\:-Z?$;^8AW%NK8E!M.MS.]?C]\=,;O7:TC;PQ5'F(*>ARV3W7@WKI:>D
MKJ=:AH:1H8I_)3^5IH9D3W7NA!_EG?SO/C!_--[/[IZ?Z5ZD^4?4N_.A]NX'
M<N^</\C>N\%L5Q#GZN6C2&"/$;IW%.E7#+&#+%50TQT.K1F2T@3W7NK?\UF,
M=M[#Y;/YBH^SQ&#QE?F,I5^&2H\5-C(GGGD\<2O*^B)&;2B,QM95)('OW7NM
M7_,?\*Y_Y8N$WQM^@K.O/F9'TENC+S87 ?*>?H6*@V37/1G355-#'4YJ'=%;
M1T,JS0U BVZU:D\4BK1.@$A]U[JUSYW?S</AQ_+[ZIZB[.[4W/N7L6N^1,M!
M!\<^J^B\''V+NO?9RM/35--+MS&"JI(JBCE6NQR"JFJX:?S5M' )&GJH(W]U
M[I"?RZOYT/Q/_F/[[[%Z4V)MWNKH7Y)=48F'<6^/C=\F]A1]:;N@Q<S4Z?Q6
MFHX:[(T]70QO6T(E J5J8!54SSTT<=1"\GNO=(WY8?S\OY=_Q)^3G5OP]SV^
M-U=Q?('LKM/:74>2V3T)C,7O8;2R>\Z^FQM(V[Z^MS.(H,8(ZJKA$]+!45>4
MA6[OC[6O[KW5C/RN^5W1'PEZ(WS\D?DCOFDZ_P"INOZ2EFS>;FI9LE/+/DID
MIJ*@H**F22IKLA75,D<4$$4;.[M^$#,ONO=5+?%W_A11\-?DC\@NK_CIN7IO
MYA?%3='R =5^->Z/E9T@G6F W_YD#TZ[?R5-ELHK-6J\'VKSI%3SO/301U!J
MJB&G?W7NK]/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6OK\ZO^%(OP;^"O<_
M9'0V;ZR^6'?.^^D*O%4O?-3T-T]!E,-LPYRDIJZB3,YC<.8V[1F2NI:G73M2
MM44SF*=)*F)T"M[KW5DOQ?\ YCOQ$^6_Q E^<_5G:=!0?'3$8?>&7WSNW?\
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M%BH-DUST9TU530QU.:AW16T=#*LT-0(MNM6I/%(JT3H!(?=>ZNK^8_\ ,?\
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M<.?_ +MK-CL?%D\N(C75--0T=-#'! T_@B 9DC#N[-[KW6T[TO\ \R=ZG_\
M$:;$_P#=72^_=>ZU&]P5<'\Y3_A2UMC;--'C-T?#W^2WMW*9G.2S046=H,KV
M3D*J%7@21*EBDJ;KHL<"KQ3H%V?5QO'$]4K+[KW5NORF_P"%#/\ *^^&_P B
M]^?%3O7M?L+"=V=;Y';>)W/MC =);HW<BU&[<7C\Q014U7CL=/3U;3T.3HV
MB=O6_C_6"/?NO='#_F"_,[XS_P M;XW]N?+[O*FP= E/B*7!T>+Q>)ISG=ZY
MLPRPX';-,5C\]=-4R%HPTSFGH:7[BKJ'AI(9I%]U[K5'_E4?"+Y"_ S^19_.
M!^;'9.U_]!'>7S+^-W<':O7_ %]@:%]N2;7VKL39N[*K;%5'B2H. JYJS<^:
MJ:2C+/)28],8TICG,M/#[KW0T? ?:6VIO^$8W:!EPM!(<W\2OYA^[<L6AO\
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M['QG4M-G/XGA.[*/*^3<.9FI\;C_ .&82HR607S3+YVI%IH[RS(I]U[K;2^
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M66S^]ZBIS>*J\<E+A1A-NU]97HM70S9.H-28A$AI!$6US1JWNO=(CXE_S_\
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M5[!_O6)Z:JJ<;2_Q'&39FBP5558C;U0*A\-4R)48Z%Y\?51ZH3[KW2!^-O\
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MXS,SG+1)64]5_$H"\--CJ.JI9(Z)S5^Z]U;'\5.D/YK_ &7M[Y#=1_S<-U_
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M2QG(U\>[,7C9)\M19<TU53HD3P%(%#.&8V]U[JEB+^27_.M[A^*W7?\ *?\
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M3_[8OOW7NO?[*O\ SR/^]M/QE_\ 3;=)_P#;%]^Z]U[_ &5?^>1_WMI^,O\
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M;3\9?_3;=)_]L7W[KW7O]E7_ )Y'_>VGXR_^FVZ3_P"V+[]U[KW^RK_SR/\
MO;3\9?\ TVW2?_;%]^Z]U[_95_YY'_>VGXR_^FVZ3_[8OOW7NO?[*O\ SR/^
M]M/QE_\ 3;=)_P#;%]^Z]U[_ &5?^>1_WMI^,O\ Z;;I/_MB^_=>Z]_LJ_\
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M3_[8OOW7NO?[*O\ SR/^]M/QE_\ 3;=)_P#;%]^Z]U[_ &5?^>1_WMI^,O\
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MH:K)8B>OVO125%/%D:>AK<=634C.H\B0U\$A'"R*>??NO=)O^5_\H=_?-3X
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M]+M>./4%$R$^Z]T?KW[KW7O?NO=$%^*?\RCXO_,SOOY=?&[H_+[PR?97PC[
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M[I3?"3^:=\5OGMUOV]OGIZH[&VINKX]2O1]_=#=Q['DZZW]LRJ^TJ:R*ESN
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB@_.3YH=9_
MSX_9GOKLO$;KW>#N7:/7G7O6NP*"/*[@W;NSL.MCQVW]M82GFE@ADK\E62?J
MDE5(H(YIVN(M+>Z]T1K!_P SSY&]2=[?'CJS^81\&\9\1-B?+G?='U!T'W#M
M#Y.XOY!XY-\9N&HJL1LS>%-3[>V[)@<QG(8#%02TLF3HZBL5Z=9P%,H]U[JZ
M/W[KW5%?RY_GB;&^/WR+Z'^/W4_QS[3[[Q_8WSBZ@^"W;'?%2E;U5L#:.Z^U
MJ^>A;%8S<-?A:^/?&YL,M'D):[&XJ'[2B^UDI\AEJ*L>"GE]U[JPSYL?+27X
ME]?]>5^V>N9^X^X^]>Z-C_'?H#J:/==/L.#.[MW\E;501Y+.5%-7KAL+C<5B
M\KD<C6IC:V6"DHY3#1U,QCB;W7ND+\3/G*W=L?RGV?WQUYB/CEW5\)=Z8O9_
MR0VO'V-%V)MNBI\_M3&[SQNX\/N>3&8*2LV_7X')";R5F&H*BG>"H2> *B2R
M>Z]TM?@W\G]V_,CJ&M^151UD>MNF.Q=TY#*?%RHR^1J),YNGKX10+AMZYK&3
MT=+_  #^]4@J:[&X\O/,N(DH*BJ>*IJ9*:#W7NCF^_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JM
MSYE_S ,K\>^XNE_B?T#T-FOE1\Q._MO;PWULKJ*CWQ1]687#[7V&8XLENK>.
MZJVDR2X+"K5S1TM-XL36U%95!Z>&'6!J]U[ID^'7\PS=G=?R'[:^%7RD^/B_
M$[YD]3[!P?="=8T/:M'W5@MT;"W+7OBZ7=NU-R4N-PLM=14N3$=%D(*G#4DU
M'5R1Q$2:F*>Z]U9][]U[JDO%?S1/E%\EMT=I5'\M[X 0?*/HCJ+?6YNK\A\D
M.XODO0_%S;V[=P[*F6ES%+UY3S;6W5D-RXK&5RU-'-F9H:#&R54$L5'+5!)'
M3W7NA=[6^?WR$Q78_5OQ[Z,^&,/8GR=R?Q?P7RW^074O8_R%Q76='U]M_,59
MQ46WVW#AL-O.DW'O"OSU+F<?004E/%BYQC:FLDRL5/X1+[KW2AJ_YI?1[?RZ
M>KOYB&"V]O#.;=[VVKUTG2/3%+3PR[IW)O;MVJBPVW.OJ&&%YJ>3.UVY9EQS
MRI*]+ (YZZ204<$DJ^Z]T?GJRO['RO6VQ,IW!MW;&T.U,CM/!5_8>T]EY^;=
M>)QF8JZ>.3(8_'92HI:&;(TE'4M)#'4O1P&=4\OAC#!![KW2]]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6F7M2:@K/\ A9SVY%\@CBWCQWPW
MP$/PM7>24,9%0=E;4FK1MORA99:H2S=IL2FJI _B.DBG0A?=>Z'WYY?S._YU
M7\OOY5?&[;/;_7/\M',_%GY8?-K'?'_J2OV+BNR\[OF':N;W'2T])59MJS<V
M+PE)G_[NUL#22P4E12C(:RM(8 $/NO=-&[O^XPOJ_P#\9HY#_H;<7OW7NB ?
MRE_A#U'_ ,*,]M?,G^81_,6[ [S['WA_LU>^.I_CIL3#]OY#:%!U?A,9@MNY
MVA?;N-QC0T5-,L.;QE,"T3P5$N)^ZJ8JBLFJ:B7W7NE!\/N^/D!V'_PGK_GC
M]!_(#N#-=^Y#X79CY4_''87;.Y*B:OKLC@-K8&G$$4M745-74U,$56M9-3&:
MJGEAIJF.F\\D4,.GW7NB:4_\HC9\_P#PG5V%_,VE^3?R3D^8/3/3%'WKT5NY
MNU,E@\'L;!8;,PT3;*VIA::LCBQ%-/BZ>1S6TU1%6SYB05A/B8T+>Z]U:#\E
MN_?@Q\M?A]_*5SW\S'=GSA^0O?O?_P ,Z;=V!^ _PA.YLI5=IY/+8[#5&6W%
ME]M[6?'/5UPJ,/5+0K49^AI_WLD8HWBI9Y*7W7N@7_X3>=STNP?YOO\ ,*^#
M/2G6GRW^/7P_I/C]B^[>IOBM\QI\I@-T]?UVU\KLNGKJ>JVQD\AF#B)L]5;\
MR=8)4R!FJJ%<=+5M4R,CP^Z]T='_ (2_?\S,_G<?^-+NQ/\ W8;@]^Z]T%'_
M  MA_P"W<WQC_P#%U]M_^\+OGW[KW4KO#X^?S:OYVORT^"64^3/P+P'\M?XK
M?"[O+$=Y[TR&]N^<)WSN'<U7CJO'US8_#IB:+%31_<0XB.B'DQ\=-3FL>MFJ
M*MJ:.B;W7NBG8WX(0?S2_P"?K_.'^*7?'?O>6UOB1M&JZ;[9W_TKUEO [?BW
M1FL+@,)CMM+5SU$59#38_#39&NKG@2D9:FKBH9'&JEADC]U[I.?S.N^-K]\?
MSM-W_P O#Y,=!?S$OF;\%/A/\6>N*:E^'GP0P&2WQE-Q[GW!A=EYZ'>F\,7M
MS,[5K9\-CJ;<U#2-5MD?\CR%-01TD<,>1JQ+[KW2$ZB^*WR][J^&'\ZCXM=;
M="?S(/C=\)]I;$ZW^2O\MO8OS1V9G.L]V[<W#TQIS68V=@I,O6UTST6:BHY:
M&*"GS553)$E/4WI\A45AD]U[I>?([YT]A_S/_P"55_(J^$776^=X4W>_S[[C
MVIU)\A=QXNI%%G8L/\1JE-M;USU34PS&FA%=5-2;BY):HI87'VZGRTR^Z]U8
M1_-VVY_*5WC\O*/H7Y,[/_F7_/KN_:'Q[ZR7 ?R[_A-#O'L;';:V_MJHK4IM
MU383;]?MZBCS%7%DJ>6LFK=Q22K2PT$AIXQ54_W?NO= #_PF/[_W;N[I[^<W
M\6Y%[QQ737Q<[ DE^/\ U]\B,S656Z=E[<[!HM_8>EV5DL96RU38&LV_2;'H
M$K*"&K:GAR$E8$B1Q))/[KW55/3WS6[C^$O_  DDP^>Z'W;N3KWL;OOYZ;X^
M.='V)L_(C#Y3"4.YZ7*[ARU305:@ST=368S:]5CTJ*=XZJF^\^XIIH9HTE7W
M7NA@VKUEENBOD/\ !GM/^4=_+(_GQ?&[OW'?(3K>+YF=B?*?HC=V'VEV;LW)
MNPW5/NZHK-S[FQ(K:V::IE8O04-'"E745<$D%?!1N/=>Z-KLCX9+_,F_G\_S
ME?B_W;\A/D#M3XI;;'4/8?87175&_JC9=)O*NBVYB,/B:/,5T;2318.@CRF1
MGGH((ECKZG[*6H<?80@^Z]TH?Y$_R([0^#?3O_"C7X]G>NZ>W.I?Y1&\.V]R
M_'NCWYEY<UD$@ZVINVJ2HQX>21*&DH*Z/K/#SBDI**DIHZRIKYUC'W)5/=>Z
M=?Y)G\I'J;^8S\1>G_YL'RD^0'R>WE\_>VNV.SNP,+\@,%W?D<+D=JKUMO7,
M8&GPE#14Y2ABQ=;%B*QYZ-H?$M%DY*2C%)3>%(_=>Z(GW1W]U9_,2_FO_P S
MW;/S_P#AM_-0_F%=!_$OMN;X[?&_X]? O96<[$VYL*HZ]RVYMM9+<VXZ/;NY
MMJ_89?<-3@JNJQE1.]5)6+-D:>I+P8^EBC]U[K8D_P"$V57\R\5\9?D3UI\I
MNOOEML;KCKSY,;NI_AVGS6V=D=F;[7K;.1K+B\5D8,MKKI1B9(G)+5-5##)5
M24M%4R4,%,D?NO=5\_\ "N^K=MQ?R?,+V5'2+\2<C\O]QU?R(KLNT<>.B:AG
MV;%0+7.[ADA?;-7OMF(C9/%'*792$#^Z]UN:4:TBTE*N/%,M M- M$M&%$(A
M"CQB()Z!&$TZ=/ITVMQ[]U[K25_F=[:_D]]_?+SY?[7[0ZB_FX?S2_DMLG.T
M2;_ZV^(>#WAVQMCI*IJMNTU!1TV.I*#);:VWBZ.*7&O)4ZY<J?XC+603*S4]
M3!3>Z]T2SXF[V_FA?S"_^$NW9>QOB]OGM_L/OCI/YMYOJS<LN/[#R&3WMNKK
M7#X?";KKL'BLM45U)D3)25^[Z!10BMJ'J<1C9L93QR+4PT:>Z]U8E_*I^3/\
MJ3XQ]+_S$]^_!?H7Y._#GY8_&;X:]I=X=_\ P/\ DQO3<U353_Z&\%)FDS])
MC]R9+*0S3BIAH*2:KC3'SQ0U].M5C(()Z3W[KW5 735)AOEU\&=S?*O>WPE_
MGO\ RB_FX=B2]M;LZ@_F-=$]7[QWAL3%YS$YW+TV QFV\S@=UTE)!MK'O$])
MDHZ/:S2XNJDR-)CHDBI8(O?NO=?1;_EP[J^1&]?@A\3]R?+7 ;GVU\E:_I+9
M$/=>+WKAUV]F#G\92K25U7DZ!(H$HZ_(O *N>%8(ECDG9!%&!H7W7NM:'Y5;
M3C_G!?\ "BKMO^5Y\E^Q>T,=\(/AE\3<'VQDN@-D;^J=@XO>^Y=P4FP,R*K,
M-C3#5U[TS;[QCQ"2;R4HPI:B:F%56-4>Z]TDOC#\4X/C-_./^6/\D#:7=_=V
M4_ET?(;X.4_=FV>J(^T,HV8Z]KH\AA%\.WMPR54]=BIFGILJ?)"(3-1U](E0
MDU12I5O[KW6+_A)U\+.J:"M^9OR8AW'VV^_NE/F[\@?CYM3#3]EU\VWJG")A
M\ 15Y;"$_:9+._Y5)?(2#SD!!>R@>_=>ZM _X56_]N/?E=_X='QQ_P#?C[5]
M^Z]U1?4]1?S>?YR7\L;^7;_+IP'P(VW\1_B?M/J'X?Y?/?-CL[OG#=C1;EVM
MUKM#&8W#9_"[5HJ/&9?'RY:@G7+)C0]7,W[=#/7TD9EJ']U[H7/G1\3,S\K?
M^%%W6W\O?_3_ -P]1_'#?/\ +4Z_VOWCB.M-QG"UNY]G];U.9K9=M^0K)2T:
MYNJQN.AK*A:5F:B-73:'BJ9(G]U[I>_S$NJ:?-_S&OY._P#PG,V?VYW/UE\#
M9OC?F-]]M8_;^_4V]EMZ83:V/W_'B]L9W+T5+2SUE*]#U_74+0&):>=LL)WA
MDK*:DGI_=>Z><)\;*#^2E_/=_EU?'#X0]E=C;>^'WSSV/VGB.U_BSNS?.4W_
M (NCRFQ\?E91GZ0Y.MJ)*>2HJ'Q,T,H05$<E%7Q-434M6::'W7NJS.G]C=#_
M !0^:._Z_P#X4.]._-/:'R]WA\NLGN'XX_S2\)V3NW&]>4F*J98GPF,QU?C=
MP28C'8=:N',5J0FBR:T&,JQ0Y"EQM-13W]U[H<_YF7P)Z7[+_P"%5/PQZ4S&
M[.Z:?9WRZZ RG=/8^6VYVWD</EJ')U4?<(\&ULK 1/M_$%=K8XBDICXOW:P\
M_=R7]U[JWK^;[L;^5[U\/A#\2/EKN?\ F"=^UVU^B-P=;]!_R^_BCN+=W86>
M[+QNS*7#4D>9W/0X&6@K\_F:6FV^T%-4Y#<5&*EY,G.1-X*F:F]U[JL?_A/;
MO_"P_P T_P#F9_RY>JNN_F/\</A5N3XMU'8O7/Q?^5^4RVSMZ==S4U7M#&92
M+^ 9"OS#X"OS<O865KHJF/(&>:D3&SU+5,AC>'W7N@D_D _RYNB]\_S=?YMU
M!FMV=\0P?R_OF_A:KI8XCN?+XE\J_7W9G84=#_?AX75MWB0;9Q[5*UI(J&DJ
M_("*J4'W7NB3?'GNCJ7^:FORZ^6?SL^#?\Z7YT]T[F[VWYC/BKV/\)NMMP=F
M;)Z7Q-/CL77X#!X=\)NO;N+Q^Y<1+4T$U7228JICDIH<=D)/)65M1,_NO=;K
M?\@;</S3SG\L+HR@^?.V>X-M_(39^0WMLRJ;OO!5VW=VUV!PN2F.W:S-4^3A
M@R;5,>*F@I/-61"LJ$I5GJGEJ)))I/=>ZI4I:FGR/_"T+<4'?<.+@I\'\2<9
M3?#ML^8$,\C]?8RHJWQ@+L7JEJJOLT+=4D BJ"BZ51V]U[K=&]^Z]U\Y_P#F
M.47\I+LW9OS?[CZ+ZW_G _S ?E+U5N/Y!YS'_/[8M!O7?/774F^,!6U>?H:6
MLW&V4V_@,)L_;=7+3F*:DPE<L6)I$K(:A]5/53>Z]TX_+_Y4_([OK^0[_P )
M^NZJ7N;?FR^^]P_-''];+W))GJC=V7-?U1E][[(QV?R4E5)"V<J9$P=-65,-
M;)(*IV>*JEGUR2O[KW0[?+/X54?\D_\ G$?R2>P_BWW_ /(W>VY_G;\@*;HC
MY79GO7M2NW_4;V1-R;#VQE<OG'3[)JZKR&.["J98X:F2>CHZW'X^JIZ=98I#
M-[KW1F_E?L:C_G#_ /"C#MC^6+\FNP>SJ#X4_"SXEX/M>IZ&V7OZHV+C-Y;F
MW#1;$RWWV2- 8ZBKG@_T@8]HRTGEITPQ%*T"5%6:CW7N@U_G@PY3^5'\<?Y<
M7\L'XQ=B?,W(="?+/Y:[ODW9ANK-YU6_>S?]'FQZ[9-)4=3;"JGEI\I4_P 0
MFW9#'A<?%70&>2GAQE3-+35,ZS>Z]T@?@5L/<?0?\USX8UW\K3^7!_.%^$?P
M[WO3[\V9\[^O?F?TQNO:FQLE#7X]8L+N2.JS>X=UT<62HJI8YI)FK:.HC:EI
MX*)7IJJN@;W7NL.-^"$'\TO^?K_.'^*7?'?O>6UOB1M&JZ;[9W_TKUEO [?B
MW1FL+@,)CMM+5SU$59#38_#39&NKG@2D9:FKBH9'&JEADC]U[K>PVQ@*/:>V
MMO;6QTM3-C]M8/$X"AFK7229X<-3QT\33-&D:-*R1J6*QJI:Y"J.![KW3Y[]
MU[KWOW7NO>_=>Z][]U[KWOW7NBS_ "HQWS#R?7V+@^%&[?CCL[M)-SP39K(?
M)W8FY=_X*7#+15PEIZ6EVOG]O5]/DWR+8UDJ)*F>!*=*E&II))(VC]U[JCW^
M5CD=Z=)?S3/G-T/\[J&GS'\S/Y&]2]<?)VH[FV#O27<?7FY^J.O*V79V!QFS
M<+/A\/6;)3;^0:HCGQE<<C65;M+5OE:L1%O?NO=6N_S2/A4/YB'P&^27P\AS
MU#M?,=O[0Q<>TMQ97[C[.CSNR<OCMQX&>M%+^^U$N8Q%$*@(KL83):.3]#>Z
M]UKU?S;N\/YK>8_E ?*OJ3Y4?R_OCCTYM+ ]9['V'OKOU/F?!V#1[DJ%RNUJ
M7%5>Q=DXK9\F8&6S.XIX:>BH<MDJ+[:HC4^:I5XBWNO=7'=J?!COROW_ -;_
M "_^.7RBV=\8^]E^%NV_BIWS5]O]-S]Z;<R.V]NSR;@H,M%01;NV7)B=R;6R
M]?G)8*QZ^:EG@K)8:VE=(HV3W7NJ=/C7F\3UA7_R^LETIU3E?D+U;L_*;N^'
M'\E7J#LO?(ZKH-V5FP=KYK,=I?)G?65.(R<>/ILUC\1EJ;;$]!M>OFBQ-5)6
MT%,L.X2U-[KW6QU\'?E]+\NMC=IR[HZVJ>F^Z/CQWGO?XV_(+JI]RKO:EQ&Z
M]B4^.KY&P^=6BQ@SN RN(S&)R&.K_P"&TCRP50CGIJ>IAGAC]U[HZOOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>ZUCOE=\_?A1VC_-<Q?17RU^3?2?1_QU_EEU6Q.WI-E=L[XI-K
MR[][QW=0R5NW:A:"L>-JG!=5X*IAR$4Y1HY=PY*E:)BV*>WNO=.?_"<+Y4_&
M[L/K3Y:=*[%[OZSW;VUD/G?\XN^Z'KO ;LI,EEIME[EWG2QT&Z(Z.*1I7PM6
M]?0B*J"F-ON(;&TB7]U[H1O^%#,]<FU/Y2E---7Q[+K_ .=Y\!Z;L..G\GVL
MN,6;<<GCR2QD+)1?<I X24^,SI W^=6(CW7NG7_A312[EK?Y5>[*;K^9:;M>
M;Y(?$2'IZK\4<TD.YY^Q,!'BY85EBF4R(SR&WA>ZZ@R,A93[KW2B^>7\OO,4
MC?S!.[</\U]J?%SXH_-?IS#4O\PO#;^Z</9%73X?K3:LFU,QGMB;ADW5A:/:
M>6S6Q8HL74_>X+-TRS4]/6P43U.N&;W7NB@?'SM?NS#_ "7ZJ[!V3\3J/M#Y
M;=^?%+=.=^&?QT[E[<FZ&PW2/Q=Z4R&W<-BQG<E-M_=>1H^R.S,ME<-6Y:"G
MVW<&*DQ%;64\6$#S^Z]U?Q\*?E=M'YM?&CK?Y);-V[N#9=%O<;KP^>V)NL1_
MQ/ 9_KK-Y';6Y<%7-"3#--B,_B,E2B>/]JI2)*F&\,T9/NO=&H]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI)_.+L
M*/\ DW?\*2Z?^9A\@ML[P;X4_.WH'$]-[Q[LQ6#J=P46U,YM[;V Q$M!]KC*
M.MKJJLA_T?[?K32>))ZBBR-944+538ZII5]U[JN+^:7M+^2\_P X_P"71WI_
M+4[,ZZ[$^0G?'\RO8O9GR0R>PNZ,_P!E.Z;TW?B<P]948_(Y*LH<*:C-UE2Z
MQ004[H3XQ&L:!1[KW5W>[O\ N,+ZO_\ &:.0_P"AMQ>_=>Z);_PF^^;?Q6_E
MV=/_ ,Q/XW?S%^^.M/C[\N=F?-CL?>G;,/<F9?:^1W%1RX+#X[R8PY"FIGW
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MT<--4YK*?:104PKLE-&\\PBB5 [D*+"_OW7NJ9_Y@O\ )EWG\D?ESL+^8/\
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M#C=O8RKKJ>7*30Y#*+]RCTT*I6S$TDE3:K]^Z]T6WNC^0G\S/ENFT>B?FO\
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M8ZB!VE0RQ*DJL64<:E /*_XCCW[KW7%ZRDC$A>JID$+*DQ>=5T%_H&N?23^
M??NO==I5TLAB$=33N9]9@"3*VOQ7U:+'U:;&]OI^??NO=>>KI8S*)*FG0P:#
M.'F5='EMIUW/IU7%K_7\>_=>ZZ2LI)!&4JJ9Q,S)"4G5M93ZA;'U$?D#W[KW
M7-JFG1I$>H@1XH_+*K2JI5?]4P)N%_Q/'OW7NL:UU"RJZUE*R/+X4=:A""Y
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MM==)X^MN/>]1ZUI'2JKMD[6R5-MFCKL1!44VSJ_%Y/;432RJ*2?"J%I9$*R
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M>TCJ=0]=[,QN"S^VJ+!4]/@]T5>1KL]CUGF9:F7+(D50[LTA=3*D: Z64"W
M!]^KUZG3/4].=:5=9MS(5.U*.6LVE0XS&[<G-54@TL&&E>>EC0"<!A#*[,"X
M8DGU$CCW[4>O:1THZ39.UZ%-T)28B&%=YSU53N<+-*?NY*Y&CE9[R'071F'H
MT@7XM[]7KU.DK6=)]6Y"EP%%6;0HIZ7:\$E-@86JZI13)+,9V5")P6O,Q;U%
MC?CZ<>]ZCUK2.EIC-K8##YC/Y_&XV*DS&Z7Q\F?KDDD9JEL4CQTY=6=D7QI(
MX&E5O?F_O5>MTZ0]9T=U3D,/A<!6;.H9\/MU\G)A:%JNJ58&S+I)5%6$X=O,
M\:$ZF-K>FW/O>H]:TCI8XS9VVL-F*S/XS%0TF7R&.QV)K*U)979Z?$HL=/$5
M9V0")%4 A03;DD^]5KUNE.DK7]+]8Y/%KA:_:5%4XM,S7[@6C>JJ545F3 6>
M>ZSAM4@47&K2/P![WJ/6M(Z4>)V)M+!92CS6)PL%'E,?MBCV;1U<<TKLF,H&
MC:&D >1E*(T49#%2YMRQY]ZKUNG3'D^H.M\Q0Y/&Y+:U'5T.9W//O+)T[U-2
MHER=2DD<E6Q696#LDL@T@A/5POT]^U'KVD=3QUGL88E\&-O4PQ4FWX]K/1_<
M3Z3CXIFJ%IK^75H$SLU]6JYMJMQ[]4]>H.EU[UUOKWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[H-^W.X.L.A>O=Q=K=R;YV]USUUM2"FGW!N
MW=%<N/I*<5LT=-3H6-WDGJ:F:*&&&-'EFE=(HD=V52JLK*;<95A@1I':NE5%
M2: D_L )/H,GIBYNH[-#)*RHB\68@ 5-.)]2:#Y]%)^.W\T'X0_*?LC_ $0=
M/=S??]EU.)_C^#V;O'8NXNL:W+4(ADJ358:+<F*Q1RB+312S,M/Y)5@1YVC$
M*LX.MSY2W#9XO'GBI'7271XY%5J@48QL^DU-,TSCCT6V/,%IN,GA1/WTU!61
MXV*YR!(JU&/*O2S^1_\ , ^*'Q2W-B=B]R=FS4/86;PC;EQW76S-EY[M#/'&
MJ\D7\2J,5MO&Y6KH<>TL4J)4U4<$$CHZ1R,RL GVSER\WA#)!'V Z3([I&FK
M!TAI&4%J&M 2:9IT]>[S;[>P25N\C4$57D?3PKIC5B!44J12N*UZ%?X[?);H
MSY8]:X_MWX]]C8/LO8.0JYL:<OAQ-2RTM92I%)-09"AJXJ>OQM?#'/"[TU53
M13*DD<FC1(C,DW3:;C99C!=(T;C-#3(]014$8P02.G[&_AW.,30.'0^8]?0@
MY!]0:$=#?--#30RU%1+%3T]/%)-//-((D1(@69W9B%554$DDV Y/LO KTLZ+
M'T1\T/C'\G-]]N]<]!]M8+M/<G1=3MRC[+EVK25M;C*.3=?WOV2TN:-,N'RP
MD;'5BLU!75*1O$R2,K"WLVW'8;O:8HIKF-HUF#&/50,0M*U6NI?B%-0%0:BH
MZ+K/=K?<))(X'#M$5#Z:T!:M,TH>!K0FA%#GHT/LHZ,>O>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MF+<6UML[OH(L5NS;F"W1BX,EB\Q#C=Q8BGS=.E9@ZB.KHJI8:F.6-:FCJHHI
MH)0NN*5$DC974$.1RM":H2IH14$@T(H1CR(-#ZCJK('%& (P<BN1D?LZIM^5
MIPGR4_FF?!+J#JVAHLQO;X<9+>OR*^1/8&/IG8[5P6Y<9'18+;%3D8@%2NW;
M6^.1L:TPE-)%'6/$U/J)&^T:MKVB[GF)"702"%"1^HZN'9Z>D8%-5*:FTUKT
M&-PTWVXV\48!:#5-(U/@1D**M:<7)KIKP6OIT>OY,]]S_&FNQN[=I_#[O_Y'
M;HWMA<I2YC-?'386"W%5TD.S6A>AH\]55^8Q60\,[Y*I:AC@@K=.BK(CC8@2
MA[:MN&Z H]S# %(H)VD ):M2NE'&-(K6GEQ\C>_O#8T98992P-?""$C32E=;
MH<UQ2OGP\R!_R0_X%N#8OR][<.9VYA.QN]?EKV!VKV;\><-B<EMVLZRJ]P:1
M3;8S=#EZ#%UHS CCD>IJ%H(Z2H<$4KRB)W]B3G[5'+;049DAMHXHYBRLMP%)
MJZE2PTU-%%20!FAQT2\I /'-+@-+.\CQ %3"2 -+!@#JH*L: $FHJ,FW?M[J
M/8'>_7.Y>INT\))N;K[>4-!2;IVZF7K<(E=3X^KIZW[2HGQ]12U+4=1)31I4
MP"815-.TE-.LD$LL;@NSO)-OE6:$Z77*M0'2:$5%0<BM0>(-"*$ ]"6XMTNT
M,<@JK889H1Z&GD?,<",''50?\OW:>UMB?S6_YP^SMD[<P>T=I[<P_P#+\Q>
MVSMK%082@HJ:FZ^K!'!2TE,D<$$2_A40#ZFUS['/,TKS[+M;N2S,;XEF))),
MXR2>/04V.-8MTW!5   M  !0 >"?3J\7W'G0RZ][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*)\Y]R
M?*_;'QIW_5?"?KK%]E?(G(Q46"V7C,ON#%;>BQZYF3P56;1LU54.-JI\5"S3
M0TTU4B22A"ZS(K02G7+T-G-=H+^0QP5)=@K,305"]H)&HXJ :=%F[R7,5NYM
M$#RTHBDA14FE>X@8XTJ*\.JW_A!-\O?B]MK =9TG\J_M7^)[]WEC\]WY\C-\
M?+OK#<F<W!F=QU"+F-VY\TV3GKZTP++-+#1PM(8*=%I:8,UVD$^_K9[JS3'<
M(:(A$,"6]RJ(B@Z8TK& /M/$G4QZ)MJ:XL (Q:2]S5DE>6W+,QI5VI(2?L P
M!110 ='E[V^0/S/Z@[1R&.V#\'*SY+=*U^(Q]1MO>W6'=>W=HYVBR'@1:FAS
M.!W--CUDADJBYAJZ*LE1(!^_$L@ </[=MMC>Q5DNQ!*#0I)%(R%?56B#Y]0P
M&>!/D:WE[<VLE$MS*A&&21 P/H5D*8]""?.H'F#?P!^.G?\ MWO#YF_-7Y(;
M$VWT[V9\O,SU9#AN@=L;PI-[+MS"=/8:3&4'\8S>/@BQ^0SF2>9GJ'IQ+%&$
MUK)>=H(##F3=+:6WM;"U=I8[42UF92GB/*^HZ58DA!04K0G-1TCV6PFCFN+N
M=0CSF.D88-H6--(U$  L236E0,4)Z'_J#MSYGU?Q0R?9O=WQ6PU'\HL;5;G^
MT^.77W9V&I8<C#09)J?'"#<%?DJS$4DE7C[5+&:O(L-)6.1Q$I7?65BMX(;>
MX)@.G]=XW%*J"U4"ZL'&!^WI?:W-RUOXDT-)1J_25U-:$@48D#(SDCCFG57_
M ,8Q_,4ZX^>_R]^26Z_Y:^\<=LGYFY?XPXJHB'R?ZTJI=HTG3N$.WJ_(58@S
M,LF7CD2HDJUBIX8I0D7A42.X(&.\';+K;+6TCOD+VHN3_87 $IE?Q !6,4X4
MJ<9KPZ#>VK>V]_<7#VKA+@P ?JP$H(TT$FDAKQKBI^5>MAOW&/0XZ][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z _Y 8SY YS8T&"^-VY^O
M-B[ZS6X,?CLIO[L?"U6ZH,'AY8JAJW)8W#4[0QYC,QR+31TM+55=-2$R/+/*
MRQ"&4PVQ[6.35=K(Z $A(R%+MB@+$'2O$D@$XH!FH17ZW#QZ;9D1R0-;J6"K
MYD*"NH^0!(&:DXH:]_Y0^X>S\IM?YM[8[4[>[#[JS/5GS[[WZJQ&\NQ]P3YN
MK;'[*I\+3PI!%)(]-C::24SSBCI(XJ6%YG$,2+8>Q9SY##&]F\$4<(DL8)2D
M:@#4Y<FOF3P&IB6-,D]!CDJ661+M9I'E,=[/&&D-3I4(!\@.)HH %< = E_-
MF[Y[CWAB.W^E/C5V5O#JZC^+W3&4^1GR5[5ZYW!4[=R-/534\R;*V'3Y&BEB
MJ:2JS4WERM>$D1OX=21)Y )VC==R/MUO;O#<7D:2_43+;V\4BAE(J/$E(."%
M%$6OXF)_#TEYPO9IXY8+:1X_ A:>:2,Z6!"GPXP1D%B-34R%4#\?5O/QJS&5
MW#\<N@,_GLE79G.9SI/JK,9G+Y.J>NJ:NKR>"H)JBIJ)I"TDT\\SN\CLQ9W8
MLQ))/L";H@CNIE4  2R  8  <@ =#2Q8O!&Q-240DGB25'3)\D.E-Z]\[2P>
MR-J]_P#9WQ\Q/]Y(<AOG/=.-28G<65Q<5-4QG$T&<J(YYMOM)5R4T[5E+ ]1
MI@\*E4E<^W=IW"/;)#(\,<YTT19:F-6J#J*@C7@$:3C-36G3&Y6+[@@C662$
M5JQBH'9:$:0Q!TY(-5[L8(ZK;Z9PO9OQ._F5[2^+.W_D7W;WWTIW%\<=W=NY
MS:7?N]Y^T\QM7([5R*4--D:/,U$25$&+R31_;I3L1&9GF9]<G@919N$L.][0
MUZ\$,,T5PD0>!!$DJNK,05&-2\:^E/GT&[&.3:-S%JLTLL4L#RE)G,CQLC(M
M0S9TM6E#Y@GJZOW'_0UZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NL%54P45-45E5*L%-202U-3,YLJ1P*6=C_@J@D^_=>Z1_P#I(V+_
M ,]/C/\ J8W_ $;[]U[KW^DC8O\ ST^,_P"IC?\ 1OOW7NO?Z2-B_P#/3XS_
M *F-_P!&^_=>Z]_I(V+_ ,]/C/\ J8W_ $;[]U[J50[[VADJN"AH<_05574N
M(Z>GB<EF8\V'I^O'OW7NE;[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[I+;OWQLKKW#G<._MX;6V/@!4P41SF[]P4FVJ,35.KQPFIK9
MH(?+)I;2NO4UC8&Q]NPP27+:8U9CQHH+']@KTW)*L(U.0H]20!_/JEK^5+V[
MUX<G_,6VY@>R.LJK?F]?YD7RKW-UIMBMWO0)-FX,A%CI<?6T5/'4FJKL95&G
MD(J*:.1&CCE:-CH-I#YYLI:6#LCA%V^U5VT&BD:J@FE 17@?ET!>3+F.M\H9
M=37]R5&H58'30C-2#3B.BE=M]8_S"OC_ /R_?E_MKM'I+X_9J+M+#=L=G?(7
MO*E[RR&2W!DZ[>#M)/708O\ N^E.4QU&M)14-$*M(8J:GC0.I+N3FPO-JW/=
M;1X9IU\-H8X(3 H152E 6\6O<:LS4J22:=%E]:[EM^V72RQ0-K2:2:43N68N
M#4A3"/A%%5=6% %>K9?BWWUENF/@5UYVY\QX^NND-E[)V#U7C<+N#;^ZJ[>M
M+/MS(XC;]!@LCD ,73U%+E,A6UGBDHX8*A8CXV$I#,$!&[[8NX;D\&W^),SO
M(2K($;6&=F H[54 5J2*YQZC#;K]K*Q6:^\.%55!4.6720H4DE$H232F?+.>
MA8^7?S6ZI^(_2=%VWN*KAW+D=ZR8_"]-[*QU?'15.Z<QGXEDQU'33S#Q4M(Z
MR1RU-9,!#2P7=]3M%%(BV/8)M]N# @TA 6E<@D1HOQ$TR:>0&2<#I5N^\Q;/
M")7R6(6-00#([?"HK@5\R< 9/1;/@E@^L<-O7>O>';GR,Z.[7^;?R9..&\L=
ML?M'#;AIMOXG"H\V,V)M&CIZ^>=L7AH%O4RQJSU]3$U5,T@CCD]FO,<\LL:6
MT$$L=I;UT%XV4NS4#2R$CXF/ <%%%'GT7;';I$[W$TJ27,]->EP515KIC05^
M%:FIXL:L?("UGV#>A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=)K>?_'G[L_\ #:SO_N++[]U[JOSW[KW7O?NO=>]^Z]U[W[KW2XZU
M_P"/[VS_ -K)/^A6]^Z]T?#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]T&_;H[9?KG<\71C;$B[6J*:DI=GU?9C5O\  Z:6KJ8(
MZBLKX\<C5M0M%1O4SQT\9C^YFCC@::!)&FC567@^*OU&OPZU81TUD ' U8%3
M05-: UH:4*>[\4QMX&G73M+UT@UXD#)H,TQ7A45J*I_Y=]?WOA/G3_,FZ@[N
M^0>^N_JKK.E^)]9CLKN*23!XFEJ^PMMY+,93^ [:AJ9\7MZB>>>.)(*8:FAI
MX342SS!Y6''-:6S[9M\]M D/B?5 A>YB$D5%UN0&<T%:G%2: #'0.Y:>X7<;
M^&>9Y?#^FH3A07C9FTH"0HKY#- *EC4DP'R4^)%+OW)]H]L=M_.WY1=.[1@Q
M35NT\5U;W''T1MW9M#BJ")9JN5*"-#FJHU,-152562J);+(:>&.)%N2C:-]-
MH(X8+.VE:M&,D/CO,2QH.XG2*$ ! /4DGHVW/9Q=&26:ZN(UIVB.7P4B 7)[
M::C45JY8#@ !UR_E.]M=Q]V_!GJ7?_>.5RNY=XUU5O+&8_>N<QC8FLSV&P>6
MJZ7$9BHA>.-F>KHHH[3$%JA46H9W>5G;W.UC;[=N4L5L J#02@.H(Y12RU^3
M$CY</+K7*5Y-?V$4LY+,=0UE=)=0[!6I_24 _/CY]#U\H/C!)\F\1M/$Q_(C
MY/?'IMJ9+)9$Y/XS=K'JRJR0R44<7@RLHH:W[RG@\>N%+)H=G-SJX+MEWG]S
M,S>!;SZ@!2XB\4+0UJHJ*'UZ7;OM/[V14\:>'2:U@D\-CBE":&H^7KU4AL7H
M3L;KO^:%TMT5U;\V_G9V]M3JKK?-=[?)RA[T^1%=V!ADI<KKQVUMO_804N.I
M'J\C5O\ <SQU*SWHS'-"JO&Q]CB[W6*\V::XFL[*)I)%AMS! (WJM'D:I+&@
M%%%*9-#T#[3:I+/=8H8KJ\E6.-I9Q-,72C52-: **DU;-<+PZV$_<6]2-U[W
M[KW7O?NO=>]^Z]T@^QNK.LNX=N-L[MKKO8_9^TFKJ7)MMCL':E#O+'_<T.KP
MU'V>1@J*?SPAW"2>/6H9@" QNIM+V:P?Q()'C>A&I&9&H>(JI!Z3W5I%>IX<
MR)(IH2KJ&6HX88$=!3LOX:_$7KC<^(WMU[\7/CSL;>6 GEJ<%NS:'3.W=N9*
MBDFC>%Y*6MH\=#4T[M#)(A:.1259EO8D>UUSS!?WB&.:YG=&^)7FD930UR"Q
M!R*](K?8K*T<216\*..#+$BL*BF"%!&#3H<]U;4VQOG;F;V=O3;N$W;M/<N-
MJL/N';.Y,7#FJ"NI*U2DU-5TE2DD%1!*I(9'1E(^H]EL,SVSB2-BK*05920R
MD9!!&01T8RQ+.I1P&5@0RL 00<$$'!!Z3NY^I>K=Z]>GJ7>/7&QMU=6MCL+B
M#USN':M#F<']KMMX)<=3_P *J()*(0T$M+2O3IX-,+PQ-&%,:D.P7TUM+X\<
MCK)4GQ%8J]6J"=0(.:FN<U/34UG%<Q^#(B-'@:&4,E%((P01B@IZ4Z:NQ^B>
MD>XL)A-M=M=/=7]G[=VU.M5MW ]@;"Q>\:.@D6'[</14V0I:B&E<0?MWB13H
M]'Z>/=[/<KC;V+V\LD;,*,T;LA(K6A*D$YSU6[V^"_4)/''(H-0KHK@&E*@,
M#3'2#V7\-?B+UQN?$;VZ]^+GQYV-O+ 3RU."W9M#IG;NW,E1231O"\E+6T>.
MAJ:=VADD0M'(I*LRWL2/:JYY@O[Q#'-<SNC?$KS2,IH:Y!8@Y%>DMOL5E:.)
M(K>%''!EB16%13!"@C!IT9+V4=&O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]TFMY_\ 'G[L_P##:SO_ +BR^_=>ZK\]^Z]U[W[KW7O?
MNO=>]^Z]TN.M?^/[VS_VLD_Z%;W[KW1\/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3-N'<>WMI8;(;CW7G<-MG;V)A%3E<]N'*
M086BIHRRIY*BJJ7B@A34RC4\@%R!>Y'N\<33,%0%B>  ))^P#JKN(P68@ <2
M30#]O5)7P_[QZ53^:;_-(R;]P=7+C>PF^%%!L'(-V!B5@SD^.V;/1U$.'E-7
MX\G+!5RQP2)3-(R3.L; .P4R+O\ 83_N3;1X<E4^L+C0U4!F!&K&*@5SY= /
M8[N+]\;B=:=WTFGN'=2(C&<YQCHQ?R'ZP_E5_*_>6]<C\@LQT/N/LOJ>AJ>N
M]Y9;/=LGK[/;;AVS/5S>&H,>7Q=50PTE37U,L4[IX6=]:2.H%B?:K[>MDC06
MOCK'*=: 1ZTD+ # *L&J% (^5.C?<;':MW=C<>"SQC0S%PKQ@5.2&!6FHD''
M&HZ#O^5IWOFH_B=W_O;M?LC+;J^/'0W>?>NW^C^\=\U,N1JLGU?U:(VH\K5U
MOB^XRD%%'#6HM3H:1_$U,%+4X7VLYSVQ1?0101A9YH(&FA04"W,O%0OX:U!T
M\!6OGTDY3W%FLYI)GU0Q33+%,QKJMXSABWG2A&KSIGU-CLOR%ZC_ - =?\FJ
M#>%!E>EZ+KS*=HIO*C5XH9\/BJ26L>HB2=(9=;Q1,$C>-9#):/2'-O82&V3_
M %(M"A$ID$>@\0Y.FG[>A,=PA\ W(8&+09-?EH U5_9T0_\ E/[!W-E^J^RO
MF?VC0M3]N_.OL&J[JKXZC1++CMHTXDI-C8-)E \M'0X4F>G8@-X:N-7&I"2)
MN=KE(YX]OA/Z5DG@BE:-+QE>AX$O@_9T'N4;=I(7OI1^I=OXQX56*E(EJ!D*
ME*?:>K6O8*Z%O7O?NO=>]^Z]U[W[KW1:>Y-W;EP&YZ"CPV8J\?2R8&EJ9(:=
M@ 9'J*I2QN#R511_L/?NO=!+_I*WW_STV2_Y+7_HWW[KW7O])6^_^>FR7_):
M_P#1OOW7NO?Z2M]_\]-DO^2U_P"C??NO=>_TE;[_ .>FR7_):_\ 1OOW7NI^
M*[%WO/E,;#+N3(O%-7T<4B,ZV*R2*"#Z?H03[]U[H\/OW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!KO[KC??;75N?Z_ZZ[FW
M1T#N+<%1A89.T-D8:AS68HJ"GK8)LE!C!D4DI:2LR%!'44L=889)*,S?<PHT
ML:>UNW7,=G,LDL2S*M?TW+!2:$"ND@D T-*BM*'!Z37<#W$91':,FG>H4L!4
M$TU BI&*T-*U&>J9-U=:=I?R_/G'\"MN=6_+WY2]Y;)^5^^]\]6]M=-_)SMF
MJ[O:>DVMAFR1W1AJBKIXI<3-C'D\E:T*JLMX 2L EC(ZBO(N9=OO&FMK>)[9
M$DCEMXA#0M(J:&"X8&O;7(H>/06>VDV6\MQ'-,Z3,T;QS.TM=*,^M2V5(IW4
MP:CA3HT_\U'&_,*H^/W?.Y^D^\\'\?>GNK?C%VWVCNG<FS<=5UO86<SVSL5E
MLA38/%Y)GIZ/:>$$=%1/49.F>HRLQEEIZ84(053E/)S67U<*7$)FDDN(HU5B
M!"B,ZJ689+MDT4T44!;4#IZ7\RBZ^FE:&01(D,CDJ"96958@*:@(,"IH6-<:
M2*]&;_E];BW#N_X)_#C=F[<_F]U;IW-\8NCL_N/<VY<M49[(9"NR^V\=4559
M6UM5)+4U554SR/)+++*SN[%F8DW]E7,\20;E=(BA56XF554 *H$C   8  X
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MN>+HQMB1=K5%-24NSZOLQJW^!TTM74P1U%97QXY&K:A:*C>IGCIXS']S-''
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M.W>RV=\VN>"&1N&IXT9J>E2":=#+5;&V57;,K.N:S:&V*KK[(;>JMI5VQ:C
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M%'6S55(@R.-JGIJN&BHWDFA:1$\81W1M2D.[1<[KL\?CV7C)'(0"Z*61F2H
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M=3_7W4B"5ET10B12((R0:8-#(QH7;[%&!FZ'V NAAU[W[KW7O?NO=>]^Z]T
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M(O-/0U$<DM*1^E4 [J5&H^M>@IL&K<;F?<:%8Y D4-10O''J/B?8Y8Z:T.D
M\".AZ_FC[GS6T/Y>ORWS6 J9:/)GIS<.%6I@;QND&YVBQE648,A5OM*R<!@U
MU/(!( )=R;"L^ZVJN*CQD-#_ $3J'\QTNYJE:';;EE-#X+T(XBJD?Y>B-XCO
MKY^_#WXA=<]M5_Q?^+L?QBZ;ZFZU_C'6&S^XL]DM^TNW,?14---D%JI<%3;8
MEJH:=ONZA%FE<_N>N9[R$0MMFV;_ 'SP+<W'U$TLE)'A00M(22!02%P"< T_
M(=$G[PW#9+-93;P""*-*QI,QE6-0 2*Q*A*C)%<TP3U=OLW=>'WYM#:F^=NR
MRS[?WGMO![KP4\\7@=Z/<5+%64KNA)*.T$R$K<V/'N/9X6MW:-N*L5/VJ:'_
M  =#>*02J'7@P!'V$5Z4GMKJ_7O?NO=>]^Z]T#W<V>S& P.+J<-D)\?/-EQ!
M++3D LGAE;2;@\7 /^P]^Z]T7#_25OO_ )Z;)?\ ):_]&^_=>Z]_I*WW_P ]
M-DO^2U_Z-]^Z]U[_ $E;[_YZ;)?\EK_T;[]U[KW^DK??_/39+_DM?^C??NO=
M>_TE;[_YZ;)?\EK_ -&^_=>Z.7LVLJ:_:FWJVLF>HJZK$4,]1/)^IWD0%F-K
M<D^_=>Z4OOW7NO>_=>Z][]U[HL7R$_X&;7_ZALK_ -#0>_=>Z+I[]U[KWOW7
MNO>_=>Z][]U[KWOW7NK%L-_Q9\5_VK:'_K4OOW7NG+W[KW7O?NO=>]^Z]T4;
MOS_C\,;_ .&U1_\ N56>_=>Z!#W[KW7O?NO=>]^Z]U[W[KW3GA?^+SB?^UG0
M?];4]^Z]U8K[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NBN[.^:?Q?[#^16Y_BAL/M[;V\N^-E;.K-];LV9MBFK<
MW%CL?CJNDH:C[O,4]+)@X:ZGJ:ZD26A;)?>Q^52].JW(-YMAN[:T6]DB987?
M0KM0:F(+84G4113W4TXI6O1='NUO-<-:HX,JKK914T6H&2!0'(Q6N:TIU%^1
M?S;^,GQ3R6V-O]U]E+@]X;T@GK-J; VSM7-=D[BKZ:E9EEK(<!MK'9;+B@C:
M.56JGHUI]2.@E+J5]^VS8;K=PS0)55^)V9(XU)X O(RK4^0K7Y=;O=T@V\@2
MM0M\*JK.Y XD*@9J#S-*#I=?'OY)](?*KKV'M'H/?^+[!V:^2K,)65M%356*
MJ:'(8X(:C'9/&U\%+D<7D(%DC9Z>JI(90CH^C0Z,S&Y;7<;1+X-RA1J T-""
MIX%2"0P/D02#T[97T6X)XD+!EX>8((X@@T((\P0".A3W7NO;.Q=L[@WIO3<&
M&VGM#:>&R.X=S[GW#D8L108^@Q$3SU59654[I#3TU/"CO)([JJ*I)( ]HX87
MN'6.-2S,0JJH)9F)H  ,DD\!THDD6%2[D*J@DDF@ &223P Z(#U3_-M_E[]U
M=H;=Z>Z^^0V.KM\;RK*C';(ASVQ=T;(Q^<J::9:<T^%S.<PF.Q&3GDG=4@2G
MK9&J6(^V$P()$EYR9N=A"T\L)")37I>-V2HKWJCLR_/4!3SIT36W,EE=RB%)
M.YJZ*JZJ],=K,H5O]J37B*CJQWV%^CSKWOW7NO>_=>Z][]U[I$=D?\>+N?\
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MS?YGW\RS<?3./WSB.H.TMA?&'M2*DWGL#,=9K5YD8^NQU3G*+#YRCH*^&#.
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M='ZV#_QY6UO^U'CO^M:^_=>Z5WOW7NO>_=>Z][]U[HL7R$_X&;7_ .H;*_\
M0T'OW7NBZ>_=>Z][]U[KWOW7NO>_=>Z][]U[JQ;#?\6?%?\ :MH?^M2^_=>Z
M<O?NO=>]^Z]U[W[KW11N_/\ C\,;_P"&U1_^Y59[]U[H$/?NO=>]^Z]U[W[K
MW7O?NO=.>%_XO.)_[6=!_P!;4]^Z]U8K[]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z3V[I=U0;3W/-L6CP61WO#MW-
M2[.Q^Z*Z?%XR?*QTTIQT.1J:6"IJ:>@EJQ"M1+%32RQQ%WCC=P%+D(0NOB$A
M:C45 +!:YH"0":< 2/MZI)J"G30FAH":"OE6@./RZHJ^.E7\N=C?SF9^IOD?
M\GLYW(=U?RY\CW5E]C;2IJS86P,+EZWL*FPT%-M[:_WU3"ZXZAHVB3)UQFR=
M49YWFEC1TIXI%W-+*XV#Q[6W$6F_$0=B'F91 6.I](XD_"H"B@P34D&63W4.
M\>%/,9 ;,R%5!2)6\8+VIJ;@!\1)8U.0* 6'_*[X/S?*C<^UMS1?,#YO?&[^
M[&!J,$VW_BSWR>I<9D?/4-4"LR=(,97?=5Z:S&LWD6T05-/%R&-DYA_<JLOT
MUI/J(-;F'Q66@I13J%!Z]'NZ;-^]"I\>XAT@BD$OAAJ^O::D>75:7P(ZF[+V
MY_,Y^1FU=F_,CYJ]_P#QP^*W6&#Z^WXGR8[[K^UZ/)]C]C:*YZ*@I_!C\:L6
MW,1$5G8T<E3#7-H\JQ2A?8JYEW"*XVF!WM;2">XD:1/IX1&5@CJM3ECWL33(
M%%K3HAV2RD@W"54N+B6*) C>-*9 97HU!A1VK2IH35J5ZLF_F:?)7>GQ"^"W
MR'^0?7.-3);\V-M7$TNTC-0KDXJ.OWIE\=@:?*3T[AHYX,1)E!6O'(K1NL!2
M0&-F'L*\I[3'OFXP6LIHCL=6:555+D ^K:=(^9Z/N8-Q?:;*6X059%[12N20
MH)'H*U/R!ZK$^4'27?'P=^(>/^?/6WS,^4W<'>O3U+UMV3VQM[M+N*LW3L3?
M.,W1D<53;DQ@VG*DF)P=!X*Z27'M011RT<,02.1YBDR"K9[^WYAO?W;+;6\4
M,I>.-HX@)H6"MH/B"C.:@!M9(:OET2;E:S;-;&]CFEDDC"NX>0F.5:C6-&57
M%2I4 C]O6PAMS.T6Z-O8'<N-U_P[<6&Q>=H/* K>'+0)41:@"0&T2+>Q//N-
MI$,;%3Q!(/Y8Z&2MJ (\\]//NG5NO>_=>Z][]U[I$=D?\>+N?_M62?\ 0R^_
M=>Z(=[]U[KWOW7NO>_=>Z][]U[KWOW7NCT=6?\>!MO\ ZA:C_P!R)O?NO="!
M[]U[KWOW7NO>_=>Z1'9'_'B[G_[5DG_0R^_=>Z(=[]U[KWOW7NO>_=>Z][]U
M[I2[,_X_#:?_ (<N"_\ <J+W[KW5@?OW7NO>_=>Z][]U[KWOW7NDUO/_ (\_
M=G_AM9W_ -Q9??NO=5^>_=>Z][]U[KWOW7NO>_=>Z7'6O_'][9_[62?]"M[]
MU[H^'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>ZI5_FR?)#YY]$],]S=C] T&QNF.J^G8^LII>X\_
M-0;[W'NBLWQE\+C9*';NWZBDKL7B<9CY,L8ZRLRL;5,\D#QT-*D;+5^Y#Y%V
MC;-TN88;HO+)+XGZ2U2.,(CM5W!#,QTX5* 5!9N*] 7G3=-PVVVEFMM$21^'
M^H:.[EG1:*I!4 :LLU2:$!<ANK?<QF<UB=B93<.'V_7;VW%C-I5V9Q>UL?64
MN*J<O6T5&T\&/@J*IX*&FGKYU6%))I(X(VD#2,D8) "CC5Y K,$4L 6()"@F
ME2!4D#CBI].AL[%$+ %B 2%% 6('#-!GYT'52?Q_^0'SBR/\S6?H7Y,9CKO:
MNS-Q?"VO[_Q'1O6--3[AHL!5R;QI\#115VYZO'09;,9>*EAJS5O!-#C2\P2G
MIF6%9Y!UN>U;<FS?56@D9UO! 9I*J77P2YH@8JJU(I6K8J3F@!FW[E?MNYMK
MHHJ&T,PBC[@C>,$%7*AF-*UII7- ,:C<S[C_ *&_5>?=G1O\P3M#?V]\KUK\
MVMH_&OKNA2FINJ-G[,Z!Q'9M;5E:*G:6MW7D]REV68Y'[M$I\="D I3$SL\Z
ML"*=NW+:[*)%FLVN'.9&>=XP,G$8CIY4J6)-:T '0=O[#<+N1C%="!.$:I"C
MDX&7,E:YK0*%QQ)/3K_+:^2?8_RC^,6,WWV]1;=I^SMK[[[!ZKWMD-HC3B\C
M7=>9&2B;)4"7(2&KC$98*?&91(T2I&R1JWS9M,.SWABMRQC9(Y$#_&JR(&H?
MF*].<M[C+NEJ))PHD5Y(WT5TEHW*$BOD:5Z/O[#71]U[W[KW7O?NO=>]^Z]U
M7?VQ_*I^#'>&^=P]C]G]2[CW-NW=&XWW;EZT]W;\Q4!R+W_RJGH*+<U/043K
M=M IJ:)4N0BJ#;V*K#G3<=LC$4$BJJKI'Z,!.GT):,D_F3T'+[E.QW*0RS([
M,6#?VTP 88! 60 '[ .AYPGQ"Z"V[\?LI\7<3M3/0=*YF+)Q9#;<W9.YZRM<
M9>L^_GTYZ;,2;@BU50#CQY1=(_;6T9*$KDWNYENA>,R^*""#X<87 H.P)HX?
MT<\>/1C'M,$5N;4!O#(((,DA;N-3WEB__&L>71;-I?RB/@%L;>>+["VOT]NG
M&[QQ&:P6X*7-GOKL.LD>JVU+'/0O5+/NJ6.LC@>&.T4Z21%1H9"A*DXN.>=S
MNHC"\J%"&73X%N*!A0TI$*5KQ%#Y]%4')^WVTGC(CAZJ=7CSFI7A6LAU 4X&
MHICAT;O9_P <>F]A=T]L?(7:NT!C.W>[Z':>-[,W6<YD:W^(0[(I(Z''(M%4
M5<N/HO#30PJQI:6$S%%>77)=B17&[7%U;Q6KM6*$N8UHHTZSJ;( )J?4FGET
M<0;9!;3R7*+22;1XC58ZM TK@D@4'H!7SZSXWX]]18KO;<?R7I=IA^[-T[$Q
MG6>3WM69FOR#I@L3.M5'C:*CGJI*#'4\E2D<TWVM+$T\JAY6=KDZ;=)WMELR
MWZ*N9 @  UD4U$@5)I@5)H.'5EVZ%;@W07]5D$9<DDZ =6D5- *Y- *GC6@Z
M&CV7]+>O>_=>Z][]U[KWOW7N@_[3_P"/ W)_U"T__N1#[]U[HB_OW7NO>_=>
MZ][]U[KWOW7NO>_=>Z-ST'_QY^2_\.6L_P#<6C]^Z]T-_OW7NO>_=>Z][]U[
MH(^[?^/$J/\ M98[_H8^_=>Z)G[]U[KWOW7NO>_=>Z][]U[KWOW7NCO=0?\
M,N]O?^1;_P!SJGW[KW0E>_=>Z][]U[KWOW7N@'[^_P"/:PW_ &O!_P"X\WOW
M7NBG^_=>Z][]U[KWOW7NO>_=>Z][]U[H_6P?^/*VM_VH\=_UK7W[KW2N]^Z]
MU[W[KW7O?NO=%B^0G_ S:_\ U#97_H:#W[KW1=/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U8MAO\ BSXK_M6T/_6I??NO=.7OW7NO>_=>Z][]U[HHW?G_ !^&-_\
M#:H__<JL]^Z]T"'OW7NO>_=>Z][]U[KWOW7NG/"_\7G$_P#:SH/^MJ>_=>ZL
M5]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=1:ZNHL915F2R592X_'8^EJ*ZOKZZH2DA@AI$,DLTTLA5(HHD5F=V8*J
M@DD >]@%C09)X#K1-,GJ@&H^17Q]'\^6AW\>]>G!L5OY6#[27>A[.P@Q)RO^
ME&:K_A@R/WWV9R'V@,WV_F\WA_<T:/5[DH;=<?U:,?A2:OWEJTZ&U:?IJ5I2
MM*XKPKT"C=1?OT-K6GT-*ZA2OCUI6O&G5KOS2^46U_B'\4^XODIFYJ*NI=@[
M*J<GMBA:J58\IF,R4H\#01N"VI<AE*FCC+(&TQ,\MBJ'V#-AVA]\O(K1*UD<
M FGPJ,L?R )_+H2[KN*;5;27#\$4D#U/ #\R0.@9_E>?&O.?&#X?;+QO9,LE
M5WAVUD<]\A/D7N'))%#5UF\>VI!D\H:YX[1M48Z TE [K9&^T,B@!K>UW-N[
M+O%ZS18AC"PP**T6&(:5I7.<M]IZ2\O[>VVVJK)F1R99FQ5I9#J:M .'#[ .
MA7F[=^'?S ^+.^-X5^_>O.Q?BCO/#;HVEOO=>>RC[9P34='*U#D4K*VO_AST
M"T\_TJ#)"8W"312K9)/:+Z.]V2[5 CQW",K(H%7#&C+0"M2?3I5]1;;G;LVI
M'A8,&-1H(R#4]:^WSU^(7Q=VGT%COC!\?/EE\EOD7W!\@MT;%ZN^+GQ<S?S$
MRG:&UL!'-6XV2KRZ;;Q4\:1;:VS@:&OJDERLE314[Z;$ J8Y)Y:WV[GN?K+B
MWMX8H%:2XN%M8TD<@-1=;#XY&8+V48\?(] O>]IMXH/I8I9I'F8)#$UQ(RK\
M-3I#91%!;NJ <8J!UM1;2V_!M/:FV=JTLAEIMM;>PNWZ>5KW9,-31TR,;DFY
M6,'DG_7]Q!*_BL6]23^TUZD-%T #T%/V=*'W3JW7O?NO=>]^Z]TB.R/^/%W/
M_P!JR3_H9??NO=$.]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1Z.K/^/ VW_U"U'_N
M1-[]U[H0/?NO=>]^Z]U[W[KW2([(_P"/%W/_ -JR3_H9??NO=$.]^Z]U[W[K
MW7O?NO=>]^Z]TI=F?\?AM/\ \.7!?^Y47OW7NK _?NO=>]^Z]U[W[KW7O?NO
M=)K>?_'G[L_\-K._^XLOOW7NJ_/?NO=>]^Z]U[W[KW7O?NO=+CK7_C^]L_\
M:R3_ *%;W[KW1\/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= ]WEW_P!-?&O8.4[/[R["V_UU
MLK$H?+E,W.[23R6NM-044"35V2K7_L4U)333OSIC(!LOVW;+C=Y1!;(TCMP"
M_P"$DT 'J20!YGI%?[A!M<1FN'"(O$G_   #)/H "3Y#I3;%[,V/V3UMM3M[
M:&>AK^NMZ[/Q._MN[FKJ6? QRXC-TB5U-6RQ9"*EJ*2-Z219&%1#$\:W\BJ0
M0&;JSDLYF@D%)$<HR@@T93I([20<BF*].VUU'=Q+-&:HZAU:A%585!H0",'S
MZ)KMC^:=\#=X;[Q'7N![]Q<^4W%N1]G[:W%6;1W!B=MY/*)((A0X[==7B8-M
MULTDI*1>+*,DS"T3.2MSZ;DS<K>(RM":*NME#(9%7C5HPQ=1ZU44\^B:+FJP
MGD$:R@EFTJVEQ&[<*+(5",?( ,:^75@OL,="'HLW?WS#^._QCK]KX3N'?[8;
M=&]EJ9=I;)VYM;,]AYVOBHC::H@PFWL?E,G]I$;AJAJ58-09!(7&GV;[9L5U
MNX9H$JJ4U.S)&BUX M(RK4^E:]%FX;O;[85$S49JZ457D=J<2%C5F('F:4'3
M]\?OD]T3\I=KY+=_1/86,WSB\%EI<#N2D2BK,!DL570%@U'E<1DZ:BRN-J+H
M^E:FCC\@5FC+J"?;>Z;/<[,XCN4*$C4IJ&5E/FK*2K#Y@GIS;]T@W5"]NX<
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M+(TR-3%92QU@W]K)MQN+B7ZB261I<'Q&=B]5P.XFN*8SCI-%9PP1^$B(J9[
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MU[JQ;#?\6?%?]JVA_P"M2^_=>Z<O?NO=>]^Z]U[W[KW11N_/^/PQO_AM4?\
M[E5GOW7N@0]^Z]U[W[KW7O?NO=>]^Z]TYX7_ (O.)_[6=!_UM3W[KW5BOOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MJ/5LR4M2RDJRT\S*P-B"%)!'OW7NB'?W_P![?\]3F_\ SO?_ (K[]U[KW]_]
M[?\ /4YO_P [W_XK[]U[KW]_][?\]3F__.]_^*^_=>Z]_?\ WM_SU.;_ /.]
M_P#BOOW7NO?W_P![?\]3F_\ SO?_ (K[]U[HTG3N5R69VE)5Y6NJ<A5#+UD(
MGJY3,VE$B(6YYL"3_M_?NO="K[]U[KWOW7NO>_=>Z1'9'_'B[G_[5DG_ $,O
MOW7NB'>_=>Z][]U[KWOW7NO>_=>Z][]U[H]'5G_'@;;_ .H6H_\ <B;W[KW0
M@>_=>Z][]U[KWOW7ND1V1_QXNY_^U9)_T,OOW7NB'>_=>Z][]U[KWOW7NO>_
M=>Z4NS/^/PVG_P"'+@O_ '*B]^Z]U8'[]U[KWOW7NO>_=>Z][]U[I-;S_P"/
M/W9_X;6=_P#<67W[KW5?GOW7NO>_=>Z][]U[KWOW7NEQUK_Q_>V?^UDG_0K>
M_=>Z/A[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKS^>7RU[L^.FQ]\MT'\>\SVENS9_3F
M\>Y]R=B[N/\  -A[:Q&T:>OJ)6R5=]Q356<S,RXVH\&%QKBJ93%-4ST=/(DK
M"GEG8[?=I4%S.(U>5(E1>Z:1G*CM%"%4:A5VQQH&(IT'.8=WGVN)VMX3(RQ/
M*7;MB0(">XU!8G2:(N>&HJ#7H=?CWWG5;_\ B'T]\D>T'P6 J=V?'_9G<N_I
M,'2ST6.HCE<#!F<DU+#45%941TE,'F*+)4RN$4!G8\DMW;;A:7\UI#J8).\2
M5H6.ER@K0 5/R Z7[7?&[LXKF6@+PI(]*A060,:5)-!7U/5;F*^8'\R?LWH+
M.?-WJOJ/XSXSX^4V$W!V+LOHC?%1N.M[!SNT=K&IDEKGS..JQ@L?E\C14TM3
M1TB8ZI33XXR\KNOD%DFQ;1970VZ>6X,^I8WG3PQ!'*U!30PU,JDT9M2^9IT'
M(]XW.[MC?PQPB+29$A?69I(Q4@ZU.E689"Z6\@3G%KO07<VU_D1TKUAWALQ*
MB';7:&S,)N_&T=98STW\5A5IJ.<@!3/15'E@E*^DR1L5)6Q(*W.P?:KB2VD^
M*-V0TX&AI4?(\1T++"]3<8(YX_AD17%>-&%<_,=(/Y=?(RA^+W1^XNR4P[;M
MWM75V(V)U!U[3N5J-S;RWO,*';F!IPG[A-;7NAF9 6BI8ZB8*?%8J=CVH[Q<
MK#72@!>63RCB0:G<_8!CU-!Y])]WW$;7 TM-35"1I6ADE<Z44?Z9B!7R%3P'
M0(?RUOD[W'\J^B=X;S[XP77VWNR=B]X]E]/YNAZRHZ^BQ1;K]Z2)I(ER.0R=
M0SF::92_W(5U5&$:$FYCS;M%OLURL=J9&C>&*53(5+_J"N=*J/Y=(>6=RGW2
MW+W(02+++&PCJ$K&Q7&HD^7KU81["_0AZ][]U[KWOW7NO>_=>ZKI_F(9?Y.;
MBZ>[0Z$Z%^)^<[TH.[NC.R]@U_86.[?VIL"# 5V]<=78B)9\=GZVDJZ\1)4)
M4%H75&7]L.'!L*^5$LX;F*ZN;E8?!FC<(8I7+A&#&AC5@.%,]!KF9KF6WDM[
M>!I?%BD34'C0(64J*AV4GC7'18.N_C[\C/DG_+DW'\!OD-\;*_XXU>TOCGU;
MUILCL7.]K;;['HLUG^N8:1Z"M^RVY5U=7C::GR>%QU1,LK.3%*T<;2,C:CF[
MW6UVC=UW2TN!.&N)9618Y(V1)":BLB@$E7(%/,5-.BJTVVXW7:CMUU 82L$<
M:NSQN&=%%& C8D ,@.:?+I.]A4G\R7Y2_'"A^$F]OBI0]*97=F*VOUMWI\H:
M_M_;VY=N# 82HITRV5VWAZ*:HS-;7;AH:1Q#1S4\?VAJ6BGFC*BHCO:':-DN
M_P!XQ7)F"%I(;?PI%D\0@E5=B @",<L"=5,#-.M7(W/=[7Z&2W$3.!'-/XD9
MC\.M&:-06<EU!TAE&FN3CJR7=57WSU3OWXH=3=#]/;>W=\>S19W:/=>^LSN6
MFQ=9M/%;,QE!!MQJ&C:LI):Z2N9:B-_#0U07PJK)3AU<A*!+:\BN9[F5EG!5
MH4"DB5G8ZZFA H*')%:^?0FFDN+:6"*"(-$=0E<L 8@JC105!;4<8!I3HFN]
M.N_D]\:_GMWC\L.O^@\A\KNL_D5UKUEM";&[1WW@]I[GV34=9TRTST5+2;AJ
M:"EKL)F)%^[<4U;Y/NF+2QKXE:<_@N[/=]LALI9A;2022O5D=HYA*0:DQAB'
M6E,K33P/H2S6UUMFX2W<<37$<T<:T5T62(QZL 2% 4:M<-75Y4Z6_P 0.EN\
M\I\LOD=\TNYNJ<7\=8^X-C=?]9[6Z7I]U8[>66GAV.\CR[CW/6X:2;$G)5'[
M45,D,\TD5*3%,RM'>5-OM_;)90;?;RF?PGDD:72RH#(!V(' ;2*5-0*MD=*-
MGLYWNYKV:,0^*D<:Q:E9Z1ENYRA*U.J@ )HH%3Y=6B^P?T)^O>_=>Z][]U[K
MWOW7NM5/_AR3YI_\_G_]AUM/_P"L7OI-_K \I?\ *!_V=7G_ &T=<8?^"Q]P
M/^CK_P!F.V_]L?7O^')/FG_S^?\ ]AUM/_ZQ>_?ZP/*7_*!_V=7G_;1U[_@L
M?<#_ *.O_9CMO_;'U[_AR3YI_P#/Y_\ V'6T_P#ZQ>_?ZP/*7_*!_P!G5Y_V
MT=>_X+'W _Z.O_9CMO\ VQ]>_P"')/FG_P _G_\ 8=;3_P#K%[]_K \I?\H'
M_9U>?]M'7O\ @L?<#_HZ_P#9CMO_ &Q]>_X<D^:?_/Y__8=;3_\ K%[]_K \
MI?\ *!_V=7G_ &T=>_X+'W _Z.O_ &8[;_VQ]6._RV?E5WWW]V5V!M_MO?G]
M[,1A-C0YC%TG]U\-@O%4M7TT!D\F,QU%*_[4CKI=V7F^FX!]P'[_ /MMLO)-
MA;3;7;>"\EP4=O&GDJHC9J4EED R.( /667W3/>7F3W-W.^M]\O/J8X;5)(U
M^GM8=+F4*36W@B)QBA)'RKU<?[Q5ZSLZ][]U[KWOW7NF3<O_ ![FX/\ M297
M_K1)[]U[JO+W[KW7O?NO=>]^Z]U[W[KW7O?NO=&>^/G_  "W/_U%8O\ Z$F]
M^Z]T8KW[KW7O?NO=>]^Z]T'_ &G_ ,>!N3_J%I__ '(A]^Z]T1?W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=&YZ#_X\_)?^'+6?^XM'[]U[H;_ '[KW7O?NO=>]^Z]
MT$?=O_'B5'_:RQW_ $,??NO=$S]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1WNH/\
MF7>WO_(M_P"YU3[]U[H2O?NO=>]^Z]U[W[KW0#]_?\>UAO\ M>#_ -QYO?NO
M=%/]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1^M@_\>5M;_M1X[_K6OOW7NE=[]U[K
MWOW7NO>_=>Z+%\A/^!FU_P#J&RO_ $-![]U[HNGOW7NO>_=>Z][]U[KWOW7N
MO>_=>ZL6PW_%GQ7_ &K:'_K4OOW7NG+W[KW7O?NO=>]^Z]T4;OS_ (_#&_\
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M**#;&W_A3MR7/UL\\<,$2[3VF(<LTTG"1K#-2U?D+'TZ6UFX/LNYAA=]ZG0
MZFNWTCS.J4Z:?;44Z,-@E5=I@8D!1:QU/D-,0K_@->F+^33M_.;:_EF_%/';
MADGEKZG:F\-P4[5$C2L*'=FZ,[E<8H+DD(F-K*14%[*@55 4 !_W F2?>+ID
M% '5?]LD:(W[64GI/R1"\&U6RN:DH6_VKLSJ/R5@/RZ*WW3\G=HC^8Q7Y;Y
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M7_ZALK_T-![]U[HNGOW7NO>_=>Z][]U[KWOW7NO>_=>ZL6PW_%GQ7_:MH?\
MK4OOW7NG+W[KW7O?NO=>]^Z]T4;OS_C\,;_X;5'_ .Y59[]U[H$/?NO=>]^Z
M]U[W[KW7O?NO=.>%_P"+SB?^UG0?];4]^Z]U8K[]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI:G_[B$:/
M_P 9(-_[]F7V/Q_RJ_\ U,_^U7H('_DO?]0'_:QT%GSZZ6V'VW_-H^!>U>XM
MP=@[9ZZ[1^/?R$V'B7V#V'E.K7S&8VU+3Y>7 5N7PU309$4=;0S!GIHJ^-JF
M5((Q]2KO<N7\MELUX\"QL\<]NY\2-)=*$.NH*X85!H*TP">M;S:)=;E;+*75
M6BG4:':/4P*-I+(5.0":5S3Y=3.L.K-J_"_^;;T_\<OBUNK?E%T]W%\6^S-_
M]Z]$9_M3.]I8["3[0K8XL!NJ!=QY3+9+&U>4K&-"7-64D171$ 9K:N[M]]V6
M2ZNT3Q(KF-(IEB2(N'5BZ'PU56"@!N%17CUNW@7:]R2"!WT/ [R1-(\@4JRA
M7&MF85U$<:&G#'5V</8W7.3H]TS478.S:FDVAFI=I;QK*#=M#(N(R8D2!L?D
M)8Z@C'Y%9IHD\$QCF$CHNC4P! )MY$*U5NX:EJI[E]1C(^8QT*Q*IK0C!H<C
M!]#Z'K7?_F*_%.A_EZ;&VK_,1ZM[Y[T[C[8^/F_=BT&T^K_EQV'_ +,IC<U#
MV'E\?AJ[&[??<=+59O;^;:FJ):I*W%5R52Q4\UETJ"DG<K[L>:)6VN>*&*.=
M'+2V\8MV3PT9P6\,JKK4 %7!&<$'H#[[8#8HQ?Q/+(\3+2.9S,'ULJ$+XFIE
M:C&A0@^H(QULG8^IDK:"AK)J2>@FJZ.FJ9:&JL)86G16:*2Q(\D9)5K&UP;>
MXL84-./0[&>I?O76^O>_=>Z][]U[J-6?\ ZO_J&G_P"A3[]U[JN#W[KW7O?N
MO=>]^Z]U[W[KW7O?NO='#Z+_ ./)D_[7=?\ ]"0^_=>Z&7W[KW7O?NO=>]^Z
M]TB.R/\ CQ=S_P#:LD_Z&7W[KW1#O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T>CJS
M_CP-M_\ 4+4?^Y$WOW7NA ]^Z]U[W[KW7O?NO=(CLC_CQ=S_ /:LD_Z&7W[K
MW1#O?NO=>]^Z]U[W[KW7O?NO=*79G_'X;3_\.7!?^Y47OW7NK _?NO=>]^Z]
MU[W[KW7O?NO=)K>?_'G[L_\ #:SO_N++[]U[JOSW[KW7O?NO=>]^Z]U[W[KW
M2XZU_P"/[VS_ -K)/^A6]^Z]T?#W[KW7O?NO=>]^Z]U[W[KW7O?NO=%@^3/1
M&\_D#BMM[0H.]-]].]8QMGINU\+U?#!A\[NBFFB@6CQ,>Y)#)4X#&<5GWWV=
M-]W5QR)%%54BHYD-]IW&/;&:0PI+)CPS)4I&<U;1@.W#3J.D9JK>19N5B]^
M@E>-,ZQ'0.X\EUY*CC731CBC+YDD_D7214W\KKX^U$A$<<==W3/.X4GB+>^X
M[L0 22%7^A/%O8F]R\[W<?9#_P!68^@[[>8V>#_F[_U>DZ+?\(?B9TC_ #*>
MD-W_ #.^6NWL_P!I]@_(3L/M9]@UF:WADJ%]C;8VSFJ[#X3#;7@H:N&EQ+XU
MJ"283)$\LLQ$DSRDL7,^8]ZN>4+E=NLF6)((XO$"JI$TC(KLSZ@2U=5*' &
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M_P#[D0^_=>Z(O[]U[KWOW7NO>_=>Z][]U[KWOW7NC<]!_P#'GY+_ ,.6L_\
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MKWOW7NBC=^?\?AC?_#:H_P#W*K/?NO= A[]U[KWOW7NO>_=>Z][]U[ISPO\
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M_99<?];.O?Z7>V/^?G]A_P#H:Y+_ .J??OZJ[7_RAVO_ &3Q?] =>_UP=_\
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M5]VG_3W/_:%<];87OFAUVHZ][]U[KWOW7NO>_=>ZTX?D]_V4K\AO_$Y=M?\
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M?NO=>]^Z]T;GH/\ X\_)?^'+6?\ N+1^_=>Z&_W[KW7O?NO=>]^Z]T$?=O\
MQXE1_P!K+'?]#'W[KW1,_?NO=>]^Z]U[W[KW7O?NO=>]^Z]T=[J#_F7>WO\
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M]U[W[KW7O?NO=:-_OL1U\Z_7O?NO=>]^Z]U[W[KW7O?NO=6^?R=_^9Q]J_\
MB,Z?_P!VM'[Q:^]3_P DNR_YZF_ZLOUG;]Q#_DL[G_SQ1_\ 5\=;"GO!SKIW
MU[W[KW7O?NO=,FY?^/<W!_VI,K_UHD]^Z]U7E[]U[KWOW7NO>_=>Z][]U[KW
MOW7NC/?'S_@%N?\ ZBL7_P!"3>_=>Z,5[]U[KWOW7NO>_=>Z#_M/_CP-R?\
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M?0T=#2)+((:=6>1FE2PWB7=-CW-7"(D8LQ''&H1$!F-: 9)-!J9B6:@J30=
M&]VZ.QW:P9=3,YNB[NQ9FI$*9/ "IHJ@**F@%3U:U\SJWX3=9KUU\@OF!U[B
M-VR[,K\WL;KC<&3Z8S?>LF*GW?3'(5QIL5A\/G?L#4T^$'DR$E#&(Q$L'W*>
M81R K8UOKO7;63E0X#2+XR0APAH*EW0-0OA:GUIBO0IW-K6WT3W":BI*H?":
M4J6%30(KD5"Y-!Z5SU7%_*$;K+L[Y8_S$ODU\:L3M'KGXO=DY_J79^RNJL%D
M,=AZYLSL6@J8LUN/);.H9#-M!,I625#TT%934E55"2::2F1@UA1SKXUI9V-I
M=EGN(UE9I&!*Z'8:$60_VFD#BI*C !/1#RSX<]S=7%N%6%VC55! )=5.MB@^
M DG@0&-*D#J_NKI8*ZEJ:*J0R4U93S4M1&LC1%DJ%*. R%74E2>58$?4$'W'
M(-,]#,YZU1?YEVZ?Y:%9T%D?@+\8.F.N-D_)"H[5VQUAU;N#-]25'QTQFTLY
MMK<<$>3SDW8>Z<7A*:K3PT.1A,]#ELA/E6E]'W*2F3W,/*<6Z)=#<[N5W@$;
M22A91</+&4-$,4;N1Q'Q*H3SI3J.N87L7MS8V\:I+K5(JQM B2!_B$C*H)&3
MVDE_*M>MJ/:F/R&)VMMK%9?)?QG*XS 8?'Y/,$W^[J*.GCCFJ;V%_/(K/]!^
MKZ>X@E8,Q(% 22!Z"O4AJ"  <XX]/_NG5NO>_=>Z][]U[KWOW7NB#;__ ./V
MW3_VNZ__ *'/OW7NDA[]U[KWOW7NO>_=>Z][]U[HZO3/_'@8K_J)RG_N1)[]
MU[H4_?NO=>]^Z]U[W[KW7O?NO=5PUW_ VL_ZBJC_ *'/OW7NHOOW7NO>_=>Z
M][]U[KWOW7NCT=6?\>!MO_J%J/\ W(F]^Z]T('OW7NO>_=>Z][]U[J-6?\ Z
MO_J&G_Z%/OW7NJX/?NO=>]^Z]U[W[KW7O?NO=>]^Z]T</HO_ (\F3_M=U_\
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M=>]^Z]U[W[KW1Z.K/^/ VW_U"U'_ +D3>_=>Z$#W[KW7O?NO=>]^Z]U&K/\
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M\G^N]O7O?NO=>]^Z]U[W[KW6I[_,*_[+'[M_[6VV?_=%B_?2_P!C/^54V_\
MTDW_ &DS=<5_O2_\K[NW^GMO^T*VZ)C[EGK'_KWOW7NO>_=>Z][]U[HYW\O7
M_LL?I+_M;;F_]T64]Q-[Y_\ *J;A_I(?^TF'K(#[K7_*^[3_ *>Y_P"T*YZV
MPO?-#KM1U[W[KW7O?NO=>]^Z]UIP_)[_ +*5^0W_ (G+MK_W?Y#WU7]N_P#E
M7]L_Z5]E_P!HT77!SW@_Y6W>_P#I;[E_VF3= ;[&/4==>]^Z]U[W[KW7O?NO
M=63_ ,J;_LJZE_\ $>;R_P#C7WC_ />5_P"5:/\ SU0?X'ZRY^Y3_P KF?\
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MTN.M?^/[VS_VLD_Z%;W[KW1\/?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK+?S6?\
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M_'N;@_[4F5_ZT2>_=>ZKR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1GOCY_P"W/\
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MV&[FM7OEB;P(RH:0T459@HI4@MD@'2#2N:=%TF[6\5PEJSCQ7!*H*DT4$FM
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M]_F%?]EC]V_]K;;/_NBQ?OI?[&?\JIM_^DF_[29NN*_WI?\ E?=V_P!/;?\
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MS/\ LCKKC_M;;^_]WN0]\Z/O!?\ *U77^DMO^T>+KL1]TO\ Y42P_P!/>_\
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M=*79G_'X;3_\.7!?^Y47OW7NK _?NO=>]^Z]U[W[KW7O?NO=)K>?_'G[L_\
M#:SO_N++[]U[JOSW[KW7O?NO=>]^Z]U[W[KW2XZU_P"/[VS_ -K)/^A6]^Z]
MT?#W[KW7O?NO=>]^Z]U[W[KW7O?NO=:RW\UG_LJZJ_\ $>;-_P#CKWT(^[5_
MRK0_YZI_\"=<D/OK?\KF/^E?:_\ 'Y^JV/>0'6(W7O?NO=>]^Z]U[W[KW0N?
M'_\ YGQTG_XESK?_ -W-%["_._\ R1=P_P">*Z_ZL2=#OVM_Y6?:/^EI8?\
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M_K_[]_K9<Q?]&V]_[)Y?^@>O?Z]/*/\ T>=L_P"RVW_ZV=>_V;?XO_\ /_\
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M[]K?^5GVC_I:6'_:7%UN:>^3_7>WKWOW7NO>_=>Z][]U[K4]_F%?]EC]V_\
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MO>_=>Z][]U[KWOW7NO>_=>Z*'\]?^R0^\/\ PV:#_P!V5#[D_P!F/^5HV_\
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M]U[W[KW1P^B_^/)D_P"UW7_]"0^_=>Z&7W[KW7O?NO=>]^Z]TB.R/^/%W/\
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M_=>Z(-O_ /X_;=/_ &NZ_P#Z'/OW7NDA[]U[KWOW7NO>_=>Z][]U[HZO3/\
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M5]VG_3W/_:%<];87OFAUVHZ][]U[KWOW7NO>_=>ZTX?D]_V4K\AO_$Y=M?\
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MP5TDN/:@BCEHX8@D<CS%)D%6SW]OS#>_NV6VMXH92\<;1Q 30L%;0?$%&<U
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M#%%#$T42),($$<9F/<] /X:Z:DDXX]-\H1R?3-(\DLBR2,T1F8NXB^%:D_Q
M:J4''AU<U[ O0JZ][]U[KWOW7NO>_=>Z*'\]?^R0^\/_  V:#_W94/N3_9C_
M )6C;_\ FLW_ %:DZA;[Q7_*D[O_ ,\O_62/K4S]],>N*'7O?NO=>]^Z]U[W
M[KW7O?NO=;+?\J+_ +)7;_Q)>[_^M-![Y_?>3_Y63_J%@_PR==;/N:_\J6G_
M #VW7^%.K+?< =96=>]^Z]U[W[KW1!_YF?\ V1UV/_VMM@_^[W'^YI^[[_RM
M5K_I+G_M'EZQO^]I_P J)?\ ^GLO^TV#K5O]]%^N._7O?NO=>]^Z]U[W[KW7
MO?NO=;2'\LS_ +(ZZX_[6V_O_=[D/?.C[P7_ "M5U_I+;_M'BZ[$?=+_ .5$
ML/\ 3WO_ &FS]'X]PMUDAU[W[KW7O?NO=)'?W_'E;I_[4>1_ZUM[]U[H@OOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z,7\>_\ @9NC_J&Q7_0T_OW7NC.^_=>Z][]U
M[KWOW7NO>_=>Z(-O_P#X_;=/_:[K_P#H<^_=>Z2'OW7NO>_=>Z][]U[KWOW7
MNCJ],_\ '@8K_J)RG_N1)[]U[H4_?NO=>]^Z]U[W[KW7O?NO=5PUW_ VL_ZB
MJC_H<^_=>ZB^_=>Z][]U[KWOW7NO>_=>Z/1U9_QX&V_^H6H_]R)O?NO="![]
MU[KWOW7NO>_=>ZC5G_ .K_ZAI_\ H4^_=>ZK@]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW1P^B_P#CR9/^UW7_ /0D/OW7NAE]^Z]U[W[KW7O?NO=(CLC_ (\7<_\
MVK)/^AE]^Z]T0[W[KW7O?NO=>]^Z]U[W[KW7O?NO='HZL_X\#;?_ %"U'_N1
M-[]U[H0/?NO=>]^Z]U[W[KW2([(_X\7<_P#VK)/^AE]^Z]T0[W[KW7O?NO=>
M]^Z]U[W[KW2EV9_Q^&T__#EP7_N5%[]U[JP/W[KW7O?NO=>]^Z]U[W[KW2:W
MG_QY^[/_  VL[_[BR^_=>ZK\]^Z]U[W[KW7O?NO=>]^Z]TN.M?\ C^]L_P#:
MR3_H5O?NO='P]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6LM_-9_[*NJO_ !'FS?\
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M)7;_ ,27N_\ ZTT'OG]]Y/\ Y63_ *A8/\,G76S[FO\ RI:?\]MU_A3JRWW
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MKW1P^B_^/)D_[7=?_P!"0^_=>Z&7W[KW7O?NO=>]^Z]TB.R/^/%W/_VK)/\
MH9??NO=$.]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1Z.K/^/ VW_U"U'_ +D3>_=>
MZ$#W[KW7O?NO=>]^Z]TB.R/^/%W/_P!JR3_H9??NO=$.]^Z]U[W[KW7O?NO=
M>]^Z]TI=F?\ 'X;3_P##EP7_ +E1>_=>ZL#]^Z]U[W[KW7O?NO=>]^Z]TFMY
M_P#'G[L_\-K._P#N++[]U[JOSW[KW7O?NO=>]^Z]U[W[KW2XZU_X_O;/_:R3
M_H5O?NO='P]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6LM_-9_[*NJO_$>;-_^.O?0
MC[M7_*M#_GJG_P "=<D/OK?\KF/^E?:_\?GZK8]Y =8C=>]^Z]U[W[KW7O?N
MO="Y\?\ _F?'2?\ XESK?_W<T7L+\[_\D7</^>*Z_P"K$G0[]K?^5GVC_I:6
M'_:7%UN:>^3_ %WMZ][]U[KWOW7NO>_=>ZU/?YA7_98_=O\ VMML_P#NBQ?O
MI?[&?\JIM_\ I)O^TF;KBO\ >E_Y7W=O]/;?]H5MT3'W+/6/_7O?NO=>]^Z]
MU[W[KW1SOY>O_98_27_:VW-_[HLI[B;WS_Y53</])#_VDP]9 ?=:_P"5]VG_
M $]S_P!H5SUMA>^:'7:CKWOW7NO>_=>Z][]U[K3A^3W_ &4K\AO_ !.7;7_N
M_P A[ZK^W?\ RK^V?]*^R_[1HNN#GO!_RMN]_P#2WW+_ +3)N@-]C'J.NO>_
M=>Z][]U[KWOW7NK)_P"5-_V5=2_^(\WE_P#&OO'_ .\K_P JT?\ GJ@_P/UE
MS]RG_E<S_P!*^Z_X_!ULT^^>_76_KWOW7NO>_=>Z][]U[K1O]]B.OG7Z][]U
M[KWOW7NO>_=>Z][]U[JWS^3O_P SC[5_\1G3_P#NUH_>+7WJ?^279?\ /4W_
M %9?K.W[B'_)9W/_ )XH_P#J^.MA3W@YUT[Z][]U[KWOW7NF3<O_ ![FX/\
MM297_K1)[]U[JO+W[KW7O?NO=>]^Z]U[W[KW7O?NO=&>^/G_  "W/_U%8O\
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MVW7^%.K+?< =96=>]^Z]U[W[KW1!_P"9G_V1UV/_ -K;8/\ [O<?[FG[OO\
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MR_\ 'N;@_P"U)E?^M$GOW7NJ\O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T9[X^?\
M +<__45B_P#H2;W[KW1BO?NO=>]^Z]U[W[KW0?\ :?\ QX&Y/^H6G_\ <B'W
M[KW1%_?NO=>]^Z]U[W[KW7O?NO=>]^Z]T;GH/_CS\E_X<M9_[BT?OW7NAO\
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M<O\ M,FZ WV,>HZZ][]U[KWOW7NO>_=>ZLG_ )4W_95U+_XCS>7_ ,:^\?\
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M]^Z]U[W[KW7O?NO='>Z@_P"9=[>_\BW_ +G5/OW7NA*]^Z]U[W[KW7O?NO=
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M?]0M/_[D0^_=>Z(O[]U[KWOW7NO>_=>Z][]U[KWOW7NC<]!_\>?DO_#EK/\
MW%H_?NO=#?[]U[KWOW7NO>_=>Z"/NW_CQ*C_ +66._Z&/OW7NB9^_=>Z][]U
M[KWOW7NO>_=>Z][]U[H[W4'_ #+O;W_D6_\ <ZI]^Z]T)7OW7NO>_=>Z][]U
M[H!^_O\ CVL-_P!KP?\ N/-[]U[HI_OW7NO>_=>Z][]U[KWOW7NO>_=>Z/UL
M'_CRMK?]J/'?]:U]^Z]TKO?NO=>]^Z]U[W[KW18OD)_P,VO_ -0V5_Z&@]^Z
M]T73W[KW7O?NO=>]^Z]U[W[KW7O?NO=6+8;_ (L^*_[5M#_UJ7W[KW3E[]U[
MKWOW7NO>_=>Z*-WY_P ?AC?_  VJ/_W*K/?NO= A[]U[KWOW7NO>_=>Z][]U
M[ISPO_%YQ/\ VLZ#_K:GOW7NK%??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW10_GK_ -DA
M]X?^&S0?^[*A]R?[,?\ *T;?_P UF_ZM2=0M]XK_ )4G=_\ GE_ZR1]:F?OI
MCUQ0Z][]U[KWOW7NO>_=>Z][]U[K8&_D\?\ ,J>W/_$A8S_W6Q>\(OO3?\E.
MR_YY6_ZNMUTZ^XS_ ,D'</\ GO'_ &CQ=7!>\7.LWNO>_=>Z][]U[HH?SU_[
M)#[P_P##9H/_ '94/N3_ &8_Y6C;_P#FLW_5J3J%OO%?\J3N_P#SR_\ 62/K
M4S]],>N*'7O?NO=>]^Z]U[W[KW7O?NO=;+?\J+_LE=O_ !)>[_\ K30>^?WW
MD_\ E9/^H6#_  R==;/N:_\ *EI_SVW7^%.K+?< =96=>]^Z]U[W[KW1!_YF
M?_9'78__ &MM@_\ N]Q_N:?N^_\ *U6O^DN?^T>7K&_[VG_*B7_^GLO^TV#K
M5O\ ?1?KCOU[W[KW7O?NO=>]^Z]U[W[KW6TA_+,_[(ZZX_[6V_O_ '>Y#WSH
M^\%_RM5U_I+;_M'BZ[$?=+_Y42P_T][_ -IL_1^/<+=9(=>]^Z]U[W[KW21W
M]_QY6Z?^U'D?^M;>_=>Z(+[]U[KWOW7NO>_=>Z][]U[KWOW7NC%_'O\ X&;H
M_P"H;%?]#3^_=>Z,[[]U[KWOW7NO>_=>Z][]U[H@V_\ _C]MT_\ :[K_ /H<
M^_=>Z2'OW7NO>_=>Z][]U[KWOW7NCJ],_P#'@8K_ *B<I_[D2>_=>Z%/W[KW
M7O?NO=>]^Z]U[W[KW5<-=_P-K/\ J*J/^AS[]U[J+[]U[KWOW7NO>_=>Z][]
MU[H]'5G_ !X&V_\ J%J/_<B;W[KW0@>_=>Z][]U[KWOW7NHU9_P#J_\ J&G_
M .A3[]U[JN#W[KW7O?NO=>]^Z]U[W[KW7O?NO='#Z+_X\F3_ +7=?_T)#[]U
M[H9??NO=>]^Z]U[W[KW2([(_X\7<_P#VK)/^AE]^Z]T0[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO='HZL_P"/ VW_ -0M1_[D3>_=>Z$#W[KW7O?NO=>]^Z]TB.R/
M^/%W/_VK)/\ H9??NO=$.]^Z]U[W[KW7O?NO=>]^Z]TI=F?\?AM/_P .7!?^
MY47OW7NK _?NO=>]^Z]U[W[KW7O?NO=)K>?_ !Y^[/\ PVL[_P"XLOOW7NJ_
M/?NO=>]^Z]U[W[KW7O?NO=+CK7_C^]L_]K)/^A6]^Z]T?#W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=:RW\UG_ +*NJO\ Q'FS?_CKWT(^[5_RK0_YZI_\"=<D/OK?
M\KF/^E?:_P#'Y^JV/>0'6(W7O?NO=>]^Z]U[W[KW0N?'_P#YGQTG_P")<ZW_
M /=S1>POSO\ \D7</^>*Z_ZL2=#OVM_Y6?:/^EI8?]I<76YI[Y/]=[>O>_=>
MZ][]U[KWOW7NM3W^85_V6/W;_P!K;;/_ +HL7[Z7^QG_ "JFW_Z2;_M)FZXK
M_>E_Y7W=O]/;?]H5MT3'W+/6/_7O?NO=>]^Z]U[W[KW1SOY>O_98_27_ &MM
MS?\ NBRGN)O?/_E5-P_TD/\ VDP]9 ?=:_Y7W:?]/<_]H5SUMA>^:'7:CKWO
MW7NO>_=>Z][]U[K3A^3W_92OR&_\3EVU_P"[_(>^J_MW_P J_MG_ $K[+_M&
MBZX.>\'_ "MN]_\ 2WW+_M,FZ WV,>HZZ][]U[KWOW7NO>_=>ZLG_E3?]E74
MO_B/-Y?_ !K[Q_\ O*_\JT?^>J#_  /UES]RG_E<S_TK[K_C\'6S3[Y[]=;^
MO>_=>Z][]U[KWOW7NM&_WV(Z^=?KWOW7NO>_=>Z][]U[KWOW7NK?/Y.__,X^
MU?\ Q&=/_P"[6C]XM?>I_P"279?\]3?]67ZSM^XA_P EG<_^>*/_ *OCK84]
MX.==.^O>_=>Z][]U[IDW+_Q[FX/^U)E?^M$GOW7NJ\O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]T9[X^?\ MS_ /45B_\ H2;W[KW1BO?NO=>]^Z]U[W[KW0?]I_\
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M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*'\]?\
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MO=>]^Z]UM(?RS/\ LCKKC_M;;^_]WN0]\Z/O!?\ *U77^DMO^T>+KL1]TO\
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MJ3N__/+_ -9(^M3/WTQZXH=>]^Z]U[W[KW7O?NO=>]^Z]UL#?R>/^94]N?\
MB0L9_P"ZV+WA%]Z;_DIV7_/*W_5UNNG7W&?^2#N'_/>/^T>+JX+WBYUF]U[W
M[KW7O?NO=%#^>O\ V2'WA_X;-!_[LJ'W)_LQ_P K1M__ #6;_JU)U"WWBO\
ME2=W_P">7_K)'UJ9^^F/7%#KWOW7NO>_=>Z][]U[KWOW7NMEO^5%_P!DKM_X
MDO=__6F@]\_OO)_\K)_U"P?X9.NMGW-?^5+3_GMNO\*=66^X ZRLZ][]U[KW
MOW7NB#_S,_\ LCKL?_M;;!_]WN/]S3]WW_E:K7_27/\ VCR]8W_>T_Y42_\
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M]^Z]T>CJS_CP-M_]0M1_[D3>_=>Z$#W[KW7O?NO=>]^Z]U&K/^ =7_U#3_\
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M]KP?^X\WOW7NBG^_=>Z][]U[KWOW7NO>_=>Z][]U[H_6P?\ CRMK?]J/'?\
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M],_\>!BO^HG*?^Y$GOW7NA3]^Z]U[W[KW7O?NO=>]^Z]U7#7?\#:S_J*J/\
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MW[KW1#O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T>CJS_CP-M_]0M1_P"Y$WOW7NA
M]^Z]U[W[KW7O?NO=(CLC_CQ=S_\ :LD_Z&7W[KW1#O?NO=>]^Z]U[W[KW7O?
MNO=*79G_ !^&T_\ PY<%_P"Y47OW7NK _?NO=>]^Z]U[W[KW7O?NO=)K>?\
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M<_\ :%<];87OFAUVHZ][]U[KWOW7NO>_=>ZTX?D]_P!E*_(;_P 3EVU_[O\
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M_P">\?\ :/%U<%[Q<ZS>Z][]U[KWOW7NBA_/7_LD/O#_ ,-F@_\ =E0^Y/\
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MTN.M?^/[VS_VLD_Z%;W[KW1\/?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK+?S6?\
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M_'N;@_[4F5_ZT2>_=>ZKR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1GOCY_P"W/\
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MZ][]U[K9;_E1?]DKM_XDO=__ %IH/?/[[R?_ "LG_4+!_ADZZV?<U_Y4M/\
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M'5Z9_P"/ Q7_ %$Y3_W(D]^Z]T*?OW7NO>_=>Z][]U[KWOW7NJX:[_@;6?\
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M?NO=>]^Z]T0?^9G_ -D==C_]K;8/_N]Q_N:?N^_\K5:_Z2Y_[1Y>L;_O:?\
M*B7_ /I[+_M-@ZU;_?1?KCOU[W[KW7O?NO=>]^Z]U[W[KW6TA_+,_P"R.NN/
M^UMO[_W>Y#WSH^\%_P K5=?Z2V_[1XNNQ'W2_P#E1+#_ $][_P!IL_1^/<+=
M9(=>]^Z]U[W[KW21W]_QY6Z?^U'D?^M;>_=>Z(+[]U[KWOW7NO>_=>Z][]U[
MKWOW7NC%_'O_ (&;H_ZAL5_T-/[]U[HSOOW7NO>_=>Z][]U[KWOW7NB#;_\
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MCQ==B/NE_P#*B6'^GO?^TV?H_'N%NLD.O>_=>Z][]U[I([^_X\K=/_:CR/\
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MZ][]U[I-;S_X\_=G_AM9W_W%E]^Z]U7Y[]U[KWOW7NO>_=>Z][]U[I<=:_\
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MZLOUG;]Q#_DL[G_SQ1_]7QUL*>\'.NG?7O?NO=>]^Z]TR;E_X]S<'_:DRO\
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M>O>_=>Z][]U[KWOW7NM3W^85_P!EC]V_]K;;/_NBQ?OI?[&?\JIM_P#I)O\
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M6W_:/%UV(^Z7_P J)8?Z>]_[39^C\>X6ZR0Z][]U[KWOW7NDCO[_ (\K=/\
MVH\C_P!:V]^Z]T07W[KW7O?NO=>]^Z]U[W[KW7O?NO=&+^/?_ S='_4-BO\
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M>N*'7O?NO=>]^Z]U[W[KW7O?NO=;+?\ *B_[)7;_ ,27N_\ ZTT'OG]]Y/\
MY63_ *A8/\,G76S[FO\ RI:?\]MU_A3JRWW '65G7O?NO=>]^Z]T0?\ F9_]
MD==C_P#:VV#_ .[W'^YI^[[_ ,K5:_Z2Y_[1Y>L;_O:?\J)?_P"GLO\ M-@Z
MU;_?1?KCOU[W[KW7O?NO=>]^Z]U[W[KW6TA_+,_[(ZZX_P"UMO[_ -WN0]\Z
M/O!?\K5=?Z2V_P"T>+KL1]TO_E1+#_3WO_:;/T?CW"W62'7O?NO=>]^Z]TD=
M_?\ 'E;I_P"U'D?^M;>_=>Z(+[]U[KWOW7NO>_=>Z][]U[KWOW7NC%_'O_@9
MNC_J&Q7_ $-/[]U[HSOOW7NO>_=>Z][]U[KWOW7NB#;_ /\ C]MT_P#:[K_^
MAS[]U[I(>_=>Z][]U[KWOW7NO>_=>Z.KTS_QX&*_ZB<I_P"Y$GOW7NA3]^Z]
MU[W[KW7O?NO=>]^Z]U7#7?\  VL_ZBJC_H<^_=>ZB^_=>Z][]U[KWOW7NO>_
M=>Z/1U9_QX&V_P#J%J/_ '(F]^Z]T('OW7NO>_=>Z][]U[J-6?\  .K_ .H:
M?_H4^_=>ZK@]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1P^B_^/)D_[7=?_P!"0^_=
M>Z&7W[KW7O?NO=>]^Z]TB.R/^/%W/_VK)/\ H9??NO=$.]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW1Z.K/^/ VW_U"U'_ +D3>_=>Z$#W[KW7O?NO=>]^Z]TB.R/^
M/%W/_P!JR3_H9??NO=$.]^Z]U[W[KW7O?NO=>]^Z]TI=F?\ 'X;3_P##EP7_
M +E1>_=>ZL#]^Z]U[W[KW7O?NO=>]^Z]TFMY_P#'G[L_\-K._P#N++[]U[JO
MSW[KW7O?NO=>]^Z]U[W[KW2XZU_X_O;/_:R3_H5O?NO='P]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW6LM_-9_[*NJO_$>;-_^.O?0C[M7_*M#_GJG_P "=<D/OK?\
MKF/^E?:_\?GZK8]Y =8C=>]^Z]U[W[KW7O?NO="Y\?\ _F?'2?\ XESK?_W<
MT7L+\[_\D7</^>*Z_P"K$G0[]K?^5GVC_I:6'_:7%UN:>^3_ %WMZ][]U[KW
MOW7NO>_=>ZU/?YA7_98_=O\ VMML_P#NBQ?OI?[&?\JIM_\ I)O^TF;KBO\
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M !^VZ?\ M=U__0Y]^Z]TD/?NO=>]^Z]U[W[KW7O?NO='5Z9_X\#%?]1.4_\
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MI_\ ARX+_P!RHO?NO=6!^_=>Z][]U[KWOW7NO>_=>Z36\_\ CS]V?^&UG?\
MW%E]^Z]U7Y[]U[KWOW7NO>_=>Z][]U[I<=:_\?WMG_M9)_T*WOW7NCX>_=>Z
M][]U[KWOW7NO>_=>Z][]U[K66_FL_P#95U5_XCS9O_QU[Z$?=J_Y5H?\]4_^
M!.N2'WUO^5S'_2OM?^/S]5L>\@.L1NO>_=>Z][]U[KWOW7NA<^/_ /S/CI/_
M ,2YUO\ ^[FB]A?G?_DB[A_SQ77_ %8DZ'?M;_RL^T?]+2P_[2XNMS3WR?Z[
MV]>]^Z]U[W[KW7O?NO=:GO\ ,*_[+'[M_P"UMMG_ -T6+]]+_8S_ )53;_\
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M>Z][]U[JWS^3O_S./M7_ ,1G3_\ NUH_>+7WJ?\ DEV7_/4W_5E^L[?N(?\
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M+%\A/^!FU_\ J&RO_0T'OW7NBZ>_=>Z][]U[KWOW7NO>_=>Z][]U[JQ;#?\
M%GQ7_:MH?^M2^_=>Z<O?NO=>]^Z]U[W[KW11N_/^/PQO_AM4?_N56>_=>Z!#
MW[KW7O?NO=>]^Z]U[W[KW3GA?^+SB?\ M9T'_6U/?NO=6*^_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NBA_/7_ +)#[P_\-F@_]V5#[D_V8_Y6C;_^:S?]6I.H6^\5_P J
M3N__ #R_]9(^M3/WTQZXH=>]^Z]U[W[KW7O?NO=>]^Z]UL#?R>/^94]N?^)"
MQG_NMB]X1?>F_P"2G9?\\K?]76ZZ=?<9_P"2#N'_ #WC_M'BZN"]XN=9O=>]
M^Z]U[W[KW10_GK_V2'WA_P"&S0?^[*A]R?[,?\K1M_\ S6;_ *M2=0M]XK_E
M2=W_ .>7_K)'UJ9^^F/7%#KWOW7NO>_=>Z][]U[KWOW7NMEO^5%_V2NW_B2]
MW_\ 6F@]\_OO)_\ *R?]0L'^&3KK9]S7_E2T_P">VZ_PIU9;[@#K*SKWOW7N
MO>_=>Z(/_,S_ .R.NQ_^UML'_P!WN/\ <T_=]_Y6JU_TES_VCR]8W_>T_P"5
M$O\ _3V7_:;!UJW^^B_7'?KWOW7NO>_=>Z][]U[KWOW7NMI#^69_V1UUQ_VM
MM_?^[W(>^='W@O\ E:KK_26W_:/%UV(^Z7_RHEA_I[W_ +39^C\>X6ZR0Z][
M]U[KWOW7NDCO[_CRMT_]J/(_]:V]^Z]T07W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=&+^/?\ P,W1_P!0V*_Z&G]^Z]T9WW[KW7O?NO=>]^Z]U[W[KW1!M_\ _'[;
MI_[7=?\ ]#GW[KW20]^Z]U[W[KW7O?NO=>]^Z]T=7IG_ (\#%?\ 43E/_<B3
MW[KW0I^_=>Z][]U[KWOW7NO>_=>ZKAKO^!M9_P!151_T.??NO=1??NO=>]^Z
M]U[W[KW7O?NO='HZL_X\#;?_ %"U'_N1-[]U[H0/?NO=>]^Z]U[W[KW4:L_X
M!U?_ %#3_P#0I]^Z]U7![]U[KWOW7NO>_=>Z][]U[KWOW7NCA]%_\>3)_P!K
MNO\ ^A(??NO=#+[]U[KWOW7NO>_=>Z1'9'_'B[G_ .U9)_T,OOW7NB'>_=>Z
M][]U[KWOW7NO>_=>Z][]U[H]'5G_ !X&V_\ J%J/_<B;W[KW0@>_=>Z][]U[
MKWOW7ND1V1_QXNY_^U9)_P!#+[]U[HAWOW7NO>_=>Z][]U[KWOW7NE+LS_C\
M-I_^'+@O_<J+W[KW5@?OW7NO>_=>Z][]U[KWOW7NDUO/_CS]V?\ AM9W_P!Q
M9??NO=5^>_=>Z][]U[KWOW7NO>_=>Z7'6O\ Q_>V?^UDG_0K>_=>Z/A[]U[K
MWOW7NO>_=>Z][]U[KWOW7NM9;^:S_P!E757_ (CS9O\ \=>^A'W:O^5:'_/5
M/_@3KDA]];_E<Q_TK[7_ (_/U6Q[R ZQ&Z][]U[KWOW7NO>_=>Z%SX__ /,^
M.D__ !+G6_\ [N:+V%^=_P#DB[A_SQ77_5B3H=^UO_*S[1_TM+#_ +2XNMS3
MWR?Z[V]>]^Z]U[W[KW7O?NO=:GO\PK_LL?NW_M;;9_\ =%B_?2_V,_Y53;_]
M)-_VDS=<5_O2_P#*^[M_I[;_ +0K;HF/N6>L?^O>_=>Z][]U[KWOW7NCG?R]
M?^RQ^DO^UMN;_P!T64]Q-[Y_\JIN'^DA_P"TF'K(#[K7_*^[3_I[G_M"N>ML
M+WS0Z[4=>]^Z]U[W[KW7O?NO=:</R>_[*5^0W_B<NVO_ '?Y#WU7]N_^5?VS
M_I7V7_:-%UP<]X/^5MWO_I;[E_VF3= ;[&/4==>]^Z]U[W[KW7O?NO=63_RI
MO^RKJ7_Q'F\O_C7WC_\ >5_Y5H_\]4'^!^LN?N4_\KF?^E?=?\?@ZV:??/?K
MK?U[W[KW7O?NO=>]^Z]UHW^^Q'7SK]>]^Z]U[W[KW7O?NO=>]^Z]U;Y_)W_Y
MG'VK_P"(SI__ ':T?O%K[U/_ "2[+_GJ;_JR_6=OW$/^2SN?_/%'_P!7QUL*
M>\'.NG?7O?NO=>]^Z]TR;E_X]S<'_:DRO_6B3W[KW5>7OW7NO>_=>Z][]U[K
MWOW7NO>_=>Z,]\?/^ 6Y_P#J*Q?_ $)-[]U[HQ7OW7NO>_=>Z][]U[H/^T_^
M/ W)_P!0M/\ ^Y$/OW7NB+^_=>Z][]U[KWOW7NO>_=>Z][]U[HW/0?\ QY^2
M_P##EK/_ '%H_?NO=#?[]U[KWOW7NO>_=>Z"/NW_ (\2H_[66._Z&/OW7NB9
M^_=>Z][]U[KWOW7NO>_=>Z][]U[H[W4'_,N]O?\ D6_]SJGW[KW0E>_=>Z][
M]U[KWOW7N@'[^_X]K#?]KP?^X\WOW7NBG^_=>Z][]U[KWOW7NO>_=>Z][]U[
MH_6P?^/*VM_VH\=_UK7W[KW2N]^Z]U[W[KW7O?NO=%B^0G_ S:__ %#97_H:
M#W[KW1=/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U8MAO^+/BO^U;0_P#6I??NO=.7
MOW7NO>_=>Z][]U[HHW?G_'X8W_PVJ/\ ]RJSW[KW0(>_=>Z][]U[KWOW7NO>
M_=>Z<\+_ ,7G$_\ :SH/^MJ>_=>ZL5]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%#^>O_
M &2'WA_X;-!_[LJ'W)_LQ_RM&W_\UF_ZM2=0M]XK_E2=W_YY?^LD?6IG[Z8]
M<4.O>_=>Z][]U[KWOW7NO>_=>ZV!OY/'_,J>W/\ Q(6,_P#=;%[PB^]-_P E
M.R_YY6_ZNMUTZ^XS_P D'</^>\?]H\75P7O%SK-[KWOW7NO>_=>Z*'\]?^R0
M^\/_  V:#_W94/N3_9C_ )6C;_\ FLW_ %:DZA;[Q7_*D[O_ ,\O_62/K4S]
M],>N*'7O?NO=>]^Z]U[W[KW7O?NO=;+?\J+_ +)7;_Q)>[_^M-![Y_?>3_Y6
M3_J%@_PR==;/N:_\J6G_ #VW7^%.K+?< =96=>]^Z]U[W[KW1!_YF?\ V1UV
M/_VMM@_^[W'^YI^[[_RM5K_I+G_M'EZQO^]I_P J)?\ ^GLO^TV#K5O]]%^N
M._7O?NO=>]^Z]U[W[KW7O?NO=;2'\LS_ +(ZZX_[6V_O_=[D/?.C[P7_ "M5
MU_I+;_M'BZ[$?=+_ .5$L/\ 3WO_ &FS]'X]PMUDAU[W[KW7O?NO=)'?W_'E
M;I_[4>1_ZUM[]U[H@OOW7NO>_=>Z][]U[KWOW7NO>_=>Z,7\>_\ @9NC_J&Q
M7_0T_OW7NC.^_=>Z][]U[KWOW7NO>_=>Z(-O_P#X_;=/_:[K_P#H<^_=>Z2'
MOW7NO>_=>Z][]U[KWOW7NCJ],_\ '@8K_J)RG_N1)[]U[H4_?NO=>]^Z]U[W
M[KW7O?NO=5PUW_ VL_ZBJC_H<^_=>ZB^_=>Z][]U[KWOW7NO>_=>Z/1U9_QX
M&V_^H6H_]R)O?NO="![]U[KWOW7NO>_=>ZC5G_ .K_ZAI_\ H4^_=>ZK@]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW1P^B_P#CR9/^UW7_ /0D/OW7NAE]^Z]U[W[K
MW7O?NO=(CLC_ (\7<_\ VK)/^AE]^Z]T0[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M='HZL_X\#;?_ %"U'_N1-[]U[H0/?NO=>]^Z]U[W[KW2([(_X\7<_P#VK)/^
MAE]^Z]T0[W[KW7O?NO=>]^Z]U[W[KW2EV9_Q^&T__#EP7_N5%[]U[JP/W[KW
M7O?NO=>]^Z]U[W[KW2:WG_QY^[/_  VL[_[BR^_=>ZK\]^Z]U[W[KW7O?NO=
M>]^Z]TN.M?\ C^]L_P#:R3_H5O?NO='P]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6
MLM_-9_[*NJO_ !'FS?\ XZ]]"/NU?\JT/^>J?_ G7)#[ZW_*YC_I7VO_ !^?
MJMCWD!UB-U[W[KW7O?NO=>]^Z]T+GQ__ .9\=)_^)<ZW_P#=S1>POSO_ ,D7
M</\ GBNO^K$G0[]K?^5GVC_I:6'_ &EQ=;FGOD_UWMZ][]U[KWOW7NO>_=>Z
MU/?YA7_98_=O_:VVS_[HL7[Z7^QG_*J;?_I)O^TF;KBO]Z7_ )7W=O\ 3VW_
M &A6W1,?<L]8_P#7O?NO=>]^Z]U[W[KW1SOY>O\ V6/TE_VMMS?^Z+*>XF]\
M_P#E5-P_TD/_ &DP]9 ?=:_Y7W:?]/<_]H5SUMA>^:'7:CKWOW7NO>_=>Z][
M]U[K3A^3W_92OR&_\3EVU_[O\A[ZK^W?_*O[9_TK[+_M&BZX.>\'_*V[W_TM
M]R_[3)N@-]C'J.NO>_=>Z][]U[KWOW7NK)_Y4W_95U+_ .(\WE_\:^\?_O*_
M\JT?^>J#_ _67/W*?^5S/_2ONO\ C\'6S3[Y[]=;^O>_=>Z][]U[KWOW7NM&
M_P!]B.OG7Z][]U[KWOW7NO>_=>Z][]U[JWS^3O\ \SC[5_\ $9T__NUH_>+7
MWJ?^279?\]3?]67ZSM^XA_R6=S_YXH_^KXZV%/>#G73OKWOW7NO>_=>Z9-R_
M\>YN#_M297_K1)[]U[JO+W[KW7O?NO=>]^Z]U[W[KW7O?NO=&>^/G_ +<_\
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MNO=1JS_@'5_]0T__ $*??NO=5P>_=>Z][]U[KWOW7NO>_=>Z][]U[HX?1?\
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M6W1,?<L]8_\ 7O?NO=>]^Z]U[W[KW1SOY>O_ &6/TE_VMMS?^Z+*>XF]\_\
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M>ZV6_P"5%_V2NW_B2]W_ /6F@]\_OO)_\K)_U"P?X9.NMGW-?^5+3_GMNO\
M"G5EON .LK.O>_=>Z][]U[H@_P#,S_[(Z['_ .UML'_W>X_W-/W??^5JM?\
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M/4==>]^Z]U[W[KW7O?NO=63_ ,J;_LJZE_\ $>;R_P#C7WC_ />5_P"5:/\
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M_P #:S_J*J/^AS[]U[J+[]U[KWOW7NO>_=>Z][]U[H]'5G_'@;;_ .H6H_\
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M=+CK7_C^]L_]K)/^A6]^Z]T?#W[KW7O?NO=>]^Z]U5ON3X5_.;,;BS^6PO\
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MG'[O>P\_WGU^\*]Q/X:Q>(6*'0A8J*1%%QJ.:5SD]!W_ ,,%;O\ ^]B';?\
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MC4M:&J:3BI\Z="KD[[O>P\@7GU^SJ]O/X;1>(&+G0Y4L*2EUSI&:5Q@]&/\
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MM_Z%Z@#_ ($3DW_E&;_G)+_ULZ]_PP5N_P#[V(=M_P#HE-K?]???O^"3WO\
MAC_;_P!"]>_X$3DW_E&;_G)+_P!;.O?\,%;O_P"]B';?_HE-K?\ 7WW[_@D]
M[_AC_;_T+U[_ ($3DW_E&;_G)+_ULZ]_PP5N_P#[V(=M_P#HE-K?]???O^"3
MWO\ AC_;_P!"]>_X$3DW_E&;_G)+_P!;.O?\,%;O_P"]B';?_HE-K?\ 7WW[
M_@D][_AC_;_T+U[_ ($3DW_E&;_G)+_ULZ%CJ3^3W\@^BLOE,]U1_,][BVCE
MLSC5Q&3K(.@=DY,RTZRI,(RM='51J/*B-=5#<6O:X]AGF?WBN><HDAW.VBG2
M-M:*7D32U"M:QE#P/F:=#;DCV+V?VXFDN-E,EM),@CD93XFI VH"DWB 9S@
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M_=%W_P ILW_..W_ZU=>_X;!^6_\ WM9[G_\ 2=M@_P#U+[]_6#;_ /HVP?\
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M_+?_ +VL]S_^D[;!_P#J7WO^L&W_ /1M@_YS7/\ ULZ]^Z+O_E-F_P"<=O\
M]:NO?\-@_+?_ +VL]S_^D[;!_P#J7W[^L&W_ /1M@_YS7/\ ULZ]^Z+O_E-F
M_P"<=O\ ]:NO?\-@_+?_ +VL]S_^D[;!_P#J7W[^L&W_ /1M@_YS7/\ ULZ]
M^Z+O_E-F_P"<=O\ ]:NO?\-@_+?_ +VL]S_^D[;!_P#J7W[^L&W_ /1M@_YS
M7/\ ULZ]^Z+O_E-F_P"<=O\ ]:NO?\-@_+?_ +VL]S_^D[;!_P#J7W[^L&W_
M /1M@_YS7/\ ULZ]^Z+O_E-F_P"<=O\ ]:NE7@OY?/S@VU224&$_FW=U4%)+
M4O5R0K\;>NIKR2*B%KRT+MRL:"U[<?3Z^]?O_;_^C;#_ ,Y[G_K9U[]T7?\
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MKG_K9U[]T7?_ "FS?\X[?_K5U[_AL'Y;_P#>UGN?_P!)VV#_ /4OOW]8-O\
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MLZ]^Z+O_ )39O^<=O_UJZ]_PV#\M_P#O:SW/_P"D[;!_^I??OZP;?_T;8/\
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MK;_LCL?^V7KW_#"W6O\ WF?\P?\ SOV-_P#87[]_K[;Y_$/^<UW_ -M/7O\
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M22W))_WZ/Y][_K5#_P!&^Q_WB;_K=UK]Q2_\IEU^V'_K3UQ_X:-W!_WLE_F
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MUM/_ .Q'WO\ K5#_ -&^Q_WB;_K=UK]Q2_\ *9=?MA_ZT]>_X:-W!_WLE_F
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M]>_X:-W!_P![)?Y@/_H=;3_^Q'W[^M4/_1OL?]XF_P"MW7OW%+_RF77[8?\
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MZES345-3R1^29'\LJ@*LA/LFSP7$$M[>.ZP0E$TQ@>)+(]:*I;M6@%6)K0<
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M=9!3U.0R-<(YIOM,72R354D$$9J*D1?;P:9)%8+MNC@EF N7:./)9D76V 2
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M( %0*L:"I-!6IX=)+Z2:.(FW17DP%5FT+D@$D@,: 5. 2:4''JN7$?*/YV]
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M_3%7"FE!5JU.:#HIO]SW?;8C=RQVQB3NDA1I#*L?F1(:(6'$C0!04!)ZLV[
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M@4M1@[-4$#!%.!J.A.[P^3_R,W1\HI_AY\-]M=2-OC8_7.&[4[M[;[Q;*9+
M[?H]S5#PXC"TF)PE129'(9S)(AJ+O514\-,0UY'+>-'MVSVD-G]??M+H>0Q0
MQ0Z0[E0"S%G!556H' DGTZ57VYW,MU]%9+'J6,22RRU*(&)"J%0JS,VDGBH
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M4LI"!4(-0]*]RT((%230 5-.G=MWU[F"5I8F\:"0Q211]^IQ2A2NFJL&!!-
M!6IH">F?X/\ S!^1G?\ \DOF1TMW_P!4;%Z<E^/L'1&0VULK;N6EW7EJ.+N+
M$Y#+_:Y[-Q5TN)R5;!214.LT%#!!%,\T2R5*HDS/<Q[!:;79VES:RO+X_CAG
M8:5)A=4JBD!@"2?B))%#1>'2?8=[N=RN[JWN(TC\#P"J@ZF'BHST9@=)( 'P
MB@-15ADO?=OR:^16X?EM%\,_BGBNGL%O#;?3='WGV;V?WO1Y?/XZGQF7R?\
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M_LN[27CS6UPJK/ 5#Z-6AU==2NNK(!S45)!'$]'[]AGH_P"O>_=>Z"+O3/\
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MGVS<[2>?;VN$DMP'>.X\-M<98+53&%H17(->(IT&X]SW#;[J&&]6!DG)19(
MZZ) I:C!V:H(&"*<#4="=WA\G_D9NCY13_#SX;[:ZD;?&Q^N<-VIW;VWWBV4
MR6!V_1[FJ'AQ&%I,3A*BDR.0SF21#47>JBIX:8AKR.6\:/;MGM(;/Z^_:70\
MABABATAW*@%F+."JJM0.!)/ITJOMSN9;KZ*R6/4L8DEEEJ40,2%4*A5F9M)/
M%0!FI..GCXD_*WN+?O9WR#^+WR2V3L? _)'X\4VU]P25G5M96IMO=N WO2F?
M&9C#KEFDJZ!A(%@JH9ZF40S2* ]UECB;WS98+6&"\M'=H)]2TD"^)$Z&C*VG
M!XU! %1Y=.;1NLUQ+-:W*JLT.DUCKHD1P2K+JR,@@@DT(XGHLO>'R7_FN?'?
MK'-_*;LKISX=OTYLN6BS^_N@]J;GW/F=\8W 5,\4$S#=#21[:K<G0&82U#P8
MXTWA1C%'*P]G&V[1LFZS+90RW0E?MCG=8Q"TGE^F*N%-*"K5J<T'13?[GN^V
MQ&[ECMC$G=)"C2&58_,B0T0L.)&@"@H"3T>WN?Y([^V]L+K#)_'[H3>W>V^^
M[<$<WL:@CDAVIM[#4CT5'6'*;RW!4M]OAZ&&.OIRM/&LU=7.LL-%!(T<CQAG
M;]JBFDD%S,D*1&CG+.QJ1IC098FAR:*,%B*BHBO=PDA1#;Q-*\@[14*BB@.I
MV/P@5& "Q_"IH:)'^6M\FM__ #"^&W57R%[/QFT</O3?-9V!!E<=L;'5F*QD
M:[5W'EL/3^"&NK\G4JSTU!$TA:L<&1F*A5LH5\X;-%L&X2VD)8HGAT+D%NZ-
M'-2JJ.+8QPZ1<J;M)OEA%=3!0[ZZA 0O;(R"E2QX+Z\>B4[ ^5/\T?Y-=H_*
MS$_&;!? 3!==_'7Y.=H_'FF3O6E[$CS55_H^JA#%7/-M^MJ:&?[J$J[VIZ;Q
MN2@C=0)&$5ULFR[-#;&]:^:2>VBN/T/ T#Q 32D@!%*>IKQQPZ(K?=]WW:6X
M%F+-4AN)(*3>-K/ATS5#0UKZ"G#/'JW;IW_3'_HTVG_LP/\ HS_TQ?95']^?
M]#O\5_NS]S]Q-XOX3_&_]RG@^T^WU_<>KS>33Z-/L!W_ -/XS?2^)X5>SQ=/
MB4I^+1VUKZ=#6R\;PE^HT>)3O\/5HU?T=6:?;T)GM'TJZ"+O3LS</4?6F<WO
MM/J???=VYZ*HP^.P/6G7,-.^2R%5G:R"BAO-5RPTM%04S3B:LJY7T4M+'+,5
M?0$9=MUHE],(WD2%34M))72H4$\%!))I0 #)('22^N6M(BZ1O*PH B4U,20/
MQ%0 *U))P 3T1'8WS][NV_\ (#J7H7Y@?#K(_&B?Y R9;&]-[XP'=.*[PQ-7
MEL)3FJJ,+E)L;C\?_#:SQ&%86_=6>20!$$2O*@EN>6;:6UENK"Z%QX%#*C0M
M"X1C0,H9FU"O'@1Y\>B"WY@N([F.WO;8P^-41.LHF0LH+%6(5-)IPX@YIPZ%
M#Y ?,[>.R>\L-\7?CAT+D?DAW[4;(C[/WAB*C?5)U;M[;&W9ZIJ.FK,UGZND
MR"K6U]2C+34,-%).Z6F?0C)Y$6V;!'<6QO;N800!_#4A#))))340J K@ Y8D
M <!4]*]PWIX)Q:6T1FFT>(P+>''&E2H+.0V6(.E0I)H2:#/3;T?\\ZWL?#_)
M';._OC]V%L#Y)_%6AI\AV3\<=M9*C[,RF3AS&/?(8:HVE6TWV,&<@S<2::<F
M*GT2/&)=*21R-;<>6A:-;O%,CV]R:1SL&C5:-I82 ZBI7SI7'"O5;'?C="9)
M(G2>W_M(5*N6JNI2A[0P;@M=.<$#H%LO_,;^1'3VZ.KJ[Y9_ _<'0?1_;F_,
M%UQANT\7WM@^UZK#9/=LOCQ*[EPF-H*=\;#5*'>9UK913%3"//-9&,4Y4M+^
M.06-XLTT2&0QF%X@ZH*MH9F.HCR! )&<#I"_,=S9O']9:&**1Q&)!*LA1F-%
MUJJC2#YD,P!Q7/1Q_DIWGWCU;7;+VKT%\5=X?)3>F\H<W735$6]<;U7MC"4N
M":E21\WN3)QU205=2:O51T<-#-+5+#4$-'XP6(-HVZVO [W5RMNB4'P-+(Y-
M?A1:5 IDE@!4<>CG<[Z>U*K;P-,S5_&L<: 4^)FJ037 "L30\.@U^(WS6SW?
MW8?<'0G<G1F<^./R,Z/AV_EMX==5^[:3L+'U>)W8';'9;#9ZA@I8*^FD01>4
M"F41/*D8>1A*(UF^\OKMD45S;S+/!-J"2!3&P9*:E9"25(KC)J,])=GWMMPD
MDMYXC#-%I+(6#J5>NEE8 !@:9P*'!ST6C&_S(?EOVAV5\@]G_&7^7)-WIM/X
M^=Z[_P"A-P;WJ?ESM;JN2?*=?5/V\\O\*S>&66*&H%I(O'55*A" [K)= =-R
MC864,#WM_P""\\,<ZH+664!9!4=R/Q'G4#]F>B<<TWMW+,EG9>,D,SPLYN8X
MR6CI7M9>&<4)QQIPZM$Z=W1V-O3K3:>Z.V^K?]"G8N7HJB?='5O]]Z'L?^#S
M1U$T<<'\;QD<5#D/+3I#-KAC55\GC/J1C[!=_#%;S,D$GBQ@T6308]8IQTM4
MC[#T+K*62>)7F3PG(JT>H/I/IJ7!^T="9[1]*N@B[T[,W#U'UIG-[[3ZGWWW
M=N>BJ,/CL#UIUS#3ODLA59VL@HH;S5<L-+14%,TXFK*N5]%+2QRS%7T!&7;=
M:)?3"-Y$A4U+225TJ%!/!022:4  R2!TDOKEK2(ND;RL* (E-3$D#\14 "M2
M2< $]$1V-\_>[MO_ " ZEZ%^8'PZR/QHG^0,F6QO3>^,!W3BN\,35Y;"4YJJ
MC"Y2;&X_'_PVL\1A6%OW5GDD 1!$KRH);GEFVEM9;JPNA<>!0RHT+0N$8T#*
M&9M0KQX$>?'H@M^8+B.YCM[VV,/C5$3K*)D+*"Q5B%32:<.(.:<.E1V-\X.V
M<KWIV/\ '_XA?%^H^2.YND*7"'NO>&X^UJ'IC;F&R&YJ7[R@P5'D*S'Y.3,9
MB2FL\Z10)#2_HEEUAUC8M.78$MH[J^N/ 68MX*+&9I'53I+$!D"K7 J:GR%,
M]/7.^3/</;6<'C-%I\5FD$4:EAJ"AM+EFH02 * ')KCI?=!?.'"=[]!]K=LX
MWJ/LO&]D=$YO?>Q^V?CCCZ6FW/NNAW/U_&7J<!CTAEAI\G-6DQK13!H8YV8A
MO$T<JHEW/EUMLN8X&EC,<RH\4YJL31R<'-150/Q"A(IYXZ4;?OB[A;R3+'('
MB+I)#@R"1.*BAH2<:36AJ.'1;LO_ #&_D1T]NCJZN^6?P/W!T'T?VYOS!=<8
M;M/%][8/M>JPV3W;+X\2NY<)C:"G?&PU2AWF=:V44Q4PCSS61C=.5+2_CD%C
M>+--$AD,9A>(.J"K:&9CJ(\@0"1G Z+'YCN;-X_K+0Q12.(Q()5D*,QHNM54
M:0?,AF .*YZ.I\A^Y>\NN<AL_:_0GQAW!\AMU[LI\U75N0J=_8WJC;&#IL,U
M,A?,9ZOAKI?NZMJG_):.EQ=1+,(9F8PHFOV'MKL+:Z#/<W @5:  (TLCDU^%
M05%!3)9E J*5..CO<;R>W*K;P&9FKDNL<: 4^)B&-37 56K3-!GH*OB'\T\_
M\@NPN[NB.W^C\K\>/D+T!/MFHWMU_4[SI.Q<?4XS>L3SXK*XG-T=-1QUD$\*
M(TB_:KXO+$NMW,BQKM]Y?3:XH;F"83P3AM#Z#&P9" RLI)H03ZFO'I)LV]MN
M,DMO-$89H2NM-0=2KU*LK "H('H"#@]%FQO\R'Y;]H=E?(/9_P 9?Y<DW>FT
M_CYWKO\ Z$W!O>I^7.UNJY)\IU]4_;SR_P *S>&66*&H%I(O'55*A" [K)=
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MQDNIIM-C#?R$3SI;HJZF=E9R<@415RS9K2H% 22.B[<KR6S0&&%IG8Z0JE5
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MX<__  NNK:>.2KQWW].JT];]E4-)#]Q$HCFT>1 %8#W'DRJCL$;4H)"M0C4
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MF)?PQ)G0P(P?0\,TZONO,,]I>"RM;;ZB3P?'/ZRQ +K\/&I2":\<CY5Z-/\
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M,+@L'CJW+YG,92J2AIJ6EQT;35%1432%8XH88D9W=F"JH)) 'NZ(TK!5!))
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M,5X5SQX=#/[0=+>O>_=>ZI\^76XLQ\_=_P"3_E^='5DG^BS;FY-MUGSI[II
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M31PU&3J:>AAIZ*"HKID>:2.G@CA1G*Q(J  1;/(LKLRJ$!8D("2%!-0 6))
MX"I)]3U(\*&-%5F+$  L: L0*5.D 5/'  ]!TI/;73G39FLUB-N8?*[@S^3H
M,+@L'CJW+YG,92J2AIJ6EQT;35%1432%8XH88D9W=F"JH)) 'NZ(TK!5!))
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MR6A\"XDK59+RY>/-0$UZ<?*JDX]>N?P]_P"WK?\ -X_ZAO@Y_P"\+5>[[_\
M\D/:O^HW_J^.FMB_Y+&Y_P#4'_U9;I;]L?$KY2;&^5N__EM\*>P>BL9N+O':
M.Q-H=V]8_(?;>;J\+7/U\J4>.S=!D=N31Y*'(T^+!@6%X_"Q!,CL)!X4ECOE
MG<V26.XI,5A:1X9(&0.OB9*D2 @J6S7B/+YK;O9[J"[>\L7B#2K&LR3*Q5M!
MH&!0@A@I(ID'%:= 1\ ,1W#D_P"8[_,*WAV]O'8N_-T[>V/\<>N]Y;AZMVC5
M[0VW%FCCJC(/AL9'79#)5E4<+1B&*>:>I,QE<K(D) C]F/,[VZ;38I CHK/<
MR*LCAY"FI5U'2J :B#0 4H//CTAY?2=MRO&F9794MXV:-"B!@KOI +N30,*D
MGSIBG5WON/.AOU[W[KW39FLUB-N8?*[@S^3H,+@L'CJW+YG,92J2AIJ6EQT;
M35%1432%8XH88D9W=F"JH)) 'NZ(TK!5!))  &22< #JK,$!9C0#))P !U4G
MU%29_P#F$?*O8'S#K<968+X@?&>/=]!\4Z+,T,N.KM];GW'&*#*[]EII0CT^
MW:.GC:GPZ2IY9Y4^]'B&N$C>^9>5[)[ &MU<:#<D$%88U.I8J^;DY>F!A<FO
M02LPW,%VEZ<6T.KZ<&H,LC#29?\ 2 55*BK5+<*5Q?$I6Q/\VO\ FL8[,120
M93<^V?AON?;35%@:G%XG:<U#4S0%O4\,57)!"Q4Z5D0H>5%K[ZPDV+;"N0K7
MBM\F,H8 _.F?LZ9V93'O.XZA34MHR_-1$RDC\Q3\NLG7=/-F_P">!\A,[AJQ
M9<-L;X&]<[(WK2TU276/,[LW-1YC%K4QJVE:@8FGF= RZA%+J6RR'52Z81<N
M0(P[GO9'0D?@2+0U/EJ(_,?+IRW0R;[*ZGM2SC1P#^-Y69:_,*#^1^?7#Y=;
MBS'S]W_D_P"7YT=62?Z+-N;DVW6?.GNFD#&CQ.+Q%5#7Q=?X2I7T5.[,W-3Q
M_=%&*8VFC99Q([RPQ^V*->68ANEP/U&5OHXO-G(*^*P/"-*X_C;A@5ZWO#MS
M YVZ _I@K]7)FBIAO"4@BKOY_P "Y.2!TW_,O$T&T?YCW\G*J3'ICMB8++_*
MS8F-$*B.DI*O-;-QE'AJ-=5TC>9HHUA7]3B$A>4%G>7Y/%VC=5K5V%J_S(69
MBQ_*N?MZ9WR/1NNV-3M!NEKY M"-(_.AI]G3G_,^IYL_WI_*KV?A*Q8-V57S
MRV1O>EIX:DPU$F&ZXIFKMPLB*RN].M')&DYY6TJH]Q)8M<G,(;?<I'%4^B=.
M& \C*J?G7(^S'#IWFI#-/81H:-]8C\<E(T=G_*F#]N>/13O@3TGW;V;VW_,T
MR_6'RX[)^/6)H/YCWR0QN0VSLSKW9N\:>MJ%R;2_?RS;DPF4JHIC'(D12*5(
MM,:MHUEF)[S3N-O9P[>LUK'.3M]N0SO,I TD4_3D04Q7(KGHEY9L9[J2^:*X
MDA O[@%42%@349_4C<US3!ICAUL&[-PV7V[M':VW]P;IR.^,]@]NX7$9K>F8
MHJ3&U>7J\;31PU&3J:>AAIZ*"HKID>:2.G@CA1G*Q(J  1;/(LKLRJ$!8D("
M2%!-0 6)) X"I)]3U(\*&-%5F+$  L: L0*5.D 5/'  ]!TI/;73G39FLUB-
MN8?*[@S^3H,+@L'CJW+YG,92J2AIJ6EQT;35%1432%8XH88D9W=F"JH)) 'N
MZ(TK!5!))  &22< #JK,$!9C0#))P !U4GU%29_^81\J]@?,.MQE9@OB!\9X
M]WT'Q3HLS0RXZNWUN?<<8H,KOV6FE"/3[=HZ>-J?#I*GEGE3[T>(:X2-[YEY
M7LGL :W5QH-R005AC4ZEBKYN3EZ8&%R:]!*S#<P7:7IQ;0ZOIP:@RR,-)E_T
M@%52HJU2W"E<7Q*5L3_-K_FL8[,12093<^V?AON?;35%@:G%XG:<U#4S0%O4
M\,57)!"Q4Z5D0H>5%K[ZPDV+;"N0K7BM\F,H8 _.F?LZ9V93'O.XZA34MHR_
M-1$RDC\Q3\NLG7=/-F_YX'R$SN&K%EPVQO@;USLC>M+35)=8\SNS<U'F,6M3
M&K:5J!B:>9T#+J$4NI;+(=5+IA%RY C#N>]D="1^!(M#4^6HC\Q\NG+=#)OL
MKJ>U+.-' /XWE9EK\PH/Y'Y]</EUN+,?/W?^3_E^='5DG^BS;FY-MUGSI[II
M QH\3B\150U\77^$J5]%3NS-S4\?W11BF-IHV6<2.\L,?MBC7EF(;I<#]1E;
MZ.+S9R"OBL#PC2N/XVX8%>M[P[<P.=N@/Z8*_5R9HJ8;PE((J[^?\"Y.2!U;
M92XO'8/ TV%Q%'!C\3A\1#B\904RZ(X*?'PB*"&-?PD4:*JC\ #V""Q=M1R2
M:D^I)Z%VD**#@!0=50_R*?\ MU_\=O\ M8]S?^]SN/V.?<S_ )+5Q]D/_5B/
MH&>WG_)'@_YN_P#5Z3HH?P)Z3[M[-[;_ )FF7ZP^7'9/QZQ-!_,>^2&-R&V=
MF=>[-WC3UM0N3:7[^6;<F$RE5%,8Y$B*12I%IC5M&LLQ.^:=QM[.';UFM8YR
M=OMR&=YE(&DBGZ<B"F*Y%<]%/+-C/=27S17$D(%_< JB0L":C/ZD;FN:8-,<
M.M@W9N&R^W=H[6V_N#=.1WQGL'MW"XC-;TS%%28VKR]7C::.&HR=33T,-/10
M5%=,CS21T\$<*,Y6)%0 "+9Y%E=F50@+$A 20H)J "Q)(' 5)/J>I'A0QHJL
MQ8@ %C0%B!2IT@"IXX 'H.E)[:Z<ZXNZ1HTDC*D:*SN[L% "BY))X  ^I]^Z
M]U3Q0Y.I_F$?.'JWL/8BM/\ $'X*9_=^3H>S892*7??9F4I1CC28)OTUF"VG
M S-+D(V\4U89*>+S0.)E';(.6-NDBE_W*O%0&/SAMP==6]'D(%%XA<FAH.@>
MKGF"_CDC_P!Q[4N1)7$MP04HN,K&":M7+&@K0]9OB/*TW\V?^;!_%Y)9,I2X
M#X8TVWEJ@24QC;0G>=*>YTI3FH-.S!19I&+-ZRQ-M] &Q[9II0M>%J>;>* *
M_.G\NF]E).\[CJK@6@6M<+X35I\J_P Z]9=APY#_ (?#[VFQ%UVY_L@&PEWD
ML2)I;,R;MH_X2TI"ZO*,7'6A+L+I>X("Z:7!7^KD(;X_KI-'^D\$:O\ C17I
MR$/^_I2OP?11Z_\ 3^,VG_C(;J%\G<M-\_?D7UU\0.I_]RW2GQX[:VAV_P#,
M?MBAFOCZ;(;#D>KP?7>-J%O'6YNOK )<FL;?[CH4C9G^X62G][V=!RU:27T^
M)IXGBM(B.XK(-+S'T4"H3^(D^0KU[='._7*6<.8H9$EN9 <!D.I(A@U8L 6_
MA49R0.K2^T^T^O\ I3K_ '3VEVENG%[,V'LS%S9?<.X<O-XHH8HK!550#)-/
M-(4CAAC1Y9I72*)'D=5(-L[.7<)5AA4N[FBJ.)/^KB> &3T*;JZCLHVEE8*B
MBK,<  =5Z? ?878W97;/R!_F!=N;6RG7F1^2E-L_:/1_6.;_ &LAANNMA1M_
M"*S,0W/VV7W'+)]_-2ZG^U72 ]YF1!3S+<PVD$&V0,)!;ZWFD7X7N)*:@I\U
M0 *&QJR>%.@[L$$MS+-N$ZE#-H6*,_$L$==)84PSEBQ7.D4'&O1&?@3A?F5D
MNV_YFDWQN[ ^.FT]JI_,>^2$6=H.Y>M-P[VKI,@,FQ,U)48;<F%ABI#3&!?'
M)!(_D5V\FE@H$O-,E@D.WB[CG=OW?;T,4L:+ITG!#Q2&M:YJ/LZ#O+,=Z\E\
M;:2%5^ON*B2)W.JHR"LL8I2F*'[>M@W9L.[*;:.UJ??M?@LKOF#;N%AWEE-K
M8Z?#XRHRL=-&,A/CJ2IJ*NIIJ&6K$K012U4LD<157D=@6,6SE"[&(,$U'2&(
M+!:X!( !-.)  )\AU(\(<(HD(+4&HJ"%+4R0"6(%> )-/4]*3VUTYUQ=TC1I
M)&5(T5G=W8* %%R23P !]3[]U[JGBAR=3_,(^</5O8>Q%:?X@_!3/[OR=#V;
M#*12[[[,RE*,<:3!-^FLP6TX&9I<A&WBFK#)3Q>:!Q,H[9!RQMTD4O\ N5>*
M@,?G#;@ZZMZ/(0*+Q"Y-#0= ]7/,%_')'_N/:ER)*XEN""E%QE8P35JY8T%:
M'K-_*7E:HW#_ #,Y\G)++N<_S,OD;#DWJP3,*2F_AJ8]"6/^8C J%A4 *B"R
M>FP%N>0%7;PM-/[NMZ4X5.NOYUX_/IODXEFORU:_7S\:UH FGCY4X?+K+\ H
M<@GSV_F[R4EQLJ3N7H%<3'&B+$,RNVLDVX&4JH)E9I,=Y+L>0"0&+%J<S%3M
M>UU^/PI]7^D\7L_Y^Z<V .-QW$_@\6#3_I_!&O\ PKU"^3N6F^?OR+ZZ^('4
M_P#N6Z4^/';6T.W_ )C]L4,U\?39#8<CU>#Z[QM0MXZW-U]8!+DUC;_<="D;
M,_W"R4_O>SH.6K22^GQ-/$\5I$1W%9!I>8^B@5"?Q$GR%>O;HYWZY2SAS%#(
MDMS(#@,AU)$,&K%@"W\*C.2!U8SW]2?)*LV?0Q_%[.=*X'?JYR-\I4]Z;=S>
MY,4^-%+5!XJ>+ Y''54-<:TT165WEB6%9@86=D*A7;&M%D/UBRLE,"%D5M51
MQ+JXI2N* UIGH1;@MRR#Z5HU>N3*K.NFAQ1'0UK3->%<=58? 6HW=U;\\/E-
MU7\LZ&+)?-ON?8>TN['[0VIN,9;:&=V+M2H; 8N@VYC7QV-J]O+B)RT3TM4*
MJHJ?%),]4XB#2#/F94O-LMI[$TLXG>'PV6DJ3L!(Q=@S!]0R&&D#AI'04Y?9
MK7<+B&[S=2HLQ=6)B>%28U" @:-)K53J)K74WD!_P)POS*R7;?\ ,TF^-W8'
MQTVGM5/YCWR0BSM!W+UIN'>U=)D!DV)FI*C#;DPL,5(:8P+XY()'\BNWDTL%
M!GS3)8)#MXNXYW;]WV]#%+&BZ=)P0\4AK6N:C[.BWEF.]>2^-M)"J_7W%1)$
M[G549!66,4I3%#]O6P;LV'=E-M':U/OVOP65WS!MW"P[RRFUL=/A\9496.FC
M&0GQU)4U%74TU#+5B5H(I:J62.(JKR.P+&+9RA=C$&":CI#$%@M< D  FG$@
M $^0ZD>$.$42$%J#45!"EJ9(!+$"O $FGJ>E)[:Z<Z:<]GL)M;"9;<NY<MC<
M!M[ 8VLS&;S>8K(\=24E)CHVEJ*FIJ)62*&"&)&=W=@JJ"20![O'&TS!$!+$
M@  5))P  //JKN(P68@ "I)P !YGJJ#XPT^X?F7\R<W\_JC$Y+;OQXZVZVS'
M1'Q'7*PR8^KW7%FJXS[DWV])*JRTN+K)(OL\8' :JI@*AXXFC <:[P4V"P&V
M AIY)!-=4R(BJT2*OFPJ6?T/;4YZ">UZ]YO3N!!$*1F*VKQD#,"\M*84Z0$]
M0"W CJ#_ "EY6J-P_P S.?)R2R[G/\S+Y&PY-ZL$S"DIOX:F/0EC_F(P*A85
M "H@LGIL [SR J[>%II_=UO2G"IUU_.O'Y],\G$LU^6K7Z^?C6M $T\?*G#Y
M=9?@%#D$^>W\W>2DN-E2=R] KB8XT18AF5VUDFW RE5!,K-)CO)=CR 2 Q8M
M3F8J=KVNOQ^%/J_TGB]G_/W3FP!QN.XG\'BP:?\ 3^"-?^%>H7R=RTWS]^1?
M77Q ZG_W+=*?'CMK:';_ ,Q^V*&:^/ILAL.1ZO!]=XVH6\=;FZ^L ER:QM_N
M.A2-F?[A9*?WO9T'+5I)?3XFGB>*TB([BL@TO,?10*A/XB3Y"O7MT<[]<I9P
MYBAD26YD!P&0ZDB&#5BP!;^%1G) Z2W\Q?Y']';G^173_P (>[>U]G=4](18
MS&?(+Y-Y+>F83"P[AQNW<@IVOL*G\B_Y3'F\O2_>Y0+8)CZ-4$@>;27^5=IN
M8K27<;:)Y9JF"W"*6,;,O?*:<"BFB?TFK^'IGF/<[=[F.PN)$CBTB:<NP4.J
MM1(Q7B&8$M_16A^+I&?RX?DU\>=T_.[^8AA=K=O;!R]?WEV]UIF.FL=C<Y#(
M^XJ/9^TJR3)38A%(^YCH(H)FET#T"-[CTFS_ #7LUW!MMBTD4BB&*02DJ:1E
MIC0-Z5J*5]>F>7-WM9[^\5)8V,LJ&,!@2X6!:E<YI0UIPH>@2_DY;?\ GK7_
M  'ZQJ.B>SOBQMKK>7<?9PP^*[1ZDW1NO-0S+G\@M6T];C-UXJBEC>J$KQ 4
M*E(RJ.7(+$T]P9=L7=91<Q7+24CU&.:-$/Z:TH&A<\*5SQZ*^18MP;:XC!);
MJE9*!X9'8?J/6I69 <UICAULIB]AJ(+6&H@:1?\ -A<V_P!N?<1=2AUW[]U[
MIISV>PFUL)EMR[ERV-P&WL!C:S,9O-YBLCQU)24F.C:6HJ:FHE9(H8(8D9W=
MV"JH)) 'N\<;3,$0$L2  !4DG   \^JNXC!9B  *DG  'F>JH/C#3[A^9?S)
MS?S^J,3DMN_'CK;K;,=$?$=<K#)CZO=<6:KC/N3?;TDJK+2XNLDB^SQ@<!JJ
MF J'CB:,!QKO!38+ ;8"&GDD$UU3(B*K1(J^;"I9_0]M3GH)[7KWF].X$$0I
M&8K:O&0,P+RTIA3I 3U +<".H/\ *7E:HW#_ #,Y\G)++N<_S,OD;#DWJP3,
M*2F_AJ8]"6/^8C J%A4 *B"R>FP#O/("KMX6FG]W6]*<*G77\Z\?GTSR<2S7
MY:M?KY^-:T 33Q\J</EUE^ 4.03Y[?S=Y*2XV5)W+T"N)CC1%B&97;62;<#*
M54$RLTF.\EV/(!(#%BU.9BIVO:Z_'X4^K_2>+V?\_=.; '&X[B?P>+!I_P!/
MX(U_X5ZA?)W+3?/WY%]=?$#J?_<MTI\>.VMH=O\ S'[8H9KX^FR&PY'J\'UW
MC:A;QUN;KZP"7)K&W^XZ%(V9_N%DI_>]G0<M6DE]/B:>)XK2(CN*R#2\Q]%
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M2#7(J*C\QTEO;47T+PEF4.I4LAHP!%*@T-#^75=^Q_Y4E'UGM+ ["Z\^>_\
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MK4/+T,$$L*O+JGKXLQ>LS$KIKJI04&   H\AT!^Q_P"5)1]9[2P.PNO/GO\
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M49C"2-CUJU266$U3PSZ0LL3%(V02\L;[%R_.T\D/C$H50^)X;1L?Q*=#]U,
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MX(-;GFE;E7!LK(%PP+B.76"U>X$S'NS6IKGCT7P<O/ RGZN[(4@Z2T6D@>1
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M.9H8WD+NL0D94U$ GZD$BX>.H1F45K0,>A>8E;X@"?4@=%>^//PRVYT%WO\
M*+NNDRN S1^0F]-G[KV[@:78T&!?:\>VL0^+J*.EK%JJC[B.N,C.QBIZ0*H"
M,DE]7LXW3?6W*VMK<@CP$="VLGQ-3EP2*"E*TXGHKV_:%L)YY@0?&=7 TTT:
M8U2E:FM:5X#C3Y]$S^/G\N/YL?%7K'&=+=%?S%ML[;ZRV]E=PY';V&SOPUP^
MZ:N'^\5;/73":NJ=V"6=S-.Y)TJMS9$1;*!%NO-FW;Y.;FYL7:1@H8K=LJG2
MH7 \$TP/7H@VSEJ^V:$6]O=H(U+%0UL&8!F+9/C"O'T'V=7 ;/Q^XL3M+:V*
MWAN*#=^[<9MS"8_=.[*;"IMN/*9&BIHHZ[(QXZ*6>*@2MJ5EF6F2:18 XB5V
M"AB YV1W8QKI4L2JDZBJDX%:"M!BM!7CT,XE95 <ZF  9@* FF32II4^5<=*
M+VUTYT0W^8#\/]_?-3JW;/5>TN_9ND=OT>\:#<N^\=)L =@4.Z*3% 24V'RM
M*,QA)&QZU:I++":IX9](66)BD;()>6-]BY?G:>2'QB4*H?$\-HV/XE.A^ZF
M:5'$'H@YAV>7>X5ACE\(:PS@IXBR*/P,-2=I-*BN1@\>H'2_Q\^<G7^\MEU'
M8'SCV'V#U1MD+1Y/JO;OP\P?6*U5#2TDE/2T5)DJ+<52V+BIG^W9/%2,H2+Q
M! K<;W#<]MN8W$-I(DC9$C7324-022IB757/GYUZ]96-_!(IEN8WC'%%MA&2
M*4 #>*U*&GD?3I$;[^#7=^V._.U.^OAU\I*;X^U7?R8>I[IZ_P!Y=24O<&#K
M,O@X5I:?<>)AGR>-DQ>5%,)!.EY8:N1R\U@B*JFVYCMIK6.UO[<SB"O@R)*8
MG5&))1CH?4M>' KY<>D\^Q3Q7+W-E.(O& \5'C\5&90 '4:T*M04.:-BHQTO
M.M?@]7],_%[M_I?K#O/=F&[O[OR&^-Z]@?*C*;?ILEG:S=W8# U^X3CX9Z2&
M$1H!%24T-9&:6,*\=0:G74.FO.8AN%Y%<30J880B);!B$$4?!*G4<\22#4DX
MICI1:[&;&UD@BE82REW:<JI<ROQ>@TC& !B@ %?/HL_1O\OGYR_''KC#=4]/
M_P POKO:NSL+)65:TX^#V%R555UF3D,M9D<C75.\):O(9&LF)>:HGF>1S9;A
M$1%-]RYGVW=IFGGL9&9O^7Q@ !@*H$- H& !@=%=AL&X;;$L,5W$%7UM*EB<
MEF/CY8G))XGHU?;72'S:RN]JK='1GS2P&P=OYK!X3'Y?8'8/QZQG8M#25^-I
M8J6HRV$JHLIBZ^D:M:-IY*.HFJJ83$E"JLP8DL=PV^./1<VK.P8D/'.T;$$U
MTL"C@TX @*:<:XZ.+RSO7?5;W"H" "DD(D (\U(>,BOF"6'I3-5#\2/A]B_C
M$>S]X[@[%W)W=WSWKN#%;G[K[LW;BZ/ 569J,! ]+CJ:EQE HH\3BL;!)*M-
M21O((O(X\A01I&WOF^MO'AQJBPPPJ5AA4LP0,:DDL:LS'B3QZMM&S+M>MV<R
MRRD-+*P4,Y4:1A0 % X <,]$E^/G\N/YL?%7K'&=+=%?S%ML[;ZRV]E=PY';
MV&SOPUP^Z:N'^\5;/73":NJ=V"6=S-.Y)TJMS9$1;*!'NO-FW;Y.;FYL7:1@
MH8K=LJG2H7 \$TP/7HAVSEJ^V:$6]O=H(U+%0UL&8!F+9/C"O'T'V=7 ;/Q^
MXL3M+:V*WAN*#=^[<9MS"8_=.[*;"IMN/*9&BIHHZ[(QXZ*6>*@2MJ5EF6F2
M:18 XB5V"AB YV1W8QKI4L2JDZBJDX%:"M!BM!7CT,XE95 <ZF  9@* FF32
MII4^5<=*+VUTYT33YG_";8/S>VEL79W8?8/;>P\9L#>])O\ Q;=5[@QV'-3D
M,=&R4K9"#*XG,4=6E([&2$-3!HY+D-I9E)_R_P PR<NR/)%'$Y=#&?%5C16X
MT*LA!/ YX=$N][(F^(B2/(@1UD!C*@EEX5U*P(!S2G$#I+=4?!S/]7]A;9W[
M5_.+YT=H4^W*NHJI=A=H]M87<& R0GIYH!%DJ.FVO13SPH91*H2JC(E1&O8$
M%Z^YA2\B:(6=G&6IWQQR!UH0<$RL/*G XZ;M-D>UD60W5U(!7LD:,HV",Z8E
M/G7!&>FKM[^7?LO?_<VZ._NL.\?D'\7^S>Q<-B]O]L93H'>-#M^FW1!A$2&B
MJ,K0Y'%Y.G_BE#3J8J:MA6*6-7D)#L[,;V/-,EM;K:S0P7$<;%HA.K$Q%LD*
M4=#I8Y*FH) Z;O.7$N)VN8I9H)'4+(864"0#AJ#HXU*,!@ 0"17K%NC^6=\?
M\]\0LG\,,1N#MK9'6^X]R)O'>N[MK[TB?=.X<K45B5V0K\_E<E0Y"+*SY6HC
MC-4)J(QE8X8X4AC@A1-P<W745^-Q98GD5=*(R?I(H72H55*Z0H^&AXY-23UJ
M?EBWELFL%:1$8ZF97_49BVIBS,&J6/Q5&1C ITR;%_ER9'8.2V=48OY[?/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tbar_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tbar_005.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M_C?[^8W_ /,<]^Z]U?\ >_=>Z][]U[KWOW7NO>_=>Z][]U[K51Z0_P"WZ_\
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MNO>_=>Z][]U[JKK^=7_VZN^;/_B'JC_WH\![T>!ZV.(ZV?\ 97_'F[2_\-G
M_P#NJI?;'3_2F]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U0#_ ""_^ZU'_C?[^8W_ /,<]^Z]U?\ >_=>Z][]U[KWOW7NO>_=>Z][
M]U[K51Z0_P"WZ_\ /R_\Q9?_  'F6]N1^?3<GEU:=[<Z;Z][]U[KWOW7NO>_
M=>ZJZ_G5_P#;J[YL_P#B'JC_ -Z/ >]'@>MCB.MG_97_ !YNTO\ PV<#_P"Z
MJE]L=/\ 2F]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$4^7WR:^4?
M06:V5COCY_+^[3^:&-W'B\M6[DS?77<72'6$&Q*Z@JZ2"@Q65I.W=S[;J,M+
MFJ>HDFBDH?,D0@99=!9-7NO=5B[ _G9_+GM'NWY ?'+8?\F+Y);@[H^+7^BG
M_3ULB+Y-_%.BJ>OO]-VTJS?75OW67R>]:+;N;_O9M3'S5:?PNLKOME314^&4
MA#[KW5]_6FX]R[QZYV!N[>FQ,GU;O'=6R=J[CW9UEF\MA<_F>NMRYS!4&3SN
MQ,OG=MU5=MW-9/:.4JI<?45=!--15,M.TD#O$RL?=>Z6WOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ ?Y!?_=:C_P ;_?S&_P#Y
MCGOW7NK_ +W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J/2'_;]?\ GY?^8LO_ (#S
M+>W(_/IN3RZM.]N=-]>]^Z]U[W[KW7O?NO=5=?SJ_P#MU=\V?_$/5'_O1X#W
MH\#UL<1UL_[*_P"/-VE_X;.!_P#=52^V.G^E-[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[J@'^7A_P!OU_\ A15_YB-_^ \WM[]U[J_[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4 _R"
M_P#NM1_XW^_F-_\ S'/?NO=7_>_=>Z][]U[KWOW7NO>_=>Z][]U[K51Z0_[?
MK_S\O_,67_P'F6]N1^?3<GEU:=[<Z;Z][]U[KWOW7NO>_=>ZJZ_G5_\ ;J[Y
ML_\ B'JC_P!Z/ >]'@>MCB.MG_97_'F[2_\ #9P/_NJI?;'3_2F]^Z]U[W[K
MW4>K-4M+4M0QT\U:M/,:.*KFDIZ66J$;&GCJ:B&"JE@IWEL'=8I&522%8BQ]
MU[JF'X$?+7YY=Y_*'N_9?>W5'7^T>FZ3)9G<.S=RP;C[$?&5&!V)XNALQC/C
MM3Y[XO=29O=^S\CW9UMG-Q9BNWWDZ?+4\.Y*-<"N8P#4617W7NKIO?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5%
MOS'_ )E7S-ZN^>.6^%/Q-^+G1G<U1MKXR=>_(S<F[NW^\]T=4-34F^^Q.P=@
M)@L=18+KG>\->U'4;*2;R,\1(J&!'H!;84GAUHL!QZ#C_9^/YTG_ '@'\'O_
M $M#L;_[GSW;0>JZQU[_ &?C^=)_W@'\'O\ TM#L;_[GSW[0>O:QT17H/+_S
MB>A_FS\__FA0_$3X9;CS/SU_V57^.[#J_EEOO'XSKC_96^I<SU3C/X3G(>CJ
MFJW#_>^ES!K)_-3TOVDB"-/(#J'M!Z]K'1ZO]GX_G2?]X!_![_TM#L;_ .Y\
M]^T'KVL=!QW%_-*_F^]'=1]I]U[V^ 7PP.S.G^N-[]I;N&&^8O8=?ESMCK_;
M.3W9GQBJ&3H2ECK<D<5B)?!$TL:R2Z5+J#<>*$9Z\'!QU>M\0.\:WY.?$OXN
M_)/)[>I=I9'Y"_'7I/O'(;5H:^;*T6V:WMGK3;._:O;U'E*BFHY\E2X6?/M3
M1U#PQ/,D8<HI)44ZOT8KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=4 _P @O_NM1_XW^_F-_P#S'/?NO=7_ 'OW7NO>_=>Z][]U[KWOW7NO>_=>
MZU4>D/\ M^O_ #\O_,67_P !YEO;D?GTW)Y=6G>W.F^O>_=>Z][]U[KWOW7N
MJNOYU?\ VZN^;/\ XAZH_P#>CP'O1X'K8XCK9_V5_P >;M+_ ,-G _\ NJI?
M;'3_ $IO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:W';?_;_ '[K_P#&6GQT_P#@
MEN]_;D?GTW)Y='G]N=-]>]^Z]U[W[KW7O?NO=$L_F2_]NZ_GQ_XI9\IO_?&[
MZ]Z/ ];'$=6:?RG?^W67\M/_ ,4 ^&__ ,#KUS[8Z?Z/_P"_=>Z][]U[KWOW
M7N@TWUW'U=UCG=@[;["WQ@=G9CM#);IQ&PZ?/U1Q\&XLELC8FY.S]V4E-D9T
M7&TTN"Z]V=E<Q/\ <31!:#'5$H)6)[>Z]T(5%6T>2HZ3(XZKIJ_'U]-!6T-=
M13Q55'6T=5$D]+5TE5 \D%335,$BO'(C,CHP()!]^Z]U)]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4
M _R"_P#NM1_XW^_F-_\ S'/?NO=7_>_=>Z][]U[KWOW7NO>_=>Z][]U[K51Z
M0_[?K_S\O_,67_P'F6]N1^?3<GEU:=[<Z;Z][]U[KWOW7NO>_=>ZJZ_G5_\
M;J[YL_\ B'JC_P!Z/ >]'@>MCB.MG_97_'F[2_\ #9P/_NJI?;'3_2F]^Z]U
M[W[KW7O?NO=>]^Z]UKA?/SXY_P S'XR_%;Y=?*[9O\Y[Y 5=1TETWW'W;MCK
M:H^+_P 1DV[(VRMLYS=V)V;)F:CK;(9X8A!0QT?W,DD]68AK9GDN3[KW1POY
M?/QU^;>-HNDOD1WS_,Z[B^2NT-]].[=W=FNB]W]#?'78VUOXSV#LC&9BEJ8=
MV=;[+V[NY6VM7Y+53J9C%4*EI4-P5]U[JWOW[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6MQVW_V_P!^Z_\ QEI\=/\ X);O?VY'
MY]-R>71Y_;G3?7O?NO=>]^Z]U[W[KW1+/YDO_;NOY\?^*6?*;_WQN^O>CP/6
MQQ'5FG\IW_MUE_+3_P#% /AO_P# Z]<^V.G^C_\ OW7NO>_=>Z][]U[JG/\
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M_P 4L^4W_OC=]>]'@>MCB.K-/Y3O_;K+^6G_ .* ?#?_ .!UZY]L=/\ 1_\
MW[KW7O?NO=>]^Z]U[W[KW06]Y?\ ,E.X/_$6]@?^\GE_?NO=$ _D>_\ ;H7^
M75_XJEU1_P"Z"'W[KW5J/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z2?\
M?W8OC\O]]-I^+^]G]PO)_>/#^/\ OU]S]G_<O7]YI_O9]Y^U_#K_ 'GD]/CU
M<>_=>Z5GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z;,OF\-MZADR>?R^+P>-A-I<AEZ^DQM#$2K,!)5ULL,"$JA/+#@'
M^GOW7N@NH?D7\?,GEJK 8WO;IO(9VB$AK<+0]G[)J\M2"*:*GE-5CH,Y)64X
MBJ)T1M:#2[JIY('OW7NA>IZFGK((:JDGAJJ:HC66"HIY4G@GB<722&:)FCDC
M<&X()!'OW7NLWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[J@'^07_W6H_\ &_W\QO\ ^8Y[]U[J_P"]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW6JCTA_V_7_ )^7_F++_P" \RWMR/SZ;D\NK3O;G3?7
MO?NO=>]^Z]U[W[KW577\ZO\ [=7?-G_Q#U1_[T> ]Z/ ];'$=;/^RO\ CS=I
M?^&S@?\ W54OMCI_I3>_=>Z][]U[K5B_E._\R [L_P#%\?GI_P#!3=E^WD^'
MIE_BZL]]VZKU[W[KW7O?NO=>]^Z]U4+_ #8?^/Y_DV?^-TOY>7_NX[&]T?AU
M=./6VU[:Z=Z][]U[KWOW7NO>_=>Z(%\<_P"6Q\9?BOW+O_NWI/ 93KW.[\SN
M0JI=G;"KDZYZAQ&S9^O^M-A8/K.EZ<V!!MOK&LVAL4=;#*;?-3BI:_$Y7-YB
MHAJ ^4KVJ/=>Z/;E<3BLYCZG$YO&8_,8JM01UF-RM'39#'U<:NLJQU-'5QS4
M\Z+(BL ZD!@#]1[]U[JCSNO^0%\*NZ,C\\=S56T]F;.WY\RJ"GQ^S=][)ZWQ
MNTL_\;Z9^A=E=,9S'[0DVCG=MQ;PP&Y<UM"3=-?C*\04%7ELE4_<13%VE?W7
MNK*OC+\5,;\7\?DL-M_N[Y(=G;=KL3@,9C]L][=P[A[DQNTFP5*:0U&S\YO[
M^.]AT$>2@"+-3UN=R%.JPH8U1S(\GNO=&I]^Z]U[W[KW7O?NO=>]^Z]TTYW/
MX+:V(K]P;FS6)VY@<5!]SD\WG<E1XC$8ZF#*AJ*_)9":GHJ. .X&N1U6Y OS
M[]U[IV]^Z]U[W[KW3!2;LVM7C#-0[EV_6C<;U\>WC29G'5(STF*2:3)QX8PU
M+C*/CHZ:1IQ!K,(C8O8*;>Z]T_\ OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM;CMO_M_OW7_ .,M/CI_
M\$MWO[<C\^FY/+H\_MSIOKWOW7NO>_=>Z][]U[HEG\R7_MW7\^/_ !2SY3?^
M^-WU[T>!ZV.(ZLT_E._]NLOY:?\ XH!\-_\ X'7KGVQT_P!'_P#?NO=>]^Z]
MU75V?_-R_ED]*]@[MZI[:^<7QSZ\[)V'F:G;V\MD[L[$Q&'W'MO-TFG[C&Y;
M&U3I/2548=3I8<JP(N"#[]U[I!_\/A?RA?\ O8K\4O\ T:^ _P"OWOW7N@[[
M?_G8?RE<SU-VCA\5_,*^+-?E,KUUO;&XV@I>T\#+4UM?7;:R=+1TE/$LVJ2>
MIJ)51%')9@/?NO=$J_E#_P WC^6)TY_+$^#'5G:?SG^-^PNQMA?&_K?;.\]F
M;F[(PN,W!MG<&,PL4&0Q&7Q\\HFHZ^CF!62-A=3[]U[JQG_A\+^4+_WL5^*7
M_HU\!_U^]^Z]TY8?^=5_*:W#E\5@,%_,%^+V7S><R5#A\/BL?V?A*JOR>5R=
M3%18_'T-+#(TM365M7.D<4:@L[L !<^_=>ZL_P#?NO=>]^Z]U[W[KW7O?NO=
M-.*S^"SLF6BPF:Q.8EP&6GP&=CQ62H\A)A<[2TU)65.%RR4DTS8W+4])7P2O
M33:)DCFC8J%=2?=>Z#+Y"U>$H.B^VZ[<N1[9P^WZ+K_=%7FLOT/1;OR7<^+Q
ME-BJF:LR/6&.Z_QF:WMD-[4,"&7'P8NCJZV6H55BAE8A&]U[K3O[ ^0.Y*[;
MW\S#:O0W\TW&=@39&FZFW)0]3?-?JVCV_P#+'M+8L76.QX)/]&>'P\GQ*[+Z
MRS?7^Y:I<(9*_8V:E%92/-6PR54CA_=>ZV[?CEN3Y,[CVSN-OE#UQTQL'=6-
MW144.TJ[HOMC=':FS=^;)./H*K&[Q=MW]9]:9O9F3K*NHGADQ#IE4B6%9$KI
M5D 7W7NC#>_=>Z][]U[KWOW7NO>_=>Z][]U[IIQ6?P6=DRT6$S6)S$N RT^
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M_P! K;7_ -;/?NO=>_T0]3?\^OZ[_P#0*VU_];/?NO=>_P!$/4W_ #Z_KO\
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M^]/^RT?\)]?YJ?QW_OQ_!/[Z_P"@O^5%U%U)_?#^[/\ %_[N?WI_N!V9M_\
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M\IW_ +=9?RT__% /AO\ _ Z]<^V.G^C_ /OW7NO>_=>ZU>_@_P#]E0_SB_\
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M[]U[KWOW7NO>_=>ZH,^5?_"CK^7_ /&KMK>/0NR\%\C/F1W%UWE*O ]A[/\
MAQU/3]KTVP,]15%;CJS%;LW5E]T[.VQ%4XS.41Q];%CZK)5-'6L89(1)'*B>
MZ]U6CM[<?\A+^=1\AJ'$[2VI\@_Y;?\ ,SE@S6>Z[WG18*I^$_RXR.4J,;5"
MHW%B<EL7/;CZQ[7W%5;9Q#RA:^;)YX83SK3M3H:@I[KW1VI-Q?SZOY:DB)N3
M;VS/YU'Q:QM5&)MS;03$]"_.[8VVEJJVLR5=DMI.,AL/N<X#!4RPTE-0/59_
M-Y&9%DDI8M<B>Z]T?/X5_P YKX&?./<)ZQV)V;D>I/D=03+C]R_%/Y(8"IZ4
M^0^V\^M/#45NW3L?=,J4N[,KC5F_RA=OUN72$ EV4>_=>ZM4]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4 _R"
M_P#NM1_XW^_F-_\ S'/?NO=7_>_=>Z][]U[KWOW7NO>_=>Z][]U[K51Z0_[?
MK_S\O_,67_P'F6]N1^?3<GEU:=[<Z;Z][]U[KWOW7NO>_=>ZJZ_G5_\ ;J[Y
ML_\ B'JC_P!Z/ >]'@>MCB.MG_97_'F[2_\ #9P/_NJI?;'3_2F]^Z]U[W[K
MW6K%_*=_YD!W9_XOC\]/_@INR_;R?#TR_P 75GONW5>O>_=>Z][]U[KWOW7N
MJA?YL/\ Q_/\FS_QNE_+R_\ =QV-[H_#JZ<>MMKVUT[U[W[KW5'G_"B7_MUW
MO_\ \6'^$G_P8W1_O8XCK1X'H8_;_3'7O?NO=>]^Z]U[W[KW7O?NO=$)_E ?
M]OAO^% 7_F*?_P"!>[,]LO\ %T\GP];*WNO5NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>ZUN.V_\ M_OW7_XRT^.G_P $MWO[<C\^FY/+
MH\_MSIOKWOW7NO>_=>Z][]U[HEG\R7_MW7\^/_%+/E-_[XW?7O1X'K8XCJS3
M^4[_ -NLOY:?_B@'PW_^!UZY]L=/]'_]^Z]U[W[KW6KW\'_^RH?YQ?\ XT^[
M&_\ ?']$>W4X=-/QZLD]WZIU[W[KW7O?NO=>]^Z]U5?_ #D_^R(ZG_Q93X6_
M_!<=+^ZO\/5D^+K:P]L]/=>]^Z]U[W[KW7O?NO=)7?&^MD=8[0W'V#V5O+:O
M7NP=GXFKSV[=[[XW#B-I[0VM@Z",RUV9W'N7/5F/PN$Q-%$-4M14SQ0QKRS
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M#&Z/]['$=:/ ]#'[?Z8Z][]U[KWOW7NO>_=>Z][]U[HA/\H#_M\-_P * O\
MS%/_ / O=F>V7^+IY/AZV5O=>K=>]^Z]U[W[KW7O?NO=5[_.3_AUK[SK7_AM
M7_AO;^'_ &NZ_P#3!_L\G^S'_>?>>7;W]Q_]&O\ H#_8^U\'\5_BW\4]>O[3
M[?CS>_=>ZIG[J^6G_"E3HGO#XG=!;NPO\C?([Q^8V^NP^ONLLEMS&_/>LVU@
MLSUIUCG>U\[4[[K,GN3#Y3&8RKV[MZ:&D?'T>4EDK61)(XHBTR^Z]U>9\)/^
M'%?[C;O_ .''O]DK_P!)7]ZT_N#_ +))_IS_ +C?W&_A%#Y/[W_Z=_\ <_\
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M  V<#_[JJ7VQT_TIO?NO=>]^Z]UJQ?RG?^9 =V?^+X_/3_X*;LOV\GP],O\
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M\/5D^+K:P]L]/=>]^Z]U[W[KW7O?NO=>]^Z]T0#^;%_VZR_F6?\ B@'S(_\
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M_P"*6?*;_P!\;OKWH\#UL<1U9I_*=_[=9?RT_P#Q0#X;_P#P.O7/MCI_H_\
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MXCK1X'HY7M_ICKWOW7NO>_=>Z][]U[KWOW7NBY?R7_\ F?\ _.-_\7QVC_\
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MN]_;D?GTW)Y='G]N=-]>]^Z]U[W[KW7O?NO=$L_F2_\ ;NOY\?\ BEGRF_\
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MXCK1X'HY7M_ICKWOW7NO>_=>Z][]U[KWOW7NBY?R7_\ F?\ _.-_\7QVC_\
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MOY>7_NX[&]T?AU=./6VU[:Z=Z][]U[JCS_A1+_VZ[W__ .+#_"3_ .#&Z/\
M>QQ'6CP/0Q^W^F.O>_=>Z][]U[KWOW7NO>_=>Z(3_* _[?#?\* O_,4__P "
M]V9[9?XNGD^'K96]UZMU[W[KW6NK_P *,?\ CQOY1?\ XW2^ W_NG[O]['$=
M:/ ]'*]O],=>]^Z]U[W[KW7O?NO=>]^Z]T7+^2__ ,S_ /YQO_B^.T?_ (%G
MI'VR_P 73R?#U?;[KU;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NM;CMO_M_OW7_ .,M/CI_\$MWO[<C\^FY/+H\_MSIOKWO
MW7NO>_=>Z][]U[HEG\R7_MW7\^/_ !2SY3?^^-WU[T>!ZV.(ZLT_E._]NLOY
M:?\ XH!\-_\ X'7KGVQT_P!'_P#?NO=>]^Z]UJ]_!_\ [*A_G%_^-/NQO_?'
M]$>W4X=-/QZLD]WZIU[W[KW7O?NO=>]^Z]U5?_.3_P"R(ZG_ ,64^%O_ ,%Q
MTO[J_P /5D^+K:P]L]/=>]^Z]U[W[KW6J?\ R;/^R(Z;_P 64^:7_P %QW1[
M>3X>F7^+JU#W;JO7O?NO=>]^Z]U[W[KW5=WRH_[+P_DS_P#B\.\__@6N\/='
MX=73CULX^VNG>O>_=>ZH\_X42_\ ;KO?_P#XL/\ "3_X,;H_WL<1UH\#T,?M
M_ICKWOW7NO>_=>Z][]U[KWOW7NBB?RUO^WP?\U[_ ,5X_EW_ /N#\BO;3\>G
M4X=;#?NG5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K2O\
MY7V\>[/Y$'S;[0_E.]H_$/N;>?Q9^7OS/7>_PX^4775'#D=BX^#MC'[7V3C\
M3OC<&[LMCL)/3[/V5L;''.TZY=]T4$V*JI(<;DTKJ!I?=>ZA?*7Y%9K^0K_/
M>^0_S5[ZZV[,W5\ _P"9=UOUSAJOL3KC:]-G#L#NC9&'VOB9,;D7K=R8RBK<
MC@_[KYK+ST+&&OJ\+G3)CH:N3'U$;^Z]U!Z7^9[?SUOY\WPA^07P^ZJ[*P7Q
M%_EO;)[BR/8O>?8>&DVY)N7<':FR\W@X]O46.Q]5EL?CWS&2EQE-CZ"IK(\C
M4T'\1JYX8HH4B?W7NMVOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_(+_P"ZU'_C?[^8W_\ ,<]^Z]U?][]U
M[KWOW7NO>_=>Z][]U[KWOW7NM5'I#_M^O_/R_P#,67_P'F6]N1^?3<GEU:=[
M<Z;Z][]U[KWOW7NO>_=>ZJZ_G5_]NKOFS_XAZH_]Z/ >]'@>MCB.MG_97_'F
M[2_\-G _^ZJE]L=/]*;W[KW7O?NO=:L7\IW_ )D!W9_XOC\]/_@INR_;R?#T
MR_Q=6>^[=5Z][]U[KWOW7NO>_=>ZJ%_FP_\ '\_R;/\ QNE_+R_]W'8WNC\.
MKIQZVVO;73O7O?NO=4>?\*)?^W7>_P#_ ,6'^$G_ ,&-T?[V.(ZT>!Z&/V_T
MQU[W[KW7O?NO=>]^Z]U[W[KW1"?Y0'_;X;_A0%_YBG_^!>[,]LO\73R?#ULK
M>Z]6Z][]U[K75_X48_\ 'C?RB_\ QNE\!O\ W3]W^]CB.M'@>CE>W^F.O>_=
M>Z][]U[KWOW7NO>_=>Z+E_)?_P"9_P#\XW_Q?':/_P "STC[9?XNGD^'J^WW
M7JW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M:W';?_;_ '[K_P#&6GQT_P#@EN]_;D?GTW)Y='G]N=-]>]^Z]U[W[KW7O?NO
M=$L_F2_]NZ_GQ_XI9\IO_?&[Z]Z/ ];'$=6:?RG?^W67\M/_ ,4 ^&__ ,#K
MUS[8Z?Z/_P"_=>Z][]U[K5[^#_\ V5#_ #B__&GW8W_OC^B/;J<.FGX]62>[
M]4Z][]U[KWOW7NO>_=>ZJO\ YR?_ &1'4_\ BRGPM_\ @N.E_=7^'JR?%UM8
M>V>GNO>_=>Z][]U[K5/_ )-G_9$=-_XLI\TO_@N.Z/;R?#TR_P 75J'NW5>O
M>_=>Z][]U[KWOW7NJ[OE1_V7A_)G_P#%X=Y__ M=X>Z/PZNG'K9Q]M=.]>]^
MZ]U1Y_PHE_[==[__ /%A_A)_\&-T?[V.(ZT>!Z&/V_TQU[W[KW7O?NO=>]^Z
M]U[W[KW11/Y:W_;X/^:]_P"*\?R[_P#W!^17MI^/3J<.MAOW3J_7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UKV_S$?^%!G3?Q%[PROP[^,_
MQS[L_F%_-+"X^:OW%TA\?,+D\GB]@3P1XRH@H-][FP&W=[[@CS83*P2O1X?
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M (W2^ W_ +I^[_>QQ'6CP/1RO;_3'7O?NO=>]^Z]U[W[KW7O?NO=%R_DO_\
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M*?-+_P""X[H]O)\/3+_%U:A[MU7KWOW7NO>_=>Z][]U[JN[Y4?\ 9>'\F?\
M\7AWG_\  M=X>Z/PZNG'K9Q]M=.]>]^Z]U1Y_P *)?\ MUWO_P#\6'^$G_P8
MW1_O8XCK1X'H8_;_ $QU[W[KW7O?NO=>]^Z]U[W[KW11/Y:W_;X/^:]_XKQ_
M+O\ _<'Y%>VGX].IPZV&_=.K]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW6NY_,8_P"$]?6'RX[TR7S(^)WR6[B_EV_-3,48I=S]S="UN7HL
M-V [5.+:JRF\]O;5W5UYN>+<]70XP0R9'%9_'?<2>.>MIZZ2%/?NO=5/]3_\
M)D_YKO3V]/D;G>M_YT]9U1+\L-S4&\OD%V)UMU[OW#=F]K;ICR^Z\]4Y_<5=
MC=^[?RM!DX\OV)GZ@24.=A-5)7.9=.L>+W7NK[?Y6'\D7XK_ ,K*IWSV+LO,
M[V[T^3W;--4TO:?R;[AJZ?)[_P _1Y+*IN'.8;;U-#Y8-IX'<.Y(DR&2435F
M2RM7# ]?6U?VU-X?=>ZN6]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4 _R"_\ NM1_XW^_F-__ #'/?NO=7_>_
M=>Z][]U[KWOW7NO>_=>Z][]U[K51Z0_[?K_S\O\ S%E_\!YEO;D?GTW)Y=6G
M>W.F^O>_=>Z][]U[KWOW7NJNOYU?_;J[YL_^(>J/_>CP'O1X'K8XCK9_V5_Q
MYNTO_#9P/_NJI?;'3_2F]^Z]U[W[KW6K%_*=_P"9 =V?^+X_/3_X*;LOV\GP
M],O\75GONW5>O>_=>Z][]U[KWOW7NJA?YL/_ !_/\FS_ ,;I?R\O_=QV-[H_
M#JZ<>MMKVUT[U[W[KW5'G_"B7_MUWO\ _P#%A_A)_P#!C='^]CB.M'@>AC]O
M],=>]^Z]U[W[KW7O?NO=>]^Z]T0G^4!_V^&_X4!?^8I__@7NS/;+_%T\GP];
M*WNO5NO>_=>ZUU?^%&/_ !XW\HO_ ,;I? ;_ -T_=_O8XCK1X'HY7M_ICKWO
MW7NO>_=>Z][]U[KWOW7NBY?R7_\ F?\ _.-_\7QVC_\  L](^V7^+IY/AZOM
M]UZMU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW6MQVW_V_P!^Z_\ QEI\=/\ X);O?VY'Y]-R>71Y_;G3?7O?NO=>]^Z]U[W[
MKW1+/YDO_;NOY\?^*6?*;_WQN^O>CP/6QQ'5FG\IW_MUE_+3_P#% /AO_P#
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M (W2^ W_ +I^[_>QQ'6CP/1RO;_3'7O?NO=>]^Z]U[W[KW7O?NO=%R_DO_\
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MYD!W9_XOC\]/_@INR_;R?#TR_P 75GONW5>O>_=>Z][]U[KWOW7NJA?YL/\
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M_P :?=C?^^/Z(]NIPZ:?CU9)[OU3KWOW7NO>_=>Z][]U[JJ_^<G_ -D1U/\
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M)_\ !C='^]CB.M'@>AC]O],=>]^Z]U[W[KW7O?NO=>]^Z]T0G^4!_P!OAO\
MA0%_YBG_ /@7NS/;+_%T\GP];*WNO5NO>_=>ZUU?^%&/_'C?RB__ !NE\!O_
M '3]W^]CB.M'@>CE>W^F.O>_=>Z][]U[KWOW7NO>_=>Z+E_)?_YG_P#SC?\
MQ?':/_P+/2/ME_BZ>3X>K[?=>K=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]UK<=M_P#;_?NO_P 9:?'3_P""6[W]N1^?3<GE
MT>?VYTWU[W[KW7O?NO=>]^Z]T2S^9+_V[K^?'_BEGRF_]\;OKWH\#UL<1U9I
M_*=_[=9?RT__ !0#X;__  .O7/MCI_H__OW7NO>_=>ZU>_@__P!E0_SB_P#Q
MI]V-_P"^/Z(]NIPZ:?CU9)[OU3KWOW7NO>_=>Z][]U[JJ_\ G)_]D1U/_BRG
MPM_^"XZ7]U?X>K)\76UA[9Z>Z][]U[KWOW7NM4_^39_V1'3?^+*?-+_X+CNC
MV\GP],O\75J'NW5>O>_=>Z][]U[KWOW7NJ[OE1_V7A_)G_\ %X=Y_P#P+7>'
MNC\.KIQZV<?;73O7O?NO=4>?\*)?^W7>_P#_ ,6'^$G_ ,&-T?[V.(ZT>!Z&
M/V_TQU[W[KW7O?NO=>]^Z]U[W[KW11/Y:W_;X/\ FO?^*\?R[_\ W!^17MI^
M/3J<.MAOW3J_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJV
M?R /YB?RV^4?<?\ ,2^,?\R+LC%X_P"1?3'=41V7\:-V[,VGLW<VR>O-T5.Z
MJO+8K;M7!M[;66[0V-@)Z.EBH*FHBK:J#&5%-4S5$M-D*'1[KW6QU0]"=%XO
M-R[FQO2W4V.W).:8S[@H>N=GTF;F-'X/LS+EJ?#1U\AI?M8O'>0^/QKIMI%O
M=>Z%GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW17/FA\N.J_@Q\:.U?
MD_W%4U)VEUEM^2OI=O8F2C_O1O[=E=(F.V=UQLJDK:BFAR6\M][CJ:?&XZ N
MJF></(R1)(Z^Z]T7G^4A\]<U_,M^!O4GS)W)UUB>I,GV7E>S<?4[&P^XZO=.
M-PT77_9>[-@131YZOQ>%J*LY*';(JGU4T8B:8H-074WNO=$PIOYJWSB^2N1[
MMW]_+9_EZ;3^3/Q<Z-W'NO8U!W)VE\FL5TCE?DUOWKW)9?%[^P?QLVO3["WU
M%D\#ALGB?LJ/.YNJQ^.RM7.! ?V9@ONO=69? _YK]8_/_P".&U_D3UAB=U;1
MAK\QN396_>M-_P",?"=B=1]I[&RLV"WYUCO["R!9,9N;;&6ALZD 2T\L,P 6
M4 >Z]T<;W[KW7O?NO=4 _P @O_NM1_XW^_F-_P#S'/?NO=7_ 'OW7NO>_=>Z
M][]U[KWOW7NO>_=>ZU4>D/\ M^O_ #\O_,67_P !YEO;D?GTW)Y=6G>W.F^O
M>_=>Z][]U[KWOW7NJNOYU?\ VZN^;/\ XAZH_P#>CP'O1X'K8XCK9_V5_P >
M;M+_ ,-G _\ NJI?;'3_ $IO?NO=>]^Z]UJQ?RG?^9 =V?\ B^/ST_\ @INR
M_;R?#TR_Q=6>^[=5Z][]U[KWOW7NO>_=>ZJ%_FP_\?S_ ";/_&Z7\O+_ -W'
M8WNC\.KIQZVVO;73O7O?NO=4>?\ "B7_ +==[_\ _%A_A)_\&-T?[V.(ZT>!
MZ&/V_P!,=>]^Z]U[W[KW7O?NO=>]^Z]T0G^4!_V^&_X4!?\ F*?_ .!>[,]L
MO\73R?#ULK>Z]6Z][]U[K75_X48_\>-_*+_\;I? ;_W3]W^]CB.M'@>CE>W^
MF.O>_=>Z][]U[KWOW7NO>_=>Z+E_)?\ ^9__ ,XW_P 7QVC_ / L](^V7^+I
MY/AZOM]UZMU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW6MQVW_P!O]^Z__&6GQT_^"6[W]N1^?3<GET>?VYTWU[W[KW7O?NO=
M>]^Z]T2S^9+_ -NZ_GQ_XI9\IO\ WQN^O>CP/6QQ'5FG\IW_ +=9?RT__% /
MAO\ _ Z]<^V.G^C_ /OW7NO>_=>ZU>_@_P#]E0_SB_\ QI]V-_[X_HCVZG#I
MI^/5DGN_5.O>_=>Z][]U[KWOW7NJK_YR?_9$=3_XLI\+?_@N.E_=7^'JR?%U
MM8>V>GNO>_=>Z][]U[K5/_DV?]D1TW_BRGS2_P#@N.Z/;R?#TR_Q=6H>[=5Z
M][]U[KWOW7NO>_=>ZKN^5'_9>'\F?_Q>'>?_ ,"UWA[H_#JZ<>MG'VUT[U[W
M[KW5'G_"B7_MUWO_ /\ %A_A)_\ !C='^]CB.M'@>AC]O],=>]^Z]U[W[KW7
MO?NO=>]^Z]T43^6M_P!O@_YKW_BO'\N__P!P?D5[:?CTZG#K8;]TZOU[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:@??7_"2O;'R0[>R'=7:
MG\SKYA[LWI_>/)9[:F0W-!C]U5W7M-5;@JMQXO ;'R^X]T9'*[>PNVZVH H(
M::6):?QJ4 87]^Z]TJ8/^$N_8M+!#34W\[+^933TU/%'!3T\'8&=A@@@A01Q
M0PQ1[_6.***-0JJH 4"PX]^Z]T;GX,_R'M\_#+Y3=7?)3,?S2OG'\C<;UO\
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MYOM&_O1_$?\ 0U_OR/X%]];[#Q?Y1XK^7U>_=>Z(S_PFP_TP?Z./YLO^G?\
MT;?Z7?\ A[7YO?Z6/]$G]Z/]''^F#^!=+_Z4/]'G]\?]_-_HV_O-K_@'\2_W
M*?86^[_=O[]U[K9']^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JCTA_P!OU_Y^7_F+
M+_X#S+>W(_/IN3RZM.]N=-]>]^Z]U[W[KW7O?NO=5=?SJ_\ MU=\V?\ Q#U1
M_P"]'@/>CP/6QQ'6S_LK_CS=I?\ ALX'_P!U5+[8Z?Z4WOW7NO>_=>ZU8OY3
MO_,@.[/_ !?'YZ?_  4W9?MY/AZ9?XNK/?=NJ]>]^Z]U[W[KW7O?NO=5"_S8
M?^/Y_DV?^-TOY>7_ +N.QO='X=73CUMM>VNG>O>_=>ZH\_X42_\ ;KO?_P#X
ML/\ "3_X,;H_WL<1UH\#T,?M_ICKWOW7NO>_=>Z][]U[KWOW7NB$_P H#_M\
M-_PH"_\ ,4__ ,"]V9[9?XNGD^'K96]UZMU[W[KW6NK_ ,*,?^/&_E%_^-TO
M@-_[I^[_ 'L<1UH\#T<KV_TQU[W[KW7O?NO=>]^Z]U[W[KW1<OY+_P#S/_\
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M^$G_ ,&-T?[V.(ZT>!Z&/V_TQU[W[KW7O?NO=>]^Z]U[W[KW11/Y:W_;X/\
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MKWOW7NO>_=>ZJZ_G5_\ ;J[YL_\ B'JC_P!Z/ >]'@>MCB.MG_97_'F[2_\
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MTZG#K8;]TZOU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0$_(/XO\
MQT^6&R?]''R6Z2ZR[SV0E6N0I=O=F[/PN[*/&9%"FG)X5\K23U.#R@5 OW-'
M)!/HNNO22#[KW5(VY?\ A*=_)*W#E:W*4WQEWCM<5TDTS8S;7R [QAQ5--/+
M+*[T5+EM]YAZ6-6DLD2OX(U555 !8^Z]U5Q\2?Y:'_";CNC^9=\@/Y=.R_A/
M\E\SWW\1]M;BW_OG,]N]J;Q;HC<%+L3>'6>U*R+ U.U_D+4;JW)/49GL['2I
M1Y7 4>/JJ:&I6H72%AG]U[K<>Z5Z(Z5^-_7V(ZHZ ZIZ_P"F>M<$]7+B=C=:
M;4PNSMLT=3D*F2MR-:N)P='14LN1R5;,\]34NK3U,SM)([.Q)]U[H6/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW5 /\@O_ +K4?^-_OYC?_P QSW[KW5_WOW7NO>_=>Z][]U[KWOW7NO>_=>ZU
M4>D/^WZ_\_+_ ,Q9?_ >9;VY'Y]-R>75IWMSIOKWOW7NO>_=>Z][]U[JKK^=
M7_VZN^;/_B'JC_WH\![T>!ZV.(ZV?]E?\>;M+_PV<#_[JJ7VQT_TIO?NO=>]
M^Z]UJQ?RG?\ F0'=G_B^/ST_^"F[+]O)\/3+_%U9[[MU7KWOW7NO>_=>Z][]
MU[JH7^;#_P ?S_)L_P#&Z7\O+_W<=C>Z/PZNG'K;:]M=.]>]^Z]U1Y_PHE_[
M==[_ /\ Q8?X2?\ P8W1_O8XCK1X'H8_;_3'7O?NO=>]^Z]U[W[KW7O?NO=$
M)_E ?]OAO^% 7_F*?_X%[LSVR_Q=/)\/6RM[KU;KWOW7NM=7_A1C_P >-_*+
M_P#&Z7P&_P#=/W?[V.(ZT>!Z.5[?Z8Z][]U[KWOW7NO>_=>Z][]U[HN7\E__
M )G_ /SC?_%\=H__  +/2/ME_BZ>3X>K[?=>K=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK<=M_]O\ ?NO_ ,9:?'3_ ."6
M[W]N1^?3<GET>?VYTWU[W[KW7O?NO=>]^Z]T2S^9+_V[K^?'_BEGRF_]\;OK
MWH\#UL<1U9I_*=_[=9?RT_\ Q0#X;_\ P.O7/MCI_H__ +]U[KWOW7NM7OX/
M_P#94/\ .+_\:?=C?^^/Z(]NIPZ:?CU9)[OU3KWOW7NO>_=>Z][]U[JJ_P#G
M)_\ 9$=3_P"+*?"W_P""XZ7]U?X>K)\76UA[9Z>Z][]U[KWOW7NM4_\ DV?]
MD1TW_BRGS2_^"X[H]O)\/3+_ !=6H>[=5Z][]U[KWOW7NO>_=>ZKN^5'_9>'
M\F?_ ,7AWG_\"UWA[H_#JZ<>MG'VUT[U[W[KW5'G_"B7_MUWO_\ \6'^$G_P
M8W1_O8XCK1X'H8_;_3'7O?NO=>]^Z]U[W[KW7O?NO=%$_EK?]O@_YKW_ (KQ
M_+O_ /<'Y%>VGX].IPZV&_=.K]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=:=O\L?XQ_)/8/\ PJ!_FK=_[Z^/?>&R^A^Q.E.Y,5U_
MW9NWJ??NW.H]\Y3*=S?%3*8S&[.[(S& H]F[FK\CC-NY"I@AHJV>2:"AJ)$!
M2&0K[KW6XE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[J@'^07_P!UJ/\ QO\ ?S&__F.>_=>ZO^]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW6JCTA_V_7_GY?\ F++_ . \RWMR/SZ;D\NK3O;G
M3?7O?NO=>]^Z]U[W[KW577\ZO_MU=\V?_$/5'_O1X#WH\#UL<1UL_P"RO^/-
MVE_X;.!_]U5+[8Z?Z4WOW7NO>_=>ZU8OY3O_ #(#NS_Q?'YZ?_!3=E^WD^'I
ME_BZL]]VZKU[W[KW7O?NO=>]^Z]U4+_-A_X_G^39_P"-TOY>7_NX[&]T?AU=
M./6VU[:Z=Z][]U[JCS_A1+_VZ[W_ /\ BP_PD_\ @QNC_>QQ'6CP/0Q^W^F.
MO>_=>Z][]U[KWOW7NO>_=>Z(3_* _P"WPW_"@+_S%/\ _ O=F>V7^+IY/AZV
M5O=>K=>]^Z]UKJ_\*,?^/&_E%_\ C=+X#?\ NG[O]['$=:/ ]'*]O],=>]^Z
M]U[W[KW7O?NO=>]^Z]T7+^2__P S_P#YQO\ XOCM'_X%GI'VR_Q=/)\/5]ON
MO5NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
MUN.V_P#M_OW7_P",M/CI_P#!+=[^W(_/IN3RZ//[<Z;Z][]U[KWOW7NO>_=>
MZ)9_,E_[=U_/C_Q2SY3?^^-WU[T>!ZV.(ZLT_E._]NLOY:?_ (H!\-__ ('7
MKGVQT_T?_P!^Z]U[W[KW6KW\'_\ LJ'^<7_XT^[&_P#?']$>W4X=-/QZLD]W
MZIU[W[KW7O?NO=>]^Z]U5?\ SD_^R(ZG_P 64^%O_P %QTO[J_P]63XNMK#V
MST]U[W[KW7O?NO=:I_\ )L_[(CIO_%E/FE_\%QW1[>3X>F7^+JU#W;JO7O?N
MO=>]^Z]U[W[KW5=WRH_[+P_DS_\ B\.\_P#X%KO#W1^'5TX];./MKIWKWOW7
MNJ//^%$O_;KO?_\ XL/\)/\ X,;H_P!['$=:/ ]#'[?Z8Z][]U[KWOW7NO>_
M=>Z][]U[HHG\M;_M\'_->_\ %>/Y=_\ [@_(KVT_'IU.'6PW[IU?KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM4_O'YD_*/;
M7_"K+X<?#/!=W;ZQOQ;["^-^Z-W[SZ0@R,1V-G]RT7Q]^5.X:7+UE!+3R3K4
MPYS8^)JP(Y43ST2.5N6U>Z]UM8>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ ?Y!?_ '6H_P#&_P!_,;_^8Y[]
MU[J_[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J/2'_;]?^?E_P"8LO\ X#S+>W(_
M/IN3RZM.]N=-]>]^Z]U[W[KW7O?NO=5=?SJ_^W5WS9_\0]4?^]'@/>CP/6QQ
M'6S_ +*_X\W:7_ALX'_W54OMCI_I3>_=>Z][]U[K5B_E._\ ,@.[/_%\?GI_
M\%-V7[>3X>F7^+JSWW;JO7O?NO=>]^Z]U[W[KW50O\V'_C^?Y-G_ (W2_EY?
M^[CL;W1^'5TX];;7MKIWKWOW7NJ//^%$O_;KO?\ _P"+#_"3_P"#&Z/]['$=
M:/ ]#'[?Z8Z][]U[KWOW7NO>_=>Z][]U[HA/\H#_ +?#?\* O_,4_P#\"]V9
M[9?XNGD^'K96]UZMU[W[KW6NK_PHQ_X\;^47_P"-TO@-_P"Z?N_WL<1UH\#T
M<KV_TQU[W[KW7O?NO=>]^Z]U[W[KW1<OY+__ #/_ /G&_P#B^.T?_@6>D?;+
M_%T\GP]7V^Z]6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[K6X[;_ .W^_=?_ (RT^.G_ ,$MWO[<C\^FY/+H\_MSIOKWOW7N
MO>_=>Z][]U[HEG\R7_MW7\^/_%+/E-_[XW?7O1X'K8XCJS3^4[_VZR_EI_\
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M5?\ SD_^R(ZG_P 64^%O_P %QTO[J_P]63XNMK#VST]U[W[KW7O?NO=:I_\
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M]'@/>CP/6QQ'6S_LK_CS=I?^&S@?_=52^V.G^E-[]U[KWOW7NM6+^4[_ ,R
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M_P#!<=+^ZO\ #U9/BZVL/;/3W7O?NO=>]^Z]UJG_ ,FS_LB.F_\ %E/FE_\
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M*C_LO#^3/_XO#O/_ .!:[P]T?AU=./6SC[:Z=Z][]U[JCS_A1+_VZ[W_ /\
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M_P#G)_\ 9$=3_P"+*?"W_P""XZ7]U?X>K)\76UA[9Z>Z][]U[KWOW7NM4_\
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M_P ?S_)L_P#&Z7\O+_W<=C>Z/PZNG'K;:]M=.]>]^Z]U1Y_PHE_[==[_ /\
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MU9I_*=_[=9?RT_\ Q0#X;_\ P.O7/MCI_H__ +]U[KWOW7NM7OX/_P#94/\
M.+_\:?=C?^^/Z(]NIPZ:?CU9)[OU3KWOW7NO>_=>Z][]U[JJ_P#G)_\ 9$=3
M_P"+*?"W_P""XZ7]U?X>K)\76UA[9Z>Z][]U[KWOW7NM4_\ DV?]D1TW_BRG
MS2_^"X[H]O)\/3+_ !=6H>[=5Z][]U[KWOW7NO>_=>ZKN^5'_9>'\F?_ ,7A
MWG_\"UWA[H_#JZ<>MG'VUT[U[W[KW5'G_"B7_MUWO_\ \6'^$G_P8W1_O8XC
MK1X'H8_;_3'7O?NO=>]^Z]U[W[KW7O?NO=%$_EK?]O@_YKW_ (KQ_+O_ /<'
MY%>VGX].IPZV&_=.K]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5 /\@O\ [K4?^-_OYC?_ ,QSW[KW5_WO
MW7NO>_=>Z][]U[KWOW7NO>_=>ZU4>D/^WZ_\_+_S%E_\!YEO;D?GTW)Y=6G>
MW.F^O>_=>Z][]U[KWOW7NJNOYU?_ &ZN^;/_ (AZH_\ >CP'O1X'K8XCK9_V
M5_QYNTO_  V<#_[JJ7VQT_TIO?NO=>]^Z]UJQ?RG?^9 =V?^+X_/3_X*;LOV
M\GP],O\ %U9[[MU7KWOW7NO>_=>Z][]U[JH7^;#_ ,?S_)L_\;I?R\O_ '<=
MC>Z/PZNG'K;:]M=.]>]^Z]U1Y_PHE_[==[__ /%A_A)_\&-T?[V.(ZT>!Z&/
MV_TQU[W[KW7O?NO=>]^Z]U[W[KW1"?Y0'_;X;_A0%_YBG_\ @7NS/;+_ !=/
M)\/6RM[KU;KWOW7NM=7_ (48_P#'C?RB_P#QNE\!O_=/W?[V.(ZT>!Z.5[?Z
M8Z][]U[KWOW7NO>_=>Z][]U[HN7\E_\ YG__ #C?_%\=H_\ P+/2/ME_BZ>3
MX>K[?=>K=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]UK<=M_]O]^Z_P#QEI\=/_@EN]_;D?GTW)Y='G]N=-]>]^Z]U[W[KW7O
M?NO=$L_F2_\ ;NOY\?\ BEGRF_\ ?&[Z]Z/ ];'$=6:?RG?^W67\M/\ \4 ^
M&_\ \#KUS[8Z?Z/_ ._=>Z][]U[K5[^#_P#V5#_.+_\ &GW8W_OC^B/;J<.F
MGX]62>[]4Z][]U[KWOW7NO>_=>ZJO_G)_P#9$=3_ .+*?"W_ ."XZ7]U?X>K
M)\76UA[9Z>Z][]U[KWOW7NM4_P#DV?\ 9$=-_P"+*?-+_P""X[H]O)\/3+_%
MU:A[MU7KWOW7NO>_=>Z][]U[JN[Y4?\ 9>'\F?\ \7AWG_\  M=X>Z/PZNG'
MK9Q]M=.]>]^Z]U1Y_P *)?\ MUWO_P#\6'^$G_P8W1_O8XCK1X'H8_;_ $QU
M[W[KW7O?NO=>]^Z]U[W[KW11/Y:W_;X/^:]_XKQ_+O\ _<'Y%>VGX].IPZV&
M_=.K]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW5 /\ (+_[K4?^-_OYC?\ \QSW[KW5_P![]U[KWOW7NO>_
M=>Z][]U[KWOW7NM5'I#_ +?K_P _+_S%E_\  >9;VY'Y]-R>75IWMSIOKWOW
M7NO>_=>Z][]U[JKK^=7_ -NKOFS_ .(>J/\ WH\![T>!ZV.(ZV?]E?\ 'F[2
M_P##9P/_ +JJ7VQT_P!*;W[KW7O?NO=:L7\IW_F0'=G_ (OC\]/_ (*;LOV\
MGP],O\75GONW5>O>_=>Z][]U[KWOW7NJA?YL/_'\_P FS_QNE_+R_P#=QV-[
MH_#JZ<>MMKVUT[U[W[KW5'G_  HE_P"W7>__ /Q8?X2?_!C='^]CB.M'@>AC
M]O\ 3'7O?NO=>]^Z]U[W[KW7O?NO=$)_E ?]OAO^% 7_ )BG_P#@7NS/;+_%
MT\GP];*WNO5NO>_=>ZUU?^%&/_'C?RB__&Z7P&_]T_=_O8XCK1X'HY7M_ICK
MWOW7NO>_=>Z][]U[KWOW7NBY?R7_ /F?_P#.-_\ %\=H_P#P+/2/ME_BZ>3X
M>K[?=>K=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]UK<=M_\ ;_?NO_QEI\=/_@EN]_;D?GTW)Y='G]N=-]>]^Z]U[W[KW7O?
MNO=$L_F2_P#;NOY\?^*6?*;_ -\;OKWH\#UL<1U9I_*=_P"W67\M/_Q0#X;_
M /P.O7/MCI_H_P#[]U[KWOW7NM7OX/\ _94/\XO_ ,:?=C?^^/Z(]NIPZ:?C
MU9)[OU3KWOW7NO>_=>Z][]U[JJ_^<G_V1'4_^+*?"W_X+CI?W5_AZLGQ=;6'
MMGI[KWOW7NO>_=>ZU3_Y-G_9$=-_XLI\TO\ X+CNCV\GP],O\75J'NW5>O>_
M=>Z][]U[KWOW7NJ[OE1_V7A_)G_\7AWG_P# M=X>Z/PZNG'K9Q]M=.]>]^Z]
MU1Y_PHE_[==[_P#_ !8?X2?_  8W1_O8XCK1X'H8_;_3'7O?NO=>]^Z]U[W[
MKW7O?NO=%$_EK?\ ;X/^:]_XKQ_+O_\ <'Y%>VGX].IPZV&_=.K]>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW5 /\@O_NM1_P"-_OYC?_S'/?NO=7_>_=>Z][]U[KWOW7NO>_=>Z][]U[K5
M1Z0_[?K_ ,_+_P Q9?\ P'F6]N1^?3<GEU:=[<Z;Z][]U[KWOW7NO>_=>ZJZ
M_G5_]NKOFS_XAZH_]Z/ >]'@>MCB.MG_ &5_QYNTO_#9P/\ [JJ7VQT_TIO?
MNO=>]^Z]UJQ?RG?^9 =V?^+X_/3_ ."F[+]O)\/3+_%U9[[MU7KWOW7NO>_=
M>Z][]U[JH7^;#_Q_/\FS_P ;I?R\O_=QV-[H_#JZ<>MMKVUT[U[W[KW5'G_"
MB7_MUWO_ /\ %A_A)_\ !C='^]CB.M'@>AC]O],=>]^Z]U[W[KW7O?NO=>]^
MZ]T0G^4!_P!OAO\ A0%_YBG_ /@7NS/;+_%T\GP];*WNO5NO>_=>ZUU?^%&/
M_'C?RB__ !NE\!O_ '3]W^]CB.M'@>CE>W^F.O>_=>Z][]U[KWOW7NO>_=>Z
M+E_)?_YG_P#SC?\ Q?':/_P+/2/ME_BZ>3X>K[?=>K=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK<=M_P#;_?NO_P 9:?'3
M_P""6[W]N1^?3<GET>?VYTWU[W[KW7O?NO=>]^Z]T2S^9+_V[K^?'_BEGRF_
M]\;OKWH\#UL<1U9I_*=_[=9?RT__ !0#X;__  .O7/MCI_H__OW7NO>_=>ZU
M>_@__P!E0_SB_P#QI]V-_P"^/Z(]NIPZ:?CU9)[OU3KWOW7NO>_=>Z][]U[J
MJ_\ G)_]D1U/_BRGPM_^"XZ7]U?X>K)\76UA[9Z>Z][]U[KWOW7NM4_^39_V
M1'3?^+*?-+_X+CNCV\GP],O\75J'NW5>O>_=>Z][]U[KWOW7NJ[OE1_V7A_)
MG_\ %X=Y_P#P+7>'NC\.KIQZV<?;73O7O?NO=4>?\*)?^W7>_P#_ ,6'^$G_
M ,&-T?[V.(ZT>!Z&/V_TQU[W[KW7O?NO=>]^Z]U[W[KW11/Y:W_;X/\ FO?^
M*\?R[_\ W!^17MI^/3J<.MAOW3J_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_(+_P"ZU'_C?[^8W_\
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M?'_BEGRF_P#?&[Z]Z/ ];'$=6:?RG?\ MUE_+3_\4 ^&_P#\#KUS[8Z?Z/\
M^_=>Z][]U[K5[^#_ /V5#_.+_P#&GW8W_OC^B/;J<.FGX]62>[]4Z][]U[KW
MOW7NO>_=>ZJO_G)_]D1U/_BRGPM_^"XZ7]U?X>K)\76UA[9Z>Z][]U[KWOW7
MNM4_^39_V1'3?^+*?-+_ ."X[H]O)\/3+_%U:A[MU7KWOW7NO>_=>Z][]U[J
MN[Y4?]EX?R9__%X=Y_\ P+7>'NC\.KIQZV<?;73O7O?NO=4>?\*)?^W7>_\
M_P 6'^$G_P &-T?[V.(ZT>!Z&/V_TQU[W[KW7O?NO=>]^Z]U[W[KW11/Y:W_
M &^#_FO?^*\?R[__ '!^17MI^/3J<.MAOW3J_7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_(+_[K4?\
MC?[^8W_\QSW[KW5_WOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4>D/^WZ_P#/R_\
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M:?RG?^W67\M/_P 4 ^&__P #KUS[8Z?Z/_[]U[KWOW7NM7OX/_\ 94/\XO\
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M0_[?K_S\O_,67_P'F6]N1^?3<GEU:=[<Z;Z][]U[KWOW7NO>_=>ZJZ_G5_\
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M,ON'<%=MGXW;VBI.PNI]C5V<W*9LED:C:=+E*R ZYIC3EC3J\D,4,TONO=;
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MZ-Q__6#V]4>O3-#Z=>_X>K_E7?\ >;/3W_G1N/\ ^L'OU1Z]>H?3KW_#U?\
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M*_\ .G=7_P!C/OW7NO?]! G\F?\ [V#=%?\ G3NK_P"QGW[KW6OO\2OYL/\
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M#BO_ *E]^Z]U[^Y6S?\ GDML_P#GAQ7_ -2^_=>Z]_<K9O\ SR6V?_/#BO\
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M\^MZY_\ 0(VS_P#6SW[KW7O]#W4G_/K>N?\ T"-L_P#UL]^Z]U[_ $/=2?\
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M9_J3X^=C==;.[!V_C=T8VFR'853+OZD%5M38]'MS;-?FJ?+[XRI;QK2T=5/
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M<[FMD;FS^!PV1DFJJ/:VZ\UMF?*8G]R6.3&5D#QR21LCM[KW55?\VVNR<O\
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M7NO>_=>Z][]U[KWOW7NO>_=>ZJ?^7?\ /#_E=? _N6O^/ORM^3W^BOM[&8#
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9>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tflow_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tflow_003.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M<U3RPM)58R@A3;<D2RG[E%AG]U[JR7L?^;A\NNO/^%$W3G\J5*;I7-?&KM#
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MKD&S]V[I&(I\]50R3XC#F'#T5-_N-,%?)4M.8ZQ95@2/W7N@7Z9^4GS8R_\
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M%16W>R^X/Y7F_?CQT?T;\A.^>W.R.S.G)L%M7H[H3=_;9BI=JYJ+,5U;75>
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M>Z!;^0%%3P?\*DOYT,%)'##20P_S%HJ6&F18XTCC^1&S BQJH"JBJ % %@+
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MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$O\
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M0283&]+/1244M,8WI7I'1&A:)E,3*"A4@>_=>ZMG_P"%$?PI[TWM\R_Y5/\
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MYOBI\D/EWLNI[ZI,I2=@=;U>7ZTK=HMYIZ^JQ4E#A(NL*=:!MM5&2JFQ*15
MBIXW:FFCJ*226"3W7NE'_+D_DA?'W^6!OSO[L;X^?(3Y9[FW)\E:"BA[0D[A
MW+L/=Z3UV*FRM519BF^RZ]Q,T62I*O-9"9=<TE+*\@%32SQJ$]^Z]TW_  :_
MD<='_P OKMWY)=X=&_*?YDY/L#Y6X?<%-V_7]A9SK/.Q5&5SE=69.+<E%%1=
M78S[',XW(9'(3TJHQQI:H=:K'U420QQ>Z]TR?R]_Y,'Q/_DM[0^5.^/C_P!R
M?++<&V^V>N<=7]IXWL//;5WE/%#U!1Y^JH*_!)MW9&W\HF7HX<UEQ"B54B3/
M*@,#R)$5]U[K6E_EY_R\?^%!FY/BWLW?'\M'^:OTMMGX7]CY[?/873>*[DW+
M4P;J-/N[+UE765>X<=C]@=CT6&S60KGJ*NNH(]VU;P54TQJ5@K'J(4]U[K8<
M_D0=V_S-MXK\U_CW_,ES^T>X]P_$[MW8O7G7_P H=AQ4C8G=U3N3&5F2W%A:
M6LH<3@Z;*-M#_<)'-5'%PU"SY"2AJ@:BBD/OW7NM@?W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=%(^8_Q+A^9/5C=1Y7Y _(/H7;L^X]F;GR.3^/.7VMMW*5
M51L++TF<QT<U=N+:>Z&2E&2H*.2>&%(DJ8XOMZ@24TL\4ONO=*#O+XI=6_)_
MXZ;G^,/R23)=W=<;VHL%2[PDWK1XBGK,B^V\C1Y:BJ9DQ.*QF+BJ8,A04LR-
M!C(55T!55L+>Z]TU?,3XF[>^9?QT[$^,&YNT.UNH>M^U=GY'K_?%1THVU\;D
MJK"YD0Q5F.CGW)M?<]-1P5-''+2LU/1Q2K!43".1)1#+%[KW12/Y7O\ *"Z4
M_E+;4WYU[\;^]ODUO#K7L3=T._<YL#NK,['W-0QYE<>F,EKZ6JPNPMO9B&2I
MI*?'K+&<F\)-' 4B354>?W7N@!Z;_P"$ZG\O?I/Y-]^?)?;E5\A<D?D35;KJ
M=\=%9#N>KP_7Q3>\E3/D:27!X.FQ%7G,:]365,L-!G,IE*&F=U:"F1H86C]U
M[H2O@Y_)&^.G\O+I#Y'=$?&OO7Y8[?VW\CJC<E17YC/=B8#<M3M=MT4=+CJB
M?;&-JMJ/M=<A]C14<(KLKM[*UFB)5\VC4I]U[H/OBO\ R _C/\//B3\MOA5T
M_P#)'YC+TC\R]NY7;G9U-N;<O7.6RE FYL6^"S51@,A%UG3&EJ,U@F%!4BKB
MKH4A424<-+5EJEO=>Z-+_*[_ )5W1G\I;IW??1/QU[)[TWUUYO[LNM[:KZ#N
M_.;:W%44>:RF+Q6'JYJ&IP&U=LR+#4T.$QBO%/\ <*K0ZXO&7DU^Z]T5G9/_
M  G^^*W6/RP^27R;ZQ[M^5W6VW?ESDLYE_D'\;-C]FX_ ;(W')N6>JKJZDJV
MCP;;HBQ4V5K:RM%'3[CA5&J*B@5_X+/+BV]U[H2_Y7?\E#X\_P I"'NJ@^,7
M>ORIW#@^]:3;(W7MSN3=FS=W4-'7[/3(Q4&8Q$6-V-A6I,E'%DZA)2\DU/4H
ME.M53S"F@T>Z]U!^%O\ )&Z%^"OR][W^:G4OR.^7.Y.U?DQD]Z9CN[!=D[EV
M#FMO9RIWYN#^\]=-)0XWKO$5E)(N5:9H7I<C \44TT2MHD/OW7NF'=O\@?X/
M;O\ YAFY/YD4VXODAMCM_><D%?O/877?=-5UQM7+UP@@IJJJKUPE+0[EE@R<
M-+3BOQZ;E3&5MG%51RI-,C^Z]TO_ (+_ ,E/XD_R[_DI\A?DK\<MS][XBN^1
M66;+[AZARO8D']R,4_W&2J8H\9AL=B\=454-&^7R*4<>5R&22BCF_P F$<JK
M*/=>Z*EN#_A-/\-Z'Y7;H^5_QV^0?S=^$^>W_D'R78.POAWWT.DL1DC75GWN
M0I(JFAQ;YS&XS*3?\"*.ERT<$?UHDI"%*^Z]U9O\D?Y;?Q2^5'PUROP2[2VA
MG7Z(R--B9*<83==92YZDR>$K1DX-P1YVJ>LK*O/ODS+5U597FL;(3S5#9%:L
M5,ZR>Z]U/^$GP.Z\^$?0&V_CU@NR>X^\MM;6V3C>L\1G._-RT.YZRFVUA4GC
MHMO4=-B\7AL/18FDAJ)(E6+&"HGB$*5M35?;TYB]U[JK3J'_ (31_#KI;K?Y
M0]![.^0_S5HOC'\I*?=IW#\<Z?MO#TNW</7;CI7HJ++4#KMELIDLCMVE:./&
MC,5^2HY#!23Y:DRM524U1%[KW1R?@U_*&ZB_E[?$KN+X;?'WY&?*P]:=NY;=
MF?@W#OW<&Q=W9[:U=O?&4F*R51M:9M@08FG6H@HH)?M\AA\C2)4F6H2G66>=
MI/=>ZY?RMOY0'1/\I#;'96Q/CAW1\D-[; [2W#0;PSFR^[\ULO<E+39>BI4H
M6R5#58'8^VLM'-44<--%)%+D9J73"C1P1R&5Y/=>Z8_YIG\F'X^?S=(NJ\9\
ME>[/D[L[:?3U7N+*;2V1TEN;9VUL:U?NB*E@J<A6MFMC[BR-55""D2.*]>L4
M*O-XXE,KD^Z]U#_F*_R6NC?YG_571G37R5^17RNIMC]#2-D\+2=;YKKW:\^9
MRWV;8^/-YV>IZYR+29"&@DF@2.A%!0Z97=J-IBLB^Z]T&/S^_D!_&?\ F6;8
M^,6U?D_\D?F-E*/XH]>Y?8'7U9L[<O7.U)Z\[C3$QY3,YL)UG-3SYC(Q8+$)
M,:2GHJ)5IE,%%"SS-)[KW1#?YZ_1OR%^0'S3_E:]'?"_Y@[DZ3^>G7.UN]^T
MNI=S]LU%/M79N2H:6CQN*S6:K\IC:":!]X_;K/2KC<7L?)_=T.0J?/38['H\
MC^Z]T1[M_;G_  JT_EO-UE\A.T/FU\=_F9MZ?MWKOKR'XO;&J_X_EMZ5._LG
M38V+"T='D.K-J5.J7[@R255#E%J,?!'+7./MZ>8'W7NMZOW[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW13:OX&_"BLS.X]PR
M?$[X]0YG>5>^6WE7T'4F#Q;YFKD01O5Y<4U%$N4JI(@L;S52RR/$JQNS1JJC
MW7NC);5VEM78NW\5M+9&V=O[.VK@J2.@PFV=JX:FV]CZ."$62&EHJ2.&FIXE
M'T2.-5'X'OW7NE![]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z";M[H3H
M[Y X.@VUWKT[UAW)M_$Y*',X?$=H;$Q>^X**MI61X:ZBCR=+4K1UT$D<;Q5$
M.B:)T1XW5E4CW7ND_P!?_%OXW=5;C&\NN.BNJ=F[Q6BEQD6[\%L;'465CI9R
M&DI8LD(/O8J:1@&:))UC9O4RD\^_=>Z'GW[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4^
M?SK.TN[^LOC9T+1]!=R[NZ%WIW!\[OB#\?LGV7L6CQM?DZ'"]T[GCP66-+%E
MJ+(8]YA351=/-2.HD1"18>_=>Z3_ /PV!\R?^]W/S_\ _0*ZD_\ L"]^Z]U[
M_AL#YD_][N?G_P#^@5U)_P#8%[]U[KW_  V!\R?^]W/S_P#_ $"NI/\ [ O?
MNO=>_P"&P/F3_P![N?G_ /\ H%=2?_8%[]U[KW_#8'S)_P"]W/S_ /\ T"NI
M/_L"]^Z]U[_AL#YD_P#>[GY__P#H%=2?_8%[]U[KW_#8'S)_[W<_/_\ ] KJ
M3_[ O?NO=>_X; ^9/_>[GY__ /H%=2?_ &!>_=>Z]_PV!\R?^]W/S_\ _0*Z
MD_\ L"]^Z]U[_AL#YD_][N?G_P#^@5U)_P#8%[]U[KW_  V!\R?^]W/S_P#_
M $"NI/\ [ O?NO=>_P"&P/F3_P![N?G_ /\ H%=2?_8%[]U[KW_#8'S)_P"]
MW/S_ /\ T"NI/_L"]^Z]U[_AL#YD_P#>[GY__P#H%=2?_8%[]U[KW_#8'S)_
M[W<_/_\ ] KJ3_[ O?NO=>_X; ^9/_>[GY__ /H%=2?_ &!>_=>Z]_PV!\R?
M^]W/S_\ _0*ZD_\ L"]^Z]U[_AL#YD_][N?G_P#^@5U)_P#8%[]U[KW_  V!
M\R?^]W/S_P#_ $"NI/\ [ O?NO=>_P"&P/F3_P![N?G_ /\ H%=2?_8%[]U[
MKW_#8'S)_P"]W/S_ /\ T"NI/_L"]^Z]U[_AL#YD_P#>[GY__P#H%=2?_8%[
M]U[KW_#8'S)_[W<_/_\ ] KJ3_[ O?NO=>_X; ^9/_>[GY__ /H%=2?_ &!>
M_=>Z]_PV!\R?^]W/S_\ _0*ZD_\ L"]^Z]U[_AL#YD_][N?G_P#^@5U)_P#8
M%[]U[KW_  V!\R?^]W/S_P#_ $"NI/\ [ O?NO=>_P"&P/F3_P![N?G_ /\
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M%[]U[KW_  V!\R?^]W/S_P#_ $"NI/\ [ O?NO=>_P"&P/F3_P![N?G_ /\
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M%[]U[KW_  V!\R?^]W/S_P#_ $"NI/\ [ O?NO=>_P"&P/F3_P![N?G_ /\
MH%=2?_8%[]U[H%>H-N_+/XJ_S:OC;\:^POG_ /(CY:]2=U_$CY-=J9G;7=>
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M%[]U[KW_  V!\R?^]W/S_P#_ $"NI/\ [ O?NO=>_P"&P/F3_P![N?G_ /\
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MJ=Z[^"X\UN:2B>FJI,>D-=0O4^Z]TBN\?YGGPR^/GQ3V3\X-^=F9C(?%/?\
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MV9T#N/9N/KM]4>YZ_M>7QX)*&LQ5-54<,%8BSS>>JJ*>!(:>H=I!X9 /=>Z
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MKVC_ #0/B/M;:&(WAN*J[$AJ*2O[:JSEXHZW*SUDV0PU3DY\E]OKD>"2E=?
M#2-%?W7NK;?YQE/3P_RG_P"9+)#!#%)+\)_D8LKQQ*A80[3R:H&( )"+P+_0
M<#W[KW5;?4?>O2FROAO_ ,)NN@\]U?M+LCY5=_?'?X[Y;XA97L""LCP>SJ[J
M#I3!5.[-Z5M11E)9IL5@LPE+1XR.6*;*U=?#3K444*U%?2>Z]U[IRHWGM/\
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M[]U[I"_RD<=CZ3^1Y\LJ:EH:.FIIM_?S2DEIZ>E2%&$6Z-ZP*&15"L%@BCC
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MZH+]@?<-FI:'.5F\*G<&(FR<E74RSR4&5IG>>1JC5YCY/?NO=!;F?Y/W\O\
MS7Q[Z=^,$W4.\*3J7X\;JCWIT'!1?(+L5,_LO(QU$U1YML;ODW7)NO#1LU1,
MGAILTD B*1)&J0P"+W7NA1V[_+=^%.T_D%LSY3;?Z,P]!WOL/K/_ $1X#?G]
MY,W5ROA?XL,\!E*2?)RT.<R:YD?>C*9*FJ\E]U_E'W?E <>Z]UGQ/\O3XQ87
M;6Z]@4N![$J^J]][ZR?8^\^GL_W?O/=6T\CE<Y7KE<AY<#E,[64,&)R647[N
MLP]/'#AJN=YWJ<?+]W5B?W7NE-\Q/@K\4/GSU/'TI\LNFMM=M[ H\C'F<%1Y
M&2JPM;B:Z*)X%K<-EL;/1Y3$U7@D>)GI:N(O$S12:XR5/NO=</B#\%_B]\$M
MD9C8?QDZT38V,W+DJ/+;LSF7W+EM_P">S$^+ITHJ$Y;<.X*[)YO(18VABBI:
M*&:N:"BID6"ECBB&GW[KW1N/?NO=>]^Z]U[W[KW5*'\W7_F>/\EG_P :Q]9_
M^^][%]^Z]U=?[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JE#XK_\ ;\G^;5_XK)_+
M:_\ <3L7W[KW5U_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z)1\P_P"7A\2OGQB=FX'Y7;!WAV7@NOMY8[L39F$QW>F_
M^LJ/'Y[#T\])1YF"EVENC!0?Q.CIZJJ2"I:-I81-,8F4RR%O=>Z#W<'\J[XI
M;LP.3VMNK<_SEW-MC-4,N,S.W-P?S3?D_F:"KIIQI>GJ:.I[ADIYX'7AHWC9
M2."/?NO=& Q_P_Z!Q/:74O<F(VONC$;VZ+ZMFZ5ZHCQ';6\,7@L/MBI6A27%
MP[4@ST>U9UF3&8U9)JC"S5,BTE,'F801:?=>Z061_EY?$W)_,"E^>LVQ-Z4O
MROI-HQ]?CM+#]\]@X!)L#%K*X2LV_0[IIMKUV'\CB8T=3A9:8U"0U)C,\$,B
M>Z]T&?RY_E(_ ;YP]K[)[V^0?2=7E.ZNO\/5;<V]VQUYV9NOI3<!QM6KHU!6
MY79V;P=9D:9(YJB.$5,LKTT<]1%3/%'4U"R>Z]T/V[?A7\8MY?%^I^%U;U70
M[=^+U9LZHZ]J.GNM-Q9GJ#''!UL<L=3BA-M3(X6O2AJTGG^YB6L"U)D=IQ(S
M$GW7NJ2_Y_W077/1'\@#Y _$CX];?W'%C:+"_&?9'1O4/]\-P]L9F7']>]E=
M?SG%X-<WD<WGZVCPF#QKRF&.:6.DI(&D*QQAF]^Z]U;ITG\7_C;G-C]";MP4
M^>[)VIUI0X?=746'W!V[G^R=MX7(?:J(*S'8NORU;C7JL0))(\8U1#.^%3]G
M&?9*H0>Z]TH>V_@5\7N\OD1T[\K>S-F;RS7?GQ^@W'3=,;ZQ7>._=FKMU-XT
M?\/RZX_$X3<V.P:C*T7[-9KQK_<Q^F?6/?NO=)+YN?RS?A)_,3QNS*+Y;]'X
MGLG)==5LM=L+>-!G<KL3<.'-1+%--%09_ 5V,R\-+/+!"\E/]V8'=$D,?D17
M'NO=*?:?P ^)^Q?B_N#X<[-ZSKMJ] ;RQF[L9OG;6V.QMT;9RF?_ -($-1!G
MZO.[JQ^:I=UY?)9N.JG^^K:K-2U526!EE8HFGW7NDOD_Y:'PXS'Q"I_@9D>O
M]_3_ !.I<%C]K0]3+\C.RZ=/X3BIH9Z?$-F8MWIN&3#Q/3P@4+9=J3QKX3"8
M69#[KW4KM3^6[\/NZ^I>DNE.SNNMU;MV7\<=Q;4W5TCD,GW5OF7<NW:W9L,5
M+134.\_[R?WON:*%:>;R9R0SQ$B4LUG'NO='.V[M["[2P&%VOMO&TV'V_MW%
MT.%PN*HU*14]+C(EA@AC!).F.-% N23:Y)-S[]U[HKVXO@Q\:]U_*+;GS-SF
MV=_5'R/VALK(]<;8WY2]]]@8JFH<#F)VJJS$T^W:3=$&V$HJNI82SQ_P:TTB
M1/)J:*(I[KW7##_!/XTX'Y3Y[YJ8K;'8%/\ )3=&S:#KO<._G[^["JJ:KP.+
MJEKJ7#3;<FW3)M=L935B^:*F_@HBCD:1T0&20M[KW3=U=_+^^+/3'?'=_P F
M^N-H]@8+O+Y(T>%H.[]^5?R#[%W))N&/;-$^.Q7W5#E-UUN,B?$4,C08^2GH
MH9*".RT;0Z5M[KW0<[,_E2_!SKSJSY#=*[*ZY[*V[UI\KMW;IW[\@MN8_P"4
MG:ZMN3,[Y-/_ !O)5%>^]VR5)5YF.D@BKGHZRF-73J:>H\D#O&WNO="G\D_@
M7\6?E]\?,?\ %CY'=?9[L[HG&R[:FCV5D.V]YX22=]GO')C7KLQBMPT&=R34
MLD4;J:O)S%G4,^IN??NO=-'?'\O#XG_)[XW83XC]^[,W_P!H= 8*';D$6RMR
M?(;L=ZFM7:,E--C3FL_#NR'<FX'I)Z2FE1\GEZQ_,@E+&2['W7NN/8W\O#XJ
M=M]A?'[M;L3;':6YNP_BQ69?(]";JJ?DUVA1U&WZG/T]/25]3&*;>4$5?45U
M)30P5$M='4R30AHI&:-Y%;W7NG;=?P+^,F]OD_L7YE;CVUV/5_(WK3:F3V-L
M??='\B.QL+3T&&S1G:MQB;>H=V4VV9:*MDG9ZB*7#2+/(D$DH=Z:G:+W7NM?
MCN'KW^6#WI\ZOE1O/^9=\9/D-\6?E#%V#D-C]6=H[4H.U>L<=O;K3K['X?&8
M3<0WUU/7/M[<=9G!31O+!E:],C04E-CL6E)$,?)+4>Z]U:-_+=^-/4?3G86_
M=Y_$JM^76(^+VY-E-MRMV_\ *#?'8F=H,KNC#YJ3P9;9N$[0G;=&'HZ"CCRD
M59D!20X_/I7XZ:@DJHJ SM[KW5POOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI<[P_[?R_ 7_P 4 ^<7_O3=;^_=>ZNC
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T%O>7_,E.X/_ !%O8'_NIJ_?NO=$ _D>
M_P#;H7^75_XJEU1_[@)[]U[JU'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW1#]P_RTOAYNKY7[=^<6<V-V-5?*?:>U)-A[;[9@
M^2O9V-GH\'*E<KX:'&4N\8<(N*<Y.OD:D.,,#33O.8S,1(/=>Z/<B"-$C4L5
M1512[M*UE%A=F)9C_4DDGZDW]^Z]T5OY;_"[XY_.GJG*]'?*/9NXNQ^I,]58
M2LS^P\?VMN_K:@R#[<K8LC0_?IM3/8-ZU:6OIZ>H1)WD030Q2:=4497W7NA>
MZCZFV7T=U[M?JWKR/<]/LO9F&Q6W]M46[NP-P=FU=-182EAHZ2F_BVY\IF,O
M/'!34\2*):Z3D%R2[NS>Z]T5?</\M+X>;J^5^W?G%G-C=C57RGVGM238>V^V
M8/DKV=C9Z/!RI7*^&AQE+O&'"+BG.3KY&I#C# TT[SF,S$2#W7NCW(@C1(U+
M%4544N[2M91879B68_U)))^I-_?NO=!YVYU/L'O7K3>O3_:>".Y^NNQ,#5[9
MWCMX92LPGWE!7V$U/]WCZBDKJ<2*+%X*F*0#]+J>??NO=!9LGXE=.[)W!UON
MDIV#OO/=.87(8'J?*=O]L[F[AJ-OQ9:D7'U=30U&Y<KDZB7,56/3[27+54M1
ME7IGG@:M,=75K/[KW02Y#^6E\.LC\G-T?+INN-PT'<._OX--V5#A.V-VX#:V
MZZC;U$V.H:S=FQZ+.0;.W/54M&8TC?)X.JLT4$UC/#'*ONO=*_H_X!_$+X[]
M7]D=,]8]([7I>M>XZGL6I[8VMNR6K[%I]QCMJ:KGW)3Y==P5&2^[H,P:ZICJ
M*)K4;0,M.(!!''&ONO=)GKW^7#\3^L<!A]B[9VCOJJZEVSN*GW1M+HO=W=F]
M-^;#Q-505(K:*+';-S6>K]OT^,Q58J3XW&?8'&XN:."3'4E*]-3&'W7NJ?/Y
MP&V]B]F_S?OY$>%W=55<VQ>O-S?/*?MW/;?W+D-K-M*3>^S=HC:%9D\]B*FD
MJ]K5>1S-#&<34O74DLM3"#3.S+[]U[J_O8'Q\ZOV'OG.]LXJDSFY>S-U;?QN
MV*_L7?.[\EOW)KA\<_F@Q6-J,G554>)Q+3G[B6EQ\=-!4U/^55*35%I??NO=
M%_B_EG?"N#Y%]B_*6#I^2#M7MXXZJ[3IX-_[EAVON.OQ "TN9S>R$RXV=E,W
M3*J^*OJ<')4Q,/-'(LY:4^Z]T\]'_P N?X5?';XZ;J^)?5?0.TL=\=]\4FZ,
M;N_J_<U5D.Q*'(T>\*NNKJ['U3[AK,I528XU63KY(:3SBGIFGE:FBB+L3[KW
M05?#C^4'_+Z^!.Z(MZ?&;HN;:VYL;C\UA]HY;>'96ZNW)-MT6Y99)LI2;6&[
M,WFEVU%EY)"<BV.6FER&F,5TE0(HPONO=#9L/X'_ !GZT^1797RQV?MOL:B[
M^[@PNW]M]D[ZR?R&[%W.F5Q^TUT8NAFP^4W76X**DQRE_MHH<9&D&N4QJIED
M+>Z]T$>POY2GP!ZTVQ\D=C;3Z2S:;"^7F:W)N7Y&]>[B[S[#WOM[<^3W>9VR
M63J,#F]UY'$462JFG):KHJ*FJ%,5*4D4T5(8/=>Z3_\ PSC_ "\JCJ[J?J+.
M])9S>&U^C^R-C=K=7Y3>W=.^=W[@Q.8ZS:H; "FW/7[DGW"F*Q*U50E-BADA
MBXHW9%HP"??NO=5<_.W8'\O/M#^8)6[9_F2_$KN;J;;'3O4_5O6_P=^4W6&U
M-_[=Q>=H:NDRN3W'2MOGJ.J:MP<6WZFMEQM!A,X:"F@23(UD"5#92+[;W7NC
M4? OXI_&#8'R%V]V?\!,Q\SJ'JG$XC=^&[KR?=79G:^;V!N.#.XNEEQ-%@<5
MVG5L^:S460EQM;'GL+!/0T5-19#%5%8*FL-.GNO=6 ]<?R\/BEU'W)WQ\@NN
MMI=D[7[C^3G]WCWMOFD^2'9=54[B;:-/-28EZF&IW?-24\F*I:B>&C>EIX&I
M8G9(#&IM[]U[IOZ>_EM?$'H+XY[T^)G4&R.Q=D= ;_3=R;EV+C_DCV;62,-_
M?<?QK[',U>\*C/8@Y-JJI>H-!E*8R2R/*Q\IU^_=>Z(W\Z_C=T1\0?Y;VW?B
M9UC\/>VN^OA?F^SNL.N>[.KL!EMS?)_(;(ZV?-'.9K<F&P^Z-PYC<M<<#4T=
M-_#J?$M55&)J9J;)4E%(F,2G/NO=$ V/\+OY)&]-M;?QWPNH_P"8=4[_ *_$
MQT746RNBNY_DYL/(8*<T%3)C89ZG<U=!@MAT=.E,T8J]Q345# RI [O+)%!+
M[KW6TSUMB=UX#KK8."WYGX]U;XPNRMK8G>>Z(8/MDR66QU#!#D:]8_\ =:UE
M8DTP7^R'M^/?NO=+3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW6C#_ -R-_P#F0[_Z(I[]U[K>>]^Z]U2A_/-_YD=\)O\ QK'_
M "X?_?A4/OW7NKK_ '[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4H?S=?^9X
M_P EG_QK'UG_ .^][%]^Z]U=?[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JE#XK_]
MOR?YM7_BLG\MK_W$[%]^Z]U=?[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JESO#_M_+\!?_% /
MG%_[TW6_OW7NKH_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!;WE_S)3N#_Q%O8'_
M +J:OW[KW1 /Y'O_ &Z%_EU?^*I=4?\ N GOW7NK4??NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=:,/_<C?_F0[_P"B*>_=>ZWGO?NO=4H?SS?^9'?";_QK'_+A_P#?A4/OW7NK
MK_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U2A_-U_YGC_)9_P#&L?6?_OO>
MQ??NO=77^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI0^*_\ V_)_FU?^*R?RVO\
MW$[%]^Z]U=?[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JESO#_ +?R_ 7_ ,4 ^<7_ +TW6_OW
M7NKH_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!;WE_S)3N#_ ,1;V!_[J:OW[KW1
M /Y'O_;H7^75_P"*I=4?^X">_=>ZM1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UHP_P#<C?\
MYD._^B*>_=>ZWGO?NO=4H?SS?^9'?";_ ,:Q_P N'_WX5#[]U[JZ_P!^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5*'\W7_F>/\ )9_\:Q]9_P#OO>Q??NO=
M77^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI0^*__;\G^;5_XK)_+:_]Q.Q??NO=
M77^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>ZI<[P_[?R_ 7_Q0#YQ?^]-UO[]U[JZ/W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW06]Y?\R4[@_\1;V!_P"ZFK]^Z]T0#^1[_P!NA?Y=
M7_BJ75'_ +@)[]U[JU'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6C#_W(W_YD._\ HBGOW7NM
MY[W[KW567\W+XS?(3Y0_'OJ'!?&'";!W)VQT_P#,'XR?)3&;>[+W?-L7$5U/
MT/GUSTU%49*GH<E/3FL:GBA#)12,-9;3Z??NO=!3_IP_GR_]X"_ #_TN+<W_
M -K?W[KW7O\ 3A_/E_[P%^ '_I<6YO\ [6_OW7NO?Z</Y\O_ '@+\ /_ $N+
M<W_VM_?NO=>_TX?SY?\ O 7X ?\ I<6YO_M;^_=>Z]_IP_GR_P#> OP _P#2
MXMS?_:W]^Z]U[_3A_/E_[P%^ '_I<6YO_M;^_=>Z]_IP_GR_]X"_ #_TN+<W
M_P!K?W[KW7O].'\^7_O 7X ?^EQ;F_\ M;^_=>Z]_IP_GR_]X"_ #_TN+<W_
M -K?W[KW7O\ 3A_/E_[P%^ '_I<6YO\ [6_OW7NO?Z</Y\O_ '@+\ /_ $N+
M<W_VM_?NO=>_TX?SY?\ O 7X ?\ I<6YO_M;^_=>Z]_IP_GR_P#> OP _P#2
MXMS?_:W]^Z]U[_3A_/E_[P%^ '_I<6YO_M;^_=>Z]_IP_GR_]X"_ #_TN+<W
M_P!K?W[KW7O].'\^7_O 7X ?^EQ;F_\ M;^_=>Z]_IP_GR_]X"_ #_TN+<W_
M -K?W[KW7O\ 3A_/E_[P%^ '_I<6YO\ [6_OW7NO?Z</Y\O_ '@+\ /_ $N+
M<W_VM_?NO=%OZ"_F+_SE?DAN;Y&[3ZZ^ ?PD7*_%SO?,_';LX[@^9FXL9$=P
MX+$XC-3G&NG7\YJZ#[/-T6F9EB8R>1?& H9O=>Z,A_IP_GR_]X"_ #_TN+<W
M_P!K?W[KW7O].'\^7_O 7X ?^EQ;F_\ M;^_=>Z]_IP_GR_]X"_ #_TN+<W_
M -K?W[KW7O\ 3A_/E_[P%^ '_I<6YO\ [6_OW7NO?Z</Y\O_ '@+\ /_ $N+
M<W_VM_?NO=>_TX?SY?\ O 7X ?\ I<6YO_M;^_=>Z]_IP_GR_P#> OP _P#2
MXMS?_:W]^Z]U[_3A_/E_[P%^ '_I<6YO_M;^_=>Z]_IP_GR_]X"_ #_TN+<W
M_P!K?W[KW7O].'\^7_O 7X ?^EQ;F_\ M;^_=>Z]_IP_GR_]X"_ #_TN+<W_
M -K?W[KW7O\ 3A_/E_[P%^ '_I<6YO\ [6_OW7NO?Z</Y\O_ '@+\ /_ $N+
M<W_VM_?NO=>_TX?SY?\ O 7X ?\ I<6YO_M;^_=>Z]_IP_GR_P#> OP _P#2
MXMS?_:W]^Z]U[_3A_/E_[P%^ '_I<6YO_M;^_=>Z]_IP_GR_]X"_ #_TN+<W
M_P!K?W[KW7O].'\^7_O 7X ?^EQ;F_\ M;^_=>Z /LGI[^;O\OOD)\!L[\A_
MC/\ $+I;J?XJ?,':7R4W5N'K#Y09GLS+U5/@<!N' O14^-K]FX:!B5SYFU?>
MAOV=(4ZN/=>ZV'_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4!]E]:?S-/CQ_,T^8
M'RJ^*OP_Z>^375WR:Z>^+&P:>HW]\IZ3H:KQM7T-2;A6J9:5MO;@EJHZJ7<#
M("ZT^G[?4OD60%?=>Z$W_9J/YY/_ 'J5^,G_ *<EI/\ [77OW7NO?[-1_/)_
M[U*_&3_TY+2?_:Z]^Z]U[_9J/YY/_>I7XR?^G):3_P"UU[]U[KW^S4?SR?\
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MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I#]G8#(;JZV["VOB5A;*[DV/NS
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M=>]^Z]U[W[KW7O?NO=>]^Z]U6U_.._[=._S(?_%)ODI_[R>4]^Z]T9OX@?\
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M%<E/'74=)B8A&N03W7NL?8WSN[8^#WR1Z$Z7^<J]9[BZ1^6F]GZKZ&^6/5V
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MLMM?'?;\/8Z_(WKW<^PJK/[AW"^2QZ1[8;;N9BKJ>##?PW)!Y:ORTTHGA;2
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M>;@FJ>J=B[HW3DHHZFJZ_P!KYS<.6R4D= @EJ<=!/55$['QQ0C6SLQLJKSP
M/?NO=*K![AP&YZ!<IMK.8?<.,:62!<C@\G#EH"\-M:":G>2,NEQ<:KC\^_=>
MZX5VYMN8N'+5&2W!A,=!@%IFSL]=E8*1*(5H#0FK:215IA*K*4\A74""M[CW
M[KW7#(;JVOB<+#N/*[DP.,V]41TDU/GLAF*>BHI$KP# R54DBP,LP93&1(0X
M(*WO[]U[IUJ:VCHJ.HR-95TU)CZ2FEK:JNJ9U@ABA@4N\LDK$(D2("S,6"A0
M23;W[KW3:NYMMOF8MNIN#"/N">@&5AP2Y6!JQZ5N!4K2B3SM3D@_N!-'^/OW
M7NJ/OF!WK\ANL/YX7\G[HS:W>V^J;X_?*# _.:O[3Z/_ (?@:?"U-1TIUG69
M'#2BJI\-!GI].1JEJGCJLS40K-! T,4.E@_NO=6E=E]5;QW/\@?CIV?B?DMO
M[K':/6Y[,H-T_'[!4^&?!]C2[MQ)CHES#UU++DUEVV:>6NIA0S(WID+Z4#-[
M]U[H?ZC-X:DJ*JCJ\OC*:KH<8V;K:6HKXH9(:)6=35RHSAHZ4-'(#*P"75AJ
MNIM[KW67&93&9J@I<KALC0Y;%UL?FHLEC*N.O@F0DC7%-$SQR+<$75B./?NO
M=-E5NW:E#FZ/;5;N?;U'N/(JK8_;]5FJ:GK9PP8@PTCRB>4$*UM,9^A_H??N
MO=*'W[KW7O?NO=>]^Z]U[W[KW5*'\QO_ +>5?R)O_%F_EI_[Y?<_OW7NKK_?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
M!7R/^-72ORTZIS?2_?FR*+?6PLW44.22EEJZC$5N.R6'<RX[-87*4,M/DL+G
M,7/::BR%%505=+,!)#*I^ONO=4B?-C"_S;_CMO[JW%[8[![+^6?\M++9A\+\
MDJWH_9.-HODKMW;E32UD<IHZ_&T\?]Y\? [TAFJ]N;>BW?+2Q2PTKQY*1,O[
M]U[JYGXG;?\ BWL7H_8_5WQ&H^O,%TML;!0X?:^R]@M'#%C8;EI8:ZC<_?T^
M2:=Y6K17QK7-5-*:S_*#)[]U[HI>U/Y6>R^B>V=Z]I?"[Y#=]_#;$]I[HJ=[
M=K=#]9R[9WQUKF\S7LQJLO3[0WGM[<,&ULE5B1S42[=J\0E0ZP&IBF2GCC]^
MZ]T>/K;IF/9&4FW;NKL#?O</8U3C:G"OOSL2IQT$M-05=3]T^/Q6(P6.PNWL
M/2-(E.LKTF(CK*U*6C.4JZ^:EBF7W7NAH]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW5*'\HK_F>/\ .F_\:Q]F?^^]ZZ]^Z]U=?[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*9\^?\ 27_LBGS3_P!"_P!_
M_IB_V4OY&_Z)OX7]O]S_ 'F_N=F?X#]M]W_DOG_BGVOC\W[6NWD]%_?NO=5.
M_P#"5_\ @W_#&GPZ_AGV_P![_%_DG_>+PWU?>?Z4MYZ/-_S<_A_V-K?[KT?G
MW[KW06_\*UL'A\Q_*!W//+0FMWOA/D9\>LGU']G2-59"+<=5EI<>CXDQH]1'
MD7P]=F(D:$K*8Y)8U8ARC>Z]U=IW?WY7?%OX;;I[WWO@-Q;RWEUST]C,E%L/
M#4+YK-[EW?6T=-18?;&-I*:\M;G-R[FJ:+&4D$5VGK*J*-.6'OW7NM4?^9MO
M+:O3_P 2/A'\L_CUL'YB;E^9_P#+0[SIOD[OS>&]?Y;/R"Z2QN\Z'MBNFR/>
M$&6W=O#K#%X';.'W'7U]5DZBHKL@\5+0034=/&99(2GNO=;DO3_:VR.]>J.M
MNZNM<S3;AZ^[8V+M;L39>;I)%E2IQF\**&OHI;H6 9H)TU+>Z-=38@CW[KW5
M8/\ /^_[<U?S!_\ Q N0_P#=ECO?NO=>^5/_ &X$^1__ (Q[[@_]\MD??NO=
M5_\ Q%Z:^=7RO_D-?%SXF=1T?Q:ZJZR^07P"VWU!NGO_ 'MV/NK?6X<=@.PL
M%_"LHE#UW1[+Q6,J,C5X.KK((ZB7LB..DJ'6H^VJE7P^_=>Z(U_-M^*V$^!%
M-_PF2^%?6T%=D/A_U%_,0Z[H.R]W;@6GCJ*O<:[NVA7TU?7I"\4"5&?3.=CY
M"=8Z-XU?6HDC "S^Z]UNT^_=>ZC)14<=9/D4I*9,A54U)155<D"+-)#0//)!
M#)*!K>*%ZFH:-2Q5&ED*@%VO[KW1$_YC'P.Z&_F.?'J;XV=XY3*;7JJG<V.W
MYT_V!M/*IB-Q[7W?LZ"J?';BV](S O78^GJ*Q98P"LE)+4(Q0,)$]U[K7PJ/
MG!_-1_D>5FT^NOYL.V\-\_?Y<F7W%A^O*+Y^=<8F:7=6V*7..\-*^_<%(E4^
M30,\$)BJ4\\HUBFSF9K?#03>Z]U?C\\\17[ZV?\ &O<4/R;H^BOC]COD!UYO
M#O.CQF6RV"RG9.W)J6K;#;#P-=@)8,])4[BW!+A7;'X]S/F::*3%R155+55%
M'4^Z]U7M\4^[-Q;=_GC_ "<^'&V(.]]A]"]F?RZ]@?+39W7'9FXIJJCP^=V]
MO1-E9+-;:PV2RF8K-JT^=HLACW?'M3XLFKHJBIK,2LTR3S^Z]TDO@-TAF/E1
MV=_.2Z/[_P#D3\J]_P#66P?YAVX-F;2H:?Y$;HV%F:+&Q;4VYD,9C8-S;9R.
M&SM+A<%)5,M%C*6MIZ&7U296')RN7'NO=)_^69\=]R?/CX'=E=5?)OY/?*S=
M6$^/_P LOEA\;^H-Q;0[_P!T]6;B@Q?3>YLGB<!D]S;AVYEL;EMZ9:@I9HXX
MURM3-C?%2TFK'O51R5<WNO=5^=I?,/Y6=K_\(^=O_-+*?(CMW:WR1PNUL5M+
M(=H; WI5[1RV8I\5W]!U:9LQDX'.4JJNLVK"ZU<R5T+5-7--4RZBRJONO='(
M_F\?'/Y&_$SXDC^:]\9OES\E:KY;?&%>LNT-_;5W-V[DY.M=X;6KLC0T6=VY
M5]<R9"+;E'@L=0Y.2>""!A7R4U*XEK:_-20UY]U[H6?FAN'^]W\]O_A.3NO[
M7['^\_67\R;</V7E\_A_C73T=3XM=EU^/RZ=6D7M>P^GOW7NE_\ -O>/9FSO
MY]_\D?9F![>[8HNM>Y<!_,*K.P.I*??E=1;4R$W7'5=3+AYZG 4TD&/K*BCJ
M*J::.6JAJ)8YB'B>,@>_=>Z1_575&^.VOYR_\TCX\=A?)_Y39GHV/XR_#W=&
M,V'C.Z\OM!\8G8-/N&'*8S!9;#S4&4VQCJNMI9:Z<X2IQM7-/)'$]7]G#]M)
M[KW0T?R8<WV+M3(?S//C1E.R^SNY=B_$?Y\=@]9= 3=R[[J]_P"?QVV\OMS
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M97CQ5--+/2M5+&TTL:12B)7E]U[J!_+&^*?S%^%/1?R2Z^[-V[\:-Q[LW_\
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MFQ=;L[&]<5&;J:C&XOLDT^2D^[[(R66QE-+%C-TB&+$8XO6T>(H8:CSY&O\
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M3'3U.1IZ#=\LL(EI<1_E5+"U2O@62._NO=8/EY_-Z^2?P?7K+Y&]^?!8X?\
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M28(:>JK\G0T].TDB_<33+'#K<,%]U[IV[Q[OZ9PG_"CKX7X#+]L=<8W-U/\
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MZ1WIV[OCM;"F'=+"3(18Z/=>Y,U/A(JJI!JF3&STB_>-)6J!5R23-[KW0?\
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M/^_].-__ )F^_=>Z]_PP7_X.H_G_ '_IQO\ _,WW[KW7O^&"_P#P=1_/^_\
M3C?_ .9OOW7NO?\ #!?_ (.H_G_?^G&__P S??NO=>_X8+_\'4?S_O\ TXW_
M /F;[]U[KW_#!?\ X.H_G_?^G&__ ,S??NO=>_X8+_\ !U'\_P"_].-__F;[
M]U[KW_#!?_@ZC^?]_P"G&_\ \S??NO=>_P"&"_\ P=1_/^_].-__ )F^_=>Z
M]_PP7_X.H_G_ '_IQO\ _,WW[KW7O^&"_P#P=1_/^_\ 3C?_ .9OOW7NO?\
M#!?_ (.H_G_?^G&__P S??NO=>_X8+_\'4?S_O\ TXW_ /F;[]U[KW_#!?\
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M8+_\'4?S_O\ TXW_ /F;[]U[KW_#!?\ X.H_G_?^G&__ ,S??NO=>_X8+_\
M!U'\_P"_].-__F;[]U[KW_#!?_@ZC^?]_P"G&_\ \S??NO=>_P"&"_\ P=1_
M/^_].-__ )F^_=>Z]_PP7_X.H_G_ '_IQO\ _,WW[KW7O^&"_P#P=1_/^_\
M3C?_ .9OOW7NO?\ #!?_ (.H_G_?^G&__P S??NO=>_X8+_\'4?S_O\ TXW_
M /F;[]U[KW_#!?\ X.H_G_?^G&__ ,S??NO=>_X8+_\ !U'\_P"_].-__F;[
M]U[KW_#!?_@ZC^?]_P"G&_\ \S??NO=>_P"&"_\ P=1_/^_].-__ )F^_=>Z
M]_PP7_X.H_G_ '_IQO\ _,WW[KW7O^&"_P#P=1_/^_\ 3C?_ .9OOW7NO?\
M#!?_ (.H_G_?^G&__P S??NO=>_X8+_\'4?S_O\ TXW_ /F;[]U[KW_#!?\
MX.H_G_?^G&__ ,S??NO=>_X8+_\ !U'\_P"_].-__F;[]U[KW_#!?_@ZC^?]
M_P"G&_\ \S??NO=>_P"&"_\ P=1_/^_].-__ )F^_=>Z]_PP7_X.H_G_ '_I
MQO\ _,WW[KW5$WVWR7_V3?\ O1_PXQ_,A_O+_?\ _P!DG_O%_LW>?^^_A/\
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M2ND> 21L(;+QZ+<<?3W[KW3[[]U[K%#!!3H8Z>&*"-I9YV2&,1 O5.TLKD*
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MP_GK_P#?15_[2-Z=_P#KW[]U[KW_  WA_/7_ .^BK_VD;T[_ /7OW[KW7O\
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MP_GK_P#?15_[2-Z=_P#KW[]U[KW_  WA_/7_ .^BK_VD;T[_ /7OW[KW7O\
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MNO>_=>Z][]U[KWOW7N@M[R_YDIW!_P"(M[ _]U-7[]U[H@'\CW_MT+_+J_\
M%4NJ/_<!/?NO=6H^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZT8?\ N1O_ ,R'?_1%/?NO=;SW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+9\D_F)\
M7/AW@]M;F^4G>W7'0^WMXY6KP6U\WV5N&+;=+75M##]Q+2T\\UHWJ%@O)HU:
MB@9@"%8CW7NM=G^6/_-C_EJ]6]O?S8,SV+\V_COLS%=N_P RCL#L[K&OW!V)
M1X^+.[>R.R-BT$&8QK.P%302UE!6PK*OI,D,B_53[]U[K:NH*ZER=#19*AF%
M10Y"DIZZCJ%4H'BJT$D;@, P#(P-B >>0#[]U[J7[]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JE#XK_ /;\
MG^;5_P"*R?RVO_<3L7W[KW5U_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z!#Y*_(+KKXH] =P_)+MNOJ<=UQTGU]N7L7=LU#"M5524VVZ9Y_M
M:*%GC6>OKI%CIZ6(R*):B6./4NJX]U[I<=9]C;.[@ZYV%VQUWFZ+<NP>S=F[
M9W_LK<6-J8ZNGKL5O"BAR&/JX98GDBDCJ*6HB=65V4AN"1S[]U[I;^_=>Z][
M]U[IHAS=#7XB?,X&>GW'3)%D#3?P2M@K%J)<:TD4E/%,)!!Y1/$\)#2J$D!5
MRI5K>Z]T#/QA[@WSWSTEL_M/LCH+L?XQ;RW(^X4RW2O;%7C*W.XG^"Y.LH('
MJY,355=&R9"GIHJR"TH;P3QZT4_7W7NA]]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M5?OR)^?.+^.WRS^'GQ2SO1?:F;G^9&]=V[(V5W-25N!I=IT%7LK"39VNIJJV
M5GW U<M'%^W$^"@@F.HQ5;^*4)[KW5@7OW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J#D\IC,+0565S.1H<3BZ*/
MS5N2R=7'000H"!KEFE9(XUN0+LP'/OW7N@,^4/<>^^A.EMT=H];?'_LCY/[O
MP%7MN#'=,=35>-HL[DTS62I**IFI),M54E%IQU-42U<H:8,T4+A1<W'NO=#Y
M!(\L$,LD$M+)+%'(]-.49XRX!*.8GDC+H38Z)&6X]+,+$^Z]UE]^Z]U[W[KW
M5>/S<_F%[:^$/8'P^V)N_IGL[>U+\Q_E/TW\3]G[^VS7[?I,'A\]W%DC14S9
M45>73.-]M31U-65IL'+#(D1C-5%*Z*?=>ZL.]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW5+G>'_;^7X"_^* ?.+_WINM_?NO=71^_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z"WO+_ )DIW!_XBWL#_P!U-7[]U[H@'\CW_MT+_+J_
M\52ZH_\ <!/?NO=6H^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZXNZ1
M(\DCK''&K/)([!%54%R23P !R2??NO=<O?NO=,E?N;;>*R^"V_E-P83&Y[=,
MU=3[9PE?E8*.KR,F+IY*NICH*:219JQZ>EAEFE6)',<2/(X"*2/=>Z>_?NO=
M>]^Z]U[W[KW7O?NO=,>Y-T;:V;AZG<.[]Q8+:N HGI8ZS.;DRU/@Z.)JZ5((
M5EJ:J2*&-IIY(XT#."[NJ+=F /NO=/GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z0VU.S^M=^5V8QFQ^P]C;SR6WIOM\_CMJ;MH-Q3T,E].BL
MAHZB:2F?5Q:15-^+>_=>Z7/OW7NF,;HVTVY'V:NXL$V[X\*NY)-J#+4YR2XY
MY_MEKVH?)]T*(U(,0G,7B,GHU:N/?NO==G<VVQN./9YW!A!NV7#5&XHMK'*P
M#(MCZ2:&FEKUH?)]RU'%45%/$\PB\:R2QH6#.H/NO=/?OW7NO>_=>Z][]U[K
MWOW7NO>_=>Z;,UF\-MO$Y#/;BR^+P&#Q-+)6Y3,YJOBQ=)30PB[S5%3.\<,,
M2#DL[A1^3[]U[J725=+7TM-74-33UM%6T\-71UE),M3%+%4J'CEBD0LDD<B,
M&5E)# @@D'W[KW377;HVUC,W@]LY+<6"Q^Y-SIDY-M;?KLM3TE=D5PL:S5C4
M-))(L]6M)$RO,8HW$2$,^D$'W[KW3Y[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM&'_N1O\ \R'?_1%/?NO=;SWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUO/\ A5C\87^1
M7\GON#<^*PL^:W=\8=[]??(K;T-)+X94I<#5/@=QS$F2-'IZ+:^X,S6S1N6#
M+2!D1ITA'OW7NOFK_P IKXPP?,K^9+\,OCCD,?19;;F_^\]IU>^L7D:5:V&I
MVSL,R;CW13R0N"DJS;>Q&332X*$D!P5N/?NO=?;K]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5*'Q
M7_[?D_S:O_%9/Y;7_N)V+[]U[JZ_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=5H_+_8.R/FGW5L3X';ZQ&'WGTOAMDS_(_P"6.S\G!1Y:GK<7
M539#!=:;?R%'4>4B/,[LH\SGZ:4T[*LVR]%[R<>Z]T0/_A/;VANWK78'RH_E
M0=S9>NR'<_\ *W[US75>W*S,3+/59KJSL*>KS'76>$D2"G,=10&KCCIXY7DH
MJ$8V.I2G:6.$>Z]U9-D?E!NSN'YF]K?"KHC+X/:%?\;>J^KNSOD9VEG,"-WS
M4=3WL<S_ '/VO@<;]W34Z9&>CP=;D\C65Q>*"B:CIJ2DJ9JZ6KQGNO=%T?L3
M^91G_B3_ #"]L]VTVT_CAV[T1D.[<=\?OE/USM>FW#1;XV5A<-79/ ;MQ>VJ
M_-5HVYN=*=(8*U*R2LHH:]9):6DEATQQ^Z]TF_Y/M=\C*7^4-\5>P*OLG8_8
M6=S/Q)ZVW1L:AW=L[)8EJ.I?'/5U4NX,Q'G,E6[BGJ-89Y5IJ&224.[,#*2G
MNO=%IZ._F'?S&?E#_((VU_,OZ8H>AY?EQ3;*^1O:><ZKEZCSNY=N9['],;]W
M5B6PV$QM)N>+-TN3&VMODT@_B%=)65X2)D_>NONO=6.4GRCW]VO_ "[>DOD7
M\?NQMF9WMGY%;/Z:J>GMS9SK"JJ\-6YWNVHHJ:BAR.V8,S39&GQN(?(22Y1(
M\RM124>/K)Y)OV9#[]U[IY[Q^8,76WR Z;^%L/8VTML=S[^Z0WO\@MX]K;HV
MDV2QF.VSUKF]N[=J!28*#*T\K9S<F5W (\:):QZ*CAHLA55 K&IX:&K]U[H$
M?AW\UOD5NSYT_(KX5]X[;Q79?7NU]@83O#XV?,3K'K;-[,V_G<)DI:&ARFS=
MTBH-=A*;>^#R55(\7V.46.OQJBH:AI9(W$GNO='*^>O=W97QG^&7R?\ D;U-
MAMC;AWGT#T/VYW71X;L22O7&5,75.W<EGI:>1,:T55-)4C'B%$6IIQ>0L9ET
MV;W7NJ/]Z_._^<8W\L7IC^:;UG@/AY6['VO\8>O?DGWG\=]T;1W!49[=>!7!
MT.;WAFL3G\?G3CMJI!2?Q2JQF.:DR4L6/CBJ:^KDK6EQ,7NO=3/F5\D(/E)V
MS_PG ^4O2.U9:J'O?N7L+M38FSM[Y5-NO3-OSI_)U<=#F:RFCKT@.,>H=*R2
MFAJK^"0TJU!:(/[KW1V.H_D]\XNM/YH-%\'OE;E>@>U>LN]?C)V#\DNCNRNE
M^LL[U'6;?K.L=QX_$Y;:>7H\ON/=%/FZ=:#,XZ:/(15U/4>7_.T<<<Z"/W7N
MA&["[H^9M7NCYRY>NRO6/Q Z9^/&/V]@/C1V!V_M"#=5!OW*U.W/XSD=RYO(
M5>X\+3P;6BRU32X>+&4?V-:'I*RI?,.U5#2T'NO=$QW]_-F^16\_Y!N/_FP_
M';:70U#VH>D9^P=U[4WV^=SNWZ/(;9W"=K[DIL7#12TM;/-0U]+E7IHJJM$8
MF@BI9Y98WDJ5]U[HR]5VC_-6V[LON?Y'Y'_9,JOI2#X;UW;W3W5^=Q6Z,;N?
M$[SP&(CRRX_=F5QE;7XO*XW(T\-4U5-C$IA12S14U+'6QTCUM?[KW1-=W?/+
M^9I7?RA^H_YI^PMQ?%#;PVC\8]M?)7N;I3>/4N?W#)O6F-+!D\W3XG/4.[**
M/94*4XJ8<?3-BLW-*#%/59""353K[KW2]_F!_/\ ^>7Q.^)^T?YI&WH?C_3_
M !(VS2_'[=?:?Q.S>P,GN+?U9MGN_.X7"O6T^_:?=='@J7/4R[BQKQ8Z';4U
M)!*DHERE?%S[]U[JSGO[L#Y41_(WX[],]+[-H-M]*[SVYVSOCY!?)W-X%=VP
M[<AV)3428/;.-H7R%!2TN8W)75[3_P 1K%K:>GHL?4P+CY9JI:N@]U[HI'P>
M_F3R=I[T_F==9=X=@=/;PI/Y;_86)JLEW5U/$<;09?86]=L5.Z\;E<G1+E,S
M1097%08[,T%?+29(4U14X^=UHL>0U./=>Z;<K\E?YB?='P*VS\^OA[LWK'<V
M[^Q=M]?=Y]*?"W>6VG6?<&P-YU6.JX<5EMW#-4IH=\9#:=7/D8IZ:#^$T=>U
M/C6AR-/#+DJOW7NC"=Q?-Z#;W>'1/Q1I\GA.DNY^W?C_ +G^3>]<MV#C8]\0
M;2VYLC*[9P=9B%HZ'(T2Y#<F4S&XS24,WG..@3'9&ME6K\,%#5^Z]T7OXR_,
MCY6;_P#F3\GO@]V'%M[<6!V]US@>[OBM\X]A=,YNCVQE,3D*C'T>5VAN['U-
M4<+_ 'TPM?4SE%H,_ M?C!]U]I231-Y/=>Z#W^7?_,!^5'S>_DIT_P \L]D^
MHNO_ )&3;,^3.ZT;#=;9#-;5$O3&6W108R"3!U&Y(LB\%1%AZ(U6G<$<CMY?
M%)"'41^Z]T1OYS?);Y9_);^49_*O^4E-W+@^H,Q\COD'_+UKNZME]?; D6@S
ME9VANO&5'VDM359N2NI]L45;%2SOC(9DGK?"(*K)-322PO[KW5BO\Y'YE_,#
M^6M_+/[*^476F:Z-[*[7ZYS6R,9E\[O?KK+8?'20]A[IQ6"IS0[?H=PR%:FC
M@R98R3YUXFDB#FG=6,0]U[HX7=WRJS=)\N.F?@?TX^#H^Z.SNH]_?([?&]=S
M8YL]1;4Z_P"N<MB<#-618N&JI)<AGL_G<S34.+66>*AIQ#75U4U0:2'&U_NO
M=,G1'8GSPP?R&^5?4GR&ZJVWOSHS8.VMG;]^+'R7V'#3[-J=VIG,?JS&S\_@
M),G7"FW%A\M'.D%=3)!0U-$T#R0Q5&L-[KW5<'R4_F1_,?X:?!SHGYU?)NNZ
M,ZGWOO'MWK5>YOA/O;;#8.LPVR^SMTI@Y\=ALT-Q29JJW9M#%U^/K\AE#CZN
M@K#35KC XZ":-*/W7NLO\_\ _P"/T_D<?^-UO@G_ .Y>6]^Z]UL3>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JESO#_M_+\!?_% /G%_[TW6_
MOW7NKH_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!;WE_S)3N#_Q%O8'_ +J:OW[K
MW1 /Y'O_ &Z%_EU?^*I=4?\ N GOW7NK4??NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=5B_S5J+M3M_XY93X2_'S=T>QN^?FQA-_=4;>WJ]!)E$V[MG$
M8:HR&\\_40PUV-F2!L8(,%!4+6Q_;Y3/8R0B07C?W7ND%_(Z^8^X/F7_ "\>
MI<[V;)50?(GH>IS'Q;^4&#RK4Z9&CWST8T>)R,F1AI@L4%9EJ)<?DY(UBC1'
MK6C1=* GW7NB6?/'9NT<-_PHN_D,[OQ&V,!B]U[RVC_,HI]V[EQ^(@I*_)Q[
M:ZFJ(\<E?5QQK/5I0I55*TXE=A")9!'IUM?W7NKE<3\V_C_E?E[7_!0YK=F*
M^3-#U#D.^X]C9WKS-X>FJ]G8_-?W?;/4.:FH5PM91R98/!&L5>TSLDA$6F-R
MONO=0]B_.GX\[^[D[YZ QN8WMA.V?C5MC9.\^W]J[PZMW%M-J'%]CK,^$K:*
MIK<;%29R#("GF$9QL]7:1&A?3,IC'NO=%N?^<U\#:SX[P_*C9>].U>V>DILY
MO3%R;JZ;^/&^NU'I*/K^NJ\9D]PY:APF K*W [8CKJ&JBARF4@HZ2J:,_:R3
M"Q]^Z]TH^X?YNOP5Z5Z]V%V]G^Q][;OZAW]MK;N]T[8ZCZ1WIV]MG!8+=<%%
M54&8W=G-NX'(8W:=+4TF0I9TCRM12U3PL9$IV1'*^Z]UR_F6=\_RY=F_#'.;
MO_F%3;4WO\1-YP;(S=3C:[9N6[/H<R)LCC:O;\]/1X&DK:F1),E+C)(*@^.
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M_'T5?D<C!B-U[2K5%9DZ>DJ$DSB2PY*>.3Q4C'W7NL/\P3_N(+_X3Z?^&O\
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M>_=>Z]_?[_A0M_WC=_*<_P#2E.TO_L$]^Z]U[^_W_"A;_O&[^4Y_Z4IVE_\
M8)[]U[KW]_O^%"W_ 'C=_*<_]*4[2_\ L$]^Z]U[^_W_  H6_P"\;OY3G_I2
MG:7_ -@GOW7NO?W^_P"%"W_>-W\IS_TI3M+_ .P3W[KW7O[_ '_"A;_O&[^4
MY_Z4IVE_]@GOW7NO?W^_X4+?]XW?RG/_ $I3M+_[!/?NO=>_O]_PH6_[QN_E
M.?\ I2G:7_V">_=>Z]_?[_A0M_WC=_*<_P#2E.TO_L$]^Z]U[^_W_"A;_O&[
M^4Y_Z4IVE_\ 8)[]U[KW]_O^%"W_ 'C=_*<_]*4[2_\ L$]^Z]U[^_W_  H6
M_P"\;OY3G_I2G:7_ -@GOW7NO?W^_P"%"W_>-W\IS_TI3M+_ .P3W[KW7O[_
M '_"A;_O&[^4Y_Z4IVE_]@GOW7NO?W^_X4+?]XW?RG/_ $I3M+_[!/?NO=>_
MO]_PH6_[QN_E.?\ I2G:7_V">_=>Z]_?[_A0M_WC=_*<_P#2E.TO_L$]^Z]T
M37XJ_%[^=K\1-^_+[L#J[XS_ ,J>'+?,?Y&Y?Y)=A0U/R*[(IXZ7*Y[%8VCJ
MZ2B-/L"-WHYLE39/)L9BTGWF3K.=!3W[KW1RO[_?\*%O^\;OY3G_ *4IVE_]
M@GOW7NO?W^_X4+?]XW?RG/\ TI3M+_[!/?NO=>_O]_PH6_[QN_E.?^E*=I?_
M &">_=>Z]_?[_A0M_P!XW?RG/_2E.TO_ +!/?NO=>_O]_P *%O\ O&[^4Y_Z
M4IVE_P#8)[]U[KW]_O\ A0M_WC=_*<_]*4[2_P#L$]^Z]U[^_P!_PH6_[QN_
ME.?^E*=I?_8)[]U[KW]_O^%"W_>-W\IS_P!*4[2_^P3W[KW7O[_?\*%O^\;O
MY3G_ *4IVE_]@GOW7NO?W^_X4+?]XW?RG/\ TI3M+_[!/?NO=>_O]_PH6_[Q
MN_E.?^E*=I?_ &">_=>Z]_?[_A0M_P!XW?RG/_2E.TO_ +!/?NO=>_O]_P *
M%O\ O&[^4Y_Z4IVE_P#8)[]U[KW]_O\ A0M_WC=_*<_]*4[2_P#L$]^Z]U[^
M_P!_PH6_[QN_E.?^E*=I?_8)[]U[KW]_O^%"W_>-W\IS_P!*4[2_^P3W[KW7
MO[_?\*%O^\;OY3G_ *4IVE_]@GOW7NO?W^_X4+?]XW?RG/\ TI3M+_[!/?NO
M= EW-\Y?YRGQ.R7Q]W+\G?C?_+OAZC[@^5?QV^-.<R/3?=_8&[,]1/WSN2DP
M25U+0Y;;&'HI?M(YY9/W*P#4JC0P)M[KW6PY[]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[JE#XK_\ ;\G^;5_XK)_+:_\ <3L7W[KW5U_OW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z*K\X^EM\?)3X?_ "8^-W7M7M3%;B^0_1/;G12[CWEDJR@H
ML1#VWMW)X"7+&.AH*^>NEQXKUF2DM3K4:2AJH/U'W7NF;X ]"[_^*WPV^-_Q
MD['KMGYO/_'SIWK_ *<&Z-DY*MK:/+P]>XRGQD.3\%?CZ">@EK(Z99'IKU"Q
M,Q5:B4 -[]U[HX?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JESO#_ +?R_ 7_
M ,4 ^<7_ +TW6_OW7NKH_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!;WE_S)3N#_
M ,1;V!_[J:OW[KW1 /Y'O_;H7^75_P"*I=4?^X">_=>ZM1]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=)_=>V<;O+;F8VMF)\]38O.T4N/KI]L;JRFR,@L<UM
M1I,MA:S'Y6@EXXEI:V&5>=+BY]^Z]T#OQJ^+O37Q$ZSQO3W0V(WCMWKG"RUL
MN&VYNWMW>';WV?\ $:JIKITI*O>6>S]=312U=942-''5+&6?]-E0+[KW0"?+
M7^6#\*?G+V!U-VI\G.L]Y[][ Z'R53F^E]S8+Y"=D=53;7KZN?&54F1P:;/W
M=@(,=DC587%3"KAB6I6:D@E64.@;W[KW2K[&_E\?%;MKO;H[Y,=@[0["S_>7
MQMQV<Q72&_\ _9ANQ\3/M^'=-",;E134M#NRFQ]1+EJ$>&NEJ:2>6M2_W3RD
MDGW7NN7RH_E_?%[YE;EZKWSW=M+>#=A=*SY]^LNRNKNWMW=%;EQ4&ZXXXLI0
MP;@V5F\#E_X?7K! 9J=JPQEHU=0K7)]U[K#MS^7?\/MH]S[O^0FV.HHMO]P;
MVV'M/K3+[TP>\<_A9XL/LK[AJ"''I292&'&5:SU=142U]+'%D*BJ?[F>JDF5
M'7W7NO='?R]?BK\;ND=W?'3I3:?9&R.G]\UF[,CN/:\/R.[*SD[U.^Y7GS-3
M2YC)[NK<WC:G)3RRRU$M'DH))))))&;7(Y;W7NF;:G\M3X=[(^(^8^"6U]A;
M_P 5\4L]M_/;1R/4R_(WLNJC_@^Z#6G)8:#+S[OES])AZ\9&M6HH8,K%23)*
M4>%D"J/=>Z9M^_RLO@]V?\2-J?!/?O5N\MR?%#9--MN@VWU#6?(;LJ*GAI=G
M/2R8BAER<.[XLW68_%/0TC4=)4Y.:FIFB4PQ(;D^Z]TN?D!_+]^+7REV7U7U
M]WQM7L??NU.E=Z;5['ZWH9?D7V1MZ>AS^QVJ6P^9GK\3NV@R&4R>.:KG,%17
MU55+&2MF_;CT>Z]UE[N^ GQA^1>_.A^S>W]M]F[EWQ\9=PC=G1^=QWR0[*V8
M<'E-$$3Y$4^"W=C*7(5TT%.D,T]=!523P//!,SPU-0DONO=)_N+^6]\2.]>^
M]F?)S?>R=YT_=NS-JXO8B[WV'W3O3JZ7-8+"UGW]+A-UP[;S^*I]V8B.I:4M
M29>*L@FCEF@J$E@E>,^Z]TJ>I_@3\4NC=X]W=@]4=61[&WM\A]R2[J[1W/M[
M=F;Q=745;T5/C8_X7)!DH_[N04U!2PP018@4*0IK\8#2RL_NO=-71W\O7XJ_
M&[I'=WQTZ4VGV1LCI_?-9NS([CVO#\CNRLY.]3ON5Y\S4TN8R>[JW-XVIR4\
MLLM1+1Y*"222221FUR.6]U[IFVI_+4^'>R/B/F/@EM?86_\ %?%+/;?SVT<C
MU,OR-[+JH_X/N@UIR6&@R\^[Y<_28>O&1K5J*&#*Q4DR2E'A9 JCW7NC%] =
M!=6_%_J+9'1/2F%S6V>J^M\'C]L[&VQF]]9_L-L9C<1#'3TF/ILAN7*9?)BB
MI((HXX(&K6CA10L:J./?NO=!)\N_@?\ &+YV[8V[LKY0[/WIO[:.U-S87>>#
MVY@>\M^]34<66VVT[X_)20;-W-M^.JK:&2HE>":<2/$^AXRKQ1E/=>Z$'MSX
MN="=_P#26>^.?>O76-[FZ:W/2T]+GMG=J9/(;_\ N?LIDJ::=\AE:NJRJUM)
M4QQS4U4M<M332HDL$L;HK#W7ND_UC\0NF.K<ULK<]%'V)OW=76VVI=H]=[I[
MK[>W1W?D,'0U4*T]2,75;JRV5DI*VNIU6*LKU_W(5D(6&JJIH41%]U[I-1?
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MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI0_GF_\
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M_B9\L]F4ZC,[5S(5M>.R*:2,UM#- M3Y;$U"R4]33R2?MDEED]U[H//Y</\
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M +QN_E.?^E*=I?\ V">_=>Z]_?[_ (4+?]XW?RG/_2E.TO\ [!/?NO=>_O\
M?\*%O^\;OY3G_I2G:7_V">_=>Z]_?[_A0M_WC=_*<_\ 2E.TO_L$]^Z]U[^_
MW_"A;_O&[^4Y_P"E*=I?_8)[]U[KW]_O^%"W_>-W\IS_ -*4[2_^P3W[KW7O
M[_?\*%O^\;OY3G_I2G:7_P!@GOW7NO?W^_X4+?\ >-W\IS_TI3M+_P"P3W[K
MW7O[_?\ "A;_ +QN_E.?^E*=I?\ V">_=>Z]_?[_ (4+?]XW?RG/_2E.TO\
M[!/?NO=>_O\ ?\*%O^\;OY3G_I2G:7_V">_=>Z]_?[_A0M_WC=_*<_\ 2E.T
MO_L$]^Z]T4GN#^89_.^Z2^5'PZ^(.[_B[_+2J>TOG!_LPG^A_(X+OWL>LPU+
M_LM.W*7<^X/X[5S;4IZJB\V.JXEHOMZ&K\TX9)?MT D/NO=&V_O]_P *%O\
MO&[^4Y_Z4IVE_P#8)[]U[KW]_O\ A0M_WC=_*<_]*4[2_P#L$]^Z]U[^_P!_
MPH6_[QN_E.?^E*=I?_8)[]U[KW]_O^%"W_>-W\IS_P!*4[2_^P3W[KW7O[_?
M\*%O^\;OY3G_ *4IVE_]@GOW7NO?W^_X4+?]XW?RG/\ TI3M+_[!/?NO=>_O
M]_PH6_[QN_E.?^E*=I?_ &">_=>Z]_?[_A0M_P!XW?RG/_2E.TO_ +!/?NO=
M>_O]_P *%O\ O&[^4Y_Z4IVE_P#8)[]U[KW]_O\ A0M_WC=_*<_]*4[2_P#L
M$]^Z]U[^_P!_PH6_[QN_E.?^E*=I?_8)[]U[KW]_O^%"W_>-W\IS_P!*4[2_
M^P3W[KW7O[_?\*%O^\;OY3G_ *4IVE_]@GOW7NO?W^_X4+?]XW?RG/\ TI3M
M+_[!/?NO=>_O]_PH6_[QN_E.?^E*=I?_ &">_=>Z]_?[_A0M_P!XW?RG/_2E
M.TO_ +!/?NO=>_O]_P *%O\ O&[^4Y_Z4IVE_P#8)[]U[KW]_O\ A0M_WC=_
M*<_]*4[2_P#L$]^Z]U[^_P!_PH6_[QN_E.?^E*=I?_8)[]U[KW]_O^%"W_>-
MW\IS_P!*4[2_^P3W[KW7O[_?\*%O^\;OY3G_ *4IVE_]@GOW7NO?W^_X4+?]
MXW?RG/\ TI3M+_[!/?NO=>_O]_PH6_[QN_E.?^E*=I?_ &">_=>ZK'_X:?\
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MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5*'Q7_P"WY/\
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M+9>3I_XE!AVW29*\*M*[X^BE6820/D%HVG@5JF)'I0)C[KW19?AA\AZ+9_\
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MI35N6AHI(EJ()F@]U[H+OY-W>?2^>^2O\\3*8CM?KNNQT?\ ,BW=N%JR/>-
MJ?PW#;4V[B:G)@M.M\6F2H*RG%8+TSR0N$E:U_?NO=.__";/M/K3?WP"W9AM
MC]@;-W?EMN?,#YD5.=QVVMR4>;FI8MT=@9G+XV>:.GFD9*?(8O(T%532V\<T
M$\4D;,K ^_=>ZV#/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4N=X?]OY?@+_ .* ?.+_ -Z;K?W[KW5T
M?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI0_X3[?]NU=L?\
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M3-58C$]E4]9LK!Y*B-:9H)*S[6#(03Y3'46544Q<TU-[KW0K]U?!;^8-W_\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JHO^8]_+AW-\@MS;'^97PUWQC?CO\
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MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NJ8_Y[V)WA7_  <VWE=E]<]E=JY#8OS
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MW[KW7O\ A\WH[_O";^;'_P"FX>PO_J'W[KW7O^'S>CO^\)OYL?\ Z;A["_\
MJ'W[KW7O^'S>CO\ O";^;'_Z;A["_P#J'W[KW7O^'S>CO^\)OYL?_IN'L+_Z
MA]^Z]U[_ (?-Z._[PF_FQ_\ IN'L+_ZA]^Z]U[_A\WH[_O";^;'_ .FX>PO_
M *A]^Z]U[_A\WH[_ +PF_FQ_^FX>PO\ ZA]^Z]U[_A\WH[_O";^;'_Z;A["_
M^H??NO=>_P"'S>CO^\)OYL?_ *;A["_^H??NO=>_X?-Z._[PF_FQ_P#IN'L+
M_P"H??NO=>_X?-Z._P"\)OYL?_IN'L+_ .H??NO=>_X?-Z._[PF_FQ_^FX>P
MO_J'W[KW7O\ A\WH[_O";^;'_P"FX>PO_J'W[KW7O^'S>CO^\)OYL?\ Z;A[
M"_\ J'W[KW7O^'S>CO\ O";^;'_Z;A["_P#J'W[KW7O^'S>CO^\)OYL?_IN'
ML+_ZA]^Z]U[_ (?-Z._[PF_FQ_\ IN'L+_ZA]^Z]U[_A\WH[_O";^;'_ .FX
M>PO_ *A]^Z]U[_A\WH[_ +PF_FQ_^FX>PO\ ZA]^Z]U[_A\WH[_O";^;'_Z;
MA["_^H??NO=>_P"'S>CO^\)OYL?_ *;A["_^H??NO=,&ZOY_'QEV)MG/[TWO
M\2_YHFS=G;4Q&0W!NC=FZOY?6^MO8S&T&)B:>JKJ^OJZ6&EHZ.FA1Y)9II4C
MC12SL%!/OW7NG#%_SX?CWG,9CLWA/AO_ #5,QALQ04F4Q.6Q?\NW?V0I:JER
M$:RT]335$5&\4\$\3H\<B.R.C!E)!!]^Z]U/_P"'S>CO^\)OYL?_ *;A["_^
MH??NO=>_X?-Z._[PF_FQ_P#IN'L+_P"H??NO=>_X?-Z._P"\)OYL?_IN'L+_
M .H??NO=>_X?-Z._[PF_FQ_^FX>PO_J'W[KW7O\ A\WH[_O";^;'_P"FX>PO
M_J'W[KW7O^'S>CO^\)OYL?\ Z;A["_\ J'W[KW7O^'S>CO\ O";^;'_Z;A["
M_P#J'W[KW7O^'S>CO^\)OYL?_IN'L+_ZA]^Z]U[_ (?-Z._[PF_FQ_\ IN'L
M+_ZA]^Z]U[_A\WH[_O";^;'_ .FX>PO_ *A]^Z]U[_A\WH[_ +PF_FQ_^FX>
MPO\ ZA]^Z]U[_A\WH[_O";^;'_Z;A["_^H??NO=>_P"'S>CO^\)OYL?_ *;A
M["_^H??NO=>_X?-Z._[PF_FQ_P#IN'L+_P"H??NO=>_X?-Z._P"\)OYL?_IN
M'L+_ .H??NO=>_X?-Z._[PF_FQ_^FX>PO_J'W[KW7O\ A\WH[_O";^;'_P"F
MX>PO_J'W[KW7O^'S>CO^\)OYL?\ Z;A["_\ J'W[KW7O^'S>CO\ O";^;'_Z
M;A["_P#J'W[KW7O^'S>CO^\)OYL?_IN'L+_ZA]^Z]U[_ (?-Z._[PF_FQ_\
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MXW_^9OOW7NO?\,%_^#J/Y_W_ *<;_P#S-]^Z]U[_ (8+_P#!U'\_[_TXW_\
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MAP]"7OCL<;5>:JQ'3T\;(Q+>Z]T-_P "O@5L'X/;!W+''N7.=Q_(;N/.+O\
M^3WR>W^J5&Y]^[GJ$(EKJZ4%_L<10ZW@Q.)@<4F-I L,*M(TTTONO='Q]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5;7\
MX[_MT[_,A_\ %)ODI_[R>4]^Z]T9OX@?]DE_%W_Q77I/_P!YK&>_=>Z,5[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[JJ[^>%_VZ%_F*_\ BJ7:_P#[@/[]U[H__1O_ #)3I_\
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M-#AZ$O?'8XVJ\U5B.GIXV1B6]U[H;_@5\"M@_![8.Y8X]RYSN/Y#=QYQ=_\
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MV.-JO-58CIZ>-D8EO=>Z&_X%? K8/P>V#N6./<N<[C^0W<><7?\ \GOD]O\
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M7\Q7^8K6?%^LV+\:?C3L6'Y%?S"_D5#54/Q[^/=#5%:>BIU+1U.^-\5,;+_
MMD8+3)+45$LD3UCQ-34S+IJ*BE]U[IU_EU?RZJ/X?T>^NZ.Z-]3?(KYX?(J:
MEW!\G?D[N"E"U%?4*%>#;.V8'5?X%LG!:4@Q^/@2)&2*.::-2L,-/[KW5G7O
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@M[R_Y
MDIW!_P"(M[ _]U-7[]U[H@'\CW_MT+_+J_\ %4NJ/_<!/?NO=6H^_=>Z+/\
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M-N96:HH8,EFUIT^QQ%'E*BFK8*!*ZK@FRCTU8F.AJS1U?A]U[JE[^2UNSHG
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MRY7<[^61@L2AI&(16]^Z]UMG;PVA\>1W_P!,]G;EV-L[,?(JIP6].ONI-^C
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M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$(_FD])=A_)3^7?\
M,'X_]2XB+.]F=R]'[PZXV/BJFL3'0RY+=D2T=-]Q4RD1TU,DDH>:5SIBB5W;
MA3[]U[H(/Y87\LG!_!'9V8W[VEONN^17S;[CQ&WU^17R>W6GGK:_^!T\,-%M
MG;R.B?P;9N"BAB@H:&&.%9!$D\T:D0PT_NO=6K>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@M[R_YDIW!_XBWL
M#_W4U?OW7NB ?R/?^W0O\NK_ ,52ZH_]P$]^Z]U:C[]U[H/NU^KMC=W=:;ZZ
M@[-P5-NCKOLK:^8V7O?;5:+P9#%[@A:GKJ*<?VH*JG>2.1?[2,R_GW[KW14Z
M+^7+\;,%MB3KS9L_>W7?4DL-+1?Z%^NOD[V%LK:,%%204E*,7B\%0;DAI,!A
M7IJ...3&8D4./D\E2[TS2U=3)+[KW1BZCX]=%U71K_&6?J+KQ_CT^PEZN/2_
M]U*--MC;J4PHUPZXE8A1I0)3 (L:Q +8%;, ??NO=$K^'W\G?^7?\$-_5?9W
MQFZ!CV;O-H-P4F!R>X.P-S=D1X"'=LB29:/;-)N/,96DVY_%/#3QUCXZ"GEJ
MH8(89Y)(HD0>Z]T/6R?@K\:NN_D?V;\MMI;9[!H/D!W'A=O;<[*WS6]_]A9Z
M+*8_:2!,70R83(;IJMOP4F.75]M#!BHHX2\IC53+*7]U[J/T_P# OXR]"]J]
MY=V]5[:['V[V;\DZ^BRW=VXZSY$=C;J7/UF,I)J"DK)Z#,;LR&-I:RAHIW@I
M9Z6C@EIHQ&E.\8ABT>Z]TQ]'?RY_B5\;L+WU@.E=F=C;*QOR<WCNGL3O'Q_(
M_LO/5&<W!O=HVS&>-;E-WUU9CLSDO%&*BMH*BEJ94&AI2EU]^Z]T(7Q(^&_Q
MW^"_4.*Z$^+FR\UUQU!@:S*UV V+D.S-U=D4F/DSM;59*M^P?=6;S=111U5?
M75=1+'!-'&\LK.REK$>Z]T96MI(J^CJZ&=ZF."MIIZ29Z*MFQLRI4H48PU%/
M)%44\H#'3)%*DB-9D96 (]U[HG'QZ_E^?%GXL=E=Q=O='[3[%VOV!\@-V1[[
M[FS6<^1/9'8T6X<Q%]T$R-?CMS;MS&,:J1*R=%=*--,7CB%HX(5C]U[K+U-\
M ?BUT;WCWG\D>L-G;ZV[W5\EAA!WGO:H[\["W&VXCM>DJ*#%/64&5W378N.7
M%4=7414+P44+T:O_ ),T152/=>ZY]$_ ;XP?&G-=Y[BZ4VMV)LW-?)3>^:[+
M[KR$GR&[&W0^:W#N)M5;FS_&-V9!<=E)P%4U-"M+*L:I$K+'&BK[KW09;+_E
M1_!OKWXX=J_$?:?7/9=!\=^[LCNK*]H]<5GRE[8SL65FWVNG.%LA7[WJLO2Q
MYHEWKXJ;(0Q5DLDLM0DDLLKO[KW0F2? 7XO/\9=D_#^+:&^:/H+K3^XW^CK;
M-!WMOVBRN!_T8?;';9PV[8]S+N_&' O1TCT!IL]&:9X8VBTD<^Z]T(&%^+G4
M^(W+F]\U$>^=P]A9S8IZR;L;<O9VX<IN"AV_).M7+B\+E_XDE;@(:JL2.HJ9
M,;-2U%7/%3R54TS4M*8?=>Z"?IS^7-\2_C]\?=Y_%KI[:'96R.C=_OO"3<NT
M*#Y*=FUU07[ ^X;-2T.<K-X5.X,1-DY*NIEGDH,K3.\\C5&KS'R>_=>Z5O57
MP7^*_3/QB?X9;,ZL6N^+\FU\SLE^G.R-Z;A[HQ9PVX):F:JQ6K>66SU9_#V>
MKFT4_P!UXH5*)"L:11*GNO=%]^'W\G?^7?\ !#?U7V=\9N@8]F[S:#<%)@<G
MN#L#<W9$> AW;(DF6CVS2;CS&5I-N?Q3PT\=8^.@IY:J&"&&>22*)$'NO=+K
MOG^6/\./D7WUMOY1;ZV!O#;GR'VUMY-GQ]Q=+=T[T^/N?R&&CF@G7$9K(;'S
M^ GS>.5Z:$+%6M.$1?&A6,E3[KW0C]%_!?XJ?&SLOMCN#I;J+#[+[([NS6.S
M_96YZ?*9')O75.(QU-BJ9XZ>MK*BDH!%0TJ(12T\/D>2HFE,D]54R2^Z]U5U
M_P *=H9]P_R6?ESUWM^GJ<]V!OVH^/\ 2['V/A*=\ME\Q)MWM/8N4R"8S&TZ
MR5E<:'&TM155'AA?PP1O+)I12WOW7NK%ND_B_P#&W.;'Z$W;@I\]V3M3K2AP
M^ZNHL/N#MW/]D[;PN0^U405F.Q=?EJW&O58@221XQJB&=\*G[.,^R50@]U[I
M0=]_ OXR?)OM;IGNSN7;/8NX.R?CUN23>'3&;V]\ANQNMJ? 92=((IJZCQ.V
M-UX;#O45,%.D%0TU!)]Q3M+3S^2">>.3W7NA<[V^.O2'R>ZBW'T-\@^M-L=O
M]1[MHZ*BW#LG?-(V;IZC^&21S4L_ED?[J*NI*B**:"KCG2JAG19HIDE4./=>
MZ1/6/Q"Z8ZMS6RMST4?8F_=U=;;:EVCUWNGNOM[='=^0P=#50K3U(Q=5NK+9
M62DK:ZG58JRO7_<A60A8:JJFA1$7W7N@A[Y_EC_#CY%]];;^46^M@;PVY\A]
MM;>39\?<72W=.]/C[G\AAHYH)UQ&:R&Q\_@)\WCE>FA"Q5K3A$7QH5C)4^Z]
MT(_1?P7^*GQL[+[8[@Z6ZBP^R^R.[LUCL_V5N>GRF1R;UU3B,=38JF>.GK:R
MHI* 14-*B$4M/#Y'DJ)I3)/55,DONO= [M7^5)\'=D;[[HW_ +5ZNW+AZGOV
MLWMF>QMDP]P[QGV;+ENQ5 S&?Q^QIL])L_$[BJI-<JY2DPD-=32R2O2SP&63
M5[KW2F'\L;X)-\0:GX&U7QUVCD_BM5[=QVVINLLQD,IF&$.' -'4Q9NIKY=P
M092BEO/39"+*I74]26J(*B.9F<^Z]UE^&7\M;X:? .FRR_&/J:3:>7S>$Q6T
MZ[=^[-[Y_M7.K@\#H-!MZDS6Z,GE\EC]MT,B>6GQ-)4P8^*=I*A:83R22-[K
MW2LV9\"OBEU[\F^Q?F!LSJQ,!WWVP<94[_W-0[OSJX[(UV*I9Z"/,2[;;)G;
M2YTT%1)3-DEQ*UI@+1B<"6;R^Z]T:S.8;';CPN8V]EX#4XG.XO(8;*4RRO 9
M*?*1/!.@>-ED0O$[#4K!A>X(-C[]U[HI6PO@5\;^NMO=8;)PV%[!SG7?2NX<
M=NSJ;KCL7NC=_:F$P60P3R2XJHI:/<F;RIG3!22LV(@JI*BFQ#)3G&0TAHZ(
MT_NO=2=V? KXI;W^4>W_ )G;AZL2?Y%[=VI0;*CWUC]WYW!PU^.PM7%78V'-
MX:AR=/@\^<35Q++0MDL=5-2R6DA*O'"T?NO=2^T?A!\<^V.\-I_)G,;2SFT_
MD3LW;-7L;&]U]5;[SG4VXJK;]<SR2;=S5?M[(8YMP[?%2XJ8\=E%JZ6"K2*J
M@BCGC60>Z]T+O7'1O574^S<ML'9&SJ"BVWN3(9O,;OBS%34[LJ\]7;E73DLA
MN')9::NR.?R.10!:FJR%74SSH%221D55'NO=$!^/G\DS^67\6^X6[OZ1^-&.
MVIN^FWGE.Q]N82LW]NC=6U\#N'+V63.[<V?E\U7;7P.8AA'@I*NAQ,,^/I"U
M'0/34C&'W[KW1E\[\$OC3N7Y0[?^9N9VUV'5?(_:FS\IU]MK?D7R"[$H:>AP
M><J&JZS$TNWJ?=46V(<?5U)$LL*X8))(D3."8HBGNO=-'77\O+XF]2_)SMOY
MB]<[$WIM3Y#=\MB7[DWECN^>P7H=QG + E <IMB;=,FU*C[&.G1*:^$'@C>>
M.+0E34++[KW1S:VDBKZ.KH9WJ8X*VFGI)GHJV;&S*E2A1C#44\D513R@,=,D
M4J2(UF1E8 CW7NJ_^OOY6?PEZJZU^0W4'7_7?8^VNNOE=N/?V[_D'MVE^3G:
M=2-RY7M*E%#N/(U-54;UFKJ6MS5&JPU<U)4T[S1JJLQ"BWNO=/&3_EH?#C,?
M$*G^!F1Z_P!_3_$ZEP6/VM#U,OR,[+IT_A.*FAGI\0V9BW>FX9,/$]/"!0ME
MVI/&OA,)A9D/NO=&QZLZQVCTSU]M/J_8:;CAV;LC!8O;6VJ7=>^<YV16PT6%
M@CI:6"7,;DR66S-9XH(HU#U-?-(;79BQ)/NO="![]U[KWOW7NM&'_N1O_P R
M'?\ T13W[KW1WOY+NPZOXM?SQ/\ A0+\?NPZIJ/>GR![.ZP^8O5<61HFP;9K
M:.\MP[_SM77XF*9V.3H<-5]AXS%U593N\*UL,L4@BFU01^Z]UL5?,WL[9_2_
MQ$^3_;._ZF&DV7UWT#VYN[<DDZ-,&I<)@:Z:2%8TCE>62HTB)(UB=Y'=45'9
M@I]U[KY_^;^*O<7PZ_ED?\)IOE3W;%F=J]8?'#^87%W?WQM:LQ5;#2X7 ?(?
ML+;F\-LY[<9?1%CHZ/!;6EB:2JI (I\XE&LJ2R:*GW7NOI(4U33UE/!64<\-
M5254,532U5-*L\<D<ZADDC=25='4@JP)!!!!M[]U[J%#F<34Y?(8"GR-)-FL
M30XO)Y/%QSJ\\%/FWJHZ2:6,'4B5+T56(R1ZC$]OI[]U[HB?\V+_ +=9?S+/
M_% /F1_[[K<?OW7NM8+<_1OR(QO\BW^5_P#)3:NZ.X_DE\3>H.D>HM\_.OX
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M-\T*SK:N[NVOOVMV74[=GDZ@QM;B=N''4N(V5A\G0#&4%?41KIR[^:X:H\S
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M@'_V8KW[KW7O^VIK_P $ _\ LQ7OW7NO?]M37_@@'_V8KW[KW7O^VIK_ ,$
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M -.2TG_VNO?NO=>_V:C^>3_WJ5^,G_IR6D_^UU[]U[KW^S4?SR?^]2OQD_\
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MU*_&3_TY+2?_ &NO?NO=>_V:C^>3_P!ZE?C)_P"G):3_ .UU[]U[J?\ 'O\
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M^*R.,AFI/X!B\331:Y$6F\3O&WNO="OU3V+O?Y#?SD?YA?QD^2Z9FBZM^/\
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M$_\ U7[]U[KW^G+I3_G\'5O_ *,#$_\ U7[]U[KW^G+I3_G\'5O_ *,#$_\
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M]ZZOBE_Z*B@_Z,]^Z]U[_ACW^4+_ -ZZOBE_Z*B@_P"C/?NO=>_X8]_E"_\
M>NKXI?\ HJ*#_HSW[KW5:OSF_EW?!KX@?*#^3GO_ .+_ ,5^ENBMZ;B_F?\
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M_144'_1GOW7NO?\ #'O\H7_O75\4O_144'_1GOW7NO?\,>_RA?\ O75\4O\
MT5%!_P!&>_=>Z]_PQ[_*%_[UU?%+_P!%10?]&>_=>Z]_PQ[_ "A?^]=7Q2_]
M%10?]&>_=>Z]_P ,>_RA?^]=7Q2_]%10?]&>_=>Z]_PQ[_*%_P"]=7Q2_P#1
M44'_ $9[]U[KW_#'O\H7_O75\4O_ $5%!_T9[]U[KW_#'O\ *%_[UU?%+_T5
M%!_T9[]U[KW_  Q[_*%_[UU?%+_T5%!_T9[]U[KW_#'O\H7_ +UU?%+_ -%1
M0?\ 1GOW7NO?\,>_RA?^]=7Q2_\ 144'_1GOW7NO?\,>_P H7_O75\4O_144
M'_1GOW7NO?\ #'O\H7_O75\4O_144'_1GOW7NO?\,>_RA?\ O75\4O\ T5%!
M_P!&>_=>Z]_PQ[_*%_[UU?%+_P!%10?]&>_=>Z]_PQ[_ "A?^]=7Q2_]%10?
M]&>_=>Z]_P ,>_RA?^]=7Q2_]%10?]&>_=>Z]_PQ[_*%_P"]=7Q2_P#144'_
M $9[]U[KW_#'O\H7_O75\4O_ $5%!_T9[]U[KW_#'O\ *%_[UU?%+_T5%!_T
M9[]U[KW_  Q[_*%_[UU?%+_T5%!_T9[]U[KW_#'O\H7_ +UU?%+_ -%10?\
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M2RU.+DJX8XI8Y6<1R(Q]U[JG7YP9#<NTO^% ?\CW&8#?W9U#M?MO;G\PZH[
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW5*'Q7_[?D_S:O\ Q63^6U_[B=B^_=>ZNO\
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=4N=X?]OY?@+_XH!\XO_>FZW]^Z]U='[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[H+>\O\ F2G<'_B+>P/_ '4U?OW7NB ?R/?^W0O\NK_Q
M5+JC_P!P$]^Z]U:C[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K1A_[D;_\R'?_ $13W[KW6\][
M]U[JE#^>;_S([X3?^-8_Y</_ +\*A]^Z]U=?[]U[KWOW7NO>_=>ZU.^DNI-^
M]R?S[?\ A0GM/K/OKL;X[;XJ^DO@;0[7["Z[IL/D)*3(9CJ/&4U#5UE'F<7D
MHJN#'U3Q5(BC:GD=DT^958^_=>Z,5_()S6QMH2_*/XU]Z]4XOKG^;#TOO.DQ
MOSFW[G=PUV_-P]JTCLTNV.RJ7<N:GJ,QE-K9>DK$^TI5:"AQ<DGBI*"@IJBF
MIQ[KW1UH=Q=+9?\ F@_(.D^->)CWW\V-L?&7H_87R?W3N[>D]/M#8.U,GD<S
MGMDXRHQ=/'-75VZ<V:[(Y),=2"FB?'K%45V2QYJ:+[SW7NB$_P B;9F/[Y^(
M/\V?XU=U4&V=W]?1_P US^8U\>\UA,9MXX7&U.#W=%@JO*T\-!4U>2DIZ:>L
MW#E6@BEK:EX(GBB,\S1>5O=>Z+GT)U_N3Y7_ ,H[L[^1QVF,)N#Y.=!=L=C?
M ?-9G<6W8J2GQ^V_CT]/N[979<..:OD>.B?:)V?2XJ>.KE,>9K*!YTDIA4:O
M=>Z/[_+8^5F2_F.=#?![$;^QKTG97QZQ>9W)\U-GY."ACJ,5V1\:LA4;%PN,
MRE D]8U)_&MV4>6W5C2CJT1P-.7:)[P'W7NKZ??NO=:_7Q?ZVZ^IO^% 7\SR
MNI=D[6I*FC^+'P*W73M28.FI5&5DI]TT/\5,<<:QODUH:>&F2K9341TZ^%)%
MC)4^Z]U'_E9=6=<4O\Q'^>)X-E;<CIMM?,/JO^[6,&,C-#C7WOUO@:S-S8Z@
M(-%05.9J4B>OG@@CFK/%"*EY5AB">Z]T2SX+Y;XL=>_RZO\ A0]MGY=;GR77
MWPLV5_-W_F9]1;LI=O96HQ3XC:.X3M'&4^W-LQT^MZ6?(U^7^TQ]%31VJ*^N
M$:QM)4MJ]U[I>_S/,]VWLW-?\)_-VQ[*VAU#LW'_ ,UGX7]3[ ZXR%1)OS=E
M!@>Q,3DL!-'G,Y3U4&#I*MMORO!58^BI,E&E6(IH<W.D!2;W7NCJ=N_]Q$GP
MW_\ &8WRD_\ >XVM[]U[I+?RS>S.X^^OD;_./Q&YNS\%LWLGKS^91V%UZO7N
MY-JQ;_KZ;KC:>TMIX;KVJA:;*4KT> S5'09?(4](E.*=*RLR4P+5%54EO=>Z
M*#\\?Y>71_P9_D-?S2N@MC[QJ^X=I8C);\[FV_MO?&V,-]IU[E>P:_:VX#MW
M:E+244<6&Q-%/]EE*&G#O/2R52S^8EXV]^Z]U>GUI\:/CWM[HK;6\<7TMUG'
MO2I^,.&V-D-[56SZ')YNMQ,M#3YB6AR&8JH9LGD89\O&E=-]S52M-6C[N5GJ
M/W/?NO=4%?RD]P_&#;/_  DZV#D/FCNK([-^+==T_P#,#;'=&;PN1FQF0;$[
MU[?W_A_L,9)3AIWRN7JJ^GH*&&-&>IJZF&G56,ND^Z]TM?YGF>[;V;FO^$_F
M[8]E;0ZAV;C_ .:S\+^I]@=<9"HDWYNR@P/8F)R6 FCSF<IZJ#!TE6VWY7@J
ML?14F2C2K$4T.;G2 I-[KW0^_P P3_N(+_X3Z?\ AK_S0_\ WU!]^Z]UL/5=
M)2U]+4T-=34];15M/-25E'5PK4Q2Q5*E)(I8W#))'(C%65@0P)!!!]^Z]UK"
M?R).@>D=Y;^_GA5.\.J=A;M%+_.>^>'6N/H-S[9I=P45)@:FMQ+5&*H<?5QS
M4-#1UEH5JTIZ>+[N.GHXZDRQT5(L/NO=*O\ DB]-X7IOKS^<9\4,17?WS^.W
M0G\Q_P"1>SNDMKYN$9C%X#%Y+;^#SDFV:"&HEK((HL'4U\2311E$-;YZUJ>"
MHJYE]^Z]U41\;>WLWU-_PF*_DXTT\\]#TKVK_,GV#U3\K\L*MJ&FI^K\Q\@N
MR,GN:+)N/0V'RTN(QV+KX90T%325TU+4))#-)&WNO=;B?R ^+WQ@[8[(^+?R
M%[CP5,F_/B=V$^7^/&]*#/56W'QF4[;6BVXV.0T,L7WU%G)),;3M0R!Z>HE6
MGUQMH6WNO=:W_P O^_?D)\9OYI_\U;N'I'K?,=A;/VK\9OY<=3\G*S8&XOX1
MOC;O635.[5W;N78M)+B\E1Y+<&'QYDG"3F+P4RSU41,L*M'[KW6SM\9V^.^Z
M_CCUAE/C@FT\[\>=[['QNX=B56$(S%#E,9N>+[AJNJEG,TU?65S2R25TU7)+
M53U33/6.]0TK'W7NM;#^57L;9FZOY?'_  H9V;N3:NW\WM.3^:'_ #9<;_=S
M)8B"JHU@_N5MVF$<=.R&.)5IW>-="J40E5L/?NO=(;L;JCK&3_A(!#DI>O\
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M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JM_\ F\_+;-_!?^6K\O\
MY1[5K8<9O7K?JN6AZ]R=1CWRL=+N7L;(4.UMMU+TZ*WE2GSN;Q\A#CQ +>8B
M(.1[KW0:?R,.E-M],_RJ_AG6XJ*HK-V=\=+;(^4W;F\LO72YK+[DW=\D,=2[
MMS6<S62J'EJ\ED9Y,I'#YZB:240000ZM$2@>Z]U87NOI+8^Z^WNJ.\JG$8J#
MLKJ6AWSMS";K_A$-17O@>Q:-(\K@Q6-::"AJLC182N=58AIL?$-/K9A[KW58
M787\R_OK"?%WYB_-79_Q@PJ]+?$#L;M[;<NP.T-YY?8>\MX;=^/=8M'N[=%
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MNO>_=>Z][]U[KWOW7NF/<FV-M;RPM=MS=^WL'NK;V3B,&2P.Y,33YRBJ$/\
M8GI:J.6"5?\ !HR/?NO=)S8W5'5O6$5;#UIUKL#KR'(R"7(1;&V=CMI+.RA0
M&F6@IJ<2L JB[ FP']![]U[I?^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ4
M/YNO_,\?Y+/_ (UCZS_]][V+[]U[JZ_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6
MLON'YN=&_ O^=-_,:W?\CX.X<)M?N/X[_ [#=>Y[8/Q\WQW'25M5U[0[RDR\
M#3[2P&9CI9*1,QCB5G:,MY?1JTOI]U[HW/\ T$$_RU?^>G^3?_I"G='_ -@G
MOW7NO?\ 003_ "U?^>G^3?\ Z0IW1_\ 8)[]U[KW_003_+5_YZ?Y-_\ I"G=
M'_V">_=>Z]_T$$_RU?\ GI_DW_Z0IW1_]@GOW7NO?]!!/\M7_GI_DW_Z0IW1
M_P#8)[]U[KW_ $$$_P M7_GI_DW_ .D*=T?_ &">_=>Z]_T$$_RU?^>G^3?_
M *0IW1_]@GOW7NO?]!!/\M7_ )Z?Y-_^D*=T?_8)[]U[KW_003_+5_YZ?Y-_
M^D*=T?\ V">_=>Z]_P!!!/\ +5_YZ?Y-_P#I"G='_P!@GOW7NO?]!!/\M7_G
MI_DW_P"D*=T?_8)[]U[KW_003_+5_P">G^3?_I"G='_V">_=>Z]_T$$_RU?^
M>G^3?_I"G='_ -@GOW7NO?\ 003_ "U?^>G^3?\ Z0IW1_\ 8)[]U[KW_003
M_+5_YZ?Y-_\ I"G='_V">_=>Z]_T$$_RU?\ GI_DW_Z0IW1_]@GOW7NO?]!!
M/\M7_GI_DW_Z0IW1_P#8)[]U[KW_ $$$_P M7_GI_DW_ .D*=T?_ &">_=>Z
M]_T$$_RU?^>G^3?_ *0IW1_]@GOW7NO?]!!/\M7_ )Z?Y-_^D*=T?_8)[]U[
MKW_003_+5_YZ?Y-_^D*=T?\ V">_=>Z]_P!!!/\ +5_YZ?Y-_P#I"G='_P!@
MGOW7NF[+_P#"B#^5_M_%Y'.9[??R*PF%Q%%4Y'+9C+_"'N3&TM+3T:&2:>HJ
M)MC)%!#$BLSN[JJJ"6( ]^Z]U)I/^%"G\LNOI::NH=X?).MHJVGAJZ.LI/@U
MW-4Q2Q5*AXY8I$V*R21R(P964D,"""0??NO=2/\ H()_EJ_\]/\ )O\ ](4[
MH_\ L$]^Z]U[_H()_EJ_\]/\F_\ TA3NC_[!/?NO=>_Z""?Y:O\ ST_R;_\
M2%.Z/_L$]^Z]U[_H()_EJ_\ /3_)O_TA3NC_ .P3W[KW7O\ H()_EJ_\]/\
M)O\ ](4[H_\ L$]^Z]U[_H()_EJ_\]/\F_\ TA3NC_[!/?NO=>_Z""?Y:O\
MST_R;_\ 2%.Z/_L$]^Z]U[_H()_EJ_\ /3_)O_TA3NC_ .P3W[KW7O\ H()_
MEJ_\]/\ )O\ ](4[H_\ L$]^Z]U[_H()_EJ_\]/\F_\ TA3NC_[!/?NO=>_Z
M""?Y:O\ ST_R;_\ 2%.Z/_L$]^Z]U[_H()_EJ_\ /3_)O_TA3NC_ .P3W[KW
M7O\ H()_EJ_\]/\ )O\ ](4[H_\ L$]^Z]U[_H()_EJ_\]/\F_\ TA3NC_[!
M/?NO=>_Z""?Y:O\ ST_R;_\ 2%.Z/_L$]^Z]U[_H()_EJ_\ /3_)O_TA3NC_
M .P3W[KW7O\ H()_EJ_\]/\ )O\ ](4[H_\ L$]^Z]U[_H()_EJ_\]/\F_\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI0_FZ_\ ,\?Y+/\
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MZ]U[_AL#YD_][N?G_P#^@5U)_P#8%[]U[KW_  V!\R?^]W/S_P#_ $"NI/\
M[ O?NO=>_P"&P/F3_P![N?G_ /\ H%=2?_8%[]U[KW_#8'S)_P"]W/S_ /\
MT"NI/_L"]^Z]U[_AL#YD_P#>[GY__P#H%=2?_8%[]U[KW_#8'S)_[W<_/_\
M] KJ3_[ O?NO=>_X; ^9/_>[GY__ /H%=2?_ &!>_=>Z]_PV!\R?^]W/S_\
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M $WIVW_]BWOW7NO?\/O?#;_GT_S_ /\ TWIVW_\ 8M[]U[KW_#[WPV_Y]/\
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MW_\ 8M[]U[KW_#[WPV_Y]/\ /_\ ]-Z=M_\ V+>_=>Z]_P /O?#;_GT_S_\
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MM_\ V+>_=>Z]_P /O?#;_GT_S_\ _3>G;?\ ]BWOW7NO?\/O?#;_ )]/\_\
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MTODJ+Y$]C[-DPF?P^H4V94X+=F,%=DHD>2/[BL%1*8GDA9C%(Z-[KW6#M?X
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MNON3<N&W)7MWE#C2:O%45'UYDL6!B:G%0 +49A/NXI7/^2NBAO=>Z:9/AO\
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MIY['UU+5#5%4T=;2[:EIJF"1>5DCD9&'()]^Z]T^_P##[WPV_P"?3_/_ /\
M3>G;?_V+>_=>Z]_P^]\-O^?3_/\ _P#3>G;?_P!BWOW7NO?\/O?#;_GT_P _
M_P#TWIVW_P#8M[]U[KW_  ^]\-O^?3_/_P#]-Z=M_P#V+>_=>Z]_P^]\-O\
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M-'% L*14J1Q^Z]T8/^5C\I/E%\P?Y M)\I.W_D#OIODI-L#Y<;E'=6UL+MG
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H+>\O\
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MB?YI_P 1OC/W-L^@V=A\H^<VSV#E*J;+T<V4R-+6UE'#604<<#"A^UFT,_\
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M.;UV'G<A+EDSVV:[-UU)MZES>'W!7Y')R44]1 E6H@I8Y@D85?=>Z6&7VO\
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M+N*27&?':/;B8:DPNWJ3>6$3%QR?W:I6G>KS&4FD>:H?R+K01^Z]T8[^9_\
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M;_SUNV?_ #_4O_7WW[KW7O[Z[-_YZW;/_G^I?^OOOW7NO?WUV;_SUNV?_/\
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M_P ];MG_ ,_U+_U]]^Z]U[^^NS?^>MVS_P"?ZE_Z^^_=>Z]_?79O_/6[9_\
M/]2_]???NO=>_OKLW_GK=L_^?ZE_Z^^_=>Z]_?79O_/6[9_\_P!2_P#7WW[K
MW7O[Z[-_YZW;/_G^I?\ K[[]U[KW]]=F_P#/6[9_\_U+_P!???NO=>_OKLW_
M )ZW;/\ Y_J7_K[[]U[KW]]=F_\ /6[9_P#/]2_]???NO=>_OKLW_GK=L_\
MG^I?^OOOW7NO?WUV;_SUNV?_ #_4O_7WW[KW7O[Z[-_YZW;/_G^I?^OOOW7N
MO?WUV;_SUNV?_/\ 4O\ U]]^Z]U[^^NS?^>MVS_Y_J7_ *^^_=>Z]_?79O\
MSUNV?_/]2_\ 7WW[KW7O[Z[-_P">MVS_ .?ZE_Z^^_=>Z]_?79O_ #UNV?\
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M]^Z]U[_H'[_DS_\ >OGHK_SFRO\ ]<_?NO=>_P"@?O\ DS_]Z^>BO_.;*_\
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M -Z^>BO_ #FRO_US]^Z]U[_H'[_DS_\ >OGHK_SFRO\ ]<_?NO=>_P"@?O\
MDS_]Z^>BO_.;*_\ US]^Z]U[_H'[_DS_ />OGHK_ ,YLK_\ 7/W[KW7O^@?O
M^3/_ -Z^>BO_ #FRO_US]^Z]U[_H'[_DS_\ >OGHK_SFRO\ ]<_?NO=>_P"@
M?O\ DS_]Z^>BO_.;*_\ US]^Z]U[_H'[_DS_ />OGHK_ ,YLK_\ 7/W[KW7O
M^@?O^3/_ -Z^>BO_ #FRO_US]^Z]U[_H'[_DS_\ >OGHK_SFRO\ ]<_?NO=>
M_P"@?O\ DS_]Z^>BO_.;*_\ US]^Z]U[_H'[_DS_ />OGHK_ ,YLK_\ 7/W[
MKW7O^@?O^3/_ -Z^>BO_ #FRO_US]^Z]U[_H'[_DS_\ >OGHK_SFRO\ ]<_?
MNO=>_P"@?O\ DS_]Z^>BO_.;*_\ US]^Z]U[_H'[_DS_ />OGHK_ ,YLK_\
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MNO=>]^Z]U[W[KW7O?NO=>]^Z]UHP_P#<C?\ YD._^B*>_=>ZWGO?NO=:G_\
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M]]=F_P#/6[9_\_U+_P!???NO=>_OKLW_ )ZW;/\ Y_J7_K[[]U[KW]]=F_\
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M+>==\W_Y->;V9T)\H^U]M="_,3/]F=T;LZ;^,.^^U\3MO!UV(I,1%79'(X+
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M&0,,UJA897>EJ%C]U[H\G\V+_MUE_,L_\4 ^9'_ONMQ^_=>ZK&^%W>V5W/\
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.?NO=>]^Z]U[W[KW7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>twwc_header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 twwc_header.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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MQ=>]@+&H5X]W=>TM$KD,3=OX"^$8$@A?2RBP'%[D@^W]R-SA^(QR?Z>.E?\
M>"G1H^PV[\ R_8W^>O1Y^MOY].(D\--V_P! 9&CTI']QFNMMUQ9/6Q/KT8O*
M14GC4#D7R[D_0V^OL46?NHAQ<0,/G&P;^3!:?[T>BZ7EPCX''V,*?S%?\'1L
M:'^=5\*ZO%_Q"HG[6QE7H5_X'7;"62JNR*Q7735]11:E+%3_ )9;4K6)72S'
MZ>X^V,NHM(#_  F,U_D2/Y](CL-P#2BGYZL?Y_Y=1?\ A[+X8?\ '#N#_P!
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M_P#M >_=>Z]_T$=_S3?^^8_Y_P#_ )\>Q?\ [0'OW7NO?]!'?\TW_OF/^?\
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MG?\ D%_]Y"?^RI;^_P#L/]^Z]U[_ *"=_P"07_WD)_[*EO[_ .P_W[KW7O\
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M#_[WT?S3O_1MYO\ ^RGW[KW7O^@;#Y!_][Z/YIW_ *-O-_\ V4^_=>Z]_P!
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M #X]B_\ V@/?NO=>_P"@CO\ FF_]\Q_S_P#_ #X]B_\ V@/?NO=>_P"@CO\
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M8VW@LKCL15SRU4(IX*VI@EJ;L:=9 CZ?=>ZK/_Z"K?Y'O_>5VZ/_ $G'L?\
M^Q7W[KW2VZ__ .%,'\HGMO<*[/ZE[G[D[5WE+05^3IMG];_$7M7>F4F@QD9E
MJ)8Z''[/GG:*%!=WT!(QZG95Y]^Z]TD*K_A5'_)'H:FHHJWY3;OHZRCGFI:N
MDJOC7V33RQ2T[%)(Y(WVH'21'!5E8 @@@@$>_=>ZP?\ 05;_ "/?^\KMT?\
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M],\^J(2>Z]T2N?\ X6R_R^UK($IOBO\ ,>7'LJ?<U4^.V33S(23J"0+NZ5)
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MDB$>Z]UKN?\ #K'_  H6_P"^?_\ ]F@Q/_1OOW7NO?\ #K'_  H6_P"^?_\
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MWV?D-\Y26*%D1Y(Z#&4]55O&KR1J6$1 +*";L+^Z]U:-LG^0'_.3[ PE)N#
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MK9J(9.B-'A,E2R4-=X?-320U\\<L#QR)(RL/?NO=!O\ ]!)_R#_[T+_S3O\
MT4F;_P#L6]^Z]U[_ *"3_D'_ -Z%_P":=_Z*3-__ &+>_=>Z]_T$G_(/_O0O
M_-._]%)F_P#[%O?NO=60_P MG^:SV3\_.P^P-A;X_EN?-3X94VRMI4.Z:'?/
MR)V%4[:PF3:IJOM7QM/55U#BI3D@&66.*&"H#Q).TK0>-/-[KW5QOOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ_*C^6=\6ZSY
M*3_)NKVYEJC<E1ECNB;8LM93MMILXSB5LRU!]J*AZMZ@&=HVK#2M4$S- 6/L
M*GDVQ:]^N*G775HJ/#U\==*5U5SQI7-*YZ,ANLPB\&N.%?Q4]*^G0(?S OY7
MFS_DW!7]G]1IB-B=ZTM&#5*T?V.*W*E&@6*#(B,::3(HBA(:Y8SJ 6&J5XQ%
M+3%G-G),6^ S042>G'@LE. :G ^0;\C44HHVW=VL^QZE/YK]GR^7[.M4KL/K
M/?\ U-O#*; [(VCG-F[QP\_@KL!FZ)J68:B0DD7U2HIYK7AFA=X9D(>)W0AC
M ]Y83;?(89D9''X2,_EZ@^1%0?+H913+,NI""#YCK=B^'GQ(ZE^-O5'7])M_
MKS;6-[(?9NWY-^;VEQ4=5F*S*5=)"^2UY"=7K(Z7[MIO%3+*L$*^E(QZB<EM
M@V&WV6!%C10^A=;T[V:F:DYI6M!P'D.@#>WKW;DDFE30>0'ECH::KX_]#UM?
M5Y2LZ3ZCJ\G7D-79&JZWPU1/,59W!EF>B,DA#R2-ZF/+L?JQN9';;=B6,49)
MXG0M3^=/GTG%Q(!34U/],?\ /TK-G]>[ Z\IJ^BV!L?9^QJ/*5K9+)TFS]LT
M6V8JFI<6:HGCHH($FG(X+N"Q'Y]O06L=J"(D5 34A5"@GU- ,]4>1I/B)/ED
MD_X>EA[?ZITC.P^O=G=K;)W+UUV!@J/<FS]W8JIPV=P]<I*RPU(_4CJ1)#/"
MX62&:-EEAE5)8G21%8)[JUCO8VBE4,C@A@?,'_5@\1Q'3D4K0L&4T(R#UK_[
M2_E+?(/XW_+'J[MCHO>>V]W]:[4[*P&:>IS&5.W<[2X2IJQ#EJ&MIS#]I6ZL
M//50-+3U*&I5G(IJ<LL?N*K;D&ZV?<(KBU=6C60'N)5PA-&!Q0]I(J"*^@Z$
MDF]1W4+)("&*D8R*TP?V];&?N7>@OU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:W
M'??\R;^>SUYW3VCL?JS^1Y1=I]:;5WQN'"[ [*Q_RBQ7BSV&HJATQN7"-34S
MT[Y"D$4ST[0AJ9W:!BS1EV]U[H)/^'6/^%"W_?/_ /\ LT&)_P"C??NO=>_X
M=8_X4+?]\_\ _P"S08G_ *-]^Z]U[_AUC_A0M_WS_P#_ +-!B?\ HWW[KW7O
M^'6/^%"W_?/_ /\ LT&)_P"C??NO=;%OQDWSW-V9T!U/O[Y#=/4W0'=>[-G8
MW-=C=-4N[X-^)M[(U>HO0?Q6FCB@JG6/QNX53X7=H"\K1&1_=>Z'7W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=?,\_X67_  <;J/YB]2_-S:6%BI=E_*?92[+["J:#
M') D>]NHXHJ=:FJF1_5-F=LS8I8@T(9CBJN3R2$E8_=>ZU(NA^Z=]_'#NOJ;
MO[J_(1XSL/ICL3:'9FS:N<S>'^(;,KH*^FCJEIYJ::6CGD@$51$L\9F@>2(L
M Y/OW7NON;_'#O39?R>Z Z7^17754:O8_=_6.R>T-L.X*R)2;TQ\%?'!.C!6
MCJ:7S&&>-E#QS(Z. RD#W7NAI]^Z]U\FO_A5E\Z8_EU_-!W7U7M3-)DNJ_AC
M@WZ#P"4E33U=-+N:.<UF]ZY&AU,M0F7,.(F1I6TG"H=$;M(#[KW6MAC\%F\O
M29W(8K#97)T&U\5#G=S5N/Q\U;#CJ&HKJ/&1UE=)&C)24KY+(X^D665DC:IJ
MJ> ,99HT;W7NH-+55-#4T];15$]'64<\-525=+,U/+%+3L'CDCD0ATD1P&5E
M(((!!!'OW7NOMB_R?_FE#\__ .7+\7/DO5Y"/(;VW+UW0;6[;:.GEI-&\>O2
MV%W,PCF>218JK*44]5!>60FGJ(6UL3?W[KW5EGOW7NOF<_\ "R[YPR]M_,KJ
MCX2[2SD-5LCXM;'AWEV!1T&06='WOVS&E0*>KB0%1+A]L1XEH29-:ME*M&1+
M7;W7NM6WX4_%_=WS3^6GQ[^*NR!/'GN\NTMK;&?(TZ1R''8ZNG$F9S#)*\:/
M%A</%7U\BZM31T[*BLY53[KW7W(>L^N=G=/]<["ZGZ[PE%MK8/66S=L[ V5M
MW&TT=)3T.*V?10X_'TD,421Q1QT]+3Q(JJBJ O  X]^Z]U3A_P *)O@XWSL_
ME7?('9^W<+%ENU^E\?%\C.H-&.3(51R?5,4]5DJ"C!>)_N,UMN3-8^(+)S-4
M0L4ET"-O=>Z^.;[]U[KZ=7_"-WYO3]W?!?LOX?;NS*5N\_A]OY:O9E/-YS,V
MQ^Y)*O)4"&6>65:AL=N.GW)$1"(XZ:DEQT)B7TR2^Z]UN'>_=>ZU:/\ A6O\
MZ8_BW_+2K.@-KYI*#M/YL[D;JBA@IZFG6IBV?MK[;);TK%AEUO)35-.V-PTQ
M6+TIF"PDCD6,GW7NOE/>_=>Z=<[@LWM?-YG;.YL-E=N[DV[E<A@MP;?SN/FQ
M%=0UV(F>GJZ.LI*A(YZ6JI9XY(Y8I(UDCD5D=592![KW6^#_ ,(IOFY)C]T?
M)S^7UNW,N:+<5#1_);IG'S+/(J5N(%-A-Y4R2&1X$-32-MJIBB6*,G[:ME+2
M$@)[KW7T(O?NO=4;?\**OG#+\%OY5GR!W?MO.0X;MCN>BI?CKU"5R"T%4,EV
MFLM-DZZC-FD^YP^VHLW7Q,J$">GA#,@?6/=>Z^.A[]U[KZLG_"2GX-)\7/Y9
MM!WUNC!PX_M+YK;G?MJNJIZ2G2LCV?MX38S9=$]1%KDEI9Z?^)9FG5Y?0N9*
MF..3R ^Z]U:G_.(_F);>_E@_ OMWY.5?\.K^P4BH^N^BMJU\T*_Q?>F]5EBQ
M, BFDB^YI\;##6Y:NC0F0X['5C1H[J%/NO=?%Z[#["WOVUOO>'9_96Y\QO7L
M'?\ N/,;NWGNW/U9KJW(Y+/3O4U=74RM^J6::1V-@%%]*@* ![KW5^/\@G^1
M3NS^;?V;G^P>R,WENO/AOTUN"CP_9>[\($&5W%F3%3UHVC@'D#Q4M1]C44\]
M?721N**GG@$<,LU3&8_=>Z^IC\3OA1\5O@UUK0]3?%/H_8?3.SZ:&C7(+M;#
MHF1RT]%!#3"OSV8F\N5SN3DA@A62KKZRHJ'"*&D(4 >Z]T:3W[KW7O?NO=5:
M?S /Y-'\OG^9)M_-P?(7HK;M%V7D\8V/QGR"ZVQ]'LG?>.9/,]/+%G8J24Y&
M.FFJ)94I,G3U]"7=B],VIK^Z]U\V+Y_?\)W_ )6_$?\ F(]#_!KJW)X?N_&?
M,/-9,?%CL=W_ +NFJHL%*ISL>ZZ15GDQ-7M"B=*W*STZ5-))CFCK:5FF:HQ]
M'[KW7U$OY>?P8ZB_ER?$GJCXG=-4TCX'8&(:IW-N>LNU;N'<6<(J,[N"O9BQ
M^XR=<TCI$&\=+3+3T4 2FIH47W7NCK>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z^(-_-B_[>F_S+/_ !?_ .9'_OQ=Q^_=>ZMY_P"$B7_;Y78?_B!>
M^/\ W6P>_=>Z^L![]U[KWOW7NO>_=>Z^>[_PL]_E_P#3W7T'QY_F =:;7V_L
MC?79>_\ (=$]Y08#$ICAN2L?$5&8VYG*L0RQPG)T%'ALM1U%0:1YZN!Z%)IU
M6AA1_=>ZT*??NO=?;>_E"=L9[O#^5W\".S]UYF3<6ZMR?%KJ&+<^>GYEK,EM
M_$T^,KZF<Z$!J)JNBF:8A0IE+E;J0??NO=6->_=>Z][]U[JK[^<1_,2V]_+!
M^!?;OR<J_P"'5_8*14?7?16U:^:%?XOO3>JRQ8F 1321?<T^-AAK<M71H3(<
M=CJQHT=U"GW7NOB]=A]A;W[:WWO#L_LK<^8WKV#O_<>8W=O/=N?JS75N1R6>
MG>IJZNIE;]4LTTCL; *+Z5 4 #W7NK\?Y!/\BG=G\V_LW/\ 8/9&;RW7GPWZ
M:W!1X?LO=^$"#*[BS)BIZT;1P#R!XJ6H^QJ*>>OKI(W%%3SP".&6:IC,?NO=
M?4Q^)WPH^*WP:ZUH>IOBGT?L/IG9]-#1KD%VMAT3(Y:>B@AIA7Y[,3>7*YW)
MR0P0K)5U]945#A%#2$* /=>Z-)[]U[KWOW7NJM/Y@'\FC^7S_,DV_FX/D+T5
MMVB[+R>,;'XSY!=;8^CV3OO',GF>GEBSL5)*<C'335$LJ4F3IZ^A+NQ>F;4U
M_=>Z^;%\_O\ A._\K?B/_,1Z'^#75N3P_=^,^8>:R8^+'8[O_=TU5%@I5.=C
MW72*L\F)J]H43I6Y6>G2II),<T=;2LTS5&/H_=>Z^HE_+S^#'47\N3XD]4?$
M[IJFD? [ Q#5.YMSUEVK=P[BSA%1G=P5[,6/W&3KFD=(@WCI:9:>B@"4U-"B
M^Z]T=;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW0(=G?'#I3N3=O76^^R-@8?<V[>J<W!GMDYNJ\D$U--3.)HXYC#)&M92)4
M*DRT]0)81,HD" EM1=>;3;;A)'+,BLT3:D8\0?RXBN:&HKGCTHBNI(%95) 8
M4(]>AO\ 9CTGZXJRN+HRL S*2IU<H2K#C\@@@_T(M[]U[KE[]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7\^:O_"A+IGX3_([?
MOQMW+\(?YA?;&<Z^.%2OWYU/T+2Y';E<V:HH*Y6Q-;D\UC)LA3Q)4+&:B.E\
M#RK((I)%74?=>Z*I_P!!7WQ\_P"];?\ -._])]PG_P!E7OW7NO?]!7WQ\_[U
MM_S3O_2?<)_]E7OW7NO?]!7WQ\_[UM_S3O\ TGW"?_95[]U[KW_05]\?/^];
M?\T[_P!)]PG_ -E7OW7NKS?Y??SGVO\ S"N@8OD#M#I7Y =$X:;=NX=I1;0^
M1FP%V!F9FV\T:O74D4-774M9C96D,:3PU3 3130N%DB8>_=>Z/#[]U[KWOW7
MNO>_=>Z][]U[KWOW7NJ4/^%!_P &9/GM_*S^0_76W<-#ENU^J\5#\A.F N,3
M*51SG4J35M3CZ%6E@*U>?V^^:Q$3"4!'KED9)0GB?W7NOC;>_=>Z^G/_ ,(W
M/F]+W;\&>S/AYN[,_>[T^(._A7;-IY_N7E.Q^X7JLC0(9:B69)FQ^XZ?<<16
M'Q1T])+CXO"IM)+[KW6Q7_,K^8V!^ GP7^2ORPS4U!]_U5UKF:O8N,R-0M.F
M2W3G0N-VMB[F.8D5^>K,?%(1!+XX3)*R,D;>_=>Z^(3N?<N?WIN7<.\=UY>N
MS^Z=V9S+;EW+GLG.:FIK<AG:B2JK*NHD/,D]342R22,>69B3]??NO=;]7_"9
M_P#D^;0^0?\ *7^=78O;=$D%=_,2VSN_X]]89JHAIZ[^$[=ZKDJH:?/42RTK
M-%5_Z0HY)G#R3(9-O8^1$C=7+^Z]UH7]E]>;KZB['[ ZGWYC6PV^.L-[;KZ\
MWGB';6:3+;*KY\;D:8M87,%933)>W.GW[KW6\+_PBF^;$>WNP?DU_+^W/7QP
MT/8-%3?)7J:!D9;Y?;,-)@]V4^LN4:6LQ*;>GC01JPCQU2Q9A8)[KW6_?W5V
MYLKH'I[M+O'L?*0X78/4'7V[^RMY92=]"PXW95!/D:QAP2S^"G<(H!9W*HJL
MQ /NO=?#*^3WR WM\K/D5W=\D^QJJKJ=Y]X=G[R[+S<=7DY<O]JVZZZ:JAQT
M$\P5_L<73R0T=)&$2.&E@AABCCBC2-?=>ZW#?^$6GPA??/?OR$^>^[<(\NW.
MD-M0]&]29&I-/+#)NCL6)*W<-1 GKJ8ZO"[=CHH"Y\<;19YE0S,L@A]U[KZ.
MWOW7NL<L44\4D$\<<T,T;Q30RH)%=9 0RLI!#*P)!!%B.#[]U[KXKO\ .J^#
M]1_+Y_F4_)KX^T6+7&==2;UJNS^DQ3XY<92G9O:+OE\)2TD:S3!HL&L\^'>3
M4GDJ,=,XBB!$:^Z]T9C_ (39_-Z7X3?S6^A*S-YG^%]6?(NKD^,O:4<WW,D7
MA[/F@BV]5E(94A1Z'=L&">2HFAF2&B:MLL9D\T?NO=?8.]^Z]U\CK_A43\[#
M\S?YI?9>T=L9T9;J+XC40^.FPQ1UXJZ2;*;>F:?>61C18T19Y=R2U6/:19)1
M-3XNDD$F@JB>Z]T7C_A/C\&X_GO_ #3?CQUOGJ Y#K'J?)2?)#N*"\927 ]/
M5-'4PT,\<L$Z34F9W%48'%U2:58TU=,4DB<*Z^Z]T>3_ (5J_!T_%S^9I7][
M[<QZT?6WS9VRW;F/\,4<$,.Z]L"EQ>\J6-8XTN\]0V,RTSN7=Y\O(2W%A[KW
M5(_\N'Y;Y7X)?.CXP_++%AY(.F^U,+F-TTL,3SR5.W,XDN'W31PJCQL9ZW;>
M1RL$9U6$DBEE=04;W7NON#;;W#AMW;=P.[-N9"GRVWMSX7%[AP.4I6UQ5-%F
MH(ZFEJ(V_,<T$J.I_((]^Z]U\T7_ (66?-QNX/FOU5\,-J9Z6IV9\3]AC<F_
M,?09:4TTF]>XXJ:N:*LI%"T\M3A]LP87[>5FDD@.3KH5\)>=9/=>ZUB_@K\5
M]T_-WYA_'/XH[/BK3D^[^U-L[.R-=CY8(9<?AFE^ZW#F%-2?$1A,!39*O9=+
MLZTS+'%+(5B?W7NON/;$V3MCK39&S^NMDXFEP.SMA;7P&S-J82BC$4-'C=L4
ML5%14T2J %C@IH(T4 ?0>_=>Z^?Y_P +>^_J^I[ ^#/Q;Q^?$>,PNSNS._MW
M;6AFA8S3[GK:;;NW<A41ZFJ$%/'B-T0T[%$C?SU(!E9"(O=>ZT-/?NO=?<._
MEG_#W:_P,^"GQH^+>VJ*""IZVZPV\F^,A%0'&MDMTY^(9'=&5EA:6=XI,AG:
MJNE$33RF"-D@#LD2GW[KW1ZO?NO=>]^Z]U[W[KW7O?NO=(G(];=?9?L#:_:V
M4V7MG(]E[(VYNO:&S]^5N&@J<KC,7OJ;&5&9H*&N=#44U+DYL-BWJ(T=5E--
M%JOI]^Z]TMO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\0;^;
M%_V]-_F6?^+_ /S(_P#?B[C]^Z]U8]_PE^[\Z1^-G\UK9G:'R"[:Z\Z5ZXH^
MENYL/5[Y[/W;1;*Q4=7F*"&.EIGKLA-!3K/4."L:&34Y!"@^_=>Z^EI_P\C_
M "G/^]D/PH_]*1VI_P#7/W[KW7O^'D?Y3G_>R'X4?^E([4_^N?OW7NDGNW^>
M+_*$V7C:[+9C^8K\5*REQ]$:^HBVEVG0[^J60,5TP46";(UE5-<?YF&"26WJ
MT:2#[]U[KY^G_"E[^>!U?_-(W]U#TE\5IMQUGQ=Z$JLWNR7>NY, ^V)-W;JW
M)#'2KD*7&UT"96AQ6#Q@GIZ7[E:6>HFK:YIZ-4BHY&]U[K5XPF$S.Y<SB=N;
M<Q.3S^X<_DZ#"8+!82@ERM96UF5E2"EI*2E@22>IJJF>1(XHHT9Y'9412Q ]
M^Z]U]R?^7[\?\M\5/@Y\2/C?N&JCK=R]*?'CJ;KO=-7 -,<F6VWA:.#*/$-3
MVA.06I\8UM9-(N?K[]U[HWWOW7NO>_=>Z^>E_P +>^_J^I[ ^#/Q;Q^?$>,P
MNSNS._MW;6AFA8S3[GK:;;NW<A41ZFJ$%/'B-T0T[%$C?SU(!E9"(O=>ZT-/
M?NO=?<._EG_#W:_P,^"GQH^+>VJ*""IZVZPV\F^,A%0'&MDMTY^(9'=&5EA:
M6=XI,AG:JNE$33RF"-D@#LD2GW[KW1ZO?NO=>]^Z]U[W[KW7O?NO=(G(];=?
M9?L#:_:V4V7MG(]E[(VYNO:&S]^5N&@J<KC,7OJ;&5&9H*&N=#44U+DYL-BW
MJ(T=5E--%JOI]^Z]TMO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW12_D;\\_A7\0Y*.F^3ORHZ'Z-RF2IZFKQ>W
MNQNS,5MW*UD5&L+RR4>(EJ1DZQ(UJ*<L8:1P/+'?_.)?W7NJ_L?_ ,*./Y)^
M3WO5=?TWSZZVCSU'&DLU?D-E[RQ.$(=87 BW-5[;AVW.UITNL65=@PD4@-%*
M$]U[JR_H'Y;?%OY5X2IW%\:/D1TMWSB*"9J7*574W96(WTU'-&D4C05T..JY
MYZ&H6.>!S%41QR!)(V*Z74GW7NC#>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z);W-_,<^ OQ
MTWU6]8=^_,GXV=+]BXZCHLA6['[0[AP>Q\I'3Y)2U/4-19&LIZCP3A6T2!"C
M:6"L2IM[KW05?\/(_P IS_O9#\*/_2D=J?\ US]^Z]UVO\X_^4ZS!1_,A^$]
MV( U?)/::CG^I.4  _Q)M[]U[H\W6?;/5?=.U*#??3G9?7_;.Q\K'%-B]Y=9
M[RQV^\54I.BR(]/D<74U5',KQLK*4F(*D$<$'W[KW0@>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7N@3[U^270'Q@VG3;]^1G<O6W1VR*S)PX6FW?V
MGN^BV3C&JZD%HZ;[[(304PGD .A#(&:QT@V]^Z]TEOC]\ROB;\L&W$OQC^1_
M2_?_ /=!:)MU-U#V+B^P%QW\1U?;BM?&5-2M,TVA] <J6"D@$ ^_=>Z,K[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NOC5_P P#^8U_,)V#_,&^;^!V+\[_F7LK!;3^87R
M;V]M7"[2^3^]]N4F,H,3O/.4E+0X^FH\Y##14=-2(D,4,*)''$HC10@"^_=>
MZ*U_P[%_--_[V6?/_P#]+([%_P#LC]^Z]U[_ (=B_FF_][+/G_\ ^ED=B_\
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M(9^<=%6[2V=GL]2Y#<^>P^1QE*^.IWD6JR<.$BKLJ^.I2/+5"FIFE$"2$-&
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M9')UE!BUJ"D$E<DKHC>Z]U4[A?YY?\TCO(3;D^*7_"?;Y0[GZO20Q8[=_?\
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M]\MFZAZ1,3BJ:1ZC'[DR$-3%*L\&'R%=/3(OFJXJ>,ZO?NO=6S]H=I];=);
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M8_CW[KW1&_?NO=>]^Z]U[W[KW6S]_*OE>3XCX!&B\8@WIO>*-[$>0&J#Z_\
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MIKH-P8O8E##E:>OEB+12U]/6)+'4NCNC3K(RR2*0[>Z]T<'^2+_VZ)_ET?\
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M;0W)OS>NY<M5QT-+C\5M*CFK\A65$TSQQ10TU+!+([.ZJ%4DD#GW[KW6G?\
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M'8_2'5W8O<O9N=IML]==4[(W1V)OG<-6?VZ+$[.HILA7U##ZL8J:GD8*/4Y
M506('OW7NOGT]E?\+=N]V[AGJNGOA1U)#T!0Y;,04V$[*WKF:G>.4H8YD7'U
M3Y3%R187!5<M.DDE12C#Y>.*258HZR9:<S5/NO=;I?\ +$_F0=)_S2OBKMKY
M.]+PUV!2;*U^S>QNN\W605N2VQN/"102UN)K'@.B5#!54M32SZ(_N:.>";QQ
M,[1)[KW5AGOW7NO>_=>Z][]U[KWOW7NOB#?S8O\ MZ;_ #+/_%__ )D?^_%W
M'[]U[JWG_A(E_P!OE=A_^(%[X_\ =;![]U[KZP'OW7NO>_=>Z][]U[KWOW7N
MO>_=>ZU]_P">'_/QZD_E 879>P\1L:G[S^4W9^(.Z-J=3R;D_NU08G )4RT?
M]X=Q5D4%750TE354U7!04\5/Y*Z:FJ0)H(Z>20>Z]U2G_+@_X603]U_(#8_2
MOSOZ$ZTZ?VEV9N?^ZV%[SZDSN5I\9@JO/URPX9=PX?,S9.88SQRQ0UN3ARZK
M!(/NFH8Z5Y12^Z]UO:>_=>Z OY-?';K/Y:_'[MWXU=QXALWUIW1L;-[%W71Q
M2>&9(<M':*LI)?K#78^I6"JI91S%4PQ2#E1[]U[KXN_\R7^7-W]_+$^3F[_C
MAWKB9YXJ*JK,GUCV;1XR2AQ&\=NM,R46=Q1=YE3RH%6KI#422T%4)*:5G*+)
M)[KW2*^"_P \ODI_+H[]V_\ (OXP;U&UMZXB&7&9G"Y6&3*8/<&+JBK5&&W!
MC4FIQD,;.RHVD31S0RHD]--!41QRK[KW7T>_@9_PKD_ES_)/"X';_P HZC.?
M"[N&H6"BR=-O*CJ]Y;,JJDJ[-+C]T8RDD:BIF" G^+X_'K$SB)9ZBWE;W7NK
MT.O/YG?\M_MFH@H.M_GO\.-Y9:HH9LDF!PGR3V?59(4].5$DTF,_BXKX8XRZ
M!C)3*%+ &UQ[]U[H'NR_YVW\HSJC 9+<FYOYB_Q(RU!BL=49.HI>M.YL/W)D
M'CIED9DIL7M&HSF2JZAA&P2""DDF<E56,ET#>Z]UK4?S ?\ A9]TYMC#Y_8_
M\N3IG<'9V]&9*.A[R[XQ#[1VO3K-$KM5XS;4%4FX,PR,_B"U[X8)*C.8JF$(
M)?=>ZT,/D%\N/DM\J>\*[Y)?(#NC?/97>-;5XFLB[$RN4_A]91-@)/+CX\0E
M E)2X2EQ\MY*6GQ]/304TA+PQHS$GW7NOJZ?\)[/YML/\T+X@P4/9U0N-^6W
MQZIMM[/[WPU6T=-+FJ;*THFP&^**GU^;[#<=&C>8M&@3(P581?MI*26;W7NK
MR>PM_P"S.J-A;U[0[&W'B]G]?]<[3W#OG>^[,Y5+14>,Q.U*26NR-?53-98Z
M>DI()99&/T52??NO=: GR,_X6T=CT/=60H/BM\1.MLQT#@MRUE'39WNC<>93
M<FX\93121QUD$&*FHZ+;$M34^.9(YXLN5IU,<BK-*6@]U[K;*_E ?S:>E_YN
MOQMJNY>NL'5]>=C;#R]#M'O#IK*Y5<U4[=RU=3_<4\E/6K#3#)83*1I.^/K?
MM83-X:B&6&&HIIXD]U[JV'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7S]/^$Y6YL%_*\_G/_S(/Y6?;U/_ '$R?;VYL=ANF9\SD89TR#])UN?R^T*6
M.HDE:61]S[%W@^3H]1\LBQI%,B5+B,>Z]U] OW[KW7O?NO=<7<1H\C!BJ*SL
M$1I6LHN;*H+,?Z  D_0"_OW7ND#U5VIU_P!W==;1[8ZKW/C]Y=?;ZP\&<VQN
M/&%UCG@F+(RO%*D<]-4T\R2PU%-/%'44U1'+3U$4<T4D:^Z]UH8?RHOY-G3'
M\R7LO^:CVAV5\G?F[T9E=A?S+_D3L*@P/Q=[IQ766*K*<U[Y#[S(TM?M?.R5
M&0$E6\?E6HC7PI&GCNI9O=>ZN,_Z!4OBC_WL,_F\_P#I6>V__M=^_=>ZOU^(
M7QZI/B;\9.D?C5C]UY??6.Z3V!ANO,=O#<"*F0R5-M]6BIZNOT>AJZ:$(U0Z
MA5>;6ZJJL%'NO=:N?_"@#H2K^4'\XS^21T+0]O=J="U78^(^46*B[<Z2W$VT
MMU83[&BQ]<:C#Y%/52U$RTI@=A]899%_M>_=>Z-3_P! W^[O^]VG\XO_ -*D
MJ?\ HSW[KW5 O=7P(WE\=/YNG6O\N_\ F7?S$/YCV^_@%\Q]O&E^-G:,ORTR
M%'19W+,M)356T^PH<]%78OP560EJ,14)CX%EME<).)(4KJC[/W7NM]3XE?#[
MXX_!GI;;_P ?_BWU?@NJNL-ORRURXC$F6LJ*ZOJXXHZG*Y;(54DU=E<K5K!"
M)JJJJ)966..,,L44:)[KW1E_?NO=:F/\FG_M_C_PH4_\/KIW_P!RLW[]U[K;
M.]^Z]UJU_P#=W7_YB7_^6CW[KW1=O^% OQLVS\OOYQ/\DKXW;QWSVAUKMKM3
M$?*+#97?'2^YJ?9VZ,>F.HL?D5EQ&3JJ#)T]).\E&D;L]#,#"\B!06#+[KW1
MFO\ H%2^*/\ WL,_F\_^E9[;_P#M=^_=>Z.#_+]_D:=2?RY_E14?)CK+Y2_+
MOO";+_'[LCHO,;6^5/8^,[4-.N]]Q[)S\&0PE9C\%M\XT1':4L-5"\%2*KST
M[K)!]J5G]U[HO'_"LC_MRAW[_P")+^/7_O8XKW[KW1M/YJ7_ &XG^7__ (H!
MN7_WEXO?NO=47_RT/^$X/QM^2G\O_P"('?NY?G!_,\V)N#M[H3K[?N8V=U;\
MEL#MC;F-J-PT4<\E'A<?4;&KYZ/'PLQ6&)ZR9D6P,C'GW[KW1],#_P )>/CE
ML?=.R=^;4^>G\S'<.Y>OM_[ [#PF [?^0>"W]MFNJ=A9FAS$=)FL13;,Q-16
MT-2U%XW2/(P,I82!CHTM[KW6SC[]U[K5K_E6_P#<0C_PH$_\M-_]T<GOW7NM
MI3W[KW7O?NO=:?O\F[.83NK_ (42_P ^/O+8.8R.5V)M9=D=-UE1 9H*&?+8
MG(T^&J7:-H0DSP5^QLTE)/Y0KP--) )HIO(ONO=;@7OW7NM%W_A2%M/:N_?Y
MZ/\ (=V+OK;6W]Z;)WIVUT9M/>.SMV8:FW'BLMBMQ]P8"CR&,R>/K(YJ2OQ]
M?23305%//"\,\+O%*C(S*?=>ZVH_^&G?Y67_ 'K3^ '_ *1OUU_]CGOW7NE-
MM+^6C_+CV#F(]Q;%_E__  FV5N"*">EBSNTOBIL3;E8L54-,L:U5'@89UCD7
MAE#V8<$'W[KW1Q,+@L'MK'08?;N&Q6 Q%*&%+B\+CH<531ZC<^."!(XDN?K9
M1[]U[K3O^!'_ '&'_P VW_Q2B@_Z%^//OW7NMR7W[KW7O?NO=:K7_"4FGG7X
M^_S)JMH9%II_YJ_R+IX9RI"M)2X3:32(#]"R+-$2/P'7^OOW7NJW?Y-O\J3X
MY?/S?O\ -=[%[GWU\EMJYS9?\SGY$[*Q5)TEW[F>I*"2D-::[R5='C&6*JJ_
M-52+YG]7C")]%'OW7NKOO^@;+X'_ //XOG__ .EJ;L_Z^>_=>ZJ ^:G_  GN
MI?Y5VW=Z?S8OY>'>^^^S^]OBA1;A[ZWEU[\YL)MKY#8S-;?VQ35%5N%Z.OCV
M]B,C197'XJ.2:"J,K5_B@E2#)TE1(E0ONO=6P_)KYI[:_F'_ /":WY)?,7:V
M$&UZ;N?X,]TY#.[36JFKUQ&=VM'DL%N+%1U,]-1RU5/C\]B\C!!4-2QBI@2.
MH1=$JD^Z]T=W^2+_ -NB?Y='_BI?3_\ [JX??NO=6E>_=>Z#3NC_ )D[VQ_X
MC3??_NKJO?NO=:='\K'8.[.T?^$A7R!V'L7$5&?W=N'IGYX08'!T8U3UD])E
M=P5 IJ=?]V5$RPLD2#EY"J#EO?NO=6W?\)D^^=F]Y_R9OB=3[:K,:<[TO0;U
MZ-[#P-%ETRTV-RVQ\W724Z5FF.)J>?)X&MPV46%XP8X:^)0\RA9I/=>ZOT]^
MZ]U[W[KW6*&>"H0R4\T4\:RSP,\,@E >E=HI4)4D!XY$=&'U5E*FQ!'OW7NL
MOOW7NM2/_A61\S=V;5^-?3O\M#H/[[/?([^85V#M?9YVIMRODH<F^UZ#,T,$
M-!%(DL"1MN[<SXS%(DTRPU=&N5IY0T1DM[KW0*?!7Y*?SS_@7\2>B_B3UE_(
M!3(;9Z7V-C]MS[C_ -F:VY@9<WE)F>KS6?JJ2G1XX:O-Y>HK:V5/-*4><H99
M=.MO=>Z&#O'YW_SV/D-TUVGT3V9_PGFAS?7_ &_L'=77.\,9-\KL#():#=U%
M-15&G5$0LJ),7C;ZI(JNI#*#[]U[HD__  DR^2/<OQ7[Z^5'\F/Y=8K,]>=E
M;3JAW;U/U[NJMCK*G$Y-*.E?>.!AGBKJNC,-=C*C!9JCIJ,>+T9FM9Y&J&*^
MZ]T;/X3;ZA^/_P#PK#_F<=-]H4E+MC(?+OHG96].DLKD\O'2#-OL[#[3R:T.
M,IVC_P NEJ,9!N6=RDP:G.$JXS%*-;P^Z]UN&>_=>Z][]U[K$9X%GCIFFB6I
MEBFGBIS( [)3E%D=4OJ9$:6(,0+*74&VH7]U[K3X^$V^H?C_ /\ "L/^9QTW
MVA24NV,A\N^B=E;TZ2RN3R\=(,V^SL/M/)K0XRG:/_+I:C&0;EG<I,&ISA*N
M,Q2C6\/NO=;AGOW7NO>_=>ZQ&>!9XZ9IHEJ98IIXJ<R .R4Y19'5+ZF1&EB#
M$"REU!MJ%_=>ZU"OA+N.KZ#_ .%7G\SOJ7LO%1;?J/EM\=]D]E],9NLRB0+F
M(=G4&T9Q34%.T=ZMIZ:+<C2,)E:"3"U4?BE5C+%[KW6WU[]U[KWOW7NB'_S0
M^Y-I_'_^7-\W>VMZICZG";6^,/<R18G*5\>+AR>0S^"K<9B<.9Y(ITC?,96L
MHZ)#X)3KG6T4ALC>Z]UI=Y_K?=_6O_").2GWGB*C"5F]-\;/[(PE%5@+(^'W
MIWGC:K$5A4$VCR%!X*N'\M!-$Q U6]^Z]UN:_P IW_MUE_+3_P#% /AO_P"^
MZVY[]U[H_P#[]U[K5:_X4D4\]9\@OY"U)2PR5%35?S5^FZ>G@B4NSR3YO;*H
MB@<EF8@ ?DGW[KW2T_X4@?\ 'W?R2_\ QL7\6_\ W)?W[KW6R;O+9VUNP]I;
MEV'OG 8K=>S=Y8+*;9W5MG.4B5]'7X_-PO3U=)4PN"DL%1!(Z.I'()]^Z]UI
M@[=JNS/^$M_S1I-EYW(;P["_D>_,??58^V\_DVK=RU?2>[,D=?@FF5*N::BT
M%4D#E),MCD^]5ILIB:M*_P!U[HT7\X/.X3='\ZC_ (3<;EVUE\9N#;NX.RN_
M<U@L[A:Z+)T=;1Y./9,U-54M3"SPU%/40NCQR([(Z,&4D$'W[KW6V![]U[K4
MQ_X5 _\ ,S/Y(_\ XTNZ[_\ =AM_W[KW6V=[]U[K1F_X4Q_S!?CCNCYY_!G^
M6]\@]^Y?:GQ)ZMW[M7Y._.O(;?V_5[M:N5(JF;:^T7H<;)-65!J,=%5M5Q-0
M/'&,WC*U'+4D@3W7NK2*3_A5]_)&H*6FH:'O3L.BHJ*GAI*.CI/CINZFBBBI
ME"1Q11IB52..-%"JJ@!0   ![]U[JC[^3#_,J^)G4?\ /G^4'2'Q1[.R>X/@
MG_,JS(WQUEC]P[5S&S_[O=H31R9A,;#0Y<TPH:6MJJK<N-C:*C?[M9=OT_E7
M[,H/=>ZO)_X5D?\ ;E#OW_Q)?QZ_]['%>_=>ZV'=FQ13[&VI!/''-#-M/!Q3
M0RH)%=9*.(,K*00RL"0018C@^_=>ZTY?E=TCVY_PG#^960_F+?#[;>X]]?RN
M/DOO?'X[YR_%W#--61;#R&XJ@Z=V;>C_ 'Q24<4\LLU"S(D$$KO@)I8:*NQL
ME#[KW0D_\*2^ZNK_ )&?"S^4IWETMO'$[^ZM[0_F5?&?=^RMV86;RP5=%EL%
MN>1"58++!41$M'/!*B34\Z203QQRQNB^Z]UM^^_=>ZU?/^%>W_;G#=O_ (L+
MT5_[EUOOW7NMCCI?_F3O4_\ XC38G_NKI??NO=*S=6U=L;ZVUG]F;TV]A=V[
M0W5B,AM_<VU]QXR'-8_(4.6B:"JHZVDJ$D@J::HA=TDCDC9'4E6!!]^Z]UK3
M=V?\)+OY6_8G8<?:73.4^2_PZW9%E,OFHX?C9VW!C,<E3FY-<KTM-N3$;CJL
M3'$K3QT]/C*^AI8(YFB6 PI%''[KW2 I_P#A+%MW )E6V-_-J_FB[2J:]'2"
M:G[K@('C+&#[M:.FQ[58BU&X$D6J[:?'JX]U[HJ>*[%_F>?R!/GA\.ND?DQ\
MPM\_S#?Y>GS:[0CZ5VWNWM**HRF[MJ9W<.5HJ.!WJLID<MEH9<;_ !7'S^-<
M[48^OH1D!3T%+54\*CW7NMV/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U\BK_A5+UIE.O?YVGRCR]8L2XOM;;70_9>VM'EUFEGV1@<)5
M&7R00QZ_XQ@\II\3S)X_&&E\PECC]U[K7<]^Z]U[W[KW7O?NO=;%?\GC)1R]
M!]D8<%/+0]OUV2=1^K3E<+AHE)Y^A-$]O2/H>3]!!?NE&1>Q/ZP ?[S(Y_Y^
MZ&/+I_18?TS_ #5?\W5MON,^C_JWC^2AO:/;/S+?;DU28X^QNJMZ[9IJ5I]"
MRU.)DHLXC"/4!)+'38FKT\%E1I+6!;W(7MI<^#N)0G^TB=0*\2"K_F0%/Y5Z
M)-_CUP5_A8'\C4?Y1UMT>Y^Z!77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,^XMP87:6W\[NK<F1IL/M
MW;.&R>X,_EZQBD-+18:!ZFJJ92 2(X((Y'8@&RJ>/?NO=?&?_GS=Z_%SY+_S
M5/E1W?\ $#.5&Z>H=]YW:55+NM,><9C\KG\1@L;CMPY/#1204]2V,KLI23S+
M/.A:JJ'J*N)C33P>_=>ZK_\ B=G>G]K_ "G^-.YOD+CDS'0.W?D!TWG>\<3)
MB#N!:K9^(W'C:C<U,U (Y36B?"QUJ&G$3^;5X]#:K'W7NON(_'GY =+?*;IG
M8G?GQWW[@NS>FNQ,=65VR=Z[;$J4E7%B*RIQM5&L<\4$]/-0Y"BJZ6>"6&.6
M"H@EAE1'C91[KW0S^_=>Z][]U[KY:'_"O3Y%?#SY"_/;K _'/=5#OCM[J#K#
M<G3/R9W'@$J!CJ?);/W!6'%8%I)-$%1F<'-49V.O>&$Z!+2TLD\CTWAIO=>Z
MU-O?NO=?:1_DJ_*?X9_)'^7]\=\#\+MX+F=E]$=,]2]4[LV5DJ.?'9S:^5P6
M%AII\5N""=;?Q0U%)5223PS5%-6$FLI:BHIIXIY/=>ZMG]^Z]U[W[KW7O?NO
M=>]^Z]UHU_\ "S_Y*_$+.?';ISXJUF[AF?F9LKNO;O:> V?@J%IIL)MG+8+*
M4N3GSE7+3F"GH,P*O&&FIXJ@5-34TT,P4T])4>_=>Z^<W[]U[KZBG_"0GY._
M#;-_R]-L?$CK'=FW\?\ +W9F8[B[C^1O7)P\N'RE?'F-U-C\9N=)WIHX<Q10
M;=GV;C99XJB9Z61(*681 PJWNO=;<GOW7NO>_=>ZUS?^%/OR*^'G7'\K?OOH
MCY*;JH8^Q^_=ES?[+?UW3)439?*[IZ_RN(R&.R5$*?1X*#!9-L=-D9I)TB^T
M=Z9Q/]RM-/[KW7R.??NO=;R?_",CY3_#/IG?'R7Z0[*W@NR?EK\B]R]5XOJ6
M+<-'/]CN3";8BR8&$PM7$LL$.9I\ID)ZBJIJC[=ZJG>EEI34K15GVGNO=?1E
M]^Z]U[W[KW7O?NO=$1_F$?RXOBS_ #-.BLIT1\G]D?QG'Z*NKV+V!@3#C-S;
M2R=0JJN6VYE)8*C[2J!2/RPRPS4=9&O@K::H@)C/NO=?.'_F)?\ "4'^8A\1
M\IN7=_QMPC?-?HRCER%?BJ_K"@^WWQ1T5/%-4"/)[,:22JKZJ..+Q*<+-DFJ
M9-)6F@:58%]U[K6B[ ZU[&ZFW)4[-[4V!O;K3=]'#%45>U>P-JUVS<E%'.6"
M/)0Y&"FJD1RC!2T0!(-CP??NO=(KW[KW6>EI:FNJ:>BHJ>>LK*R>&EI*2EA:
MHEEEJ&"1QQQH"[R.Y"JJ@DD@ $GW[KW5TWP9_P"$^O\ -'^=^6Q<VROCGN?I
MSK*KJQ%D.YOD5CZOJ3"0PJL3M/1TV0IAG,ZC)*!&V,Q-7$T@9'EBT2M'[KW6
M^E_+'_X2Q? WX*UFWNT.\(5^9GR$Q!I,A2;A[.V]!3;0PU=3.LJ5&"V>SU=-
M)402*ABJLK4Y"6.1%GI5HY+!?=>ZV6J3:>UL?F%W#0;:V_19]<%2;77.4F&I
MJ:L&,Q\C2P8X5*1K,*""5W>.GU^)'8LJ DGW[KW1./YFW1F^/DS_ "\_FAT%
MUE3TU;V+VQ\;NV-F[&QU7+]O'5Y;)XBI%!1M)8B(UE2(X0Y&E#(&;T@^_=>Z
M^(+N';V?VCG\YM3=>#S&V-T[8S&3V]N7;6X<9-A<ACLAA9GIJRAKJ.I2*HI*
MRDJ(I(IH98TDBD1D=592![KW6^[_ ,(<]Y[IEJ?YBW7DN2K)ME4$'QLWG18=
MY5-/393+-O.AJJF)#ZUFK:2BHTE9>&6DB#<JGOW7NOH!^_=>Z][]U[KWOW7N
M@Q[G[FZP^//5F^.[.Z-XXSK_ *KZVP51N7>^\\RDTE-CZ&E95>>5*>*>=QK=
M%"QPN[,P55)('OW7NOB!_/+M[9_R"^<GS-[ZZ\GK*G8'=WRN^1/;VQZG(T;X
MZHDP_96[\QF<8\]/*%D@F>BK8"\;J&1B58 @^_=>ZLB_X3G_ #+Z%^"_\TGJ
M7N?Y*;IFV)U1E=F=D=9Y7?38Z;)TF(JM]8_PX^LR:4RR5,6--7%%#-/'!(*<
M2K/,$IXYI8_=>Z^PUB\G09K&8[,XJJCK<7EJ&DR>-K8;E)H*^-9894N =,D;
MJPN!P??NO=3O?NO=>]^Z]U[W[KW7O?NO=?-?_P"%FWPY[SQ'S ZO^;E/M2LS
M7QZWKTILSI^MWGB*6:KCPFY-EY+,S&@S)6,QT29.DRE+)03/(%J72J@ 62 >
M3W7NM43X=?$7NSYS_(GK;XS] [3R.ZM_]BYZ@QQDI:.2HI,1CFGBCR&>R\R#
M118?$P2>:JGD95"@1IJFDBC?W7NONCX/'-A\+A\0]4]<^*Q>/QSULD8B:8T,
M21&5E!8*9"NHC4;7M<^_=>Z=/?NO=$1_F$?RXOBS_,TZ*RG1'R?V1_&<?HJZ
MO8O8&!,.,W-M+)U"JJY;;F4E@J/M*H%(_+#+#-1UD:^"MIJB F,^Z]U\X?\
MF)?\)0?YB'Q'RFY=W_&W"-\U^C*.7(5^*K^L*#[??%'14\4U0(\GLQI)*JOJ
MHXXO$IPLV2:IDTE::!I5@7W7NM:+L#K7L;J;<E3LWM38&]NM-WT<,515[5[
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MMW/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6N#_/=_D.8W^9Y0[/\
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M19;)U==(8T@@.YZ? 0$I^MQ&\LI3_,PS2?M^_=>Z OXR8/\ GI?S._FST_\
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M9S[6G-;/5S866DBIJ9,/0?=WS">Z]T?#^=!_*,W9\XWZF^7/P^[ 7H+^9/\
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M.Q9JTF3*8+9^[,?CGJ"0%P-164=9/%$38$G)4*RN%N;1!CPH]Q+[JVVJ.WF
MX,Z$T_B"L!7_ &C4_/H3<N24+IZ@$#[*@_X1U?3[AGH5=&0^'_9\?37R@Z+[
M(J:B.CQNW>QMO)G:J67PK'C,U+_#\HY:X "XZKJCR;?ZKB_L[Y;OOW=?P3'
M$BACZ*W8Q_8QZ27T/CPNGJII]HR/YCK?0]Y2]1UU[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]TD=W=?[#[ H3C-^;)VCO;&E2AQ^[MMT>Y("#>X\59
M#-'8W/\ 9_)_K[]U[HGN5_E9?RQL[E,EG,Y_+E^!^9S69KZS*Y?+Y7XA]?9&
MJJZK(R--45-343;>>6>HGE=WDD=V=W8LQ))/OW7NC"=:_&KXY=,4]!2=/= =
M)]44F+IZ2DQE+UKU5@MBQTT6/#+!% F+H*588X [B-4 "!F"@7/OW7NAL]^Z
M]U[W[KW7O?NO=>]^Z]U0%_/DWM\"?A;\0^[/F/VG\>/BIN3Y=[AV'N+J7XT[
MZW[TGM;=&\:W=F[,?74>,%#E*O'/G)*/!K75>1JQ%6(D=+'.IDC:==7NO=%W
M_P"$HO\ +KWA\(_Y?&4[;[=VQ4;2[G^9VZ<1VKDMOY;$KB\GC=G[:I9:396/
MR/[TKM+40UF6S,<<@ADIHLRM-/3Q5,4X/NO=;0OOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z9-Q[:VYO'!93:^[L!A-U
M;9SE))09K;NX\5!G*&L@E_7#54E5'+3U$+6%TDC93^1[]U[H)^DOB_\ &GXS
MX_+XGXX?'CHSX_8K<%8,CGL9TEU+@.J:>NJ D<0GJX<#CZ".IF\<,2:Y%9M*
M(M[* /=>Z'/W[KW7O?NO=>]^Z]U[W[KW21W=U_L/L"A.,WYLG:.]L:5*''[N
MVW1[D@(-[CQ5D,T=C<_V?R?Z^_=>Z)[E?Y67\L;.Y3)9S.?RY?@?F<UF:^LR
MN7R^5^(?7V1JJNJR,C35%34U$VWGEGJ)Y7=Y)'=G=V+,223[]U[HPG6OQJ^.
M73%/04G3W0'2?5%)BZ>DI,92]:]58+8L=-%CPRP10)BZ"E6&. .XC5  @9@H
M%S[]U[H;/?NO=>]^Z]U[W[KW7O?NO=%V[0^(/Q,[OWIMSLCNGXO?';M[L/9T
MU)4[1W[VATGMK?\ FL5)02Q3028W*9;&5==0O#-3P21M#.A1XXV4AD4CW7NC
M"0004L$--30Q4]-3Q1P4]/!&(D1(@%1$10%5%4     "P]^Z]UE]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW46MH:+)4LU#D:.ER%#4IXZBCK
M:=*J*1;@Z7CD#(XN ;$'W[KW2$I^G^I:2>*II>KNNJ:I@<20U%/LG&0NC+]&
M5UI0RD?U!O[]U[H1??NO=>]^Z]U[W[KW7O?NO=,FY-M[?WC@<MM;=>%QFXMM
MYZAGQF:P>9HH\C2U5/4C3)#/#*K1R(P_!7_$<@>_=>Z>_?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW3)DMM[?S&3V]FLKA<9D<QM*NK<GMC*5E%'45&/J,E1U&/J)J25E+
MP//1551!(48:XY&1K@^_=>Z>_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=(W-]<]?;EJOOMQ[$V;N"NY_RS-[8H<K+R #^Y/!(
M_P!%4?7\#^@]^Z]T^8; 8+;M(,?M_"XG!4"D%:+#8Z'&0C2 HM' B(+* /T_
M0 >_=>Z=O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,.3VOMO,Y?;>X
M,M@<3DL[L^KR-=M3,5M!%456.FR])+0U4E%.RF2G:IHYY89=##R1L5:XM;W7
MNG[W[KW7O?NO=)'/=?[#W34I6;GV3M'<=7&"L=5GMMT67D4$*I >HAD8 A$'
M!^B@?@>_=>Z?<5B,3@J&'&83%X[#XVF4)3X_%446/@C"@ !(H52-0  +!1P/
M?NO=./OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NFW+8;#YZBDQN=Q6-
MS6.F!$U!EJ&+(POJ5E.J*971KJS#E?H2/H3[]U[IDP&P=B;4J):O:^RMI;;J
MIT$<U3@-N4>'D=5O96>GAC9@-3<$_D_U]^Z]TK??NO=>]^Z]TVY;#8?/44F-
MSN*QN:QTP(FH,M0Q9&%]2LIU13*Z-=68<K]"1]"??NO=,F V#L3:E1+5[7V5
MM+;=5.@CFJ<!MRCP\CJM[*ST\,;,!J;@G\G^OOW7NE;[]U[KWOW7NH.2Q>-S
M-'-CLOCJ'*X^I7344.2I(ZZ&0#\/%*K(P_UU/OW7NDSA>M^O-M5BY';FPMEX
M#(*I5:["[6H<5, ?J!+!!&X!O_JO?NO=+3W[KW7O?NO=0LAC<?EJ62ARM!19
M*AFT^:CR%*E9$^DW&J.161K'D7'OW7NDCC.K.L<+5QY##=<[#Q-?"08JW&;0
MQ]!,NDAAIDBIT=;,JGAOJ ?Q[]U[I=^_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZC5='29"FEHZ^EIJVDG 6:EJX%J8W"D, R.&5@" >1]0
M#[]U[I'8KJ[K/!UL.2PG7>Q</D:=E>"OQ6T<?CYD*,&!26&G212&52"&%B ?
MJ/?NO=+KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW6DK_PMLZ-AW'\2/AU\BJ?$RU.2ZH[^W7U3692FCE<T^/[JP+Y)C4^,^(0&
MNV71HDDJ_MRRK'$RFH=9/=>Z^;C[]U[KWOW7NO>_=>Z/7_+?[%AZ[^6?7PK)
MX*;&[ZARW7==-42B(:MQQAJ!%)X+S96GH(U'Y+V')'L'<^6!OMLEH*F.DH_V
MI[OV*6/1KLLW@W"UX-5?V\/Y@=;5OO'#H=]>]^Z]UO7?!GNF+OWXJ=,]B25G
MWN;FVE1;;W>[OJD_C&T+XS(O*"S,C5-13-4H&-S%-&_(8$Y2<M;E^]K&&>M2
M4 ?_ $Z]K?S%?L(ZCO<+?Z:9D\JU'V'(Z-E[/.D?7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6M+4_R
M&-Y_*#^9WV+\W_YF'R'D^5G3/6>]8Y_A-\;I:$8_!8G#2PTM;'#N;%+30XQ8
M\9D2T!I*2-QFI**')9>IF$[8]/=>ZV65554*H"JH"JJBP 'T 'X ]^Z]UW[]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[JD'_A1O\?C\BOY-7S7V_2R1T^9ZTZ_Q
MWR!P]9)1??>,=#9*CW-DU5 R,K56!Q^6IA(''B\_D8.B-&_NO=?'%]^Z]U[W
M[KW7O?NO=.^W\YDML9[";EPT_P!KF-O9?&YS%5.G5XZG$S)4026/UT2QJ;?X
M>VIX5N$:-\JRE2/4,*'^1ZLC%"&'$$$?:.MT;K#?>,[0ZZV1V)AF4X[>>V,-
MN*G0?6,Y.!))(6!)(>"0O&XN;,I%S;WBAN-DVW3R0/QC=E^VAI7\QGJ28)1.
MBN/, _MZ7?M'T[UL$?R,/D,F*W/V-\9\_D%CIMU0MV3U]#/+I!R&(BCI\U21
M N2TM3CTI*E45  E%4NQN0/<N>U^[Z6DLG/Q?J1_:,,/V4('R8]!GF&UJ%E'
MEVM]GE_J^8ZV6/<R=!7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[I.[PVI@]][2W1L?<]%'D]M;RV[F]J;AQTRJZ5%#N*FE
MHZN!U8,I66GFD4@J00>01Q[]U[KX3'R8Z+W)\8OD5WI\<]X235&YNB^V^PNI
M\Q738U\1]W+L+*U6,^^CIGDF,4%<M,M1"!-(IBD1DDD4AV]U[H$/?NO=>]^Z
M]U[W[KW6PE_*,[QI]P]<[HZ'RM7&N:Z^K:G=6U:=V5&EPVXY]58L2ZB[_8Y6
M5WE;0 /OH5!)O:$?<W9S!.EZH[9 $<^CJ,5^U1C_ $IZ%_+]UK0Q'BN1_I3_
M )C_ (1U<-[BWH0]"'U+V=NCICLO9':NS*A:;<VP]QX[<6+,M_'*U"X,E-.%
M*L]-5PF2"901KBD=;B_M;MU^^V3I<1_$C!A\_4'Y$5!^1Z:GA%PA1N!%.M\[
MI?MK:?>O5>QNW-DU/W.V]]8"DS5&C.'DIY'O'544]N!4T%7'/3S <"6)P"18
MG*?;[Z/<X$GB-5=0P^7J#\P<'YCJ.9X6MW*-Q!I_J^WH3_:SIKKWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH]_G8_SHMH_R<MI?
M&7=.:ZOB[GR'>?;F6VWF=BTF\H]H92#:>T<:9L_G<29*6LCJJW&U^0P$:031
MQ4\_W#0R5-*TB3Q^Z]T+W\O/^=G_ "\?YE^.H:/X^=U46%[5EI%J<E\?NV5@
MV!O6E*K$THAQDM3-39N* SQK)4X>OR-*CD(TROZ??NO=6R>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KY77_"OOXAMT'_ #/*;O["
MX_[79GS'ZPP._P U"2?M_P!Y^MXJ?;>X:=([#031TVWZZ0@D/+D)&N#<#W7N
MM4SW[KW7O?NO=>]^Z]T//QH[PRGQX[FV?V?01U-70XJK:BW-BJ5U5JW%9,".
MNIEUE4,GCM)%J8*)XXF) %_9-O\ M"[Y:/;M0%A5"?PN,J?VX/R)Z5V5T;.4
M./+B/4'C_J]>MP?;^?P^ZL%AMS;>R%+EL#N#&4.9PV3HI1-%44V2C6:":-U)
M#))&ZD'_ !]XNSPM;.T;@AE)5@>((-".I#1@X##((J#Z@]/'MKJW5W_\G/YI
M1=4[\E^-/8F62FZ_[/RZU6PLID*K1%B]R5(2):.[G3'2YT+'&.;+6I#I7_*9
MI!)_MUS)]%)]#,:)(:QDGX9#^'[&\OZ7^FZ#V^V'BKXR\5'=\U]?R_P?9UM0
M^YQZ"'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M\F#_ (54_.JF^8'\T+=_7&S\\,OU1\.<$.@-N?:5,5323;CI)VK-[5T1C!(F
M7,NF)EO(P88:)E"ZB/?NO=:V%#75N,K:/)8VLJL?D<?54]=05]#4/23034CB
M2*:&6,J\4L3JK(ZL&5@"""/?NO=;.'\NG_A5=_,2^&";=V%WCE*?YI]'8IJ>
MB;!]NY>:GWC0T<2J@CQ>]E2IKIS&JW5<O2Y06'BC>G2Q7W7NM\S^7=_PH$_E
ML_S(*C#;-ZT[>7JCO3*Q4B1] ]ZI!L'/55341RR-38*HDGEPVYY$%/4,8L9D
M:BK2)/-44L",M_=>ZNR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M:Q/_  K%^$<GRI_E<[E[>VOA9,IV9\+]ST_>F(:D6G6H?;%2BXW>U,99].FC
MIL3+#F:A4D5Y/X+&J"1],3^Z]U\GWW[KW7O?NO=>]^Z]U[W[KW5\O\JCY41Y
M#&R?&C>^3C3(XQ:O*=4U=;4DO44S>6HKL0I?@O26>HIU#%C"TR!52G6\-^Y'
M+FD_O"$8-%F ' \%?\\*?G3U/0JV&^J/ 8\,K]GF/\H_/TZNS]Q'T)NNU9D9
M71F5U8,K*=)!7D$$<@@^_ TZ]UMO_P K;^8)2_([9]'TMVIETC[WV1B4CH<C
M7S!6W5B\<A KHV9BTF7HHD7[]#ZIEM6QZ@U2M/D#R1S8-ZC%O.?UT'$_Z(H_
M$/Z0_%^T<2 "MWVSZ5O$3X"?]Y/I]GI^SJX#V/\ HDZ][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>ZJ;_ )UG\QS"?RP_@%VY\@(*S&/V[G*0]8?'
M?;N099?O]Y[QAFCQ\[4_F@>HHL%3QU66K465"]+121*ZRRQ7]U[KXO64RF3S
MF3R.;S>1K\QF<Q7U>4RV6RE7)D*JJJLA(TM14U-1*SRSSSRN[R2.[.[L68DD
MGW[KW4#W[KW7O?NO=>]^Z]U]#/\ D%_S'?D]\6.F>O\ :/S*[4[![MZDWVU/
ME<-2;VR-3NO-[$Q&5CB.-6@K:N2?)5U''&6FJ,?+)_D\4JT]%'&U((JJ-=R]
MP$V[<C;D!H% 21AEEDKDBG$+\+"E:@D5H 1!!LAGM]8PYR >!7R'VGB#]E>M
MZ?:VZ=M[WV[AMW;0SF+W+MC<-!3Y3!Y["UB9"EJJ>J%TEAFC+(ZD?T-P00;$
M$>Y%AF2X021D,K %6!J"#Y@CHA="A(84(P0>(Z?O;O5>O>_=>Z][]U[KWOW7
MNO>_=>Z3^[,=D<QM;<N)P]4M#E\IM_,X[%US3R4HAJ:VFDB@E,L2M+&(Y65M
M2*66UU!( ]MRJ74@8)! /H:=64T()]>M=/\ X;&_FD_]YD8/_P!*&[$_^L'N
M(/ZF;[_RF#_LHN/^@.A/^];/_?7_ !A/\_7O^&QOYI/_ 'F1@_\ TH;L3_ZP
M>_?U,WW_ )3!_P!E%Q_T!U[]ZV?^^O\ C"?Y^O?\-C?S2?\ O,C!_P#I0W8G
M_P!8/?OZF;[_ ,I@_P"RBX_Z Z]^];/_ 'U_QA/\_7O^&QOYI/\ WF1@_P#T
MH;L3_P"L'OW]3-]_Y3!_V47'_0'7OWK9_P"^O^,)_GZ]_P -C?S2?^\R,'_Z
M4-V)_P#6#W[^IF^_\I@_[*+C_H#KW[UL_P#?7_&$_P _7O\ AL;^:3_WF1@_
M_2ANQ/\ ZP>_?U,WW_E,'_91<?\ 0'7OWK9_[Z_XPG^?KW_#8W\TG_O,C!_^
ME#=B?_6#W[^IF^_\I@_[*+C_ * Z]^];/_?7_&$_S]>_X;&_FD_]YD8/_P!*
M&[$_^L'OW]3-]_Y3!_V47'_0'7OWK9_[Z_XPG^?KW_#8W\TG_O,C!_\ I0W8
MG_U@]^_J9OO_ "F#_LHN/^@.O?O6S_WU_P 83_/U[_AL;^:3_P!YD8/_ -*&
M[$_^L'OW]3-]_P"4P?\ 91<?] =>_>MG_OK_ (PG^?KW_#8W\TG_ +S(P?\
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M)_GZ]_PV-_-)_P"\R,'_ .E#=B?_ %@]^_J9OO\ RF#_ +*+C_H#KW[UL_\
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MW[UL_P#?7_&$_P _7O\ AL;^:3_WF1@__2ANQ/\ ZP>_?U,WW_E,'_91<?\
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M^IF^_P#*8/\ LHN/^@.O?O6S_P!]?\83_/U[_AL;^:3_ -YD8/\ ]*&[$_\
MK![]_4S??^4P?]E%Q_T!U[]ZV?\ OK_C"?Y^O?\ #8W\TG_O,C!_^E#=B?\
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M_P!*&[$_^L'OW]3-]_Y3!_V47'_0'7OWK9_[Z_XPG^?KW_#8W\TG_O,C!_\
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M(P?_ *4-V)_]8/?OZF;[_P I@_[*+C_H#KW[UL_]]?\ &$_S]>_X;&_FD_\
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M?\83_/U[_AL;^:3_ -YD8/\ ]*&[$_\ K![]_4S??^4P?]E%Q_T!U[]ZV?\
MOK_C"?Y^O?\ #8W\TG_O,C!_^E#=B?\ U@]^_J9OO_*8/^RBX_Z Z]^];/\
MWU_QA/\ /U[_ (;&_FD_]YD8/_TH;L3_ .L'OW]3-]_Y3!_V47'_ $!U[]ZV
M?^^O^,)_GZ]_PV-_-)_[S(P?_I0W8G_U@]^_J9OO_*8/^RBX_P"@.O?O6S_W
MU_QA/\_7O^&QOYI/_>9&#_\ 2ANQ/_K![]_4S??^4P?]E%Q_T!U[]ZV?^^O^
M,)_GZ]_PV-_-)_[S(P?_ *4-V)_]8/?OZF;[_P I@_[*+C_H#KW[UL_]]?\
M&$_S]>_X;&_FD_\ >9&#_P#2ANQ/_K![]_4S??\ E,'_ &47'_0'7OWK9_[Z
M_P",)_GZ]_PV-_-)_P"\R,'_ .E#=B?_ %@]^_J9OO\ RF#_ +*+C_H#KW[U
ML_\ ?7_&$_S]>_X;&_FD_P#>9&#_ /2ANQ/_ *P>_?U,WW_E,'_91<?] =>_
M>MG_ +Z_XPG^?KW_  V-_-)_[S(P?_I0W8G_ -8/?OZF;[_RF#_LHN/^@.O?
MO6S_ -]?\83_ #]>_P"&QOYI/_>9&#_]*&[$_P#K![]_4S??^4P?]E%Q_P!
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M] =>_>MG_OK_ (PG^?KW_#8W\TG_ +S(P?\ Z4-V)_\ 6#W[^IF^_P#*8/\
MLHN/^@.O?O6S_P!]?\83_/U[_AL;^:3_ -YD8/\ ]*&[$_\ K![]_4S??^4P
M?]E%Q_T!U[]ZV?\ OK_C"?Y^O?\ #8W\TG_O,C!_^E#=B?\ U@]^_J9OO_*8
M/^RBX_Z Z]^];/\ WU_QA/\ /U[_ (;&_FD_]YD8/_TH;L3_ .L'OW]3-]_Y
M3!_V47'_ $!U[]ZV?^^O^,)_GZ]_PV-_-)_[S(P?_I0W8G_U@]^_J9OO_*8/
M^RBX_P"@.O?O6S_WU_QA/\_7O^&QOYI/_>9&#_\ 2ANQ/_K![]_4S??^4P?]
ME%Q_T!U[]ZV?^^O^,)_GZ]_PV-_-)_[S(P?_ *4-V)_]8/?OZF;[_P I@_[*
M+C_H#KW[UL_]]?\ &$_S]>_X;&_FD_\ >9&#_P#2ANQ/_K![]_4S??\ E,'_
M &47'_0'7OWK9_[Z_P",)_GZ]_PV-_-)_P"\R,'_ .E#=B?_ %@]^_J9OO\
MRF#_ +*+C_H#KW[UL_\ ?7_&$_S]>_X;&_FD_P#>9&#_ /2ANQ/_ *P>_?U,
MWW_E,'_91<?] =>_>MG_ +Z_XPG^?KW_  V-_-)_[S(P?_I0W8G_ -8/?OZF
M;[_RF#_LHN/^@.O?O6S_ -]?\83_ #]>_P"&QOYI/_>9&#_]*&[$_P#K![]_
M4S??^4P?]E%Q_P! =>_>MG_OK_C"?Y^O?\-C?S2?^\R,'_Z4-V)_]8/?OZF;
M[_RF#_LHN/\ H#KW[UL_]]?\83_/U[_AL;^:3_WF1@__ $H;L3_ZP>_?U,WW
M_E,'_91<?] =>_>MG_OK_C"?Y^O?\-C?S2?^\R,'_P"E#=B?_6#W[^IF^_\
M*8/^RBX_Z Z]^];/_?7_ !A/\_7O^&QOYI/_ 'F1@_\ TH;L3_ZP>_?U,WW_
M )3!_P!E%Q_T!U[]ZV?^^O\ C"?Y^O?\-C?S2?\ O,C!_P#I0W8G_P!8/?OZ
MF;[_ ,I@_P"RBX_Z Z]^];/_ 'U_QA/\_7O^&QOYI/\ WF1@_P#TH;L3_P"L
M'OW]3-]_Y3!_V47'_0'7OWK9_P"^O^,)_GZ]_P -C?S2?^\R,'_Z4-V)_P#6
M#W[^IF^_\I@_[*+C_H#KW[UL_P#?7_&$_P _7O\ AL;^:3_WF1@__2ANQ/\
MZP>_?U,WW_E,'_91<?\ 0'7OWK9_[Z_XPG^?KW_#8W\TG_O,C!_^E#=B?_6#
MW[^IF^_\I@_[*+C_ * Z]^];/_?7_&$_S]>_X;&_FD_]YD8/_P!*&[$_^L'O
MW]3-]_Y3!_V47'_0'7OWK9_[Z_XPG^?KW_#8W\TG_O,C!_\ I0W8G_U@]^_J
M9OO_ "F#_LHN/^@.O?O6S_WU_P 83_/U[_AL;^:3_P!YD8/_ -*&[$_^L'OW
M]3-]_P"4P?\ 91<?] =>_>MG_OK_ (PG^?KW_#8W\TG_ +S(P?\ Z4-V)_\
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MMY%66DJW0Z:F..^IJ"NT2/3R@:25DB-I(9%7&OFKEQ^7;C1DQ/4Q,?,>8/\
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M.1L:=ZV6;8IS!,/FK#X77R(_U5!P>A]:7:7B!T_,>8/H>AA]E/2GIPQ.7RN
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M3*0"?4_VU'$6?P4J-XXM3,2\SRRR8[<P<Q3\PRZY31171&/A0'_"3YDY/R
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M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,.Z/[L?W?RO\ ?3^
M_P!U?M'_ (Y_>C[?^'^"XU?=_=_Y-X;VOY/3]+^_=>ZU3OGE%_PD1FJ=TQ?)
MFH^!E)NJ3.5";KJ?B\N2;<4>5:K/W3UPZ127*&O6L\AK?N(V?7Y?O0?W/?NO
M=40Y3XX_\) \SV'B]Q](?S">RMB9QQ]GC-C=O]-]F;_V(LI=Y/N:N/-]?82N
M6703$&KMUR4*J%9J.28:F*-\MY;FV989FA/$ND9D>GF %[JG^CW>G2JS=8Y
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"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
